{"meta":{"query_hash":"ca2496bf98f8","filters":{"venue":"The Lancet Oncology"},"cohort_total":832,"direct_labels_cover":9,"predictions_cover":832,"exported":832,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/ca2496bf98f8","api":"https://metacan.xera.ac/api/v1/cohort?venue=The+Lancet+Oncology"},"results":[{"id":"W1527808522","doi":"10.1016/s1470-2045(15)70198-1","title":"Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Hedgehog Signaling Pathway Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":244,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Vismodegib; Basal cell carcinoma; Medicine; Interim analysis; Internal medicine; Adverse effect; Interim; Oncology; Clinical endpoint; Population; Clinical trial; Surgery; Basal cell","score_opus":0.07487761994898005,"score_gpt":0.36777701402804236,"score_spread":0.2928993940790623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1527808522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99674803,0.00008557089,0.00010205034,0.00019513784,0.00024036015,0.00051842886,0.000071157534,0.000005380299,0.0020338553],"genre_scores_gemma":[0.99801326,0.000016123155,0.0010143721,0.000367564,0.0001451954,0.00008033088,0.00027186133,0.000014218776,0.000077081284],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99872524,0.0003140075,0.0002936786,0.00031018376,0.00014194995,0.00021495219],"domain_scores_gemma":[0.9990404,0.000035621102,0.00022306158,0.00045905856,0.00018635225,0.000055489247],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058386644,0.00013776794,0.0005228159,0.00009190986,0.000026611784,0.0000146989305,0.0007729029,0.00009944154,0.0000063879656],"category_scores_gemma":[0.00011625998,0.00009455653,0.000035072957,0.00021778929,0.00010535229,0.00001225086,0.00033807257,0.00010450494,0.0000015900813],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5479377,0.008446066,0.37972122,0.000060476166,0.002556663,0.000034558154,0.0054934085,0.0054047015,0.036719803,0.00012062929,0.002514196,0.010990577],"study_design_scores_gemma":[0.45428458,0.07864235,0.38825318,0.00005930696,0.0011587559,0.000003569385,0.0015897801,0.003636917,0.04264482,0.00015597744,0.028482098,0.0010886794],"about_ca_topic_score_codex":0.00008014059,"about_ca_topic_score_gemma":0.0005681144,"teacher_disagreement_score":0.093653135,"about_ca_system_score_codex":0.000058283596,"about_ca_system_score_gemma":0.0001510653,"threshold_uncertainty_score":0.38559037},"labels":[],"label_agreement":null},{"id":"W1534401608","doi":"10.1016/s1470-2045(15)70137-3","title":"Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":134,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Institute for Health and Care Research; Cancer Research UK","keywords":"Medicine; Epirubicin; Docetaxel; Clinical endpoint; Bevacizumab; Breast cancer; Internal medicine; Cyclophosphamide; Chemotherapy; Oncology; Fluorouracil; Neoadjuvant therapy; Mucositis; Phases of clinical research; Clinical trial; Surgery; Cancer","score_opus":0.04623737131073502,"score_gpt":0.36962232590410127,"score_spread":0.32338495459336625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1534401608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910595,0.0007582425,0.000111352325,0.0033973234,0.00019132394,0.0030664636,0.0010474626,0.000017347233,0.00035100494],"genre_scores_gemma":[0.99410266,0.00025513183,0.0010947514,0.000880626,0.0005478752,0.0026486192,0.000084677165,0.000043308075,0.00034234533],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99814624,0.00027976054,0.00035482176,0.00054098124,0.0001609834,0.0005172025],"domain_scores_gemma":[0.9984997,0.00020319074,0.00029438178,0.00048186304,0.00026768932,0.00025319884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067274633,0.00030912246,0.0009485048,0.00002651399,0.00013758166,0.000034425688,0.00049261533,0.00014338254,0.000016585966],"category_scores_gemma":[0.00012786782,0.00020077908,0.000034264693,0.00012731965,0.00026355634,0.00001975113,0.00019815369,0.00010463884,0.0000020666014],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92138404,0.0015803,0.0003780049,0.000022435643,0.000893209,0.0000058221876,0.0029706857,0.000020393714,0.032393456,0.000022269638,0.017864307,0.022465086],"study_design_scores_gemma":[0.92573106,0.025022404,0.0023219138,0.000041241576,0.00028113482,0.000045288256,0.00088311365,0.0000122392585,0.020148568,0.00013591716,0.024959596,0.00041751485],"about_ca_topic_score_codex":0.0009414062,"about_ca_topic_score_gemma":0.0007274644,"teacher_disagreement_score":0.023442104,"about_ca_system_score_codex":0.00017333971,"about_ca_system_score_gemma":0.0004385541,"threshold_uncertainty_score":0.8187533},"labels":[],"label_agreement":null},{"id":"W1585884249","doi":"10.1016/s1470-2045(15)00130-8","title":"Excessive imaging for breast cancer in Ontario","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Breast cancer; Stage (stratigraphy); Medicine; Breast imaging; Gynecology; Cancer; Medical physics; Mammography; Internal medicine","score_opus":0.20196037369195638,"score_gpt":0.4302839649687756,"score_spread":0.2283235912768192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1585884249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8755145,0.0011733109,0.00031517676,0.08274198,0.00080661965,0.000647518,0.00004100264,0.000049076636,0.03871083],"genre_scores_gemma":[0.9901414,0.000023276885,0.0006227291,0.007499352,0.0007738624,0.00012385685,0.0000046199957,0.000008189365,0.00080270495],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99925554,0.000042191565,0.00013958776,0.00014352621,0.00011147946,0.00030765354],"domain_scores_gemma":[0.9995018,0.000070090275,0.00006409382,0.00016882175,0.0001170749,0.00007809698],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005445561,0.0000761751,0.00032185644,0.000030677522,0.00003259911,0.000007814059,0.00013650728,0.00004620348,0.00014084524],"category_scores_gemma":[0.000049496826,0.000049740287,0.00003522098,0.00008363687,0.000068932175,0.000061029827,0.00003984565,0.00022869403,0.000012612969],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003138424,0.000049478615,0.8905545,0.000021142776,0.000034663073,0.00013583354,0.003450914,0.00017087143,0.00027242475,0.00082967407,0.043644313,0.05769779],"study_design_scores_gemma":[0.006817204,0.0002682885,0.77159995,0.00013730057,0.000074873125,0.00052198477,0.0014787808,0.000546321,0.00006610932,0.002669645,0.21569586,0.0001236771],"about_ca_topic_score_codex":0.06708393,"about_ca_topic_score_gemma":0.34117255,"teacher_disagreement_score":0.27408862,"about_ca_system_score_codex":0.0010357774,"about_ca_system_score_gemma":0.001052539,"threshold_uncertainty_score":0.93912846},"labels":[],"label_agreement":null},{"id":"W1821272131","doi":"10.1016/s1470-2045(15)00379-4","title":"Developments in paediatric care in Latin America","year":2015,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Latin Americans; Commission; Health care; Political science; Medicine; Economic growth; Business; Economics; Law","score_opus":0.15006815097757562,"score_gpt":0.3906157659402286,"score_spread":0.240547614962653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1821272131","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03194166,0.005960225,0.000003930961,0.8372482,0.0008352515,0.00085004646,0.000034723253,0.00006184101,0.12306412],"genre_scores_gemma":[0.043434393,0.00060740806,0.002152605,0.94572294,0.006630393,0.00014877018,0.00033955192,0.00003722022,0.0009266991],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980768,0.00030502377,0.00036688824,0.0003056846,0.00035467595,0.0005909331],"domain_scores_gemma":[0.9991518,0.00018018403,0.0001692406,0.0003545478,0.000096736905,0.000047460486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048734152,0.00020828603,0.00095152063,0.0002113559,0.000022792263,0.000008120896,0.00035317516,0.00059558236,0.0000512388],"category_scores_gemma":[0.00018866964,0.00014687373,0.000050963736,0.0005261825,0.000088265246,0.00002785554,0.0001355287,0.0022951777,0.0001601416],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024485533,0.000011589544,0.05495322,0.00009782166,0.000016920349,0.0023647135,0.0016780631,0.000014933278,0.0000016361295,0.000004023037,0.9102542,0.03035806],"study_design_scores_gemma":[0.0019218541,0.0003008104,0.030718101,0.00013805523,0.000035423036,0.00005657193,0.0005691882,0.0000067673946,0.0000013469025,0.00007319677,0.96602935,0.0001493354],"about_ca_topic_score_codex":0.0007637921,"about_ca_topic_score_gemma":0.0013284906,"teacher_disagreement_score":0.12213743,"about_ca_system_score_codex":0.0014806332,"about_ca_system_score_gemma":0.0014317894,"threshold_uncertainty_score":0.9971532},"labels":[],"label_agreement":null},{"id":"W1837576367","doi":"10.1016/s1470-2045(15)00229-6","title":"Fewer than three doses of HPV vaccine","year":2015,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"","keywords":"Medicine; Immunogenicity; Vaccination; Scopus; Human papillomavirus; Clinical trial; Cervical cancer; Virology; Oncology; Internal medicine; Immunology; Cancer; MEDLINE; Biology; Immune system","score_opus":0.15748893925231677,"score_gpt":0.41841447650743335,"score_spread":0.2609255372551166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1837576367","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008105654,0.0018364708,0.000011083898,0.7485042,0.00048797304,0.00046070784,0.000058114136,0.00004149404,0.24778937],"genre_scores_gemma":[0.030749215,0.0009592574,0.00019742912,0.91394824,0.04131153,0.00012810432,0.00035206645,0.000095145464,0.012258991],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997939,0.00022483253,0.00033990524,0.00030057228,0.00060419977,0.00059149286],"domain_scores_gemma":[0.99782056,0.0005047274,0.0001685325,0.00096226507,0.0004470366,0.00009689549],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009127762,0.00022549227,0.001422827,0.00011024955,0.000040910454,0.000008601685,0.0005840925,0.0007494854,0.010855442],"category_scores_gemma":[0.0002516231,0.00012622576,0.00016713855,0.00020748086,0.00021234222,0.000018929779,0.00025310297,0.0025966328,0.00022624624],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012602583,0.00005404564,0.0018249208,0.00045109325,0.00018049526,0.00028006974,0.000104262035,3.54588e-7,0.000019867977,0.00007568408,0.9606767,0.0350722],"study_design_scores_gemma":[0.0033345807,0.001282676,0.03058959,0.0000190636,0.00021047553,0.00011620327,0.000019170628,0.000008432783,0.000068402245,0.0024108798,0.9618197,0.00012083977],"about_ca_topic_score_codex":0.00042164497,"about_ca_topic_score_gemma":0.0007646695,"teacher_disagreement_score":0.23553038,"about_ca_system_score_codex":0.000270163,"about_ca_system_score_gemma":0.00077027146,"threshold_uncertainty_score":0.9997044},"labels":[],"label_agreement":null},{"id":"W1850035702","doi":"10.1016/s1470-2045(15)00311-3","title":"Discordance between the results and conclusions of ICON7 – Authors' reply","year":2015,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Cancer Research UK","keywords":"Bevacizumab; Medicine; Ovarian cancer; Chemotherapy; Oncology; Internal medicine; Population; Overall survival; Cancer","score_opus":0.1103282341605306,"score_gpt":0.37946278162361025,"score_spread":0.26913454746307963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1850035702","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004537482,0.001974329,0.0000063048847,0.97711724,0.0005770014,0.0007634006,0.00063512113,0.00002950498,0.014359625],"genre_scores_gemma":[0.07448849,0.0021824285,0.00057732925,0.8942769,0.021063913,0.00025000103,0.0005742528,0.00006735936,0.006519297],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980463,0.0004537971,0.00046632928,0.000388444,0.0002865567,0.0003586025],"domain_scores_gemma":[0.99664813,0.0015454447,0.0004650455,0.0011457932,0.00012254511,0.0000730657],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001181442,0.00023862644,0.0012302805,0.000042422103,0.00012450933,0.000012495175,0.00032654888,0.00037992,0.00003384576],"category_scores_gemma":[0.00029840914,0.0001102203,0.00010348629,0.00012221509,0.00059609354,0.000018919254,0.00025443613,0.0013314349,0.00001970775],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025934904,0.000038693004,0.0034831397,0.000077957346,0.00034865635,0.00021387551,0.0006480962,3.7814576e-7,0.000005093424,0.00016325532,0.98930854,0.0054529635],"study_design_scores_gemma":[0.00351029,0.0010266963,0.020324659,0.0001989915,0.0008311746,0.000104390405,0.000057583013,0.000003066063,0.000027408294,0.0011346812,0.97267383,0.00010720842],"about_ca_topic_score_codex":0.0003611723,"about_ca_topic_score_gemma":0.00005067762,"teacher_disagreement_score":0.0828403,"about_ca_system_score_codex":0.0002121746,"about_ca_system_score_gemma":0.0004889741,"threshold_uncertainty_score":0.5784496},"labels":[],"label_agreement":null},{"id":"W1935362880","doi":"10.1016/s1470-2045(15)00223-5","title":"Global cancer surgery: delivering safe, affordable, and timely cancer surgery","year":2015,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":685,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Centre for Global Health Research; St. Michael's Hospital","funders":"","keywords":"Medicine; Cancer; Cancer surgery; Global health; Surgery; Public health; Nursing; Internal medicine","score_opus":0.17122752256125046,"score_gpt":0.4991732710837786,"score_spread":0.32794574852252817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1935362880","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015436733,0.98664856,0.00004879372,0.002584097,0.0037193496,0.00085010764,0.00028604953,0.00010783208,0.0056008333],"genre_scores_gemma":[0.000011813263,0.9885211,0.00050849793,0.0028514052,0.0059712436,0.00053471455,0.000084253996,0.000071329654,0.001445644],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969041,0.0006775146,0.00074731023,0.0005842862,0.00024884992,0.0008379933],"domain_scores_gemma":[0.9958868,0.0024234974,0.0006833195,0.0006190214,0.00014551285,0.0002418741],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018927887,0.0005660582,0.0056735915,0.00013029526,0.00018957435,0.000014830968,0.0003193547,0.00086369825,0.0005487659],"category_scores_gemma":[0.00020179697,0.00034102515,0.0004188493,0.0005164204,0.00067139853,0.00008010904,0.00015140162,0.00080390525,0.000044577948],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032932276,0.00005532211,0.002894714,0.0035308576,0.0006636669,0.00020792113,0.000042401058,0.0000070455094,9.089626e-8,0.000109854846,0.13187549,0.8602833],"study_design_scores_gemma":[0.000639979,0.00008956706,0.00036495147,0.003929543,0.0014422957,0.0012389094,0.000012000521,0.000011072864,1.18086604e-7,0.00019931249,0.9917144,0.00035780616],"about_ca_topic_score_codex":0.00054187723,"about_ca_topic_score_gemma":0.0009271367,"teacher_disagreement_score":0.8599255,"about_ca_system_score_codex":0.0020700926,"about_ca_system_score_gemma":0.004679611,"threshold_uncertainty_score":0.99990416},"labels":[],"label_agreement":null},{"id":"W1936755136","doi":"10.1016/s1470-2045(15)00205-3","title":"The expanding role of primary care in cancer control","year":2015,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":544,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; University of Manitoba; University of Toronto; Ontario Institute for Cancer Research","funders":"Cancer Research UK; Public Health Wales; National Institute for Health and Care Research; Betsi Cadwaladr University Health Board","keywords":"Primary care; Cancer; Primary (astronomy); Control (management); Primary cancer; Medicine; Family medicine; Computer science; Internal medicine; Artificial intelligence","score_opus":0.22097489652309535,"score_gpt":0.47503436473613914,"score_spread":0.2540594682130438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1936755136","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010794714,0.9732056,0.0000014863763,0.00049742946,0.00029947213,0.0008577588,0.000050201288,0.000015223371,0.024964854],"genre_scores_gemma":[0.0012329502,0.99657553,0.000027693744,0.0006028685,0.0010679245,0.00031888657,0.000027560412,0.000020484413,0.0001261229],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99825144,0.00042244,0.00048637626,0.00019722845,0.00025597456,0.00038655387],"domain_scores_gemma":[0.9984574,0.0004888113,0.00039239635,0.00046588594,0.00013586311,0.00005966064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012414382,0.00019842904,0.0024022763,0.000053324413,0.00006355815,0.0000079496285,0.00045089808,0.00025456416,0.000017923756],"category_scores_gemma":[0.000097008124,0.000093702045,0.00019383393,0.00022474436,0.00017453398,0.000023437111,0.000092208145,0.0006477229,0.0000118995495],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027147707,0.000010636463,0.00048057333,0.0025526325,0.00010148407,0.000024994197,0.000458032,0.000003373171,0.0000017988547,0.00017063314,0.0019944848,0.99392986],"study_design_scores_gemma":[0.0013094817,0.00029779435,0.00014488015,0.0057757427,0.00059874903,0.000069294,0.0007070704,0.0000027231395,6.231153e-7,0.00009252888,0.9909116,0.00008949594],"about_ca_topic_score_codex":0.00048004038,"about_ca_topic_score_gemma":0.0010475665,"teacher_disagreement_score":0.9938404,"about_ca_system_score_codex":0.0014929667,"about_ca_system_score_gemma":0.002260238,"threshold_uncertainty_score":0.40095648},"labels":[],"label_agreement":null},{"id":"W1948945226","doi":"10.1016/s1470-2045(15)00002-9","title":"Breast cancer risk in women with PALB2 mutations in different populations","year":2015,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Cancer Research UK","keywords":"Breast cancer; PALB2; Medicine; Context (archaeology); Population; Cancer; Oncology; Odds ratio; Incidence (geometry); Scopus; Gynecology; Internal medicine; Demography; Germline mutation; MEDLINE; Genetics; Mutation; Biology; Environmental health","score_opus":0.03538884622093482,"score_gpt":0.3258172434171433,"score_spread":0.2904283971962085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1948945226","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5173344,0.00073820306,0.00007945707,0.4781922,0.0006124796,0.000627861,0.0010606643,0.000019409177,0.0013353372],"genre_scores_gemma":[0.7457481,0.0011295349,0.0007063824,0.23298359,0.0118468655,0.004001252,0.0017145323,0.00015332621,0.0017164256],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979729,0.00052534736,0.00031928997,0.00045072986,0.00017880904,0.00055294397],"domain_scores_gemma":[0.9988953,0.00006177713,0.00025410924,0.0006363379,0.00010951154,0.000042978856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037041356,0.0002792104,0.0005094045,0.00013409903,0.0000676595,0.000019707268,0.00044805402,0.00061939517,0.00009057957],"category_scores_gemma":[0.000037697002,0.00018799305,0.000038196697,0.00024428568,0.0002114271,0.0000037093043,0.00011792622,0.0011523836,0.000011360753],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005700303,0.00010421224,0.035657227,0.000043938995,0.0001645689,0.000067908004,0.0013390173,0.0056422157,0.00021570009,0.000016600103,0.9487222,0.007456403],"study_design_scores_gemma":[0.0028016155,0.0002941857,0.16210867,0.000059877868,0.00007718373,0.00012263657,0.00030806777,0.00008146212,0.00004553438,0.001590672,0.83207804,0.00043205102],"about_ca_topic_score_codex":0.0008310519,"about_ca_topic_score_gemma":0.015282906,"teacher_disagreement_score":0.24520864,"about_ca_system_score_codex":0.0012234391,"about_ca_system_score_gemma":0.0008750528,"threshold_uncertainty_score":0.852822},"labels":[],"label_agreement":null},{"id":"W1950224348","doi":"10.1016/s1470-2045(15)00035-2","title":"Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Nausea and vomiting management","field":"Medicine","cited_by":141,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Nausea; Vomiting; Medicine; NK1 receptor antagonist; Chemotherapy; Chemotherapy-induced nausea and vomiting; Dexamethasone; Granisetron; Internal medicine; Placebo; Gastroenterology; Anesthesia; Antiemetic; Receptor","score_opus":0.08553834392799094,"score_gpt":0.40894196704447805,"score_spread":0.3234036231164871,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1950224348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928674,0.00015156076,0.00039815842,0.0011600385,0.00005084104,0.005239936,0.000029560038,0.000008209709,0.000094265444],"genre_scores_gemma":[0.99844277,0.00006471656,0.0008799585,0.00013913201,0.00012366909,0.00028733548,0.000027579916,0.000017791288,0.000017072918],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.998304,0.00032144866,0.00081077183,0.00020115591,0.00018569826,0.00017692948],"domain_scores_gemma":[0.9976544,0.0008987551,0.0009920407,0.00019299072,0.00020832267,0.00005350922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002685402,0.00015049604,0.0014692796,0.00011600272,0.000022178194,0.000004841105,0.000065716384,0.000081720704,0.000013676275],"category_scores_gemma":[0.0002481742,0.00009456708,0.00009574171,0.00012465281,0.00008802704,0.000044015964,0.000012147317,0.00009444776,5.981846e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9470839,0.0010236728,0.013665003,0.00019852386,0.00048706564,0.0000010541512,0.0005726678,0.000020521142,0.005958608,0.00005303045,0.000009373797,0.030926583],"study_design_scores_gemma":[0.9089702,0.0073099826,0.04013921,0.00020175347,0.00057379284,9.876115e-7,0.00007659263,0.00043772237,0.04206426,0.0000565645,0.00007821351,0.00009073816],"about_ca_topic_score_codex":0.000043171596,"about_ca_topic_score_gemma":0.000108087785,"teacher_disagreement_score":0.038113713,"about_ca_system_score_codex":0.000083011364,"about_ca_system_score_gemma":0.0002440403,"threshold_uncertainty_score":0.38563338},"labels":[],"label_agreement":null},{"id":"W1964525628","doi":"10.1016/s1470-2045(14)70181-0","title":"When is downstream pathway inhibition important?","year":2014,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Pertuzumab; Trastuzumab; Medicine; Lapatinib; Oncology; Internal medicine; Trastuzumab emtansine; Breast cancer; Vinorelbine; Taxane; Cancer; Everolimus; Metastatic breast cancer; Context (archaeology); Neratinib; Clinical trial; Chemotherapy","score_opus":0.0997091515519647,"score_gpt":0.3847506483452985,"score_spread":0.2850414967933338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1964525628","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018929195,0.00048821565,0.000025237663,0.92127806,0.000737509,0.00094196765,0.00014971498,0.000145235,0.074341156],"genre_scores_gemma":[0.0022815599,0.0006792725,0.0003730253,0.9505557,0.033962,0.0003123933,0.00060854305,0.00010740546,0.011120147],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99639595,0.00063098996,0.0005857501,0.0006063208,0.0007611807,0.001019814],"domain_scores_gemma":[0.99729115,0.0005257832,0.0003480866,0.0015187919,0.00019506588,0.00012114879],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.001660512,0.00037106714,0.0013771976,0.00016410399,0.00011298387,0.000035101544,0.00048651017,0.0015216306,0.0038702034],"category_scores_gemma":[0.00021016225,0.00023951365,0.00021912997,0.00016620079,0.0004634633,0.000031216063,0.00018565152,0.0045847693,0.0013681452],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000170217,0.000042382722,0.0005603359,0.0004733989,0.00012181529,0.0017670899,0.00048154837,6.837535e-8,0.00034545816,0.00006840312,0.9849236,0.011045663],"study_design_scores_gemma":[0.0017865006,0.0010288332,0.0001365258,0.00025391628,0.0001240448,0.00088000327,0.0000199297,0.000017197295,0.00080278947,0.004480712,0.9902334,0.00023610846],"about_ca_topic_score_codex":0.00029622883,"about_ca_topic_score_gemma":0.00007788986,"teacher_disagreement_score":0.06322101,"about_ca_system_score_codex":0.00074148696,"about_ca_system_score_gemma":0.0011076418,"threshold_uncertainty_score":0.9997746},"labels":[],"label_agreement":null},{"id":"W1966238809","doi":"10.1016/s1470-2045(03)01117-3","title":"Isolated limb perfusion with melphalan in the treatment of malignant melanoma of the extremities: a systematic review of randomised controlled trials","year":2003,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Melphalan; Melanoma; Perfusion; Limb perfusion; Randomized controlled trial; Clinical trial; Surgery; Chemotherapy; Internal medicine; Oncology","score_opus":0.086090373439733,"score_gpt":0.3647785349593234,"score_spread":0.2786881615195904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966238809","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020351369,0.9702156,0.000010862383,0.0005934883,0.00019251942,0.024949761,0.000022584927,0.000009850607,0.0038017945],"genre_scores_gemma":[0.0010342711,0.995422,0.000020644926,0.00034800783,0.00008505367,0.0020601556,0.000013917566,0.00002542422,0.0009905449],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9866939,0.009552531,0.0028950302,0.00023243626,0.0003904009,0.0002357013],"domain_scores_gemma":[0.98941636,0.005267538,0.003972009,0.001180636,0.0001329327,0.00003054723],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0073908325,0.00039657232,0.014985176,0.00015247105,0.000042020692,0.0000046816044,0.00041119868,0.00019584007,0.00015491342],"category_scores_gemma":[0.0011255837,0.000114892115,0.0014939865,0.00043531443,0.0001686384,0.0000076021406,0.000028529561,0.00021178354,0.0000032076575],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013339987,0.0010416033,0.000004231067,0.9488985,0.0035194918,0.00010603862,0.0012273333,7.007933e-7,0.000020200945,0.00022106651,0.00045763055,0.031163212],"study_design_scores_gemma":[0.07577894,0.0071811257,0.000002743565,0.6137908,0.045811284,0.0017373086,0.0006785556,0.000020198722,0.000011977859,0.000012303937,0.25478503,0.00018970204],"about_ca_topic_score_codex":0.000044965913,"about_ca_topic_score_gemma":0.000052220494,"teacher_disagreement_score":0.33510768,"about_ca_system_score_codex":0.00025603216,"about_ca_system_score_gemma":0.0004187857,"threshold_uncertainty_score":0.9996384},"labels":[],"label_agreement":null},{"id":"W1966436678","doi":"10.1016/s1470-2045(07)70084-0","title":"Scoring systems: predictive accuracy through specificity","year":2007,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Cardiac, Anesthesia and Surgical Outcomes","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Scoring system; Colorectal cancer; Predictive value; Outcome (game theory); Predictive value of tests; Predictive modelling; Surgery; Intensive care medicine; Cancer; Internal medicine; Machine learning; Computer science","score_opus":0.10220063095012856,"score_gpt":0.3693338189685991,"score_spread":0.2671331880184706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966436678","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015823544,0.0020271856,0.00041472848,0.65124875,0.0025165654,0.001119963,0.00003883335,0.00021744348,0.3408342],"genre_scores_gemma":[0.0034413042,0.001646099,0.00032597617,0.91033286,0.06497353,0.00011754022,0.00019338365,0.00009735237,0.018871948],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967399,0.0006830055,0.0005764237,0.0005122728,0.000611506,0.00087686634],"domain_scores_gemma":[0.9928318,0.005579907,0.00034927676,0.0010138062,0.00014550236,0.00007967541],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0014280326,0.00041490476,0.0028465872,0.00009367032,0.00013496549,0.000038416914,0.00034987132,0.0013032781,0.0001694],"category_scores_gemma":[0.00051138934,0.00024865998,0.0005902861,0.00021677838,0.00036563483,0.00006508178,0.00011265424,0.0033659523,0.00034828566],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070887164,0.0000460511,0.0018255252,0.00041622567,0.0005133177,0.010358151,0.000472092,0.0000100566185,0.00000961958,0.0017148862,0.98326075,0.000664469],"study_design_scores_gemma":[0.0014521253,0.00036404614,0.004036953,0.0002259472,0.00052358146,0.0026862712,0.00017996291,0.000014357752,0.00001568491,0.000073094925,0.99018437,0.00024359218],"about_ca_topic_score_codex":0.00020006901,"about_ca_topic_score_gemma":0.0000058248784,"teacher_disagreement_score":0.32196224,"about_ca_system_score_codex":0.00059536606,"about_ca_system_score_gemma":0.00028828657,"threshold_uncertainty_score":0.99999654},"labels":[],"label_agreement":null},{"id":"W1967485936","doi":"10.1016/s1470-2045(13)70083-4","title":"The Fluorspar Mines of Newfoundland","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Geological and Geochemical Analysis","field":"Earth and Planetary Sciences","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Environmental science","score_opus":0.02556321535008661,"score_gpt":0.2405836253936181,"score_spread":0.2150204100435315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1967485936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92751414,0.0006948418,0.0000054802076,0.030335208,0.00010568351,0.00007174663,0.00000485213,0.000011485542,0.04125655],"genre_scores_gemma":[0.99770343,0.00019492015,0.00017704903,0.0008705526,0.0002456891,0.0000024871185,0.000008605369,5.2722424e-7,0.00079675164],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99936086,0.000118949065,0.00013167426,0.00008510441,0.00008342153,0.00021996415],"domain_scores_gemma":[0.99889797,0.000781875,0.00006641349,0.00017541116,0.00004010422,0.000038216145],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00029592044,0.00005569097,0.00019287164,0.000007954593,0.0001264667,0.00001547148,0.00036615532,0.000040826435,0.0057621063],"category_scores_gemma":[0.000101526966,0.00002008459,0.000048853013,0.00012114748,0.00029497565,0.000027198914,0.000019486233,0.00008205073,0.0004879743],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054462882,0.000016764254,0.8837389,0.0000054552447,0.000048860034,0.000001864754,0.00008684396,0.00018091494,0.0004982873,0.00087625574,0.018721864,0.09576954],"study_design_scores_gemma":[0.00016979236,0.00013534688,0.7478381,0.0000012559788,0.000018504314,0.000006985216,0.00008451951,0.0016505825,0.00006986111,0.06165242,0.18832408,0.000048565857],"about_ca_topic_score_codex":0.008458265,"about_ca_topic_score_gemma":0.024276635,"teacher_disagreement_score":0.16960222,"about_ca_system_score_codex":0.0000015156576,"about_ca_system_score_gemma":0.00001249918,"threshold_uncertainty_score":0.9981445},"labels":[],"label_agreement":null},{"id":"W1967732005","doi":"10.1016/s1470-2045(05)01748-1","title":"Complementary treatment: who cares how it works, as long as it does?","year":2005,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Complementary and Alternative Medicine Studies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Victoria Park","funders":"","keywords":"Argument (complex analysis); Reflection (computer programming); Welfare; Epistemology; Psychology; Medical education; Medicine; Philosophy; Political science; Law; Computer science","score_opus":0.10152416960418124,"score_gpt":0.41804095446159356,"score_spread":0.3165167848574123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1967732005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.50620127,0.0014801966,0.000036370624,0.43709698,0.0005890187,0.0006687942,0.000031162184,0.000062610445,0.053833563],"genre_scores_gemma":[0.95054483,0.002515777,0.00027207908,0.027663823,0.0067349593,0.00009732463,0.00011767948,0.000019764577,0.012033774],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99848217,0.00020383207,0.000256522,0.0003077721,0.00024143474,0.00050824846],"domain_scores_gemma":[0.99877954,0.0005035291,0.00012366212,0.0004163441,0.0000647544,0.00011216002],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00030339308,0.00025192078,0.0007839292,0.000063862695,0.00026779078,0.000018853005,0.00023790236,0.000026038517,0.0036571443],"category_scores_gemma":[0.00007339619,0.00013054162,0.00010852225,0.00011753881,0.0002896462,0.00008366508,0.00015638229,0.00025727658,0.00019592108],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027329884,0.0009132582,0.1532613,0.00010521721,0.0023636846,0.001186441,0.017242929,0.000018285458,0.00048189698,0.0058614356,0.43208367,0.3837489],"study_design_scores_gemma":[0.007216797,0.0036087562,0.0139932055,0.0001491303,0.00034948217,0.00019557927,0.009023898,0.00004420275,0.0008132944,0.0004778257,0.96397835,0.00014946738],"about_ca_topic_score_codex":0.0006031137,"about_ca_topic_score_gemma":0.0073980093,"teacher_disagreement_score":0.5318947,"about_ca_system_score_codex":0.00043102496,"about_ca_system_score_gemma":0.00010448159,"threshold_uncertainty_score":0.99725366},"labels":[],"label_agreement":null},{"id":"W1968735621","doi":"10.1016/s1470-2045(15)70027-6","title":"Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":122,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Janssen Pharmaceuticals; Takeda Oncology; GlaxoSmithKline; Public Health Agency; Astellas Pharma Canada; Novartis; Exelixis; Ministry of Education, Culture, Sports, Science and Technology; Bayer; Bristol-Myers Squibb; AstraZeneca; Pfizer","keywords":"Medicine; Prednisone; Prostate cancer; Abiraterone acetate; Internal medicine; Placebo; Clinical endpoint; Enzalutamide; Androgen deprivation therapy; Clinical trial; Population; Oncology; Cancer; Surgery; Urology; Pathology; Androgen receptor","score_opus":0.09142640043602607,"score_gpt":0.3987588878018678,"score_spread":0.30733248736584173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968735621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9729393,0.0006388988,0.000018169469,0.004810386,0.00029654836,0.020076925,0.0000696506,0.00004603255,0.0011040827],"genre_scores_gemma":[0.9904562,0.00027187367,0.00030078198,0.000491718,0.00039880033,0.005800022,0.00017784955,0.000046565303,0.002056164],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972979,0.0004661203,0.0005849799,0.0004063847,0.00055120996,0.00069342915],"domain_scores_gemma":[0.9983804,0.0003164034,0.00033611254,0.00039619833,0.00032022878,0.0002506373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011027253,0.00031330448,0.0014464076,0.00014282374,0.00009859286,0.00003991783,0.00019065733,0.00010309517,0.00010619435],"category_scores_gemma":[0.00008775408,0.00016416673,0.000097770164,0.00029782456,0.0002326985,0.00012357066,0.000036337242,0.00039786717,0.000018885004],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98556006,0.0024537516,0.0017387568,0.00006348491,0.00094016286,0.00013712014,0.0053326376,0.00017905717,0.00011325897,0.000013633435,0.0010736192,0.0023944627],"study_design_scores_gemma":[0.98812604,0.007750344,0.0006194017,0.00008567672,0.0005466497,0.000006347105,0.0006112666,0.000575257,0.00027368715,0.000041742966,0.0011826796,0.0001808898],"about_ca_topic_score_codex":0.00046669872,"about_ca_topic_score_gemma":0.001124265,"teacher_disagreement_score":0.017516918,"about_ca_system_score_codex":0.0010849455,"about_ca_system_score_gemma":0.0020052572,"threshold_uncertainty_score":0.6694525},"labels":[],"label_agreement":null},{"id":"W1968899146","doi":"10.1016/s1470-2045(14)71207-0","title":"Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2007,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"National Cancer Institute","keywords":"Carboplatin; Medicine; Cetuximab; Paclitaxel; Oncology; Radiation therapy; Stage (stratigraphy); Internal medicine; Lung cancer; Chemotherapy; Nuclear medicine; Cancer; Cisplatin; Colorectal cancer","score_opus":0.04436868744910295,"score_gpt":0.3865590085254279,"score_spread":0.34219032107632497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968899146","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98438835,0.0003902497,0.0012003575,0.0004099006,0.0008436175,0.0114771295,0.0011067131,0.000064162574,0.00011953418],"genre_scores_gemma":[0.99420035,0.00027667327,0.0010841892,0.00030188943,0.0006224943,0.002821832,0.0002874432,0.000079970865,0.00032514],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99756527,0.00023981766,0.000463991,0.0005702896,0.0005221743,0.00063848763],"domain_scores_gemma":[0.9973685,0.0008055219,0.0005338754,0.00046514126,0.0004890216,0.00033792874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005145323,0.0005180626,0.0016423024,0.0000697663,0.00019663604,0.00008745523,0.00015244453,0.00010126077,0.00007010727],"category_scores_gemma":[0.000052353604,0.00023810344,0.000048767448,0.00016359388,0.00028289272,0.00019600711,0.000043025357,0.00028501023,8.359664e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85781956,0.0028566471,0.12314814,0.00017031355,0.0023168512,0.00008350664,0.0071488395,0.00019864751,0.000027231466,0.000021715541,0.0028249016,0.0033836602],"study_design_scores_gemma":[0.905369,0.078700684,0.0017395596,0.00018154256,0.0025539566,0.000015582655,0.0014160665,0.0013093689,0.00025890817,0.0000010449386,0.008044799,0.00040949468],"about_ca_topic_score_codex":0.0022137542,"about_ca_topic_score_gemma":0.0066829375,"teacher_disagreement_score":0.12140858,"about_ca_system_score_codex":0.0017139772,"about_ca_system_score_gemma":0.0024898765,"threshold_uncertainty_score":0.9709577},"labels":[],"label_agreement":null},{"id":"W1970668319","doi":"10.1016/s1470-2045(09)70078-6","title":"Breast-tissue composition and other risk factors for breast cancer in young women: a cross-sectional study","year":2009,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Digital Radiography and Breast Imaging","field":"Medicine","cited_by":184,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; Health Sciences Centre; Sunnybrook Health Science Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Breast cancer; Mammography; Menstrual cycle; Gynecology; Cross-sectional study; Obstetrics; Follicular phase; Breast density; Risk factors for breast cancer; Breast development; Hormone; Cancer; Physiology; Internal medicine; Pathology","score_opus":0.024450156422956518,"score_gpt":0.3550274863330137,"score_spread":0.33057732991005717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970668319","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99571407,0.00006447583,0.000050750976,0.0015180954,0.00015070612,0.0005962232,0.0004963013,0.000040373514,0.0013690117],"genre_scores_gemma":[0.99874836,0.000014149737,0.000040176663,0.0005605396,0.00046951903,0.00008336577,0.000007297436,0.0000101850865,0.000066383756],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99912095,0.000075484095,0.0001859785,0.00020588042,0.0001054932,0.00030622023],"domain_scores_gemma":[0.99955857,0.000118783,0.000082352926,0.00012984176,0.000045771787,0.000064683234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004142487,0.00011861079,0.00033347012,0.00009629674,0.00010238743,0.000041375974,0.00007772205,0.000059200163,0.00005843479],"category_scores_gemma":[0.000007836354,0.00007919378,0.000039755545,0.00016666761,0.00011517829,0.00009826391,0.000014911546,0.0001852482,0.0000016503279],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016141441,0.0005394349,0.9676371,0.000012239992,0.00006979468,0.0000076725955,0.0016141414,0.00002284829,0.0003964442,0.000105235355,0.00005422648,0.027926672],"study_design_scores_gemma":[0.0038496929,0.0007637254,0.9928452,0.000015497431,0.000029303199,0.000937253,0.0005069277,0.000073335636,0.00001664374,0.00054957287,0.00032714554,0.000085739215],"about_ca_topic_score_codex":0.00041774887,"about_ca_topic_score_gemma":0.00022841842,"teacher_disagreement_score":0.027840933,"about_ca_system_score_codex":0.0001690944,"about_ca_system_score_gemma":0.000042686886,"threshold_uncertainty_score":0.32294285},"labels":[],"label_agreement":null},{"id":"W1971159432","doi":"10.1016/s1470-2045(14)70375-4","title":"Outcomes and endpoints in trials of cancer treatment: the past, present, and future","year":2014,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":218,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Surrogate endpoint; Clinical endpoint; Clinical trial; Intensive care medicine; Quality of life (healthcare); Medicine; Endpoint Determination; Overall survival; Cancer; Disease; Oncology; Internal medicine; Nursing","score_opus":0.7857781232112138,"score_gpt":0.682581246318719,"score_spread":0.1031968768924948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971159432","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000038309303,0.9868216,0.000087666456,0.008113361,0.00086652546,0.0022499438,0.00042621625,0.000016625369,0.0013797836],"genre_scores_gemma":[0.0000017739864,0.9759104,0.017563183,0.00016325882,0.0055831396,0.0005243314,0.0000021241942,0.000031947704,0.00021982077],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9843611,0.01291778,0.0019282105,0.00033865235,0.00015147809,0.000302766],"domain_scores_gemma":[0.79889166,0.1990688,0.0013844278,0.0005835702,0.000025646126,0.00004588539],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01370645,0.00034473906,0.008195514,0.000056099092,0.000046743757,0.00001581304,0.00041448197,0.00047662872,0.00013622068],"category_scores_gemma":[0.016484449,0.00012898455,0.00031800976,0.00012311443,0.00044936303,0.000011484653,0.00018631307,0.00046071102,0.000003206503],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000077623,0.00006846736,0.00014023788,0.0037896594,0.0004403824,0.0000040982195,0.0001319219,2.3413868e-8,5.394221e-8,0.019677699,0.0025469493,0.9731229],"study_design_scores_gemma":[0.0016061615,0.00018035852,0.00020385582,0.00075278786,0.001685013,0.000008635299,0.000017925548,0.0000015052088,3.3544532e-7,0.18328075,0.8121597,0.00010297039],"about_ca_topic_score_codex":0.00006389874,"about_ca_topic_score_gemma":0.0001058075,"teacher_disagreement_score":0.9730199,"about_ca_system_score_codex":0.00008960785,"about_ca_system_score_gemma":0.00013472085,"threshold_uncertainty_score":0.9918001},"labels":[],"label_agreement":null},{"id":"W1972912578","doi":"10.1016/s1470-2045(13)70184-0","title":"Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":287,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Regeneron Pharmaceuticals; Sanofi","keywords":"Aflibercept; Docetaxel; Medicine; Prednisone; Prostate cancer; Placebo; Clinical endpoint; Internal medicine; Oncology; Chemotherapy; Surgery; Cancer; Bevacizumab; Urology; Randomized controlled trial; Pathology","score_opus":0.12222259731709838,"score_gpt":0.4218269267105545,"score_spread":0.2996043293934561,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972912578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97867167,0.0006958747,0.000023544546,0.0055069095,0.00004525828,0.014039671,0.00005144671,0.000014666862,0.00095096877],"genre_scores_gemma":[0.98710364,0.0007758833,0.00080375455,0.00002775521,0.00009548404,0.009780367,0.00010774759,0.000021131438,0.0012842283],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99885935,0.0001405895,0.00028156012,0.00023006026,0.00018355211,0.000304914],"domain_scores_gemma":[0.9989219,0.00046958323,0.00018975213,0.00018913075,0.00015199464,0.00007769747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033376465,0.0001676648,0.0007250297,0.000088447596,0.00007044489,0.00002054704,0.000056924848,0.000048502385,0.00005683813],"category_scores_gemma":[0.000015636986,0.00008154004,0.000037602553,0.00016152942,0.00023000565,0.00009155652,0.00000952307,0.000070775364,0.0000012763094],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9840288,0.0016513892,0.00015531937,0.00012621701,0.00063236157,0.000022133461,0.0032602213,0.00003301264,0.0022867604,0.00009742087,0.00019348347,0.007512861],"study_design_scores_gemma":[0.95448893,0.03908378,0.00045390287,0.000062135194,0.00059352536,0.000010995775,0.00087828166,0.0006176771,0.002879546,0.00008146839,0.00075937307,0.000090353824],"about_ca_topic_score_codex":0.0008561152,"about_ca_topic_score_gemma":0.0014878552,"teacher_disagreement_score":0.03743239,"about_ca_system_score_codex":0.00035504275,"about_ca_system_score_gemma":0.0006097909,"threshold_uncertainty_score":0.33251065},"labels":[],"label_agreement":null},{"id":"W1975647972","doi":"10.1016/s1470-2045(14)70081-6","title":"The value of randomised trials for prostate cancer management","year":2014,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Management of prostate cancer; Value (mathematics); MEDLINE; Randomized controlled trial; Oncology; Cancer; Gynecology; Medical physics; Internal medicine; Statistics","score_opus":0.10652173638972241,"score_gpt":0.3987593430601752,"score_spread":0.2922376066704528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975647972","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00043073954,0.006281795,0.00006698114,0.97750175,0.0014048009,0.008811453,0.0002695378,0.00003149294,0.005201428],"genre_scores_gemma":[0.001674044,0.049281012,0.00063041836,0.90086186,0.01375997,0.022372542,0.0003906816,0.000099721314,0.010929766],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972379,0.0008295826,0.0008048707,0.00033065825,0.00025593137,0.00054106355],"domain_scores_gemma":[0.9935886,0.00452698,0.00092870335,0.0007710978,0.00014609867,0.000038492028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037659681,0.00028804515,0.002194467,0.00004762018,0.00015023744,0.00001910115,0.0003493431,0.00030536109,0.000053699925],"category_scores_gemma":[0.00023480783,0.00012377326,0.0004637955,0.000074598494,0.00024847288,0.000010380646,0.00006829667,0.00052091863,0.000010455987],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010320398,0.00005634579,0.000077941324,0.0008434846,0.0022110492,0.00005263688,0.00015287762,0.000011441435,0.000013122684,0.000701629,0.94402736,0.041531723],"study_design_scores_gemma":[0.04870025,0.00094568066,0.00018298472,0.00028733563,0.0025948815,0.000011403315,0.000023709654,0.000028192795,0.000327182,0.0018404946,0.9449404,0.000117490585],"about_ca_topic_score_codex":0.00008182311,"about_ca_topic_score_gemma":0.000024588595,"teacher_disagreement_score":0.07663993,"about_ca_system_score_codex":0.00037582783,"about_ca_system_score_gemma":0.00027263566,"threshold_uncertainty_score":0.50473267},"labels":[],"label_agreement":null},{"id":"W1976250589","doi":"10.1016/s1470-2045(13)70026-3","title":"Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Growth Hormone and Insulin-like Growth Factors","field":"Medicine","cited_by":166,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Amgen","keywords":"Exemestane; Fulvestrant; Postmenopausal women; Medicine; Oncology; Breast cancer; Hormone receptor; Internal medicine; Aromatase inhibitor; Cancer; Gynecology; Aromatase; Estrogen receptor","score_opus":0.03208678168695916,"score_gpt":0.32787530743548443,"score_spread":0.29578852574852527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976250589","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96999806,0.0005630102,0.00029092873,0.009309033,0.0002991251,0.01698895,0.00024345845,0.00014218033,0.002165226],"genre_scores_gemma":[0.9779209,0.00060283515,0.001011282,0.0025904148,0.0017311268,0.014742096,0.000111899564,0.00012246692,0.0011669791],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968248,0.00022394159,0.0007117525,0.0006031679,0.000422092,0.0012142326],"domain_scores_gemma":[0.9972328,0.0007007585,0.0005110123,0.0005707893,0.00056724634,0.00041742375],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006701979,0.00058593496,0.0022947865,0.0001325364,0.00026898758,0.00006325055,0.00034452937,0.00025966385,0.00069407537],"category_scores_gemma":[0.000050733404,0.0002705147,0.00013096388,0.00035277096,0.00045972658,0.00030109796,0.00003215199,0.00056282495,0.000059180755],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96396834,0.0014247019,0.000052650747,0.000055260225,0.0014517086,0.00009267,0.0016132543,0.000008681293,0.01678216,0.00014092232,0.0030121545,0.011397484],"study_design_scores_gemma":[0.928259,0.06042133,0.0006058699,0.00007801797,0.00085058523,0.0006081636,0.0014581978,0.00005302445,0.0011100436,0.000047158876,0.0060784556,0.00043012793],"about_ca_topic_score_codex":0.00027450448,"about_ca_topic_score_gemma":0.000108868684,"teacher_disagreement_score":0.05899663,"about_ca_system_score_codex":0.00049833313,"about_ca_system_score_gemma":0.0011557352,"threshold_uncertainty_score":0.9999747},"labels":[],"label_agreement":null},{"id":"W1976585485","doi":"10.1016/s1470-2045(11)70037-7","title":"Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne; Centre hospitalier universitaire de Québec","funders":"","keywords":"Bevacizumab; Metastatic breast cancer; Medicine; Paclitaxel; Placebo; HER2 negative; Oncology; Breast cancer; Internal medicine; Open label; Double blind; Cancer; Clinical trial; Chemotherapy; Pathology; Alternative medicine","score_opus":0.24401072602498708,"score_gpt":0.47205516413850956,"score_spread":0.22804443811352249,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976585485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9443246,0.0003429457,0.00018283291,0.011985638,0.00051946286,0.040701516,0.00025669424,0.00007239308,0.001613912],"genre_scores_gemma":[0.9618961,0.0010980745,0.0010320175,0.0009838972,0.0002992884,0.031606015,0.00009382014,0.000058693666,0.0029320715],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972443,0.00064238656,0.00071769353,0.00057493313,0.00021658694,0.0006041081],"domain_scores_gemma":[0.9968787,0.0017753274,0.0004890004,0.00041248876,0.000265416,0.00017910097],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011131021,0.0004666574,0.00225709,0.00016723196,0.00020684586,0.000031499447,0.00035384163,0.00010841909,0.0013381933],"category_scores_gemma":[0.00009646717,0.0002229247,0.00009697904,0.0003979815,0.00019228524,0.00013263337,0.0000779366,0.0002684081,0.000020272404],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9069812,0.046674997,0.0004682051,0.00008133917,0.003031873,0.00045772796,0.007877151,0.000020160069,0.000024326664,0.000104750114,0.0008246223,0.0334536],"study_design_scores_gemma":[0.86847365,0.12201446,0.0002290115,0.000117380056,0.0034732982,0.00024000133,0.0015210093,0.0009821403,0.00027274954,0.00027553822,0.0021634158,0.0002373496],"about_ca_topic_score_codex":0.005014015,"about_ca_topic_score_gemma":0.068269074,"teacher_disagreement_score":0.07533947,"about_ca_system_score_codex":0.00136594,"about_ca_system_score_gemma":0.0014315981,"threshold_uncertainty_score":0.9995747},"labels":[],"label_agreement":null},{"id":"W1977580610","doi":"10.1016/s1470-2045(10)70296-5","title":"A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":148,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"National Cancer Institute","keywords":"Bladder cancer; NODAL; Oncology; Medicine; Internal medicine; Cancer","score_opus":0.09256945034448312,"score_gpt":0.3755695150153489,"score_spread":0.2830000646708658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977580610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94441277,0.001361794,0.0315826,0.0022985681,0.00016407993,0.0018906731,0.00009558097,0.000045868346,0.018148089],"genre_scores_gemma":[0.952891,0.0001427023,0.04495557,0.00090256834,0.00009096606,0.0005745331,0.000008095097,0.000018772285,0.000415777],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99926263,0.000030281994,0.000175075,0.00019172183,0.00010549606,0.00023477788],"domain_scores_gemma":[0.99956095,0.000029520521,0.00008812655,0.00017357481,0.00009404086,0.000053814478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020016232,0.000115139934,0.00039601282,0.000030898,0.00005885305,0.000002727326,0.000077737306,0.000056014906,0.00004151064],"category_scores_gemma":[0.0000069058588,0.00007569247,0.00003655365,0.000040765586,0.00009103272,0.000022064529,0.000046357294,0.00009844599,0.0000010904234],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018201007,0.004495846,0.41425875,0.0014427733,0.009928405,0.0003077342,0.11069667,0.0006415731,0.13900512,0.02308647,0.0042853,0.27365035],"study_design_scores_gemma":[0.05176034,0.0064827474,0.29794288,0.00028829352,0.0027949258,0.00014415849,0.001946476,0.027213933,0.56709,0.01920627,0.024187753,0.000942241],"about_ca_topic_score_codex":0.000106938816,"about_ca_topic_score_gemma":0.00010207904,"teacher_disagreement_score":0.42808485,"about_ca_system_score_codex":0.00020060783,"about_ca_system_score_gemma":0.000670166,"threshold_uncertainty_score":0.30866495},"labels":[],"label_agreement":null},{"id":"W1981283022","doi":"10.1016/s1470-2045(14)70121-4","title":"The need to expand global access to radiotherapy","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Computer science; Business","score_opus":0.03977384840597784,"score_gpt":0.4564466225348249,"score_spread":0.416672774128847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981283022","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23068905,0.0019133124,0.05204026,0.6461907,0.004193126,0.0017416616,0.000011767374,0.00021640387,0.06300374],"genre_scores_gemma":[0.45577633,0.0027568606,0.023096923,0.49527496,0.01707491,0.00049417984,0.000007533676,0.000068922796,0.0054493593],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99850965,0.0003391112,0.00022464088,0.00025598746,0.00015217252,0.0005184387],"domain_scores_gemma":[0.99808186,0.0008991967,0.000078553065,0.0007008766,0.000061051265,0.00017846921],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010508756,0.00015873412,0.00054193777,0.000028629198,0.00034256367,0.000032126958,0.00077052886,0.00014907336,0.00011171766],"category_scores_gemma":[0.0003008855,0.000078186684,0.00006716843,0.00032035424,0.0002733056,0.000047393543,0.00009609291,0.00026195895,0.00010646296],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071312315,0.00016424837,0.023572283,0.000015412843,0.00023627332,0.000029024477,0.0011444511,0.00040655662,0.0020928488,0.018758647,0.41219917,0.53424984],"study_design_scores_gemma":[0.0025535708,0.001703004,0.030929912,0.0000123850095,0.000024912197,0.00016132339,0.00008034667,0.00010432126,0.00012732479,0.002421603,0.961777,0.00010432629],"about_ca_topic_score_codex":0.000021846203,"about_ca_topic_score_gemma":0.00021208794,"teacher_disagreement_score":0.5495778,"about_ca_system_score_codex":0.00039508613,"about_ca_system_score_gemma":0.00014162943,"threshold_uncertainty_score":0.31883603},"labels":[],"label_agreement":null},{"id":"W1982314007","doi":"10.1016/s1470-2045(06)70622-2","title":"Use of antidepressants and risk of colorectal cancer: a nested case-control study","year":2006,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer, Stress, Anesthesia, and Immune Response","field":"Medicine","cited_by":140,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Health; McGill University; Jewish General Hospital","funders":"National Cancer Institute","keywords":"Colorectal cancer; Medicine; Internal medicine; Incidence (geometry); Cancer registry; Cancer; Population; Rate ratio; Oncology; Confidence interval; Environmental health","score_opus":0.034354148197534434,"score_gpt":0.3183250091567965,"score_spread":0.28397086095926205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982314007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99572974,0.0026023858,0.000007070491,0.00040623828,0.00011656992,0.00081738643,0.0001249407,0.00002273654,0.00017294737],"genre_scores_gemma":[0.99784,0.0014960796,0.00007131083,0.00008109591,0.00032139738,0.000054456992,0.0000020540433,0.000014927896,0.00011871918],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99851805,0.0005933555,0.00035368477,0.00017515405,0.00012801708,0.00023173285],"domain_scores_gemma":[0.9982219,0.0010029374,0.00032399094,0.0003076884,0.0001085917,0.000034931796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055053673,0.00012816285,0.0008912109,0.00006984067,0.00006508125,0.000005791135,0.00008818189,0.00008997394,0.000036609377],"category_scores_gemma":[0.00017458503,0.000084607986,0.00006691944,0.0001446312,0.00033699058,0.000042828426,0.000032977798,0.00018792524,8.694054e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01199415,0.0005791319,0.9655158,0.0000674287,0.00035192913,0.00061845465,0.0009876414,0.000111179725,0.0062342407,0.000019006948,0.0011402828,0.01238078],"study_design_scores_gemma":[0.007911578,0.0019147735,0.9819025,0.000045013243,0.0008092099,0.0017146464,0.0005442143,0.00045060285,0.0014453284,0.000014947057,0.003166914,0.00008031043],"about_ca_topic_score_codex":0.02009572,"about_ca_topic_score_gemma":0.0061433455,"teacher_disagreement_score":0.016386688,"about_ca_system_score_codex":0.000047642796,"about_ca_system_score_gemma":0.0001707138,"threshold_uncertainty_score":0.9864296},"labels":[],"label_agreement":null},{"id":"W1984251852","doi":"10.1016/s1470-2045(14)70018-x","title":"Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology","year":2014,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":235,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Geriatric oncology; Prostate cancer; Task force; Multidisciplinary approach; Geriatrics; Cancer; Family medicine; Internal medicine; Gerontology; Physical therapy; Psychiatry","score_opus":0.092242447733692,"score_gpt":0.4246081119954325,"score_spread":0.3323656642617405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984251852","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0066301613,0.9651243,0.000014469878,0.008786062,0.0015201633,0.005960071,0.0005465179,0.0000151426175,0.011403103],"genre_scores_gemma":[0.0037072499,0.99435395,0.00043688208,0.00009032859,0.000115858784,0.00036249132,0.0002444749,0.000019342595,0.0006694404],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99800575,0.00037681576,0.0009200937,0.00020840851,0.00025618414,0.00023273053],"domain_scores_gemma":[0.9978271,0.0002805045,0.001282122,0.00039149585,0.00019500495,0.000023737906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092402217,0.00016860518,0.0017028864,0.0001365183,0.000025054276,0.0000017535094,0.0004989556,0.00019590391,0.00011637733],"category_scores_gemma":[0.000019289968,0.00008795784,0.00031737454,0.00059782085,0.00028299616,0.000018392631,0.00033514295,0.00038295676,0.0000011973254],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043052575,0.0009354102,0.006137387,0.011922893,0.0016250071,0.0000024257558,0.0008093816,0.000004549032,0.000006895383,0.00044422256,0.011127099,0.9665542],"study_design_scores_gemma":[0.00467341,0.0004194005,0.004016603,0.007840645,0.00083262514,0.0000027432957,0.0001562692,0.000016167442,0.000018533605,0.000075663025,0.98187375,0.000074173804],"about_ca_topic_score_codex":0.00011417846,"about_ca_topic_score_gemma":0.00007016633,"teacher_disagreement_score":0.9707467,"about_ca_system_score_codex":0.0007191339,"about_ca_system_score_gemma":0.0005602014,"threshold_uncertainty_score":0.35868165},"labels":[],"label_agreement":null},{"id":"W1984729575","doi":"10.1016/s1470-2045(09)70295-5","title":"Should a biopsy be recommended to confirm metastatic disease in women with breast cancer?","year":2009,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Breast cancer; Metastatic breast cancer; Progesterone receptor; Oncology; Concordance; Biopsy; Internal medicine; Hormone receptor; Cancer; Estrogen receptor; Gynecology","score_opus":0.16106710979578487,"score_gpt":0.44171524985814115,"score_spread":0.2806481400623563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984729575","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013145709,0.00034963407,0.000009982097,0.9794904,0.00028377416,0.002009734,0.0008110713,0.00009007185,0.0038096325],"genre_scores_gemma":[0.010475367,0.00049557426,0.0005097581,0.977997,0.0048284363,0.0023856726,0.00014407176,0.00011402278,0.0030501042],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955978,0.0008200251,0.00047888418,0.0007373504,0.0007593382,0.0016066078],"domain_scores_gemma":[0.99743503,0.0005196975,0.00018723149,0.0012412597,0.0001712266,0.00044556506],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001272954,0.0004746002,0.0018079319,0.00036684243,0.000073236326,0.000038422073,0.00079156714,0.00033616362,0.0020564133],"category_scores_gemma":[0.00012316198,0.00029364388,0.00007847405,0.0007103347,0.0002557715,0.000037005495,0.00015035762,0.0037231469,0.00009701874],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0080392845,0.000176355,0.0013780001,0.0005549127,0.0002790722,0.008837014,0.0008806263,0.000016501639,0.0000431552,0.000018515904,0.9561264,0.023650184],"study_design_scores_gemma":[0.0040829075,0.0014164011,0.016177466,0.0006158013,0.00020114459,0.0006305479,0.00012853209,0.000024038656,0.0000061565397,0.0002313964,0.976135,0.00035061451],"about_ca_topic_score_codex":0.0015895981,"about_ca_topic_score_gemma":0.00087102957,"teacher_disagreement_score":0.02329957,"about_ca_system_score_codex":0.0031252452,"about_ca_system_score_gemma":0.0027546475,"threshold_uncertainty_score":0.99995154},"labels":[],"label_agreement":null},{"id":"W1987942446","doi":"10.1016/s1470-2045(12)70127-4","title":"Screening of symptomatic women for ovarian cancer – Authors' reply","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Ovarian cancer; Gynecology; Oncology; Internal medicine; Cancer","score_opus":0.08046158177394504,"score_gpt":0.38738397600514635,"score_spread":0.3069223942312013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987942446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88906646,0.0031753727,0.0020335817,0.09076509,0.0014882799,0.0019731058,0.00010679104,0.000112004585,0.011279334],"genre_scores_gemma":[0.9846841,0.00017442007,0.0076031107,0.0042005256,0.001644411,0.0010211089,0.000008749093,0.000020213149,0.0006433495],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99900943,0.000082683946,0.00023064729,0.00012823577,0.00010224547,0.00044676664],"domain_scores_gemma":[0.99899507,0.0003270142,0.00016134024,0.00035440314,0.000048214046,0.00011398675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008900248,0.00010077589,0.0005424131,0.00003695717,0.000061526356,0.000003962422,0.00010025211,0.00007067862,0.00033546836],"category_scores_gemma":[0.00008198864,0.00006191076,0.000072024544,0.000102963146,0.000070539165,0.000038484195,0.000033459826,0.000099694975,0.0000083302875],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035936171,0.0018846926,0.52106315,0.0010715902,0.002800944,0.00001883786,0.020366445,0.00005187057,0.0020729261,0.030115627,0.09464474,0.32231557],"study_design_scores_gemma":[0.009631652,0.0015944307,0.3865691,0.00022666602,0.0006131466,0.0000646443,0.0006688288,0.00027836984,0.0017710644,0.0009544661,0.59746796,0.00015966677],"about_ca_topic_score_codex":0.00014227003,"about_ca_topic_score_gemma":0.000016417736,"teacher_disagreement_score":0.50282323,"about_ca_system_score_codex":0.00028232665,"about_ca_system_score_gemma":0.00013566711,"threshold_uncertainty_score":0.36731434},"labels":[],"label_agreement":null},{"id":"W1990879009","doi":"10.1016/s1470-2045(08)70210-9","title":"A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China","year":2008,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":474,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Colposcopy; Endocervical curettage; Cervical intraepithelial neoplasia; Medicine; Gynecology; Cervical cancer; Obstetrics; Population; Cross-sectional study; Cancer; Internal medicine; Pathology","score_opus":0.32577779341712393,"score_gpt":0.5356799611736501,"score_spread":0.2099021677565262,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990879009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860808,0.00030187826,0.00044262115,0.009553762,0.00017832723,0.0012574412,0.0000095181995,0.000023796612,0.0021518364],"genre_scores_gemma":[0.9945088,0.00062123867,0.0017264715,0.0011841239,0.0014208553,0.00026978645,0.00000902767,0.000017379869,0.00024232802],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978382,0.00023315703,0.0008762868,0.00029171145,0.00030516522,0.00045547282],"domain_scores_gemma":[0.9965318,0.0027361445,0.00017225533,0.00029608523,0.00015468893,0.000109066736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016693152,0.00012701945,0.0008602033,0.00013589376,0.00010474199,0.000009108734,0.0003043934,0.00017769088,0.0005212286],"category_scores_gemma":[0.0020506643,0.00008893342,0.00010730748,0.00052107923,0.00019224155,0.000068332134,0.00015709468,0.0007183506,0.0000051478514],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004767654,0.0005912267,0.9516702,0.000069032634,0.00004462516,0.000038501705,0.00093024416,0.00003684816,0.000016043059,0.00022019834,0.00096549967,0.040649924],"study_design_scores_gemma":[0.01678573,0.0015019873,0.97469103,0.000039661943,0.000014882129,0.000057038582,0.0002490065,0.0004631321,0.000014837334,0.00056736806,0.0055230916,0.00009222407],"about_ca_topic_score_codex":0.0035500445,"about_ca_topic_score_gemma":0.008833607,"teacher_disagreement_score":0.0405577,"about_ca_system_score_codex":0.00020495451,"about_ca_system_score_gemma":0.0011935899,"threshold_uncertainty_score":0.57070875},"labels":[],"label_agreement":null},{"id":"W1993929185","doi":"10.1016/s1470-2045(12)70511-9","title":"ChIPing away at breast cancer","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Genomics and Chromatin Dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Ontario Institute for Cancer Research","funders":"","keywords":"Enhancer; Chromatin immunoprecipitation; Chromatin; Biology; Human genome; Gene; Computational biology; Promoter; Genetics; Epigenetics; Transcription factor; Regulation of gene expression; Gene expression; Genome","score_opus":0.019497571234393885,"score_gpt":0.29595339947435284,"score_spread":0.27645582823995896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1993929185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98681414,0.0011540868,0.00007791973,0.0031505409,0.0005004061,0.000085601605,0.000048744816,0.000010626316,0.008157958],"genre_scores_gemma":[0.99367195,0.0006643391,0.00027557847,0.0019900373,0.002363936,0.000030571267,0.000036294456,0.00001626025,0.00095104513],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992946,0.000070787806,0.000103856655,0.0001228553,0.000045493634,0.00036240873],"domain_scores_gemma":[0.9995377,0.000013292654,0.000070991824,0.00029907882,0.000021802676,0.00005714006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027839275,0.00009156052,0.00015083012,0.000008610757,0.00011302317,0.000006216156,0.00022480277,0.00011182765,0.00011072558],"category_scores_gemma":[0.000009014242,0.00006413735,0.000045866982,0.000032242213,0.00007383314,0.0000016099336,0.00021276565,0.000084033905,0.00004539079],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032690345,0.00016396405,0.14398615,0.00004100024,0.0002082918,0.000002465056,0.0006096149,0.00030280827,0.7893462,0.0023773862,0.045886107,0.01674907],"study_design_scores_gemma":[0.0010677733,0.000118133124,0.19087902,0.000008094509,0.000044171178,0.00032940524,0.00010384722,0.00025149566,0.010949616,0.00014125532,0.7958401,0.00026708312],"about_ca_topic_score_codex":0.000028446957,"about_ca_topic_score_gemma":0.00017127913,"teacher_disagreement_score":0.7783966,"about_ca_system_score_codex":0.0000692255,"about_ca_system_score_gemma":0.00004774315,"threshold_uncertainty_score":0.2615445},"labels":[],"label_agreement":null},{"id":"W1997212925","doi":"10.1016/s1470-2045(14)70115-9","title":"The growing burden of cancer in India: epidemiology and social context","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":445,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Indian Council of Medical Research","keywords":"Epidemiology; Quarter (Canadian coin); Context (archaeology); Demography; Incidence (geometry); Cancer; Population; Medicine; Environmental health; Geography; Sociology; Pathology","score_opus":0.12824508697313297,"score_gpt":0.42863037410366706,"score_spread":0.3003852871305341,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997212925","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86593854,0.0036362617,0.000030841435,0.123818055,0.00020524353,0.00017184444,0.0000036972342,0.000011422052,0.0061840746],"genre_scores_gemma":[0.9881594,0.00051589176,0.00006868997,0.01021808,0.0009334419,0.000029326016,0.0000010840705,0.0000049477417,0.00006912771],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9988037,0.00044933808,0.00025752367,0.00012003771,0.000068752975,0.00030066204],"domain_scores_gemma":[0.99852324,0.001137291,0.00013811313,0.00013609197,0.000038706705,0.000026571437],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002439919,0.0000684175,0.0005318375,0.000021886091,0.00010881792,0.0000023492153,0.00014633656,0.00011076714,0.000020832282],"category_scores_gemma":[0.000491663,0.0000367991,0.000036269434,0.00007715659,0.00038441262,0.00003532933,0.00006621916,0.00028617986,0.0000032194587],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016374597,0.000020289412,0.31659043,0.000081907914,0.00012905056,0.000018900573,0.0055124355,0.00006567984,0.0014240404,0.13092148,0.006769487,0.5368289],"study_design_scores_gemma":[0.0032548096,0.0005646889,0.68619615,0.00009559909,0.00008486761,0.000055109198,0.0037991868,0.0007754755,0.00011272004,0.008162222,0.2968024,0.00009673983],"about_ca_topic_score_codex":0.0018217093,"about_ca_topic_score_gemma":0.0011172062,"teacher_disagreement_score":0.53673214,"about_ca_system_score_codex":0.00009036755,"about_ca_system_score_gemma":0.0000962561,"threshold_uncertainty_score":0.27538916},"labels":[],"label_agreement":null},{"id":"W1998119861","doi":"10.1016/s1470-2045(00)00192-3","title":"Cervical-cancer screening beyond the year 2000","year":2001,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Cervical cancer; Medicine; Cervical cancer screening; Human papillomavirus; Cytology; Cancer screening; Disease; Cancer; Cervical screening; Gynecology; Obstetrics; Oncology; Internal medicine; Pathology","score_opus":0.1133289028550536,"score_gpt":0.4230474455792471,"score_spread":0.3097185427241935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998119861","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.060131215,0.0031753252,0.00021017136,0.2838924,0.00031702744,0.00051802467,0.00001366475,0.000089058805,0.6516531],"genre_scores_gemma":[0.93642205,0.0036395711,0.00035287952,0.040371798,0.0060515846,0.0001627146,0.000012012996,0.00003370308,0.012953684],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99868155,0.00017243542,0.0001614972,0.00018947934,0.00029955994,0.0004954921],"domain_scores_gemma":[0.9989337,0.00032864718,0.000040738305,0.00048235845,0.000103228325,0.00011135631],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00073805015,0.0001009647,0.00034977935,0.000031611748,0.00018276843,0.000019170537,0.00035056856,0.00010378,0.01966405],"category_scores_gemma":[0.00007094917,0.000048857066,0.000082878985,0.000310268,0.00026701987,0.00002748531,0.00014169655,0.0006430177,0.00036315154],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004145963,0.00018209325,0.05191751,0.00007255617,0.0002249071,0.00013388181,0.0011902947,0.00004239302,0.00037551357,0.005013905,0.18084422,0.75585675],"study_design_scores_gemma":[0.0019320967,0.00024204107,0.21584466,0.0000069065736,0.000057153033,0.00007087935,0.0001864301,0.00021985396,0.000058729285,0.0010973839,0.78022313,0.0000607514],"about_ca_topic_score_codex":0.00034867047,"about_ca_topic_score_gemma":0.0005378123,"teacher_disagreement_score":0.87629086,"about_ca_system_score_codex":0.00016123349,"about_ca_system_score_gemma":0.00024913746,"threshold_uncertainty_score":0.9812321},"labels":[],"label_agreement":null},{"id":"W1999442391","doi":"10.1016/s1470-2045(08)70177-3","title":"Part II: Milestones in personalised medicine—trastuzumab","year":2008,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Trastuzumab; Oncology; Medicine; Imatinib; Breast cancer; Internal medicine; Oncogene; Cancer; Ovarian cancer; Cancer research; Bioinformatics; Myeloid leukemia; Biology; Cell cycle","score_opus":0.269792299096941,"score_gpt":0.452685699643005,"score_spread":0.18289340054606396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999442391","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8238352,0.0015243185,0.000004999004,0.107687265,0.00042775518,0.00046080354,0.000006820878,0.00006542072,0.06598742],"genre_scores_gemma":[0.98200756,0.002252728,0.00022893936,0.0073509463,0.0028694414,0.0001486875,0.000016591473,0.000027680875,0.0050974255],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980972,0.00032269786,0.00029909992,0.00027223662,0.0004222255,0.0005865631],"domain_scores_gemma":[0.99882334,0.0004123964,0.0000630777,0.00048509773,0.000083016974,0.00013305976],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011750585,0.0001431879,0.00069952477,0.000115408606,0.000168829,0.0000021044532,0.00031391234,0.00014696113,0.0019002953],"category_scores_gemma":[0.00040591398,0.00008843211,0.000053313,0.00036483165,0.0008881162,0.000027880411,0.00009745077,0.0006778377,0.00015541403],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024005196,0.00061630324,0.11662166,0.00020639338,0.00011797685,0.0026460106,0.02232324,0.000017224163,0.0039770617,0.0025638249,0.8317631,0.016746681],"study_design_scores_gemma":[0.0058348915,0.0019484237,0.11412207,0.0001440876,0.000029859022,0.001216903,0.0008304686,0.000108138236,0.00022115256,0.00031645177,0.87510806,0.00011948488],"about_ca_topic_score_codex":0.00058646325,"about_ca_topic_score_gemma":0.00043821064,"teacher_disagreement_score":0.15817237,"about_ca_system_score_codex":0.0004789611,"about_ca_system_score_gemma":0.00066905795,"threshold_uncertainty_score":0.9990121},"labels":[],"label_agreement":null},{"id":"W2002431108","doi":"10.1016/s1470-2045(11)70103-6","title":"Sentinel nodes in colorectal cancer: cul-de-sac or clarion call?","year":2011,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Lumpectomy; Breast cancer; Axillary Lymph Node Dissection; Sentinel node; Mastectomy; Lymph node; Dissection (medical); Sentinel lymph node; Surgery; General surgery; Cancer; Internal medicine","score_opus":0.044321614251565174,"score_gpt":0.3242253386356955,"score_spread":0.27990372438413036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002431108","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18350098,0.0044002645,0.000032532374,0.79916954,0.0015068969,0.00082379795,0.00040689835,0.000075929296,0.010083166],"genre_scores_gemma":[0.12821952,0.01236744,0.00060587726,0.8245273,0.024917448,0.0018028638,0.0011408668,0.00019179608,0.0062268553],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99780434,0.00039370873,0.0002918591,0.0005502823,0.00012773905,0.0008320953],"domain_scores_gemma":[0.9991278,0.000098194025,0.00023439305,0.00043206924,0.00007157983,0.000035942423],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032107503,0.0003853337,0.00075177895,0.000056913676,0.00011087255,0.00001384549,0.00056270196,0.0011835468,0.00010424342],"category_scores_gemma":[0.00006370969,0.0002465546,0.00013233724,0.000109602835,0.00031219656,0.0000026310795,0.00034307863,0.0010502508,0.000031170694],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001224085,0.000087141896,0.018695572,0.00008297507,0.00038418794,0.0003161427,0.00037153254,0.000006758452,0.0034548158,0.0000098281635,0.9737037,0.0016632635],"study_design_scores_gemma":[0.0021897769,0.00023875445,0.02628674,0.00005442451,0.00016010691,0.00019742196,0.000040899948,0.0000070902347,0.0029678773,0.00009253144,0.96740437,0.0003600335],"about_ca_topic_score_codex":0.002172122,"about_ca_topic_score_gemma":0.0048660184,"teacher_disagreement_score":0.055281468,"about_ca_system_score_codex":0.00034813696,"about_ca_system_score_gemma":0.0005617691,"threshold_uncertainty_score":0.9999987},"labels":[],"label_agreement":null},{"id":"W2002566754","doi":"10.1016/s1470-2045(07)70002-5","title":"Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy","year":2007,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":202,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Center for Research Resources; National Institutes of Health","keywords":"Medicine; Cystectomy; Survivin; Bladder cancer; Hazard ratio; Oncology; Internal medicine; Apoptosis; Cancer; Univariate analysis; Urology; Gastroenterology; Pathology; Multivariate analysis; Confidence interval; Biology","score_opus":0.08985829872637918,"score_gpt":0.37150324276310487,"score_spread":0.2816449440367257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002566754","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961552,0.00051941304,0.00045207416,0.0010248328,0.00029092445,0.00074800244,0.00040005377,0.00001679203,0.0003927242],"genre_scores_gemma":[0.9980321,0.0003592003,0.00080447615,0.00039387212,0.00018801852,0.00014209321,0.000018393554,0.000009548135,0.000052278407],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99918944,0.00006306191,0.00027353194,0.00015619925,0.00012102591,0.00019674742],"domain_scores_gemma":[0.99923915,0.0002626814,0.00012807762,0.00021587488,0.0000935345,0.000060670765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000431639,0.000093565315,0.00042892166,0.00004412894,0.000026717667,0.0000022818247,0.00005454283,0.000106952415,0.00006964534],"category_scores_gemma":[0.00006322156,0.000060697643,0.00006083153,0.00010976953,0.00033158137,0.000037756552,0.00002354787,0.00008534335,4.5399597e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01848095,0.0004409981,0.94292104,0.00041086078,0.001242684,0.000005715119,0.0006709688,0.0000012208636,0.008913778,0.00014626326,0.004624727,0.022140795],"study_design_scores_gemma":[0.0065381816,0.002083648,0.9658893,0.00010057189,0.00068371923,0.000015933205,0.000054569507,0.000081972685,0.01786519,0.0001805647,0.006444975,0.00006138659],"about_ca_topic_score_codex":0.0005026084,"about_ca_topic_score_gemma":0.00018910797,"teacher_disagreement_score":0.02296825,"about_ca_system_score_codex":0.000073757015,"about_ca_system_score_gemma":0.00011833759,"threshold_uncertainty_score":0.2475178},"labels":[],"label_agreement":null},{"id":"W2003747306","doi":"10.1016/s1470-2045(14)70409-7","title":"Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group","year":2015,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Heart Failure Treatment and Management","field":"Medicine","cited_by":563,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Hospital for Sick Children; SickKids Foundation","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute","keywords":"Medicine; Asymptomatic; Guideline; Heart failure; Cardiomyopathy; Intensive care medicine; Population; Psychological intervention; Cancer; Pediatrics; Cardiology; Internal medicine; Environmental health; Psychiatry; Pathology","score_opus":0.07668287512611396,"score_gpt":0.4013047604394293,"score_spread":0.3246218853133154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003747306","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019205644,0.94439423,0.0022720487,0.038496546,0.0032738412,0.008288234,0.0026983828,0.000057509897,0.00032715147],"genre_scores_gemma":[0.000289938,0.9819599,0.004235895,0.00069678086,0.0025858744,0.0036660903,0.006140128,0.00006330072,0.00036209344],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99764675,0.00033983332,0.0010774715,0.00039694688,0.00025655932,0.00028244063],"domain_scores_gemma":[0.9961901,0.0013314157,0.0012526489,0.0006579596,0.00050927006,0.000058646983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020527067,0.0003144349,0.0023358972,0.000089158195,0.00008155539,0.000010596549,0.00041601347,0.00020354414,0.000044859014],"category_scores_gemma":[0.0005674323,0.00017702016,0.0004628489,0.00023452193,0.00008036092,0.00003665031,0.00013244277,0.00020618415,0.0000019800675],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013026637,0.00031168395,0.0008089342,0.0020952176,0.0030799357,0.000008297608,0.00044071293,0.000013435734,0.0000031375496,0.00014448883,0.21873295,0.77423096],"study_design_scores_gemma":[0.0030466863,0.00032266072,0.000850221,0.002038349,0.0026490141,0.000018017676,0.00002835208,0.000040349412,0.000007026238,0.00017146129,0.9906826,0.00014523132],"about_ca_topic_score_codex":0.0020555304,"about_ca_topic_score_gemma":0.0023660313,"teacher_disagreement_score":0.7740857,"about_ca_system_score_codex":0.0003959006,"about_ca_system_score_gemma":0.0008450763,"threshold_uncertainty_score":0.7218673},"labels":[],"label_agreement":null},{"id":"W2005205748","doi":"10.1016/s1470-2045(14)71106-4","title":"Stereotactic radiosurgery alone for brain metastases","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"Elekta; Medtronic","keywords":"Radiosurgery; Medicine; Radiation therapy; Adjuvant radiotherapy; Stereotactic radiation therapy; Melanoma; Whole brain radiotherapy; Adjuvant; Radiology; Brain metastasis; Medical physics; Oncology; Internal medicine; Cancer; Metastasis","score_opus":0.1652645879779496,"score_gpt":0.39626723882358356,"score_spread":0.23100265084563396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005205748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.62285763,0.005000923,0.0029446196,0.35256556,0.0017619083,0.0026101836,0.0002660888,0.00023716984,0.011755939],"genre_scores_gemma":[0.9612041,0.000078836296,0.0119989505,0.022139404,0.0017430638,0.00029742945,0.00015394969,0.000037087582,0.0023471732],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988102,0.00032612775,0.00020103095,0.00018475975,0.00013375822,0.00034414942],"domain_scores_gemma":[0.99801326,0.0012362187,0.00009924555,0.00041735248,0.00007836231,0.00015554001],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001923831,0.00012798626,0.00066651584,0.000044198267,0.000059880953,0.000010978869,0.00009897114,0.000058164194,0.00008168106],"category_scores_gemma":[0.0006018241,0.00007277992,0.00012396429,0.00010066603,0.000101173406,0.000036263307,0.000035447585,0.0001233885,0.00007074022],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004611534,0.0008986585,0.004454421,0.000115341536,0.0013183048,0.0005216874,0.00072882377,0.000018554545,0.00041129827,0.0076664425,0.91667974,0.06257522],"study_design_scores_gemma":[0.009748871,0.0020824275,0.0022445656,0.000015340634,0.0005188748,0.0008078761,0.00025510087,0.000085777174,0.0004498062,0.001757689,0.98193544,0.00009820704],"about_ca_topic_score_codex":0.000045579254,"about_ca_topic_score_gemma":0.000032754902,"teacher_disagreement_score":0.33834648,"about_ca_system_score_codex":0.00015008006,"about_ca_system_score_gemma":0.00025510593,"threshold_uncertainty_score":0.2967879},"labels":[],"label_agreement":null},{"id":"W2005967211","doi":"10.1016/s1470-2045(08)70007-x","title":"Does Canadian research investment relate to cancer burden?","year":2008,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Institute of Cancer Research; Canadian Institutes of Health Research","funders":"","keywords":"Medicine; Cancer; Investment (military); MEDLINE; Internal medicine","score_opus":0.16088777916785127,"score_gpt":0.43653804374463645,"score_spread":0.2756502645767852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005967211","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005855633,0.0013171434,0.000001033366,0.94533676,0.0029232525,0.0017751462,0.00030923716,0.00009857833,0.04238323],"genre_scores_gemma":[0.00083970744,0.002397705,0.0002814409,0.90828043,0.04918812,0.0006602723,0.0002051471,0.00011988642,0.038027298],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99329025,0.0018531437,0.00063045486,0.00086371286,0.0012087888,0.0021536371],"domain_scores_gemma":[0.99586093,0.0010584347,0.00019013871,0.0018685427,0.00038216592,0.00063976174],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.0031587244,0.00043791957,0.001630532,0.0005676489,0.00050094887,0.00003584759,0.0010494473,0.0013571798,0.0012860313],"category_scores_gemma":[0.0005853579,0.00024544125,0.00018397777,0.00060824124,0.00061483064,0.00003564332,0.00031011298,0.006875713,0.0011442499],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00017179085,0.000022002245,0.0004621135,0.00022552602,0.00031999956,0.002148991,0.0064647133,0.0000074582426,0.000014577392,0.00010859267,0.9889649,0.0010893082],"study_design_scores_gemma":[0.0012208961,0.00057975604,0.0019530986,0.00044404378,0.00012537278,0.00019704759,0.00024535554,0.000003209184,0.000025287873,0.0007488789,0.99412334,0.00033368677],"about_ca_topic_score_codex":0.64696807,"about_ca_topic_score_gemma":0.63741755,"teacher_disagreement_score":0.04626487,"about_ca_system_score_codex":0.0041352822,"about_ca_system_score_gemma":0.007091325,"threshold_uncertainty_score":0.99999976},"labels":[],"label_agreement":null},{"id":"W2008171713","doi":"10.1016/s1470-2045(06)70615-5","title":"Diffuse brainstem glioma in children: critical review of clinical trials","year":2006,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":639,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Clinical trial; Brainstem; Radiation therapy; Glioma; Overall survival; Consistency (knowledge bases); Intensive care medicine; Oncology; Internal medicine","score_opus":0.364698182033378,"score_gpt":0.5608016764064655,"score_spread":0.1961034943730875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008171713","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002888863,0.98748773,8.369606e-7,0.0052610305,0.00042585787,0.0030317118,0.00012172123,0.000027978484,0.0033542553],"genre_scores_gemma":[0.00011037488,0.9950861,0.0001268267,0.001842523,0.002077038,0.00046527875,0.00022569072,0.000041340074,0.000024852838],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9882528,0.0066686985,0.0038911242,0.00047636215,0.00027876982,0.00043225495],"domain_scores_gemma":[0.986848,0.010707997,0.0012160167,0.001013438,0.00008619964,0.0001283519],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011738794,0.00039858333,0.013699929,0.00016740197,0.000027228312,0.000006498178,0.0003730005,0.0006466645,0.0001539659],"category_scores_gemma":[0.009202675,0.00019812478,0.0017119872,0.00044426447,0.00032399906,0.000016649547,0.00012458247,0.0008315982,0.000082034065],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059228103,0.0023458502,0.0015263571,0.056525387,0.0005423861,0.00034832305,0.0000042788956,1.19953585e-8,1.1857549e-7,0.0013142145,0.03300671,0.90432715],"study_design_scores_gemma":[0.004699736,0.0005892832,0.0020049803,0.09305518,0.004967182,0.00067440333,0.0000011458426,3.8571724e-7,5.5595183e-7,0.00005352947,0.8938108,0.00014278654],"about_ca_topic_score_codex":0.000038706985,"about_ca_topic_score_gemma":0.00001841375,"teacher_disagreement_score":0.90418434,"about_ca_system_score_codex":0.00017200639,"about_ca_system_score_gemma":0.00067795045,"threshold_uncertainty_score":0.99914324},"labels":[],"label_agreement":null},{"id":"W2008814726","doi":"10.1016/s1470-2045(03)01017-9","title":"Clinical-practice guidelines in Europe: time for European co-operation for cancer guidelines","year":2003,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Regional Laboratory Medicine Program","funders":"","keywords":"Cancer; Medicine; Clinical Practice; Scopus; Cancer survival; Family medicine; MEDLINE; Demography; Political science; Internal medicine; Sociology; Law","score_opus":0.5479520958621692,"score_gpt":0.6384755372412064,"score_spread":0.09052344137903723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008814726","genre_codex":"commentary","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02357344,0.0017988442,0.034940157,0.88889664,0.00303983,0.0066162343,0.00023927484,0.00022003574,0.04067552],"genre_scores_gemma":[0.008502586,0.0066659497,0.5600647,0.40037698,0.01483095,0.00087534013,0.000543622,0.00020745279,0.007932462],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9944925,0.0016036021,0.0027696316,0.00047209553,0.00022060965,0.00044156908],"domain_scores_gemma":[0.9869842,0.008431545,0.0007652284,0.0005528967,0.0031603172,0.00010580059],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.021938335,0.0002032591,0.0007732174,0.00006585238,0.00013527613,0.000030860785,0.0002408861,0.00013528253,0.0002985248],"category_scores_gemma":[0.14950491,0.00014302916,0.00013785454,0.0002095701,0.000107996966,0.00021153106,0.00004370977,0.0003564089,0.00023568429],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025855538,0.00026997252,0.0020523292,0.00005505368,0.00012368776,0.000018106393,0.00010406634,0.0003542794,0.0017121701,0.0014738837,0.7830211,0.2082298],"study_design_scores_gemma":[0.00923097,0.0010409988,0.0016926056,0.000041907937,0.0003478171,0.000069168746,0.0002211481,0.0044086115,0.0001238181,0.00027498414,0.9823887,0.00015932453],"about_ca_topic_score_codex":0.00013311228,"about_ca_topic_score_gemma":0.00029241148,"teacher_disagreement_score":0.5251245,"about_ca_system_score_codex":0.00013805204,"about_ca_system_score_gemma":0.0008403371,"threshold_uncertainty_score":0.85765916},"labels":[],"label_agreement":null},{"id":"W2008823106","doi":"10.1016/s1470-2045(08)70041-x","title":"Trials in palliative treatment—have the goal posts been moved?","year":2008,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Gemcitabine; Oncology; Internal medicine; Pancreatic cancer; Clinical trial; Cancer; Kidney cancer; Renal cell carcinoma; Temsirolimus; Clinical endpoint; Cabozantinib; Cosmesis; Quality of life (healthcare); Surgery; Discovery and development of mTOR inhibitors","score_opus":0.2596304731499695,"score_gpt":0.46816843483746245,"score_spread":0.20853796168749295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008823106","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.043886114,0.0015959458,0.000008846063,0.8850125,0.00039232284,0.002848531,0.00015166061,0.00004754936,0.066056505],"genre_scores_gemma":[0.012242327,0.01774097,0.00045574983,0.8999819,0.025151275,0.0015966654,0.00062225346,0.00010645104,0.04210237],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99137336,0.0055169174,0.0010184911,0.00052309036,0.00049022376,0.0010779168],"domain_scores_gemma":[0.9850908,0.013038003,0.00058563484,0.0010670297,0.00013158737,0.00008698174],"candidate_categories":["research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.004033792,0.00046797952,0.0044476255,0.00018864039,0.00021204555,0.000017937087,0.00065553124,0.0014953692,0.00061481155],"category_scores_gemma":[0.002046133,0.00020934419,0.00042702458,0.00021833701,0.00097495876,0.000026495341,0.00014516126,0.003276317,0.0003630799],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014884912,0.0002276701,0.05739259,0.000062346415,0.0011342585,0.0043017752,0.0029189826,0.0000010021495,0.00003443091,0.00006877037,0.9288425,0.0035271982],"study_design_scores_gemma":[0.008910126,0.0020970302,0.078410424,0.00010197603,0.000805738,0.00042629897,0.00025647998,0.00006210412,0.000018138251,0.0007141139,0.9080045,0.00019307231],"about_ca_topic_score_codex":0.0014918102,"about_ca_topic_score_gemma":0.00059956155,"teacher_disagreement_score":0.031643786,"about_ca_system_score_codex":0.0015200742,"about_ca_system_score_gemma":0.001766439,"threshold_uncertainty_score":0.9998009},"labels":[],"label_agreement":null},{"id":"W2009643025","doi":"10.1016/s1470-2045(08)70224-9","title":"Cancer inquiry unveils Canada's troubled health system","year":2008,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Commission; Breast cancer; Immunohistochemistry; Medicine; Cancer; Gynecology; Pathology; Political science; Internal medicine; Law","score_opus":0.6561342398067538,"score_gpt":0.6042411413789155,"score_spread":0.05189309842783829,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009643025","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.387937,0.0023876934,0.00007583318,0.5582132,0.0022630806,0.0009036897,0.000030880747,0.00014496254,0.048043676],"genre_scores_gemma":[0.96021503,0.0031929736,0.00030845133,0.029866908,0.0028085778,0.00010483634,0.000005332423,0.000021472686,0.0034764458],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972308,0.000545783,0.0004384768,0.000270287,0.00086347316,0.00065116386],"domain_scores_gemma":[0.99396133,0.004571631,0.00015655991,0.0006793449,0.00035988775,0.00027122287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004887074,0.00011013116,0.0007919563,0.000033287266,0.0002552656,0.0000040304585,0.00038902863,0.00023931326,0.00013380486],"category_scores_gemma":[0.0022295346,0.00006858186,0.000053758427,0.00020718819,0.00047368492,0.000014820795,0.00012257294,0.0018595768,0.000042391282],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025285012,0.00028459966,0.042160835,0.0019151246,0.00039913118,0.0015302075,0.004443054,0.00007722748,0.00028878156,0.0654446,0.87028235,0.010645593],"study_design_scores_gemma":[0.008272843,0.0017662973,0.103505686,0.00054884,0.000058117268,0.0009316576,0.0019370202,0.00032333905,0.0002171906,0.0011945098,0.88100886,0.00023561044],"about_ca_topic_score_codex":0.43445447,"about_ca_topic_score_gemma":0.82286435,"teacher_disagreement_score":0.57227796,"about_ca_system_score_codex":0.0030752358,"about_ca_system_score_gemma":0.021451447,"threshold_uncertainty_score":0.984096},"labels":[],"label_agreement":null},{"id":"W2012710514","doi":"10.1016/s1470-2045(09)70114-7","title":"The Brief Pain Inventory: revealing the effect of cancer pain","year":2009,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; McGill Pain Questionnaire; Cancer pain; Visual analogue scale; Physical therapy; Alternative medicine","score_opus":0.0261271755007328,"score_gpt":0.34406071249484954,"score_spread":0.31793353699411675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012710514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.70434445,0.007517202,0.00040329914,0.26538563,0.00055010227,0.0016823603,0.000003372426,0.00011087226,0.020002682],"genre_scores_gemma":[0.97114486,0.0011925299,0.000045471348,0.024104437,0.001331183,0.000074432726,0.000004260056,0.000011238703,0.002091575],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967906,0.0024002371,0.00020062293,0.00012585554,0.00016495147,0.0003177361],"domain_scores_gemma":[0.99683404,0.002449519,0.000145454,0.00051029184,0.000027485356,0.00003318985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013354423,0.00010877982,0.00036993605,0.000021433132,0.000192191,0.000010864173,0.00036490848,0.000064429645,0.00003216666],"category_scores_gemma":[0.0011206783,0.000043152602,0.00008699438,0.00016338483,0.00018610353,0.000013789576,0.000044434928,0.00028351095,0.0000063677],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016178361,0.000056577093,0.1697557,0.00016900279,0.00026997985,0.000030030333,0.0011883428,0.000064076194,0.0015380507,0.005510102,0.40825313,0.41154715],"study_design_scores_gemma":[0.0021227144,0.0018968662,0.09754263,0.000115617804,0.00020195119,0.0000013069765,0.00018063867,0.0024824461,0.0003876244,0.001258425,0.8937275,0.000082314065],"about_ca_topic_score_codex":0.0001367395,"about_ca_topic_score_gemma":0.00019898357,"teacher_disagreement_score":0.48547432,"about_ca_system_score_codex":0.00008582217,"about_ca_system_score_gemma":0.000051655898,"threshold_uncertainty_score":0.46284035},"labels":[],"label_agreement":null},{"id":"W2013614225","doi":"10.1016/s1470-2045(13)70308-5","title":"Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group","year":2013,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":143,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; London Health Sciences Centre; Ontario Institute for Cancer Research; Queen's University","funders":"American Academy of Clinical Neuropsychology; Breast Cancer Research Foundation","keywords":"Neurocognitive; Quality of life (healthcare); Clinical trial; Medicine; Clinical study design; Reliability (semiconductor); Independence (probability theory); Medical physics; Oncology; Intensive care medicine; Psychology; Physical therapy; Internal medicine; Cognition; Psychiatry; Nursing","score_opus":0.6563948950622244,"score_gpt":0.5635441045459594,"score_spread":0.09285079051626499,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013614225","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0066388864,0.94575846,0.00002013996,0.04129527,0.0005719103,0.0046743928,0.0003272095,0.000047488473,0.00066622597],"genre_scores_gemma":[0.0008392784,0.9847882,0.0010624456,0.0109811295,0.0012320982,0.00075629354,0.00020574726,0.000053907454,0.000080899474],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9641242,0.03004496,0.004046897,0.0009268485,0.0003369745,0.000520099],"domain_scores_gemma":[0.9130193,0.08280145,0.0026762146,0.0011549195,0.00008292399,0.0002652158],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.03490806,0.0005670585,0.00997205,0.00009560556,0.00009793171,0.000024520461,0.0004082699,0.0004604799,0.0001268658],"category_scores_gemma":[0.063367836,0.00024263575,0.0009960271,0.00021519062,0.0003648645,0.000035867768,0.0004160759,0.0015457792,0.00004358483],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065781333,0.000678273,0.0023077843,0.0012572273,0.0014941501,0.00081511174,0.00015132864,4.1221895e-7,9.197962e-7,0.0008064771,0.0062219203,0.9856086],"study_design_scores_gemma":[0.0041429377,0.0016026378,0.026185822,0.001649327,0.0026890358,0.0002852588,0.00015161849,0.0000024180363,9.7136926e-8,0.00024946284,0.9628146,0.00022674949],"about_ca_topic_score_codex":0.00035670484,"about_ca_topic_score_gemma":0.00043113242,"teacher_disagreement_score":0.98538184,"about_ca_system_score_codex":0.000042522857,"about_ca_system_score_gemma":0.00035893577,"threshold_uncertainty_score":0.99376523},"labels":[],"label_agreement":null},{"id":"W2013905542","doi":"10.1016/s1470-2045(12)70561-2","title":"The conundrum of clinical trials in adult germ-cell tumours","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Germ cell tumors; Clinical trial; Etoposide; Chemotherapy; Oncology; Testicular cancer; Cancer; Malignancy; Internal medicine; Bleomycin","score_opus":0.22170314846267947,"score_gpt":0.5119216264592878,"score_spread":0.2902184779966084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013905542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9804449,0.0029233498,0.000005778617,0.009081612,0.00053541653,0.00045362313,0.00001124954,0.000014304754,0.0065297345],"genre_scores_gemma":[0.9968529,0.000629347,0.00014596301,0.0012478904,0.00081138615,0.00003418047,0.0000057644133,0.0000079785505,0.00026463636],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972616,0.001596763,0.00065383816,0.000090484966,0.00010839408,0.00028895357],"domain_scores_gemma":[0.9943294,0.004772199,0.00040958612,0.00033869702,0.000048382895,0.00010172263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005676434,0.00007630369,0.00086182647,0.000015817073,0.000036356014,0.0000031598133,0.000119455675,0.00008493091,0.000040929448],"category_scores_gemma":[0.0045756344,0.00003325421,0.00018382695,0.00006421604,0.00018568875,0.000015978565,0.000039053608,0.00019285336,0.00005943308],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014094906,0.0009896262,0.9697413,0.00002970966,0.00007845396,0.000029823006,0.00015992638,9.689333e-7,0.000070028604,0.0024792764,0.0040808036,0.0209306],"study_design_scores_gemma":[0.008492422,0.00054630166,0.9638559,0.0000299439,0.00036447885,0.000031540196,0.00021331086,0.000038036873,0.00016032673,0.00039211914,0.025831651,0.00004393537],"about_ca_topic_score_codex":0.000068089525,"about_ca_topic_score_gemma":0.000048160455,"teacher_disagreement_score":0.021750847,"about_ca_system_score_codex":0.000035363686,"about_ca_system_score_gemma":0.00017863895,"threshold_uncertainty_score":0.5477792},"labels":[],"label_agreement":null},{"id":"W2014633297","doi":"10.1016/s1470-2045(14)70203-7","title":"VeriStrat validated in patients with non-small-cell lung cancer","year":2014,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Gefitinib; Medicine; Oncology; Internal medicine; Lung cancer; Clinical Oncology; Chemotherapy; Targeted therapy; Tyrosine-kinase inhibitor; Cancer; Epidermal growth factor receptor; Cancer research","score_opus":0.021411344125403336,"score_gpt":0.33752057463548435,"score_spread":0.316109230510081,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014633297","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21997982,0.00046137685,0.000053339605,0.7286645,0.000937523,0.0024770147,0.0001920305,0.00008161154,0.047152735],"genre_scores_gemma":[0.083046585,0.00020901936,0.00049570506,0.89880615,0.005213735,0.00081307534,0.002170817,0.00011809856,0.0091268085],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986525,0.0001313797,0.0002378694,0.00033267873,0.00018995164,0.00045557742],"domain_scores_gemma":[0.9990264,0.000102104175,0.0002096291,0.00051146856,0.00010602763,0.000044344775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000116387535,0.00026503115,0.0008001273,0.00007939981,0.0000592049,0.000014959076,0.00020637443,0.00043663481,0.00030451568],"category_scores_gemma":[0.000006852967,0.00014980257,0.000056164936,0.00015139427,0.00008842147,0.000021510963,0.00003351109,0.0010919234,0.000036273144],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038207162,0.0001701094,0.119373,0.00035619145,0.00033720644,0.0002533124,0.00042847154,0.000020562886,0.000005562265,0.000002775476,0.8778544,0.00081632845],"study_design_scores_gemma":[0.011612511,0.00086463627,0.07186407,0.00025865444,0.0011920275,0.00001069311,0.000015210839,0.000032950167,0.000018381012,0.000009889293,0.91391325,0.00020773111],"about_ca_topic_score_codex":0.00068009674,"about_ca_topic_score_gemma":0.000267116,"teacher_disagreement_score":0.17014161,"about_ca_system_score_codex":0.0007078972,"about_ca_system_score_gemma":0.00065869454,"threshold_uncertainty_score":0.61087716},"labels":[],"label_agreement":null},{"id":"W2016863751","doi":"10.1016/s1470-2045(14)71185-4","title":"Skeletal muscle anabolism in patients with advanced cancer","year":2014,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Wasting; Cachexia; Myostatin; Sarcopenia; Cancer; Skeletal muscle; Adipose tissue; Weight loss; Internal medicine; Population; Anabolism; Oncology; Obesity","score_opus":0.041392163077914546,"score_gpt":0.3623387152181815,"score_spread":0.32094655214026696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016863751","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08799265,0.0003114597,0.0000043054993,0.9042045,0.00067854626,0.0007486858,0.00003058422,0.000056822362,0.005972434],"genre_scores_gemma":[0.027362455,0.00038517095,0.00050784217,0.96331644,0.0073028165,0.00020452561,0.00023359015,0.00004736749,0.00063977286],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99843895,0.00021774105,0.00027223336,0.00028487103,0.00023402237,0.0005521565],"domain_scores_gemma":[0.99910104,0.000134755,0.00019811165,0.00041300795,0.00009704152,0.000056024302],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026497504,0.00019409168,0.0008819326,0.00011616777,0.00006017385,0.0000058010314,0.00018470656,0.00041936367,0.00025245248],"category_scores_gemma":[0.000025819914,0.000120091834,0.000044316806,0.00014342897,0.0001344836,0.000024022549,0.00003391455,0.0020543418,0.000049431004],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003451204,0.000097143085,0.019325301,0.00058848684,0.00003075878,0.00013895545,0.00027971496,0.0000032878745,0.0000031580225,0.000029127543,0.9477381,0.03142083],"study_design_scores_gemma":[0.006744514,0.0005430923,0.1799483,0.00028725367,0.000040529485,0.000007674603,0.0000069368725,0.000006820179,8.347427e-7,0.00006440101,0.8122338,0.000115827475],"about_ca_topic_score_codex":0.00010610412,"about_ca_topic_score_gemma":0.00014171496,"teacher_disagreement_score":0.160623,"about_ca_system_score_codex":0.00033859006,"about_ca_system_score_gemma":0.00022872092,"threshold_uncertainty_score":0.89252067},"labels":[],"label_agreement":null},{"id":"W2017402841","doi":"10.1016/s1470-2045(10)70021-8","title":"Male hypogonadism associated with advanced cancer: a systematic review","year":2010,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Hormonal and reproductive studies","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Concordia University; McGill University","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Cachexia; Wasting; Androgen deficiency; Testosterone (patch); Cancer; Sarcopenia; Internal medicine; Epidemiology; Androgen deprivation therapy; Androgen; Quality of life (healthcare); Oncology; Prostate cancer; Endocrinology; Hormone","score_opus":0.08823081872278844,"score_gpt":0.4098366423465363,"score_spread":0.32160582362374784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017402841","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000011841287,0.9811857,6.7448e-7,0.004107811,0.00034481086,0.004658537,0.000063833904,0.000069537266,0.009557305],"genre_scores_gemma":[0.000007657293,0.98871905,0.000056282577,0.0013074296,0.00090307294,0.0026479606,0.000063315376,0.00005396187,0.0062412927],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99751383,0.00063142274,0.00066501816,0.00046661103,0.00026726612,0.00045582405],"domain_scores_gemma":[0.9973158,0.0006054092,0.0008914564,0.0008654977,0.00023417994,0.000087662214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012516895,0.00043982518,0.008247463,0.000052012718,0.00013847629,0.000005531559,0.00035879982,0.00029520274,0.00008802569],"category_scores_gemma":[0.0011164452,0.00017593693,0.00036865036,0.0003775526,0.00032584893,0.000021031077,0.000103370454,0.0012944405,0.00011423283],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033441687,0.000090733556,0.000006725523,0.8207366,0.0015698049,0.00012778462,0.00006578804,3.577768e-8,5.938871e-7,0.000100198224,0.0030672695,0.17420103],"study_design_scores_gemma":[0.00033659345,0.00027460427,0.000015271393,0.39010483,0.009101004,0.00079703704,0.000014832967,9.447347e-8,7.470283e-8,0.000011387736,0.5991983,0.00014598225],"about_ca_topic_score_codex":0.000015921278,"about_ca_topic_score_gemma":0.00018212537,"teacher_disagreement_score":0.596131,"about_ca_system_score_codex":0.000375812,"about_ca_system_score_gemma":0.00075630314,"threshold_uncertainty_score":0.71744996},"labels":[],"label_agreement":null},{"id":"W2018508414","doi":"10.1016/s1470-2045(11)70265-0","title":"Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":195,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pyrogenesis (Canada); Royal Victoria Hospital; Princess Margaret Cancer Centre","funders":"National Center for Research Resources; National Institutes of Health; National Cancer Institute; Celgene","keywords":"Medicine; Internal medicine; Adverse effect; Neutropenia; Cohort; Population; Lymphoma; Refractory (planetary science); Surgery; Gastroenterology; Toxicity","score_opus":0.21118876763172023,"score_gpt":0.4264847079896755,"score_spread":0.2152959403579553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018508414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9803185,0.0001562868,0.00066273456,0.0017075881,0.00078602723,0.0016635172,0.000105146646,0.000039349336,0.014560852],"genre_scores_gemma":[0.9859898,0.00006916593,0.005821385,0.0014608259,0.003122705,0.00064232317,0.00034356688,0.00007770755,0.0024725355],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975226,0.0006783971,0.00035840762,0.00058176974,0.00017215092,0.0006866577],"domain_scores_gemma":[0.99843246,0.00014144399,0.00016780158,0.0009084799,0.00016090639,0.00018890502],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013438502,0.00022224926,0.0004899024,0.00004556687,0.0002528968,0.000048043126,0.0012974839,0.00038287518,0.00008895532],"category_scores_gemma":[0.00053017883,0.0001693499,0.00006900252,0.00011615814,0.00045359027,0.000012811223,0.00044431907,0.00019494354,0.000047777095],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17250189,0.010911684,0.0000065660156,0.000020140304,0.00011516758,0.000044927765,0.00049111975,8.8930926e-7,0.6600002,0.0013862186,0.116659366,0.037861817],"study_design_scores_gemma":[0.16334927,0.043798316,0.000012743674,0.000006574703,0.000044261764,0.000057899597,0.00009979774,0.0001045548,0.19937436,0.0004906259,0.5923886,0.00027298983],"about_ca_topic_score_codex":0.00004475535,"about_ca_topic_score_gemma":0.00016874909,"teacher_disagreement_score":0.47572923,"about_ca_system_score_codex":0.00012434761,"about_ca_system_score_gemma":0.00044236894,"threshold_uncertainty_score":0.6905889},"labels":[],"label_agreement":null},{"id":"W2018625819","doi":"10.1016/s1470-2045(02)00903-8","title":"Antisense therapy for cancer—the time of truth","year":2002,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"DNA and Nucleic Acid Chemistry","field":"Biochemistry, Genetics and Molecular Biology","cited_by":168,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver General Hospital","funders":"Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; National Foundation for Cancer Research","keywords":"Oligonucleotide; Antisense therapy; Computational biology; Gene; Genetic enhancement; Biology; Functional genomics; RNA; DNA; Chemistry; Cancer research; Genomics; Genome; Genetics; Locked nucleic acid","score_opus":0.06778498299737551,"score_gpt":0.37312699938485633,"score_spread":0.3053420163874808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018625819","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00074272096,0.99495435,0.00001081134,0.00045508464,0.0002840131,0.0005512362,0.00026842643,0.000009668465,0.0027236717],"genre_scores_gemma":[0.00010294447,0.9943799,0.00007769802,0.0004011988,0.002004743,0.00023720917,0.0001471527,0.000045141376,0.0026040613],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99882025,0.00017735992,0.00033206897,0.00029268145,0.00007423129,0.0003034285],"domain_scores_gemma":[0.998584,0.0002016006,0.00040538685,0.00072243024,0.0000546514,0.000031949585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035992704,0.0002548412,0.0011477709,0.000013530886,0.00007698887,0.0000073106526,0.00076275395,0.00044782134,0.00010952956],"category_scores_gemma":[0.0000674438,0.00013111284,0.00040077427,0.00007358461,0.00026489035,7.673984e-7,0.00010368702,0.00019817929,0.000016722042],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010089343,0.000061924235,0.0000012349238,0.0012345656,0.0004052442,0.000001939588,0.000031873366,6.44542e-7,0.003147713,0.00004314462,0.0673237,0.9276471],"study_design_scores_gemma":[0.0005489034,0.00024968773,9.065142e-7,0.00022767975,0.00023004197,0.00004726462,0.000006552816,0.0000038728476,0.0023582175,0.000034562665,0.99613494,0.00015736249],"about_ca_topic_score_codex":0.000004897235,"about_ca_topic_score_gemma":0.00000259961,"teacher_disagreement_score":0.92881125,"about_ca_system_score_codex":0.000027537686,"about_ca_system_score_gemma":0.00020105323,"threshold_uncertainty_score":0.53466266},"labels":[],"label_agreement":null},{"id":"W2018748803","doi":"10.1016/s1470-2045(12)70221-8","title":"Canadian cuts overshadow good news on cancer statistics","year":2012,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cancer; Colorectal cancer; Prostate cancer; Breast cancer; Lung cancer; Demography; Gerontology; Oncology; Internal medicine","score_opus":0.1593767799649948,"score_gpt":0.4008904376809729,"score_spread":0.24151365771597808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018748803","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00038074146,0.0011695467,0.00002543296,0.87618333,0.0020901388,0.00046615617,0.0011050472,0.000047869395,0.11853176],"genre_scores_gemma":[0.003098181,0.0007763122,0.00058001827,0.9531154,0.028564839,0.00010179831,0.00047659662,0.000056809455,0.013230032],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99751014,0.00021726021,0.00028552447,0.0003466388,0.0004284819,0.0012119445],"domain_scores_gemma":[0.9983442,0.00031144117,0.00022134345,0.0007238308,0.000121399906,0.00027782624],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00035030462,0.00033214188,0.00096470653,0.0001211238,0.000148284,0.000023910414,0.00043698263,0.00090678904,0.002047289],"category_scores_gemma":[0.000106395186,0.0002279882,0.000100117744,0.0001485944,0.00013583165,0.000038498583,0.000052907486,0.002820292,0.0006436929],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015688056,0.000010932969,0.005374594,0.00008224468,0.0001440897,0.0011452115,0.00017302169,0.0000054828547,0.0000038958533,0.0005592287,0.9818885,0.01045594],"study_design_scores_gemma":[0.0008896987,0.0004679437,0.0039588925,0.00018542669,0.00036390967,0.00018472609,0.000050244704,0.000010700622,0.000005257367,0.00027843876,0.99336785,0.00023693785],"about_ca_topic_score_codex":0.3614223,"about_ca_topic_score_gemma":0.45536974,"teacher_disagreement_score":0.10530173,"about_ca_system_score_codex":0.002683246,"about_ca_system_score_gemma":0.002556128,"threshold_uncertainty_score":0.99948025},"labels":[],"label_agreement":null},{"id":"W2022412505","doi":"10.1016/s1470-2045(11)70008-0","title":"Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: a multicentre, randomised controlled trial","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Spinal Fractures and Fixation Techniques","field":"Medicine","cited_by":521,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Randomized controlled trial; Clinical endpoint; Surgery; Vertebral compression fracture; Balloon; Percutaneous","score_opus":0.02882977539405042,"score_gpt":0.33857593388888635,"score_spread":0.30974615849483594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022412505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98471284,0.00020013923,0.00050212693,0.00075672555,0.00040991764,0.010779363,0.000022245398,0.000045199693,0.0025714587],"genre_scores_gemma":[0.9960249,0.00030786305,0.0012649267,0.00042751478,0.00029344382,0.0015230777,0.00006196005,0.000016755259,0.00007958167],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9987821,0.00014492408,0.0003856561,0.00021924451,0.00019142397,0.00027664143],"domain_scores_gemma":[0.99881876,0.00043351296,0.0003336083,0.0002604582,0.000088908375,0.000064781845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023542761,0.00020155139,0.0011210891,0.000077431294,0.00005151244,0.000004445979,0.00011610086,0.00017261357,0.0002504886],"category_scores_gemma":[0.000041331234,0.0000963761,0.00016119087,0.000070800685,0.000072137365,0.000032512755,0.000019659372,0.00011868353,0.0000011589892],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9781439,0.0020527598,0.0072848364,0.00004266449,0.0004565638,0.00002520043,0.0005971557,0.000022595737,0.000015571519,0.00005262216,0.0007806639,0.010525518],"study_design_scores_gemma":[0.8768821,0.013621309,0.08748571,0.00007233063,0.00048254733,9.2939035e-7,0.00007160349,0.00039813074,0.00060085836,0.00003140931,0.020251917,0.00010119089],"about_ca_topic_score_codex":0.00020751453,"about_ca_topic_score_gemma":0.00009380129,"teacher_disagreement_score":0.10126178,"about_ca_system_score_codex":0.00019634135,"about_ca_system_score_gemma":0.00006482021,"threshold_uncertainty_score":0.39301032},"labels":[],"label_agreement":null},{"id":"W2024903800","doi":"10.1016/s1470-2045(13)70383-8","title":"Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":226,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Trastuzumab; Medicine; Clinical endpoint; Breast cancer; Internal medicine; Population; Surgery; Oncology; Clinical trial; Cancer","score_opus":0.11089225089377973,"score_gpt":0.41324273047037563,"score_spread":0.3023504795765959,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024903800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98665726,0.00001862491,0.000030587013,0.0014520307,0.00007204372,0.01095211,0.00016727282,0.000018821831,0.00063125207],"genre_scores_gemma":[0.9960765,0.000024928944,0.00046606845,0.00024833894,0.00014669934,0.0027515744,0.000034638233,0.000033971453,0.00021728234],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9979556,0.00050604716,0.0004073259,0.00035882657,0.0003229823,0.00044921302],"domain_scores_gemma":[0.9983242,0.0004306408,0.00019823508,0.00044459937,0.00048184887,0.00012044411],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006726031,0.0001777201,0.0008233569,0.0000637702,0.00007258895,0.000039767758,0.0005096229,0.00011292661,0.00032563097],"category_scores_gemma":[0.00008046901,0.000101732665,0.000016394779,0.00022421729,0.00017956874,0.0001391882,0.00007495715,0.00032806123,0.0000072044563],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.64803696,0.01971039,0.16542637,0.00028251263,0.0005025218,0.00014465778,0.013310817,0.000020517418,0.0016874294,0.00006186318,0.0006780553,0.15013793],"study_design_scores_gemma":[0.10890289,0.086550355,0.8025949,0.00016079914,0.00012170668,0.00007566154,0.00086707727,0.0001375835,0.00028555395,0.000071695904,0.00007334756,0.00015843622],"about_ca_topic_score_codex":0.004386217,"about_ca_topic_score_gemma":0.00898566,"teacher_disagreement_score":0.6371685,"about_ca_system_score_codex":0.0004572294,"about_ca_system_score_gemma":0.0012625956,"threshold_uncertainty_score":0.66306776},"labels":[],"label_agreement":null},{"id":"W2026650308","doi":"10.1016/s1470-2045(03)00984-7","title":"A model for decision making for the use of radiotherapy in lung cancer","year":2003,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":112,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cancer Care Ontario","keywords":"Radiation therapy; Lung cancer; Medicine; Medical physics; Radiation treatment planning; Cancer; Intensive care medicine; Oncology; Internal medicine","score_opus":0.30230056246561,"score_gpt":0.5166585408664045,"score_spread":0.2143579784007945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026650308","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00001882103,0.9824395,0.010293915,0.0014509298,0.00037326495,0.0051872833,0.00019131151,0.000008445938,0.00003648751],"genre_scores_gemma":[0.000041663465,0.9788583,0.01217544,0.0015260392,0.00046092243,0.00666882,0.0000134570355,0.000049463608,0.00020590285],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987723,0.00011081265,0.00045631314,0.00025786657,0.00010258152,0.00030012964],"domain_scores_gemma":[0.99418455,0.004868544,0.00034968284,0.00050980016,0.000064403815,0.000022989594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005638474,0.0002229617,0.002029201,0.00006820419,0.00005525654,0.000009049519,0.00020343107,0.0002203844,0.000025151825],"category_scores_gemma":[0.0001171067,0.00009878306,0.00040530672,0.00013732101,0.00006249583,0.000019242058,0.00002161922,0.0001909035,3.3188203e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054513285,0.00013717172,0.00012502869,0.0065201824,0.00065741566,0.0000028610018,0.00020363065,0.00085868797,1.1801759e-7,0.0006313927,0.03051394,0.9598044],"study_design_scores_gemma":[0.002524186,0.00025043305,0.000019233697,0.010207668,0.0021245347,0.000017147147,0.0000037827485,0.02344262,1.9250356e-7,0.00012894708,0.96119004,0.00009120527],"about_ca_topic_score_codex":0.00004934332,"about_ca_topic_score_gemma":0.0005461677,"teacher_disagreement_score":0.9597132,"about_ca_system_score_codex":0.001343523,"about_ca_system_score_gemma":0.0008019679,"threshold_uncertainty_score":0.40282562},"labels":[],"label_agreement":null},{"id":"W2029032030","doi":"10.1016/s1470-2045(14)71198-2","title":"Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":162,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Juravinski Cancer Centre; Hôtel-Dieu de Québec; Centre hospitalier universitaire de Québec","funders":"Amgen","keywords":"Medicine; Panitumumab; Chemoradiotherapy; Internal medicine; Clinical endpoint; Head and neck squamous-cell carcinoma; Oncology; Cetuximab; Mucositis; Head and neck cancer; Radiation therapy; Surgery; Clinical trial; Cancer; Colorectal cancer","score_opus":0.07095194315395562,"score_gpt":0.3716621512149996,"score_spread":0.300710208061044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029032030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860786,0.00091129454,0.000019289593,0.0022918489,0.00015773544,0.007020294,0.00001600261,0.000018658293,0.0034862708],"genre_scores_gemma":[0.99637777,0.00008226804,0.0005293346,0.0017431309,0.00020219655,0.00061554543,0.00000519942,0.000035192395,0.00040936033],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980648,0.0004193102,0.0004541237,0.0003302067,0.00031436054,0.0004171758],"domain_scores_gemma":[0.9983244,0.00044001042,0.000337346,0.00050264964,0.00026372875,0.00013185442],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006867216,0.00026941608,0.0022255862,0.000048687965,0.00009396131,0.0000167295,0.00035313048,0.000101792975,0.00001642482],"category_scores_gemma":[0.0002320902,0.00010729858,0.000037277478,0.00030309273,0.0004670342,0.00008369817,0.000105342115,0.00033998291,0.0000010155546],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9447376,0.0023334217,0.045614,0.000059789618,0.00010563369,0.000028292248,0.0018944363,0.00000820186,0.00015970261,0.0000127800395,0.00074043835,0.0043056924],"study_design_scores_gemma":[0.94515187,0.045234494,0.0057618953,0.00013446428,0.00017045446,0.00002611303,0.000399203,0.00022452492,0.00024755808,0.000013126186,0.0024781285,0.00015814594],"about_ca_topic_score_codex":0.00038940762,"about_ca_topic_score_gemma":0.0026759726,"teacher_disagreement_score":0.042901073,"about_ca_system_score_codex":0.00021615211,"about_ca_system_score_gemma":0.0012051801,"threshold_uncertainty_score":0.4375509},"labels":[],"label_agreement":null},{"id":"W2029982246","doi":"10.1016/s1470-2045(13)70101-3","title":"Vertebral compression fracture after stereotactic body radiotherapy for spinal metastases","year":2013,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":191,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; Princess Margaret Cancer Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"University of Toronto; Canadian Association of Radiation Oncology","keywords":"Medicine; Vertebral compression fracture; Myelopathy; Radiosurgery; Adverse effect; Spinal cord compression; Vertebral body; Complication; Radiation therapy; Radiology; Spinal fracture; Surgery; Internal medicine; Spinal cord","score_opus":0.1175536820902281,"score_gpt":0.444949903591429,"score_spread":0.3273962215012009,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029982246","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003022947,0.98900056,0.0009133584,0.0036008412,0.00057328044,0.0050221705,0.00015403255,0.00007502016,0.00063048984],"genre_scores_gemma":[0.00005855877,0.98034805,0.004279243,0.008914621,0.0017547422,0.0024289824,0.0004051452,0.000100331345,0.0017103462],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972417,0.0007800694,0.0006259993,0.00047820574,0.00030740048,0.0005666775],"domain_scores_gemma":[0.9976101,0.0005420642,0.0005543124,0.001038599,0.00007460837,0.00018030088],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000719936,0.0005247925,0.0034866373,0.00015021871,0.000084382336,0.00004623498,0.0004626595,0.0002692758,0.0024814089],"category_scores_gemma":[0.00013792989,0.00027557986,0.00066288316,0.00012895837,0.00014749788,0.000076548284,0.00010800175,0.00063114846,0.00018663982],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015940211,0.000401298,0.000011893305,0.025633613,0.0019435751,0.0001707928,0.00004720402,2.5022422e-7,0.0000010774783,0.00016335228,0.17273438,0.79729855],"study_design_scores_gemma":[0.0034156146,0.00120637,0.00012933997,0.0033312915,0.0071748323,0.00013839499,0.000016791168,0.000052905692,4.214524e-7,0.00011095075,0.9841607,0.00026236326],"about_ca_topic_score_codex":0.000013274652,"about_ca_topic_score_gemma":0.0000022677038,"teacher_disagreement_score":0.81142634,"about_ca_system_score_codex":0.00023959382,"about_ca_system_score_gemma":0.00034068024,"threshold_uncertainty_score":0.99996966},"labels":[],"label_agreement":null},{"id":"W2031320118","doi":"10.1016/s1470-2045(14)71113-1","title":"RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer-related molecular mechanisms research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":270,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"National Institute of General Medical Sciences; National Cancer Institute; National Institutes of Health; Prostate Cancer Foundation; Doris Duke Charitable Foundation; Howard Hughes Medical Institute; U.S. Department of Defense","keywords":"Prostate cancer; Oncology; Prostatectomy; Medicine; Cohort; Internal medicine; Tumor progression; Multivariate analysis; Prostate-specific antigen; Cancer","score_opus":0.02743596481291197,"score_gpt":0.35465089479141604,"score_spread":0.32721492997850404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031320118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9814146,0.0008726171,0.015035338,0.001300313,0.000113473245,0.0006879263,0.00013127206,0.000019389172,0.0004250348],"genre_scores_gemma":[0.9959933,0.00038519106,0.0027441892,0.00024078593,0.000054403463,0.00020834274,0.00027378032,0.000018356817,0.000081620514],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981053,0.0005928742,0.00027767,0.00036514457,0.00026136253,0.00039768656],"domain_scores_gemma":[0.99908197,0.000072196635,0.00023601168,0.00039046176,0.00016295463,0.00005643302],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011120096,0.00016505613,0.00052593206,0.00018453048,0.00008142843,0.000011010035,0.0003056763,0.00012568141,0.0000244416],"category_scores_gemma":[0.00022947906,0.00010546937,0.000093382136,0.0008827486,0.0003380429,0.000005075867,0.00013141634,0.00021284554,0.0000018346487],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038185415,0.0008279513,0.005035709,0.00008824869,0.0077285725,0.000047565612,0.00046367137,0.045825973,0.90192413,0.001444591,0.00081574015,0.031979293],"study_design_scores_gemma":[0.03791988,0.0072798324,0.07904319,0.00059666525,0.004165956,0.00005320325,0.00046609636,0.10245807,0.73135674,0.00059641676,0.03463061,0.0014333666],"about_ca_topic_score_codex":0.0005575425,"about_ca_topic_score_gemma":0.00748793,"teacher_disagreement_score":0.17056742,"about_ca_system_score_codex":0.00016654527,"about_ca_system_score_gemma":0.00044775632,"threshold_uncertainty_score":0.4300916},"labels":[],"label_agreement":null},{"id":"W2031365500","doi":"10.1016/s1470-2045(15)70002-1","title":"Putting palliative care on the global health agenda","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Hospice Palliative Care Association","funders":"","keywords":"Palliative care; Nursing; Political science; Medicine","score_opus":0.7447579008297739,"score_gpt":0.5591897808951655,"score_spread":0.18556811993460842,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031365500","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06605029,0.0049343556,0.001011271,0.83175826,0.0017607798,0.0010010217,0.00045318235,0.00008889736,0.092941955],"genre_scores_gemma":[0.74986076,0.00019523749,0.0023582336,0.24471536,0.0023611628,0.00016216659,0.000032305194,0.000023324284,0.0002914328],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960619,0.0013257457,0.0016290183,0.00035687003,0.000090084504,0.00053636986],"domain_scores_gemma":[0.99599266,0.001498748,0.001665865,0.00063187693,0.00006777816,0.00014309985],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.020731956,0.00014973743,0.0009388705,0.000041821626,0.00033074451,0.0000466738,0.0005697862,0.00010915055,0.00012006426],"category_scores_gemma":[0.003325321,0.00011209263,0.00007705947,0.00017763437,0.00012227944,0.000079001664,0.00009364605,0.00028293076,0.0030317872],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033897333,0.000040495972,0.029041277,0.000059897044,0.000057985064,0.0000015131646,0.017032195,0.00032988994,4.6594895e-8,0.6379222,0.3131209,0.0023596806],"study_design_scores_gemma":[0.0010366053,0.00036886203,0.024479697,0.000031787797,0.0000034598622,0.000003996018,0.008988555,0.00068525376,6.8833964e-7,0.102840416,0.86141956,0.00014112149],"about_ca_topic_score_codex":0.0012980592,"about_ca_topic_score_gemma":0.0011251124,"teacher_disagreement_score":0.6838105,"about_ca_system_score_codex":0.0031577265,"about_ca_system_score_gemma":0.0006692978,"threshold_uncertainty_score":0.99774444},"labels":[],"label_agreement":null},{"id":"W2032391990","doi":"10.1016/s1470-2045(03)01197-5","title":"Autonomic dysreflexia associated with intramedullary astrocytoma of the spinal cord","year":2003,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Spinal Cord Injury Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; University Health Network; Toronto Western Hospital; University of Toronto","funders":"Heart and Stroke Foundation of Canada; Christopher and Dana Reeve Foundation","keywords":"Autonomic dysreflexia; Medicine; Spinal cord; Spinal cord injury; Autonomic nervous system; Anesthesia; Internal medicine; Heart rate; Blood pressure","score_opus":0.08996694803334179,"score_gpt":0.4137380897802274,"score_spread":0.3237711417468856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032391990","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97099966,0.00014990798,0.000033576332,0.006221454,0.0001788975,0.00044438356,0.0000057338716,0.00003725531,0.02192912],"genre_scores_gemma":[0.9971028,0.000019509564,0.00055164524,0.0014688692,0.00016454846,0.000029956718,0.0000027214548,0.000019006613,0.00064094947],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984166,0.00049229624,0.00022714729,0.00017509577,0.0002693758,0.00041945293],"domain_scores_gemma":[0.99891484,0.00015441915,0.0001780433,0.0005488798,0.00013620892,0.00006759281],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00098774,0.00012232013,0.000497096,0.000044722172,0.000092366325,0.000006599434,0.00035684876,0.000116405405,0.0001791545],"category_scores_gemma":[0.0005977956,0.000060249477,0.000066816974,0.00032600565,0.00052093825,0.000024011251,0.00007504131,0.00063893734,0.000034113425],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28663963,0.002631562,0.407086,0.00041733545,0.002692095,0.0006547652,0.0006290402,0.00006927109,0.09762171,0.064419575,0.03919342,0.09794557],"study_design_scores_gemma":[0.007653004,0.061640915,0.85187894,0.00030819525,0.0002940265,0.00093959726,0.00037077285,0.00012145241,0.016557027,0.0011854654,0.05884519,0.00020542416],"about_ca_topic_score_codex":0.000022905484,"about_ca_topic_score_gemma":0.00010210704,"teacher_disagreement_score":0.4447929,"about_ca_system_score_codex":0.00037467576,"about_ca_system_score_gemma":0.0008531722,"threshold_uncertainty_score":0.27759004},"labels":[],"label_agreement":null},{"id":"W2032741873","doi":"10.1016/s1470-2045(00)00139-x","title":"Canadian researchers uncover vital new clues in cancer","year":2000,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Granzyme B; Cytotoxic T cell; Granzyme; Perforin; Programmed cell death; Biology; Immune system; Cancer cell; Receptor; Apoptosis; Cancer; Cancer research; Immunology; Cell biology; T cell; CD8; Biochemistry","score_opus":0.0746943148202789,"score_gpt":0.4036168362799058,"score_spread":0.3289225214596269,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032741873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9557303,0.001986562,0.000001665981,0.020358805,0.00008324123,0.0002291516,0.00003053504,0.000008167172,0.02157157],"genre_scores_gemma":[0.97220397,0.0033485626,0.00006443161,0.005546717,0.0012751766,0.00006515859,0.000039897594,0.000029231946,0.017426876],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983899,0.00036366392,0.0001322396,0.0002692069,0.00014204172,0.00070294546],"domain_scores_gemma":[0.9992544,0.0000361324,0.000020400146,0.00043879778,0.000032842167,0.00021739611],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007341369,0.000113008624,0.00019329281,0.00006442471,0.000080444406,0.000019252397,0.0005393809,0.0001830443,0.0021124918],"category_scores_gemma":[0.000049987088,0.00008708095,0.000044177876,0.00019607981,0.00014100877,0.0000035446953,0.0000542734,0.00031014628,0.00016542777],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012258956,0.00014469936,0.020206543,0.000019153727,0.00021044194,0.00013260772,0.0010518492,0.0027475113,0.20054297,0.00013101888,0.3138901,0.44866416],"study_design_scores_gemma":[0.001832079,0.0017186201,0.004428943,0.000008070864,0.0000049329046,0.000012065029,0.00007270892,0.000044413766,0.021171125,0.00048000203,0.9700555,0.00017150586],"about_ca_topic_score_codex":0.13963349,"about_ca_topic_score_gemma":0.861991,"teacher_disagreement_score":0.72235745,"about_ca_system_score_codex":0.00033374157,"about_ca_system_score_gemma":0.0021460317,"threshold_uncertainty_score":0.99879974},"labels":[],"label_agreement":null},{"id":"W2033816200","doi":"10.1016/s1470-2045(14)71135-0","title":"Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":544,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Université Laval; Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Olaparib; Medicine; Carboplatin; Tolerability; Internal medicine; Regimen; Ovarian cancer; Chemotherapy; Oncology; Paclitaxel; Response Evaluation Criteria in Solid Tumors; Clinical endpoint; Phases of clinical research; Urology; Cancer; Randomized controlled trial; Cisplatin; Adverse effect","score_opus":0.05582660886094198,"score_gpt":0.39046445905146526,"score_spread":0.3346378501905233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033816200","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8005265,0.00028367963,0.028165802,0.13403223,0.0030143333,0.014160028,0.00024002204,0.00038743208,0.01918997],"genre_scores_gemma":[0.9655396,0.00032156947,0.0034488037,0.019811882,0.006624247,0.0034945467,0.00012605177,0.000076403994,0.0005569159],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99824333,0.00038656933,0.00038515314,0.00033599444,0.00020507103,0.00044388114],"domain_scores_gemma":[0.9977868,0.001113923,0.00033306007,0.00045458126,0.00019611978,0.00011550656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001281428,0.00023252338,0.0011043639,0.00005660988,0.00016071652,0.000016153906,0.00015857881,0.00015283229,0.0002255932],"category_scores_gemma":[0.00014443508,0.00014177457,0.00014020392,0.000159517,0.00025641607,0.000035939946,0.000010728521,0.00032570562,0.000011489171],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92692107,0.0005837316,0.000023670615,0.00004037392,0.000359983,0.000006240074,0.0010977912,0.000014615329,0.003906357,0.0021956407,0.019254502,0.045596037],"study_design_scores_gemma":[0.7619015,0.019123029,0.00007515105,0.000094537245,0.00018496731,0.00004039328,0.00006304402,0.0015497475,0.007345175,0.000861339,0.2085955,0.00016564416],"about_ca_topic_score_codex":0.00003397959,"about_ca_topic_score_gemma":0.0000995833,"teacher_disagreement_score":0.18934101,"about_ca_system_score_codex":0.00031226632,"about_ca_system_score_gemma":0.00040164823,"threshold_uncertainty_score":0.5781399},"labels":[],"label_agreement":null},{"id":"W20378407","doi":"10.1016/s1470-2045(10)70058-9","title":"Synthèse des portraits socioéconomiques des territoires de CLE de l’île de Montréal : CLE de Rosemont–Petite-Patrie.","year":2009,"lang":"fr","type":"article","venue":"The Lancet Oncology","topic":"French Urban and Social Studies","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Art; Humanities; Political science","score_opus":0.06041559281854616,"score_gpt":0.3113909747832302,"score_spread":0.25097538196468405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W20378407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80429995,0.091008164,0.00064795563,0.049615223,0.0005320534,0.00030170343,0.000051299965,0.00020813679,0.053335495],"genre_scores_gemma":[0.9287737,0.044428304,0.007752577,0.005783991,0.0049736463,0.000055342072,0.0000035849955,0.000031272568,0.008197579],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955191,0.0016886971,0.00038974025,0.00034219486,0.00016944962,0.0018908397],"domain_scores_gemma":[0.9981478,0.00094248756,0.00022866458,0.00024350072,0.00010053548,0.00033703385],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":["sts"],"category_scores_codex":[0.0028021333,0.00030757117,0.0007592391,0.00004243695,0.0020729124,0.00012239825,0.0007178818,0.0005570629,0.0001725671],"category_scores_gemma":[0.0006487472,0.0002794749,0.00025130215,0.00025851486,0.0034729387,0.0002503667,0.00009166724,0.0005731727,0.000045796693],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026917152,0.0007478065,0.06821447,0.00009360756,0.00031463482,0.0002923142,0.24920093,0.00023839605,0.0008985101,0.16491993,0.15084983,0.3639604],"study_design_scores_gemma":[0.00072861795,0.0005662567,0.1843414,0.000089462126,0.00016873953,0.000043924712,0.009020198,0.00029053562,0.00026469294,0.3337585,0.47037908,0.00034857506],"about_ca_topic_score_codex":0.11676886,"about_ca_topic_score_gemma":0.25525448,"teacher_disagreement_score":0.36361182,"about_ca_system_score_codex":0.0049411403,"about_ca_system_score_gemma":0.0011933291,"threshold_uncertainty_score":0.9999657},"labels":[],"label_agreement":null},{"id":"W2038407564","doi":"10.1016/s1470-2045(14)70246-3","title":"Made-to-measure medicine: BRCA and gynaecological cancer","year":2014,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Scopus; Genetic testing; Test (biology); Medicine; Breast cancer; Family medicine; Cancer; Bioinformatics; Library science; MEDLINE; Political science; Biology; Computer science; Internal medicine; Law","score_opus":0.05327035473538556,"score_gpt":0.34340143654642424,"score_spread":0.2901310818110387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2038407564","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004597471,0.003392569,0.00034276984,0.9766205,0.0017494897,0.0005023724,0.000065917535,0.00003213006,0.012696765],"genre_scores_gemma":[0.015573605,0.0012530481,0.00051305606,0.9475006,0.030030202,0.0005144903,0.00022346241,0.0000639596,0.0043276036],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977037,0.00053311617,0.00029758178,0.0006775575,0.00022123936,0.00056686223],"domain_scores_gemma":[0.9985907,0.00020006228,0.00019522427,0.0007927499,0.00014215181,0.000079096775],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00071927335,0.0003377135,0.0006959318,0.000059766786,0.00014525643,0.000018552011,0.0007536549,0.0013769951,0.00046654372],"category_scores_gemma":[0.00030655536,0.00022071852,0.000071839066,0.000115119336,0.00056889944,0.0000013512675,0.00030026928,0.0011540623,0.000056591154],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007051078,0.000007681864,0.00025307728,0.000047215606,0.00013148224,0.00002893452,0.0000957261,0.000029899857,0.003469929,0.000033577697,0.9851746,0.010657385],"study_design_scores_gemma":[0.0008496251,0.0006492634,0.0019192209,0.000024212075,0.000114845614,0.000116551106,0.000021559423,0.000008147467,0.00032056746,0.00029105923,0.99539864,0.0002863021],"about_ca_topic_score_codex":0.00006939936,"about_ca_topic_score_gemma":0.00020053018,"teacher_disagreement_score":0.029119944,"about_ca_system_score_codex":0.00022199027,"about_ca_system_score_gemma":0.0003989145,"threshold_uncertainty_score":0.9999194},"labels":[],"label_agreement":null},{"id":"W2040267226","doi":"10.1016/s1470-2045(01)00438-7","title":"Stop teaching breast self-examination, say Canadian experts","year":2001,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Breast self-examination; Task force; Harm; Medicine; Suspect; Family medicine; Task (project management); Advice (programming); Modality (human–computer interaction); Medical advice; Psychology; Medical education; Nursing; Breast cancer; Management; Social psychology; Political science; Criminology","score_opus":0.08041438990951585,"score_gpt":0.371436560841335,"score_spread":0.29102217093181915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040267226","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.61793333,0.0003344054,0.00010947785,0.073617846,0.00032344638,0.00024992038,0.000007271917,0.0001223855,0.30730194],"genre_scores_gemma":[0.9746468,0.00009441873,0.0008061923,0.021577913,0.0013912215,0.000022092196,0.000012881268,0.0000111614845,0.0014372888],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988875,0.00020146213,0.0001481116,0.00016714568,0.00016002629,0.0004357925],"domain_scores_gemma":[0.9992918,0.00009228034,0.000052798223,0.00029914782,0.00007596468,0.00018802639],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00097300875,0.00009859726,0.00027925734,0.0000670357,0.00023322161,0.000015176401,0.0001932909,0.000102448386,0.00031167737],"category_scores_gemma":[0.00009670322,0.000068018424,0.000038074228,0.00012429676,0.000053314187,0.00006954134,0.000027993698,0.0002874064,0.00007967371],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045658532,0.00018491852,0.20004691,0.000036374964,0.0001879211,0.0015745618,0.013485421,0.000044630793,0.0008934066,0.013573961,0.31440347,0.45511183],"study_design_scores_gemma":[0.0010457089,0.00023762969,0.21964212,0.00003783939,0.00005070537,0.0024182394,0.0014718584,0.00022587317,0.00001633135,0.00029208997,0.7744574,0.00010424155],"about_ca_topic_score_codex":0.044048008,"about_ca_topic_score_gemma":0.077754304,"teacher_disagreement_score":0.4600539,"about_ca_system_score_codex":0.0006741957,"about_ca_system_score_gemma":0.00043279678,"threshold_uncertainty_score":0.96231776},"labels":[],"label_agreement":null},{"id":"W2040879959","doi":"10.1016/s1470-2045(05)70304-1","title":"Neuroblastoma screening in Canada","year":2005,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Neuroblastoma; Medicine; Environmental health; Biology; Genetics","score_opus":0.051705001077346234,"score_gpt":0.3386298162075189,"score_spread":0.2869248151301727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040879959","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9464127,0.000063784086,0.000008905503,0.038489223,0.000055855642,0.00019934066,0.0000037881669,0.000019996101,0.014746406],"genre_scores_gemma":[0.9924869,0.000042386644,0.0005066389,0.00608315,0.00032454132,0.00002188673,0.0000028327838,0.0000101029245,0.0005215714],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9990765,0.00011813648,0.00012194632,0.00013235972,0.00016060221,0.0003904729],"domain_scores_gemma":[0.9994566,0.00017541328,0.000028547802,0.00022537158,0.000018055105,0.000096052754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014290091,0.00007380352,0.00024905402,0.000040959596,0.000038198807,0.000003716106,0.00012035153,0.000024108387,0.00013847348],"category_scores_gemma":[0.000060329457,0.00004710017,0.000021083002,0.00013576927,0.00003988647,0.000025436648,0.000052560976,0.00029375943,0.00006391369],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005345413,0.00064977614,0.2921765,0.00006788341,0.00020604738,0.008467601,0.00039835673,0.0008480683,0.0071670352,0.00066829013,0.09872079,0.58528423],"study_design_scores_gemma":[0.0058116224,0.0006388266,0.68312514,0.000026529227,0.000018090936,0.0005906399,0.000070117174,0.0013722115,0.0019590661,0.000034347904,0.3062772,0.00007622399],"about_ca_topic_score_codex":0.26724103,"about_ca_topic_score_gemma":0.9290202,"teacher_disagreement_score":0.6617792,"about_ca_system_score_codex":0.00035006722,"about_ca_system_score_gemma":0.0008688379,"threshold_uncertainty_score":0.7376385},"labels":[],"label_agreement":null},{"id":"W2041265397","doi":"10.1016/s1470-2045(11)70153-x","title":"Effect of dignity therapy on distress and end-of-life experience in terminally ill patients: a randomised controlled trial","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Patient Dignity and Privacy","field":"Medicine","cited_by":769,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Winnipeg Regional Health Authority; University of Manitoba; CancerCare Manitoba","funders":"National Cancer Institute; Canadian Institutes of Health Research; Canada Research Chairs; Memorial Sloan-Kettering Cancer Center","keywords":"Dignity; Palliative care; Medicine; Quality of life (healthcare); Distress; End-of-life care; Hospital Anxiety and Depression Scale; Randomized controlled trial; Anxiety; Psychiatry; Nursing; Clinical psychology","score_opus":0.09930062075559846,"score_gpt":0.37275175737684946,"score_spread":0.273451136621251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041265397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923214,0.00009336295,0.0000036372187,0.00015487945,0.00015800147,0.002660153,0.000017064855,0.000008475695,0.0045830626],"genre_scores_gemma":[0.9989676,0.00013347111,0.00002283936,0.0005234324,0.00007381444,0.0002522521,0.0000064960927,0.0000053877125,0.0000147070705],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99829435,0.00093226583,0.00035563795,0.00012859679,0.0001279287,0.00016119384],"domain_scores_gemma":[0.9974749,0.001914397,0.0002521084,0.00024388013,0.000064309446,0.000050425777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008561335,0.00011124475,0.001045136,0.000049384198,0.000023583676,0.0000012350404,0.00014447328,0.00008266729,0.00007890583],"category_scores_gemma":[0.0019323032,0.0000586153,0.00008100146,0.00006651328,0.00023703487,0.000030149275,0.000031327476,0.00015405971,0.000001290702],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94198936,0.00083020265,0.030185299,0.000048685113,0.00005373,0.0000065854097,0.006384192,1.4705552e-7,0.0004693191,0.000037537236,0.0000336123,0.019961309],"study_design_scores_gemma":[0.9370376,0.019015387,0.038405463,0.00006535544,0.00004992387,0.0000013062177,0.000062762694,0.000012962367,0.0048766225,0.000097054224,0.00031362413,0.00006192957],"about_ca_topic_score_codex":0.000098955665,"about_ca_topic_score_gemma":0.000016030843,"teacher_disagreement_score":0.01989938,"about_ca_system_score_codex":0.000026970642,"about_ca_system_score_gemma":0.000059204463,"threshold_uncertainty_score":0.23902626},"labels":[],"label_agreement":null},{"id":"W2042528112","doi":"10.1016/s1470-2045(09)70031-2","title":"Exercise intolerance in cancer and the role of exercise therapy to reverse dysfunction","year":2009,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":305,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary","funders":"","keywords":"Medicine; Exercise intolerance; Cancer; Cancer treatment; Exercise therapy; Cancer therapy; Intensive care medicine; Internal medicine; Randomized controlled trial","score_opus":0.03157482436770046,"score_gpt":0.33837824389223403,"score_spread":0.30680341952453355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042528112","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00078313256,0.99577206,0.000005698164,0.0006269299,0.0007829567,0.0013149804,0.000037826627,0.000006995516,0.00066938915],"genre_scores_gemma":[0.00018650228,0.99604374,0.000078568715,0.00076369016,0.0017463865,0.0006251352,0.000026851294,0.00002746163,0.00050167704],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99846905,0.00030562739,0.0004181251,0.0003900867,0.00010575324,0.0003113614],"domain_scores_gemma":[0.99888957,0.00005523215,0.00030048296,0.0006416693,0.000059625123,0.000053401018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079150405,0.00028745848,0.0016868821,0.00006756586,0.000055908127,0.00001117836,0.0004634986,0.0003605433,0.000017141872],"category_scores_gemma":[0.000038961785,0.00016002465,0.0002023006,0.00022358439,0.00022176007,0.000003322642,0.00011877191,0.0003107202,0.0000051861516],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009941212,0.00004174496,0.0000035028474,0.0003611314,0.00004461897,5.0405566e-7,0.0002285497,0.000009052347,0.00024975874,0.000093283714,0.0053821513,0.99259156],"study_design_scores_gemma":[0.001934679,0.00013139618,0.00004087987,0.001468901,0.0002186001,0.000012285757,0.000045856847,0.000002092349,0.00016279276,0.00020224741,0.99559945,0.00018080951],"about_ca_topic_score_codex":0.00047333766,"about_ca_topic_score_gemma":0.0004855912,"teacher_disagreement_score":0.9924108,"about_ca_system_score_codex":0.00004606568,"about_ca_system_score_gemma":0.00030446294,"threshold_uncertainty_score":0.65256155},"labels":[],"label_agreement":null},{"id":"W2042844054","doi":"10.1016/s1470-2045(15)70157-9","title":"Targeting the microenvironment in ovarian cancer","year":2015,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ovarian cancer; Cancer; Tumor microenvironment; Cancer research; Oncology; Medicine; Biology; Computational biology; Internal medicine","score_opus":0.059247390125151386,"score_gpt":0.3343081014540412,"score_spread":0.2750607113288898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042844054","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009785983,0.00731255,0.000004085391,0.9816325,0.0010112867,0.0009547261,0.00007938879,0.00002111996,0.008005772],"genre_scores_gemma":[0.0062438287,0.005156254,0.00023690403,0.9661969,0.017517876,0.001030819,0.00017273723,0.000062324456,0.0033823627],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979578,0.00041338394,0.00034045143,0.00039204446,0.0002884346,0.00060787506],"domain_scores_gemma":[0.9986609,0.0003054091,0.00022382285,0.0007304388,0.000030928164,0.000048487105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008390102,0.00028573195,0.0008954164,0.000051568994,0.00008127832,0.000017895076,0.0003650864,0.00047975074,0.0008179081],"category_scores_gemma":[0.000038445072,0.00013967342,0.00010363153,0.0001122125,0.00020009466,0.00001639371,0.00013637965,0.0019603346,0.00016580638],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000121232195,0.00009414416,0.004116165,0.000063034066,0.00024212089,0.00095736305,0.00054623384,0.00003273094,0.00004561765,0.000027046084,0.9895703,0.004183997],"study_design_scores_gemma":[0.0030322385,0.00023770842,0.006354143,0.0001281777,0.00033693522,0.00007973205,0.00006543313,0.00001491779,0.000034722543,0.00018617869,0.9893902,0.00013959248],"about_ca_topic_score_codex":0.0010892515,"about_ca_topic_score_gemma":0.00025008037,"teacher_disagreement_score":0.016506588,"about_ca_system_score_codex":0.0017693246,"about_ca_system_score_gemma":0.0005255249,"threshold_uncertainty_score":0.895552},"labels":[],"label_agreement":null},{"id":"W2043541016","doi":"10.1016/s1470-2045(11)70222-4","title":"The tubal hypothesis of ovarian cancer: caution needed","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Ovarian cancer; Medicine; Breast cancer; Oncology; Gynecology; Germline mutation; Internal medicine; Hazard ratio; Ovarian carcinoma; Cancer; BRCA mutation; Family history; Mutation; Obstetrics; Genetics; Biology; Gene; Confidence interval","score_opus":0.06706038960577423,"score_gpt":0.3148672844619313,"score_spread":0.24780689485615706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043541016","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95190406,0.002208647,0.00062854105,0.009214443,0.0010734972,0.00031848677,0.000047977155,0.000020103425,0.034584265],"genre_scores_gemma":[0.9953005,0.0011352275,0.0013754099,0.0008953343,0.00063856493,0.00007011398,0.0000059465533,0.000012900921,0.00056602474],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992321,0.00017912086,0.00016579931,0.00014531412,0.000067610614,0.00021006897],"domain_scores_gemma":[0.99925774,0.00006514268,0.00012947254,0.00044921105,0.00007610283,0.000022326378],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043673028,0.00008091969,0.0001478085,0.000013103091,0.00013841172,0.00000511444,0.00039603567,0.000116324656,0.00006919587],"category_scores_gemma":[0.000087981556,0.000048810998,0.000052956468,0.000084865445,0.00028908253,0.000001645665,0.00008646279,0.000088610264,0.000009189512],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027086982,0.00023254455,0.0060786554,0.000043390803,0.00084731093,0.0000060049747,0.0041524805,0.00025193492,0.5193069,0.011691612,0.1485687,0.30611178],"study_design_scores_gemma":[0.0012261637,0.0004653652,0.025106432,0.0000075411062,0.00008949278,0.00003166519,0.00091191806,0.00006476261,0.39821962,0.0034080488,0.57030165,0.00016734355],"about_ca_topic_score_codex":0.00038005176,"about_ca_topic_score_gemma":0.00076745305,"teacher_disagreement_score":0.42173293,"about_ca_system_score_codex":0.000069513975,"about_ca_system_score_gemma":0.00027901033,"threshold_uncertainty_score":0.19904546},"labels":[],"label_agreement":null},{"id":"W2044083199","doi":"10.1016/s1470-2045(12)70013-x","title":"Don't pick the loser: lessons from the GeparQuinto trial","year":2012,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Taxane; Trastuzumab; Medicine; Lapatinib; Anthracycline; Oncology; Internal medicine; Epirubicin; Breast cancer; Docetaxel; Regimen; Chemotherapy; Cancer","score_opus":0.253008395605485,"score_gpt":0.4743445344544751,"score_spread":0.22133613884899012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2044083199","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0045629116,0.003960639,0.000014306686,0.9515893,0.0046727345,0.0025556823,0.000250821,0.00010025749,0.032293346],"genre_scores_gemma":[0.00533635,0.001621507,0.00009878996,0.8205509,0.15748172,0.00084475835,0.00029140848,0.00012164878,0.013652927],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.993484,0.0028457276,0.00055920606,0.0005713605,0.0010527525,0.0014869455],"domain_scores_gemma":[0.9897723,0.006509757,0.000351248,0.003093469,0.00015101247,0.00012220173],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.0037632403,0.0004553913,0.0014704196,0.000055905333,0.00039784328,0.00007721762,0.002565215,0.001364105,0.004237229],"category_scores_gemma":[0.0007282671,0.00018579653,0.0003617266,0.00026351798,0.0012205084,0.00003946741,0.000630907,0.008403945,0.0017509811],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0066204723,0.00007669606,0.00029167635,0.000058890342,0.00043306692,0.00023696206,0.0011759327,4.826823e-7,0.0000430977,0.0002483823,0.9823861,0.008428233],"study_design_scores_gemma":[0.015018788,0.00074125594,0.0010245255,0.0000994577,0.0005477885,0.00012273349,0.00015593969,0.0000066149323,0.0000267582,0.0014583906,0.98058677,0.0002109542],"about_ca_topic_score_codex":0.0032015971,"about_ca_topic_score_gemma":0.0014417649,"teacher_disagreement_score":0.15280898,"about_ca_system_score_codex":0.00080290955,"about_ca_system_score_gemma":0.0014223959,"threshold_uncertainty_score":0.99993235},"labels":[],"label_agreement":null},{"id":"W2044168781","doi":"10.1016/s1470-2045(13)70019-6","title":"IGF-1R inhibition: right direction, wrong pathway?","year":2013,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Growth Hormone and Insulin-like Growth Factors","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Breast cancer; Medicine; Cancer research; Fulvestrant; Tamoxifen; Cancer; Internal medicine; Oncology","score_opus":0.03881329493364188,"score_gpt":0.28422666119629947,"score_spread":0.24541336626265758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2044168781","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018793646,0.0009858594,0.000023882589,0.8368934,0.002532317,0.00091447064,0.00005595223,0.0003243216,0.13947615],"genre_scores_gemma":[0.017403591,0.0007130265,0.00021536101,0.9105471,0.04195729,0.0003498669,0.00089626684,0.00012431075,0.027793227],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99704784,0.000429175,0.0006267594,0.0005777187,0.00043668385,0.00088181987],"domain_scores_gemma":[0.997809,0.00039907006,0.0003851299,0.0010277984,0.00025178518,0.00012725142],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.00046864265,0.00049744657,0.0014579186,0.00019799129,0.00025460092,0.000042848256,0.00033332757,0.0016751479,0.0022226265],"category_scores_gemma":[0.00013062524,0.0003109437,0.0002893666,0.0002956048,0.00036909172,0.000120481476,0.00013705283,0.0038327822,0.0025091968],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009380664,0.000069578564,0.00030223402,0.0001690925,0.00018480387,0.0008290061,0.00021263822,1.9644101e-7,0.00043866129,0.00019495247,0.99514735,0.0023577102],"study_design_scores_gemma":[0.0018792374,0.00074975623,0.002851806,0.00011555382,0.00025446215,0.0007500727,0.000029312552,0.000009446536,0.0008224782,0.0010847114,0.9911085,0.00034469986],"about_ca_topic_score_codex":0.00018970924,"about_ca_topic_score_gemma":0.000026498441,"teacher_disagreement_score":0.11168293,"about_ca_system_score_codex":0.0004712033,"about_ca_system_score_gemma":0.00045343247,"threshold_uncertainty_score":0.99993426},"labels":[],"label_agreement":null},{"id":"W2044764573","doi":"10.1016/s1470-2045(02)00845-8","title":"Thyroid cancer in a child born after the Chernobyl disaster","year":2002,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Radiation Dose and Imaging","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Alberta; University of Alberta Hospital","funders":"","keywords":"Thyroid cancer; Chernobyl Nuclear Accident; Thyroid; Scopus; Medicine; Thyroid carcinoma; Incidence (geometry); Radioactive iodine; Pediatrics; Nuclear medicine; Internal medicine; Environmental health; MEDLINE; Physics; Chemistry","score_opus":0.03298809204586942,"score_gpt":0.32030675737812425,"score_spread":0.2873186653322548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2044764573","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010204757,0.005196556,0.0000034581992,0.93208194,0.000630682,0.0005298588,0.000041083036,0.00003785807,0.051273838],"genre_scores_gemma":[0.057049606,0.0017437135,0.000014267232,0.9093183,0.02035354,0.00043695196,0.00003533379,0.00005460588,0.010993666],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99828476,0.00030961417,0.0003060396,0.00030894447,0.00023539516,0.0005552377],"domain_scores_gemma":[0.99881834,0.0002235432,0.00016314477,0.00073567126,0.000027184853,0.00003212472],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00035770333,0.00025170576,0.0007155924,0.00008586504,0.000069266556,0.000028961898,0.00039301705,0.00043238892,0.0021054395],"category_scores_gemma":[0.00004839386,0.00012627715,0.00012603647,0.00018392951,0.0002080523,0.000048530546,0.000082406594,0.0028883177,0.00034458647],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017263988,0.000031038417,0.006833911,0.00005821997,0.00010074789,0.00042646035,0.0017732386,0.000004463812,0.000009641212,0.0000050337358,0.98161054,0.008974048],"study_design_scores_gemma":[0.0014554872,0.00008828469,0.03734578,0.00015103491,0.000137159,0.0002898045,0.000049504433,0.00012248494,0.000006071171,0.000056112403,0.9601528,0.00014547417],"about_ca_topic_score_codex":0.00017732944,"about_ca_topic_score_gemma":0.00024102033,"teacher_disagreement_score":0.046844848,"about_ca_system_score_codex":0.00030317382,"about_ca_system_score_gemma":0.000110099456,"threshold_uncertainty_score":0.99941206},"labels":[],"label_agreement":null},{"id":"W2044834268","doi":"10.1016/s1470-2045(11)70084-5","title":"Genetic variants associated with breast-cancer risk","year":2011,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital","funders":"","keywords":"CHEK2; Breast cancer; Genome-wide association study; Penetrance; Odds ratio; Cancer; Medicine; Oncology; Scopus; Genetics; Biology; Mutation; Internal medicine; Single-nucleotide polymorphism; MEDLINE; Germline mutation; Gene; Genotype; Phenotype","score_opus":0.02555895387443447,"score_gpt":0.2861538338174263,"score_spread":0.26059487994299185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2044834268","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10778799,0.0059677972,0.0013961176,0.8470032,0.004348316,0.001888875,0.00497304,0.00018570328,0.026448967],"genre_scores_gemma":[0.068832755,0.005379922,0.0020430589,0.8805362,0.031991445,0.0010934024,0.0010471526,0.00032287615,0.008753187],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99743134,0.0007407627,0.00028839448,0.0006519596,0.00021397675,0.00067354145],"domain_scores_gemma":[0.9979817,0.000096604665,0.00055946107,0.0010892662,0.00022789004,0.000045043802],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00040873044,0.00038663586,0.00058250816,0.000051893378,0.00017002092,0.00002518738,0.00093551143,0.0013117209,0.00049157016],"category_scores_gemma":[0.00007923218,0.00025894062,0.00011534586,0.0001557828,0.0004025687,0.0000025364236,0.00020073047,0.0013902056,0.00006905779],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020893729,0.0000421379,0.003558309,0.000019903453,0.0009473436,0.000078254285,0.0001253658,0.000082704064,0.0004454959,0.000004566416,0.9902011,0.004285843],"study_design_scores_gemma":[0.001358882,0.00042228278,0.057500362,0.000042542313,0.00048599474,0.00023394907,0.00001027132,0.000017313188,0.00023898768,0.0004357754,0.93880975,0.000443871],"about_ca_topic_score_codex":0.00021340839,"about_ca_topic_score_gemma":0.00060254516,"teacher_disagreement_score":0.053942055,"about_ca_system_score_codex":0.0002847288,"about_ca_system_score_gemma":0.0009747918,"threshold_uncertainty_score":0.9999863},"labels":[],"label_agreement":null},{"id":"W2045950562","doi":"10.1016/s1470-2045(09)70087-7","title":"Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study","year":2009,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Institute for Health and Care Research; GlaxoSmithKline","keywords":"Medicine; Lapatinib; Internal medicine; Breast cancer; Response Evaluation Criteria in Solid Tumors; Oncology; Inflammatory breast cancer; Trastuzumab; Anthracycline; Cohort; Progressive disease; Metastatic breast cancer; Cancer; Refractory (planetary science); Taxane; Gastroenterology; Chemotherapy","score_opus":0.0591464160017507,"score_gpt":0.4011642093019165,"score_spread":0.3420177933001658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045950562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99317026,0.00012342699,7.803016e-7,0.003733417,0.0001135068,0.0020040441,0.00007584815,0.000022822143,0.00075590936],"genre_scores_gemma":[0.99862367,0.00022000115,0.000055885223,0.000551856,0.00018806821,0.00013752433,0.000007468698,0.00002569771,0.0001898218],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99701905,0.00095985853,0.0005948839,0.00039381627,0.0005643815,0.00046802495],"domain_scores_gemma":[0.998422,0.00036070493,0.000305572,0.0006916629,0.00013754547,0.00008249694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017935339,0.00021321846,0.00083483756,0.00011859633,0.00010826487,0.000011807612,0.00033154048,0.00014704965,0.000062691615],"category_scores_gemma":[0.00018047396,0.00011351811,0.00003301568,0.00041946402,0.00028820962,0.0000822313,0.000097782264,0.0008037238,7.806316e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06819284,0.0030503024,0.8744791,0.000045514586,0.00006917744,0.00006635314,0.005372385,0.000029042643,0.00064689777,0.0000068234153,0.000575564,0.047465965],"study_design_scores_gemma":[0.058242355,0.009106859,0.92976576,0.0004260856,0.000031581138,0.00001229342,0.0005324653,0.00005765484,0.00011336888,0.000026823784,0.0015585796,0.00012615869],"about_ca_topic_score_codex":0.0011506161,"about_ca_topic_score_gemma":0.005954369,"teacher_disagreement_score":0.055286646,"about_ca_system_score_codex":0.0004892116,"about_ca_system_score_gemma":0.0008560717,"threshold_uncertainty_score":0.46291342},"labels":[],"label_agreement":null},{"id":"W2046583400","doi":"10.1016/s1470-2045(02)00676-9","title":"Trastuzumab: hopes and realities","year":2002,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":169,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St Mary's Hospital; McGill University; Montreal General Hospital; Royal Victoria Hospital","funders":"","keywords":"Trastuzumab; Political science; Medicine; Internal medicine; Breast cancer; Cancer","score_opus":0.39974076953613047,"score_gpt":0.5236081176257247,"score_spread":0.12386734808959421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046583400","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000062507606,0.92502415,0.0000018898052,0.005375589,0.00021476464,0.0009129678,0.000058693684,0.00006593886,0.06833977],"genre_scores_gemma":[0.0000054448496,0.98595333,0.00014778516,0.0010502848,0.0025772837,0.00029718998,0.000032216627,0.000057165078,0.00987927],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977141,0.0007145994,0.0004019195,0.00034670543,0.0002690998,0.00055359275],"domain_scores_gemma":[0.99807894,0.00088926265,0.00015343793,0.00069465704,0.000051759274,0.00013196278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011126227,0.00027891112,0.002736175,0.000114577495,0.00009123498,0.000024326562,0.00036015385,0.0004075839,0.0007625805],"category_scores_gemma":[0.00022217976,0.00015382581,0.00017445559,0.0002053471,0.000509972,0.0000184379,0.00016815223,0.0011706697,0.00027590606],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024755589,0.000030971627,0.0000048786264,0.011444029,0.00013844142,0.00012223539,0.00021884812,1.4862845e-8,1.0916722e-7,0.0006143583,0.11734895,0.8700524],"study_design_scores_gemma":[0.0005156162,0.00056972395,0.000018550672,0.003755905,0.0005347277,0.0011590562,0.000045518824,0.000001972819,1.9732117e-7,0.00013275082,0.9931282,0.00013777894],"about_ca_topic_score_codex":0.00016665188,"about_ca_topic_score_gemma":0.00006793722,"teacher_disagreement_score":0.8757793,"about_ca_system_score_codex":0.00049615593,"about_ca_system_score_gemma":0.00067408563,"threshold_uncertainty_score":0.83497214},"labels":[],"label_agreement":null},{"id":"W2046984143","doi":"10.1016/s1470-2045(10)70204-7","title":"Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial","year":2010,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":447,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec; Centre Hospitalier Universitaire Sainte-Justine; McMaster University","funders":"National Institutes of Health; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute of Allergy and Infectious Diseases; Eunice Kennedy Shriver National Institute of Child Health and Human Development; University of Miami","keywords":"Dexrazoxane; Medicine; Doxorubicin; Anthracycline; Chemotherapy; Internal medicine; Surgery; Cancer; Breast cancer","score_opus":0.01014617022172221,"score_gpt":0.29535533113951923,"score_spread":0.285209160917797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046984143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993719,0.000038339964,0.00014898683,0.00025189703,0.0002321292,0.004749164,0.000037676917,0.000040556773,0.00078228256],"genre_scores_gemma":[0.9983473,0.00016605423,0.00060721696,0.00008375961,0.00039575942,0.00026774296,0.0000370278,0.000030527623,0.00006463559],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99818295,0.0003023048,0.00049762457,0.00033839923,0.00033110016,0.00034759945],"domain_scores_gemma":[0.9984013,0.00030870168,0.00048431975,0.0005574789,0.00016833768,0.00007990545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008174249,0.00023983305,0.0014877724,0.00012472471,0.000056562047,0.00000718918,0.00018927616,0.00029560074,0.000045927754],"category_scores_gemma":[0.0001899935,0.00014980389,0.00019779542,0.00032515122,0.00027504598,0.000047627713,0.00004165079,0.00070525386,0.000002658564],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21033444,0.0005441005,0.27915573,0.00007067649,0.0017907473,0.00008470233,0.0007252486,0.000048423175,0.50426084,0.00014923271,0.000011168955,0.0028246916],"study_design_scores_gemma":[0.35230365,0.0024485388,0.43860444,0.000098584474,0.00091029983,0.00024538446,0.000040754625,0.000044145523,0.20513876,0.000055508892,0.000004179444,0.000105748426],"about_ca_topic_score_codex":0.0010170034,"about_ca_topic_score_gemma":0.001469446,"teacher_disagreement_score":0.2991221,"about_ca_system_score_codex":0.00030856678,"about_ca_system_score_gemma":0.00059614767,"threshold_uncertainty_score":0.6108826},"labels":[],"label_agreement":null},{"id":"W2048434417","doi":"10.1016/s1470-2045(11)70185-1","title":"Dignity therapy for patients who are terminally ill","year":2011,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Patient Dignity and Privacy","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Grey Nuns Community Hospital","funders":"","keywords":"Dignity; Terminally ill; Distress; Psychosocial; Meaning (existential); Psychological intervention; Death with dignity; Psychotherapist; Medicine; Life review; Depression (economics); Psychology; Palliative care; Intensive care medicine; Psychiatry; Nursing; Alternative medicine","score_opus":0.1579440727531785,"score_gpt":0.35930289649930053,"score_spread":0.20135882374612202,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048434417","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08477643,0.00042139977,0.00005702685,0.8610261,0.0018853309,0.0036793596,0.00067905826,0.00015103826,0.047324233],"genre_scores_gemma":[0.005236096,0.00063202035,0.00036010228,0.97826165,0.009249594,0.0003284774,0.0008642287,0.00006897543,0.0049988376],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99815106,0.00032608438,0.0003307608,0.00036256204,0.0002273223,0.00060220645],"domain_scores_gemma":[0.9976787,0.0006243461,0.00046104577,0.0008327412,0.00034038603,0.000062799314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036473727,0.00032375506,0.0012383643,0.00008178078,0.00014709425,0.000012988571,0.000592804,0.0009407993,0.00021838683],"category_scores_gemma":[0.00033682215,0.000200513,0.00024171115,0.00007503523,0.00021128202,0.000046328074,0.00010347108,0.001592788,0.00012082784],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013917659,0.00027192707,0.011689525,0.00024381158,0.00017424911,0.000081145336,0.0006345883,1.8642456e-8,0.0000052042597,0.000016245049,0.969267,0.016224531],"study_design_scores_gemma":[0.0049158097,0.0030398471,0.03566337,0.00016342688,0.00016551433,0.000018387203,0.00001341018,0.0000015677667,0.00004051245,0.0019301567,0.95382345,0.00022453479],"about_ca_topic_score_codex":0.000030279429,"about_ca_topic_score_gemma":0.000011055262,"teacher_disagreement_score":0.11723554,"about_ca_system_score_codex":0.00014040277,"about_ca_system_score_gemma":0.0002038717,"threshold_uncertainty_score":0.81766826},"labels":[],"label_agreement":null},{"id":"W2050126505","doi":"10.1016/s1470-2045(06)70983-4","title":"Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study","year":2006,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":244,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McGill University; Coalition for Research in Women's Health; Hôtel-Dieu de Montréal; Lunenfeld-Tanenbaum Research Institute","funders":"National Cancer Institute; Canadian Breast Cancer Research Alliance; Breast Cancer Alliance; Cancer Research Institute","keywords":"Ovarian cancer; BRCA mutation; Medicine; Gynecology; Odds ratio; Breast cancer; Tubal ligation; Family history; Cancer; Population; Oncology; Obstetrics; Case-control study; Internal medicine; Family planning; Environmental health","score_opus":0.04654725572640173,"score_gpt":0.3675856329846427,"score_spread":0.32103837725824097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050126505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98785317,0.00055166654,0.000104216284,0.006854351,0.0003163081,0.0030653372,0.0007154382,0.000024561285,0.000514922],"genre_scores_gemma":[0.99722123,0.00007211763,0.00040995548,0.00017857432,0.0006425674,0.0012340684,0.00001017565,0.000018799828,0.00021252311],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986739,0.00026001688,0.00034985883,0.0003450967,0.00010217577,0.00026895103],"domain_scores_gemma":[0.9982837,0.0008925653,0.00024367051,0.00042912827,0.00011307653,0.00003786625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065677543,0.00014077537,0.0007036581,0.00008268379,0.000087158944,0.0000056717354,0.00008072313,0.00007604414,0.00017131068],"category_scores_gemma":[0.00030939656,0.00008140045,0.000077551034,0.0002318248,0.00010719063,0.00003269274,0.000014606727,0.00015923259,0.0000012760875],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004181399,0.001914609,0.96258706,0.000055983463,0.0010435135,0.00080640515,0.008656402,0.0016604722,0.000064771615,0.00054186885,0.0019968755,0.016490642],"study_design_scores_gemma":[0.024308523,0.0031777758,0.9583552,0.000035697663,0.0013145449,0.00015716215,0.0074177794,0.00021109937,0.00031340617,0.00079602416,0.0037912258,0.000121543366],"about_ca_topic_score_codex":0.020566056,"about_ca_topic_score_gemma":0.03260537,"teacher_disagreement_score":0.020127123,"about_ca_system_score_codex":0.00040686494,"about_ca_system_score_gemma":0.0003875869,"threshold_uncertainty_score":0.9859561},"labels":[],"label_agreement":null},{"id":"W2050315067","doi":"10.1016/s1470-2045(09)70126-3","title":"Concurrent hormone and radiation therapy in patients with breast cancer: how does chemotherapy affect treatment?","year":2009,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Breast cancer; Medicine; Radiation therapy; Antiestrogen; Tamoxifen; Oncology; Internal medicine; Cancer; Hormonal therapy; Chemotherapy; Hormone therapy; Adjuvant; Gynecology","score_opus":0.007894214839771763,"score_gpt":0.25809263601925636,"score_spread":0.2501984211794846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050315067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7456958,0.00751631,0.0000019749818,0.24548958,0.00019761024,0.00087281223,0.000116102885,0.000016318663,0.00009347977],"genre_scores_gemma":[0.72988105,0.10201623,0.000028149781,0.15922998,0.006202923,0.0003249728,0.0016377724,0.00009938805,0.0005795616],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985858,0.00034117568,0.00013065671,0.0004197179,0.000116306706,0.0004062971],"domain_scores_gemma":[0.99935293,0.00004393954,0.00019664828,0.0003284528,0.00003995118,0.00003806508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001228939,0.000357576,0.0005562929,0.000051338047,0.00006595504,0.00002977276,0.00018835785,0.000783481,0.000006014159],"category_scores_gemma":[0.0000037207485,0.00017387302,0.00006894846,0.00007575507,0.00015387498,0.0000046526607,0.000021186712,0.00052670256,0.0000014737938],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023208344,0.00034462972,0.03539489,0.000031994605,0.0007715304,0.00004960799,0.00021208716,0.0000068829568,0.00399403,0.0000034203183,0.3694107,0.5874594],"study_design_scores_gemma":[0.016823202,0.008963223,0.18953891,0.00003916399,0.000096041,0.00003419619,0.0000078356725,0.00000862496,0.0020652637,0.000014658653,0.7819428,0.00046608245],"about_ca_topic_score_codex":0.000057885587,"about_ca_topic_score_gemma":0.00003487838,"teacher_disagreement_score":0.58699334,"about_ca_system_score_codex":0.00013590268,"about_ca_system_score_gemma":0.000119774835,"threshold_uncertainty_score":0.70903355},"labels":[],"label_agreement":null},{"id":"W2050352131","doi":"10.1016/s1470-2045(14)70127-5","title":"Complications of prostate cancer treatment – Author's reply","year":2014,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Scopus; Prostate cancer; Prostatectomy; Population; Cancer; MEDLINE; Cohort; Gynecology; Oncology; Internal medicine","score_opus":0.09472766165938883,"score_gpt":0.3868066538992569,"score_spread":0.29207899223986805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050352131","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017199628,0.0025604055,0.000008397953,0.9801861,0.00047596853,0.0015490094,0.00043221682,0.000065536995,0.01300241],"genre_scores_gemma":[0.008268808,0.007763956,0.0005062668,0.965427,0.0056657805,0.0035591535,0.000931384,0.00007196455,0.0078057055],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982943,0.00022243768,0.00043197183,0.0004171728,0.0001951338,0.0004389922],"domain_scores_gemma":[0.99777204,0.0003867051,0.00048950134,0.0011235954,0.00016646253,0.000061718194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021931922,0.00030189657,0.0013116184,0.0000712783,0.00008639758,0.0000090802105,0.00021504256,0.00031292267,0.00013058555],"category_scores_gemma":[0.000024539662,0.00017002322,0.000200791,0.00011838054,0.00027650755,0.000014017374,0.000047472684,0.0005831553,0.00006735931],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017355078,0.00021267317,0.004119703,0.00023553659,0.00066269963,0.00011854425,0.00044453467,0.0000068784043,0.0000410597,0.00013805088,0.9732647,0.020582078],"study_design_scores_gemma":[0.002690811,0.0020608632,0.0071067163,0.00022335861,0.00088523835,0.00009175388,0.00001407233,0.00001781225,0.0003439018,0.0003404659,0.986086,0.00013901066],"about_ca_topic_score_codex":0.00090277597,"about_ca_topic_score_gemma":0.00009228863,"teacher_disagreement_score":0.020443067,"about_ca_system_score_codex":0.0010111537,"about_ca_system_score_gemma":0.0006061642,"threshold_uncertainty_score":0.69333464},"labels":[],"label_agreement":null},{"id":"W2050629268","doi":"10.1016/s1470-2045(05)70424-1","title":"Selection of adjuvant chemotherapy for treatment of node-positive breast cancer","year":2005,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":134,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; University of Ottawa; University of Alberta; Santé Montérégie; Université de Sherbrooke; Memorial University of Newfoundland; BC Cancer Agency; University of Toronto; Hôpital du Saint-Sacrement; Sunnybrook Health Science Centre","funders":"","keywords":"Epirubicin; Anthracycline; Regimen; Medicine; Internal medicine; Docetaxel; Cyclophosphamide; Oncology; Breast cancer; Taxane; Doxorubicin; Chemotherapy; Cancer","score_opus":0.048863306834817946,"score_gpt":0.39525919132361115,"score_spread":0.3463958844887932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050629268","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021388459,0.9954558,0.000051385097,0.0008382998,0.00017598833,0.0010043359,0.0019496718,0.000007830985,0.00030279436],"genre_scores_gemma":[0.00070659653,0.9955844,0.00042423338,0.000118579854,0.0017448046,0.0009386662,0.0002662881,0.000042561594,0.00017385387],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988312,0.00014711996,0.0003691061,0.00032169212,0.0000671757,0.0002636728],"domain_scores_gemma":[0.99887264,0.0001005248,0.00055414654,0.0003071239,0.00014060392,0.000024982366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000111534384,0.0003187993,0.0018314928,0.000038397273,0.000053378382,0.0000022441427,0.00019676349,0.00028656152,0.000029899424],"category_scores_gemma":[0.000006416315,0.00019090314,0.0004168764,0.00009488655,0.00017050402,0.0000014572577,0.000035853052,0.00004715262,0.0000015149512],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057422876,0.00032410226,0.00009531365,0.0008113623,0.001792157,3.4228444e-7,0.000104498744,0.0000048957763,0.00016941447,0.000029745546,0.001464205,0.99462974],"study_design_scores_gemma":[0.0021568509,0.00092720246,0.0005555902,0.00048034728,0.0012898173,0.000071398346,0.000015398746,0.0000021232313,0.001102859,0.000008372443,0.99322367,0.0001663897],"about_ca_topic_score_codex":0.00014687459,"about_ca_topic_score_gemma":0.0002943173,"teacher_disagreement_score":0.9944633,"about_ca_system_score_codex":0.0003171801,"about_ca_system_score_gemma":0.00043071806,"threshold_uncertainty_score":0.7784804},"labels":[],"label_agreement":null},{"id":"W2050701036","doi":"10.1016/s1470-2045(13)70446-7","title":"Surgery versus SABR for NSCLC","year":2013,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"SABR volatility model; Radiation therapy; Medicine; Lung cancer; Stage (stratigraphy); Ablative case; Surgery; Oncology","score_opus":0.12285970875660586,"score_gpt":0.37818727135757757,"score_spread":0.2553275626009717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050701036","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011992254,0.0013477615,0.000008900429,0.9759015,0.0039886106,0.0012718542,0.00008686589,0.00007667883,0.016118642],"genre_scores_gemma":[0.001701655,0.0016320891,0.00037427756,0.9484592,0.037912082,0.0023650376,0.00077270914,0.00007707544,0.0067058844],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985441,0.00012217784,0.00025890913,0.00033769946,0.0001732054,0.00056393235],"domain_scores_gemma":[0.99552184,0.003439191,0.00019500835,0.00069685146,0.000096371485,0.000050720395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031487775,0.0002541151,0.0012330229,0.00006177708,0.000076224795,0.000017166247,0.0001852322,0.000646673,0.00054825],"category_scores_gemma":[0.000125654,0.00014581687,0.00032587312,0.000063701715,0.0001225777,0.000019361578,0.00004634397,0.0007665392,0.00041162645],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069539284,0.00006912535,0.00041142688,0.00029211183,0.00064426445,0.00018789504,0.000044818018,1.8179443e-7,0.000001669783,0.00008307286,0.98407334,0.01349668],"study_design_scores_gemma":[0.004261494,0.0007568961,0.0009555143,0.00013163383,0.00084352534,0.00004751586,0.000009077251,0.000003983932,0.000025544532,0.00019197242,0.99262637,0.00014646196],"about_ca_topic_score_codex":0.00014879253,"about_ca_topic_score_gemma":0.00004811139,"teacher_disagreement_score":0.03392347,"about_ca_system_score_codex":0.000837291,"about_ca_system_score_gemma":0.00047145103,"threshold_uncertainty_score":0.6002953},"labels":[],"label_agreement":null},{"id":"W2052968703","doi":"10.1016/s1470-2045(11)70128-0","title":"Abandonment of treatment for childhood cancer: position statement of a SIOP PODC Working Group","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":261,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stollery Children's Hospital; Hospital for Sick Children","funders":"","keywords":"Scopus; Medicine; Abandonment (legal); Cancer; Family medicine; Pediatrics; MEDLINE; Internal medicine; Political science","score_opus":0.10395944798347974,"score_gpt":0.37270104627841205,"score_spread":0.2687415982949323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052968703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99065363,0.00042795917,0.0011643531,0.0029015092,0.00014923488,0.00153072,0.00006741246,0.000019535713,0.0030856326],"genre_scores_gemma":[0.9945696,0.00083397544,0.003444796,0.0003761841,0.00025643728,0.0003694919,0.000026351538,0.000015030996,0.00010813791],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9989878,0.00008932198,0.00032004845,0.0001536796,0.00015698199,0.00029218607],"domain_scores_gemma":[0.99918115,0.00021831549,0.00020944791,0.00027654477,0.000060630417,0.000053932115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004173677,0.00010375193,0.00051549857,0.00005185841,0.00003768347,0.0000013757941,0.00012621665,0.00006674535,0.000115495604],"category_scores_gemma":[0.00002394506,0.00006133697,0.00008493908,0.00008440831,0.00012051849,0.000015898266,0.00004915097,0.000069748945,0.0000026873984],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045940273,0.009999206,0.03700535,0.00094860623,0.004508981,0.0001344729,0.08699835,0.000079488345,0.19642678,0.014020194,0.009171598,0.5947667],"study_design_scores_gemma":[0.13747059,0.080615,0.37072065,0.0015693671,0.002864167,0.0003411111,0.0027271467,0.003408936,0.3224983,0.0055748923,0.07158446,0.0006253881],"about_ca_topic_score_codex":0.000773063,"about_ca_topic_score_gemma":0.0001423706,"teacher_disagreement_score":0.5941413,"about_ca_system_score_codex":0.0015506855,"about_ca_system_score_gemma":0.00043099534,"threshold_uncertainty_score":0.40549886},"labels":[],"label_agreement":null},{"id":"W2054340543","doi":"10.1016/s1470-2045(13)70473-x","title":"Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Pemetrexed; Docetaxel; Cetuximab; Medicine; Oncology; Internal medicine; Open label; Lung cancer; Chemotherapy; Clinical trial; Cancer; Colorectal cancer; Cisplatin","score_opus":0.07556084289108853,"score_gpt":0.44264760369058054,"score_spread":0.367086760799492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054340543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97214395,0.0014181511,0.00009620254,0.0062558744,0.00038517956,0.017467808,0.00007489869,0.000058866222,0.0020990563],"genre_scores_gemma":[0.95419127,0.0004388857,0.0051228143,0.004153549,0.0007752236,0.030710207,0.00007308811,0.000074556265,0.0044604302],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99788576,0.0003215053,0.00049197656,0.00047880987,0.00023258464,0.00058933743],"domain_scores_gemma":[0.9982651,0.00048614116,0.00038290196,0.000515249,0.00019269744,0.0001579121],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00039371985,0.00035797368,0.0013200234,0.000119107804,0.00012334909,0.00008472712,0.0003466245,0.00014435558,0.003165899],"category_scores_gemma":[0.00007888036,0.00014529786,0.00005502197,0.00044992566,0.00016033441,0.00013249868,0.00006412282,0.0003648055,0.00002288339],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9417759,0.006504459,0.003113013,0.00015726968,0.0005726591,0.00043777973,0.0029080142,0.000010155856,0.00027989055,0.0000021857227,0.00484413,0.039394516],"study_design_scores_gemma":[0.9664498,0.018939095,0.0007865006,0.00046605198,0.0008165133,0.000042164575,0.00035245522,0.0026863096,0.0005147098,0.000007788388,0.0086596245,0.00027901272],"about_ca_topic_score_codex":0.0007219877,"about_ca_topic_score_gemma":0.002830722,"teacher_disagreement_score":0.039115503,"about_ca_system_score_codex":0.00052559294,"about_ca_system_score_gemma":0.0031686504,"threshold_uncertainty_score":0.99774534},"labels":[],"label_agreement":null},{"id":"W2055235037","doi":"10.1016/s1470-2045(13)70411-x","title":"Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":386,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Jewish General Hospital; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"GlaxoSmithKline","keywords":"Medicine; Lapatinib; Trastuzumab; Breast cancer; Internal medicine; Clinical endpoint; Neoadjuvant therapy; Oncology; Population; Pertuzumab; Cyclophosphamide; Chemotherapy; Surgery; Clinical trial; Cancer","score_opus":0.18881223491172663,"score_gpt":0.5311267806640083,"score_spread":0.3423145457522817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055235037","genre_codex":"empirical","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5985378,0.000105501465,0.000059802278,0.029696796,0.00035280126,0.36383355,0.0003623278,0.000061582236,0.0069898204],"genre_scores_gemma":[0.21918662,0.00020062082,0.0017318189,0.0064199204,0.0023177478,0.76850456,0.000079095444,0.00009989448,0.0014597122],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9966963,0.001062556,0.0006635443,0.00046211842,0.0004041742,0.0007112891],"domain_scores_gemma":[0.997268,0.00075883436,0.000323923,0.00076644553,0.0006293235,0.0002534773],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002291285,0.0002651981,0.0014645834,0.000070961556,0.00018718764,0.00006841885,0.0009037923,0.00019302501,0.0034208298],"category_scores_gemma":[0.00015159142,0.00015942618,0.00008639585,0.00020568584,0.00037404735,0.0001681933,0.00017125536,0.00046581536,0.000056674766],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7537297,0.006436328,0.000091984475,0.0001540822,0.00032896493,0.000018733776,0.0012104472,0.000008798616,0.066954084,0.0002454347,0.027943831,0.1428776],"study_design_scores_gemma":[0.8416265,0.033629015,0.0005422068,0.00021146153,0.0000697222,0.000078150544,0.00020758959,0.0011826596,0.01226596,0.00039222592,0.10958391,0.00021057457],"about_ca_topic_score_codex":0.006577065,"about_ca_topic_score_gemma":0.00023309169,"teacher_disagreement_score":0.40467104,"about_ca_system_score_codex":0.00037830314,"about_ca_system_score_gemma":0.0017562559,"threshold_uncertainty_score":0.99749017},"labels":[],"label_agreement":null},{"id":"W2055346449","doi":"10.1016/s1470-2045(14)71205-7","title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1354,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Janssen Research and Development","keywords":"Abiraterone acetate; Prednisone; Medicine; Prostate cancer; Placebo; Internal medicine; Oncology; Castration; Urology; Abiraterone; Enzalutamide; Cancer; Androgen deprivation therapy; Hormone; Androgen receptor; Pathology","score_opus":0.15890906001276825,"score_gpt":0.4258998720708133,"score_spread":0.2669908120580451,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055346449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97999656,0.0012359832,0.00007198528,0.003110346,0.00016069006,0.013286943,0.00019430928,0.000055568646,0.0018875914],"genre_scores_gemma":[0.99102753,0.0005633815,0.00027294434,0.00008901483,0.00018337353,0.0047456753,0.00019599556,0.000057940702,0.0028641436],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.995339,0.0011372853,0.0009978913,0.00068211573,0.000950179,0.0008935454],"domain_scores_gemma":[0.9970813,0.0007721098,0.00066802575,0.0007054448,0.0004818679,0.0002912504],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0029988727,0.00051346363,0.0032825975,0.0004817025,0.00012812486,0.000057915062,0.00036290666,0.00012711262,0.00019067863],"category_scores_gemma":[0.00009622835,0.0003006473,0.00021976221,0.0010922953,0.00040412525,0.00017520985,0.00008584069,0.00051378645,0.000007720719],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9464379,0.002250246,0.0020993405,0.00011443043,0.014893086,0.00046957773,0.017457305,0.013764849,0.0015997664,0.000026489806,0.0003336929,0.00055333256],"study_design_scores_gemma":[0.9573971,0.011831927,0.001784175,0.000074258365,0.007183235,0.000012477719,0.0056852424,0.014815172,0.00073730893,0.000026562908,0.00015600615,0.00029652027],"about_ca_topic_score_codex":0.0035522305,"about_ca_topic_score_gemma":0.010290279,"teacher_disagreement_score":0.011772063,"about_ca_system_score_codex":0.0017690195,"about_ca_system_score_gemma":0.0030783482,"threshold_uncertainty_score":0.99994457},"labels":[],"label_agreement":null},{"id":"W2055827929","doi":"10.1016/s1470-2045(12)70391-1","title":"Conditional survival of patients with metastatic renal-cell carcinoma","year":2012,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Sunitinib; Renal cell carcinoma; Oncology; Sorafenib; Internal medicine; Context (archaeology); Population; Clear cell renal cell carcinoma; Carcinoma; Kidney cancer; Targeted therapy; Cancer","score_opus":0.056122131624055105,"score_gpt":0.2929632004744176,"score_spread":0.2368410688503625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055827929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.69173217,0.0009368859,0.00005455555,0.27254885,0.0006929016,0.0018403758,0.00094343646,0.00004814158,0.031202655],"genre_scores_gemma":[0.8329477,0.000019389887,0.00093968114,0.15313433,0.0040969234,0.0001545546,0.005393022,0.000090931,0.0032234597],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975433,0.0005253302,0.00040749702,0.00031000466,0.0006428334,0.00057107554],"domain_scores_gemma":[0.99776495,0.00063348253,0.0005252527,0.0007392465,0.0002524272,0.00008465685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035561292,0.00035787126,0.0014465029,0.00011366419,0.000051965104,0.000005105746,0.00025764597,0.00031840528,0.0007059579],"category_scores_gemma":[0.000024593905,0.00019349651,0.00017123435,0.00012089834,0.00036591463,0.00003247337,0.00007614762,0.0011948001,0.0001253332],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015627955,0.00064089877,0.07786378,0.0008080829,0.000694846,0.0008948686,0.0002267704,0.0000037318741,0.000097279844,0.00007817129,0.91688067,0.00024811339],"study_design_scores_gemma":[0.008668612,0.0032164468,0.31463754,0.000049952985,0.002330668,0.000129285,0.000021468082,0.0000019149306,0.000593843,0.0001425675,0.6699572,0.000250486],"about_ca_topic_score_codex":0.000058862493,"about_ca_topic_score_gemma":0.000012291162,"teacher_disagreement_score":0.24692345,"about_ca_system_score_codex":0.00036000155,"about_ca_system_score_gemma":0.00039269336,"threshold_uncertainty_score":0.7890559},"labels":[],"label_agreement":null},{"id":"W2057136886","doi":"10.1016/s1470-2045(07)70352-2","title":"Onto solid footing","year":2007,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Patient Dignity and Privacy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Computer science; Environmental science","score_opus":0.2004752038912596,"score_gpt":0.424780362219567,"score_spread":0.22430515832830739,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057136886","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004487105,0.0003325423,0.0000935737,0.79532427,0.0009022674,0.00035083393,0.000013996939,0.000100185076,0.19839522],"genre_scores_gemma":[0.00403877,0.00011003995,0.0005968822,0.96214366,0.025922248,0.000019240193,0.000189572,0.000036796322,0.0069427816],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99833494,0.00023973716,0.00029271792,0.00024620895,0.00024845233,0.000637963],"domain_scores_gemma":[0.9982822,0.0007210339,0.0002168766,0.000658335,0.00007095499,0.000050616796],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0008222831,0.00020835763,0.0008777036,0.000088259265,0.00010375835,0.000010154402,0.00038576996,0.00093596004,0.0003133218],"category_scores_gemma":[0.00027171863,0.00013596575,0.00013800092,0.000104917366,0.0001543729,0.000021973248,0.00012903639,0.00302469,0.0004717518],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017388197,0.00003247765,0.00046158908,0.00015906419,0.00010979005,0.0008580055,0.00042566608,3.3636024e-7,0.000074320385,0.00006111322,0.9928457,0.00479803],"study_design_scores_gemma":[0.0012160772,0.0005561152,0.00087642303,0.0001112642,0.00017916947,0.0002913134,0.00002474323,0.000006724908,0.00009478445,0.0008252372,0.9956747,0.0001434227],"about_ca_topic_score_codex":0.00006628018,"about_ca_topic_score_gemma":0.000044291504,"teacher_disagreement_score":0.19145243,"about_ca_system_score_codex":0.00023556087,"about_ca_system_score_gemma":0.00023758181,"threshold_uncertainty_score":0.9992754},"labels":[],"label_agreement":null},{"id":"W2059624809","doi":"10.1016/s1470-2045(07)70384-4","title":"Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3","year":2007,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":558,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Cancer Institute","keywords":"Temozolomide; Medicine; Radiation therapy; Oncology; Internal medicine; Population; Nomogram; Clinical trial; Cancer","score_opus":0.030776179021699386,"score_gpt":0.3178752894288564,"score_spread":0.287099110407157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059624809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971387,0.00010848007,0.0001976611,0.00026758897,0.00016365624,0.0018211944,0.00015496771,0.000024434099,0.00012333275],"genre_scores_gemma":[0.9989344,0.00002103067,0.0005578521,0.000053240754,0.00020595099,0.00012633005,0.00007837826,0.00001704832,0.0000057922134],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99862516,0.000089078145,0.00045598307,0.00023793714,0.00025372696,0.00033811363],"domain_scores_gemma":[0.9968867,0.0020895556,0.0004130252,0.00028549138,0.00022989581,0.00009534476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058408245,0.00016195013,0.0010856249,0.00020415806,0.000055466237,0.000005507629,0.000097958204,0.00010924497,0.000024188734],"category_scores_gemma":[0.00044293117,0.000093562405,0.00015096243,0.00052657403,0.00017619936,0.000028674705,0.000036736594,0.00010067578,3.9717605e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030953906,0.0019541222,0.9544869,0.000076598684,0.0020436912,0.00001835075,0.0006252728,0.00002076494,0.0001347769,0.000066922235,0.000046305548,0.009572357],"study_design_scores_gemma":[0.073130414,0.011465589,0.910371,0.00004232592,0.0037109463,0.0000017269952,0.00017351062,0.00016532108,0.0005246704,0.000016158358,0.00031897015,0.000079366495],"about_ca_topic_score_codex":0.00010045002,"about_ca_topic_score_gemma":0.0014008951,"teacher_disagreement_score":0.044115927,"about_ca_system_score_codex":0.00006962319,"about_ca_system_score_gemma":0.000082205996,"threshold_uncertainty_score":0.38153642},"labels":[],"label_agreement":null},{"id":"W2060209146","doi":"10.1016/s1470-2045(04)01712-7","title":"See-and-treat strategy for diagnosis and management of cervical squamous intraepithelial lesions","year":2005,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute","keywords":"Medicine; Colposcopy; Referral; Cervical cancer; Biopsy; Squamous intraepithelial lesion; Cervical intraepithelial neoplasia; Cancer; Surgery; Radiology; Internal medicine; Family medicine","score_opus":0.25136549489886695,"score_gpt":0.48961594857555507,"score_spread":0.23825045367668812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060209146","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006635243,0.98128086,0.000015439517,0.0027135417,0.00006306072,0.0019465996,0.00015498816,0.00002073921,0.013738393],"genre_scores_gemma":[0.0005781445,0.99604774,0.00030714396,0.00026242208,0.0011574693,0.0009599138,0.000054141525,0.000031282056,0.0006017448],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985172,0.00019128865,0.00041041244,0.0003224084,0.00017432618,0.00038433538],"domain_scores_gemma":[0.99822044,0.0010962479,0.00012051121,0.00035293604,0.000065859946,0.00014402895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005343413,0.00022788049,0.001973687,0.00008175144,0.00007675943,0.000011722222,0.0002095636,0.00029932582,0.00072026864],"category_scores_gemma":[0.00004391155,0.00012866581,0.00019832789,0.00013664542,0.00027582154,0.000014180643,0.00021168216,0.00043612553,0.00001623614],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028095313,0.00013951113,0.000024409741,0.026370708,0.00020241093,0.000025515696,0.00003564109,2.8144493e-7,7.497532e-8,0.0028280728,0.0030775664,0.96701485],"study_design_scores_gemma":[0.0020440167,0.0011039501,0.0011483429,0.0007328737,0.0020835572,0.00006874594,0.000040924442,0.000011444892,8.770924e-7,0.00023316924,0.9924169,0.000115188544],"about_ca_topic_score_codex":0.000056429984,"about_ca_topic_score_gemma":0.00014751407,"teacher_disagreement_score":0.98933935,"about_ca_system_score_codex":0.00014846801,"about_ca_system_score_gemma":0.00019512007,"threshold_uncertainty_score":0.78864366},"labels":[],"label_agreement":null},{"id":"W2063944010","doi":"10.1016/s1470-2045(07)70409-6","title":"Venous thromboembolism in cervical cancer","year":2008,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Venous thromboembolism; Medicine; Cervical cancer; Cancer; Oncology; Internal medicine; Thrombosis","score_opus":0.12888677164208906,"score_gpt":0.42827921194673413,"score_spread":0.29939244030464507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063944010","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009770352,0.96511614,0.0000016434196,0.003747718,0.0009816514,0.0018177306,0.0000279826,0.000085124695,0.028124295],"genre_scores_gemma":[0.00006798192,0.99125093,0.00009156641,0.004012635,0.0029472867,0.0010681959,0.00006200661,0.00008505756,0.00041435024],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972482,0.00045405977,0.0007132341,0.0005201373,0.0002762725,0.00078815164],"domain_scores_gemma":[0.9982839,0.00033618562,0.00032437555,0.00088982383,0.000042985474,0.00012273387],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044095065,0.00045967908,0.0067090658,0.00020663215,0.000106277555,0.000013077275,0.00058149314,0.0005723987,0.0005784781],"category_scores_gemma":[0.000057750083,0.0002757972,0.0004535191,0.00045856487,0.00023075516,0.000027570206,0.0002850607,0.0012151259,0.00044891523],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023227209,0.0009986205,0.000025234103,0.0064033465,0.0004903269,0.000617097,0.00043081093,0.0000023054556,1.11891126e-7,0.001512535,0.069479525,0.9200169],"study_design_scores_gemma":[0.0009881185,0.0003761049,0.0020876566,0.0045066155,0.0013183566,0.00045782467,0.000026088614,0.0000031539305,1.4166015e-7,0.00012910034,0.9898466,0.0002602233],"about_ca_topic_score_codex":0.0007397052,"about_ca_topic_score_gemma":0.00064939057,"teacher_disagreement_score":0.92036706,"about_ca_system_score_codex":0.00085353485,"about_ca_system_score_gemma":0.0010118431,"threshold_uncertainty_score":0.9999694},"labels":[],"label_agreement":null},{"id":"W2064047759","doi":"10.1016/s1470-2045(10)70297-7","title":"Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Clinical Research Institute","funders":"Genentech","keywords":"Medicine; Breast cancer; Internal medicine; Discontinuation; Trastuzumab; Oncology; Human Epidermal Growth Factor Receptor 2; Clinical trial; Cancer","score_opus":0.1137773007743218,"score_gpt":0.37204568943079974,"score_spread":0.25826838865647794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064047759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9324552,0.0001503602,0.0000091443535,0.0101790745,0.00018095902,0.0011005031,0.00008801618,0.00005179819,0.055784978],"genre_scores_gemma":[0.9950726,0.000068906906,0.0004910829,0.0032106803,0.00050953246,0.00017981202,0.0000057900565,0.00003715214,0.00042444625],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980269,0.0004205777,0.0002363085,0.00029849424,0.00033014605,0.0006875733],"domain_scores_gemma":[0.99855727,0.00043961155,0.000117814554,0.0005395789,0.00024091669,0.000104836865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008817233,0.00017529537,0.0004900378,0.000054594184,0.0001244183,0.000012200766,0.00042004182,0.00011382848,0.00045352775],"category_scores_gemma":[0.00010596235,0.00008749304,0.000033161792,0.00039162126,0.00029083103,0.000050643353,0.00014863211,0.0007459852,0.00007347353],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016429834,0.0002923263,0.9640808,0.00004089275,0.000070148766,0.00008248053,0.0020300609,0.00000956863,0.00002590978,0.00018067729,0.0013277048,0.030216452],"study_design_scores_gemma":[0.0032700854,0.0014508598,0.99051666,0.00022974244,0.000051379855,0.00008404573,0.00025287442,0.00006767064,0.00019401331,0.00019672822,0.0035721085,0.00011385618],"about_ca_topic_score_codex":0.0074049635,"about_ca_topic_score_gemma":0.0024572401,"teacher_disagreement_score":0.06261743,"about_ca_system_score_codex":0.00059231784,"about_ca_system_score_gemma":0.00059994916,"threshold_uncertainty_score":0.9992048},"labels":[],"label_agreement":null},{"id":"W2064892114","doi":"10.1016/s1470-2045(07)70046-3","title":"Use of warfarin and risk of urogenital cancer: a population-based, nested case-control study","year":2007,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Jewish General Hospital","funders":"","keywords":"Medicine; Warfarin; Genitourinary system; Cancer registry; Incidence (geometry); Cancer; Population; Prostate cancer; Internal medicine; Nested case-control study; Confounding; Gynecology; Odds ratio","score_opus":0.02995590776402292,"score_gpt":0.3157091838420222,"score_spread":0.2857532760779993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064892114","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967071,0.0013267163,0.00035810383,0.000082291386,0.00089318736,0.00038657605,0.00019848393,0.0000061446326,0.00004143276],"genre_scores_gemma":[0.9968659,0.0003193307,0.00023202042,0.00017473334,0.0023230142,0.000022357197,0.000010761812,0.000011598971,0.000040277984],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990499,0.0002325488,0.0002692259,0.0001787803,0.000074666284,0.00019487317],"domain_scores_gemma":[0.99916506,0.00016413035,0.00022940805,0.00030946746,0.00008891495,0.000043002357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006716881,0.0001029936,0.00035387708,0.00003702585,0.000053214586,0.000004214014,0.000102105914,0.000105751205,0.000010150738],"category_scores_gemma":[0.00013549847,0.00007658584,0.000057205725,0.00007858324,0.00010458656,0.0000030030878,0.00004146008,0.00009467211,2.537848e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016387206,0.00021854571,0.94348645,0.00002206254,0.00028476314,0.000004683642,0.00030282736,0.00063123513,0.029708765,0.000057071113,0.0006430519,0.023001807],"study_design_scores_gemma":[0.005099426,0.0010269664,0.9432125,0.000005924698,0.00047523147,0.00013101836,0.00037500155,0.00020988827,0.004389225,0.000025240382,0.044893138,0.00015641439],"about_ca_topic_score_codex":0.006551828,"about_ca_topic_score_gemma":0.018338893,"teacher_disagreement_score":0.044250086,"about_ca_system_score_codex":0.000016730397,"about_ca_system_score_gemma":0.00009782774,"threshold_uncertainty_score":0.9995739},"labels":[],"label_agreement":null},{"id":"W2065116344","doi":"10.1016/s1470-2045(11)70421-1","title":"Chemotherapy for colorectal cancer","year":2012,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Bevacizumab; Medicine; Oxaliplatin; Chemotherapy; Colorectal cancer; Oncology; Internal medicine; Clinical trial; Cancer; Randomized controlled trial; Surgery","score_opus":0.06792156756469317,"score_gpt":0.3798708501176678,"score_spread":0.3119492825529746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065116344","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005790868,0.0064749965,0.000009840364,0.9659078,0.0018163455,0.001591262,0.00022344745,0.00008391124,0.018101515],"genre_scores_gemma":[0.005449842,0.0031843565,0.0003202093,0.93398964,0.043156393,0.0028594746,0.00020661815,0.00008173284,0.010751731],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99855816,0.000077045755,0.00021363654,0.0002913532,0.0001672306,0.0006925675],"domain_scores_gemma":[0.9989449,0.0004273837,0.00017718377,0.00029618267,0.000109784625,0.000044567223],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023130499,0.00030463355,0.0012154973,0.000043697146,0.00015484336,0.000010010856,0.00019580271,0.0005844916,0.0005658124],"category_scores_gemma":[0.000029577788,0.00016985976,0.00024167713,0.000081923194,0.00021439514,0.000018258555,0.000052503154,0.00089670945,0.000036429967],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015442516,0.00007118481,0.0013454871,0.00017883893,0.0009603622,0.00004272367,0.00052410224,1.2822237e-7,0.00007178928,0.000028970833,0.96682125,0.028410891],"study_design_scores_gemma":[0.003894814,0.0012256202,0.0056290203,0.00004356272,0.0006880996,0.00007921681,0.000026517358,0.000004503458,0.00015799853,0.00015515115,0.9879171,0.00017839766],"about_ca_topic_score_codex":0.00014860841,"about_ca_topic_score_gemma":0.0001870101,"teacher_disagreement_score":0.041340046,"about_ca_system_score_codex":0.00068658433,"about_ca_system_score_gemma":0.0003190864,"threshold_uncertainty_score":0.692668},"labels":[],"label_agreement":null},{"id":"W2065624579","doi":"10.1016/s1470-2045(09)70039-7","title":"Accessing unfunded cancer drugs in publicly funded hospitals","year":2009,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Cancer Care Ontario","funders":"","keywords":"Nice; Excellence; Medicine; Health care; Psychological intervention; Irinotecan; Public health; Cancer drugs; Cancer; Family medicine; Colorectal cancer; Actuarial science; Business; Nursing; Political science; Economic growth; Economics","score_opus":0.4789897163383777,"score_gpt":0.49689069406148134,"score_spread":0.017900977723103617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065624579","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014813782,0.0052554864,0.00007857881,0.9380532,0.0023427792,0.001105639,0.0003768889,0.000111925736,0.03786174],"genre_scores_gemma":[0.011953276,0.0011114539,0.0006296073,0.9663587,0.014208815,0.00051736087,0.00020910618,0.00009184126,0.0049198368],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9908436,0.0016470274,0.004818359,0.0011092765,0.000176261,0.0014054906],"domain_scores_gemma":[0.99118406,0.0026062669,0.0046565775,0.0013589344,0.00008345696,0.00011071574],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.022513641,0.0004938351,0.0035934588,0.00063959666,0.0002449957,0.00027981104,0.0016776462,0.00148821,0.0012696785],"category_scores_gemma":[0.0017255758,0.0005003246,0.00023339444,0.00047444273,0.00021767881,0.0005130463,0.0001736185,0.002629618,0.001728642],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020583208,0.000040195213,0.012715236,0.00027831408,0.00008860287,0.000016159858,0.0013131059,0.000037036054,2.0673923e-7,0.0072691645,0.9767108,0.0015106247],"study_design_scores_gemma":[0.0013873699,0.000090607464,0.018194491,0.00014614835,0.000015598196,0.000008866735,0.00024269742,0.0002927604,7.0698957e-7,0.046461787,0.93262196,0.0005369955],"about_ca_topic_score_codex":0.008834419,"about_ca_topic_score_gemma":0.0041886456,"teacher_disagreement_score":0.044088796,"about_ca_system_score_codex":0.003582165,"about_ca_system_score_gemma":0.0006086051,"threshold_uncertainty_score":0.9998081},"labels":[],"label_agreement":null},{"id":"W2069649975","doi":"10.1016/s1470-2045(14)70035-x","title":"Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Sunnybrook Health Science Centre; University of Toronto","funders":"National Cancer Institute; Canadian Institutes of Health Research; Avon Foundation for Women","keywords":"Anastrozole; Exemestane; Medicine; Aromatase inhibitor; Breast cancer; Bone mineral; Internal medicine; Aromatase; Oncology; Cancer; Osteoporosis; Gynecology","score_opus":0.01923397270228526,"score_gpt":0.32154278623470234,"score_spread":0.30230881353241706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069649975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944355,0.000058486974,0.000098311604,0.0012399094,0.00019973538,0.0036285578,0.000039931587,0.000015810498,0.00028374305],"genre_scores_gemma":[0.99811363,0.000027670174,0.00018730419,0.00034128636,0.00018906861,0.0009702903,0.000021815777,0.000011715963,0.00013721111],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9985353,0.0003547577,0.00037912428,0.00018690998,0.00018577192,0.0003581684],"domain_scores_gemma":[0.9975196,0.001494753,0.00044444032,0.0002642747,0.00015066689,0.00012623465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066897867,0.00015187413,0.0023329866,0.00010993547,0.00006992185,0.0000036196943,0.00006738239,0.00008443861,0.000015611482],"category_scores_gemma":[0.0001325566,0.00008167745,0.00017056683,0.00023749714,0.00011516999,0.000015012335,0.0000121210405,0.000113503855,8.921506e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9851653,0.00082229637,0.00463457,0.00014604155,0.0032037094,0.000012301566,0.00033140637,0.00004650068,0.001385049,0.000065389635,0.00015630528,0.0040311306],"study_design_scores_gemma":[0.8190474,0.014110791,0.16132534,0.000041312906,0.0039433856,0.00000602332,0.000023490893,0.0010892665,0.00019954151,0.000010598632,0.00014478186,0.00005811024],"about_ca_topic_score_codex":0.0008294388,"about_ca_topic_score_gemma":0.0008419271,"teacher_disagreement_score":0.16611794,"about_ca_system_score_codex":0.0001874911,"about_ca_system_score_gemma":0.00019187397,"threshold_uncertainty_score":0.33307096},"labels":[],"label_agreement":null},{"id":"W2070825440","doi":"10.1016/s1470-2045(15)70122-1","title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":1255,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation","funders":"National Cancer Institute; Bristol-Myers Squibb","keywords":"Ipilimumab; Placebo; Medicine; Adjuvant; Oncology; Melanoma; Internal medicine; Stage (stratigraphy); Resection; Surgery; Cancer; Immunotherapy; Cancer research; Pathology","score_opus":0.11659487388885283,"score_gpt":0.37045905221319325,"score_spread":0.25386417832434044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070825440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9773476,0.00018135618,0.0005559263,0.0016723368,0.0035092134,0.0035666951,0.000056852783,0.00011479787,0.012995228],"genre_scores_gemma":[0.99377334,0.00015141325,0.00018366799,0.00030895323,0.0018955735,0.0005057707,0.000044121396,0.000029931709,0.0031072127],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977139,0.0005428843,0.00059774634,0.00034319007,0.00039745864,0.00040476813],"domain_scores_gemma":[0.99810904,0.00043810508,0.0004261126,0.0006711239,0.00016350657,0.00019210459],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018094234,0.00022431363,0.0010571409,0.00017683585,0.00009942638,0.00001751597,0.0001997765,0.00017691437,0.000573138],"category_scores_gemma":[0.00021339979,0.00015530587,0.00017328227,0.00022330375,0.00020144893,0.000047395828,0.0001274255,0.0004530229,0.000116351526],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98496616,0.0005832948,0.000028076578,0.000046287125,0.0004598098,0.00025992215,0.00076761877,0.000073213436,0.000379758,0.00037030232,0.0056839916,0.006381589],"study_design_scores_gemma":[0.82345665,0.016343815,0.000041514377,0.00001885889,0.0005735339,0.000119406104,0.000604118,0.00040174034,0.00056668406,0.00008511742,0.15765058,0.00013796648],"about_ca_topic_score_codex":0.0008602751,"about_ca_topic_score_gemma":0.0015363883,"teacher_disagreement_score":0.16150947,"about_ca_system_score_codex":0.00036373304,"about_ca_system_score_gemma":0.00023000003,"threshold_uncertainty_score":0.63331896},"labels":[],"label_agreement":null},{"id":"W2073681230","doi":"10.1016/s1470-2045(11)70146-2","title":"Combination therapy in metastatic renal cell carcinoma","year":2011,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Alberta Health Services","funders":"","keywords":"Temsirolimus; Medicine; Bevacizumab; Sunitinib; Renal cell carcinoma; Oncology; Internal medicine; Toxicity; Combination therapy; Discovery and development of mTOR inhibitors; Chemotherapy; PI3K/AKT/mTOR pathway","score_opus":0.10222718322988199,"score_gpt":0.3187340458167887,"score_spread":0.2165068625869067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073681230","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.36994952,0.0020545206,0.000010272292,0.55759716,0.00052129244,0.0016023887,0.000020851516,0.000056434335,0.06818754],"genre_scores_gemma":[0.4549526,0.00055808085,0.00059266825,0.53169596,0.0028351983,0.00037246992,0.00049736165,0.000091564376,0.00840411],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997506,0.00079936435,0.00041772722,0.00040492046,0.00030584176,0.00056612137],"domain_scores_gemma":[0.99837875,0.00037956543,0.00029676227,0.00081134593,0.00008405266,0.000049509028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005985164,0.00035327993,0.0012146626,0.000219342,0.0000455379,0.000010474741,0.00034844983,0.00048058855,0.00045562393],"category_scores_gemma":[0.000022578892,0.0002134231,0.00017197525,0.00018026223,0.00016794328,0.00002866236,0.000060925617,0.001958615,0.00024385721],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009132522,0.0004594413,0.0041094283,0.00023991702,0.00015158,0.00697094,0.0010992676,9.326063e-7,0.00069298176,0.00010216863,0.9804753,0.004784787],"study_design_scores_gemma":[0.010416984,0.0049101054,0.05177034,0.00005557718,0.00035343049,0.00052958465,0.00003664633,0.000017785715,0.0033809214,0.0015017249,0.92674553,0.00028137083],"about_ca_topic_score_codex":0.00046186743,"about_ca_topic_score_gemma":0.00005536808,"teacher_disagreement_score":0.08500308,"about_ca_system_score_codex":0.0006327025,"about_ca_system_score_gemma":0.0003768805,"threshold_uncertainty_score":0.8703141},"labels":[],"label_agreement":null},{"id":"W2083185084","doi":"10.1016/s1470-2045(14)71111-8","title":"PSA test not recommended by Canadian Task Force","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Overdiagnosis; Task force; False positive paradox; Test (biology); Prostate cancer; Medicine; Task (project management); Prostate-specific antigen; Cancer; Computer science; Internal medicine; Political science; Artificial intelligence; Management; Economics; Biology","score_opus":0.03295197470442415,"score_gpt":0.31397679413694224,"score_spread":0.2810248194325181,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083185084","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1859053,0.00073261623,0.00005275266,0.62556857,0.00078375224,0.00095253193,0.00031331345,0.00011524351,0.18557593],"genre_scores_gemma":[0.95044905,0.00036300818,0.00020414217,0.04616716,0.00055160926,0.00013785437,0.00008737807,0.000015307649,0.0020245025],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991397,0.000079547826,0.00013417241,0.00017485024,0.00007031907,0.00040137777],"domain_scores_gemma":[0.9989727,0.00038042007,0.000055797922,0.0003533241,0.000034385983,0.0002033689],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034287066,0.00010633002,0.0003570495,0.00002896307,0.000101353166,0.00000911414,0.00012690395,0.00008212017,0.00021423078],"category_scores_gemma":[0.00013450166,0.00006688776,0.000040184965,0.00007020398,0.000057021814,0.00001822942,0.000022614327,0.00017176787,0.00017157594],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014816469,0.00021444309,0.040819563,0.000031886233,0.000096225616,0.000042062522,0.00034932725,0.0000017228657,0.0017578814,0.0018540312,0.8730615,0.08162323],"study_design_scores_gemma":[0.002806479,0.0012048397,0.018541878,0.000017050263,0.000079913334,0.000044067263,0.000032244232,0.00007556564,0.002215877,0.00048032842,0.9744229,0.00007889027],"about_ca_topic_score_codex":0.014002008,"about_ca_topic_score_gemma":0.04699557,"teacher_disagreement_score":0.7645438,"about_ca_system_score_codex":0.0005141151,"about_ca_system_score_gemma":0.00023287995,"threshold_uncertainty_score":0.99256384},"labels":[],"label_agreement":null},{"id":"W2084148280","doi":"10.1016/s1470-2045(11)70330-8","title":"Prostate cancer therapy: finding the right balance","year":2011,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Androgen suppression; Prostate cancer; Androgen; Oncology; Internal medicine; Randomized controlled trial; Cancer; Radiation therapy; Disease; Hormone","score_opus":0.0704486714911461,"score_gpt":0.345523327705107,"score_spread":0.27507465621396093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084148280","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0044332715,0.017577691,0.0000018678785,0.9483374,0.0017093524,0.0018743052,0.0002231059,0.0001013326,0.025741717],"genre_scores_gemma":[0.006211724,0.05284297,0.00007585409,0.9107137,0.013780341,0.0026833543,0.0002028236,0.00009516944,0.013394114],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976527,0.0003525449,0.00034990333,0.0005066355,0.00029277496,0.0008454472],"domain_scores_gemma":[0.9978719,0.0004767938,0.00039489532,0.0010906406,0.00010754604,0.000058270216],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00050352776,0.00043410534,0.0011265065,0.000054897147,0.0002631495,0.00003391161,0.0005750108,0.00052008464,0.0013548362],"category_scores_gemma":[0.000023954832,0.0001856569,0.00021258123,0.00017145621,0.0004051925,0.000037905225,0.00011040133,0.0021768967,0.00019928862],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003543673,0.000082443825,0.006131321,0.00010499612,0.00063151174,0.00078802684,0.0011280187,9.185407e-7,0.000021175798,0.00013380802,0.97597843,0.014644997],"study_design_scores_gemma":[0.0026796304,0.0006828918,0.0066342438,0.00023456446,0.00033170904,0.00013861171,0.000019304673,0.0000055262913,0.00039277514,0.0008100781,0.9878511,0.0002195981],"about_ca_topic_score_codex":0.00041418412,"about_ca_topic_score_gemma":0.00010058998,"teacher_disagreement_score":0.03762371,"about_ca_system_score_codex":0.0006305706,"about_ca_system_score_gemma":0.000578777,"threshold_uncertainty_score":0.99955803},"labels":[],"label_agreement":null},{"id":"W2087433133","doi":"10.1016/s1470-2045(14)70090-7","title":"Complications of prostate cancer treatment","year":2014,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Canadian Association of Nurses in Oncology; University of British Columbia","funders":"","keywords":"Prostate cancer; Medicine; Prostate; Cancer; Oncology; Internal medicine","score_opus":0.0864906108586704,"score_gpt":0.37815624116704516,"score_spread":0.2916656303083748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087433133","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0026142763,0.0027298566,0.0000043893633,0.97611976,0.0003384064,0.001301305,0.00036602985,0.000044523564,0.016481433],"genre_scores_gemma":[0.01481946,0.014589942,0.00026124975,0.95586747,0.005770138,0.0033741433,0.00088634365,0.0000615579,0.0043696994],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99872565,0.00015104024,0.0003142544,0.00029849514,0.00015112176,0.0003594332],"domain_scores_gemma":[0.998388,0.00031095868,0.00033996062,0.0007927929,0.00012391075,0.00004439731],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012438206,0.0002447609,0.0011115503,0.00005421335,0.00006268756,0.000006099506,0.0001730123,0.00029318247,0.00012934335],"category_scores_gemma":[0.0000113577435,0.00013321768,0.00016273672,0.000088568704,0.00023544558,0.000010139364,0.000035216013,0.0004627025,0.00006585904],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012641554,0.00019959614,0.0048660603,0.00022679134,0.0005988831,0.00008242381,0.00031953125,0.000006319408,0.00003439585,0.00012800374,0.9699507,0.023460919],"study_design_scores_gemma":[0.0027144041,0.0017127552,0.0065928935,0.00017514275,0.00074297306,0.00006260493,0.000009533726,0.000011067601,0.000358395,0.00025425767,0.9872576,0.0001083769],"about_ca_topic_score_codex":0.00056438654,"about_ca_topic_score_gemma":0.00009165077,"teacher_disagreement_score":0.023352541,"about_ca_system_score_codex":0.0008168102,"about_ca_system_score_gemma":0.00047477917,"threshold_uncertainty_score":0.5432459},"labels":[],"label_agreement":null},{"id":"W2087748477","doi":"10.1016/s1470-2045(14)70363-8","title":"Role of bisphosphonates in non-metastatic prostate cancer","year":2014,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Zoledronic acid; Prostate cancer; Medicine; Denosumab; Oncology; Androgen deprivation therapy; Internal medicine; Cancer; Radiation therapy; Cabozantinib; Osteonecrosis of the jaw; Osteoporosis; Bisphosphonate","score_opus":0.032227840651259984,"score_gpt":0.3558734122866907,"score_spread":0.32364557163543073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087748477","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06795355,0.0034304399,8.1327e-7,0.9209201,0.00036252724,0.0013006959,0.0000918545,0.000025835832,0.005914219],"genre_scores_gemma":[0.11506558,0.0020359252,0.00042225388,0.8760871,0.0009788208,0.0006616104,0.00023328768,0.000060146718,0.0044552265],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99847025,0.00018818508,0.00039293978,0.0002426077,0.00017535745,0.0005306637],"domain_scores_gemma":[0.99882627,0.0003275435,0.0003100071,0.00042421307,0.00006185126,0.000050119404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035386038,0.00020855796,0.0012585069,0.000099785495,0.00002667236,0.0000028312722,0.0001619105,0.000324252,0.00014856794],"category_scores_gemma":[0.0000409045,0.00012453253,0.00007252043,0.00015575392,0.00014472427,0.000013170817,0.000038485185,0.0011862735,0.00008047447],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009575186,0.00018499275,0.036081158,0.0013672066,0.00026208902,0.00053930137,0.0009113261,0.0000056525973,0.0001099709,0.000018946685,0.9285113,0.031050527],"study_design_scores_gemma":[0.004493754,0.00072920724,0.025041692,0.00030379594,0.00022361333,0.00007845866,0.000027253298,0.00006439569,0.0001714314,0.0008143825,0.9679437,0.00010830873],"about_ca_topic_score_codex":0.005345731,"about_ca_topic_score_gemma":0.0011624042,"teacher_disagreement_score":0.047112033,"about_ca_system_score_codex":0.0002356441,"about_ca_system_score_gemma":0.00051731104,"threshold_uncertainty_score":0.80811816},"labels":[],"label_agreement":null},{"id":"W2088382500","doi":"10.1016/s1470-2045(12)70167-5","title":"Polyglutamine diseases and the risk of cancer","year":2012,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Genetic Neurodegenerative Diseases","field":"Neuroscience","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Child and Family Research Institute","funders":"","keywords":"Cancer; Medicine; Internal medicine","score_opus":0.048379976375082324,"score_gpt":0.3252523891109662,"score_spread":0.27687241273588387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088382500","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2466234,0.007936863,0.000007847878,0.7405944,0.0012482385,0.0006902144,0.0016299986,0.000039086153,0.0012299464],"genre_scores_gemma":[0.32471317,0.006884756,0.000016597207,0.6589656,0.007856232,0.0002802464,0.0000106218085,0.00004478475,0.0012279901],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959352,0.0026686562,0.00026044998,0.00037906738,0.00027890992,0.0004776891],"domain_scores_gemma":[0.9954034,0.0032887033,0.0004773578,0.0007385792,0.000039930437,0.000052046216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002772771,0.000262115,0.00073583226,0.000043430828,0.00018306506,0.00002104981,0.0007871353,0.00018453033,0.00018948076],"category_scores_gemma":[0.0008762998,0.0001235799,0.00012979524,0.0001298794,0.0019765291,0.000028443674,0.00029366318,0.00092604494,0.00002182082],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045259917,0.00006973646,0.008949005,0.00012469689,0.00008697985,0.000036221132,0.0003708388,0.000030534193,0.0059740706,0.0007027858,0.9796394,0.0035631366],"study_design_scores_gemma":[0.0022123703,0.00011472317,0.030856937,0.000021192956,0.000935262,0.000025095544,0.000016158336,0.0000490101,0.0144469775,0.0015502506,0.9495372,0.00023480692],"about_ca_topic_score_codex":0.00020241359,"about_ca_topic_score_gemma":0.00003800459,"teacher_disagreement_score":0.08162881,"about_ca_system_score_codex":0.000034892037,"about_ca_system_score_gemma":0.00014194529,"threshold_uncertainty_score":0.7282604},"labels":[],"label_agreement":null},{"id":"W2090708746","doi":"10.1016/s1470-2045(12)70532-6","title":"Status of radiotherapy resources in Africa: an International Atomic Energy Agency analysis","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":297,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Pace; Radiation oncology; Agency (philosophy); Radiation therapy; Brachytherapy; Atomic energy; Business; Medicine; Economic growth; Geography; Surgery; Economics","score_opus":0.03439045985104002,"score_gpt":0.3853314686181866,"score_spread":0.3509410087671466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090708746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97541195,0.002393198,0.0017397839,0.0044094007,0.00033971205,0.0001664271,0.000008680797,0.00003041981,0.0155004505],"genre_scores_gemma":[0.9814942,0.008350894,0.0066177454,0.0017999,0.00077663525,0.00005991746,0.0000194249,0.000013556576,0.0008677607],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987168,0.00029908228,0.00030741884,0.00019945379,0.00012281543,0.00035443128],"domain_scores_gemma":[0.9990103,0.00030218466,0.0001751999,0.0003903195,0.000049409533,0.00007255999],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003545978,0.00010542043,0.00063480245,0.00024320467,0.00003518135,0.0000045357806,0.00030703587,0.00014609974,0.001445873],"category_scores_gemma":[0.000044363296,0.00006739404,0.00009168862,0.00042756167,0.00031060402,0.00009696451,0.000023703322,0.00020041225,0.00000600948],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029840185,0.0013559392,0.67154086,0.000024399365,0.003085321,0.00010529819,0.017322248,0.0012221143,0.015977845,0.017770575,0.004042511,0.2645689],"study_design_scores_gemma":[0.0039346814,0.0010861803,0.46351472,0.000009014234,0.00015410625,0.00004155892,0.0003432382,0.004113821,0.00014134248,0.0039135134,0.52263415,0.00011367897],"about_ca_topic_score_codex":0.00050351437,"about_ca_topic_score_gemma":0.00030483401,"teacher_disagreement_score":0.51859164,"about_ca_system_score_codex":0.0003036115,"about_ca_system_score_gemma":0.000105922285,"threshold_uncertainty_score":0.99946696},"labels":[],"label_agreement":null},{"id":"W2091061603","doi":"10.1016/s1470-2045(03)01163-x","title":"Breast cancer trial with erythropoietin terminated unexpectedly","year":2003,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":472,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Erythropoietin; Epoetin alfa; Cancer; Radiation therapy; Oncology; Internal medicine; Anemia; Hemoglobin; Clinical trial","score_opus":0.03356449566456138,"score_gpt":0.34192028979714534,"score_spread":0.30835579413258396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091061603","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.872594,0.00045311957,0.000016702588,0.062147606,0.0005176006,0.0009158303,0.000023861494,0.00015796801,0.06317332],"genre_scores_gemma":[0.99073285,0.0004202465,0.0010818072,0.0021848448,0.0009929237,0.00019843534,0.000015238482,0.000032548858,0.004341098],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987199,0.00024192028,0.00019778323,0.0002556487,0.00017226461,0.0004125398],"domain_scores_gemma":[0.9991816,0.00012224396,0.00010958305,0.00040062045,0.00008565377,0.000100271274],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00027822817,0.00018348602,0.0005606354,0.00003508171,0.00012793638,0.000010721851,0.00010742997,0.00012825122,0.0014981584],"category_scores_gemma":[0.000028394787,0.0000931195,0.00006600264,0.00021358655,0.0003331319,0.000022760232,0.00001933917,0.00030809274,0.00008594393],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3888077,0.010271621,0.09683296,0.00048434953,0.0028800468,0.0049674795,0.0073310467,0.000051910545,0.008676708,0.020391382,0.35799402,0.10131076],"study_design_scores_gemma":[0.3560099,0.009213479,0.030182377,0.00030784387,0.0010761986,0.0111615565,0.0025023336,0.000025793186,0.00502511,0.00035761806,0.58352375,0.0006140489],"about_ca_topic_score_codex":0.00015495376,"about_ca_topic_score_gemma":0.00020237007,"teacher_disagreement_score":0.22552973,"about_ca_system_score_codex":0.0002548991,"about_ca_system_score_gemma":0.00042351274,"threshold_uncertainty_score":0.9994146},"labels":[],"label_agreement":null},{"id":"W2093711999","doi":"10.1016/s1470-2045(11)70331-x","title":"Radiogenomics: associations in all the wrong places?","year":2011,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Effects of Radiation Exposure","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Radiogenomics; Scopus; Medicine; Radiation therapy; Single-nucleotide polymorphism; SNP; Prospective cohort study; Bioinformatics; Oncology; MEDLINE; Internal medicine; Genetics; Biology; Gene; Genotype","score_opus":0.08418806426636781,"score_gpt":0.3442430314413792,"score_spread":0.26005496717501136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2093711999","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008264961,0.0008821681,0.000007978695,0.95500624,0.00091997796,0.001006099,0.00006934218,0.000071348906,0.033771887],"genre_scores_gemma":[0.0069557475,0.00037388856,0.00031272136,0.97294116,0.013822348,0.00019800372,0.0004078032,0.00006471933,0.004923627],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99766284,0.0009388045,0.00036484527,0.0002766439,0.00021769738,0.0005391464],"domain_scores_gemma":[0.996684,0.0019718835,0.00042652764,0.00082350057,0.000058645463,0.000035430057],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0016405426,0.00023194436,0.0008703398,0.00012019121,0.00008723221,0.000016815258,0.0006164783,0.0009720481,0.00023527822],"category_scores_gemma":[0.00046040298,0.0001333179,0.00013863729,0.00014481194,0.00017651658,0.000034850862,0.000078145305,0.0030948916,0.0003677742],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007102385,0.000034128134,0.0050367434,0.00004120519,0.00023792071,0.00023322093,0.0014349084,0.000010458979,0.000027459466,0.00021903016,0.99187917,0.00077476224],"study_design_scores_gemma":[0.0016956024,0.00026399049,0.023927988,0.000026114943,0.00024843807,0.00016683363,0.000037442667,0.000042333828,0.000009856726,0.00060734694,0.97283745,0.00013657719],"about_ca_topic_score_codex":0.00023551183,"about_ca_topic_score_gemma":0.00045416568,"teacher_disagreement_score":0.028848259,"about_ca_system_score_codex":0.0008103575,"about_ca_system_score_gemma":0.00037598007,"threshold_uncertainty_score":0.999205},"labels":[],"label_agreement":null},{"id":"W2095826876","doi":"10.1016/s1470-2045(09)70334-1","title":"Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study","year":2009,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1187,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Ipilimumab; Adverse effect; Clinical endpoint; Internal medicine; Melanoma; Clinical trial; Intention-to-treat analysis; Phases of clinical research; Randomized controlled trial; Gastroenterology; Surgery; Immunotherapy; Cancer","score_opus":0.03300815461349548,"score_gpt":0.35211559063508846,"score_spread":0.31910743602159297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095826876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99089503,0.00051970675,0.00002110932,0.0016994162,0.000135964,0.004800705,0.000006296145,0.00008791396,0.0018338652],"genre_scores_gemma":[0.9975108,0.00014774122,0.00025549784,0.0015407886,0.00014526749,0.0001880558,0.00003379962,0.000025728734,0.00015234885],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99826956,0.00023680396,0.0004245672,0.00034658684,0.00023764117,0.00048482872],"domain_scores_gemma":[0.998999,0.00015016468,0.00019934418,0.00049923017,0.00008243728,0.00006984211],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056647003,0.00025381809,0.0008265198,0.00014240059,0.00009655743,0.000016920601,0.00020541376,0.000105239116,0.00009288111],"category_scores_gemma":[0.00001877505,0.00014807764,0.00008670743,0.00045325755,0.00008662756,0.00008944559,0.000014337707,0.00030594118,0.000008896756],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85710865,0.005183978,0.037369754,0.000011163377,0.00031331062,0.000068053916,0.0032286004,0.000035427758,0.00088707823,0.0000058915157,0.00009378365,0.09569432],"study_design_scores_gemma":[0.8226077,0.010962223,0.16329266,0.00006380224,0.00014714956,0.000009921631,0.00052935246,0.00009203379,0.00030878372,0.000010864622,0.0017985522,0.00017694492],"about_ca_topic_score_codex":0.00009706428,"about_ca_topic_score_gemma":0.00023774666,"teacher_disagreement_score":0.12592292,"about_ca_system_score_codex":0.00032586025,"about_ca_system_score_gemma":0.00012745145,"threshold_uncertainty_score":0.6038431},"labels":[],"label_agreement":null},{"id":"W2096367061","doi":"10.1016/s1470-2045(14)70440-1","title":"Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":788,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University; Hôpital Maisonneuve-Rosemont; Université de Montréal","funders":"Novartis Pharmaceuticals Corporation; Celgene; Amgen","keywords":"Panobinostat; Bortezomib; Medicine; Dexamethasone; Multiple myeloma; Placebo; Clinical endpoint; Internal medicine; Oncology; Clinical trial; Pathology","score_opus":0.044164886168599204,"score_gpt":0.3379999064510631,"score_spread":0.2938350202824639,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096367061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944659,0.00075373036,0.00013360295,0.00036861794,0.00036423316,0.003458718,0.00005391641,0.000030608342,0.00037066895],"genre_scores_gemma":[0.99642885,0.0006686442,0.0012851495,0.00018853262,0.0004941846,0.0003683368,0.00019341783,0.00007071377,0.00030218228],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99609375,0.0012249385,0.0005952734,0.0009235052,0.00034738088,0.000815152],"domain_scores_gemma":[0.99668264,0.0017808407,0.00034810035,0.00072215166,0.00015560708,0.00031063668],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019130595,0.00044686763,0.0010774601,0.00016161945,0.00024241125,0.000061019375,0.00029733247,0.00053223455,0.000020039808],"category_scores_gemma":[0.0018909165,0.00031203465,0.0000626661,0.00022424242,0.00081457174,0.000029313505,0.0003105186,0.0006934688,0.0000054146494],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97802806,0.00058591604,0.0013043671,0.000060486465,0.00019527451,0.00004059787,0.0007976962,0.000030235633,0.010836832,0.000010636371,0.0007862629,0.0073236227],"study_design_scores_gemma":[0.9648802,0.009657118,0.0017172762,0.00004537152,0.00014953234,0.000025626965,0.0002853938,0.0010219131,0.004733415,0.000004834616,0.017024819,0.0004544457],"about_ca_topic_score_codex":0.0002160797,"about_ca_topic_score_gemma":0.002165465,"teacher_disagreement_score":0.016238557,"about_ca_system_score_codex":0.00024974224,"about_ca_system_score_gemma":0.00045903743,"threshold_uncertainty_score":0.9999332},"labels":[],"label_agreement":null},{"id":"W2096615679","doi":"10.1016/s1470-2045(11)70406-5","title":"Phase 2 trial design in neuro-oncology revisited: a report from the RANO group","year":2012,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; Western University","funders":"","keywords":"Medicine; Bevacizumab; Clinical trial; Temozolomide; Clinical study design; Discontinuation; Oncology; Population; Glioma; Drug development; Medical physics; Internal medicine; Intensive care medicine; Drug; Pharmacology; Chemotherapy; Cancer research","score_opus":0.2338715737795336,"score_gpt":0.450051414387947,"score_spread":0.2161798406084134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096615679","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00033191065,0.98408765,0.000039403036,0.005417719,0.0016157924,0.0062526953,0.00007559436,0.000062211664,0.0021170415],"genre_scores_gemma":[0.00027889642,0.98655856,0.00047032075,0.0025720135,0.0069976924,0.0024395408,0.00056369626,0.00007354672,0.00004576124],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99212533,0.0049439333,0.0013159923,0.0006226522,0.00026942277,0.00072264223],"domain_scores_gemma":[0.98862,0.0085272165,0.0010752704,0.0015759219,0.000048058766,0.0001535495],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0045139957,0.0005379833,0.0049240557,0.0001323282,0.00011019354,0.000022373792,0.0005742393,0.00072923524,0.0003916716],"category_scores_gemma":[0.000904309,0.00024554363,0.0006155919,0.00044780574,0.00021658046,0.00003777742,0.00018480158,0.0012438874,0.00025495698],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010490258,0.0034922722,0.000050975497,0.00049889705,0.0006756924,0.006288261,0.00016325124,1.591388e-7,0.0000062879944,0.00019577787,0.03399704,0.94414115],"study_design_scores_gemma":[0.0732781,0.0032833132,0.00003347945,0.0012136053,0.005581999,0.0020015128,0.00001516975,0.0000023211587,0.0000011624055,0.00010755263,0.9142959,0.00018590319],"about_ca_topic_score_codex":0.00016964416,"about_ca_topic_score_gemma":0.0000927923,"teacher_disagreement_score":0.94395524,"about_ca_system_score_codex":0.0007273096,"about_ca_system_score_gemma":0.0007902869,"threshold_uncertainty_score":0.9999997},"labels":[],"label_agreement":null},{"id":"W2098276344","doi":"10.1016/s1470-2045(13)70335-8","title":"Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":436,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"National Institute for Health and Care Research","keywords":"Medicine; Bevacizumab; Breast cancer; Internal medicine; Oncology; Anthracycline; Clinical endpoint; Taxane; Chemotherapy; Population; Triple-negative breast cancer; Ixabepilone; Cancer; Surgery; Randomized controlled trial; Metastatic breast cancer","score_opus":0.030516842716199154,"score_gpt":0.3359500223103854,"score_spread":0.30543317959418625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098276344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98742485,0.0021714468,0.000015468268,0.0049201655,0.0003355521,0.0018587803,0.0003153819,0.000014165458,0.0029441663],"genre_scores_gemma":[0.993267,0.0032568132,0.00016914099,0.00087280397,0.0010158231,0.001197045,0.00007168627,0.000020510262,0.00012918972],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99817884,0.00045329204,0.0004902897,0.00035896013,0.00012923688,0.00038938632],"domain_scores_gemma":[0.9987804,0.0002875946,0.00035021282,0.00039627697,0.00013844331,0.000047023033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005658009,0.00022275324,0.0007678991,0.000057448582,0.000072774616,0.000009180809,0.00030342056,0.00015680438,0.00005912456],"category_scores_gemma":[0.00012980643,0.0001430158,0.0001275033,0.00016698883,0.00022603836,0.000008666421,0.00011115851,0.00016971321,0.0000064866686],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8349676,0.00081324176,0.0012796342,0.000017282842,0.0005332465,0.000009893367,0.0015296846,0.000032746946,0.023242949,0.000020206078,0.0061472706,0.1314062],"study_design_scores_gemma":[0.9488831,0.0034379873,0.033094086,0.0000348575,0.000080875136,0.000034724588,0.0004920453,0.000023683653,0.008619139,0.00021765758,0.004831149,0.00025070406],"about_ca_topic_score_codex":0.0024515025,"about_ca_topic_score_gemma":0.0007034087,"teacher_disagreement_score":0.1311555,"about_ca_system_score_codex":0.00015797072,"about_ca_system_score_gemma":0.00032137506,"threshold_uncertainty_score":0.5832015},"labels":[],"label_agreement":null},{"id":"W2098494491","doi":"10.1016/s1470-2045(14)70508-x","title":"Knowledge, attitudes, and behaviours towards cancer screening in indigenous populations: a systematic review","year":2014,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Colorectal Cancer Screening and Detection","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Government of Northwest Territories; University of Alberta","funders":"H2020 European Research Council; Alberta Innovates - Health Solutions","keywords":"Indigenous; Traditional knowledge; Cancer; Psychology; Geography; Medicine; Biology; Ecology","score_opus":0.16485263619804466,"score_gpt":0.46993107081090646,"score_spread":0.30507843461286177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098494491","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000033317876,0.99480003,0.00007094208,0.00036057754,0.00030525538,0.0037040722,0.00001954115,0.00008318836,0.0006230775],"genre_scores_gemma":[0.00015536834,0.99598724,0.00029355858,0.0005242067,0.0005954502,0.002051835,0.0000572804,0.000045214383,0.00028986172],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99721456,0.0009987898,0.00086084916,0.00037917664,0.00017611869,0.00037048158],"domain_scores_gemma":[0.99844176,0.00028215544,0.00056973635,0.00053174805,0.00008243894,0.00009213943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020307172,0.0003386294,0.0047018444,0.00021225041,0.000113282396,0.000019440511,0.0002330789,0.00034996387,0.000024425992],"category_scores_gemma":[0.00034884881,0.0002071318,0.0002466758,0.0005233998,0.00008739196,0.000029774354,0.00011491924,0.00085908815,0.000015092418],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042291435,0.000032399927,0.00009329556,0.5118218,0.00008926892,0.000018127783,0.000114767325,2.5625303e-7,8.787992e-9,0.000019918523,0.00032298046,0.48744485],"study_design_scores_gemma":[0.00053067214,0.00063411304,0.00092658965,0.67170614,0.005065434,0.0009423846,0.0000071034333,0.000016165122,4.283185e-8,0.000008584067,0.31993493,0.00022782314],"about_ca_topic_score_codex":0.0014849202,"about_ca_topic_score_gemma":0.0056916717,"teacher_disagreement_score":0.48721704,"about_ca_system_score_codex":0.0005228335,"about_ca_system_score_gemma":0.0006277251,"threshold_uncertainty_score":0.844659},"labels":[],"label_agreement":null},{"id":"W2098499757","doi":"10.1016/s1470-2045(12)70509-0","title":"Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":526,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Genentech","keywords":"Bevacizumab; Medicine; Oxaliplatin; Capecitabine; Colorectal cancer; Clinical endpoint; Internal medicine; Bolus (digestion); Chemotherapy; Fluorouracil; Surgery; Gastroenterology; Phases of clinical research; Randomized controlled trial; Cancer","score_opus":0.0801800099192156,"score_gpt":0.4280330432983145,"score_spread":0.3478530333790989,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098499757","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9556504,0.004255192,0.000055987934,0.018023448,0.0015514758,0.014808889,0.00010533986,0.00009409279,0.0054552085],"genre_scores_gemma":[0.9728013,0.00094710407,0.0002663637,0.003913471,0.0033051067,0.016110232,0.00005197626,0.00003811669,0.0025663192],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982659,0.00021551336,0.00042234836,0.00026431834,0.00018188957,0.00064999034],"domain_scores_gemma":[0.99782014,0.0013274911,0.0002780635,0.0003180887,0.00010734864,0.00014886212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005724936,0.00031565074,0.0020278734,0.00005234278,0.00024714856,0.000011575339,0.00010486266,0.00013989925,0.0005713242],"category_scores_gemma":[0.00016737457,0.0001629429,0.00040740607,0.00007710455,0.00014605146,0.000032266333,0.000015654228,0.00011872452,0.000020369216],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9428982,0.0021809107,0.00014550333,0.00002760546,0.0015025219,0.0000138890455,0.0021288828,0.000016123266,0.0010510284,0.00006888897,0.003870051,0.046096373],"study_design_scores_gemma":[0.8285955,0.01749676,0.00021631393,0.000022422455,0.0012846339,0.000014977495,0.00015008802,0.0005906598,0.0015292092,0.00003741248,0.14991964,0.00014238013],"about_ca_topic_score_codex":0.00025540285,"about_ca_topic_score_gemma":0.0003901502,"teacher_disagreement_score":0.14604959,"about_ca_system_score_codex":0.0014280755,"about_ca_system_score_gemma":0.00081543345,"threshold_uncertainty_score":0.6644619},"labels":[],"label_agreement":null},{"id":"W2098898117","doi":"10.1016/s1470-2045(11)70231-5","title":"HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data","year":2011,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":193,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; St. Michael's Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"Amis de l'Institut Bordet; Cancer Research UK; Strategiske Forskningsråd","keywords":"Anthracycline; Internal medicine; Oncology; Medicine; Breast cancer; Hazard ratio; Cyclophosphamide; Adjuvant; Chemotherapy; Methotrexate; Cancer; Confidence interval","score_opus":0.43518734685932126,"score_gpt":0.5262071644404532,"score_spread":0.09101981758113198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098898117","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00053428137,0.9810751,0.00001646411,0.001971715,0.00011357496,0.003919573,0.011092628,0.000020546575,0.0012560858],"genre_scores_gemma":[0.00096024014,0.9950384,0.0006355856,0.00036861247,0.00030922994,0.0014931833,0.0008823695,0.00006850537,0.00024390616],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962712,0.0008118865,0.001106093,0.0008052682,0.00046702666,0.0005385103],"domain_scores_gemma":[0.9947843,0.0015606148,0.0013285469,0.0018970377,0.00026290969,0.00016657765],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018300174,0.00048879115,0.008480076,0.0003619417,0.000066293134,0.000010018741,0.00080240803,0.0003735364,0.00095230626],"category_scores_gemma":[0.00015774384,0.0002686893,0.001091053,0.00055436284,0.00053411117,0.0000475321,0.00030884834,0.0003498516,0.00000269925],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038821243,0.0004549126,0.00011739662,0.0023179774,0.22241807,0.000022669232,0.0017073323,0.0000015490269,0.0000010313018,0.00006042619,0.0015357832,0.76748073],"study_design_scores_gemma":[0.0021648556,0.008791714,0.00021542287,0.00055172696,0.31585014,0.0001218113,0.0003623083,0.00005872585,0.000009017431,0.000039366347,0.67166495,0.00016995374],"about_ca_topic_score_codex":0.0030347356,"about_ca_topic_score_gemma":0.00058209966,"teacher_disagreement_score":0.7673108,"about_ca_system_score_codex":0.00054670003,"about_ca_system_score_gemma":0.0021766876,"threshold_uncertainty_score":0.9999765},"labels":[],"label_agreement":null},{"id":"W2099777151","doi":"10.1016/s1470-2045(08)70235-3","title":"Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis","year":2008,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":425,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institutes of Health","keywords":"Prostate cancer; Medicine; Body mass index; Overweight; Hazard ratio; Proportional hazards model; Internal medicine; Cancer; Prostate; Oncology; Gynecology; Confidence interval","score_opus":0.03654156562712102,"score_gpt":0.3206869880629975,"score_spread":0.2841454224358765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099777151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98643756,0.004332514,0.000016595839,0.005658336,0.00015116646,0.0019717808,0.00028766438,0.000064409476,0.0010799477],"genre_scores_gemma":[0.9292866,0.06767072,0.00005894342,0.00036923,0.00030642253,0.0018503357,0.00015300172,0.00003012143,0.00027459796],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99758387,0.00025630344,0.00049739075,0.00062400446,0.00035652085,0.0006818959],"domain_scores_gemma":[0.99848217,0.00034609585,0.00030214482,0.00049332756,0.00017242406,0.00020385974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040632195,0.0003330622,0.0012049371,0.00009048021,0.00017818365,0.000031170795,0.00015622718,0.000117656884,0.000101200974],"category_scores_gemma":[0.000031483018,0.00021524834,0.00007692721,0.0007335752,0.0005484807,0.00013116602,0.00005422578,0.00036632956,0.000004349234],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027633167,0.0003281815,0.98793036,0.000104323124,0.0014712381,0.00092571427,0.0021912677,0.0011009506,0.00014108319,0.000059596474,0.000923443,0.0020605226],"study_design_scores_gemma":[0.009147445,0.0008687578,0.9853522,0.0001578449,0.0010208081,0.00005436444,0.00015196181,0.0006389702,0.00060914556,0.000045624845,0.0017165514,0.0002363292],"about_ca_topic_score_codex":0.0025118699,"about_ca_topic_score_gemma":0.0143634025,"teacher_disagreement_score":0.063338205,"about_ca_system_score_codex":0.00085438986,"about_ca_system_score_gemma":0.00075646467,"threshold_uncertainty_score":0.87775725},"labels":[],"label_agreement":null},{"id":"W2100175209","doi":"10.1016/s1470-2045(09)70067-1","title":"The price function of toxicity","year":2009,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Transparency (behavior); Toxicity; Scrutiny; Valuation (finance); Value (mathematics); Economics; Function (biology); Payment; Business; Medicine; Computer science; Computer security; Finance; Law; Biology","score_opus":0.41469738112595195,"score_gpt":0.46161273388584745,"score_spread":0.0469153527598955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100175209","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38523027,0.0034673722,0.0052041905,0.4856817,0.0015726829,0.0007399203,0.0000583386,0.00006881067,0.11797672],"genre_scores_gemma":[0.96441483,0.0003627506,0.00046930902,0.032853868,0.0010077781,0.000030053026,0.0000041207104,0.0000075589974,0.00084973767],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973557,0.00045832116,0.0016426954,0.00019272047,0.00004887861,0.00030170352],"domain_scores_gemma":[0.9962455,0.0016953932,0.0014502573,0.00052276225,0.00004225909,0.00004380704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.019091396,0.00008245852,0.00064312475,0.00004727611,0.000246806,0.000020118205,0.00038705443,0.00010049718,0.00013031048],"category_scores_gemma":[0.0018131667,0.00006175124,0.00006801421,0.00013161404,0.00010858245,0.00010216247,0.000028763054,0.00017700788,0.0006006461],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011298911,0.0000848021,0.0031780044,0.000033791748,0.000046470217,2.6478622e-7,0.001185393,0.00010149858,0.000039649167,0.880358,0.11055758,0.004301552],"study_design_scores_gemma":[0.0006396839,0.00038217948,0.115091935,0.000008682481,0.000005887973,0.0000041108715,0.00046126774,0.0007393549,0.000018530429,0.1512873,0.7312632,0.00009784419],"about_ca_topic_score_codex":0.000086775806,"about_ca_topic_score_gemma":0.00011402759,"teacher_disagreement_score":0.7290707,"about_ca_system_score_codex":0.00026423848,"about_ca_system_score_gemma":0.00009472029,"threshold_uncertainty_score":0.7720291},"labels":[],"label_agreement":null},{"id":"W2101027485","doi":"10.1016/s1470-2045(13)70181-5","title":"Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":433,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"Amgen","keywords":"Medicine; Panitumumab; Fluorouracil; Cetuximab; Internal medicine; Oncology; Clinical endpoint; Radiation therapy; Clinical trial; Surgery; Chemotherapy; Colorectal cancer; Cancer","score_opus":0.08315162691552298,"score_gpt":0.3725965093969344,"score_spread":0.2894448824814114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101027485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924672,0.0002028806,0.000004829081,0.0017396408,0.000081666774,0.0047187884,0.000020018924,0.0000107596,0.0007541941],"genre_scores_gemma":[0.99799514,0.000055753357,0.0007530374,0.0005140534,0.00008234229,0.0003869934,0.0000083973255,0.000021357844,0.00018295064],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99841535,0.00041194225,0.0003641883,0.00028390193,0.00020090937,0.0003236938],"domain_scores_gemma":[0.998803,0.00040465558,0.00024317807,0.00036608448,0.00008581379,0.0000972288],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004745244,0.00021034622,0.0012366506,0.000042474283,0.00012896693,0.000023595108,0.00019780124,0.000048337424,0.00006620708],"category_scores_gemma":[0.00012178102,0.000078535515,0.000013797209,0.00018877564,0.0003093521,0.00011325518,0.00012184037,0.00026558244,0.0000013061433],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9118059,0.0037248859,0.059106555,0.00020000273,0.00009163587,0.000023117136,0.0042489953,6.8437845e-7,0.00019100148,0.00001939783,0.0005313854,0.020056413],"study_design_scores_gemma":[0.8452397,0.0701471,0.08249322,0.00013964997,0.0002868875,0.00003584894,0.0006175105,0.00030609817,0.00019222485,0.000033791817,0.0003578115,0.00015017133],"about_ca_topic_score_codex":0.00063358207,"about_ca_topic_score_gemma":0.0051326607,"teacher_disagreement_score":0.066566244,"about_ca_system_score_codex":0.000082318395,"about_ca_system_score_gemma":0.00038162444,"threshold_uncertainty_score":0.32025853},"labels":[],"label_agreement":null},{"id":"W2101058247","doi":"10.1016/s1470-2045(08)70107-4","title":"Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial","year":2008,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":522,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Oncolytic virus; Refractory (planetary science); Medicine; Oncology; Cancer; Liver cancer; Phases of clinical research; Cancer research; Internal medicine; Virology; Clinical trial; Biology","score_opus":0.1005350859476827,"score_gpt":0.3687444118071548,"score_spread":0.2682093258594721,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101058247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99756134,0.00073789776,0.000017524848,0.00021315967,0.00010229749,0.0011165584,0.00013269637,0.000010785006,0.000107719745],"genre_scores_gemma":[0.995283,0.0018266707,0.00059367093,0.0011750141,0.0002793601,0.00022872034,0.00014116509,0.000039130144,0.00043328106],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978666,0.0007235134,0.00035410732,0.00033232334,0.00028000778,0.0004434789],"domain_scores_gemma":[0.99880636,0.00017070754,0.000231019,0.00057086966,0.00014281647,0.00007825804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048591362,0.00019431535,0.00058081734,0.00009119349,0.000073256786,0.0000065605486,0.00037419292,0.00013174802,0.0001369212],"category_scores_gemma":[0.00015502903,0.00012050552,0.00006738198,0.00025685952,0.00036707992,0.0000114870245,0.00011002582,0.00027326777,0.000007354486],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8919766,0.00318344,0.004813318,0.000064445834,0.00040339038,0.00012705356,0.0004618339,0.00017765422,0.075521246,0.0000042446286,0.0058837575,0.017383026],"study_design_scores_gemma":[0.49167496,0.20584343,0.037762195,0.00011410801,0.000295129,0.00006157163,0.00009706478,0.00024973028,0.08300186,0.00003163748,0.17978469,0.0010836213],"about_ca_topic_score_codex":0.00026328585,"about_ca_topic_score_gemma":0.0019081011,"teacher_disagreement_score":0.40030164,"about_ca_system_score_codex":0.0001716286,"about_ca_system_score_gemma":0.0012363936,"threshold_uncertainty_score":0.49140725},"labels":[],"label_agreement":null},{"id":"W2101095958","doi":"10.1016/s1470-2045(15)00244-2","title":"Consensus on the management of intracranial germ-cell tumours","year":2015,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Delphi Technique in Research","field":"Social Sciences","cited_by":249,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Chugai Pharmaceutical; Children's Cancer and Leukaemia Group","keywords":"Multidisciplinary approach; Delphi method; Delphi; Medicine; Consensus conference; Germ cell; Germ cell tumors; Political science; Internal medicine; Chemotherapy; Computer science","score_opus":0.4008159004287329,"score_gpt":0.5433592322362883,"score_spread":0.14254333180755546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101095958","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003931008,0.5555481,0.0000037226598,0.012781956,0.0005134613,0.001985674,0.000036762915,0.00007365995,0.4290174],"genre_scores_gemma":[0.00018970869,0.9953991,0.00041208783,0.00023186415,0.0009349796,0.00028641924,0.0000042261586,0.000026367712,0.0025152138],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99394405,0.0040290705,0.0004571111,0.00026088746,0.0007359045,0.0005729586],"domain_scores_gemma":[0.9956031,0.002886039,0.00051841507,0.0007724246,0.00014179529,0.00007824956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01219494,0.00020825419,0.0013084661,0.00008224372,0.00023708283,0.000031332944,0.0022935183,0.00035234087,0.00019779683],"category_scores_gemma":[0.00024582466,0.00010612656,0.00020779413,0.0004494182,0.0013598459,0.000010377907,0.00033238667,0.00094529043,0.00031605197],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000036235317,0.00009057507,0.0000011719902,0.0013925693,0.00007385924,0.00013302967,0.00063975726,3.8138768e-7,9.112029e-8,0.077496566,0.13506198,0.7850738],"study_design_scores_gemma":[0.00016043306,0.00013573516,0.000001980895,0.00078648975,0.00019190734,0.000010671448,0.000865128,8.9954625e-7,4.54657e-7,0.0041228333,0.9936132,0.00011030465],"about_ca_topic_score_codex":0.00030343005,"about_ca_topic_score_gemma":0.0001658365,"teacher_disagreement_score":0.8585512,"about_ca_system_score_codex":0.000521346,"about_ca_system_score_gemma":0.0010666584,"threshold_uncertainty_score":0.5010409},"labels":[],"label_agreement":null},{"id":"W2101922439","doi":"10.1016/s1470-2045(14)70379-1","title":"Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cell Adhesion Molecules Research","field":"Medicine","cited_by":1019,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Merck KGaA","keywords":"Temozolomide; Medicine; Chemoradiotherapy; Internal medicine; Oncology; Clinical endpoint; Phases of clinical research; Progression-free survival; Clinical trial; Chemotherapy","score_opus":0.045915261996500485,"score_gpt":0.37465635131886754,"score_spread":0.32874108932236706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101922439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9659881,0.000036595302,0.000990556,0.0013795169,0.00010575278,0.030642932,0.00008805726,0.00010463192,0.0006638613],"genre_scores_gemma":[0.98973286,0.00004495761,0.004629586,0.0004585425,0.00029760686,0.003887892,0.00018029397,0.0001234306,0.00064483826],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9957612,0.0011880577,0.0005673053,0.000754226,0.00077572156,0.0009534852],"domain_scores_gemma":[0.9956366,0.0019121933,0.00039599257,0.00097533275,0.000702846,0.00037707694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012187075,0.0005015694,0.0018758692,0.00019044388,0.00027263703,0.00010671891,0.0005192494,0.00014006464,0.00015860249],"category_scores_gemma":[0.0005677318,0.00023804589,0.0000734693,0.00053805066,0.00025529184,0.0001131292,0.00014840475,0.0003664224,0.000022363985],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94668704,0.020153515,0.003415984,0.0000648938,0.0011842978,0.00037047776,0.0010833301,0.000025312658,0.00020199548,0.00001771386,0.0010083468,0.025787063],"study_design_scores_gemma":[0.6979056,0.28668925,0.00075581844,0.000081835446,0.0008794467,0.00001657043,0.00021482325,0.0009085794,0.0008150163,0.000012433491,0.01148046,0.00024019051],"about_ca_topic_score_codex":0.0001292195,"about_ca_topic_score_gemma":0.0009742738,"teacher_disagreement_score":0.26653573,"about_ca_system_score_codex":0.0007629987,"about_ca_system_score_gemma":0.00070348626,"threshold_uncertainty_score":0.970723},"labels":[],"label_agreement":null},{"id":"W2102195694","doi":"10.1016/s1470-2045(14)70244-x","title":"Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":305,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal","funders":"University of Arizona Cancer Center; Amgen","keywords":"Medicine; Placebo; Clinical endpoint; Internal medicine; Population; Progression-free survival; Randomized controlled trial; Oncology; Phases of clinical research; Adverse effect; Clinical trial; Surgery; Chemotherapy; Pathology","score_opus":0.05990155337821918,"score_gpt":0.3706850085049904,"score_spread":0.31078345512677125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102195694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97411895,0.004427747,0.005301976,0.0050410624,0.0013280862,0.007527007,0.000081823004,0.00004259234,0.0021307517],"genre_scores_gemma":[0.98153365,0.00287691,0.0007721107,0.002213168,0.006613671,0.004863739,0.00015316001,0.00006649876,0.00090709864],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99798054,0.0003652346,0.00042203758,0.0005058191,0.00015273289,0.00057363854],"domain_scores_gemma":[0.99857897,0.00024006578,0.00036772873,0.00054898846,0.00016439955,0.00009985683],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012897508,0.0003105234,0.00095963775,0.000045400473,0.00020538263,0.000036806054,0.0004333587,0.00025190428,0.00010789904],"category_scores_gemma":[0.00007206736,0.00017945193,0.00035287105,0.00010906584,0.0001482236,0.000004859335,0.000050881972,0.00013607093,0.0000066731127],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95319176,0.000518477,0.00006273219,0.000015123836,0.0006385878,0.0000015677261,0.000111464105,0.000105276245,0.012391318,0.00029370005,0.00821921,0.024450786],"study_design_scores_gemma":[0.65372574,0.00348529,0.000016823855,0.000010978819,0.00017330566,0.0000055085093,0.000029150015,0.0002532259,0.009399851,0.000017495799,0.33268258,0.00020006963],"about_ca_topic_score_codex":0.000079072466,"about_ca_topic_score_gemma":0.0003852809,"teacher_disagreement_score":0.32446337,"about_ca_system_score_codex":0.000053607673,"about_ca_system_score_gemma":0.00028401695,"threshold_uncertainty_score":0.73178375},"labels":[],"label_agreement":null},{"id":"W2102306754","doi":"10.1016/s1470-2045(15)00086-8","title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":867,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôtel-Dieu de Québec; Centre hospitalier universitaire de Québec; University of British Columbia; Princess Margaret Cancer Centre","funders":"Wellbeing of Women; Medical Research Council; National Institute for Health and Care Research","keywords":"Bevacizumab; Medicine; Ovarian cancer; Oncology; Chemotherapy; Internal medicine; Cancer","score_opus":0.08231778117429578,"score_gpt":0.3864691238198101,"score_spread":0.3041513426455143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102306754","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96464825,0.00018324978,0.0007150588,0.023824433,0.00040416745,0.0064759543,0.00059827924,0.00006933617,0.003081274],"genre_scores_gemma":[0.98685056,0.00043159223,0.003946378,0.0018277022,0.0017178293,0.0038669913,0.00005451642,0.000069693415,0.0012347641],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997938,0.00023823275,0.0004793565,0.00041424355,0.0003900033,0.0005401879],"domain_scores_gemma":[0.9975942,0.00079025864,0.0004503272,0.0005981666,0.0003165652,0.00025052848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013527706,0.00029336056,0.0017584144,0.000058297337,0.00006833569,0.000021324262,0.00018874106,0.00013159386,0.00015281478],"category_scores_gemma":[0.00017852095,0.00013847806,0.00008155473,0.0001774238,0.00022706871,0.000057956164,0.000020778718,0.00017807362,0.0000018224742],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.958147,0.001396635,0.001035584,0.00007005001,0.0013762014,0.00009597093,0.0042691543,0.000055326702,0.00006125376,0.000111190646,0.0075567067,0.02582494],"study_design_scores_gemma":[0.8280505,0.049055815,0.0005853222,0.000118692384,0.00044042157,0.00002956269,0.00048148562,0.00008705429,0.00059206743,0.0001229064,0.12026391,0.00017224833],"about_ca_topic_score_codex":0.0005599897,"about_ca_topic_score_gemma":0.001761647,"teacher_disagreement_score":0.13009648,"about_ca_system_score_codex":0.00085661904,"about_ca_system_score_gemma":0.002682829,"threshold_uncertainty_score":0.56469715},"labels":[],"label_agreement":null},{"id":"W2103251300","doi":"10.1016/s1470-2045(13)70110-4","title":"Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":253,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Hospital for Sick Children; Ontario Institute for Cancer Research; University Health Network; University of Toronto; SickKids Foundation","funders":"Canadian Institutes of Health Research; Terry Fox Foundation","keywords":"Methylation; Malignancy; CpG site; Cohort; DNA methylation; Biomarker; Oncology; Medicine; Pyrosequencing; Cancer; Internal medicine; Pathology; Biology; Cancer research; Gene; Genetics; Gene expression","score_opus":0.017512960069337925,"score_gpt":0.3098881122709735,"score_spread":0.29237515220163557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103251300","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941791,0.00020556193,0.0000183372,0.0042061736,0.00001653786,0.0012046937,0.0000066585944,0.000004474011,0.00015844694],"genre_scores_gemma":[0.9995292,0.000035725367,0.0002143033,0.00010315019,0.000026283564,0.0000779773,0.000004528005,0.0000049477408,0.000003888035],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99926114,0.00035392624,0.00014565676,0.000112478316,0.000060084043,0.00006669036],"domain_scores_gemma":[0.9994328,0.000111323876,0.00016028984,0.00022679898,0.00004777772,0.000021036909],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030078174,0.00006563563,0.00024260883,0.000024389037,0.000032262567,0.000005424186,0.00005512285,0.000032883643,0.00001133149],"category_scores_gemma":[0.000059765127,0.000029999444,0.000018581672,0.000051536157,0.000101700716,0.000029919729,0.000026452259,0.00008300362,6.6969307e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007951942,0.0016494199,0.7107931,0.000018248153,0.00029910868,0.0000027267004,0.0180951,0.000005208519,0.23061736,0.00064257777,0.00009681789,0.03770082],"study_design_scores_gemma":[0.0016073473,0.0015515754,0.9737307,0.000015608442,0.00018419923,0.000010018486,0.0015126185,0.00013936368,0.0199944,0.0012153364,0.00001293219,0.000025909905],"about_ca_topic_score_codex":0.0002807908,"about_ca_topic_score_gemma":0.0001458891,"teacher_disagreement_score":0.2629376,"about_ca_system_score_codex":0.000020554433,"about_ca_system_score_gemma":0.000028449786,"threshold_uncertainty_score":0.12233418},"labels":[],"label_agreement":null},{"id":"W2104985658","doi":"10.1016/s1470-2045(06)70624-6","title":"Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study","year":2006,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":108,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; McGill University; Université de Montréal; Hôtel-Dieu de Montréal; Coalition for Research in Women's Health; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Breast cancer; Mammography; BRCA mutation; Obstetrics; Gynecology; Oophorectomy; Odds ratio; Oncology; Cancer; Internal medicine; Surgery; Hysterectomy","score_opus":0.01136395743167024,"score_gpt":0.2930139361479605,"score_spread":0.2816499787162903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104985658","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99558043,0.0026129978,0.00045612775,0.00048689338,0.00006308084,0.0003588862,0.0002988905,0.0000058571454,0.00013684158],"genre_scores_gemma":[0.9987165,0.00032248438,0.00045199934,0.00011125912,0.0002720009,0.00009527013,0.0000060806406,0.000011579889,0.000012853242],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990291,0.00030593615,0.00019510416,0.00023629876,0.000060365277,0.0001731907],"domain_scores_gemma":[0.99951863,0.00006838075,0.00014024103,0.00019767343,0.000052087322,0.000022960905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054348295,0.000100012956,0.00022838225,0.00006105299,0.000073503135,0.00001032399,0.00008239017,0.0000943933,0.000009740454],"category_scores_gemma":[0.000022949847,0.00008034887,0.00002542092,0.00013094499,0.00018866023,0.000004287167,0.000048364767,0.00011489424,1.1998286e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049903715,0.00008348319,0.94590324,0.00001742695,0.0002508884,0.000077134835,0.00085535785,0.002269876,0.008173162,0.000032825068,0.00027610734,0.041561466],"study_design_scores_gemma":[0.0043364633,0.00035157413,0.99062216,0.000008697283,0.00015930139,0.000702764,0.0016897166,0.0004889958,0.00064875145,0.00019320799,0.00068067235,0.00011771217],"about_ca_topic_score_codex":0.0034380248,"about_ca_topic_score_gemma":0.019433364,"teacher_disagreement_score":0.044718906,"about_ca_system_score_codex":0.000032871572,"about_ca_system_score_gemma":0.00007160015,"threshold_uncertainty_score":0.9984594},"labels":[],"label_agreement":null},{"id":"W2105263683","doi":"10.1016/s1470-2045(10)70104-2","title":"Size of sentinel-node metastasis and chances of non-sentinel-node involvement and survival in early stage vulvar cancer: results from GROINSS-V, a multicentre observational study","year":2010,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":263,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Sentinel node; Vulvar cancer; Lymphadenectomy; Metastasis; Stage (stratigraphy); Cancer; Oncology; Surgery; Radiology; Internal medicine; Breast cancer","score_opus":0.11081995486043818,"score_gpt":0.37555933868468816,"score_spread":0.26473938382425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105263683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99392605,0.0003869959,0.0000033511503,0.003993088,0.00026389924,0.00069222646,0.00041765728,0.000011484471,0.00030523652],"genre_scores_gemma":[0.9975654,0.00077264936,0.00065737474,0.0004782111,0.00030593725,0.0000709026,0.000039333958,0.000012855122,0.00009737696],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982962,0.00020022245,0.0005720342,0.0003405433,0.00032316704,0.0002678599],"domain_scores_gemma":[0.9978822,0.0012312891,0.00036037408,0.00031216315,0.00012917623,0.00008482071],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082001794,0.00017682748,0.000923165,0.000075765965,0.000043884844,0.000008448827,0.0001442454,0.000087778215,0.00008832828],"category_scores_gemma":[0.00037631253,0.00011708189,0.00004862595,0.0003120501,0.00018584903,0.000061903185,0.0001463629,0.00027767822,0.000001094177],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00482782,0.0010196912,0.974788,0.000104192,0.00045519214,0.000027310876,0.0027933104,0.000009079343,0.014681968,0.000056845667,0.00004801861,0.0011885377],"study_design_scores_gemma":[0.027366765,0.0004338996,0.96797794,0.000058022826,0.00031879017,0.0000012197448,0.00095074513,0.00020494453,0.0019441675,0.000091877206,0.0005581089,0.00009351411],"about_ca_topic_score_codex":0.016657494,"about_ca_topic_score_gemma":0.0100112315,"teacher_disagreement_score":0.022538945,"about_ca_system_score_codex":0.000050074752,"about_ca_system_score_gemma":0.00012091663,"threshold_uncertainty_score":0.9898907},"labels":[],"label_agreement":null},{"id":"W2106285196","doi":"10.1016/s1470-2045(10)70223-0","title":"External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study","year":2010,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":944,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Mount Sinai Hospital; Princess Margaret Cancer Centre","funders":"Ligue Contre le Cancer; AstraZeneca; American Society for Radiation Oncology","keywords":"Medicine; Goserelin; Androgen suppression; Prostate cancer; Clinical endpoint; Urology; Cyproterone acetate; Radiation therapy; Androgen; Prostate; Antiandrogen; Internal medicine; Androgen deprivation therapy; Randomized controlled trial; Medroxyprogesterone acetate; Cancer; Surgery; Hormone","score_opus":0.034388300340051865,"score_gpt":0.3603229668372296,"score_spread":0.3259346664971777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106285196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934013,0.0001086632,0.000046003493,0.0007757769,0.00014114715,0.0050581917,0.0003688506,0.00003201823,0.00006803534],"genre_scores_gemma":[0.99369174,0.00026905432,0.0031122493,0.00010666592,0.00028143788,0.0020735576,0.00011384808,0.000034887256,0.0003165761],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99856114,0.00022493367,0.0003402234,0.00034430952,0.00022998106,0.00029942932],"domain_scores_gemma":[0.9983731,0.00032169017,0.00049826555,0.00049081014,0.00020138765,0.000114726354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007597491,0.00019843296,0.00081945996,0.000051341016,0.00010579019,0.000016675576,0.00013528572,0.000051939205,0.00012318186],"category_scores_gemma":[0.00007024668,0.00008693463,0.000040464278,0.00010885381,0.00014760158,0.00008919533,0.000022010028,0.00020463353,0.0000019010236],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4010421,0.0018791249,0.57157016,0.0001391041,0.00078411977,0.00012103741,0.0032122126,0.000101525366,0.0016922029,0.000011615434,0.00031114617,0.01913565],"study_design_scores_gemma":[0.2749784,0.02867135,0.68150175,0.00020867462,0.0021585694,0.00008789326,0.00035937483,0.00022780355,0.010848249,0.000053206455,0.00071661087,0.00018810121],"about_ca_topic_score_codex":0.00059265253,"about_ca_topic_score_gemma":0.0069674095,"teacher_disagreement_score":0.12606367,"about_ca_system_score_codex":0.00009279698,"about_ca_system_score_gemma":0.00039822282,"threshold_uncertainty_score":0.38879782},"labels":[],"label_agreement":null},{"id":"W2108275065","doi":"10.1016/s1470-2045(05)70394-6","title":"Chemotherapy-induced anaemia during adjuvant treatment for breast cancer: development of a prediction model","year":2005,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Logistic regression; Chemotherapy; Receiver operating characteristic; Internal medicine; Area under the curve; Oncology; Sample size determination; Cancer; Surgery; Statistics","score_opus":0.05331006828365456,"score_gpt":0.35086283400032575,"score_spread":0.2975527657166712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108275065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9764346,0.00027457206,0.0001699943,0.0212319,0.00007640807,0.00071686954,0.000094629264,0.000058076777,0.00094293547],"genre_scores_gemma":[0.98429537,0.00072349387,0.0125990715,0.00046226726,0.0006972111,0.00037312764,0.00002348416,0.00002063127,0.00080532575],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991416,0.00002288497,0.0002726642,0.00018909932,0.0001016028,0.0002721814],"domain_scores_gemma":[0.9994965,0.000034828747,0.00012057768,0.00022634439,0.000059831073,0.0000618964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014146359,0.00014500595,0.0004817374,0.000036104135,0.00010669691,0.000002488148,0.00007047205,0.0000951316,0.000071425726],"category_scores_gemma":[0.000003885322,0.000086631895,0.00008051353,0.000056444973,0.000047093294,0.000022182896,0.000015610327,0.00007350817,0.0000046688647],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054325415,0.0017148985,0.008294994,0.00024261841,0.0007850732,0.000008840134,0.009166446,0.00086594326,0.1565337,0.00016797904,0.0019398091,0.8148472],"study_design_scores_gemma":[0.07815271,0.00435155,0.25487757,0.00054702687,0.0010043222,0.0006242879,0.0012927883,0.03368077,0.5584252,0.00016050367,0.06633956,0.00054375234],"about_ca_topic_score_codex":0.000034374072,"about_ca_topic_score_gemma":0.00017405432,"teacher_disagreement_score":0.8143034,"about_ca_system_score_codex":0.0010669209,"about_ca_system_score_gemma":0.00044977135,"threshold_uncertainty_score":0.3532746},"labels":[],"label_agreement":null},{"id":"W2108319301","doi":"10.1016/s1470-2045(10)70256-4","title":"Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China","year":2010,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":160,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Fogarty International Center","keywords":"Colposcopy; Medicine; Cervical cancer; Squamous intraepithelial lesion; Cervix; Population; Cervical intraepithelial neoplasia; Gynecology; Biopsy; Cytology; Cancer; Obstetrics; Oncology; Internal medicine; Pathology","score_opus":0.12761277244206512,"score_gpt":0.41634827178975076,"score_spread":0.2887354993476856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108319301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917658,0.00059044786,0.000013573373,0.0012461954,0.0001061797,0.0005727013,0.005207827,0.000027456937,0.00046983315],"genre_scores_gemma":[0.9925839,0.00011602238,0.002547842,0.00062672497,0.0006139295,0.00010058791,0.0033826544,0.000018177729,0.000010160804],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99799794,0.00018425794,0.0005657,0.00040326055,0.0005268798,0.00032194893],"domain_scores_gemma":[0.9962432,0.0018875139,0.00044794343,0.001021271,0.0003079889,0.00009209412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008609112,0.00016559147,0.001327298,0.00015331479,0.00017673352,0.000009088591,0.00066672836,0.00014617605,0.00087555],"category_scores_gemma":[0.0007145479,0.00011055599,0.00011275281,0.00052494946,0.00024837258,0.000055320623,0.00041657218,0.00049858773,0.0000019457586],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002851632,0.00030050927,0.87703437,0.00014040989,0.003530628,0.0000033512338,0.0006716533,0.00024245815,0.0037804847,0.000033823988,0.00061475375,0.110795945],"study_design_scores_gemma":[0.0036717355,0.0013313426,0.98083484,0.000038768474,0.0047470806,4.04582e-7,0.00008782359,0.0077114794,0.0007733509,0.00039409578,0.00029952478,0.00010958066],"about_ca_topic_score_codex":0.0553749,"about_ca_topic_score_gemma":0.025706202,"teacher_disagreement_score":0.11068636,"about_ca_system_score_codex":0.00012171398,"about_ca_system_score_gemma":0.00035232177,"threshold_uncertainty_score":0.9920721},"labels":[],"label_agreement":null},{"id":"W2108765055","doi":"10.1016/s1470-2045(15)00034-0","title":"Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Nausea and vomiting management","field":"Medicine","cited_by":151,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Anthracycline; Nausea; Vomiting; Chemotherapy; Cyclophosphamide; Chemotherapy-induced nausea and vomiting; Randomized controlled trial; Palonosetron; Cancer; Internal medicine; Oncology; Antiemetic; Breast cancer","score_opus":0.07038524306020998,"score_gpt":0.3918463014891096,"score_spread":0.3214610584288996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108765055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99282116,0.0002762439,0.0001734412,0.0011157199,0.000046593686,0.0054944702,0.000022365895,0.0000073809333,0.00004259987],"genre_scores_gemma":[0.99817,0.0005487528,0.00073452044,0.00010207731,0.00011601525,0.00025669322,0.000015852354,0.00001782902,0.000038268892],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99870306,0.0001419461,0.00060446485,0.00022344045,0.0001499342,0.0001771334],"domain_scores_gemma":[0.998573,0.0004051492,0.00063257996,0.00016628792,0.00016429496,0.000058702666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010753139,0.00015167696,0.0011039767,0.00008368823,0.000028171959,0.0000058897454,0.000049581613,0.00009242198,0.00000810112],"category_scores_gemma":[0.00013692521,0.00009208958,0.00005058696,0.00010749905,0.00011964579,0.000064122985,0.000016600337,0.00010038887,2.5243386e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9689403,0.0011779397,0.00429739,0.00017219693,0.00042184474,0.0000023976606,0.0010260191,0.0000059207255,0.0019975363,0.000023545177,0.000007672585,0.021927217],"study_design_scores_gemma":[0.9437579,0.012320478,0.028858043,0.00016859925,0.00037064188,0.00000372196,0.00016122361,0.00033424643,0.013822494,0.00006013207,0.0000521577,0.00009038107],"about_ca_topic_score_codex":0.000041220123,"about_ca_topic_score_gemma":0.00014631335,"teacher_disagreement_score":0.02518244,"about_ca_system_score_codex":0.000058568483,"about_ca_system_score_gemma":0.00019789085,"threshold_uncertainty_score":0.37553042},"labels":[],"label_agreement":null},{"id":"W2109063533","doi":"10.1016/s1470-2045(05)70390-9","title":"Mammographic breast density as an intermediate phenotype for breast cancer","year":2005,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Digital Radiography and Breast Imaging","field":"Medicine","cited_by":630,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Hospital for Sick Children; University of Toronto; Ontario Institute for Cancer Research","funders":"Medical Research Council; Canada Research Chairs; National Breast Cancer Foundation","keywords":"Breast cancer; Breast density; Mammography; MAMMOGRAPHIC DENSITY; Breast tissue; Medicine; Risk factors for breast cancer; Oncology; Cancer; Internal medicine","score_opus":0.06242076777872589,"score_gpt":0.4033152415651653,"score_spread":0.3408944737864394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109063533","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00045733384,0.9864471,0.000028764567,0.003950099,0.000955906,0.0017007402,0.0014562414,0.00020698702,0.0047968263],"genre_scores_gemma":[0.0023063729,0.9869794,0.00019381713,0.002372397,0.0069666123,0.00041542348,0.0003086994,0.00010164805,0.00035561164],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976159,0.00024267488,0.00054768415,0.0005883768,0.00021276347,0.00079263875],"domain_scores_gemma":[0.9980197,0.00029960225,0.000421168,0.0008003326,0.00017902516,0.00028020472],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006850283,0.0005339659,0.00285099,0.000310485,0.00014023602,0.000058173646,0.00061185635,0.00039708198,0.00020346727],"category_scores_gemma":[0.000029777046,0.0003256843,0.00087045925,0.0005461227,0.00046461634,0.00015817511,0.000118136835,0.00079681067,0.00008471622],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059085194,0.0002470053,0.00019736576,0.0034114155,0.0005996405,0.000055348453,0.00006105648,1.418902e-7,5.188086e-7,0.00063740247,0.0025762268,0.99162304],"study_design_scores_gemma":[0.001375556,0.00039629216,0.0031360255,0.0036426655,0.0028671275,0.010603896,0.000025849222,0.00000849943,1.495531e-7,0.00047346158,0.9771149,0.0003555818],"about_ca_topic_score_codex":0.00011048836,"about_ca_topic_score_gemma":0.00026038298,"teacher_disagreement_score":0.99126744,"about_ca_system_score_codex":0.00024769176,"about_ca_system_score_gemma":0.00077028875,"threshold_uncertainty_score":0.99991953},"labels":[],"label_agreement":null},{"id":"W2109575571","doi":"10.1016/s1470-2045(06)70576-9","title":"Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors","year":2006,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":539,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Hospital for Sick Children; University of British Columbia; Canadian College of Naturopathic Medicine; University of Toronto; McMaster University","funders":"Sick Kids Foundation","keywords":"Clinical trial; Medicine; Protocol (science); Systematic review; Alternative medicine; Meta-analysis; Placebo; Family medicine; Patient participation; MEDLINE; Internal medicine; Pathology","score_opus":0.8673190754124493,"score_gpt":0.7341545071881482,"score_spread":0.13316456822430112,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109575571","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00047301434,0.99186665,0.000009356502,0.0017410065,0.00009470941,0.005506854,0.0001344879,0.000007224168,0.00016667022],"genre_scores_gemma":[0.0007403511,0.9968411,0.00012553095,0.0008350737,0.0000760603,0.0012165976,0.000047083846,0.000019604695,0.000098652075],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.96708953,0.019828016,0.011289395,0.0005261277,0.00092428573,0.00034261204],"domain_scores_gemma":[0.8927435,0.09817652,0.006709184,0.0014563128,0.0006232576,0.00029119683],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.09075666,0.0002691824,0.029447773,0.00035884613,0.000021147001,0.0000044009184,0.00035994063,0.0007455957,0.00031236213],"category_scores_gemma":[0.3134471,0.00012513576,0.0033568763,0.0014596822,0.00034453179,0.000013367425,0.00016275606,0.0015252607,0.000002339451],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000072998155,0.000114947456,0.0014331463,0.91398484,0.07381599,0.000012817623,0.00008982957,0.0000014395807,1.0829445e-7,0.00015254373,0.00019188414,0.010129439],"study_design_scores_gemma":[0.00049457647,0.0006625715,0.0002330753,0.17618325,0.79721767,0.0000029152657,0.000030478692,0.00000334595,0.0000013527849,0.00017669314,0.024873827,0.00012026694],"about_ca_topic_score_codex":0.0007410283,"about_ca_topic_score_gemma":0.0022140194,"teacher_disagreement_score":0.7378016,"about_ca_system_score_codex":0.00018110042,"about_ca_system_score_gemma":0.0021544134,"threshold_uncertainty_score":0.9849611},"labels":[],"label_agreement":null},{"id":"W2109611268","doi":"10.1016/s1470-2045(15)00201-6","title":"Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":157,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"National Cancer Institute; Sunesis","keywords":"Cytarabine; Medicine; Refractory (planetary science); Placebo; Myeloid leukaemia; Double blind; Internal medicine; Chemotherapy; Physics","score_opus":0.09009627044355988,"score_gpt":0.38511582346662937,"score_spread":0.2950195530230695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109611268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97237617,0.00019003464,0.00009158526,0.0077502676,0.00061797164,0.015323391,0.00006141999,0.00016712805,0.003422032],"genre_scores_gemma":[0.989919,0.00017380403,0.0009776512,0.00092294806,0.0010010004,0.0032818136,0.00043230123,0.0001246809,0.0031667785],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9941397,0.0011630397,0.0011679714,0.0008993927,0.0014200306,0.0012099149],"domain_scores_gemma":[0.99315107,0.0036195735,0.0006082805,0.0012479604,0.0008614329,0.0005116573],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004155756,0.00064574904,0.0028024062,0.00051609206,0.0002556917,0.00005208016,0.00087151077,0.00042294402,0.00027719818],"category_scores_gemma":[0.0023538603,0.00037085378,0.00016956193,0.00094742636,0.00050686207,0.00028965034,0.00033630125,0.0018417815,0.00023799324],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.970024,0.0037053952,0.0036970729,0.000058124508,0.001454376,0.001118746,0.003641857,0.00095750944,0.00007559603,0.000029645465,0.014423744,0.00081393577],"study_design_scores_gemma":[0.9522977,0.023834415,0.0028984402,0.000085287735,0.00082239637,0.0000708324,0.0014090899,0.004227944,0.00004610452,0.000010299105,0.013874338,0.00042314318],"about_ca_topic_score_codex":0.00059531257,"about_ca_topic_score_gemma":0.0028248404,"teacher_disagreement_score":0.02012902,"about_ca_system_score_codex":0.0068519292,"about_ca_system_score_gemma":0.005553394,"threshold_uncertainty_score":0.99987435},"labels":[],"label_agreement":null},{"id":"W2109847618","doi":"10.1016/s1470-2045(04)01468-8","title":"Environmental, genetic, and molecular features of prostate cancer","year":2004,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Prostate cancer; Carcinogenesis; Cancer; Disease; Prostate; Oncology; Androgen; Medicine; Stage (stratigraphy); Internal medicine; Cancer research; Biology; Hormone","score_opus":0.052135824976632876,"score_gpt":0.40191947715364446,"score_spread":0.3497836521770116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109847618","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008863409,0.9952945,6.2055767e-7,0.0012293173,0.00008355699,0.0013614305,0.00014592557,0.000012581547,0.0009857445],"genre_scores_gemma":[0.00026634114,0.99772835,0.0002020772,0.00019224102,0.0002021136,0.00033450118,0.00006197307,0.00003566984,0.0009767385],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99884975,0.0001610761,0.00024701713,0.0002576962,0.00017113177,0.00031330742],"domain_scores_gemma":[0.9993019,0.00007790713,0.00017825325,0.000350788,0.000013037658,0.00007808568],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016013287,0.00022596809,0.0015357654,0.000063881,0.000042301534,0.0000060438833,0.00015440093,0.00021015368,0.00009086785],"category_scores_gemma":[0.000009776133,0.000116215626,0.00014194184,0.000089197434,0.00043696826,0.0000098422415,0.00012121132,0.00042150504,0.000011181344],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016526498,0.000090467256,0.000113622205,0.011680596,0.0005163084,0.00024111853,0.00018579944,6.7379455e-7,0.000048426235,0.00006729732,0.000893929,0.9859965],"study_design_scores_gemma":[0.0017299934,0.0005158659,0.0006206229,0.0035551924,0.0012096833,0.0002693639,0.000020463938,1.6171099e-7,0.00008624142,0.00014828911,0.9917331,0.000111023815],"about_ca_topic_score_codex":0.00006519017,"about_ca_topic_score_gemma":0.000008270621,"teacher_disagreement_score":0.9908392,"about_ca_system_score_codex":0.00037179654,"about_ca_system_score_gemma":0.0006634532,"threshold_uncertainty_score":0.47391358},"labels":[],"label_agreement":null},{"id":"W2111285159","doi":"10.1016/s1470-2045(11)70141-3","title":"Delivering affordable cancer care in high-income countries","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":714,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Institute for Health and Care Research; King's College London; King's College Hospital NHS Foundation Trust; Department of Health and Social Care; Conquer Cancer Foundation","keywords":"Medicine; Health care; Cancer; Concordance; Modalities; Health technology; Public economics; Economic growth; Economics","score_opus":0.05469430517267371,"score_gpt":0.2706740393965379,"score_spread":0.21597973422386418,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111285159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85543525,0.00922296,0.00012900577,0.0014658045,0.0010992265,0.00020406525,0.00014837552,0.000039688235,0.13225564],"genre_scores_gemma":[0.99348646,0.0036024612,0.00048396375,0.0014661332,0.00049944717,0.00009535135,0.0000030429833,0.000021427437,0.0003416899],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99879646,0.000020999563,0.0004220672,0.00025681633,0.000017592583,0.00048607096],"domain_scores_gemma":[0.99928397,0.0000518769,0.00025530017,0.00032857832,0.000030861567,0.000049391492],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004763253,0.00013766119,0.0006239578,0.00010358732,0.00009646338,0.000021912221,0.00042287243,0.00013900685,0.0012103514],"category_scores_gemma":[0.00003603469,0.00012547546,0.000053313237,0.00012161365,0.00013758705,0.00021893956,0.000092637696,0.0002272395,0.00046689538],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002904725,0.000029758501,0.5848868,0.00006266415,0.000042922624,0.000016571179,0.006659801,0.000181196,0.0000025940446,0.4030004,0.00081544515,0.0040113656],"study_design_scores_gemma":[0.0017129929,0.00021488954,0.5774561,0.00003452985,0.0000080840055,0.000004491265,0.0002725132,0.00009166617,0.000104936145,0.036158446,0.38365608,0.0002852503],"about_ca_topic_score_codex":0.015150598,"about_ca_topic_score_gemma":0.013066325,"teacher_disagreement_score":0.38284066,"about_ca_system_score_codex":0.0005681771,"about_ca_system_score_gemma":0.000093455565,"threshold_uncertainty_score":0.9997027},"labels":[],"label_agreement":null},{"id":"W2111404068","doi":"10.1016/s1470-2045(14)70012-9","title":"Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":978,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Medical Research Council; National Health and Medical Research Council; National Cancer Institute; National Institutes of Health; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; Genentech; F. Hoffmann-La Roche","keywords":"Vemurafenib; Dacarbazine; Medicine; Internal medicine; Melanoma; Population; Oncology; Progression-free survival; Metastatic melanoma; Chemotherapy; Cancer research; Cancer","score_opus":0.0286159142605539,"score_gpt":0.3339014764236995,"score_spread":0.3052855621631456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111404068","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99506813,0.00031286658,0.0003243542,0.00025117994,0.00010798077,0.0011329814,0.000041513744,0.000004699333,0.0027562866],"genre_scores_gemma":[0.9989465,0.00012769057,0.00037134535,0.0001959751,0.000107638305,0.000047935137,0.000051433864,0.000013991938,0.00013752749],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982852,0.00067222095,0.00041700812,0.0003223228,0.00008594214,0.00021730294],"domain_scores_gemma":[0.9989133,0.0003558692,0.0002529949,0.0003504614,0.00006953995,0.00005783344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011778183,0.00015636784,0.00067078695,0.000048021153,0.000062176274,0.00001137866,0.00030448026,0.00012444291,0.0000081633925],"category_scores_gemma":[0.0002849355,0.000115953546,0.000031851654,0.00008858667,0.0002112981,0.000007345978,0.00027289,0.00011055446,9.1193925e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11723933,0.005918985,0.0074286326,0.00013672051,0.00066282664,0.000055513443,0.006525965,0.000016317386,0.71319085,0.003644714,0.0005567797,0.14462338],"study_design_scores_gemma":[0.7619356,0.023933085,0.091748916,0.00008302523,0.00034691312,0.00018076375,0.0014294119,0.0005928241,0.11127973,0.0009786859,0.006951217,0.00053980714],"about_ca_topic_score_codex":0.00012726754,"about_ca_topic_score_gemma":0.00042344426,"teacher_disagreement_score":0.6446963,"about_ca_system_score_codex":0.000012129177,"about_ca_system_score_gemma":0.00008710973,"threshold_uncertainty_score":0.4728448},"labels":[],"label_agreement":null},{"id":"W2111498373","doi":"10.1016/s1470-2045(14)70265-7","title":"Risk of late effects of treatment in children newly diagnosed with standard-risk acute lymphoblastic leukaemia: a report from the Childhood Cancer Survivor Study cohort","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":141,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; University of Toronto; Hospital for Sick Children; University of Alberta","funders":"National Cancer Institute; Swiss Cancer Research Foundation; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung","keywords":"Medicine; Pediatrics; Cohort; Cohort study; Epidemiology; Cancer; Incidence (geometry); Population; Internal medicine","score_opus":0.008375098535697043,"score_gpt":0.2933682577099663,"score_spread":0.2849931591742692,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111498373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99431723,0.0003379609,0.0002386406,0.00052334846,0.00014219122,0.003776961,0.00029173488,0.00004034554,0.00033160407],"genre_scores_gemma":[0.99661624,0.0017204152,0.00025336264,0.00017162932,0.0004311208,0.000626296,0.000045123048,0.00005120154,0.000084584826],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99606633,0.0015800953,0.00065653265,0.0005291286,0.0006070158,0.00056090945],"domain_scores_gemma":[0.9922627,0.0053705573,0.00074802386,0.0013249395,0.00017517377,0.0001185914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001810211,0.00033559356,0.0017157701,0.00009130938,0.00010921458,0.000009930208,0.00045833836,0.00017782905,0.000034801098],"category_scores_gemma":[0.0011898272,0.00015645586,0.00011939308,0.00042739816,0.00044541984,0.000037106372,0.00016375471,0.000533083,0.0000072144403],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040467945,0.0009741274,0.977296,0.000024211313,0.0039593596,0.00037884552,0.0042954017,0.00050756644,0.00014642002,0.0000059258787,0.00048489348,0.007880473],"study_design_scores_gemma":[0.03802337,0.009013641,0.9476969,0.00015332295,0.003182032,0.00015326068,0.00021062707,0.000387104,0.00070760626,0.00007776436,0.00025264214,0.00014168855],"about_ca_topic_score_codex":0.08058838,"about_ca_topic_score_gemma":0.017508566,"teacher_disagreement_score":0.06307981,"about_ca_system_score_codex":0.002178321,"about_ca_system_score_gemma":0.0024948532,"threshold_uncertainty_score":0.9770191},"labels":[],"label_agreement":null},{"id":"W2112121482","doi":"10.1016/s1470-2045(15)70076-8","title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2666,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"National Institutes of Health; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; GlaxoSmithKline; Bristol-Myers Squibb","keywords":"Open label; Medicine; Nivolumab; Oncology; Chemotherapy; Internal medicine; Ipilimumab; Randomized controlled trial; Immunotherapy; Cancer","score_opus":0.05803676378711036,"score_gpt":0.3752254400827541,"score_spread":0.31718867629564373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112121482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98230904,0.0010480715,0.0000060482075,0.0036368757,0.0005850302,0.009512851,0.000028259547,0.00004919258,0.0028246061],"genre_scores_gemma":[0.9936758,0.00046165872,0.00047281646,0.0014604217,0.00041828217,0.002877564,0.000060291244,0.000049961312,0.0005231707],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978956,0.00040204023,0.00052001374,0.00038738665,0.00027084592,0.00052410614],"domain_scores_gemma":[0.9986183,0.0002262894,0.00032333424,0.0005623119,0.00013673933,0.00013301772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008499426,0.0003240201,0.0017268931,0.000084179796,0.00006261166,0.00004530974,0.0003079918,0.00015717978,0.00014333453],"category_scores_gemma":[0.00007141629,0.00017363168,0.00009712103,0.00024954963,0.00022945176,0.00012703107,0.00004423072,0.00018063726,0.000016055223],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92947155,0.005111363,0.0019595388,0.00001318586,0.0008096154,0.00007856489,0.000819838,0.0000016111674,0.00026483016,0.000005621738,0.00083226763,0.06063199],"study_design_scores_gemma":[0.905581,0.05465214,0.0021153914,0.00007474726,0.00022721932,0.000008712235,0.00009579988,0.00006879399,0.00037418402,0.00001079027,0.036587715,0.00020352949],"about_ca_topic_score_codex":0.00013211323,"about_ca_topic_score_gemma":0.00020118506,"teacher_disagreement_score":0.060428463,"about_ca_system_score_codex":0.00074691576,"about_ca_system_score_gemma":0.000615879,"threshold_uncertainty_score":0.7080494},"labels":[],"label_agreement":null},{"id":"W2113057788","doi":"10.1016/s1470-2045(14)70380-8","title":"Outcomes and endpoints in cancer trials: bridging the divide","year":2014,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":91,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Medical Research Council; National Institutes of Health; Cancer Research UK","keywords":"Clinical endpoint; Medicine; Clinical trial; Psychological intervention; Intensive care medicine; Bridging (networking); Cancer; Disease; Clinical study design; Modalities; Randomized controlled trial; Computer science; Internal medicine; Nursing","score_opus":0.14362320288141806,"score_gpt":0.4459898483730344,"score_spread":0.30236664549161635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113057788","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006178801,0.99467,0.0000599024,0.0025265375,0.0006837416,0.000609168,0.00011610424,0.0000055941614,0.00071107835],"genre_scores_gemma":[0.00060644734,0.9939282,0.000033309472,0.0020356453,0.0027553495,0.00032816824,0.000054572447,0.000032996264,0.00022531181],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99770147,0.0009872224,0.00055913074,0.00034300974,0.00007149371,0.00033767865],"domain_scores_gemma":[0.9976675,0.0012638634,0.00043163777,0.00057473476,0.000021011372,0.000041237323],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002783763,0.00026905668,0.0019711345,0.0000376823,0.00008102806,0.000034906774,0.0005155626,0.0002987154,0.000016565093],"category_scores_gemma":[0.0010876914,0.00013455297,0.00024196369,0.0000695989,0.00016692703,0.0000010328181,0.00037194864,0.00034368638,0.00000855565],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029633238,0.000017529574,0.0003047728,0.0005981153,0.00017207535,0.0000040185346,0.000039517963,0.0000071470517,0.000012548653,0.0002546505,0.012290302,0.9862697],"study_design_scores_gemma":[0.00060374854,0.00007981579,0.00022939565,0.00036461753,0.00030459365,0.00002428315,0.0000074044824,0.0000044465323,0.000009253876,0.00016266905,0.9980383,0.00017150438],"about_ca_topic_score_codex":0.00018378433,"about_ca_topic_score_gemma":0.0019447098,"teacher_disagreement_score":0.9860982,"about_ca_system_score_codex":0.000078085985,"about_ca_system_score_gemma":0.0003537195,"threshold_uncertainty_score":0.54869115},"labels":[],"label_agreement":null},{"id":"W2113322173","doi":"10.1016/s1470-2045(12)70559-4","title":"External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1029,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Health Sciences Centre; Western University; Sunnybrook Health Science Centre; University of Calgary","funders":"National Cancer Institute","keywords":"Renal cell carcinoma; Medicine; Prognostic model; Population; Oncology; Database; Internal medicine; Computer science; Overall survival; Environmental health","score_opus":0.08719604319912287,"score_gpt":0.3307886472917002,"score_spread":0.24359260409257733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113322173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913383,0.00009765066,0.004361558,0.0015579794,0.00005502073,0.001719255,0.000024050565,0.000016370377,0.0008297745],"genre_scores_gemma":[0.9946337,0.0000015452563,0.004535074,0.00034907783,0.000056525274,0.00022616546,0.000032225154,0.000018310202,0.00014737365],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99870086,0.00026228614,0.00031441802,0.00021530822,0.00034203322,0.00016507607],"domain_scores_gemma":[0.99883354,0.00025699296,0.00028083837,0.00043478428,0.00014179341,0.00005207891],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033766386,0.00014094356,0.00041213582,0.000052889176,0.000059163747,0.000017665543,0.00018398277,0.000028119723,0.000063541265],"category_scores_gemma":[0.000033962464,0.000069300586,0.000038085367,0.000083829844,0.00009107333,0.00007715075,0.00006587522,0.00015842528,0.000005051768],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006956387,0.0009995666,0.9602619,0.00006340569,0.00011689252,0.00000916437,0.00075165625,0.03161767,0.0048564756,0.00025136193,0.00013679716,0.00023948189],"study_design_scores_gemma":[0.0077984226,0.0015207804,0.5654354,0.00007328937,0.00081597874,0.000042112086,0.00043605483,0.4177311,0.005337233,0.0006617105,0.000023509872,0.00012437828],"about_ca_topic_score_codex":0.000826339,"about_ca_topic_score_gemma":0.00018434133,"teacher_disagreement_score":0.39482644,"about_ca_system_score_codex":0.00011820731,"about_ca_system_score_gemma":0.00015702083,"threshold_uncertainty_score":0.2825996},"labels":[],"label_agreement":null},{"id":"W2113344831","doi":"10.1016/s1470-2045(09)70314-6","title":"Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial","year":2009,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1405,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; University of Toronto; Sunnybrook Health Science Centre","funders":"National Cancer Institute; Genomic Health; U.S. Department of Health and Human Services","keywords":"Tamoxifen; Medicine; Internal medicine; Breast cancer; Oncology; Hazard ratio; Proportional hazards model; Anthracycline; Chemotherapy; Cyclophosphamide; Retrospective cohort study; Gynecology; Cancer; Confidence interval","score_opus":0.008274236675616017,"score_gpt":0.2673977770089922,"score_spread":0.2591235403333762,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113344831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99515057,0.00035444315,0.00004826474,0.0019523967,0.00006342032,0.0012002438,0.0009142787,0.0000052459363,0.0003111639],"genre_scores_gemma":[0.9984028,0.0003634302,0.00009396353,0.0005853605,0.00016004546,0.0003285193,0.000046721187,0.0000120291925,0.000007156657],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9983449,0.00049554335,0.00026217342,0.00040301817,0.00018553955,0.00030883428],"domain_scores_gemma":[0.9989283,0.00017473125,0.00035858882,0.00032367138,0.00017443599,0.00004028887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041542706,0.00022944115,0.0007942038,0.000071973685,0.00007383073,0.0000058395226,0.00022461328,0.0001194587,0.000009391318],"category_scores_gemma":[0.00007666785,0.00012936385,0.000081027654,0.00049848284,0.00044154236,0.0000054260804,0.00006096897,0.00016525068,1.5918826e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.62871385,0.001449358,0.2855937,0.000018304918,0.007420266,0.0000058269343,0.0051181763,0.0010129419,0.06529313,0.00020190411,0.00007002119,0.0051025264],"study_design_scores_gemma":[0.05639826,0.0048529697,0.92213494,0.00007077165,0.000714069,0.000011188576,0.000187184,0.000069024514,0.015357234,0.000064332235,0.000007987542,0.00013205921],"about_ca_topic_score_codex":0.00011459331,"about_ca_topic_score_gemma":0.00014731685,"teacher_disagreement_score":0.63654125,"about_ca_system_score_codex":0.00026309863,"about_ca_system_score_gemma":0.00021120669,"threshold_uncertainty_score":0.52753043},"labels":[],"label_agreement":null},{"id":"W2113721264","doi":"10.1016/s1470-2045(09)70279-7","title":"Eradication of a disease: how we cured asymptomatic prostate cancer","year":2000,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Asymptomatic; Prostate cancer; Disease; Medicine; Cancer; Prostate; Oncology; Internal medicine","score_opus":0.031400975568474994,"score_gpt":0.3364240071741232,"score_spread":0.3050230316056482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113721264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7120525,0.009536166,0.0000046211976,0.27481917,0.00011485079,0.000889298,0.000090145855,0.00005113814,0.0024420812],"genre_scores_gemma":[0.970173,0.025255805,0.00021083714,0.0015150307,0.0002883495,0.00063984154,0.000035271685,0.000013297205,0.0018685813],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992792,0.00008668742,0.0001469414,0.00015065697,0.00012810726,0.00020842197],"domain_scores_gemma":[0.9993511,0.00008442125,0.00010403931,0.000328359,0.00004401083,0.0000881112],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013950541,0.00009629234,0.00037004537,0.00002491108,0.000042529162,0.0000060777465,0.00008973913,0.000037560098,0.00060512056],"category_scores_gemma":[0.000018170047,0.00005699569,0.00005531749,0.00012262246,0.0001247771,0.00003435274,0.000012188273,0.00008932715,0.000029770012],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042444603,0.0013373297,0.117581554,0.00084968196,0.0007041653,0.0000813264,0.004299402,0.00014118895,0.0012174242,0.0015378129,0.099364154,0.7686415],"study_design_scores_gemma":[0.006702173,0.0012034995,0.3864317,0.000454969,0.0006189138,0.00001990399,0.00008364885,0.00054965925,0.0016640661,0.0017527007,0.6003772,0.00014156627],"about_ca_topic_score_codex":0.000043526285,"about_ca_topic_score_gemma":0.000028517361,"teacher_disagreement_score":0.7684999,"about_ca_system_score_codex":0.00019616097,"about_ca_system_score_gemma":0.00026010617,"threshold_uncertainty_score":0.6625646},"labels":[],"label_agreement":null},{"id":"W2115081639","doi":"10.1016/s1470-2045(14)70376-6","title":"Evidence-based care for trilateral retinoblastoma","year":2014,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Hospital for Sick Children","funders":"","keywords":"Retinoblastoma; Scopus; Medicine; Pediatrics; Clinical trial; Epidemiology; Incidence (geometry); Family medicine; MEDLINE; Pathology; Political science","score_opus":0.10890512585081343,"score_gpt":0.37147253368953076,"score_spread":0.26256740783871735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115081639","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0041373908,0.0022171903,0.00015182736,0.9856829,0.0011701195,0.001807978,0.00005672064,0.00012628634,0.0046495795],"genre_scores_gemma":[0.023143044,0.0001321735,0.0018626843,0.9534878,0.016594209,0.000632038,0.00075223285,0.00007265454,0.0033231317],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99778265,0.00058066467,0.00032191892,0.0004674386,0.00020316904,0.0006441774],"domain_scores_gemma":[0.9968609,0.0017469618,0.00028041014,0.0008558183,0.0001976698,0.000058243062],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00050495146,0.0003427516,0.0014284761,0.000095144205,0.00017973053,0.000012885026,0.0003555077,0.0015743949,0.00017704736],"category_scores_gemma":[0.0002805718,0.0002091584,0.00035989107,0.00008053291,0.0002816471,0.000025855126,0.000045944587,0.0014825701,0.00024005928],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023036385,0.000047508525,0.0018449163,0.0007901015,0.00031041517,0.0009368551,0.00017128205,0.00000236965,0.000025564106,0.00002564562,0.987396,0.0061457264],"study_design_scores_gemma":[0.0065947166,0.0049408665,0.00091418443,0.00051750237,0.0012122683,0.00025095837,0.00001469321,0.00004528151,0.00019301409,0.00017301115,0.98495466,0.00018883945],"about_ca_topic_score_codex":0.000019065556,"about_ca_topic_score_gemma":0.000026809672,"teacher_disagreement_score":0.032195073,"about_ca_system_score_codex":0.0005189279,"about_ca_system_score_gemma":0.00066453294,"threshold_uncertainty_score":0.99972177},"labels":[],"label_agreement":null},{"id":"W2115528152","doi":"10.1016/s1470-2045(15)00038-8","title":"Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":281,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Astex Pharmaceuticals; National Cancer Institute; Stand Up To Cancer; Entertainment Industry Foundation","keywords":"Tolerability; Medicine; Decitabine; International Prognostic Scoring System; Internal medicine; Hypomethylating agent; Myelodysplastic syndromes; Adverse effect; Neutropenia; Febrile neutropenia; Oncology; Pharmacology; Gastroenterology; Bone marrow; Toxicity; Biology; DNA methylation","score_opus":0.029835544640734405,"score_gpt":0.33339687282781183,"score_spread":0.30356132818707743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115528152","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99475765,0.00010650937,0.00007928524,0.0013825062,0.0000638538,0.0031813942,0.000033589407,0.000026814483,0.00036837778],"genre_scores_gemma":[0.99892324,0.00007719749,0.0005791194,0.00015219119,0.00006523077,0.0000754147,0.000040725477,0.000021919743,0.00006493303],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99754846,0.0006267449,0.00058521406,0.00040008238,0.00041541847,0.0004241035],"domain_scores_gemma":[0.99796313,0.0008822665,0.00021215095,0.0004671736,0.00025270515,0.00022254982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019161938,0.00021959824,0.0012288014,0.0001446612,0.00006152816,0.000011186221,0.00016021816,0.0001490428,0.000025972857],"category_scores_gemma":[0.0007440055,0.00013307687,0.000027941664,0.00033983585,0.00040022764,0.0001250972,0.00018346458,0.0005503343,0.000005452789],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21772376,0.002762782,0.7624103,0.00013056093,0.0003862571,0.00022366336,0.0050308695,0.00006036277,0.00022663172,0.000022091692,0.00016506108,0.010857705],"study_design_scores_gemma":[0.27319378,0.0072698887,0.71633875,0.00004892046,0.00028602214,0.000108945416,0.00078461185,0.0016102991,0.000018785679,0.000034156663,0.00019306202,0.00011278381],"about_ca_topic_score_codex":0.00013590847,"about_ca_topic_score_gemma":0.00021211094,"teacher_disagreement_score":0.05547002,"about_ca_system_score_codex":0.0005741566,"about_ca_system_score_gemma":0.00038901102,"threshold_uncertainty_score":0.54267174},"labels":[],"label_agreement":null},{"id":"W2116183806","doi":"10.1016/s1470-2045(12)70567-3","title":"Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":137,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of British Columbia; McMaster University","funders":"Medical Research Council; National Institute for Health and Care Research","keywords":"Bevacizumab; Medicine; Ovarian cancer; Carboplatin; Clinical endpoint; Quality of life (healthcare); Internal medicine; Randomized controlled trial; Oncology; Chemotherapy; Endometrial cancer; Gynecologic oncology; Cancer; Clinical trial; Surgery","score_opus":0.07110357242492646,"score_gpt":0.4109774263119079,"score_spread":0.33987385388698144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116183806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8564069,0.00009550038,0.00013336012,0.1375898,0.0007460686,0.0034949165,0.0002293524,0.00003281807,0.0012712801],"genre_scores_gemma":[0.9855762,0.0004913788,0.0014914894,0.009533488,0.00078090245,0.0018163198,0.0000807273,0.000029547211,0.00019993905],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9979135,0.0004194882,0.0006295534,0.0003417157,0.00042277586,0.0002730028],"domain_scores_gemma":[0.9970587,0.0016255195,0.0004875196,0.0005433433,0.00019761627,0.0000873093],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00077353796,0.00023985465,0.0012398786,0.00005989023,0.000085859225,0.0000459859,0.00029079756,0.00012152229,0.0017350399],"category_scores_gemma":[0.0003343799,0.000108690634,0.000089639536,0.00023661731,0.0001441922,0.00009872023,0.000026360245,0.00026296815,0.000013766548],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8768721,0.0012429716,0.060469843,0.00001681976,0.0011285681,0.000014152576,0.0027122344,0.0001110754,0.00038020912,0.000952729,0.0034079489,0.052691318],"study_design_scores_gemma":[0.9028552,0.0049492763,0.06551111,0.00013169264,0.00017429437,0.0000033320828,0.0009459048,0.00022697712,0.0009621893,0.00033103165,0.023731368,0.00017758149],"about_ca_topic_score_codex":0.002945672,"about_ca_topic_score_gemma":0.007036828,"teacher_disagreement_score":0.1291693,"about_ca_system_score_codex":0.0005912221,"about_ca_system_score_gemma":0.0012831581,"threshold_uncertainty_score":0.9991775},"labels":[],"label_agreement":null},{"id":"W2116799256","doi":"10.1016/s1470-2045(10)70265-5","title":"Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study","year":2010,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":293,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Lynch syndrome; Endometrial cancer; Colorectal cancer; Cohort; Oncology; Medicine; Internal medicine; Gynecology; Cancer; DNA mismatch repair","score_opus":0.015752714071996615,"score_gpt":0.31767708056204846,"score_spread":0.30192436649005183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116799256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99408,0.000119753044,0.0000058147,0.00046263984,0.00097462075,0.0018899605,0.00004056361,0.000020285494,0.0024063257],"genre_scores_gemma":[0.9986487,0.00015983892,0.0005212521,0.00013542347,0.00023327084,0.00024737942,0.0000055161545,0.000016502921,0.00003210448],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984468,0.00036903453,0.00033147915,0.00029971145,0.0002468909,0.000306048],"domain_scores_gemma":[0.9982462,0.0010697964,0.000195797,0.0003043896,0.000106724256,0.00007712308],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015468398,0.00014950758,0.00082074484,0.00015883216,0.00005696939,0.000005754224,0.0001675651,0.00016975023,0.00018823109],"category_scores_gemma":[0.0009571915,0.00010538525,0.000049477196,0.00041483052,0.00040271351,0.000021549879,0.00009916734,0.0007480713,0.0000062061436],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027327952,0.00025118975,0.98394316,0.000015395633,0.00023318967,0.000074227595,0.0013254269,0.000017353777,0.008897149,0.00003876179,0.00024587885,0.0022254407],"study_design_scores_gemma":[0.0073265294,0.004949267,0.9850136,0.0000148191075,0.0002417065,0.00030083748,0.00040234355,0.00010285274,0.0010130423,0.00011074184,0.00042731335,0.000096936245],"about_ca_topic_score_codex":0.0020590352,"about_ca_topic_score_gemma":0.009145874,"teacher_disagreement_score":0.007884107,"about_ca_system_score_codex":0.0003286695,"about_ca_system_score_gemma":0.00042100277,"threshold_uncertainty_score":0.5103612},"labels":[],"label_agreement":null},{"id":"W2117355364","doi":"10.1016/s1470-2045(15)00216-8","title":"Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":121,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"","keywords":"Medicine; Bevacizumab; Erlotinib; Internal medicine; Colorectal cancer; Maintenance therapy; Oncology; Clinical endpoint; Progression-free survival; Chemotherapy; Cancer; Randomized controlled trial; Surgery; Epidermal growth factor receptor","score_opus":0.12324925473229352,"score_gpt":0.4226656086118182,"score_spread":0.29941635387952464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117355364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9819165,0.00046490668,0.000012198863,0.003312239,0.00031087536,0.008415885,0.000062711486,0.000051686227,0.005453029],"genre_scores_gemma":[0.99021643,0.00045556427,0.0014775984,0.001890957,0.00029420294,0.004276385,0.000038837083,0.000056376655,0.001293639],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99762464,0.00038290638,0.00043292766,0.00050030113,0.00041654607,0.00064266415],"domain_scores_gemma":[0.9984393,0.00034035873,0.00032078486,0.0003778155,0.00032611648,0.00019561198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007586781,0.00039021514,0.0018189924,0.000079896905,0.00014115716,0.000047081518,0.0003709925,0.0000799561,0.0001982523],"category_scores_gemma":[0.00018404658,0.00016800522,0.00004380916,0.00042561672,0.000376237,0.00014335221,0.000117343625,0.00034553808,0.000017151662],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9516242,0.0042463443,0.015137438,0.000018103674,0.00094650197,0.00022804439,0.0028831922,0.0000130167,0.00001585918,0.000038718867,0.0023252699,0.022523291],"study_design_scores_gemma":[0.8869565,0.09640283,0.0046465728,0.00013426815,0.0004026437,0.00007897777,0.0007628187,0.00009075761,0.00007667091,0.000052237927,0.010134066,0.0002616444],"about_ca_topic_score_codex":0.0014225176,"about_ca_topic_score_gemma":0.0060259406,"teacher_disagreement_score":0.09215649,"about_ca_system_score_codex":0.0007686729,"about_ca_system_score_gemma":0.0017375271,"threshold_uncertainty_score":0.68510544},"labels":[],"label_agreement":null},{"id":"W2117964602","doi":"10.1016/s1470-2045(11)70214-5","title":"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1113,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Juravinski Cancer Centre; Vancouver General Hospital; Hôtel-Dieu de Montréal; Centre Hospitalier de l’Université de Montréal; Université de Montréal; BC Cancer Agency; Princess Margaret Cancer Centre; Jewish General Hospital","funders":"AstraZeneca","keywords":"Medicine; Olaparib; Internal medicine; Tolerability; Breast cancer; Ovarian cancer; Oncology; BRCA mutation; PARP inhibitor; Clinical endpoint; Triple-negative breast cancer; Adverse effect; Response Evaluation Criteria in Solid Tumors; Cancer; Serous fluid; Phases of clinical research; Clinical trial","score_opus":0.11106092244593813,"score_gpt":0.3838345029660907,"score_spread":0.27277358052015255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117964602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882612,0.00004453457,0.00003544999,0.0014671265,0.000726463,0.008553026,0.00043224305,0.000072567884,0.0004073596],"genre_scores_gemma":[0.99524146,0.00008360401,0.0006702085,0.0013326462,0.00029971497,0.0019245067,0.00008638415,0.00006379875,0.00029765393],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99659085,0.0009409626,0.00071507384,0.0006441341,0.00037275,0.00073624623],"domain_scores_gemma":[0.99787706,0.00035956895,0.0005279848,0.0007264408,0.00028181527,0.00022711609],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00054896437,0.00043598266,0.0015807158,0.00016676048,0.00017256026,0.0000358586,0.0006359565,0.00016079385,0.0014142034],"category_scores_gemma":[0.000084842344,0.00023127689,0.00004221551,0.00068341586,0.00022429084,0.00017343876,0.00015735088,0.0006481685,0.000022745704],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7266828,0.03020309,0.21164231,0.00007036807,0.00084629864,0.00037496744,0.015544612,0.0000018179228,0.00022432528,0.000022490718,0.0018753612,0.012511566],"study_design_scores_gemma":[0.47375298,0.011457595,0.5127542,0.00017156325,0.00034525982,0.00003103232,0.00068874116,0.00014563525,0.00023653844,0.000026032416,0.00015210675,0.0002383171],"about_ca_topic_score_codex":0.0064090365,"about_ca_topic_score_gemma":0.011189224,"teacher_disagreement_score":0.30111188,"about_ca_system_score_codex":0.0008835015,"about_ca_system_score_gemma":0.0007893453,"threshold_uncertainty_score":0.99949867},"labels":[],"label_agreement":null},{"id":"W2117969937","doi":"10.1016/s1470-2045(14)70471-1","title":"HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis","year":2014,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":729,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"Instituto de Salud Carlos III; European Commission","keywords":"Meta-analysis; Medicine; Head and neck cancer; Oncology; Larynx; Head and neck squamous-cell carcinoma; Cancer; Carcinogenesis; Internal medicine; Genotype; HPV infection; Cervical cancer; Pathology; Biology; Gene; Surgery; Genetics","score_opus":0.1688515908043484,"score_gpt":0.4355661928634556,"score_spread":0.26671460205910724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117969937","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006779765,0.99361616,0.000007710363,0.002785084,0.00006215028,0.0025307683,0.000025956604,0.000025258509,0.0008791326],"genre_scores_gemma":[0.00036026092,0.994857,0.00006582851,0.0029291722,0.00018437229,0.0012220029,0.000009275273,0.000026446463,0.0003456442],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9968162,0.0012096817,0.0009441579,0.0005135452,0.00015901646,0.00035736433],"domain_scores_gemma":[0.99791443,0.0007566403,0.00057740556,0.0005814678,0.00005929486,0.000110786816],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.002179542,0.00042743894,0.015964031,0.00021513445,0.00010036643,0.00001878593,0.00013071654,0.0002644079,0.00005428351],"category_scores_gemma":[0.0003349924,0.00021841399,0.0005187606,0.00057259155,0.00019688069,0.00003295781,0.00012318105,0.0005376512,0.0000083334135],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025227942,0.000019480996,0.000014414861,0.8969188,0.04151538,0.000024795072,0.00021995546,7.5711576e-8,1.7601018e-7,0.000028442464,0.0004701414,0.060763117],"study_design_scores_gemma":[0.0005835368,0.0004210188,0.000062094085,0.024363333,0.6014651,0.00030494228,0.000028260327,0.000008498991,1.3822147e-7,0.000019675485,0.37255156,0.00019185153],"about_ca_topic_score_codex":0.00045728014,"about_ca_topic_score_gemma":0.006095353,"teacher_disagreement_score":0.87255543,"about_ca_system_score_codex":0.00031372163,"about_ca_system_score_gemma":0.00018238192,"threshold_uncertainty_score":0.998645},"labels":[],"label_agreement":null},{"id":"W2118779298","doi":"10.1016/s1470-2045(15)70081-1","title":"Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Adrenal and Paraganglionic Tumors","field":"Medicine","cited_by":333,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Université de Montréal; University of Colorado Denver; Leids Universitair Medisch Centrum; Centre Léon Bérard; Università degli Studi di Padova; Università Cattolica del Sacro Cuore; Erasmus Medisch Centrum; Astellas Pharma; University of Miami","keywords":"Medicine; Tolerability; Adrenocortical carcinoma; Clinical endpoint; Placebo; Internal medicine; Population; Oncology; Carcinoma; Clinical trial; Adverse effect; Surgery; Pathology","score_opus":0.1504030667974675,"score_gpt":0.41161209600715803,"score_spread":0.2612090292096905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118779298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881198,0.00007664893,0.000954149,0.0014380532,0.00042375145,0.007417547,0.00003466015,0.00007328317,0.0014621543],"genre_scores_gemma":[0.9950964,0.00000193431,0.0018602414,0.0006549162,0.000546057,0.001210484,0.00010038034,0.000038284637,0.00049128715],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99804616,0.00025976583,0.00044393243,0.00036285236,0.00034475588,0.00054255495],"domain_scores_gemma":[0.9975664,0.0011136767,0.00020935814,0.00044427923,0.00034780995,0.00031846954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008396,0.0002617386,0.0010464416,0.000069219364,0.00011241912,0.000014060249,0.00022267268,0.000071768045,0.00007714333],"category_scores_gemma":[0.0004540747,0.0001318433,0.000088768815,0.00023758017,0.00019633157,0.000065476044,0.00006542138,0.00032443414,0.000051271312],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9867577,0.0033728105,0.001031657,0.0000461819,0.0003588007,0.0013323763,0.0015647145,0.000080556165,0.000002472299,0.00012713726,0.0013622844,0.003963295],"study_design_scores_gemma":[0.9457346,0.04519438,0.0010562086,0.000030054838,0.0012085037,0.00036619022,0.0017678911,0.0003967827,0.000056918274,0.00004627851,0.0039366963,0.00020549964],"about_ca_topic_score_codex":0.000025112528,"about_ca_topic_score_gemma":0.0001601722,"teacher_disagreement_score":0.04182157,"about_ca_system_score_codex":0.00016422676,"about_ca_system_score_gemma":0.0008249115,"threshold_uncertainty_score":0.53764135},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W2120100820","doi":"10.1016/s1470-2045(11)70303-5","title":"Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":357,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Bevacizumab; Nasopharyngeal carcinoma; Medicine; Oncology; Internal medicine; Radiation therapy; Chemotherapy","score_opus":0.1398796454562106,"score_gpt":0.3966526387327276,"score_spread":0.25677299327651704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120100820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9819584,0.00032536633,0.0048880395,0.0051577985,0.00083145424,0.0026046243,0.0007835209,0.000053647418,0.0033971418],"genre_scores_gemma":[0.98353356,0.000063279665,0.012786097,0.0014295473,0.0011870393,0.0007084532,0.00016938522,0.000013432272,0.0001092234],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99895394,0.00005908194,0.00032141086,0.00021776263,0.0001834122,0.00026438187],"domain_scores_gemma":[0.9991308,0.00016038609,0.00015224935,0.00021325029,0.00025348848,0.0000898572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038710865,0.00013603535,0.0007150242,0.00006772396,0.0001259607,0.0000022118147,0.000117806885,0.000087468485,0.00013080772],"category_scores_gemma":[0.0002698296,0.00009240861,0.00011436604,0.00012251477,0.00016106534,0.00005594388,0.00003301187,0.00012066901,0.000010134612],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7912587,0.0017709027,0.0004878656,0.00027987725,0.00029680037,0.00005329449,0.00528188,0.00002124315,0.01021045,0.0069991574,0.031161113,0.1521787],"study_design_scores_gemma":[0.66296744,0.04253789,0.021375665,0.00017069362,0.00044158407,0.000104835264,0.00045927585,0.0006364238,0.018441055,0.0009752267,0.25152895,0.00036093956],"about_ca_topic_score_codex":0.000031617692,"about_ca_topic_score_gemma":0.0001280568,"teacher_disagreement_score":0.22036782,"about_ca_system_score_codex":0.00030478855,"about_ca_system_score_gemma":0.0006063956,"threshold_uncertainty_score":0.37683138},"labels":[],"label_agreement":null},{"id":"W2120639027","doi":"10.1016/s1470-2045(12)70525-9","title":"Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":223,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Translational Research in Oncology; Hôpital du Saint-Sacrement; Essar Steel Algoma (Canada); Dr. H. Bliss Murphy Cancer Centre; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Docetaxel; Hazard ratio; Anthracycline; Cyclophosphamide; Clinical endpoint; Taxane; Cancer; Chemotherapy; Oncology; Surgery; Randomized controlled trial; Confidence interval","score_opus":0.018305453951353627,"score_gpt":0.3107389978638279,"score_spread":0.2924335439124743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120639027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891178,0.0038012152,0.0000063685957,0.0035871621,0.000771025,0.00076109916,0.00034694228,0.000007837726,0.0016005514],"genre_scores_gemma":[0.99606,0.0017173112,0.000038843205,0.00070062,0.00094951683,0.00022888773,0.00003543659,0.000017830731,0.0002515695],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99858826,0.00033931743,0.00028159283,0.00024643866,0.00011660072,0.00042781205],"domain_scores_gemma":[0.99915683,0.00013200364,0.00021609961,0.00037081516,0.00006703044,0.000057192046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049513706,0.00020016468,0.00057956215,0.0000225035,0.00010432263,0.000005858634,0.00025391404,0.00014165635,0.000078993784],"category_scores_gemma":[0.00007668021,0.0001155728,0.0001055385,0.00011346372,0.00034727695,0.0000072184503,0.00021500216,0.00014001534,0.0000047125136],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7567268,0.0022288235,0.09601332,0.000083621955,0.0014895868,0.000011164448,0.0028351631,0.000038202605,0.07857207,0.00033215535,0.023141602,0.0385275],"study_design_scores_gemma":[0.76402617,0.0008240457,0.16127859,0.00007018419,0.0004353098,0.00008468302,0.00041405743,0.000009194256,0.04337011,0.00010247069,0.029036352,0.0003488554],"about_ca_topic_score_codex":0.0005905054,"about_ca_topic_score_gemma":0.0005917834,"teacher_disagreement_score":0.065265276,"about_ca_system_score_codex":0.0000879911,"about_ca_system_score_gemma":0.000127007,"threshold_uncertainty_score":0.4712922},"labels":[],"label_agreement":null},{"id":"W2120711586","doi":"10.1016/s1470-2045(14)70005-1","title":"Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":112,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Rituximab; Follicular lymphoma; Clinical endpoint; Internal medicine; International Prognostic Index; Vincristine; Regimen; Prednisone; Cyclophosphamide; Population; Lymphoma; Oncology; Gastroenterology; Surgery; Randomized controlled trial; Chemotherapy","score_opus":0.025716597926266682,"score_gpt":0.35121340322397865,"score_spread":0.32549680529771197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120711586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966029,0.00046031756,0.0000429115,0.0006687423,0.000038041828,0.0009465871,0.000038213544,0.0000109488155,0.0011913702],"genre_scores_gemma":[0.9988902,0.00053822855,0.00015499072,0.000230883,0.00004691976,0.00006503441,0.000017673716,0.00000864762,0.000047409634],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99856496,0.00041682448,0.00045129814,0.00020201213,0.00016522035,0.00019966178],"domain_scores_gemma":[0.9985726,0.00070934097,0.0002244334,0.0003774209,0.000058819765,0.000057424048],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085725123,0.00013304861,0.0014593778,0.00016991375,0.000025926704,0.0000030419644,0.00010507546,0.000057134195,0.00006992476],"category_scores_gemma":[0.00009768567,0.00008379804,0.00013424509,0.00040381151,0.00013097972,0.000012232936,0.000053340358,0.00005129539,0.0000015233769],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15153833,0.0568159,0.5843416,0.0003221491,0.013448017,0.0020286266,0.0072056977,0.0005179915,0.006185865,0.00103362,0.00026540644,0.1762968],"study_design_scores_gemma":[0.6829539,0.0082918005,0.27904138,0.00003844142,0.009897011,0.00010536201,0.0006754579,0.0075536007,0.0031375524,0.000038772545,0.008110094,0.0001566422],"about_ca_topic_score_codex":0.00034148825,"about_ca_topic_score_gemma":0.00021356189,"teacher_disagreement_score":0.5314156,"about_ca_system_score_codex":0.000116365416,"about_ca_system_score_gemma":0.00006440347,"threshold_uncertainty_score":0.3417185},"labels":[],"label_agreement":null},{"id":"W2120901491","doi":"10.1016/s1470-2045(12)70346-7","title":"Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":588,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Canadian Cancer Society Research Institute; Cancer Research UK; Chugai Pharmaceutical; Cancer Research Institute","keywords":"Medicine; Ifosfamide; Soft tissue sarcoma; Chemotherapy; Hazard ratio; Surgery; Radiation therapy; Clinical endpoint; Sarcoma; Internal medicine; Neutropenia; Doxorubicin; Randomized controlled trial; Oncology; Soft tissue; Etoposide; Confidence interval; Pathology","score_opus":0.03809641802320107,"score_gpt":0.34358341347774546,"score_spread":0.3054869954545444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120901491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9656439,0.00581599,0.0002789704,0.014787892,0.00035014638,0.01181773,0.000021238193,0.000102251826,0.0011819014],"genre_scores_gemma":[0.9892213,0.0006016885,0.0023970557,0.0029041977,0.001696091,0.002753964,0.00004252614,0.00004707764,0.0003361055],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980871,0.0003198272,0.000405093,0.0002891598,0.00020140676,0.00069738703],"domain_scores_gemma":[0.99626046,0.0027658558,0.00023772471,0.00040371416,0.00012333778,0.00020890015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092771725,0.00028626205,0.0016571083,0.000070740556,0.00016193431,0.000019008392,0.000119224016,0.00016578891,0.00012829853],"category_scores_gemma":[0.0003976794,0.00014393631,0.00014293325,0.000120384924,0.00020799885,0.000057220677,0.000031051874,0.00020704576,0.0000133009735],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9309942,0.002082898,0.013428356,0.000050471066,0.0009564948,0.000044341472,0.0012129397,0.0000016836532,0.0015845995,0.0001794044,0.0056734686,0.043791134],"study_design_scores_gemma":[0.93053716,0.0044903937,0.021413978,0.000056151544,0.0010008693,0.00015846253,0.00023330774,0.00022819692,0.0013250974,0.00007814311,0.040308565,0.00016964285],"about_ca_topic_score_codex":0.00005194581,"about_ca_topic_score_gemma":0.000102633654,"teacher_disagreement_score":0.04362149,"about_ca_system_score_codex":0.00012170478,"about_ca_system_score_gemma":0.00012877709,"threshold_uncertainty_score":0.58695525},"labels":[],"label_agreement":null},{"id":"W2121847974","doi":"10.1016/s1470-2045(15)70127-0","title":"Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":955,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Bevacizumab; FOLFIRI; Ramucirumab; Medicine; Oxaliplatin; Oncology; Internal medicine; Colorectal cancer; Second-line therapy; Placebo; Chemotherapy; Overall survival; Cancer; Pathology","score_opus":0.09086894514201639,"score_gpt":0.35377839830773355,"score_spread":0.2629094531657172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121847974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98884094,0.00055950193,0.0000027917372,0.00084554433,0.00008087163,0.009438425,0.000025278518,0.000041571704,0.00016507004],"genre_scores_gemma":[0.9965404,0.000061322775,0.0002687185,0.00007419139,0.000059218153,0.0028275005,0.000059528997,0.000043563545,0.000065526416],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99797136,0.00026273218,0.00038075555,0.0004861631,0.0004067153,0.000492264],"domain_scores_gemma":[0.9987286,0.00039430097,0.0002531028,0.0002860781,0.00020073284,0.00013718604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045988295,0.00039866293,0.0011986163,0.00018374782,0.0001114915,0.000031823904,0.00011119752,0.00006733317,0.000049651084],"category_scores_gemma":[0.00004839051,0.00019195763,0.00003070219,0.0004020326,0.00021942143,0.00014602504,0.00006991912,0.00030313674,0.000001479491],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6018692,0.004607948,0.38206232,0.00005682293,0.00043901746,0.00051781995,0.008939328,0.000027489486,0.000002343682,0.0000010735534,0.000007112916,0.0014695234],"study_design_scores_gemma":[0.6475266,0.05345634,0.2960895,0.00008615061,0.00033071815,0.000037762493,0.0018710938,0.00023782389,0.00012612218,0.000003146347,0.000050136838,0.00018456561],"about_ca_topic_score_codex":0.0002046667,"about_ca_topic_score_gemma":0.031230839,"teacher_disagreement_score":0.08597283,"about_ca_system_score_codex":0.00047346405,"about_ca_system_score_gemma":0.00028568585,"threshold_uncertainty_score":0.9864467},"labels":[],"label_agreement":null},{"id":"W2122019520","doi":"10.1016/s1470-2045(05)70434-4","title":"Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium","year":2005,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":380,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Institute of Environmental Health Sciences; National Cancer Institute; National Institutes of Health","keywords":"Lymphoma; Odds ratio; Single-nucleotide polymorphism; Follicular lymphoma; Genotype; Allele; Medicine; Immunology; Diffuse large B-cell lymphoma; Internal medicine; Oncology; Biology; Genetics; Gene","score_opus":0.018200695965837014,"score_gpt":0.29873375294802484,"score_spread":0.28053305698218783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122019520","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989653,0.0016823438,0.00004024343,0.0070293704,0.00008334687,0.0003154649,0.000017581398,0.000009301516,0.001169329],"genre_scores_gemma":[0.994991,0.0021618449,0.0015085685,0.00091578637,0.0003145756,0.00005698039,0.0000064798646,0.000007015976,0.000037716618],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991438,0.00016443637,0.00028657017,0.0001824219,0.00007980673,0.00014297321],"domain_scores_gemma":[0.99882966,0.00059872726,0.00019977048,0.00030905197,0.000028405266,0.00003439764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043971214,0.00009201042,0.00038468794,0.000025467118,0.000038329224,0.0000073028114,0.00006327995,0.00007950108,0.000026448353],"category_scores_gemma":[0.00012728272,0.000048455866,0.000027330965,0.00006195908,0.00015123132,0.000021028993,0.000054664644,0.000055246455,0.0000054275756],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037461202,0.00029973482,0.8576423,0.000009428415,0.0001766979,0.00015087289,0.002494636,0.000006788199,0.00041135895,0.00010878549,0.00095668365,0.1373681],"study_design_scores_gemma":[0.0064538484,0.0002961607,0.9827149,0.00003356187,0.00025911542,0.00041654846,0.00013427618,0.00064168125,0.0002180336,0.00037831944,0.00840786,0.000045699755],"about_ca_topic_score_codex":0.0029782795,"about_ca_topic_score_gemma":0.0017065433,"teacher_disagreement_score":0.1373224,"about_ca_system_score_codex":0.0001372133,"about_ca_system_score_gemma":0.00011288419,"threshold_uncertainty_score":0.45022875},"labels":[],"label_agreement":null},{"id":"W2122040419","doi":"10.1016/s1470-2045(02)00875-6","title":"Hormonal risk factors for breast cancer: identification, chemoprevention, and other intervention strategies","year":2002,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Breast cancer; Tamoxifen; Medicine; Tolerability; Psychological intervention; Clinical trial; Family history; Oncology; Cancer; Gynecology; Internal medicine; Adverse effect","score_opus":0.11875684668306657,"score_gpt":0.4330071391026873,"score_spread":0.3142502924196207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122040419","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008091851,0.99411404,0.0004215768,0.00040632256,0.0005195578,0.001399874,0.0019424577,0.000054391607,0.00033256836],"genre_scores_gemma":[0.001937943,0.99481183,0.00003698994,0.00006761834,0.0013385828,0.00048603571,0.00014852827,0.00004976162,0.0011227357],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984633,0.00018954172,0.0005867916,0.00035624046,0.0001247506,0.00027941432],"domain_scores_gemma":[0.9984849,0.00022730557,0.0007609709,0.00036361025,0.0000931232,0.00007005098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054332666,0.0002930266,0.0015326347,0.00009318981,0.0001401353,0.00005418893,0.00019566224,0.00030720493,0.00051868806],"category_scores_gemma":[0.000039427017,0.00017474373,0.00045740034,0.00014257072,0.00017934958,0.00006510646,0.000044532862,0.00040751108,0.000013881638],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000071221075,0.00009621229,0.00049313006,0.0046747,0.0005045035,9.003321e-7,0.00021186726,5.834017e-7,9.718985e-7,0.00041295573,0.008006889,0.9855261],"study_design_scores_gemma":[0.00096498156,0.00021283895,0.0051186117,0.0016134224,0.0023801562,0.000107027205,0.000186649,0.000016443062,7.671082e-7,0.00041841486,0.9888066,0.00017407956],"about_ca_topic_score_codex":0.0006473406,"about_ca_topic_score_gemma":0.0003476882,"teacher_disagreement_score":0.985352,"about_ca_system_score_codex":0.00030377237,"about_ca_system_score_gemma":0.00020967181,"threshold_uncertainty_score":0.71258426},"labels":[],"label_agreement":null},{"id":"W2123591186","doi":"10.1016/s1470-2045(11)70336-9","title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2358,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement","funders":"","keywords":"Pertuzumab; Trastuzumab; Docetaxel; Medicine; Internal medicine; Clinical endpoint; Breast cancer; Oncology; Population; Chemotherapy; Clinical trial; Cancer","score_opus":0.06039123479763487,"score_gpt":0.3881995916148677,"score_spread":0.32780835681723286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123591186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98991364,0.00062415435,0.000035673347,0.0016070766,0.00009459064,0.0057829297,0.00009619097,0.000025801271,0.0018199647],"genre_scores_gemma":[0.9948663,0.0020799239,0.0010205805,0.0005565817,0.00021305663,0.0009848844,0.0000042989313,0.00005015329,0.00022418257],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973057,0.0006045143,0.00058696745,0.00047970162,0.00030872686,0.000714398],"domain_scores_gemma":[0.99807256,0.0007802699,0.0002570654,0.00042898356,0.00018015005,0.0002809792],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012268149,0.00028160147,0.0013826881,0.00007187853,0.00009425821,0.00002452541,0.00037797246,0.00016648805,0.00053421175],"category_scores_gemma":[0.00018251331,0.0001635873,0.000020910848,0.00026439741,0.00074774714,0.00014242057,0.00022013525,0.00057035714,0.0000041162943],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7835139,0.0014757863,0.0012245548,0.00012937323,0.00023867193,0.00033712073,0.011193513,0.000004279875,0.00085414754,0.000033903343,0.000086587475,0.20090817],"study_design_scores_gemma":[0.9200645,0.021745184,0.052397255,0.000736895,0.00013850472,0.00032958286,0.0016262453,0.00023671793,0.00031059448,0.000027563321,0.002144502,0.00024246814],"about_ca_topic_score_codex":0.00152276,"about_ca_topic_score_gemma":0.0019324941,"teacher_disagreement_score":0.2006657,"about_ca_system_score_codex":0.00069442374,"about_ca_system_score_gemma":0.0015359735,"threshold_uncertainty_score":0.6670897},"labels":[],"label_agreement":null},{"id":"W2124385271","doi":"10.1016/s1470-2045(13)70067-6","title":"Comparison of imiquimod, topical fluorouracil, and electrocautery for the treatment of anal intraepithelial neoplasia in HIV-positive men who have sex with men: an open-label, randomised controlled trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":176,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Imiquimod; Medicine; Open label; Men who have sex with men; Fluorouracil; Human immunodeficiency virus (HIV); Intraepithelial neoplasia; Randomized controlled trial; Gynecology; Internal medicine; Dermatology; Family medicine; Chemotherapy; Cancer","score_opus":0.06802685372697216,"score_gpt":0.4116889270562707,"score_spread":0.34366207332929855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124385271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9661809,0.00047720814,0.0003908279,0.009642676,0.000023840226,0.011220214,0.0000231219,0.0000074344107,0.012033758],"genre_scores_gemma":[0.996385,0.000356902,0.00025441096,0.0002343204,0.00046489437,0.0018056076,0.00001828104,0.000011251939,0.00046935322],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984692,0.00044863916,0.00040203487,0.00020386066,0.00016802874,0.0003082419],"domain_scores_gemma":[0.99748844,0.0018893577,0.00014971408,0.00025102124,0.00014098598,0.00008045353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061657693,0.00013735027,0.0015128424,0.00004385772,0.00006615758,0.000021457852,0.00021707271,0.00009968339,0.00018366025],"category_scores_gemma":[0.00006772021,0.0000611067,0.00004178301,0.00006925814,0.00026470306,0.00005325917,0.000041766605,0.00018218404,7.8192437e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9263197,0.0017245832,0.0027271025,0.000031134507,0.00045847218,0.0000044266035,0.0030667956,0.0000075134035,0.0024391112,0.0003491453,0.0015762075,0.061295778],"study_design_scores_gemma":[0.8930456,0.05307709,0.015525532,0.000010965431,0.00030455278,0.000012411482,0.0011674635,0.03205013,0.003958145,0.00018920207,0.0005818494,0.00007706109],"about_ca_topic_score_codex":0.00084255653,"about_ca_topic_score_gemma":0.0010999345,"teacher_disagreement_score":0.061218716,"about_ca_system_score_codex":0.00014826038,"about_ca_system_score_gemma":0.00025762536,"threshold_uncertainty_score":0.2491859},"labels":[],"label_agreement":null},{"id":"W2125620887","doi":"10.1016/s1470-2045(11)70033-x","title":"Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":611,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Trastuzumab; Medicine; Internal medicine; Interim analysis; Breast cancer; Oncology; Clinical endpoint; Population; Adjuvant; Surgery; Clinical trial; Hazard ratio; Cancer; Confidence interval","score_opus":0.0317431920055709,"score_gpt":0.327746268557953,"score_spread":0.2960030765523821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125620887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9861064,0.00008037547,0.000029323826,0.0012603024,0.00012222835,0.01065909,0.00018105566,0.000018316392,0.0015429087],"genre_scores_gemma":[0.9924694,0.000118228796,0.00048422947,0.0002472261,0.0002929461,0.00598994,0.000012433144,0.000047391208,0.00033825505],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983104,0.00028604502,0.00034372698,0.00029445052,0.0002965003,0.0004688609],"domain_scores_gemma":[0.9988332,0.00029477046,0.00019032467,0.00034932155,0.00023596094,0.00009641372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004283765,0.00021672936,0.0014567061,0.00008817028,0.000031444535,0.000005919117,0.00015160191,0.000117492105,0.0003424112],"category_scores_gemma":[0.000024280613,0.00010693829,0.00013956633,0.00016125411,0.00023586857,0.000034811754,0.000014578484,0.00018500206,0.000005137856],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9043131,0.001344048,0.08148384,0.000030326328,0.00080757705,0.000019322293,0.0048755277,5.714757e-7,0.000038994556,0.000019111632,0.00011944926,0.0069481684],"study_design_scores_gemma":[0.7753505,0.032881625,0.19053718,0.00011370447,0.00028636077,0.0000052371292,0.00015475294,0.000011443968,0.00020606918,0.000017644581,0.00033458762,0.00010086752],"about_ca_topic_score_codex":0.0012226381,"about_ca_topic_score_gemma":0.0011301577,"teacher_disagreement_score":0.12896255,"about_ca_system_score_codex":0.00063356105,"about_ca_system_score_gemma":0.00079115096,"threshold_uncertainty_score":0.4360817},"labels":[],"label_agreement":null},{"id":"W2125681453","doi":"10.1016/s1470-2045(11)70404-1","title":"Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studies","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Endometriosis Research and Treatment","field":"Medicine","cited_by":932,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; BC Cancer Agency","funders":"Medical Research and Materiel Command; U.S. Public Health Service; University of South China; American University of Sharjah; Bundesministerium für Bildung und Forschung; Lon V. Smith Foundation; National Cancer Institute; Seventh Framework Programme; University College London; National Institute of Allergy and Infectious Diseases; Medical Research Council; Roswell Park Alliance Foundation, Roswell Park Cancer Institute; Deutsches Krebsforschungszentrum; National Health and Medical Research Council; State of Connecticut Department of Public Health; California Breast Cancer Research Program; Kræftens Bekæmpelse; California Department of Public Health; Oak Foundation; Cancer Council Tasmania; National Institutes of Health; Ovarian Cancer Research Fund","keywords":"Endometriosis; Ovarian cancer; Medicine; Serous fluid; Odds ratio; Oncology; Internal medicine; Case-control study; Logistic regression; Clear cell; Cancer; Gynecology; Carcinoma","score_opus":0.0728237132127975,"score_gpt":0.3976482121092373,"score_spread":0.3248244988964398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125681453","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9707373,0.026666088,0.000034555902,0.0016708142,0.00003500012,0.0003031657,0.00028477353,0.000006803578,0.0002615212],"genre_scores_gemma":[0.9822341,0.017159969,0.00035121446,0.000038137325,0.00012232161,0.000043908418,0.0000062028034,0.000003987848,0.000040144438],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99836814,0.00068026484,0.00035685624,0.00010532337,0.0002285448,0.0002608943],"domain_scores_gemma":[0.9843169,0.014627993,0.0005556529,0.00018950256,0.00023848996,0.000071468996],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.002149964,0.00008564878,0.0015109687,0.0004115831,0.000040717536,0.0000010829962,0.00006336555,0.0000988721,0.000059438466],"category_scores_gemma":[0.010756309,0.000047897138,0.00015715492,0.0010121881,0.00016243805,0.00002409348,0.00004325722,0.00014840189,6.720321e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053793297,0.0002310592,0.934186,0.00006334145,0.046994135,0.000014724591,0.0005888778,0.0000047681865,0.0004350948,0.000091794456,0.00014421769,0.016708063],"study_design_scores_gemma":[0.005016565,0.0010812794,0.9543116,0.000013232896,0.036719464,0.000014894183,0.0002532139,0.000023852599,0.0015665866,0.000047989022,0.0009123226,0.00003896026],"about_ca_topic_score_codex":0.0015200326,"about_ca_topic_score_gemma":0.0006692667,"teacher_disagreement_score":0.02012565,"about_ca_system_score_codex":0.00032065515,"about_ca_system_score_gemma":0.000052371426,"threshold_uncertainty_score":0.99757653},"labels":[],"label_agreement":null},{"id":"W2125690417","doi":"10.1016/s1470-2045(00)00256-4","title":"Role of nitric oxide in carcinogenesis and tumour progression","year":2001,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Nitric Oxide and Endothelin Effects","field":"Medicine","cited_by":572,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"American Society for Investigative Pathology","keywords":"Cytostasis; Cancer research; Nitric oxide; Carcinogenesis; DNA damage; Mutation; Nitric oxide synthase; Carcinogen; Biology; Inflammation; Apoptosis; Chemistry; Cancer; Immunology; DNA; Biochemistry; Genetics; Gene; In vitro; Endocrinology; Cytotoxicity","score_opus":0.06680968871380165,"score_gpt":0.3968322013162112,"score_spread":0.33002251260240956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125690417","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.026269263,0.96850324,7.5128827e-7,0.00011866092,0.000040110925,0.0009093592,0.0000075590556,0.000021472935,0.004129593],"genre_scores_gemma":[0.0026379914,0.99624866,0.00023204024,0.000110658715,0.00044520534,0.00013552584,0.000015183544,0.000031544714,0.00014316982],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984017,0.00048283197,0.00043225585,0.00023261236,0.0001335851,0.00031699683],"domain_scores_gemma":[0.9986147,0.000660299,0.00029127902,0.00033922042,0.00003043743,0.00006405563],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080599275,0.00022076177,0.0024536897,0.00024011046,0.000023271039,0.0000029143428,0.00017509912,0.00030891458,0.00002293994],"category_scores_gemma":[0.00016415959,0.000120396195,0.00014359727,0.00051937334,0.000098648976,0.000013474251,0.00009860169,0.00044748437,0.000022129581],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000112067544,0.00008089035,0.0018012892,0.006934501,0.000058686324,0.0001395947,0.000035932753,1.8372332e-7,0.00020412893,0.000045599856,0.00022978184,0.99035734],"study_design_scores_gemma":[0.0013808443,0.00030222716,0.003488245,0.0053831595,0.00089169026,0.0009875312,0.000040292303,0.000007195317,0.0000421307,0.00016998783,0.9871757,0.00013096709],"about_ca_topic_score_codex":0.00011701464,"about_ca_topic_score_gemma":0.00002085703,"teacher_disagreement_score":0.9902264,"about_ca_system_score_codex":0.00016670475,"about_ca_system_score_gemma":0.00035326014,"threshold_uncertainty_score":0.49096143},"labels":[],"label_agreement":null},{"id":"W2126357214","doi":"10.1016/s1470-2045(12)70226-7","title":"Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":194,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; BC Cancer Agency","funders":"National Cancer Institute; U.S. Public Health Service","keywords":"Medicine; Breast cancer; Hazard ratio; Placebo; Internal medicine; Clinical endpoint; Oncology; Adjuvant; Adjuvant therapy; Cancer; Randomized controlled trial; Confidence interval; Surgery; Gastroenterology; Pathology","score_opus":0.07326399201664018,"score_gpt":0.42403138067342394,"score_spread":0.35076738865678375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126357214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5540431,0.0013326919,0.000014853315,0.014043971,0.00073930074,0.4240989,0.0014216088,0.000095695475,0.0042098337],"genre_scores_gemma":[0.669688,0.00024649067,0.0006505221,0.0004522084,0.0014163507,0.3259378,0.00008258583,0.000037271417,0.0014887503],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977447,0.0004229388,0.0005910074,0.0002752335,0.00025776066,0.00070835045],"domain_scores_gemma":[0.99833417,0.00071862014,0.00031033557,0.0002074839,0.00019588345,0.00023353045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001058397,0.00027158545,0.0015789769,0.00007174346,0.00014922192,0.000009329744,0.00007909219,0.00016682777,0.00015723448],"category_scores_gemma":[0.000066008295,0.00014080793,0.00019840796,0.00008414783,0.00014742308,0.000079658435,0.00002681396,0.00013034139,0.0000066303337],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9554692,0.0033318927,0.009221449,0.00017069402,0.0006137113,0.000020376101,0.00052082416,0.000005478916,0.000038279843,0.00016945171,0.0013355215,0.029103138],"study_design_scores_gemma":[0.9297442,0.0031285689,0.011528447,0.00005935766,0.00059189013,0.0007211666,0.000078408,0.0011880493,0.000050360915,0.000025712867,0.05275205,0.00013182603],"about_ca_topic_score_codex":0.0014135372,"about_ca_topic_score_gemma":0.00040651267,"teacher_disagreement_score":0.11564488,"about_ca_system_score_codex":0.00060530595,"about_ca_system_score_gemma":0.0011482441,"threshold_uncertainty_score":0.57419807},"labels":[],"label_agreement":null},{"id":"W2126863660","doi":"10.1016/s1470-2045(08)70336-x","title":"Effects of comorbidity on screening and early diagnosis of cancer in elderly people","year":2008,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Comorbidity; Life expectancy; Medicine; Cancer; Cancer screening; Population; Gerontology; Clinical trial; MEDLINE; Psychiatry; Environmental health; Internal medicine","score_opus":0.15260097971444953,"score_gpt":0.43551549771047127,"score_spread":0.28291451799602174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126863660","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07004964,0.9281047,0.0000029097191,0.00034714976,0.00014924382,0.0008361488,0.00003083059,0.000010816686,0.00046854187],"genre_scores_gemma":[0.015330374,0.9838079,0.00011904099,0.0001740695,0.00028478628,0.00023873315,0.000005308729,0.000019230307,0.000020549234],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984099,0.00034585307,0.00048718878,0.00024548973,0.0002252224,0.0002863198],"domain_scores_gemma":[0.9976852,0.0014303124,0.00046784084,0.00030124115,0.000056935172,0.000058462872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036243684,0.0002244908,0.0029309546,0.00013101014,0.000036226418,0.0000026734072,0.00022564278,0.00028020455,0.000021273989],"category_scores_gemma":[0.00022744844,0.00014390681,0.00019353641,0.00034090935,0.00018315109,0.000025450227,0.00008488924,0.0005843397,0.000002246957],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021827217,0.000070873466,0.024245223,0.008258313,0.00013608058,0.00007600403,0.00051201636,0.0000020740179,0.0000016144907,0.00005596772,0.0014417163,0.96498185],"study_design_scores_gemma":[0.0021190054,0.0024174165,0.08991273,0.031233296,0.0007292029,0.00011436654,0.000031951073,0.000003697114,0.00003439387,0.000023583973,0.8731987,0.00018167439],"about_ca_topic_score_codex":0.004573119,"about_ca_topic_score_gemma":0.0016825945,"teacher_disagreement_score":0.9648002,"about_ca_system_score_codex":0.00014005562,"about_ca_system_score_gemma":0.0003119189,"threshold_uncertainty_score":0.6913218},"labels":[],"label_agreement":null},{"id":"W2127018518","doi":"10.1016/s1470-2045(15)70128-2","title":"Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":335,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Jewish General Hospital","funders":"Genentech","keywords":"Medicine; Internal medicine; Tolerability; Brentuximab vedotin; Rituximab; Antibody-drug conjugate; Oncology; Refractory (planetary science); Lymphoma; Phases of clinical research; Adverse effect; Clinical trial; Antibody; Immunology; Monoclonal antibody; Hodgkin lymphoma","score_opus":0.036975464534527845,"score_gpt":0.3523724593174217,"score_spread":0.3153969947828939,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127018518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938109,0.0018750799,0.0000025361637,0.0016190562,0.00022138742,0.0013298314,0.00002562057,0.000024115328,0.0010914777],"genre_scores_gemma":[0.9979154,0.0011603396,0.000039709375,0.0004450865,0.0001710409,0.00004784182,0.000006502718,0.000024918918,0.00018914985],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99792105,0.00061772857,0.00041307067,0.00040169826,0.0002463688,0.00040008454],"domain_scores_gemma":[0.9981904,0.0006199568,0.00031995325,0.0006588202,0.000066774395,0.00014407618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010013905,0.00026721915,0.0011129692,0.00008201844,0.00011210947,0.000014104774,0.00020369173,0.00014967898,0.000012225467],"category_scores_gemma":[0.00015539714,0.00013891111,0.00006391523,0.0002638344,0.00037805273,0.00006471055,0.00024092433,0.00021219351,0.000007607597],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0642446,0.027305808,0.72249913,0.000882865,0.0013195704,0.0028492322,0.025759263,0.00016437485,0.047808174,0.00020367885,0.003711288,0.10325201],"study_design_scores_gemma":[0.21685308,0.011379373,0.7484221,0.0002789526,0.0006866841,0.0005267663,0.0017624678,0.0026750304,0.008842267,0.00006128293,0.008213401,0.00029859316],"about_ca_topic_score_codex":0.0018174658,"about_ca_topic_score_gemma":0.0011764263,"teacher_disagreement_score":0.1526085,"about_ca_system_score_codex":0.0027388078,"about_ca_system_score_gemma":0.0027556177,"threshold_uncertainty_score":0.7161887},"labels":[],"label_agreement":null},{"id":"W2127385754","doi":"10.1016/s1470-2045(14)70030-0","title":"Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":263,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; BC Cancer Agency","funders":"National Cancer Institute; Novartis Pharmaceuticals Corporation","keywords":"Sorafenib; Open label; Renal cell carcinoma; Medicine; Oncology; Internal medicine; Second line treatment; Hepatocellular carcinoma; Clinical trial; Overall survival","score_opus":0.1290889388003442,"score_gpt":0.3833123518399601,"score_spread":0.25422341303961593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127385754","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98845893,0.00015386623,0.00026119084,0.00066799764,0.000352197,0.0074238754,0.00019276173,0.00003553628,0.0024536643],"genre_scores_gemma":[0.9897204,0.000016851884,0.0070930105,0.00022128462,0.0005820067,0.0011182216,0.0008920076,0.00004688245,0.00030933385],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975691,0.000676231,0.0005713541,0.00043251915,0.00027082113,0.00047999044],"domain_scores_gemma":[0.9971031,0.0011968514,0.000494917,0.0007708613,0.0002389098,0.00019536287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007454352,0.0003335291,0.001647583,0.000079190395,0.00012302102,0.000018482888,0.00032287266,0.00009614835,0.00006720136],"category_scores_gemma":[0.00013518096,0.00017634057,0.00010796718,0.00014004226,0.00018449062,0.00007698567,0.000049019596,0.00011744198,0.000009518396],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9745477,0.013240558,0.00028974365,0.000075420765,0.00044767832,0.000034684712,0.0004979447,0.000020021545,0.0042451057,0.00011666976,0.0007065658,0.005777896],"study_design_scores_gemma":[0.78225845,0.19002637,0.00057855906,0.000009508261,0.0018237497,0.000005515016,0.000058018515,0.0005331376,0.017751705,0.00006580775,0.006740255,0.00014892421],"about_ca_topic_score_codex":0.00011683957,"about_ca_topic_score_gemma":0.00010873547,"teacher_disagreement_score":0.19228926,"about_ca_system_score_codex":0.0003284307,"about_ca_system_score_gemma":0.00037210155,"threshold_uncertainty_score":0.719096},"labels":[],"label_agreement":null},{"id":"W2127424726","doi":"10.1016/s1470-2045(08)70153-0","title":"Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study","year":2008,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":3195,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Sarcopenic obesity; Sarcopenia; Obesity; Body mass index; Internal medicine; Geriatric oncology; Population; Hazard ratio; Cancer; Gastroenterology; Confidence interval","score_opus":0.09781448145996925,"score_gpt":0.4135071674502254,"score_spread":0.3156926859902562,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127424726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968641,0.00004573888,0.000007145289,0.0023106358,0.000013437986,0.0006947115,0.000007794691,0.000005137411,0.00005130735],"genre_scores_gemma":[0.9985636,0.000014380032,0.0005405904,0.0008305276,0.000028981533,0.000013581629,0.0000012765396,0.0000035160238,0.0000035575617],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991001,0.00029768355,0.00031097492,0.000106362,0.00008649785,0.000098364755],"domain_scores_gemma":[0.9991504,0.00033643952,0.00019885886,0.00019794004,0.00007895042,0.000037390142],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005971654,0.00004566558,0.00027894264,0.000030194611,0.00006326094,8.2567783e-7,0.00006784423,0.000021731204,0.000004614448],"category_scores_gemma":[0.00018753599,0.00002591366,0.000013624559,0.000091173395,0.00019437302,0.00001629363,0.000023376293,0.00019476189,1.7986453e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005496426,0.00082321616,0.9982071,0.00008484687,0.0000032098667,0.0000012837177,0.00010320433,0.0000021719782,0.000011705725,0.000031602,0.00003504889,0.00014698898],"study_design_scores_gemma":[0.004801453,0.0019234342,0.9929373,0.00015407725,0.000032518896,0.000015919564,0.000034588043,0.000016432161,0.000005110482,0.00004527225,0.000012226693,0.000021614276],"about_ca_topic_score_codex":0.00004863274,"about_ca_topic_score_gemma":0.0001821279,"teacher_disagreement_score":0.005269726,"about_ca_system_score_codex":0.000035564517,"about_ca_system_score_gemma":0.00017107445,"threshold_uncertainty_score":0.10567284},"labels":[],"label_agreement":null},{"id":"W2128083415","doi":"10.1016/s1470-2045(13)70510-2","title":"Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":526,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Juravinski Cancer Centre; Institut universitaire de cardiologie et de pneumologie de Québec; Alberta Cancer Foundation","funders":"Merck KGaA","keywords":"Medicine; Placebo; Chemoradiotherapy; Clinical endpoint; Internal medicine; Population; Lung cancer; Surgery; Phases of clinical research; Hazard ratio; Cancer; Clinical trial; Oncology; Confidence interval; Pathology","score_opus":0.08993665752350942,"score_gpt":0.43539217495574034,"score_spread":0.3454555174322309,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128083415","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.945483,0.0031691666,0.0005948705,0.020048415,0.0016735637,0.020653915,0.00008144759,0.00011829083,0.008177314],"genre_scores_gemma":[0.8852832,0.005107578,0.0023926278,0.0064561935,0.013410655,0.06143029,0.00007886163,0.00020739631,0.025633221],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973777,0.00018809059,0.0005021088,0.00051389117,0.00035318892,0.0010650455],"domain_scores_gemma":[0.99727285,0.0012379162,0.00023926151,0.0007342948,0.00027795127,0.0002377458],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012399283,0.00036299354,0.0014766181,0.00011806607,0.0002105619,0.000053975455,0.0004187261,0.00020792817,0.0016595522],"category_scores_gemma":[0.00012649687,0.00023148254,0.00027744196,0.00022721582,0.00032771955,0.000106006286,0.00012697259,0.00057313376,0.00005828293],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9244736,0.00049788255,0.0001767278,0.00038415077,0.0008568019,0.000037407874,0.0016455301,0.00001617181,0.0032074368,0.000018865281,0.065470144,0.0032153013],"study_design_scores_gemma":[0.89604825,0.00358879,0.000046522546,0.000059416358,0.00041500432,0.00000575931,0.00032057226,0.0009831968,0.004060821,0.000017762011,0.09421468,0.00023924715],"about_ca_topic_score_codex":0.0008858728,"about_ca_topic_score_gemma":0.0006373264,"teacher_disagreement_score":0.06019984,"about_ca_system_score_codex":0.0008988513,"about_ca_system_score_gemma":0.00094964035,"threshold_uncertainty_score":0.9992531},"labels":[],"label_agreement":null},{"id":"W2128628205","doi":"10.1016/s1470-2045(13)70479-0","title":"Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":231,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Bristol-Myers Squibb (Canada)","funders":"National Cancer Institute","keywords":"Medicine; Dasatinib; Docetaxel; Prostate cancer; Internal medicine; Oncology; Clinical endpoint; Placebo; Chemotherapy; Cancer; Urology; Clinical trial; Tyrosine kinase; Pathology","score_opus":0.13220226536863128,"score_gpt":0.4325167925736302,"score_spread":0.3003145272049989,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128628205","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9750188,0.00039559655,0.000003849188,0.011994314,0.00007293758,0.008157258,0.00003273284,0.000024983237,0.0042995033],"genre_scores_gemma":[0.989922,0.0004365796,0.00083175016,0.0011517074,0.00017347519,0.0050305165,0.000048011225,0.000021150263,0.002384826],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99858046,0.00022724069,0.00039109634,0.00024035007,0.00015553673,0.00040530326],"domain_scores_gemma":[0.9989488,0.0003982435,0.00019534882,0.00022543552,0.00006715487,0.00016502067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005739131,0.0001733197,0.0007670064,0.000065125016,0.0000873222,0.000022566379,0.0000608064,0.00006195327,0.00029417776],"category_scores_gemma":[0.00004802216,0.00008268281,0.00002223481,0.00015312147,0.00014082626,0.00008415496,0.000016022359,0.00023324777,0.00002347451],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98730594,0.0006337442,0.00074490946,0.0001128074,0.00020811359,0.00018932158,0.0013796663,0.000005242481,0.00024093484,0.00008861641,0.0016653932,0.0074252994],"study_design_scores_gemma":[0.9881122,0.00500848,0.0019303762,0.000062993924,0.00032309964,0.00012878698,0.00035439315,0.0002178533,0.000103551654,0.0000940707,0.0035646132,0.00009956994],"about_ca_topic_score_codex":0.004274504,"about_ca_topic_score_gemma":0.0073625096,"teacher_disagreement_score":0.014903159,"about_ca_system_score_codex":0.00014057683,"about_ca_system_score_gemma":0.0008462758,"threshold_uncertainty_score":0.64618},"labels":[],"label_agreement":null},{"id":"W2128694012","doi":"10.1016/s1470-2045(08)70231-6","title":"Cancer patterns in Inuit populations","year":2008,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Urological Disorders and Treatments","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Circumpolar star; Life expectancy; Epidemiology; Cancer; Demography; Medicine; Biology; Population; Environmental health; Pathology; Internal medicine","score_opus":0.297517825632857,"score_gpt":0.48077680248405485,"score_spread":0.18325897685119785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128694012","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006708138,0.9935278,0.0000017980196,0.0016523615,0.00019887519,0.00074263033,0.00012062567,0.00002848125,0.0030565956],"genre_scores_gemma":[0.0013038712,0.9959942,0.000044103454,0.0011598091,0.000383414,0.00039938273,0.00009124087,0.000019679568,0.0006042649],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99892676,0.00020999393,0.00029517757,0.00021055905,0.00008195684,0.0002755275],"domain_scores_gemma":[0.999386,0.000119558244,0.00013665337,0.00030022446,0.000013772147,0.00004375267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006945279,0.00019005171,0.0016699114,0.00006900694,0.000043091448,0.000002885087,0.00014993198,0.0002962243,0.0005443562],"category_scores_gemma":[0.000032491454,0.00009494876,0.00018556157,0.00017773508,0.000062388914,0.000009676235,0.000055882534,0.00047629495,0.0001098256],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021665179,0.00020128288,0.008350987,0.0006137885,0.00011407181,0.00024052766,0.00011352748,6.880911e-7,8.524431e-9,0.00017986313,0.0019170857,0.9882465],"study_design_scores_gemma":[0.00084224506,0.0001990021,0.021873739,0.00082415954,0.0003991667,0.00016693184,0.0000046031973,0.0000017892348,4.420587e-9,0.00018803267,0.975417,0.00008330052],"about_ca_topic_score_codex":0.0006592956,"about_ca_topic_score_gemma":0.0045944965,"teacher_disagreement_score":0.98816323,"about_ca_system_score_codex":0.0003245217,"about_ca_system_score_gemma":0.00030635454,"threshold_uncertainty_score":0.59603184},"labels":[],"label_agreement":null},{"id":"W2128967557","doi":"10.1016/s1470-2045(00)00019-x","title":"Repopulation of tumour cells between cycles of chemotherapy: a neglected factor","year":2000,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Effects of Radiation Exposure","field":"Medicine","cited_by":153,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Repopulation; Clonogenic assay; Chemotherapy; Cancer research; Biology; Radiation therapy; Cell; Immunology; Oncology; Medicine; Internal medicine; Stem cell; Cell biology; Haematopoiesis; Genetics","score_opus":0.08015071912839168,"score_gpt":0.40092475537340433,"score_spread":0.32077403624501266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128967557","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011815792,0.98350465,0.000014030829,0.00063267344,0.00016522467,0.0016454702,0.00015387218,0.000067439,0.0020008718],"genre_scores_gemma":[0.005986093,0.99184567,0.000505715,0.00011513078,0.0010493007,0.000031277556,0.00018428358,0.00005116071,0.00023135278],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979505,0.00059161504,0.00081832084,0.00021958444,0.00020421839,0.00021575403],"domain_scores_gemma":[0.9972534,0.0008828699,0.0011638644,0.00056965946,0.000079602854,0.000050601222],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002866684,0.00023868377,0.0032178487,0.000153821,0.000022329346,0.0000026947778,0.00025910485,0.0004606009,0.00022483272],"category_scores_gemma":[0.0001396888,0.00014938826,0.00032381562,0.00030521967,0.00011388982,0.000021674632,0.000021833317,0.00043208076,0.000024492489],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010862181,0.00008500725,0.00046350085,0.008949239,0.0004063269,0.000007637408,0.00022170824,0.0000021316555,0.00044525164,0.000023576737,0.001985751,0.98730123],"study_design_scores_gemma":[0.0012097656,0.00074186554,0.009904402,0.0027091878,0.0011007393,0.00004280937,0.0000046835003,0.0000042085935,0.00034384808,0.000056286408,0.98374695,0.00013525295],"about_ca_topic_score_codex":0.00003981067,"about_ca_topic_score_gemma":0.0000063513435,"teacher_disagreement_score":0.987166,"about_ca_system_score_codex":0.00014828789,"about_ca_system_score_gemma":0.00039602397,"threshold_uncertainty_score":0.6091876},"labels":[],"label_agreement":null},{"id":"W2129298960","doi":"10.1016/s1470-2045(15)70142-7","title":"Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":164,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital","funders":"Narodowe Centrum Nauki","keywords":"Medicine; Breast cancer; PALB2; Hazard ratio; Internal medicine; Odds ratio; Cancer; Oncology; Prospective cohort study; Gynecology; Mutation; Confidence interval; Germline mutation; Genetics","score_opus":0.029255847640818716,"score_gpt":0.37145603228828383,"score_spread":0.3422001846474651,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129298960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937615,0.00024883865,0.00016850917,0.0043885964,0.000083356856,0.000258388,0.000039909544,0.000008490322,0.0010424167],"genre_scores_gemma":[0.99671704,0.00018646527,0.00066736765,0.0014397602,0.00029393425,0.00044675285,0.000012723969,0.000009821076,0.00022612805],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990337,0.00017990968,0.00019174098,0.000291859,0.00009085374,0.0002119302],"domain_scores_gemma":[0.9993887,0.000051515948,0.00009852357,0.00027628412,0.000118642645,0.00006635909],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078430754,0.00009841044,0.00037390855,0.00004446075,0.00003298875,0.000011855831,0.0001397217,0.00010788381,0.000018994666],"category_scores_gemma":[0.000058909583,0.000062068386,0.000029966595,0.00027083696,0.00024317476,0.0000036225329,0.00007231954,0.00012916907,0.0000026751227],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00086319837,0.000059418515,0.99185103,0.0000026858959,0.00086765294,0.000008808492,0.00067204173,0.00052915985,0.00004757589,0.000035403726,0.00071020686,0.004352815],"study_design_scores_gemma":[0.0021078018,0.00036722238,0.9912152,0.000002325335,0.00015337067,0.000039325943,0.0005588354,0.00007741257,0.00003928202,0.00023077091,0.0051101884,0.00009822028],"about_ca_topic_score_codex":0.00017159461,"about_ca_topic_score_gemma":0.0035054109,"teacher_disagreement_score":0.004399982,"about_ca_system_score_codex":0.00022714703,"about_ca_system_score_gemma":0.0004345365,"threshold_uncertainty_score":0.25310755},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"agree"},{"id":"W2129306198","doi":"10.1016/s1470-2045(01)00617-9","title":"Persistent human papillomavirus infection and cervical neoplasia","year":2002,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":256,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Carcinogenesis; Cervical intraepithelial neoplasia; Biology; Cervical cancer; Genotype; HPV infection; Cancer research; Loss of heterozygosity; Oncogene; Tumor suppressor gene; Telomerase; Intraepithelial neoplasia; Cancer; Gene; Immunology; Genetics; Allele; Cell cycle","score_opus":0.246386251105243,"score_gpt":0.4686531876521851,"score_spread":0.2222669365469421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129306198","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007001505,0.9010409,0.0000010991587,0.0012884985,0.00017529793,0.0007070855,0.000014439038,0.000055088178,0.096647575],"genre_scores_gemma":[0.0002809059,0.9944995,0.000016113758,0.00066204055,0.0022886794,0.000153704,0.000056275727,0.00003567526,0.0020070774],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99819136,0.00041778112,0.00034982697,0.00035118236,0.00024329951,0.00044653847],"domain_scores_gemma":[0.99889696,0.00027368098,0.000118446245,0.00045938883,0.00006677444,0.00018474001],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005075822,0.00025514796,0.0020585454,0.00010555841,0.00018335877,0.00002595862,0.00017319688,0.00046678248,0.004561815],"category_scores_gemma":[0.00006393692,0.00014530586,0.00039841165,0.00022016675,0.0002660225,0.000018520475,0.0001908492,0.0012593596,0.00027375738],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005532805,0.00008978981,0.000104780986,0.008437656,0.00021142638,0.000058096415,0.000073557305,4.388715e-8,3.049452e-7,0.00041315416,0.0067422106,0.98381364],"study_design_scores_gemma":[0.0010636135,0.0010094771,0.001764918,0.0004888195,0.001155173,0.00084461976,0.0000093448325,0.0000062658446,1.0557122e-7,0.00006431378,0.9934563,0.00013702131],"about_ca_topic_score_codex":0.00016450942,"about_ca_topic_score_gemma":0.00019432268,"teacher_disagreement_score":0.9867141,"about_ca_system_score_codex":0.0004481851,"about_ca_system_score_gemma":0.00017714691,"threshold_uncertainty_score":0.99634814},"labels":[],"label_agreement":null},{"id":"W2129559903","doi":"10.1016/s1470-2045(13)70311-5","title":"Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group","year":2013,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":128,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Queen's University; London Health Sciences Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Clinical trial; Medicine; Clinical study design; Oncology; Intensive care medicine; Population; Schedule; Disease; Medical physics; Internal medicine; Computer science","score_opus":0.4126715099977182,"score_gpt":0.5398693156544768,"score_spread":0.12719780565675864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129559903","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0045093955,0.956017,0.000008824325,0.03336838,0.00056691625,0.0051559475,0.0001399845,0.000044595647,0.00018895949],"genre_scores_gemma":[0.00075718353,0.9900646,0.003435726,0.0018403305,0.0017502012,0.00144443,0.00054042414,0.000057771897,0.000109317894],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.97012776,0.025391337,0.0029018817,0.000780076,0.00033681895,0.00046212174],"domain_scores_gemma":[0.9718578,0.024977393,0.001819557,0.0010849305,0.00006635739,0.00019399557],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.03340705,0.0004445969,0.00511234,0.00010145162,0.00014512525,0.00003322141,0.00023997892,0.000393691,0.00008642732],"category_scores_gemma":[0.019123837,0.00018996988,0.0004983918,0.00021076323,0.00013963318,0.000038563987,0.00026952053,0.0009437148,0.00003881947],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012009139,0.00031244356,0.0003182075,0.00044562048,0.0005964222,0.00075073703,0.0003463477,4.6488935e-7,4.653858e-7,0.00018561003,0.019851403,0.97599137],"study_design_scores_gemma":[0.0023667566,0.0015733854,0.008400331,0.0056170444,0.0018103223,0.0007546187,0.000238346,0.0000036331699,1.7741255e-7,0.00028328964,0.9787667,0.00018538725],"about_ca_topic_score_codex":0.00026732456,"about_ca_topic_score_gemma":0.00039268084,"teacher_disagreement_score":0.975806,"about_ca_system_score_codex":0.00018979056,"about_ca_system_score_gemma":0.00033752254,"threshold_uncertainty_score":0.99531084},"labels":[],"label_agreement":null},{"id":"W2129978807","doi":"10.1016/s1470-2045(15)00199-0","title":"Dexamethasone in the prophylaxis of radiation-induced pain flare after palliative radiotherapy for bone metastases: a double-blind, randomised placebo-controlled, phase 3 trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":171,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Ottawa; Princess Margaret Cancer Centre; University of Calgary; Kingston General Hospital; Ottawa Hospital; CancerCare Manitoba; Centre Hospitalier de l’Université de Montréal; Juravinski Hospital; Hôpital Maisonneuve-Rosemont; Sunnybrook Health Science Centre; Centre Hospitalier Universitaire de Sherbrooke; Cancer Care Ontario; Ontario Institute for Cancer Research; Grand River Hospital; Queen's University; McMaster University","funders":"","keywords":"Medicine; Placebo; Dexamethasone; Analgesic; Radiation therapy; Clinical endpoint; Palliative care; Randomized controlled trial; Anesthesia; Surgery; Internal medicine","score_opus":0.13037721851186684,"score_gpt":0.41523441587961,"score_spread":0.2848571973677432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129978807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9421279,0.0022684336,0.008265752,0.016366057,0.00036074335,0.029850516,0.000095065916,0.000037950707,0.0006275954],"genre_scores_gemma":[0.9789928,0.00008918922,0.0037691244,0.004282237,0.000835343,0.011718216,0.00010387957,0.000035382243,0.00017378037],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9943355,0.0035279891,0.0008657307,0.00033111984,0.0005107493,0.00042895428],"domain_scores_gemma":[0.9940826,0.004339173,0.0005801286,0.00068332336,0.00018236726,0.00013235593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017323028,0.00026924623,0.0017852469,0.00020848365,0.00005101906,0.000024901632,0.0003325828,0.00012531046,0.00013811112],"category_scores_gemma":[0.0035047294,0.00014294067,0.00032877605,0.000385316,0.0001470138,0.00007178094,0.00002893547,0.00029397814,0.0000055688915],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96543634,0.0019442664,0.00006870619,0.00014745689,0.0008548319,0.0000728157,0.004756034,0.00003099838,0.0002621687,0.0002640427,0.003685222,0.022477144],"study_design_scores_gemma":[0.9750425,0.009087465,0.000059401253,0.000033826407,0.00094538706,0.0000047547273,0.0020599952,0.0017487772,0.00016982347,0.00043731657,0.01026286,0.00014788608],"about_ca_topic_score_codex":0.000053317683,"about_ca_topic_score_gemma":0.000071080365,"teacher_disagreement_score":0.036864962,"about_ca_system_score_codex":0.00020656288,"about_ca_system_score_gemma":0.0005738406,"threshold_uncertainty_score":0.600385},"labels":[],"label_agreement":null},{"id":"W2131133701","doi":"10.1016/s1470-2045(11)70363-1","title":"Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: an observational study","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":281,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Key Research and Development Program of China; Vrije Universiteit Brussel; Fonds Wetenschappelijk Onderzoek","keywords":"Medicine; Pediatrics; Neurocognitive; Bayley Scales of Infant Development; Child Behavior Checklist; Gestational age; Intelligence quotient; Pregnancy; Observational study; Cognition; Internal medicine; Psychiatry; Psychomotor learning","score_opus":0.09336844782096625,"score_gpt":0.3987549622373315,"score_spread":0.3053865144163652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131133701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99641097,0.00043537174,0.0000048256848,0.001216152,0.00016950876,0.0015908363,0.00007516587,0.000025524307,0.000071622926],"genre_scores_gemma":[0.9959362,0.000079461235,0.000057859463,0.0026482204,0.0007084682,0.0002859733,0.000045497454,0.000018729625,0.00021959908],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990304,0.00016222896,0.00017699413,0.00019517746,0.00013847653,0.0002967149],"domain_scores_gemma":[0.9994388,0.00015129564,0.000050218496,0.0002130454,0.000031111664,0.00011549793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000396399,0.00014053805,0.00052706985,0.000049218288,0.000040647104,0.000010816825,0.00008125463,0.000079654885,0.00024209602],"category_scores_gemma":[0.00004285732,0.000082513434,0.000038513175,0.00009659601,0.00006250273,0.000099743025,0.00005066983,0.00020382451,0.0000067211827],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026238703,0.0005587883,0.9780575,0.000009935987,0.00017638726,0.000013220912,0.008952797,3.899475e-7,0.000021870756,0.000003497908,0.00021376846,0.009367993],"study_design_scores_gemma":[0.0064135264,0.0012467895,0.9913611,0.000027325943,0.00009299978,0.000015628846,0.0006056305,5.80264e-7,0.000025233572,0.0000028051656,0.000100500736,0.00010787044],"about_ca_topic_score_codex":0.00024399889,"about_ca_topic_score_gemma":0.00085072964,"teacher_disagreement_score":0.013303629,"about_ca_system_score_codex":0.00008572065,"about_ca_system_score_gemma":0.00006683673,"threshold_uncertainty_score":0.33648002},"labels":[],"label_agreement":null},{"id":"W2131145274","doi":"10.1016/s1470-2045(15)00232-6","title":"Cancer incidence in indigenous people in Australia, New Zealand, Canada, and the USA: a comparative population-based study","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":129,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Blue Quills First Nations College; University of Alberta; Ministry of Health","funders":"World Health Organization","keywords":"Indigenous; Demography; Cancer registry; Population; Geography; Medicine; Life expectancy; Incidence (geometry); Population health; Cancer incidence; Ethnic group; Socioeconomics; Environmental health; Political science; Ecology; Sociology; Biology","score_opus":0.19749027479980646,"score_gpt":0.4351334547109858,"score_spread":0.23764317991117934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131145274","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909476,0.00024588918,0.0000028721884,0.0077176467,0.00012172424,0.0008175754,0.000005721733,0.000005865289,0.000135103],"genre_scores_gemma":[0.9967744,0.000013257165,0.000053732514,0.0024392402,0.00018968574,0.000096823904,0.0000052300093,0.0000043343516,0.00042332636],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986592,0.00033912915,0.00025662401,0.00017609874,0.00026262933,0.0003063004],"domain_scores_gemma":[0.99921316,0.0003118581,0.00010764949,0.00021059786,0.000055533892,0.00010119891],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009579366,0.000109872926,0.000580377,0.000044987617,0.00005096616,0.00001156768,0.00017998306,0.000052730582,0.000034410514],"category_scores_gemma":[0.00011652969,0.00006287056,0.000014714275,0.00032580885,0.000060178616,0.00004295725,0.000041512838,0.00033865852,0.0000036985],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016138712,0.00004280136,0.9779155,0.000004279605,0.000015503163,0.000068985275,0.015495545,0.0016308803,0.0000020288992,0.00003407955,0.0028575733,0.00031890982],"study_design_scores_gemma":[0.007952231,0.00035167043,0.98802036,0.000041269017,0.000034025157,0.00002094996,0.0023397633,0.00023674668,0.0000035901242,0.00019912169,0.000729199,0.000071049704],"about_ca_topic_score_codex":0.9958572,"about_ca_topic_score_gemma":0.9997695,"teacher_disagreement_score":0.013155782,"about_ca_system_score_codex":0.0008998575,"about_ca_system_score_gemma":0.0022488048,"threshold_uncertainty_score":0.3989283},"labels":[],"label_agreement":null},{"id":"W2131719808","doi":"10.1016/s1470-2045(10)70207-2","title":"Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial","year":2010,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1919,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint John Regional Hospital; Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute","keywords":"Medicine; Axillary Lymph Node Dissection; Sentinel lymph node; Breast cancer; Lumpectomy; Mastectomy; Surgery; Axilla; Sentinel node; Lymph node; Clinical endpoint; Randomized controlled trial; Cancer; Internal medicine","score_opus":0.02129551545244373,"score_gpt":0.32099030728354333,"score_spread":0.2996947918310996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131719808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99316823,0.00005636858,0.0001283484,0.0038338255,0.0009757088,0.0008695625,0.0005353298,0.000026474456,0.0004061264],"genre_scores_gemma":[0.9963081,0.0001311619,0.0001786979,0.00074400124,0.0015172627,0.000445577,0.00059005694,0.000035305704,0.0000498328],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976698,0.00056520506,0.00046554126,0.00057001633,0.00030107243,0.0004283191],"domain_scores_gemma":[0.9983297,0.0005012383,0.00038314625,0.00046689215,0.0002497312,0.000069281516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061404164,0.0003188209,0.0006439848,0.00003443286,0.0003090357,0.000039563438,0.00033932232,0.00022570258,0.000100068864],"category_scores_gemma":[0.00014312626,0.00017933614,0.0001233068,0.00015822619,0.0004943406,0.000017486498,0.00012386538,0.00036775105,0.0000056832773],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42951414,0.0009080696,0.56477636,0.000008496728,0.00062815053,0.000006238852,0.00024405845,0.00014209683,0.0026089954,0.000024595674,0.0005783524,0.00056043896],"study_design_scores_gemma":[0.31484807,0.00034546177,0.68300045,0.000037430473,0.00016313873,0.000017998787,0.00011349733,0.00009738152,0.00040263313,0.00006505499,0.00070001365,0.0002088513],"about_ca_topic_score_codex":0.0018394652,"about_ca_topic_score_gemma":0.0038296145,"teacher_disagreement_score":0.118224084,"about_ca_system_score_codex":0.00016593425,"about_ca_system_score_gemma":0.00031325314,"threshold_uncertainty_score":0.73131156},"labels":[],"label_agreement":null},{"id":"W2132870547","doi":"10.1016/s1470-2045(14)71173-8","title":"Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1580,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Boehringer Ingelheim","keywords":"Medicine; Afatinib; Pemetrexed; Lung cancer; Internal medicine; Adenocarcinoma; Lung; Gemcitabine; Chemotherapy; Population; Gastroenterology; Oncology; Cisplatin; Surgery; Gefitinib; Epidermal growth factor receptor; Cancer","score_opus":0.17100506631650386,"score_gpt":0.4951860196022361,"score_spread":0.32418095328573227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132870547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9628026,0.004286501,0.015245482,0.0063499417,0.00082092703,0.0036389676,0.0044686613,0.000058399357,0.002328557],"genre_scores_gemma":[0.9868315,0.00010659501,0.0047779633,0.00082980306,0.00088065316,0.00021072917,0.0062123933,0.000032644304,0.000117742136],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997747,0.0005902059,0.0006582255,0.0004483922,0.0002613775,0.00029480283],"domain_scores_gemma":[0.9928087,0.0054675075,0.0005859752,0.0007228797,0.00026358626,0.00015133004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019404739,0.0002310315,0.0017194519,0.00015674949,0.00010913282,0.000026355588,0.00024782043,0.000114329756,0.00019219457],"category_scores_gemma":[0.0009088597,0.0001580474,0.00020674226,0.00029645988,0.00014978842,0.000103850914,0.000048327933,0.00013611017,0.0000018832362],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6963817,0.002798289,0.11018233,0.0003810475,0.08172291,0.00022535921,0.019564223,0.005411376,0.00422535,0.0021610167,0.041376535,0.035569873],"study_design_scores_gemma":[0.66074675,0.001862386,0.023279697,0.00007401693,0.03959235,0.000006313746,0.0008956725,0.26969802,0.00096621393,0.00026454806,0.0023190489,0.00029497573],"about_ca_topic_score_codex":0.00096315285,"about_ca_topic_score_gemma":0.0003780268,"teacher_disagreement_score":0.26428664,"about_ca_system_score_codex":0.0003370136,"about_ca_system_score_gemma":0.00069110113,"threshold_uncertainty_score":0.6444986},"labels":[],"label_agreement":null},{"id":"W2133367407","doi":"10.1016/s1470-2045(01)00489-2","title":"Current and future developments in the use of temozolomide for the treatment of brain tumours","year":2001,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":248,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Cancer Research Society; American Association for Cancer Research","keywords":"Temozolomide; Medicine; Glioma; Concomitant; Oncology; Chemotherapy; Radiation therapy; Drug; Clinical trial; Dacarbazine; Internal medicine; Phases of clinical research; Brain tumor; Pharmacology; Pathology; Cancer research","score_opus":0.22527878642532184,"score_gpt":0.43536852915759616,"score_spread":0.21008974273227432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133367407","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002830061,0.98607826,0.0000016786379,0.0075327097,0.0002598355,0.0031238955,0.00009679449,0.0000048603993,0.00007189728],"genre_scores_gemma":[0.00023461967,0.9975245,0.00018270503,0.00027258496,0.0005367604,0.0011255514,0.00007842499,0.000017740618,0.000027115706],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998583,0.00035386847,0.00048182253,0.0002027518,0.0001267881,0.00025176734],"domain_scores_gemma":[0.9959258,0.003150296,0.00039767317,0.00045722016,0.000039918083,0.000029101368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047205103,0.0002582933,0.001827096,0.00007960375,0.000054476277,0.0000070235533,0.00020519267,0.00014144821,0.000008411974],"category_scores_gemma":[0.00006304152,0.00008874272,0.00024063748,0.00021939196,0.0001438225,0.000012265763,0.000029300127,0.00015394262,0.0000016832295],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000101704056,0.0008547703,0.0014012235,0.0012665947,0.00035802502,0.00002232483,0.000664674,4.4615135e-7,2.6836787e-7,0.0003838452,0.005463742,0.9894824],"study_design_scores_gemma":[0.0026110872,0.0009508431,0.0056176702,0.0011319297,0.0015747377,0.00012056329,0.0001044094,0.0000018907407,0.0000025753286,0.0000284606,0.98778623,0.00006959807],"about_ca_topic_score_codex":0.000050136718,"about_ca_topic_score_gemma":0.00019830391,"teacher_disagreement_score":0.9894128,"about_ca_system_score_codex":0.00022085274,"about_ca_system_score_gemma":0.00026621582,"threshold_uncertainty_score":0.3618823},"labels":[],"label_agreement":null},{"id":"W2133427336","doi":"10.1016/s1470-2045(03)01322-6","title":"Management of Wilms' tumour: current practice and future goals","year":2003,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Renal and related cancers","field":"Biochemistry, Genetics and Molecular Biology","cited_by":197,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Alberta","funders":"","keywords":"Wilms tumour; Radiation therapy; Medicine; Wilms' tumor; Intensive care medicine; Childhood cancer; Quality of life (healthcare); Chemotherapy; Cancer; Pediatrics; Surgery; Internal medicine; Nursing","score_opus":0.03233062085068108,"score_gpt":0.3780878001615636,"score_spread":0.34575717931088257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133427336","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000018810424,0.9807397,0.00001222565,0.0005611258,0.00079068984,0.0004096444,0.000023914108,0.000004931511,0.017438935],"genre_scores_gemma":[0.000007647904,0.9976699,0.00028943957,0.0002101395,0.0011780256,0.000068413414,0.00006514056,0.000021379368,0.0004899382],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986097,0.0004497232,0.00031555153,0.00029637365,0.00009357427,0.00023505522],"domain_scores_gemma":[0.9990666,0.000041575342,0.00043119557,0.00037213296,0.00004328521,0.00004521358],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004762051,0.00022746791,0.00087858184,0.00002506761,0.000047446727,0.000007317472,0.00030132208,0.00034211212,0.000010893098],"category_scores_gemma":[0.00001154412,0.0001287952,0.00016175096,0.00010304908,0.00014207633,0.0000017516279,0.00014809927,0.00036699834,0.000010008907],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000046950405,0.000044753764,4.4210893e-7,0.0046339566,0.00054131285,0.000018016368,0.000014345691,9.1054267e-7,0.000012900873,0.0011103483,0.011131318,0.98244476],"study_design_scores_gemma":[0.00034750218,0.00019568387,0.0000018416094,0.0008800244,0.0009375847,0.00018671929,0.00004971545,1.263892e-7,0.00001534888,0.000037871472,0.99719787,0.00014974095],"about_ca_topic_score_codex":0.0000021857982,"about_ca_topic_score_gemma":0.0000011752153,"teacher_disagreement_score":0.9860665,"about_ca_system_score_codex":0.000036505007,"about_ca_system_score_gemma":0.00015039649,"threshold_uncertainty_score":0.52521163},"labels":[],"label_agreement":null},{"id":"W2133436228","doi":"10.1016/s1470-2045(02)00788-x","title":"Nucleoside analogues and nucleobases in cancer treatment","year":2002,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Biochemical and Molecular Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":606,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Nucleoside; Nucleobase; Purine; Nucleoside analogue; Cytotoxicity; Nucleoside transporter; Pyrimidine; Biochemistry; Cancer cell; Chemistry; Biology; Cancer; Pharmacology; Enzyme; Transporter; In vitro; DNA; Gene; Genetics","score_opus":0.16611701688756003,"score_gpt":0.43807110515966147,"score_spread":0.27195408827210144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133436228","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015421137,0.9952965,0.0000016266695,0.0006168122,0.000069686335,0.00044120644,0.00007445432,0.000008794223,0.0019488301],"genre_scores_gemma":[0.00034038804,0.9973983,0.000049224975,0.00035841798,0.00064550876,0.00029578808,0.00013004898,0.00003356655,0.00074876385],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984661,0.00035699963,0.00025302765,0.00043537703,0.000078682024,0.00040984014],"domain_scores_gemma":[0.9993123,0.00006293796,0.00010188373,0.00042552935,0.00002043012,0.00007695128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019145661,0.0002769684,0.0010086171,0.0000535078,0.00005154062,0.000017519093,0.00032299993,0.00042625764,0.00005248442],"category_scores_gemma":[0.000046605473,0.00016175854,0.00016772536,0.00012029762,0.00023745386,0.0000011157332,0.00022025863,0.00025651738,0.00002226064],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003257405,0.000113271366,0.00003065853,0.00068303425,0.00014783634,0.00003555069,0.000020895262,3.6704375e-7,0.00043898987,0.000043097865,0.004533415,0.9939203],"study_design_scores_gemma":[0.00046891565,0.0004027118,0.000018850667,0.00037443684,0.00012983405,0.000058922873,0.0000071153636,0.0000028828626,0.00021097966,0.000022110617,0.9981217,0.0001815783],"about_ca_topic_score_codex":0.00023391367,"about_ca_topic_score_gemma":0.00071826985,"teacher_disagreement_score":0.9937387,"about_ca_system_score_codex":0.00011115816,"about_ca_system_score_gemma":0.00016186296,"threshold_uncertainty_score":0.6596322},"labels":[],"label_agreement":null},{"id":"W2134021845","doi":"10.1016/s1470-2045(11)70338-2","title":"Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":151,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame; Université de Montréal; Juravinski Cancer Centre; McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Aflibercept; Paracentesis; Ascites; Placebo; Surgery; Population; Clinical endpoint; Internal medicine; Ovarian cancer; Chemotherapy; Bevacizumab; Gastroenterology; Randomized controlled trial; Cancer","score_opus":0.06439106428427824,"score_gpt":0.35626371206261853,"score_spread":0.2918726477783403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134021845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9798348,0.00052863656,0.000048446145,0.0007050807,0.00026717523,0.017912993,0.00006733073,0.000031079013,0.00060446584],"genre_scores_gemma":[0.9842626,0.00044855048,0.0010730996,0.00011338174,0.00015096067,0.01382263,0.000040531326,0.00003478335,0.000053462958],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99805087,0.00023199047,0.0006533118,0.00039982382,0.00020617535,0.00045781708],"domain_scores_gemma":[0.9983747,0.00041897665,0.00043766972,0.00051741156,0.00014356681,0.00010768207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045145443,0.0003173487,0.0019872237,0.00013982807,0.000071676746,0.000008071747,0.0001523135,0.00008454267,0.00016528102],"category_scores_gemma":[0.000023863233,0.00016412219,0.00015808031,0.00019749926,0.00009571074,0.00004631126,0.000020795123,0.000078851386,0.000004015928],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.79693866,0.028030645,0.042424075,0.000081252445,0.0017175005,0.000039535724,0.009726483,0.000020270607,0.000013593121,0.00011925814,0.000042168675,0.12084656],"study_design_scores_gemma":[0.88933736,0.05391699,0.053094074,0.00018319851,0.00183,0.000005439174,0.0005373101,0.00006966141,0.00041062792,0.000054071275,0.00040171985,0.00015956134],"about_ca_topic_score_codex":0.0004601215,"about_ca_topic_score_gemma":0.0012665632,"teacher_disagreement_score":0.120687,"about_ca_system_score_codex":0.0006724789,"about_ca_system_score_gemma":0.00034991113,"threshold_uncertainty_score":0.6692709},"labels":[],"label_agreement":null},{"id":"W2135359531","doi":"10.1016/s1470-2045(05)70093-0","title":"Cardiac tumours: diagnosis and management","year":2005,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Cardiac tumors and thrombi","field":"Medicine","cited_by":841,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Intracardiac injection; Autopsy; Chemotherapy; Constitutional symptoms; Radiation therapy; Radiology; Incidence (geometry); Disease; Surgery; Internal medicine","score_opus":0.09777482929734728,"score_gpt":0.41384492416532465,"score_spread":0.3160700948679774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135359531","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00002229893,0.94267017,7.8520105e-7,0.0022409111,0.00061188237,0.0013075975,0.000047865207,0.00005466545,0.053043857],"genre_scores_gemma":[0.000018723742,0.9929472,0.00021920311,0.0008346327,0.003849933,0.00073177513,0.00005461107,0.00004478662,0.0012991333],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985419,0.0002910911,0.0003168166,0.00033046945,0.00014779367,0.00037192513],"domain_scores_gemma":[0.998799,0.0003032602,0.00016652347,0.00061051117,0.000019595755,0.000101061196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065927004,0.000284546,0.0031997717,0.00008468302,0.00006703874,0.000016901904,0.00016854596,0.00020798118,0.000100418954],"category_scores_gemma":[0.000024000947,0.0001654503,0.00047692846,0.00015158826,0.00015298378,0.000015615988,0.000220274,0.00047500274,0.00020328026],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011629592,0.000046927995,0.00009686209,0.0050591263,0.0004624261,0.00015669492,0.00003403574,2.9089858e-8,1.1119393e-8,0.0015196686,0.060766283,0.9318463],"study_design_scores_gemma":[0.000495986,0.00015271669,0.00087142305,0.0028739944,0.004905481,0.00033296717,0.000022776618,1.6736995e-7,7.966593e-8,0.00004288126,0.9901419,0.00015958368],"about_ca_topic_score_codex":0.000015208312,"about_ca_topic_score_gemma":0.000007159181,"teacher_disagreement_score":0.9316867,"about_ca_system_score_codex":0.00023346275,"about_ca_system_score_gemma":0.00010449589,"threshold_uncertainty_score":0.67468673},"labels":[],"label_agreement":null},{"id":"W2135655084","doi":"10.1016/s1470-2045(11)70378-3","title":"A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":80,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Breast Cancer Research Foundation","keywords":"Breast cancer; Medicine; Clinical trial; Neoadjuvant therapy; Clinical endpoint; Medical physics; Surrogate endpoint; Population; Oncology; Cancer; Intensive care medicine; Internal medicine","score_opus":0.18231508853691675,"score_gpt":0.481869523507254,"score_spread":0.29955443497033724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135655084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9740572,0.007998339,0.00017029126,0.014021677,0.00049557094,0.0007822834,0.0015496104,0.000017949005,0.00090709515],"genre_scores_gemma":[0.99299765,0.002802731,0.00069367554,0.0013188837,0.001599078,0.00048417077,0.0000635045,0.000014993557,0.000025344063],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99840105,0.0006826864,0.0003454535,0.00018499691,0.00005222147,0.00033361372],"domain_scores_gemma":[0.99908805,0.00046178384,0.00014202645,0.00021513453,0.000035000816,0.00005800686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025383455,0.0001205483,0.0005905646,0.000019521587,0.00007932631,0.0000076938195,0.00010884009,0.00013213172,0.000020973068],"category_scores_gemma":[0.00029227667,0.00007638346,0.00008098696,0.000041178777,0.0001913592,0.0000042523097,0.0001051445,0.00011555277,0.0000029140247],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00887581,0.00071383914,0.6298376,0.00007360435,0.0006705021,0.000009566112,0.0022350147,0.000003995486,0.008002608,0.002363536,0.025532736,0.32168123],"study_design_scores_gemma":[0.024131518,0.0014399441,0.7864833,0.00011747948,0.0005599844,0.00034175522,0.0025374056,0.000024006817,0.009919704,0.0019747019,0.17189044,0.0005797859],"about_ca_topic_score_codex":0.0001349634,"about_ca_topic_score_gemma":0.0016458747,"teacher_disagreement_score":0.32110146,"about_ca_system_score_codex":0.000054586275,"about_ca_system_score_gemma":0.000104330444,"threshold_uncertainty_score":0.31148273},"labels":[],"label_agreement":null},{"id":"W2135671488","doi":"10.1016/s1470-2045(11)70287-x","title":"Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":507,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; University of Alberta","funders":"GlaxoSmithKline","keywords":"Medicine; Vaccine efficacy; Cohort; Serostatus; Cervical cancer; Vaccine trial; Vaccination; Adjuvant; HPV infection; Internal medicine; Oncology; Immunology; Cancer; Virus; Viral load","score_opus":0.09181201552947253,"score_gpt":0.4050317562153602,"score_spread":0.31321974068588765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135671488","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864049,0.0004136091,0.00007595144,0.00024093817,0.00020770275,0.0040223054,0.000062205196,0.00002028716,0.008552121],"genre_scores_gemma":[0.9986631,0.00041875924,0.000016947426,0.00010348389,0.00040749487,0.00021868666,0.000030755018,0.00002495775,0.000115770315],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9972864,0.00061306974,0.00086522603,0.00040324221,0.00045382496,0.00037828003],"domain_scores_gemma":[0.9973172,0.00071383745,0.0005600356,0.0007318727,0.00056158623,0.00011546398],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018101606,0.00023277797,0.0017903702,0.00028457557,0.0001083669,0.000008528628,0.00033798523,0.00025360667,0.004997227],"category_scores_gemma":[0.00041934836,0.00013235424,0.00036140537,0.0017225167,0.00023437053,0.00004977038,0.0002275181,0.00062315277,0.0000039777315],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8539444,0.0022525277,0.102551095,0.00017786749,0.0038565844,0.000004405522,0.002489257,0.00004738523,0.0018996431,0.000014687916,0.0003190253,0.03244313],"study_design_scores_gemma":[0.389295,0.0036829498,0.59813315,0.000008869065,0.002412392,0.000001627365,0.00012416292,0.0001919589,0.0057608206,0.000027083579,0.0002669215,0.00009503824],"about_ca_topic_score_codex":0.004310604,"about_ca_topic_score_gemma":0.003609761,"teacher_disagreement_score":0.49558207,"about_ca_system_score_codex":0.0002457122,"about_ca_system_score_gemma":0.00038932197,"threshold_uncertainty_score":0.9959123},"labels":[],"label_agreement":null},{"id":"W2136344041","doi":"10.1016/s1470-2045(14)70063-4","title":"Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":1174,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Montreal General Hospital","funders":"Universität Duisburg-Essen; Aarhus Universitet; Universität zu Köln; Universitair Medisch Centrum Groningen; University College London; National Institute for Health and Care Research; Universitaire Ziekenhuizen Leuven, KU Leuven; Canadian Cancer Society Research Institute; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; EORTC Charitable Trust; Aarhus Universitetshospital; Cancer Research UK; Amgen","keywords":"Ifosfamide; Doxorubicin; Soft tissue sarcoma; Medicine; Sarcoma; Oncology; Soft tissue; Chemotherapy; Internal medicine; Surgery; Pathology; Cisplatin","score_opus":0.11187372635953846,"score_gpt":0.4083463554134927,"score_spread":0.2964726290539542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136344041","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9553599,0.00295365,0.002601522,0.019094786,0.0014571649,0.017450295,0.00011512425,0.00012780176,0.00083980366],"genre_scores_gemma":[0.98712796,0.001037667,0.0038318066,0.0009855713,0.0010570128,0.0052940263,0.0001492203,0.000055813696,0.00046092272],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99698114,0.0005526704,0.0010625647,0.00048468984,0.00026689007,0.00065203366],"domain_scores_gemma":[0.9864056,0.011757237,0.0005996271,0.0008047862,0.00024694912,0.00018579858],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010896298,0.00045735942,0.004058494,0.0001411002,0.00015461366,0.00001312972,0.00021027093,0.00014538973,0.00016161654],"category_scores_gemma":[0.0024646174,0.00023267392,0.00051310076,0.00019946224,0.00024134718,0.00004172239,0.00003880973,0.00013955157,0.000026271477],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8934473,0.0057304734,0.000015357755,0.00008597766,0.0018846015,0.00014622918,0.00060428475,0.00014307485,0.0033751833,0.00037969687,0.0012505343,0.09293731],"study_design_scores_gemma":[0.8750051,0.05835024,0.00005509326,0.00006787469,0.0037846765,0.00006423535,0.00023446535,0.0027166966,0.012034513,0.00029520062,0.047199722,0.0001921753],"about_ca_topic_score_codex":0.00015456793,"about_ca_topic_score_gemma":0.0008299924,"teacher_disagreement_score":0.09274514,"about_ca_system_score_codex":0.00055023585,"about_ca_system_score_gemma":0.0003295789,"threshold_uncertainty_score":0.9488167},"labels":[],"label_agreement":null},{"id":"W2136541422","doi":"10.1016/s1470-2045(13)70380-2","title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":799,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre; Vancouver General Hospital","funders":"Celgene","keywords":"Pomalidomide; Dexamethasone; Medicine; Lenalidomide; Refractory (planetary science); Internal medicine; Multiple myeloma; Clinical endpoint; Bortezomib; Population; Thalidomide; Progressive disease; Clinical trial; Phases of clinical research; Oncology; Gastroenterology; Chemotherapy","score_opus":0.08314179518883183,"score_gpt":0.37908462025288053,"score_spread":0.2959428250640487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136541422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9790796,0.00041982348,0.00021164303,0.0024101676,0.000621192,0.016491434,0.00019868699,0.0001022131,0.00046521847],"genre_scores_gemma":[0.9681648,0.0002829813,0.023841418,0.0007101689,0.0007880835,0.0047636456,0.0005446757,0.000110326386,0.00079388765],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9957555,0.0009451378,0.0007030018,0.0008387118,0.0005533803,0.0012042847],"domain_scores_gemma":[0.9912619,0.0061507057,0.00047567487,0.0010704839,0.00041189103,0.00062937115],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014325252,0.00053278287,0.002065135,0.00017679659,0.00039569417,0.00012191742,0.000582161,0.00033792236,0.00030414134],"category_scores_gemma":[0.0036781013,0.0003268925,0.00010754036,0.00032106193,0.00056940474,0.00036107883,0.00034283605,0.0006251469,0.0001077757],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9197107,0.0059189573,0.0011369856,0.00011179763,0.0011793218,0.00014667738,0.00036059134,0.0000031673915,0.0024949748,0.00004369903,0.0044143163,0.0644788],"study_design_scores_gemma":[0.9480376,0.03400479,0.0086432,0.000101165526,0.0005582949,0.000031060266,0.00012600255,0.0010994432,0.00059999956,0.00011892035,0.0063177077,0.00036180654],"about_ca_topic_score_codex":0.0012482923,"about_ca_topic_score_gemma":0.00036216233,"teacher_disagreement_score":0.06411699,"about_ca_system_score_codex":0.0006013755,"about_ca_system_score_gemma":0.00065676705,"threshold_uncertainty_score":0.99991834},"labels":[],"label_agreement":null},{"id":"W2137043950","doi":"10.1016/s1470-2045(15)00006-6","title":"Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":434,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"AstraZeneca; Eli Lilly and Company","keywords":"Afatinib; Erlotinib; Medicine; Clinical endpoint; Internal medicine; Lung cancer; Erlotinib Hydrochloride; Oncology; Population; Randomized controlled trial; Surgery; Cancer; Epidermal growth factor receptor","score_opus":0.06509205628352367,"score_gpt":0.4127227631918144,"score_spread":0.34763070690829073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137043950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9760129,0.0005500681,0.0000098057935,0.0006435172,0.000720855,0.009161214,0.00017534928,0.000018669305,0.012707621],"genre_scores_gemma":[0.99702364,0.000015350204,0.0004210868,0.00021808733,0.00026442218,0.00085159024,0.0001679471,0.000029429024,0.0010084292],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982089,0.0004341275,0.0005355892,0.0002670282,0.0002638419,0.0002905076],"domain_scores_gemma":[0.9976114,0.0005994525,0.00065058115,0.0006642896,0.00032781824,0.00014644189],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034927475,0.00023353388,0.0013501475,0.00004453721,0.00009729912,0.000010380627,0.00030463273,0.0000904564,0.00013342766],"category_scores_gemma":[0.00017415136,0.000107524225,0.000092284514,0.00015912385,0.00017262342,0.000088045075,0.00005223423,0.00010903666,0.0000028926638],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9791286,0.010686673,0.0021620921,0.00003937075,0.00050561136,0.000014867433,0.0032920113,0.000071345385,0.0003634615,0.00009852868,0.00069817627,0.0029392883],"study_design_scores_gemma":[0.93078166,0.06107069,0.0011517083,0.00001570981,0.0020654022,0.0000034833947,0.0005008799,0.00036744424,0.0017602202,0.000021142945,0.0021581713,0.00010349958],"about_ca_topic_score_codex":0.00018776795,"about_ca_topic_score_gemma":0.00016859252,"teacher_disagreement_score":0.05038402,"about_ca_system_score_codex":0.00042059415,"about_ca_system_score_gemma":0.0011898157,"threshold_uncertainty_score":0.43847105},"labels":[],"label_agreement":null},{"id":"W2137508065","doi":"10.1016/s1470-2045(11)70004-3","title":"Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":396,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Gemcitabine; Medicine; Placebo; Axitinib; Internal medicine; Oncology; Double blind; Ursodeoxycholic acid; Pancreatic cancer; Chemotherapy; Cancer","score_opus":0.13174673638970355,"score_gpt":0.39103431325916943,"score_spread":0.2592875768694659,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137508065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96202195,0.00034111508,0.00006274196,0.0009204235,0.0002966157,0.009184003,0.000018730427,0.000105374835,0.027049057],"genre_scores_gemma":[0.9951906,0.00008442862,0.0012259986,0.00029202807,0.00044248064,0.0018998286,0.00009320551,0.00006605269,0.00070534373],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99584013,0.0008232718,0.0008476966,0.0006979217,0.0006190484,0.0011719572],"domain_scores_gemma":[0.9966582,0.0012790897,0.00034878502,0.0010895864,0.00030311503,0.00032121586],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001972642,0.00047019703,0.0025126934,0.00031133537,0.00019954384,0.00001643547,0.0005544704,0.00026761682,0.00079560734],"category_scores_gemma":[0.0004441609,0.00029176596,0.000113718124,0.00063220924,0.0005621618,0.00013792311,0.000202739,0.0009909722,0.00013921135],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7660201,0.0030606312,0.22167656,0.0000811381,0.0006768656,0.00047303556,0.0060882163,0.000013994426,0.000020330333,0.00015750511,0.00025338432,0.0014782086],"study_design_scores_gemma":[0.7161739,0.02170548,0.25771278,0.000073196716,0.0009805918,0.00003411126,0.002214515,0.00037109884,0.000019175062,0.000037372218,0.00041869297,0.00025910535],"about_ca_topic_score_codex":0.0005551724,"about_ca_topic_score_gemma":0.000565922,"teacher_disagreement_score":0.04984627,"about_ca_system_score_codex":0.00094900146,"about_ca_system_score_gemma":0.0013865955,"threshold_uncertainty_score":0.99995345},"labels":[],"label_agreement":null},{"id":"W2137616140","doi":"10.1016/s1470-2045(14)71160-x","title":"Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":387,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Notre-Dame; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"National Cancer Institute; Canadian Cancer Society Research Institute; Eli Lilly and Company","keywords":"Cystectomy; Urothelial carcinoma; Medicine; Urology; Open label; Chemotherapy; Carcinoma; Oncology; Urothelial cancer; Bladder cancer; Randomized controlled trial; Internal medicine; Cancer","score_opus":0.051772857023881236,"score_gpt":0.35889775882615577,"score_spread":0.30712490180227453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137616140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912723,0.00005377618,0.00003066866,0.0016308285,0.000939205,0.0042451443,0.000071737195,0.000026066116,0.0017303219],"genre_scores_gemma":[0.99543864,0.000021982902,0.0001806169,0.0024796114,0.00094051904,0.000688847,0.000034008903,0.00005636874,0.0001594257],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997358,0.0008421267,0.00053703797,0.00041487563,0.00035445727,0.00049346866],"domain_scores_gemma":[0.9982937,0.00037104837,0.00026621207,0.0008302934,0.000088590954,0.00015016945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007043824,0.0003116741,0.001167613,0.00007442013,0.00007714509,0.000025126297,0.0006603099,0.00019829343,0.00042206384],"category_scores_gemma":[0.00014952634,0.00014523156,0.000093874114,0.00025098154,0.00042921837,0.00010358285,0.00012645379,0.0003925225,0.000012157809],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97077745,0.0034976073,0.012139959,0.000026740743,0.00033290486,0.000026197855,0.001241759,8.938037e-7,0.00023947361,0.000028249666,0.00047420844,0.011214531],"study_design_scores_gemma":[0.922922,0.02568744,0.04271385,0.000060102317,0.00035610265,0.000012083608,0.000060292503,0.00007084658,0.000671204,0.000051464034,0.007209624,0.0001849856],"about_ca_topic_score_codex":0.00028380463,"about_ca_topic_score_gemma":0.0006410227,"teacher_disagreement_score":0.04785547,"about_ca_system_score_codex":0.00020673861,"about_ca_system_score_gemma":0.00051329524,"threshold_uncertainty_score":0.5922371},"labels":[],"label_agreement":null},{"id":"W2137935883","doi":"10.1016/s1470-2045(09)70262-1","title":"Ki67 in breast cancer: prognostic and predictive potential","year":2010,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1226,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Breast cancer; Oncology; Medicine; Pathological; Oestrogen receptor; Internal medicine; Predictive marker; Cancer; Human Epidermal Growth Factor Receptor 2; Gynecology; Progesterone receptor; Bioinformatics; Estrogen receptor; Biology","score_opus":0.0245620792448499,"score_gpt":0.3433855665218097,"score_spread":0.3188234872769598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137935883","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005975485,0.9954819,0.000006913146,0.0015078384,0.0005022531,0.0006725295,0.0007276412,0.000012632037,0.0004907606],"genre_scores_gemma":[0.0019711466,0.9945383,0.000052823016,0.00020567133,0.0021097574,0.0008310046,0.00019128628,0.000036567333,0.00006345746],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985539,0.00027193158,0.00025970937,0.00045997236,0.0000779903,0.0003765141],"domain_scores_gemma":[0.9992567,0.00007427625,0.00020738968,0.00036977252,0.000042857242,0.000049006117],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002226047,0.00032355968,0.0011601241,0.000045949524,0.00007993283,0.000012902435,0.0003122331,0.0004976837,0.000017232736],"category_scores_gemma":[0.00003321442,0.00020252485,0.000118382195,0.000098376404,0.00033092438,0.0000020367763,0.0003211752,0.00048854237,0.000007527861],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020133094,0.00010222864,0.0015684434,0.0010114566,0.00040096085,0.00003228092,0.00006510255,0.0000022671036,0.000019938134,0.000030931773,0.0022001981,0.99436486],"study_design_scores_gemma":[0.0008286601,0.00013405904,0.0070325052,0.00065837277,0.00068072934,0.00059868704,0.000018810759,0.0000021256967,0.0000020525754,0.000041569565,0.98979163,0.00021077665],"about_ca_topic_score_codex":0.0001070599,"about_ca_topic_score_gemma":0.0005306008,"teacher_disagreement_score":0.9941541,"about_ca_system_score_codex":0.00009238767,"about_ca_system_score_gemma":0.00038945777,"threshold_uncertainty_score":0.82587236},"labels":[],"label_agreement":null},{"id":"W2138156952","doi":"10.1016/s1470-2045(13)70556-4","title":"Single versus multiple fractions of repeat radiation for painful bone metastases: a randomised, controlled, non-inferiority trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":298,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; McMaster University; Juravinski Hospital; Queen's University; Sunnybrook Health Science Centre; Centre Hospitalier Universitaire de Sherbrooke; University of Calgary; University of Toronto","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Medicine; Randomized controlled trial; Oncology; Internal medicine; Physical therapy; Nuclear medicine","score_opus":0.06335275486606788,"score_gpt":0.35184966037814175,"score_spread":0.28849690551207385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138156952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91658324,0.00052736857,0.018013181,0.023533579,0.0024000898,0.026666354,0.00015600755,0.0001341243,0.011986081],"genre_scores_gemma":[0.98755443,0.00007811965,0.0064075585,0.0012341934,0.0009269511,0.0030675207,0.00013353073,0.000022922473,0.0005747498],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.998207,0.00044791587,0.0006093197,0.00021629116,0.00022087948,0.00029860035],"domain_scores_gemma":[0.99449325,0.004166121,0.00049291766,0.0005332381,0.00020700926,0.00010746824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020242946,0.00015372066,0.0012755039,0.000095922456,0.00009566521,0.000017437074,0.00012312595,0.000079701946,0.00046964095],"category_scores_gemma":[0.006075396,0.00010260738,0.00032650423,0.00012201055,0.00012070786,0.00010351871,0.00003836786,0.000147374,0.000039224095],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9394165,0.001481858,0.00018333828,0.00017654439,0.001073695,0.0000099172985,0.00029066662,0.00003610675,0.0031032667,0.00030863078,0.032863457,0.021055961],"study_design_scores_gemma":[0.9276016,0.0030769242,0.00083351665,0.000015539139,0.0019287658,0.000003905196,0.0005410598,0.005221384,0.0002639858,0.00030583784,0.06010223,0.00010524608],"about_ca_topic_score_codex":0.00016431685,"about_ca_topic_score_gemma":0.00004584346,"teacher_disagreement_score":0.070971236,"about_ca_system_score_codex":0.00012816244,"about_ca_system_score_gemma":0.00016507714,"threshold_uncertainty_score":0.72732556},"labels":[],"label_agreement":null},{"id":"W2138256570","doi":"10.1016/s1470-2045(08)70028-7","title":"Cancer registration in developing countries: luxury or necessity?","year":2008,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":164,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Pediatric Oncology Group of Ontario","keywords":"Developing country; Cancer; Developed country; Low and middle income countries; Business; Health care; Population; Environmental health; Economic growth; Medicine; Economics","score_opus":0.3596719865317487,"score_gpt":0.5027934480522409,"score_spread":0.1431214615204922,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138256570","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005859787,0.9824506,0.00005192879,0.007560557,0.00042514887,0.00073155813,0.00001970583,0.00004948091,0.008652408],"genre_scores_gemma":[0.000011787092,0.9896562,0.00056914,0.0065223626,0.0016753853,0.00027566392,0.0000514603,0.000024986193,0.0012129965],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99804157,0.00027807098,0.0006219091,0.0003389574,0.00026836657,0.0004511455],"domain_scores_gemma":[0.99861073,0.00037537733,0.00044832058,0.00041741054,0.000090670546,0.000057513793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005973603,0.00027894028,0.0022543517,0.00010407911,0.000112741975,0.00001653924,0.00032437063,0.0004377169,0.00016306597],"category_scores_gemma":[0.00018135345,0.00015641771,0.00014038738,0.0004889947,0.0001720607,0.000075451375,0.00007506289,0.00070772803,0.00006585705],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044598227,0.000022206495,0.0004145054,0.006791917,0.00014076821,0.000999295,0.0003651515,0.0000032806208,6.761432e-8,0.0011214159,0.07617244,0.91352296],"study_design_scores_gemma":[0.00065238215,0.00014471923,0.00027973688,0.012547501,0.00023649911,0.0012125862,0.00003899185,0.000004252052,3.0834477e-7,0.000030005893,0.98467237,0.00018065122],"about_ca_topic_score_codex":0.00073902647,"about_ca_topic_score_gemma":0.004110066,"teacher_disagreement_score":0.9133423,"about_ca_system_score_codex":0.0016323457,"about_ca_system_score_gemma":0.0057109366,"threshold_uncertainty_score":0.99992573},"labels":[],"label_agreement":null},{"id":"W2138662170","doi":"10.1016/s1470-2045(13)70107-4","title":"Subsequent neoplasms of the CNS among survivors of childhood cancer: a systematic review","year":2013,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":121,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Cancer Institute","keywords":"Medicine; Cancer; Radiation therapy; Population; Childhood cancer; Incidence (geometry); Pediatrics; Internal medicine; Oncology; Environmental health","score_opus":0.06366249309083598,"score_gpt":0.3630867245911064,"score_spread":0.2994242315002704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138662170","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009187354,0.98815936,1.9870048e-7,0.0013804216,0.0003982427,0.007990289,0.000100291654,0.000016700676,0.0010357322],"genre_scores_gemma":[0.0008998978,0.9952618,0.00001582541,0.00038816614,0.00017141923,0.0030914452,0.000027287471,0.00003998953,0.00010419852],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9965717,0.0012161817,0.0013005944,0.00026423536,0.0003220679,0.0003252275],"domain_scores_gemma":[0.9954455,0.0008271031,0.0020677277,0.0014465904,0.0001400803,0.00007300474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00096941664,0.0003805676,0.007468549,0.000067398905,0.000047190922,0.0000045810466,0.0006400334,0.00024690334,0.00020432379],"category_scores_gemma":[0.00030413482,0.00014654029,0.0009516137,0.00042697354,0.00025566333,0.000016625347,0.00015656705,0.0003976641,0.000034625893],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000035371916,0.00038252684,0.00045711998,0.961673,0.00174958,0.000013037336,0.00013160832,4.4053021e-7,5.639624e-7,0.00026654438,0.0027726074,0.0325494],"study_design_scores_gemma":[0.00077975955,0.0002741231,0.0007552816,0.81936836,0.022156624,0.00018397075,0.000025695097,9.801706e-7,0.00001118923,0.000019615316,0.15627186,0.00015253013],"about_ca_topic_score_codex":0.0009485215,"about_ca_topic_score_gemma":0.0006266405,"teacher_disagreement_score":0.15349925,"about_ca_system_score_codex":0.0003148137,"about_ca_system_score_gemma":0.00064992375,"threshold_uncertainty_score":0.59757394},"labels":[],"label_agreement":null},{"id":"W2138746991","doi":"10.1016/s1470-2045(13)70449-2","title":"Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":404,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Montreal Children's Hospital; BC Children's Hospital; University of Toronto; SickKids Foundation","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Cancer Institute; Canadian Institutes of Health Research; National Center for Advancing Translational Sciences; Pediatric Brain Tumor Foundation","keywords":"Medulloblastoma; Medicine; Cancer research","score_opus":0.05283324484993569,"score_gpt":0.40220487391839227,"score_spread":0.3493716290684566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138746991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898467,0.00025426125,0.00023291726,0.008941847,0.00011679988,0.00033763723,0.000026687012,0.00004305361,0.00020008026],"genre_scores_gemma":[0.99606985,0.00029407197,0.0005461944,0.0027186174,0.0001594397,0.00012476975,0.000061284896,0.000010335908,0.000015420188],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99856514,0.0003698617,0.00030159776,0.0003141573,0.00011896893,0.00033027463],"domain_scores_gemma":[0.9988686,0.00024496575,0.000103444014,0.0004963361,0.00010911996,0.00017755308],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058628083,0.00014006426,0.00069661805,0.000050453797,0.000068161746,0.00003231318,0.00015339277,0.00013769008,0.00024750666],"category_scores_gemma":[0.000113245456,0.00007896084,0.00012069872,0.00030434955,0.00024767124,0.00005257324,0.00007547347,0.00025756587,0.00006310378],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001221559,0.0005607262,0.9167105,0.000010619924,0.00086505886,0.00014556831,0.00041844364,0.0000041880385,0.00039258227,0.00019446992,0.00095894566,0.079616755],"study_design_scores_gemma":[0.0026425526,0.0013620844,0.987187,0.00002135914,0.00077864906,0.00005749645,0.000500285,0.0010725172,0.0005471476,0.00018469583,0.0055457214,0.0001004579],"about_ca_topic_score_codex":0.0005605078,"about_ca_topic_score_gemma":0.0009023143,"teacher_disagreement_score":0.0795163,"about_ca_system_score_codex":0.000044503315,"about_ca_system_score_gemma":0.000041384017,"threshold_uncertainty_score":0.32199293},"labels":[],"label_agreement":null},{"id":"W2138809580","doi":"10.1016/s1470-2045(12)70473-4","title":"Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":280,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Abiraterone acetate; Prednisone; Prostate cancer; Medicine; Placebo; Oncology; Castration; Internal medicine; Pain control; Enzalutamide; Cancer; Hormone; Androgen deprivation therapy; Surgery; Pathology; Alternative medicine","score_opus":0.04245628526734094,"score_gpt":0.342165039565691,"score_spread":0.2997087542983501,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138809580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915587,0.0023299041,0.000014612125,0.0005665398,0.000028509274,0.0047029033,0.00077816873,0.000009079309,0.000011608176],"genre_scores_gemma":[0.99852526,0.00045104473,0.000057152323,0.000060262828,0.000029755698,0.000416834,0.0004236538,0.000016955715,0.000019078077],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965437,0.0021074177,0.00041966696,0.00029615496,0.00031519003,0.00031787617],"domain_scores_gemma":[0.99677855,0.0022199834,0.00037707016,0.00044806293,0.00007913171,0.00009719889],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029400643,0.00021531858,0.0013359524,0.000101793106,0.00007499267,0.00000919696,0.00013368376,0.00005514129,0.000014946632],"category_scores_gemma":[0.0001150732,0.00009553632,0.000027735881,0.00030164025,0.000463734,0.00013335966,0.000056405966,0.00020274588,2.8869593e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.69900006,0.00044026252,0.2900956,0.0001576639,0.004181913,0.000006448909,0.0024299675,0.00008424066,0.000779446,0.0000025730058,0.000046428024,0.0027754116],"study_design_scores_gemma":[0.627124,0.0101595875,0.3550452,0.00021589856,0.004447541,0.000001175118,0.00029904646,0.0022997994,0.00026272432,0.0000073628617,0.000030231187,0.00010742792],"about_ca_topic_score_codex":0.00039672802,"about_ca_topic_score_gemma":0.00080541434,"teacher_disagreement_score":0.07187603,"about_ca_system_score_codex":0.00008116023,"about_ca_system_score_gemma":0.00014922483,"threshold_uncertainty_score":0.3895858},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W2140075859","doi":"10.1016/s1470-2045(13)70158-x","title":"Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data","year":2013,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":245,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Surrogate endpoint; Radiation therapy; Lung cancer; Clinical endpoint; Internal medicine; Oncology; Clinical trial; Chemotherapy; Randomized controlled trial; Meta-analysis; Survival analysis; Cancer; Surgery","score_opus":0.4131700831971058,"score_gpt":0.5358208102113513,"score_spread":0.12265072701424551,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140075859","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01188783,0.9814287,0.000019596135,0.00075985433,0.00008933726,0.0037806025,0.0019895507,0.0000053043827,0.000039232385],"genre_scores_gemma":[0.0014144207,0.9947174,0.001504065,0.00030552252,0.000085095984,0.0011917637,0.0007063518,0.000035721452,0.000039633193],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955765,0.0015077685,0.0017114443,0.00061562227,0.0002670705,0.00032161275],"domain_scores_gemma":[0.9936325,0.0038578047,0.0014251433,0.0009097547,0.000111098794,0.00006368797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049204864,0.00039587662,0.012564118,0.00043108512,0.000022289356,0.000015833793,0.00043979217,0.00024426644,0.00021339123],"category_scores_gemma":[0.00038535,0.00020807193,0.000618368,0.00052567886,0.00014481021,0.00008199216,0.00013032397,0.00022817105,1.1846841e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014989016,0.0009159741,0.015081192,0.008913022,0.13171767,0.0000067238443,0.0006903885,0.00008757598,0.00000665377,0.000061502855,0.0012850399,0.8397353],"study_design_scores_gemma":[0.05299344,0.0027518303,0.01494603,0.005102759,0.44782978,0.000005624646,0.00011256026,0.0009991879,0.000062320876,0.0000824016,0.47437328,0.0007407788],"about_ca_topic_score_codex":0.0020619526,"about_ca_topic_score_gemma":0.0035110593,"teacher_disagreement_score":0.83899456,"about_ca_system_score_codex":0.00037476668,"about_ca_system_score_gemma":0.0004811836,"threshold_uncertainty_score":0.858858},"labels":[],"label_agreement":null},{"id":"W2140116071","doi":"10.1016/s1470-2045(14)71222-7","title":"The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":375,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Queen Elizabeth II Health Sciences Centre; University of British Columbia; Sunnybrook Health Science Centre; Dalhousie University; University of Toronto; University Health Network; BC Cancer Agency; Princess Margaret Cancer Centre; University of Calgary","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Renal cell carcinoma; Medicine; Oncology; Internal medicine; Population based study; Epidemiology","score_opus":0.05650128386318062,"score_gpt":0.29932592221088883,"score_spread":0.2428246383477082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140116071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99175525,0.00044877658,0.00020354851,0.0012695967,0.00007156349,0.0056302734,0.00012621576,0.0000635416,0.0004312219],"genre_scores_gemma":[0.99429435,0.0000117697045,0.0024498585,0.00056886533,0.00009075303,0.0011418845,0.001036865,0.00007937759,0.00032630193],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959715,0.0008381574,0.0007793487,0.00068764685,0.001000663,0.0007227064],"domain_scores_gemma":[0.99673146,0.00094053504,0.00054465205,0.0010484623,0.0005169315,0.00021793065],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011283325,0.0005364352,0.0010227298,0.00021157296,0.00019852242,0.000062446095,0.0005131071,0.00006454319,0.000046618716],"category_scores_gemma":[0.00022946589,0.00026352992,0.000093487484,0.00047223037,0.0001787278,0.00013427039,0.00010060985,0.00048387767,0.000022744383],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023718925,0.004313419,0.9581407,0.00007312281,0.00032868463,0.00077512866,0.0014009448,0.01042247,0.000106808286,0.000017168808,0.0004179897,0.0002846534],"study_design_scores_gemma":[0.06825849,0.023449183,0.8764234,0.0000904744,0.0014676352,0.00007308549,0.00060317764,0.027545024,0.0013176407,0.00009234059,0.00021433999,0.00046521844],"about_ca_topic_score_codex":0.001662072,"about_ca_topic_score_gemma":0.0029213533,"teacher_disagreement_score":0.08171729,"about_ca_system_score_codex":0.0007664306,"about_ca_system_score_gemma":0.0015528074,"threshold_uncertainty_score":0.9999817},"labels":[],"label_agreement":null},{"id":"W2140258972","doi":"10.1016/s1470-2045(08)70295-x","title":"Cancer patterns in Inuit populations","year":2008,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; MEDLINE","score_opus":0.08490454540519131,"score_gpt":0.3684336520764244,"score_spread":0.2835291066712331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140258972","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.040801696,0.001329904,0.0000046591254,0.94626015,0.00094838225,0.00049125025,0.00026436427,0.000064422384,0.009835173],"genre_scores_gemma":[0.080109626,0.0042120926,0.0000390251,0.9024004,0.0073745847,0.00024614268,0.00026416016,0.0000519437,0.005302056],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984324,0.00019603403,0.0003093005,0.0002833692,0.00022502594,0.0005538789],"domain_scores_gemma":[0.99919593,0.00008968251,0.00020520735,0.00042600694,0.000047789672,0.00003537305],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016078164,0.00021911478,0.00089245284,0.00012827516,0.00007717875,0.000007522314,0.00024048318,0.00086533173,0.0009012098],"category_scores_gemma":[0.00004617291,0.00015428876,0.00012590374,0.00021174346,0.00010480827,0.000024246994,0.000050986528,0.0022630019,0.00005993759],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000830062,0.000034615885,0.042730525,0.00006643543,0.000071699185,0.0005608197,0.0009473331,0.00002320568,0.0000041606654,0.000020914771,0.94978195,0.005675329],"study_design_scores_gemma":[0.0027726651,0.00016457484,0.0702113,0.0001230669,0.00012406161,0.000059402002,0.00006965621,0.000024612493,0.0000012809153,0.00040954154,0.9258674,0.00017247854],"about_ca_topic_score_codex":0.0051382766,"about_ca_topic_score_gemma":0.019911168,"teacher_disagreement_score":0.04385978,"about_ca_system_score_codex":0.0012325506,"about_ca_system_score_gemma":0.0007234696,"threshold_uncertainty_score":0.9979729},"labels":[],"label_agreement":null},{"id":"W2140324582","doi":"10.1016/s1470-2045(13)70606-5","title":"Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: a population-based cohort study","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":223,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto; University Health Network; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Institute for Clinical Evaluative Sciences","keywords":"Medicine; Cumulative incidence; Prostate cancer; Prostatectomy; Erectile dysfunction; Incidence (geometry); Urinary incontinence; Cancer registry; Cohort; Radiation therapy; Population; Complication; Comorbidity; Retrospective cohort study; Surgery; Cancer; Internal medicine","score_opus":0.03113809499732038,"score_gpt":0.3560763615609574,"score_spread":0.324938266563637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140324582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9849424,0.0002791325,0.0011707259,0.00671895,0.00020004381,0.0063797063,0.0001228638,0.00007429516,0.000111915266],"genre_scores_gemma":[0.98331267,0.00020890021,0.0018250017,0.0019009575,0.00033328737,0.012081519,0.000043003052,0.000034582892,0.0002600646],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985024,0.0002398819,0.0003976759,0.00036933811,0.00019292883,0.00029781123],"domain_scores_gemma":[0.99829316,0.00066734845,0.00028289767,0.00050590554,0.00017228365,0.00007838379],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006352829,0.00018780195,0.00067977374,0.00007025656,0.00012367954,0.000012465328,0.00014628892,0.000074809446,0.00017991339],"category_scores_gemma":[0.00011704444,0.000102461076,0.00007240749,0.00023094018,0.00015109696,0.000054087915,0.000024823972,0.00014213487,0.0000032262183],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015657125,0.0014371426,0.96932393,0.00014844605,0.0002180571,0.000009573672,0.00060747674,0.000108290755,0.00016166923,0.000051276464,0.00066277257,0.011614222],"study_design_scores_gemma":[0.009791701,0.008382821,0.9583776,0.00016681358,0.00024277858,0.00002810411,0.00007596259,0.0017762032,0.00034262167,0.00009657913,0.020591216,0.00012760055],"about_ca_topic_score_codex":0.0014583815,"about_ca_topic_score_gemma":0.0019717712,"teacher_disagreement_score":0.019928444,"about_ca_system_score_codex":0.00044091258,"about_ca_system_score_gemma":0.0004039932,"threshold_uncertainty_score":0.41782415},"labels":[],"label_agreement":null},{"id":"W2140587309","doi":"10.1016/s1470-2045(12)70490-4","title":"Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Liver physiology and pathology","field":"Medicine","cited_by":550,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Vancouver General Hospital","funders":"","keywords":"Medicine; Placebo; Clinical endpoint; Internal medicine; Hepatocellular carcinoma; Sorafenib; Population; Neutropenia; Performance status; Randomized controlled trial; Surgery; Oncology; Cancer; Chemotherapy; Pathology","score_opus":0.0695716841107646,"score_gpt":0.374972235833241,"score_spread":0.30540055172247643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140587309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890679,0.0013026142,0.00009588098,0.00071639556,0.000505796,0.0064547015,0.00004556308,0.0000335022,0.001777628],"genre_scores_gemma":[0.9953263,0.000044092092,0.0004186038,0.00041449204,0.0011897964,0.0014904562,0.000050739523,0.000019474648,0.0010460824],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982158,0.0006058103,0.00042706943,0.00021549815,0.00006823176,0.00046762446],"domain_scores_gemma":[0.9976687,0.0014364333,0.000268743,0.0004525882,0.000082228165,0.000091336165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009615795,0.00020231232,0.0017834551,0.000057998765,0.00009072544,0.0000012853258,0.0001242459,0.0001449277,0.00025284194],"category_scores_gemma":[0.00013793865,0.00011278939,0.00023594005,0.000068546215,0.00016846752,0.00003646159,0.000027563769,0.00012954816,0.000022261916],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8136836,0.012784535,0.066107005,0.00011059513,0.0012757329,0.00009063624,0.009616604,0.0000071130903,0.08985066,0.00042983188,0.0007087139,0.0053349193],"study_design_scores_gemma":[0.9252228,0.029112995,0.008361223,0.000008420311,0.0015035594,0.00013607544,0.0010906834,0.00028900153,0.014922947,0.00016387031,0.01903565,0.00015279168],"about_ca_topic_score_codex":0.000009456963,"about_ca_topic_score_gemma":0.000009701602,"teacher_disagreement_score":0.11153913,"about_ca_system_score_codex":0.000070830596,"about_ca_system_score_gemma":0.00012990077,"threshold_uncertainty_score":0.45994177},"labels":[],"label_agreement":null},{"id":"W2140859993","doi":"10.1016/s1470-2045(05)70432-0","title":"Health-related quality of life in patients with glioblastoma: a randomised controlled trial","year":2005,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":329,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Queen's University; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Quality of life (healthcare); Temozolomide; Radiation therapy; Clinical endpoint; Randomized controlled trial; Internal medicine; Cancer; Clinical trial; Physical therapy; Oncology","score_opus":0.03270685746671431,"score_gpt":0.3344756783315177,"score_spread":0.3017688208648034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140859993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9738881,0.00034663794,0.0000013452926,0.020635327,0.00009234609,0.003914383,0.0000062416693,0.000020362439,0.0010952764],"genre_scores_gemma":[0.9979472,0.000026505706,0.000091584254,0.0013901803,0.00014773017,0.00035657297,0.000010123893,0.000008876772,0.000021181284],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980046,0.0006804763,0.0007401221,0.00014421904,0.00018305068,0.00024752488],"domain_scores_gemma":[0.99836427,0.00075984054,0.000462674,0.00025913134,0.0000692062,0.00008488864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012391373,0.000110845605,0.0017922106,0.00006852936,0.000030783744,0.000002266463,0.00007328074,0.00008100358,0.00008286533],"category_scores_gemma":[0.0003969319,0.000055337936,0.00010057092,0.00015412214,0.00008607107,0.000019169878,0.000016227732,0.00014995731,0.0000120933955],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92926884,0.0032891908,0.0630601,0.000020239515,0.0002842335,0.000004334186,0.0003767657,0.00003526847,0.0000120979885,0.00021690891,0.00088759133,0.0025444368],"study_design_scores_gemma":[0.8120909,0.004704858,0.18253864,0.00002622718,0.00006489283,0.0000011656583,0.000021568778,0.000031426964,0.000018076751,0.000022684642,0.00043838393,0.000041170948],"about_ca_topic_score_codex":0.00020503503,"about_ca_topic_score_gemma":0.0008439477,"teacher_disagreement_score":0.11947855,"about_ca_system_score_codex":0.0001800231,"about_ca_system_score_gemma":0.00026672657,"threshold_uncertainty_score":0.22566155},"labels":[],"label_agreement":null},{"id":"W2141046618","doi":"10.1016/s1470-2045(04)01596-7","title":"Assessment of therapeutic response in patients with metastatic bone disease","year":2004,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Osteoclast; Bone resorption; Disease; Bone disease; Osteoporosis; Oncology; Resorption; Internal medicine; Pathology","score_opus":0.0991501852052402,"score_gpt":0.45508676674341525,"score_spread":0.35593658153817503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141046618","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0044966377,0.9915521,0.0000072726148,0.0008740931,0.000090228554,0.0025825382,0.00008831483,0.00001680564,0.00029200278],"genre_scores_gemma":[0.0214021,0.9766701,0.0006720602,0.00061816914,0.000031165808,0.00026515534,0.00016811972,0.000041162726,0.00013195566],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99764466,0.0010251419,0.00051751017,0.00023411305,0.00023857335,0.00034002075],"domain_scores_gemma":[0.9982758,0.0005378149,0.00042286675,0.00057054276,0.000048858754,0.00014411674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075534167,0.0002468237,0.0024795132,0.00014472807,0.000028794006,0.0000025233533,0.00011788774,0.00009527857,0.000038662198],"category_scores_gemma":[0.000057516816,0.00011829677,0.00013174354,0.00026315116,0.00012111945,0.000015817388,0.000031462336,0.00041735187,0.0000163192],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018522408,0.004809225,0.021180926,0.042204257,0.0011979485,0.00079264573,0.00015322573,0.000004663252,5.1283436e-8,0.00070067437,0.00006693045,0.9103671],"study_design_scores_gemma":[0.015223003,0.005412497,0.4627259,0.012027286,0.0044106357,0.00003886015,0.000008799697,0.0000018055952,2.5454419e-8,0.00018978542,0.4997869,0.00017448222],"about_ca_topic_score_codex":0.000042304255,"about_ca_topic_score_gemma":0.000022729437,"teacher_disagreement_score":0.91019255,"about_ca_system_score_codex":0.0007870137,"about_ca_system_score_gemma":0.0037259199,"threshold_uncertainty_score":0.66096216},"labels":[],"label_agreement":null},{"id":"W2142148449","doi":"10.1016/s1470-2045(09)70155-x","title":"Molecular predictive and prognostic markers in non-small-cell lung cancer","year":2009,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":215,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Lung cancer; Oncology; Targeted therapy; Internal medicine; Adjuvant; Chemotherapy; Cancer; Adjuvant chemotherapy; Intensive care medicine","score_opus":0.028587391361870357,"score_gpt":0.3983639984049767,"score_spread":0.36977660704310633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142148449","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00066571485,0.97790766,0.000025967081,0.00097445014,0.00016239937,0.0029021031,0.00005410183,0.000026354168,0.017281277],"genre_scores_gemma":[0.00056698534,0.996451,0.00021713215,0.0007041726,0.0003019003,0.001189587,0.000078048295,0.00003249126,0.0004586387],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987754,0.00019062022,0.00029069962,0.00032100175,0.00009218574,0.0003300528],"domain_scores_gemma":[0.9992015,0.00021564799,0.0001855909,0.00028240195,0.0000370724,0.00007778051],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021277563,0.00026113234,0.0014972005,0.000102820726,0.000042819494,0.0000099205645,0.00012877055,0.0002452461,0.000028977314],"category_scores_gemma":[0.00003242771,0.0001548057,0.00011359587,0.00021305172,0.00008208529,0.000016988228,0.000046713907,0.0004610373,0.000006174241],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011174269,0.00020786752,0.0011524003,0.008703496,0.0006916821,0.0004731892,0.00050871633,0.0000101844025,0.00000108859,0.000049054168,0.002601026,0.98548955],"study_design_scores_gemma":[0.0031296103,0.0007631234,0.003167872,0.00897887,0.008492436,0.00015026912,0.000060657014,0.000106150896,7.8416605e-7,0.000043823908,0.9748993,0.00020712194],"about_ca_topic_score_codex":0.00013268528,"about_ca_topic_score_gemma":0.00008567468,"teacher_disagreement_score":0.9852824,"about_ca_system_score_codex":0.0006691587,"about_ca_system_score_gemma":0.0010661663,"threshold_uncertainty_score":0.63127935},"labels":[],"label_agreement":null},{"id":"W2142226415","doi":"10.1016/s1470-2045(15)70064-1","title":"Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":285,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Fudan University; Natural Science Foundation of Shanghai; Eli Lilly and Company","keywords":"Gemcitabine; Medicine; Internal medicine; Regimen; Metastatic breast cancer; Oncology; Breast cancer; Clinical endpoint; Triple-negative breast cancer; Chemotherapy; Cisplatin; Paclitaxel; Cancer; Clinical trial","score_opus":0.2756851049856489,"score_gpt":0.49839696780858883,"score_spread":0.22271186282293992,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142226415","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86695004,0.005018692,0.0003033056,0.08364437,0.00714631,0.028003449,0.002436406,0.00021647073,0.00628097],"genre_scores_gemma":[0.9301834,0.007571583,0.0050672423,0.010990878,0.010565735,0.019403793,0.0011680502,0.00025958256,0.014789748],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99625874,0.0007251907,0.00089014485,0.0007166208,0.00039153962,0.0010177636],"domain_scores_gemma":[0.9945408,0.0032008898,0.00063274155,0.00064059615,0.00050530356,0.0004796694],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018006056,0.00058821926,0.002434988,0.00014612584,0.00029657222,0.0000614093,0.0006509187,0.00022351062,0.0012483535],"category_scores_gemma":[0.00082038325,0.00038098334,0.00023172985,0.00044748036,0.00033938786,0.00021753041,0.0001926221,0.0005145154,0.000115539886],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90903074,0.0043578884,0.000020395695,0.00007259145,0.0023218323,0.00013445747,0.002594487,0.00010611436,0.00047393152,0.00022016901,0.059065107,0.021602282],"study_design_scores_gemma":[0.88193566,0.026291635,0.000040380193,0.000051695082,0.0020975275,0.00011891107,0.0006126682,0.0039375667,0.00037127556,0.0006003404,0.08357895,0.00036337067],"about_ca_topic_score_codex":0.0019235061,"about_ca_topic_score_gemma":0.0024116405,"teacher_disagreement_score":0.07265349,"about_ca_system_score_codex":0.0018621085,"about_ca_system_score_gemma":0.002480096,"threshold_uncertainty_score":0.9998642},"labels":[],"label_agreement":null},{"id":"W2142466432","doi":"10.1016/s1470-2045(12)70560-0","title":"Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":740,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; National Cancer Institute; Institut National Du Cancer; Sanofi; Roche; Bayer; AstraZeneca; Unicancer; Novartis; Pfizer; Amgen","keywords":"Medicine; Docetaxel; Androgen deprivation therapy; Prostate cancer; Internal medicine; Oncology; Estramustine; Clinical endpoint; Chemotherapy; Goserelin; Prostate-specific antigen; Urology; Cancer; Randomized controlled trial","score_opus":0.14905012062048997,"score_gpt":0.44504975400106633,"score_spread":0.29599963338057633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142466432","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96770895,0.001382793,0.000027183407,0.017832682,0.00014818058,0.011559781,0.000038916638,0.000034928325,0.0012665897],"genre_scores_gemma":[0.97286826,0.008064532,0.0013034997,0.0026238172,0.00051047903,0.009630096,0.00010943185,0.000057726025,0.0048321383],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977265,0.00044350725,0.0004713348,0.0003990828,0.00030034024,0.00065921515],"domain_scores_gemma":[0.99863744,0.00035198074,0.00024196779,0.0004425977,0.00017765522,0.00014838659],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011929037,0.00026563444,0.0011188668,0.00011912808,0.00012860137,0.000092088005,0.0003521029,0.00008572644,0.00087159174],"category_scores_gemma":[0.00006730586,0.00012246238,0.000039737137,0.0004975838,0.000262637,0.00025983344,0.00008246191,0.0004094558,0.00007312008],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9152576,0.002894945,0.0013802142,0.00008777365,0.0006759848,0.00040859246,0.0018694534,0.000011793266,0.010478036,0.000028302804,0.006630282,0.06027706],"study_design_scores_gemma":[0.97248507,0.012260279,0.0014043674,0.00012646521,0.00015506311,0.00009701401,0.0003003701,0.0005111106,0.0036003033,0.00035014102,0.00850944,0.00020037952],"about_ca_topic_score_codex":0.0012176653,"about_ca_topic_score_gemma":0.0007363964,"teacher_disagreement_score":0.06007668,"about_ca_system_score_codex":0.0002924768,"about_ca_system_score_gemma":0.001160226,"threshold_uncertainty_score":0.9543318},"labels":[],"label_agreement":null},{"id":"W2142875113","doi":"10.1016/s1470-2045(07)70278-4","title":"Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial","year":2007,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1078,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; Saint John Regional Hospital; Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute","keywords":"Medicine; Axillary Lymph Node Dissection; Sentinel lymph node; Breast cancer; Surgery; Lymph node; Stage (stratigraphy); Randomized controlled trial; Dissection (medical); Cancer; Internal medicine","score_opus":0.02027302097998062,"score_gpt":0.33800450789262054,"score_spread":0.3177314869126399,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142875113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941274,0.0001241258,0.00033124437,0.0034470842,0.00033520866,0.0007257243,0.0005162928,0.000016183263,0.00037676847],"genre_scores_gemma":[0.9979325,0.0002984931,0.00021777122,0.0005166775,0.000604265,0.00013367677,0.000249499,0.00001825734,0.000028854603],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99795485,0.00037766126,0.0006895441,0.00044242674,0.00022418227,0.00031131812],"domain_scores_gemma":[0.99807423,0.00082220277,0.0005014159,0.00037806353,0.00017473467,0.000049343966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011427252,0.00022228401,0.0006181591,0.000037350477,0.00015938365,0.000011278654,0.000208375,0.0002223186,0.000013135446],"category_scores_gemma":[0.0003240648,0.00012637522,0.000112040085,0.00014701988,0.0005049808,0.000009351066,0.0001383173,0.00018681816,9.000216e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5503063,0.00072686106,0.44461986,0.000006158222,0.00036952636,0.000003404815,0.00014036035,0.00003061617,0.0009291175,0.000019436537,0.00020585347,0.0026424893],"study_design_scores_gemma":[0.31646806,0.0003096356,0.68226385,0.000028864986,0.00012201788,0.0000076169745,0.000103036386,0.000013686234,0.0003967869,0.00006887085,0.000111695284,0.0001059086],"about_ca_topic_score_codex":0.0011910942,"about_ca_topic_score_gemma":0.0009507845,"teacher_disagreement_score":0.23764397,"about_ca_system_score_codex":0.00014194954,"about_ca_system_score_gemma":0.00014912474,"threshold_uncertainty_score":0.5153432},"labels":[],"label_agreement":null},{"id":"W2144143639","doi":"10.1016/s1470-2045(15)70114-2","title":"Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Chromatin Remodeling and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":182,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill Genome Centre; McGill University; London Health Sciences Centre; Vancouver General Hospital; Children’s Health Research Institute; Children's Hospital of Eastern Ontario; Ottawa Hospital; Centre Hospitalier Universitaire Sainte-Justine; University of Alberta; University of Ottawa; University of British Columbia; Alberta Hospital Edmonton; University of Calgary; Hospital for Sick Children; Western University; McGill University and Génome Québec Innovation Centre; University of Toronto; University of Alberta Hospital; Montreal Children's Hospital; Children's & Women's Health Centre of British Columbia; Alberta Children's Hospital; SickKids Foundation; McMaster University; Université de Montréal","funders":"National Cancer Institute; Genome Canada","keywords":"Biology; Atypical teratoid rhabdoid tumor; Immunohistochemistry; Pathology; Chemotherapy; Cancer research; Oncology; Medicine; Genetics","score_opus":0.030455597976323034,"score_gpt":0.3249774823903661,"score_spread":0.2945218844140431,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144143639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99724245,0.0011277227,0.0009673289,0.0003181386,0.000041532625,0.00011418743,0.000017224236,0.000009739704,0.00016170129],"genre_scores_gemma":[0.9976315,0.00022911088,0.0013358563,0.0005231804,0.00014240514,0.000012139245,0.00010777455,0.000009335833,0.000008719917],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987411,0.00042315095,0.00027301055,0.0002862319,0.00007129937,0.00020518781],"domain_scores_gemma":[0.99939924,0.000019134679,0.00010237637,0.00034703917,0.000056192788,0.00007601801],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008301784,0.00011623369,0.00041479798,0.000051428255,0.000020767491,0.000008533096,0.00024203058,0.00019223409,0.000006652539],"category_scores_gemma":[0.000090942034,0.00008005064,0.00007023103,0.00017784606,0.00020639665,0.000002351971,0.00010715523,0.00017978826,0.0000016276402],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013404546,0.0002761307,0.8007901,0.0000070696897,0.0001448137,0.000019138835,0.0003009302,0.0052930615,0.18419097,0.00020892214,0.0002944442,0.0071339663],"study_design_scores_gemma":[0.00401533,0.0025593142,0.9673156,0.000011415756,0.00030555262,0.00019462213,0.00041140785,0.00622435,0.015921233,0.000816318,0.0018733575,0.00035147005],"about_ca_topic_score_codex":0.000072651426,"about_ca_topic_score_gemma":0.00019920217,"teacher_disagreement_score":0.16826974,"about_ca_system_score_codex":0.000030303945,"about_ca_system_score_gemma":0.00011982037,"threshold_uncertainty_score":0.32643703},"labels":[],"label_agreement":null},{"id":"W2144921015","doi":"10.1016/s1470-2045(15)00363-0","title":"Intravenous pegylated asparaginase versus intramuscular native Escherichia coli l-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":240,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec; Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine; McMaster University","funders":"National Cancer Institute; Dana-Farber Cancer Institute; Enzon Pharmaceuticals","keywords":"Medicine; Asparaginase; Internal medicine; Gastroenterology; Pediatrics; Surgery; Leukemia; Lymphoblastic Leukemia","score_opus":0.07495321031302048,"score_gpt":0.38566004730027914,"score_spread":0.31070683698725865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144921015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97607857,0.0005388503,0.00044444817,0.006615662,0.0017218261,0.008254257,0.00010947835,0.00020383234,0.0060330885],"genre_scores_gemma":[0.9892966,0.00045544576,0.0018544707,0.0033069402,0.0019406885,0.0020894136,0.00039827783,0.00015811718,0.00050003774],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9928363,0.0020713955,0.001176203,0.001085104,0.0010119738,0.0018190094],"domain_scores_gemma":[0.9931251,0.0034530358,0.00052138494,0.0013840803,0.00053116126,0.0009852406],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0036191263,0.00075617136,0.0026993696,0.00038811972,0.00024321621,0.00016707255,0.001748486,0.00064960856,0.00023347595],"category_scores_gemma":[0.0054054125,0.0005585136,0.00015348649,0.0015119384,0.0008915167,0.00031885988,0.00080184697,0.0016992721,0.00038961618],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.9190345,0.011027841,0.000024877609,0.00006567723,0.0017425566,0.014610065,0.0049272003,0.00026868613,0.0017941078,0.00052053365,0.034440774,0.0115432115],"study_design_scores_gemma":[0.94979227,0.021575877,0.00023225516,0.00013653893,0.0010312923,0.0006629527,0.0006938564,0.011557737,0.0006454264,0.00044420222,0.012638956,0.00058864703],"about_ca_topic_score_codex":0.0016001393,"about_ca_topic_score_gemma":0.000430347,"teacher_disagreement_score":0.03075779,"about_ca_system_score_codex":0.0055565285,"about_ca_system_score_gemma":0.009747946,"threshold_uncertainty_score":0.99968666},"labels":[],"label_agreement":null},{"id":"W2145118120","doi":"10.1016/s1470-2045(13)70162-1","title":"Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":138,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Princess Margaret Cancer Centre; Ottawa Regional Cancer Foundation; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"Celgene","keywords":"Medicine; Tolerability; Response Evaluation Criteria in Solid Tumors; Internal medicine; Regimen; Metastatic Urothelial Carcinoma; Paclitaxel; Clinical endpoint; Adverse effect; Gastroenterology; Progressive disease; Refractory (planetary science); Phases of clinical research; Oncology; Progression-free survival; Chemotherapy; Bladder cancer; Cancer; Clinical trial; Urothelial carcinoma","score_opus":0.10664524640324281,"score_gpt":0.38548825514371515,"score_spread":0.27884300874047235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145118120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914436,0.0006044806,0.00005987929,0.0018742656,0.00027357275,0.004740172,0.00017314992,0.000040159033,0.0007907704],"genre_scores_gemma":[0.99563843,0.000018919232,0.00091541535,0.0005820418,0.00047735142,0.0013223877,0.000033362216,0.000035265093,0.0009768297],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984183,0.00021638592,0.00043299282,0.00030519284,0.00015803467,0.00046909708],"domain_scores_gemma":[0.9986592,0.00040812377,0.00017657343,0.0004960735,0.00012586724,0.00013415788],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002184668,0.00023430849,0.0008984948,0.000051741903,0.00010412158,0.00001634778,0.00013006965,0.000052492764,0.00054445775],"category_scores_gemma":[0.000056228404,0.00013951701,0.000151402,0.00011878544,0.00015459322,0.00006676752,0.000027765474,0.00007076407,0.00006044465],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029481277,0.12845775,0.0636709,0.000580598,0.0048696534,0.00032256305,0.033371918,0.000015535812,0.60379046,0.0005576562,0.006032946,0.12884873],"study_design_scores_gemma":[0.40183094,0.26833233,0.055149633,0.000062324536,0.0070903436,0.00022789298,0.012394323,0.0015804443,0.19259728,0.0023700972,0.057619922,0.0007444522],"about_ca_topic_score_codex":0.0009591978,"about_ca_topic_score_gemma":0.0007145761,"teacher_disagreement_score":0.41119316,"about_ca_system_score_codex":0.00029316582,"about_ca_system_score_gemma":0.00016911092,"threshold_uncertainty_score":0.59614307},"labels":[],"label_agreement":null},{"id":"W2145140579","doi":"10.1016/s1470-2045(06)70904-4","title":"Image-guided radiotherapy: rationale, benefits, and limitations","year":2006,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Advanced Radiotherapy Techniques","field":"Physics and Astronomy","cited_by":335,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"University of Texas MD Anderson Cancer Center","keywords":"Radiation therapy; Medical physics; Computer science; Medicine; Radiology","score_opus":0.10250541464930628,"score_gpt":0.39277465590586425,"score_spread":0.29026924125655795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145140579","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000013877192,0.96692055,0.018536007,0.0008052942,0.00011887496,0.0009160511,0.00013901929,0.00010506924,0.012457715],"genre_scores_gemma":[5.636481e-7,0.9325592,0.063597485,0.0002492643,0.0021739549,0.00052097876,0.00026035638,0.000061648694,0.00057655777],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985876,0.00031022224,0.00041121288,0.00030477182,0.00009131587,0.00029485227],"domain_scores_gemma":[0.9980843,0.000997264,0.0003865543,0.0004405917,0.00005349963,0.00003780083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029498103,0.00031947877,0.0013634418,0.00007808761,0.00017643085,0.000043395903,0.0003605233,0.00014941093,0.00013018596],"category_scores_gemma":[0.000011982324,0.0002132674,0.0001927543,0.00017042656,0.00020568952,0.00007960569,0.00004569399,0.00041864347,0.000008354413],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000032287994,0.00003761354,0.000012433379,0.00033060528,0.00016733332,0.0000010352759,0.000041879808,0.000005522682,0.0000023780224,0.03666987,0.025845237,0.93688285],"study_design_scores_gemma":[0.00032745735,0.00005283749,0.000009700616,0.00026376962,0.0001694246,0.000021281425,0.0000054291477,0.000026941982,0.0000010305133,0.0021655466,0.99673396,0.00022263279],"about_ca_topic_score_codex":0.000032603555,"about_ca_topic_score_gemma":0.000010653706,"teacher_disagreement_score":0.97088873,"about_ca_system_score_codex":0.0001302707,"about_ca_system_score_gemma":0.00021319979,"threshold_uncertainty_score":0.8696792},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"not_applicable","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"systematic_review","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W2145280166","doi":"10.1016/s1470-2045(10)70218-7","title":"Definition and classification of cancer cachexia: an international consensus","year":2011,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":5631,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Cachexia; Consensus conference; Cancer cachexia; Cancer; Intensive care medicine; Medicine; Political science; Internal medicine","score_opus":0.5331106926091742,"score_gpt":0.5308219039922553,"score_spread":0.0022887886169189464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145280166","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00026982668,0.9717596,0.0000052597325,0.0034915828,0.0004720896,0.0004406834,0.00007875475,0.000025382902,0.02345682],"genre_scores_gemma":[0.0002810332,0.99652356,0.0014248712,0.00067028357,0.0007516514,0.00011873045,0.00014213075,0.000013547396,0.00007422235],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99907714,0.000223573,0.0003551404,0.0001543823,0.00006730385,0.00012247502],"domain_scores_gemma":[0.9991025,0.00016151104,0.00037247752,0.00021185348,0.000096638956,0.000055061148],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044328935,0.00010172118,0.00089052453,0.000086078464,0.00003677118,0.0000031437291,0.000101235986,0.00020775467,0.00016823322],"category_scores_gemma":[0.000046584322,0.00006636501,0.00005418075,0.0000635882,0.00016666454,0.000013844488,0.00002332954,0.00033493934,0.000014397538],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012172873,0.00010631717,0.0004563017,0.007180629,0.00010390087,0.000006284562,0.00015781721,6.071127e-9,0.000006217901,0.03815192,0.0020744374,0.95163447],"study_design_scores_gemma":[0.00069519255,0.00014237005,0.0023412737,0.002269749,0.0004176465,0.00019754835,0.000028402832,0.0000062001495,5.246782e-7,0.0010233643,0.99282193,0.000055793073],"about_ca_topic_score_codex":0.00007648586,"about_ca_topic_score_gemma":0.00009393711,"teacher_disagreement_score":0.9907475,"about_ca_system_score_codex":0.00014826522,"about_ca_system_score_gemma":0.00034911672,"threshold_uncertainty_score":0.27062866},"labels":[],"label_agreement":null},{"id":"W2145376545","doi":"10.1016/s1470-2045(15)70057-4","title":"Response assessment criteria for brain metastases: proposal from the RANO group","year":2015,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":1088,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Queen's University; London Health Sciences Centre; Ontario Institute for Cancer Research","funders":"Breast Cancer Research Foundation","keywords":"Group (periodic table); Computer science; Medicine; Medical physics; Psychology; Physics","score_opus":0.2039613437360562,"score_gpt":0.5016602951475275,"score_spread":0.2976989514114713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145376545","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000031945998,0.93628657,0.0009778764,0.051659558,0.0009820051,0.006213633,0.0032019569,0.00007766006,0.00056881906],"genre_scores_gemma":[0.000017548518,0.94118404,0.03920492,0.008546957,0.0034897903,0.0035341564,0.0029449735,0.0001291228,0.000948509],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98731273,0.010432285,0.00073113263,0.0005794284,0.00034936663,0.00059506996],"domain_scores_gemma":[0.98918843,0.008549438,0.0005227997,0.0014511888,0.00012434031,0.000163822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016177688,0.0005481637,0.0037651423,0.000063717736,0.0002022048,0.00005689448,0.00063954457,0.00032951424,0.00034080114],"category_scores_gemma":[0.000807393,0.00022866174,0.0007372277,0.00020190101,0.0002873988,0.000035058696,0.00021684627,0.00067283574,0.000093933515],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003496071,0.0004387046,0.0000025610998,0.001616627,0.002216417,0.00021660938,0.00019084553,1.15893506e-7,0.000005420227,0.004270516,0.32472068,0.6628254],"study_design_scores_gemma":[0.0053380975,0.0027975424,0.000039306073,0.0013117866,0.0069252243,0.00031906704,0.00012859856,0.0000087358585,4.698593e-7,0.0012799905,0.98163104,0.00022015267],"about_ca_topic_score_codex":0.00010721723,"about_ca_topic_score_gemma":0.00008575148,"teacher_disagreement_score":0.6626053,"about_ca_system_score_codex":0.0007189925,"about_ca_system_score_gemma":0.0026056417,"threshold_uncertainty_score":0.9324555},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"not_applicable","genre":"methods","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":["metaresearch"],"domain":"methods","study_design":"theoretical_or_conceptual","genre":"methods","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"split"},{"id":"W2145426305","doi":"10.1016/s1470-2045(05)70101-7","title":"Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial","year":2005,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":1580,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Placebo; Medicine; Double blind; Virus-like particle; Human papillomavirus; Internal medicine; Virology; Recombinant DNA; Alternative medicine; Pathology; Biology","score_opus":0.08610090242738114,"score_gpt":0.4192445002258663,"score_spread":0.3331435977984851,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145426305","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9795076,0.0009853895,0.0000043354717,0.0076610288,0.00020666112,0.0061769984,0.000005769403,0.00006837557,0.00538381],"genre_scores_gemma":[0.9943287,0.00026956064,0.00003570645,0.00092406495,0.0018098765,0.0012990928,0.000012095994,0.000031937416,0.0012889844],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99669623,0.0008571071,0.0007103246,0.000452631,0.00038222922,0.0009014534],"domain_scores_gemma":[0.99792504,0.0009865199,0.00018477633,0.00048910035,0.00010287662,0.0003116551],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0027353484,0.0002732978,0.0015130005,0.00012176084,0.000364465,0.000042927273,0.00023888156,0.00017365016,0.0035902814],"category_scores_gemma":[0.00042587082,0.00017219903,0.00013595245,0.00027344603,0.00015828805,0.00009181967,0.00015674793,0.0008035593,0.00004955073],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96535707,0.0038358339,0.00054397533,0.000097795266,0.00017717677,0.00006305576,0.0038688986,0.000023436154,0.0060550184,0.00009483786,0.0004762968,0.019406624],"study_design_scores_gemma":[0.9797681,0.0058107944,0.0020314716,0.00001466196,0.00025934153,0.000029016144,0.00041047353,0.0008579771,0.0012353796,0.0000623272,0.009327931,0.00019252811],"about_ca_topic_score_codex":0.0003303721,"about_ca_topic_score_gemma":0.0050764135,"teacher_disagreement_score":0.019214097,"about_ca_system_score_codex":0.0006735886,"about_ca_system_score_gemma":0.00024325524,"threshold_uncertainty_score":0.9973206},"labels":[],"label_agreement":null},{"id":"W2145434047","doi":"10.1016/s1470-2045(14)70417-6","title":"Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McMaster University","funders":"Janssen Research and Development; National Cancer Institute","keywords":"Abiraterone acetate; Prostate cancer; Medicine; Oncology; Chemotherapy; Protocol (science); Internal medicine; Castration; Abiraterone; Cancer; Urology; Androgen deprivation therapy; Alternative medicine; Hormone; Pathology; Androgen receptor","score_opus":0.1270490815713082,"score_gpt":0.4639079775581205,"score_spread":0.3368588959868123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145434047","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9111521,0.00003893242,0.000092776354,0.002207463,0.00004959637,0.08618813,0.00014199107,0.000018475808,0.0001105178],"genre_scores_gemma":[0.7926154,0.000018549099,0.00440272,0.0003845294,0.0001530284,0.20177172,0.00010516035,0.000037125497,0.00051175815],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982018,0.00026926975,0.00041626225,0.00034321006,0.00030277474,0.00046668036],"domain_scores_gemma":[0.99857605,0.00017580182,0.00040194913,0.0003638719,0.00039024273,0.00009208291],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000626966,0.00020493104,0.0009600341,0.00012925887,0.00012221378,0.00010640509,0.0003094692,0.00005324063,0.000100063364],"category_scores_gemma":[0.00004381229,0.000106162595,0.00006377717,0.00049934327,0.00024836336,0.00018467585,0.00008353697,0.00014775906,0.0000013835697],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86799604,0.0030496216,0.079715885,0.0006192496,0.0037943562,0.000016383708,0.0017631762,0.000054107826,0.00072590465,0.000022002137,0.000253573,0.041989725],"study_design_scores_gemma":[0.69737697,0.023253705,0.256343,0.00036238795,0.004404973,0.0000017324369,0.000077944474,0.0027449853,0.0021459663,0.000118442236,0.012830456,0.00033941751],"about_ca_topic_score_codex":0.0002408679,"about_ca_topic_score_gemma":0.0006947275,"teacher_disagreement_score":0.17662713,"about_ca_system_score_codex":0.00018495579,"about_ca_system_score_gemma":0.00043724588,"threshold_uncertainty_score":0.4329185},"labels":[],"label_agreement":null},{"id":"W2145453495","doi":"10.1016/s1470-2045(11)70235-2","title":"CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":811,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Rituximab; CHOP; Diffuse large B-cell lymphoma; Open label; Internal medicine; Oncology; Lymphoma; Chemotherapy; Clinical trial","score_opus":0.046055733105281375,"score_gpt":0.3159028828759636,"score_spread":0.2698471497706822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145453495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907629,0.000014785448,0.0000027879266,0.00025538582,0.0002259202,0.005212453,0.00006258204,0.000016888482,0.0034462933],"genre_scores_gemma":[0.9977812,0.00004337305,0.00085165794,0.0003170328,0.00010723504,0.000681837,0.000029405257,0.000035616787,0.00015262506],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99790716,0.00045479392,0.0005654558,0.00036986254,0.0003923417,0.0003103589],"domain_scores_gemma":[0.9983307,0.00020667685,0.00056282105,0.0006882984,0.0001496831,0.00006178943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008306747,0.00023735345,0.0010443203,0.00007057602,0.00006801935,0.000015588786,0.00067489105,0.000098232355,0.00004335795],"category_scores_gemma":[0.000043469157,0.00010048069,0.000042558186,0.00022420178,0.00015492659,0.00010293396,0.0001511203,0.00011437491,0.0000025235374],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48262542,0.13484728,0.3756017,0.000012821149,0.0003676744,0.000017178745,0.0049421173,1.7672616e-7,0.000020935078,0.00003625464,0.000065298016,0.0014631377],"study_design_scores_gemma":[0.64991856,0.017947316,0.3305367,0.00006307852,0.0002092111,0.000007821829,0.00070759,0.000024985513,0.00026706012,0.0000096767335,0.00022600814,0.00008201209],"about_ca_topic_score_codex":0.0018191708,"about_ca_topic_score_gemma":0.006389767,"teacher_disagreement_score":0.16729312,"about_ca_system_score_codex":0.0002325536,"about_ca_system_score_gemma":0.00021953728,"threshold_uncertainty_score":0.40974835},"labels":[],"label_agreement":null},{"id":"W2145665617","doi":"10.1016/s1470-2045(10)70245-x","title":"Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review","year":2010,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Salivary Gland Tumors Diagnosis and Treatment","field":"Medicine","cited_by":395,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Adenoid cystic carcinoma; Chemotherapy; Asymptomatic; Clinical trial; Oncology; Regimen; Internal medicine; Radiation therapy; Disease; Natural history; Cancer; Carcinoma","score_opus":0.11250866762771078,"score_gpt":0.39742384113460155,"score_spread":0.2849151735068908,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145665617","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006679735,0.9855173,0.0000027273045,0.0008651709,0.00039074654,0.011888086,0.000074959,0.000012602192,0.0005804026],"genre_scores_gemma":[0.014069594,0.98144674,0.00007739049,0.0007585,0.00014011873,0.0033400317,0.000053484073,0.000040924562,0.00007320068],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9936777,0.0032224308,0.0018465912,0.0003519314,0.00052895816,0.00037240644],"domain_scores_gemma":[0.9941723,0.002057651,0.0016663288,0.0019645505,0.00009021906,0.000048953978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032482015,0.0004947255,0.005971014,0.00010324951,0.00005593564,0.000008941658,0.0012034089,0.00016206842,0.000053197666],"category_scores_gemma":[0.00015166843,0.00015332458,0.0007002469,0.0006481968,0.00018323476,0.000015794023,0.00014532839,0.0007223496,0.000021728272],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001947579,0.00072616845,0.00017128824,0.9600246,0.0014480017,0.00044225928,0.0003501544,2.1839799e-7,8.681961e-8,0.0007181658,0.00059424224,0.035330057],"study_design_scores_gemma":[0.003097417,0.0020763932,0.00070047035,0.91891736,0.022550445,0.004727898,0.00028349643,0.0000035147295,7.7269726e-7,0.00006571507,0.04735568,0.00022086524],"about_ca_topic_score_codex":0.000049980466,"about_ca_topic_score_gemma":0.000043881904,"teacher_disagreement_score":0.046761442,"about_ca_system_score_codex":0.00021689113,"about_ca_system_score_gemma":0.00048402263,"threshold_uncertainty_score":0.62523955},"labels":[],"label_agreement":null},{"id":"W2146102224","doi":"10.1016/s1470-2045(02)00930-0","title":"The role of systemic chemotherapy in the management of muscle-invasive bladder cancer","year":2002,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Chemotherapy; Bladder cancer; Gemcitabine; Cystectomy; Oncology; Context (archaeology); Transitional cell carcinoma; Vinblastine; Internal medicine; Cisplatin; Clinical trial; Cancer; Surgery","score_opus":0.06863531054331733,"score_gpt":0.3817276324511727,"score_spread":0.31309232190785535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146102224","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002087076,0.97606564,9.09669e-7,0.0012403687,0.00022916571,0.002338861,0.000058442474,0.000011286818,0.019846646],"genre_scores_gemma":[0.0034366217,0.9938548,0.000025954401,0.00048713834,0.0004772105,0.0010115877,0.000010073312,0.000038052123,0.00065852335],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979664,0.00052551634,0.00063078786,0.00024528877,0.0002829853,0.00034904145],"domain_scores_gemma":[0.9978918,0.00056059676,0.0005579427,0.0009072325,0.00005522372,0.000027234459],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006623445,0.00028798607,0.0018743234,0.000057128367,0.00006393915,0.000006358688,0.0007164707,0.00020609035,0.00013544872],"category_scores_gemma":[0.0000094845855,0.0001141985,0.00031861852,0.0003225478,0.0002324994,0.0000123358495,0.000063957166,0.0004042567,0.000019505409],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010843008,0.00017819798,0.00005188995,0.0066777356,0.001601411,0.000031658423,0.0013167945,9.21427e-7,0.0000033561153,0.0007445686,0.0015809786,0.98770404],"study_design_scores_gemma":[0.001883007,0.00034006915,0.00024561805,0.007985418,0.0021671893,0.000101683574,0.0010746054,0.0000016152597,0.00000953629,0.00019284805,0.9858975,0.00010092025],"about_ca_topic_score_codex":0.00026300809,"about_ca_topic_score_gemma":0.0001596522,"teacher_disagreement_score":0.9876031,"about_ca_system_score_codex":0.00029077113,"about_ca_system_score_gemma":0.00032634256,"threshold_uncertainty_score":0.46568796},"labels":[],"label_agreement":null},{"id":"W2146561872","doi":"10.1016/s1470-2045(07)70280-2","title":"COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial","year":2007,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Inflammatory mediators and NSAID effects","field":"Medicine","cited_by":106,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"National Cancer Institute; Pennsylvania Department of Health","keywords":"Medicine; Proportional hazards model; Prostate cancer; Radiation therapy; Oncology; Hazard ratio; Androgen deprivation therapy; Internal medicine; Immunohistochemistry; Multivariate analysis; Cancer; Metastasis; Prostate; Survival analysis; Cohort; Confidence interval","score_opus":0.12963120339120784,"score_gpt":0.4283932411821041,"score_spread":0.2987620377908963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146561872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99160117,0.0006837048,0.00017008363,0.0036819407,0.0010996874,0.0009950318,0.00032454205,0.00004599515,0.0013978748],"genre_scores_gemma":[0.9934994,0.0002751087,0.00027634075,0.0020795586,0.0031991971,0.000053986525,0.00034772404,0.000018208748,0.0002504842],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99799883,0.0003760396,0.000554714,0.0003095887,0.0003743189,0.0003865122],"domain_scores_gemma":[0.99607,0.0019427696,0.0003713871,0.0014407453,0.000079963385,0.0000951342],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035610166,0.00015646018,0.00096908095,0.000084296546,0.000103252336,0.000007653977,0.0006559349,0.00018367392,0.00048214564],"category_scores_gemma":[0.00055712374,0.00007408494,0.00012353843,0.00044143267,0.0002378143,0.00006963614,0.00026956183,0.00040831207,0.000025726962],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1135418,0.00053362816,0.7221696,0.00011885563,0.0027530515,0.00015841553,0.0045213164,0.000059271853,0.01714641,0.00013980175,0.11570486,0.023153005],"study_design_scores_gemma":[0.07165682,0.0013810595,0.70047843,0.000142765,0.006393086,0.0000073651795,0.00059572095,0.001996291,0.007152114,0.00012296962,0.2098233,0.00025005735],"about_ca_topic_score_codex":0.00031048857,"about_ca_topic_score_gemma":0.0008384693,"teacher_disagreement_score":0.09411844,"about_ca_system_score_codex":0.00008593673,"about_ca_system_score_gemma":0.00018653943,"threshold_uncertainty_score":0.52791566},"labels":[],"label_agreement":null},{"id":"W2146701863","doi":"10.1016/s1470-2045(13)70501-1","title":"Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":270,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Brentuximab vedotin; ABVD; Medicine; Dacarbazine; Internal medicine; Vinblastine; Oncology; Bleomycin; Phases of clinical research; Lymphoma; Surgery; Chemotherapy; CD30; Vincristine; Cyclophosphamide","score_opus":0.05715420935216558,"score_gpt":0.35931487641307147,"score_spread":0.3021606670609059,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146701863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843252,0.000038389222,0.000071700895,0.004405242,0.00016123184,0.01005733,0.000043667915,0.00007878109,0.0008184957],"genre_scores_gemma":[0.9900072,0.000024920135,0.002380936,0.001796026,0.00021144046,0.004879539,0.00020651783,0.000049769485,0.0004436318],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981671,0.00021339493,0.000350334,0.0004670107,0.0002886041,0.00051358785],"domain_scores_gemma":[0.99788606,0.0007448471,0.0002903842,0.00063226174,0.00029298736,0.00015343336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028480854,0.0003155717,0.0009736783,0.00006355608,0.00022771324,0.00011483247,0.00033953058,0.000099586825,0.00011879276],"category_scores_gemma":[0.00009739404,0.00014701375,0.00003470117,0.00024602877,0.00012619208,0.00024271762,0.00011873073,0.00008407543,0.0000673415],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08871958,0.1468432,0.5346357,0.00010378656,0.0016477568,0.00032922407,0.0027340858,0.000010270064,0.000052545256,0.00040973895,0.02769823,0.1968159],"study_design_scores_gemma":[0.37447622,0.079413705,0.53960586,0.00007753942,0.00060086866,0.000025592066,0.00037419144,0.00020787025,0.00004974413,0.0000622772,0.0049087796,0.00019736167],"about_ca_topic_score_codex":0.00056953245,"about_ca_topic_score_gemma":0.00061635626,"teacher_disagreement_score":0.28575665,"about_ca_system_score_codex":0.0004236396,"about_ca_system_score_gemma":0.0003970371,"threshold_uncertainty_score":0.5995047},"labels":[],"label_agreement":null},{"id":"W2147387301","doi":"10.1016/s1470-2045(11)70057-2","title":"Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas","year":2011,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":645,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Oncology; Medicine; Outcome (game theory); Internal medicine; Medical physics; Mathematics","score_opus":0.22363914146036262,"score_gpt":0.49018725007671715,"score_spread":0.26654810861635453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147387301","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24015962,0.7364537,0.000013294842,0.0069546634,0.002112422,0.010609576,0.00027581432,0.000033421544,0.0033875054],"genre_scores_gemma":[0.13314404,0.86386245,0.00092521287,0.00032086164,0.00020046966,0.0013609878,0.00006584335,0.00007694123,0.00004320581],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98058724,0.012693997,0.005117077,0.0005816098,0.00048470974,0.0005353556],"domain_scores_gemma":[0.9828348,0.009717113,0.0053406344,0.0019036742,0.00011705633,0.00008671194],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.018074982,0.00052361656,0.010647062,0.0006643116,0.000029409175,0.0000039882666,0.0007703635,0.00067402294,0.000102535945],"category_scores_gemma":[0.0026842414,0.00025966248,0.001211615,0.0009173762,0.00046293647,0.00002931624,0.00038853186,0.0010447702,0.0000019756458],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011110092,0.05715236,0.39962935,0.040385906,0.0056895097,0.015890619,0.0020114074,0.000021128651,0.004637678,0.017722676,0.0024522273,0.44329703],"study_design_scores_gemma":[0.021243768,0.0037543455,0.2448472,0.006281174,0.0038286655,0.0012095603,0.000105732885,0.000008369066,0.00012500305,0.00024281058,0.71805716,0.0002962321],"about_ca_topic_score_codex":0.0004300579,"about_ca_topic_score_gemma":0.0004955476,"teacher_disagreement_score":0.7156049,"about_ca_system_score_codex":0.0011193278,"about_ca_system_score_gemma":0.0020699445,"threshold_uncertainty_score":0.9999856},"labels":[],"label_agreement":null},{"id":"W2148004875","doi":"10.1016/s1470-2045(11)70058-4","title":"Mucinous carcinomas of the ovary and colorectum: different organ, same dilemma","year":2011,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":149,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; University of Calgary; Alberta Health Services","funders":"Canadian Institutes of Health Research","keywords":"Ovary; Mucinous Tumor; Mucinous carcinoma; Mucin; Pathology; Adenocarcinoma; Carcinoma; Rectum; Medicine; Biology; Cancer; Internal medicine; Pancreas","score_opus":0.13044719982098338,"score_gpt":0.35886265752626,"score_spread":0.22841545770527663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148004875","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0048781796,0.9865648,6.295128e-7,0.0020953966,0.00066723884,0.0016232373,0.00009204963,0.000025933967,0.0040525286],"genre_scores_gemma":[0.008535823,0.989285,0.000051448726,0.0005864124,0.0007496874,0.00031557318,0.000027247104,0.000046819172,0.00040201188],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99822825,0.0004589309,0.00047585473,0.00035715633,0.00013685538,0.00034292982],"domain_scores_gemma":[0.9979279,0.0005329379,0.0004650583,0.00092939206,0.00005679498,0.0000879071],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002760528,0.00036673248,0.0029125863,0.000055178043,0.000084281004,0.000006903273,0.00034766705,0.00031585494,0.0002527977],"category_scores_gemma":[0.000056078155,0.0001496345,0.00032864636,0.00016329889,0.00034584754,0.000010881397,0.00027623,0.0005161299,0.000021582244],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001715796,0.0005771928,0.00647763,0.007773266,0.0012947281,0.000089070934,0.00062145933,3.7743714e-8,0.0000013895451,0.003184382,0.009919902,0.96988934],"study_design_scores_gemma":[0.0014433985,0.0009364801,0.02131284,0.0024970924,0.003938099,0.00052773487,0.000015651383,3.8703948e-7,0.0000104251885,0.00018085106,0.9690009,0.00013617544],"about_ca_topic_score_codex":0.00025606918,"about_ca_topic_score_gemma":0.0001890886,"teacher_disagreement_score":0.9697532,"about_ca_system_score_codex":0.00035241223,"about_ca_system_score_gemma":0.0005144821,"threshold_uncertainty_score":0.6101918},"labels":[],"label_agreement":null},{"id":"W2148413869","doi":"10.1016/s1470-2045(08)70148-7","title":"Role of the cerebellum in the neurocognitive sequelae of treatment of tumours of the posterior fossa: an update","year":2008,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto","funders":"","keywords":"Neurocognitive; Cerebellum; Cognition; Psychology; Neuroscience; Population; Neuroimaging; Posterior fossa; Medicine; Surgery","score_opus":0.08011164677112421,"score_gpt":0.3728488131099985,"score_spread":0.2927371663388743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148413869","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.31822795,0.67445195,5.0431897e-8,0.0017979322,0.00015725142,0.003178748,0.00034007724,0.000005486286,0.0018405378],"genre_scores_gemma":[0.2618497,0.737514,0.000012245141,0.00020986453,0.000111298956,0.00023483468,0.000026663598,0.000024126175,0.000017232534],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969397,0.0015279531,0.0007751413,0.00024425957,0.0002447543,0.00026815338],"domain_scores_gemma":[0.9967886,0.00071584975,0.0012253715,0.0011230111,0.00011627235,0.000030859163],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003218689,0.00031810734,0.0025600719,0.000080252175,0.000052928215,0.0000022329825,0.00065350736,0.00018929804,0.00002566695],"category_scores_gemma":[0.00006770542,0.000109106695,0.0006390676,0.00039302223,0.00059788674,0.000017281865,0.00013113042,0.000255965,0.0000028751597],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006290394,0.006437348,0.019469671,0.0033807524,0.0014943281,0.00011430487,0.0074827694,0.000008271862,0.0005633633,0.0007197897,0.00063667126,0.9590637],"study_design_scores_gemma":[0.013986706,0.01572608,0.18916212,0.011638332,0.01287646,0.0025617513,0.002840074,0.000012152935,0.006072958,0.0007347549,0.7439064,0.00048224072],"about_ca_topic_score_codex":0.00045850294,"about_ca_topic_score_gemma":0.00061553245,"teacher_disagreement_score":0.95858145,"about_ca_system_score_codex":0.00019594381,"about_ca_system_score_gemma":0.00059932616,"threshold_uncertainty_score":0.4449242},"labels":[],"label_agreement":null},{"id":"W2149654081","doi":"10.1016/s1470-2045(14)70472-3","title":"Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":128,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University; University of Ottawa; Jewish General Hospital; Regional Municipality of Durham; Princess Margaret Cancer Centre; BC Cancer Agency; Queen's University; Juravinski Cancer Centre","funders":"Cancer Care Ontario; Cancer Research Institute","keywords":"Medicine; Internal medicine; Erlotinib; Gefitinib; Placebo; Lung cancer; Population; Performance status; Oncology; Cancer; Adverse effect; Clinical trial; Surgery; Epidermal growth factor receptor; Pathology","score_opus":0.044423323650779334,"score_gpt":0.3947671100906369,"score_spread":0.3503437864398576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149654081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98401546,0.00016149983,0.00045019793,0.00114628,0.00022898028,0.008974734,0.000059929705,0.00008597804,0.0048769084],"genre_scores_gemma":[0.9921492,0.00006737306,0.0017843074,0.0008938534,0.00025654145,0.003746466,0.00019914811,0.000065264154,0.00083784515],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980379,0.00030313153,0.00045599492,0.0004197973,0.00025172866,0.00053147215],"domain_scores_gemma":[0.998246,0.000586128,0.0003636096,0.0004747957,0.00017447084,0.00015500927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040641552,0.00032433769,0.0012399488,0.00012668104,0.00012602108,0.000023236322,0.00019341041,0.00008343421,0.00019574405],"category_scores_gemma":[0.000044659526,0.00016062846,0.00006475082,0.00040234395,0.00014125857,0.00008595685,0.000030510439,0.00031885452,0.000012386349],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9790225,0.0024276634,0.0111183785,0.00016935267,0.00072190637,0.00006273805,0.0018647835,0.00089167926,0.00006739775,0.000014385419,0.00072255597,0.0029166585],"study_design_scores_gemma":[0.9813638,0.008394375,0.0022673006,0.00025844618,0.002108727,0.000016911046,0.00023220162,0.001737246,0.0002669911,0.000006758544,0.0031174668,0.00022982151],"about_ca_topic_score_codex":0.00037986448,"about_ca_topic_score_gemma":0.0025910952,"teacher_disagreement_score":0.008851077,"about_ca_system_score_codex":0.0004641504,"about_ca_system_score_gemma":0.00091011875,"threshold_uncertainty_score":0.6550239},"labels":[],"label_agreement":null},{"id":"W2150203804","doi":"10.1016/s1470-2045(15)00285-5","title":"Global Task Force on Radiotherapy for Cancer Control","year":2015,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Task force; Radiation therapy; Control (management); Task (project management); Computer science; Medicine; Political science; Engineering; Internal medicine; Artificial intelligence; Systems engineering; Public administration","score_opus":0.04132175517005908,"score_gpt":0.4265265278868563,"score_spread":0.3852047727167972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150203804","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010589964,0.01069684,0.009326333,0.9588204,0.0055764136,0.0023973433,0.0008964855,0.00015196356,0.012028347],"genre_scores_gemma":[0.00016111645,0.0032301766,0.002587034,0.9096137,0.06979947,0.0010768592,0.00019819645,0.00008601181,0.013247404],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99740505,0.000425395,0.00039898144,0.00056516554,0.0003083189,0.00089706224],"domain_scores_gemma":[0.9969628,0.0014578108,0.00040536516,0.00086827733,0.00020501339,0.00010071916],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00082541857,0.0004676032,0.0019959651,0.000061789964,0.00016708358,0.000011474773,0.0006080474,0.0017688391,0.00023991926],"category_scores_gemma":[0.00015730258,0.0002797645,0.00029605374,0.000143826,0.0006260807,0.00003231132,0.000020494044,0.0016867999,0.00003120271],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005726757,0.00008917816,0.0004071961,0.00011442566,0.0009897946,0.0002621035,0.00011707071,0.0001427841,0.00004219263,0.00047645293,0.96717656,0.024455475],"study_design_scores_gemma":[0.01585903,0.004232053,0.00010810475,0.00007957154,0.00040490358,0.00039743984,0.000011688412,0.00020247819,0.000004871251,0.003873464,0.9745349,0.00029144573],"about_ca_topic_score_codex":0.000028911898,"about_ca_topic_score_gemma":0.00007369158,"teacher_disagreement_score":0.06422305,"about_ca_system_score_codex":0.0025686761,"about_ca_system_score_gemma":0.0012408496,"threshold_uncertainty_score":0.9999654},"labels":[],"label_agreement":null},{"id":"W2151730005","doi":"10.1016/s1470-2045(09)70311-0","title":"Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival","year":2009,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":1974,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Regional Laboratory Medicine Program","funders":"","keywords":"Medicine; Cetuximab; Head and neck cancer; Clinical endpoint; Radiation therapy; Rash; Internal medicine; Oncology; Head and neck squamous-cell carcinoma; Randomized controlled trial; Surgery; Cancer; Colorectal cancer","score_opus":0.154146220113929,"score_gpt":0.43423469870752923,"score_spread":0.2800884785936002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151730005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95659167,0.0058357213,0.00049078156,0.033274267,0.00040444836,0.0024157995,0.00049796357,0.00006442635,0.00042494162],"genre_scores_gemma":[0.9754176,0.016001666,0.0028816075,0.0016928273,0.0032810457,0.00018899335,0.00039571003,0.00003953093,0.000101010824],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99809927,0.0002891556,0.0004244739,0.00057798484,0.00019915237,0.00040997425],"domain_scores_gemma":[0.99748605,0.0015492412,0.00021350714,0.0005171639,0.00008105977,0.00015299767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00096074975,0.0002637849,0.0017128584,0.000055244807,0.00023951771,0.000028776594,0.00019389475,0.00018514383,0.00001836945],"category_scores_gemma":[0.00027571004,0.0001870078,0.0000528346,0.00011226928,0.00020157045,0.00013769772,0.000079715726,0.00029181098,8.041395e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.65067136,0.0005187,0.012511834,0.00013309398,0.0009378187,0.000029685993,0.0021528602,0.0000030624133,0.010156752,0.0005295189,0.005852334,0.316503],"study_design_scores_gemma":[0.8684928,0.006928365,0.07174842,0.00012610751,0.00048205032,0.000014941034,0.00021063667,0.0010042303,0.000102616796,0.0009179015,0.049681198,0.00029073213],"about_ca_topic_score_codex":0.00023728282,"about_ca_topic_score_gemma":0.00045526034,"teacher_disagreement_score":0.31621227,"about_ca_system_score_codex":0.00014900602,"about_ca_system_score_gemma":0.00032402767,"threshold_uncertainty_score":0.76259565},"labels":[],"label_agreement":null},{"id":"W2152162065","doi":"10.1016/s1470-2045(15)00169-2","title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":613,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"BC Cancer Agency; Canadian Institutes of Health Research; H. Lundbeck A/S; University of British Columbia; Celgene; Terry Fox Research Institute; Genome British Columbia; Dr. Mildred Scheel Stiftung für Krebsforschung; Michael Smith Health Research BC; Amgen; Alfred Benzon Foundation; Genome Canada; Deutsche Krebshilfe","keywords":"Medicine; Rituximab; Follicular lymphoma; Internal medicine; Oncology; Population; Vincristine; Prednisone; International Prognostic Index; Cyclophosphamide; Lymphoma; Surgery; Chemotherapy","score_opus":0.06967241767753558,"score_gpt":0.3970410134681473,"score_spread":0.3273685957906117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152162065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924354,0.000069132846,0.0033590805,0.0005894536,0.00006087209,0.0033650843,0.00009761544,0.0000070403044,0.000016330283],"genre_scores_gemma":[0.9898498,0.000082238,0.008038856,0.000031075157,0.000071165116,0.0012486669,0.0006683157,0.000007678799,0.0000022054742],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99878746,0.00018651613,0.00060368073,0.00021067559,0.000109652916,0.00010200858],"domain_scores_gemma":[0.99765456,0.0011615584,0.00057771354,0.00019690208,0.00038421378,0.000025034813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011888477,0.000085684565,0.0006481889,0.00018244295,0.000030066363,0.0000047710037,0.00004457736,0.00011137907,9.22583e-7],"category_scores_gemma":[0.0034988744,0.00006149389,0.00011632469,0.00045339623,0.000056419347,0.00003736616,0.000006127255,0.00004316618,6.609819e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020965936,0.0022143754,0.96662915,0.00002096135,0.0003464284,3.2078356e-7,0.00082146155,0.00030869333,0.000035953995,0.00019559424,0.000009953661,0.008451179],"study_design_scores_gemma":[0.095708214,0.003712841,0.8830721,0.000046091547,0.00087651506,3.2252106e-7,0.0000842412,0.014415066,0.00067069934,0.001357782,0.000011346883,0.000044817534],"about_ca_topic_score_codex":0.0006432296,"about_ca_topic_score_gemma":0.0013566847,"teacher_disagreement_score":0.08355708,"about_ca_system_score_codex":0.000583307,"about_ca_system_score_gemma":0.00019052229,"threshold_uncertainty_score":0.41887322},"labels":[],"label_agreement":null},{"id":"W2152261493","doi":"10.1016/s1470-2045(06)70579-4","title":"Proteins with whey-acidic-protein motifs and cancer","year":2006,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Animal Genetics and Reproduction","field":"Biochemistry, Genetics and Molecular Biology","cited_by":200,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Canadian Institutes of Health Research","keywords":"Gene; Biology; Carcinogenesis; Cancer; Cancer research; Computational biology; Genetics","score_opus":0.04870910941863724,"score_gpt":0.3448152108010417,"score_spread":0.29610610138240445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152261493","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010891918,0.99538773,0.0001389459,0.0005942543,0.00012659283,0.00109545,0.000044943317,0.000015198111,0.0015076916],"genre_scores_gemma":[0.00035616814,0.9916191,0.00053776166,0.0000923821,0.0027505187,0.0005492746,0.000103220154,0.000053167074,0.0039384174],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985677,0.0002206183,0.00024357335,0.00055368367,0.00009376206,0.00032065072],"domain_scores_gemma":[0.9990794,0.0000068876993,0.000269749,0.0005415619,0.000056279852,0.000046142126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030100232,0.00030090378,0.0008631631,0.000029498106,0.00011648094,0.000021973188,0.00026879122,0.00040673593,0.000013243839],"category_scores_gemma":[0.000015909987,0.00016418035,0.000096736294,0.000093920025,0.0003848877,0.0000013226554,0.00016114656,0.0002955495,0.000008028566],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011564279,0.00006606052,0.000023550854,0.0026595374,0.0002682348,0.000012293495,0.00001855492,0.000010104855,0.0031327475,0.00023375632,0.0042727776,0.98918676],"study_design_scores_gemma":[0.00027653357,0.0006849081,0.000024429,0.0004647004,0.00023723448,0.00012934115,0.0000071907284,0.000001231106,0.00034651154,0.000029103234,0.9975618,0.0002369903],"about_ca_topic_score_codex":0.00016404112,"about_ca_topic_score_gemma":0.00036671103,"teacher_disagreement_score":0.99328905,"about_ca_system_score_codex":0.00004081265,"about_ca_system_score_gemma":0.00034444535,"threshold_uncertainty_score":0.66950804},"labels":[],"label_agreement":null},{"id":"W2152280560","doi":"10.1016/s1470-2045(12)70237-1","title":"Radiotherapy for head and neck tumours in 2012 and beyond: conformal, tailored, and adaptive?","year":2012,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Cancer Institute","keywords":"Medicine; Radiation therapy; Head and neck; Head and neck cancer; Medical physics; Parotid gland; Radiology; Nuclear medicine; Pathology; Surgery","score_opus":0.1385623288787938,"score_gpt":0.4182639424880143,"score_spread":0.2797016136092205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152280560","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00082813075,0.9908898,0.000010845825,0.0040149563,0.00021477952,0.001473849,0.000044914057,0.000018549612,0.0025041758],"genre_scores_gemma":[0.00022743503,0.995735,0.00078939425,0.00156377,0.00097110274,0.0003336038,0.000016382919,0.00003241222,0.00033088692],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99873686,0.00014039522,0.00033361945,0.00024778134,0.00006869439,0.00047262752],"domain_scores_gemma":[0.9989602,0.00053307664,0.00016608948,0.00019492667,0.000026516052,0.00011917],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006953291,0.00028796645,0.0027935144,0.00009119619,0.00008853217,0.000009773963,0.00008099983,0.00026076823,0.000019234729],"category_scores_gemma":[0.000027684586,0.0001682629,0.00006990708,0.000079194004,0.00034993605,0.000067758556,0.00007259529,0.00039883415,0.0000022399215],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004886492,0.00004437963,0.00045401193,0.004410415,0.0001788242,0.000009260646,0.00076560775,1.2800832e-8,8.329605e-7,0.0013485758,0.005546905,0.9867525],"study_design_scores_gemma":[0.0037912135,0.0015753512,0.0015199935,0.0013795145,0.000526683,0.0004171467,0.000111785055,0.0000072700145,1.8110256e-7,0.00009016822,0.9904092,0.0001714876],"about_ca_topic_score_codex":0.00003286052,"about_ca_topic_score_gemma":0.0002373059,"teacher_disagreement_score":0.986581,"about_ca_system_score_codex":0.00011718989,"about_ca_system_score_gemma":0.00019445884,"threshold_uncertainty_score":0.68615615},"labels":[],"label_agreement":null},{"id":"W2152283335","doi":"10.1016/s1470-2045(07)70216-4","title":"CYP3A4/5 and pharmacogenetics in patients with sarcoma – Authors' reply","year":2007,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of British Columbia; Vancouver Coastal Health Research Institute; Princess Margaret Cancer Centre; BC Cancer Agency; SickKids Foundation; University of Toronto; Mount Sinai Hospital; Lunenfeld-Tanenbaum Research Institute","funders":"","keywords":"Oncology; Medicine; Breast cancer; Docetaxel; CYP3A4; Internal medicine; Pharmacogenetics; Cancer; Scopus; Osteosarcoma; Sarcoma; Cancer research; Pathology; MEDLINE; Biology; Genotype; Cytochrome P450; Genetics","score_opus":0.022248374246121406,"score_gpt":0.30564249019674405,"score_spread":0.28339411595062264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152283335","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82663435,0.0022974822,0.0002726876,0.16637969,0.00050081423,0.0006734672,0.000071026436,0.00001606584,0.0031544066],"genre_scores_gemma":[0.19844915,0.0033920438,0.0032872315,0.7811749,0.009980344,0.00007944554,0.001861142,0.00016525087,0.0016104741],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99830717,0.0003205275,0.00028388386,0.0004460021,0.00018544648,0.00045694417],"domain_scores_gemma":[0.99907005,0.000075475145,0.00020719506,0.00050793134,0.00009332985,0.00004603671],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064732943,0.00025281872,0.0003921875,0.00008047685,0.000061512445,0.000018947912,0.00029453484,0.0006055949,0.000010813463],"category_scores_gemma":[0.000050097155,0.00017777547,0.00004013511,0.000101083126,0.00019275301,0.0000018688543,0.00015126332,0.00082714733,0.000004974121],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018596945,0.00025552732,0.19583689,0.00021056917,0.0003419128,0.00021162273,0.00030159578,0.0000823403,0.010515515,0.000021559297,0.7515968,0.038765963],"study_design_scores_gemma":[0.001948076,0.00085076096,0.051605668,0.000015043535,0.000048324528,0.0000050446306,0.000004629963,0.000008347358,0.002542355,0.00007678622,0.94265044,0.00024454144],"about_ca_topic_score_codex":0.00002655659,"about_ca_topic_score_gemma":0.00007361615,"teacher_disagreement_score":0.6281852,"about_ca_system_score_codex":0.000041284795,"about_ca_system_score_gemma":0.00009384521,"threshold_uncertainty_score":0.7249473},"labels":[],"label_agreement":null},{"id":"W2152643817","doi":"10.1016/s1470-2045(04)01565-7","title":"Molecular therapy in pancreatic adenocarcinoma","year":2004,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Pancreatic cancer; Radiation therapy; Immunotherapy; Disease; Targeted therapy; Adenocarcinoma; Oncology; Cancer; Chemotherapy; Genetic enhancement; Internal medicine; Gene","score_opus":0.15541389936879954,"score_gpt":0.45313519882315073,"score_spread":0.2977212994543512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152643817","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016654418,0.9752321,0.000013931527,0.0019684175,0.0001412155,0.002391955,0.000010591317,0.000053666972,0.018522639],"genre_scores_gemma":[0.0005583999,0.99570286,0.00043456643,0.0010206132,0.0006008833,0.0007792771,0.000065327564,0.00007065526,0.0007674433],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99645287,0.0012101728,0.0007302827,0.0004777426,0.0003030427,0.0008259167],"domain_scores_gemma":[0.9975224,0.0009517246,0.00026953113,0.0010474848,0.000060005124,0.0001488468],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014940497,0.0004301135,0.0053133434,0.00027595795,0.000066748515,0.000012551442,0.0006031018,0.0007890073,0.0003240713],"category_scores_gemma":[0.00025803072,0.00023873962,0.0004047414,0.0005530357,0.00042325066,0.00002090083,0.00013328392,0.0016445327,0.00060325034],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040311628,0.00048116804,0.0040602796,0.011815052,0.0009211056,0.0033617038,0.00034610514,0.0000010060019,0.000002265685,0.0022563587,0.00083652657,0.9755153],"study_design_scores_gemma":[0.004113966,0.0015932183,0.0021187374,0.007078465,0.0012411564,0.0015169249,0.000036274952,0.000008196411,7.750023e-7,0.00072368525,0.98133254,0.00023605561],"about_ca_topic_score_codex":0.00016756331,"about_ca_topic_score_gemma":0.000031818625,"teacher_disagreement_score":0.980496,"about_ca_system_score_codex":0.0011517081,"about_ca_system_score_gemma":0.0036692545,"threshold_uncertainty_score":0.9735519},"labels":[],"label_agreement":null},{"id":"W2152905269","doi":"10.1016/s1470-2045(12)70087-6","title":"Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":953,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Afatinib; Medicine; Erlotinib; Gefitinib; Internal medicine; Clinical endpoint; Hazard ratio; Placebo; Lung cancer; Oncology; Performance status; Chemotherapy; Adenocarcinoma; Randomized controlled trial; Surgery; Cancer; Epidermal growth factor receptor; Confidence interval; Pathology","score_opus":0.03765453655497886,"score_gpt":0.40357536614862405,"score_spread":0.3659208295936452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152905269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98956275,0.0009952454,0.00049139163,0.0009808997,0.00036985302,0.006951853,0.00033945526,0.000020487658,0.00028807606],"genre_scores_gemma":[0.9720966,0.0004026507,0.022351637,0.0004536573,0.0006859982,0.0033412394,0.00008571102,0.000055205695,0.0005272701],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99861413,0.000110561494,0.00047165106,0.00022929635,0.00017360687,0.0004007506],"domain_scores_gemma":[0.99777454,0.0011445216,0.00048644486,0.00028309555,0.00019580862,0.00011559615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003379942,0.00023912193,0.0010875778,0.00006591623,0.00006344567,0.000006362424,0.00009950212,0.000072479605,0.00026782634],"category_scores_gemma":[0.00011299625,0.00012423753,0.000094268966,0.0001504936,0.00015494805,0.00009107152,0.000022673212,0.00012304173,5.7337013e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97559595,0.0027116633,0.0045613186,0.0007667326,0.0014805763,0.0000043938267,0.004030999,0.00001836582,0.0006087182,0.000020931071,0.00068814226,0.009512194],"study_design_scores_gemma":[0.97853273,0.00999559,0.0013524304,0.00025391477,0.003679655,0.0000052191713,0.0005117324,0.00022120975,0.0018394139,0.000008430234,0.0034202894,0.00017938075],"about_ca_topic_score_codex":0.000051199077,"about_ca_topic_score_gemma":0.00026886273,"teacher_disagreement_score":0.021860246,"about_ca_system_score_codex":0.00011396554,"about_ca_system_score_gemma":0.00056178897,"threshold_uncertainty_score":0.50662595},"labels":[],"label_agreement":null},{"id":"W2152969899","doi":"10.1016/s1470-2045(13)70589-8","title":"Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":206,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute; U.S. Public Health Service; U.S. Department of Health and Human Services","keywords":"Medicine; Breast cancer; Chemotherapy; Hazard ratio; Lumpectomy; Internal medicine; Mastectomy; Oncology; Cancer; Clinical endpoint; Surgery; Randomized controlled trial; Confidence interval","score_opus":0.027297002398603727,"score_gpt":0.3294643913437202,"score_spread":0.30216738894511647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152969899","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9462642,0.001420732,0.010367367,0.03533376,0.0014701117,0.0028520185,0.00047658588,0.000041265197,0.0017739497],"genre_scores_gemma":[0.9940698,0.0006887694,0.00046006416,0.0016706465,0.0021677471,0.00076337217,0.000057888206,0.0000190088,0.000102706304],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99908483,0.00015115218,0.00020964017,0.00023690153,0.00007114083,0.00024632312],"domain_scores_gemma":[0.9992032,0.00016989307,0.00018970353,0.0002830864,0.00012299464,0.00003111861],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003767011,0.00013889097,0.0004294526,0.000015861486,0.0000730805,0.0000040012187,0.00024324423,0.00012098522,0.000031063122],"category_scores_gemma":[0.00006614978,0.000090708105,0.00012685795,0.000059948827,0.00022766364,0.0000017958318,0.000045432902,0.0000654494,0.00000192617],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84100115,0.00047708696,0.0020863684,0.00006600697,0.00085495197,5.713134e-7,0.00034268558,0.00006166694,0.02928466,0.0009009754,0.04047607,0.08444781],"study_design_scores_gemma":[0.6972562,0.00305222,0.014793128,0.00005304398,0.00023350515,0.000051439838,0.00005935902,0.00047449916,0.010483612,0.0015096064,0.27164155,0.00039182848],"about_ca_topic_score_codex":0.00005979493,"about_ca_topic_score_gemma":0.000106557614,"teacher_disagreement_score":0.23116547,"about_ca_system_score_codex":0.000033700955,"about_ca_system_score_gemma":0.00012776928,"threshold_uncertainty_score":0.36989692},"labels":[],"label_agreement":null},{"id":"W2153954237","doi":"10.1016/s1470-2045(13)70253-5","title":"Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":432,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; BC Cancer Agency; University of Toronto; University of Calgary","funders":"National Institutes of Health; Cancer Research UK; National Cancer Institute; Kræftens Bekæmpelse","keywords":"Ovarian cancer; Ovarian tissue cryopreservation; Oncology; Hormone receptor; Internal medicine; Medicine; Gynecology; Biology; Cancer research; Cancer; Breast cancer; Fertility; Fertility preservation","score_opus":0.05828470196006116,"score_gpt":0.37146549834479403,"score_spread":0.3131807963847329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153954237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97685486,0.00092749594,0.00006373697,0.017828694,0.00039364622,0.0015796083,0.000050638908,0.0000933892,0.0022079318],"genre_scores_gemma":[0.9945417,0.00040062246,0.000969401,0.0016270914,0.0009192531,0.001009038,0.00004113677,0.000030256688,0.00046151297],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99797344,0.000487514,0.00034941727,0.0005172425,0.00023722455,0.00043513792],"domain_scores_gemma":[0.9984553,0.00021154604,0.00018472578,0.00076978456,0.00012352115,0.00025510901],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005608004,0.00024499145,0.001040472,0.000121070494,0.00018493089,0.000058208643,0.00019474764,0.00010513266,0.0023614184],"category_scores_gemma":[0.000038989758,0.00014889993,0.0000754941,0.0003939135,0.00014583845,0.00011952244,0.0001032105,0.00024801758,0.00008955296],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012848191,0.0037384783,0.90663916,0.000046531935,0.003961376,0.00020812663,0.0049649426,0.000045339733,0.017523084,0.000714741,0.024492,0.0363814],"study_design_scores_gemma":[0.0071969437,0.0022757149,0.9505436,0.000018938103,0.002117627,0.000018879397,0.00141892,0.00015516087,0.00078819116,0.00009937796,0.035166536,0.00020015429],"about_ca_topic_score_codex":0.0067529436,"about_ca_topic_score_gemma":0.0019119116,"teacher_disagreement_score":0.043904398,"about_ca_system_score_codex":0.0002017684,"about_ca_system_score_gemma":0.00016143905,"threshold_uncertainty_score":0.9998612},"labels":[],"label_agreement":null},{"id":"W2154350319","doi":"10.1016/s1470-2045(01)00456-9","title":"Depression in cancer patients","year":2001,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":268,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Depression (economics); Cancer; Epidemiology; Medicine; Psychiatry; Intensive care medicine; Internal medicine","score_opus":0.12533192905507254,"score_gpt":0.44481256621605314,"score_spread":0.31948063716098063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154350319","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024484086,0.977517,8.957507e-7,0.00038997622,0.0012506145,0.00072055665,0.000033916396,0.000030353327,0.019811857],"genre_scores_gemma":[0.00017247096,0.99565035,0.0000064191345,0.0009989826,0.001477841,0.00044727497,0.00010078642,0.000034479086,0.0011113735],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985788,0.00031270596,0.0003411725,0.0002697964,0.00015505459,0.00034245438],"domain_scores_gemma":[0.99908704,0.00018415818,0.00019888689,0.00042774875,0.00004248359,0.000059705457],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002879975,0.00021758968,0.0019404833,0.000093199655,0.00003085251,0.0000052471355,0.0002507592,0.00037651436,0.00038250064],"category_scores_gemma":[0.0000422536,0.00011907073,0.00018907369,0.00035306916,0.000056513887,0.000015492304,0.00009826096,0.0007250871,0.00007388684],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007234194,0.000098764634,0.0052671563,0.0032999003,0.000041981115,0.000042377465,0.00015093491,1.4916242e-7,2.8513167e-8,0.0000107645465,0.0077417386,0.98327386],"study_design_scores_gemma":[0.00095711136,0.0001271938,0.0013331715,0.0062051504,0.00039514765,0.000031149866,0.000014459359,5.8291096e-7,1.2498754e-7,0.000016473934,0.99079937,0.00012009242],"about_ca_topic_score_codex":0.00095664815,"about_ca_topic_score_gemma":0.004886846,"teacher_disagreement_score":0.98315376,"about_ca_system_score_codex":0.00064617116,"about_ca_system_score_gemma":0.00045165126,"threshold_uncertainty_score":0.48555636},"labels":[],"label_agreement":null},{"id":"W2154581953","doi":"10.1016/s1470-2045(10)70151-0","title":"Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study","year":2010,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":268,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Bevacizumab; Internal medicine; Adverse effect; Lung cancer; Clinical endpoint; Population; Chemotherapy; Surgery; Oncology; Phases of clinical research; Incidence (geometry); Clinical trial","score_opus":0.022379649479756486,"score_gpt":0.3924690575272414,"score_spread":0.3700894080474849,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154581953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99111545,0.0007613528,0.00013797566,0.0036608637,0.00029367185,0.0025734184,0.000053435106,0.000029846487,0.0013740073],"genre_scores_gemma":[0.99720526,0.00063274556,0.0005705137,0.000688128,0.00025353912,0.00037873726,0.00002913686,0.000029336588,0.00021262521],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987611,0.00008208621,0.00038034952,0.00031357343,0.00013424107,0.0003286471],"domain_scores_gemma":[0.9986758,0.00043734198,0.00019686882,0.0004992162,0.00009948945,0.00009127738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003614156,0.00020604808,0.00073238835,0.00009667119,0.00010756224,0.000006873547,0.00016507384,0.00011309777,0.00013195134],"category_scores_gemma":[0.000048836893,0.0001327551,0.000060126025,0.00023754878,0.00012709571,0.000036724174,0.000038407503,0.00039114154,0.000002562978],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03870433,0.024494503,0.6029387,0.000491334,0.0008135745,0.0003462706,0.025808662,0.0029456164,0.030601796,0.0000550244,0.0007306563,0.2720695],"study_design_scores_gemma":[0.3912926,0.01866634,0.54466856,0.0001936552,0.0012285932,0.00003419171,0.0014338228,0.010875456,0.0067988206,0.00004460792,0.024267353,0.0004960247],"about_ca_topic_score_codex":0.0009979252,"about_ca_topic_score_gemma":0.005359361,"teacher_disagreement_score":0.35258827,"about_ca_system_score_codex":0.00017839132,"about_ca_system_score_gemma":0.00044845877,"threshold_uncertainty_score":0.5413596},"labels":[],"label_agreement":null},{"id":"W2154582201","doi":"10.1016/s1470-2045(11)70389-8","title":"Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bone health and osteoporosis research","field":"Medicine","cited_by":108,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Juravinski Cancer Centre; University of Toronto; University Health Network; Queen's University; McMaster University; Women's College Hospital","funders":"Canadian Institutes of Health Research","keywords":"Exemestane; Medicine; Postmenopausal women; Breast cancer; Oncology; Cancer; Primary prevention; Randomized controlled trial; Internal medicine; Gynecology; Aromatase; Disease","score_opus":0.027134062633625323,"score_gpt":0.3490563849927078,"score_spread":0.32192232235908247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154582201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9773225,0.0015932531,0.0000028303077,0.010043648,0.000121105775,0.010830518,0.000042699638,0.000007681008,0.000035769022],"genre_scores_gemma":[0.99746585,0.00034583194,0.0000438787,0.00079234474,0.00023627229,0.0009981456,0.000010726942,0.000012342106,0.00009462974],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9979516,0.0007871246,0.00044851197,0.00013217465,0.00022112958,0.00045942338],"domain_scores_gemma":[0.9979795,0.0010917976,0.000370746,0.0003015219,0.00015899484,0.000097423545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021577328,0.00012015006,0.0011372173,0.000046247344,0.000104162384,0.0000029963333,0.0001088095,0.00011036438,0.000024641506],"category_scores_gemma":[0.00012546616,0.00004736869,0.000048290323,0.00020516614,0.00025268563,0.000031050917,0.000039106257,0.00027932748,1.1185918e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94306695,0.0005004231,0.047599565,0.00031723178,0.00014920844,0.0000016203893,0.0013415864,0.0000015114903,0.0040205154,0.00003979939,0.00010209695,0.0028594884],"study_design_scores_gemma":[0.5192094,0.004207928,0.47567394,0.00004098646,0.00016513596,0.000063392814,0.00030940436,0.000026018593,0.00010711371,0.00003214124,0.00012983162,0.000034747194],"about_ca_topic_score_codex":0.00050151325,"about_ca_topic_score_gemma":0.0012498792,"teacher_disagreement_score":0.4280744,"about_ca_system_score_codex":0.0002338097,"about_ca_system_score_gemma":0.00071268773,"threshold_uncertainty_score":0.1931639},"labels":[],"label_agreement":null},{"id":"W2155440695","doi":"10.1016/s1470-2045(05)70255-2","title":"Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials","year":2005,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":230,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; University of Toronto; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Associazione Italiana per la Ricerca sul Cancro","keywords":"Vinorelbine; Medicine; Gemcitabine; Neutropenia; Internal medicine; Chemotherapy; Hazard ratio; Lung cancer; Clinical endpoint; Surgery; Oncology; Clinical trial; Cisplatin; Confidence interval","score_opus":0.09235030140493503,"score_gpt":0.4565041393492671,"score_spread":0.3641538379443321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155440695","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.035699338,0.95397747,0.000011015162,0.0010193167,0.00014335841,0.007273162,0.00011392177,0.000025609539,0.001736823],"genre_scores_gemma":[0.0038353594,0.99231845,0.00037005986,0.00024501196,0.000459324,0.002171921,0.0001749179,0.000053073298,0.0003718976],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997067,0.0006291593,0.0012571159,0.0005082919,0.00013761145,0.00040082444],"domain_scores_gemma":[0.99648964,0.0015429525,0.0011280067,0.000667331,0.00006530301,0.000106769534],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00091825303,0.0004999825,0.008717425,0.00044543092,0.000060162256,0.000013246969,0.00021608363,0.00031611032,0.00016705366],"category_scores_gemma":[0.000069980175,0.00026492262,0.00093804824,0.0008701772,0.00006852667,0.000026111014,0.000037413392,0.0002804632,0.0000032756022],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033330005,0.00074293924,0.00031033973,0.0011175318,0.015984511,0.000028582355,0.00076639606,0.00005874024,0.00005544381,0.0000090263275,0.00006201592,0.9775315],"study_design_scores_gemma":[0.19180217,0.0014901613,0.00393477,0.0029610975,0.22159737,0.000019186415,0.000057234243,0.0002891054,0.000041542735,0.0000040650784,0.57737684,0.00042642673],"about_ca_topic_score_codex":0.00064813806,"about_ca_topic_score_gemma":0.0026062606,"teacher_disagreement_score":0.977105,"about_ca_system_score_codex":0.001230114,"about_ca_system_score_gemma":0.0014425342,"threshold_uncertainty_score":0.9999803},"labels":[],"label_agreement":null},{"id":"W2155487288","doi":"10.1016/s1470-2045(09)70187-1","title":"TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies","year":2009,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":158,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thunder Bay Regional Research Institute","funders":"National Cancer Institute; Deutsche Forschungsgemeinschaft","keywords":"Genotype; Heterozygote advantage; Cervical cancer; Allele; Odds ratio; Arginine; Genetics; Biology; Genetic epidemiology; Epidemiology; Allele frequency; Internal medicine; Cancer; Medicine; Gene","score_opus":0.12895856000093608,"score_gpt":0.3991768301553864,"score_spread":0.2702182701544503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155487288","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.936289,0.030726612,0.00007126291,0.030413907,0.00021102901,0.0002936715,0.0009191502,0.0000522072,0.0010231388],"genre_scores_gemma":[0.98847574,0.004156457,0.00049094675,0.0059363265,0.00048405887,0.0000134748,0.00037864357,0.000012170876,0.000052154308],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99848074,0.00021106892,0.00033458235,0.00038226097,0.00027536406,0.0003159864],"domain_scores_gemma":[0.99834424,0.00030944674,0.00020544356,0.000978142,0.00007854511,0.000084170664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005984798,0.0001571461,0.0012098111,0.00015541347,0.00006559351,0.000007803754,0.00044562016,0.00016814098,0.00014030766],"category_scores_gemma":[0.00017915996,0.00010856909,0.00007956108,0.0005569172,0.00026618844,0.000037091937,0.00034530452,0.00033962142,0.000007195308],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012385223,0.0021410224,0.07931065,0.0002768469,0.10933292,0.0011987349,0.025681378,0.0005403443,0.18339519,0.0030865911,0.15946338,0.42318773],"study_design_scores_gemma":[0.011572182,0.0020765772,0.8893783,0.0002008121,0.046926267,0.00008486647,0.0012770869,0.0031299603,0.0032610104,0.0013198494,0.040368427,0.0004046226],"about_ca_topic_score_codex":0.00083648396,"about_ca_topic_score_gemma":0.0022385672,"teacher_disagreement_score":0.8100677,"about_ca_system_score_codex":0.00012704206,"about_ca_system_score_gemma":0.00020142944,"threshold_uncertainty_score":0.44273192},"labels":[],"label_agreement":null},{"id":"W2156667572","doi":"10.1016/s1470-2045(02)00775-1","title":"Impact of the Human Genome Project on the clinical management of sporadic cancers","year":2002,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Gene expression and cancer classification","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"American Society of Clinical Oncology; European Society for Medical Oncology; Cancer Research Society; American Association for Cancer Research","keywords":"DNA microarray; Human genome; Computational biology; Cancer; Molecular pathology; Breast cancer; Gene; Genome; Biology; Molecular diagnostics; Function (biology); DNA sequencing; Bioinformatics; Gene expression; Genetics","score_opus":0.24435742766123925,"score_gpt":0.48726423163551086,"score_spread":0.2429068039742716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156667572","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007492751,0.9713401,0.0000070678357,0.00040840943,0.00046026066,0.0017914989,0.000107451495,0.0000072724397,0.018385144],"genre_scores_gemma":[0.014181294,0.9835094,0.00001715655,0.00015973936,0.0005448575,0.00017453292,0.00004632564,0.000023657063,0.0013430034],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978726,0.000882548,0.0005760867,0.0003071499,0.00014819633,0.00021345068],"domain_scores_gemma":[0.9976357,0.00006235832,0.0009145596,0.0013216732,0.00004160677,0.000024096405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008457757,0.0002145393,0.0008698456,0.000032404932,0.00008567011,0.0000050956032,0.0011541275,0.00028163884,0.00007134658],"category_scores_gemma":[0.000023156808,0.000085831,0.0006589847,0.00019924107,0.0003483372,7.4910287e-7,0.00021212483,0.00033838066,0.0000065282484],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019152972,0.00041063683,0.00022123434,0.003112657,0.0023043368,0.000004045798,0.00014283792,0.000041061267,0.0011968897,0.0021244197,0.10987086,0.8803795],"study_design_scores_gemma":[0.00030860424,0.0005021864,0.0016760436,0.00052519183,0.00028041398,0.0000060661896,0.00003060371,9.101115e-7,0.000025474797,0.000026542066,0.9965202,0.00009776163],"about_ca_topic_score_codex":0.000033283726,"about_ca_topic_score_gemma":0.000012557431,"teacher_disagreement_score":0.88664937,"about_ca_system_score_codex":0.00014198571,"about_ca_system_score_gemma":0.0004189641,"threshold_uncertainty_score":0.35000867},"labels":[],"label_agreement":null},{"id":"W2158179945","doi":"10.1016/s1470-2045(03)01137-9","title":"Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer","year":2003,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":281,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University; University Health Network; University of Toronto","funders":"Cancer Research Society; American Association for Cancer Research","keywords":"Erlotinib; Gefitinib; Cetuximab; Epidermal growth factor receptor; Medicine; Lung cancer; Amphiregulin; Cancer research; Epidermal growth factor; Tyrosine kinase; Cancer; Carcinogenesis; Trastuzumab; Oncology; Receptor; Internal medicine; Colorectal cancer; Breast cancer","score_opus":0.39172005433816587,"score_gpt":0.5739504872546254,"score_spread":0.18223043291645952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158179945","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013638576,0.96213764,0.000003794673,0.0047400687,0.00075698114,0.0059504695,0.00012974568,0.000025171697,0.02611972],"genre_scores_gemma":[0.000042362513,0.9928949,0.0005066438,0.0009603435,0.0024196634,0.0014925742,0.000028993501,0.00016147939,0.0014930641],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98578453,0.0077217245,0.0028142326,0.0009705826,0.0014627426,0.0012461598],"domain_scores_gemma":[0.9877647,0.006816526,0.0016856885,0.0020206966,0.0013287391,0.0003836151],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.015143493,0.00060081214,0.00895162,0.00043330865,0.00008685899,0.000009156713,0.0012228203,0.0009977088,0.0012725111],"category_scores_gemma":[0.0028298688,0.0003285006,0.0008824637,0.0017587129,0.0012556056,0.000030494271,0.00031496075,0.004996294,0.00009774208],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054930756,0.000577866,0.0009038722,0.32551903,0.0005920468,0.000107480606,0.00011001945,1.2251978e-7,0.0000022088884,0.000091811286,0.16155949,0.50998676],"study_design_scores_gemma":[0.001717922,0.0031959591,0.000033387652,0.22319888,0.000964565,0.000066200904,0.000018922985,0.0000011000875,0.000059878334,0.000015395375,0.7705081,0.00021965725],"about_ca_topic_score_codex":0.0005597971,"about_ca_topic_score_gemma":0.0001393926,"teacher_disagreement_score":0.60894865,"about_ca_system_score_codex":0.0011440917,"about_ca_system_score_gemma":0.01195771,"threshold_uncertainty_score":0.99991673},"labels":[],"label_agreement":null},{"id":"W2158681922","doi":"10.1016/s1470-2045(09)70025-7","title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","year":2009,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":7801,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Ontario Institute for Cancer Research; Queen's University; Hôpital Notre-Dame; Western University; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Temozolomide; Radiation therapy; Concomitant; Internal medicine; Hazard ratio; Clinical endpoint; Oncology; Adjuvant; Cancer; Clinical trial; Surgery; Confidence interval","score_opus":0.021054825445956833,"score_gpt":0.3383414721996334,"score_spread":0.31728664675367657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158681922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936991,0.0010067241,0.0000066893535,0.001666732,0.00014315073,0.003368469,0.0000063426214,0.000010219647,0.000092614224],"genre_scores_gemma":[0.9989315,0.0004946194,0.000055971585,0.00026545968,0.00010150355,0.00013202404,0.0000020777818,0.000012512328,0.0000043289338],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978578,0.0008801051,0.00048369443,0.0002647096,0.0002549969,0.0002587126],"domain_scores_gemma":[0.9972085,0.0019660278,0.00030574,0.00043502334,0.00003332354,0.00005143518],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010348876,0.00020128726,0.002074958,0.00029896514,0.000031180196,0.00000472601,0.00015585643,0.00008981375,0.000016053795],"category_scores_gemma":[0.00011280664,0.00009877042,0.00015524316,0.0008582099,0.00017610958,0.000018220791,0.000012503559,0.0002005326,1.7758941e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9358662,0.007526355,0.03387414,0.000017228616,0.0027654653,0.0002565104,0.0025787523,0.00025822595,0.009121067,0.00009721516,0.000040520987,0.0075983363],"study_design_scores_gemma":[0.7804674,0.035099775,0.17850035,0.0000668242,0.0013194148,0.000004963076,0.00028694488,0.0004901248,0.0036178112,0.000009647759,0.000053093296,0.00008365556],"about_ca_topic_score_codex":0.00022904751,"about_ca_topic_score_gemma":0.002129935,"teacher_disagreement_score":0.1553988,"about_ca_system_score_codex":0.00023632005,"about_ca_system_score_gemma":0.00011663125,"threshold_uncertainty_score":0.4027741},"labels":[],"label_agreement":null},{"id":"W2158872144","doi":"10.1016/s1470-2045(14)71021-6","title":"Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":351,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Genome British Columbia; Princess Margaret Cancer Centre; University of Toronto; University Health Network; Centre for Addiction and Mental Health; Ontario Institute for Cancer Research","funders":"Cancer Research UK Cambridge Institute, University of Cambridge; NIHR Cambridge Biomedical Research Centre; Canadian Institutes of Health Research; Ontario Institute for Cancer Research; Wellcome Trust; Hutchison Whampoa Limited; National Institute for Health and Care Research; Cancer Research UK; University of Cambridge; Academy of Medical Sciences; Prostate Cancer Canada; Government of Ontario; National Institutes of Health; Movember Foundation","keywords":"Medicine; Prostate cancer; Prostatectomy; Hazard ratio; Oncology; Cohort; Biochemical recurrence; Internal medicine; Radiation therapy; Retrospective cohort study; Clinical endpoint; Cancer; Prostate; Proportional hazards model; Clinical trial; Confidence interval","score_opus":0.02177070498801827,"score_gpt":0.3035306737901098,"score_spread":0.28175996880209153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158872144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964531,0.00049585575,0.00001865412,0.00053650275,0.00009459294,0.0018325566,0.0005108121,0.000010165266,0.000047749487],"genre_scores_gemma":[0.99779,0.001253094,0.00025021788,0.000063800464,0.00009759329,0.00048155608,0.00004638211,0.000009632268,0.000007747745],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992267,0.000087681154,0.00022683117,0.00022783186,0.00008197775,0.00014901548],"domain_scores_gemma":[0.9994798,0.00007080021,0.00017571772,0.0001780881,0.000056391757,0.00003923687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038650312,0.00009886166,0.0005197189,0.000023474311,0.000031422955,0.0000021727474,0.000060815863,0.00004461589,0.00000895759],"category_scores_gemma":[0.00003969669,0.000064758126,0.000040037983,0.000052120333,0.00020747907,0.000014304256,0.000044288183,0.000097461,5.426666e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012069156,0.0004735986,0.92444044,0.000055609227,0.00020512847,8.2069863e-7,0.00042812419,0.0000019827303,0.07134623,0.000021856,0.00046270294,0.0013565572],"study_design_scores_gemma":[0.004264246,0.0044708475,0.9163278,0.000049808503,0.00026629752,0.000009181352,0.00018290056,0.00008935252,0.07370759,0.000065248176,0.0005256989,0.000041040457],"about_ca_topic_score_codex":0.00017444765,"about_ca_topic_score_gemma":0.00005179036,"teacher_disagreement_score":0.008112678,"about_ca_system_score_codex":0.0003429435,"about_ca_system_score_gemma":0.000059905713,"threshold_uncertainty_score":0.26407596},"labels":[],"label_agreement":null},{"id":"W2160120519","doi":"10.1016/s1470-2045(09)70162-7","title":"Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial","year":2009,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":591,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Sunitinib; Medicine; Discontinuation; Renal cell carcinoma; Expanded access; Internal medicine; Adverse effect; Population; Clinical trial; Oncology","score_opus":0.12229784488383882,"score_gpt":0.39522004052956183,"score_spread":0.272922195645723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160120519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885221,0.0005971067,0.00016794394,0.0023978874,0.00012985784,0.0016577266,0.000025311763,0.00002515429,0.0064769024],"genre_scores_gemma":[0.9964422,0.00009918619,0.0016918227,0.0007691712,0.00061488035,0.000051402087,0.00006272979,0.000014626193,0.00025396212],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9986795,0.0002803303,0.00036313696,0.00020801168,0.00013388,0.0003350932],"domain_scores_gemma":[0.99848366,0.000694307,0.00019892515,0.000420387,0.00007386503,0.00012886312],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078766816,0.00015567646,0.0008280139,0.00006327081,0.00007116142,0.00000956851,0.00016886,0.00006995136,0.00003155884],"category_scores_gemma":[0.00012092989,0.00009560887,0.000096679505,0.00010148248,0.00012238715,0.00006671121,0.000035850182,0.0001404931,0.0000019943445],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81471705,0.008446345,0.006640718,0.00063033716,0.00049869635,0.00029850076,0.006070517,0.00006768457,0.03855073,0.005351483,0.005956104,0.11277185],"study_design_scores_gemma":[0.52715623,0.062092304,0.31971565,0.00006445928,0.0023658657,0.00053929724,0.0006510979,0.00023701007,0.058543865,0.0017462663,0.026460528,0.00042744618],"about_ca_topic_score_codex":0.00004318222,"about_ca_topic_score_gemma":0.000016216993,"teacher_disagreement_score":0.31307492,"about_ca_system_score_codex":0.000093312236,"about_ca_system_score_gemma":0.00015275672,"threshold_uncertainty_score":0.38988167},"labels":[],"label_agreement":null},{"id":"W2160305510","doi":"10.1016/s1470-2045(06)70664-7","title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","year":2006,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2085,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Rituximab; CHOP; Internal medicine; Vincristine; International Prognostic Index; Chemotherapy; Clinical endpoint; Diffuse large B-cell lymphoma; Lymphoma; Oncology; Prednisone; Surgery; Cyclophosphamide; Gastroenterology; Randomized controlled trial","score_opus":0.011568933367359015,"score_gpt":0.2673967495049783,"score_spread":0.2558278161376193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160305510","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9734367,0.0005853328,0.000039275033,0.006485387,0.0023896205,0.011198374,0.00008594783,0.000100384445,0.005678972],"genre_scores_gemma":[0.9877065,0.0006240792,0.00017269564,0.0033751924,0.002035218,0.004848215,0.00031292022,0.000087943496,0.00083723065],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962612,0.0006201012,0.000927905,0.0006544058,0.00071102247,0.0008253797],"domain_scores_gemma":[0.9970536,0.0013978968,0.00061212067,0.00068407075,0.00013708226,0.000115206814],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011544727,0.0005698652,0.002038391,0.00012505276,0.0002144192,0.000088947905,0.0005683306,0.00032041452,0.00022778899],"category_scores_gemma":[0.00007045313,0.00029824828,0.00042649094,0.00027918833,0.00024744534,0.00010694559,0.00006523229,0.00028931044,0.00003821738],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9362409,0.039760977,0.009694339,0.000012005089,0.0010438066,0.000041853662,0.00053547794,0.0000024683914,0.000062573745,0.00013565065,0.00851318,0.003956763],"study_design_scores_gemma":[0.9374016,0.0055430788,0.015823886,0.000033689437,0.00045481668,0.000014785025,0.00008266584,0.00022570293,0.000108988024,0.000043990007,0.03997402,0.00029280572],"about_ca_topic_score_codex":0.0012052536,"about_ca_topic_score_gemma":0.0012042302,"teacher_disagreement_score":0.034217898,"about_ca_system_score_codex":0.0015189352,"about_ca_system_score_gemma":0.0003287251,"threshold_uncertainty_score":0.99994695},"labels":[],"label_agreement":null},{"id":"W2161689638","doi":"10.1016/s1470-2045(11)70175-9","title":"Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":1028,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Cancer Institute","keywords":"Medicine; Hepatocellular carcinoma; Liver transplantation; Transplantation; Consensus conference; Listing (finance); Donation; Family medicine; Internal medicine; Political science; Law","score_opus":0.3238269917420179,"score_gpt":0.3579941574896356,"score_spread":0.03416716574761769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161689638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.963594,0.000086031,0.010340315,0.014005194,0.0006029145,0.0019166976,0.00022590139,0.00007598497,0.009152965],"genre_scores_gemma":[0.9668106,0.0001637412,0.02955289,0.00060419657,0.0004481109,0.00064644683,0.0012287591,0.000017278413,0.00052798877],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99911225,0.00009164185,0.00026794648,0.00023557815,0.00007522889,0.0002173324],"domain_scores_gemma":[0.99905556,0.00021754357,0.00013611255,0.0002704435,0.00024746393,0.000072853945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005455621,0.00011420802,0.00028940357,0.000050384373,0.00011855249,0.000009899211,0.00013517126,0.000107997526,0.00024265547],"category_scores_gemma":[0.000060607676,0.00008404804,0.000103777915,0.000043368953,0.00008508317,0.000052533167,0.00001061874,0.00009154808,0.000010431648],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068856925,0.0010053801,0.9117855,0.0002928759,0.00048416335,0.001857377,0.009229869,2.6933427e-7,0.0026526651,0.02642221,0.0122684855,0.027115501],"study_design_scores_gemma":[0.024564672,0.0078116455,0.17751965,0.00010096101,0.0029935685,0.0077503533,0.0013144984,0.053315427,0.03644729,0.008928683,0.6785483,0.00070495077],"about_ca_topic_score_codex":0.0001428544,"about_ca_topic_score_gemma":0.000081229635,"teacher_disagreement_score":0.73426586,"about_ca_system_score_codex":0.000076498945,"about_ca_system_score_gemma":0.00017359662,"threshold_uncertainty_score":0.34273797},"labels":[],"label_agreement":null},{"id":"W2162139554","doi":"10.1016/s1470-2045(13)70045-7","title":"Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":418,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; Ontario Institute for Cancer Research; University Health Network; University of Toronto; Princess Margaret Cancer Centre; Toronto Western Hospital; Hospital for Sick Children; University of British Columbia; Impact","funders":"National Cancer Institute; Canadian Institutes of Health Research; Vrije Universiteit Amsterdam","keywords":"Retinoblastoma; Biology; Gene; Cancer research; Allele; Mutation; Oncogene; Genetics; Cell cycle","score_opus":0.08976245876623609,"score_gpt":0.41596714531929263,"score_spread":0.32620468655305657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162139554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917439,0.0008008809,0.000016046022,0.006151872,0.00018576295,0.00046900424,0.000003439315,0.000022883403,0.0006061988],"genre_scores_gemma":[0.9936049,0.0011375723,0.0036515363,0.0009472224,0.00032921738,0.00007562238,0.000015909338,0.000008214658,0.00022980053],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990572,0.0002914441,0.00030949872,0.00015029826,0.000059736878,0.00013184446],"domain_scores_gemma":[0.999046,0.00036595142,0.00020735936,0.00022008253,0.00011765013,0.000042931435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046173495,0.00008120772,0.00051452854,0.000028651264,0.00007118935,0.0000031526488,0.000055738165,0.00012214364,0.00006802826],"category_scores_gemma":[0.00023254231,0.000047500416,0.000040900748,0.000036866364,0.0003945826,0.00004173738,0.000059638514,0.00014708549,0.00006963565],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005604847,0.00032163612,0.94770753,0.00004832445,0.00052083714,0.000020459818,0.001464545,7.6723944e-7,0.035632957,0.00012435201,0.001610595,0.01198752],"study_design_scores_gemma":[0.003967611,0.0012932164,0.9852494,0.00003762118,0.00027086114,0.00010913995,0.00044402556,0.00005604881,0.0035882504,0.0010250452,0.003904495,0.000054300086],"about_ca_topic_score_codex":0.000013422868,"about_ca_topic_score_gemma":0.000010092208,"teacher_disagreement_score":0.037541866,"about_ca_system_score_codex":0.000047427355,"about_ca_system_score_gemma":0.00006701385,"threshold_uncertainty_score":0.19370107},"labels":[],"label_agreement":null},{"id":"W2162327900","doi":"10.1016/s1470-2045(13)70037-8","title":"Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Refractory (planetary science); Internal medicine; Clinical endpoint; Dosing; Regimen; Intention-to-treat analysis; Surgery; Complete remission; Clinical trial; Gastroenterology; Chemotherapy","score_opus":0.05924214384470794,"score_gpt":0.3954304370345984,"score_spread":0.33618829318989046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162327900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845771,0.00006187783,0.000017957886,0.0030765906,0.000109648136,0.00767021,0.000020986798,0.000048027287,0.00441756],"genre_scores_gemma":[0.9932418,0.00010270084,0.0024838569,0.0013660127,0.00017062004,0.0007308029,0.00005989025,0.00006573927,0.0017785889],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99637663,0.0010593033,0.00074037537,0.0005150963,0.0005180181,0.0007905895],"domain_scores_gemma":[0.99675095,0.0011496674,0.0004413366,0.0010993949,0.00036158485,0.0001970762],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017183296,0.00031323778,0.0015906072,0.00022983502,0.0001259383,0.00004394217,0.00085764163,0.00016596433,0.0003005881],"category_scores_gemma":[0.0004434974,0.00017126091,0.000044384604,0.00063396385,0.00036347585,0.00029071516,0.0003822015,0.0010617258,0.00006917176],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7016032,0.024753548,0.04760155,0.00023020867,0.0021616335,0.001725074,0.015710726,0.000015062338,0.058036942,0.00010872468,0.03010306,0.1179503],"study_design_scores_gemma":[0.9228147,0.042476553,0.02449878,0.00022871615,0.0004643646,0.00008639365,0.0022540118,0.00034432072,0.0010093646,0.00008740021,0.0053895977,0.0003457913],"about_ca_topic_score_codex":0.001468355,"about_ca_topic_score_gemma":0.0006292034,"teacher_disagreement_score":0.22121154,"about_ca_system_score_codex":0.0009298897,"about_ca_system_score_gemma":0.0012409866,"threshold_uncertainty_score":0.6983817},"labels":[],"label_agreement":null},{"id":"W2162479847","doi":"10.1016/s1470-2045(05)70210-2","title":"Time to reconsider subcutaneous mastectomy for breast-cancer prevention?","year":2005,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Coalition for Research in Women's Health; Sunnybrook Health Science Centre; University of Toronto; Women's College Hospital","funders":"","keywords":"Medicine; Prophylactic Mastectomy; Breast cancer; Prophylactic Surgery; Tamoxifen; Mastectomy; Oophorectomy; Genetic testing; BRCA mutation; Gynecology; Cancer; Oncology; Lifetime risk; Internal medicine; Surgery; Hysterectomy","score_opus":0.0669606223564708,"score_gpt":0.4100729233009038,"score_spread":0.343112300944433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162479847","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000028232533,0.98932177,0.00019886046,0.0040524495,0.0005728759,0.0020945466,0.0010018334,0.00003248773,0.0026969372],"genre_scores_gemma":[0.000008376003,0.96430993,0.0028830683,0.001538898,0.005928479,0.0026876326,0.00023895077,0.00010237658,0.022302285],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998013,0.0003312432,0.00047101558,0.00060192903,0.00009698555,0.00048581956],"domain_scores_gemma":[0.99847806,0.00016205692,0.0003203239,0.00081169425,0.0001473209,0.0000805539],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00051758863,0.00035813064,0.0011970465,0.00006991071,0.00011611369,0.00002394385,0.00066892913,0.0005406736,0.001322816],"category_scores_gemma":[0.00007006854,0.0002598612,0.00040253752,0.00016016793,0.00012300792,0.000002444896,0.00020664665,0.00024481677,0.0006071488],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011911934,0.000034661523,2.4561928e-7,0.00049973815,0.00032789927,0.0000026706216,0.000018914998,0.000049831542,0.00004429746,0.000012643622,0.1287275,0.8701625],"study_design_scores_gemma":[0.00045140236,0.00035947992,0.0000017578473,0.0004258966,0.0005322066,0.00093466154,0.0000066941343,0.000005136379,0.000016025075,0.00007163097,0.9968728,0.00032232335],"about_ca_topic_score_codex":0.0000028115621,"about_ca_topic_score_gemma":0.00009048228,"teacher_disagreement_score":0.86984015,"about_ca_system_score_codex":0.00040472974,"about_ca_system_score_gemma":0.001412377,"threshold_uncertainty_score":0.99998534},"labels":[],"label_agreement":null},{"id":"W2162556132","doi":"10.1016/s1470-2045(09)70178-0","title":"Total mesometrial resection for cancer of the cervix: the future surgical procedure, or oblivion?","year":2009,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre","funders":"","keywords":"Medicine; Cervical cancer; Cervix; Surgical resection; Compartment (ship); Resection; Cancer; Stage (stratigraphy); Adjuvant therapy; Surgery; Gynecology; Internal medicine","score_opus":0.06776605957267769,"score_gpt":0.3822829355227033,"score_spread":0.31451687595002564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162556132","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0075266273,0.003658657,0.0000027935655,0.97736865,0.0049271765,0.002934154,0.00028650026,0.00004427789,0.0032511356],"genre_scores_gemma":[0.038386036,0.0055182115,0.0001406994,0.6787001,0.24644071,0.0022027006,0.00029330832,0.00012434139,0.02819393],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974154,0.0005152651,0.0005014246,0.00040127608,0.00059597165,0.0005706408],"domain_scores_gemma":[0.99686736,0.0016344833,0.00048120512,0.00073360716,0.00023097942,0.00005239134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007623695,0.00033054553,0.0012877287,0.0001238125,0.00024284513,0.000018579654,0.0006098277,0.0009656203,0.0004825492],"category_scores_gemma":[0.00035792947,0.000114045295,0.0005123552,0.001092717,0.00025013712,0.000028782602,0.00011347439,0.0018041542,0.0000076225215],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018989656,0.00017166621,0.00022848204,0.00038145148,0.00055174186,0.000062982595,0.00013486364,0.000004341278,0.000020166122,0.00012499538,0.9557836,0.023546042],"study_design_scores_gemma":[0.010550003,0.0033824206,0.004014135,0.00013236862,0.00094883423,0.0003215178,0.000050361417,0.000006379437,0.00020666416,0.0005424762,0.9797065,0.00013831361],"about_ca_topic_score_codex":0.00021400455,"about_ca_topic_score_gemma":0.00073258835,"teacher_disagreement_score":0.29866862,"about_ca_system_score_codex":0.00051124423,"about_ca_system_score_gemma":0.00085414917,"threshold_uncertainty_score":0.7838253},"labels":[],"label_agreement":null},{"id":"W2162854541","doi":"10.1016/s1470-2045(12)70508-9","title":"Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":131,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto","funders":"GlaxoSmithKline","keywords":"Lapatinib; Adjuvant; Medicine; Oncology; Breast cancer; Stage (stratigraphy); Internal medicine; Cancer; Trastuzumab; Gynecology","score_opus":0.07012591633160038,"score_gpt":0.43312643149354113,"score_spread":0.36300051516194076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162854541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9583134,0.00089959224,0.00019712056,0.016438672,0.0007040156,0.010826145,0.00071770285,0.00008856259,0.011814777],"genre_scores_gemma":[0.97340095,0.00056931196,0.00025942796,0.0026061388,0.0062675728,0.012500803,0.000025021456,0.00006587848,0.0043048672],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99697,0.0006431795,0.0004200011,0.00030043916,0.000399548,0.0012668484],"domain_scores_gemma":[0.99700576,0.0016115445,0.00025164025,0.00049090566,0.00026300858,0.00037713218],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0031772368,0.00025030988,0.0016684793,0.00007509331,0.00016571653,0.00002378903,0.00028195578,0.00016863836,0.0011341055],"category_scores_gemma":[0.00028716942,0.00013693534,0.00013803635,0.00018825127,0.00035563423,0.00008770498,0.00004865575,0.00052650156,0.00004688924],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95526165,0.000985699,0.0014646892,0.00010709206,0.00060583977,0.00003696105,0.0036695998,0.0000032830844,0.00064589526,0.00022607045,0.008144134,0.02884906],"study_design_scores_gemma":[0.8459197,0.009523089,0.0023845248,0.00007631385,0.00023568254,0.00011448001,0.00060916104,0.00008333527,0.00034138912,0.00003601993,0.14050385,0.0001724331],"about_ca_topic_score_codex":0.0005403818,"about_ca_topic_score_gemma":0.00021453135,"teacher_disagreement_score":0.13235971,"about_ca_system_score_codex":0.00084532896,"about_ca_system_score_gemma":0.00096989167,"threshold_uncertainty_score":0.999779},"labels":[],"label_agreement":null},{"id":"W2162901058","doi":"10.1016/s1470-2045(15)00051-0","title":"Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":306,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Translational Research in Oncology","funders":"Novartis Pharmaceuticals Corporation","keywords":"Everolimus; Medicine; Trastuzumab; Internal medicine; Metastatic breast cancer; Breast cancer; Oncology; Response Evaluation Criteria in Solid Tumors; Paclitaxel; Placebo; Cancer; Clinical trial; Phases of clinical research; Pathology","score_opus":0.10727531899554954,"score_gpt":0.43749981331845356,"score_spread":0.330224494322904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162901058","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97645533,0.00021121831,0.00030190306,0.008558732,0.0003009627,0.012748362,0.00053736806,0.000046446094,0.0008397009],"genre_scores_gemma":[0.99407697,0.00023058416,0.0004911964,0.00030713328,0.00054700114,0.0036311368,0.00027537998,0.00005668483,0.0003839034],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976958,0.00026163115,0.00044901963,0.0004166292,0.0005957697,0.00058117224],"domain_scores_gemma":[0.9972435,0.0006641244,0.0003778719,0.00045165574,0.0009928999,0.0002699285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057486893,0.00030498137,0.0012115391,0.00009925956,0.000113024566,0.000014335804,0.00020479965,0.00014960412,0.00007479532],"category_scores_gemma":[0.00011442007,0.00016838349,0.00010742452,0.0002730631,0.0002982128,0.00009537329,0.000036522724,0.0002469804,0.000008672566],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.956636,0.0056366078,0.0013402315,0.0001130174,0.00063471234,0.000027853079,0.0031878937,0.0005460073,0.00002694526,0.0000484198,0.00049187714,0.031310443],"study_design_scores_gemma":[0.92902184,0.062473096,0.0010240938,0.00024644166,0.0006221152,0.000034966604,0.00060532294,0.0007358648,0.00068745395,0.00004291158,0.0043245493,0.00018132658],"about_ca_topic_score_codex":0.0011013348,"about_ca_topic_score_gemma":0.0019008245,"teacher_disagreement_score":0.056836486,"about_ca_system_score_codex":0.0023579716,"about_ca_system_score_gemma":0.0019362107,"threshold_uncertainty_score":0.68664795},"labels":[],"label_agreement":null},{"id":"W2163398618","doi":"10.1016/s1470-2045(13)70007-x","title":"New policies to address the global burden of childhood cancers","year":2013,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":122,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; McMaster University","funders":"","keywords":"Medicine; Remuneration; Government (linguistics); Global health; Economic growth; Millennium Development Goals; Public health; Health care; Health policy; Childhood cancer; Public relations; Cancer; Nursing; Developing country; Political science; Business; Finance","score_opus":0.1133052629903105,"score_gpt":0.4391050741731601,"score_spread":0.32579981118284956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163398618","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000117609015,0.9295517,0.000020196425,0.044975065,0.0011173282,0.0029975444,0.0002520282,0.00008759158,0.020880908],"genre_scores_gemma":[0.00007454038,0.97962075,0.0004957512,0.008382158,0.0097643575,0.00028207485,0.000046285582,0.00006362092,0.0012704529],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962717,0.0009212658,0.0010296644,0.00047300168,0.0005579099,0.0007464017],"domain_scores_gemma":[0.99610716,0.00087590126,0.00081813376,0.0017539171,0.00012554723,0.00031936076],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011256452,0.0005357503,0.004328592,0.000085681306,0.00011607342,0.000027601252,0.0016254605,0.00044509038,0.00046852202],"category_scores_gemma":[0.00046694212,0.00027393593,0.00059470866,0.00071255775,0.00031725154,0.000033551638,0.00048613484,0.0008777556,0.0003640935],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006599781,0.000042701522,0.000021241713,0.0035176375,0.00085404934,0.000006494077,0.004150745,0.000008708419,2.5004724e-7,0.0019031247,0.22755355,0.7618755],"study_design_scores_gemma":[0.00094200065,0.0005276891,0.0003865663,0.0052260607,0.0014585275,0.00025423415,0.00052809605,4.6857772e-7,9.660253e-7,0.00030525037,0.990111,0.00025912633],"about_ca_topic_score_codex":0.03110674,"about_ca_topic_score_gemma":0.003087156,"teacher_disagreement_score":0.76255745,"about_ca_system_score_codex":0.0012374577,"about_ca_system_score_gemma":0.004749211,"threshold_uncertainty_score":0.9999713},"labels":[],"label_agreement":null},{"id":"W2163524004","doi":"10.1016/s1470-2045(08)70195-5","title":"Cardiorespiratory exercise testing in clinical oncology research: systematic review and practice recommendations","year":2008,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Cardiovascular and exercise physiology","field":"Medicine","cited_by":223,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary","funders":"Lance Armstrong Foundation","keywords":"Medicine; Cardiorespiratory fitness; Internal medicine; Oncology; MEDLINE; Clinical Practice; Test (biology); Clinical trial; Physical therapy","score_opus":0.6042289766429304,"score_gpt":0.5878831163428533,"score_spread":0.01634586030007712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163524004","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000027640083,0.97626925,0.0000020429432,0.004598412,0.0003835741,0.005957821,0.000017083228,0.000054132586,0.012714937],"genre_scores_gemma":[0.0000044867757,0.992523,0.0008482108,0.0033216148,0.0010930576,0.0019584417,0.00006526186,0.00006470849,0.00012118054],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9749192,0.020935996,0.0023229013,0.00074470794,0.00035004318,0.0007271377],"domain_scores_gemma":[0.97210425,0.02459151,0.00090702536,0.0016693398,0.0005088518,0.00021904607],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.025732879,0.00041174341,0.01394826,0.00031977674,0.00021116424,0.000012820625,0.0004991761,0.00087971217,0.000018410821],"category_scores_gemma":[0.032754414,0.00025334352,0.00093077467,0.001088613,0.0007693409,0.00007309932,0.00049843517,0.0036177437,0.00025502406],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016605889,0.00020886475,0.0000015211555,0.47584864,0.0006947398,0.0007801145,0.00009460946,1.3776626e-7,7.456749e-8,0.000038324473,0.023780834,0.49838609],"study_design_scores_gemma":[0.0007924093,0.0005104777,0.000022493852,0.22674519,0.010018669,0.010008345,0.00009950129,0.000001048728,1.5459575e-8,0.000027751863,0.7516057,0.0001684144],"about_ca_topic_score_codex":0.000107151405,"about_ca_topic_score_gemma":0.000027732944,"teacher_disagreement_score":0.72782487,"about_ca_system_score_codex":0.0007780932,"about_ca_system_score_gemma":0.0027113254,"threshold_uncertainty_score":0.9999919},"labels":[],"label_agreement":null},{"id":"W2163563579","doi":"10.1016/s1470-2045(14)70051-8","title":"Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":292,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Vemurafenib; Rash; Adverse effect; Internal medicine; Nausea; Clinical endpoint; Population; Dacarbazine; Expanded access; Interim analysis; Dermatology; Surgery; Oncology; Gastroenterology; Clinical trial; Metastatic melanoma; Chemotherapy; Cancer","score_opus":0.03517410555670822,"score_gpt":0.3139019102081614,"score_spread":0.2787278046514532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163563579","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949029,0.000030557167,0.00009614218,0.0002278753,0.00015999397,0.0011552665,0.000027816493,0.00001745484,0.0033819783],"genre_scores_gemma":[0.997593,0.000009733186,0.0008644376,0.0008209051,0.00015771808,0.00008422242,0.00026051953,0.000028358041,0.00018112652],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99773294,0.0009934418,0.00029090204,0.00043200437,0.00013350631,0.0004171795],"domain_scores_gemma":[0.9989026,0.00007119676,0.00015272923,0.0007030849,0.00007953819,0.000090846166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085654244,0.00020279638,0.00046584656,0.00003626823,0.000111620786,0.000032051605,0.00076218473,0.00008911734,0.000031361134],"category_scores_gemma":[0.00008864375,0.00012882835,0.0000143917205,0.00012836406,0.000090722475,0.000011594971,0.00028744095,0.00017429165,0.000026549375],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031731594,0.024646433,0.8312964,0.00009524908,0.0009929746,0.00015395838,0.0053033107,0.00051210116,0.03734244,0.0017391319,0.003532278,0.062654175],"study_design_scores_gemma":[0.0794867,0.03651858,0.7938864,0.000023809176,0.00021058676,0.000023482557,0.00093287823,0.0006405738,0.0027680646,0.00019153845,0.08456129,0.0007560689],"about_ca_topic_score_codex":0.0001597276,"about_ca_topic_score_gemma":0.0027679089,"teacher_disagreement_score":0.08102901,"about_ca_system_score_codex":0.000038051265,"about_ca_system_score_gemma":0.00009390497,"threshold_uncertainty_score":0.52534676},"labels":[],"label_agreement":null},{"id":"W2163925767","doi":"10.1016/s1470-2045(05)70242-4","title":"Hernias and Ewing's sarcoma family of tumours: a pooled analysis and meta-analysis","year":2005,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Hernia repair and management","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Cancer Institute; University of Queensland","keywords":"Ewing's sarcoma; Sarcoma; Medicine; Meta-analysis; Odds ratio; Umbilical hernia; Family history; Hernia; Logistic regression; Oncology; Internal medicine; Surgery; Pathology","score_opus":0.18935566732405995,"score_gpt":0.4266113620291372,"score_spread":0.23725569470507724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163925767","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003404555,0.9913533,0.00012696038,0.002034016,0.00001912417,0.0007453316,0.00007230147,0.00004102649,0.0052675176],"genre_scores_gemma":[0.0018060172,0.9937241,0.0010820829,0.0014984206,0.00021622101,0.00012348613,0.00006738172,0.000026782744,0.0014554721],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99732506,0.0008149343,0.00076043006,0.00049283827,0.00026581658,0.00034093016],"domain_scores_gemma":[0.9978978,0.0004662857,0.0005754652,0.00087088795,0.00006707819,0.00012246432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017302665,0.00038059268,0.009935925,0.0006568698,0.00005138097,0.000016907927,0.00025288513,0.00026048176,0.00033758022],"category_scores_gemma":[0.000071789094,0.00020289511,0.0022760595,0.0012643238,0.00019908485,0.000023853763,0.00023119105,0.00039912178,0.000014741508],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005894241,0.00012296191,0.00020426491,0.0026202921,0.64476603,0.000076281176,0.0001796468,0.000005304749,7.4275204e-7,0.00010951445,0.00096631463,0.3508897],"study_design_scores_gemma":[0.00029331588,0.00011300984,0.0007667681,0.000021932896,0.50979173,0.000022762051,0.00002726361,0.0000304429,9.644168e-8,0.000008723073,0.48883772,0.00008623279],"about_ca_topic_score_codex":0.0002524387,"about_ca_topic_score_gemma":0.00053225114,"teacher_disagreement_score":0.4878714,"about_ca_system_score_codex":0.00008263676,"about_ca_system_score_gemma":0.00013305897,"threshold_uncertainty_score":0.82738227},"labels":[],"label_agreement":null},{"id":"W2164327861","doi":"10.1016/s1470-2045(07)70169-9","title":"Opportunities for improving the therapeutic ratio for patients with sarcoma","year":2007,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":143,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of British Columbia; Vancouver Coastal Health Research Institute; Princess Margaret Cancer Centre; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; SickKids Foundation; University of Toronto","funders":"National Cancer Institute; Michael Smith Health Research BC; University of Toronto; Canadian Institutes of Health Research; Terry Fox Foundation; Canada Research Chairs","keywords":"Medicine; Sarcoma; Dermatofibrosarcoma protuberans; Imatinib; Synovial sarcoma; Fibromatosis; Radiation therapy; Oncology; Pazopanib; Cancer research; Imatinib mesylate; Bone Sarcoma; Bioinformatics; Pathology; Internal medicine; Cancer; Biology; Sunitinib","score_opus":0.27773844185431484,"score_gpt":0.41716269453241417,"score_spread":0.13942425267809933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164327861","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007976036,0.9887157,0.00033956362,0.0029288526,0.00029153828,0.006684264,0.00014892756,0.0000382486,0.0007731183],"genre_scores_gemma":[0.0004005734,0.9885531,0.00078503473,0.0035149402,0.001194719,0.0045447107,0.0004385387,0.00007733009,0.0004910228],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986437,0.00015859789,0.00037585583,0.00025118073,0.00014473501,0.00042592624],"domain_scores_gemma":[0.9959813,0.0028863747,0.00037944934,0.00055617106,0.00014467537,0.000052083247],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007170985,0.00030919487,0.0016203941,0.000059613914,0.00021881671,0.000022230826,0.0002635907,0.00019618301,0.00001804694],"category_scores_gemma":[0.000062628984,0.00011739075,0.00032518886,0.000077109326,0.00015998055,0.000020293752,0.00003979351,0.00022659107,0.0000052754654],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003101104,0.000338474,0.00017999506,0.0029089486,0.000567092,0.000010176055,0.00007579034,4.5718622e-8,3.593822e-8,0.0020262974,0.00219651,0.99138653],"study_design_scores_gemma":[0.003259197,0.0022095644,0.00030985015,0.0007489924,0.0036903853,0.000046460915,0.0000950795,0.000005545213,6.6118326e-7,0.000113757174,0.98938406,0.00013646518],"about_ca_topic_score_codex":0.000010368155,"about_ca_topic_score_gemma":0.00003410178,"teacher_disagreement_score":0.99125004,"about_ca_system_score_codex":0.00025323717,"about_ca_system_score_gemma":0.00050877826,"threshold_uncertainty_score":0.4787056},"labels":[],"label_agreement":null},{"id":"W2164437838","doi":"10.1016/s1470-2045(15)00222-3","title":"Expanding global access to radiotherapy","year":2015,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":1085,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Princess Margaret Cancer Centre; University of Toronto; Queen's University; University Health Network","funders":"World Health Organization","keywords":"Radiation therapy; Low and middle income countries; Middle income; Developed country; Developing country; Medicine; Business; Economic growth; Economics; Environmental health; Demographic economics; Surgery; Population","score_opus":0.20159668286846,"score_gpt":0.5736985221372256,"score_spread":0.3721018392687656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164437838","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000005622548,0.9643009,0.0015799953,0.005964874,0.0029729155,0.0018492623,0.00005554176,0.00015094221,0.02311995],"genre_scores_gemma":[8.4130545e-7,0.97089946,0.005134226,0.012682178,0.009578824,0.0003545623,0.00004650602,0.00006256875,0.0012408571],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973544,0.0006679068,0.00055924035,0.00051131914,0.00023889773,0.00066824513],"domain_scores_gemma":[0.99776226,0.0005567817,0.00036563352,0.00095769553,0.000084435385,0.00027318206],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012974929,0.0004636824,0.0042591863,0.00010657067,0.00013852853,0.000030025705,0.0011700463,0.00076234346,0.00029956567],"category_scores_gemma":[0.00016103938,0.00025404224,0.00035085934,0.0006342197,0.000313041,0.00007369484,0.00018372004,0.0008456046,0.00020820177],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003457802,0.000084045656,0.000052712367,0.0012046205,0.00041261184,0.00015785224,0.000116603485,0.0000032074986,2.8778567e-7,0.0004683402,0.13172573,0.8654282],"study_design_scores_gemma":[0.0017098772,0.0010054692,0.000018117527,0.0015282464,0.00060668355,0.002096134,0.000017784461,0.0000017873118,1.7094919e-7,0.0004440537,0.9923059,0.00026581218],"about_ca_topic_score_codex":0.0000083894865,"about_ca_topic_score_gemma":0.000020152318,"teacher_disagreement_score":0.86516243,"about_ca_system_score_codex":0.0028937315,"about_ca_system_score_gemma":0.001677346,"threshold_uncertainty_score":0.9999912},"labels":[],"label_agreement":null},{"id":"W2164777416","doi":"10.1016/s1470-2045(15)00041-8","title":"Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":152,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute","keywords":"Medicine; Docetaxel; Bevacizumab; Capecitabine; Clinical endpoint; Neoadjuvant therapy; Internal medicine; Oncology; Breast cancer; Gemcitabine; Cyclophosphamide; Taxane; Chemotherapy; Surgery; Cancer; Clinical trial; Colorectal cancer","score_opus":0.0375631773273734,"score_gpt":0.35795323757138886,"score_spread":0.32039006024401545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164777416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9807934,0.002860694,0.000041143252,0.008409084,0.0011946765,0.002595488,0.0003439007,0.000026504098,0.0037351083],"genre_scores_gemma":[0.9950592,0.00054171757,0.00013805463,0.0012283878,0.0010146984,0.0016898548,0.000052009284,0.00003448385,0.00024160207],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99711037,0.0008120251,0.00077405496,0.00047429703,0.00022838288,0.00060085807],"domain_scores_gemma":[0.9981978,0.00033120642,0.000528262,0.00058679347,0.0002158202,0.00014009513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011907333,0.00036698647,0.0021631746,0.00008665901,0.00008013962,0.000011023014,0.00048967835,0.00033228207,0.00006831649],"category_scores_gemma":[0.00025202916,0.00023293695,0.00029460274,0.00014535306,0.00042983622,0.000010344487,0.00024064754,0.00032286494,0.000012074696],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96040344,0.0012143119,0.0031739485,0.00001823457,0.0011767102,0.000064106745,0.0015620652,0.000087470544,0.0023885644,0.000045242236,0.004647237,0.025218675],"study_design_scores_gemma":[0.96634614,0.002957489,0.015525128,0.000019689418,0.00033702253,0.00007546927,0.0004890618,0.000045815617,0.00094199565,0.00015064805,0.012847019,0.00026453403],"about_ca_topic_score_codex":0.0010476909,"about_ca_topic_score_gemma":0.0023561283,"teacher_disagreement_score":0.02495414,"about_ca_system_score_codex":0.00048831163,"about_ca_system_score_gemma":0.0017732496,"threshold_uncertainty_score":0.9498893},"labels":[],"label_agreement":null},{"id":"W2165413853","doi":"10.1016/s1470-2045(12)70425-4","title":"Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies","year":2012,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":1159,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Child Health and Human Development; National Cancer Institute; Norwegian Institute of Public Health; University of California, San Francisco; University of North Carolina at Chapel Hill; Instituto Nacional De Salud Pública; Institut Gustave-Roussy; Wuhan University; Syddansk Universitet; Universidad de Costa Rica; Universitetet i Bergen; Odense Universitetshospital; Memorial Sloan-Kettering Cancer Center; Università degli Studi di Padova; Universiteit Maastricht; Imperial College London; World Health Organization; University of Southern California; University College London; Cancer Research UK; London School of Hygiene and Tropical Medicine; Loma Linda University; University of Otago; Shanghai Institute Of Planned Parenthood Research; Deutsches Krebsforschungszentrum; University of Pittsburgh; National and Kapodistrian University of Athens; Karolinska Institutet; Universidad de Chile; Institut National de la Santé et de la Recherche Médicale; University of Minnesota; Università degli Studi di Milano; University of Pennsylvania; Vanderbilt University; University of Toronto; National University of Singapore; Kaiser Permanente","keywords":"Menarche; Breast cancer; Epidemiology; Menopause; Medicine; Obstetrics; Gynecology; Cancer; Demography; Internal medicine; Sociology","score_opus":0.5872332569421976,"score_gpt":0.511669772123417,"score_spread":0.07556348481878061,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165413853","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008762612,0.97599596,0.0000067620676,0.005318762,0.0002434208,0.0011464546,0.0083746305,0.000072887626,0.00007848358],"genre_scores_gemma":[0.028081067,0.9642375,0.00015611824,0.0013865894,0.002517836,0.0032806615,0.00013594909,0.00007341895,0.00013084916],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9934278,0.0024101157,0.0012186001,0.0010015793,0.00048861076,0.0014532731],"domain_scores_gemma":[0.9939081,0.0028900218,0.0016172668,0.0009295276,0.00017744044,0.00047766283],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0041651456,0.000957547,0.013972496,0.00022464813,0.00034577533,0.00003480502,0.00053249055,0.0005386745,0.0017598838],"category_scores_gemma":[0.00012786328,0.00040600664,0.0007297953,0.0007573954,0.0009481416,0.00009355676,0.0006723873,0.0017491059,0.000015835349],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010957413,0.00023231644,0.023808667,0.0019711582,0.6010848,0.00006736276,0.00449692,0.00002300333,9.687665e-7,0.00005863612,0.0026617146,0.36449867],"study_design_scores_gemma":[0.0008772411,0.00026946937,0.038856823,0.00035686765,0.5218909,0.00017284819,0.00050174695,0.0000030338247,1.3600186e-7,0.00008182286,0.43659395,0.00039516392],"about_ca_topic_score_codex":0.008477413,"about_ca_topic_score_gemma":0.007884198,"teacher_disagreement_score":0.43393224,"about_ca_system_score_codex":0.0012219946,"about_ca_system_score_gemma":0.00079937757,"threshold_uncertainty_score":0.9998392},"labels":[],"label_agreement":null},{"id":"W2165693726","doi":"10.1016/s1470-2045(08)70179-7","title":"Cancer survival in five continents: a worldwide population-based study (CONCORD)","year":2008,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":1469,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; National Institute for Health and Care Research; Cancer Research UK","keywords":"Relative survival; Medicine; Demography; Cancer; Population; Cancer registry; Breast cancer; Prostate cancer; Colorectal cancer; Survival rate; Survival analysis; Gerontology; Oncology; Internal medicine; Environmental health","score_opus":0.18474573467920447,"score_gpt":0.42316363617726677,"score_spread":0.2384179014980623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165693726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841825,0.0003021788,0.000026103573,0.010752362,0.00037188467,0.0005945395,0.0000082643,0.00004772414,0.0037144898],"genre_scores_gemma":[0.9929742,0.00004826409,0.00015543665,0.0053918427,0.00063047145,0.00013903236,0.000013054173,0.000011956658,0.0006357429],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998609,0.00026172612,0.0002994591,0.00022928236,0.00025157322,0.00034896127],"domain_scores_gemma":[0.9991468,0.00027665248,0.00011626076,0.00030818125,0.00008782571,0.00006427979],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005831097,0.00012598665,0.000602332,0.0000717855,0.000098399076,0.0000052692485,0.00018803388,0.00006762751,0.00020181629],"category_scores_gemma":[0.00019199208,0.00008720601,0.000054080007,0.0003202873,0.000064930784,0.000046919544,0.00003901365,0.00031988492,0.000024683106],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011975156,0.00017774892,0.9930336,0.0000081529315,0.000035839665,0.0003151346,0.00077160675,0.00045231514,0.000037779413,0.000048430407,0.0023512489,0.0015706249],"study_design_scores_gemma":[0.0058532795,0.0005533186,0.9850866,0.000056340403,0.00004883837,0.000022134303,0.000768797,0.00038930555,0.000013145827,0.00005528068,0.007058591,0.00009433536],"about_ca_topic_score_codex":0.022215223,"about_ca_topic_score_gemma":0.039522666,"teacher_disagreement_score":0.017307442,"about_ca_system_score_codex":0.00039775617,"about_ca_system_score_gemma":0.00033925075,"threshold_uncertainty_score":0.9842959},"labels":[],"label_agreement":null},{"id":"W2165854883","doi":"10.1016/s1470-2045(11)70119-x","title":"Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":415,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Population Health Research Institute; McMaster University; University of Toronto; Hospital for Sick Children","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Cancer Research Institute","keywords":"Asymptomatic; Medicine; Observational study; Asymptomatic carrier; Germline mutation; Internal medicine; Prospective cohort study; Cancer; Mutation; Pediatrics; Oncology; Genetics; Biology","score_opus":0.06143933199466351,"score_gpt":0.32017331968553014,"score_spread":0.25873398769086664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165854883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948499,0.0003300357,0.00013781834,0.0016792208,0.0000778721,0.0009556257,0.000009279584,0.000047995956,0.0019122572],"genre_scores_gemma":[0.9981586,0.000018761417,0.0010435627,0.0004657987,0.00008128206,0.0001534282,0.000019425523,0.000019826284,0.00003934734],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99896646,0.00013817016,0.00020335757,0.00028991813,0.00015936626,0.00024272925],"domain_scores_gemma":[0.9994244,0.00008799621,0.000099476805,0.00024049358,0.00008950248,0.000058151087],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049957295,0.00012700674,0.00039205854,0.0000678571,0.00004492472,0.000006009438,0.000085236185,0.000065065295,0.000029058561],"category_scores_gemma":[0.00011540955,0.000089414934,0.00001961192,0.0002777246,0.0001985465,0.00003838285,0.000037076537,0.0003348265,0.000004718684],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022926973,0.00039875947,0.98117733,0.00003492729,0.00014906537,0.0012464953,0.0067968434,0.00001810293,0.006095025,0.00035427054,0.00028227924,0.0011541952],"study_design_scores_gemma":[0.006737894,0.001257224,0.98772,0.000040891355,0.00006276229,0.0013580514,0.0008985554,0.00038344262,0.000831831,0.000303788,0.0002857227,0.00011980501],"about_ca_topic_score_codex":0.00018994563,"about_ca_topic_score_gemma":0.00042962848,"teacher_disagreement_score":0.0065426934,"about_ca_system_score_codex":0.0002722466,"about_ca_system_score_gemma":0.00022258339,"threshold_uncertainty_score":0.36462352},"labels":[],"label_agreement":null},{"id":"W2166326729","doi":"10.1016/s1470-2045(12)70257-7","title":"Markers of survival and metastatic potential in childhood CNS primitive neuro-ectodermal brain tumours: an integrative genomic analysis","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":174,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Hospital for Sick Children; Alberta Children's Hospital; SickKids Foundation; University of Toronto","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; Canadian Institutes of Health Research; Brain Tumour Charity; National Cancer Institute; Cancer Research UK; Brain Tumour Research; Cancer Research Institute","keywords":"Biology; Immunohistochemistry; Internal medicine; Oncology; Lineage markers; Pathology; Bioinformatics; Gene; Medicine; Genetics; Immunology; Phenotype","score_opus":0.025722737562476183,"score_gpt":0.3212109845479067,"score_spread":0.2954882469854305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166326729","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937864,0.0004079067,0.000057936028,0.0043810103,0.000085650514,0.00037834086,0.00003892063,0.000011220991,0.00085261156],"genre_scores_gemma":[0.9986149,0.000088904344,0.0004535539,0.00060594524,0.00013366141,0.00003957787,0.000043775188,0.000011555808,0.000008096118],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984759,0.00067406666,0.00023441392,0.00018442761,0.00011022554,0.00032096598],"domain_scores_gemma":[0.9989964,0.00051153137,0.0001376177,0.00021992081,0.000033264303,0.00010131427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063001324,0.00014423231,0.0008079247,0.0001922637,0.000036125173,0.0000062075173,0.0000884976,0.000046047597,0.00006336995],"category_scores_gemma":[0.0001195883,0.00008796869,0.000102208985,0.00029650214,0.00016277851,0.00006766486,0.00005405267,0.0001860596,0.0000028546815],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014651786,0.0030196945,0.9622307,0.000028882285,0.0028853717,0.00018736592,0.0087241735,0.0001550628,0.0119070355,0.0014947833,0.0002690303,0.007632727],"study_design_scores_gemma":[0.0036095283,0.000898939,0.99028033,0.000012385752,0.001673582,0.000055425546,0.0020928637,0.0003880458,0.0007834333,0.00005971362,0.000072742274,0.000073039504],"about_ca_topic_score_codex":0.00032677254,"about_ca_topic_score_gemma":0.0008272111,"teacher_disagreement_score":0.028049607,"about_ca_system_score_codex":0.00009044138,"about_ca_system_score_gemma":0.00007397341,"threshold_uncertainty_score":0.3587259},"labels":[],"label_agreement":null},{"id":"W2166656480","doi":"10.1016/s1470-2045(09)70230-x","title":"Management of HER2-positive breast cancer in Asia: consensus statement from the Asian Oncology Summit 2009","year":2009,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Summit; Statement (logic); Breast cancer; Oncology; Internal medicine; Medicine; Political science; Cancer; Geography; Cartography; Law","score_opus":0.12434831521486477,"score_gpt":0.48312958374674864,"score_spread":0.35878126853188386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166656480","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000071899,0.88655156,0.0000044544618,0.059892792,0.0005377293,0.0041064,0.002049373,0.000035534973,0.046750236],"genre_scores_gemma":[0.00035318302,0.9945443,0.00036516532,0.0013739041,0.0012350183,0.000846244,0.00017826524,0.000070763526,0.001033147],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9933098,0.002852161,0.0014025343,0.00072434364,0.0006536251,0.0010575554],"domain_scores_gemma":[0.99606013,0.0014397745,0.0008267585,0.001315714,0.00018988657,0.0001677242],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0028273826,0.00055247266,0.004088838,0.00017714717,0.000095235555,0.00001734067,0.0011208392,0.0006281101,0.0011378052],"category_scores_gemma":[0.000051503543,0.00030647163,0.00035404472,0.00071420695,0.0007201951,0.000018205024,0.0003781211,0.0020924436,0.00014612207],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064524874,0.0004380401,0.00016012677,0.0029948938,0.0012403397,0.0017336719,0.0003764571,0.0000041889093,8.406495e-7,0.0004942429,0.05789101,0.93402094],"study_design_scores_gemma":[0.0025137893,0.0009474272,0.0057789786,0.012819355,0.0015794218,0.000206213,0.000864374,0.0000048014713,0.000002117298,0.00022452995,0.97481394,0.00024503464],"about_ca_topic_score_codex":0.00340663,"about_ca_topic_score_gemma":0.006225097,"teacher_disagreement_score":0.9337759,"about_ca_system_score_codex":0.0039589508,"about_ca_system_score_gemma":0.0028812427,"threshold_uncertainty_score":0.9999387},"labels":[],"label_agreement":null},{"id":"W2166678252","doi":"10.1016/s1470-2045(11)70286-8","title":"Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":703,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; University of Alberta","funders":"GlaxoSmithKline","keywords":"Medicine; Cervical cancer; Vaccine efficacy; Cervical intraepithelial neoplasia; Serostatus; Clinical endpoint; Surrogate endpoint; Clinical trial; Randomized controlled trial; Internal medicine; Gynecology; Vaccination; Oncology; Cancer; Immunology; Viral load; Human immunodeficiency virus (HIV)","score_opus":0.1649345748730365,"score_gpt":0.39859530325464876,"score_spread":0.23366072838161225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166678252","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98258173,0.0000948574,0.000021514186,0.0009022937,0.00030151533,0.002758748,0.00006170924,0.00002192693,0.013255697],"genre_scores_gemma":[0.9983146,0.0002004891,0.000063120366,0.00029449657,0.0008126446,0.00009000251,0.00002816026,0.000025246989,0.00017121638],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99666715,0.00082075037,0.0010381518,0.00036046834,0.0006305869,0.00048289463],"domain_scores_gemma":[0.9971521,0.0009517869,0.00046868075,0.0009687831,0.00032407744,0.00013457291],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016578049,0.00024357854,0.0021932288,0.000323137,0.00007035159,0.000005768485,0.00069955253,0.00024098282,0.011656684],"category_scores_gemma":[0.0003774727,0.00011545444,0.00058142556,0.0013858557,0.00029409575,0.000033051318,0.00027934177,0.00064359774,0.000009529968],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94973314,0.002636661,0.0259718,0.00010661139,0.003015579,0.00003523371,0.002589253,0.000018198352,0.0003282567,0.000121729674,0.00055420614,0.014889345],"study_design_scores_gemma":[0.58989376,0.0046041417,0.39811695,0.000010092506,0.0037197375,0.0000072249545,0.00032613127,0.00011919525,0.0023971582,0.00005884232,0.0006351338,0.00011162372],"about_ca_topic_score_codex":0.001235613,"about_ca_topic_score_gemma":0.0017167783,"teacher_disagreement_score":0.37214515,"about_ca_system_score_codex":0.00013882092,"about_ca_system_score_gemma":0.00042476947,"threshold_uncertainty_score":0.9892468},"labels":[],"label_agreement":null},{"id":"W2167195670","doi":"10.1016/s1470-2045(15)00027-3","title":"Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":380,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Terry Fox Foundation","keywords":"Medicine; Metformin; Gemcitabine; Erlotinib; Clinical endpoint; Pancreatic cancer; Placebo; Internal medicine; Population; Cancer; Clinical trial; Oncology; Surgery; Insulin","score_opus":0.040079280554151754,"score_gpt":0.34324842754807783,"score_spread":0.30316914699392605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167195670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96293515,0.030841233,0.000047782152,0.00014638097,0.0006119039,0.0032480953,0.00002704962,0.000015717082,0.0021267012],"genre_scores_gemma":[0.9825193,0.009246845,0.000335345,0.0012745026,0.0018014867,0.0042410544,0.00016057884,0.00004604576,0.0003747988],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981127,0.000399672,0.0004114213,0.00035681273,0.00021463205,0.00050478644],"domain_scores_gemma":[0.99887526,0.00008744549,0.00028134114,0.00047744613,0.00014587503,0.00013263151],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012098886,0.00024317527,0.001028967,0.000056588644,0.000055276898,0.000018506373,0.0003589256,0.00018236846,0.000050174487],"category_scores_gemma":[0.00016654165,0.00014537708,0.000103214705,0.00015175264,0.00012591583,0.000010352377,0.000066223816,0.00019564238,0.0000095708065],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.945672,0.00039635145,0.0004060405,0.000010331529,0.00020188442,0.000002983963,0.00016769243,0.00019073354,0.00025289116,0.00004233772,0.0015693421,0.051087465],"study_design_scores_gemma":[0.8325521,0.0025474913,0.000033837376,0.000012047379,0.00015964477,0.0000013041933,0.000070952236,0.000031317486,0.0015319586,0.000060663875,0.16281252,0.00018620424],"about_ca_topic_score_codex":0.00007086262,"about_ca_topic_score_gemma":0.00049034675,"teacher_disagreement_score":0.16124317,"about_ca_system_score_codex":0.000098997916,"about_ca_system_score_gemma":0.000538043,"threshold_uncertainty_score":0.59283054},"labels":[],"label_agreement":null},{"id":"W2167355583","doi":"10.1016/s1470-2045(11)70150-4","title":"Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Rituximab; Medicine; Bortezomib; Follicular lymphoma; Internal medicine; Clinical endpoint; Lymphoma; Oncology; Clinical trial; Surgery; Multiple myeloma","score_opus":0.05732662351427194,"score_gpt":0.3184787071032654,"score_spread":0.2611520835889935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167355583","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9821003,0.00051513326,0.000059930262,0.001465771,0.0011806709,0.0060838205,0.00015903352,0.00019121476,0.008244143],"genre_scores_gemma":[0.99285215,0.00034882966,0.0025218602,0.001566708,0.0007664821,0.0013152901,0.00029729452,0.0001064519,0.00022491215],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99495894,0.00085205864,0.0010842399,0.0010483387,0.00073331187,0.0013231253],"domain_scores_gemma":[0.99628,0.0011182881,0.00058689085,0.0012919554,0.00034129448,0.00038157066],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010642748,0.0007844082,0.003546779,0.00029398763,0.00029026714,0.000042669217,0.00045092765,0.00049340783,0.0003710532],"category_scores_gemma":[0.0005033579,0.0004644581,0.00040338945,0.00063531904,0.00060744624,0.00022804402,0.00018785924,0.00045473513,0.0004482662],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91673243,0.059008498,0.002743847,0.00006267176,0.0012893771,0.0037898624,0.0018420711,0.0000018793668,0.000013344057,0.0003510195,0.0029726925,0.011192287],"study_design_scores_gemma":[0.94974166,0.020688085,0.016196147,0.00018237712,0.0016967194,0.00017025678,0.00035865235,0.00013782225,0.00053549476,0.000089873865,0.009655544,0.0005473866],"about_ca_topic_score_codex":0.001230822,"about_ca_topic_score_gemma":0.0007687646,"teacher_disagreement_score":0.03832041,"about_ca_system_score_codex":0.001857334,"about_ca_system_score_gemma":0.0012453968,"threshold_uncertainty_score":0.9997807},"labels":[],"label_agreement":null},{"id":"W2168108459","doi":"10.1016/s1470-2045(12)70379-0","title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1387,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; BC Cancer Agency","funders":"Janssen Research and Development; UCLH Biomedical Research Centre","keywords":"Abiraterone acetate; Medicine; Placebo; Prednisone; Prostate cancer; Clinical endpoint; Interim analysis; Internal medicine; Enzalutamide; Docetaxel; Population; Oncology; Androgen deprivation therapy; Clinical trial; Cancer; Androgen receptor; Pathology","score_opus":0.18733768892073796,"score_gpt":0.45450891352613365,"score_spread":0.26717122460539566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168108459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98377466,0.0020158333,0.0000366939,0.0025252688,0.00025799108,0.010718818,0.0003864799,0.00001464593,0.0002695927],"genre_scores_gemma":[0.992819,0.0007175906,0.000120541124,0.000055391465,0.0002155359,0.00391535,0.000096358635,0.00002131474,0.0020388823],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974428,0.0006404388,0.0007126536,0.00024953968,0.0003933646,0.0005612333],"domain_scores_gemma":[0.99766606,0.0008552834,0.00055557623,0.0005318313,0.0002778269,0.00011340019],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001641254,0.00025928149,0.0021501505,0.00016138237,0.00015786044,0.000013555997,0.00019760417,0.000056607896,0.00013749774],"category_scores_gemma":[0.000052384887,0.00011732227,0.00044380027,0.00044234368,0.00025065572,0.00006796759,0.00003532356,0.000103790604,0.0000018582055],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9420376,0.0056364276,0.0147894565,0.00013018167,0.016882641,0.0000145626955,0.006387701,0.0005752128,0.010894626,0.00011251055,0.00015852197,0.002380588],"study_design_scores_gemma":[0.9551365,0.0074936403,0.008343978,0.000025561247,0.018755082,0.000005030901,0.0012187206,0.00083658943,0.006760625,0.00003229629,0.0012620721,0.00012990896],"about_ca_topic_score_codex":0.0007652444,"about_ca_topic_score_gemma":0.0014673716,"teacher_disagreement_score":0.013098926,"about_ca_system_score_codex":0.00041981207,"about_ca_system_score_gemma":0.0006199691,"threshold_uncertainty_score":0.47842634},"labels":[],"label_agreement":null},{"id":"W2168579528","doi":"10.1016/s1470-2045(13)70154-2","title":"Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":654,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"National Institutes of Health; Institute of Cancer Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; F. Hoffmann-La Roche","keywords":"Capecitabine; Medicine; Bevacizumab; Internal medicine; Irinotecan; Colorectal cancer; Hazard ratio; Clinical endpoint; Oxaliplatin; Adverse effect; Oncology; Population; Cancer; Randomized controlled trial; Chemotherapy; Surgery; Confidence interval","score_opus":0.06574882485102473,"score_gpt":0.37486971767816896,"score_spread":0.3091208928271442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168579528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9819716,0.0008351921,0.000004619072,0.0029614654,0.00057798997,0.010096133,0.00010227122,0.000072258495,0.0033784285],"genre_scores_gemma":[0.99190694,0.00038403113,0.00049284,0.00047790594,0.00039713105,0.005576536,0.0002802889,0.000055453784,0.00042886654],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99711823,0.0004929546,0.0006247403,0.00058717275,0.00036254886,0.0008143731],"domain_scores_gemma":[0.9981194,0.0005410101,0.00031472053,0.00047329182,0.00032837075,0.0002231868],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00042383076,0.0004476239,0.0019946944,0.00012128738,0.00021493525,0.000068266236,0.00041990238,0.000116293566,0.0010965796],"category_scores_gemma":[0.00018597502,0.00025288365,0.00005703213,0.0004775462,0.0002883559,0.00027468175,0.00015811955,0.0003787011,0.000040890685],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9297702,0.0054951906,0.0014344502,0.000044838973,0.0012439676,0.00014058636,0.0022275376,0.000018496801,0.00034778513,0.000023990902,0.0018914329,0.057361525],"study_design_scores_gemma":[0.92419684,0.05920648,0.011296713,0.000069311594,0.0009945101,0.000016910348,0.00037581738,0.00038259992,0.00009886155,0.0000384112,0.0030199003,0.00030366686],"about_ca_topic_score_codex":0.0066756485,"about_ca_topic_score_gemma":0.02527192,"teacher_disagreement_score":0.057057858,"about_ca_system_score_codex":0.0013150559,"about_ca_system_score_gemma":0.00071954285,"threshold_uncertainty_score":0.9999923},"labels":[],"label_agreement":null},{"id":"W2168794802","doi":"10.1016/s1470-2045(12)70285-1","title":"Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Alberta; University of British Columbia; Health Sciences Centre; Western University; University of Toronto","funders":"National Cancer Institute","keywords":"Medicine; Renal cell carcinoma; Oncology; Targeted therapy; Internal medicine; Population; Cancer","score_opus":0.04824841459005484,"score_gpt":0.2997648199313557,"score_spread":0.2515164053413008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168794802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971425,0.0001736638,0.000034569846,0.00023225987,0.000042978074,0.0015181435,0.000068977344,0.000032517382,0.0007544093],"genre_scores_gemma":[0.99813586,0.0000013884573,0.00055378675,0.00021517715,0.00011113625,0.00016141798,0.00070761313,0.00003328543,0.000080334656],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99821365,0.0005082127,0.00028827426,0.00020450486,0.00042569364,0.0003596453],"domain_scores_gemma":[0.99864465,0.00033244936,0.00028195736,0.0004242806,0.00020494529,0.00011170821],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035841146,0.00022165311,0.0007520477,0.00009484576,0.00007523508,0.000004460891,0.000104202605,0.00004555185,0.00017853643],"category_scores_gemma":[0.000015581656,0.00010946015,0.000059727663,0.00024061895,0.00009316972,0.000050214545,0.000014844892,0.00015699395,0.000010563584],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073922365,0.0037959563,0.9872893,0.00003432907,0.00033843322,0.00003613846,0.0005020988,0.00007450622,0.00028078497,0.000028675466,0.00007035564,0.00015716835],"study_design_scores_gemma":[0.02210584,0.010219232,0.96486706,0.000011431065,0.0005475517,0.0000082838815,0.00020827184,0.00002591388,0.0017431894,0.000011368632,0.00013518681,0.00011668671],"about_ca_topic_score_codex":0.00034623317,"about_ca_topic_score_gemma":0.00010989118,"teacher_disagreement_score":0.022422273,"about_ca_system_score_codex":0.00022387161,"about_ca_system_score_gemma":0.00018166049,"threshold_uncertainty_score":0.44636554},"labels":[],"label_agreement":null},{"id":"W2169012257","doi":"10.1016/s1470-2045(15)70056-2","title":"Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":220,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Medical Association; University of Alberta","funders":"Merck","keywords":"Vorinostat; Tolerability; Medicine; Internal medicine; Placebo; Population; Oncology; Adverse effect; Surgery; Histone deacetylase; Pathology","score_opus":0.03588223247442272,"score_gpt":0.360391855471871,"score_spread":0.3245096229974483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169012257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867711,0.00027875733,0.00003416266,0.0009120066,0.0002687158,0.009505991,0.000042558964,0.000029213223,0.0021575016],"genre_scores_gemma":[0.9945743,0.000098256474,0.00020204092,0.0005430324,0.000811387,0.0025102776,0.00017583916,0.00007432574,0.0010105501],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9966799,0.00088167057,0.00055626687,0.00061844586,0.000494488,0.0007692252],"domain_scores_gemma":[0.9983164,0.00015804401,0.0003318974,0.0007790076,0.00021948593,0.00019517593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015148799,0.000376136,0.0010765332,0.00014038644,0.000098111894,0.000038057275,0.0005544655,0.00026902347,0.000021181597],"category_scores_gemma":[0.00023020529,0.00023118459,0.00014754992,0.0001825684,0.00028264752,0.000011982289,0.000101719015,0.0003895996,0.000017617205],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.985701,0.0016693614,0.00049792195,0.000016366834,0.00017580226,0.000053614098,0.00043741637,0.0001487677,0.0039660777,0.000015454407,0.0034013283,0.0039168713],"study_design_scores_gemma":[0.937817,0.015080368,0.00006397434,0.000039772716,0.000037340295,0.000011337006,0.00006956158,0.00012915501,0.028612586,0.0000110824085,0.017835995,0.00029184116],"about_ca_topic_score_codex":0.000021959435,"about_ca_topic_score_gemma":0.0001739518,"teacher_disagreement_score":0.047884032,"about_ca_system_score_codex":0.00018936161,"about_ca_system_score_gemma":0.0004907615,"threshold_uncertainty_score":0.9427434},"labels":[],"label_agreement":null},{"id":"W2169429264","doi":"10.1016/s1470-2045(11)70333-3","title":"Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":154,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GDI Integrated Facility Services (Canada); Université de Montréal; McGill University Health Centre","funders":"Biotechnology and Biological Sciences Research Council; Canadian Institutes of Health Research; Fondation Cancer","keywords":"Dove; Ovarian cancer; Prospective cohort study; Medicine; Gynecology; Oncology; Cancer; Internal medicine; Political science","score_opus":0.07418821961832656,"score_gpt":0.3901691244541551,"score_spread":0.3159809048358285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169429264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9743012,0.0007363832,0.00005744057,0.01586321,0.00043701107,0.0031071203,0.0010401509,0.00002554029,0.004431905],"genre_scores_gemma":[0.99062955,0.00057447713,0.0017499708,0.0007674707,0.0010272792,0.0051424582,0.00002577755,0.00002048075,0.0000625081],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99852145,0.00021046514,0.00043033846,0.00021616239,0.00020662628,0.00041495528],"domain_scores_gemma":[0.9966796,0.0021181717,0.00044501384,0.0005667204,0.000130213,0.000060264494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010429863,0.00015537074,0.00078782707,0.000033997683,0.000072233925,0.0000071057707,0.00021148194,0.00007011735,0.00007806643],"category_scores_gemma":[0.00017433416,0.00007869298,0.00009201317,0.00018005112,0.00016395382,0.00005068846,0.00006430794,0.00015269789,0.000002619439],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002781564,0.0020480535,0.95770705,0.00013728604,0.0015784325,0.0000024760698,0.013163928,0.000006900021,0.00021529473,0.006876151,0.005947998,0.009534858],"study_design_scores_gemma":[0.011095243,0.004268272,0.9730181,0.00016299036,0.00053843093,0.000003323837,0.00061519846,0.000039159426,0.0013755824,0.0009853549,0.007815467,0.00008289755],"about_ca_topic_score_codex":0.0036719984,"about_ca_topic_score_gemma":0.00029000055,"teacher_disagreement_score":0.016328339,"about_ca_system_score_codex":0.00071751466,"about_ca_system_score_gemma":0.00041841337,"threshold_uncertainty_score":0.5550988},"labels":[],"label_agreement":null},{"id":"W2171655986","doi":"10.1016/s1470-2045(11)70117-6","title":"Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Breast cancer; Clinical trial; Protocol (science); Neoadjuvant therapy; Biopsy; Cancer; Blood collection; Oncology; Internal medicine; Medical physics; Surgery; Pathology; Alternative medicine; Emergency medicine","score_opus":0.1882908449813799,"score_gpt":0.41782961570556126,"score_spread":0.22953877072418136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171655986","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892253,0.0020660486,0.0010502756,0.0020830347,0.0010239927,0.0007847811,0.0009766731,0.0000101092955,0.0027797713],"genre_scores_gemma":[0.9845376,0.007045356,0.0047370936,0.00067124964,0.0026348387,0.00008440283,0.000060507293,0.00002083088,0.0002081108],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99903834,0.00016935368,0.00038631808,0.00020540277,0.000038333783,0.00016222722],"domain_scores_gemma":[0.99906915,0.00032742743,0.0002587522,0.00021403581,0.00008744982,0.000043179847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012816681,0.00009174459,0.00044835583,0.000016836202,0.000056484158,0.0000061667133,0.00013615112,0.00015544516,0.00007564802],"category_scores_gemma":[0.00026003533,0.00006301321,0.000080060025,0.000037849484,0.00015604515,0.0000020040477,0.00008568015,0.00007208969,0.0000016790129],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022637546,0.001016765,0.09098598,0.0001117979,0.0023009833,0.000009364992,0.0024594169,0.000048590697,0.37134382,0.0057307594,0.1263362,0.37701878],"study_design_scores_gemma":[0.016932905,0.0062099597,0.19087677,0.00009919898,0.0011099123,0.00006875461,0.00077412266,0.0011451412,0.280618,0.011108719,0.49027976,0.0007767453],"about_ca_topic_score_codex":0.0004696105,"about_ca_topic_score_gemma":0.0009132341,"teacher_disagreement_score":0.37624204,"about_ca_system_score_codex":0.000027659164,"about_ca_system_score_gemma":0.00020061272,"threshold_uncertainty_score":0.25696042},"labels":[],"label_agreement":null},{"id":"W2173158856","doi":"10.1016/s1470-2045(15)00197-7","title":"Classification of treatment-related mortality in children with cancer: a systematic assessment","year":2015,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; SickKids Foundation; London Health Sciences Centre; Pediatric Oncology Group; Hospital for Sick Children","funders":"National Institute for Health and Care Research","keywords":"Medicine; Systematic review; Cancer; Intensive care medicine; MEDLINE; Internal medicine; Political science","score_opus":0.1856014357122295,"score_gpt":0.477525115467459,"score_spread":0.2919236797552295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2173158856","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007998253,0.98312813,0.000004713871,0.000831348,0.00018927113,0.00577963,0.00014535258,0.00006003492,0.0018632945],"genre_scores_gemma":[0.0038125135,0.99353117,0.00011263328,0.00011486307,0.00033322637,0.0015885847,0.00031953983,0.00005270795,0.00013478157],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9952225,0.002158945,0.0014324993,0.00043948856,0.00040302658,0.0003435602],"domain_scores_gemma":[0.99640816,0.00040279914,0.0017308493,0.001225768,0.00012426288,0.000108174485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025872393,0.00041992922,0.0064553344,0.00016070844,0.000031864434,0.000008363668,0.00036334587,0.0003926404,0.000040939965],"category_scores_gemma":[0.0000788202,0.00021865334,0.00025901894,0.00052813283,0.00021477698,0.000032865548,0.000050315935,0.0005646043,0.000016440643],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003517728,0.0026821487,0.14067893,0.49346083,0.018219542,0.000054292916,0.004341238,0.000025543353,0.0000015664824,0.002267686,0.0015843121,0.33633214],"study_design_scores_gemma":[0.019520702,0.0073554455,0.17467724,0.39175588,0.042998806,0.0013772543,0.0008344145,0.00013106837,7.872235e-7,0.0002764627,0.3598282,0.0012437251],"about_ca_topic_score_codex":0.003008523,"about_ca_topic_score_gemma":0.002712329,"teacher_disagreement_score":0.3582439,"about_ca_system_score_codex":0.0033125002,"about_ca_system_score_gemma":0.005100072,"threshold_uncertainty_score":0.9047308},"labels":[],"label_agreement":null},{"id":"W2185514522","doi":"10.1016/s1470-2045(15)00364-2","title":"Hypofractionation for prostate cancer and PROs","year":2015,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Prostate; Oncology; Cancer; MEDLINE; Medical physics; General surgery; Internal medicine","score_opus":0.08919415730930157,"score_gpt":0.38333831448689665,"score_spread":0.29414415717759507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2185514522","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025737414,0.0046949266,0.0000073525266,0.98692507,0.0007292169,0.0025514823,0.0004107669,0.000047563954,0.002059893],"genre_scores_gemma":[0.0016337214,0.00810702,0.00059672823,0.9533906,0.016002536,0.008028222,0.0010612565,0.00006481727,0.011115106],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99900407,0.000058103135,0.00017879198,0.0002891815,0.00016033555,0.0003095202],"domain_scores_gemma":[0.9990131,0.00026176812,0.00019569363,0.00024761635,0.00023526595,0.000046506684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031114064,0.0001812222,0.00059335964,0.000045457684,0.0000757227,0.00001783333,0.00006988936,0.00035796015,0.000031489133],"category_scores_gemma":[0.00006347131,0.00010764802,0.000053889074,0.000052093594,0.00011027238,0.00003422118,0.000032643304,0.0006124493,0.000012114552],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000388882,0.00004319022,0.0012008289,0.0003049476,0.00020313858,0.000055036217,0.00023362017,0.0000013839332,0.000013553193,0.000042423693,0.9536087,0.04390429],"study_design_scores_gemma":[0.0037635854,0.00097636884,0.0015110322,0.00009708934,0.00042577396,0.00008276283,0.000019612122,0.000032517226,0.00007486887,0.0015157949,0.99138904,0.000111548434],"about_ca_topic_score_codex":0.00011310274,"about_ca_topic_score_gemma":0.000056450266,"teacher_disagreement_score":0.04379274,"about_ca_system_score_codex":0.0006897673,"about_ca_system_score_gemma":0.00060983805,"threshold_uncertainty_score":0.4389759},"labels":[],"label_agreement":null},{"id":"W2185554757","doi":"10.1016/s1470-2045(15)00166-7","title":"Response assessment after stereotactic body radiotherapy for spinal metastasis: a report from the SPIne response assessment in Neuro-Oncology (SPINO) group","year":2015,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":249,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Sunnybrook Health Science Centre; University of British Columbia; University of Toronto; University Health Network; Centre hospitalier universitaire de Québec; Toronto Western Hospital; Université Laval","funders":"Genentech; Elekta; Novartis; Sigma-Tau Pharmaceuticals; Varian Medical Systems; Spectrum Pharmaceuticals; Merck","keywords":"Medicine; Modalities; Radiosurgery; Clinical trial; Radiation oncology; Medical physics; Oncology; Radiation therapy; Radiology; Internal medicine","score_opus":0.13831410719411144,"score_gpt":0.489116862030939,"score_spread":0.35080275483682755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2185554757","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0030762486,0.9188643,0.0025182802,0.05861738,0.0020044742,0.013665293,0.00046711878,0.00014233573,0.00064458145],"genre_scores_gemma":[0.0008605669,0.9270492,0.03327396,0.02019943,0.002248085,0.014297099,0.0006561236,0.00033842883,0.0010770703],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.97493553,0.018941619,0.0024752885,0.0014156426,0.0010470576,0.001184848],"domain_scores_gemma":[0.9880589,0.005968015,0.002084711,0.0032766531,0.00024273321,0.00036895328],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.032269586,0.001042567,0.006200462,0.00047431828,0.00014783505,0.000102050246,0.0012625208,0.00051452563,0.00041364206],"category_scores_gemma":[0.0027713445,0.00059729326,0.0009513132,0.0006591121,0.00042844293,0.0001259838,0.00047262682,0.0020701522,0.000034503417],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1552495,0.0041534854,0.00041652445,0.0068055866,0.006889272,0.030911382,0.0006227309,0.000003119949,0.00009793774,0.00062811526,0.060902227,0.7333201],"study_design_scores_gemma":[0.01053205,0.0075028534,0.024468714,0.0020386789,0.0074318643,0.0013695398,0.00023157238,0.00009343934,1.4728822e-7,0.00022025453,0.94561225,0.0004986582],"about_ca_topic_score_codex":0.00009162392,"about_ca_topic_score_gemma":0.00009450563,"teacher_disagreement_score":0.88471,"about_ca_system_score_codex":0.0037737843,"about_ca_system_score_gemma":0.0068576746,"threshold_uncertainty_score":0.99964786},"labels":[],"label_agreement":null},{"id":"W2190659314","doi":"10.1016/s1470-2045(15)00480-5","title":"Limited screening with versus without 18F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Daiichi Sankyo Europe; Daiichi-Sankyo; Agence Nationale de la Recherche","keywords":"Medicine; Occult; Venous thromboembolism; Open label; Radiology; Malignancy; Randomized controlled trial; Fluorodeoxyglucose; Positron emission tomography; Internal medicine; Pathology; Thrombosis; Alternative medicine","score_opus":0.17560773969901336,"score_gpt":0.40355915050439,"score_spread":0.22795141080537665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2190659314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9604707,0.00038380185,0.00034532748,0.005695228,0.0010406052,0.021168552,0.000021438678,0.0001579465,0.010716419],"genre_scores_gemma":[0.97854805,0.0002150856,0.009646398,0.0035042074,0.0012589688,0.0062216837,0.00014854109,0.00010443368,0.0003526179],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99649775,0.0007637,0.0007548008,0.0006629402,0.0004006075,0.00092021265],"domain_scores_gemma":[0.9971449,0.00084159325,0.00047359822,0.00093666994,0.0002996338,0.00030362018],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0034648592,0.00042755474,0.0036426722,0.00015974932,0.00021027916,0.00010539255,0.0008109181,0.00005922106,0.000039989944],"category_scores_gemma":[0.0007812646,0.00026520804,0.00010842085,0.00033612398,0.000216731,0.00024163596,0.00022926486,0.00041077723,0.000020878719],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9773779,0.0069777844,0.00015439365,0.00006500732,0.0009827465,0.0006384884,0.0010517286,0.00015817009,0.0002354505,0.0022289278,0.005751418,0.0043780166],"study_design_scores_gemma":[0.95242244,0.028118445,0.0008535383,0.00014707487,0.0013918005,0.00015647418,0.0011283197,0.0020670462,0.000092513255,0.00032197166,0.012942668,0.00035772249],"about_ca_topic_score_codex":0.0005436322,"about_ca_topic_score_gemma":0.001216218,"teacher_disagreement_score":0.024955442,"about_ca_system_score_codex":0.00030565774,"about_ca_system_score_gemma":0.0007094853,"threshold_uncertainty_score":0.99998003},"labels":[],"label_agreement":null},{"id":"W2191219754","doi":"10.1016/s1470-2045(15)00465-9","title":"Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":410,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; McMaster University; Juravinski Cancer Centre","funders":"Janssen Research and Development","keywords":"Bendamustine; Medicine; Rituximab; Ibrutinib; Internal medicine; Chronic lymphocytic leukemia; Placebo; Oncology; Gastroenterology; Lymphoma; Leukemia; Pathology","score_opus":0.13129195784477976,"score_gpt":0.38503411858453745,"score_spread":0.2537421607397577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2191219754","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9788823,0.002192649,0.00022852577,0.0009928191,0.00014280963,0.015851984,0.00008431864,0.00035268796,0.0012719224],"genre_scores_gemma":[0.9916122,0.00032696532,0.0017222492,0.0005654421,0.00080281845,0.0031024124,0.0002519831,0.0002084521,0.0014074568],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9939083,0.0006927122,0.0011502715,0.0014515923,0.0008639209,0.0019332087],"domain_scores_gemma":[0.9937594,0.0023710195,0.0006060019,0.0014853227,0.00074793067,0.0010303587],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0027990588,0.0010352015,0.003595498,0.00038596964,0.0004893611,0.00018390616,0.0006850158,0.0003925034,0.000067958594],"category_scores_gemma":[0.00052255334,0.0005919786,0.00013047109,0.00093805825,0.0014375306,0.00018874396,0.00039477277,0.00045623965,0.000037904134],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.9775483,0.004635626,0.0006297493,0.0012263547,0.0016491325,0.0020010236,0.003070029,0.00025711255,0.00010172141,0.000102744714,0.0020200107,0.0067581697],"study_design_scores_gemma":[0.866789,0.04515382,0.00012858612,0.00046812362,0.00267764,0.008700125,0.0016653505,0.06949015,0.00034785626,0.00002738809,0.0038700402,0.00068196136],"about_ca_topic_score_codex":0.002445562,"about_ca_topic_score_gemma":0.0049949274,"teacher_disagreement_score":0.11075937,"about_ca_system_score_codex":0.035793945,"about_ca_system_score_gemma":0.045895047,"threshold_uncertainty_score":0.99965316},"labels":[],"label_agreement":null},{"id":"W2193716145","doi":"10.1016/s1470-2045(15)00464-7","title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":849,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; London Health Sciences Centre","funders":"Cilag; Onyx Pharmaceuticals; Amgen; Takeda Oncology; Spectrum Pharmaceuticals; Array BioPharma; Janssen Pharmaceuticals; Genentech; Celgene; Sanofi; Bristol-Myers Squibb; Chugai Pharmaceutical","keywords":"Carfilzomib; Medicine; Bortezomib; Dexamethasone; Multiple myeloma; Clinical endpoint; Internal medicine; Refractory (planetary science); Population; Tolerability; Interim analysis; Oncology; Surgery; Clinical trial; Adverse effect","score_opus":0.17996979241503736,"score_gpt":0.430217007053223,"score_spread":0.25024721463818567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2193716145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98729885,0.0005953084,0.000081875536,0.00092031056,0.00022804893,0.010107491,0.00016189637,0.00006632349,0.00053988723],"genre_scores_gemma":[0.98487,0.00019668363,0.012556703,0.00028904655,0.00024072385,0.001199077,0.00014712497,0.00006606619,0.00043457438],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968764,0.00076083466,0.00043599843,0.000698146,0.00044074815,0.0007878339],"domain_scores_gemma":[0.994006,0.003943342,0.00027305644,0.0007137231,0.00040713107,0.0006567886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001539815,0.00039321335,0.0013671273,0.000116290066,0.000272709,0.00007722509,0.00033131687,0.00017965205,0.000034688666],"category_scores_gemma":[0.0038049726,0.0002168784,0.000037551927,0.00022871282,0.00035889063,0.00020772433,0.00033244304,0.00042364356,0.00001037668],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7683562,0.0099084135,0.10727012,0.00008900758,0.0014364038,0.00032568077,0.0030035276,0.0000013070622,0.00016548904,0.000009595526,0.0016008117,0.107833415],"study_design_scores_gemma":[0.887664,0.048803218,0.047909793,0.000060037662,0.0008842844,0.000048255697,0.0027042273,0.0014238436,0.000083997315,0.00001817139,0.010111257,0.00028892187],"about_ca_topic_score_codex":0.0004368147,"about_ca_topic_score_gemma":0.0017666958,"teacher_disagreement_score":0.119307764,"about_ca_system_score_codex":0.00034654897,"about_ca_system_score_gemma":0.00053738407,"threshold_uncertainty_score":0.8844044},"labels":[],"label_agreement":null},{"id":"W2197280774","doi":"10.1016/s1470-2045(15)00250-8","title":"Fatigue and mortality: from description to action","year":2015,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Scopus; Lung cancer; Cancer; Quality of life (healthcare); Observational study; Internal medicine; Oncology; Family medicine; MEDLINE","score_opus":0.2718236066418764,"score_gpt":0.4084351184512572,"score_spread":0.1366115118093808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2197280774","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13640437,0.0006304534,0.00021595952,0.8499904,0.0029525815,0.00043890247,0.0001240506,0.00008118514,0.009162062],"genre_scores_gemma":[0.036671843,0.00025244305,0.00012111357,0.9337505,0.025588045,0.00010967733,0.00066212314,0.000035607296,0.0028086083],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99883705,0.00023033792,0.00016318998,0.00028301834,0.00023550623,0.00025086413],"domain_scores_gemma":[0.9991504,0.00010777447,0.000094533934,0.00047698902,0.00009399178,0.00007628729],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035065017,0.00016413558,0.00062980765,0.000055757806,0.000040255967,0.000021871687,0.00012296259,0.0005766111,0.00012895775],"category_scores_gemma":[0.00005593158,0.00011346912,0.00004972638,0.00008596237,0.00007401195,0.000031889667,0.00006532505,0.001080471,0.0000631338],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019097739,0.000008583306,0.0019934853,0.00006950159,0.000103340724,0.00011914024,0.0011281185,4.5421243e-7,0.00016888064,0.000010651549,0.9849881,0.0112187965],"study_design_scores_gemma":[0.0006782635,0.0003005051,0.009790735,0.00006402552,0.00031057574,0.000044744513,0.00024448882,0.0000073674455,0.000030130393,0.0009755876,0.98743415,0.00011940233],"about_ca_topic_score_codex":0.0052175415,"about_ca_topic_score_gemma":0.007953237,"teacher_disagreement_score":0.09973252,"about_ca_system_score_codex":0.00035237733,"about_ca_system_score_gemma":0.00018509361,"threshold_uncertainty_score":0.7887397},"labels":[],"label_agreement":null},{"id":"W2203645865","doi":"10.1016/s1470-2045(15)00029-7","title":"Metformin for pancreatic cancer","year":2015,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Metformin; Medicine; Pancreatic cancer; Diabetes mellitus; Internal medicine; Gemcitabine; Type 2 diabetes; Cancer; Oncology; Erlotinib; Placebo; Pharmacology; Endocrinology; Pathology","score_opus":0.06869754596636672,"score_gpt":0.3532410433157031,"score_spread":0.28454349734933637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2203645865","genre_codex":"review","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0054476378,0.7679481,0.00025926947,0.21111253,0.004340058,0.0014606796,0.0010369037,0.000050378887,0.008344423],"genre_scores_gemma":[0.00010836224,0.11067642,0.0006862171,0.8214157,0.053884998,0.0018644065,0.0013122541,0.0001067603,0.009944851],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981023,0.00024378553,0.00028994918,0.00047206038,0.00018038285,0.00071150303],"domain_scores_gemma":[0.99857265,0.00007817041,0.0002729212,0.00082115305,0.00020388242,0.00005123757],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079399225,0.0003285619,0.00087866455,0.000036826383,0.00008811278,0.00002287966,0.0007567269,0.0010500313,0.0001226259],"category_scores_gemma":[0.0001449532,0.00022103998,0.00020513147,0.00006659062,0.00018128309,0.000002393871,0.00013658442,0.0006146927,0.00003268104],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013067533,0.00001147886,0.000015078282,0.00011998213,0.0002492993,0.0000065859676,0.000042831423,0.0000053062113,0.00034820073,0.000030389949,0.9113285,0.08771166],"study_design_scores_gemma":[0.0012933627,0.00031793155,0.000005998496,0.000019853467,0.000331334,0.000016014055,0.000019508789,0.000012492781,0.0015885782,0.00089532114,0.9951937,0.0003058823],"about_ca_topic_score_codex":0.000075290656,"about_ca_topic_score_gemma":0.00016202478,"teacher_disagreement_score":0.6572717,"about_ca_system_score_codex":0.00010851216,"about_ca_system_score_gemma":0.00063982734,"threshold_uncertainty_score":0.9013749},"labels":[],"label_agreement":null},{"id":"W2209448786","doi":"10.1016/s1470-2045(15)00462-3","title":"Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":363,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; University of British Columbia; Princess Margaret Cancer Centre; Vancouver General Hospital; BC Children's Hospital; Université Laval; Hôpital de l'Enfant-Jésus; Child and Family Research Institute; BC Cancer Agency; Hôtel-Dieu de Québec; CancerCare Manitoba; Capital District Health Authority; University of Toronto; Dalhousie University; Royal Victoria Hospital; Centre hospitalier universitaire de Québec; McMaster University; Hôpital Maisonneuve-Rosemont; Juravinski Hospital","funders":"Canadian Institutes of Health Research; National Institutes of Health","keywords":"Anti-thymocyte globulin; Medicine; Transplantation; Internal medicine; Graft-versus-host disease; Clinical endpoint; Gastroenterology; Globulin; Immunosuppression; Randomized controlled trial; Surgery","score_opus":0.06285534341132204,"score_gpt":0.3304848937193195,"score_spread":0.26762955030799745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2209448786","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837565,0.0005669974,0.00086340687,0.0009872826,0.0005689919,0.010154128,0.00013037112,0.00012427427,0.002848053],"genre_scores_gemma":[0.99166787,0.00097033003,0.0053959237,0.00034574524,0.00018777585,0.0005285263,0.00076405134,0.000061068655,0.00007868914],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99542564,0.0012684015,0.0010729043,0.0007700587,0.0006678869,0.00079507823],"domain_scores_gemma":[0.99575365,0.0024377217,0.0005920053,0.0005911046,0.00031641123,0.00030910157],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010749677,0.00058090885,0.0024970286,0.00012793126,0.00014978797,0.000088316876,0.00045005773,0.0004007032,0.00009150417],"category_scores_gemma":[0.00025762894,0.00033709127,0.000095333526,0.00040701887,0.00029175341,0.00023732064,0.000051941544,0.00049215945,0.00013739044],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9715972,0.0051441626,0.01644598,0.00022998064,0.0006776799,0.0015981722,0.0029558565,0.00051785406,0.0003283033,0.000042695327,0.00015300595,0.00030912133],"study_design_scores_gemma":[0.97274053,0.0148542635,0.0051710266,0.00075267843,0.002234206,0.000077848046,0.00067391753,0.0014287477,0.0014133092,0.000024691572,0.00020442496,0.00042436732],"about_ca_topic_score_codex":0.00046565995,"about_ca_topic_score_gemma":0.00081320206,"teacher_disagreement_score":0.011274952,"about_ca_system_score_codex":0.0005653058,"about_ca_system_score_gemma":0.0008861045,"threshold_uncertainty_score":0.9999081},"labels":[],"label_agreement":null},{"id":"W2210363578","doi":"10.1016/s1470-2045(15)00381-2","title":"Postmarket policy considerations for biosimilar oncology drugs","year":2015,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":64,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Biosimilar; Context (archaeology); Authorization; Business; Marketing authorization; Competition (biology); Interchangeability; Medicine","score_opus":0.240915421907452,"score_gpt":0.4804593703366855,"score_spread":0.23954394842923352,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2210363578","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[3.5711562e-7,0.93067616,0.00007306386,0.0340464,0.0021096494,0.0018939092,0.0012371973,0.00012181561,0.029841451],"genre_scores_gemma":[0.000003760084,0.9793897,0.004257005,0.008932823,0.0018827011,0.0006093778,0.00028666185,0.00007141024,0.0045665475],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9926233,0.0044249254,0.001080475,0.0007003582,0.00006141521,0.0011094834],"domain_scores_gemma":[0.9893931,0.008473861,0.0007344183,0.0010035303,0.00029634198,0.00009870868],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.004796681,0.0006431379,0.0046013086,0.00028426433,0.00042643287,0.00003508813,0.00090988807,0.002610071,0.00084541045],"category_scores_gemma":[0.0023632296,0.00037421013,0.0007909953,0.0003980369,0.00120564,0.000040331503,0.0003844149,0.0014198485,0.0004406415],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012418903,0.00014589209,2.1041085e-7,0.0008357193,0.00075650733,0.000009183063,0.00012945234,7.448681e-8,0.000012825953,0.020572986,0.35445058,0.6229624],"study_design_scores_gemma":[0.001663195,0.0010324909,6.3057894e-7,0.00034381374,0.001974369,0.0006749211,0.00007628737,0.0000013191501,0.000014290273,0.00851815,0.9852737,0.00042681853],"about_ca_topic_score_codex":0.00003812011,"about_ca_topic_score_gemma":0.000057352372,"teacher_disagreement_score":0.63082314,"about_ca_system_score_codex":0.0007656778,"about_ca_system_score_gemma":0.0042316355,"threshold_uncertainty_score":0.99987096},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"not_applicable","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"high"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"split"},{"id":"W2219463573","doi":"10.1016/s1470-2045(15)00554-9","title":"TIME for a successful cancer vaccine in NSCLC?","year":2015,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Pembrolizumab; Nivolumab; Docetaxel; Oncology; Lung cancer; Internal medicine; Clinical trial; Chemotherapy; Clinical endpoint; Cancer; Immunotherapy; Phases of clinical research","score_opus":0.055105661926996514,"score_gpt":0.3677829949587555,"score_spread":0.312677333031759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2219463573","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00582178,0.005293079,0.0000067318833,0.97964585,0.0010450643,0.0013978537,0.00018367542,0.00006118299,0.0065447995],"genre_scores_gemma":[0.00057784293,0.0012010005,0.00015431154,0.9591843,0.018599888,0.00089670497,0.0003878122,0.00007853964,0.018919598],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99826896,0.00018501129,0.00039557568,0.00034602793,0.00020420561,0.0006002177],"domain_scores_gemma":[0.9986427,0.00038526874,0.00023566057,0.00056465244,0.0001313085,0.00004041133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009910007,0.00027226098,0.0012423524,0.00013312517,0.000040583665,0.000011674169,0.00039879195,0.0008280278,0.0008857682],"category_scores_gemma":[0.00006896558,0.00017004937,0.00017356875,0.00021374116,0.00012200652,0.000027716053,0.000053328647,0.0012285657,0.00006980103],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007467036,0.000042667732,0.00030634692,0.00021601163,0.000262603,0.0001601908,0.00024411053,0.0000013811352,0.00034504873,0.0000028046218,0.9783917,0.012560111],"study_design_scores_gemma":[0.011687802,0.0007709252,0.0007434237,0.00021826389,0.00020068858,0.000107953754,0.000022462884,0.000060684506,0.000044492717,0.00017676842,0.98576593,0.00020058679],"about_ca_topic_score_codex":0.0007450464,"about_ca_topic_score_gemma":0.0007935152,"teacher_disagreement_score":0.020461531,"about_ca_system_score_codex":0.0008902824,"about_ca_system_score_gemma":0.0009984811,"threshold_uncertainty_score":0.96985406},"labels":[],"label_agreement":null},{"id":"W2233483325","doi":"10.1016/s1470-2045(15)00515-x","title":"Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":424,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; Cancer Research UK; North Carolina GlaxoSmithKline Foundation; Novartis; Celgene; Bayer Corporation; Bristol-Myers Squibb; AstraZeneca; F. Hoffmann-La Roche; Astellas Pharma US; Pfizer; Durham University; Abbott Laboratories","keywords":"Sunitinib; Everolimus; Renal cell carcinoma; Medicine; Oncology; Open label; Internal medicine; Phases of clinical research; Clinical trial","score_opus":0.0994465300835262,"score_gpt":0.3632002380958994,"score_spread":0.2637537080123732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2233483325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9788777,0.000097670825,0.00017824392,0.0012283109,0.0005388852,0.009313815,0.00015937405,0.000037685615,0.009568274],"genre_scores_gemma":[0.99205655,0.000038764618,0.00386818,0.0005404098,0.0005466934,0.0009794561,0.00012921022,0.000072764735,0.0017679427],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99734724,0.0004915844,0.00053159264,0.00051838515,0.00034143214,0.0007697847],"domain_scores_gemma":[0.99584067,0.0024177926,0.0004390298,0.0007722495,0.0002576581,0.00027259538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070004707,0.00037270845,0.0012898508,0.0000864935,0.00017330772,0.00003348157,0.00050615304,0.0001139465,0.0003221618],"category_scores_gemma":[0.00021198238,0.0001812497,0.00012885909,0.00014671615,0.00020198232,0.00012002005,0.0001515675,0.00020989319,0.00014541521],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9768999,0.0057232287,0.0002960944,0.00009473922,0.00028285212,0.00018259189,0.000376411,0.0000012633769,0.005750544,0.000015291625,0.0049355277,0.0054415553],"study_design_scores_gemma":[0.9201706,0.054690897,0.00071592483,0.00004325932,0.0016001046,0.000010767302,0.00010907925,0.00009499256,0.011221578,0.000024448831,0.011078305,0.00024004022],"about_ca_topic_score_codex":0.000079155565,"about_ca_topic_score_gemma":0.00005600007,"teacher_disagreement_score":0.056729298,"about_ca_system_score_codex":0.00045151482,"about_ca_system_score_gemma":0.00048015456,"threshold_uncertainty_score":0.7391149},"labels":[],"label_agreement":null},{"id":"W2239698670","doi":"10.1016/s1470-2045(15)00518-5","title":"Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":283,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"Sanofi; Amgen","keywords":"Enzalutamide; Bicalutamide; Prostate cancer; Medicine; Oncology; Internal medicine; Androgen receptor; Cancer","score_opus":0.09227178365285235,"score_gpt":0.4254760336601119,"score_spread":0.3332042500072595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2239698670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859946,0.0004328025,0.000062256244,0.0047189174,0.00013019734,0.008243828,0.00017379351,0.000026413309,0.00021721612],"genre_scores_gemma":[0.996784,0.00061062834,0.00023648953,0.0001205038,0.00014052159,0.0015839171,0.000031721647,0.000028042943,0.00046422085],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984608,0.00020138109,0.00033843564,0.000306302,0.00025857025,0.0004344526],"domain_scores_gemma":[0.9978093,0.0013350528,0.00018673138,0.00033000004,0.00021232691,0.00012660747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070602505,0.00018668843,0.00080859987,0.00008199182,0.00010684311,0.000008198959,0.00013249797,0.00004555884,0.00005799303],"category_scores_gemma":[0.0001401829,0.00007633577,0.00005608948,0.00015833144,0.0003973737,0.00005865935,0.00006230402,0.00012634708,0.0000031110233],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92806435,0.0022376934,0.013496845,0.00011002139,0.0011685941,0.000019931304,0.0017606085,0.0000025377947,0.0005082309,0.000047962072,0.0002585196,0.05232469],"study_design_scores_gemma":[0.9598843,0.019421104,0.012574334,0.00012431016,0.0008997969,0.000004163893,0.00029172434,0.000013017782,0.00072158553,0.0000538328,0.005891768,0.00012006665],"about_ca_topic_score_codex":0.00006959252,"about_ca_topic_score_gemma":0.000119512646,"teacher_disagreement_score":0.052204624,"about_ca_system_score_codex":0.0002093755,"about_ca_system_score_gemma":0.00033104143,"threshold_uncertainty_score":0.31128824},"labels":[],"label_agreement":null},{"id":"W2243880855","doi":"10.1016/s1470-2045(15)00582-3","title":"Chemotherapy-induced vomiting in children: some progress, more questions","year":2016,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Nausea and vomiting management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Vomiting; Chemotherapy; Chemotherapy-induced nausea and vomiting; MEDLINE; Pediatrics; General surgery; Internal medicine; Antiemetic","score_opus":0.03916238553065602,"score_gpt":0.35188558386436525,"score_spread":0.3127231983337092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2243880855","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.077639446,0.0004171981,0.000004419601,0.9155082,0.00034615272,0.0012108396,0.000018308972,0.00017005253,0.004685366],"genre_scores_gemma":[0.03347826,0.00033426337,0.0003759259,0.92565334,0.036325794,0.0003115892,0.00013909668,0.000099072015,0.0032826706],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99786484,0.00028622104,0.00038879437,0.00043896752,0.00025435243,0.0007668037],"domain_scores_gemma":[0.998635,0.0002207912,0.00028512356,0.00076634716,0.00004839814,0.00004434716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007652203,0.0003070348,0.0009591006,0.00018568042,0.00008990654,0.000021529397,0.00041727626,0.0006901699,0.00011439802],"category_scores_gemma":[0.00008740486,0.00018319715,0.00012759557,0.00015092742,0.00022739256,0.00004427208,0.0001266464,0.0019262102,0.00013529051],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013287007,0.00008120203,0.027389007,0.00014894789,0.0002915781,0.00042814686,0.00014218416,1.4519073e-7,0.00008353948,0.00046631208,0.9360204,0.034815677],"study_design_scores_gemma":[0.0052233804,0.0003644902,0.052952804,0.0005346564,0.00017517857,0.00020111186,0.0000145484155,0.000007205867,0.00009648039,0.0009402992,0.93922436,0.00026550918],"about_ca_topic_score_codex":0.000039455528,"about_ca_topic_score_gemma":0.000010181167,"teacher_disagreement_score":0.04416119,"about_ca_system_score_codex":0.00038764966,"about_ca_system_score_gemma":0.00020868644,"threshold_uncertainty_score":0.8368532},"labels":[],"label_agreement":null},{"id":"W2261388716","doi":"10.1016/s1470-2045(16)00029-2","title":"Prophylactic dexamethasone for radiation-induced bone-pain flare – Authors' reply","year":2016,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Ottawa; Princess Margaret Cancer Centre; University of Calgary; Kingston General Hospital; Centre Hospitalier de l’Université de Montréal; Juravinski Hospital; Hôpital Maisonneuve-Rosemont; Cancer Care Ontario; Ontario Institute for Cancer Research; Grand River Hospital; Queen's University; McMaster University; Centre Hospitalier Universitaire de Sherbrooke; Sunnybrook Health Science Centre; Ottawa Hospital; CancerCare Manitoba; Health Sciences Centre","funders":"","keywords":"Medicine; Placebo; Dexamethasone; Internal medicine; Gastroenterology; Alternative medicine; Pathology","score_opus":0.07930828486497739,"score_gpt":0.36456867781310165,"score_spread":0.2852603929481243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2261388716","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007877316,0.00043488314,0.003003143,0.9850023,0.0013830672,0.0039889524,0.00014877891,0.00019394414,0.005057209],"genre_scores_gemma":[0.0029868595,0.00004996883,0.0053149518,0.94269866,0.020283028,0.0014144242,0.000605854,0.00014179714,0.026504444],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99556714,0.0016119712,0.0006434177,0.00072214205,0.0005444483,0.00091086974],"domain_scores_gemma":[0.99457943,0.0027193006,0.0007170197,0.0016333964,0.0002096423,0.00014121943],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0050622704,0.00044103252,0.0015290927,0.00022594328,0.00014899744,0.00003678294,0.0004962889,0.0006455959,0.00061964366],"category_scores_gemma":[0.0044195526,0.00026673317,0.000324087,0.00018136878,0.00015505939,0.00006201149,0.000112196416,0.0014037621,0.0002512583],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000903344,0.000072491166,0.00006436093,0.001669038,0.00034839864,0.00049264875,0.00014455886,1.834435e-7,0.0002311728,0.00016531565,0.92257935,0.07332912],"study_design_scores_gemma":[0.005419565,0.0013360851,0.0003199251,0.00012806876,0.0013850799,0.000060470746,0.000046068537,0.00011351491,0.00004790595,0.0020324867,0.9887931,0.00031773854],"about_ca_topic_score_codex":0.000023066128,"about_ca_topic_score_gemma":0.0000052967325,"teacher_disagreement_score":0.073011376,"about_ca_system_score_codex":0.00046571807,"about_ca_system_score_gemma":0.0006957468,"threshold_uncertainty_score":0.9999785},"labels":[],"label_agreement":null},{"id":"W2264000214","doi":"10.1016/s1470-2045(15)00551-3","title":"Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":565,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Puma Biotechnology","keywords":"Neratinib; Medicine; Trastuzumab; Internal medicine; Breast cancer; Oncology; Placebo; Regimen; Cancer; Metastatic breast cancer; Adjuvant therapy; Gynecology; Pathology","score_opus":0.04734896813518842,"score_gpt":0.3900358492526455,"score_spread":0.3426868811174571,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2264000214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96999234,0.00041613763,0.00009621986,0.015315072,0.00041398627,0.012587519,0.0002594172,0.0000558643,0.0008634477],"genre_scores_gemma":[0.98718923,0.00031599985,0.00013311187,0.0028059112,0.0014675491,0.0075665126,0.000032997614,0.00007094114,0.00041777093],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9959418,0.001144232,0.00066567294,0.00059343065,0.00067377905,0.0009810483],"domain_scores_gemma":[0.99716645,0.0012969549,0.0002734593,0.00064282055,0.00036524297,0.00025508276],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014908942,0.0003979465,0.0016640909,0.00018026745,0.0000987517,0.000033773107,0.00033577357,0.00023442211,0.0017216203],"category_scores_gemma":[0.000106633786,0.00018019552,0.00018369165,0.000253747,0.00041360746,0.00009667927,0.00004490789,0.0005783624,0.000056618053],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90583587,0.0028865994,0.013377731,0.000025568155,0.00034868772,0.00013164995,0.0006484192,0.000025587895,0.00028856227,0.0000062894715,0.00089527835,0.07552978],"study_design_scores_gemma":[0.96825814,0.008802828,0.018161023,0.00033243877,0.00016377025,0.000013295726,0.000047666425,0.00022325478,0.00048289483,0.0000072509065,0.0032524853,0.00025492458],"about_ca_topic_score_codex":0.00047519946,"about_ca_topic_score_gemma":0.0015867901,"teacher_disagreement_score":0.07527485,"about_ca_system_score_codex":0.0010288445,"about_ca_system_score_gemma":0.001560501,"threshold_uncertainty_score":0.9991909},"labels":[],"label_agreement":null},{"id":"W2267333092","doi":"10.1016/s1470-2045(15)00386-1","title":"Rare cancers: a sea of opportunity","year":2016,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Queen's University; BC Cancer Agency","funders":"Institute of Cancer Research; Institut National Du Cancer","keywords":"Cancer; Histogenesis; Context (archaeology); Pathognomonic; Medicine; Bioinformatics; Biology; Oncology; Pathology; Internal medicine; Disease","score_opus":0.23402373160054568,"score_gpt":0.44630697736033387,"score_spread":0.21228324575978819,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2267333092","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000033460088,0.97711223,9.569237e-7,0.0024738163,0.00025524912,0.00078392954,0.00023197077,0.000027040716,0.019081365],"genre_scores_gemma":[0.00009369517,0.9972458,0.00007614049,0.0007088915,0.00092178176,0.00034617013,0.0000763134,0.000027472455,0.0005037231],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986647,0.0003359147,0.00038604302,0.00020886179,0.0001318813,0.00027263633],"domain_scores_gemma":[0.9979928,0.0007286714,0.00040149578,0.0006999635,0.0000609141,0.00011614382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003827581,0.00022582863,0.002816768,0.00006125626,0.000033300355,0.000002502208,0.0002357474,0.00025278502,0.0008002518],"category_scores_gemma":[0.00013141075,0.00009644429,0.00037725375,0.00011406371,0.00015907384,0.000011286329,0.00008695809,0.0002597187,0.00012796144],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004193336,0.00014697656,0.00026216672,0.004151119,0.00047313346,0.00020959234,0.000028865079,7.3915007e-9,1.0400547e-7,0.00037950248,0.026455984,0.9678506],"study_design_scores_gemma":[0.0010717777,0.0003496917,0.000133463,0.007549329,0.001594788,0.0003217591,0.000009664433,1.1593291e-7,0.0000015409834,0.000071741786,0.98880863,0.00008749898],"about_ca_topic_score_codex":0.00010542628,"about_ca_topic_score_gemma":0.000056242596,"teacher_disagreement_score":0.9677631,"about_ca_system_score_codex":0.0006303084,"about_ca_system_score_gemma":0.0019613102,"threshold_uncertainty_score":0.87621963},"labels":[],"label_agreement":null},{"id":"W2280894559","doi":"10.1016/s1470-2045(15)00560-4","title":"Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":741,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Cleveland Clinic; Memorial Sloan-Kettering Cancer Center","keywords":"Medicine; Oncology; Cancer; Cohort; Stage (stratigraphy); Internal medicine; Hazard ratio; Proportional hazards model; Confidence interval","score_opus":0.04022950691569897,"score_gpt":0.3569615610435162,"score_spread":0.3167320541278172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2280894559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9796467,0.0006984505,0.00033967342,0.01419742,0.0011348894,0.0033669642,0.0002449293,0.00003330814,0.0003376865],"genre_scores_gemma":[0.99537516,0.00042137678,0.00035210417,0.00056781666,0.00065506215,0.002153164,0.00003255734,0.000022196784,0.0004205494],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986734,0.00012191155,0.00040528105,0.00027860331,0.00022247023,0.00029837008],"domain_scores_gemma":[0.99858695,0.00060839596,0.00028709366,0.00016063167,0.00031334834,0.000043583997],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00100495,0.00015222709,0.00061914447,0.000034101406,0.00025016582,0.000014593794,0.00013621351,0.00005950989,0.000027575514],"category_scores_gemma":[0.00007113619,0.000077182405,0.000032668006,0.000117200325,0.00007628357,0.000056913912,0.00005371902,0.00009210864,9.912923e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014999884,0.0006977879,0.7148395,0.0008088139,0.0040193917,0.000011751802,0.026302552,0.00034133505,0.0233438,0.0015244992,0.06145362,0.15165702],"study_design_scores_gemma":[0.110968344,0.006924608,0.56180173,0.0034492582,0.0032990125,0.000025086492,0.03999522,0.01050024,0.06270025,0.00012409834,0.199028,0.0011841542],"about_ca_topic_score_codex":0.00019211999,"about_ca_topic_score_gemma":0.0006373878,"teacher_disagreement_score":0.15303782,"about_ca_system_score_codex":0.0008190399,"about_ca_system_score_gemma":0.00041161815,"threshold_uncertainty_score":0.3147407},"labels":[],"label_agreement":null},{"id":"W2289763126","doi":"10.1016/s1470-2045(16)00023-1","title":"DCIS and invasive interval breast cancer","year":2016,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital","funders":"","keywords":"Medicine; Breast cancer; Ductal carcinoma; Cancer; Incidence (geometry); Oncology; Population; Retrospective cohort study; Cohort; Cancer registry; Internal medicine; Gynecology","score_opus":0.13369203461183,"score_gpt":0.39356853282843784,"score_spread":0.25987649821660785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2289763126","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0062999977,0.0016495248,0.000014013836,0.97676784,0.00074560597,0.00030064164,0.00024294895,0.00005167196,0.013927731],"genre_scores_gemma":[0.009573889,0.0027343305,0.00009781201,0.95387894,0.02933579,0.00010335102,0.000032610256,0.000033788692,0.004209503],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984397,0.00017595665,0.00023603007,0.000354627,0.00024317375,0.0005504908],"domain_scores_gemma":[0.9987952,0.0003689575,0.00019132254,0.0004476975,0.00012717953,0.0000696138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003481957,0.00024162316,0.00091335614,0.00005678939,0.000076558434,0.000018569946,0.00031335303,0.00059563125,0.00086421164],"category_scores_gemma":[0.00006763573,0.00012712093,0.00010001962,0.0000745332,0.00036422463,0.000050496143,0.00019111001,0.0013892987,0.000113616974],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003981278,0.00000418257,0.0036514283,0.000132629,0.00016366741,0.0008366855,0.00016947094,7.886449e-8,0.00010809609,0.0000354603,0.961999,0.032501157],"study_design_scores_gemma":[0.0013730384,0.00030222346,0.0074376217,0.0007114709,0.0002536945,0.0023451282,0.000049883114,0.0000017298669,0.00003189985,0.00043703878,0.98689353,0.00016270799],"about_ca_topic_score_codex":0.00061424245,"about_ca_topic_score_gemma":0.0004292988,"teacher_disagreement_score":0.03233845,"about_ca_system_score_codex":0.00038974945,"about_ca_system_score_gemma":0.00049190555,"threshold_uncertainty_score":0.94625115},"labels":[],"label_agreement":null},{"id":"W2290950904","doi":"10.1016/s1470-2045(15)00613-0","title":"Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1822,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Calgary","funders":"University of California, Los Angeles; Novartis; Daiichi-Sankyo; Pfizer; AstraZeneca; Eli Lilly and Company; GlaxoSmithKline; U.S. Department of Defense","keywords":"Fulvestrant; Palbociclib; Metastatic breast cancer; Medicine; Placebo; Internal medicine; Oncology; Gynecology; Cancer; Breast cancer; Estrogen receptor","score_opus":0.12359904773172471,"score_gpt":0.4149209742192354,"score_spread":0.2913219264875107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2290950904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96481967,0.0021749714,0.0005811652,0.007998017,0.0006042545,0.022109782,0.0015490246,0.0000544999,0.000108610315],"genre_scores_gemma":[0.9884078,0.0026320722,0.00058915414,0.00017176497,0.00052436313,0.0073074047,0.000062323445,0.00005784004,0.0002472751],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962571,0.0008829798,0.0010010242,0.0005819036,0.0005457136,0.00073124445],"domain_scores_gemma":[0.9924019,0.004889149,0.0013844419,0.00080094807,0.0003689285,0.0001546299],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00059271476,0.0005879899,0.0035984502,0.00020126272,0.00016044178,0.000013609078,0.00041842132,0.00012750113,0.00020939013],"category_scores_gemma":[0.00012076191,0.0002531136,0.0011333455,0.00051390927,0.0008510839,0.00009407445,0.000030168732,0.00016547665,0.0000023859664],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92660457,0.0028472736,0.0000849642,0.000044828284,0.018238919,0.000019354926,0.0023965596,0.00054804207,0.009399512,0.00011149618,0.000034896064,0.03966961],"study_design_scores_gemma":[0.9468176,0.014563386,0.0010726503,0.00014022375,0.008859046,0.00002253284,0.00046385848,0.0006455318,0.02638,0.000036872534,0.0007420401,0.00025628845],"about_ca_topic_score_codex":0.00039338408,"about_ca_topic_score_gemma":0.0005001402,"teacher_disagreement_score":0.03941332,"about_ca_system_score_codex":0.0010323165,"about_ca_system_score_gemma":0.0009422986,"threshold_uncertainty_score":0.99999213},"labels":[],"label_agreement":null},{"id":"W2295354328","doi":"10.1016/s1470-2045(15)00614-2","title":"Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":470,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Ignyta; National Institutes of Health; University of Washington; Astex Pharmaceuticals; Eli Lilly and Company; Novartis Institutes for BioMedical Research; Ariad Pharmaceuticals; Genentech; Pfizer; Novartis Pharmaceuticals Corporation; Chugai Pharmaceutical; Servier; Universität Heidelberg","keywords":"Ceritinib; Crizotinib; Medicine; ALK inhibitor; Internal medicine; Anaplastic lymphoma kinase; Lung cancer; Oncology; Tyrosine-kinase inhibitor; Clinical trial; Cancer","score_opus":0.04046967010096525,"score_gpt":0.3862219429664884,"score_spread":0.3457522728655231,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2295354328","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98305506,0.00013232476,0.000020019652,0.009349887,0.0001864919,0.002628687,0.0012266496,0.000012432124,0.0033884726],"genre_scores_gemma":[0.99806935,0.00033719838,0.00028474999,0.00054506684,0.00020394831,0.00015435954,0.00012121413,0.000015937563,0.0002681925],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9988525,0.00023918136,0.00026723318,0.00026780125,0.00012356453,0.00024972428],"domain_scores_gemma":[0.9986581,0.0005590025,0.00024583173,0.0003847432,0.00009096927,0.00006132015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003047984,0.00013821808,0.0005039352,0.000023117755,0.000087709974,0.0000104296305,0.00019493952,0.000080041566,0.00008471293],"category_scores_gemma":[0.000066880035,0.000058256595,0.000017878949,0.0001232845,0.00014519379,0.00007634992,0.00008798479,0.00015023045,0.0000024059811],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78882253,0.006001228,0.09214197,0.00003862979,0.00080992223,0.000027690068,0.004775498,0.000003923829,0.0051531484,0.000023640887,0.0060761306,0.09612568],"study_design_scores_gemma":[0.74846417,0.002224434,0.23609027,0.00022494828,0.0005978648,9.2322415e-7,0.00013595629,0.000073960335,0.0010075009,0.000008897867,0.011059755,0.00011132406],"about_ca_topic_score_codex":0.004069437,"about_ca_topic_score_gemma":0.0037489969,"teacher_disagreement_score":0.1439483,"about_ca_system_score_codex":0.00022599295,"about_ca_system_score_gemma":0.00034422954,"threshold_uncertainty_score":0.61517984},"labels":[],"label_agreement":null},{"id":"W2295672901","doi":"10.1016/s1470-2045(15)00581-1","title":"Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":369,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; University of Toronto; University of Calgary; McGill University; Centre Hospitalier Universitaire Sainte-Justine; Hospital for Sick Children","funders":"National Institute of Neurological Disorders and Stroke; National Institutes of Health; Deutsche Kinderkrebsstiftung; Hospital for Sick Children; Brain Tumour Foundation of Canada; St. Baldrick's Foundation; Dr. Mildred Scheel Stiftung für Krebsforschung; National Cancer Institute; University of Toronto; Canadian Institutes of Health Research; Pediatric Brain Tumor Foundation; Terry Fox Research Institute; Magyar Tudományos Akadémia; Alex's Lemonade Stand Foundation for Childhood Cancer; Merck; CURE Childhood Cancer; American Cancer Society","keywords":"Medulloblastoma; Medicine; Subgroup analysis; Radiation therapy; Oncology; Chemoradiotherapy; Internal medicine; Retrospective cohort study; Surgery; Confidence interval; Pathology","score_opus":0.02245403311570908,"score_gpt":0.34877826364288894,"score_spread":0.32632423052717985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2295672901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932657,0.00043040083,0.002783622,0.0026951758,0.00006421571,0.0006364192,0.000025693671,0.000013310661,0.00008545549],"genre_scores_gemma":[0.99812186,0.00009268427,0.0012877379,0.00019122886,0.0000655932,0.00021789111,0.000006040847,0.000011904646,0.00000509019],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99880123,0.00021547328,0.0003973892,0.00024882806,0.00014616452,0.0001909208],"domain_scores_gemma":[0.9986127,0.00052509253,0.00024490608,0.00029008088,0.00027944858,0.000047742356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008370183,0.000109221815,0.0007643961,0.00012978348,0.000020837162,0.0000035168607,0.000068848545,0.000116055664,0.000019499543],"category_scores_gemma":[0.00080877997,0.000055453213,0.00022033446,0.00032677373,0.00021274204,0.00002215008,0.0000459121,0.00008757432,9.804216e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028219472,0.00055622583,0.9118922,0.00006274429,0.002307808,0.00006494203,0.00011994376,0.0000057468596,0.07452737,0.0022828428,0.00006597194,0.005292278],"study_design_scores_gemma":[0.0050909664,0.0033853948,0.9348959,0.00014884214,0.0031961203,0.000020837188,0.00006982568,0.00042471028,0.051140152,0.0013533012,0.0002024563,0.00007149437],"about_ca_topic_score_codex":0.000052381518,"about_ca_topic_score_gemma":0.00008166959,"teacher_disagreement_score":0.02338722,"about_ca_system_score_codex":0.00008529337,"about_ca_system_score_gemma":0.000060808503,"threshold_uncertainty_score":0.22613163},"labels":[],"label_agreement":null},{"id":"W2312262713","doi":"10.1016/s1470-2045(16)00010-3","title":"Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":478,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; Mount Sinai Hospital","funders":"","keywords":"Nomogram; Soft tissue; Medicine; Resection; Retrospective cohort study; Surgical resection; Overall survival; Soft tissue sarcoma; Radiology; Pathology; Surgery; Oncology","score_opus":0.02897161080700858,"score_gpt":0.32198575573604044,"score_spread":0.2930141449290319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2312262713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982623,0.0005201151,0.00028775234,0.0003378752,0.000039430517,0.00034078577,0.00015765012,0.0000028999161,0.000051175128],"genre_scores_gemma":[0.9991736,0.00018058011,0.00054362445,0.000010799831,0.000022922439,0.000052273557,0.0000067339943,0.0000032620592,0.000006215961],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988455,0.00023951469,0.00039646708,0.00017320245,0.00022166553,0.00012363419],"domain_scores_gemma":[0.9989654,0.00043855983,0.00023745249,0.00021402887,0.00010843837,0.000036163077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055436447,0.00009177525,0.0006320263,0.00009742114,0.0000143988045,0.0000018291486,0.00006879646,0.000038266528,0.000030529696],"category_scores_gemma":[0.00010678306,0.00004387721,0.000055794077,0.00025239235,0.00023234656,0.000027088885,0.000075110256,0.000052281033,1.12186456e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034299367,0.00040722918,0.9816068,0.00008336956,0.00028804006,0.000014212112,0.0015541353,0.000008422261,0.0019955768,0.0003050752,0.000007394123,0.010299851],"study_design_scores_gemma":[0.004917305,0.0007608622,0.95471466,0.0004354979,0.0003398763,0.000011965118,0.00020875543,0.000028535247,0.03819001,0.00017635002,0.0001692198,0.000046946818],"about_ca_topic_score_codex":0.00042542414,"about_ca_topic_score_gemma":0.0012040009,"teacher_disagreement_score":0.036194436,"about_ca_system_score_codex":0.00010373111,"about_ca_system_score_gemma":0.00006155391,"threshold_uncertainty_score":0.17892608},"labels":[],"label_agreement":null},{"id":"W2319418820","doi":"10.1016/s1470-2045(16)00117-0","title":"Targeted therapy in BRAF-mutated lung adenocarcinoma","year":2016,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Adenocarcinoma; Targeted therapy; Cancer research; Lung; Oncology; Medicine; Adenocarcinoma of the lung; Internal medicine; Cancer","score_opus":0.031531213826955166,"score_gpt":0.2888015405649193,"score_spread":0.25727032673796413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2319418820","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15270494,0.010921586,0.000112379916,0.81708837,0.0018685957,0.0010303363,0.00024740043,0.00007075442,0.01595561],"genre_scores_gemma":[0.13101515,0.0027956697,0.00013792711,0.8321052,0.024909707,0.00027112602,0.0014963149,0.00012807717,0.007140826],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974941,0.0006776527,0.0003377899,0.00056926924,0.00014374004,0.000777453],"domain_scores_gemma":[0.9986754,0.000099501995,0.00021776425,0.0009037691,0.000061122315,0.00004242963],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00048055852,0.00035499423,0.00065286236,0.00008265548,0.000066103064,0.000016736574,0.0008498153,0.001410364,0.00019366656],"category_scores_gemma":[0.00005391529,0.00021623983,0.0001400289,0.000098014614,0.00018638281,0.0000024306528,0.00018117845,0.0009493719,0.000100001904],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002689546,0.000019927647,0.0019803063,0.000029307574,0.00011023301,0.00038418785,0.00007383219,8.341801e-7,0.056343332,0.000022963884,0.9364287,0.0043374104],"study_design_scores_gemma":[0.0021929112,0.00066412805,0.0026435968,0.000024436153,0.00001804817,0.00012102446,0.0000082946435,0.000006726152,0.009699738,0.00019748358,0.984104,0.00031964504],"about_ca_topic_score_codex":0.00005247441,"about_ca_topic_score_gemma":0.00007240902,"teacher_disagreement_score":0.04767526,"about_ca_system_score_codex":0.00008254322,"about_ca_system_score_gemma":0.0003086884,"threshold_uncertainty_score":0.99988604},"labels":[],"label_agreement":null},{"id":"W2326502592","doi":"10.1016/s1470-2045(15)00539-2","title":"Paediatric cancer stage in population-based cancer registries: the Toronto consensus principles and guidelines","year":2016,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Pediatric Oncology Group; Princess Margaret Cancer Centre; Hospital for Sick Children; University of Toronto","funders":"National Cancer Institute; Medical Research Council; Hospital for Sick Children; World Health Organization","keywords":"Medicine; Stage (stratigraphy); Population; Cancer; Incidence (geometry); Delphi method; Family medicine; Environmental health; Internal medicine; Computer science","score_opus":0.222017052685827,"score_gpt":0.47752872812394814,"score_spread":0.25551167543812114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2326502592","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005728277,0.9423439,0.000004831733,0.052872293,0.00096208206,0.001795658,0.0006045352,0.000071339404,0.0007725268],"genre_scores_gemma":[0.00010354063,0.9861707,0.00015234009,0.005577215,0.004919471,0.0008431478,0.000063503016,0.00006876513,0.002101331],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99584407,0.0012353335,0.0013774519,0.0005821842,0.00039383463,0.0005671544],"domain_scores_gemma":[0.99410766,0.003355155,0.0011359251,0.001087995,0.00018924288,0.0001240451],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002648701,0.00049021485,0.00296304,0.00008268126,0.00014739577,0.000025369409,0.0004972943,0.00044910747,0.0004027113],"category_scores_gemma":[0.0013963622,0.00023276586,0.00024639987,0.00026936235,0.0003306235,0.000032328597,0.00015974785,0.0005894735,0.000010649431],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003230776,0.00006967903,0.010145895,0.011532717,0.00037925033,0.000042672717,0.000615664,0.000018782022,2.4472263e-7,0.0008436145,0.034591887,0.9414365],"study_design_scores_gemma":[0.0017291635,0.00010435924,0.0032151036,0.008794793,0.00063899794,0.000028463099,0.00012800307,0.000017729828,1.837983e-7,0.00004157531,0.9850177,0.00028388342],"about_ca_topic_score_codex":0.046053465,"about_ca_topic_score_gemma":0.16651863,"teacher_disagreement_score":0.95042586,"about_ca_system_score_codex":0.0018092522,"about_ca_system_score_gemma":0.0035595566,"threshold_uncertainty_score":0.96029896},"labels":[],"label_agreement":null},{"id":"W2329267790","doi":"10.1016/s1470-2045(16)00037-1","title":"Wernicke-Korsakoff syndrome in patients with cancer: a systematic review","year":2016,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Alcoholism and Thiamine Deficiency","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Disease; Pediatrics; Ataxia; Cancer; Psychiatry; Intensive care medicine; Internal medicine","score_opus":0.05493484664456953,"score_gpt":0.3811513260763749,"score_spread":0.3262164794318054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2329267790","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000547992,0.9900197,0.0000016253163,0.0010849528,0.00029983642,0.005668973,0.000091504924,0.000046728506,0.0027319177],"genre_scores_gemma":[0.000058376067,0.99582285,0.000013311311,0.0011706296,0.00019439876,0.0014862887,0.00007615336,0.000060106544,0.0011179011],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9968559,0.00080514123,0.0010186713,0.00042116983,0.00035351963,0.00054558297],"domain_scores_gemma":[0.9972669,0.00049163203,0.00091239874,0.0011496136,0.000088601904,0.00009084506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012702097,0.0004538698,0.0076659666,0.00014100726,0.000045745208,0.000006992443,0.0005779,0.00028205916,0.00019191901],"category_scores_gemma":[0.00030608408,0.00017274877,0.00026570578,0.0004679613,0.00015508514,0.000037822647,0.00011623569,0.00063088717,0.000536278],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000044454548,0.000110048204,0.00015906223,0.94840485,0.00023012683,0.00016500952,0.000022502547,9.575822e-9,2.2744813e-9,0.0001483743,0.0015505139,0.049165048],"study_design_scores_gemma":[0.0012280323,0.0004985829,0.00013456897,0.5546768,0.0032370007,0.0003671511,0.000001591876,8.3325475e-8,3.3043897e-9,0.0000055203654,0.43970007,0.00015061615],"about_ca_topic_score_codex":0.000032580156,"about_ca_topic_score_gemma":0.000025261374,"teacher_disagreement_score":0.43814954,"about_ca_system_score_codex":0.0005689945,"about_ca_system_score_gemma":0.00075372256,"threshold_uncertainty_score":0.70444906},"labels":[],"label_agreement":null},{"id":"W2332223853","doi":"10.1016/s1470-2045(15)00545-8","title":"Paediatric extracranial germ-cell tumours","year":2016,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto; SickKids Foundation","funders":"Sparks; Cancer Research UK; Teenage Cancer Trust","keywords":"Germ cell; Medicine; Germ cell tumors; Risk stratification; Disease; Clinical trial; Oncology; Pediatrics; Pathology; Intensive care medicine; Internal medicine; Chemotherapy; Biology","score_opus":0.07173120171155324,"score_gpt":0.396332931647973,"score_spread":0.3246017299364198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2332223853","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000383583,0.98932654,0.0000103934535,0.00076485216,0.0005745351,0.0009517334,0.00011590073,0.00009098379,0.008126703],"genre_scores_gemma":[0.0002245422,0.9929431,0.0001647787,0.00035601476,0.0041603716,0.00018404095,0.00008103239,0.00005967517,0.0018264571],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99827564,0.00037206654,0.0003715587,0.00033901547,0.00018036335,0.00046135182],"domain_scores_gemma":[0.9980539,0.00064630667,0.00042021074,0.00066630024,0.000038299917,0.00017498975],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00029031924,0.00034415952,0.0021901205,0.000080638754,0.00006998669,0.000010637206,0.0002830353,0.000312623,0.0003792489],"category_scores_gemma":[0.00013423579,0.00015198509,0.00059939164,0.00015978773,0.000106835825,0.00001632893,0.00009208579,0.0003665836,0.0019500912],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000053478358,0.00028815304,0.00021247363,0.004113256,0.00014872164,0.00089821627,0.000010887685,1.6392164e-8,1.7399704e-7,0.0001057192,0.0073718634,0.98679703],"study_design_scores_gemma":[0.0021199475,0.0003766366,0.00046216664,0.0016811916,0.0048824754,0.00071450695,0.0000024522978,4.0455856e-7,9.808294e-8,0.000115900475,0.9894851,0.00015915839],"about_ca_topic_score_codex":0.0000090271515,"about_ca_topic_score_gemma":0.000002582815,"teacher_disagreement_score":0.9866379,"about_ca_system_score_codex":0.00028830537,"about_ca_system_score_gemma":0.0010041841,"threshold_uncertainty_score":0.998827},"labels":[],"label_agreement":null},{"id":"W2339311613","doi":"10.1016/s1470-2045(16)30033-x","title":"Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1175,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Ottawa Hospital; McGill University","funders":"European Society for Medical Oncology; Boehringer Ingelheim","keywords":"Afatinib; Gefitinib; Medicine; Internal medicine; Lung cancer; Oncology; Population; Clinical endpoint; Randomized controlled trial; Epidermal growth factor receptor; Cancer","score_opus":0.04042620639566981,"score_gpt":0.40655069506489666,"score_spread":0.36612448866922687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2339311613","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9650932,0.0005435644,0.00024605944,0.00524533,0.00069729635,0.014685846,0.00041830647,0.000035044162,0.013035372],"genre_scores_gemma":[0.9889732,0.0005944843,0.0005554717,0.00046228236,0.00062506594,0.006309278,0.0002389847,0.000043205167,0.002198035],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982007,0.00023140771,0.00055297033,0.0003777637,0.000232213,0.0004049102],"domain_scores_gemma":[0.99680245,0.001705522,0.0005971078,0.00040592597,0.0003468392,0.00014214564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023528114,0.0003075065,0.0014247695,0.00007388002,0.00019339132,0.00002012219,0.00020236282,0.00011795278,0.00049346604],"category_scores_gemma":[0.00012265531,0.00014154638,0.00011598271,0.00016150187,0.00015847546,0.000087053966,0.0000411895,0.00008712494,0.000015821272],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9712113,0.007917766,0.0012832746,0.000046386616,0.003003733,0.000073044335,0.0023946518,0.000027923425,0.00023791914,0.000111848705,0.00084760843,0.01284453],"study_design_scores_gemma":[0.9616703,0.028687034,0.0007298147,0.00016028043,0.0045104614,0.000004461681,0.00011722901,0.00024945792,0.0010163462,0.000019480985,0.0026634878,0.00017164451],"about_ca_topic_score_codex":0.000580292,"about_ca_topic_score_gemma":0.0004465189,"teacher_disagreement_score":0.02388001,"about_ca_system_score_codex":0.0009452555,"about_ca_system_score_gemma":0.0011203759,"threshold_uncertainty_score":0.57720935},"labels":[],"label_agreement":null},{"id":"W2339943063","doi":"10.1016/s1470-2045(16)00080-2","title":"Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":259,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; Princess Margaret Cancer Centre","funders":"Ariad Pharmaceuticals","keywords":"Ponatinib; Medicine; Imatinib; Internal medicine; Myeloid leukemia; Imatinib mesylate; Oncology; Clinical trial; Clinical endpoint; Nilotinib","score_opus":0.14917091176216268,"score_gpt":0.447745619994161,"score_spread":0.29857470823199833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2339943063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94218534,0.0003561066,0.00060016796,0.025018655,0.004449434,0.008364982,0.00029887556,0.00018855339,0.018537859],"genre_scores_gemma":[0.9525493,0.0023959342,0.010473812,0.0041709384,0.015809625,0.007238053,0.00071408926,0.00017550206,0.0064727603],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975819,0.00032926377,0.0006078525,0.0005504899,0.00029365873,0.0006368104],"domain_scores_gemma":[0.99486005,0.0034514721,0.0003922049,0.00092774944,0.00017054091,0.00019800071],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013723791,0.0003038144,0.0010528781,0.00008199015,0.00017355422,0.0000479604,0.0010769905,0.00024685054,0.0010466644],"category_scores_gemma":[0.0017967954,0.0001694616,0.00012468985,0.00011752124,0.00024076545,0.000309152,0.00023431469,0.00026211972,0.00016169966],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7218275,0.0019942503,0.000034423865,0.00003246378,0.00067024946,0.00010295284,0.00026043772,0.0000023098155,0.0076348507,0.001765154,0.024573302,0.24110211],"study_design_scores_gemma":[0.7431617,0.012624355,0.000057722587,0.00006655265,0.0002864519,0.000052579922,0.000044042263,0.0003264584,0.0010049695,0.00028408665,0.24192837,0.00016273974],"about_ca_topic_score_codex":0.000109034096,"about_ca_topic_score_gemma":0.00027160294,"teacher_disagreement_score":0.24093938,"about_ca_system_score_codex":0.003405822,"about_ca_system_score_gemma":0.0020803993,"threshold_uncertainty_score":0.9998665},"labels":[],"label_agreement":null},{"id":"W2344407614","doi":"10.1016/s1470-2045(16)00152-2","title":"Under-reporting of harm in clinical trials","year":2016,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Pharmacovigilance and Adverse Drug Reactions","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":112,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Queen's University","funders":"","keywords":"Medicine; Observational study; Harm; Clinical trial; Tolerability; Pharmacovigilance; Intensive care medicine; Clinical Practice; Adverse effect; Family medicine; Pharmacology; Internal medicine","score_opus":0.8462647241493233,"score_gpt":0.7183082145743631,"score_spread":0.1279565095749602,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2344407614","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018529802,0.9627978,0.000030570536,0.0024912267,0.0051516844,0.0014315391,0.00025982468,0.000076271404,0.027575783],"genre_scores_gemma":[0.00056634744,0.99212086,0.00003876326,0.0019260412,0.0037543625,0.00028179924,0.00004424184,0.00004804936,0.0012195593],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9766662,0.014264426,0.0075630285,0.00054987863,0.00016872138,0.0007877149],"domain_scores_gemma":[0.96865916,0.020353287,0.010107367,0.00061302213,0.00008769072,0.0001794772],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.04598886,0.0004639379,0.007604078,0.00023821395,0.00012711376,0.000008307658,0.0009689713,0.0014191823,0.0014936845],"category_scores_gemma":[0.006225767,0.0002550419,0.0013653891,0.00041056357,0.0006169766,0.00007764935,0.0002406803,0.003372416,0.0005264744],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020557437,0.0003770244,0.00023823722,0.0017427051,0.00080112973,0.00011281045,0.00006953017,0.000012114447,0.00003965854,0.0015680919,0.021538798,0.9732943],"study_design_scores_gemma":[0.0024149674,0.000091176815,0.000052704727,0.0016855138,0.001482962,0.00012678142,0.000042362655,0.000012392595,0.000025764011,0.0007041206,0.99309087,0.00027040925],"about_ca_topic_score_codex":0.000015814105,"about_ca_topic_score_gemma":0.00002515984,"teacher_disagreement_score":0.9730239,"about_ca_system_score_codex":0.00031368312,"about_ca_system_score_gemma":0.0014751514,"threshold_uncertainty_score":0.99999017},"labels":[],"label_agreement":null},{"id":"W2344504503","doi":"10.1016/s1470-2045(16)00156-x","title":"Proton beam therapy for medulloblastoma","year":2016,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Radiation Therapy and Dosimetry","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children","funders":"","keywords":"Medulloblastoma; Proton therapy; Proton; Beam (structure); Medicine; Physics; Nuclear physics; Optics; Cancer research","score_opus":0.06182798544108919,"score_gpt":0.3657506457445373,"score_spread":0.3039226603034481,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2344504503","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021949336,0.00093371107,0.00027034333,0.9856392,0.0009814141,0.0037165785,0.00008839132,0.00013213482,0.0060432963],"genre_scores_gemma":[0.0004715242,0.0009865795,0.00031521256,0.9391018,0.043168217,0.0013834401,0.0001378807,0.00007386294,0.014361444],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984177,0.00022308776,0.0002911398,0.00032401708,0.00020985957,0.000534224],"domain_scores_gemma":[0.99790084,0.0009927854,0.00026942688,0.00069061463,0.000099621044,0.00004668474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007538732,0.00025533867,0.00089326483,0.00009843187,0.000094317635,0.0000124667495,0.00035120817,0.0009644204,0.0006336168],"category_scores_gemma":[0.00009532286,0.00012721543,0.00022252442,0.00008882771,0.00018567067,0.000027960838,0.000021364025,0.0009222618,0.00021490516],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018578012,0.000038141443,0.00017045748,0.0001584307,0.00026599635,0.000038632017,0.00010658651,1.3811047e-7,0.0009541823,0.000060072205,0.97052276,0.025826808],"study_design_scores_gemma":[0.0058895643,0.0022176635,0.00022874719,0.000061533574,0.000069148555,0.000110899775,0.00000505886,0.0000043026507,0.0033634459,0.0014267927,0.9864606,0.000162206],"about_ca_topic_score_codex":0.0000043589907,"about_ca_topic_score_gemma":7.7043836e-7,"teacher_disagreement_score":0.04653736,"about_ca_system_score_codex":0.00019217955,"about_ca_system_score_gemma":0.00033979164,"threshold_uncertainty_score":0.74384934},"labels":[],"label_agreement":null},{"id":"W2346524736","doi":"10.1016/s1470-2045(16)00107-8","title":"Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":217,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Ottawa Hospital; Health Sciences Centre; University of Toronto","funders":"National Medical Research Council; Cancer Council Victoria; National Health and Medical Research Council; American Society for Radiation Oncology","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Radiation therapy; Population; Hormonal therapy; Internal medicine; Randomized controlled trial; Prostate-specific antigen; Cancer; Oncology","score_opus":0.03918470300119959,"score_gpt":0.34027947658870444,"score_spread":0.30109477358750486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2346524736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923989,0.0006894751,0.000030800922,0.0023409436,0.000071865165,0.0042660395,0.00005034102,0.000017659218,0.00013395818],"genre_scores_gemma":[0.99542063,0.0027298613,0.00043314908,0.00040157256,0.00016513368,0.0007748146,0.000022054137,0.00002598549,0.000026768337],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.998679,0.00014174117,0.00033616726,0.00030210824,0.00019924792,0.00034176811],"domain_scores_gemma":[0.99890876,0.00028769352,0.00033722413,0.0002605239,0.00012930433,0.00007649808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037112954,0.0001959636,0.00071920187,0.000080830796,0.00005798626,0.000010456876,0.000070882124,0.000073361436,0.000032824533],"category_scores_gemma":[0.00004438155,0.000087057175,0.00003651386,0.00016104954,0.00017028322,0.00009618234,0.000024078301,0.00012121565,0.0000025097668],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.57843065,0.0015529437,0.3022346,0.000046684556,0.0003117446,0.0000250077,0.0018440534,0.000008776371,0.0005230828,0.000005843868,0.0001453199,0.114871286],"study_design_scores_gemma":[0.90635085,0.009267952,0.076989464,0.0005319244,0.00022441802,0.0000065052004,0.00010756528,0.00008963958,0.0042955037,0.000031472307,0.0019586207,0.00014606169],"about_ca_topic_score_codex":0.00018279036,"about_ca_topic_score_gemma":0.00020295146,"teacher_disagreement_score":0.3279202,"about_ca_system_score_codex":0.00025729177,"about_ca_system_score_gemma":0.00028670742,"threshold_uncertainty_score":0.35500887},"labels":[],"label_agreement":null},{"id":"W2379981061","doi":"10.1016/s1470-2045(16)00163-7","title":"5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":874,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement","funders":"European Society for Medical Oncology","keywords":"Pertuzumab; Docetaxel; Medicine; Trastuzumab; Clinical endpoint; Epirubicin; Internal medicine; Breast cancer; Oncology; Neoadjuvant therapy; Surgery; Cancer; Clinical trial","score_opus":0.0391025579184239,"score_gpt":0.3926124320995352,"score_spread":0.35350987418111135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2379981061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99195963,0.00014583787,0.000084337895,0.002201405,0.00010013136,0.004381781,0.00053197204,0.000022694263,0.00057221384],"genre_scores_gemma":[0.99691164,0.00090649474,0.0004117213,0.00035562928,0.00015826874,0.0005735823,0.00002136768,0.000045279892,0.0006160266],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99701023,0.0006587361,0.0006393618,0.00052728795,0.0005145281,0.0006498341],"domain_scores_gemma":[0.9975587,0.0009272776,0.00035278735,0.00058657036,0.00035239424,0.00022225226],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009315777,0.0002798767,0.0016708447,0.00017698445,0.00007588004,0.000027188584,0.00045923115,0.0001639564,0.0010567012],"category_scores_gemma":[0.00025820133,0.00013603267,0.000069626774,0.0006935148,0.0005247497,0.00016406765,0.00020000011,0.00035733794,0.000008250068],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80430627,0.0019323777,0.080806665,0.000069502596,0.0012644838,0.00012750982,0.0011836339,0.00002165848,0.00031059227,0.000025383479,0.00020121863,0.109750725],"study_design_scores_gemma":[0.800248,0.010094863,0.18535934,0.00044183873,0.0008347936,0.000008658558,0.000311298,0.0003504642,0.00017814893,0.0000052797927,0.0019486233,0.00021865466],"about_ca_topic_score_codex":0.0014808715,"about_ca_topic_score_gemma":0.0058472753,"teacher_disagreement_score":0.10953207,"about_ca_system_score_codex":0.0008623668,"about_ca_system_score_gemma":0.0012301556,"threshold_uncertainty_score":0.9998565},"labels":[],"label_agreement":null},{"id":"W2413013962","doi":"10.1016/s1470-2045(16)30240-6","title":"Genome-wide association studies in oesophageal adenocarcinoma and Barrett's oesophagus: a large-scale meta-analysis","year":2016,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":180,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; McMaster University; University of British Columbia","funders":"H2020 European Research Council; National Center for Advancing Translational Sciences; Johns Hopkins University; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute for Health and Care Research; National Institute of Neurological Disorders and Stroke; Medical Research Council; University of Texas MD Anderson Cancer Center; National Cancer Institute; Academy of Medical Sciences; Cancer Research UK; Francis Crick Institute; European Commission","keywords":"Adenocarcinoma; Genome-wide association study; Barrett's oesophagus; Single-nucleotide polymorphism; Genetic association; SNP; Biology; Internal medicine; Medicine; Genetics; Cancer; Gene; Genotype","score_opus":0.21109433644482933,"score_gpt":0.4567632876625054,"score_spread":0.24566895121767607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2413013962","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007574976,0.9910821,0.0000074809354,0.006301718,0.00010491805,0.0016230089,0.00032473964,0.00004400439,0.0004362845],"genre_scores_gemma":[0.0021934316,0.99112535,0.00013779625,0.0011699364,0.0007479546,0.0012378589,0.00012826824,0.00004777774,0.0032116482],"study_design_codex":"meta_analysis","study_design_gemma":"not_applicable","domain_scores_codex":[0.99519444,0.0017506633,0.0008253451,0.0007434363,0.0005306851,0.0009554432],"domain_scores_gemma":[0.9939545,0.004269783,0.000603534,0.00080365693,0.00015926223,0.0002092965],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0031959177,0.0005371392,0.008406692,0.00049712585,0.00014091926,0.000026344536,0.00034344682,0.0004443666,0.00050749123],"category_scores_gemma":[0.00083822774,0.00025560154,0.0015718596,0.0008462105,0.0002019698,0.000064388696,0.00030340205,0.00084820227,0.00016845067],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051112403,0.0006927249,0.091138355,0.013801598,0.8018354,0.00462612,0.0023793508,0.0000014241576,1.0021271e-7,0.00017536426,0.008187576,0.076650836],"study_design_scores_gemma":[0.003303546,0.0008973159,0.020352943,0.00035622314,0.39484185,0.000093241564,0.00014727254,0.0000021491194,6.332702e-7,0.00033390542,0.57937,0.00030091146],"about_ca_topic_score_codex":0.000040905234,"about_ca_topic_score_gemma":0.0005874024,"teacher_disagreement_score":0.5711824,"about_ca_system_score_codex":0.002578062,"about_ca_system_score_gemma":0.0005564277,"threshold_uncertainty_score":0.9999896},"labels":[],"label_agreement":null},{"id":"W2415950182","doi":"10.1016/s1470-2045(16)30107-3","title":"Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":939,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Exelixis; Memorial Sloan-Kettering Cancer Center","keywords":"Cabozantinib; Everolimus; Meteor (satellite); Renal cell carcinoma; Medicine; Open label; Oncology; Internal medicine; Clinical trial; Astronomy; Physics","score_opus":0.16141156173900909,"score_gpt":0.39215930367378826,"score_spread":0.23074774193477918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2415950182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96240294,0.000490262,0.000021076377,0.006424485,0.0011014674,0.0029836153,0.00028199638,0.000046465462,0.02624769],"genre_scores_gemma":[0.993469,0.00019091296,0.0017008412,0.0005517947,0.0013884,0.00043924365,0.00012737034,0.000039592625,0.0020928632],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99658215,0.000859413,0.0008136334,0.00069615047,0.00031745393,0.00073117524],"domain_scores_gemma":[0.99512917,0.0031428428,0.00039942848,0.0010375987,0.000087567925,0.00020339052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013633386,0.0003413868,0.0014063779,0.00011471029,0.00009505507,0.000023920456,0.0006361691,0.00022921358,0.00024898114],"category_scores_gemma":[0.0007576591,0.00018454499,0.000116511976,0.00023857449,0.00020648532,0.0001231055,0.00025642995,0.00039533453,0.00020370547],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9172742,0.0016178791,0.00015333359,0.000009779518,0.00009035854,0.0011283142,0.0003778183,0.0000024980566,0.041119795,0.000035071793,0.0047554085,0.033435594],"study_design_scores_gemma":[0.9237135,0.015989129,0.0024718856,0.00007186712,0.00028323475,0.000042497875,0.00006830324,0.000030298892,0.02002587,0.00013278933,0.036952574,0.00021804092],"about_ca_topic_score_codex":0.0007244276,"about_ca_topic_score_gemma":0.0004970331,"teacher_disagreement_score":0.033217553,"about_ca_system_score_codex":0.00056750275,"about_ca_system_score_gemma":0.0006409242,"threshold_uncertainty_score":0.7525526},"labels":[],"label_agreement":null},{"id":"W2418044106","doi":"10.1016/s1470-2045(16)00103-0","title":"The five Rs of chemotherapy","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Radiation Therapy and Dosimetry","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Radiation therapy; Radiosensitivity; Repopulation; Medicine; Radioresistance; Chemotherapy; Cancer research; Population; Cancer; Nuclear medicine; Oncology; Surgery; Stem cell; Internal medicine; Biology; Genetics","score_opus":0.027345301404987747,"score_gpt":0.34289696466038505,"score_spread":0.3155516632553973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2418044106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.79616934,0.00091034186,0.00020477765,0.17918769,0.0003138843,0.0002430476,0.0000055330433,0.000035421188,0.022929994],"genre_scores_gemma":[0.986251,0.0017395729,0.00013135592,0.0064055463,0.00060310314,0.000012204752,5.7620446e-7,0.000007434638,0.0048492],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99951994,0.000081862825,0.00012224444,0.000064396496,0.000075398355,0.00013617042],"domain_scores_gemma":[0.9988617,0.0006991064,0.000087579436,0.00029323972,0.000034861157,0.000023557415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047189323,0.000046078338,0.00019744367,0.000014066178,0.00005777155,0.0000018962515,0.00013645187,0.000053849995,0.00020549315],"category_scores_gemma":[0.0000906334,0.000016003469,0.000044265245,0.00007029476,0.00020735369,0.000013908998,0.000009905492,0.000067326684,0.00004925915],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071088835,0.00018309955,0.02091371,0.00002147452,0.00037932728,0.000008299004,0.0019231798,0.0000021796714,0.06799139,0.034215286,0.11847935,0.7487738],"study_design_scores_gemma":[0.005040418,0.0009007338,0.06773258,0.000017991291,0.00002453206,0.000030206775,0.0001273494,0.000018102046,0.0148988655,0.00449144,0.9066714,0.000046364457],"about_ca_topic_score_codex":0.000007740915,"about_ca_topic_score_gemma":0.0000061677783,"teacher_disagreement_score":0.7881921,"about_ca_system_score_codex":0.000040043902,"about_ca_system_score_gemma":0.00006854638,"threshold_uncertainty_score":0.22500059},"labels":[],"label_agreement":null},{"id":"W2461640426","doi":"10.1016/s1470-2045(16)30155-3","title":"Reducing radiation doses for breast tomosynthesis?","year":2016,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Digital Radiography and Breast Imaging","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre","funders":"","keywords":"Tomosynthesis; Medicine; Mammography; Digital Breast Tomosynthesis; Digital mammography; Breast cancer; Breast imaging; Medical physics; Nuclear medicine; Radiology; Breast cancer screening; Cancer; Internal medicine","score_opus":0.03716022325636447,"score_gpt":0.31847475284541304,"score_spread":0.28131452958904857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2461640426","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00052339456,0.0003823654,0.00025217727,0.9642443,0.0008348971,0.00064082316,0.0004049336,0.000128809,0.032588318],"genre_scores_gemma":[0.022301732,0.0002545556,0.00074841664,0.90748924,0.06300016,0.00026682118,0.0002791927,0.000095281895,0.0055645877],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99849606,0.00012202405,0.00027084257,0.0003406863,0.00017549856,0.00059489283],"domain_scores_gemma":[0.9980172,0.0010875489,0.00023543744,0.0005242764,0.00008610362,0.000049455208],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005090238,0.00024114028,0.0007930519,0.00015728387,0.000103330705,0.000037951784,0.00028175928,0.00043324492,0.00010750733],"category_scores_gemma":[0.00012585902,0.00013409808,0.00028862132,0.00012608086,0.00020151283,0.00009272391,0.00003744941,0.00063495035,0.000058853042],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023754642,0.00001544769,0.00007452218,0.00014159107,0.00014280196,0.00005720794,0.000042984182,1.255242e-7,0.00011399749,0.000080898,0.61091584,0.388177],"study_design_scores_gemma":[0.0014384547,0.0002442991,0.0009873399,0.0003272666,0.0003226964,0.002027505,0.000013779086,0.000009596501,0.00016325367,0.0011902844,0.99310124,0.00017430118],"about_ca_topic_score_codex":0.000013980427,"about_ca_topic_score_gemma":0.0000013879854,"teacher_disagreement_score":0.38800272,"about_ca_system_score_codex":0.0001798616,"about_ca_system_score_gemma":0.00021152876,"threshold_uncertainty_score":0.5468361},"labels":[],"label_agreement":null},{"id":"W2462276505","doi":"10.1016/s1470-2045(16)30095-x","title":"Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":165,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; Dalhousie University","funders":"Research for Patient Benefit Programme; North Bristol NHS Trust; Marie Curie; National Institute for Health and Care Research","keywords":"Medicine; Radiation therapy; Mesothelioma; Surgery; Randomized controlled trial; Incidence (geometry); Pleural disease; Adverse effect; Odds ratio; Clinical endpoint; Intention-to-treat analysis; Population; Internal medicine; Lung; Respiratory disease","score_opus":0.041873360183480306,"score_gpt":0.38633625637563057,"score_spread":0.34446289619215026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2462276505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9803276,0.003060864,0.00005573971,0.0053266,0.00009491092,0.010956361,0.00013733553,0.000013067916,0.000027519505],"genre_scores_gemma":[0.9947031,0.00040730834,0.00026881663,0.00036907083,0.00027294483,0.0034990201,0.000020910025,0.000018705727,0.00044011822],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99841523,0.0003893211,0.0004549519,0.0002503553,0.0001865913,0.00030356884],"domain_scores_gemma":[0.997941,0.0014951266,0.00026450062,0.00019266306,0.000036889927,0.00006979113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009044655,0.0001788562,0.00083046296,0.000048839127,0.00007712794,0.000016853954,0.00016915203,0.00007093012,0.00015186625],"category_scores_gemma":[0.00045126752,0.00006952769,0.00011470789,0.00007762401,0.00021490979,0.000114468574,0.000048601938,0.00008421852,0.0000017367585],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9790141,0.0048500462,0.00493794,0.00016776643,0.00027101333,0.000042652402,0.00020933128,0.0000015189316,0.005060248,0.00013567203,0.00019309694,0.005116615],"study_design_scores_gemma":[0.9746228,0.0052708974,0.015222639,0.000106697895,0.00060804246,0.000088258275,0.00009673608,0.00061906694,0.00057982875,0.00018481645,0.0024862704,0.00011396939],"about_ca_topic_score_codex":0.00001395541,"about_ca_topic_score_gemma":0.00008711525,"teacher_disagreement_score":0.014375504,"about_ca_system_score_codex":0.00008120426,"about_ca_system_score_gemma":0.00021589789,"threshold_uncertainty_score":0.28352568},"labels":[],"label_agreement":null},{"id":"W2464046943","doi":"10.1016/s1470-2045(16)30034-1","title":"Phosphenes in patients receiving radiotherapy","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-Jean","funders":"","keywords":"Phosphene; Medicine; Radiation therapy; Ophthalmology; Retina; Neuroscience; Psychology; Stimulation; Surgery; Internal medicine","score_opus":0.026839031987170196,"score_gpt":0.327159132281375,"score_spread":0.3003201002942048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2464046943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9719851,0.0003646957,0.00004434961,0.018241381,0.00030317003,0.0002682914,0.0000020630628,0.000033584438,0.008757371],"genre_scores_gemma":[0.9946758,0.0004911632,0.0008921693,0.0026523152,0.00025041387,0.000032199787,0.0000030044644,0.000011208146,0.0009916928],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99925303,0.00015938214,0.00013313843,0.00014122414,0.00006915159,0.0002440492],"domain_scores_gemma":[0.9994222,0.00021561587,0.000053812564,0.0002489329,0.000024467408,0.000034954217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028784928,0.000081043145,0.00033718973,0.00003051793,0.00003697091,0.0000017348153,0.000094530646,0.00011002556,0.00022045863],"category_scores_gemma":[0.00008126454,0.00003715424,0.000037166436,0.00008027653,0.000105179526,0.00003100085,0.000021622902,0.00009897807,0.000100788624],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008588132,0.00029664452,0.8521902,0.000004608801,0.00006735234,0.000036861053,0.00018834278,2.4096957e-7,0.0004469896,0.00026677118,0.0016700361,0.14397316],"study_design_scores_gemma":[0.012221307,0.0010280834,0.9014879,0.00003930175,0.000026417605,0.00001956939,0.000011185324,0.000002389423,0.0003062631,0.0004922816,0.08431558,0.000049744936],"about_ca_topic_score_codex":0.000016200196,"about_ca_topic_score_gemma":0.00006788803,"teacher_disagreement_score":0.14392342,"about_ca_system_score_codex":0.000276075,"about_ca_system_score_gemma":0.00006859725,"threshold_uncertainty_score":0.24138674},"labels":[],"label_agreement":null},{"id":"W2464196345","doi":"10.1016/s1470-2045(16)30065-1","title":"Prophylactic cranial irradiation for patients with lung cancer","year":2016,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":108,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prophylactic cranial irradiation; Neurocognitive; Brain metastasis; Lung cancer; Incidence (geometry); Oncology; Quality of life (healthcare); Internal medicine; Cancer; Lung; Radiation therapy; Surgery; Metastasis","score_opus":0.08109539761877588,"score_gpt":0.47817937414475764,"score_spread":0.39708397652598176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2464196345","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000320882,0.98865,0.00003206329,0.003422365,0.0005487899,0.0056441436,0.00022844141,0.000046384277,0.0013957267],"genre_scores_gemma":[0.000111631656,0.990256,0.00014976326,0.00029665505,0.0035985487,0.004272269,0.00006562179,0.0000610719,0.0011884201],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99837637,0.00022268386,0.00028485493,0.00032770418,0.0002870914,0.000501294],"domain_scores_gemma":[0.99823684,0.0006761601,0.00033973256,0.00041921227,0.00025554243,0.0000725365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038595067,0.00026422192,0.0018790425,0.00008016694,0.00013246087,0.000011258631,0.00024143598,0.00018848797,0.00009093814],"category_scores_gemma":[0.00027849988,0.00010669391,0.00015859221,0.0001543406,0.0001825128,0.00003947913,0.00007301673,0.000367112,0.000029507757],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010529242,0.000096937874,0.00058515935,0.028326754,0.00072980195,0.000006541716,0.000094378374,8.3457344e-8,1.4693552e-7,0.000092827126,0.016154418,0.95286006],"study_design_scores_gemma":[0.0037879236,0.0013347839,0.00083183096,0.0041433084,0.0017687636,0.000008150284,0.0000024175324,0.0000025021436,7.713381e-8,0.000027007163,0.9879487,0.00014453297],"about_ca_topic_score_codex":0.000030629468,"about_ca_topic_score_gemma":0.00005663801,"teacher_disagreement_score":0.9717943,"about_ca_system_score_codex":0.0016407883,"about_ca_system_score_gemma":0.0016715736,"threshold_uncertainty_score":0.43508512},"labels":[],"label_agreement":null},{"id":"W2468311487","doi":"10.1016/s1470-2045(16)30120-6","title":"Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":177,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Université de Sherbrooke","funders":"Canadian Cancer Society Research Institute; KWF Kankerbestrijding; Agenzia Italiana del Farmaco, Ministero della Salute; National Health and Medical Research Council; Cancer Research UK","keywords":"Medicine; Endometrial cancer; Chemoradiotherapy; Adjuvant; Oncology; Radiation therapy; Quality of life (healthcare); Open label; Internal medicine; Cancer; Clinical trial; Gynecology","score_opus":0.10892158562130659,"score_gpt":0.4203140416483053,"score_spread":0.3113924560269987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2468311487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882762,0.0020790466,0.00039941684,0.0027321854,0.00075804925,0.005007878,0.000619348,0.000038545215,0.00008934447],"genre_scores_gemma":[0.984654,0.0062147407,0.0023858063,0.0012561985,0.0026377314,0.0025832613,0.000016183269,0.000046571382,0.00020547502],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99732405,0.0006431877,0.00067204825,0.00049720996,0.00031053327,0.0005529627],"domain_scores_gemma":[0.9955624,0.0027629875,0.0006124379,0.0005583771,0.00015185315,0.00035194497],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019259487,0.0002968928,0.0024165034,0.0001030309,0.000096866774,0.000023228464,0.00032526668,0.00017584457,0.0006715321],"category_scores_gemma":[0.00075818057,0.00013963332,0.00006922795,0.00031032757,0.0003550297,0.00014445173,0.000052152816,0.00016145078,0.0000013235631],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84598136,0.0032856949,0.0014655812,0.000061986306,0.0013541605,0.0000076863325,0.00041462915,5.5912045e-7,0.010702765,0.00003988947,0.00011161615,0.13657407],"study_design_scores_gemma":[0.9411598,0.04468994,0.0032458422,0.00003535757,0.00036897528,0.0000031736633,0.00007083798,0.000012443143,0.0033529073,0.0000935358,0.006762132,0.00020505323],"about_ca_topic_score_codex":0.001173198,"about_ca_topic_score_gemma":0.0008373658,"teacher_disagreement_score":0.13636902,"about_ca_system_score_codex":0.00054092734,"about_ca_system_score_gemma":0.00043700298,"threshold_uncertainty_score":0.7352806},"labels":[],"label_agreement":null},{"id":"W2469109222","doi":"10.1016/s1470-2045(16)30097-3","title":"Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":343,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of British Columbia; BC Cancer Agency","funders":"Genentech; F. Hoffmann-La Roche; Gilead Sciences","keywords":"Bendamustine; Obinutuzumab; Medicine; Rituximab; Internal medicine; Neutropenia; Population; Oncology; Surgery; Lymphoma; Chemotherapy","score_opus":0.055703202204740475,"score_gpt":0.36469524390968916,"score_spread":0.3089920417049487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2469109222","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.982556,0.00041917822,0.00004153198,0.003395673,0.0010430663,0.010265208,0.00013002679,0.0000678574,0.0020814673],"genre_scores_gemma":[0.9933901,0.0006791112,0.0007572304,0.0015051152,0.0009893286,0.0022323837,0.00010157282,0.00007036208,0.00027481036],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99639237,0.00056994735,0.0009470468,0.00070198625,0.00048292862,0.0009057103],"domain_scores_gemma":[0.9957838,0.0022041071,0.00063053315,0.0008840189,0.00022334448,0.0002741784],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009224884,0.0005540237,0.002633352,0.00017565613,0.0001624976,0.000049068847,0.0005604739,0.00026716522,0.00034426412],"category_scores_gemma":[0.00044919696,0.00026345084,0.00015245905,0.00026175336,0.00026861092,0.00018422843,0.00018687491,0.00021255299,0.00011351119],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8672314,0.016816115,0.0021113823,0.000022691074,0.00084242894,0.00024494898,0.00045022604,0.000008016613,0.000114391434,0.00006106199,0.002123691,0.10997361],"study_design_scores_gemma":[0.9476983,0.024462795,0.008547101,0.00024876374,0.00065175124,0.000015154758,0.00008005757,0.0002745062,0.0001859273,0.000014072523,0.01749084,0.00033075028],"about_ca_topic_score_codex":0.0004398847,"about_ca_topic_score_gemma":0.0004231529,"teacher_disagreement_score":0.10964286,"about_ca_system_score_codex":0.0033259955,"about_ca_system_score_gemma":0.0014245405,"threshold_uncertainty_score":0.99998176},"labels":[],"label_agreement":null},{"id":"W2480841917","doi":"10.1016/s1470-2045(16)30249-2","title":"Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":526,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Princess Margaret Cancer Centre; Hospital for Sick Children; University of Toronto","funders":"Foundation of Hope for Research and Treatment of Mental Illness; Hope Foundation","keywords":"Medicine; Asymptomatic; Observational study; Prospective cohort study; Colonoscopy; Pediatrics; Cancer; Colorectal cancer; Internal medicine","score_opus":0.03202712947594968,"score_gpt":0.3102890552416203,"score_spread":0.27826192576567066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2480841917","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99476874,0.00016769435,0.00018022468,0.0036851007,0.000087357286,0.00073547947,0.000022567396,0.000025683074,0.00032717976],"genre_scores_gemma":[0.9991432,0.000021251511,0.00042303905,0.00015050678,0.000069166745,0.00008092942,0.000010623818,0.000017084665,0.00008418508],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990396,0.00012364596,0.00021740753,0.00024287289,0.00017944531,0.00019701822],"domain_scores_gemma":[0.9993173,0.00017394693,0.00012485398,0.00022854852,0.00011134387,0.000044008688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047312208,0.00010602973,0.00041619522,0.00006501541,0.000024250392,0.000003323708,0.00007726973,0.00005948441,0.000019447432],"category_scores_gemma":[0.00020928142,0.00006255992,0.000024295336,0.0002309243,0.00020832624,0.000033440883,0.00003434682,0.0001486436,0.0000027195804],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020070262,0.0001647514,0.9517487,0.00003211231,0.000110617606,0.00022407643,0.0014729815,0.000008093808,0.04251607,0.0003172752,0.00031900295,0.0010792891],"study_design_scores_gemma":[0.018247651,0.001214225,0.97542524,0.00011821562,0.00006834729,0.00041477106,0.000574979,0.00008557667,0.0030685582,0.00024521403,0.00042509873,0.000112132926],"about_ca_topic_score_codex":0.00009694371,"about_ca_topic_score_gemma":0.00051814277,"teacher_disagreement_score":0.039447512,"about_ca_system_score_codex":0.00025178856,"about_ca_system_score_gemma":0.00023329054,"threshold_uncertainty_score":0.25511196},"labels":[],"label_agreement":null},{"id":"W2483834070","doi":"10.1016/s1470-2045(16)30173-5","title":"Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":291,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Cilag; Johnson and Johnson","keywords":"Medicine; Prostate cancer; Concomitant; Clinical trial; Lymph node; Asymptomatic; Radium-223; Cancer; Internal medicine; Oncology; Surgery; Bone metastasis","score_opus":0.16484752784240742,"score_gpt":0.44727528475559597,"score_spread":0.28242775691318855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2483834070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98307264,0.00041856267,0.0000048153684,0.013085292,0.00020991785,0.0023528102,0.00018592921,0.000021174435,0.00064885966],"genre_scores_gemma":[0.99702454,0.001143083,0.0002445962,0.00042778606,0.00019444544,0.00044361746,0.000054601114,0.000021555637,0.00044577822],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9985675,0.00025858474,0.0002818819,0.00030267469,0.00025291726,0.000336446],"domain_scores_gemma":[0.99908775,0.0002212298,0.00016707859,0.00026536835,0.00015603566,0.00010253291],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047330768,0.00016043198,0.0004876709,0.00008352287,0.00009523188,0.00012169175,0.0003593854,0.000045033197,0.0001298351],"category_scores_gemma":[0.000051424347,0.00007236603,0.000013728256,0.0001431057,0.0003228304,0.0004901302,0.000104062616,0.00014936808,0.0000034411505],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6867419,0.011493723,0.14454362,0.00006256473,0.0009421085,0.00025001814,0.0036521582,0.0000010756519,0.009180187,0.00081791094,0.0008969849,0.14141774],"study_design_scores_gemma":[0.8036093,0.04201247,0.13564974,0.00026026968,0.00018457406,0.000011967863,0.00027295257,0.000025012398,0.0012624726,0.00077410834,0.01568312,0.00025400828],"about_ca_topic_score_codex":0.0005488482,"about_ca_topic_score_gemma":0.0013382263,"teacher_disagreement_score":0.14116374,"about_ca_system_score_codex":0.00039825143,"about_ca_system_score_gemma":0.00047063973,"threshold_uncertainty_score":0.2951001},"labels":[],"label_agreement":null},{"id":"W2486629951","doi":"10.1016/s1470-2045(16)30206-6","title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","year":2016,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2995,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Multiple myeloma; Minimal residual disease; Medicine; Bone marrow; Myeloma protein; Clinical trial; Disease; Oncology; Monoclonal; Internal medicine; Monoclonal antibody; Immunology; Antibody","score_opus":0.18498453553729838,"score_gpt":0.47315065993772726,"score_spread":0.2881661244004289,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2486629951","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01412162,0.96139175,0.000045813922,0.014862262,0.0009585162,0.005429416,0.0014962993,0.00008896026,0.0016053616],"genre_scores_gemma":[0.013467692,0.97596234,0.0050115963,0.0002617118,0.0020302013,0.001880135,0.0004590807,0.00008205197,0.000845173],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961369,0.001536417,0.0006693133,0.0006260934,0.00032479045,0.0007064535],"domain_scores_gemma":[0.99205893,0.006709743,0.00030407836,0.0005457985,0.00008561104,0.00029582737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021337345,0.00040678272,0.0018704394,0.00031590305,0.00013359974,0.000047488447,0.00036150703,0.00028564798,0.00012416841],"category_scores_gemma":[0.0018515522,0.0002344533,0.00022903844,0.00013002945,0.00036102778,0.00003178114,0.00029896875,0.0005151417,0.000026549902],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023493724,0.0003069696,0.0032239594,0.0022672915,0.0005630242,0.0018249976,0.00007575133,3.1896562e-8,0.00004428211,0.00023419263,0.00292003,0.96504575],"study_design_scores_gemma":[0.0096286945,0.0007584005,0.043472875,0.0051850956,0.00033504853,0.00033920567,0.00003231898,0.00008015893,9.2287826e-7,0.00010176696,0.93984616,0.00021937524],"about_ca_topic_score_codex":0.00001475625,"about_ca_topic_score_gemma":0.000060488397,"teacher_disagreement_score":0.96482635,"about_ca_system_score_codex":0.00083439413,"about_ca_system_score_gemma":0.0010635423,"threshold_uncertainty_score":0.9560728},"labels":[],"label_agreement":null},{"id":"W2498753998","doi":"10.1016/s1470-2045(16)30215-7","title":"Cumulative burden of cardiovascular morbidity in paediatric, adolescent, and young adult survivors of Hodgkin's lymphoma: an analysis from the St Jude Lifetime Cohort Study","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":179,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute","keywords":"Hodgkin lymphoma; Medicine; Cohort; Young adult; Pediatrics; Lymphoma; Gerontology; Cohort study; Demography; Internal medicine; Sociology","score_opus":0.025987212733697945,"score_gpt":0.2994177467544547,"score_spread":0.2734305340207568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2498753998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99712306,0.0005544367,0.00026557373,0.00081372476,0.00008956813,0.0008410566,0.00009684682,0.00001615295,0.00019957678],"genre_scores_gemma":[0.9980495,0.0011236572,0.00005820814,0.00012232704,0.0005667044,0.000030315825,0.000022078884,0.000012656362,0.000014579019],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99769425,0.0011012104,0.00036031145,0.00030110008,0.00034696126,0.0001961633],"domain_scores_gemma":[0.9983609,0.00046618053,0.00021558734,0.00073161715,0.00017169668,0.00005403353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019436745,0.00014204378,0.0011558449,0.00009395231,0.000042755237,0.0000044099975,0.0002000472,0.0001352017,0.000019496252],"category_scores_gemma":[0.00021790058,0.000074723364,0.00024245579,0.0004289747,0.00023198048,0.00005487403,0.00006847298,0.00013398638,0.0000011364071],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004960495,0.00031622607,0.9790381,0.000015939819,0.003399511,0.000013078523,0.004353521,0.00020294402,0.0043381145,0.000018073843,0.00004825577,0.007760144],"study_design_scores_gemma":[0.0054843468,0.00034475006,0.98545104,0.000031425694,0.0026523003,0.0000054116317,0.002129662,0.00032516758,0.003220817,0.00008185987,0.00018482668,0.00008839357],"about_ca_topic_score_codex":0.022995366,"about_ca_topic_score_gemma":0.0061356276,"teacher_disagreement_score":0.016859738,"about_ca_system_score_codex":0.00015077746,"about_ca_system_score_gemma":0.00009373061,"threshold_uncertainty_score":0.9835106},"labels":[],"label_agreement":null},{"id":"W2504623699","doi":"10.1016/s1470-2045(16)30167-x","title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":924,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency; University of Toronto","funders":"NIHR Oxford Biomedical Research Centre; National Institutes of Health; National Cancer Institute; National Institute for Health and Care Research; Bristol-Myers Squibb","keywords":"Brentuximab vedotin; Medicine; Nivolumab; Internal medicine; Oncology; Autologous stem-cell transplantation; Clinical endpoint; Transplantation; Lymphoma; Surgery; Clinical trial; Hodgkin lymphoma; Immunotherapy; Cancer","score_opus":0.033560026239753946,"score_gpt":0.3124283474722595,"score_spread":0.27886832123250554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2504623699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903803,0.00043808483,0.00045487308,0.0061330595,0.0002903796,0.0017666998,0.00019614023,0.000048044472,0.0002924155],"genre_scores_gemma":[0.99665457,0.00030644482,0.0014720694,0.0004089352,0.00042105615,0.00046429996,0.00002805663,0.000023686058,0.00022086344],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99854475,0.00018717037,0.00039303536,0.00033213376,0.0001581626,0.0003847735],"domain_scores_gemma":[0.9983104,0.001002184,0.00021614843,0.0002933206,0.00006645816,0.000111522444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002367314,0.00020683375,0.0007761262,0.00005551912,0.00006140576,0.000010949534,0.0000976558,0.0001935058,0.000047572594],"category_scores_gemma":[0.000036925085,0.000110304754,0.00014298737,0.00005581271,0.00024016287,0.000053032923,0.000025135296,0.000052226158,0.00000939279],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.290303,0.019752966,0.007708684,0.00044878264,0.0004874701,0.00039212912,0.002147906,8.066588e-7,0.013161451,0.00032468428,0.0027802414,0.66249186],"study_design_scores_gemma":[0.8808955,0.024965467,0.030187948,0.00025058366,0.0020699133,0.00040076568,0.00022377605,0.00043523975,0.019013705,0.000107953856,0.041150328,0.00029882145],"about_ca_topic_score_codex":0.00003475613,"about_ca_topic_score_gemma":0.00015923107,"teacher_disagreement_score":0.66219306,"about_ca_system_score_codex":0.00025957226,"about_ca_system_score_gemma":0.00017071162,"threshold_uncertainty_score":0.44980973},"labels":[],"label_agreement":null},{"id":"W2505666614","doi":"10.1016/s1470-2045(16)30313-8","title":"Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":498,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Calgary; Queen's University; University of Toronto; BC Cancer Agency","funders":"National Health and Medical Research Council; National Institute for Health and Care Research; Canadian Cancer Society Research Institute; Medical Research Council; National Cancer Institute; Krebsliga Schweiz; Cancer Research UK","keywords":"Temozolomide; Medicine; Glioma; Internal medicine; Radiation therapy; Chemotherapy; Oncology; Oligodendroglioma; Surgery; Gastroenterology; Astrocytoma","score_opus":0.05562643958390778,"score_gpt":0.38883921043138453,"score_spread":0.33321277084747675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2505666614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9737081,0.0008607181,0.000055014,0.01948021,0.00075712777,0.004465329,0.000037765425,0.00009041842,0.0005453335],"genre_scores_gemma":[0.99382395,0.0017603805,0.00049238454,0.0015526908,0.0007318299,0.0014320447,0.000012125772,0.00006510406,0.0001294965],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9969487,0.00085588003,0.0006343174,0.0006140889,0.00025803456,0.0006889802],"domain_scores_gemma":[0.9968733,0.0015284951,0.00033585413,0.0010296671,0.00005764316,0.00017501718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014334528,0.000392582,0.0016038717,0.00020586084,0.00012621972,0.000046008696,0.00070283917,0.00018512586,0.00047007177],"category_scores_gemma":[0.00019827207,0.0002006213,0.000111416826,0.00040685953,0.00023194801,0.00011819806,0.00014128111,0.00030723875,0.00008327228],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39518598,0.053845618,0.07595977,0.00004119029,0.0038369452,0.0036250434,0.0036904698,0.000005313252,0.07714307,0.0007938875,0.019537421,0.36633527],"study_design_scores_gemma":[0.93712574,0.0184011,0.017643882,0.00013043755,0.00036361843,0.000113349735,0.0003553467,0.000051005856,0.007444388,0.0003194721,0.017732175,0.00031949856],"about_ca_topic_score_codex":0.00070200925,"about_ca_topic_score_gemma":0.0010359801,"teacher_disagreement_score":0.54193974,"about_ca_system_score_codex":0.0007421492,"about_ca_system_score_gemma":0.0001655312,"threshold_uncertainty_score":0.8181099},"labels":[],"label_agreement":null},{"id":"W2513951655","doi":"10.1016/s1470-2045(16)30214-5","title":"Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":541,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Dalhousie University","funders":"Medical Research Council; Deutsche Krebshilfe; Fonds Wetenschappelijk Onderzoek; Fonds De La Recherche Scientifique - FNRS; Bundesministerium für Bildung und Forschung; Norges Forskningsråd; Cancer Research UK; Academy of Finland; ZonMw; Deutsche Forschungsgemeinschaft; European Science Foundation; European Commission; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; National Cancer Institute; Sundhed og Sygdom, Det Frie Forskningsråd","keywords":"Osteosarcoma; Open label; Medicine; Chemotherapy; Oncology; Randomized controlled trial; Internal medicine; Pathology","score_opus":0.07297720028559644,"score_gpt":0.40048151067345056,"score_spread":0.3275043103878541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2513951655","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94418156,0.00006050171,0.000039494895,0.042181924,0.00047208928,0.012884088,0.00007007352,0.00001957841,0.000090714784],"genre_scores_gemma":[0.9910486,0.000021383921,0.0025953068,0.0014846277,0.00022719796,0.004438008,0.0000484563,0.000028238377,0.000108218046],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99794716,0.00069550175,0.00051211717,0.0003207427,0.00023105319,0.00029344708],"domain_scores_gemma":[0.9943197,0.0047109593,0.00028630332,0.00038614395,0.00019523843,0.00010169924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000874909,0.00020338409,0.0014292352,0.00010304812,0.00005184583,0.000020963975,0.00041291022,0.00009573259,0.000081167396],"category_scores_gemma":[0.0006911083,0.00009657091,0.000055573604,0.000103772545,0.00010277798,0.00008826409,0.00006461848,0.00008965309,0.000007968039],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9451553,0.009280105,0.03219073,0.0000061287074,0.00057091966,0.000014921477,0.0008965759,0.0000038049784,0.0010759496,0.00021457349,0.0024097404,0.008181246],"study_design_scores_gemma":[0.87657845,0.039698314,0.07850509,0.00008007239,0.00016226835,7.69356e-7,0.00012185427,0.00003683195,0.0012982598,0.000050231596,0.003356942,0.000110946734],"about_ca_topic_score_codex":0.00012012479,"about_ca_topic_score_gemma":0.00041380536,"teacher_disagreement_score":0.06857689,"about_ca_system_score_codex":0.00032037465,"about_ca_system_score_gemma":0.00020546181,"threshold_uncertainty_score":0.39380473},"labels":[],"label_agreement":null},{"id":"W2514454733","doi":"10.1016/s1470-2045(16)30321-7","title":"EANO guidelines for the diagnosis and treatment of meningiomas","year":2016,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Meningioma and schwannoma management","field":"Medicine","cited_by":858,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute for Health and Care Research; CMC Microsystems; Merck KGaA; Boehringer Ingelheim; Roche; GlaxoSmithKline","keywords":"Medicine; Radiosurgery; Meningioma; Radiation therapy; Grading (engineering); Radiology","score_opus":0.4616444835712515,"score_gpt":0.5002393630257916,"score_spread":0.038594879454540154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2514454733","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000643859,0.9815413,0.00010030098,0.013497209,0.00032960562,0.0025440543,0.000056877067,0.000023244784,0.0018430192],"genre_scores_gemma":[0.000022131082,0.99197024,0.0011786362,0.00017844905,0.0016536284,0.0021178182,0.000021658154,0.000030724972,0.002826735],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99860245,0.00017322181,0.0005741969,0.00025562439,0.000116977404,0.0002775197],"domain_scores_gemma":[0.99661344,0.0021863994,0.00040576715,0.0006297144,0.00011636224,0.00004830709],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007629689,0.00026665605,0.0021163474,0.00007181197,0.00009780915,0.00000845463,0.00023069534,0.00015557848,0.00006988753],"category_scores_gemma":[0.00025029882,0.00009172654,0.00036240256,0.00009269483,0.00017013252,0.000011529641,0.000086962216,0.0000649398,0.000014896823],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008406925,0.000057074136,0.000019333867,0.0020329854,0.00091118994,0.000044031272,0.00009272172,5.335141e-8,6.8177417e-7,0.0015372053,0.03505306,0.9601676],"study_design_scores_gemma":[0.0013778816,0.0014579942,0.000020027717,0.0021471162,0.0033807673,0.00024662048,0.00002683632,0.000006028572,0.0000032989465,0.0001305954,0.99110776,0.000095048155],"about_ca_topic_score_codex":0.000017486711,"about_ca_topic_score_gemma":0.0000065137992,"teacher_disagreement_score":0.9600725,"about_ca_system_score_codex":0.00013740784,"about_ca_system_score_gemma":0.00015096208,"threshold_uncertainty_score":0.37405},"labels":[],"label_agreement":null},{"id":"W2526176932","doi":"10.1016/s1470-2045(16)30305-9","title":"Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":133,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency; University of Toronto","funders":"National Health and Medical Research Council; Medical Research Council; National Institute for Health and Care Research; Canadian Cancer Society Research Institute; European Organisation for Research and Treatment of Cancer; National Cancer Institute; Krebsliga Schweiz; Cancer Research UK","keywords":"Temozolomide; Medicine; Radiation therapy; Internal medicine; Glioma; Oligodendroglioma; Clinical endpoint; Quality of life (healthcare); Chemotherapy; Oncology; Randomized controlled trial; Surgery; Astrocytoma","score_opus":0.06117070943676122,"score_gpt":0.38973305534424574,"score_spread":0.3285623459074845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2526176932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818018,0.00028548585,0.000046358404,0.0105637545,0.0003576248,0.006337088,0.0001423699,0.00006530472,0.00040023055],"genre_scores_gemma":[0.9977943,0.00017410127,0.000077960685,0.001111082,0.00012951324,0.00052887783,0.00002248237,0.000037352303,0.00012433779],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950428,0.0020810233,0.0013592801,0.0005004346,0.00040279617,0.000613649],"domain_scores_gemma":[0.99646956,0.0012841261,0.0011694053,0.0006441277,0.0002527588,0.00018004424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028635724,0.00031306056,0.0023845206,0.00018884,0.00013280842,0.0000100179195,0.0004285548,0.00013309768,0.00013920836],"category_scores_gemma":[0.0011564184,0.0001613067,0.000060269726,0.00056374667,0.0004723852,0.00012008361,0.00033692335,0.00047801906,0.000031121846],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2809475,0.021233512,0.6625003,0.00013341711,0.0018563725,0.000061203595,0.0036492525,0.0000024137194,0.00030154592,0.000102893144,0.0035585144,0.025653029],"study_design_scores_gemma":[0.48718825,0.019938871,0.4912083,0.00036788656,0.00020230106,0.0000062005397,0.0005268921,0.000003812978,0.000055308796,0.0001531751,0.00017892303,0.00017007042],"about_ca_topic_score_codex":0.0038001824,"about_ca_topic_score_gemma":0.003254036,"teacher_disagreement_score":0.20624074,"about_ca_system_score_codex":0.0006218604,"about_ca_system_score_gemma":0.00042660846,"threshold_uncertainty_score":0.65778965},"labels":[],"label_agreement":null},{"id":"W2529469085","doi":"10.1016/s1470-2045(16)30369-2","title":"International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer","year":2016,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":347,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McGill University","funders":"Institut National Du Cancer","keywords":"Medicine; Intensive care medicine; Venous thromboembolism; Cancer; Venous thrombosis; Thrombosis; Grading (engineering); Major bleeding; Internal medicine","score_opus":0.2379228769798971,"score_gpt":0.5208992725229508,"score_spread":0.28297639554305365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2529469085","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013674367,0.9693607,0.000011672141,0.007354193,0.0009904928,0.0059701228,0.00021602283,0.00001746086,0.0024049368],"genre_scores_gemma":[0.0027611274,0.99295354,0.0012777167,0.0011141701,0.00082303124,0.0009662326,0.00004019237,0.00003132571,0.000032668515],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99746305,0.00057353964,0.0010152028,0.00039182825,0.00023553628,0.00032086376],"domain_scores_gemma":[0.9969246,0.001560755,0.00076880347,0.00042571573,0.000286757,0.000033401055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022511708,0.00028123296,0.0033247543,0.00012243573,0.000049415652,0.000013400977,0.00035936412,0.00019307232,0.000012622566],"category_scores_gemma":[0.0009346326,0.000114884446,0.000142251,0.00016713013,0.00017892175,0.00005738222,0.00010704905,0.00022986968,0.0000022827703],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043398468,0.0025376289,0.004926308,0.0014958071,0.00081489456,0.000020863496,0.00046746252,0.0000013989072,1.16005715e-7,0.00019659815,0.002560297,0.98654467],"study_design_scores_gemma":[0.0040472243,0.0037105232,0.031831138,0.006023182,0.0010937465,0.0000108129725,0.00005693242,0.000004314234,2.594558e-7,0.000033280365,0.95305675,0.0001318647],"about_ca_topic_score_codex":0.0003993308,"about_ca_topic_score_gemma":0.00041173014,"teacher_disagreement_score":0.98641276,"about_ca_system_score_codex":0.00036270672,"about_ca_system_score_gemma":0.00034970793,"threshold_uncertainty_score":0.46848518},"labels":[],"label_agreement":null},{"id":"W2530874255","doi":"10.1016/s1470-2045(16)30491-0","title":"Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":216,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"Evans Medical Foundation; A. Alfred Taubman Medical Research Institute; Patient-Centered Outcomes Research Institute; V Foundation for Cancer Research; Prostate Cancer Foundation","keywords":"Medicine; Radiation therapy; Prostatectomy; Retrospective cohort study; Cohort; Prostate cancer; Androgen deprivation therapy; Oncology; Internal medicine; Clinical endpoint; Metastasis; Surgery; Cancer; Clinical trial","score_opus":0.028402166999602674,"score_gpt":0.33383297628999814,"score_spread":0.30543080929039546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2530874255","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9800164,0.0006086188,0.00007393335,0.018386623,0.00003919495,0.0007137448,0.00011715054,0.000007737566,0.000036562386],"genre_scores_gemma":[0.9941522,0.0017653295,0.0031826016,0.0003634692,0.00003124443,0.00035605708,0.000006105723,0.000007853108,0.00013516065],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99907845,0.00018118712,0.00027636968,0.00019147484,0.00011776357,0.00015477704],"domain_scores_gemma":[0.99932885,0.00017525422,0.0001440403,0.00018607013,0.00011721372,0.000048571193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060724834,0.000092938724,0.00063404336,0.00015161869,0.000019154828,0.0000022142765,0.000053673615,0.0000378174,0.00004489252],"category_scores_gemma":[0.00006520146,0.000048621172,0.000034161767,0.0003762875,0.00008847145,0.000026965306,0.000026512329,0.000045995028,6.423255e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013708381,0.00023384651,0.8001425,0.000026194326,0.0010482252,0.000019004672,0.018657789,0.000035376062,0.15410976,0.00008269148,0.00015012489,0.0117860995],"study_design_scores_gemma":[0.004737474,0.0014877799,0.75556016,0.000101635516,0.00016572866,0.0000047240583,0.00018623327,0.000007835323,0.23525023,0.000040922914,0.0024045252,0.0000527272],"about_ca_topic_score_codex":0.00013718825,"about_ca_topic_score_gemma":0.00033643207,"teacher_disagreement_score":0.08114047,"about_ca_system_score_codex":0.00076098944,"about_ca_system_score_gemma":0.00032961913,"threshold_uncertainty_score":0.1989961},"labels":[],"label_agreement":null},{"id":"W2534459715","doi":"10.1016/s1470-2045(16)30510-1","title":"Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards","year":2016,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":198,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada; University of British Columbia","funders":"Boehringer Ingelheim","keywords":"Clinical trial; Medicine; Quality of life (healthcare); Cancer; Quality (philosophy); Health care; Family medicine; Nursing","score_opus":0.7267668108285595,"score_gpt":0.577075975979053,"score_spread":0.14969083484950652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2534459715","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025808427,0.9481663,0.0010698573,0.0011829815,0.0021434303,0.0008626496,0.041801546,0.0000119747565,0.0021803845],"genre_scores_gemma":[0.0027877016,0.99389803,0.00065104396,0.00043757312,0.0016831899,0.00010895345,0.000353974,0.000032963108,0.00004659531],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99236584,0.0006792294,0.005825239,0.00072627806,0.000064975524,0.00033841503],"domain_scores_gemma":[0.9866531,0.0052242884,0.007025418,0.00091709866,0.00009190443,0.00008822038],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.026065158,0.00026386912,0.006292969,0.00018804187,0.000046976336,0.00004136623,0.0008533997,0.0004100046,0.0003764646],"category_scores_gemma":[0.016572746,0.00018885601,0.000418759,0.00009995191,0.00019279537,0.00020530749,0.00040472293,0.0003973437,0.00000919201],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039507478,0.000061530365,0.034848575,0.0006500564,0.0010833062,0.0000018016243,0.00011209697,9.877023e-7,9.812822e-8,0.0017356502,0.002593526,0.9585173],"study_design_scores_gemma":[0.0021969196,0.00006356155,0.0032890737,0.0007812477,0.00015965782,7.8905776e-7,0.00003147403,0.000117147305,5.6982852e-8,0.0031060816,0.9900256,0.000228394],"about_ca_topic_score_codex":0.0011545676,"about_ca_topic_score_gemma":0.001481437,"teacher_disagreement_score":0.98743206,"about_ca_system_score_codex":0.00054682855,"about_ca_system_score_gemma":0.00080653187,"threshold_uncertainty_score":0.9917111},"labels":[],"label_agreement":null},{"id":"W2536396512","doi":"10.1016/s1470-2045(16)30508-3","title":"Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":643,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre; University of Ottawa; Ottawa Hospital","funders":"National Cancer Institute; AstraZeneca","keywords":"Osimertinib; Lung cancer; Medicine; Open label; Cancer; Oncology; Internal medicine; Adenocarcinoma; Clinical trial","score_opus":0.06472232217388303,"score_gpt":0.4461270129553907,"score_spread":0.3814046907815077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2536396512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96515226,0.0013761533,0.0011288644,0.0089955395,0.00065656455,0.01068486,0.00046547787,0.00011416468,0.011426136],"genre_scores_gemma":[0.9860511,0.00024408822,0.0026331726,0.0025221768,0.0004469859,0.0033260793,0.000063111,0.000064668704,0.004648625],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99810594,0.00018712594,0.0003962126,0.00053746667,0.00014954469,0.00062368193],"domain_scores_gemma":[0.9979934,0.0006895262,0.0002975699,0.00055756944,0.00029924727,0.0001626951],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028999447,0.00030042842,0.0008288603,0.00006545162,0.00026206867,0.00003291011,0.00038040295,0.00011315439,0.00022090919],"category_scores_gemma":[0.000104654995,0.00015909206,0.00006806381,0.00022388605,0.00011406251,0.00014927128,0.0001416532,0.00015175412,0.000026811816],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049166318,0.08704337,0.05548121,0.00043431288,0.007315743,0.0004341015,0.025355719,0.000054386805,0.18039238,0.00034903156,0.024906602,0.5690668],"study_design_scores_gemma":[0.7143987,0.06837609,0.01912476,0.0012998723,0.013269087,0.00007615656,0.0053220964,0.0023349102,0.06395339,0.00021068526,0.1103705,0.0012637479],"about_ca_topic_score_codex":0.00037573287,"about_ca_topic_score_gemma":0.00043423683,"teacher_disagreement_score":0.66523236,"about_ca_system_score_codex":0.00090732233,"about_ca_system_score_gemma":0.0005248894,"threshold_uncertainty_score":0.6487586},"labels":[],"label_agreement":null},{"id":"W2536769127","doi":"10.1016/s1470-2045(16)30532-0","title":"Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1086,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center","keywords":"Medicine; Oncology; Maintenance therapy; Clinical endpoint; Internal medicine; Systemic therapy; Radiation therapy; Lung cancer; Performance status; Progression-free survival; Targeted therapy; Chemotherapy; Cancer; Randomized controlled trial","score_opus":0.0456415097933536,"score_gpt":0.37584147898149683,"score_spread":0.3301999691881432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2536769127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9668931,0.002831329,0.0020802873,0.0029012095,0.00043787996,0.024635682,0.00012049249,0.00005715245,0.000042913343],"genre_scores_gemma":[0.9609918,0.0101583395,0.00047246882,0.0011232796,0.00031385542,0.026608866,0.000031657746,0.00006521489,0.00023453914],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99762785,0.00040116123,0.0005455039,0.00053541537,0.00031250983,0.00057753915],"domain_scores_gemma":[0.9962934,0.0019487635,0.00057085353,0.00051935064,0.0005413414,0.00012627972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058145315,0.0004309623,0.0014904472,0.00006595936,0.0001639399,0.000025641464,0.00019679913,0.00010499383,0.000117169235],"category_scores_gemma":[0.000077340796,0.00015590987,0.00015203496,0.00016823973,0.00018818295,0.00009662446,0.000025617748,0.0001420664,0.0000059591434],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.69973004,0.0066783717,0.2235446,0.00012870152,0.0018743754,0.000035962898,0.0026261432,0.000021559765,0.00006385303,0.0000029167534,0.00035956403,0.06493391],"study_design_scores_gemma":[0.9396849,0.027591968,0.026603876,0.0010402835,0.0007770882,0.0000053090293,0.0005176284,0.000876515,0.0006588357,0.00000507106,0.001973076,0.00026542728],"about_ca_topic_score_codex":0.000073837095,"about_ca_topic_score_gemma":0.00048410508,"teacher_disagreement_score":0.23995489,"about_ca_system_score_codex":0.00084296416,"about_ca_system_score_gemma":0.00045568764,"threshold_uncertainty_score":0.635782},"labels":[],"label_agreement":null},{"id":"W2539908888","doi":"10.1016/s1470-2045(16)30525-3","title":"Biochemical and imaging surveillance in Li-Fraumeni syndrome – Authors’ reply","year":2016,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Observational study; Medicine; Li–Fraumeni syndrome; Germline mutation; Internal medicine; Mutation; Genetics; Biology","score_opus":0.02532850457482967,"score_gpt":0.30306148105869074,"score_spread":0.2777329764838611,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2539908888","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.021566898,0.003890041,0.00007356372,0.9664459,0.0010040964,0.000638959,0.00007212823,0.00013116108,0.0061772247],"genre_scores_gemma":[0.058491044,0.0013164305,0.0005281688,0.9284163,0.007957346,0.00017040581,0.00018962694,0.0001581856,0.0027725108],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972321,0.00045689938,0.0004684731,0.00071952457,0.0002809971,0.00084201706],"domain_scores_gemma":[0.9980576,0.00048301835,0.00025436745,0.0010486409,0.00006493869,0.00009143013],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0010938396,0.0003643998,0.0013291619,0.00019172442,0.00004993363,0.000018314047,0.00035223627,0.0008631649,0.000122467],"category_scores_gemma":[0.00032055538,0.00024214487,0.00011551777,0.00021156896,0.00046476314,0.000028099052,0.00018352125,0.0029034861,0.00009793082],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022823094,0.000018772133,0.0015721575,0.00018908638,0.00009161948,0.0072364435,0.000121461235,2.097413e-7,0.008577201,0.000022929888,0.9777406,0.0042012786],"study_design_scores_gemma":[0.002992486,0.00022346259,0.0032705448,0.0004279605,0.00007521508,0.006958334,0.000008695212,0.000027597887,0.00031713484,0.00041136052,0.98499507,0.00029212245],"about_ca_topic_score_codex":0.00009760087,"about_ca_topic_score_gemma":0.000025516514,"teacher_disagreement_score":0.038029645,"about_ca_system_score_codex":0.00061677606,"about_ca_system_score_gemma":0.0003577225,"threshold_uncertainty_score":0.99939686},"labels":[],"label_agreement":null},{"id":"W2547090839","doi":"10.1016/s1470-2045(16)30522-8","title":"Sarcoma and germ-line DICER1 mutations","year":2016,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University; Jewish General Hospital","funders":"","keywords":"Sarcoma; Genetics; Biology; Proband; Cancer; Germline; Population; Gene; Mutation; Medicine; Pathology","score_opus":0.07094434047944337,"score_gpt":0.3597795450764759,"score_spread":0.28883520459703255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2547090839","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010862761,0.0028336016,0.000012423627,0.97262394,0.00035652932,0.0004771214,0.00010582035,0.00006678642,0.012661029],"genre_scores_gemma":[0.021041887,0.0019803224,0.0003490639,0.95685124,0.015623655,0.00028303268,0.00027677693,0.000049800587,0.0035442128],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987364,0.00018376436,0.00022595776,0.0002939917,0.00016112506,0.0003987619],"domain_scores_gemma":[0.99813426,0.001083307,0.00014955786,0.0005238736,0.000053965687,0.000055046632],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020875092,0.00022009786,0.00078820676,0.00007426549,0.000098472396,0.000012996416,0.00014209584,0.00044663798,0.00038294398],"category_scores_gemma":[0.0000635738,0.000108961765,0.00009674979,0.000060230006,0.0002707453,0.000018069166,0.00007961387,0.0007287343,0.00025980387],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000068796726,0.000082285165,0.00399494,0.00006386973,0.00028315553,0.0018596537,0.00010963834,5.1365546e-8,0.000030335443,0.00022190028,0.9446808,0.04860455],"study_design_scores_gemma":[0.002850912,0.00044313085,0.014019212,0.000099811085,0.00051178306,0.00085752807,0.000010534379,0.0000035192304,0.000038994785,0.0014665499,0.9795801,0.000117917225],"about_ca_topic_score_codex":0.000045728808,"about_ca_topic_score_gemma":0.000028959854,"teacher_disagreement_score":0.048486635,"about_ca_system_score_codex":0.00017143502,"about_ca_system_score_gemma":0.00014534457,"threshold_uncertainty_score":0.4443332},"labels":[],"label_agreement":null},{"id":"W2548570873","doi":"10.1016/s1470-2045(16)30312-6","title":"21st century pharmacovigilance: efforts, roles, and responsibilities","year":2016,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":80,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Pharmacovigilance; Biosimilar; Medicine; Agency (philosophy); Patient safety; Under-reporting; Business; Adverse effect; Pharmacology; Health care; Political science","score_opus":0.08451045535989471,"score_gpt":0.4112558686540705,"score_spread":0.3267454132941758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2548570873","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000009090669,0.984086,0.000005092745,0.001968736,0.0012500468,0.00058224157,0.00037879875,0.00008413191,0.011635906],"genre_scores_gemma":[0.00000774653,0.99048054,0.00020252801,0.0013350263,0.00072379684,0.00009554048,0.00004486242,0.000035940182,0.0070740446],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952571,0.0028024884,0.0006055993,0.0005590733,0.000046118595,0.00072961295],"domain_scores_gemma":[0.9961235,0.002745235,0.00036206076,0.0006758789,0.000046745474,0.000046599787],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0023526466,0.0004636403,0.0027780493,0.000101369,0.00021546955,0.000020565536,0.0006672798,0.0011202553,0.00097354053],"category_scores_gemma":[0.00026148878,0.00021269613,0.00030713927,0.00013982176,0.0012105197,0.00003505042,0.00039851834,0.0010885512,0.00032656323],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017662656,0.000050090766,0.0000066566486,0.0017273648,0.0005225161,0.000012644384,0.000040951516,1.783393e-9,0.00006393489,0.007633544,0.020076757,0.9696889],"study_design_scores_gemma":[0.000782102,0.00020589001,0.000006347567,0.0018779564,0.0008135959,0.00034808018,0.00003835348,5.515898e-8,0.00003554572,0.0005212221,0.9950723,0.00029853455],"about_ca_topic_score_codex":0.0000049115984,"about_ca_topic_score_gemma":0.000008326218,"teacher_disagreement_score":0.97499555,"about_ca_system_score_codex":0.00014000291,"about_ca_system_score_gemma":0.00031933983,"threshold_uncertainty_score":0.9999397},"labels":[],"label_agreement":null},{"id":"W2557127686","doi":"10.1016/s1470-2045(16)30579-4","title":"A common global risk stratification system for hepatoblastoma","year":2016,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Hepatoblastoma; Risk stratification; Medicine; Stratification (seeds); Oncology; Internal medicine","score_opus":0.05063985268760364,"score_gpt":0.34817495926777675,"score_spread":0.2975351065801731,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2557127686","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022067837,0.0004946089,0.0010510639,0.9464562,0.0038156752,0.002833575,0.001519508,0.00026689522,0.021494623],"genre_scores_gemma":[0.39943314,0.00023712,0.0022259525,0.54310435,0.04999917,0.0020789017,0.00050869124,0.00013254171,0.0022801422],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978,0.00045713544,0.0004234028,0.00044532202,0.0002885267,0.0005856139],"domain_scores_gemma":[0.99747986,0.00079166144,0.0005196542,0.0009915028,0.00016067908,0.0000566474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006549892,0.00030064367,0.0010801533,0.000038256327,0.00012396635,0.00001779832,0.0004615336,0.0010798548,0.000070896596],"category_scores_gemma":[0.00011924712,0.00017244313,0.00019511244,0.00009264589,0.00023120464,0.000015323214,0.000068480644,0.00096254575,0.00015714826],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008569547,0.000015843538,0.0021082775,0.00056237105,0.00020377895,0.000053324413,0.000048082595,9.4865044e-7,0.00018219571,0.00021475759,0.97785366,0.017899787],"study_design_scores_gemma":[0.0021486743,0.0014836785,0.0020039496,0.00021518698,0.0004976432,0.00032697068,0.000031209063,0.00007135631,0.00030128713,0.0011111675,0.99161774,0.00019114258],"about_ca_topic_score_codex":0.000098676,"about_ca_topic_score_gemma":0.0002497101,"teacher_disagreement_score":0.40335187,"about_ca_system_score_codex":0.0018837214,"about_ca_system_score_gemma":0.00054522546,"threshold_uncertainty_score":0.83288294},"labels":[],"label_agreement":null},{"id":"W2557305032","doi":"10.1016/s1470-2045(16)30625-8","title":"Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Hearing, Cochlea, Tinnitus, Genetics","field":"Neuroscience","cited_by":257,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; McMaster University","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Sodium thiosulfate; Clinical endpoint; Cisplatin; Hearing loss; Regimen; Ototoxicity; Phases of clinical research; Confidence interval; Randomized controlled trial; Clinical trial; Internal medicine; Audiology; Chemotherapy","score_opus":0.14479622522191735,"score_gpt":0.39017761747898005,"score_spread":0.2453813922570627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2557305032","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934183,0.000027321124,0.00008889376,0.00065829157,0.000497227,0.0048700636,0.000008669235,0.000023743189,0.0004075038],"genre_scores_gemma":[0.99784154,0.00009265073,0.0009872256,0.0003357979,0.00017030627,0.00047686222,0.0000014190199,0.000026814776,0.000067412526],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971382,0.00089695264,0.00070670625,0.0004226818,0.0003388789,0.0004965844],"domain_scores_gemma":[0.99525195,0.0035254657,0.0006692781,0.0003956406,0.00008742518,0.000070247785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013316906,0.00022789814,0.0010315402,0.00010078991,0.00010377143,0.000019837627,0.00069993077,0.00013018755,0.000019845384],"category_scores_gemma":[0.002305225,0.0001299914,0.00003671376,0.00028260436,0.00015268743,0.0001044431,0.00022518834,0.00024236063,0.000011273541],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5410853,0.000914504,0.0014388775,0.000030672567,0.00007643981,0.000008615567,0.0009938383,0.000042030035,0.4388734,0.000115002964,0.000017336797,0.01640397],"study_design_scores_gemma":[0.61627084,0.001736081,0.005380477,0.0001386621,0.000050029925,0.000002336009,0.000010213619,0.00017152294,0.3759761,0.00001186316,0.00012775883,0.0001241299],"about_ca_topic_score_codex":0.00013843317,"about_ca_topic_score_gemma":0.00036803973,"teacher_disagreement_score":0.07518556,"about_ca_system_score_codex":0.00026445236,"about_ca_system_score_gemma":0.0006293309,"threshold_uncertainty_score":0.53008956},"labels":[],"label_agreement":null},{"id":"W2557666746","doi":"10.1016/s1470-2045(16)30559-9","title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1200,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; University Health Network","funders":"Cancer Research UK; Clovis Oncology; Ovarian Cancer Research Fund; Stand Up To Cancer; Healthway; U.S. Department of Defense; National Ovarian Cancer Coalition; Ovarian Cancer Research Fund Alliance; American Association for Cancer Research","keywords":"Open label; Oncology; Medicine; Internal medicine; Ovarian carcinoma; Platinum; Ovarian cancer; Clinical trial; Cancer; Chemistry","score_opus":0.14688348836785434,"score_gpt":0.4311228869311657,"score_spread":0.2842393985633114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2557666746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9389584,0.000045597906,0.00016098154,0.04551269,0.0028035252,0.0017018901,0.00018641306,0.00007823498,0.010552277],"genre_scores_gemma":[0.9863991,0.0002041723,0.0018744243,0.006392455,0.0035674865,0.00032264204,0.00010226329,0.000037618487,0.0010998024],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99744517,0.00070461346,0.00058668846,0.00048816067,0.0002766014,0.00049876823],"domain_scores_gemma":[0.99790907,0.00076391915,0.0003131701,0.00071965385,0.00013594546,0.0001582655],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011505918,0.00023274336,0.0007727897,0.000121268626,0.000104701336,0.000037323796,0.00057967554,0.0002370173,0.0010078973],"category_scores_gemma":[0.00033995102,0.00014159924,0.000046594385,0.000195227,0.00031009517,0.00023901864,0.00014932407,0.00042226686,0.00015393637],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6919988,0.011997277,0.0075711594,0.000034891647,0.0006844923,0.0017047127,0.0065989406,0.000015418074,0.07713088,0.05217449,0.074634776,0.07545417],"study_design_scores_gemma":[0.74154055,0.005069163,0.0046818783,0.0001850904,0.00010270174,0.00021100549,0.00037045372,0.00032634553,0.0075494763,0.002479778,0.23716561,0.00031796173],"about_ca_topic_score_codex":0.0004780208,"about_ca_topic_score_gemma":0.00055232545,"teacher_disagreement_score":0.16253084,"about_ca_system_score_codex":0.0007400271,"about_ca_system_score_gemma":0.00041835604,"threshold_uncertainty_score":0.9999053},"labels":[],"label_agreement":null},{"id":"W2558422895","doi":"10.1016/s1470-2045(16)30630-1","title":"Reducing cisplatin ototoxicity in children: some hope and many questions","year":2016,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Hospital for Sick Children; SickKids Foundation","funders":"","keywords":"Ototoxicity; Medicine; Cisplatin; Amifostine; Etoposide; Hearing loss; Oncology; Audiology; Internal medicine; Chemotherapy","score_opus":0.0319433415984729,"score_gpt":0.3228738333002321,"score_spread":0.2909304917017592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2558422895","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08926875,0.0013305936,0.000019392859,0.90527546,0.00023139277,0.0009214411,0.00014369735,0.000047374477,0.0027618906],"genre_scores_gemma":[0.054674882,0.0021077234,0.0016129742,0.9207021,0.017050587,0.0002957421,0.00028010993,0.00006981507,0.003206064],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983262,0.00042373867,0.00027886295,0.00037035948,0.00013800857,0.00046286627],"domain_scores_gemma":[0.9988529,0.0003734496,0.00015711937,0.00054476684,0.000021575663,0.000050196533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062587234,0.0002383606,0.0008692069,0.00011457462,0.000079182544,0.000012086411,0.0001414091,0.00047122367,0.00015344954],"category_scores_gemma":[0.0000832904,0.00013037607,0.00007613575,0.00007505421,0.0002149046,0.000033305503,0.00009782382,0.0012567183,0.000065090695],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018765611,0.00011582153,0.009671544,0.00011717825,0.00038258036,0.001105901,0.00015578406,0.0000014157126,0.00011513777,0.0012058674,0.9517256,0.03521551],"study_design_scores_gemma":[0.004823076,0.0007765661,0.06519915,0.00043754408,0.00037222359,0.0015274107,0.000008311261,0.000012529527,0.000041591757,0.0022917837,0.92427725,0.00023254602],"about_ca_topic_score_codex":0.00026846502,"about_ca_topic_score_gemma":0.000028095132,"teacher_disagreement_score":0.05552761,"about_ca_system_score_codex":0.00024937853,"about_ca_system_score_gemma":0.00014631808,"threshold_uncertainty_score":0.54598856},"labels":[],"label_agreement":null},{"id":"W2558674288","doi":"10.1016/s1470-2045(16)30572-1","title":"Relevance of randomised controlled trials in oncology","year":2016,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":117,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Queen's University; CancerCare Manitoba; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Randomized controlled trial; Relevance (law); Medicine; Clinical trial; Medical physics; Intensive care medicine; Surrogate endpoint; Clinical significance; Alternative medicine; MEDLINE; Physical therapy; Internal medicine; Pathology","score_opus":0.19916237634647957,"score_gpt":0.4003345978127974,"score_spread":0.20117222146631783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2558674288","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00001833431,0.8726778,0.00017893124,0.001663192,0.0016429558,0.0027424295,0.00040887616,0.000020886302,0.12064662],"genre_scores_gemma":[0.00015097998,0.99460995,0.0001871925,0.0005210877,0.0017014319,0.0010535456,0.000014812705,0.0000596972,0.0017013106],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9907885,0.0016971333,0.006151612,0.00060064887,0.00004015575,0.0007219168],"domain_scores_gemma":[0.9727542,0.017809369,0.008436084,0.0008609385,0.000053959393,0.0000854674],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.024749523,0.00048814574,0.025655499,0.00046581365,0.000052126692,0.000020746083,0.001101179,0.00097479654,0.0008796213],"category_scores_gemma":[0.015653888,0.00029020093,0.001913343,0.00026166416,0.00036619685,0.000121990175,0.00013518176,0.00069303246,0.0007876684],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003670778,0.00011685209,0.000019287041,0.0011949715,0.0006208607,0.000013369873,0.00013387924,0.0000021861758,3.2702894e-7,0.11055506,0.0073240353,0.8763484],"study_design_scores_gemma":[0.05084454,0.0002689492,0.000012593816,0.001393278,0.00019187389,0.0000137727075,0.000007815882,0.0000051895227,3.838236e-7,0.022353098,0.9246069,0.00030158038],"about_ca_topic_score_codex":0.00010025041,"about_ca_topic_score_gemma":0.0001226472,"teacher_disagreement_score":0.9172829,"about_ca_system_score_codex":0.001087666,"about_ca_system_score_gemma":0.00085845235,"threshold_uncertainty_score":0.99999034},"labels":[],"label_agreement":null},{"id":"W2558685144","doi":"10.1016/s1470-2045(16)30577-0","title":"Referral criteria for outpatient specialty palliative cancer care: an international consensus","year":2016,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":307,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute; National Institutes of Health; Multinational Association of Supportive Care in Cancer","keywords":"Medicine; Referral; Palliative care; Specialty; Family medicine; Ambulatory care; Health care; Nursing","score_opus":0.5375981897176354,"score_gpt":0.594040011233374,"score_spread":0.05644182151573862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2558685144","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017640505,0.9800139,0.00003750136,0.0023657633,0.0032560339,0.0012870005,0.002137138,0.000033826618,0.010692401],"genre_scores_gemma":[0.000053468368,0.9888888,0.0017795702,0.0005873833,0.0069642887,0.00047637257,0.0004743251,0.00004025776,0.0007355129],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982029,0.000366747,0.0005663352,0.00034843743,0.00019059662,0.00032498132],"domain_scores_gemma":[0.99752146,0.00090182456,0.0005842651,0.00043471705,0.0004695887,0.000088131834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035117473,0.00029136083,0.0022356452,0.000084877174,0.000050472678,0.000007676744,0.0003868017,0.00033679785,0.0003531016],"category_scores_gemma":[0.00043144877,0.0001552411,0.00032174485,0.00007394304,0.00024572382,0.000024564615,0.000081951555,0.000298745,0.000027684944],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008556651,0.00009975686,0.0003224033,0.005998799,0.00077123364,0.000022812797,0.0030340473,1.2719785e-7,0.0000031630761,0.0017957716,0.028252268,0.95884395],"study_design_scores_gemma":[0.0017308735,0.0008480833,0.00010051215,0.010093216,0.0008188575,0.0000095607575,0.00027398625,0.0000018609363,0.000009284194,0.00015362499,0.98578876,0.0001713899],"about_ca_topic_score_codex":0.00008846269,"about_ca_topic_score_gemma":0.0003166568,"teacher_disagreement_score":0.9586726,"about_ca_system_score_codex":0.0008665414,"about_ca_system_score_gemma":0.0008320853,"threshold_uncertainty_score":0.63305485},"labels":[],"label_agreement":null},{"id":"W2559562829","doi":"10.1016/s1470-2045(16)30558-7","title":"Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":254,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Polycythaemia; Ruxolitinib; Internal medicine; Polycythemia vera; Clinical endpoint; Myeloproliferative neoplasm; Randomized controlled trial; Pediatrics; Myelofibrosis","score_opus":0.16147605963586667,"score_gpt":0.4526537947164275,"score_spread":0.2911777350805609,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559562829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9412561,0.0011108342,0.00013235652,0.040202383,0.00023916444,0.015564099,0.00019566849,0.000033439213,0.0012659455],"genre_scores_gemma":[0.98420393,0.0012537964,0.0003227449,0.0011716305,0.0005380358,0.010004262,0.000011015725,0.000036029163,0.0024585251],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99726325,0.0009768902,0.00065605354,0.00039186023,0.00021411684,0.0004978315],"domain_scores_gemma":[0.98943895,0.009074833,0.00040855867,0.00077745126,0.00017282531,0.00012737194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018274601,0.00033125165,0.0021294018,0.00006940554,0.00027693447,0.000027264385,0.00038594738,0.00010006586,0.00018839755],"category_scores_gemma":[0.000582151,0.00011944914,0.0001847017,0.000109073626,0.00024017502,0.00005205218,0.00006370582,0.000092325674,0.00003064182],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9003091,0.01888389,0.010002546,0.00001939407,0.003543913,0.00010422305,0.0030063747,0.0000013322008,0.00376391,0.0014177873,0.0020908753,0.056856684],"study_design_scores_gemma":[0.8149011,0.06080186,0.008061018,0.000054375912,0.0018761286,0.000064758824,0.0005275814,0.00008398751,0.003660789,0.00018112375,0.10963235,0.00015488482],"about_ca_topic_score_codex":0.00017280699,"about_ca_topic_score_gemma":0.00018570098,"teacher_disagreement_score":0.10754148,"about_ca_system_score_codex":0.00046144731,"about_ca_system_score_gemma":0.00055138994,"threshold_uncertainty_score":0.48709947},"labels":[],"label_agreement":null},{"id":"W2560704457","doi":"10.1016/s1470-2045(16)30624-6","title":"Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":961,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital; Princess Margaret Cancer Centre; Juravinski Cancer Centre; University of Toronto; McMaster University","funders":"National Cancer Institute; University of Oxford","keywords":"Nivolumab; Ipilimumab; Medicine; Tolerability; Internal medicine; Lung cancer; Oncology; Cancer; Surgery; Adverse effect; Immunotherapy","score_opus":0.08906368332496893,"score_gpt":0.43502498492940195,"score_spread":0.345961301604433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560704457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9846685,0.00097119174,0.00013924694,0.005578604,0.00050478487,0.006190637,0.00043307838,0.000057448902,0.0014565157],"genre_scores_gemma":[0.9865239,0.002748437,0.0012613916,0.00074174337,0.00050557515,0.001851879,0.000055939985,0.000057718884,0.0062533855],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978866,0.00017156283,0.00068080844,0.0005446956,0.00017375576,0.0005425901],"domain_scores_gemma":[0.99783057,0.00043721157,0.00043599308,0.0009868011,0.0001849954,0.00012444658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088625256,0.00030718854,0.0011409156,0.00006967179,0.00017975635,0.000015966887,0.0005466697,0.00014390163,0.00012511974],"category_scores_gemma":[0.00007398571,0.00016516903,0.00008680905,0.00016615662,0.00017423432,0.000114346505,0.000118499745,0.00010818528,0.000008291192],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42255557,0.016206112,0.0012320387,0.0002137974,0.0015053928,0.000090895126,0.0051192855,0.00005194705,0.1997503,0.000012973055,0.002281403,0.35098028],"study_design_scores_gemma":[0.743577,0.09012265,0.0025951446,0.00037695683,0.0012648251,0.0000464164,0.001078899,0.0023346515,0.06256197,0.000042162355,0.095542185,0.0004571658],"about_ca_topic_score_codex":0.002656492,"about_ca_topic_score_gemma":0.0066185766,"teacher_disagreement_score":0.35052314,"about_ca_system_score_codex":0.0011257086,"about_ca_system_score_gemma":0.00076955545,"threshold_uncertainty_score":0.67353976},"labels":[],"label_agreement":null},{"id":"W2560708148","doi":"10.1016/s1470-2045(16)30632-5","title":"Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":236,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Royal Victoria Regional Health Centre; Royal Victoria Hospital; Dalhousie University","funders":"Pharmacyclics","keywords":"Rituximab; Medicine; Ibrutinib; Internal medicine; Population; Waldenstrom macroglobulinemia; Oncology; Lymphoma; Leukemia; Chronic lymphocytic leukemia","score_opus":0.10975313428633213,"score_gpt":0.454956165901559,"score_spread":0.3452030316152269,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560708148","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927904,0.000020880509,0.00006226933,0.0015135179,0.00055026385,0.0034907798,0.00021953142,0.000043965843,0.001308415],"genre_scores_gemma":[0.99469846,0.000053979118,0.0030016073,0.0005005107,0.00086837733,0.0002533087,0.00018662833,0.00004327385,0.00039384994],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977619,0.00026039284,0.0005112894,0.00045289332,0.00046793305,0.00054560526],"domain_scores_gemma":[0.99727285,0.0006597445,0.00034631425,0.00090562436,0.000645111,0.00017036239],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001014993,0.00020225292,0.0007796208,0.000087055785,0.00009315627,0.000029253457,0.0010931217,0.00016188042,0.0002521218],"category_scores_gemma":[0.00057741784,0.00010385498,0.0000337319,0.00016508505,0.00039205202,0.0003194936,0.00026340707,0.000203905,0.000030128811],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.794345,0.03701985,0.003163285,0.00010717449,0.0006133705,0.00017939425,0.0009003841,9.942744e-7,0.0061845076,0.00093331205,0.0037274286,0.15282528],"study_design_scores_gemma":[0.9372995,0.033352926,0.0018556232,0.00008862187,0.0001424949,0.00005159631,0.00012291329,0.00067592436,0.0016514851,0.00013138622,0.024455369,0.00017214447],"about_ca_topic_score_codex":0.00020460262,"about_ca_topic_score_gemma":0.00016246524,"teacher_disagreement_score":0.15265313,"about_ca_system_score_codex":0.0034755317,"about_ca_system_score_gemma":0.0028967324,"threshold_uncertainty_score":0.90883946},"labels":[],"label_agreement":null},{"id":"W2562329111","doi":"10.1016/s1470-2045(16)30652-0","title":"Access to essential medicines for children with cancer: a joint SIOP-CCI position statement","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; McMaster University; University of Toronto","funders":"","keywords":"Medicine; Position statement; Statement (logic); Joint (building); Position (finance); Position paper; MEDLINE; Cancer; Oncology; Family medicine; Internal medicine; Pathology; Law","score_opus":0.12794439905631794,"score_gpt":0.4782464798019758,"score_spread":0.3503020807456579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2562329111","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4149876,0.00033263266,0.0020819702,0.57976115,0.00026806365,0.0011425586,0.000043117594,0.00003646383,0.001346457],"genre_scores_gemma":[0.96384025,0.0020749178,0.0005158221,0.030423734,0.0023709056,0.0004989226,0.000011203201,0.000014683837,0.0002495599],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991423,0.00007183455,0.0001686228,0.00017619126,0.0001419169,0.00029916802],"domain_scores_gemma":[0.9992798,0.00026986928,0.000105464926,0.00015101339,0.0000914939,0.00010236468],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042881095,0.00009794154,0.00035532415,0.000023230077,0.00011765014,0.000011533083,0.00012936567,0.000033757442,0.0003642884],"category_scores_gemma":[0.000088427754,0.00003897765,0.000030098554,0.00007874068,0.00009036672,0.00007399052,0.000090163674,0.000086605185,0.000020140462],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025174968,0.00060221023,0.05088035,0.00022686014,0.002000971,0.000046846053,0.001358074,0.00002365383,0.053295713,0.0012686965,0.43266496,0.4324567],"study_design_scores_gemma":[0.011345786,0.0036018034,0.19937623,0.00021194243,0.00078335335,0.000099821555,0.00009049371,0.000024740732,0.012376573,0.00043207392,0.77149284,0.00016433168],"about_ca_topic_score_codex":0.00019494642,"about_ca_topic_score_gemma":0.0004074942,"teacher_disagreement_score":0.5493374,"about_ca_system_score_codex":0.00014680052,"about_ca_system_score_gemma":0.00009553916,"threshold_uncertainty_score":0.39887026},"labels":[],"label_agreement":null},{"id":"W2566177347","doi":"10.1016/s1470-2045(16)30641-6","title":"Can modelling of PSA dynamics accelerate drug development for prostate cancer?","year":2016,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Docetaxel; Oncology; Cancer; Retrospective cohort study; Clinical trial; Internal medicine; Mitoxantrone; Prednisone; Gynecology; Chemotherapy","score_opus":0.12021579097227539,"score_gpt":0.37582139221186084,"score_spread":0.2556056012395854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2566177347","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0083542075,0.0015135738,0.00049335376,0.9840013,0.0005953672,0.0022977681,0.00083832804,0.000050735827,0.0018553619],"genre_scores_gemma":[0.02701667,0.023583645,0.008289097,0.7115027,0.025018068,0.0077558067,0.00470432,0.00045360904,0.19167612],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99786955,0.00012638299,0.00043740412,0.0003980908,0.0003059496,0.0008626096],"domain_scores_gemma":[0.9984569,0.00035339466,0.00032840806,0.00046068837,0.00033296453,0.000067651876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058132457,0.00030585146,0.0011205192,0.00012272234,0.00013851601,0.000013113644,0.00037720526,0.00039965048,0.00006319668],"category_scores_gemma":[0.000015110717,0.0001605085,0.00012555053,0.00011343763,0.00025103395,0.000025003079,0.00010924474,0.00091175095,0.0000096694075],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022731014,0.000055932254,0.0006130937,0.0018414336,0.00089319854,0.00016579716,0.0018024123,0.00010792924,0.0001000799,0.00010240216,0.9377052,0.054339375],"study_design_scores_gemma":[0.004651324,0.0003146931,0.000035301,0.0005043679,0.00021584623,0.000017292376,0.0000534513,0.0015809345,0.0015684022,0.0010919776,0.9897497,0.00021666053],"about_ca_topic_score_codex":0.00027239585,"about_ca_topic_score_gemma":0.0004673856,"teacher_disagreement_score":0.27249864,"about_ca_system_score_codex":0.0016189154,"about_ca_system_score_gemma":0.0025728128,"threshold_uncertainty_score":0.65453464},"labels":[],"label_agreement":null},{"id":"W2582286477","doi":"10.1016/s1470-2045(17)30064-5","title":"Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":219,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Internal medicine; Placebo; Regimen; Clinical endpoint; Oncology; Chemotherapy; Phases of clinical research; Response Evaluation Criteria in Solid Tumors; Clinical trial; Head and neck squamous-cell carcinoma; Paclitaxel; Surgery; Head and neck cancer; Radiation therapy; Pathology","score_opus":0.04651944937229081,"score_gpt":0.3421933897887764,"score_spread":0.2956739404164856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2582286477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952439,0.0005871544,0.000012629785,0.0002549468,0.00026711987,0.002848925,0.000078291305,0.000004712456,0.0007023164],"genre_scores_gemma":[0.999025,0.000047096044,0.00014026697,0.0001045039,0.00018973193,0.00032781865,0.000025632382,0.000020948788,0.00011903806],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99837077,0.00041558588,0.00039830146,0.0003470962,0.00015187182,0.00031636635],"domain_scores_gemma":[0.99834114,0.00025406005,0.00055046583,0.00070418714,0.000085467225,0.000064668784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007083409,0.00022670755,0.0007830232,0.000033458,0.00018386752,0.00003738397,0.00039456558,0.00013868036,0.00001683243],"category_scores_gemma":[0.00031662235,0.00011431215,0.00007234619,0.000053948424,0.0004129216,0.000008713456,0.00017831437,0.00020474718,5.560299e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9825686,0.00045373297,0.0123005975,0.000046344052,0.00010013441,0.0000065258123,0.00027460713,0.000019649617,0.0028116114,0.000009602695,0.00024021535,0.001168354],"study_design_scores_gemma":[0.97964203,0.0076480657,0.005564186,0.000031201595,0.00021399882,0.000008197683,0.000047207563,0.000121679484,0.0058688833,0.000029431516,0.0006550661,0.00017007413],"about_ca_topic_score_codex":0.00013964814,"about_ca_topic_score_gemma":0.00075725024,"teacher_disagreement_score":0.007194333,"about_ca_system_score_codex":0.000039136972,"about_ca_system_score_gemma":0.00022329236,"threshold_uncertainty_score":0.46615142},"labels":[],"label_agreement":null},{"id":"W2583378635","doi":"10.1016/s1470-2045(17)30041-4","title":"Advancing access and equity: the vision of a new generation in cancer control","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Global Health and Surgery","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"International agency; Cancer; Cancer incidence; Cancer prevention; Disease; Incidence (geometry); Medicine; Mortality rate; Internal medicine","score_opus":0.13593512422011397,"score_gpt":0.5034144697509542,"score_spread":0.36747934553084016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2583378635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89080566,0.0012299805,0.00009075689,0.10347864,0.0003141791,0.00029017558,0.0000037360662,0.000004995166,0.0037818542],"genre_scores_gemma":[0.990229,0.001116077,0.000038623435,0.007773219,0.000734249,0.000014924135,0.0000012385035,0.000002887715,0.00008978434],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9994148,0.000083776504,0.00014158472,0.00008001739,0.00007347665,0.00020631739],"domain_scores_gemma":[0.999393,0.00013309915,0.00013331315,0.00025745307,0.000030293042,0.000052842577],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009765004,0.000043114313,0.0002875772,0.00001572912,0.000113162874,0.00001356686,0.00014095646,0.000050040046,0.000022823124],"category_scores_gemma":[0.00026008525,0.000021775164,0.000015334479,0.000026468231,0.00008044868,0.000061086015,0.000084144645,0.00012229582,0.0000011697238],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017739207,0.00007170179,0.31932384,0.00014433826,0.000027731016,0.000029901294,0.00068416406,0.00011337968,0.005648641,0.0019550219,0.05065598,0.6195714],"study_design_scores_gemma":[0.005902014,0.00040656084,0.8824617,0.0001097179,0.00005179811,0.0000348134,0.000054468688,0.0053810733,0.00029981925,0.0018865425,0.103354245,0.00005723636],"about_ca_topic_score_codex":0.0024232096,"about_ca_topic_score_gemma":0.006634818,"teacher_disagreement_score":0.6195141,"about_ca_system_score_codex":0.000069267735,"about_ca_system_score_gemma":0.0002971439,"threshold_uncertainty_score":0.37023842},"labels":[],"label_agreement":null},{"id":"W2583641997","doi":"10.1016/s1470-2045(17)30003-7","title":"Adjuvant ipilimumab for stage III melanoma: the patient voice","year":2017,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Ipilimumab; Medicine; Internal medicine; Melanoma; Discontinuation; Placebo; Adverse effect; Oncology; Adjuvant; Adjuvant therapy; Hazard ratio; Cancer; Gastroenterology; Immunotherapy; Pathology; Cancer research","score_opus":0.06020058253608758,"score_gpt":0.3461598513023324,"score_spread":0.28595926876624483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2583641997","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0051363246,0.0036472643,0.000042258547,0.9694189,0.002926593,0.002252573,0.00036730716,0.000068360554,0.016140444],"genre_scores_gemma":[0.0085595865,0.0010437315,0.00014781859,0.9419667,0.016942618,0.00076823623,0.0003801051,0.00008588958,0.03010528],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979599,0.0002674504,0.00042164492,0.00039808586,0.00028583387,0.00066709204],"domain_scores_gemma":[0.99662423,0.00086172286,0.00063714356,0.0017251282,0.00011585996,0.000035940906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008994337,0.0003365507,0.0011054764,0.00004904295,0.00047273547,0.00004310396,0.0008768646,0.00071148976,0.0002780311],"category_scores_gemma":[0.0001075525,0.00016041749,0.00037289795,0.000051059073,0.00054835214,0.00003009875,0.00013287671,0.0015634461,0.00006075862],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005822307,0.000046595498,0.00002713586,0.00018305029,0.0005476059,0.00021966528,0.0006878109,3.6073192e-7,0.00019585756,0.000026889873,0.9615363,0.030706419],"study_design_scores_gemma":[0.007692222,0.0019813005,0.0005610025,0.000105925785,0.00038934316,0.00021220127,0.0001295599,0.000018348817,0.00012320197,0.00012465964,0.98845226,0.00020996768],"about_ca_topic_score_codex":0.00035222486,"about_ca_topic_score_gemma":0.00021129644,"teacher_disagreement_score":0.030496452,"about_ca_system_score_codex":0.00038803738,"about_ca_system_score_gemma":0.0005236422,"threshold_uncertainty_score":0.6792482},"labels":[],"label_agreement":null},{"id":"W2587429794","doi":"10.1016/s1470-2045(17)30072-4","title":"Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Hedgehog Signaling Pathway Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":206,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Merck Sharp and Dohme; Bristol-Myers Squibb","keywords":"Vismodegib; Medicine; Basal cell carcinoma; Regimen; Placebo; Internal medicine; Population; Dosing; Basal Cell Nevus Syndrome; Oncology; Urology; Pathology; Basal cell","score_opus":0.0508492730864267,"score_gpt":0.339065832435165,"score_spread":0.28821655934873835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587429794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99100286,0.00027486647,0.00019778698,0.0010859261,0.0005738672,0.0029279036,0.000023062148,0.000019398321,0.003894346],"genre_scores_gemma":[0.9969759,0.000051479892,0.00030092697,0.00052427355,0.0010452968,0.00057426933,0.00006243935,0.0000447974,0.00042061417],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997681,0.00042675482,0.0004924725,0.000578342,0.00020105975,0.00062036974],"domain_scores_gemma":[0.997757,0.0001631174,0.00060043344,0.0012447846,0.00014128952,0.00009335068],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011954035,0.0003388997,0.001016612,0.000071946946,0.0004153599,0.000075258795,0.00075283245,0.0001972322,0.0000074001027],"category_scores_gemma":[0.00025442484,0.00022049967,0.00017868356,0.000051461575,0.00036706156,0.00001223315,0.0003576865,0.00032615312,0.000009276608],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97570765,0.0010477803,0.01081731,0.000018768907,0.00024322855,0.000037847447,0.00047297816,0.000099150384,0.009466964,0.000020971629,0.0011108812,0.0009564454],"study_design_scores_gemma":[0.9794144,0.0030409638,0.0017995383,0.00003293505,0.00012753844,0.000004025308,0.000108487104,0.00014523501,0.009705246,0.00001995483,0.0052964664,0.00030518844],"about_ca_topic_score_codex":0.00014882139,"about_ca_topic_score_gemma":0.0005043791,"teacher_disagreement_score":0.009017771,"about_ca_system_score_codex":0.00009871873,"about_ca_system_score_gemma":0.00019396385,"threshold_uncertainty_score":0.89917153},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W2589695286","doi":"10.1016/s1470-2045(17)30085-2","title":"Predicting outcomes after a positive interim FDG-PET scan in advanced Hodgkin's lymphoma","year":2017,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lymphoma; Rituximab; Oncology; Stage (stratigraphy); Internal medicine; Interim; Classical Hodgkin lymphoma; Follicular lymphoma; Hodgkin lymphoma; Progression-free survival; Positron emission tomography; Nuclear medicine; Overall survival","score_opus":0.033576701464211094,"score_gpt":0.3488544561523942,"score_spread":0.3152777546881831,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589695286","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.42997777,0.0005862024,0.0000011056451,0.55358124,0.000987602,0.00093031407,0.00018396224,0.00007223627,0.013679585],"genre_scores_gemma":[0.56459385,0.00031784127,0.00033821486,0.42780113,0.003657425,0.0010353532,0.00024342543,0.00007202449,0.0019407296],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973447,0.00036042838,0.0004894936,0.0006473403,0.00030859507,0.00084947306],"domain_scores_gemma":[0.9973265,0.00073617935,0.00048425546,0.0012863721,0.000084633284,0.00008204291],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00039427617,0.0005268082,0.0019553127,0.00017272588,0.00013205435,0.000053450884,0.000528485,0.00056352536,0.00014318789],"category_scores_gemma":[0.00022577729,0.00032203572,0.00029304507,0.00007483361,0.0003100456,0.000084517975,0.00030236025,0.00087323977,0.00013732097],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027555886,0.00060599484,0.5118071,0.00022702312,0.0009913004,0.04411148,0.0011140343,0.0000010309444,0.000017076027,0.000027792013,0.3920521,0.046289504],"study_design_scores_gemma":[0.009072025,0.00086897984,0.5962225,0.0006985021,0.00037178578,0.0011319666,0.000058666228,0.000011802131,0.000046289886,0.000098212964,0.39116666,0.00025261907],"about_ca_topic_score_codex":0.000645569,"about_ca_topic_score_gemma":0.00059488084,"teacher_disagreement_score":0.13461608,"about_ca_system_score_codex":0.0016987572,"about_ca_system_score_gemma":0.00045922413,"threshold_uncertainty_score":0.99992317},"labels":[],"label_agreement":null},{"id":"W2591745019","doi":"10.1016/s1470-2045(17)30121-3","title":"The drama of prostate cancer diagnostics","year":2017,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Prostate; Biopsy; Cancer; Population; Prostate biopsy; Gynecology; Prostate-specific antigen; Management of prostate cancer; Radiology; Oncology; Internal medicine","score_opus":0.05375259614490459,"score_gpt":0.36606365046757433,"score_spread":0.31231105432266976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591745019","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0039464347,0.01941359,6.1379404e-7,0.9651595,0.0017099063,0.0012363654,0.00039752436,0.000030528245,0.008105559],"genre_scores_gemma":[0.010628463,0.2244297,0.000087555585,0.7290225,0.018795265,0.002378384,0.0002836009,0.00010764731,0.014266871],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998259,0.0001895046,0.00036336717,0.00030349367,0.00029331446,0.00059132674],"domain_scores_gemma":[0.99606174,0.0015718522,0.00068625377,0.0014209542,0.00020970665,0.00004946485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045416757,0.00028239615,0.0010690846,0.000030786545,0.00032256194,0.00004007706,0.00060297357,0.00044249222,0.000075076954],"category_scores_gemma":[0.0002980748,0.00012945337,0.00017579888,0.00005124269,0.0007796928,0.000022010832,0.00016267075,0.0013900467,0.000041817795],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023164756,0.000063142055,0.007880659,0.00023423569,0.0005272765,0.00073724956,0.0002919221,0.000001314529,0.0000049694113,0.0001255178,0.9584858,0.031416267],"study_design_scores_gemma":[0.0019696099,0.0007865025,0.0077967783,0.00036968227,0.0006899593,0.00006457304,0.00002171643,0.000004085279,0.00022711864,0.00073628186,0.98720473,0.00012894694],"about_ca_topic_score_codex":0.00043897817,"about_ca_topic_score_gemma":0.00022234378,"teacher_disagreement_score":0.23613696,"about_ca_system_score_codex":0.0004095459,"about_ca_system_score_gemma":0.00084285776,"threshold_uncertainty_score":0.60391384},"labels":[],"label_agreement":null},{"id":"W2592144107","doi":"10.1016/s1470-2045(17)30074-8","title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","year":2017,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2408,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Cancer Institute","keywords":"Guideline; Clinical trial; Medicine; Medical physics; Response Evaluation Criteria in Solid Tumors; Immunotherapy; Cancer; Intensive care medicine; Oncology; Internal medicine; Pathology","score_opus":0.8623875272759276,"score_gpt":0.6325735133841923,"score_spread":0.22981401389173528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592144107","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000045233654,0.98602355,0.00024217449,0.005322613,0.0016004028,0.006041316,0.0005378904,0.000050149818,0.00013666535],"genre_scores_gemma":[0.0000020180644,0.9689936,0.020674385,0.002767974,0.0031763674,0.0021363564,0.00012491312,0.00010048696,0.002023891],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953505,0.0016178797,0.001952556,0.000417611,0.00012230272,0.0005391888],"domain_scores_gemma":[0.9759513,0.020703636,0.0016317893,0.0012187395,0.00045098198,0.000043549768],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.020591635,0.0004207717,0.005353143,0.00019059339,0.00020938966,0.00008925449,0.00062823476,0.0006114243,0.000033310425],"category_scores_gemma":[0.025401723,0.00024230272,0.00095107686,0.00015425762,0.00022029044,0.00005381668,0.0000633879,0.00034541028,0.0000053774556],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033729736,0.00006217045,0.000004426758,0.0038885102,0.000519349,0.0000119247015,0.000065733955,8.306854e-8,0.00018506774,0.000015354522,0.020008754,0.9415089],"study_design_scores_gemma":[0.008306851,0.0012825343,0.00004781538,0.008308829,0.0013929557,0.0001796262,0.000016313932,0.000041807747,0.0000065314375,0.00013789204,0.9800229,0.0002559164],"about_ca_topic_score_codex":0.00009149541,"about_ca_topic_score_gemma":0.000104667386,"teacher_disagreement_score":0.96001416,"about_ca_system_score_codex":0.00050188135,"about_ca_system_score_gemma":0.0016844468,"threshold_uncertainty_score":0.9880818},"labels":[],"label_agreement":null},{"id":"W2593722738","doi":"10.1016/s1470-2045(17)30168-7","title":"Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Clusterin in disease pathology","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Regional Municipality of Durham; Hamilton Health Sciences; Juravinski Cancer Centre; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Docetaxel; Medicine; Prostate cancer; Prednisone; Clusterin; Internal medicine; Clinical endpoint; Oncology; Population; Enzalutamide; Randomized controlled trial; Chemotherapy; Cancer","score_opus":0.0888808162791997,"score_gpt":0.4204282111513942,"score_spread":0.33154739487219453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2593722738","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9794723,0.00009022466,0.00007549066,0.0044161323,0.0002610318,0.015149997,0.00018884166,0.000018848848,0.00032718334],"genre_scores_gemma":[0.9914568,0.000084027844,0.002709819,0.00032826685,0.00016970707,0.004761552,0.00012731738,0.000031217707,0.0003312957],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99830836,0.0003486672,0.00042703684,0.0003715248,0.00018141432,0.000362992],"domain_scores_gemma":[0.99798286,0.00055737863,0.0006103695,0.00054027204,0.00020370937,0.000105412655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080961525,0.00020427343,0.00094888406,0.000065733366,0.00025909432,0.00009250517,0.00027553958,0.00007007604,0.000025498157],"category_scores_gemma":[0.00073619414,0.00011951398,0.0000233039,0.00006620922,0.0003417891,0.00017141431,0.000104950144,0.00015800234,0.0000011870426],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9856129,0.004259092,0.0011510163,0.0001388955,0.0002075093,0.00007355506,0.0007678889,0.000015937203,0.00028349555,0.00013293266,0.00028052938,0.007076217],"study_design_scores_gemma":[0.9714425,0.017874945,0.0066991337,0.00012771778,0.00068827975,0.000011880296,0.00013042077,0.0012942951,0.000047494104,0.00014740968,0.0013837699,0.00015210992],"about_ca_topic_score_codex":0.00031928913,"about_ca_topic_score_gemma":0.0026577243,"teacher_disagreement_score":0.014170388,"about_ca_system_score_codex":0.0001659452,"about_ca_system_score_gemma":0.0004690737,"threshold_uncertainty_score":0.48736385},"labels":[],"label_agreement":null},{"id":"W2594529508","doi":"10.1016/s1470-2045(17)30180-8","title":"Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":491,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Dacarbazine; Medicine; Neuroblastoma RAS viral oncogene homolog; Hazard ratio; Melanoma; Internal medicine; Clinical endpoint; Population; Adverse effect; Oncology; Progression-free survival; Randomized controlled trial; Vemurafenib; Cancer; Confidence interval; Chemotherapy; Metastatic melanoma; Cancer research; Colorectal cancer","score_opus":0.05756250214883237,"score_gpt":0.3665577832550817,"score_spread":0.30899528110624935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594529508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9826784,0.00012876837,0.000021809992,0.00052769243,0.0009830422,0.0021465197,0.00007460718,0.000012372542,0.013426766],"genre_scores_gemma":[0.9974016,0.00014673085,0.000793519,0.0003195207,0.00063837506,0.00026416662,0.00019610162,0.000030318266,0.00020968956],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981857,0.00033407993,0.00034605662,0.000476838,0.00015035163,0.00050699146],"domain_scores_gemma":[0.9981112,0.00012487055,0.00041527534,0.0011605998,0.000085068365,0.000103014376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069734885,0.00024678957,0.00063579436,0.000033616565,0.00026037375,0.0000720822,0.0012516886,0.00020074655,0.000046228626],"category_scores_gemma":[0.00057658675,0.00016084609,0.00004649681,0.000052565007,0.00020600152,0.000016208982,0.0004937221,0.0002162379,0.000025963973],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9413875,0.0017882733,0.0025046552,0.000012705067,0.00016538399,0.000037572514,0.00010189913,0.0000060338884,0.03283108,0.0001461193,0.0011645388,0.01985425],"study_design_scores_gemma":[0.89130294,0.013356244,0.0029745344,0.00001950546,0.000071828734,0.000003948862,0.000038682945,0.000037227255,0.007827321,0.000021356254,0.084079355,0.00026705253],"about_ca_topic_score_codex":0.000045433368,"about_ca_topic_score_gemma":0.00043202387,"teacher_disagreement_score":0.082914814,"about_ca_system_score_codex":0.000046626126,"about_ca_system_score_gemma":0.00020772261,"threshold_uncertainty_score":0.6559113},"labels":[],"label_agreement":null},{"id":"W2603276734","doi":"10.1016/s1470-2045(17)30162-6","title":"Stereotactic body radiotherapy for patients with hepatocellular carcinoma and intermediate grade cirrhosis","year":2017,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Hepatocellular carcinoma; Medicine; Cirrhosis; Liver transplantation; Milan criteria; Internal medicine; Liver function; Gastroenterology; Oncology; Transplantation","score_opus":0.07017228260266349,"score_gpt":0.29543840819648487,"score_spread":0.22526612559382136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603276734","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.68229705,0.0014813659,0.00002579831,0.3119827,0.00049863564,0.0030824307,0.00016825099,0.000064274005,0.00039949373],"genre_scores_gemma":[0.8311467,0.00058067986,0.0005643076,0.15749912,0.006334667,0.00097370986,0.0012264588,0.00016739305,0.0015069697],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976886,0.00028367454,0.00034549466,0.0006319996,0.00029297883,0.00075728033],"domain_scores_gemma":[0.99754906,0.0005357479,0.0005003258,0.0011409183,0.00014787067,0.00012606187],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000343905,0.000543172,0.0015819896,0.00014120339,0.00029243142,0.00008140937,0.00042512149,0.0007667724,0.00006218496],"category_scores_gemma":[0.000057697787,0.00032149887,0.00022596157,0.000055833632,0.0004233574,0.000074665346,0.000080249745,0.0011493978,0.000013840097],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010580824,0.00014780436,0.7633838,0.0004518553,0.0008925641,0.0009824121,0.00030324506,4.040105e-9,0.000016212414,0.000006410851,0.23041339,0.0023442083],"study_design_scores_gemma":[0.011841099,0.0053695776,0.12787357,0.00015037472,0.0017350239,0.00017239913,0.000008038209,0.00028818942,0.00006368568,0.00007640019,0.85202837,0.0003932846],"about_ca_topic_score_codex":0.00009255807,"about_ca_topic_score_gemma":0.000009555243,"teacher_disagreement_score":0.63551027,"about_ca_system_score_codex":0.00030266703,"about_ca_system_score_gemma":0.00022958464,"threshold_uncertainty_score":0.9999237},"labels":[],"label_agreement":null},{"id":"W2610443697","doi":"10.1016/s1470-2045(17)30259-0","title":"Widening the gap: additional concerns with crowdfunding in health care","year":2017,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University","funders":"","keywords":"Health care; Population; Medicine; Public relations; Service (business); Population ageing; Political science; Business; Economic growth; Marketing; Environmental health; Law; Economics","score_opus":0.11710791013667125,"score_gpt":0.3282794166360063,"score_spread":0.21117150649933503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2610443697","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006039505,0.006127043,0.00010929944,0.83921194,0.0012559167,0.00051710766,0.0038826275,0.0000339514,0.1482582],"genre_scores_gemma":[0.06862035,0.0013963183,0.00038897374,0.89627373,0.024631383,0.00043082936,0.0010135187,0.00012168534,0.007123188],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977489,0.00013065088,0.000705515,0.0005159888,0.000053647967,0.0008452646],"domain_scores_gemma":[0.996603,0.0006950226,0.0016960629,0.00091661065,0.000041250787,0.00004804586],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001203983,0.00030653138,0.0013042571,0.00013490218,0.00063742825,0.0001711339,0.0012715476,0.00049385504,0.001787732],"category_scores_gemma":[0.0002425065,0.00021560563,0.00012698873,0.00008097806,0.0005135667,0.00019278645,0.00013934511,0.0026062757,0.00038252727],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000055123597,0.000006642242,0.0019586121,0.00007875445,0.00006316704,0.00007503676,0.0014064385,0.00005245281,2.9748142e-8,0.016480954,0.97841346,0.0014093283],"study_design_scores_gemma":[0.00089707406,0.00019879367,0.004613063,0.00014488547,0.000007082557,0.00004363346,0.00017314331,0.00002570833,2.471388e-7,0.008123102,0.9854891,0.00028418493],"about_ca_topic_score_codex":0.0019682338,"about_ca_topic_score_gemma":0.0024810464,"teacher_disagreement_score":0.141135,"about_ca_system_score_codex":0.0012747869,"about_ca_system_score_gemma":0.0006039289,"threshold_uncertainty_score":0.99969476},"labels":[],"label_agreement":null},{"id":"W2610700401","doi":"10.1016/s1470-2045(17)30266-8","title":"Engaging specialist oncologists in the assessment of oncology drugs in Canada","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Agency for Drugs and Technologies in Health; Sunnybrook Health Science Centre; Health Sciences Centre; University of Alberta; McMaster University","funders":"","keywords":"Medicine; Oncology; Clinical Oncology; Internal medicine; Family medicine; Cancer drugs; Cancer","score_opus":0.5078851034052443,"score_gpt":0.5233580489296832,"score_spread":0.015472945524438897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2610700401","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.59782904,0.00024997443,0.00004889292,0.26018795,0.0012414794,0.000634095,0.000087568944,0.0000063559546,0.13971464],"genre_scores_gemma":[0.9813559,0.00022044448,0.0007533155,0.016652934,0.000759383,0.00014617815,0.00000814715,0.000011738452,0.00009197453],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994326,0.0020061976,0.002670117,0.0003520643,0.000108738226,0.00053688185],"domain_scores_gemma":[0.99145854,0.00433506,0.0030288124,0.0010930151,0.000032923625,0.000051661817],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.040583987,0.00014423202,0.0015101145,0.00012975158,0.0002961365,0.000041602663,0.0015246393,0.00014258159,0.00018269336],"category_scores_gemma":[0.0029898835,0.0001207362,0.00005786304,0.00010682071,0.00026872213,0.00015478511,0.00016085694,0.00062469905,0.00005212489],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003701821,0.00017153681,0.7466816,0.00010291061,0.000032412256,0.0000224087,0.0062879203,0.0003682484,0.0000023471912,0.214366,0.028916154,0.0030114881],"study_design_scores_gemma":[0.0015158481,0.00010697051,0.7443408,0.000024091545,0.0000033630874,0.0000072932,0.005130955,0.0013877838,0.0000010165969,0.009167579,0.23819637,0.00011797219],"about_ca_topic_score_codex":0.807712,"about_ca_topic_score_gemma":0.9674514,"teacher_disagreement_score":0.38352686,"about_ca_system_score_codex":0.0056993705,"about_ca_system_score_gemma":0.0033637465,"threshold_uncertainty_score":0.99811757},"labels":[],"label_agreement":null},{"id":"W2610966285","doi":"10.1016/s1470-2045(17)30263-2","title":"Genomic biomarkers for precision radiation medicine","year":2017,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Institute of Cancer Research; Ontario Institute for Cancer Research; University of Toronto; University Health Network","funders":"","keywords":"Radiation therapy; Precision medicine; Medical physics; Medicine; Personalized medicine; Bioinformatics; Internal medicine; Pathology; Biology","score_opus":0.037809324979623235,"score_gpt":0.3356601559436628,"score_spread":0.2978508309640395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2610966285","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002441979,0.0074745966,0.0019092464,0.97556984,0.0037825934,0.0011075854,0.00046290155,0.000016171947,0.00723511],"genre_scores_gemma":[0.0051973695,0.015066816,0.0014375787,0.8614149,0.10552983,0.00049278955,0.0059550204,0.00014184568,0.0047638374],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99871206,0.00011979651,0.0002615318,0.00042592236,0.000096976815,0.00038369058],"domain_scores_gemma":[0.9980564,0.00032918045,0.00042834983,0.0010646123,0.000085929336,0.000035494384],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068238325,0.00022888082,0.0004929495,0.0000443093,0.00021188351,0.000028405453,0.0008258099,0.00086388673,0.000028338467],"category_scores_gemma":[0.00046517042,0.0001628897,0.0001282865,0.000019519804,0.00026848158,0.0000013597414,0.00017283131,0.00035871143,0.000017782004],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002559823,0.000007173296,0.000033676486,0.000040846928,0.0001509201,0.000010636633,0.000040413834,0.000018642495,0.0052409666,0.000025700709,0.9618044,0.032370664],"study_design_scores_gemma":[0.0016571931,0.00079659227,0.00021856689,0.00002127689,0.00012972737,0.000031339685,0.000009120226,0.000072814015,0.00049170974,0.0008950867,0.9954767,0.00019983962],"about_ca_topic_score_codex":0.00008141375,"about_ca_topic_score_gemma":0.00008116036,"teacher_disagreement_score":0.1141549,"about_ca_system_score_codex":0.00011433905,"about_ca_system_score_gemma":0.000307326,"threshold_uncertainty_score":0.6663086},"labels":[],"label_agreement":null},{"id":"W2616596696","doi":"10.1016/s1470-2045(17)30312-1","title":"Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":656,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Cancer Institute; Genentech; GlaxoSmithKline","keywords":"Medicine; Lapatinib; Capecitabine; Trastuzumab emtansine; Taxane; Trastuzumab; Internal medicine; Oncology; Breast cancer; Interim analysis; Metastatic breast cancer; Pertuzumab; Population; Cancer; Clinical trial; Colorectal cancer","score_opus":0.1471450445887598,"score_gpt":0.43954737622099455,"score_spread":0.2924023316322347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2616596696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98494554,0.00013448857,0.000016429623,0.00258871,0.00038989837,0.0046955883,0.0046465998,0.000024572506,0.0025581955],"genre_scores_gemma":[0.996963,0.0003407483,0.00041817423,0.00012329427,0.00039244283,0.00064687256,0.0007915624,0.000045144032,0.0002787554],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9959414,0.00097457494,0.00089181674,0.00076327624,0.00068284996,0.0007461075],"domain_scores_gemma":[0.99553156,0.0014321563,0.0008806374,0.0012990611,0.0006509746,0.00020558393],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013818458,0.00037678983,0.0026592202,0.00022181869,0.00021390764,0.00006149373,0.00096286,0.00020483423,0.00030803186],"category_scores_gemma":[0.0012220845,0.00024946325,0.00013051505,0.00058935577,0.0006024683,0.00021982324,0.00025843916,0.00064328586,0.0000047213593],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96454495,0.0030293334,0.009050699,0.000028708904,0.002948453,0.00017453752,0.003082528,0.00015446664,0.00032376943,0.000010182299,0.0004710185,0.01618137],"study_design_scores_gemma":[0.78597236,0.012271999,0.19764684,0.00031986594,0.0019914757,0.0000021570988,0.00021550198,0.00095877744,0.00013612276,0.000008775104,0.00025493436,0.00022118169],"about_ca_topic_score_codex":0.027265567,"about_ca_topic_score_gemma":0.055466086,"teacher_disagreement_score":0.18859614,"about_ca_system_score_codex":0.0019199827,"about_ca_system_score_gemma":0.0017509408,"threshold_uncertainty_score":0.99999577},"labels":[],"label_agreement":null},{"id":"W2619858681","doi":"10.1016/s1470-2045(17)30376-5","title":"Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":539,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Ottawa Hospital","funders":"National Cancer Institute; Novartis Pharmaceuticals Corporation","keywords":"Fulvestrant; Medicine; Breast cancer; Placebo; Internal medicine; Metastatic breast cancer; Oncology; Cancer; Aromatase inhibitor; Estrogen receptor; Tamoxifen; Pathology","score_opus":0.04915608166519876,"score_gpt":0.3711958041582476,"score_spread":0.32203972249304885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2619858681","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97696203,0.0026944613,0.00016576912,0.0047411057,0.0030209997,0.0066238586,0.0006408256,0.00006307281,0.005087887],"genre_scores_gemma":[0.987353,0.003535581,0.0005135144,0.0005260637,0.0036193496,0.0034437468,0.00018812715,0.000113383794,0.000707188],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9950958,0.00089189946,0.001034458,0.0011889457,0.00046437225,0.0013245544],"domain_scores_gemma":[0.99608105,0.0006665515,0.0010923136,0.0016010362,0.00026568183,0.00029338288],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019154157,0.0007759189,0.0019672692,0.00012583433,0.0009087071,0.00014854386,0.0017107591,0.00071156974,0.00020470333],"category_scores_gemma":[0.00037854663,0.0006033732,0.00034865976,0.00016668082,0.0009476177,0.00005481239,0.0004460631,0.00091765996,0.000037841604],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8667482,0.00043683848,0.000016117196,0.000026836879,0.0007395917,0.00008483009,0.0004677753,0.0017677342,0.12441086,0.000078017416,0.0021180687,0.0031051086],"study_design_scores_gemma":[0.9630767,0.006175831,0.00011746399,0.000095415446,0.000325697,0.00007787204,0.00025767807,0.00032511682,0.017737085,0.000054180695,0.011000577,0.0007563927],"about_ca_topic_score_codex":0.001259578,"about_ca_topic_score_gemma":0.0023487522,"teacher_disagreement_score":0.10667377,"about_ca_system_score_codex":0.0007610809,"about_ca_system_score_gemma":0.0018014087,"threshold_uncertainty_score":0.9996418},"labels":[],"label_agreement":null},{"id":"W2620608626","doi":"10.1016/s1470-2045(17)30423-0","title":"Measuring value and benefit—a matter of perspective","year":2017,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; McMaster University","funders":"","keywords":"Scopus; Medicine; Psychological intervention; Medical prescription; Health care; Alternative medicine; Prescription drug; Family medicine; MEDLINE; Library science; Political science; Pharmacology; Computer science; Nursing; Law; Pathology","score_opus":0.09881712241165262,"score_gpt":0.2869346739451015,"score_spread":0.1881175515334489,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2620608626","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007144695,0.00614819,0.000051339073,0.63229805,0.0010233973,0.0002376381,0.00039808892,0.00001497551,0.3526836],"genre_scores_gemma":[0.16820352,0.0039915275,0.00065756775,0.7836217,0.019909251,0.000110649926,0.000037729238,0.00016541846,0.023302644],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99852806,0.000024192152,0.0005130269,0.00044629694,0.00003054075,0.0004578611],"domain_scores_gemma":[0.99771476,0.00016182363,0.0011860746,0.000839147,0.000062314044,0.00003591196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007237485,0.00024396226,0.0014087338,0.00012751919,0.00015948658,0.000061495724,0.0007428138,0.00063543074,0.0003199262],"category_scores_gemma":[0.00012674731,0.00021850216,0.00014576613,0.000030928506,0.00042965537,0.0001415124,0.00018838249,0.0010321214,0.00041273632],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000053002237,0.000017889113,0.0072965687,0.00012811396,0.00023055337,0.000037348178,0.000898169,0.000008840323,0.000002233846,0.17395301,0.8166044,0.000769875],"study_design_scores_gemma":[0.0005274235,0.00008512826,0.01756649,0.00003435954,0.000024227586,0.00003249087,0.000028979555,0.000015940752,0.000007168131,0.19335042,0.78810674,0.00022062054],"about_ca_topic_score_codex":0.001575453,"about_ca_topic_score_gemma":0.00006553914,"teacher_disagreement_score":0.32938096,"about_ca_system_score_codex":0.00034734939,"about_ca_system_score_gemma":0.00006109063,"threshold_uncertainty_score":0.89102596},"labels":[],"label_agreement":null},{"id":"W2620651944","doi":"10.1016/s1470-2045(17)30429-1","title":"Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":775,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Bristol-Myers Squibb","keywords":"Dabrafenib; Trametinib; Medicine; Melanoma; Asymptomatic; Clinical endpoint; Oncology; MEK inhibitor; Internal medicine; Brain metastasis; Phases of clinical research; Clinical trial; Metastatic melanoma; Cancer; Metastasis; Vemurafenib; Cancer research; Biology; MAPK/ERK pathway","score_opus":0.06803476530507808,"score_gpt":0.3693754023310494,"score_spread":0.3013406370259713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2620651944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921213,0.0000980471,0.000097396594,0.0016723595,0.0005507236,0.0022552793,0.00025161938,0.000019135885,0.0029341732],"genre_scores_gemma":[0.99562854,0.000043542317,0.0014559528,0.0012678724,0.000546632,0.0002453519,0.00034632007,0.00004430251,0.00042149078],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973586,0.0006460969,0.00046082947,0.0006459358,0.00020790496,0.00068059727],"domain_scores_gemma":[0.9976071,0.00017089462,0.00049035205,0.0014924972,0.0000873243,0.00015180388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010757813,0.0003349062,0.00081946276,0.000051713367,0.0003483401,0.00015614748,0.0016811994,0.0002517022,0.000065115615],"category_scores_gemma":[0.0007101872,0.00022113953,0.000065203385,0.00006675661,0.00033418866,0.000025304776,0.0006534105,0.0002996603,0.000024967418],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.690795,0.023356315,0.035740267,0.00015633204,0.0016391957,0.0007052405,0.0018158405,0.00008625597,0.12515377,0.0020004131,0.03676676,0.081784606],"study_design_scores_gemma":[0.7498624,0.017876778,0.017721744,0.000054586762,0.00022056648,0.000033651646,0.00015916154,0.0003824114,0.017977215,0.00016198092,0.19475456,0.0007949995],"about_ca_topic_score_codex":0.00028960968,"about_ca_topic_score_gemma":0.0016609972,"teacher_disagreement_score":0.1579878,"about_ca_system_score_codex":0.000071233015,"about_ca_system_score_gemma":0.00033073843,"threshold_uncertainty_score":0.90178084},"labels":[],"label_agreement":null},{"id":"W2620810773","doi":"10.1016/s1470-2045(17)30325-x","title":"Improving childhood cancer care in Latin America and the Caribbean: a PAHO Childhood Cancer Working Group position statement","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Scopus; Global health; Medicine; Cancer; Childhood cancer; Family medicine; Political science; MEDLINE; Public health; Internal medicine; Nursing","score_opus":0.03539205654018276,"score_gpt":0.354677557437213,"score_spread":0.3192855008970303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2620810773","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8453057,0.010847004,0.00005365368,0.13790895,0.00085104234,0.0018138983,0.00010442204,0.0000832517,0.003032105],"genre_scores_gemma":[0.98072886,0.0036093006,0.00041851308,0.012332767,0.002203214,0.00057719456,0.00003704438,0.00004573794,0.0000473682],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9972811,0.0005997355,0.00057179295,0.0005193206,0.00036892405,0.00065913546],"domain_scores_gemma":[0.9976905,0.00037183042,0.0007237132,0.0010190934,0.00007649639,0.00011838602],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011426284,0.00030466303,0.001044183,0.00007239279,0.00071227265,0.000114659626,0.0005332358,0.00015124532,0.0000730384],"category_scores_gemma":[0.00023185978,0.00019092497,0.00011320637,0.00013799588,0.00061059993,0.00011970035,0.0003759739,0.0008558566,0.0000053870062],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041390047,0.00056909054,0.2339053,0.0004970283,0.00079883053,0.000104290084,0.17527008,0.00015160334,0.00059193507,0.0017764854,0.0035436233,0.57865274],"study_design_scores_gemma":[0.017537313,0.0005531566,0.9442235,0.00070926524,0.00035088073,0.000040772327,0.007588239,0.00023973713,0.00009946055,0.00045632053,0.027866825,0.00033449498],"about_ca_topic_score_codex":0.035464447,"about_ca_topic_score_gemma":0.054034527,"teacher_disagreement_score":0.7103182,"about_ca_system_score_codex":0.0006949149,"about_ca_system_score_gemma":0.00049155246,"threshold_uncertainty_score":0.9709585},"labels":[],"label_agreement":null},{"id":"W2621250710","doi":"10.1016/s1470-2045(17)30415-1","title":"Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":147,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Princess Margaret Cancer Centre; Kingston General Hospital; University of Toronto","funders":"","keywords":"Medicine; Breast cancer; Colorectal cancer; Clinical trial; Cancer; Cohort; Internal medicine; Oncology; Pancreatic cancer; Cost effectiveness; Randomized controlled trial; Retrospective cohort study","score_opus":0.03926225781668552,"score_gpt":0.3084167639594485,"score_spread":0.269154506142763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2621250710","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97010326,0.003250907,0.00012852611,0.0037605048,0.00025969572,0.0005673241,0.00006834436,0.000010186634,0.021851236],"genre_scores_gemma":[0.99696016,0.0016822969,0.00012727937,0.00064551854,0.00033255006,0.00009609105,0.0000010876349,0.000018032153,0.00013697034],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99907684,0.00002213076,0.0002661857,0.0003252307,0.00003379578,0.0002758201],"domain_scores_gemma":[0.99842983,0.00014268451,0.0007226695,0.0005766886,0.00008259614,0.000045543507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083604496,0.0001452058,0.00075180974,0.000037612434,0.0005394447,0.00016907061,0.00038057208,0.00016155906,0.000036962865],"category_scores_gemma":[0.000096459524,0.00009781867,0.00003090309,0.00004385561,0.0005473044,0.00027177567,0.00017493866,0.00046008168,0.0000035412043],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010414516,0.000028525383,0.9648193,0.000010806491,0.00015193813,0.0000029986854,0.0028753302,0.000028652561,0.0000015893552,0.024770489,0.00021450799,0.00699173],"study_design_scores_gemma":[0.001142258,0.00030811172,0.98479074,0.000024661242,0.000051397932,0.000005213749,0.0011313726,0.00012588169,0.00000702872,0.0058430615,0.0064340183,0.00013626587],"about_ca_topic_score_codex":0.004525398,"about_ca_topic_score_gemma":0.006038256,"teacher_disagreement_score":0.0268569,"about_ca_system_score_codex":0.00022447591,"about_ca_system_score_gemma":0.00006010254,"threshold_uncertainty_score":0.68410784},"labels":[],"label_agreement":null},{"id":"W2621656000","doi":"10.1016/s1470-2045(17)30404-7","title":"Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"Eisai; National Institute for Health and Care Research; Cancer Research UK; University College London; Les Laboratories Pierre Fabre; AstraZeneca; Celgene; Genomic Health; Research England; Pfizer; Amgen","keywords":"Epirubicin; Medicine; Capecitabine; Cyclophosphamide; Breast cancer; Internal medicine; Fluorouracil; Gastroenterology; Chemotherapy; Cancer; Surgery; Colorectal cancer","score_opus":0.08496628285504446,"score_gpt":0.4261559906783022,"score_spread":0.34118970782325775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2621656000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94946855,0.006183103,0.000055108398,0.015543991,0.0018975803,0.024231123,0.0015850061,0.000023489698,0.001012055],"genre_scores_gemma":[0.9661761,0.014123822,0.0002835027,0.0021294034,0.0016161412,0.014857707,0.00018098291,0.00006278354,0.0005695607],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99618596,0.001347622,0.0007546495,0.00072497147,0.00024908822,0.0007376834],"domain_scores_gemma":[0.9957924,0.002083959,0.0008458201,0.0009262161,0.00022271782,0.00012889468],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0026626266,0.000535012,0.002095292,0.000039011422,0.00083424145,0.00023491954,0.0012144072,0.00029317164,0.00015664932],"category_scores_gemma":[0.0017559058,0.00027376282,0.00020532211,0.0001011568,0.00039708268,0.000029767125,0.0002548296,0.00025811122,0.0000020322457],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9426078,0.0011713281,0.000037987105,0.000010500042,0.0015544712,0.000034989305,0.00042278125,0.000006032955,0.00920506,0.00001405914,0.015753673,0.029181313],"study_design_scores_gemma":[0.96142614,0.008458877,0.00013886958,0.000021083635,0.000554692,0.000023712459,0.0002871706,0.000053893003,0.0027216875,0.000049566945,0.025921699,0.00034262068],"about_ca_topic_score_codex":0.0012020521,"about_ca_topic_score_gemma":0.0033001332,"teacher_disagreement_score":0.028838692,"about_ca_system_score_codex":0.00018628131,"about_ca_system_score_gemma":0.0007360952,"threshold_uncertainty_score":0.99997145},"labels":[],"label_agreement":null},{"id":"W2623725180","doi":"10.1016/s1470-2045(17)30339-x","title":"Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":580,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Ignyta; Shionogi; AstraZeneca; Associazione Italiana per la Ricerca sul Cancro; Astellas Pharma; Eli Lilly and Company","keywords":"Ceritinib; Crizotinib; Medicine; Anaplastic lymphoma kinase; Lung cancer; ALK inhibitor; Internal medicine; Chemotherapy; Oncology; Docetaxel; Pemetrexed; Gastroenterology; Cisplatin","score_opus":0.04534884463340635,"score_gpt":0.4133336191056075,"score_spread":0.3679847744722012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2623725180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9619135,0.0006901593,0.00001527056,0.008796905,0.00056432246,0.010969549,0.00006133995,0.00002805908,0.01696088],"genre_scores_gemma":[0.9910239,0.0015949364,0.0006561208,0.0022036333,0.0007178829,0.002614627,0.000047007634,0.000060473434,0.0010814274],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983894,0.00017737865,0.0003723526,0.00041064373,0.00017518444,0.0004750034],"domain_scores_gemma":[0.998349,0.00028177028,0.00045639838,0.00065190945,0.00012567459,0.00013523168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005353074,0.000284415,0.0013572027,0.000054018423,0.00033214624,0.00010762573,0.00042195566,0.00013901903,0.00018174261],"category_scores_gemma":[0.00007924026,0.00016961434,0.00006359263,0.00006837053,0.0002177148,0.00013298875,0.00006758898,0.00027477866,0.0000033230394],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9393207,0.0030424315,0.020210078,0.000073836294,0.0009590885,0.00003108732,0.0022506223,0.0000014481452,0.00014881854,0.000012333374,0.0041224957,0.02982705],"study_design_scores_gemma":[0.9631067,0.006986218,0.013187671,0.00013864863,0.0006674747,0.000002782725,0.00010263124,0.0000950685,0.00009492955,0.000010903215,0.015415606,0.00019140082],"about_ca_topic_score_codex":0.00085769984,"about_ca_topic_score_gemma":0.0011331049,"teacher_disagreement_score":0.02963565,"about_ca_system_score_codex":0.0002794537,"about_ca_system_score_gemma":0.0005413057,"threshold_uncertainty_score":0.6916672},"labels":[],"label_agreement":null},{"id":"W2653632515","doi":"10.1016/s1470-2045(17)30381-9","title":"Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":306,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute","keywords":"Doxorubicin; Medicine; Open label; Soft tissue sarcoma; Sarcoma; Oncology; Phases of clinical research; Internal medicine; Chemotherapy; Soft tissue; Clinical trial; Radiology; Pathology","score_opus":0.18838234775149656,"score_gpt":0.4786800370415504,"score_spread":0.29029768929005384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2653632515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9691612,0.0012938878,0.00016098071,0.012924151,0.0023879707,0.0072810994,0.00009727929,0.00008832229,0.006605089],"genre_scores_gemma":[0.98734796,0.0015627759,0.0057312585,0.0017893432,0.00092250307,0.0013819282,0.00017523962,0.00007000743,0.0010189821],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9960495,0.0007976041,0.00091486244,0.000785705,0.00050560816,0.00094670564],"domain_scores_gemma":[0.9946977,0.0023451815,0.0006673878,0.0017824564,0.00019570593,0.00031155377],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018314444,0.00047253916,0.0020192116,0.00018873518,0.00043848922,0.00023245817,0.0017632176,0.000175915,0.0008505104],"category_scores_gemma":[0.002501484,0.00030042592,0.00010253812,0.00019017853,0.0003669269,0.0005996028,0.0005358894,0.00054663146,0.00015969957],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86243534,0.009738929,0.0009754676,0.00005186896,0.00073939573,0.003097924,0.0007430529,0.000121364414,0.002775054,0.0003950931,0.0018405801,0.11708595],"study_design_scores_gemma":[0.9353746,0.010189237,0.0021070705,0.00020702906,0.00062687445,0.0001060135,0.0005547672,0.00356167,0.0034059198,0.0002166847,0.04330819,0.00034190185],"about_ca_topic_score_codex":0.00246973,"about_ca_topic_score_gemma":0.009482529,"teacher_disagreement_score":0.11674405,"about_ca_system_score_codex":0.00095214974,"about_ca_system_score_gemma":0.00080329267,"threshold_uncertainty_score":0.9999448},"labels":[],"label_agreement":null},{"id":"W2699278758","doi":"10.1016/s1470-2045(17)30318-2","title":"Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":570,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa","funders":"Cancer Research UK","keywords":"Medicine; Chemoradiotherapy; Regimen; Lung cancer; Radiation therapy; Etoposide; Chemotherapy regimen; Internal medicine; Clinical endpoint; Performance status; Surgery; Randomized controlled trial; Chemotherapy; Oncology","score_opus":0.15045437894064043,"score_gpt":0.4667886956623838,"score_spread":0.3163343167217434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2699278758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9807629,0.001177687,0.000013062536,0.005767933,0.0016097073,0.0063020294,0.00013645043,0.000060053248,0.004170154],"genre_scores_gemma":[0.99137837,0.0025605266,0.00019735772,0.0014506269,0.0017439899,0.0014886457,0.00006559295,0.00007466504,0.0010401994],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968519,0.0005788234,0.00048076053,0.000675016,0.00049031945,0.00092317665],"domain_scores_gemma":[0.99710894,0.0004804021,0.00042628107,0.0014255613,0.00028063337,0.00027818832],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013909034,0.00039148054,0.0017439977,0.00008958431,0.0005141053,0.00017724882,0.0014839284,0.0001913051,0.00029497093],"category_scores_gemma":[0.00036522374,0.00024864209,0.000062160834,0.00015849095,0.00074971543,0.00033992765,0.00041788907,0.0008797793,0.000011911797],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89005584,0.0045053526,0.07243042,0.00022919542,0.00061051943,0.00013513256,0.002352051,0.0000041831045,0.0006390958,0.00003632375,0.0045136255,0.024488276],"study_design_scores_gemma":[0.9205495,0.018314356,0.01795355,0.00013041719,0.00027997146,0.0000018998685,0.00017710461,0.00050433143,0.00040653624,0.0000035078426,0.041352227,0.00032660583],"about_ca_topic_score_codex":0.0031041836,"about_ca_topic_score_gemma":0.0049625635,"teacher_disagreement_score":0.05447687,"about_ca_system_score_codex":0.0013145186,"about_ca_system_score_gemma":0.0013289542,"threshold_uncertainty_score":0.9999966},"labels":[],"label_agreement":null},{"id":"W2724863835","doi":"10.1016/s1470-2045(17)30448-5","title":"Radiosurgery for resected brain metastases—a new standard of care?","year":2017,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Radiosurgery; Medicine; Neurocognitive; Randomized controlled trial; Radiation therapy; Brain tumor; Brain metastasis; Nuclear medicine; Internal medicine; Cognition; Cancer; Metastasis; Pathology; Psychiatry","score_opus":0.08474161213672306,"score_gpt":0.38636621793527054,"score_spread":0.3016246057985475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2724863835","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010033773,0.0047999145,0.00036367515,0.9847627,0.0010969182,0.0017996104,0.0026790278,0.000055811623,0.003438918],"genre_scores_gemma":[0.003553337,0.00076686544,0.018614119,0.9200506,0.03276183,0.0004674738,0.0065536755,0.00022870992,0.01700337],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99752057,0.0005619946,0.0004846001,0.00043477342,0.00036512568,0.00063292077],"domain_scores_gemma":[0.99488884,0.002424894,0.00068359997,0.0016543121,0.00024835713,0.00009998918],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012660313,0.00035907538,0.0025555645,0.00013473896,0.00015657213,0.000021995773,0.00046119554,0.0006198955,0.00026565057],"category_scores_gemma":[0.000997083,0.00021783914,0.0005525784,0.0000778776,0.00030160515,0.000027338097,0.000095285766,0.0010521009,0.000014531167],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032918088,0.000038759703,0.0000627866,0.0007837485,0.0012846531,0.0010422507,0.00021407264,0.000001013563,0.000044267286,0.0002467806,0.9730503,0.019939577],"study_design_scores_gemma":[0.0075063705,0.0036997334,0.000170272,0.00019744462,0.00164317,0.00029562775,0.00004487946,0.00000181896,0.00037538965,0.0009335083,0.9849541,0.00017764408],"about_ca_topic_score_codex":0.00022325969,"about_ca_topic_score_gemma":0.000116854804,"teacher_disagreement_score":0.06471213,"about_ca_system_score_codex":0.00034198308,"about_ca_system_score_gemma":0.001623475,"threshold_uncertainty_score":0.88832223},"labels":[],"label_agreement":null},{"id":"W2726395676","doi":"10.1016/s1470-2045(17)30438-2","title":"The TNM classification of malignant tumours—towards common understanding and reasonable expectations","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":286,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; National Institutes of Health; World Health Organization","keywords":"CLARITY; Profiling (computer programming); Disease; Medicine; Cancer; Pathology; Internal medicine; Computer science; Biology","score_opus":0.1075127998060665,"score_gpt":0.3980224307440145,"score_spread":0.290509630937948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2726395676","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.71482635,0.0006945445,0.0017380463,0.23731676,0.00033408395,0.00026631163,0.0000032377422,0.000030458637,0.044790205],"genre_scores_gemma":[0.9980209,0.0005439545,0.0005035645,0.00030911883,0.00024264197,0.000013416022,0.000003792068,0.000008043946,0.0003545779],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99935186,0.0001182516,0.00014883235,0.00009992558,0.00011324557,0.00016789162],"domain_scores_gemma":[0.99895,0.00033630486,0.00021859856,0.00041657436,0.000032414864,0.00004609321],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094502576,0.000056992405,0.0002397619,0.000018707755,0.0006903283,0.000038846752,0.00021101942,0.000043572843,0.000007237186],"category_scores_gemma":[0.00057767157,0.000029914068,0.00002750759,0.000028462495,0.0005848614,0.00003330339,0.00006282112,0.0002562542,0.0000024557985],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008335382,0.00019401223,0.24133655,0.0001734164,0.00023740015,0.00006617209,0.006297978,0.000017688533,0.01757106,0.52058345,0.02576925,0.18691951],"study_design_scores_gemma":[0.0029029553,0.00040001216,0.90164185,0.0001678012,0.00019694686,0.0002613093,0.007933341,0.021045603,0.0003767317,0.025796687,0.0391599,0.00011684285],"about_ca_topic_score_codex":0.00016230723,"about_ca_topic_score_gemma":0.00009306016,"teacher_disagreement_score":0.6603053,"about_ca_system_score_codex":0.00008883668,"about_ca_system_score_gemma":0.00008958207,"threshold_uncertainty_score":0.5309517},"labels":[],"label_agreement":null},{"id":"W2726463501","doi":"10.1016/s1470-2045(17)30441-2","title":"Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":1192,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame; Juravinski Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Radiosurgery; Brain metastasis; Radiation therapy; Clinical endpoint; Randomized controlled trial; Surgery; Metastasis; Internal medicine; Cancer","score_opus":0.08135849473403658,"score_gpt":0.40909258631001555,"score_spread":0.327734091575979,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2726463501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7688495,0.0018259725,0.0021699462,0.20669162,0.00067467196,0.018770676,0.0005701785,0.000103183134,0.00034428688],"genre_scores_gemma":[0.97340995,0.0001195241,0.0049136444,0.012823508,0.0014443684,0.0037728606,0.00041055123,0.000099967605,0.003005612],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9959203,0.0017922672,0.000654209,0.00055500586,0.00033609814,0.000742141],"domain_scores_gemma":[0.98987895,0.0073889717,0.00075268233,0.0013452081,0.00023091277,0.0004032948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024546024,0.00044439468,0.0025766804,0.00010983336,0.0007315984,0.00015582643,0.00037950935,0.00008323853,0.00021979169],"category_scores_gemma":[0.003421563,0.00023869427,0.00045496336,0.00009619639,0.0005079959,0.00016482179,0.000044220036,0.00033016084,0.000015501217],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9533536,0.0027942504,0.0001945695,0.00008766845,0.0038304364,0.00086947804,0.0009652078,0.000035922465,0.0013116276,0.0002378555,0.03057709,0.0057423045],"study_design_scores_gemma":[0.9027603,0.008063393,0.0006788808,0.00009724612,0.0019148882,0.00014396988,0.00026530225,0.0048000184,0.00009853654,0.00009568072,0.08081877,0.00026296513],"about_ca_topic_score_codex":0.0000925216,"about_ca_topic_score_gemma":0.00016855168,"teacher_disagreement_score":0.2045605,"about_ca_system_score_codex":0.00029813588,"about_ca_system_score_gemma":0.00074066693,"threshold_uncertainty_score":0.973367},"labels":[],"label_agreement":null},{"id":"W2729284305","doi":"10.1016/s1470-2045(17)30445-x","title":"Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based study","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":503,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Consumers, Health, Agriculture and Food Executive Agency; Queen's University; Queen's University Belfast; European Commission","keywords":"Relative survival; Medicine; Incidence (geometry); European union; Cancer registry; Population; Demography; Cancer; Referral; Pediatrics; Internal medicine; Family medicine; Environmental health","score_opus":0.0724263099790792,"score_gpt":0.3657372715329165,"score_spread":0.2933109615538373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2729284305","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990731,0.00015036427,5.4822e-7,0.0043634535,0.000090864865,0.00059751817,0.00007495455,0.0000072649705,0.0039840126],"genre_scores_gemma":[0.9992575,0.00009045323,0.000105596526,0.00014363696,0.00017341736,0.000015575066,0.000054964607,0.000007560568,0.00015129353],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999133,0.00018918648,0.0002878957,0.00015448323,0.00009068408,0.00014476784],"domain_scores_gemma":[0.99892735,0.00017632548,0.00026485577,0.0005307378,0.00006310459,0.000037596445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030641595,0.00008738053,0.00054779183,0.00004656929,0.000051057174,0.0000051008665,0.00014495359,0.000042147734,0.000031078984],"category_scores_gemma":[0.00020009701,0.00005579195,0.000027646041,0.00004894125,0.00008077618,0.00002958531,0.000031282507,0.000078208934,7.1803663e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005510237,0.00025201277,0.9682473,0.00005506144,0.0000639691,0.00007478969,0.002971326,0.00018168143,0.0009735845,0.000019577747,0.00024837142,0.021402096],"study_design_scores_gemma":[0.018921698,0.001943299,0.9737187,0.000044531847,0.000073479474,0.0000032758655,0.00035916053,0.00024246938,0.00057892286,0.000010184494,0.004056111,0.000048148595],"about_ca_topic_score_codex":0.0040942705,"about_ca_topic_score_gemma":0.0020510366,"teacher_disagreement_score":0.021353947,"about_ca_system_score_codex":0.00011798234,"about_ca_system_score_gemma":0.00024540775,"threshold_uncertainty_score":0.618934},"labels":[],"label_agreement":null},{"id":"W2737389832","doi":"10.1016/s1470-2045(17)30469-2","title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1863,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"European Society for Medical Oncology","keywords":"Olaparib; Medicine; BRCA mutation; Ovarian cancer; Internal medicine; Oncology; Placebo; PARP inhibitor; Clinical endpoint; Population; Randomized controlled trial; Cancer; Pathology","score_opus":0.05211112076256093,"score_gpt":0.3733703096465478,"score_spread":0.3212591888839869,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2737389832","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9710769,0.00020943624,0.000106527325,0.011763165,0.000689771,0.0084555615,0.000056535475,0.00006344953,0.007578632],"genre_scores_gemma":[0.9910946,0.00062429765,0.00031849268,0.003515606,0.0010215628,0.002676675,0.000058087822,0.000053524607,0.00063713564],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973008,0.00046616426,0.0006501529,0.0005628604,0.00038488954,0.0006351458],"domain_scores_gemma":[0.9971354,0.0006848363,0.00092669716,0.00080925104,0.00029612676,0.00014770788],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016828789,0.0003670365,0.0015845819,0.00014848867,0.00043861766,0.0000924792,0.0002797686,0.00029106782,0.00018501125],"category_scores_gemma":[0.0003290029,0.00022994308,0.00010023305,0.00015052731,0.0005417186,0.00024011912,0.00004959268,0.0006896918,0.000018444713],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9785604,0.0007137279,0.0018979452,0.000020323794,0.00043320868,0.0001393949,0.0015498745,0.00003959517,0.0006978901,0.0004580743,0.0011672177,0.014322332],"study_design_scores_gemma":[0.98058623,0.0056815348,0.0069252714,0.00021541808,0.00015627207,0.0000727819,0.00010872608,0.00026348312,0.00070827716,0.00034321242,0.004665223,0.00027359],"about_ca_topic_score_codex":0.0008258184,"about_ca_topic_score_gemma":0.00078033906,"teacher_disagreement_score":0.020017695,"about_ca_system_score_codex":0.0004338318,"about_ca_system_score_gemma":0.0006244626,"threshold_uncertainty_score":0.93768066},"labels":[],"label_agreement":null},{"id":"W2739585441","doi":"10.1016/s1470-2045(17)30426-6","title":"Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Ottawa Hospital; Health Sciences Centre","funders":"Cancer Council Victoria","keywords":"Androgen deprivation therapy; Medicine; Prostate cancer; Quality of life (healthcare); Asymptomatic; Clinical endpoint; Internal medicine; Randomized controlled trial; Cancer; Pediatrics; Oncology","score_opus":0.0682546867180194,"score_gpt":0.3932217866723322,"score_spread":0.32496709995431283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2739585441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98181266,0.0012226286,0.000014231423,0.005950878,0.00039657284,0.010237774,0.00026714458,0.000019697463,0.0000784428],"genre_scores_gemma":[0.9929235,0.0036196413,0.0003177344,0.00044913584,0.0001725734,0.0022618526,0.00020421532,0.000031284842,0.00002003697],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977777,0.0002541564,0.0008574282,0.0003708179,0.00024214145,0.00049777725],"domain_scores_gemma":[0.9970651,0.00068071816,0.0013251547,0.00054482446,0.00021262131,0.0001715592],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012789705,0.00025226452,0.0014301628,0.000070331924,0.00022415497,0.00002775205,0.00016801657,0.00013713427,0.000018221544],"category_scores_gemma":[0.0003446621,0.00015472484,0.00008898044,0.00009688468,0.00020932636,0.00013582583,0.000041347954,0.00019721466,0.000003144032],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.838914,0.0023783862,0.12874427,0.0001788316,0.00090289686,0.0000041943213,0.002313237,0.000026364167,0.00007015326,0.0000202408,0.00047226957,0.025975166],"study_design_scores_gemma":[0.83028275,0.012150364,0.15542763,0.0001401171,0.00017323685,6.6428936e-7,0.00010779364,0.00071294676,0.00035342123,0.00006207948,0.00044056485,0.00014844934],"about_ca_topic_score_codex":0.0019781655,"about_ca_topic_score_gemma":0.0011629227,"teacher_disagreement_score":0.02668337,"about_ca_system_score_codex":0.0003609281,"about_ca_system_score_gemma":0.00070778036,"threshold_uncertainty_score":0.6309496},"labels":[],"label_agreement":null},{"id":"W2740402187","doi":"10.1016/s1470-2045(17)30458-8","title":"Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis","year":2017,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":339,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Toronto; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Institut National Du Cancer","keywords":"Meta-analysis; Radiation therapy; Medicine; Head and neck; Oncology; Head and neck cancer; Internal medicine; Surgery","score_opus":0.2827684759502197,"score_gpt":0.5024295914096837,"score_spread":0.21966111545946398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2740402187","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00033536344,0.9937345,0.0000036463039,0.0021012416,0.000070438626,0.00057422614,0.00007863811,0.00001438144,0.003087612],"genre_scores_gemma":[0.0005841775,0.9978113,0.00030440267,0.00037254364,0.00030270088,0.00016554026,0.00016129584,0.000019537181,0.0002784794],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99837977,0.00048638086,0.00046330056,0.00029891776,0.00015119043,0.00022042287],"domain_scores_gemma":[0.99854285,0.00019497523,0.0005340496,0.0006051521,0.000069089125,0.00005390245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086605555,0.00021744438,0.006008095,0.0002599154,0.00008412156,0.000008266599,0.00021008302,0.00022819603,0.00027238313],"category_scores_gemma":[0.00004340601,0.00012309635,0.00051388115,0.00030415386,0.0001876379,0.00005151973,0.000037050522,0.00040512974,0.0000023425964],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022641831,0.00009771727,0.00021165157,0.0010288944,0.073215656,0.000011947809,0.00049132993,0.000008051794,0.0000045093357,0.0001432613,0.0012846938,0.9232759],"study_design_scores_gemma":[0.0007465891,0.00038285347,0.0014169269,0.00011485253,0.07806256,0.000019253737,0.00003082064,0.000046124023,4.8897704e-7,0.000045018784,0.9190405,0.000093982024],"about_ca_topic_score_codex":0.0020158752,"about_ca_topic_score_gemma":0.007590841,"teacher_disagreement_score":0.9231819,"about_ca_system_score_codex":0.0004289442,"about_ca_system_score_gemma":0.00057256967,"threshold_uncertainty_score":0.5019724},"labels":[],"label_agreement":null},{"id":"W2740545693","doi":"10.1016/s1470-2045(17)30573-9","title":"Androgen deprivation in prostate cancer: first do no harm","year":2017,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Prostatectomy; Oncology; Radiation therapy; Cancer; Internal medicine; Prostate-specific antigen; Gynecology","score_opus":0.07795646313435715,"score_gpt":0.3914052653661275,"score_spread":0.31344880223177035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2740545693","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.020969283,0.00409421,4.88702e-7,0.95323163,0.00079538306,0.0015575328,0.00014202102,0.000049789825,0.019159658],"genre_scores_gemma":[0.031840812,0.06362659,0.00025816617,0.7699058,0.038804036,0.0038205532,0.0021631413,0.00022754144,0.08935335],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99813557,0.00016202021,0.0002687982,0.00042417567,0.00030557477,0.00070384605],"domain_scores_gemma":[0.99848455,0.00019202588,0.00024948665,0.00087234686,0.00014689086,0.000054675667],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000522236,0.0002579401,0.0008849096,0.00013237337,0.00020118142,0.000049349455,0.00048002155,0.0005114194,0.00035256203],"category_scores_gemma":[0.00010984669,0.00015472154,0.000091058944,0.00010389002,0.000299943,0.000057762412,0.00015535411,0.001958928,0.00026949975],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011084547,0.0000546117,0.029729052,0.00045656165,0.00017807388,0.0026185852,0.0004895456,0.0000018869024,0.000036001773,0.000008666624,0.95716757,0.008151017],"study_design_scores_gemma":[0.005115274,0.00040586625,0.007166506,0.00036352582,0.00010613989,0.00009403707,0.000012323894,0.000022394437,0.000119727294,0.00027527547,0.9861593,0.00015961],"about_ca_topic_score_codex":0.00075724896,"about_ca_topic_score_gemma":0.00042795626,"teacher_disagreement_score":0.18332583,"about_ca_system_score_codex":0.0009660183,"about_ca_system_score_gemma":0.0008166836,"threshold_uncertainty_score":0.85106766},"labels":[],"label_agreement":null},{"id":"W2745668487","doi":"10.1016/s1470-2045(17)30576-4","title":"Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":154,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Astex Pharmaceuticals","keywords":"Medicine; Myeloid leukaemia; Internal medicine","score_opus":0.05811141162999822,"score_gpt":0.3966105076241037,"score_spread":0.3384990959941055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2745668487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97501624,0.00009999566,0.000029422363,0.011532716,0.00043815168,0.0051284037,0.0009883792,0.00007213162,0.006694553],"genre_scores_gemma":[0.99104434,0.00074538647,0.0014419544,0.00091274135,0.0022536775,0.00057337584,0.0011245367,0.00006977726,0.0018342262],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963411,0.0005990194,0.0007810821,0.0007623364,0.000510317,0.0010061575],"domain_scores_gemma":[0.9951888,0.001597174,0.0006637366,0.0020190394,0.00021940646,0.0003118527],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000999634,0.00044470988,0.0017598927,0.00016683537,0.0003878445,0.00007844487,0.0008291398,0.00035172675,0.000197712],"category_scores_gemma":[0.0018758866,0.00025120293,0.00017326359,0.00017303658,0.00061315566,0.00022927088,0.00022310729,0.0008769841,0.00016776289],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93315905,0.004629975,0.002053884,0.000010280453,0.000880783,0.0017657003,0.0018831915,0.0000040751056,0.0011532563,0.000014855789,0.0062740534,0.048170876],"study_design_scores_gemma":[0.9462946,0.012809262,0.005321898,0.00007860585,0.0007107223,0.000030920717,0.00018750489,0.0007928487,0.0011249654,0.000058711375,0.032335564,0.00025440138],"about_ca_topic_score_codex":0.0020883474,"about_ca_topic_score_gemma":0.0010904478,"teacher_disagreement_score":0.047916472,"about_ca_system_score_codex":0.0018311486,"about_ca_system_score_gemma":0.0011400668,"threshold_uncertainty_score":0.99999404},"labels":[],"label_agreement":null},{"id":"W2748154165","doi":"10.1016/s1470-2045(17)30471-0","title":"Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Clinical endpoint; Everolimus; Placebo; Discontinuation; Quality of life (healthcare); Internal medicine; Adverse effect; Clinical trial; Surgery; Pathology","score_opus":0.09983468570026899,"score_gpt":0.4149173118146561,"score_spread":0.3150826261143871,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2748154165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97327614,0.0001069983,0.000101549595,0.007462499,0.0008237675,0.01773398,0.000087445966,0.000067948844,0.00033969095],"genre_scores_gemma":[0.9962328,0.00009619702,0.00064260524,0.00028078046,0.00039634778,0.0017617515,0.000162421,0.00006907577,0.00035802543],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.994923,0.0008937078,0.0015339418,0.0006881415,0.0006759763,0.0012852408],"domain_scores_gemma":[0.99251163,0.003757385,0.001891215,0.0010199734,0.00033846634,0.00048133163],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001116549,0.0004695961,0.0028055243,0.00025603262,0.00040078984,0.000043877175,0.0006112492,0.000027590317,0.00013901477],"category_scores_gemma":[0.0056770975,0.00029166669,0.00026233433,0.00020520567,0.00047931762,0.00024145289,0.00015002374,0.0008734588,0.000012720031],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.978978,0.002934964,0.014614936,0.00028978367,0.0003072801,0.0003695979,0.000053187974,0.00039517944,0.0000902537,0.000024014944,0.0012192301,0.00072361913],"study_design_scores_gemma":[0.95940006,0.0199739,0.017226811,0.00019662493,0.00021602628,0.00016000638,0.000115046045,0.0021403653,0.00007900728,0.000012411363,0.00025957887,0.00022014481],"about_ca_topic_score_codex":0.0003858456,"about_ca_topic_score_gemma":0.0016660225,"teacher_disagreement_score":0.022956677,"about_ca_system_score_codex":0.00035360298,"about_ca_system_score_gemma":0.0012275011,"threshold_uncertainty_score":0.99995357},"labels":[],"label_agreement":null},{"id":"W2749746182","doi":"10.1016/s1470-2045(17)30578-8","title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":401,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"Onyx Pharmaceuticals; Amgen","keywords":"Carfilzomib; Bortezomib; Medicine; Interim analysis; Multiple myeloma; Dexamethasone; Proteasome inhibitor; Tolerability; Internal medicine; Refractory (planetary science); Clinical trial; Oncology; Surgery; Adverse effect","score_opus":0.2558644524284098,"score_gpt":0.49781809117761694,"score_spread":0.2419536387492071,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2749746182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920183,0.000048265436,0.000015578187,0.0010271071,0.0004124186,0.0027856946,0.00025713348,0.000038471673,0.003397071],"genre_scores_gemma":[0.99573916,0.00019233716,0.0011914826,0.0002813523,0.0005518643,0.000355512,0.00035800683,0.00004002802,0.0012902657],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9959409,0.0015354583,0.00080725225,0.0006059749,0.00041629752,0.0006940891],"domain_scores_gemma":[0.9954241,0.0012098558,0.0006361769,0.0021952828,0.0001692113,0.00036537956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027521588,0.00031066564,0.0024086442,0.00033848346,0.0002767042,0.000097766424,0.0014431723,0.00026698425,0.0007839966],"category_scores_gemma":[0.0030020846,0.00017270984,0.00013839184,0.0002972493,0.00040531505,0.00033822912,0.00041417955,0.00054154475,0.000014583625],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9226177,0.008086774,0.0058806534,0.000037317084,0.002242309,0.0013861432,0.00074412866,0.000006845998,0.0071369153,0.000034709003,0.0003214163,0.051505122],"study_design_scores_gemma":[0.89356005,0.024723459,0.06643164,0.00004897486,0.0011563214,0.000030783696,0.00026932498,0.009049005,0.0006584504,0.000038937276,0.0038134935,0.00021953501],"about_ca_topic_score_codex":0.00424354,"about_ca_topic_score_gemma":0.03634358,"teacher_disagreement_score":0.06055099,"about_ca_system_score_codex":0.00036651,"about_ca_system_score_gemma":0.00085414236,"threshold_uncertainty_score":0.98124063},"labels":[],"label_agreement":null},{"id":"W2749747068","doi":"10.1016/s1470-2045(17)30517-x","title":"Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":1113,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Foothills Medical Centre; University of Calgary; Sunnybrook Health Science Centre; Juravinski Cancer Centre","funders":"Celldex Therapeutics","keywords":"Temozolomide; Medicine; Internal medicine; Clinical endpoint; Oncology; Progression-free survival; Phases of clinical research; Clinical trial; Chemotherapy; Surgery","score_opus":0.053021347482432236,"score_gpt":0.37165072096852086,"score_spread":0.3186293734860886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2749747068","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9822843,0.000053117954,0.000121370496,0.0073353243,0.00066191104,0.0049038343,0.00006442433,0.000053518048,0.0045221965],"genre_scores_gemma":[0.99389875,0.000040148407,0.0013509087,0.00059072586,0.0016803684,0.0021693867,0.00010133588,0.000044811135,0.00012358662],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99834716,0.000090981084,0.00035176988,0.0004120582,0.00033105144,0.00046699436],"domain_scores_gemma":[0.99748427,0.00071153766,0.0005894551,0.00081696594,0.00024276442,0.00015500214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044951428,0.00028599484,0.0008999619,0.00009677834,0.00048479417,0.00014401197,0.00048162372,0.00012850913,0.000084991225],"category_scores_gemma":[0.00024164606,0.00014793151,0.00014774721,0.00005567251,0.0002829683,0.00018744302,0.00010091637,0.00022604401,0.00002021845],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9503551,0.0036693956,0.023178572,0.000023528522,0.0008125104,0.0002635996,0.0002483571,0.000025193754,0.000090004956,0.00013727004,0.0022355749,0.018960863],"study_design_scores_gemma":[0.94251907,0.012373275,0.0068597654,0.00015296426,0.0006015801,0.00005475304,0.0000441225,0.000120554796,0.00091416034,0.000037808597,0.03613635,0.00018558963],"about_ca_topic_score_codex":0.000092481845,"about_ca_topic_score_gemma":0.0003345678,"teacher_disagreement_score":0.033900775,"about_ca_system_score_codex":0.00020529203,"about_ca_system_score_gemma":0.00023146711,"threshold_uncertainty_score":0.6032472},"labels":[],"label_agreement":null},{"id":"W2752964876","doi":"10.1016/s1470-2045(17)30459-x","title":"Radiotherapy for the treatment of malignant pleural mesothelioma","year":2017,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; University of Toronto; University Health Network","funders":"","keywords":"Extrapleural Pneumonectomy; Radiation therapy; Medicine; Mesothelioma; Decortication; Pleural disease; Oncology; Radiology; Pneumonectomy; Internal medicine; Lung; Respiratory disease; Lung cancer; Pathology","score_opus":0.27779452603899,"score_gpt":0.48394010614513727,"score_spread":0.20614558010614725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2752964876","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000627435,0.99436796,0.0000113199685,0.0027458537,0.0002516663,0.0016577941,0.00034112638,0.000010822017,0.0005507153],"genre_scores_gemma":[0.000044805358,0.99515754,0.00017698495,0.00025988583,0.0011878962,0.0005986508,0.000120726254,0.000026254336,0.0024272683],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99919796,0.00009969206,0.00025769204,0.0001578244,0.00010144981,0.00018535503],"domain_scores_gemma":[0.99829936,0.0007015688,0.00033111355,0.0006186338,0.000011118962,0.000038217353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016733258,0.00019384519,0.0014849391,0.000026487864,0.00012717006,0.000005926827,0.00027243685,0.00011329886,0.0001255675],"category_scores_gemma":[0.000019120502,0.00007141013,0.0005233361,0.000025200454,0.00026549833,0.00000973581,0.000016753891,0.00006114706,0.000019843028],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044515257,0.0002925307,0.00009778778,0.001506428,0.00084000325,0.000009897804,0.000060145958,6.850045e-7,0.000002320428,0.0003407802,0.0028755523,0.9935287],"study_design_scores_gemma":[0.001331263,0.0017954741,0.0011809382,0.0005552112,0.0022050436,0.000087119086,0.000008467438,0.000009980267,0.0000025046186,0.00008731649,0.9926649,0.00007180407],"about_ca_topic_score_codex":0.000026836446,"about_ca_topic_score_gemma":0.000008549057,"teacher_disagreement_score":0.9934569,"about_ca_system_score_codex":0.00026247764,"about_ca_system_score_gemma":0.00018339668,"threshold_uncertainty_score":0.29120207},"labels":[],"label_agreement":null},{"id":"W2753659610","doi":"10.1016/s1470-2045(17)30582-x","title":"Definition and recommendations for advance care planning: an international consensus supported by the European Association for Palliative Care","year":2017,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":1382,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Japanese Association of Cardiac Rehabilitation; L'Oreal USA","keywords":"Advance care planning; Delphi method; Delphi; Pooling; Palliative care; Health care; Process (computing); Adaptation (eye); Medicine; Nursing; Process management; Psychology; Medical education; Political science; Computer science; Business","score_opus":0.5513145969617606,"score_gpt":0.5722748071410236,"score_spread":0.020960210179263083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2753659610","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007586767,0.96923286,0.00018502469,0.005174591,0.00067875435,0.0018160959,0.005122562,0.000032002088,0.017682219],"genre_scores_gemma":[0.00034630328,0.98319983,0.0038932527,0.00036687596,0.001053687,0.00038644424,0.010416763,0.000036092864,0.00030075797],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99860954,0.0004714106,0.00037082145,0.00024322311,0.00010518103,0.0001998151],"domain_scores_gemma":[0.9957989,0.002277253,0.0010356435,0.00030965972,0.00053822366,0.000040363022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006711324,0.00018883897,0.0009824804,0.00004392767,0.00024182141,0.000022865179,0.0002750252,0.0001706104,0.00000634448],"category_scores_gemma":[0.0014013386,0.00011563649,0.0001579578,0.000035473855,0.00010827902,0.000036823825,0.000045503362,0.00025844123,0.0000024784194],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023415491,0.000048761543,0.0013601794,0.004000844,0.0007316489,0.000005250724,0.010373628,4.3469515e-7,0.0000028561033,0.0015360768,0.046901703,0.93480444],"study_design_scores_gemma":[0.0015293582,0.000417277,0.00017672771,0.002914428,0.0009506453,0.0000069776247,0.0033906605,0.000003439306,0.0000035740013,0.00027952052,0.9902128,0.00011459344],"about_ca_topic_score_codex":0.000014208562,"about_ca_topic_score_gemma":0.000053021842,"teacher_disagreement_score":0.9433111,"about_ca_system_score_codex":0.0003948399,"about_ca_system_score_gemma":0.00022135035,"threshold_uncertainty_score":0.47155192},"labels":[],"label_agreement":null},{"id":"W2758277690","doi":"10.1016/s1470-2045(17)30703-9","title":"SRS versus WBRT for resected brain metastases – Authors' reply","year":2017,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Radiosurgery; Medicine; Whole brain radiotherapy; Radiation therapy; Stereotactic radiotherapy; Nuclear medicine; Surgery; Internal medicine; Brain metastasis; Metastasis; Cancer","score_opus":0.17450924352181243,"score_gpt":0.43067172043897917,"score_spread":0.25616247691716676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2758277690","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00066014833,0.00093901024,0.00009101927,0.9821554,0.0029857096,0.0019434268,0.0011756102,0.0001221561,0.009927542],"genre_scores_gemma":[0.0009596724,0.0001882872,0.0072011612,0.9373126,0.027170355,0.0009978954,0.0062317457,0.00014479866,0.01979348],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967197,0.00086507516,0.00044249563,0.0007007133,0.0003533646,0.00091863086],"domain_scores_gemma":[0.9930788,0.0037271006,0.0005740377,0.0023246533,0.00018027716,0.00011508741],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020989957,0.00046762338,0.0018253583,0.00012891814,0.0003941963,0.00005728531,0.0006762827,0.0007545272,0.0005037336],"category_scores_gemma":[0.0024743124,0.0002834429,0.00048338907,0.00008952566,0.0004108863,0.00004033561,0.00016355369,0.001798693,0.000107855056],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038472125,0.00009829758,0.00001736293,0.00024986314,0.00168824,0.002363519,0.00009829857,5.6162787e-7,0.0000325674,0.00029799482,0.98392594,0.0073801675],"study_design_scores_gemma":[0.012511871,0.0039839596,0.00038027717,0.00009732448,0.0020940327,0.00037550955,0.000020918003,0.000012897235,0.00006491812,0.00087507546,0.9793261,0.00025710175],"about_ca_topic_score_codex":0.00028860025,"about_ca_topic_score_gemma":0.00013918041,"teacher_disagreement_score":0.044842772,"about_ca_system_score_codex":0.00036818942,"about_ca_system_score_gemma":0.000597097,"threshold_uncertainty_score":0.9999618},"labels":[],"label_agreement":null},{"id":"W2758552192","doi":"10.1016/s1470-2045(17)30566-1","title":"Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Liver physiology and pathology","field":"Medicine","cited_by":343,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Notre-Dame","funders":"National Institutes of Health; National Cancer Institute; National Institute for Health and Care Research; Amgen","keywords":"Medicine; Capecitabine; Epirubicin; Internal medicine; Placebo; Clinical endpoint; Gastroenterology; Phases of clinical research; Cancer; Chemotherapy; Performance status; Oncology; Surgery; Clinical trial; Pathology; Breast cancer; Colorectal cancer","score_opus":0.09008277766277609,"score_gpt":0.4101330386963679,"score_spread":0.3200502610335918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2758552192","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9817064,0.0014088323,0.00019218404,0.0069100563,0.00143329,0.006193274,0.000043135173,0.000058688587,0.002054183],"genre_scores_gemma":[0.9872441,0.0034925481,0.00040287475,0.0024523064,0.002905823,0.0021779207,0.00006906502,0.00004134156,0.0012140103],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968759,0.0007647928,0.0007399282,0.0006567192,0.00021426058,0.00074841426],"domain_scores_gemma":[0.9965499,0.0015561247,0.00076467753,0.0007803353,0.00017539063,0.00017355432],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017290831,0.0004430652,0.002437392,0.00025069359,0.0005806608,0.00003261821,0.00037860285,0.00038937022,0.00063811854],"category_scores_gemma":[0.0005320557,0.00026222007,0.00019603429,0.00020031752,0.0006376394,0.00020450697,0.00013488182,0.0008932771,0.000035638022],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9736636,0.00074072706,0.000938684,0.000029744508,0.0004862285,0.0005201674,0.0008400354,0.0001263533,0.0033571897,0.00013509649,0.00041613265,0.018746039],"study_design_scores_gemma":[0.97210264,0.019935088,0.0031212936,0.000065207685,0.00047969134,0.0004854845,0.000117279975,0.0006849688,0.0005914398,0.00037841292,0.001812311,0.0002261808],"about_ca_topic_score_codex":0.0005592911,"about_ca_topic_score_gemma":0.0011638878,"teacher_disagreement_score":0.01919436,"about_ca_system_score_codex":0.0003009876,"about_ca_system_score_gemma":0.00054543046,"threshold_uncertainty_score":0.999983},"labels":[],"label_agreement":null},{"id":"W2761190519","doi":"10.1016/s1470-2045(17)30600-9","title":"Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":158,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Seed Growers' Association","keywords":"Anastrozole; Medicine; Tamoxifen; Aromatase inhibitor; Internal medicine; Breast cancer; Clinical endpoint; Oncology; Adjuvant therapy; Clinical trial; Gynecology; Cancer","score_opus":0.05707933250787036,"score_gpt":0.3853302614165258,"score_spread":0.3282509289086555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761190519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923719,0.0021351906,0.00010529671,0.0020635074,0.0007733075,0.0009944994,0.00018338687,0.000023871498,0.0013490214],"genre_scores_gemma":[0.9926294,0.0022791885,0.00016835873,0.000702805,0.0029503189,0.00022721107,0.0007983296,0.000022995277,0.00022136509],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99850565,0.00040185743,0.00023972348,0.00038359297,0.00010998876,0.00035918754],"domain_scores_gemma":[0.9980357,0.000039696755,0.00023310159,0.0015797383,0.00003408059,0.00007765748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074005866,0.0001842205,0.000376895,0.000021292097,0.00028643533,0.00006029423,0.0006071093,0.00020345267,0.00007532102],"category_scores_gemma":[0.00015589691,0.000116507734,0.000118851945,0.000020918891,0.00029249163,0.000012294219,0.0003451537,0.00023947028,0.000044646826],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.51551956,0.0006538606,0.000021271828,0.000010596078,0.00029088845,0.00035687018,0.000059255515,0.0000020974146,0.4321602,0.0000644798,0.015781026,0.035079904],"study_design_scores_gemma":[0.5855955,0.0039804387,0.0002045234,0.000016020815,0.0001232059,0.0002883293,0.000017620881,0.000115049195,0.17485744,0.00030475835,0.2342191,0.0002780253],"about_ca_topic_score_codex":0.000025478837,"about_ca_topic_score_gemma":0.000020742247,"teacher_disagreement_score":0.25730276,"about_ca_system_score_codex":0.000018007793,"about_ca_system_score_gemma":0.00012895543,"threshold_uncertainty_score":0.47510475},"labels":[],"label_agreement":null},{"id":"W2761538670","doi":"10.1016/s1470-2045(17)30787-8","title":"Extended adjuvant therapy: the role of subset analyses","year":2017,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; University of Toronto","funders":"","keywords":"Anastrozole; Medicine; Aromatase inhibitor; Tamoxifen; Adjuvant; Aromatase; Oncology; Clinical endpoint; Internal medicine; Breast cancer; Adjuvant therapy; Letrozole; Exemestane; Clinical trial; Gynecology; Cancer","score_opus":0.04827145982047389,"score_gpt":0.358169260865085,"score_spread":0.3098978010446111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761538670","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2084136,0.10603129,0.000017444823,0.63809985,0.0015049811,0.0013210372,0.000264331,0.000050079052,0.04429738],"genre_scores_gemma":[0.56868243,0.028358882,0.0001743977,0.37119648,0.023685478,0.000248871,0.0015973034,0.00017207982,0.005884082],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99818796,0.0006579489,0.00024324807,0.00033044015,0.00016340979,0.0004169853],"domain_scores_gemma":[0.9977491,0.0001230545,0.00048408404,0.0015403038,0.00007745965,0.000026015548],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005233847,0.00027480267,0.0006450998,0.00003044015,0.00020457429,0.000022418273,0.0013856036,0.0011107123,0.0000303181],"category_scores_gemma":[0.00007249736,0.00013057934,0.0002839951,0.000043852844,0.00055798196,0.0000017085281,0.00021106882,0.0011575351,0.000025008401],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030678877,0.000042784042,0.00010527537,0.000018722363,0.0008105139,0.000068673806,0.00008384748,0.000005595155,0.15860026,0.000030268375,0.8262249,0.013702332],"study_design_scores_gemma":[0.00063667644,0.00060490996,0.00040828146,0.000014299404,0.00014212658,0.000099108234,0.000025477273,0.000010642978,0.06993799,0.0004917073,0.927468,0.00016078261],"about_ca_topic_score_codex":0.000069614915,"about_ca_topic_score_gemma":0.000012810949,"teacher_disagreement_score":0.36026883,"about_ca_system_score_codex":0.000017319646,"about_ca_system_score_gemma":0.00021217886,"threshold_uncertainty_score":0.8566831},"labels":[],"label_agreement":null},{"id":"W2762323160","doi":"10.1016/s1470-2045(17)30605-8","title":"Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Clusterin in disease pathology","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia; Centre Hospitalier de l’Université de Montréal; Juravinski Cancer Centre","funders":"","keywords":"Cabazitaxel; Docetaxel; Medicine; Prostate cancer; Enzalutamide; Mitoxantrone; Prednisone; Oncology; Internal medicine; Chemotherapy; Cancer; Urology; Androgen deprivation therapy; Androgen receptor","score_opus":0.0842271304700907,"score_gpt":0.3939221756151177,"score_spread":0.309695045145027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762323160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857412,0.00031538558,0.000014563988,0.003621634,0.0002023383,0.008528084,0.0004577163,0.000048883292,0.0010702127],"genre_scores_gemma":[0.99442196,0.00036259068,0.0018968235,0.00023965098,0.00014763698,0.0021313708,0.00023187623,0.00006561626,0.0005024806],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972316,0.00043846155,0.00059575855,0.0007353984,0.00039757811,0.0006012076],"domain_scores_gemma":[0.9972349,0.00046040132,0.00081955333,0.00089513155,0.00033305254,0.00025697908],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007395562,0.00046154796,0.0015205285,0.00014708444,0.0003641789,0.0002144274,0.0005132757,0.000120530014,0.00006117206],"category_scores_gemma":[0.00043477284,0.00027446818,0.000027634338,0.0001539882,0.0010126352,0.00037675962,0.00031354182,0.00039967906,0.0000034332804],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.958909,0.0032073928,0.031516813,0.00018293099,0.001053914,0.0006416683,0.0013641171,0.000032153246,0.00027404274,0.000052944608,0.0003430336,0.0024220275],"study_design_scores_gemma":[0.89700013,0.030209893,0.06911595,0.00038653085,0.0014799044,0.00012601167,0.0002812198,0.00046656854,0.00005770821,0.000029988048,0.00048288237,0.00036317966],"about_ca_topic_score_codex":0.0012756934,"about_ca_topic_score_gemma":0.008907382,"teacher_disagreement_score":0.061908804,"about_ca_system_score_codex":0.00029356702,"about_ca_system_score_gemma":0.0006688192,"threshold_uncertainty_score":0.99997073},"labels":[],"label_agreement":null},{"id":"W2765335987","doi":"10.1016/s1470-2045(17)30597-1","title":"Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":219,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Paul's Hospital; Queen's University; Vancouver General Hospital; University of Calgary; Ottawa Hospital; University Health Network; Dalhousie University; St. Joseph’s Healthcare Hamilton; Institut universitaire de cardiologie et de pneumologie de Québec; Juravinski Cancer Centre; Memorial University of Newfoundland; BC Cancer Agency; Brock University","funders":"Partenariat Canadien Contre Le Cancer; Terry Fox Research Institute; Pancreatic Cancer Action Network","keywords":"Medicine; Lung cancer; National Lung Screening Trial; Lung cancer screening; Cancer; Internal medicine; Body mass index; Family history; Prospective cohort study; Incidence (geometry); Oncology","score_opus":0.09311705415612477,"score_gpt":0.39621573381541525,"score_spread":0.3030986796592905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765335987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872271,0.0015358614,0.0020216836,0.002836297,0.00045714487,0.0056581683,0.00009613931,0.00003683893,0.00013077959],"genre_scores_gemma":[0.9923594,0.00037876793,0.00013470423,0.00015325741,0.00083152356,0.0059694625,0.0000030227445,0.000040724895,0.00012914372],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99811345,0.00025473474,0.00036692794,0.00044114853,0.00023901339,0.00058469997],"domain_scores_gemma":[0.99821854,0.00023910234,0.000557442,0.00057700963,0.0002870962,0.00012078658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009204989,0.00022887364,0.00072248187,0.000067864676,0.0011607519,0.00006347121,0.00025951007,0.00009908005,0.000028086364],"category_scores_gemma":[0.00009177659,0.00014043525,0.00010839253,0.00014826795,0.00012618193,0.000107786946,0.000050938357,0.00035612768,7.934787e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015911043,0.0015075367,0.9643438,0.00005848658,0.0023593132,0.0000056974836,0.010232306,0.003964754,0.00038909802,0.000014541011,0.00070333754,0.014830025],"study_design_scores_gemma":[0.01657432,0.011672631,0.82225335,0.00029302988,0.0090083415,0.000009028189,0.0036055534,0.1302535,0.0036877587,0.00008394452,0.0021837272,0.00037479558],"about_ca_topic_score_codex":0.47987708,"about_ca_topic_score_gemma":0.58704776,"teacher_disagreement_score":0.14209042,"about_ca_system_score_codex":0.0018054263,"about_ca_system_score_gemma":0.00044181646,"threshold_uncertainty_score":0.89276826},"labels":[],"label_agreement":null},{"id":"W2766668723","doi":"10.1016/s1470-2045(17)30698-8","title":"Future cancer research priorities in the USA: a Lancet Oncology Commission","year":2017,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":210,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; SickKids Foundation; Hospital for Sick Children","funders":"National Cancer Institute","keywords":"Commission; Cancer prevention; Cancer; Medicine; Political science; Public relations; Business; Internal medicine","score_opus":0.45080538052915314,"score_gpt":0.639479793813089,"score_spread":0.1886744132839358,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766668723","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000046001533,0.8914121,0.000004995415,0.045088835,0.003136837,0.0021430172,0.00006162193,0.000040633247,0.058065973],"genre_scores_gemma":[0.000024474704,0.9584252,0.00055804686,0.0039145197,0.02899187,0.0013928426,0.000045325094,0.00006426115,0.00658344],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.990914,0.005939901,0.00078631047,0.00063387956,0.000509125,0.0012168138],"domain_scores_gemma":[0.99169713,0.005163709,0.000694774,0.0021587277,0.00017076598,0.00011489677],"candidate_categories":["research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.008558052,0.00050980307,0.004946388,0.00027488143,0.0009073709,0.00004098903,0.0025840364,0.0018155252,0.00046609915],"category_scores_gemma":[0.00058331445,0.00023395619,0.00036425673,0.00045000148,0.0021849286,0.000080006226,0.00031580927,0.0066899126,0.00014860288],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006178877,0.00022980716,0.00035869627,0.003336488,0.00021659824,0.0007357362,0.0014014344,5.3412646e-7,0.0000010364497,0.0031980309,0.13069025,0.85921353],"study_design_scores_gemma":[0.0024992833,0.0013312607,0.00067112455,0.0037042387,0.00037408198,0.0015156871,0.00040603214,0.0000019434592,2.3895987e-7,0.0007460642,0.98850757,0.00024247589],"about_ca_topic_score_codex":0.00026863092,"about_ca_topic_score_gemma":0.004233488,"teacher_disagreement_score":0.858971,"about_ca_system_score_codex":0.0019757303,"about_ca_system_score_gemma":0.0046025887,"threshold_uncertainty_score":0.9994803},"labels":[],"label_agreement":null},{"id":"W2766848342","doi":"10.1016/s1470-2045(17)30677-0","title":"Cancer incidence and mortality among young adults aged 20–39 years worldwide in 2012: a population-based study","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":587,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"European Commission; World Health Organization","keywords":"Life expectancy; Cancer; Demography; Medicine; Young adult; Socioeconomic status; Population; Incidence (geometry); Disease; Human Development Index; Cancer registry; Gerontology; Environmental health; Pathology; Human development (humanity); Internal medicine","score_opus":0.054312270788177595,"score_gpt":0.3959895759348087,"score_spread":0.34167730514663114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766848342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98901594,0.00036463505,0.0000067717483,0.008475788,0.00046247194,0.001056213,0.00002289425,0.00005188802,0.00054337777],"genre_scores_gemma":[0.9964705,0.00006050851,0.00010960672,0.0022924917,0.0006531089,0.00016812686,0.000013092924,0.000020053036,0.00021249976],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99797124,0.00052322354,0.00041654336,0.00039169198,0.0003332369,0.00036408546],"domain_scores_gemma":[0.9980096,0.00036362858,0.00039187603,0.0010523616,0.000049862057,0.00013264749],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021523314,0.0001680126,0.0007444413,0.00007955171,0.00022705461,0.000042212505,0.0003877134,0.00011060304,0.00009972545],"category_scores_gemma":[0.0007301445,0.00013583971,0.000049782117,0.00010617543,0.00022531138,0.00016110658,0.00014767733,0.00048515567,0.000007448463],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064666715,0.0002086162,0.99214053,0.00006271795,0.000060737773,0.000114949224,0.004438829,0.000036476333,0.00001881588,0.000016704487,0.00076639006,0.0014885656],"study_design_scores_gemma":[0.005837956,0.00023791206,0.9921661,0.00021058018,0.00009493883,0.0000061823685,0.00062410237,0.00019496355,0.0000054184943,0.00018331409,0.00029347508,0.00014506788],"about_ca_topic_score_codex":0.11406259,"about_ca_topic_score_gemma":0.63770175,"teacher_disagreement_score":0.52363914,"about_ca_system_score_codex":0.00029747607,"about_ca_system_score_gemma":0.00028086113,"threshold_uncertainty_score":0.89183694},"labels":[],"label_agreement":null},{"id":"W2767266730","doi":"10.1016/s1470-2045(17)30700-3","title":"Incomplete excision of cervical precancer as a predictor of treatment failure: a systematic review and meta-analysis","year":2017,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":345,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Institut National Du Cancer; Universiteit van Amsterdam; Medical Research Council; Genesis Research Trust; British Society for Colposcopy and Cervical Pathology","keywords":"Medicine; Cervical intraepithelial neoplasia; Meta-analysis; Cervical cancer; MEDLINE; Surgery; Oncology; Internal medicine; Cancer","score_opus":0.44142660882086193,"score_gpt":0.5322687875650057,"score_spread":0.0908421787441438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767266730","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000011606691,0.9890897,0.000007484656,0.0024298031,0.000023123832,0.004631089,0.00030692623,0.000011963145,0.003498718],"genre_scores_gemma":[0.00020409029,0.99647087,0.00009549505,0.00030470363,0.00016741008,0.0015358245,0.00006395873,0.000026166108,0.0011314559],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99606246,0.0013794495,0.0013596765,0.000428296,0.0004577932,0.00031235372],"domain_scores_gemma":[0.995102,0.0012636905,0.0013524389,0.0018393175,0.0002845817,0.00015799502],"candidate_categories":["metaepi_broad","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00186337,0.00038376346,0.020014001,0.00019977071,0.00006331854,0.0000113920705,0.00059347396,0.00029367322,0.0034564757],"category_scores_gemma":[0.00056535646,0.00016281953,0.0025137598,0.00041779084,0.00035214412,0.000023826622,0.00026401755,0.00039100525,0.000023810602],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009636571,0.0001040807,0.0000029559455,0.842932,0.123148024,0.000012165488,0.00006832645,8.5246455e-8,9.050922e-8,0.00014375987,0.00034411525,0.03314804],"study_design_scores_gemma":[0.0005078694,0.0010385751,0.00002200575,0.008874615,0.6097468,0.00006833249,0.000004629841,0.0000036058082,1.9265572e-7,0.00004637163,0.3796068,0.00008015181],"about_ca_topic_score_codex":0.00032125675,"about_ca_topic_score_gemma":0.00044175205,"teacher_disagreement_score":0.8340574,"about_ca_system_score_codex":0.00040590923,"about_ca_system_score_gemma":0.00092147465,"threshold_uncertainty_score":0.9974545},"labels":[],"label_agreement":null},{"id":"W2767287110","doi":"10.1016/s1470-2045(17)30690-3","title":"Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":349,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Internal medicine; Quality of life (healthcare); Lung cancer; Discontinuation; Response Evaluation Criteria in Solid Tumors; Oncology; Clinical endpoint; Cancer; Clinical trial; Chemotherapy; Progressive disease; Immunotherapy; Nursing","score_opus":0.18616216440643962,"score_gpt":0.4962273689759054,"score_spread":0.3100652045694658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767287110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91165274,0.0010611933,0.00009745704,0.06862611,0.0029306712,0.0065281517,0.0003340748,0.000034705845,0.008734879],"genre_scores_gemma":[0.9901337,0.002504407,0.0013871811,0.0037818984,0.0007026153,0.0004729541,0.000191144,0.000036195193,0.0007899267],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997184,0.0004853861,0.0012421189,0.0004084145,0.00023073031,0.0004493856],"domain_scores_gemma":[0.9956933,0.00173261,0.001493737,0.00080476166,0.000168627,0.00010693764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032027632,0.00022200294,0.0014373505,0.000092525785,0.0002509063,0.000044575325,0.0008987804,0.00019487247,0.0000553449],"category_scores_gemma":[0.0021784748,0.00016322156,0.00016593825,0.00010108808,0.00034158496,0.00016050081,0.00011544837,0.00032263796,0.000005675601],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91526204,0.0017880724,0.000033287342,0.00004851667,0.0006152205,0.000009041111,0.0016373093,0.0000037492312,0.0019574775,0.0002770084,0.003323325,0.07504494],"study_design_scores_gemma":[0.958053,0.0065040262,0.0026915385,0.00019289774,0.00005534448,0.000008597883,0.00030353683,0.0004369573,0.00044704345,0.00012674267,0.031013735,0.00016658808],"about_ca_topic_score_codex":0.002048178,"about_ca_topic_score_gemma":0.0012608862,"teacher_disagreement_score":0.07848092,"about_ca_system_score_codex":0.00052398443,"about_ca_system_score_gemma":0.0008059217,"threshold_uncertainty_score":0.66559815},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"agree"},{"id":"W2767470081","doi":"10.1016/s1470-2045(17)30691-5","title":"Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":172,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre","funders":"National Cancer Institute; National Institutes of Health; American College of Radiology Imaging Network","keywords":"Medicine; Bevacizumab; Docetaxel; Internal medicine; Gemcitabine; Vinorelbine; Oncology; Pemetrexed; Lung cancer; Chemotherapy; Regimen; Cancer; Chemotherapy regimen; Surgery; Cisplatin","score_opus":0.057940193869425914,"score_gpt":0.41199314246569974,"score_spread":0.35405294859627384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767470081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98570263,0.00019719034,0.00001165234,0.0031980192,0.00028304584,0.008695468,0.00005123038,0.000034875968,0.0018258714],"genre_scores_gemma":[0.9934255,0.00065461843,0.0011186627,0.0014494227,0.000574856,0.0020215951,0.00006839297,0.000067132096,0.00061982265],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99796945,0.00024161777,0.00036044963,0.00055727025,0.00028334616,0.0005878425],"domain_scores_gemma":[0.9976763,0.00018724198,0.00049392186,0.0012674716,0.00018284137,0.00019220516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048329218,0.0003326497,0.0013869549,0.00006002157,0.0002982674,0.00010645507,0.0007040026,0.00014124613,0.0002460267],"category_scores_gemma":[0.000052349467,0.00015649531,0.000030079282,0.0001136309,0.00019735495,0.00018872762,0.0001149288,0.0003442785,0.0000063159937],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.77058613,0.008719599,0.20456629,0.000085377826,0.0004345477,0.00013305925,0.001343623,0.0000070254914,0.000063701154,0.0000033812503,0.0012787114,0.012778552],"study_design_scores_gemma":[0.9007351,0.022450252,0.07173043,0.00038552773,0.00065317063,0.000007227611,0.0000849171,0.0007266361,0.00057496,0.0000027553542,0.0024076565,0.00024141265],"about_ca_topic_score_codex":0.0024590562,"about_ca_topic_score_gemma":0.01738923,"teacher_disagreement_score":0.13283587,"about_ca_system_score_codex":0.00080186216,"about_ca_system_score_gemma":0.0009382821,"threshold_uncertainty_score":0.97035986},"labels":[],"label_agreement":null},{"id":"W2768649895","doi":"10.1016/s1470-2045(17)30716-7","title":"Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":529,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; McGill University","funders":"Johnson and Johnson; F. Hoffmann-La Roche; Eli Lilly and Company","keywords":"Pertuzumab; Medicine; Trastuzumab; Trastuzumab emtansine; Docetaxel; Oncology; Internal medicine; Breast cancer; Carboplatin; Regimen; Neoadjuvant therapy; Metastatic breast cancer; Cancer; Chemotherapy","score_opus":0.09179359523436297,"score_gpt":0.4422125994061898,"score_spread":0.3504190041718268,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768649895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.962174,0.00048137346,0.00002469492,0.02392821,0.0007957061,0.0076175556,0.00042731198,0.00005918563,0.004491955],"genre_scores_gemma":[0.9933774,0.0014462597,0.0004870856,0.0016280047,0.0013054729,0.00095723785,0.0000874663,0.000120957026,0.00059012603],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99576676,0.0006100551,0.00070551207,0.00095026643,0.0007471818,0.001220228],"domain_scores_gemma":[0.99641323,0.0009439858,0.0005173766,0.0013212246,0.00040359545,0.0004005923],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001228867,0.0005741048,0.002064518,0.00014998257,0.000655012,0.00025647972,0.0011903433,0.00030262227,0.00050095294],"category_scores_gemma":[0.00056171115,0.0003693966,0.00008591436,0.00022767205,0.0010881653,0.00030360115,0.00035952148,0.0010881908,0.000020451464],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85918576,0.0037418848,0.0039152834,0.000104014594,0.00048037744,0.00035257402,0.0028362728,0.0000075218773,0.00011568796,0.000035909037,0.003260805,0.12596393],"study_design_scores_gemma":[0.8948277,0.015718453,0.078963086,0.0004696586,0.0003081653,0.00010292238,0.00042301894,0.0013531379,0.000060846258,0.000017359871,0.0073090256,0.00044657246],"about_ca_topic_score_codex":0.0043462273,"about_ca_topic_score_gemma":0.004473965,"teacher_disagreement_score":0.12551735,"about_ca_system_score_codex":0.002941645,"about_ca_system_score_gemma":0.0025102806,"threshold_uncertainty_score":0.9998758},"labels":[],"label_agreement":null},{"id":"W2768980003","doi":"10.1016/s1470-2045(17)30717-9","title":"Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":589,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; BC Cancer Agency","funders":"National Institute for Health and Care Research; Puma Biotechnology","keywords":"Medicine; Neratinib; Trastuzumab; Internal medicine; Breast cancer; Oncology; Clinical endpoint; Placebo; Regimen; Metastatic breast cancer; Adverse effect; Cancer; Clinical trial; Pathology","score_opus":0.09916280515671266,"score_gpt":0.4624950642930083,"score_spread":0.36333225913629563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768980003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97413385,0.00074785936,0.00006236865,0.014821355,0.0003595762,0.0060447026,0.00031656734,0.000026457623,0.0034872908],"genre_scores_gemma":[0.991768,0.00074808294,0.00011389345,0.0012137842,0.0013877923,0.004362972,0.000043733773,0.00004102296,0.0003206895],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963283,0.0010440797,0.0008247164,0.0005159047,0.00058079936,0.00070622866],"domain_scores_gemma":[0.9968558,0.0008126576,0.00056521414,0.0012714689,0.00031284033,0.00018200849],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003355339,0.00031464038,0.0028018306,0.00041633865,0.00017913547,0.00006395772,0.0006490671,0.0002711853,0.0020875307],"category_scores_gemma":[0.0002038683,0.0001940339,0.0005494572,0.00045235822,0.0006231558,0.00007957287,0.0000755382,0.0007271996,0.000016226715],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9646903,0.0014215796,0.005973177,0.000033778204,0.002384654,0.00017481571,0.0008515592,0.0003357587,0.0011915093,0.000030247813,0.00061758055,0.022294996],"study_design_scores_gemma":[0.9722398,0.003379461,0.016510552,0.00011121165,0.0013976252,0.000012416141,0.00011106795,0.0037510223,0.0008788596,0.000018104736,0.0013976514,0.00019226511],"about_ca_topic_score_codex":0.0031479276,"about_ca_topic_score_gemma":0.0060423156,"teacher_disagreement_score":0.022102732,"about_ca_system_score_codex":0.00053375494,"about_ca_system_score_gemma":0.0016197104,"threshold_uncertainty_score":0.9988247},"labels":[],"label_agreement":null},{"id":"W2772259112","doi":"10.1016/s1470-2045(17)30856-2","title":"Go, no-go decision making for phase 3 clinical trials: ACT IV revisited – Authors' reply","year":2017,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Foothills Medical Centre; University of Calgary; Sunnybrook Health Science Centre; Juravinski Cancer Centre","funders":"Novartis; Actelion Pharmaceuticals; Roche; Merck; Bristol-Myers Squibb","keywords":"Go/no go; Phase (matter); Clinical decision making; Medicine; Psychology; Intensive care medicine; Economics; Operations management; Chemistry","score_opus":0.8258981385330232,"score_gpt":0.7328234551869758,"score_spread":0.0930746833460474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2772259112","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00041700422,0.00071970513,0.0017404483,0.94614935,0.006029553,0.0040705167,0.00030556787,0.00015814941,0.0404097],"genre_scores_gemma":[0.0006936047,0.0043484485,0.018997889,0.83291197,0.11073796,0.00039674493,0.0004336926,0.00018733904,0.03129234],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9817237,0.009195617,0.004164814,0.0017197864,0.0016837197,0.0015123136],"domain_scores_gemma":[0.4854073,0.50051343,0.004184318,0.007295518,0.0022183224,0.0003810947],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","research_integrity","insufficient_payload"],"category_scores_codex":[0.17597353,0.0005497911,0.006004576,0.00022094334,0.00050705863,0.00016082398,0.0028371988,0.007166192,0.0010099566],"category_scores_gemma":[0.66696155,0.00033149618,0.0015986447,0.00016057809,0.0014200285,0.000068951515,0.000879056,0.02523979,0.001281213],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014971576,0.00025517895,0.00014071717,0.000804617,0.00048014385,0.0012773782,0.000043042473,1.1036972e-7,0.000026859958,0.0004858031,0.868039,0.113475576],"study_design_scores_gemma":[0.015397139,0.00530784,0.00015530664,0.0027052632,0.00089921674,0.00013868645,0.0000073771453,0.00026547236,0.0000047823205,0.0361997,0.938612,0.00030720932],"about_ca_topic_score_codex":0.000013409036,"about_ca_topic_score_gemma":0.000033849272,"teacher_disagreement_score":0.49631646,"about_ca_system_score_codex":0.00048072092,"about_ca_system_score_gemma":0.002823231,"threshold_uncertainty_score":0.9999137},"labels":[],"label_agreement":null},{"id":"W2775223042","doi":"10.1016/s1470-2045(17)30612-5","title":"An integrated multidisciplinary algorithm for the management of spinal metastases: an International Spine Oncology Consortium report","year":2017,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":355,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Multidisciplinary approach; Radiosurgery; Spinal cord; Metastasis; Vertebral column; Spinal column; Radiology; Cancer; Medical physics; Radiation therapy; Surgery; Internal medicine","score_opus":0.2200781386489042,"score_gpt":0.5176297738599871,"score_spread":0.2975516352110829,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2775223042","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000379663,0.93434936,0.03317132,0.0054363585,0.003987271,0.011188097,0.001325983,0.0001518424,0.010351829],"genre_scores_gemma":[0.000033348795,0.90593696,0.085529,0.00046398645,0.0011319349,0.0016928633,0.0030928864,0.00007922639,0.0020397962],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99594873,0.0008174653,0.0014862968,0.00075682724,0.00047979635,0.00051085325],"domain_scores_gemma":[0.9939756,0.00032218048,0.002372952,0.00279283,0.0003457299,0.00019070297],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0052178605,0.00052466756,0.0033196057,0.0002171143,0.00024470693,0.000044131266,0.0019745217,0.0002294289,0.0002344974],"category_scores_gemma":[0.0002216434,0.0002776647,0.0006018221,0.00015509994,0.00072156655,0.00013867866,0.0004935006,0.00062809465,0.000019856614],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006242617,0.0012553587,0.000006264689,0.0060362895,0.004461788,0.002264666,0.000058879265,0.000002842625,4.4849205e-7,0.0013901705,0.0025655911,0.98133343],"study_design_scores_gemma":[0.003298191,0.0028406966,0.00035589837,0.0022365055,0.01403411,0.0010263226,0.00062756037,0.0013247046,4.688755e-7,0.00017631373,0.97383076,0.0002484403],"about_ca_topic_score_codex":0.000053467673,"about_ca_topic_score_gemma":0.000030664174,"teacher_disagreement_score":0.981085,"about_ca_system_score_codex":0.0004061006,"about_ca_system_score_gemma":0.0009682312,"threshold_uncertainty_score":0.9999676},"labels":[],"label_agreement":null},{"id":"W2776537462","doi":"10.1016/s1470-2045(17)30693-9","title":"Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group","year":2017,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":107,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Queen's University","funders":"Bayer Fund; Roche; Teva Pharmaceutical Industries; Karyopharm Therapeutics; Novartis; Dietmar Hopp Stiftung; AbbVie; Merck; GlaxoSmithKline; Pfizer; Boehringer Ingelheim; Siemens USA; AstraZeneca; National Institutes of Health; Medtronic","keywords":"Medicine; Clinical trial; Systemic therapy; Oncology; Guideline; Internal medicine; Efficacy; Regimen; Surrogate endpoint; Clinical study design; Intensive care medicine; Drug; Cancer; Pharmacology; Pathology; Breast cancer","score_opus":0.3621266698721051,"score_gpt":0.5249072376343089,"score_spread":0.1627805677622038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2776537462","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00945312,0.91706944,0.0037163557,0.029322889,0.0022407537,0.035037756,0.0029719204,0.00011167273,0.00007611327],"genre_scores_gemma":[0.006902603,0.9112608,0.03280088,0.020766731,0.0045262775,0.014177328,0.008769356,0.0005316654,0.00026438912],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9621099,0.031203903,0.0035039713,0.0013721269,0.00061975396,0.0011903257],"domain_scores_gemma":[0.95144165,0.042985976,0.0031100935,0.0020862664,0.00014358846,0.00023241513],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.031871982,0.0010147471,0.008178258,0.00033125124,0.00029095937,0.00010165728,0.0013822397,0.0006662931,0.00006455137],"category_scores_gemma":[0.006484521,0.0005072248,0.0009020382,0.00037578674,0.0005174477,0.00008627196,0.00034365515,0.0018758588,0.000016444888],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16893214,0.004361388,0.0007397596,0.0008110047,0.002835613,0.0012953626,0.00013012455,0.000028277822,0.0000015040064,0.00008301714,0.11800157,0.70278025],"study_design_scores_gemma":[0.10453157,0.016872717,0.0006205332,0.0038872825,0.004693494,0.00018634017,0.000095625655,0.00006588942,2.575135e-7,0.00007124631,0.8685731,0.0004018969],"about_ca_topic_score_codex":0.00029122757,"about_ca_topic_score_gemma":0.00048206036,"teacher_disagreement_score":0.75057155,"about_ca_system_score_codex":0.001449847,"about_ca_system_score_gemma":0.0028253966,"threshold_uncertainty_score":0.9997379},"labels":[],"label_agreement":null},{"id":"W2776736524","doi":"10.1016/s1470-2045(17)30912-9","title":"Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1–2 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency","funders":"National Center for Advancing Translational Sciences; BC Cancer Agency; University of British Columbia","keywords":"Brentuximab vedotin; Medicine; Bendamustine; Anaplastic large-cell lymphoma; Internal medicine; Oncology; Regimen; Lymphoma; Chemotherapy; Chemotherapy regimen; Refractory (planetary science); Surgery; CD30; Rituximab","score_opus":0.15133620773205653,"score_gpt":0.43123620369396665,"score_spread":0.2798999959619101,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2776736524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9762187,0.00014956741,0.000004164636,0.01070439,0.0020011605,0.00094928354,0.000044732715,0.00006744061,0.009860534],"genre_scores_gemma":[0.99459213,0.0003630569,0.0006448728,0.001285513,0.002144681,0.00016057842,0.00010675313,0.000028358325,0.0006740591],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982164,0.0002393704,0.0004367727,0.00040791696,0.0002607765,0.0004387679],"domain_scores_gemma":[0.99786973,0.00042227405,0.0004279222,0.0010484912,0.00008665753,0.00014492206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005708588,0.00022892319,0.0007722151,0.000098068194,0.00021354412,0.000069841175,0.00056538597,0.00018474551,0.0004370606],"category_scores_gemma":[0.0009177689,0.00014018863,0.00009916503,0.00006119031,0.00021131533,0.00015532516,0.00015885105,0.00017790604,0.00008081919],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4206067,0.058773234,0.012444201,0.000057107376,0.00053245114,0.004338177,0.0025190422,0.000018941557,0.0013148494,0.00069438055,0.0074903294,0.49121058],"study_design_scores_gemma":[0.71075845,0.013420738,0.06275389,0.00012551167,0.00029377377,0.00021838477,0.00030369114,0.0013514517,0.00064794393,0.000072466806,0.20982465,0.00022902714],"about_ca_topic_score_codex":0.0005507993,"about_ca_topic_score_gemma":0.0011530695,"teacher_disagreement_score":0.49098155,"about_ca_system_score_codex":0.0013034537,"about_ca_system_score_gemma":0.00047571963,"threshold_uncertainty_score":0.5716726},"labels":[],"label_agreement":null},{"id":"W2778244968","doi":"10.1016/s1470-2045(17)30915-4","title":"Complications during minimal invasive thoracic surgery: are new surgeons prepared?","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Thoracotomy; Cardiothoracic surgery; Surgery; Robotic surgery; Open surgery; General surgery; Lung cancer","score_opus":0.11012324832517882,"score_gpt":0.39920204456266895,"score_spread":0.2890787962374901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2778244968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88014096,0.00037338008,0.000004373445,0.099844,0.0003159826,0.00041841847,0.000033866345,0.00006708298,0.01880195],"genre_scores_gemma":[0.99583185,0.00084143993,0.00018253211,0.0011214961,0.00068161584,0.00017641652,0.000024947345,0.000016540898,0.0011231903],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990515,0.00008733995,0.00018856188,0.00024745,0.00011213986,0.00031298096],"domain_scores_gemma":[0.9978114,0.000589349,0.0002995861,0.0010998842,0.000066389046,0.00013339901],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024208135,0.00012425098,0.0005548235,0.000036372323,0.0004837562,0.000037826834,0.00024141188,0.00007671339,0.00011652437],"category_scores_gemma":[0.00030873052,0.00008191087,0.000119146964,0.000045202,0.00015773848,0.000055956152,0.00011681652,0.00014618991,0.00013060705],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042124113,0.00026306542,0.8924811,0.00010090504,0.0002703943,0.0001581434,0.00043975547,0.0000030511562,0.0002165355,0.00033054414,0.09905562,0.0062596677],"study_design_scores_gemma":[0.00087471615,0.000095343436,0.9425271,0.00017610454,0.0001864308,0.00013716739,0.00008597541,0.0000038530684,0.0013547343,0.00023638849,0.054239586,0.00008261033],"about_ca_topic_score_codex":0.000640614,"about_ca_topic_score_gemma":0.003107423,"teacher_disagreement_score":0.11569088,"about_ca_system_score_codex":0.0003372698,"about_ca_system_score_gemma":0.0004920128,"threshold_uncertainty_score":0.37207106},"labels":[],"label_agreement":null},{"id":"W2780407194","doi":"10.1016/s1470-2045(17)30692-7","title":"Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group","year":2017,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"AbbVie; Novartis; Roche; Merck; GlaxoSmithKline","keywords":"Clinical trial; Clinical endpoint; Medicine; Context (archaeology); Guideline; Clinical study design; Oncology; Surrogate endpoint; Medical physics; Internal medicine; Intensive care medicine; Pathology","score_opus":0.45547192864289415,"score_gpt":0.5629153715408106,"score_spread":0.10744344289791646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2780407194","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000024057923,0.79262197,0.101229854,0.08229474,0.0018317194,0.020460797,0.001373383,0.00007937,0.000084089304],"genre_scores_gemma":[0.00010473639,0.8826772,0.07180785,0.022064278,0.0045991912,0.016162334,0.0018154893,0.00026222947,0.00050668186],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9658709,0.027529547,0.0034327204,0.0013564655,0.0004493126,0.0013610135],"domain_scores_gemma":[0.89476395,0.10025779,0.0024414307,0.002146766,0.00016307067,0.00022700982],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.06924551,0.0010536062,0.008304909,0.00026269178,0.0005962915,0.00012239793,0.0015503142,0.00089511526,0.00008560105],"category_scores_gemma":[0.010790668,0.00052831153,0.0022012233,0.00029985906,0.0011426199,0.00007169537,0.00035237378,0.0017697107,0.000012501928],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.081321955,0.0012369173,0.0000017968023,0.000639322,0.0022328233,0.00020018648,0.0000716687,0.000007791347,0.000002346425,0.0010202818,0.21182212,0.7014428],"study_design_scores_gemma":[0.075292766,0.023293182,0.0000051066227,0.00094973267,0.006039667,0.00042594568,0.00022403226,0.00022127647,6.090939e-7,0.00073548657,0.89240706,0.00040514182],"about_ca_topic_score_codex":0.000078321114,"about_ca_topic_score_gemma":0.00030564785,"teacher_disagreement_score":0.70103765,"about_ca_system_score_codex":0.0009950671,"about_ca_system_score_gemma":0.0038678737,"threshold_uncertainty_score":0.9997168},"labels":[],"label_agreement":null},{"id":"W2785671534","doi":"10.1016/s1470-2045(17)30899-9","title":"Chromatin organisation and cancer prognosis: a pan-cancer study","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Genomics and Chromatin Dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Norges Forskningsråd; Universitetet i Oslo; National Institute for Health and Care Research; Institute of Genetics; Helse Sør-Øst RHF; NIHR Bristol Biomedical Research Centre; National Institutes of Health; Cancer Research UK; Wellcome Trust","keywords":"Cancer; Chromatin; Oncology; Colorectal cancer; Hazard ratio; Stage (stratigraphy); Medicine; Internal medicine; Cohort; Cancer research; Biology; Gene; Genetics","score_opus":0.02451727799611411,"score_gpt":0.32319909924616175,"score_spread":0.29868182125004766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2785671534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958747,0.0007076578,0.000056056397,0.0019906594,0.00022544376,0.000393647,0.00001767284,0.000014629015,0.0007195174],"genre_scores_gemma":[0.9960692,0.0008110554,0.0003229242,0.00094158464,0.0014144492,0.00022125445,0.000010581189,0.000017460214,0.00019152429],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.999241,0.000114935014,0.00014432796,0.00023173339,0.000061012874,0.00020697417],"domain_scores_gemma":[0.9995464,0.000013719554,0.000103605715,0.0002454232,0.00006108816,0.000029762883],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028592665,0.00010721226,0.00018177553,0.000012868613,0.0001368011,0.000021547035,0.0001951443,0.00009309984,0.00007260362],"category_scores_gemma":[0.000021234056,0.00007586276,0.000018858158,0.000051292955,0.00015681415,0.000002053416,0.0001512883,0.000073700816,0.000012148168],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034182836,0.0004919897,0.19624808,0.000052285603,0.00041479224,0.0000042206934,0.00527365,0.000023507733,0.7058209,0.00027747103,0.011688821,0.07936244],"study_design_scores_gemma":[0.0065622474,0.006799166,0.68961555,0.000043209737,0.00033866332,0.00006596275,0.004309187,0.002166315,0.0591784,0.00110411,0.22903936,0.00077784364],"about_ca_topic_score_codex":0.00013929117,"about_ca_topic_score_gemma":0.0017718568,"teacher_disagreement_score":0.6466425,"about_ca_system_score_codex":0.00003562231,"about_ca_system_score_gemma":0.0001111377,"threshold_uncertainty_score":0.30935934},"labels":[],"label_agreement":null},{"id":"W2787010973","doi":"10.1016/s1470-2045(18)30032-9","title":"Young adults: a unique group in cancer epidemiological research – Authors' reply","year":2018,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"World Health Organization","keywords":"Scopus; Cancer; Incidence (geometry); Demography; Medicine; International agency; Epidemiology; Population; Cancer registry; Young adult; Gerontology; MEDLINE; Pathology; Environmental health; Internal medicine; Political science","score_opus":0.2359367407698882,"score_gpt":0.4880265055722506,"score_spread":0.2520897648023624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2787010973","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.021256108,0.002151918,0.0000485368,0.9595382,0.0022521662,0.0019143238,0.000121481,0.00021312342,0.01250413],"genre_scores_gemma":[0.005237985,0.0029263967,0.001228948,0.9268281,0.05853267,0.0012097595,0.00033262657,0.000121669735,0.003581837],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98280555,0.011291276,0.0013953152,0.001410509,0.0010680526,0.002029269],"domain_scores_gemma":[0.9903226,0.006263705,0.00056752947,0.0021897259,0.00045132506,0.00020514698],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.021826882,0.00057328626,0.0030741463,0.00041869038,0.00022170505,0.000029592398,0.0014163689,0.0026772758,0.0009443515],"category_scores_gemma":[0.005988473,0.00037469887,0.00030232398,0.00084018224,0.0017645581,0.00006152275,0.00061025925,0.013017345,0.00028946812],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018695327,0.00015867276,0.009754938,0.00063209987,0.00016308822,0.0012724584,0.0026193026,7.0048264e-7,0.00001742444,0.00035925483,0.98169297,0.0014595405],"study_design_scores_gemma":[0.0028994258,0.0021433863,0.019238198,0.0015715391,0.00008756495,0.00036594606,0.00029087128,0.000050334194,0.0000082139995,0.005143517,0.9678203,0.0003807051],"about_ca_topic_score_codex":0.027002899,"about_ca_topic_score_gemma":0.017381532,"teacher_disagreement_score":0.056280505,"about_ca_system_score_codex":0.0020082607,"about_ca_system_score_gemma":0.0012474912,"threshold_uncertainty_score":0.99996895},"labels":[],"label_agreement":null},{"id":"W2787725515","doi":"10.1016/s1470-2045(18)30079-2","title":"Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":623,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Hôpital Notre-Dame; Université de Sherbrooke","funders":"Agenzia Italiana del Farmaco, Ministero della Salute; National Health and Medical Research Council; Cancer Research UK; Cancer Australia; Strong; Cancer Research Institute","keywords":"Medicine; Endometrial cancer; Radiation therapy; Chemoradiotherapy; Carboplatin; Internal medicine; Oncology; Lymphadenectomy; Clinical endpoint; Clinical trial; Surgery; Gynecology; Cancer; Chemotherapy; Cisplatin","score_opus":0.11775227188093922,"score_gpt":0.43636421173025913,"score_spread":0.3186119398493199,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2787725515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98653567,0.0005120862,0.00019003732,0.0028888506,0.002946197,0.004889138,0.0008319986,0.000045855006,0.0011601554],"genre_scores_gemma":[0.96621823,0.0048835627,0.010963591,0.0013177296,0.013331906,0.002169529,0.00021400968,0.00007160329,0.0008298186],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99762154,0.0003122629,0.00066899287,0.0004944084,0.00038039495,0.0005224056],"domain_scores_gemma":[0.9966971,0.0014475004,0.0007284566,0.00059783173,0.00032489284,0.00020419095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015205853,0.0002744739,0.0017028417,0.0001646222,0.00013800121,0.000035249042,0.00066944456,0.00015489197,0.0007030406],"category_scores_gemma":[0.0006713935,0.00015884402,0.00007974094,0.00047611774,0.0003628282,0.00015451599,0.00005161526,0.00022247083,0.000004294282],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8196641,0.0032654346,0.000063398904,0.000018604202,0.0017192134,0.000020990781,0.00066897157,0.0000056923727,0.0022833203,0.000033776378,0.00096435315,0.17129214],"study_design_scores_gemma":[0.8416431,0.075489506,0.0002754802,0.000029677403,0.00039068915,0.000012234286,0.0000911441,0.0002507189,0.00489986,0.00006868037,0.0766901,0.00015880178],"about_ca_topic_score_codex":0.0013878318,"about_ca_topic_score_gemma":0.00060272304,"teacher_disagreement_score":0.17113334,"about_ca_system_score_codex":0.0007291508,"about_ca_system_score_gemma":0.00049745536,"threshold_uncertainty_score":0.7697802},"labels":[],"label_agreement":null},{"id":"W2788428060","doi":"10.1016/s1470-2045(18)30076-7","title":"Cancer groundshot: going global before going to the moon","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Commission; Political science; Cancer; Global health; European commission; Pandemic; Public relations; European union; Public administration; Health care; Medicine; Economic growth; Coronavirus disease 2019 (COVID-19); Business; Law; Economics; International trade; Internal medicine","score_opus":0.06443721358206132,"score_gpt":0.3251231178188614,"score_spread":0.26068590423680005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2788428060","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5054734,0.002517529,0.002324839,0.07597943,0.004099454,0.0004889956,0.00032403183,0.00008673797,0.40870562],"genre_scores_gemma":[0.9707573,0.00031553974,0.00038546667,0.019130876,0.006336238,0.00009674788,0.0000034653808,0.000024010971,0.002950374],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984428,0.000035309462,0.0004573919,0.00036916777,0.00003260506,0.00066270144],"domain_scores_gemma":[0.99887407,0.000075699114,0.00030745112,0.0005962973,0.000048593207,0.00009792033],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011065194,0.00017786356,0.00056541414,0.00004342031,0.00040424513,0.00009177219,0.00081420963,0.00013949534,0.0006883123],"category_scores_gemma":[0.00016570193,0.00012724189,0.0000988915,0.0002798832,0.00024550295,0.00017971625,0.00020297266,0.00023041708,0.0052490924],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028430746,0.00004924,0.12299893,0.00001796879,0.00013504439,0.0000047478097,0.0033150604,0.00016290518,0.000011029164,0.60100734,0.1968144,0.07519899],"study_design_scores_gemma":[0.0005000064,0.00029249812,0.07839909,0.000013793776,0.000009765974,0.000010572868,0.00005986893,0.0005638658,0.000012041548,0.04273036,0.877244,0.000164119],"about_ca_topic_score_codex":0.0014154369,"about_ca_topic_score_gemma":0.014446331,"teacher_disagreement_score":0.68042964,"about_ca_system_score_codex":0.00076843123,"about_ca_system_score_gemma":0.00010966011,"threshold_uncertainty_score":0.9955254},"labels":[],"label_agreement":null},{"id":"W2789626795","doi":"10.1016/s1470-2045(18)30143-8","title":"Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Musculoskeletal synovial abnormalities and treatments","field":"Medicine","cited_by":115,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Institut National Du Cancer","keywords":"Pigmented villonodular synovitis; Medicine; Nilotinib; Clinical endpoint; Internal medicine; Synovitis; Surgery; Progressive disease; Adverse effect; Oncology; Dermatology; Clinical trial; Tyrosine kinase; Rheumatoid arthritis; Disease; Receptor","score_opus":0.10193185493969692,"score_gpt":0.41602375562944066,"score_spread":0.31409190068974374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789626795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9604686,0.00023988442,0.00009190192,0.0051756334,0.00095654675,0.0030676792,0.000036948604,0.00008414295,0.029878693],"genre_scores_gemma":[0.99117416,0.00011661643,0.001871498,0.0041522523,0.0012648023,0.00026845213,0.00008202372,0.000036928053,0.0010332741],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997758,0.00033919557,0.0005469218,0.0004244943,0.0002245511,0.0007068409],"domain_scores_gemma":[0.99872077,0.00020771507,0.000215078,0.00057882344,0.0001135771,0.00016402706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059503876,0.00026088432,0.0009344756,0.00007609891,0.00014856223,0.000036629066,0.00043437287,0.00015753761,0.00077119604],"category_scores_gemma":[0.00024593837,0.00017546646,0.000066149754,0.00029719848,0.00032424828,0.00014484854,0.0002835222,0.00028680122,0.0002238828],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.55631095,0.05049775,0.001697636,0.00022179322,0.0008858105,0.0013947308,0.0019378393,0.000005603282,0.015310359,0.0033445708,0.0057202973,0.36267266],"study_design_scores_gemma":[0.70836025,0.05046489,0.0009410854,0.00025706584,0.00024221822,0.00013219887,0.00040780642,0.00043999826,0.0016180646,0.00041928975,0.23639701,0.00032011946],"about_ca_topic_score_codex":0.0005118783,"about_ca_topic_score_gemma":0.0009670789,"teacher_disagreement_score":0.36235255,"about_ca_system_score_codex":0.00038938626,"about_ca_system_score_gemma":0.00020561385,"threshold_uncertainty_score":0.8444056},"labels":[],"label_agreement":null},{"id":"W2791290180","doi":"10.1016/s1470-2045(18)30144-x","title":"Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":576,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"National Cancer Institute; Kite Pharma; EMD Serono; MacroGenics; Sanofi; GlaxoSmithKline; Amgen; Pfizer; Genentech; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Durvalumab; Medicine; Internal medicine; Oncology; Lung cancer; Anaplastic lymphoma kinase; Response Evaluation Criteria in Solid Tumors; Cohort; Progressive disease; Cancer; Nivolumab; Anaplastic large-cell lymphoma; Immunotherapy; Chemotherapy; Lymphoma; Malignant pleural effusion","score_opus":0.13285510740048945,"score_gpt":0.45235716903037204,"score_spread":0.3195020616298826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791290180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843174,0.0005144307,0.00008992344,0.005767821,0.0009343648,0.005087559,0.000061268096,0.000086522465,0.0031407068],"genre_scores_gemma":[0.9801368,0.0006400453,0.001796787,0.0060132514,0.0021097192,0.0013425566,0.0000710707,0.00007026906,0.007819506],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99807215,0.00021339016,0.00044009124,0.0005207222,0.00015260067,0.0006010415],"domain_scores_gemma":[0.99844104,0.000220108,0.00023884555,0.0007874049,0.00018825635,0.00012432254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071149087,0.00031665855,0.0009313436,0.00006213387,0.00029301186,0.000055008248,0.0005194657,0.0001450491,0.0008080586],"category_scores_gemma":[0.00003266413,0.00017433007,0.00006400422,0.00020270573,0.00020324675,0.00011347145,0.000110488174,0.00015411372,0.000031169042],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39431208,0.05721429,0.005688755,0.00023454208,0.0024695238,0.0003394756,0.014692141,0.000008419827,0.30899167,0.000033326192,0.019243954,0.19677182],"study_design_scores_gemma":[0.3101373,0.3131844,0.0016180378,0.0001895102,0.0016699247,0.000175294,0.0021010481,0.0014852739,0.0501548,0.00007127991,0.31861204,0.00060107996],"about_ca_topic_score_codex":0.0013528867,"about_ca_topic_score_gemma":0.006361111,"teacher_disagreement_score":0.29936808,"about_ca_system_score_codex":0.000631496,"about_ca_system_score_gemma":0.0006696901,"threshold_uncertainty_score":0.8847675},"labels":[],"label_agreement":null},{"id":"W2791813598","doi":"10.1016/s1470-2045(18)30110-4","title":"Vulvar field resection: innovative procedure or same old?","year":2018,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Medicine; Resection; MEDLINE; Surgery; Medical physics","score_opus":0.09205123661033167,"score_gpt":0.3879892835994605,"score_spread":0.29593804698912884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791813598","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0033490642,0.00028829556,0.0000068976647,0.94829017,0.0017512613,0.00084434106,0.000047064626,0.000105636296,0.045317262],"genre_scores_gemma":[0.0011254334,0.00025609098,0.00026226765,0.86699325,0.053067893,0.00025496676,0.00017156037,0.00003934911,0.0778292],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99815387,0.0002287302,0.00033762128,0.00042595962,0.00033440732,0.0005194226],"domain_scores_gemma":[0.9977878,0.0009634401,0.0002421798,0.00060284394,0.00035090375,0.00005286253],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00034616434,0.00029121188,0.001082317,0.00014014139,0.00012325741,0.00001634129,0.00033240256,0.0010675676,0.0039559705],"category_scores_gemma":[0.00082849537,0.00014488972,0.000096727366,0.0010084583,0.00020820649,0.00003030841,0.00011911953,0.0022167137,0.00038155454],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052157,0.00007634031,0.00044976803,0.0003195331,0.00044262112,0.0007622704,0.00030684198,3.8017603e-8,0.000022359449,0.00005831847,0.9885921,0.003754136],"study_design_scores_gemma":[0.0046328674,0.0077020857,0.00093064917,0.00016417805,0.00023597742,0.0004492501,0.00005342004,8.2608653e-7,0.0003460934,0.0008309216,0.98449045,0.00016328887],"about_ca_topic_score_codex":0.0003044365,"about_ca_topic_score_gemma":0.00031518072,"teacher_disagreement_score":0.081296936,"about_ca_system_score_codex":0.0004228077,"about_ca_system_score_gemma":0.0005895714,"threshold_uncertainty_score":0.99695456},"labels":[],"label_agreement":null},{"id":"W2794642699","doi":"10.1016/s1470-2045(18)30162-1","title":"Genetic testing for young women with breast cancer","year":2018,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; Women's College Hospital; University of Toronto","funders":"","keywords":"Breast cancer; Genetic testing; Oncology; Medicine; Cancer; Internal medicine","score_opus":0.03221763229642136,"score_gpt":0.31213406249182885,"score_spread":0.27991643019540746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794642699","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13549572,0.001681326,0.0018444813,0.8479017,0.002794961,0.0019489003,0.001893739,0.000092730115,0.006346463],"genre_scores_gemma":[0.026160352,0.0002852552,0.01694015,0.84150463,0.10254178,0.0056582647,0.00038990745,0.0002742447,0.006245394],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981741,0.00014997485,0.00022909301,0.00056572707,0.0001433293,0.00073782995],"domain_scores_gemma":[0.998445,0.00011107522,0.0002811389,0.0007659754,0.00035774964,0.000039112234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031544248,0.0002994656,0.00044408883,0.00003824948,0.00018358686,0.000033221342,0.0006928573,0.0006818762,0.000097189644],"category_scores_gemma":[0.000061014012,0.0002038021,0.00005179957,0.00012299034,0.00040098408,0.0000019443062,0.00014595845,0.0005001707,0.00001625776],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032463044,0.000012075572,0.0012026276,0.00009329512,0.00028263766,0.000015214891,0.00015929934,0.00007210833,0.003927781,0.0000015803879,0.9869809,0.006927838],"study_design_scores_gemma":[0.00099656,0.00096847664,0.0039267894,0.000032684922,0.00010957971,0.00048266974,0.00004114139,0.000031008785,0.00040625542,0.00015386954,0.9925242,0.00032678706],"about_ca_topic_score_codex":0.000072768235,"about_ca_topic_score_gemma":0.00028076282,"teacher_disagreement_score":0.10933537,"about_ca_system_score_codex":0.0004496498,"about_ca_system_score_gemma":0.0011166803,"threshold_uncertainty_score":0.83108085},"labels":[],"label_agreement":null},{"id":"W2794658314","doi":"10.1016/s1470-2045(18)30203-1","title":"Slogans and donor pages of cancer centres: do they convey discordant messages?","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Corporate Identity and Reputation","field":"Business, Management and Accounting","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Advertising; Cancer; Identity (music); Brand names; Business; Internal medicine; Aesthetics","score_opus":0.04159577411960745,"score_gpt":0.3019653635248387,"score_spread":0.26036958940523125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794658314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96645457,0.00039378085,0.00005337853,0.011191842,0.0009706148,0.0001932993,0.000006791348,0.000037413924,0.020698331],"genre_scores_gemma":[0.9952821,0.0006883037,0.0000451412,0.0012154347,0.002206782,0.000013034802,0.000006149436,0.000007829878,0.0005352133],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994076,0.000034353117,0.0001547303,0.00013640273,0.00008094746,0.00018600578],"domain_scores_gemma":[0.99942243,0.00005961042,0.00025200995,0.00015366457,0.000106320775,0.0000059540134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040485876,0.00008005389,0.00023201517,0.000041363357,0.00015242372,0.000068102025,0.00017071184,0.00003847951,0.00020740823],"category_scores_gemma":[0.0000457038,0.00004916286,0.000025010098,0.00011825201,0.0002623663,0.00021850633,0.00014697152,0.00007892167,0.00006366986],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00083784945,0.00027820098,0.5980272,0.0006590907,0.00031843997,0.00004306754,0.0018113384,0.000099578654,0.0084789125,0.2273336,0.107970946,0.054141715],"study_design_scores_gemma":[0.0020205127,0.0001079839,0.46938467,0.00012298251,0.0002683186,0.00000837565,0.0016371171,0.0005563914,0.00055851374,0.07909163,0.4459689,0.00027461478],"about_ca_topic_score_codex":0.002607666,"about_ca_topic_score_gemma":0.014954971,"teacher_disagreement_score":0.33799794,"about_ca_system_score_codex":0.000017597837,"about_ca_system_score_gemma":0.000028279437,"threshold_uncertainty_score":0.8345225},"labels":[],"label_agreement":null},{"id":"W2795355542","doi":"10.1016/s1470-2045(17)30609-5","title":"Periosteal aneurysmal bone cyst","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bone Tumor Diagnosis and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Neurovascular bundle; Medicine; Presentation (obstetrics); Surgery; Aneurysmal bone cyst; Range of motion; Swelling; Radiology; Pathology","score_opus":0.05811514374355914,"score_gpt":0.361509540922831,"score_spread":0.30339439717927186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795355542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90393144,0.0002918877,0.0000024557178,0.025514534,0.00034403516,0.00020807251,0.0000094257275,0.000062800114,0.06963534],"genre_scores_gemma":[0.9902292,0.00004943984,0.00033230873,0.0050624935,0.0020338611,0.000037126516,0.000012211901,0.000013546261,0.002229822],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992562,0.00007826717,0.00012925368,0.00015565036,0.000096130505,0.0002845176],"domain_scores_gemma":[0.9994111,0.000082432976,0.00005405779,0.0003345788,0.000048259604,0.00006959208],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002157973,0.000092277616,0.00036241952,0.000023120343,0.00010751428,0.0000073681645,0.00008672249,0.00006006702,0.0005155668],"category_scores_gemma":[0.000043825727,0.000053146206,0.000048869075,0.00008061324,0.0002527801,0.000019239507,0.000052302763,0.00014640082,0.00083730154],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006805027,0.0038834235,0.5200358,0.00019112694,0.0005887994,0.009210305,0.0054729143,0.0000011768761,0.018417245,0.018616475,0.2780472,0.13873053],"study_design_scores_gemma":[0.005519562,0.004031572,0.41071773,0.00001852215,0.00019338798,0.0038670623,0.00012177293,0.000036313446,0.00096660905,0.00024421216,0.574181,0.00010224017],"about_ca_topic_score_codex":0.00006158701,"about_ca_topic_score_gemma":0.000119315126,"teacher_disagreement_score":0.29613382,"about_ca_system_score_codex":0.00007704912,"about_ca_system_score_gemma":0.000077319855,"threshold_uncertainty_score":0.99994063},"labels":[],"label_agreement":null},{"id":"W2795488377","doi":"10.1016/s1470-2045(18)30146-3","title":"Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Liver physiology and pathology","field":"Medicine","cited_by":349,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Daiichi-Sankyo; ArQule","keywords":"Medicine; Placebo; Sorafenib; Internal medicine; Hepatocellular carcinoma; Clinical endpoint; Population; Gastroenterology; Cirrhosis; Adverse effect; Intention-to-treat analysis; Phases of clinical research; Clinical trial; Surgery; Pathology","score_opus":0.07760832321810575,"score_gpt":0.3859511444927207,"score_spread":0.308342821274615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795488377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99371237,0.00029162873,0.00050651794,0.00034171337,0.0002069481,0.0042188335,0.00017179445,0.000021231552,0.0005289509],"genre_scores_gemma":[0.9967703,0.000032362026,0.0010881603,0.00023447651,0.0004649196,0.00073009596,0.00009990105,0.00001594125,0.00056384655],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99764645,0.0008519011,0.00067395973,0.00036295288,0.000108784385,0.00035592378],"domain_scores_gemma":[0.9966084,0.0018726832,0.00055406516,0.00063127646,0.00026901806,0.00006457918],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010677993,0.00023451289,0.003366042,0.0002506624,0.000089852074,0.0000015906347,0.00019430844,0.00015866844,0.000510328],"category_scores_gemma":[0.00021154335,0.00013684385,0.00049724284,0.00038180748,0.00046159807,0.000024095307,0.000037920276,0.00011378273,0.000007245584],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8091602,0.0073377453,0.030873902,0.000075558826,0.011522949,0.00009775861,0.005245002,0.00002643163,0.1305982,0.0002858609,0.00014143215,0.0046349526],"study_design_scores_gemma":[0.82182664,0.08668678,0.017590985,0.000013665979,0.018669223,0.000032743785,0.00088105624,0.0035162938,0.04846993,0.0002997302,0.0018336164,0.00017931366],"about_ca_topic_score_codex":0.000053935255,"about_ca_topic_score_gemma":0.00014203103,"teacher_disagreement_score":0.08212828,"about_ca_system_score_codex":0.00006253946,"about_ca_system_score_gemma":0.00020177617,"threshold_uncertainty_score":0.55877334},"labels":[],"label_agreement":null},{"id":"W2799371667","doi":"10.1016/s1470-2045(18)30097-4","title":"Incorporating the patient experience into regulatory decision making in the USA, Europe, and Canada","year":2018,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":199,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Canada","funders":"","keywords":"Medicine; Identification (biology); Process (computing); Quality of life (healthcare); Health care; MEDLINE; Quality (philosophy); Regulatory focus theory; Nursing; Economic growth","score_opus":0.07301386959545315,"score_gpt":0.3813628747180579,"score_spread":0.30834900512260477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2799371667","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022741055,0.9700759,0.000010344463,0.0011503845,0.0011094363,0.000871094,0.0000068017625,0.00000961209,0.0040253815],"genre_scores_gemma":[0.051739108,0.9383667,0.00011619939,0.008132561,0.0013329329,0.00019189315,0.000009719086,0.000033868688,0.00007701981],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976992,0.0009312736,0.000454458,0.00030422077,0.00033677064,0.00027405],"domain_scores_gemma":[0.9974297,0.0012733307,0.00037001722,0.00081194117,0.00007737145,0.00003758715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012664476,0.0002270416,0.000978258,0.000039512546,0.00021163322,0.000026807684,0.00056136504,0.00013809856,0.000027152402],"category_scores_gemma":[0.00030209444,0.00009251859,0.000063938394,0.00034589265,0.00033574257,0.000025093474,0.0002651212,0.0006485601,0.000006253848],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006013448,0.000012479028,0.00064909493,0.00082921464,0.000022195127,0.00011841146,0.00679252,3.837474e-7,2.316527e-7,0.00034962132,0.0103061255,0.9808596],"study_design_scores_gemma":[0.00016023069,0.00016655578,0.0010864692,0.0031481741,0.00010750582,0.00028916338,0.001312101,0.0000040939663,2.1052004e-7,0.00008947622,0.9935269,0.00010912138],"about_ca_topic_score_codex":0.12278792,"about_ca_topic_score_gemma":0.9217217,"teacher_disagreement_score":0.98322076,"about_ca_system_score_codex":0.00039821552,"about_ca_system_score_gemma":0.0013977702,"threshold_uncertainty_score":0.8830535},"labels":[],"label_agreement":null},{"id":"W2799574682","doi":"10.1016/s1470-2045(18)30242-0","title":"Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":394,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency; University of Calgary; McGill University; University of Toronto; Toronto General Hospital; University Health Network; Hospital for Sick Children","funders":"National Heart, Lung, and Blood Institute; Strategic Research Council; Canadian Institutes of Health Research; Brain Tumour Research; National Cancer Institute; Fondation de l'Hôpital de Montréal pour enfants; BC Cancer Foundation; Lékařská fakulta, Masarykova univerzita; Eunice Kennedy Shriver National Institute of Child Health and Human Development; Masarykova Univerzita; Nationales Centrum für Tumorerkrankungen Heidelberg; Göteborgs Universitet; Universitetet i Oslo; Karolinska Institutet; Terry Fox Research Institute; Cancerfonden; Universität Zürich; Bundesministerium für Bildung und Forschung; Norges Forskningsråd; Semmelweis Egyetem; Bundesamt für Gesundheit; Pediatric Brain Tumor Foundation; Deutsche Krebshilfe; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Broad Institute; Forskningsrådet om Hälsa, Arbetsliv och Välfärd; Universidad Nacional Autónoma de México; Pediatric Oncology Group of Ontario; FH Foundation; Instituto Mexicano del Seguro Social; Colorado State University; Barncancerfonden; Ontario Institute for Cancer Research; University of Miami; European Molecular Biology Organization; University of Bern; Ministerstvo Zdravotnictví Ceské Republiky; Rockefeller University; Massachusetts Institute of Technology; Universität Basel; National Institutes of Health; Children's Hospital Foundation; John D. and Catherine T. MacArthur Foundation; Genome Canada; Garron Family Cancer Centre; European Commission; Sontag Foundation; Hospital for Sick Children; Genome British Columbia; Strategiske Forskningsråd; Cancer Research UK; World Health Organization; Deutsche Kinderkrebsstiftung; University of Chicago; University of California; Vetenskapsrådet; European Research Council; V Foundation for Cancer Research; Government of Ontario; Alexander and Margaret Stewart Trust; Deutsches Krebsforschungszentrum","keywords":"Medulloblastoma; Genetic predisposition; Retrospective cohort study; Medicine; Prospective cohort study; Cohort; Clinical trial; Oncology; Pediatrics; Internal medicine; Pathology","score_opus":0.03558688702811941,"score_gpt":0.3766558975379356,"score_spread":0.3410690105098162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2799574682","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99552965,0.0002337066,0.0000060876573,0.00066483585,0.00011901797,0.0032023392,0.000006426196,0.000009768747,0.00022818174],"genre_scores_gemma":[0.9987078,0.00032668337,0.00023397517,0.000043524586,0.00036002722,0.00031300768,0.0000012390901,0.0000075409534,0.000006206635],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985232,0.000412465,0.00042877215,0.00033026363,0.00013527166,0.00017006062],"domain_scores_gemma":[0.9993244,0.00020515308,0.00015835879,0.00022162177,0.000050433646,0.000040036666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087251177,0.000100836514,0.0005402362,0.000088125504,0.000028711958,0.00000584582,0.00005444174,0.00008518078,0.0000150126825],"category_scores_gemma":[0.00020031081,0.000069596455,0.00002464329,0.00018010943,0.00029889547,0.000025302428,0.00005779837,0.00015559189,0.0000019037208],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011126572,0.001847251,0.9840674,0.00002796987,0.00007921059,0.000063290645,0.0014348918,9.3956703e-7,0.00012290041,0.00006532545,0.000015469268,0.0011488037],"study_design_scores_gemma":[0.050882317,0.017847521,0.92933774,0.00005681645,0.00022435375,0.00005212253,0.00015366457,0.000109982895,0.00036645035,0.0009138685,0.0000038827684,0.000051305335],"about_ca_topic_score_codex":0.00008672786,"about_ca_topic_score_gemma":0.001102478,"teacher_disagreement_score":0.054729663,"about_ca_system_score_codex":0.00017604425,"about_ca_system_score_gemma":0.00007175146,"threshold_uncertainty_score":0.28380612},"labels":[],"label_agreement":null},{"id":"W2799848443","doi":"10.1016/s1470-2045(18)30096-2","title":"Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology","year":2018,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":120,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Radiation oncology; Guideline; Radiation therapy; Medicine; Precision oncology; Medical physics; Oncology; Internal medicine; Cancer; Pathology","score_opus":0.047103449275449474,"score_gpt":0.4542423468226427,"score_spread":0.40713889754719323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2799848443","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005135635,0.98765707,0.0037701614,0.0047961245,0.0002053973,0.0025352044,0.000081197395,0.000041902793,0.00039937856],"genre_scores_gemma":[0.000079778736,0.97977996,0.011985862,0.0057178787,0.0008189806,0.00076027086,0.0005915629,0.00006910395,0.00019658118],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983053,0.00035580664,0.0005016454,0.000365206,0.00013967726,0.00033234555],"domain_scores_gemma":[0.9978944,0.0006569583,0.0008386221,0.0004219043,0.00012860111,0.000059478225],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010769765,0.00028910392,0.0016541688,0.00003644226,0.0002780499,0.000021588236,0.00020740664,0.00016944895,0.000016875678],"category_scores_gemma":[0.00006319069,0.0001355018,0.00028255588,0.00019187228,0.00043779894,0.000029977838,0.000044704655,0.00031328475,0.0000026464734],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023243629,0.00009081671,0.000010446588,0.00045217067,0.001795945,0.000005081887,0.0007126683,0.0000033537435,0.000026102814,0.000054569045,0.12527126,0.87134516],"study_design_scores_gemma":[0.0032296567,0.0029101942,0.000014500746,0.0005166915,0.0026001905,0.0001412621,0.00019832402,0.00025331663,0.000002353692,0.00003559818,0.98995525,0.00014268412],"about_ca_topic_score_codex":0.00007351188,"about_ca_topic_score_gemma":0.00000635379,"teacher_disagreement_score":0.87120247,"about_ca_system_score_codex":0.00087407103,"about_ca_system_score_gemma":0.0008073478,"threshold_uncertainty_score":0.5525603},"labels":[],"label_agreement":null},{"id":"W2802450491","doi":"10.1016/s1470-2045(18)30287-0","title":"Body-mass index and metastatic melanoma outcomes","year":2018,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Melanoma; Body mass index; Incidence (geometry); Oncology; Internal medicine; Population; Obesity; Cancer research; Environmental health","score_opus":0.05080202648312223,"score_gpt":0.3475610063345605,"score_spread":0.2967589798514383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802450491","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00980749,0.0015541259,0.000037418748,0.97330153,0.0009788985,0.0005823526,0.000059256054,0.00007334209,0.013605603],"genre_scores_gemma":[0.0093424935,0.0008195774,0.00045568575,0.9717417,0.006691253,0.00008531802,0.0001076847,0.000055074277,0.010701248],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983635,0.000289209,0.00032990906,0.0003210042,0.00023156949,0.00046480788],"domain_scores_gemma":[0.99851537,0.0005084723,0.00024136297,0.0006368563,0.000056968052,0.00004099032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061649305,0.00028917537,0.0012192464,0.00009669942,0.000090712965,0.000023242439,0.00027723194,0.0004934645,0.0006429042],"category_scores_gemma":[0.00006217856,0.00016054115,0.00015736854,0.000103096965,0.000575897,0.000025212266,0.0000665593,0.0011596432,0.00008054587],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012010984,0.000021066458,0.0056613293,0.00017827532,0.0010777833,0.00045552495,0.00012909986,1.9507842e-8,0.00020685836,0.000018642415,0.987425,0.0036252541],"study_design_scores_gemma":[0.0041515185,0.00088018423,0.021111965,0.000057736404,0.00044793583,0.00042377354,0.00003343813,0.000011028812,0.00003540814,0.0006215089,0.9720438,0.00018168954],"about_ca_topic_score_codex":0.00012333115,"about_ca_topic_score_gemma":0.00004327967,"teacher_disagreement_score":0.015450635,"about_ca_system_score_codex":0.00017533955,"about_ca_system_score_gemma":0.00023489061,"threshold_uncertainty_score":0.70393497},"labels":[],"label_agreement":null},{"id":"W2803437699","doi":"10.1016/s1470-2045(18)30270-5","title":"Does a patient's sex predict the efficacy of cancer immunotherapy?","year":2018,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Immunotherapy; Cancer; Lung cancer; Cancer immunotherapy; Pembrolizumab; Oncology; Internal medicine; Melanoma; Meta-analysis; Scopus; Nivolumab; Clinical trial; MEDLINE; Cancer research","score_opus":0.027200920113298246,"score_gpt":0.329764280774798,"score_spread":0.3025633606614998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2803437699","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.033383273,0.0076667634,0.0000046185573,0.9505314,0.003246214,0.0014724373,0.00022070343,0.0001295245,0.0033450488],"genre_scores_gemma":[0.01087825,0.009528354,0.00007523144,0.9472069,0.023628747,0.00037729187,0.000094510164,0.00014272988,0.008067943],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975398,0.0005135209,0.0005906529,0.0003695975,0.0004223742,0.0005640274],"domain_scores_gemma":[0.9970532,0.0007735636,0.00064485933,0.0013584038,0.00014278584,0.000027155918],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00065975543,0.00035283057,0.00114075,0.00007632902,0.0001276362,0.000017433385,0.0007500869,0.00072690233,0.0012455735],"category_scores_gemma":[0.000051067273,0.00012746429,0.00037779228,0.00022236771,0.0015714584,0.000023270028,0.000101235244,0.0015080787,0.000017404625],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005475748,0.00009004828,0.00068556645,0.00017666651,0.0015788976,0.000048560087,0.0019322261,4.5588214e-7,0.0020093853,0.0000049191817,0.9385976,0.049399905],"study_design_scores_gemma":[0.0047377674,0.0014999659,0.003949959,0.00024520204,0.00032302304,0.000056369994,0.000104810926,0.0000047358863,0.0015809987,0.00011153458,0.987205,0.00018058105],"about_ca_topic_score_codex":0.0009887604,"about_ca_topic_score_gemma":0.00016571609,"teacher_disagreement_score":0.04921932,"about_ca_system_score_codex":0.00030157404,"about_ca_system_score_gemma":0.0005841445,"threshold_uncertainty_score":0.9996674},"labels":[],"label_agreement":null},{"id":"W2804105316","doi":"10.1016/s1470-2045(18)30292-4","title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1011,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"Astex Pharmaceuticals; Novartis","keywords":"Medicine; Breast cancer; Oncology; Internal medicine; Hormone receptor; Endocrine system; Hormone therapy; Gynecology; Cancer; Hormone","score_opus":0.03244725651231038,"score_gpt":0.37153790821677674,"score_spread":0.33909065170446634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2804105316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97346145,0.0015196329,0.0019472756,0.013647632,0.00068910193,0.0068775667,0.0005947945,0.00023187489,0.0010306442],"genre_scores_gemma":[0.9709054,0.0009339511,0.0040883077,0.0053974106,0.008384014,0.008894483,0.00008738841,0.00013810645,0.0011709216],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99719924,0.00025978073,0.00048521534,0.0005944814,0.00035137596,0.0011099178],"domain_scores_gemma":[0.9977175,0.0005559595,0.00039516098,0.00062710536,0.0004687953,0.00023548215],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006434701,0.0004429968,0.0014350833,0.00008500854,0.00029959783,0.000023697841,0.00038420217,0.00012429779,0.00073072256],"category_scores_gemma":[0.000058295213,0.00026549594,0.00010939832,0.0002980472,0.000845491,0.00017937215,0.00005855953,0.00036739043,0.000025171805],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78637385,0.00059524464,0.000034802553,0.000027036938,0.000775877,0.000017088369,0.0016092253,0.000018225448,0.06990329,0.00012868957,0.0014614916,0.13905516],"study_design_scores_gemma":[0.751824,0.026331494,0.0011577785,0.0000683643,0.0001533673,0.00025642593,0.00031961038,0.000091082424,0.00536067,0.00025483992,0.2138532,0.00032915318],"about_ca_topic_score_codex":0.000055663295,"about_ca_topic_score_gemma":0.00006673896,"teacher_disagreement_score":0.2123917,"about_ca_system_score_codex":0.0011012761,"about_ca_system_score_gemma":0.0008761207,"threshold_uncertainty_score":0.99997973},"labels":[],"label_agreement":null},{"id":"W2805341297","doi":"10.1016/s1470-2045(18)30354-1","title":"Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":206,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada","funders":"Amgen","keywords":"Carfilzomib; Medicine; Dosing; Refractory (planetary science); Interim analysis; Interim; Multiple myeloma; Lenalidomide; Internal medicine; Oncology; Clinical trial; Materials science","score_opus":0.05709115066878615,"score_gpt":0.3817391800709356,"score_spread":0.32464802940214943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805341297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957838,0.000081175676,0.000023705674,0.0005790176,0.000117425225,0.0016914011,0.000076941506,0.00002960743,0.0016169065],"genre_scores_gemma":[0.99871624,0.000030827185,0.0006907875,0.00008395552,0.00016351277,0.000087677894,0.00007943975,0.000021438922,0.00012612998],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99739134,0.0007033726,0.00056158745,0.00047466945,0.00038992765,0.00047912117],"domain_scores_gemma":[0.99730384,0.0012295457,0.000341312,0.000698348,0.00026729275,0.0001596783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010914977,0.0002289043,0.0011425557,0.00032264518,0.00011349536,0.000015405976,0.00021494218,0.000104952494,0.000031897453],"category_scores_gemma":[0.0010185365,0.00013951183,0.00008446286,0.00071994244,0.00045006795,0.00009747558,0.00013220856,0.00035404533,0.000009249703],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6216363,0.0037792565,0.35087758,0.000031561158,0.0020978758,0.00013965848,0.004238474,0.0000037567513,0.000959187,0.0000028104578,0.00022242405,0.01601115],"study_design_scores_gemma":[0.4303021,0.025733875,0.5401656,0.000060885224,0.00082039903,0.0000033373672,0.0011668913,0.0005168282,0.00030623176,0.0000024478593,0.0008066337,0.000114728224],"about_ca_topic_score_codex":0.0013233575,"about_ca_topic_score_gemma":0.0037639863,"teacher_disagreement_score":0.19133414,"about_ca_system_score_codex":0.0002881306,"about_ca_system_score_gemma":0.00016634232,"threshold_uncertainty_score":0.56891274},"labels":[],"label_agreement":null},{"id":"W2805592007","doi":"10.1016/s1470-2045(18)30351-6","title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":2536,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"Merck","keywords":"Medicine; Pembrolizumab; Sorafenib; Internal medicine; Clinical endpoint; Hepatocellular carcinoma; Adverse effect; Response Evaluation Criteria in Solid Tumors; Population; Oncology; Discontinuation; Clinical trial; Phases of clinical research; Surgery; Cancer; Immunotherapy","score_opus":0.07727556601902094,"score_gpt":0.32807063219425886,"score_spread":0.25079506617523795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805592007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837359,0.0001898708,0.0000520611,0.00083941314,0.000121297606,0.010185095,0.000026854663,0.00007721362,0.004772302],"genre_scores_gemma":[0.995565,0.000041934105,0.0011706855,0.0006509269,0.00051266,0.0013567345,0.00024823996,0.00008142297,0.00037241267],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970579,0.00048345063,0.00055419083,0.00067115773,0.00035948347,0.0008737895],"domain_scores_gemma":[0.99804467,0.00020775077,0.00032830858,0.00091901905,0.00026032372,0.0002399122],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00065221544,0.00047552105,0.0016054908,0.00015715919,0.00021007094,0.00005261987,0.00051938056,0.00022289211,0.00017927875],"category_scores_gemma":[0.000068570036,0.00026378318,0.00008132695,0.0005639262,0.0004077969,0.00017853007,0.00013637118,0.00041760624,0.000080979116],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5517698,0.0033450557,0.4360516,0.00003854976,0.00019938471,0.00042776664,0.00062072143,2.8386566e-7,0.0001672977,0.000016871843,0.00028033773,0.0070823506],"study_design_scores_gemma":[0.9003534,0.064579494,0.026952945,0.00015061095,0.00072745123,0.000057246172,0.000051686267,0.0013580105,0.001614832,0.000023288785,0.0037684862,0.00036259615],"about_ca_topic_score_codex":0.00034096354,"about_ca_topic_score_gemma":0.0002724214,"teacher_disagreement_score":0.40909865,"about_ca_system_score_codex":0.00035651893,"about_ca_system_score_gemma":0.00059945934,"threshold_uncertainty_score":0.99998146},"labels":[],"label_agreement":null},{"id":"W2806421431","doi":"10.1016/s1470-2045(18)30365-6","title":"Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":409,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Olaparib; Medicine; Prostate cancer; Internal medicine; Oncology; Enzalutamide; PARP inhibitor; Placebo; Clinical endpoint; Docetaxel; Population; Androgen deprivation therapy; Clinical trial; Cancer; Androgen receptor; Pathology","score_opus":0.063617209979282,"score_gpt":0.3828651709096185,"score_spread":0.3192479609303365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806421431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98121595,0.00020173941,0.000012200815,0.004527442,0.00018302698,0.012224278,0.000052876618,0.00004164697,0.0015408413],"genre_scores_gemma":[0.99354964,0.00009567144,0.00022515119,0.00035799338,0.00039556366,0.0040394845,0.00014135626,0.000035122277,0.0011600158],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99772143,0.0003794297,0.00047153435,0.00036667034,0.00042335538,0.0006375573],"domain_scores_gemma":[0.9986042,0.0002642942,0.000270338,0.0003938541,0.0003217043,0.00014561533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094779657,0.00027444592,0.0012844147,0.00014172762,0.00017457386,0.00004397904,0.0001701367,0.00007391293,0.00019312638],"category_scores_gemma":[0.00003678713,0.00012676454,0.000058273476,0.00036850292,0.00050975056,0.00010584325,0.00002481538,0.00035064743,0.000022754595],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.990548,0.0019789357,0.0029984643,0.0000622484,0.00078426645,0.00012910969,0.0011758307,0.0000160463,0.00032166517,0.00006827464,0.00054727006,0.0013698973],"study_design_scores_gemma":[0.9548543,0.041057363,0.0011545251,0.00010458466,0.0005319158,0.000008342437,0.00015341448,0.00009402092,0.0007001543,0.000039067218,0.0011464215,0.00015590953],"about_ca_topic_score_codex":0.00037165615,"about_ca_topic_score_gemma":0.0032568295,"teacher_disagreement_score":0.039078426,"about_ca_system_score_codex":0.0004132538,"about_ca_system_score_gemma":0.0011225702,"threshold_uncertainty_score":0.51693076},"labels":[],"label_agreement":null},{"id":"W2810571299","doi":"10.1016/s1470-2045(18)30427-3","title":"How economic sanctions compromise cancer care in Iran","year":2018,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Compromise; Sanctions; Economic sanctions; Political science; Medicine; Business; Law","score_opus":0.05767427401511837,"score_gpt":0.41220277876244277,"score_spread":0.3545285047473244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2810571299","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0036319895,0.006995059,0.00005685382,0.9602826,0.006054545,0.00085331476,0.00015045797,0.00008582372,0.02188933],"genre_scores_gemma":[0.0017940059,0.0058759158,0.0018206539,0.89527065,0.07998852,0.00049163034,0.00026520857,0.000085046304,0.014408371],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99827814,0.00032590068,0.0002701304,0.00045312571,0.00009508974,0.0005776267],"domain_scores_gemma":[0.9985525,0.000392452,0.00024725616,0.0007246556,0.00003929319,0.00004384113],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00021144826,0.00030174016,0.0012854552,0.00013234357,0.00018072376,0.000014007254,0.00041388988,0.0012699899,0.0007726092],"category_scores_gemma":[0.000027201839,0.00020278161,0.00014039376,0.00008777307,0.0012182725,0.000047728732,0.000054424105,0.0025928232,0.000105248],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005693602,0.000029099718,0.0019334311,0.00014748533,0.00017078567,0.0003646418,0.00081864715,0.000032769884,0.0000197178,0.00002890253,0.9859263,0.009958863],"study_design_scores_gemma":[0.0038538487,0.00091218005,0.0010891837,0.000099770026,0.0001465439,0.00024725017,0.00018186947,0.000063756124,0.000013566239,0.00023635523,0.9929446,0.00021109558],"about_ca_topic_score_codex":0.00010263709,"about_ca_topic_score_gemma":0.0026079516,"teacher_disagreement_score":0.073933974,"about_ca_system_score_codex":0.002580487,"about_ca_system_score_gemma":0.0006048915,"threshold_uncertainty_score":0.99970824},"labels":[],"label_agreement":null},{"id":"W2883673963","doi":"10.1016/s1470-2045(18)30343-7","title":"Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":137,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Cancer Institute; AstraZeneca","keywords":"Medicine; Internal medicine; Olaparib; Tolerability; Quality of life (healthcare); Placebo; Clinical endpoint; Oncology; Ovarian cancer; Adverse effect; Nausea; Progression-free survival; Randomized controlled trial; Cancer; Chemotherapy; Surgery","score_opus":0.028783105922643652,"score_gpt":0.3335244201553895,"score_spread":0.30474131423274586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883673963","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98211074,0.0003105651,0.00007725537,0.01171437,0.00018652284,0.005222136,0.00009860895,0.00004010319,0.00023969174],"genre_scores_gemma":[0.9922023,0.000104262566,0.0005747293,0.006219851,0.00013271299,0.00065263425,0.000029252433,0.000034927085,0.000049342507],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968846,0.0009253595,0.0009991764,0.00043206237,0.00031355425,0.0004452661],"domain_scores_gemma":[0.9973835,0.0008168407,0.0010268249,0.00034144905,0.00028316653,0.00014822888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008197259,0.00029020495,0.001977123,0.00012041827,0.00009632932,0.000013117091,0.00007063522,0.00018349187,0.00008434101],"category_scores_gemma":[0.00029767913,0.00016921568,0.000059291215,0.00024324642,0.00067012303,0.00008835647,0.000020628719,0.00035502337,0.000001437743],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9476436,0.000758966,0.03250853,0.00005692126,0.00054405426,0.000012476839,0.010530485,0.0000065340582,0.00013602292,0.000053328728,0.00026552248,0.007483558],"study_design_scores_gemma":[0.8686193,0.008130614,0.12169332,0.00021577867,0.00007613471,0.000012743075,0.00046679666,0.0001803216,0.0001560703,0.00006919899,0.00019885993,0.00018084342],"about_ca_topic_score_codex":0.00062735984,"about_ca_topic_score_gemma":0.0010279209,"teacher_disagreement_score":0.08918478,"about_ca_system_score_codex":0.000284034,"about_ca_system_score_gemma":0.0005138154,"threshold_uncertainty_score":0.69004154},"labels":[],"label_agreement":null},{"id":"W2884001607","doi":"10.1016/s1470-2045(18)30333-4","title":"Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal; University Health Network","funders":"","keywords":"Nova (rocket); Placebo; Double blind; Medicine; Quality of life (healthcare); Oncology; Gynecology; Ovarian cancer; Internal medicine; Cancer; Alternative medicine; Pathology; Nursing","score_opus":0.14681145589951522,"score_gpt":0.4253526568431366,"score_spread":0.2785412009436214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2884001607","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9820429,0.00010411935,0.00006343582,0.003125781,0.00087131746,0.007880219,0.00033013485,0.000058792677,0.0055233124],"genre_scores_gemma":[0.9955879,0.00007016075,0.0002624704,0.00069018564,0.001648259,0.0013663325,0.0002770337,0.00003251456,0.00006518083],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963817,0.0010468207,0.001145069,0.00048967527,0.0004835005,0.0004532484],"domain_scores_gemma":[0.9958993,0.0016686202,0.0010722394,0.0007339268,0.00046516763,0.00016072138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001775898,0.0003052381,0.0021468792,0.00013825597,0.0000806962,0.000012013579,0.00023686184,0.00022301446,0.00042475152],"category_scores_gemma":[0.00039720398,0.00017083637,0.00011030988,0.00046567744,0.0005610806,0.000065450375,0.00002790394,0.00044101867,0.0000115749845],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98739225,0.002152664,0.0038568433,0.000015183191,0.0010828834,0.0000069797106,0.0013418038,0.000016774782,0.00019858064,0.00004968534,0.001749495,0.0021368407],"study_design_scores_gemma":[0.97447187,0.01679018,0.005176454,0.0001577368,0.0003241983,6.9058694e-7,0.000089204936,0.000071572846,0.00056525687,0.000020852112,0.0021272788,0.00020473302],"about_ca_topic_score_codex":0.0030953914,"about_ca_topic_score_gemma":0.0059319353,"teacher_disagreement_score":0.014637516,"about_ca_system_score_codex":0.00046805735,"about_ca_system_score_gemma":0.0010228473,"threshold_uncertainty_score":0.6966505},"labels":[],"label_agreement":null},{"id":"W2886412900","doi":"10.1016/s1470-2045(18)30425-x","title":"A roadmap for restoring trust in Big Data","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Medical Research Council","keywords":"Big data; Public relations; Human services; Political science; Corporate governance; Exploit; Medicine; Business; Computer science; Computer security; Law","score_opus":0.9121562296899259,"score_gpt":0.688809364006139,"score_spread":0.22334686568378692,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2886412900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5555696,0.00046041652,0.0011495677,0.2899286,0.0030672387,0.0015375173,0.000057216264,0.0000994519,0.1481304],"genre_scores_gemma":[0.96797085,0.0005040876,0.0068425857,0.0065394007,0.012593128,0.000082160026,0.00002410252,0.000023115872,0.0054205703],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986852,0.00017102396,0.00024924215,0.00028525907,0.00023161113,0.0003776589],"domain_scores_gemma":[0.9884916,0.009617404,0.000059404458,0.001591223,0.00016734998,0.0000730497],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.010163795,0.000058858983,0.00035005788,0.00004866452,0.000067678,0.0000072312955,0.0007866272,0.00025011838,0.000057470133],"category_scores_gemma":[0.024362558,0.000037612645,0.000023905348,0.00016146035,0.00047413964,0.000023625129,0.00049015885,0.0010590401,0.00009275315],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016012434,0.0011043876,0.14587614,0.0009462256,0.00024906706,0.0002579213,0.0043319,0.000003050401,0.007702972,0.15646549,0.21400258,0.45304784],"study_design_scores_gemma":[0.0044394997,0.0018993013,0.029307866,0.00012423994,0.000027900885,0.00002535203,0.00018319006,0.000774013,0.0002966553,0.055863474,0.9069866,0.00007193131],"about_ca_topic_score_codex":0.00013706587,"about_ca_topic_score_gemma":0.0048697474,"teacher_disagreement_score":0.692984,"about_ca_system_score_codex":0.00014274231,"about_ca_system_score_gemma":0.00060964044,"threshold_uncertainty_score":0.98385566},"labels":[],"label_agreement":null},{"id":"W2887665498","doi":"10.1016/s1470-2045(18)30364-4","title":"Biological material collection to advance translational research and treatment of children with CNS tumours: position paper from the SIOPE Brain Tumour Group","year":2018,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Brain Tumour Charity; Rosetrees Trust; Cancer Research UK","keywords":"Biobank; Translational research; Medicine; Childhood cancer; Biorepository; Medical diagnosis; Disease; Data collection; Cancer; Bioinformatics; Intensive care medicine; Medical physics; Pathology; Internal medicine; Biology","score_opus":0.11314543967697425,"score_gpt":0.40792931324774995,"score_spread":0.2947838735707757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887665498","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21144913,0.7644554,0.0000090410795,0.018316243,0.00018287466,0.004368696,0.00088506186,0.000031180283,0.00030241354],"genre_scores_gemma":[0.024269614,0.97032714,0.00064419385,0.00038876393,0.0021019334,0.0010163705,0.001186298,0.00003101546,0.000034656776],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979969,0.00082428806,0.00030308845,0.00038374247,0.0002082417,0.00028371435],"domain_scores_gemma":[0.9982616,0.0011141772,0.00014914326,0.00031403542,0.00008897966,0.00007210005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004927558,0.00024183029,0.0012309711,0.00007343732,0.00019621686,0.00001923643,0.00013915966,0.000195418,0.000139377],"category_scores_gemma":[0.0000398397,0.0000960356,0.0001023003,0.00027292693,0.00033262355,0.00002361969,0.000037909616,0.00016588534,0.000019639247],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011151891,0.0062886495,0.015178383,0.00066474866,0.004284417,0.00019083565,0.0023140938,0.000002567664,0.0015832473,0.002642842,0.023291022,0.9324073],"study_design_scores_gemma":[0.005327482,0.023647774,0.11626457,0.0024103944,0.0013993072,0.0005536629,0.000055339056,0.0000013013973,0.000143185,0.00045476254,0.8495243,0.00021788769],"about_ca_topic_score_codex":0.0003018747,"about_ca_topic_score_gemma":0.0005403388,"teacher_disagreement_score":0.9321894,"about_ca_system_score_codex":0.00026439587,"about_ca_system_score_gemma":0.00017775029,"threshold_uncertainty_score":0.3916218},"labels":[],"label_agreement":null},{"id":"W2887875384","doi":"10.1016/s1470-2045(18)30449-2","title":"CCR4-targeted therapy in cutaneous T-cell lymphoma","year":2018,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Cutaneous lymphoproliferative disorders research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Mycosis fungoides; CCR4; Medicine; Cutaneous T-cell lymphoma; Lymphoma; Vorinostat; T cell; Bexarotene; Cancer research; Immunology; Chemokine receptor; Chemokine; Biology; Inflammation; Immune system","score_opus":0.06080439211977353,"score_gpt":0.35552555913635736,"score_spread":0.29472116701658385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887875384","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11324213,0.0022503554,0.0000058301634,0.8142356,0.00065815425,0.0020220361,0.00006801559,0.0001492916,0.06736853],"genre_scores_gemma":[0.030098839,0.0037871923,0.00024646896,0.92754054,0.013995989,0.00032311253,0.00047951064,0.00019757535,0.023330789],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954692,0.0011026841,0.0005578292,0.00076597277,0.0007001307,0.0014041564],"domain_scores_gemma":[0.99704623,0.0009502238,0.00024205037,0.0013650018,0.0002980504,0.00009844716],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00068999093,0.00054249156,0.0017469259,0.0003552168,0.00013823721,0.000039653038,0.00091866567,0.0015656028,0.001698756],"category_scores_gemma":[0.00025763936,0.00035899688,0.00022904301,0.0004781157,0.0007942814,0.000026566877,0.00018759657,0.0021642537,0.0012667613],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024270117,0.0004688927,0.0018058191,0.00016910599,0.00017070139,0.0142829325,0.00095746544,0.0000010213784,0.0009843262,0.000007098964,0.9675127,0.01121287],"study_design_scores_gemma":[0.008701737,0.003017416,0.0003619294,0.00007066496,0.00004797965,0.008627373,0.00009377845,0.00012630339,0.0005995951,0.00048788066,0.9775129,0.00035242306],"about_ca_topic_score_codex":0.0003970797,"about_ca_topic_score_gemma":0.00030493538,"teacher_disagreement_score":0.11330487,"about_ca_system_score_codex":0.0011886209,"about_ca_system_score_gemma":0.0016238951,"threshold_uncertainty_score":0.9998862},"labels":[],"label_agreement":null},{"id":"W2888567495","doi":"10.1016/s1470-2045(18)30448-0","title":"Near-infrared fluorescence for detection of sentinel lymph nodes in women with cervical and uterine cancers (FILM): a randomised, phase 3, multicentre, non-inferiority trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":344,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Sunnybrook Health Science Centre; Hôtel-Dieu de Québec","funders":"National Cancer Institute; National Institutes of Health","keywords":"Indocyanine green; Medicine; Lymph; Sentinel lymph node; Surgery; Lymph node; Cervical cancer; Surgical margin; Radiology; Cancer; Pathology; Internal medicine; Breast cancer; Resection","score_opus":0.02975133024637914,"score_gpt":0.3510060640054008,"score_spread":0.32125473375902164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888567495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968791,0.00006214553,0.0002604273,0.00057760393,0.00023314646,0.0015039035,0.0000294882,0.000021226868,0.00043298685],"genre_scores_gemma":[0.997014,0.00014510046,0.0009604467,0.00047611402,0.0008183529,0.00049751205,0.000006185237,0.00001343273,0.00006887241],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99882144,0.000112958005,0.00031611277,0.00024436315,0.00013734038,0.00036780944],"domain_scores_gemma":[0.9990122,0.00038814798,0.00015641715,0.00021892591,0.00011166523,0.000112643655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046393677,0.00014752061,0.00077953003,0.00005991514,0.00007736938,0.000011096764,0.00009501535,0.00009974174,0.0000771006],"category_scores_gemma":[0.00021339866,0.000088461245,0.000046044785,0.000281862,0.0003365813,0.000044961187,0.000044085613,0.000112969945,0.00000225832],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9279557,0.0005037614,0.005635636,0.00018924107,0.00015697301,0.00001720993,0.001201274,0.0000027888639,0.008258257,0.00000481472,0.000018240533,0.056056123],"study_design_scores_gemma":[0.91253775,0.0054013827,0.06886339,0.00007837391,0.00017357488,0.000028720218,0.0002711934,0.005244884,0.005276427,0.000090106056,0.0019059259,0.00012824476],"about_ca_topic_score_codex":0.0005477102,"about_ca_topic_score_gemma":0.00015537736,"teacher_disagreement_score":0.06322775,"about_ca_system_score_codex":0.00039199492,"about_ca_system_score_gemma":0.0002662403,"threshold_uncertainty_score":0.3607345},"labels":[],"label_agreement":null},{"id":"W2888793209","doi":"10.1016/s1470-2045(18)30418-2","title":"Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review","year":2018,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"European Organisation for Research and Treatment of Cancer; Boehringer Ingelheim","keywords":"Medicine; Breast cancer; Randomized controlled trial; Sample size determination; MEDLINE; Systematic review; Clinical trial; Quality of life (healthcare); Meta-analysis; Missing data; Data quality; Medical physics; Alternative medicine; Cancer; Family medicine; Internal medicine; Pathology; Statistics","score_opus":0.23198629264013598,"score_gpt":0.520737163619044,"score_spread":0.288750870978908,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888793209","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001158571,0.98224705,0.000045519922,0.0005047159,0.00018899425,0.013826786,0.0029697616,0.000011450715,0.00008986007],"genre_scores_gemma":[0.00034651317,0.99545026,0.00032628988,0.00046769722,0.00008876596,0.0023094,0.0009413524,0.000026293577,0.000043411575],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9859836,0.0065878555,0.0062744007,0.00050636544,0.0003234532,0.00032432313],"domain_scores_gemma":[0.9782687,0.013677434,0.0064431974,0.0012700097,0.00023799154,0.000102673206],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.010686419,0.0004439817,0.039217856,0.0004292073,0.000022335442,0.0000045526685,0.00042052555,0.0001662198,0.00053518673],"category_scores_gemma":[0.0061093695,0.00021034095,0.0009393116,0.0009147972,0.0003510597,0.000032893164,0.00016157971,0.00031368938,0.0000023537689],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01724589,0.0006573306,0.00018356531,0.8571489,0.059263323,0.00013918665,0.00009625149,0.0000014448359,0.0000017009378,0.000046605262,0.0008594001,0.064356424],"study_design_scores_gemma":[0.110653706,0.0009865885,0.0000864222,0.19581266,0.6736194,0.00025495375,0.000030313211,0.0001518646,2.5360234e-7,0.000017519358,0.018152291,0.00023401785],"about_ca_topic_score_codex":0.00022450619,"about_ca_topic_score_gemma":0.00039884835,"teacher_disagreement_score":0.6613362,"about_ca_system_score_codex":0.00024963697,"about_ca_system_score_gemma":0.0011185182,"threshold_uncertainty_score":0.975046},"labels":[],"label_agreement":null},{"id":"W2891576771","doi":"10.1016/s1470-2045(18)30456-x","title":"Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":128,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Janssen Research and Development","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Placebo; Clinical endpoint; Internal medicine; Prostate-specific antigen; Oncology; Randomized controlled trial; Urology; Cancer; Pathology","score_opus":0.046862068757382316,"score_gpt":0.4188538237009971,"score_spread":0.3719917549436148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891576771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99195045,0.00015621407,0.000002522987,0.001256332,0.00010424171,0.0061446526,0.00019864729,0.000006230302,0.00018069976],"genre_scores_gemma":[0.9992719,0.00006521642,0.000019405481,0.0001049973,0.00005773617,0.0003541944,0.0000628098,0.0000113243395,0.00005239073],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9954666,0.002552219,0.0010133593,0.00022309611,0.00043879126,0.00030595742],"domain_scores_gemma":[0.9968157,0.0013362191,0.0010415941,0.00049448205,0.000219315,0.000092730465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039550895,0.00016351746,0.0022835354,0.00019355978,0.00007058162,0.0000037212094,0.00017218867,0.000058096743,0.000059656788],"category_scores_gemma":[0.00047180397,0.00007069937,0.00017890181,0.0007484143,0.00051425054,0.000032325825,0.000021199177,0.00020991956,7.2554076e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9179854,0.0012718799,0.073700055,0.00021851783,0.0019740576,0.0000023000273,0.0015924975,0.00034250622,0.00070168177,0.000021305168,0.00004034736,0.002149492],"study_design_scores_gemma":[0.8492323,0.03766044,0.10895023,0.0001391979,0.0013060858,2.2462022e-7,0.00011837169,0.0008743818,0.0016285151,0.00001630994,0.000009834429,0.00006410818],"about_ca_topic_score_codex":0.003625235,"about_ca_topic_score_gemma":0.00841355,"teacher_disagreement_score":0.068753056,"about_ca_system_score_codex":0.00024840055,"about_ca_system_score_gemma":0.000909419,"threshold_uncertainty_score":0.54802954},"labels":[],"label_agreement":null},{"id":"W2895886892","doi":"10.1016/s1470-2045(18)30588-6","title":"Pelvic radiotherapy in prostate cancer: an unresolved question","year":2018,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Prostate cancer; Radiation therapy; Medicine; Prostate; Cancer; Oncology; Radiology; Internal medicine","score_opus":0.04924383599259098,"score_gpt":0.38039663500597126,"score_spread":0.3311527990133803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2895886892","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0483449,0.0072380495,0.000003378307,0.93994546,0.0011263376,0.0012064327,0.00013079091,0.00010343061,0.001901243],"genre_scores_gemma":[0.0044277958,0.03410511,0.00068288407,0.93150437,0.023347467,0.0018470022,0.00081946526,0.000114346265,0.0031515397],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99769676,0.00054058246,0.00035587949,0.0005246706,0.00022785137,0.0006542628],"domain_scores_gemma":[0.99864995,0.00017490341,0.0002522072,0.0007490301,0.000102898746,0.000070977396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057908316,0.00033850604,0.0011220814,0.00013053238,0.00006922149,0.000024938774,0.00026467786,0.0005078381,0.00035755846],"category_scores_gemma":[0.000021399945,0.0002130343,0.000092468115,0.00018156297,0.00027052886,0.000055546603,0.00003547471,0.001303137,0.000045341985],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010112686,0.0002119742,0.018076245,0.00020502257,0.00022334224,0.0012964692,0.0010279102,0.000006211273,0.000092289316,0.000034759683,0.95005876,0.027755763],"study_design_scores_gemma":[0.005102444,0.0027846352,0.018894479,0.00037828175,0.00017745013,0.000104878935,0.000022772847,0.00006746165,0.00009969343,0.0002838399,0.9718707,0.00021332807],"about_ca_topic_score_codex":0.0015580349,"about_ca_topic_score_gemma":0.0015422903,"teacher_disagreement_score":0.0439171,"about_ca_system_score_codex":0.0018091364,"about_ca_system_score_gemma":0.00066689815,"threshold_uncertainty_score":0.8687287},"labels":[],"label_agreement":null},{"id":"W2896015079","doi":"10.1016/s1470-2045(18)30415-7","title":"Integration of oncology and palliative care: a Lancet Oncology Commission","year":2018,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":834,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Italfarmaco; Ipsen; European Society for Medical Oncology; Helsinn; Marie Curie; GW Pharmaceuticals; Les Laboratories Pierre Fabre; National Institute for Health and Care Research; Teva Pharmaceutical Industries; European Commission; Amgen; Pfizer; Merck","keywords":"Palliative care; Medicine; Multidisciplinary approach; Oncology; Health care; Commission; Quality of life (healthcare); Nursing; End-of-life care; Family medicine; Internal medicine","score_opus":0.464774379592267,"score_gpt":0.5651483393700169,"score_spread":0.10037395977774988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896015079","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00032179747,0.94612896,0.00010217032,0.0017665247,0.00061555684,0.001059985,0.00014021332,0.00004114361,0.049823634],"genre_scores_gemma":[0.0003164776,0.9914821,0.004912822,0.0005272698,0.0019620736,0.00013959226,0.00028005886,0.000041278854,0.00033837208],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99632543,0.0015692001,0.0010143147,0.00044105458,0.00022125867,0.0004287177],"domain_scores_gemma":[0.9947142,0.002617357,0.0013977851,0.00066701963,0.00047553334,0.00012810752],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011640186,0.00042984588,0.0056922226,0.0001984074,0.00007806177,0.0000050266185,0.0004295971,0.0010812895,0.000098827426],"category_scores_gemma":[0.00094370416,0.0002505994,0.00032004417,0.00033138483,0.001007022,0.000034935005,0.00024208822,0.0010100625,0.00003516119],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006982887,0.0001995944,0.00024093472,0.009937059,0.00052591786,0.000055273824,0.007907378,1.079791e-7,0.000048072972,0.0013327857,0.023296485,0.9557581],"study_design_scores_gemma":[0.0023493238,0.0054515027,0.00014067613,0.011510382,0.001626916,0.00007811984,0.0014061005,0.0000064740443,0.00006591716,0.00022809638,0.9769416,0.00019491362],"about_ca_topic_score_codex":0.0001458128,"about_ca_topic_score_gemma":0.00033576746,"teacher_disagreement_score":0.9555632,"about_ca_system_score_codex":0.0008891097,"about_ca_system_score_gemma":0.0015757682,"threshold_uncertainty_score":0.99999464},"labels":[],"label_agreement":null},{"id":"W2896458230","doi":"10.1016/s1470-2045(18)30618-1","title":"Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":159,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre; University of Alberta","funders":"National Health and Medical Research Council; AstraZeneca Australia; Siemens; National Health Research Institutes; Engineering and Physical Sciences Research Council; National Institute for Health and Care Research; F. Hoffmann-La Roche","keywords":"Obinutuzumab; Medicine; Follicular lymphoma; Vincristine; Bendamustine; Rituximab; Internal medicine; Prednisone; Clinical endpoint; CHOP; Oncology; Cyclophosphamide; Surgery; Lymphoma; Gastroenterology; Randomized controlled trial; Chemotherapy","score_opus":0.03272674167592464,"score_gpt":0.3595032829152931,"score_spread":0.32677654123936845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896458230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940763,0.00072456844,0.00025366293,0.0022063784,0.00024685985,0.0021707886,0.00016088867,0.000014334504,0.00014618634],"genre_scores_gemma":[0.99671185,0.00027053675,0.0013506823,0.000293317,0.00047888383,0.00073657866,0.00007677887,0.00001731189,0.00006404335],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983406,0.00038396812,0.0006358206,0.0002285082,0.00018409634,0.00022700836],"domain_scores_gemma":[0.9970863,0.0015948478,0.00048538644,0.00053110765,0.00025467388,0.000047721944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014825654,0.0001643166,0.001372138,0.00020249498,0.000048306156,0.0000034249706,0.00013288653,0.00010859689,0.00031296193],"category_scores_gemma":[0.00041930372,0.00010259196,0.0005256138,0.0003849735,0.0003331264,0.000028903265,0.00002578416,0.00004563317,0.000002397502],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95156294,0.0038556508,0.0023084963,0.00010761942,0.0050744656,0.000032389566,0.0011665086,0.000009725997,0.010481895,0.00009494338,0.00034197702,0.024963384],"study_design_scores_gemma":[0.8270851,0.024861146,0.051330943,0.0001030891,0.00949965,0.00006775875,0.00010953867,0.0011110781,0.07159489,0.00020724296,0.013888089,0.00014151951],"about_ca_topic_score_codex":0.00009700675,"about_ca_topic_score_gemma":0.00007385877,"teacher_disagreement_score":0.124477886,"about_ca_system_score_codex":0.0001672723,"about_ca_system_score_gemma":0.00045817214,"threshold_uncertainty_score":0.41835788},"labels":[],"label_agreement":null},{"id":"W2896600825","doi":"10.1016/s1470-2045(18)30700-9","title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1409,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Ono Pharmaceutical; Bristol-Myers Squibb","keywords":"Ipilimumab; Nivolumab; Medicine; Internal medicine; Oncology; Immunotherapy; Cancer","score_opus":0.059457284228469,"score_gpt":0.3855917897477813,"score_spread":0.3261345055193123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896600825","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870612,0.0007673303,0.000044805096,0.00282389,0.0023739187,0.0031433688,0.00007041116,0.000114998715,0.0036000481],"genre_scores_gemma":[0.99394614,0.00091822835,0.0010971633,0.0008566226,0.0010848689,0.00025854167,0.00004600564,0.00006444114,0.0017280016],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964208,0.0005532781,0.0011547316,0.00055680436,0.00043573175,0.00087864464],"domain_scores_gemma":[0.9968739,0.0011628116,0.0005888959,0.00104268,0.00018957535,0.00014214455],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001466869,0.00042033056,0.002274485,0.00022323645,0.00014639842,0.000017662709,0.00052874006,0.00032731006,0.0011513],"category_scores_gemma":[0.0006880736,0.00027406582,0.00035417653,0.00054951006,0.000811893,0.00013123832,0.00013475811,0.00046289962,0.00009868885],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9536278,0.0014436648,0.0004076472,0.000089749155,0.00079047517,0.00011350821,0.0018764051,0.0000049150417,0.008165564,0.000032139167,0.0015735803,0.031874556],"study_design_scores_gemma":[0.9513123,0.015526126,0.0026232742,0.0001233043,0.00040074377,0.000051053634,0.0011377593,0.00051434047,0.004532529,0.00003452764,0.02342135,0.0003226896],"about_ca_topic_score_codex":0.00067046203,"about_ca_topic_score_gemma":0.003888741,"teacher_disagreement_score":0.031551868,"about_ca_system_score_codex":0.0008381379,"about_ca_system_score_gemma":0.00083742844,"threshold_uncertainty_score":0.99997115},"labels":[],"label_agreement":null},{"id":"W2897382264","doi":"10.1016/s1470-2045(18)30586-2","title":"The effect of postmastectomy radiotherapy on patient-reported outcomes","year":2018,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences","funders":"","keywords":"Medicine; Breast cancer; Radiation therapy; Mastectomy; Axillary Lymph Node Dissection; Oncology; Lymph node; Cancer; Axillary lymph nodes; Disease; Internal medicine; Sentinel lymph node","score_opus":0.015034009161065233,"score_gpt":0.30716272129331373,"score_spread":0.2921287121322485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897382264","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.25712013,0.0032249044,0.000009806149,0.73091686,0.0023989198,0.0011097242,0.0001313805,0.000038233633,0.0050500566],"genre_scores_gemma":[0.17322557,0.0028175456,0.00019659528,0.7949409,0.023321766,0.0011361034,0.00068421534,0.00025549578,0.00342185],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979298,0.00070741365,0.00032360543,0.00038382635,0.0002116332,0.0004437026],"domain_scores_gemma":[0.9976006,0.0006734112,0.00049609283,0.0011297618,0.00008085135,0.000019289775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003754775,0.00036701016,0.00079732394,0.000029719977,0.00019152727,0.000012002827,0.0005488371,0.0005409836,0.000019636369],"category_scores_gemma":[0.00014702992,0.0001653786,0.00024096071,0.0000626994,0.00057613,9.3868744e-7,0.000142007,0.0004904231,0.0000147276705],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00165834,0.00002500094,0.0073926114,0.00003280213,0.0019354628,0.00003848412,0.00007411149,0.0000016673976,0.00084354426,0.000004723771,0.9779237,0.010069539],"study_design_scores_gemma":[0.0023623267,0.004571112,0.0053674127,0.00001993435,0.00017009676,0.00005596976,0.000007842545,5.094377e-7,0.0071050418,0.000022415166,0.9801516,0.00016577344],"about_ca_topic_score_codex":0.000051305145,"about_ca_topic_score_gemma":0.000044127377,"teacher_disagreement_score":0.08389458,"about_ca_system_score_codex":0.00009457337,"about_ca_system_score_gemma":0.00008367378,"threshold_uncertainty_score":0.67439437},"labels":[],"label_agreement":null},{"id":"W2897867911","doi":"10.1016/s1470-2045(18)30589-8","title":"Towards improving accuracy, effectiveness, and efficiency in breast cancer screening","year":2018,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Digital Radiography and Breast Imaging","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Breast cancer; Medicine; Breast cancer screening; Cancer; Medical physics; Computer science; Oncology; Internal medicine; Mammography","score_opus":0.02638061643442126,"score_gpt":0.3265582997418236,"score_spread":0.30017768330740235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897867911","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09430366,0.0017220265,0.00028694238,0.8901783,0.00076053594,0.0009143616,0.00016651269,0.00012800975,0.011539622],"genre_scores_gemma":[0.4920534,0.00045655185,0.0004730666,0.49178243,0.014723773,0.00021596513,0.000070895556,0.00008905226,0.0001348858],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980562,0.00028861876,0.00026736336,0.00047455373,0.00023222168,0.00068104366],"domain_scores_gemma":[0.9986491,0.0006120795,0.00019435165,0.00039702005,0.00008910492,0.000058324546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009351304,0.00030989407,0.0009780633,0.00024067957,0.000096000804,0.000058934922,0.00030868925,0.00043779486,0.0000506426],"category_scores_gemma":[0.00010488747,0.00020197369,0.00012195185,0.00037518097,0.0005465011,0.00012949284,0.00019248633,0.0016722683,0.000008176132],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001212844,0.000108306034,0.052011143,0.0015028666,0.00024859438,0.0012884376,0.00032798023,0.0000028639536,0.0003817945,0.000040046838,0.22565234,0.7172228],"study_design_scores_gemma":[0.004864843,0.0005949775,0.5032997,0.0018984943,0.00038707256,0.005347058,0.00006228748,0.00034242842,0.00008270713,0.00041468398,0.48217708,0.0005286302],"about_ca_topic_score_codex":0.0010663087,"about_ca_topic_score_gemma":0.000043216176,"teacher_disagreement_score":0.7166942,"about_ca_system_score_codex":0.000184978,"about_ca_system_score_gemma":0.00033715912,"threshold_uncertainty_score":0.8236248},"labels":[],"label_agreement":null},{"id":"W2899334087","doi":"10.1016/s1470-2045(18)30536-9","title":"Age at last screening and remaining lifetime risk of cervical cancer in older, unvaccinated women: a modelling study","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; Canadian Cancer Society; Centre hospitalier universitaire de Québec; Université de Montréal; University of British Columbia; McGill University","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Cervical cancer; Demography; Incidence (geometry); Population; Cancer; Cervical screening; Gynecology; Cancer registry; Obstetrics; Internal medicine; Environmental health","score_opus":0.07594709274700287,"score_gpt":0.3951939684561794,"score_spread":0.31924687570917654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899334087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99110913,0.0005267883,0.00020715996,0.0013762305,0.00005632487,0.00051676674,0.000010990998,0.000026869144,0.0061697215],"genre_scores_gemma":[0.997796,0.0004837704,0.00030620347,0.00047403917,0.0005942083,0.00008284087,0.0000021182675,0.00001914196,0.0002416739],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982947,0.00037839366,0.00030307815,0.0002831473,0.0002403776,0.0005002744],"domain_scores_gemma":[0.99890834,0.00045749926,0.000098728065,0.00029998957,0.00012631656,0.00010914155],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016235372,0.00012107257,0.0006790762,0.00010623059,0.0001182966,0.000008232019,0.00016594786,0.000108337044,0.0016275086],"category_scores_gemma":[0.00014074064,0.00008161716,0.0000322546,0.0003599024,0.00021218725,0.000027688156,0.0002840774,0.0005135859,0.000008974112],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014132835,0.00081806583,0.8660815,0.00027940355,0.00036485822,0.00023644383,0.037396695,0.0011578761,0.0006542714,0.000117436546,0.0006702359,0.07809038],"study_design_scores_gemma":[0.011508477,0.0034669458,0.9454944,0.00009186562,0.0000997986,0.000026122527,0.0032737905,0.03280972,0.00015144129,0.00029823405,0.00263487,0.00014434135],"about_ca_topic_score_codex":0.0012586105,"about_ca_topic_score_gemma":0.0055345087,"teacher_disagreement_score":0.0794129,"about_ca_system_score_codex":0.0002946344,"about_ca_system_score_gemma":0.00011734198,"threshold_uncertainty_score":0.99928516},"labels":[],"label_agreement":null},{"id":"W2899388060","doi":"10.1016/s1470-2045(18)30751-4","title":"The silent victims of the US embargo against Iran","year":2018,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Ethics and Legal Issues in Pediatric Healthcare","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Counterfeit; Ask price; Family medicine; Medicine; Psychology; Traditional medicine; Political science; Business; Law","score_opus":0.08276957762902769,"score_gpt":0.3919243443804915,"score_spread":0.3091547667514638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899388060","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009655956,0.0027727506,0.0000032233074,0.91645116,0.004251052,0.0008168191,0.00005986506,0.000039238003,0.06594994],"genre_scores_gemma":[0.037023716,0.0047817286,0.000078681536,0.9027022,0.048254,0.0000762285,0.000050585462,0.000059794333,0.006973029],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99660736,0.0011499085,0.00059782906,0.00032867567,0.0006125258,0.0007036857],"domain_scores_gemma":[0.9953285,0.0019066795,0.00053851615,0.001849622,0.00031184754,0.00006483996],"candidate_categories":["research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0023912895,0.00027924025,0.0009545231,0.000041731735,0.00044153072,0.000019856343,0.0012502188,0.0014237555,0.00009181983],"category_scores_gemma":[0.0006802543,0.00011309791,0.00026481654,0.00023672893,0.0011692033,0.000013569307,0.00031910092,0.005919706,0.000094828705],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010592735,0.000025164496,0.000906491,0.0003592061,0.00012340564,0.00008964021,0.0017589013,0.0000018290277,0.000013252372,0.00033750111,0.9937513,0.0025273664],"study_design_scores_gemma":[0.0007050383,0.00048740325,0.0014673974,0.00013969946,0.0001954318,0.00006159233,0.0001289664,0.0000270381,0.000026801603,0.00088791485,0.99575305,0.00011964532],"about_ca_topic_score_codex":0.00031968087,"about_ca_topic_score_gemma":0.00031783007,"teacher_disagreement_score":0.058976915,"about_ca_system_score_codex":0.00026943875,"about_ca_system_score_gemma":0.00087665336,"threshold_uncertainty_score":0.9998726},"labels":[],"label_agreement":null},{"id":"W2899472327","doi":"10.1016/s1470-2045(18)30754-x","title":"Developing cancer care institutions for the developing world","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Global Health and Surgery","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Developing country; Cancer; Business; Political science; Medicine; Economic growth; Economics; Internal medicine","score_opus":0.22709938437415975,"score_gpt":0.47520720641394265,"score_spread":0.2481078220397829,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899472327","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1949615,0.009488284,0.02599611,0.67285067,0.008850282,0.0026850535,0.00007422671,0.00025640128,0.08483746],"genre_scores_gemma":[0.9041672,0.0007509497,0.008792217,0.079808205,0.005013993,0.0004469508,0.000014520604,0.000013643854,0.0009923452],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99908966,0.000052325497,0.00018148098,0.00013103941,0.00008087357,0.0004646385],"domain_scores_gemma":[0.99895674,0.00045598773,0.00006195953,0.00022839545,0.00023979961,0.00005709224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046337524,0.00008354971,0.00028050924,0.000038813152,0.00056623126,0.000007450835,0.00015578611,0.00006144459,0.000035296773],"category_scores_gemma":[0.00019027371,0.000043238553,0.00004408026,0.00026952958,0.00024198656,0.0000215792,0.000048732298,0.0001608198,0.000041288684],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015017432,0.000032647175,0.03469268,0.00057908276,0.00020652886,0.000022421847,0.0037426976,0.000018140692,0.00009483551,0.50746363,0.23882678,0.21281882],"study_design_scores_gemma":[0.0007600682,0.00007379625,0.035428118,0.00009919627,0.000044554363,0.000027047703,0.00044241396,0.000040949664,0.00012316497,0.0004350955,0.96246374,0.00006188445],"about_ca_topic_score_codex":0.0002637478,"about_ca_topic_score_gemma":0.006610144,"teacher_disagreement_score":0.7236369,"about_ca_system_score_codex":0.00055663433,"about_ca_system_score_gemma":0.0026115724,"threshold_uncertainty_score":0.46328172},"labels":[],"label_agreement":null},{"id":"W2900298813","doi":"10.1016/s1470-2045(18)30566-7","title":"Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":306,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; Medical Research Council; Wellbeing of Women; Mauritius Research Council; Cancer Research UK","keywords":"Debulking; Medicine; Stage (stratigraphy); Chemotherapy; Oncology; Clinical trial; Randomized controlled trial; Surgery; Ovarian cancer; Internal medicine; Gynecologic oncology; Cancer","score_opus":0.1755971065629348,"score_gpt":0.4055934884821742,"score_spread":0.22999638191923938,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900298813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9778238,0.0036059876,0.00002445971,0.01603197,0.00070825167,0.0006633793,0.00058056344,0.00001958451,0.00054199534],"genre_scores_gemma":[0.992218,0.0030533972,0.0006493392,0.0027722446,0.0008387547,0.000087887944,0.00035739224,0.000017807557,0.000005168142],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9976491,0.0006047118,0.0006719351,0.00045329565,0.00027309562,0.0003478675],"domain_scores_gemma":[0.9939649,0.004239971,0.0004915494,0.0011647859,0.00006888839,0.00006991114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024067047,0.00019391597,0.0016695305,0.00013771385,0.00008877761,0.000022554626,0.00037620525,0.00011683715,0.0003839256],"category_scores_gemma":[0.000613143,0.00010623219,0.00012927958,0.0006159989,0.00026485726,0.00006637078,0.00018779491,0.00019603247,0.000004082961],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0135622,0.0004799005,0.2235754,0.000017233688,0.0137559865,0.000077254525,0.005757094,0.000060428825,0.0003757474,0.00018930866,0.008363437,0.733786],"study_design_scores_gemma":[0.01589875,0.0012339127,0.9333803,0.00014546589,0.007151503,0.0000060874036,0.000926195,0.0006279738,0.0008394663,0.00015422201,0.039455365,0.00018074334],"about_ca_topic_score_codex":0.003950125,"about_ca_topic_score_gemma":0.009416049,"teacher_disagreement_score":0.73360527,"about_ca_system_score_codex":0.00028466753,"about_ca_system_score_gemma":0.00045038064,"threshold_uncertainty_score":0.5971434},"labels":[],"label_agreement":null},{"id":"W2900348927","doi":"10.1016/s1470-2045(18)30537-0","title":"Temporal patterns in the risk of chronic health conditions in survivors of childhood cancer diagnosed 1970–99: a report from the Childhood Cancer Survivor Study cohort","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":259,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Cancer Institute; National Institutes of Health; American Lebanese Syrian Associated Charities","keywords":"Medicine; Cumulative incidence; Cancer; Incidence (geometry); Hazard ratio; Cohort; Pediatrics; Retrospective cohort study; Proportional hazards model; Internal medicine; Pediatric cancer; Cohort study; Confidence interval","score_opus":0.044148029212780694,"score_gpt":0.39117160089673203,"score_spread":0.3470235716839513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900348927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95770067,0.0028791938,0.000015436437,0.032264803,0.0010185785,0.0041814432,0.0015556238,0.00004633437,0.00033790478],"genre_scores_gemma":[0.9878469,0.0029508995,0.000026100133,0.0053016474,0.002571412,0.0010437847,0.00018255306,0.00005426678,0.000022424398],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9914183,0.0043158797,0.0018558538,0.0007249794,0.00088252564,0.00080242974],"domain_scores_gemma":[0.9931382,0.0028218823,0.0017212473,0.001986821,0.00021142596,0.00012040948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008276055,0.00041052533,0.00205482,0.00015855853,0.00024425212,0.000016090853,0.0010792866,0.00019748227,0.00044528113],"category_scores_gemma":[0.00075349386,0.00023389068,0.00022411426,0.0009421657,0.00078082946,0.000084497275,0.00021867908,0.0012547207,0.000008447916],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002724211,0.0030070536,0.93418443,0.00006992121,0.0006378968,0.00006836236,0.056306306,0.00004984698,0.000013179308,0.00003265121,0.0038000369,0.0015578892],"study_design_scores_gemma":[0.006968926,0.0019512405,0.97675514,0.0005222335,0.00032588898,0.000043701122,0.010227218,0.000029528854,0.000049436283,0.0002510585,0.002657693,0.00021791138],"about_ca_topic_score_codex":0.6348308,"about_ca_topic_score_gemma":0.9107594,"teacher_disagreement_score":0.27592862,"about_ca_system_score_codex":0.0006811306,"about_ca_system_score_gemma":0.0029087968,"threshold_uncertainty_score":0.9537785},"labels":[],"label_agreement":null},{"id":"W2900592090","doi":"10.1016/s1470-2045(18)30711-3","title":"Radiosurgery and risk of intracranial malignancies: more research needed","year":2018,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Pediatric Oncology Group; University Health Network; University of Toronto","funders":"","keywords":"Radiosurgery; Medicine; Radiation therapy; Malignancy; Cohort; Retrospective cohort study; Radiology; Surgery; Internal medicine","score_opus":0.09148683743019372,"score_gpt":0.3818851779728545,"score_spread":0.2903983405426608,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900592090","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.47626188,0.0011494029,0.0000010181349,0.5202177,0.00033206516,0.00044636533,0.00009066913,0.000019511406,0.0014813724],"genre_scores_gemma":[0.16805963,0.020347578,0.0013097494,0.74952036,0.057891797,0.0006627742,0.00041034914,0.00019461587,0.0016031546],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99755055,0.00076314737,0.00034294598,0.00033993457,0.00041901902,0.0005844314],"domain_scores_gemma":[0.996519,0.0021824178,0.00024600409,0.000725279,0.00026418862,0.00006310128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018437692,0.00021549137,0.0012318346,0.00021424938,0.00012914123,0.0000138660935,0.00022129023,0.00072228827,0.00019220333],"category_scores_gemma":[0.00047115076,0.00012447577,0.00012775588,0.00022502374,0.001129182,0.000017028577,0.00013608497,0.0015864567,0.000045689496],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003574884,0.00012537533,0.011146703,0.00021840708,0.00055233453,0.0016037293,0.00060939183,1.3039201e-7,0.00022553872,0.00002774915,0.9818991,0.0032340721],"study_design_scores_gemma":[0.0029949448,0.0012927558,0.017973496,0.0002347866,0.0006198342,0.00050790195,0.00023444029,0.000015527356,0.00051278446,0.000445055,0.9750441,0.00012441192],"about_ca_topic_score_codex":0.0006144798,"about_ca_topic_score_gemma":0.00004388814,"teacher_disagreement_score":0.30820227,"about_ca_system_score_codex":0.00016680777,"about_ca_system_score_gemma":0.0002719885,"threshold_uncertainty_score":0.6892453},"labels":[],"label_agreement":null},{"id":"W2900820241","doi":"10.1016/s1470-2045(18)30659-4","title":"Risk of radiation-associated intracranial malignancy after stereotactic radiosurgery: a retrospective, multicentre, cohort study","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":123,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; London Health Sciences Centre; Western University","funders":"","keywords":"Radiosurgery; Medicine; Malignancy; Cohort; Incidence (geometry); Population; Retrospective cohort study; Radiology; Radiation therapy; Surgery; Internal medicine","score_opus":0.016536977888361205,"score_gpt":0.3076291367489019,"score_spread":0.2910921588605407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900820241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99572825,0.00021680999,0.000025570715,0.00094479555,0.00048093268,0.0014142958,0.000086119304,0.00004279077,0.0010604606],"genre_scores_gemma":[0.9980712,0.0001890809,0.0002733214,0.00043146807,0.0007148948,0.00012892907,0.000016894875,0.000020431038,0.00015380325],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997975,0.0008233541,0.00035970518,0.000269778,0.0002435445,0.00032860984],"domain_scores_gemma":[0.9984858,0.0004193572,0.00036020437,0.00049502123,0.00016659907,0.00007302049],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001410867,0.00015841545,0.0008321628,0.000060488688,0.00009516132,0.000008478741,0.00010220714,0.00008990057,0.0005096757],"category_scores_gemma":[0.00045666323,0.00009963631,0.00010936429,0.00023807168,0.0001808567,0.000039312785,0.000041970787,0.00022958525,0.00005479485],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020702467,0.0017862245,0.9854799,0.000010285049,0.0019087899,0.00020225438,0.0013444545,4.7793503e-7,0.0000264173,0.000035462217,0.0010533761,0.0060820905],"study_design_scores_gemma":[0.008875127,0.003233391,0.98442984,0.000022973109,0.001743561,0.000045416906,0.0001930465,0.000106630396,0.00007633048,0.00009529873,0.0010922846,0.00008607868],"about_ca_topic_score_codex":0.00040344964,"about_ca_topic_score_gemma":0.0005240724,"teacher_disagreement_score":0.00680488,"about_ca_system_score_codex":0.00034776534,"about_ca_system_score_gemma":0.000116651965,"threshold_uncertainty_score":0.55805916},"labels":[],"label_agreement":null},{"id":"W2901760736","doi":"10.1016/s1470-2045(18)30576-x","title":"Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":244,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Princess Margaret Cancer Centre","funders":"UCLH Biomedical Research Centre; National Cancer Institute; Cancer Research UK; National Institutes of Health; National Institute for Health and Care Research; GlaxoSmithKline; American Society of Hematology","keywords":"Conjugate; Antibody-drug conjugate; Multiple myeloma; Medicine; Refractory (planetary science); Antibody; Cancer research; Drug; Oncology; Antigen; Internal medicine; Pharmacology; Immunology; Monoclonal antibody; Materials science","score_opus":0.0496385688750652,"score_gpt":0.38452979460518505,"score_spread":0.33489122573011987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901760736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99539006,0.00019843603,0.00011763141,0.0015664396,0.00016941347,0.0017158792,0.000018990453,0.00006168916,0.00076144177],"genre_scores_gemma":[0.9958239,0.00042904672,0.0019751396,0.0002910034,0.00088206405,0.00007897225,0.00018945467,0.000027591688,0.0003028283],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980774,0.00048020657,0.0003609711,0.0003609073,0.00026543826,0.00045509537],"domain_scores_gemma":[0.99870163,0.0005136667,0.00020628232,0.00031593835,0.00012947439,0.00013302501],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008918267,0.00019366885,0.0005353737,0.00013474263,0.0001945973,0.000027099617,0.0001009442,0.00013710397,0.00011200046],"category_scores_gemma":[0.0003816281,0.000106091284,0.000032293025,0.00023516186,0.0002674855,0.00012929527,0.000057678262,0.00035116586,0.000040820516],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.68203104,0.0019969696,0.034160886,0.00014090806,0.0001157652,0.0006250221,0.0026253131,0.000006773062,0.24832067,0.000015458989,0.0012388702,0.028722351],"study_design_scores_gemma":[0.74611235,0.025976142,0.15177397,0.00035935824,0.00016057843,0.00021530749,0.0010915603,0.029046722,0.025115265,0.00008702136,0.019612722,0.00044902568],"about_ca_topic_score_codex":0.00021912849,"about_ca_topic_score_gemma":0.00041468348,"teacher_disagreement_score":0.2232054,"about_ca_system_score_codex":0.00015835559,"about_ca_system_score_gemma":0.00027019373,"threshold_uncertainty_score":0.43262768},"labels":[],"label_agreement":null},{"id":"W2902516639","doi":"10.1016/s1470-2045(18)30663-6","title":"Competing risks of extended adjuvant aromatase inhibitors","year":2018,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Letrozole; Medicine; Tamoxifen; Breast cancer; Aromatase inhibitor; Oncology; Internal medicine; Aromatase; Adjuvant therapy; Adjuvant; Gynecology; Placebo; Cancer; Randomized controlled trial; Anastrozole; Alternative medicine; Pathology","score_opus":0.0460646919073738,"score_gpt":0.3401484784589049,"score_spread":0.2940837865515311,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902516639","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6297494,0.0090980325,0.00004953527,0.33735406,0.0033262346,0.0011530761,0.0004561057,0.0000888436,0.018724713],"genre_scores_gemma":[0.32627553,0.0034425808,0.0021741446,0.5853487,0.07403372,0.00018780895,0.006114589,0.0003002091,0.0021227065],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997922,0.0006520272,0.0003732808,0.00040013375,0.00016464785,0.00048791055],"domain_scores_gemma":[0.9984854,0.00012268017,0.00046068887,0.0008058691,0.000083322215,0.0000420554],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0006549235,0.0002907188,0.0006887303,0.000048992268,0.0000975442,0.000009742743,0.0006011416,0.0014433222,0.000035077854],"category_scores_gemma":[0.00011727495,0.0001931835,0.00019679808,0.00007891844,0.00051403325,0.000001386258,0.00029342223,0.0011856158,0.00007016071],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019161229,0.00004219474,0.00006940226,0.00009317675,0.00024447596,0.00012522971,0.00007192234,0.0000038249373,0.051850647,0.000009434847,0.9454311,0.0018669408],"study_design_scores_gemma":[0.00090445625,0.0011592509,0.00011212996,0.00006953741,0.00014105876,0.00016897965,0.00003320867,0.000013901378,0.050753225,0.00010181909,0.9463034,0.000238989],"about_ca_topic_score_codex":0.000037720863,"about_ca_topic_score_gemma":0.000007394543,"teacher_disagreement_score":0.30347386,"about_ca_system_score_codex":0.000031513297,"about_ca_system_score_gemma":0.00017445767,"threshold_uncertainty_score":0.999853},"labels":[],"label_agreement":null},{"id":"W2902706178","doi":"10.1016/s1470-2045(18)30788-5","title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":548,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Obinutuzumab; Ibrutinib; Chlorambucil; Medicine; Oncology; Internal medicine; Open label; Chronic lymphocytic leukemia; Venetoclax; Clinical trial; Leukemia; Chemotherapy; Cyclophosphamide","score_opus":0.16909667303358808,"score_gpt":0.4438783636128727,"score_spread":0.2747816905792846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902706178","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97489643,0.0021626754,0.00004799807,0.00088906084,0.0020077615,0.0088682845,0.00008194969,0.00010744956,0.010938382],"genre_scores_gemma":[0.9893438,0.0027869863,0.0003868274,0.0002749316,0.0037095018,0.0011965805,0.0001425422,0.0000967025,0.0020621275],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9944673,0.0007188064,0.0014329052,0.0009766138,0.00073262904,0.001671737],"domain_scores_gemma":[0.9941512,0.0026550256,0.00060215115,0.001886903,0.0003308876,0.0003738612],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017691832,0.0006341409,0.0029683276,0.00028123695,0.00026910438,0.00006260517,0.0013089008,0.00053417106,0.0010303073],"category_scores_gemma":[0.0011968671,0.00043643895,0.00023671726,0.00086218223,0.001541097,0.00017372638,0.00058961014,0.0004590179,0.00041429565],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.9694715,0.0012135911,0.0000023895545,0.00030306578,0.0006738472,0.0010633393,0.004450598,0.0011698011,0.00066589244,0.00023992745,0.0030350594,0.017710973],"study_design_scores_gemma":[0.7049532,0.03965658,0.0000034361015,0.00019579119,0.0004312973,0.00025813628,0.00030880637,0.21628615,0.0027620587,0.000051566145,0.034809537,0.00028346633],"about_ca_topic_score_codex":0.013366558,"about_ca_topic_score_gemma":0.009103237,"teacher_disagreement_score":0.3365853,"about_ca_system_score_codex":0.47276327,"about_ca_system_score_gemma":0.13617796,"threshold_uncertainty_score":0.9998829},"labels":[],"label_agreement":null},{"id":"W2902844274","doi":"10.1016/s1470-2045(18)30621-1","title":"Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":163,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Korea Health Industry Development Institute; Ministry of Health and Welfare; National Cancer Institute; U.S. Department of Health and Human Services; National Institutes of Health; U.S. Public Health Service; Novartis Pharmaceuticals Corporation","keywords":"Medicine; Letrozole; Aromatase inhibitor; Internal medicine; Breast cancer; Tamoxifen; Placebo; Oncology; Clinical endpoint; Interim analysis; Cancer; Gynecology; Randomized controlled trial","score_opus":0.04278072334570308,"score_gpt":0.3548242458836685,"score_spread":0.3120435225379654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902844274","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919772,0.0015399309,0.000025280528,0.0019889933,0.0007558109,0.0030624773,0.00020196833,0.0000233547,0.00042495283],"genre_scores_gemma":[0.9933754,0.00058314914,0.0001708942,0.0017482585,0.0023897241,0.0014751676,0.00011974845,0.00004285209,0.000094768766],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971168,0.0009924257,0.0006350944,0.00047033752,0.00018165402,0.0006037012],"domain_scores_gemma":[0.9984257,0.00029394007,0.00039537507,0.000614814,0.00014520274,0.00012493072],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012089798,0.00034328637,0.0010514898,0.00012397378,0.0001016503,0.000025042278,0.0003708408,0.00063873717,0.00013079203],"category_scores_gemma":[0.000069181035,0.00022245076,0.00022433644,0.00020647417,0.00062062015,0.000013986419,0.0000997858,0.0004191717,0.000024832112],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7866093,0.0012913152,0.00019544459,0.000010836751,0.00032414906,0.000056100842,0.00011082102,0.000054255455,0.2039669,0.000014135324,0.0026751335,0.004691622],"study_design_scores_gemma":[0.8859926,0.01234179,0.00011655241,0.000032294083,0.00014493019,0.00006490253,0.000028938723,0.00015569625,0.077148125,0.000014526555,0.023695149,0.00026447768],"about_ca_topic_score_codex":0.00021010196,"about_ca_topic_score_gemma":0.0002914774,"teacher_disagreement_score":0.12681876,"about_ca_system_score_codex":0.00012322848,"about_ca_system_score_gemma":0.00072918367,"threshold_uncertainty_score":0.9071279},"labels":[],"label_agreement":null},{"id":"W2903247006","doi":"10.1016/s1470-2045(18)30830-1","title":"National cancer control plans","year":2018,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Scopus; Cancer; Medicine; Nice; Family medicine; Quarter (Canadian coin); Primary care; MEDLINE; Political science; Computer science; Geography; Internal medicine","score_opus":0.18148294881658775,"score_gpt":0.4288465343402003,"score_spread":0.24736358552361257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903247006","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006155309,0.00065943715,0.00006211134,0.9173066,0.0012838102,0.00034586331,0.0003776257,0.00006656554,0.07928243],"genre_scores_gemma":[0.0068728724,0.0001998406,0.00012303462,0.91625994,0.07114967,0.00015787409,0.00015738106,0.000025797704,0.005053573],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982189,0.00017739159,0.0002496406,0.00029266038,0.0005535735,0.0005078571],"domain_scores_gemma":[0.998754,0.00034490298,0.00019882528,0.00033625073,0.00031995733,0.00004603846],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00061365985,0.0002050622,0.00078414753,0.00005806869,0.000107260545,0.000015658949,0.00037820684,0.00068926014,0.0013613818],"category_scores_gemma":[0.00014293879,0.00012797957,0.000121415476,0.00010160683,0.00028991338,0.000029322677,0.000046005396,0.0016479612,0.00039246312],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033701313,0.000008373812,0.0013824457,0.000049374423,0.00021218893,0.0003255444,0.00007426233,0.0000053877384,0.000021892194,0.00010013032,0.99644893,0.0010344723],"study_design_scores_gemma":[0.0020309493,0.0003848356,0.0019522593,0.00012519851,0.00023501251,0.00035237471,0.00001334847,0.000075746655,0.000007881283,0.0006233586,0.99406254,0.00013647413],"about_ca_topic_score_codex":0.0003222857,"about_ca_topic_score_gemma":0.00038735656,"teacher_disagreement_score":0.07422886,"about_ca_system_score_codex":0.00058554567,"about_ca_system_score_gemma":0.001125373,"threshold_uncertainty_score":0.99955153},"labels":[],"label_agreement":null},{"id":"W2907304754","doi":"10.1016/s1470-2045(18)30950-1","title":"Patients' crowdfunding campaigns for alternative cancer treatments","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"FinTech, Crowdfunding, Digital Finance","field":"Business, Management and Accounting","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Simon Fraser University","funders":"","keywords":"Medicine; Alternative medicine; Adverse effect; Popularity; Cancer; Cancer survival; Cancer treatment; Cancer therapy; Intensive care medicine; Internal medicine; Pathology","score_opus":0.052118109488045856,"score_gpt":0.3145241346615955,"score_spread":0.26240602517354966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907304754","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9353032,0.000059357124,0.00029858592,0.0016916443,0.0019976215,0.0010742255,0.000050209157,0.00011776419,0.059407357],"genre_scores_gemma":[0.98992884,0.000018493125,0.00017660769,0.003881612,0.0019871667,0.00033291028,0.000050636343,0.000041148323,0.003582603],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99874866,0.000014291232,0.00022696136,0.0003348612,0.00014591959,0.0005293281],"domain_scores_gemma":[0.99902713,0.00019218904,0.00033780682,0.00028766153,0.00014548785,0.000009719923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002956451,0.00020240604,0.00041136137,0.00010155084,0.00016518931,0.00013261277,0.00048034775,0.00008303334,0.00024383383],"category_scores_gemma":[0.00012008136,0.00014327135,0.00009565044,0.00024383442,0.00007909127,0.0006062363,0.00019852589,0.00014082271,0.0006707252],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010901279,0.0005523746,0.6598909,0.00037857873,0.00036796508,0.000009661102,0.0004982683,0.00032397913,0.00094422366,0.23119467,0.05447793,0.050271336],"study_design_scores_gemma":[0.005294828,0.00023870495,0.05228489,0.00009767356,0.000112773196,0.0000013795373,0.00015261289,0.001826849,0.00035123224,0.019752808,0.9194755,0.000410726],"about_ca_topic_score_codex":0.00039775885,"about_ca_topic_score_gemma":0.00021661738,"teacher_disagreement_score":0.86499757,"about_ca_system_score_codex":0.00029308343,"about_ca_system_score_gemma":0.00003596132,"threshold_uncertainty_score":0.8621039},"labels":[],"label_agreement":null},{"id":"W2911465702","doi":"10.1016/s1470-2045(18)30898-2","title":"Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":106,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Astellas Foundation for Research on Metabolic Disorders; Cancer Research UK; Ironwood Pharmaceuticals, Incorporated; Pfizer","keywords":"Enzalutamide; Medicine; Prostate cancer; Clinical endpoint; Placebo; Quality of life (healthcare); Internal medicine; Discontinuation; Oncology; Prostate-specific antigen; Clinical trial; Visual analogue scale; Cancer; Physical therapy; Pathology; Nursing","score_opus":0.07290594750234178,"score_gpt":0.41209821916643674,"score_spread":0.33919227166409494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911465702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97908205,0.00030542765,0.000005346682,0.0032877158,0.00035472287,0.013705093,0.000038448914,0.00004795041,0.003173242],"genre_scores_gemma":[0.9907557,0.00020385713,0.0003906296,0.0004014333,0.00014642018,0.0028516205,0.00008868319,0.000044506804,0.0051171626],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972925,0.00025149263,0.00070284895,0.00047275523,0.0005219627,0.00075839605],"domain_scores_gemma":[0.998251,0.00061529205,0.0003404403,0.00050143455,0.00012924509,0.00016258848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095372705,0.00031573314,0.0012823793,0.00015474728,0.00011515177,0.00004588211,0.00015925762,0.00010051052,0.00032387546],"category_scores_gemma":[0.00010776175,0.00015264079,0.00014378552,0.0003867937,0.000120538054,0.00014319498,0.000055988403,0.00044314307,0.00003590102],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.938973,0.0011243644,0.046812262,0.000114095565,0.0010473533,0.0014622463,0.0036187163,0.00010755192,0.0035829365,0.000011456039,0.00030448122,0.0028415294],"study_design_scores_gemma":[0.984182,0.0052624526,0.0038339007,0.00018041655,0.0005358305,0.00003230719,0.0016458044,0.00052129384,0.0018962981,0.000013434766,0.0016760303,0.00022020936],"about_ca_topic_score_codex":0.0010470324,"about_ca_topic_score_gemma":0.0024447755,"teacher_disagreement_score":0.045209013,"about_ca_system_score_codex":0.00060335046,"about_ca_system_score_gemma":0.0015216569,"threshold_uncertainty_score":0.622451},"labels":[],"label_agreement":null},{"id":"W2911475883","doi":"10.1016/s1470-2045(19)30012-9","title":"Limitations of simulation models for cervical cancer screening – Authors' reply","year":2019,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Medicine; Cervical cancer; Incidence (geometry); Cervix; Cancer; Demography; Cohort; Cervical screening; Disease; Gynecology; Oncology; Internal medicine","score_opus":0.43574307576817817,"score_gpt":0.46450395424091767,"score_spread":0.028760878472739504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911475883","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010773571,0.0006850859,0.024288,0.95045215,0.0004784967,0.0015498487,0.00025577168,0.000046956142,0.022135975],"genre_scores_gemma":[0.048497938,0.00063491514,0.0036921226,0.91971815,0.017742513,0.0005998515,0.00073864026,0.00009643184,0.008279419],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980967,0.00022394632,0.000415601,0.000353481,0.0004160193,0.0004942462],"domain_scores_gemma":[0.99450654,0.003998365,0.00022672926,0.0006244632,0.00059259165,0.00005133534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073030917,0.00018258898,0.0009987593,0.00012231342,0.00008244601,0.000011902924,0.0003147761,0.0006709952,0.0006119634],"category_scores_gemma":[0.00046491346,0.00012472655,0.00023129415,0.00018510943,0.00015540478,0.000044726563,0.00009810891,0.0016175368,0.000016198768],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016308598,0.000042319956,0.000106220214,0.00096058,0.00024730354,0.000012666092,0.00036509364,0.024429398,0.000025297626,0.0003765734,0.91253394,0.059269734],"study_design_scores_gemma":[0.002154339,0.0005871247,0.0011759207,0.000060119244,0.00028969022,0.000005618011,0.000025144856,0.12195043,0.00001440187,0.0021534264,0.87146914,0.00011462922],"about_ca_topic_score_codex":0.00026800088,"about_ca_topic_score_gemma":0.000120191464,"teacher_disagreement_score":0.09752104,"about_ca_system_score_codex":0.00023734622,"about_ca_system_score_gemma":0.00059008854,"threshold_uncertainty_score":0.70274824},"labels":[],"label_agreement":null},{"id":"W2911490798","doi":"10.1016/s1470-2045(18)30860-x","title":"Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":397,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Bayer Fund","keywords":"Abiraterone acetate; Medicine; Prostate cancer; Prednisone; Abiraterone; Placebo; Urology; Radium-223; Internal medicine; Castration; Prednisolone; Oncology; Cancer; Androgen deprivation therapy; Bone metastasis; Hormone; Alternative medicine; Pathology","score_opus":0.047407643392600944,"score_gpt":0.3646799658367788,"score_spread":0.31727232244417786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911490798","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824536,0.0010679218,0.0000053155245,0.0028660535,0.00011002316,0.012891278,0.00042904075,0.000019477307,0.00015729356],"genre_scores_gemma":[0.9948187,0.0007931552,0.00029698078,0.00015935657,0.00014544283,0.0024057936,0.00020495117,0.00002610042,0.0011495539],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981055,0.0002792534,0.00050721184,0.00037704612,0.0003004543,0.00043048867],"domain_scores_gemma":[0.9988095,0.0003418453,0.0002694989,0.00027227047,0.00015927819,0.00014757832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008241965,0.00023621044,0.0013148803,0.00017035512,0.00007531748,0.00002988273,0.00007971226,0.00009245238,0.00014923011],"category_scores_gemma":[0.000057012843,0.00012226294,0.000042427728,0.00024656887,0.0002147948,0.00013267284,0.000052504514,0.00023109476,0.000004644142],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98655653,0.0013696029,0.0017833014,0.00020752689,0.00047441508,0.000048706625,0.0013277716,0.000036686328,0.00354208,0.000019030005,0.00036581027,0.0042685266],"study_design_scores_gemma":[0.9760144,0.017262544,0.003051037,0.00017780777,0.00039510103,0.000014558142,0.00017999836,0.000071271985,0.0017890792,0.000016018144,0.00088742375,0.00014080328],"about_ca_topic_score_codex":0.00029996634,"about_ca_topic_score_gemma":0.0009165573,"teacher_disagreement_score":0.015892942,"about_ca_system_score_codex":0.00017907892,"about_ca_system_score_gemma":0.0005482538,"threshold_uncertainty_score":0.49857378},"labels":[],"label_agreement":null},{"id":"W2912630069","doi":"10.1016/s1470-2045(18)30863-5","title":"Quality of life in men with prostate cancer","year":2019,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Prostate cancer; Quality of life (healthcare); Prostate; Medicine; Cancer; Oncology; Gerontology; Internal medicine; Nursing","score_opus":0.06595235535805974,"score_gpt":0.37068719479208645,"score_spread":0.3047348394340267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912630069","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06591213,0.0015376529,0.0000020898528,0.88259524,0.0004997918,0.0008768042,0.000154307,0.00002672019,0.048395254],"genre_scores_gemma":[0.082463264,0.0010025449,0.000028903803,0.8985653,0.0052068722,0.00029445387,0.00014747931,0.000053819935,0.012237387],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982282,0.00043574627,0.00037614777,0.0002794558,0.0003000921,0.0003803928],"domain_scores_gemma":[0.9984821,0.00037080378,0.00035740144,0.00064969435,0.000111017216,0.000028991544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007120756,0.00019430755,0.0014887399,0.000071375194,0.000013942352,0.0000041341214,0.000247765,0.00045857398,0.00024881365],"category_scores_gemma":[0.00004988404,0.000110205896,0.00007670427,0.00017624635,0.0001850174,0.000017823739,0.000059345617,0.0015696216,0.00002056816],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033554535,0.00003159001,0.08272821,0.0013406547,0.00016677949,0.000085121734,0.0020723892,0.0000068250642,0.00004272336,0.00002820756,0.9087094,0.0014326433],"study_design_scores_gemma":[0.0035220766,0.00044797355,0.04151316,0.00023842508,0.00008179151,0.000011018803,0.00026066246,0.0000042020324,0.000018581704,0.000060473754,0.953692,0.00014961476],"about_ca_topic_score_codex":0.012609145,"about_ca_topic_score_gemma":0.017021239,"teacher_disagreement_score":0.044982612,"about_ca_system_score_codex":0.00030196283,"about_ca_system_score_gemma":0.0011734482,"threshold_uncertainty_score":0.993966},"labels":[],"label_agreement":null},{"id":"W2913336223","doi":"10.1016/s1470-2045(18)30897-0","title":"Essential TNM: a registry tool to reduce gaps in cancer staging information","year":2019,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Centre International de Recherche sur le Cancer; World Health Organization","keywords":"Medicine; Cancer; Cancer registry; Stage (stratigraphy); Population; Oncology; Disease; Prostate cancer; Internal medicine; Gynecology; Environmental health","score_opus":0.19966496151969765,"score_gpt":0.4846025077963191,"score_spread":0.28493754627662143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913336223","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010043911,0.97745854,0.00005244455,0.0037961286,0.0010894805,0.00168153,0.00006711955,0.000051512052,0.014798829],"genre_scores_gemma":[0.00026839273,0.9926753,0.00033515235,0.0038353105,0.0016808007,0.00036196667,0.000100855585,0.000020730917,0.00072151114],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99814713,0.0001833118,0.00064622256,0.00025368156,0.00027893294,0.00049073825],"domain_scores_gemma":[0.99866116,0.00013368821,0.00040621718,0.00063933234,0.00008592874,0.00007368115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008039817,0.00025494583,0.0018967198,0.00016479651,0.000040963296,0.00003364335,0.00043378622,0.00032683028,0.00015658235],"category_scores_gemma":[0.0002270726,0.00017057649,0.00016952632,0.00046925445,0.000053446365,0.00015436961,0.00016636169,0.00080901483,0.00033407813],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023863977,0.000019522719,0.000071290735,0.0065970444,0.00006922547,0.00004432406,0.0003514824,0.000021582846,0.0000055933674,0.00020149592,0.032740586,0.9596392],"study_design_scores_gemma":[0.00073397224,0.00020257595,0.00012763996,0.0099807065,0.00038251097,0.00015893338,0.000116869676,0.0000072855087,0.0000039242777,0.000016582595,0.98808336,0.00018564328],"about_ca_topic_score_codex":0.0007458433,"about_ca_topic_score_gemma":0.00022695542,"teacher_disagreement_score":0.9594536,"about_ca_system_score_codex":0.0012484466,"about_ca_system_score_gemma":0.0015140354,"threshold_uncertainty_score":0.69559073},"labels":[],"label_agreement":null},{"id":"W2914004109","doi":"10.1016/s1470-2045(18)30779-4","title":"Endpoint selection in HER2-positive early breast cancer","year":2019,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Surrogate endpoint; Breast cancer; Clinical endpoint; Oncology; Internal medicine; Clinical trial; Cancer; Disease; Trastuzumab; Stage (stratigraphy)","score_opus":0.016734888017355624,"score_gpt":0.29623716129831196,"score_spread":0.27950227328095634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914004109","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05346717,0.0013951135,0.000023203926,0.9374924,0.001033704,0.00068071863,0.00090607494,0.000031816227,0.0049698334],"genre_scores_gemma":[0.2130257,0.0022812174,0.00011020747,0.75490767,0.024099119,0.0007790799,0.00074759347,0.00012444281,0.003924974],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99813694,0.00038492115,0.00022223714,0.00055302493,0.00013822535,0.0005646725],"domain_scores_gemma":[0.99928194,0.00006924283,0.00019764833,0.00034293538,0.00009036519,0.000017889979],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019352214,0.00033247948,0.0006204952,0.000058122667,0.00007247316,0.00001661946,0.000351505,0.0007973143,0.00008744124],"category_scores_gemma":[0.000013236463,0.00024224915,0.00011621754,0.0001180303,0.00016016563,0.000003095242,0.00018750654,0.00096883794,0.000072294526],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006798422,0.00006333724,0.018072652,0.00005252272,0.00046867575,0.00006049903,0.00023932842,0.00003122039,0.0014159624,0.000012784371,0.97577447,0.0031287004],"study_design_scores_gemma":[0.0013901968,0.00027156356,0.21031064,0.000052484887,0.00010147525,0.00014692915,0.000022599468,0.0000031565276,0.000612251,0.00005585543,0.7867407,0.0002921596],"about_ca_topic_score_codex":0.0021476953,"about_ca_topic_score_gemma":0.0022838882,"teacher_disagreement_score":0.19223799,"about_ca_system_score_codex":0.00041514484,"about_ca_system_score_gemma":0.00028896276,"threshold_uncertainty_score":0.98786336},"labels":[],"label_agreement":null},{"id":"W2914106356","doi":"10.1016/s1470-2045(18)30953-7","title":"CHISELing a path forward in the treatment of early-stage non-small-cell lung cancer","year":2019,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Medicine; Clinical trial; Randomized controlled trial; SABR volatility model; Radiation therapy; Stage (stratigraphy); Lung cancer; Internal medicine","score_opus":0.038591505470496876,"score_gpt":0.3427920122693942,"score_spread":0.3042005067988973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914106356","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3991483,0.0070629474,0.000007892162,0.5790894,0.00095968833,0.0035520832,0.00024226542,0.000026015807,0.00991141],"genre_scores_gemma":[0.22934888,0.040817857,0.0003501344,0.69972,0.014382319,0.004320679,0.000467146,0.00016779413,0.010425178],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979892,0.00028064445,0.00042082876,0.00043194837,0.0002833677,0.0005940176],"domain_scores_gemma":[0.99788225,0.0006405906,0.00037031888,0.001019125,0.000057429465,0.00003029971],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034948834,0.00038457292,0.0014717192,0.000097776705,0.00005416092,0.000015062733,0.00038672125,0.0005034419,0.00018132674],"category_scores_gemma":[0.0000067122396,0.00018280679,0.00030207584,0.00015867136,0.000088892884,0.00001786971,0.00004067039,0.0008382836,0.000034749974],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005793283,0.0011361075,0.1486614,0.0012862398,0.0009559508,0.0011908478,0.01000649,0.000074276875,0.000031648982,0.000018151266,0.8326825,0.0033770972],"study_design_scores_gemma":[0.008137566,0.0033233666,0.0176675,0.00041993335,0.0014661222,0.000020503045,0.0001422895,0.000116116455,0.00014337595,0.000015277488,0.96834886,0.00019910577],"about_ca_topic_score_codex":0.0036733816,"about_ca_topic_score_gemma":0.0008370747,"teacher_disagreement_score":0.16979939,"about_ca_system_score_codex":0.0016076439,"about_ca_system_score_gemma":0.00064838654,"threshold_uncertainty_score":0.74546444},"labels":[],"label_agreement":null},{"id":"W2914512849","doi":"10.1016/s1470-2045(18)30939-2","title":"Conservative management of adnexal masses","year":2019,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Adnexal mass; Scopus; Malignancy; Ovarian cancer; Gynecology; MEDLINE; Cancer; Pathology; Internal medicine","score_opus":0.09741370730472958,"score_gpt":0.3681989465383599,"score_spread":0.2707852392336303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914512849","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013395837,0.0007891747,0.000008690417,0.88699514,0.0007197567,0.0008796121,0.000099594785,0.00002550414,0.10914297],"genre_scores_gemma":[0.0052342545,0.0022659001,0.0016708614,0.9692737,0.004077797,0.00025676822,0.0002473386,0.000043246062,0.016930161],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99875027,0.00016519107,0.0002676087,0.00028207432,0.00022136816,0.0003134746],"domain_scores_gemma":[0.99844605,0.00047449605,0.00027661704,0.00070991006,0.00007362873,0.000019294717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022590952,0.00020848784,0.0010704381,0.00004855244,0.000025420699,0.0000054670277,0.00022635609,0.00035985827,0.0005785504],"category_scores_gemma":[0.000009465302,0.00012351108,0.00014073958,0.00009482466,0.00016720471,0.000013033249,0.00009995353,0.0007251043,0.00021447036],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020864117,0.00011760244,0.0030599977,0.00092768203,0.0016078633,0.0011982709,0.000096259246,8.6088005e-7,0.0000027025396,0.0009285638,0.98826355,0.003588035],"study_design_scores_gemma":[0.0032281464,0.00087701535,0.012840385,0.00038580867,0.0009914163,0.00006048163,0.000060193277,0.000002428171,0.0000627865,0.00028268291,0.98110497,0.000103679326],"about_ca_topic_score_codex":0.00007484609,"about_ca_topic_score_gemma":0.000009289768,"teacher_disagreement_score":0.0922128,"about_ca_system_score_codex":0.0002851701,"about_ca_system_score_gemma":0.00022464499,"threshold_uncertainty_score":0.63347214},"labels":[],"label_agreement":null},{"id":"W2916014925","doi":"10.1016/s1470-2045(18)30902-1","title":"10-year performance of four models of breast cancer risk: a validation study","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":171,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; Public Health Ontario; University of Toronto; Lunenfeld-Tanenbaum Research Institute","funders":"National Center for Advancing Translational Sciences; National Health and Medical Research Council; National Cancer Institute; National Medical Research Council; NSW Ministry of Health; National Breast Cancer Foundation","keywords":"Breast cancer; Medicine; Cohort; Family history; Cancer; Oncology; Ovarian cancer; Cohort study; Prospective cohort study; Gynecology; Internal medicine","score_opus":0.031200918139862987,"score_gpt":0.31178036523778446,"score_spread":0.2805794470979215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2916014925","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99467796,0.00010248062,0.00006871427,0.00024463015,0.0001539265,0.00033982887,0.00009262701,0.0000049961677,0.0043148356],"genre_scores_gemma":[0.9983017,0.00029881287,0.00028862592,0.000049025304,0.00022790412,0.000059240272,0.000013007947,0.000012588467,0.00074910413],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99919194,0.00017204361,0.00020475502,0.00017861156,0.00010977239,0.00014287746],"domain_scores_gemma":[0.9990797,0.000027117716,0.00024956773,0.00046229552,0.0001661156,0.00001522031],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048560704,0.00008172921,0.00023611591,0.000026162177,0.000029693983,0.0000026487444,0.00028085354,0.00008407689,0.00043924234],"category_scores_gemma":[0.000015185803,0.00006129172,0.000041825115,0.00009740593,0.00007632147,0.0000050177932,0.00009995873,0.00008377782,0.000022266911],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00543907,0.0007910728,0.56864405,0.00021523901,0.00085845724,0.0000010028714,0.002194939,0.14113145,0.2437315,0.00028469323,0.008046927,0.028661624],"study_design_scores_gemma":[0.013738587,0.009560489,0.674663,0.00007570738,0.00051709596,0.00006753005,0.002193893,0.01564154,0.2527309,0.0007181953,0.02935231,0.0007407297],"about_ca_topic_score_codex":0.00009523537,"about_ca_topic_score_gemma":0.0000644234,"teacher_disagreement_score":0.1254899,"about_ca_system_score_codex":0.00005127287,"about_ca_system_score_gemma":0.00022528066,"threshold_uncertainty_score":0.48093957},"labels":[],"label_agreement":null},{"id":"W2916100539","doi":"10.1016/s1470-2045(18)30907-0","title":"Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":175,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital; University of Calgary","funders":"Janssen Pharmaceuticals; National Cancer Institute; Takeda Pharmaceuticals U.S.A.; Sanofi Genzyme; Genentech; National Institutes of Health; European Society for Medical Oncology; Eisai; Bayer Fund; Clovis Oncology; Active Biotech; Ipsen Biopharmaceuticals; Bavarian Nordic; Novartis; AbbVie; Exelixis; Sanofi; Merck; GlaxoSmithKline; Roche; Astellas Pharma US; Pfizer; Bristol-Myers Squibb; AstraZeneca; Boehringer Ingelheim","keywords":"Cabozantinib; Medicine; Renal cell carcinoma; Retrospective cohort study; Oncology; Cohort; Internal medicine; Urology","score_opus":0.01779356237453034,"score_gpt":0.2916839099226428,"score_spread":0.2738903475481125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2916100539","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8984776,0.00025255757,0.0000031879545,0.00052578043,0.00035050913,0.0037174537,0.0000075951675,0.00004901008,0.09661629],"genre_scores_gemma":[0.99179417,0.00005870477,0.00046869155,0.00044209522,0.00026971524,0.0001857945,0.000018884879,0.000049264945,0.0067126923],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974395,0.00034892457,0.00045064886,0.0006625755,0.00039340835,0.0007049622],"domain_scores_gemma":[0.99824613,0.00023734478,0.00022423352,0.0010442324,0.000116769384,0.00013129356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078836776,0.0003076003,0.00124683,0.00012627062,0.000064843436,0.000012752082,0.00030205317,0.0001546063,0.00035514907],"category_scores_gemma":[0.00004574644,0.00020928727,0.00012002015,0.00034699365,0.00008802306,0.00006033683,0.00016336485,0.0007093539,0.00070410076],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028779285,0.001990076,0.9735431,0.000067620975,0.0000516556,0.0007232099,0.0015376803,0.00004809671,0.018161245,0.000011600744,0.0007478812,0.00023992447],"study_design_scores_gemma":[0.023500824,0.005111143,0.96150297,0.000022388293,0.00019424019,0.000046711848,0.0012908654,0.0002922117,0.00571162,0.000011132352,0.0021208234,0.0001950834],"about_ca_topic_score_codex":0.00060593954,"about_ca_topic_score_gemma":0.00041199155,"teacher_disagreement_score":0.09331654,"about_ca_system_score_codex":0.00082841,"about_ca_system_score_gemma":0.0002359521,"threshold_uncertainty_score":0.90500253},"labels":[],"label_agreement":null},{"id":"W2916231496","doi":"10.1016/s1470-2045(18)30941-0","title":"Adolescents and young adults with cancer and the risk of subsequent primary neoplasms: not just big children","year":2019,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children","funders":"","keywords":"Medicine; Young adult; Cancer; Pediatrics; MEDLINE; Childhood cancer; Family medicine; Oncology; Gerontology; Internal medicine","score_opus":0.02894674781683117,"score_gpt":0.2941405866666177,"score_spread":0.26519383884978653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2916231496","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5244009,0.0036918758,0.00000561216,0.4681258,0.0007875738,0.0017295679,0.00043125814,0.00003764326,0.00078982394],"genre_scores_gemma":[0.25424147,0.015843108,0.00011994878,0.718061,0.010461594,0.00016202284,0.00022171639,0.000108580876,0.0007805882],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967593,0.00092420034,0.00055733504,0.00060598395,0.0006013088,0.00055188825],"domain_scores_gemma":[0.99707234,0.0007440927,0.000920983,0.001056093,0.0001369151,0.00006955571],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0013430446,0.00045108702,0.002029696,0.00008709954,0.000121365134,0.000021947415,0.00043641785,0.00059438316,0.000021230944],"category_scores_gemma":[0.00010243698,0.00022829896,0.00012554349,0.00013579107,0.0013369144,0.000035674224,0.00025224467,0.002617761,0.000008419648],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017002422,0.00012815824,0.4891399,0.0040074904,0.002065703,0.00008668665,0.0092278775,0.0000052452306,0.000016443179,0.00003692634,0.46989942,0.008383727],"study_design_scores_gemma":[0.030804887,0.0010403842,0.84289,0.0029497114,0.002566891,0.00079076114,0.0002885624,0.000015530753,0.000041486852,0.0000362811,0.11811093,0.00046452976],"about_ca_topic_score_codex":0.011408768,"about_ca_topic_score_gemma":0.0041390196,"teacher_disagreement_score":0.35375014,"about_ca_system_score_codex":0.00022453128,"about_ca_system_score_gemma":0.0006255437,"threshold_uncertainty_score":0.99968326},"labels":[],"label_agreement":null},{"id":"W2917351544","doi":"10.1016/s1470-2045(19)30072-5","title":"Global elimination of cervical cancer as a public health problem","year":2019,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":123,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Cervical cancer; Medicine; Vaccination; Cervical screening; Public health; Human papillomavirus; Epidemiology; Cancer; Disease; Action (physics); Global health; Family medicine; Gynecology; Oncology; Immunology; Internal medicine; Pathology","score_opus":0.15353283899402628,"score_gpt":0.45725399017779955,"score_spread":0.3037211511837733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2917351544","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003586583,0.00165454,0.000026150516,0.8781507,0.00039406898,0.001039395,0.00015922701,0.00004133608,0.1181759],"genre_scores_gemma":[0.020652328,0.0017304168,0.00015856078,0.96337885,0.009618656,0.00023734524,0.00036584918,0.000036968275,0.0038210284],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969665,0.00056454545,0.00045817692,0.00039353815,0.0007533419,0.0008639319],"domain_scores_gemma":[0.9981293,0.00034079922,0.00031678815,0.00065063935,0.00044665448,0.000115782146],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011602658,0.00021864318,0.0013397773,0.00009647616,0.00006150814,0.00001799815,0.0005179019,0.0007410147,0.0052621504],"category_scores_gemma":[0.00014401638,0.00013920428,0.00016677781,0.0004122362,0.0002588442,0.000032611493,0.00020681348,0.0018496464,0.000186243],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038469798,0.000092735674,0.0015398139,0.001993167,0.00014824308,0.000042878586,0.00018485925,0.0000012492766,0.0000025328764,0.0011648041,0.8932894,0.101155646],"study_design_scores_gemma":[0.002201658,0.0016185166,0.030084683,0.00006360921,0.00006895401,0.000097277676,0.000030084462,0.000037889717,0.0000029153953,0.0009982693,0.96468306,0.000113110895],"about_ca_topic_score_codex":0.0027944113,"about_ca_topic_score_gemma":0.0010982865,"teacher_disagreement_score":0.11435487,"about_ca_system_score_codex":0.0017899756,"about_ca_system_score_gemma":0.0047152983,"threshold_uncertainty_score":0.9956472},"labels":[],"label_agreement":null},{"id":"W2921728285","doi":"10.1016/s1470-2045(19)30092-0","title":"Choosing Wisely India: ten low-value or harmful practices that should be avoided in cancer care","year":2019,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Healthcare cost, quality, practices","field":"Health Professions","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; University of Toronto","funders":"","keywords":"Specialty; Best practice; Concordance; Multidisciplinary approach; Medicine; Health care; Private sector; Palliative care; Family medicine; Nursing; Public relations; Medical education; Political science","score_opus":0.9202317752949634,"score_gpt":0.6991229596263484,"score_spread":0.22110881566861496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921728285","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00074284076,0.91876566,0.0000024946605,0.054667093,0.0058729094,0.007588529,0.0004037849,0.00020669965,0.0117499735],"genre_scores_gemma":[0.00034735503,0.9516728,0.0002359828,0.037041035,0.004658401,0.0032641846,0.0002101462,0.00021156046,0.0023585602],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.96203035,0.031530622,0.0022996636,0.0012412783,0.0007623464,0.0021357455],"domain_scores_gemma":[0.9632029,0.026131291,0.007955678,0.0019396109,0.00045884014,0.0003116708],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.0123803895,0.0009223999,0.0060271374,0.00042399403,0.0009458128,0.00006424581,0.0021276653,0.0029457805,0.0012116452],"category_scores_gemma":[0.008130033,0.0005554705,0.0003363091,0.0009796605,0.00029330875,0.0006385744,0.0009735242,0.011574537,0.0010263687],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00092599995,0.00022955646,0.0065748324,0.15537691,0.00050637516,0.0002903398,0.0275767,0.0000040820637,7.2934176e-7,0.0007754631,0.031666204,0.7760728],"study_design_scores_gemma":[0.0017584506,0.00022114241,0.0009785029,0.022507992,0.0010574537,0.000041955078,0.010566839,0.0000042813735,3.7760725e-7,0.00005286032,0.9622143,0.0005958651],"about_ca_topic_score_codex":0.018932525,"about_ca_topic_score_gemma":0.038671862,"teacher_disagreement_score":0.9305481,"about_ca_system_score_codex":0.0051870923,"about_ca_system_score_gemma":0.020305833,"threshold_uncertainty_score":0.99975145},"labels":[],"label_agreement":null},{"id":"W2921993687","doi":"10.1016/s1470-2045(19)30094-4","title":"Should we expand the carbon ion footprint of prostate cancer?","year":2019,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Radiation Therapy and Dosimetry","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Footprint; Carbon footprint; Oncology; Cancer; Internal medicine; Oceanography; Greenhouse gas; Archaeology; Geology","score_opus":0.08110415414711854,"score_gpt":0.3652762029762045,"score_spread":0.284172048829086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921993687","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.058405984,0.004458478,0.0000020315535,0.9258066,0.0014704533,0.0009875925,0.00003414732,0.000037552672,0.008797198],"genre_scores_gemma":[0.11034797,0.008262532,0.000032681917,0.85751677,0.011979718,0.00022923757,0.000065008,0.0000664676,0.011499626],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984065,0.00038494516,0.00033173856,0.00024627786,0.00028308964,0.00034741306],"domain_scores_gemma":[0.9981309,0.0005607325,0.00040524386,0.0008056777,0.000075422526,0.000022004459],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006221126,0.00021014799,0.0008792468,0.000073012845,0.00004856796,0.000007971456,0.00035577425,0.00060796505,0.00011432401],"category_scores_gemma":[0.00004632226,0.0001027245,0.00012916878,0.00014583,0.0002625354,0.000009640958,0.000058328325,0.0017369383,0.000015826006],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012147991,0.000055184693,0.0052999062,0.0006002997,0.0004869164,0.00006515814,0.0023792984,0.00006528711,0.0023735096,0.00015803288,0.9659138,0.02138781],"study_design_scores_gemma":[0.0018113583,0.0005573741,0.002281481,0.0001327753,0.00020424461,0.00004045846,0.00006924246,0.000065183805,0.0019370297,0.00050379825,0.9922803,0.00011672896],"about_ca_topic_score_codex":0.00034994536,"about_ca_topic_score_gemma":0.00003834671,"teacher_disagreement_score":0.06828981,"about_ca_system_score_codex":0.00020468583,"about_ca_system_score_gemma":0.00039449823,"threshold_uncertainty_score":0.7546229},"labels":[],"label_agreement":null},{"id":"W2935020610","doi":"10.1016/s1470-2045(19)30141-x","title":"Interactive architecture—UV protection unfolding above you!","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Impact of Light on Environment and Health","field":"Environmental Science","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Metropolitan University","funders":"","keywords":"Noon; Sunlight; Architecture; Ultraviolet; Environmental science; Computer science; Meteorology; Visual arts; Art; Atmospheric sciences; Geography; Physics; Optics","score_opus":0.027879197004789857,"score_gpt":0.2988077342344727,"score_spread":0.27092853722968285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2935020610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8705091,0.000015648422,0.0005260865,0.012113764,0.0004352994,0.0005459011,0.0000022506101,0.000047710993,0.11580426],"genre_scores_gemma":[0.99442637,0.000025058094,0.00045027732,0.0024548774,0.00032633386,0.000032002186,0.0000022634933,0.0000127134845,0.002270127],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987916,0.00019468449,0.00016235797,0.00022020347,0.00017498444,0.00045617303],"domain_scores_gemma":[0.99939126,0.00009522394,0.00014242843,0.00030070942,0.000001923186,0.00006848018],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00071914966,0.000117801304,0.00023390671,0.000023400497,0.00012310912,0.000013695625,0.00027894825,0.00008427025,0.0047038277],"category_scores_gemma":[0.000027705744,0.000075672266,0.00004303005,0.00010056978,0.00012106837,0.00011825649,0.00015497535,0.00040051874,0.003905167],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030408523,0.00072455266,0.4527929,0.00009636201,0.00015742143,0.000035972742,0.023529468,0.004705621,0.20379709,0.002713648,0.012550765,0.29585534],"study_design_scores_gemma":[0.0013318195,0.0009774076,0.3491317,0.000016298027,0.000017439672,0.00006300002,0.00035996534,0.00037700243,0.0033818542,0.0029996713,0.6411153,0.00022856495],"about_ca_topic_score_codex":0.00026380116,"about_ca_topic_score_gemma":0.00010471294,"teacher_disagreement_score":0.62856454,"about_ca_system_score_codex":0.00056023174,"about_ca_system_score_gemma":0.000016601707,"threshold_uncertainty_score":0.9968704},"labels":[],"label_agreement":null},{"id":"W2935541805","doi":"10.1016/s1470-2045(19)30029-4","title":"Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":537,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Ovarian cancer; BRCA mutation; Oncology; Progressive disease; Chemotherapy; Progression-free survival; Population; Phases of clinical research; Carboplatin; Combination therapy; Surgery; Gastroenterology; Cancer; Cisplatin","score_opus":0.24555150791936622,"score_gpt":0.4816545343169153,"score_spread":0.23610302639754907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2935541805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9556818,0.0015929674,0.0005653496,0.02727901,0.0019136475,0.008377397,0.00033588408,0.0000790354,0.004174937],"genre_scores_gemma":[0.96995115,0.002940644,0.0059324647,0.007960144,0.0034657284,0.0027192926,0.0001604646,0.000103298305,0.006766839],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981915,0.00022301881,0.00055625127,0.0003878538,0.00017222625,0.0004691967],"domain_scores_gemma":[0.9980692,0.00054866925,0.00042826074,0.0006918242,0.00015986688,0.00010217861],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004694136,0.00025204784,0.0012571242,0.000073772855,0.00007872333,0.00002044171,0.00033481428,0.0001907979,0.0013218476],"category_scores_gemma":[0.000034855468,0.0001656186,0.0001200971,0.00018737983,0.00015324338,0.000077342906,0.000034606583,0.00013669845,0.000037997044],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7075873,0.023263782,0.00036267185,0.00011784896,0.0012694707,0.00001944347,0.0029781393,0.00011944393,0.1236561,0.0015975718,0.007833914,0.13119431],"study_design_scores_gemma":[0.54338145,0.03649398,0.000042030457,0.00006787481,0.00021667875,0.000010686525,0.000072020215,0.0013405011,0.023033194,0.0005610614,0.3946285,0.0001520198],"about_ca_topic_score_codex":0.0004103262,"about_ca_topic_score_gemma":0.00022918945,"teacher_disagreement_score":0.38679457,"about_ca_system_score_codex":0.0006964681,"about_ca_system_score_gemma":0.0004957653,"threshold_uncertainty_score":0.99959105},"labels":[],"label_agreement":null},{"id":"W2938589827","doi":"10.1016/s1470-2045(19)30082-8","title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":813,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Janssen Research and Development","keywords":"Abiraterone acetate; Prostate cancer; Medicine; Prednisone; Internal medicine; Oncology; Androgen deprivation therapy; Urology; Cancer","score_opus":0.06476036434540433,"score_gpt":0.3773706945959527,"score_spread":0.31261033025054835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2938589827","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99192536,0.00015267839,0.000056792054,0.0009216665,0.00021918083,0.006174786,0.00036993207,0.00001993979,0.00015966651],"genre_scores_gemma":[0.99717706,0.00047530074,0.00031586003,0.000099537225,0.0001271118,0.000636387,0.0005758891,0.00002493753,0.0005678997],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973656,0.0006291393,0.0005761815,0.00041094513,0.00050677516,0.0005113538],"domain_scores_gemma":[0.9981218,0.00056537543,0.0004859494,0.00041353374,0.0003065402,0.00010680996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094347476,0.000260711,0.0017603216,0.0003014013,0.00006573943,0.000022802193,0.00014196942,0.00008652164,0.0001946413],"category_scores_gemma":[0.000047263828,0.00014904134,0.00014176016,0.00074810995,0.00021415284,0.00012769073,0.000048639093,0.00038431535,0.00001178648],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8935666,0.0013527622,0.086735435,0.00007707863,0.0046561034,0.00010261063,0.0026197734,0.008883883,0.00018617416,0.00004618794,0.00004904062,0.0017243454],"study_design_scores_gemma":[0.861499,0.006639343,0.12629086,0.000058524878,0.003176355,0.0000013408561,0.00016694635,0.001604876,0.00033789908,0.000022280947,0.000055452554,0.00014712474],"about_ca_topic_score_codex":0.0038106835,"about_ca_topic_score_gemma":0.0055815713,"teacher_disagreement_score":0.039555423,"about_ca_system_score_codex":0.00046700198,"about_ca_system_score_gemma":0.00083888817,"threshold_uncertainty_score":0.60777295},"labels":[],"label_agreement":null},{"id":"W2940012666","doi":"10.1016/s1470-2045(19)30155-x","title":"Importance of early treatment in metastatic prostate cancer: a question of life or death","year":2019,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Abiraterone acetate; Medicine; Prostate cancer; Prednisone; Oncology; Docetaxel; Cancer; Internal medicine; Prostate; Androgen deprivation therapy","score_opus":0.10795924696837893,"score_gpt":0.4141552426201033,"score_spread":0.30619599565172434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2940012666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5795115,0.005264423,0.0000017244236,0.41022357,0.0002780162,0.0030162032,0.00040427345,0.000023726609,0.0012765247],"genre_scores_gemma":[0.5112113,0.07461925,0.0017579462,0.3233933,0.006420155,0.005231552,0.0017564476,0.0003325869,0.07527754],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977941,0.0004303588,0.000590198,0.00034027285,0.00033268204,0.00051241164],"domain_scores_gemma":[0.99815637,0.0005118789,0.00053776446,0.00059750286,0.00014999232,0.000046476078],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050041487,0.0002792525,0.0017996008,0.00019224607,0.000020573967,0.0000049092296,0.00021722303,0.00026117958,0.0001486844],"category_scores_gemma":[0.000092247785,0.00013973155,0.0001327533,0.00026094264,0.00021584035,0.000036198056,0.00004881677,0.00074737164,0.0000143673915],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028332762,0.0009849772,0.6144473,0.0053487904,0.0026298335,0.003496328,0.00401741,0.000045267443,0.0005149028,0.00011467462,0.32595146,0.014116306],"study_design_scores_gemma":[0.038419127,0.024822567,0.14814302,0.0022635476,0.0019226142,0.00017266988,0.00021061944,0.000112043854,0.0013923992,0.0007623773,0.7812035,0.0005755216],"about_ca_topic_score_codex":0.0031539735,"about_ca_topic_score_gemma":0.0009025831,"teacher_disagreement_score":0.46630427,"about_ca_system_score_codex":0.00091987115,"about_ca_system_score_gemma":0.0030456271,"threshold_uncertainty_score":0.5698087},"labels":[],"label_agreement":null},{"id":"W2942308489","doi":"10.1016/s1470-2045(19)30100-7","title":"Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Musculoskeletal synovial abnormalities and treatments","field":"Medicine","cited_by":128,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"Daiichi Sankyo Europe","keywords":"Medicine; Retrospective cohort study; Cohort; Surgery; Giant Cell Tumors; Univariate analysis; Proportional hazards model; Sarcoma; Multivariate analysis; Internal medicine; Giant cell; Pathology","score_opus":0.01609272539954112,"score_gpt":0.3045513844286504,"score_spread":0.2884586590291093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2942308489","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97886604,0.000009476945,6.0631504e-7,0.00042938636,0.00048462674,0.0011603272,0.000034257042,0.00003239674,0.018982891],"genre_scores_gemma":[0.9981391,0.000021334075,0.00006590096,0.00016006219,0.0002045356,0.00002225287,0.00008835612,0.000019194364,0.0012792515],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99872774,0.00013537769,0.00024619472,0.00025630154,0.00039300954,0.00024136336],"domain_scores_gemma":[0.99902785,0.000083547224,0.00016839511,0.00045457899,0.00019465835,0.00007095911],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021484247,0.00015547454,0.00075235055,0.00004531514,0.00004095019,0.000008513085,0.00022807854,0.00006651241,0.00059388625],"category_scores_gemma":[0.000024379715,0.00008005576,0.00006331003,0.00010481387,0.00009827552,0.00008271571,0.00008465497,0.00018470263,0.00005854755],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021706156,0.004590267,0.9919652,0.000016144175,0.00031030856,0.000044141594,0.00025878122,0.0000013589944,0.000018823263,0.00028529775,0.00008017269,0.000258886],"study_design_scores_gemma":[0.013644314,0.007643036,0.9758016,0.000008764861,0.00017059883,0.00000856869,0.00017737025,0.000008513569,0.000016092883,0.000026369275,0.0024057312,0.000089034125],"about_ca_topic_score_codex":0.00037372767,"about_ca_topic_score_gemma":0.00009163143,"teacher_disagreement_score":0.01927308,"about_ca_system_score_codex":0.00016544605,"about_ca_system_score_gemma":0.00006278628,"threshold_uncertainty_score":0.6502638},"labels":[],"label_agreement":null},{"id":"W2943536090","doi":"10.1016/s1470-2045(19)30247-5","title":"Do not use robotic surgery in oncology patients when conventional surgical approaches are equally effective – Authors' reply","year":2019,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Cardiac, Anesthesia and Surgical Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Robotic surgery; Health care; General surgery; Cancer surgery; Population; Quality of life (healthcare); Surgery; Cancer; Nursing; Internal medicine","score_opus":0.13210549576522035,"score_gpt":0.3289182035455605,"score_spread":0.19681270778034016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943536090","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07051595,0.00045318037,0.000027803155,0.90809494,0.0042969477,0.0032684822,0.000090779125,0.00013747296,0.013114465],"genre_scores_gemma":[0.062460773,0.00030561863,0.00045398707,0.89608645,0.012732535,0.0008679792,0.0022487312,0.00021278612,0.024631139],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9911052,0.004967717,0.0010584631,0.0009820545,0.000794917,0.0010916766],"domain_scores_gemma":[0.9679383,0.02998349,0.00074828265,0.0010009197,0.00019505066,0.00013394596],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.003752176,0.0006114798,0.005384809,0.00037290118,0.00009057146,0.000051177743,0.00040534796,0.0021481032,0.0003141836],"category_scores_gemma":[0.0019497499,0.00040650892,0.0012761259,0.0002468314,0.00048701026,0.000096708434,0.00021212343,0.0038967987,0.00034364735],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037604293,0.0005496758,0.28619254,0.0005257283,0.00067460886,0.010793102,0.0004812466,0.00003885323,0.0000010355511,0.0008185287,0.6917424,0.004421864],"study_design_scores_gemma":[0.0046394677,0.0006175569,0.17296432,0.00022300963,0.00038842665,0.00068758015,0.000044909895,0.00003265656,0.0000015410864,0.00008718841,0.8199464,0.00036694316],"about_ca_topic_score_codex":0.00012784504,"about_ca_topic_score_gemma":0.000035882178,"teacher_disagreement_score":0.12820399,"about_ca_system_score_codex":0.0010967276,"about_ca_system_score_gemma":0.0007209893,"threshold_uncertainty_score":0.99983865},"labels":[],"label_agreement":null},{"id":"W2943864790","doi":"10.1016/s1470-2045(19)30178-0","title":"Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":86,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"Cilag; Genentech; F. Hoffmann-La Roche; Roche; Merck; Amgen","keywords":"Medicine; Clinical endpoint; Ovarian cancer; Carboplatin; Population; Progression-free survival; Internal medicine; Placebo; Oncology; Phases of clinical research; Clinical trial; Gynecology; Cancer; Chemotherapy; Pathology","score_opus":0.08349518990222415,"score_gpt":0.400998555831424,"score_spread":0.31750336592919987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943864790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98393303,0.004071753,0.00038711305,0.0031403434,0.00093887275,0.0052897003,0.00025464335,0.000028965047,0.0019555578],"genre_scores_gemma":[0.9766869,0.0063316827,0.00048732077,0.0013314887,0.003342299,0.0039199954,0.00024101701,0.00006789528,0.0075914324],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981265,0.00013737945,0.0004320348,0.00061829796,0.00012168481,0.00056409265],"domain_scores_gemma":[0.9986362,0.00027876053,0.000279805,0.00058438955,0.00009431692,0.00012656533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051799085,0.00035419955,0.00086860266,0.00004769428,0.00018685838,0.000030390454,0.0002779208,0.00033489693,0.0002546524],"category_scores_gemma":[0.00006694959,0.0002201455,0.000234556,0.00011118062,0.00012321328,0.000008221553,0.00009200764,0.0001104847,0.000014712393],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9424542,0.00033716287,0.00007201877,0.000050626197,0.0005009715,0.000008769316,0.00026371377,0.00035909374,0.020993628,0.00035760782,0.0020784044,0.032523796],"study_design_scores_gemma":[0.63447493,0.0074551506,0.00001909328,0.0000179146,0.0001977575,0.000024776227,0.000103482846,0.00019458852,0.013447782,0.000051648734,0.3437537,0.0002591943],"about_ca_topic_score_codex":0.00047969923,"about_ca_topic_score_gemma":0.0021537584,"teacher_disagreement_score":0.3416753,"about_ca_system_score_codex":0.00020655943,"about_ca_system_score_gemma":0.00063419715,"threshold_uncertainty_score":0.8977273},"labels":[],"label_agreement":null},{"id":"W2945852816","doi":"10.1016/s1470-2045(19)30152-4","title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":385,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"Celgene","keywords":"Pomalidomide; Lenalidomide; Dexamethasone; Bortezomib; Medicine; Refractory (planetary science); Multiple myeloma; Open label; Oncology; Internal medicine; Thalidomide; Randomized controlled trial; Biology","score_opus":0.07880100858038529,"score_gpt":0.38267076028817626,"score_spread":0.30386975170779096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2945852816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9779234,0.00020226554,0.000096165284,0.0010302482,0.000095152485,0.019233564,0.00013907047,0.00008129615,0.0011988457],"genre_scores_gemma":[0.97982305,0.0002544149,0.012497858,0.0007517229,0.00029945045,0.0027328562,0.00039414738,0.000101689046,0.0031448342],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968541,0.0006150987,0.00052936515,0.00070916855,0.0003936116,0.0008986097],"domain_scores_gemma":[0.9950304,0.003007004,0.0004168356,0.00085208454,0.00031560482,0.00037808987],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011828637,0.00043283644,0.0017900378,0.00012467198,0.00022366867,0.000080142694,0.00039290416,0.00021994974,0.00020000641],"category_scores_gemma":[0.0009904037,0.00020530724,0.00007162076,0.0002572597,0.00030215917,0.00022276727,0.00014388243,0.0003995273,0.00003175916],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.938972,0.0044974564,0.024284596,0.0001406316,0.001215255,0.00018064793,0.00023407038,0.0000025634704,0.00066060585,0.00001741285,0.0014430622,0.028351672],"study_design_scores_gemma":[0.91049916,0.06807929,0.0052726814,0.00018141909,0.00065345643,0.00010213589,0.000082476276,0.0007664319,0.00039074704,0.000013174523,0.013679678,0.00027936877],"about_ca_topic_score_codex":0.0002095204,"about_ca_topic_score_gemma":0.00027300027,"teacher_disagreement_score":0.06358183,"about_ca_system_score_codex":0.00029393964,"about_ca_system_score_gemma":0.0006554853,"threshold_uncertainty_score":0.83721864},"labels":[],"label_agreement":null},{"id":"W2946386783","doi":"10.1016/s1470-2045(19)30167-6","title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1681,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System","funders":"F. Hoffmann-La Roche","keywords":"Carboplatin; Medicine; Paclitaxel; Atezolizumab; Chemotherapy; Oncology; Nab-paclitaxel; Open label; Internal medicine; Lung cancer; Cisplatin; Cancer; Randomized controlled trial; Nivolumab; Immunotherapy","score_opus":0.048483638906467647,"score_gpt":0.3745263839184664,"score_spread":0.3260427450119987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946386783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96768534,0.0011366642,0.0005747847,0.0072062244,0.00033774733,0.02202023,0.00008264299,0.000048754555,0.0009075878],"genre_scores_gemma":[0.9867935,0.001625546,0.0022427002,0.002967075,0.00028008406,0.0040318826,0.0001960679,0.0001121823,0.0017509314],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99742454,0.0002184191,0.000713366,0.0006279192,0.00028712663,0.0007285972],"domain_scores_gemma":[0.99759746,0.0008134393,0.00060436566,0.00068671687,0.00016855438,0.00012944343],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008126488,0.0005305943,0.0020577987,0.00014240602,0.00014968435,0.00006186465,0.00041415278,0.00016517162,0.0003009691],"category_scores_gemma":[0.000020889243,0.0003147473,0.00012890251,0.0004013135,0.00016897693,0.000112553185,0.000032862346,0.00026672045,0.0000090966505],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96773916,0.0068942425,0.0010051813,0.0003043417,0.0013081951,0.00006326105,0.0061034197,0.00030583754,0.0058303345,0.000008782099,0.00072054274,0.009716677],"study_design_scores_gemma":[0.926024,0.03383809,0.00055793393,0.00027515853,0.0006166384,0.000056270404,0.000587897,0.025125645,0.004592743,0.000017057639,0.007892759,0.000415774],"about_ca_topic_score_codex":0.00464751,"about_ca_topic_score_gemma":0.0066877445,"teacher_disagreement_score":0.04171515,"about_ca_system_score_codex":0.0016692925,"about_ca_system_score_gemma":0.0012568606,"threshold_uncertainty_score":0.99993044},"labels":[],"label_agreement":null},{"id":"W2946486395","doi":"10.1016/s1470-2045(19)30091-9","title":"Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b–2 study","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":139,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Open label; Medicine; Internal medicine; Oncology; Lymphoma; Brentuximab vedotin; Phases of clinical research; Diffuse large B-cell lymphoma; Clinical trial; Hodgkin lymphoma","score_opus":0.018808620936235258,"score_gpt":0.3208220799402624,"score_spread":0.30201345900402715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946486395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911921,0.00013058513,0.0000020822906,0.0004010086,0.000059500635,0.006889974,0.000012403154,0.00003050552,0.0012818339],"genre_scores_gemma":[0.9981705,0.00006690197,0.00013766489,0.00073521945,0.000028056069,0.00049708504,0.00018351883,0.000042364514,0.0001386705],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99813765,0.00039858418,0.0003503242,0.0004231682,0.00022816496,0.0004621254],"domain_scores_gemma":[0.99874985,0.00017287952,0.000218195,0.0006897876,0.00008953488,0.00007975811],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004977711,0.00027260458,0.000996538,0.0001226294,0.000063004016,0.00003774616,0.00032518106,0.00010397976,0.00003946995],"category_scores_gemma":[0.000013258488,0.00015041353,0.000018294262,0.000348493,0.00005122146,0.0001557085,0.00007483771,0.00013992301,0.000035761528],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07708689,0.25749868,0.6565954,0.000026202,0.00016207718,0.00012485293,0.0036368414,0.0000019653512,0.00012338742,0.000030970332,0.00006433398,0.0046484116],"study_design_scores_gemma":[0.57552654,0.029419927,0.3938788,0.00007395621,0.00009068096,0.000006250712,0.00035870657,0.00015086179,0.00012677655,0.000007889273,0.00023996782,0.000119635304],"about_ca_topic_score_codex":0.0010048179,"about_ca_topic_score_gemma":0.0013607536,"teacher_disagreement_score":0.49843967,"about_ca_system_score_codex":0.00079442974,"about_ca_system_score_gemma":0.0003066534,"threshold_uncertainty_score":0.6133686},"labels":[],"label_agreement":null},{"id":"W2947615258","doi":"10.1016/s1470-2045(19)30304-3","title":"Selumetinib in paediatric low-grade glioma: a new era?","year":2019,"lang":"it","type":"letter","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; SickKids Foundation; University of Toronto","funders":"","keywords":"Selumetinib; Medicine; Glioma; Family medicine; Internal medicine; Cancer research; Cancer","score_opus":0.03938761532343604,"score_gpt":0.31674450708439383,"score_spread":0.2773568917609578,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947615258","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23575866,0.0111719975,0.0000042263487,0.7372542,0.0043806536,0.0025757083,0.00011826497,0.0000946415,0.00864163],"genre_scores_gemma":[0.2886659,0.008686295,0.0006761771,0.6108492,0.08034421,0.0008365781,0.0010397985,0.00037003413,0.008531845],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9937735,0.0013934893,0.0011029443,0.0011395,0.00066366635,0.0019268817],"domain_scores_gemma":[0.9937815,0.003339414,0.0007307038,0.0018273684,0.000092933784,0.00022807607],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.0013505345,0.00093789486,0.0033991828,0.00073517824,0.00011470423,0.00006260591,0.0010413553,0.0019172623,0.0018612967],"category_scores_gemma":[0.00037104505,0.00061813655,0.0005276056,0.0012839326,0.00022821985,0.00006396171,0.0003783451,0.0039648334,0.0061118426],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047340814,0.0012368781,0.030531155,0.0005071992,0.0006741764,0.008545337,0.0009887398,0.000035254772,0.00028376587,0.00016980953,0.9486525,0.00790174],"study_design_scores_gemma":[0.023952423,0.0017104467,0.034940723,0.00045785343,0.0014013037,0.0005191942,0.0001020343,0.00007978156,0.00018405446,0.0003709591,0.93569297,0.00058825605],"about_ca_topic_score_codex":0.0010500851,"about_ca_topic_score_gemma":0.0003331041,"teacher_disagreement_score":0.12640505,"about_ca_system_score_codex":0.0012612136,"about_ca_system_score_gemma":0.0015788669,"threshold_uncertainty_score":0.999627},"labels":[],"label_agreement":null},{"id":"W2947820602","doi":"10.1016/s1470-2045(19)30308-0","title":"Scale-up of radiotherapy for cervical cancer in the era of human papillomavirus vaccination in low-income and middle-income countries: a model-based analysis of need and economic impact","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; Commonwealth Fund","keywords":"Cervical cancer; Low and middle income countries; Human papillomavirus; Scale (ratio); Radiation therapy; Medicine; Socioeconomics; Economics; Economic growth; Developing country; Cancer; Geography; Internal medicine","score_opus":0.020819552417263503,"score_gpt":0.3930930907106677,"score_spread":0.3722735382934042,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947820602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949669,0.0017896221,0.0004416121,0.0017790212,0.000080356986,0.0007684027,0.00010179724,0.0000046543355,0.00006761711],"genre_scores_gemma":[0.99681395,0.0017644509,0.0006510022,0.00058842736,0.00007981238,0.00006340398,0.000009055864,0.000011567441,0.000018347399],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988631,0.00020219508,0.0004742683,0.00018315019,0.00007972552,0.00019758665],"domain_scores_gemma":[0.9982342,0.0010516203,0.00033967817,0.0003006049,0.00004819049,0.000025681047],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010308368,0.00012757232,0.0011999533,0.00022901244,0.000028394079,0.00000250322,0.00017503877,0.000176773,0.00011709299],"category_scores_gemma":[0.000017494398,0.00007008175,0.000101143974,0.00025684686,0.0002608176,0.00004986744,0.000013378606,0.00020523465,1.3083518e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059026806,0.00012940001,0.95879364,0.00046270256,0.00052507874,0.0000015329749,0.0035914897,0.024799267,0.0021264376,0.0007039024,0.000007822961,0.0029560383],"study_design_scores_gemma":[0.01344731,0.0017799038,0.8347646,0.00017050384,0.0002999986,0.000005867179,0.00021550244,0.14796464,0.00041943492,0.0007551635,0.000082645405,0.000094457624],"about_ca_topic_score_codex":0.00047431243,"about_ca_topic_score_gemma":0.0030434618,"teacher_disagreement_score":0.12402907,"about_ca_system_score_codex":0.00039688725,"about_ca_system_score_gemma":0.00025042784,"threshold_uncertainty_score":0.28578508},"labels":[],"label_agreement":null},{"id":"W2947985696","doi":"10.1016/s1470-2045(19)30322-5","title":"India's new health scheme: what does it mean for cancer care?","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Healthcare Systems and Reforms","field":"Economics, Econometrics and Finance","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Government (linguistics); Health care; Medicine; Economic growth; Population; Scheme (mathematics); Environmental health; Economics","score_opus":0.07996591785183273,"score_gpt":0.3536374365807042,"score_spread":0.27367151872887147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947985696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5689908,0.049786527,0.00045561662,0.34286124,0.015418336,0.0031664348,0.00042137865,0.00011305354,0.018786589],"genre_scores_gemma":[0.9275435,0.01584186,0.0013629118,0.038141277,0.0048261643,0.0002950186,0.000048913982,0.00006466982,0.011875673],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99848366,0.00004198065,0.0005373893,0.00033257325,0.000032270542,0.0005721008],"domain_scores_gemma":[0.9988805,0.00005809659,0.00044053135,0.00045167553,0.0000370065,0.00013215608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011079294,0.00013351286,0.0008171069,0.000071339535,0.00013578634,0.00005527808,0.00034717898,0.00017857215,0.0002999827],"category_scores_gemma":[0.000024125693,0.000078089215,0.00010218071,0.00011918311,0.000038056307,0.00017585991,0.00005560058,0.00022528465,0.00041289604],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002997285,0.00010812964,0.12582421,0.002091311,0.00034072148,0.0000034649959,0.0798201,0.000064663356,0.000030331761,0.3206521,0.06368973,0.4070755],"study_design_scores_gemma":[0.0012079579,0.000268315,0.0086301165,0.000058566206,0.0000012295695,0.0000034533991,0.0043287417,0.000048671052,0.00001149427,0.0052431137,0.9800588,0.00013957563],"about_ca_topic_score_codex":0.008776037,"about_ca_topic_score_gemma":0.0079612145,"teacher_disagreement_score":0.916369,"about_ca_system_score_codex":0.00055833126,"about_ca_system_score_gemma":0.00041333382,"threshold_uncertainty_score":0.9978246},"labels":[],"label_agreement":null},{"id":"W2948900598","doi":"10.1016/s1470-2045(19)30150-0","title":"Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":479,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"Daiichi-Sankyo; Incyte; National Cancer Institute; National Cancer Research Institute; Celgene","keywords":"Medicine; Cytarabine; Internal medicine; Chemotherapy; Salvage therapy; Chemotherapy regimen; Febrile neutropenia; Etoposide; Surgery; Mitoxantrone; Fludarabine; Phases of clinical research; Transplantation; Refractory (planetary science); Oncology; Gastroenterology; Neutropenia; Cyclophosphamide","score_opus":0.09386240084003972,"score_gpt":0.4315224040450322,"score_spread":0.3376600032049925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948900598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95338273,0.0004359538,0.000020446028,0.014408673,0.0016789129,0.014454041,0.000038868813,0.00013928284,0.015441098],"genre_scores_gemma":[0.9594557,0.0038808289,0.002068767,0.011433624,0.0032696282,0.0023739014,0.00016666266,0.00023987307,0.017110975],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9940971,0.0018220068,0.0012242467,0.0008429292,0.00061851996,0.0013952062],"domain_scores_gemma":[0.99159557,0.005741438,0.0005953174,0.001549245,0.00019635048,0.00032206895],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0048349807,0.00051604887,0.00322813,0.0002583583,0.00015604934,0.00008163437,0.0014324634,0.000593186,0.0024863544],"category_scores_gemma":[0.002403027,0.00030977165,0.00021460374,0.0006310203,0.00035937873,0.00020426566,0.00039456686,0.0019401954,0.0010269302],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9343994,0.0025961269,0.000091356946,0.00005597408,0.0009621986,0.0008062828,0.0010768995,0.000006421541,0.027127923,0.0002044086,0.021573666,0.011099324],"study_design_scores_gemma":[0.8707371,0.014714375,0.00009417959,0.0000802201,0.00035469752,0.00008397985,0.00042867186,0.005053406,0.0007152452,0.000042381558,0.10737738,0.00031836616],"about_ca_topic_score_codex":0.00023712897,"about_ca_topic_score_gemma":0.00025184784,"teacher_disagreement_score":0.08580371,"about_ca_system_score_codex":0.0018656424,"about_ca_system_score_gemma":0.0026940643,"threshold_uncertainty_score":0.99993545},"labels":[],"label_agreement":null},{"id":"W2954737844","doi":"10.1016/s1470-2045(19)30299-2","title":"Leptomeningeal metastasis of classical Hodgkin lymphoma in a patient with malignant posterior reversible encephalopathy syndrome","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Neurological Complications and Syndromes","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Western University","funders":"","keywords":"Medicine; Posterior reversible encephalopathy syndrome; Dacarbazine; Encephalopathy; Fluid-attenuated inversion recovery; Hypertensive encephalopathy; Hyperintensity; Pathology; Surgery; Radiology; Chemotherapy; Internal medicine; Magnetic resonance imaging; Blood pressure","score_opus":0.03330577865551398,"score_gpt":0.2916589347096551,"score_spread":0.2583531560541411,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954737844","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98888236,0.00010511694,0.000011947695,0.0066040936,0.000060767157,0.00050096866,0.000012296141,0.000021916258,0.0038005332],"genre_scores_gemma":[0.9972464,0.00002456847,0.0012850411,0.0011835383,0.000018954028,0.00005225404,0.000005892476,0.000009760502,0.00017357679],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99880195,0.00022151555,0.0002757122,0.00024552373,0.00017424671,0.00028106497],"domain_scores_gemma":[0.9991214,0.00021170829,0.0001367925,0.0004246586,0.000048586666,0.00005681517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003112968,0.00011429898,0.00069291453,0.00008924993,0.000026065589,0.0000046151035,0.00018260539,0.00007432985,0.00021381569],"category_scores_gemma":[0.000028831313,0.000061470804,0.00005712929,0.0002957434,0.0001512619,0.000031673466,0.00009646559,0.00015360344,0.000058829108],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020275317,0.0061144466,0.6211112,0.0008722861,0.0007250514,0.012051973,0.005815466,0.0001234598,0.1291676,0.012480622,0.002879512,0.18838304],"study_design_scores_gemma":[0.007938768,0.024751639,0.9176452,0.00017345401,0.00017208981,0.015582506,0.0005770835,0.00019515927,0.002243822,0.0004686166,0.03000174,0.00024991884],"about_ca_topic_score_codex":0.000026990969,"about_ca_topic_score_gemma":0.000014565552,"teacher_disagreement_score":0.29653397,"about_ca_system_score_codex":0.000085100946,"about_ca_system_score_gemma":0.000118303324,"threshold_uncertainty_score":0.25067067},"labels":[],"label_agreement":null},{"id":"W2956873218","doi":"10.1016/s1470-2045(19)30338-9","title":"The fragility of phase 3 trials supporting FDA-approved anticancer medicines: a retrospective analysis","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":73,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; Thunder Bay Regional Health Sciences Centre; NOSM University","funders":"","keywords":"Medicine; Fragility; Statistical significance; Confidence interval; Clinical trial; Randomized controlled trial; Sample size determination; Internal medicine; Statistics","score_opus":0.5921369313792776,"score_gpt":0.6538412243340906,"score_spread":0.061704292954813056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2956873218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81976503,0.00022492342,0.117596924,0.027809277,0.0030116134,0.004015514,0.00043536138,0.00016785089,0.026973533],"genre_scores_gemma":[0.8908183,0.00014803812,0.10644417,0.0009137549,0.0012400616,0.00010349573,0.000003040534,0.000024942994,0.00030418704],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9891735,0.0071529504,0.0022806316,0.000407328,0.0004883953,0.0004972038],"domain_scores_gemma":[0.7651045,0.23076786,0.0022865057,0.0014119773,0.0003466518,0.00008255004],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.06059473,0.00018809318,0.0033816986,0.000056998353,0.000121083795,0.000017525113,0.00072724454,0.00020576065,0.001152381],"category_scores_gemma":[0.32081234,0.00008717444,0.0004791774,0.00072523236,0.00073040323,0.000028413728,0.00016066946,0.00054752093,0.000021757465],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010997554,0.0021158163,0.06531785,0.00056233193,0.013640428,0.000030424304,0.003882408,0.000019821011,0.01003998,0.7591866,0.02642429,0.10778248],"study_design_scores_gemma":[0.0062549007,0.0009452164,0.007274076,0.000028611606,0.0028981762,0.0000022786496,0.00059540954,0.0015911041,0.0009897358,0.9749924,0.004287995,0.0001400957],"about_ca_topic_score_codex":0.000037275808,"about_ca_topic_score_gemma":0.0000762558,"teacher_disagreement_score":0.2602176,"about_ca_system_score_codex":0.00013747791,"about_ca_system_score_gemma":0.00018205373,"threshold_uncertainty_score":0.9997607},"labels":[],"label_agreement":null},{"id":"W2959633209","doi":"10.1016/s1470-2045(19)30459-0","title":"Improving affordability of new Essential Cancer Medicines","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Public Health Ontario","funders":"","keywords":"Essential medicines; Business; Access to medicines; Investment (military); Workforce; Quality (philosophy); Low and middle income countries; Supply chain; Cancer drugs; Medicine; Health care; Cancer; Economic growth; Developing country; Marketing; Nursing; Public health; Political science; Economics","score_opus":0.08620239956862087,"score_gpt":0.3603103379768915,"score_spread":0.27410793840827063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2959633209","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.906022,0.0014620711,0.0002242099,0.031075407,0.0014052602,0.00023945868,0.00008818429,0.000018510686,0.05946488],"genre_scores_gemma":[0.9929344,0.00048561188,0.00018249913,0.004374633,0.0011341488,0.000011049198,0.000002758122,0.000010805203,0.0008641076],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990865,0.000021870412,0.00040897037,0.00019842837,0.000015939255,0.00026830204],"domain_scores_gemma":[0.9991373,0.0001366479,0.00031323393,0.00033268894,0.000014181116,0.00006595186],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007376635,0.00008516996,0.0005552163,0.000044451255,0.000027933449,0.0000084953635,0.00033620044,0.00008076758,0.0024153974],"category_scores_gemma":[0.00007263185,0.00006842923,0.00007523077,0.00008805793,0.00010286015,0.000060029048,0.00009396695,0.0001690304,0.00031693594],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004268916,0.00017436969,0.2302528,0.00027798535,0.00022631178,0.0000016498941,0.0019924399,0.00042460105,0.0030034839,0.6823355,0.03972759,0.041156366],"study_design_scores_gemma":[0.002928004,0.00020671549,0.031844888,0.000011062979,0.000021855565,0.000004595723,0.00006571269,0.0070486255,0.0013143008,0.099344335,0.85698617,0.00022371892],"about_ca_topic_score_codex":0.0019928506,"about_ca_topic_score_gemma":0.0002257174,"teacher_disagreement_score":0.8172586,"about_ca_system_score_codex":0.00009538725,"about_ca_system_score_gemma":0.00010754612,"threshold_uncertainty_score":0.99849653},"labels":[],"label_agreement":null},{"id":"W2963015093","doi":"10.1016/s1470-2045(19)30395-x","title":"Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":456,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Hôpital Notre-Dame; Université de Sherbrooke","funders":"National Health and Medical Research Council; Canadian Cancer Society Research Institute; KWF Kankerbestrijding; Strong; European SocieTy for Radiotherapy and Oncology; Agenzia Italiana del Farmaco, Ministero della Salute; National Cancer Research Institute; Cancer Australia; Cancer Research UK; Merck","keywords":"Medicine; Endometrial cancer; Radiation therapy; Chemoradiotherapy; Clinical endpoint; Carboplatin; Oncology; Internal medicine; Lymphadenectomy; Post-hoc analysis; Gynecology; Surgery; Clinical trial; Cancer; Chemotherapy; Cisplatin","score_opus":0.03306297968360868,"score_gpt":0.3534208534692313,"score_spread":0.32035787378562264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2963015093","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99401945,0.0023924222,0.00003536204,0.00065830327,0.0006480756,0.0017918986,0.00035191549,0.000013932168,0.000088658046],"genre_scores_gemma":[0.987983,0.010833231,0.00019355092,0.00019533825,0.0004537194,0.00024685854,0.00003793459,0.000019977744,0.000036398145],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978458,0.00046157866,0.00060347863,0.00035343767,0.00036133756,0.00037436854],"domain_scores_gemma":[0.99706537,0.0016740025,0.0005993274,0.0004347422,0.00011634219,0.000110210094],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012381721,0.00022254097,0.0028760699,0.00047709662,0.000022983008,0.0000057851307,0.00018766854,0.00012905878,0.0009367648],"category_scores_gemma":[0.00016537722,0.00012894023,0.00015187575,0.0014944088,0.00015339792,0.00004345404,0.000023885024,0.00025442988,7.559241e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8790481,0.0009283927,0.032967903,0.00006280408,0.0045804754,0.000018204419,0.0011045254,0.000041505104,0.0031847118,0.00001544521,0.0000061435935,0.078041755],"study_design_scores_gemma":[0.90714294,0.03219416,0.057099618,0.000051104435,0.0016342419,0.0000029628036,0.00023897165,0.00008971982,0.0009346767,0.0000116690535,0.00045968915,0.00014022656],"about_ca_topic_score_codex":0.0036095511,"about_ca_topic_score_gemma":0.0009917956,"teacher_disagreement_score":0.07790153,"about_ca_system_score_codex":0.0003761749,"about_ca_system_score_gemma":0.00028008924,"threshold_uncertainty_score":0.9999765},"labels":[],"label_agreement":null},{"id":"W2963476376","doi":"10.1016/s1470-2045(19)30388-2","title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1153,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre","funders":"Merck Sharp and Dohme; Les Laboratories Pierre Fabre; Merck; Meso Scale Diagnostics; Roche; British Microcirculation Society; Amgen","keywords":"Ipilimumab; Pembrolizumab; Post-hoc analysis; Open label; Medicine; Post hoc; Oncology; Internal medicine; Clinical trial; Immunotherapy; Cancer","score_opus":0.04835099458072202,"score_gpt":0.3901170919169451,"score_spread":0.3417660973362231,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2963476376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9764865,0.000868357,0.0000017031892,0.0040186634,0.0014034907,0.008194679,0.00019730403,0.00008014354,0.008749179],"genre_scores_gemma":[0.99524987,0.00046536903,0.0003580199,0.002116715,0.00048472604,0.00033760542,0.00022944155,0.00004963147,0.00070861063],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963122,0.0010947612,0.000905788,0.00071272906,0.00032463358,0.00064987765],"domain_scores_gemma":[0.99613106,0.0018642851,0.00041951227,0.001296699,0.000146143,0.00014231299],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017737034,0.0003504626,0.0018477615,0.00012106525,0.00011261271,0.00005782685,0.0008537883,0.00021483163,0.00057625386],"category_scores_gemma":[0.00042211125,0.00023242015,0.00010341095,0.00027041952,0.00013863425,0.00023082951,0.0001917475,0.0005255613,0.00019706391],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9470787,0.0052267807,0.00060905074,0.00001207628,0.0006599836,0.00016835945,0.003352647,0.000013068284,0.014997446,0.000023177208,0.00066833926,0.027190346],"study_design_scores_gemma":[0.939757,0.03466911,0.0054983757,0.000060151313,0.0003012871,0.000015311196,0.004935682,0.0005993159,0.00024293912,0.000022913631,0.013622421,0.00027553376],"about_ca_topic_score_codex":0.0017867284,"about_ca_topic_score_gemma":0.0033827967,"teacher_disagreement_score":0.029442329,"about_ca_system_score_codex":0.0004988312,"about_ca_system_score_gemma":0.00044677278,"threshold_uncertainty_score":0.94778186},"labels":[],"label_agreement":null},{"id":"W2965073418","doi":"10.1016/s1470-2045(19)30516-9","title":"Advancing cancer care and prevention in the Caribbean: a survey of strategies for the region","year":2019,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"World Health Organization; National Institutes of Health; AES Corporation; AbbVie; John Templeton Foundation; Foundation for the National Institutes of Health","keywords":"Specialty; Caribbean region; Palliative care; Medicine; Health care; Cancer prevention; Healthcare system; Public health; Caribbean island; Developing country; Business; Family medicine; Cancer; Economic growth; Nursing; Political science; Latin Americans","score_opus":0.3874149358166617,"score_gpt":0.5140616115443222,"score_spread":0.12664667572766047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965073418","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00038703886,0.995119,0.00012387549,0.000960181,0.0002421893,0.002193653,0.00005824095,0.000006617651,0.00090924074],"genre_scores_gemma":[0.007482,0.9911112,0.00007259607,0.00037600653,0.00038578952,0.00044238384,0.000058491325,0.000014570229,0.000056926358],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983668,0.0006727873,0.00035196703,0.00020411154,0.000145772,0.00025857746],"domain_scores_gemma":[0.9973382,0.0016982089,0.0003765548,0.00043708447,0.00013412161,0.00001587795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015651397,0.00016853813,0.0013167138,0.00003774665,0.00007036031,0.000015475385,0.00033677806,0.00018570661,0.000004495851],"category_scores_gemma":[0.00018239273,0.00007044464,0.00014447358,0.00021625358,0.0001247353,0.00004406931,0.00005582113,0.00041555974,7.860833e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024642958,0.000009687106,0.00072819705,0.00993218,0.000114383845,0.0000066252196,0.0017571679,0.00002247168,3.5837994e-7,0.0005854377,0.0034696523,0.9831274],"study_design_scores_gemma":[0.00079092645,0.00071113795,0.0038738078,0.0064473758,0.0011156268,0.0001086102,0.00476575,0.00001769269,1.8823478e-7,0.00019334251,0.98188025,0.000095321775],"about_ca_topic_score_codex":0.0045362115,"about_ca_topic_score_gemma":0.025649622,"teacher_disagreement_score":0.9830321,"about_ca_system_score_codex":0.00021867048,"about_ca_system_score_gemma":0.001242489,"threshold_uncertainty_score":0.99212974},"labels":[],"label_agreement":null},{"id":"W2965089489","doi":"10.1016/s1470-2045(19)30171-8","title":"Optimising efficacy and reducing toxicity of anticancer radioimmunotherapy","year":2019,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":204,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"European Research Council; Weill Cornell Medical College; Genentech; Labex Immuno-Oncology; European Research Area Network on Cardiovascular Diseases; PharmaMar; Institut Universitaire de France; Chancellerie des Universités de Paris; Cancéropôle Ile de France; Ligue Contre le Cancer; Fondation pour la Recherche Médicale; Fondation pour la recherche juridique; U.S. Department of Defense; European Commission; Institut National de la Santé et de la Recherche Médicale; Bayer HealthCare; Servier; AstraZeneca; Institut National Du Cancer; Fondation Leducq; Agence Nationale de la Recherche; E-Rare; Bristol-Myers Squibb; Direction Générale de l’offre de Soins; Association pour la Recherche sur le Cancer; Seerave Foundation","keywords":"Radioimmunotherapy; Immunotherapy; Medicine; Radiation therapy; Toxicity; Oncology; Internal medicine; Cancer; Immunology; Monoclonal antibody; Antibody","score_opus":0.15012238987139914,"score_gpt":0.43593377494448915,"score_spread":0.28581138507309,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965089489","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013534584,0.9934805,0.00001917669,0.00079748215,0.0005298209,0.0011743905,0.000019925397,0.000031426312,0.0025937909],"genre_scores_gemma":[0.00018958989,0.99727803,0.0006664989,0.0006551443,0.0006693744,0.000027301416,0.000017374055,0.00004998723,0.00044670235],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998164,0.00033565995,0.00063735445,0.00033488407,0.0001833583,0.0003447608],"domain_scores_gemma":[0.9978686,0.00072070834,0.00056888873,0.00074955367,0.000049039332,0.00004319155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012415752,0.0002984938,0.003153604,0.00012347236,0.00006569167,0.000014660252,0.00026406578,0.00036151896,0.00016878745],"category_scores_gemma":[0.000064456726,0.00017407694,0.00033015778,0.0002908142,0.0004066157,0.000027337484,0.00006878718,0.00054806995,0.000009231953],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013025504,0.00008249911,0.0000061925716,0.0077666026,0.0008284284,0.00000811045,0.00026860123,8.90108e-7,0.0004673424,0.0000499554,0.001120994,0.98809785],"study_design_scores_gemma":[0.003429644,0.00074293156,0.000109596695,0.009243932,0.0011206234,0.00040633258,0.000020102128,0.0000072207954,0.00005700501,0.0000068332647,0.9846777,0.00017807784],"about_ca_topic_score_codex":0.000057432608,"about_ca_topic_score_gemma":0.000002635877,"teacher_disagreement_score":0.98791975,"about_ca_system_score_codex":0.0002878789,"about_ca_system_score_gemma":0.00069460797,"threshold_uncertainty_score":0.70986515},"labels":[],"label_agreement":null},{"id":"W2967350775","doi":"10.1016/s1470-2045(19)30413-9","title":"Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":780,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Calgary","funders":"Cilag; Foundation Medicine; Pharmacyclics; EMD Serono; Genentech; Astellas Pharma; Eisai; Jounce Therapeutics; Acceleron; Chugai Pharmaceutical; Horizon Pharma; National Cancer Institute; Intuitive Surgical; Gilead Sciences; Calithera Biosciences; Celldex Therapeutics; Ipsen; Array BioPharma; Center for Outcomes Research and Evaluation, Yale School of Medicine; Bayer HealthCare; Society of Memorial Sloan Kettering; Exelixis; Sanofi; Bristol-Myers Squibb; Ono Pharmaceutical; Eli Lilly and Company; EUSA Pharma; AstraZeneca; Memorial Sloan-Kettering Cancer Center; GlaxoSmithKline; Agilent Technologies; Amgen; Pfizer","keywords":"Nivolumab; Sunitinib; Ipilimumab; Medicine; Renal cell carcinoma; Internal medicine; Oncology; Carcinoma; First line; Randomized controlled trial; Clinical trial; Immunotherapy; Cancer","score_opus":0.06296786444902643,"score_gpt":0.34241897178061087,"score_spread":0.27945110733158446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2967350775","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9801894,0.0013050522,0.000030348023,0.0014522342,0.00080712367,0.0112564135,0.00046515212,0.000031823853,0.0044624624],"genre_scores_gemma":[0.9956458,0.0004472919,0.0006269198,0.00007693384,0.00058635836,0.00077586423,0.0005426728,0.00003808766,0.0012600663],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971778,0.00044066945,0.0010393271,0.0005833267,0.00023035619,0.00052853534],"domain_scores_gemma":[0.9916437,0.0067783403,0.00053656794,0.0007737587,0.00012289101,0.0001446948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008401435,0.00037509718,0.0025836753,0.00012306713,0.00008280694,0.000008682581,0.00018028746,0.00021192098,0.000073409145],"category_scores_gemma":[0.00055631687,0.00023557091,0.00034345879,0.00013793206,0.00015265285,0.00004555048,0.000059193077,0.00022298613,0.0000118925],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9803102,0.0018927617,0.000041308987,0.000055382763,0.00036735713,0.00011223228,0.001468691,0.00017086399,0.004216969,0.000035349738,0.00013447217,0.011194413],"study_design_scores_gemma":[0.9404457,0.046234738,0.000759444,0.000062304454,0.0010507778,0.000014779998,0.00031431898,0.001095534,0.0053685657,0.00005487749,0.0044159917,0.00018297281],"about_ca_topic_score_codex":0.00053970533,"about_ca_topic_score_gemma":0.000841362,"teacher_disagreement_score":0.044341974,"about_ca_system_score_codex":0.000909349,"about_ca_system_score_gemma":0.00052537327,"threshold_uncertainty_score":0.9606303},"labels":[],"label_agreement":null},{"id":"W2967398918","doi":"10.1016/s1470-2045(19)30407-3","title":"Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":365,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Bristol-Myers Squibb; Ono Pharmaceutical; European Society for Medical Oncology; Cancer Research Society; American Association for Cancer Research","keywords":"Nivolumab; Medicine; Docetaxel; Lung cancer; Internal medicine; Oncology; Clinical trial; Survival analysis; Cancer; Progressive disease; Chemotherapy; Immunotherapy","score_opus":0.011169927419285955,"score_gpt":0.26970985525713,"score_spread":0.258539927837844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2967398918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928929,0.00037305802,0.000032065745,0.00087510556,0.00010493563,0.001468242,0.000019212614,0.00004323859,0.0041912496],"genre_scores_gemma":[0.99706036,0.00028985977,0.00033811654,0.0006684382,0.0000862784,0.00013283356,0.000053537413,0.000032953827,0.0013376522],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984831,0.0001708017,0.00027110946,0.00036340638,0.00022797793,0.00048358666],"domain_scores_gemma":[0.9989225,0.00010292378,0.00022104074,0.000569071,0.00011941084,0.00006500104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035758788,0.00022035206,0.0009798359,0.00015959954,0.00004702067,0.000011673656,0.00021442054,0.000114432056,0.00030986883],"category_scores_gemma":[0.0000063703847,0.00012431196,0.00010239463,0.0009948253,0.00009018908,0.000050339593,0.00003158708,0.00027722304,0.000012772232],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03486811,0.0002796736,0.9581072,0.00008981333,0.001668724,0.000021668837,0.00058435916,0.0002833709,0.000527874,0.0000027203025,0.00015845503,0.003408036],"study_design_scores_gemma":[0.042462863,0.0034572675,0.949221,0.0001464404,0.0017667353,0.0000037669645,0.00021475037,0.00040126126,0.00021330756,0.0000014009156,0.0018966885,0.0002144917],"about_ca_topic_score_codex":0.0015540118,"about_ca_topic_score_gemma":0.0073091737,"teacher_disagreement_score":0.008886168,"about_ca_system_score_codex":0.00048839836,"about_ca_system_score_gemma":0.0003408858,"threshold_uncertainty_score":0.5069295},"labels":[],"label_agreement":null},{"id":"W2967453129","doi":"10.1016/s1470-2045(19)30410-3","title":"Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":462,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; University of Ottawa; University Health Network; University of Toronto; McGill University; University of British Columbia; Western University","funders":"Canadian Cancer Society Research Institute; University of Texas MD Anderson Cancer Center; Cancer Research Institute; Eisai; Canadian Cancer Society; Ontario Institute for Cancer Research","keywords":"Transoral robotic surgery; Medicine; Neck dissection; Radiation therapy; Basal cell; Dissection (medical); Open label; Randomized controlled trial; Surgery; Oncology; Radiology; Carcinoma; Internal medicine","score_opus":0.11332656014311564,"score_gpt":0.3992188345265018,"score_spread":0.28589227438338616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2967453129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875932,0.0014477179,0.000085943764,0.003827511,0.0026526037,0.0033683814,0.000019425168,0.00004557752,0.000959674],"genre_scores_gemma":[0.9960295,0.00033400994,0.00034828013,0.0008949799,0.0016404903,0.00034045445,0.00003835978,0.000035072506,0.00033887444],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99855804,0.00029351754,0.00030911074,0.0003322467,0.00010803653,0.00039903363],"domain_scores_gemma":[0.998264,0.0011291812,0.00011437928,0.00031110787,0.000056459718,0.00012487794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007991651,0.00018950476,0.0014609192,0.000049862327,0.00016163691,0.000029436473,0.00015950839,0.00012971023,0.00009360178],"category_scores_gemma":[0.00006356017,0.00012708006,0.00006714457,0.00010970391,0.00010302057,0.000114898154,0.000022955066,0.00019197226,0.00000521829],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96445996,0.0014093745,0.0007683363,0.00017874865,0.00008685584,0.000030076091,0.0010107667,0.0000060555285,0.012150845,0.00004951949,0.005940378,0.013909062],"study_design_scores_gemma":[0.9406351,0.038779963,0.0010862427,0.0000146080665,0.0002759296,0.000030054622,0.00018088106,0.0010127295,0.0010225173,0.000028498285,0.016744047,0.0001894162],"about_ca_topic_score_codex":0.00007818732,"about_ca_topic_score_gemma":0.00011483657,"teacher_disagreement_score":0.03737059,"about_ca_system_score_codex":0.00014840053,"about_ca_system_score_gemma":0.00032094464,"threshold_uncertainty_score":0.51821744},"labels":[],"label_agreement":null},{"id":"W2970380239","doi":"10.1016/s1470-2045(18)30858-1","title":"Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium","year":2019,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Hearing, Cochlea, Tinnitus, Genetics","field":"Neuroscience","cited_by":143,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster Children's Hospital; Hospital for Sick Children; University of British Columbia; McMaster University; BC Children's Hospital","funders":"National Cancer Institute; Cancer Research UK","keywords":"Ototoxicity; Guideline; Harmonization; Medicine; Hearing loss; Multidisciplinary approach; Tinnitus; Family medicine; Psychiatry; Audiology; Surgery; Chemotherapy; Pathology","score_opus":0.06916719563057598,"score_gpt":0.3792822199720031,"score_spread":0.3101150243414271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970380239","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04343269,0.8470222,0.0068933014,0.05227454,0.0074443673,0.0316541,0.010963749,0.0001380489,0.00017700736],"genre_scores_gemma":[0.016680323,0.97424,0.000614037,0.0030790654,0.0011859833,0.0033095286,0.0006919813,0.00008523066,0.00011383576],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99679166,0.0009240908,0.0009521438,0.0006807796,0.0002721121,0.00037921916],"domain_scores_gemma":[0.9942207,0.0029272516,0.0016266415,0.0006629677,0.00052321865,0.000039234972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012947229,0.0003523012,0.0011886338,0.00007127256,0.00022584351,0.00008007233,0.0007865544,0.00023855637,0.000011301611],"category_scores_gemma":[0.0022826104,0.0001952173,0.00011115106,0.00050170737,0.00021028031,0.000083715626,0.00018175023,0.00046651883,0.0000011799931],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013961621,0.0014180661,0.06659575,0.012613382,0.001336382,0.000032830707,0.012091311,0.001343165,0.0021816464,0.0015472431,0.09362409,0.80582],"study_design_scores_gemma":[0.0028419262,0.00023689118,0.015678348,0.0033948955,0.00042917678,0.00004627313,0.0001567697,0.0009675098,0.0003505319,0.000098744036,0.9753867,0.00041224217],"about_ca_topic_score_codex":0.0021346794,"about_ca_topic_score_gemma":0.054553486,"teacher_disagreement_score":0.8817626,"about_ca_system_score_codex":0.00032706762,"about_ca_system_score_gemma":0.0009577669,"threshold_uncertainty_score":0.96269846},"labels":[],"label_agreement":null},{"id":"W2971424022","doi":"10.1016/s1470-2045(19)30535-2","title":"Barriers to treatment for patients with breast cancer in Kenya","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Incidence (geometry); Breast cancer; Disease; Quarter (Canadian coin); Population; Health care; Cancer; Demography; Internal medicine; Environmental health; Economic growth","score_opus":0.05031095409804269,"score_gpt":0.3685023787750488,"score_spread":0.3181914246770061,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2971424022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824071,0.000053071635,0.000011969036,0.013120495,0.00016274367,0.0010366741,0.00008037054,0.000014769249,0.0031128195],"genre_scores_gemma":[0.99324757,0.000027078335,0.00034094704,0.005487004,0.00022970911,0.00022400355,0.000007280487,0.000009532081,0.0004268599],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99932826,0.000029023915,0.00009969855,0.00016095248,0.00009803341,0.00028405842],"domain_scores_gemma":[0.9995219,0.00006157759,0.00003707011,0.00020118892,0.00006523016,0.00011304946],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013164154,0.00008559944,0.000330332,0.000030823896,0.000030378513,0.0000041832327,0.000089073306,0.000045674875,0.00029725264],"category_scores_gemma":[0.000021886122,0.00004543836,0.000027864864,0.00011328719,0.000025826661,0.000028575743,0.000016565476,0.00006527317,0.000031236483],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053290124,0.000041605144,0.9694889,0.000012517696,0.000040293336,0.0000054599627,0.0005475141,0.00018602231,0.00005488065,0.000118853306,0.001657183,0.022517767],"study_design_scores_gemma":[0.008232377,0.0036071974,0.8974159,0.0000860792,0.000049587456,0.000012687067,0.00029541182,0.00006390515,0.000040671355,0.00003619512,0.09007755,0.00008246135],"about_ca_topic_score_codex":0.0005798507,"about_ca_topic_score_gemma":0.001621129,"teacher_disagreement_score":0.08842037,"about_ca_system_score_codex":0.0005624592,"about_ca_system_score_gemma":0.00029248232,"threshold_uncertainty_score":0.32547078},"labels":[],"label_agreement":null},{"id":"W2972019042","doi":"10.1016/s1470-2045(19)30336-5","title":"2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer","year":2019,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":658,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McGill University","funders":"University of North Carolina at Chapel Hill; Trakya Üniversitesi; National Institutes of Health; Universidad de Granada; Universidad de la República Uruguay; University of Southern California; Universidad de Navarra; University of Rochester; Memorial Sloan-Kettering Cancer Center; Universidad Nacional Autónoma de México; Mahidol University; Foundation for the National Institutes of Health","keywords":"Medicine; Thrombosis; Intensive care medicine; Clinical trial; Venous thrombosis; Grading (engineering); Cancer; Venous thromboembolism; Low molecular weight heparin; Clinical Practice; Family medicine; Surgery; Internal medicine","score_opus":0.23019862109672373,"score_gpt":0.5194032340421533,"score_spread":0.28920461294542954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972019042","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00089692016,0.98166037,0.000010396756,0.009066753,0.0015083271,0.005859554,0.00016794808,0.000011196734,0.0008185113],"genre_scores_gemma":[0.000083106424,0.99449,0.00097280485,0.0020159613,0.0012117809,0.0008549588,0.00008830397,0.00003583533,0.00024724792],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99816895,0.00022890297,0.0008147288,0.0003398257,0.00019917602,0.00024844718],"domain_scores_gemma":[0.9964627,0.0016915257,0.0007665681,0.0005236707,0.0005200766,0.00003546194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010873962,0.00025686368,0.0029568172,0.00007052654,0.00004362785,0.000011859647,0.00030205486,0.00021021834,0.000032876535],"category_scores_gemma":[0.00053906604,0.00010570161,0.00019622533,0.00010501145,0.00016569709,0.00003745612,0.00009829212,0.00027937096,0.0000091986085],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039320823,0.0020134067,0.00051439146,0.001876177,0.0019287687,0.0000034477214,0.00020240736,0.0000058801356,1.4090678e-8,0.00031665806,0.019006096,0.97373956],"study_design_scores_gemma":[0.003568728,0.0059470236,0.01047255,0.0017862713,0.003997479,0.0000074902046,0.000057920544,0.00000805676,5.766874e-8,0.000015866262,0.9740303,0.00010821725],"about_ca_topic_score_codex":0.00046603085,"about_ca_topic_score_gemma":0.00017336285,"teacher_disagreement_score":0.9736313,"about_ca_system_score_codex":0.00027557238,"about_ca_system_score_gemma":0.00055291085,"threshold_uncertainty_score":0.43103868},"labels":[],"label_agreement":null},{"id":"W2972165994","doi":"10.1016/s1470-2045(19)30489-9","title":"MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc)","year":2019,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; Public Health Ontario; University of Toronto","funders":"","keywords":"Mammography; Medicine; Breast cancer; Cancer; Gynecology; Obstetrics; Breast cancer screening; Mammography screening; Oncology; Internal medicine","score_opus":0.023814572005953417,"score_gpt":0.30582374074023805,"score_spread":0.2820091687342846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972165994","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17241526,0.0029311639,0.0035083683,0.80154264,0.0051348913,0.0031880199,0.0076829707,0.00007181077,0.0035248648],"genre_scores_gemma":[0.06730843,0.007119238,0.010951355,0.84455293,0.056699935,0.0076986183,0.0017569246,0.00048065043,0.003431941],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977533,0.0003050217,0.00027719288,0.0006711707,0.00018031191,0.0008129771],"domain_scores_gemma":[0.9984639,0.00022070075,0.00033801116,0.00081762735,0.00012732546,0.000032393153],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00053730747,0.00035043998,0.0006202395,0.00011606084,0.0001059945,0.000025700674,0.0007241526,0.0009226265,0.000060650164],"category_scores_gemma":[0.00003060864,0.0002561443,0.00011527297,0.00020177991,0.00027297804,0.00000399868,0.00015421855,0.001084063,0.0000091175525],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00841895,0.000024474706,0.0033946305,0.00008711178,0.00068244926,0.00001720822,0.00022856754,0.0015119155,0.00040222757,0.0000040254004,0.9682798,0.01694867],"study_design_scores_gemma":[0.005864523,0.00089122367,0.0070208064,0.00003929395,0.000121961304,0.000026980832,0.00015713133,0.000045268407,0.00014798409,0.00005154477,0.98525155,0.00038176548],"about_ca_topic_score_codex":0.00031431962,"about_ca_topic_score_gemma":0.0012952707,"teacher_disagreement_score":0.10510682,"about_ca_system_score_codex":0.00031652662,"about_ca_system_score_gemma":0.0007022583,"threshold_uncertainty_score":0.9999891},"labels":[],"label_agreement":null},{"id":"W2973153606","doi":"10.1016/s1470-2045(19)30456-5","title":"Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":1052,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Nova Scotia Health Authority; Government of New Brunswick; Canadian Partnership Against Cancer; Dr. H. Bliss Murphy Cancer Centre; Saskatchewan Cancer Agency; CancerCare Manitoba; Cancer Care Ontario; Alberta Health Services","funders":"Department of Health, Government of Western Australia; Public Health Agency; Cancer Council Victoria; Partenariat Canadien Contre Le Cancer; Cancer Society of New Zealand; Cancer Institute NSW; Kreftforeningen; Cancer Research UK; World Health Organization; Cancer Focus Northern Ireland; Northern Ireland Environment Agency; Kræftens Bekæmpelse; Scottish Government","keywords":"Medicine; Cancer; Population; Colorectal cancer; Incidence (geometry); Demography; Cancer registry; Lung cancer; Stomach cancer; Environmental health; Oncology; Internal medicine","score_opus":0.12235468485963746,"score_gpt":0.43464199303880136,"score_spread":0.3122873081791639,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2973153606","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917973,0.0010838248,0.0000025690404,0.005267325,0.00035335755,0.0012154101,0.000019741212,0.00003654444,0.00022389788],"genre_scores_gemma":[0.99803454,0.00011593119,0.00008826125,0.0012587269,0.00022930453,0.0001939968,0.00001483376,0.000015468631,0.00004896572],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978686,0.00049535977,0.00042355136,0.00036987654,0.0004067473,0.00043584098],"domain_scores_gemma":[0.99879134,0.00044319377,0.00017328917,0.00044019707,0.00008485517,0.00006711501],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022935816,0.00018029763,0.00084714824,0.00012041821,0.00005297649,0.000025773803,0.0002497996,0.0001268278,0.00013673682],"category_scores_gemma":[0.000089931105,0.00013098617,0.000029725843,0.00034654577,0.00010822205,0.00011940649,0.00011676493,0.00040900084,0.000019185842],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008594636,0.00011330666,0.9969086,0.000110386805,0.00003306116,0.000114994546,0.0006681848,0.00030040316,0.0000068736044,0.00023690624,0.000096042524,0.00055180007],"study_design_scores_gemma":[0.004206318,0.0006788995,0.9928861,0.00023874769,0.00004714908,0.000009321746,0.000508541,0.00056464627,0.000005894007,0.00021740301,0.00049051375,0.00014646752],"about_ca_topic_score_codex":0.0489264,"about_ca_topic_score_gemma":0.19634813,"teacher_disagreement_score":0.14742173,"about_ca_system_score_codex":0.00053628377,"about_ca_system_score_gemma":0.00042191462,"threshold_uncertainty_score":0.9574069},"labels":[],"label_agreement":null},{"id":"W2973514824","doi":"10.1016/s1470-2045(19)30569-8","title":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":536,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Institute for Health and Care Research; Institute of Cancer Research; Metropolitan Museum of Art; Cancer Research UK; Manchester Biomedical Research Centre; Accuray; Cilag; NIHR Bristol Biomedical Research Centre; National Health Insurance Service; Royal Marsden NHS Foundation Trust","keywords":"Medicine; Radiation therapy; Prostate cancer; Dose fractionation; Clinical endpoint; Androgen deprivation therapy; Prostate; Internal medicine; Randomized controlled trial; Oncology; Urology; Cancer","score_opus":0.06750216261748353,"score_gpt":0.43494058957700754,"score_spread":0.367438426959524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2973514824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9669291,0.0004956252,0.00013457653,0.018438052,0.0043785395,0.008619555,0.0006025026,0.00008900937,0.00031303242],"genre_scores_gemma":[0.9743706,0.010811938,0.0018244942,0.007351899,0.001938432,0.0023463464,0.000808018,0.00008573304,0.0004625276],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99791074,0.0002232209,0.00048564223,0.0006507129,0.00024309926,0.0004866121],"domain_scores_gemma":[0.9978706,0.0007437144,0.00037171153,0.0005936239,0.0002680555,0.00015225561],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071781094,0.0003455223,0.0013739035,0.00009355986,0.00020323048,0.00012507287,0.0004977347,0.00022025939,0.000707736],"category_scores_gemma":[0.000073708026,0.00024222303,0.00013011757,0.00017623263,0.00013497737,0.00039843435,0.00007497474,0.00038897953,0.000014889283],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92790985,0.0032075567,0.006815318,0.000022753055,0.0054677636,0.00005097092,0.0009416619,0.00002584528,0.04238351,0.00005037408,0.0053390646,0.007785318],"study_design_scores_gemma":[0.8816173,0.02139883,0.0053569437,0.00008425838,0.00069241284,0.000022962347,0.00006031797,0.007170938,0.005653219,0.00012620147,0.077509515,0.00030710208],"about_ca_topic_score_codex":0.001284175,"about_ca_topic_score_gemma":0.00015280933,"teacher_disagreement_score":0.07217045,"about_ca_system_score_codex":0.0016043658,"about_ca_system_score_gemma":0.00051872124,"threshold_uncertainty_score":0.9877569},"labels":[],"label_agreement":null},{"id":"W2977514272","doi":"10.1016/s1470-2045(19)30580-7","title":"A critique of the fragility index – Authors' reply","year":2019,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; NOSM University; Princess Margaret Cancer Centre; Thunder Bay Regional Health Sciences Centre","funders":"","keywords":"Fragility; Scopus; Medicine; Confidence interval; Meta-analysis; Statistical significance; Index (typography); MEDLINE; Internal medicine; Computer science; Political science","score_opus":0.39568517824955574,"score_gpt":0.47117584875158947,"score_spread":0.07549067050203373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977514272","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0036202422,0.0010326398,0.00040781495,0.9617861,0.004128768,0.0013193385,0.00087033055,0.000045175202,0.026789624],"genre_scores_gemma":[0.01411991,0.00012716382,0.00029681774,0.9695213,0.008007664,0.00018813726,0.000057167403,0.000058501268,0.007623333],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9911419,0.0029992212,0.0042501045,0.0007500565,0.00015675597,0.0007019213],"domain_scores_gemma":[0.9871281,0.0048781987,0.00514674,0.0026789291,0.00012071188,0.000047321886],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.031215057,0.00031843627,0.0028578255,0.00016519088,0.00018518475,0.000038128135,0.0018134605,0.0012762358,0.00075282063],"category_scores_gemma":[0.006792189,0.00025258897,0.00036591457,0.0002164515,0.0004065902,0.00011999604,0.00030135363,0.0027535937,0.0014580747],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019431985,0.000029134952,0.010579875,0.0006982637,0.00010503225,0.0000026299767,0.00081942,0.000023491,4.568059e-7,0.013149559,0.97452307,0.000049664843],"study_design_scores_gemma":[0.0005739496,0.00008088028,0.013693977,0.000089436304,0.000017327931,0.000016624479,0.00010008689,0.00036359995,0.0000014497778,0.039631497,0.9451886,0.00024260923],"about_ca_topic_score_codex":0.002349207,"about_ca_topic_score_gemma":0.0002608849,"teacher_disagreement_score":0.029334482,"about_ca_system_score_codex":0.0009316182,"about_ca_system_score_gemma":0.0007219042,"threshold_uncertainty_score":0.9999926},"labels":[],"label_agreement":null},{"id":"W2978525767","doi":"10.1016/s1470-2045(19)30394-8","title":"Access to radiotherapy among circumpolar Inuit populations","year":2019,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Circumpolar star; Indigenous; Referral; Radiation therapy; Geography; Population; Epidemiology; Medicine; Environmental health; Oceanography; Family medicine; Ecology; Pathology; Biology; Surgery","score_opus":0.22781396163676448,"score_gpt":0.5406879605641577,"score_spread":0.3128739989273932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978525767","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000078396304,0.9842788,0.0011770728,0.0038529981,0.0032750552,0.0032809991,0.00007199845,0.00014260781,0.0038420868],"genre_scores_gemma":[0.000017509496,0.97773546,0.0031763006,0.009586394,0.0060052685,0.0004029989,0.00009279591,0.000114993985,0.0028682593],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972173,0.0007006375,0.0006820992,0.00056529354,0.00020729644,0.00062738714],"domain_scores_gemma":[0.9970639,0.0008452765,0.0004954016,0.0013566696,0.000065922985,0.00017285274],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000781176,0.00047425047,0.0040484155,0.0002666419,0.00018493165,0.0000319944,0.001160355,0.0009185151,0.00082011556],"category_scores_gemma":[0.0001497665,0.00028171318,0.00047623453,0.0005934464,0.00034036115,0.00011318888,0.00014448789,0.0013338437,0.00032244518],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012599319,0.00011632286,0.00090022467,0.0024727716,0.00050368207,0.000068310204,0.00053939834,0.00002001688,0.0000012377288,0.0009408717,0.029447922,0.96486324],"study_design_scores_gemma":[0.001066288,0.0006538684,0.0010115922,0.0017719154,0.0009168755,0.00053038355,0.000014603618,0.000009806761,1.6142376e-7,0.0002158461,0.99350417,0.00030446463],"about_ca_topic_score_codex":0.00003245558,"about_ca_topic_score_gemma":0.00017850033,"teacher_disagreement_score":0.9645588,"about_ca_system_score_codex":0.0014773635,"about_ca_system_score_gemma":0.0011859477,"threshold_uncertainty_score":0.9999635},"labels":[],"label_agreement":null},{"id":"W2979269615","doi":"10.1016/s1470-2045(19)30583-2","title":"A critique of the fragility index","year":2019,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Fragility; Clinical trial; Oncology; Food and drug administration; Alternative medicine; Clinical Oncology; Internal medicine; Pharmacology; Cancer; Pathology","score_opus":0.6148560317831308,"score_gpt":0.6006552477939483,"score_spread":0.014200783989182453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979269615","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003977251,0.000042157277,0.008388404,0.95539504,0.0037320459,0.0011905093,0.00037929075,0.000054253935,0.030420583],"genre_scores_gemma":[0.0010377213,0.000044563043,0.08900053,0.8955948,0.011252907,0.0001092191,0.000003256689,0.00006466117,0.0028923412],"study_design_codex":"not_applicable","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9895657,0.008127145,0.001026491,0.00037444953,0.00043606592,0.00047016746],"domain_scores_gemma":[0.83799034,0.15906188,0.0007995872,0.0019747573,0.00015438825,0.00001906498],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0075797588,0.00026176666,0.0020703329,0.000027509055,0.000057887173,0.000011235771,0.0018764359,0.0016908356,0.00067763956],"category_scores_gemma":[0.10159788,0.00012780126,0.00034780678,0.00015173647,0.0008782987,0.000012825063,0.00052005635,0.004472336,0.00006628814],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008612447,0.00005137842,0.00020246409,0.000580056,0.00011241091,0.00001789564,0.00007429919,3.5145663e-7,0.000008655669,0.02566626,0.9717716,0.0014284778],"study_design_scores_gemma":[0.00044108744,0.0000797752,0.00033901224,0.000070958,0.00010735989,0.000008421639,0.000005245925,0.000011487001,0.000029991226,0.54920286,0.44961867,0.000085160886],"about_ca_topic_score_codex":0.000040659677,"about_ca_topic_score_gemma":0.000017325021,"teacher_disagreement_score":0.52353656,"about_ca_system_score_codex":0.0001264686,"about_ca_system_score_gemma":0.0003253767,"threshold_uncertainty_score":0.9996052},"labels":[],"label_agreement":null},{"id":"W2979548369","doi":"10.1016/s1470-2045(19)30493-0","title":"Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"National Cancer Institute; Novartis","keywords":"Medicine; Refractory (planetary science); Quality of life (healthcare); Young adult; Pediatrics; Oncology; Internal medicine; Biology","score_opus":0.03486376564826552,"score_gpt":0.34536738574798603,"score_spread":0.3105036200997205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979548369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949364,0.00027531333,0.0000071051595,0.00032551892,0.00019952594,0.0022890137,0.00005417752,0.000037170175,0.0018757824],"genre_scores_gemma":[0.9981363,0.00027362234,0.00014904515,0.0005904725,0.00020006375,0.00008341647,0.00005001191,0.000027627892,0.00048945844],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99738544,0.0005882599,0.0006992227,0.00042285403,0.00045749042,0.0004467332],"domain_scores_gemma":[0.9982268,0.00037502882,0.000436516,0.00067391136,0.00013143347,0.00015627971],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088572694,0.00021856422,0.0010131605,0.000095141244,0.00003358359,0.000011974808,0.00015685058,0.00026384686,0.00076371414],"category_scores_gemma":[0.00030328083,0.00013147658,0.000069722104,0.00036435423,0.00021976358,0.00007167063,0.00014025088,0.00043022234,0.000016794509],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8169523,0.003942167,0.114571415,0.00013763367,0.00031728213,0.00019497989,0.0015288381,0.0000025307381,0.047454167,0.000005431292,0.00046327012,0.014429998],"study_design_scores_gemma":[0.6494795,0.06680353,0.2782211,0.0003159372,0.00034057858,0.0005649751,0.00045600565,0.00014315784,0.0017803201,0.000043587468,0.0014670446,0.00038427318],"about_ca_topic_score_codex":0.00079138106,"about_ca_topic_score_gemma":0.0006716986,"teacher_disagreement_score":0.1674728,"about_ca_system_score_codex":0.00047114855,"about_ca_system_score_gemma":0.0007665189,"threshold_uncertainty_score":0.8362134},"labels":[],"label_agreement":null},{"id":"W2982460038","doi":"10.1016/s1470-2045(19)30653-9","title":"Sparing of swallowing-related organs in radiotherapy for oropharyngeal squamous cell carcinoma–Authors’ reply","year":2019,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Medicine; Swallowing; Radiation therapy; Dysphagia; Cancer; Quality of life (healthcare); Surgery; Internal medicine","score_opus":0.047700985395617304,"score_gpt":0.3288354211786673,"score_spread":0.28113443578305003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982460038","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20645626,0.0068053924,0.00002907262,0.7687434,0.0023555728,0.002138955,0.0000661454,0.000075088916,0.013330127],"genre_scores_gemma":[0.38373822,0.0008918338,0.0008749249,0.5951255,0.007223863,0.00021562111,0.00015656081,0.00016910532,0.011604355],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976255,0.00026604647,0.0006685631,0.0004960417,0.00022180048,0.0007220402],"domain_scores_gemma":[0.99768245,0.0010817228,0.0003426798,0.00075596647,0.00009938821,0.000037767488],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082976976,0.00034280925,0.0025706228,0.00017665238,0.000061116436,0.000005712097,0.00038378517,0.0008184735,0.00012289402],"category_scores_gemma":[0.00013242853,0.00023863587,0.00023557998,0.00022176097,0.0001667109,0.000024316772,0.00007775839,0.0018710748,0.0000199215],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010925435,0.00011157816,0.012417057,0.0015477742,0.00015672881,0.00041374273,0.003204493,0.000011872721,0.0033558696,0.000014374766,0.97667205,0.0010018969],"study_design_scores_gemma":[0.010870722,0.002972759,0.008022855,0.0001590366,0.00027976758,0.00007302604,0.00007960959,0.00014045858,0.00076958275,0.000059983675,0.976308,0.00026418376],"about_ca_topic_score_codex":0.0004467372,"about_ca_topic_score_gemma":0.00008103725,"teacher_disagreement_score":0.17728198,"about_ca_system_score_codex":0.0005609385,"about_ca_system_score_gemma":0.0005632965,"threshold_uncertainty_score":0.97312886},"labels":[],"label_agreement":null},{"id":"W2982569177","doi":"10.1016/s1470-2045(19)30404-8","title":"Core elements of national cancer control plans: a tool to support plan development and review","year":2019,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Kingston General Hospital","funders":"World Health Organization","keywords":"Checklist; Process (computing); Core (optical fiber); Plan (archaeology); Control (management); Process management; Quality (philosophy); Critical appraisal; Population; Business; Computer science; Management science; Medicine; Engineering; Geography; Psychology; Environmental health; Alternative medicine","score_opus":0.47981905966532695,"score_gpt":0.5123818453119852,"score_spread":0.03256278564665821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982569177","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007826539,0.992802,0.000010498666,0.0010767891,0.0002168208,0.0020805174,0.00037164587,0.000012878763,0.0033505685],"genre_scores_gemma":[0.000045388213,0.98443997,0.0005216574,0.013445396,0.00042088062,0.0005142767,0.00018175141,0.000016479024,0.00041420577],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99815047,0.000103923456,0.0007565137,0.00027453387,0.0004117377,0.00030282416],"domain_scores_gemma":[0.99883443,0.00021863569,0.0004590315,0.00024930158,0.00016097316,0.00007762824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013287897,0.00023129425,0.0025727337,0.00006488796,0.000037401376,0.0000045591205,0.00026545738,0.00015582239,0.00030337885],"category_scores_gemma":[0.00016557141,0.00013812861,0.00011264069,0.00015069099,0.000048596972,0.000021472539,0.00008769745,0.00029805995,0.00008385614],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013534969,0.000020760548,0.0006926319,0.028982047,0.00038255332,0.00002385593,0.00008380528,3.7762402e-7,5.9570596e-7,0.00020744873,0.07006935,0.89940125],"study_design_scores_gemma":[0.0010055879,0.00039639306,0.00023276123,0.033130977,0.00079632504,0.00020104847,0.000009822617,8.961978e-7,3.5591924e-7,0.000009054254,0.96407914,0.00013761886],"about_ca_topic_score_codex":0.00002776081,"about_ca_topic_score_gemma":0.00010558121,"teacher_disagreement_score":0.8992636,"about_ca_system_score_codex":0.0004844025,"about_ca_system_score_gemma":0.002818966,"threshold_uncertainty_score":0.5632721},"labels":[],"label_agreement":null},{"id":"W2982581267","doi":"10.1016/s1470-2045(19)30625-4","title":"Navigating prostate cancer control in Nigeria","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; Queen's University","funders":"","keywords":"Nigerians; Prostate cancer; Medicine; Cancer; Demography; Population; Gynecology; Environmental health; Internal medicine; Political science; Sociology","score_opus":0.06358863863930656,"score_gpt":0.4129022455259878,"score_spread":0.3493136068866812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982581267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96688217,0.0008398569,0.000009088302,0.022702517,0.00031174367,0.0005025519,0.000007199612,0.000032040123,0.008712842],"genre_scores_gemma":[0.985044,0.00014168822,0.00013711436,0.0138436165,0.00044107888,0.00008004252,0.0000033905606,0.000009029613,0.0003000555],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990762,0.000103485254,0.00018576917,0.00015959358,0.00012811935,0.0003468444],"domain_scores_gemma":[0.9994858,0.00011949631,0.00008285139,0.00022387832,0.00004568016,0.00004228706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006281047,0.00008244123,0.00042421266,0.000010863003,0.00003076555,0.000007625999,0.00012689715,0.000071049406,0.00029594026],"category_scores_gemma":[0.00005147502,0.00005288818,0.000035067293,0.0001378968,0.000054321583,0.00004530303,0.000029700805,0.00045487416,0.0001280839],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011180206,0.000022794891,0.9601309,0.00004118105,0.000029723436,0.000073735246,0.0018069611,0.00023921966,0.0072470997,0.00021426928,0.0019724644,0.027103674],"study_design_scores_gemma":[0.026214853,0.0020797667,0.71701735,0.0012976878,0.00010175084,0.00031722567,0.0039642137,0.0036801232,0.0009966588,0.0013091197,0.24260214,0.00041911268],"about_ca_topic_score_codex":0.00065023405,"about_ca_topic_score_gemma":0.000982521,"teacher_disagreement_score":0.24311352,"about_ca_system_score_codex":0.00021867256,"about_ca_system_score_gemma":0.00017850136,"threshold_uncertainty_score":0.32403383},"labels":[],"label_agreement":null},{"id":"W2982865643","doi":"10.1016/s1470-2045(19)30668-0","title":"Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; Roche; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Docetaxel; Medicine; Ramucirumab; Clinical endpoint; Internal medicine; Metastatic Urothelial Carcinoma; Population; Oncology; Placebo; Progression-free survival; Surgery; Clinical trial; Chemotherapy; Cancer; Urothelial carcinoma; Bladder cancer; Pathology","score_opus":0.0584573287324271,"score_gpt":0.3466840245943807,"score_spread":0.2882266958619536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982865643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98630637,0.00028254002,0.00005202714,0.0007148662,0.00063970365,0.009751482,0.00038968038,0.000045307184,0.0018179974],"genre_scores_gemma":[0.99715924,0.00007692796,0.0005325208,0.00056730176,0.0002401511,0.0007589902,0.00023290113,0.00006400637,0.00036795685],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968677,0.00053846545,0.0008101468,0.00061082613,0.00055045594,0.00062239886],"domain_scores_gemma":[0.99769646,0.0007928398,0.000457112,0.0007014297,0.00019174292,0.00016039381],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00077859976,0.00046652928,0.001868829,0.00017734556,0.00005760202,0.000023646831,0.00025082743,0.00018240522,0.0003018766],"category_scores_gemma":[0.00008394589,0.00026406508,0.00013909487,0.0003203748,0.0002552227,0.00012781448,0.000052460226,0.00042857532,0.000017929575],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9900825,0.0014618792,0.0029490944,0.00009338162,0.0005890677,0.00012732222,0.000865245,0.00026957935,0.00008768275,0.000021271273,0.00010543767,0.0033475528],"study_design_scores_gemma":[0.9626059,0.028306741,0.005913953,0.000095132964,0.00045054374,0.00000953751,0.00011653964,0.0004552579,0.00035223924,0.000015712361,0.0013899958,0.00028843287],"about_ca_topic_score_codex":0.00047000468,"about_ca_topic_score_gemma":0.00069984153,"teacher_disagreement_score":0.027476572,"about_ca_system_score_codex":0.00040006,"about_ca_system_score_gemma":0.001532333,"threshold_uncertainty_score":0.99998116},"labels":[],"label_agreement":null},{"id":"W2984712394","doi":"10.1016/s1470-2045(19)30688-6","title":"Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":352,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Spinal Cord Injury BC; Kelowna General Hospital","funders":"","keywords":"Enzalutamide; Abiraterone acetate; Prostate cancer; Medicine; Prednisone; Open label; Oncology; Internal medicine; Abiraterone; Randomized controlled trial; Crossover study; Docetaxel; Cancer; Androgen deprivation therapy; Placebo; Androgen receptor; Pathology","score_opus":0.12050590991124985,"score_gpt":0.4350927641428153,"score_spread":0.3145868542315654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2984712394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882034,0.0024086353,0.0000070600663,0.0018919099,0.00018212433,0.00656575,0.00013810176,0.000016870836,0.00058611407],"genre_scores_gemma":[0.99345267,0.002168076,0.001378401,0.00022833176,0.000109288056,0.0006488142,0.00004325965,0.000025897314,0.0019452851],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978944,0.00038720178,0.0005748714,0.00035939534,0.00025127575,0.0005328497],"domain_scores_gemma":[0.99876004,0.00039234466,0.00029077035,0.0003317654,0.00011528641,0.00010980018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012132733,0.00020579848,0.0011693926,0.000092639406,0.000077775294,0.000054000535,0.00022044378,0.00007414512,0.00013249482],"category_scores_gemma":[0.00010085403,0.00012784392,0.000039118113,0.00021520209,0.0002795868,0.00018576793,0.00014937768,0.00030871262,0.000010558882],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85709536,0.0007265379,0.0006203942,0.00035559922,0.00037271585,0.00022825583,0.0053120465,0.0006219709,0.13075444,0.00007389422,0.00015270579,0.0036860758],"study_design_scores_gemma":[0.9748497,0.0050443434,0.0005623537,0.00021947971,0.00027769827,0.000039989107,0.00103087,0.005583844,0.0110960575,0.0000716467,0.0010683456,0.00015569286],"about_ca_topic_score_codex":0.0012702949,"about_ca_topic_score_gemma":0.0007277565,"teacher_disagreement_score":0.11965838,"about_ca_system_score_codex":0.0006514315,"about_ca_system_score_gemma":0.00141965,"threshold_uncertainty_score":0.5213324},"labels":[],"label_agreement":null},{"id":"W2989816903","doi":"10.1016/s1470-2045(19)30736-3","title":"The incomplete story of complete mesocolic excision","year":2019,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Mesorectum; Total mesorectal excision; Colorectal cancer; Lymph node; Surgery; Population; Cancer; Wide local excision; General surgery; Internal medicine","score_opus":0.11227423577646004,"score_gpt":0.36813596403465226,"score_spread":0.2558617282581922,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989816903","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012828694,0.0019510903,0.000007247377,0.9373995,0.001721165,0.0019601756,0.00012403156,0.000067344154,0.043940764],"genre_scores_gemma":[0.040775005,0.0013501248,0.00021683,0.92941505,0.012461136,0.0004843673,0.00028196527,0.00012594447,0.0148896],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966765,0.0013443966,0.0004458702,0.00038256944,0.0005460485,0.00060458714],"domain_scores_gemma":[0.9923928,0.0055687763,0.00050396175,0.0013404945,0.00015000091,0.000044008088],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0011858437,0.00032606898,0.0016139766,0.0000749646,0.00022458038,0.000011774142,0.0007385866,0.0006146328,0.00026536104],"category_scores_gemma":[0.00023258138,0.00015942862,0.00032061472,0.00019270113,0.0006106948,0.00001893222,0.00032144622,0.002989046,0.00039574577],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012103175,0.000043169526,0.0005186123,0.00016791394,0.00038727943,0.0002579096,0.000168317,0.0000015138334,0.000112858455,0.000094193645,0.9882699,0.008767993],"study_design_scores_gemma":[0.0028189754,0.0014805056,0.010671793,0.00011790088,0.00025794975,0.00016769562,0.000023417035,0.000029247743,0.000015536083,0.00044922315,0.9838252,0.0001425424],"about_ca_topic_score_codex":0.00009216192,"about_ca_topic_score_gemma":0.000057467492,"teacher_disagreement_score":0.029051164,"about_ca_system_score_codex":0.00072456355,"about_ca_system_score_gemma":0.0004364225,"threshold_uncertainty_score":0.9993111},"labels":[],"label_agreement":null},{"id":"W2989894179","doi":"10.1016/s1470-2045(19)30684-9","title":"Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":644,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Prostate Cancer UK; Public Health Agency; Division of Research, Evaluation, and Communication; Prostate Cancer Foundation; Movember Foundation; AstraZeneca; Medical Research Council; Institute of Cancer Research; Cancer Research UK; Royal Marsden NHS Foundation Trust; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; U.S. Department of Veterans Affairs","keywords":"Olaparib; Medicine; Prostate cancer; Open label; Oncology; Internal medicine; Urology; Cancer; Randomized controlled trial; Gene; Biology; Poly ADP ribose polymerase; Genetics","score_opus":0.06985848620486315,"score_gpt":0.3983035503391584,"score_spread":0.3284450641342952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989894179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98577255,0.0003149389,0.000005262122,0.0022625683,0.00014296887,0.010059017,0.00009013608,0.00004278644,0.0013097492],"genre_scores_gemma":[0.9915929,0.00013533571,0.0019578305,0.0005485338,0.00015101947,0.0022675411,0.00033710498,0.000037107773,0.0029726448],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99797,0.00035653292,0.00041013522,0.00039715457,0.00034868415,0.0005175379],"domain_scores_gemma":[0.998748,0.00020268434,0.00022081839,0.0004906395,0.00021199527,0.00012585628],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065050466,0.00022007033,0.0008185846,0.00009072928,0.00014391918,0.000047822094,0.00021126062,0.000058173395,0.00022457528],"category_scores_gemma":[0.0000498832,0.000110979185,0.0000323108,0.0003338486,0.00015791031,0.00017606796,0.0000611533,0.00031449733,0.000033027827],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9596585,0.005033165,0.0270315,0.00011363914,0.0007090644,0.00014430795,0.0026242207,0.00008611616,0.0013989221,0.000045459612,0.00112815,0.0020269298],"study_design_scores_gemma":[0.964244,0.0114346,0.015192544,0.00014105094,0.00037022217,0.000008330198,0.0002920953,0.00044641033,0.00075902836,0.000015368965,0.0069114133,0.00018494885],"about_ca_topic_score_codex":0.00032808215,"about_ca_topic_score_gemma":0.0029954626,"teacher_disagreement_score":0.011838956,"about_ca_system_score_codex":0.0004377957,"about_ca_system_score_gemma":0.001497502,"threshold_uncertainty_score":0.45255998},"labels":[],"label_agreement":null},{"id":"W2990013460","doi":"10.1016/s1470-2045(19)30744-2","title":"Multiplicity in oncology randomised controlled trials: a threat to medical evidence?","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Health and Medical Research Impacts","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Laura and John Arnold Foundation","keywords":"Observational study; Medicine; Randomized controlled trial; Clinical trial; Alternative medicine; Confounding; Evidence-based medicine; MEDLINE; Grading (engineering); Family medicine; Internal medicine; Pathology","score_opus":0.4347278422398513,"score_gpt":0.5693328463959209,"score_spread":0.13460500415606957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990013460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5095883,0.0008889782,0.000118138414,0.46362203,0.00055349607,0.006721906,0.0000030606136,0.00004805194,0.01845606],"genre_scores_gemma":[0.84231704,0.0026307064,0.00044669127,0.15071267,0.0018365654,0.00092470914,0.0000050502954,0.00001918725,0.0011073584],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99003875,0.0056890105,0.0012855754,0.00037808853,0.0010616303,0.0015469196],"domain_scores_gemma":[0.82758534,0.15448001,0.00076518673,0.0019243439,0.00053430756,0.014710783],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["metaresearch","insufficient_payload"],"category_scores_codex":[0.06345762,0.00019284055,0.004391685,0.00020240233,0.000052405623,0.000009351532,0.0004406176,0.0005323228,0.0039685206],"category_scores_gemma":[0.5861981,0.00009276405,0.00026362672,0.00036751787,0.00020600103,0.000048057333,0.00014488856,0.0013742343,0.0009250793],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5291411,0.0010766835,0.009019871,0.000341251,0.00030276965,0.0010893455,0.0027628508,0.000008773492,0.00419098,0.00052503333,0.11561264,0.33592865],"study_design_scores_gemma":[0.59455514,0.008596823,0.010417998,0.00089934445,0.0001593598,0.0002627905,0.00045357933,0.002438603,0.00018033844,0.00037712045,0.38147408,0.00018482498],"about_ca_topic_score_codex":0.00048153911,"about_ca_topic_score_gemma":0.0007327715,"teacher_disagreement_score":0.5227405,"about_ca_system_score_codex":0.0009796245,"about_ca_system_score_gemma":0.0154043,"threshold_uncertainty_score":0.99985284},"labels":[],"label_agreement":null},{"id":"W2990422537","doi":"10.1016/s1470-2045(19)30656-4","title":"Prognostic value of patient-reported outcomes from international randomised clinical trials on cancer: a systematic review","year":2019,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":129,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Rigour; Medicine; Systematic review; Clinical trial; Quality of life (healthcare); MEDLINE; Intensive care medicine; Internal medicine","score_opus":0.32166189865803924,"score_gpt":0.5304250247647438,"score_spread":0.2087631261067046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990422537","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009789407,0.9778135,0.0000043193454,0.0017656676,0.005859895,0.012339301,0.00033692128,0.000040989282,0.0017415063],"genre_scores_gemma":[0.0001164795,0.99143624,0.00002066375,0.0039864653,0.0011239838,0.0025943446,0.00034348475,0.000047014357,0.00033134685],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.98627925,0.0077707595,0.0046410244,0.00047953776,0.0005661931,0.0002632334],"domain_scores_gemma":[0.9727443,0.020351894,0.0053523197,0.0012184009,0.00023488195,0.00009822296],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.009070413,0.00042672746,0.018288298,0.000099190234,0.000022891645,0.000009356961,0.0005775789,0.00045222385,0.00041302465],"category_scores_gemma":[0.018632742,0.00020203274,0.0023556212,0.00018911576,0.00011083317,0.00001689643,0.00010786372,0.00081735814,0.00007779832],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001955462,0.0002571096,0.00036287066,0.74826884,0.0075128037,0.000057942194,0.0001287413,3.9458357e-7,6.150263e-8,0.000083925544,0.00606202,0.23530982],"study_design_scores_gemma":[0.008704474,0.00039787902,0.00003579781,0.47489116,0.03249994,0.00003403562,0.000021122212,0.0000038025764,1.1189315e-7,0.000014250387,0.48324466,0.0001527626],"about_ca_topic_score_codex":0.0003135688,"about_ca_topic_score_gemma":0.00009319606,"teacher_disagreement_score":0.47718266,"about_ca_system_score_codex":0.00035209832,"about_ca_system_score_gemma":0.0014392077,"threshold_uncertainty_score":0.9962862},"labels":[],"label_agreement":null},{"id":"W2990762362","doi":"10.1016/s1470-2045(19)30750-8","title":"2019 international clinical practice guidelines for the treatment of venous thromboembolism – Authors' reply","year":2019,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McMaster University","funders":"","keywords":"Medicine; Venous thromboembolism; Thrombosis; Intensive care medicine; Clinical Practice; Venous thrombosis; Cancer; Low molecular weight heparin; Fondaparinux; Internal medicine; Family medicine","score_opus":0.21854719688498989,"score_gpt":0.497356358120722,"score_spread":0.2788091612357321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990762362","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000281502,0.00332642,0.00024762136,0.9705174,0.011436434,0.00318901,0.00019285844,0.00005515449,0.01075361],"genre_scores_gemma":[0.00009162149,0.03199391,0.0060339,0.90514463,0.04558864,0.0004739174,0.00043566045,0.00007790384,0.010159795],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99674374,0.00042093708,0.0012545418,0.0005636533,0.0004971755,0.00051995803],"domain_scores_gemma":[0.9901313,0.0058189854,0.0011757473,0.0015877854,0.0012449471,0.000041194937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026194279,0.0003665161,0.0024667783,0.000086434244,0.00012102595,0.000029747753,0.0008198748,0.0006788849,0.00020170116],"category_scores_gemma":[0.0025894674,0.00018471295,0.00062181696,0.00008963829,0.0002867026,0.000050078772,0.0001467164,0.0008887097,0.00016799242],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046039032,0.0014595857,0.000037845326,0.0001237259,0.0033832332,0.00009696215,0.00048169802,0.000019600802,0.000005423499,0.0005999328,0.9509652,0.042366378],"study_design_scores_gemma":[0.003369174,0.0056238933,0.0020428372,0.00010003608,0.0036315832,0.000115563875,0.00018747927,0.00016163854,0.000008336657,0.00030703365,0.9842786,0.00017378517],"about_ca_topic_score_codex":0.00047727104,"about_ca_topic_score_gemma":0.000024131337,"teacher_disagreement_score":0.06537274,"about_ca_system_score_codex":0.00032210827,"about_ca_system_score_gemma":0.00052030757,"threshold_uncertainty_score":0.75323755},"labels":[],"label_agreement":null},{"id":"W2990772450","doi":"10.1016/s1470-2045(19)30673-4","title":"Sebaceous carcinoma: evidence-based clinical practice guidelines","year":2019,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":205,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"National Cancer Institute","keywords":"Medicine; Radiation therapy; Sebaceous carcinoma; Carcinoma; Biopsy; Lymph node; Eyelid; Physical examination; Dermatology; Medical diagnosis; Surgery; Radiology; Pathology","score_opus":0.6629900588417426,"score_gpt":0.6042140844306624,"score_spread":0.05877597441108018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990772450","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000062555378,0.9379038,0.00003178184,0.03797335,0.0034443312,0.002192619,0.000030692612,0.00009096863,0.018326161],"genre_scores_gemma":[0.000010268076,0.95882076,0.007795892,0.019405166,0.011407506,0.00035430916,0.000038477654,0.00009983888,0.002067755],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9939605,0.0021181076,0.0019027592,0.0008370495,0.0004892702,0.00069231546],"domain_scores_gemma":[0.97739625,0.01809475,0.001482184,0.0020245588,0.0008595945,0.00014268064],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0053024055,0.0005986126,0.0064734872,0.000113768045,0.00014092939,0.000023435283,0.00083813764,0.0008161619,0.00015517985],"category_scores_gemma":[0.019376324,0.00033305166,0.0009473999,0.00036865874,0.00045379958,0.000082092425,0.0003955704,0.0018300193,0.0015249526],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041415554,0.00012297681,0.00035572526,0.012270506,0.00060620654,0.00050974934,0.000024883897,7.965536e-7,3.5512773e-8,0.000072206894,0.25691983,0.7287029],"study_design_scores_gemma":[0.0015806933,0.0014372324,0.00022664866,0.01345196,0.0077814334,0.0015408341,0.000040594183,0.000008883146,1.6538496e-7,0.000009430462,0.97361016,0.00031196856],"about_ca_topic_score_codex":0.000076246644,"about_ca_topic_score_gemma":0.000043685635,"teacher_disagreement_score":0.72839093,"about_ca_system_score_codex":0.0008054783,"about_ca_system_score_gemma":0.005235213,"threshold_uncertainty_score":0.99991214},"labels":[],"label_agreement":null},{"id":"W2990849834","doi":"10.1016/s1470-2045(19)30693-x","title":"Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1–2 study","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":169,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"School of Medicine, Stanford University; Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino; Penn State Health Children's Hospital; F. Hoffmann-La Roche; Pfizer","keywords":"Atezolizumab; Medicine; Adverse effect; Internal medicine; Clinical trial; Population; Phases of clinical research; Lymphoma; Clinical endpoint; Incidence (geometry); Surgery; Pediatrics; Cancer; Immunotherapy","score_opus":0.012094129770249843,"score_gpt":0.3121682710117557,"score_spread":0.3000741412415059,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990849834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913092,0.0017683783,0.00001518118,0.0010142388,0.0001492747,0.005283452,0.00008381966,0.000080577665,0.00029585525],"genre_scores_gemma":[0.9970819,0.000856804,0.0003428829,0.0006125431,0.00031626143,0.00021808136,0.000082620965,0.000051340834,0.0004375599],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99820906,0.00017125277,0.00035266698,0.0005177851,0.00017474029,0.00057447446],"domain_scores_gemma":[0.9988739,0.00018658378,0.00024086452,0.00048652283,0.00008789783,0.0001242209],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052901974,0.00032200164,0.0009540382,0.00008796677,0.0001548098,0.000038704697,0.00018213589,0.00014226294,0.00003515971],"category_scores_gemma":[0.000028689523,0.0001950806,0.00007683644,0.00017684637,0.000204977,0.00007809277,0.000066726716,0.00009827774,0.000008579088],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22053054,0.003517711,0.45514652,0.0002809037,0.0017774167,0.0001469765,0.01501442,0.000002080047,0.003104107,0.000015099704,0.002942428,0.2975218],"study_design_scores_gemma":[0.22912332,0.02011545,0.7423343,0.00025018616,0.0007912181,0.0014543178,0.00218711,0.0006786172,0.00074210064,0.000010072048,0.0019625511,0.00035077537],"about_ca_topic_score_codex":0.0011906413,"about_ca_topic_score_gemma":0.0010071481,"teacher_disagreement_score":0.29717103,"about_ca_system_score_codex":0.00023544554,"about_ca_system_score_gemma":0.00022399182,"threshold_uncertainty_score":0.7955156},"labels":[],"label_agreement":null},{"id":"W2992921938","doi":"10.1016/s1470-2045(19)30671-0","title":"Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":343,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Merck Sharp and Dohme; Merck","keywords":"Medicine; Pembrolizumab; Tolerability; Interim analysis; Refractory (planetary science); Internal medicine; Oncology; Cohort; Response Evaluation Criteria in Solid Tumors; Adverse effect; Clinical trial; Phases of clinical research; Cancer; Surgery; Immunotherapy","score_opus":0.0939061329066039,"score_gpt":0.4336228266562593,"score_spread":0.3397166937496554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2992921938","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922919,0.00036444786,0.000016719054,0.001137271,0.00045036594,0.0023915202,0.00014931402,0.00004297522,0.0031554692],"genre_scores_gemma":[0.9946181,0.0008820528,0.0014475577,0.0019732397,0.00029295858,0.00014786732,0.000119891105,0.000047438887,0.0004708617],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965416,0.0008691705,0.0008501738,0.0006416919,0.0004062817,0.0006910567],"domain_scores_gemma":[0.9959361,0.0020744924,0.00087169773,0.0006613256,0.00024309875,0.00021329404],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00084889116,0.00037553877,0.002165463,0.0002952968,0.00012182656,0.000032325046,0.0006754303,0.00019265777,0.0009381586],"category_scores_gemma":[0.0008800973,0.00019142478,0.000086569824,0.0015508557,0.00021019284,0.0005337049,0.0003982117,0.0004869296,0.00002764383],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8556673,0.014930422,0.0014714666,0.00009460417,0.0012182838,0.00034257612,0.00090590736,0.000043623364,0.0022352254,0.000017221588,0.00015627897,0.12291711],"study_design_scores_gemma":[0.7120536,0.21800539,0.02014119,0.00020836722,0.004270619,0.00009021759,0.0015583384,0.0015756435,0.00090226583,0.000023071083,0.040581793,0.0005895277],"about_ca_topic_score_codex":0.00012796554,"about_ca_topic_score_gemma":0.0012306437,"teacher_disagreement_score":0.20307498,"about_ca_system_score_codex":0.0005348611,"about_ca_system_score_gemma":0.00052166224,"threshold_uncertainty_score":0.99997514},"labels":[],"label_agreement":null},{"id":"W2995934717","doi":"10.1016/s1470-2045(19)30788-0","title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":796,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"UCLH Biomedical Research Centre; National Institute for Health and Care Research; Seattle Genetics; GlaxoSmithKline; U.S. Department of Veterans Affairs","keywords":"Medicine; Internal medicine; Refractory (planetary science); Population; Multiple myeloma; Discontinuation; Toxicity; Phases of clinical research; Gastroenterology; Oncology; Surgery","score_opus":0.13348396835885917,"score_gpt":0.452415809330682,"score_spread":0.3189318409718228,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2995934717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9739405,0.00021224761,0.0000599618,0.0030332715,0.00044117865,0.014781623,0.00014120099,0.00011386939,0.0072761723],"genre_scores_gemma":[0.98233926,0.00012009984,0.0025472913,0.0013065193,0.0006666297,0.0020880757,0.00019551253,0.00007420656,0.010662379],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9967175,0.0007683425,0.0005537908,0.0006408391,0.00038194508,0.0009375958],"domain_scores_gemma":[0.9951255,0.0029768925,0.000262796,0.0011596489,0.0001828193,0.00029236518],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020201295,0.0003414265,0.0014971438,0.0001237246,0.00026102524,0.000059110902,0.0007875013,0.00016301348,0.0010452389],"category_scores_gemma":[0.0010886728,0.00019011334,0.00011135524,0.00024328,0.00013800137,0.00013805705,0.00036059742,0.0005302013,0.0006059409],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.757389,0.027109876,0.039715745,0.00021782493,0.0020562322,0.0013086526,0.0017324876,0.000004224663,0.014622511,0.00016127198,0.019302985,0.13637915],"study_design_scores_gemma":[0.8422973,0.037394945,0.0085075665,0.000074395684,0.00041335294,0.00025021945,0.0009601491,0.0017731392,0.0008759734,0.000087758635,0.10708819,0.00027699806],"about_ca_topic_score_codex":0.000351167,"about_ca_topic_score_gemma":0.00062061724,"teacher_disagreement_score":0.13610215,"about_ca_system_score_codex":0.0003725667,"about_ca_system_score_gemma":0.0006026983,"threshold_uncertainty_score":0.9998679},"labels":[],"label_agreement":null},{"id":"W2999399991","doi":"10.1016/s1470-2045(19)30738-7","title":"Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":615,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital; University Health Network","funders":"EIT Health; European Research Council; Walter Ahlströmin Säätiö; KAUTE-Säätiö; Syöpäjärjestöt; Forskningsrådet om Hälsa, Arbetsliv och Välfärd; Vetenskapsrådet; Emil Aaltosen Säätiö; Orionin Tutkimussäätiö; Tekniikan Edistämissäätiö; Tampereen Yliopisto; Tampereen Teknillinen Yliopisto; Cancerfonden; Academy of Finland","keywords":"Medicine; Grading (engineering); Prostate cancer; Concordance; Prostate; Receiver operating characteristic; Population; Biopsy; Radiology; Pathology; Cancer; Internal medicine","score_opus":0.1147713191908764,"score_gpt":0.39265864242285775,"score_spread":0.27788732323198134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999399991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9658963,0.0013422627,0.00004674978,0.03023032,0.00009348912,0.0022538535,0.000105148974,0.000017909022,0.000013946787],"genre_scores_gemma":[0.9943708,0.0013495989,0.00021627462,0.0012903678,0.00019986476,0.0025442697,0.000014168567,0.0000129908,0.0000016570893],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99907076,0.000080036625,0.0003253183,0.0002288294,0.000087228145,0.00020784805],"domain_scores_gemma":[0.9980346,0.0016075373,0.00012084778,0.0001296507,0.000043195276,0.00006416063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026900956,0.00011003422,0.0004985154,0.000046843834,0.000045606314,0.000007668035,0.00007021044,0.000039359333,0.000026140517],"category_scores_gemma":[0.00047846668,0.00007441713,0.000037394206,0.00018324643,0.000066258224,0.00002578529,0.000029412122,0.00009950147,0.0000011748248],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006996834,0.00060219225,0.9182379,0.00017775895,0.000060876348,0.000025069574,0.0033106063,0.0006128372,0.000024288918,0.00022407885,0.000113201924,0.075911485],"study_design_scores_gemma":[0.0029655057,0.007171433,0.97329885,0.0003180482,0.00040062712,0.000003384488,0.0025367877,0.004118512,0.005717499,0.0019352459,0.0013524207,0.00018168475],"about_ca_topic_score_codex":0.0007125074,"about_ca_topic_score_gemma":0.0014051734,"teacher_disagreement_score":0.0757298,"about_ca_system_score_codex":0.00014113532,"about_ca_system_score_gemma":0.00011193779,"threshold_uncertainty_score":0.30346423},"labels":[],"label_agreement":null},{"id":"W3003402209","doi":"10.1016/s1470-2045(19)30790-9","title":"International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium","year":2020,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":306,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada; University of British Columbia","funders":"Health Canada; Genentech; National Cancer Institute; National Institutes of Health; European Organisation for Research and Treatment of Cancer; U.S. Food and Drug Administration; National Institute for Health and Care Research; Boehringer Ingelheim","keywords":"Terminology; Medicine; Quality of life (healthcare); Missing data; Alternative medicine; Randomized controlled trial; Quality (philosophy); MEDLINE; Clinical trial; Management science; Medical physics; Family medicine; Medical education; Computer science; Nursing; Political science; Pathology; Engineering","score_opus":0.7358815487013696,"score_gpt":0.6023151836046768,"score_spread":0.13356636509669273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3003402209","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008548805,0.89188904,0.0007680976,0.083933316,0.0017133594,0.00758289,0.01239029,0.000009172578,0.0008589608],"genre_scores_gemma":[0.0070507918,0.98636436,0.00027573653,0.0033640529,0.00029823856,0.0024711,0.000099497345,0.000027594424,0.000048643804],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.97743,0.005976577,0.015766194,0.00040091516,0.00018693288,0.00023936655],"domain_scores_gemma":[0.9240876,0.04980104,0.025113141,0.0006761864,0.00026524934,0.000056826735],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.07561361,0.0002539502,0.01366475,0.00041699788,0.000094927804,0.00001866284,0.0007073983,0.00024086826,0.0003159477],"category_scores_gemma":[0.06772136,0.00014824633,0.001535692,0.0005451518,0.00027358445,0.00006087136,0.0001079316,0.00031913375,0.0000019721701],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019204415,0.0010759922,0.049602635,0.0258137,0.115112506,0.0000011547172,0.014436623,0.000942913,0.0000021362464,0.110747166,0.038251683,0.6248091],"study_design_scores_gemma":[0.02431912,0.000060014605,0.0013673096,0.00042391877,0.0024347943,7.0545826e-7,0.0006568968,0.0010027584,2.9576933e-7,0.00065873325,0.96891284,0.00016262966],"about_ca_topic_score_codex":0.00078664394,"about_ca_topic_score_gemma":0.0010204505,"teacher_disagreement_score":0.93066114,"about_ca_system_score_codex":0.00059621234,"about_ca_system_score_gemma":0.001350531,"threshold_uncertainty_score":0.9518503},"labels":[],"label_agreement":null},{"id":"W3004211670","doi":"10.1016/s1470-2045(19)30859-9","title":"Targeting MET in EGFR resistance in non-small-cell lung cancer—ready for daily practice?","year":2020,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca Schweiz; Takeda Pharmaceutical Company; Roche; Merck Sharp and Dohme; Bristol-Myers Squibb","keywords":"Afatinib; Osimertinib; Medicine; Gefitinib; Erlotinib; Lung cancer; T790M; Cancer research; Tyrosine kinase; Oncology; Resistance mutation; Internal medicine; Cancer; Epidermal growth factor receptor; Biology; Receptor; Genetics","score_opus":0.046250517288371484,"score_gpt":0.4013117916393306,"score_spread":0.35506127435095913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004211670","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010054996,0.0068016984,0.00014614334,0.95857203,0.0007507233,0.002713398,0.00028721394,0.000047538964,0.029675731],"genre_scores_gemma":[0.004842239,0.002380749,0.014058216,0.95798504,0.008576565,0.0033786495,0.0012465745,0.00012157572,0.007410371],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99779737,0.00029101476,0.0005196907,0.00053987984,0.0001895134,0.00066251645],"domain_scores_gemma":[0.99765253,0.001300362,0.00044732267,0.00041414896,0.00013035489,0.000055295095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005140225,0.00031277112,0.0011607053,0.00012854736,0.00008636248,0.000022061324,0.00031373106,0.00045700645,0.000054169555],"category_scores_gemma":[0.0003228958,0.0002281967,0.00009287258,0.00030062246,0.00007345362,0.0000680057,0.0000651785,0.0016887109,0.000016968557],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009185551,0.0001307678,0.0017497276,0.0012282977,0.00027986304,0.0015322162,0.003318891,0.000043606662,0.00016725814,0.000081374965,0.98999494,0.00055448967],"study_design_scores_gemma":[0.0071231825,0.00033323295,0.0004919089,0.00034642866,0.000978975,0.000013385694,0.00043008354,0.0001811488,0.000028066193,0.0001869386,0.9896671,0.00021950714],"about_ca_topic_score_codex":0.001199476,"about_ca_topic_score_gemma":0.0024169586,"teacher_disagreement_score":0.02226536,"about_ca_system_score_codex":0.0016332068,"about_ca_system_score_gemma":0.0012330482,"threshold_uncertainty_score":0.93055916},"labels":[],"label_agreement":null},{"id":"W3004892473","doi":"10.1016/s1470-2045(20)30076-0","title":"Advancing the systemic therapy of lung cancer: quality or quantity?","year":2020,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"Pfizer Canada; Merck Sharp and Dohme; Bristol-Myers Squibb Canada; Roche; AstraZeneca","keywords":"Pembrolizumab; Pemetrexed; Medicine; Lung cancer; Oncology; Internal medicine; Chemotherapy; Placebo; Cancer; Immunotherapy; Pathology; Alternative medicine","score_opus":0.09466019374412431,"score_gpt":0.41580427094612077,"score_spread":0.32114407720199645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004892473","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014809137,0.024327967,0.000047999896,0.9563418,0.001650068,0.001411439,0.00014346148,0.00008981041,0.0011782965],"genre_scores_gemma":[0.026217181,0.04184763,0.000075222764,0.9192675,0.010941452,0.0002556554,0.00006373437,0.000068539295,0.0012630987],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99679047,0.0011114891,0.0007714516,0.00037884596,0.00041662456,0.0005311394],"domain_scores_gemma":[0.9966812,0.0012979783,0.0008518781,0.0009955876,0.00013470728,0.000038626476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013818016,0.00033115406,0.0017039843,0.000053982887,0.00015195982,0.000015699712,0.00076608924,0.0005159074,0.0005182573],"category_scores_gemma":[0.0001376516,0.00014766409,0.0003451658,0.00033438695,0.00046462708,0.000032787706,0.000085720094,0.001928024,0.000010343305],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009858187,0.000033765133,0.0018720299,0.0013171673,0.0011494855,0.0001717737,0.0011570109,0.000002090844,0.00479543,0.00003503279,0.96976644,0.00984161],"study_design_scores_gemma":[0.0038572026,0.00070034544,0.0013504109,0.00055347505,0.00022977116,0.00024284092,0.00022420289,0.00003395635,0.00036292087,0.00003276614,0.99221265,0.0001994297],"about_ca_topic_score_codex":0.002125384,"about_ca_topic_score_gemma":0.0005074615,"teacher_disagreement_score":0.037074335,"about_ca_system_score_codex":0.00051666144,"about_ca_system_score_gemma":0.0012874703,"threshold_uncertainty_score":0.8376412},"labels":[],"label_agreement":null},{"id":"W3005292744","doi":"10.1016/s1470-2045(19)30801-0","title":"Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":213,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Hôpital Charles-Le Moyne","funders":"Merck Sharp and Dohme; Eli Lilly and Company","keywords":"Pemetrexed; Medicine; Pembrolizumab; Lung cancer; Carboplatin; Internal medicine; Placebo; Response Evaluation Criteria in Solid Tumors; Oncology; Cancer; Surgery; Progressive disease; Chemotherapy; Cisplatin; Pathology; Immunotherapy","score_opus":0.040831192833675936,"score_gpt":0.33795517121566354,"score_spread":0.2971239783819876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005292744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9753358,0.00087474915,0.00013636502,0.0016275138,0.0005272906,0.020693235,0.00005214998,0.00009363948,0.0006592541],"genre_scores_gemma":[0.9939695,0.0002043958,0.00047733376,0.0021038305,0.00023653141,0.002493558,0.000108056505,0.00009262889,0.00031415583],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9957497,0.0005034042,0.0014418389,0.0007830829,0.0005537744,0.00096818944],"domain_scores_gemma":[0.9964872,0.0015032109,0.0009949688,0.00054201944,0.00015405161,0.00031855475],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00091464736,0.00067310315,0.003037033,0.0002180132,0.00020078338,0.00006977404,0.00028015423,0.0002383213,0.0002485855],"category_scores_gemma":[0.0003629086,0.0003788592,0.00037275854,0.00059162034,0.00016034838,0.00014478242,0.00011035964,0.00063940964,0.000005925468],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9518723,0.0012865447,0.030622093,0.0002725505,0.0026906526,0.000528646,0.006779513,0.00020582389,0.00023473556,5.33099e-7,0.00047167932,0.00503493],"study_design_scores_gemma":[0.9795827,0.0077885306,0.002004673,0.00017956903,0.0034069002,0.00001999954,0.0008284522,0.004893707,0.0002526384,8.017948e-7,0.00057406054,0.00046793494],"about_ca_topic_score_codex":0.0012686144,"about_ca_topic_score_gemma":0.0017903722,"teacher_disagreement_score":0.028617421,"about_ca_system_score_codex":0.00061857584,"about_ca_system_score_gemma":0.001172344,"threshold_uncertainty_score":0.9998663},"labels":[],"label_agreement":null},{"id":"W3005639301","doi":"10.1016/s1470-2045(19)30800-9","title":"Late mortality and chronic health conditions in long-term survivors of early-adolescent and young adult cancers: a retrospective cohort analysis from the Childhood Cancer Survivor Study","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":373,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; University of Toronto; Hospital for Sick Children","funders":"National Cancer Institute; National Institutes of Health; American Lebanese Syrian Associated Charities","keywords":"Medicine; Hazard ratio; Cancer; Pediatrics; Young adult; Retrospective cohort study; Common Terminology Criteria for Adverse Events; Proportional hazards model; Survivorship curve; Cohort; Population; Cohort study; Gerontology; Internal medicine; Confidence interval","score_opus":0.04938348953489941,"score_gpt":0.37836495008373433,"score_spread":0.3289814605488349,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005639301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9669443,0.0032938996,0.000029886052,0.026699906,0.00021452653,0.0019697498,0.0007260236,0.00004649647,0.00007523298],"genre_scores_gemma":[0.99005836,0.003685223,0.0000132463165,0.0052222493,0.00075342413,0.00015739638,0.000076300086,0.00002537534,0.000008424494],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99641365,0.0012778172,0.000742949,0.0006533463,0.00045664463,0.00045562384],"domain_scores_gemma":[0.9981228,0.0003623422,0.00051815377,0.00063769304,0.00014699489,0.00021201381],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015204296,0.00027379984,0.0017895891,0.000079327416,0.00017350086,0.000023912165,0.00027884686,0.00010900943,0.00008365609],"category_scores_gemma":[0.00018320384,0.00018802907,0.00012147998,0.0008658302,0.00047640986,0.00007154375,0.00018266433,0.0007211816,0.0000016815502],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034593683,0.00033340132,0.9654138,0.00011536759,0.0024665385,0.000017082984,0.030728687,0.00004370709,0.000019885314,0.00004678589,0.00017802346,0.00029079523],"study_design_scores_gemma":[0.0042391047,0.0011891723,0.9905032,0.00016308356,0.0013363604,0.000003815807,0.0021369397,0.00017405674,0.000012369823,0.000060827148,0.000014183448,0.00016691661],"about_ca_topic_score_codex":0.330706,"about_ca_topic_score_gemma":0.7986814,"teacher_disagreement_score":0.4679754,"about_ca_system_score_codex":0.00090840226,"about_ca_system_score_gemma":0.00086497766,"threshold_uncertainty_score":0.7667603},"labels":[],"label_agreement":null},{"id":"W3006303699","doi":"10.1016/s1470-2045(19)30818-6","title":"Predicting acute ovarian failure in female survivors of childhood cancer: a cohort study in the Childhood Cancer Survivor Study (CCSS) and the St Jude Lifetime Cohort (SJLIFE)","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Alberta","funders":"Canadian Institutes of Health Research; National Institutes of Health; National Cancer Institute; Novo Nordisk; American Lebanese Syrian Associated Charities","keywords":"Childhood cancer; Cohort; Medicine; Ovarian cancer; Cohort study; Oncology; Cancer; Internal medicine","score_opus":0.031038659193574215,"score_gpt":0.3388556691149781,"score_spread":0.3078170099214039,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006303699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9050862,0.0012310328,0.000006042252,0.08174793,0.00042377427,0.010416799,0.00023156093,0.00010428641,0.0007523596],"genre_scores_gemma":[0.98487616,0.0010401305,0.00004757793,0.010136013,0.0018314186,0.001922724,0.000028907629,0.00008691281,0.000030158486],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98963404,0.0052411514,0.0016897672,0.0011455178,0.0012994278,0.0009900884],"domain_scores_gemma":[0.9951039,0.0022737484,0.00080881733,0.0014197687,0.00016636841,0.00022742768],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.010662138,0.0006268656,0.0029467084,0.0001700817,0.00032079124,0.00006788082,0.0014368248,0.00025607971,0.00014385051],"category_scores_gemma":[0.00093097927,0.0003598831,0.00019715949,0.0014969823,0.00066052447,0.0001471717,0.00058325153,0.002058148,0.0000075042444],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018546256,0.0022896419,0.8396844,0.000101610596,0.001665144,0.00009331781,0.15292913,0.00013363855,0.000013036538,0.00007111387,0.0006477382,0.000516559],"study_design_scores_gemma":[0.020686984,0.0020030334,0.92700845,0.00019121394,0.001177445,0.000055918947,0.0474443,0.0002175244,0.0000106822445,0.000049984013,0.000826703,0.00032774813],"about_ca_topic_score_codex":0.0783569,"about_ca_topic_score_gemma":0.37415385,"teacher_disagreement_score":0.29579696,"about_ca_system_score_codex":0.0002827398,"about_ca_system_score_gemma":0.0009862093,"threshold_uncertainty_score":0.9998853},"labels":[],"label_agreement":null},{"id":"W3009369214","doi":"10.1016/s1470-2045(19)30855-1","title":"Definitive radiotherapy with image-guided adaptive brachytherapy for primary vaginal cancer","year":2020,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Merck Sharp and Dohme; European SocieTy for Radiotherapy and Oncology; Takeda Pharmaceutical Company; Roche","keywords":"Brachytherapy; Medicine; Cervical cancer; Radiation therapy; External beam radiotherapy; Radiology; Cancer; Vaginal cancer; Cervix; Internal medicine","score_opus":0.15849496485545733,"score_gpt":0.43546477191865146,"score_spread":0.27696980706319413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009369214","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000055111977,0.9802597,0.00081093784,0.006562865,0.00034042116,0.003777359,0.00052096474,0.00009505006,0.007627146],"genre_scores_gemma":[0.0000036711804,0.97432107,0.008343561,0.008862386,0.004257313,0.0033269117,0.00023877129,0.0001236512,0.0005226407],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99765277,0.00041205718,0.00049561716,0.0006031161,0.0002685269,0.00056792394],"domain_scores_gemma":[0.9973607,0.0013460997,0.00050833856,0.0004234152,0.00017991987,0.0001815343],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003260782,0.0005655485,0.0044582346,0.000103388404,0.000119630015,0.00002009413,0.0003459304,0.00031513668,0.00031571896],"category_scores_gemma":[0.000054696757,0.00028047344,0.0005137762,0.0005566532,0.00029318515,0.000046002853,0.00004326849,0.0007101656,0.000035349487],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006446847,0.00017939653,0.000013817174,0.004100081,0.0031567465,0.00018501493,0.00016905266,2.885432e-7,0.0000031729883,0.00048583912,0.006341657,0.9789181],"study_design_scores_gemma":[0.012012527,0.0060193934,0.000065019834,0.0022239587,0.003517151,0.00040421888,0.000020219124,0.0000028530712,0.0000036078295,0.00017644993,0.9752551,0.000299544],"about_ca_topic_score_codex":0.00010189107,"about_ca_topic_score_gemma":0.00003922015,"teacher_disagreement_score":0.97861856,"about_ca_system_score_codex":0.0014794077,"about_ca_system_score_gemma":0.002251888,"threshold_uncertainty_score":0.9999647},"labels":[],"label_agreement":null},{"id":"W3009777504","doi":"10.1016/s1470-2045(20)30092-9","title":"Statistical significance and clinical evidence – Authors' reply","year":2020,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Observational study; Medicine; Confounding; Bonferroni correction; Clinical trial; Randomized controlled trial; Publication bias; Alternative medicine; Medical physics; Family medicine; Meta-analysis; Internal medicine; Statistics; Pathology","score_opus":0.8081831323988989,"score_gpt":0.6434700718790197,"score_spread":0.16471306051987922,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009777504","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000029305822,0.00020472678,0.08240694,0.9103821,0.0030271746,0.0010976491,0.00044474498,0.00023106558,0.002176282],"genre_scores_gemma":[0.00003926976,0.00068846205,0.44243127,0.535697,0.0203881,0.0000917971,0.00000744462,0.000070313865,0.000586352],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.97845197,0.016075168,0.0024757038,0.0013732457,0.0007040291,0.0009198725],"domain_scores_gemma":[0.6407304,0.3569089,0.0008750665,0.0011574704,0.00012535091,0.00020281553],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.014154453,0.00052073674,0.0035642171,0.000040637293,0.00016815116,0.00008946879,0.0014262146,0.0015525691,0.000688881],"category_scores_gemma":[0.40939498,0.0003432887,0.00025037734,0.00020094837,0.0024227314,0.000046505094,0.0006518733,0.008254902,0.0002810246],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041945712,0.000051064355,0.00014303211,0.00048781844,0.00020729765,0.001357533,0.00006462126,4.00234e-8,0.0000035224923,0.025245564,0.95535666,0.016663373],"study_design_scores_gemma":[0.00052242243,0.00068335526,0.00020805736,0.00014382796,0.00043792994,0.00003672298,0.0000074180043,0.00007587728,0.0000017303495,0.48720786,0.5104384,0.00023640298],"about_ca_topic_score_codex":0.000025329786,"about_ca_topic_score_gemma":0.00000804082,"teacher_disagreement_score":0.46196228,"about_ca_system_score_codex":0.00014579942,"about_ca_system_score_gemma":0.00050465594,"threshold_uncertainty_score":0.9999019},"labels":[],"label_agreement":null},{"id":"W3009834583","doi":"10.1016/s1470-2045(20)30077-2","title":"Anti-PD-1 shows promise against advanced paediatric Hodgkin lymphoma","year":2020,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Pembrolizumab; Medicine; Refractory (planetary science); Interim; Lymphoma; Clinical trial; Internal medicine; Oncology; Interim analysis; Cancer; Immunotherapy","score_opus":0.03841565935122185,"score_gpt":0.30755215407944975,"score_spread":0.26913649472822787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009834583","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012295121,0.005119967,0.000014561473,0.9604991,0.0020363424,0.0015663622,0.00016711921,0.00028913858,0.018012268],"genre_scores_gemma":[0.007402726,0.005722951,0.0005485036,0.9595336,0.022710748,0.0002531097,0.0005287001,0.00012484295,0.0031748316],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99701023,0.00045814973,0.00059539056,0.00067077344,0.00041457696,0.00085086445],"domain_scores_gemma":[0.9979372,0.00040715755,0.0004785314,0.0009871705,0.00008783874,0.000102105885],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004617094,0.00051593455,0.0017976146,0.00014297166,0.00015311208,0.000031414504,0.00070416374,0.0009574151,0.00039168017],"category_scores_gemma":[0.00013121923,0.00034110347,0.00043495628,0.00046278498,0.00036360562,0.000048132377,0.00015483281,0.0016657157,0.00024009252],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003184556,0.00007280194,0.00017541072,0.00036698283,0.00041136405,0.0021742368,0.00031574373,0.0000011134135,0.0027938108,0.0000032052462,0.8774946,0.113006175],"study_design_scores_gemma":[0.009940499,0.0010226824,0.0012936151,0.000110175446,0.00035068943,0.0002667469,0.000059235394,0.000028880826,0.00030337585,0.00006653758,0.986167,0.0003905352],"about_ca_topic_score_codex":0.000028252054,"about_ca_topic_score_gemma":0.0000138753985,"teacher_disagreement_score":0.11261564,"about_ca_system_score_codex":0.0006308115,"about_ca_system_score_gemma":0.0009908362,"threshold_uncertainty_score":0.9999041},"labels":[],"label_agreement":null},{"id":"W3011900353","doi":"10.1016/s1470-2045(20)30085-1","title":"Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":52,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; McMaster University","funders":"National Health and Medical Research Council; European Organisation for Research and Treatment of Cancer; Canadian Cancer Society; KWF Kankerbestrijding; Breast Cancer Now; Susan G. Komen for the Cure","keywords":"Ductal carcinoma; Medicine; Radiation therapy; Randomized controlled trial; Quality of life (healthcare); Oncology; Adjuvant therapy; Breast cancer; In situ; Internal medicine; Cancer; Nursing","score_opus":0.03920554261291111,"score_gpt":0.32529996260174476,"score_spread":0.28609441998883367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011900353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988134,0.0042004553,0.000114275965,0.0047992878,0.00015034204,0.0019598498,0.0005051653,0.0000070101246,0.00012960614],"genre_scores_gemma":[0.99500346,0.0019204029,0.00040521086,0.0009958181,0.0010642881,0.0005421779,0.00003998206,0.00002166093,0.000006973012],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9979488,0.0006140188,0.0006698674,0.00037556555,0.000105827574,0.0002859232],"domain_scores_gemma":[0.9984753,0.0005241812,0.00049892516,0.0003328828,0.00009479626,0.00007392331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010038737,0.00021972,0.0013214247,0.000028146866,0.00004700179,0.0000062933505,0.00020400406,0.00015436497,0.00000927435],"category_scores_gemma":[0.00040522477,0.00014831501,0.00022439139,0.00006757548,0.00026127076,0.0000043288082,0.00007268789,0.00011709661,5.879557e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9177703,0.00040319155,0.008365124,0.00005100067,0.0006538897,0.00000420386,0.0014207454,0.000010281838,0.065462075,0.000008619181,0.0004598482,0.0053906622],"study_design_scores_gemma":[0.9568727,0.0033582535,0.031019606,0.000015539823,0.000092504524,0.0000097506045,0.00034248506,0.00010274219,0.007124593,0.00004190652,0.00084614084,0.00017377778],"about_ca_topic_score_codex":0.00029299856,"about_ca_topic_score_gemma":0.00035991624,"teacher_disagreement_score":0.058337484,"about_ca_system_score_codex":0.00003056334,"about_ca_system_score_gemma":0.00022508179,"threshold_uncertainty_score":0.6048111},"labels":[],"label_agreement":null},{"id":"W3013503990","doi":"10.1016/s1470-2045(20)30022-x","title":"Sustainable care for children with cancer: a Lancet Oncology Commission","year":2020,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":346,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Waterloo; University of Toronto; Hospital for Sick Children","funders":"National Institute for Health and Care Research; CHILDREN with CANCER UK; World Health Organization","keywords":"Psychological intervention; Referral; Medicine; Productivity; Global health; Health care; Scale (ratio); Cancer; Environmental health; Economic growth; Family medicine; Economics; Geography; Nursing","score_opus":0.09321128440859124,"score_gpt":0.43797778461338216,"score_spread":0.34476650020479094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3013503990","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003156836,0.94904035,0.00006162292,0.034839433,0.0004732693,0.0063468763,0.00056009507,0.00027016262,0.008376647],"genre_scores_gemma":[0.000042469324,0.9770251,0.0014294625,0.0065658963,0.009695752,0.002316352,0.0009266349,0.00019058821,0.0018077627],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99519265,0.0012325644,0.00094614946,0.0009350828,0.0004207602,0.0012727961],"domain_scores_gemma":[0.9956662,0.0012373225,0.0010548905,0.0013053477,0.00035796815,0.00037824188],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013103109,0.00077455724,0.007941049,0.0001430112,0.00037685304,0.000037836133,0.0010956398,0.000885752,0.0001575452],"category_scores_gemma":[0.00039697357,0.00046434387,0.000588815,0.0005574531,0.00037874703,0.000057966707,0.00038695175,0.0018712948,0.00005093603],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016080018,0.00018361094,0.00023435462,0.04126737,0.0015498053,0.00017876162,0.004070067,0.000002262881,2.115239e-7,0.001336897,0.16804506,0.7815236],"study_design_scores_gemma":[0.006136135,0.0039157365,0.00014953046,0.005765855,0.004025994,0.0006446426,0.0018050898,0.0000021916117,0.0000013548439,0.000080312464,0.9769598,0.00051335944],"about_ca_topic_score_codex":0.0015738383,"about_ca_topic_score_gemma":0.0018317583,"teacher_disagreement_score":0.8089147,"about_ca_system_score_codex":0.0025421293,"about_ca_system_score_gemma":0.0076585915,"threshold_uncertainty_score":0.99978083},"labels":[],"label_agreement":null},{"id":"W3013709580","doi":"10.1016/s1470-2045(20)30094-2","title":"Childhood cancer care: closing equity gaps on the ground","year":2020,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Scopus; Commission; Psychological intervention; Cancer; Family medicine; Health care; Population; Equity (law); MEDLINE; Nursing; Political science; Environmental health; Internal medicine; Law","score_opus":0.11966734661634615,"score_gpt":0.3994078636176031,"score_spread":0.27974051700125696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3013709580","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006140869,0.004344674,0.000007939588,0.94527704,0.0030356904,0.001467236,0.0002784111,0.00026030588,0.03918786],"genre_scores_gemma":[0.022040475,0.0011904142,0.00008586469,0.90808284,0.067221686,0.00027548216,0.00028406817,0.00014468502,0.0006745077],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99464655,0.001576732,0.0006954868,0.0008796035,0.0010968791,0.0011047755],"domain_scores_gemma":[0.9951258,0.0021810276,0.00062230293,0.0017764986,0.00014952413,0.00014488025],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0011111845,0.0006557957,0.00201426,0.00007970296,0.00046851253,0.00008537966,0.0014123095,0.00093044346,0.0007012368],"category_scores_gemma":[0.0005408604,0.0003783043,0.00043793494,0.00034238066,0.0006029335,0.000044014803,0.0006141392,0.0072591063,0.00038678074],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003190992,0.000071716226,0.00013544201,0.00059729244,0.000539534,0.0004248949,0.0083772335,0.0000026186785,0.000029248153,0.00047628683,0.98365563,0.005370984],"study_design_scores_gemma":[0.0020291405,0.0008900676,0.002615943,0.0006177341,0.000675336,0.00013982064,0.0006671622,0.0000036267743,0.00008909321,0.0014910654,0.99036604,0.0004149638],"about_ca_topic_score_codex":0.00158597,"about_ca_topic_score_gemma":0.0008324055,"teacher_disagreement_score":0.06418599,"about_ca_system_score_codex":0.0013219805,"about_ca_system_score_gemma":0.0015292865,"threshold_uncertainty_score":0.9998669},"labels":[],"label_agreement":null},{"id":"W3020482066","doi":"10.1016/s1470-2045(20)30112-1","title":"Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":261,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Eisai; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Trastuzumab; Fulvestrant; Internal medicine; Breast cancer; Oncology; Metastatic breast cancer; Cancer; Chemotherapy; Tamoxifen","score_opus":0.053427430914663586,"score_gpt":0.3829554564653619,"score_spread":0.3295280255506983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3020482066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9714132,0.0021060328,0.0011998727,0.014284483,0.00019085883,0.008647365,0.001182818,0.000142461,0.00083290704],"genre_scores_gemma":[0.9861772,0.0015566782,0.005922321,0.002477188,0.0008035535,0.0027006485,0.00008627267,0.00018778129,0.000088363406],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9957322,0.000600987,0.00082479435,0.0009859314,0.0007050584,0.0011510216],"domain_scores_gemma":[0.99727976,0.0006044228,0.00066100684,0.00061296887,0.00041300655,0.00042881985],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005428988,0.00074749405,0.0035109275,0.00011486896,0.00018095165,0.000046911315,0.0006968445,0.00024058255,0.00047478132],"category_scores_gemma":[0.000053845684,0.00044619758,0.00008638174,0.0009333872,0.0010338059,0.00034336827,0.0001165535,0.0010092055,0.000006258132],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8245567,0.00088629534,0.000033229513,0.00017025373,0.0011425564,0.00029071106,0.032222293,0.00035667288,0.006510944,0.000026758738,0.00007793835,0.13372564],"study_design_scores_gemma":[0.8765252,0.09846667,0.0005172402,0.0006340889,0.00034766452,0.00029773766,0.0147869345,0.00018796329,0.0025512544,0.000015410971,0.005072714,0.0005970846],"about_ca_topic_score_codex":0.00020723027,"about_ca_topic_score_gemma":0.0006096729,"teacher_disagreement_score":0.13312855,"about_ca_system_score_codex":0.0039141374,"about_ca_system_score_gemma":0.0041316296,"threshold_uncertainty_score":0.99990964},"labels":[],"label_agreement":null},{"id":"W3023738757","doi":"10.1016/s1470-2045(20)30061-9","title":"Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":127,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University Health Network; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Manchester Biomedical Research Centre; Clovis Oncology; Memorial Sloan-Kettering Cancer Center; Stand Up To Cancer; Entertainment Industry Foundation; V Foundation for Cancer Research; University College London; American Association for Cancer Research","keywords":"Placebo; Medicine; Oncology; Internal medicine; Ovarian carcinoma; Ovarian cancer; Cancer; Alternative medicine; Pathology","score_opus":0.04068493652222073,"score_gpt":0.3485534876066515,"score_spread":0.3078685510844308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3023738757","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94540614,0.00010878446,0.0005585403,0.041160095,0.00063332537,0.008467938,0.002356452,0.00010456289,0.0012041817],"genre_scores_gemma":[0.9856491,0.00003978945,0.0028330376,0.007347767,0.0013187564,0.00060266705,0.0021193908,0.000039153212,0.000050311715],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974719,0.00055622566,0.00075833144,0.00052342645,0.00029038146,0.00039971858],"domain_scores_gemma":[0.996346,0.0022034233,0.0005613186,0.0003727097,0.00029573232,0.0002208462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073929963,0.0003036253,0.0015885502,0.000050279465,0.00021128813,0.00002629036,0.0001391361,0.00020091514,0.000085294596],"category_scores_gemma":[0.0009917811,0.00017183399,0.00014654784,0.0001365496,0.0002268333,0.00006914426,0.000055085507,0.00039827405,0.000008376133],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97918904,0.0005097961,0.0011851772,0.00001852905,0.00044625596,0.000028740187,0.002092366,0.00000379825,0.00042758114,0.00009376711,0.005989914,0.010015048],"study_design_scores_gemma":[0.95955133,0.011966951,0.0040475284,0.00006977442,0.00045286672,0.000008262092,0.00018693307,0.0010036641,0.0003624383,0.00007632558,0.02206791,0.00020599349],"about_ca_topic_score_codex":0.000055997276,"about_ca_topic_score_gemma":0.00003535869,"teacher_disagreement_score":0.040243007,"about_ca_system_score_codex":0.00016091218,"about_ca_system_score_gemma":0.00030455008,"threshold_uncertainty_score":0.7007187},"labels":[],"label_agreement":null},{"id":"W3033009715","doi":"10.1016/s1470-2045(20)30166-2","title":"Response assessment in diffuse intrinsic pontine glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group","year":2020,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Glioma; Clinical trial; Oncology; Internal medicine; Medical physics","score_opus":0.0919955913500505,"score_gpt":0.412632248934347,"score_spread":0.3206366575842965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033009715","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.053918287,0.7320413,0.000018103243,0.20675558,0.0016724565,0.0046517514,0.00018249477,0.00013124158,0.00062875263],"genre_scores_gemma":[0.023908574,0.9654161,0.0014611098,0.0040757135,0.0018006495,0.0028099546,0.00038414096,0.00012392359,0.000019843648],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.97876036,0.016804758,0.0018719936,0.0011227287,0.00046287436,0.0009772539],"domain_scores_gemma":[0.96813434,0.029014146,0.0011300064,0.0014357978,0.00006600406,0.00021967705],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0072554145,0.00081117696,0.0044038715,0.00078662066,0.00021870052,0.000076891374,0.0009987421,0.0007039532,0.00016990435],"category_scores_gemma":[0.0016871439,0.0004793282,0.0005242779,0.0023975158,0.00018090279,0.000065658416,0.0007364503,0.0034016066,0.000081560844],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009615944,0.006811098,0.013893647,0.00062318053,0.0007363995,0.011580706,0.0012020923,0.0000035478497,0.00008427547,0.0008642724,0.016705204,0.9378796],"study_design_scores_gemma":[0.010809679,0.0020345931,0.08831618,0.0013426198,0.0017622615,0.0003082101,0.00023461258,0.000022547938,5.832285e-7,0.00010166283,0.8947282,0.00033885255],"about_ca_topic_score_codex":0.00024476516,"about_ca_topic_score_gemma":0.0014229184,"teacher_disagreement_score":0.93754077,"about_ca_system_score_codex":0.0037253904,"about_ca_system_score_gemma":0.0030756195,"threshold_uncertainty_score":0.9997658},"labels":[],"label_agreement":null},{"id":"W3033099933","doi":"10.1016/s1470-2045(20)30081-4","title":"Quality of life in patients with cervical cancer after open versus minimally invasive radical hysterectomy (LACC): a secondary outcome of a multicentre, randomised, open-label, phase 3, non-inferiority trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; National Institutes of Health; Medtronic; Gateway Foundation; Roche; AstraZeneca; University of Texas MD Anderson Cancer Center; V Foundation for Cancer Research","keywords":"Medicine; Cervical cancer; Clinical endpoint; Quality of life (healthcare); Hysterectomy; Population; Surgery; Randomized controlled trial; Radical Hysterectomy; Cancer; Internal medicine","score_opus":0.1497248583454132,"score_gpt":0.4317359927658011,"score_spread":0.28201113442038794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033099933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98751205,0.0001942955,0.0000046012706,0.004094928,0.00031877874,0.0056342874,0.0003021006,0.000010732876,0.0019282225],"genre_scores_gemma":[0.9944087,0.00004976142,0.0006374075,0.0037749987,0.00033413447,0.0007025791,0.00005201297,0.000022041037,0.000018317529],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968512,0.0007986946,0.0011477269,0.00042917597,0.00039124396,0.00038193588],"domain_scores_gemma":[0.9968965,0.001610344,0.0005942465,0.00039589123,0.00018416118,0.00031885193],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007949508,0.0002560481,0.0026059516,0.00005999655,0.000034323748,0.00002112526,0.0007321396,0.00017724179,0.0010448052],"category_scores_gemma":[0.0013370735,0.00015252426,0.00010859853,0.0004620222,0.00025802667,0.00014515752,0.00058383145,0.00045625004,0.000009895493],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7413967,0.003906628,0.24921013,0.000332234,0.00048387298,0.000030074088,0.00068819075,6.331888e-7,0.000097994714,0.000009931517,0.00011591111,0.0037276843],"study_design_scores_gemma":[0.75187564,0.012609472,0.23417515,0.00008121071,0.0002836459,3.7453032e-7,0.000095613206,0.000012198987,0.00014250382,0.000008250684,0.0005837156,0.00013226196],"about_ca_topic_score_codex":0.0025140282,"about_ca_topic_score_gemma":0.003429501,"teacher_disagreement_score":0.01503499,"about_ca_system_score_codex":0.00026708847,"about_ca_system_score_gemma":0.0012120468,"threshold_uncertainty_score":0.9998684},"labels":[],"label_agreement":null},{"id":"W3033224838","doi":"10.1016/s1470-2045(20)30283-7","title":"Knowing your tumour?","year":2020,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Pancreatic cancer; Medicine; Oncology; Internal medicine; Precision medicine; Profiling (computer programming); Overall survival; Clinical trial; Cancer; Pathology","score_opus":0.1608465594569304,"score_gpt":0.41732075858220313,"score_spread":0.2564741991252727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033224838","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015424613,0.00068302714,0.00005381991,0.8436099,0.00048382877,0.0006657842,0.000024297258,0.00013381166,0.15280306],"genre_scores_gemma":[0.0017702131,0.00061032677,0.0010603328,0.9417324,0.034165923,0.0001474443,0.0001933998,0.00006805284,0.020251874],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971358,0.0007141533,0.00039767943,0.00044418738,0.00043022595,0.000877936],"domain_scores_gemma":[0.99778646,0.0010983741,0.0001872121,0.0006834904,0.00010972903,0.0001347452],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00070811715,0.0003037226,0.0020514205,0.00009593719,0.00016992046,0.000018462013,0.0006051603,0.00095671497,0.0010339293],"category_scores_gemma":[0.0005571475,0.00018627034,0.00021631349,0.00020626074,0.00045882424,0.000022469478,0.00024988403,0.0054103155,0.0019837646],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030709174,0.00003606303,0.0019079914,0.00029768306,0.00037855475,0.0073568337,0.00036762786,1.2865621e-7,0.00020151386,0.000079469035,0.9866645,0.0024025901],"study_design_scores_gemma":[0.0020995943,0.0010204616,0.0016824441,0.00009880748,0.0007051978,0.000905374,0.000074373726,0.00012294143,0.000019967683,0.00075099303,0.9923472,0.00017263557],"about_ca_topic_score_codex":0.000060176124,"about_ca_topic_score_gemma":0.0000077762,"teacher_disagreement_score":0.1325512,"about_ca_system_score_codex":0.00039084762,"about_ca_system_score_gemma":0.0012344174,"threshold_uncertainty_score":0.99987924},"labels":[],"label_agreement":null},{"id":"W3033356285","doi":"10.1016/s1470-2045(20)30275-8","title":"Developing anti-CD19 antibody-based combinations in lymphoma","year":2020,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Blinatumomab; Antibody-drug conjugate; Medicine; Lymphoma; Refractory (planetary science); Antibody; CD19; Cancer research; Internal medicine; Oncology; Immunology; Monoclonal antibody; Biology","score_opus":0.11330106448099528,"score_gpt":0.40981677696904834,"score_spread":0.2965157124880531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033356285","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013636792,0.00016788387,0.00018559526,0.9726844,0.00049458834,0.00093155797,0.000032306085,0.000121031866,0.011745889],"genre_scores_gemma":[0.0125614265,0.00037256145,0.0009904272,0.9767824,0.004932344,0.00012310206,0.0009626621,0.000095198164,0.0031798931],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971949,0.00070999586,0.000417534,0.00045437974,0.00046896032,0.000754257],"domain_scores_gemma":[0.9979109,0.0010336837,0.00016404415,0.00069466204,0.00013338341,0.000063298714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006564673,0.0002914146,0.0013088761,0.00030211077,0.000104681596,0.000029129622,0.0006225569,0.00068779907,0.0008688622],"category_scores_gemma":[0.0002386491,0.00021925615,0.00014882289,0.0006524679,0.00031987566,0.000025146219,0.00015122724,0.0021465952,0.0002968087],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035616488,0.0001722533,0.0024405168,0.0005532551,0.00017711041,0.0055142315,0.00031630346,0.000005945725,0.007180984,0.00046083247,0.9751101,0.007712282],"study_design_scores_gemma":[0.0069701835,0.000385109,0.0054678395,0.00018984058,0.000059475795,0.0001504383,0.000027916585,0.00035163245,0.0005052798,0.0006278304,0.98503864,0.00022582298],"about_ca_topic_score_codex":0.00013863515,"about_ca_topic_score_gemma":0.00005891745,"teacher_disagreement_score":0.0099285105,"about_ca_system_score_codex":0.0010713523,"about_ca_system_score_gemma":0.0022550288,"threshold_uncertainty_score":0.9513432},"labels":[],"label_agreement":null},{"id":"W3033591069","doi":"10.1016/s1470-2045(20)30064-4","title":"Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group","year":2020,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":234,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Expert opinion; Clinical trial; Oncology; Glioma; MEDLINE; Intensive care medicine; Medical physics; Pediatrics; Internal medicine","score_opus":0.09717844553045905,"score_gpt":0.41825016120089087,"score_spread":0.3210717156704318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033591069","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.023054304,0.8166029,0.000018089746,0.1532497,0.0017927638,0.0044657937,0.00020493065,0.00012086807,0.000490667],"genre_scores_gemma":[0.019896898,0.9686599,0.0014871744,0.0036825123,0.0024564224,0.0032858544,0.0003889943,0.00012944384,0.000012797895],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.97472835,0.020428943,0.0019680946,0.0012229979,0.0005521373,0.001099473],"domain_scores_gemma":[0.96062684,0.036452744,0.001210446,0.0014026297,0.000059330094,0.0002480195],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.008453383,0.0008653427,0.0043936395,0.00095906627,0.00024859374,0.00007773496,0.0011134307,0.0008540648,0.00018389798],"category_scores_gemma":[0.0014725133,0.000520358,0.00065333606,0.003357148,0.00017437547,0.00006969601,0.00067559927,0.003806261,0.00010609146],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007950631,0.0068391617,0.024926959,0.0013847309,0.0009416307,0.015579094,0.0017397383,0.000024141533,0.00008130463,0.00086154725,0.033792876,0.9058782],"study_design_scores_gemma":[0.0071482216,0.0016971694,0.06506184,0.0011450228,0.0021675818,0.00026565214,0.00029234332,0.000054533462,5.958404e-7,0.00013623122,0.92163795,0.0003928333],"about_ca_topic_score_codex":0.00019239547,"about_ca_topic_score_gemma":0.00084819255,"teacher_disagreement_score":0.90548533,"about_ca_system_score_codex":0.0043426454,"about_ca_system_score_gemma":0.004263751,"threshold_uncertainty_score":0.9997248},"labels":[],"label_agreement":null},{"id":"W3034965161","doi":"10.1016/s1470-2045(20)30314-4","title":"COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":624,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Foundation Medicine; Merck Sharp and Dohme; Bristol-Myers Squibb Canada; Grifols; PharmaMar; Otsuka Pharmaceutical; Eisai; Institut National de la Santé et de la Recherche Médicale; G1 Therapeutics; Clovis Oncology; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; Takeda Pharmaceutical Company; AbbVie; Samsung; Bristol-Myers Squibb; European Respiratory Society; Merck; Spectrum Pharmaceuticals; Bayer; Gilead Sciences; Celgene; Novartis; Exelixis; Sanofi; Roche Italia; GlaxoSmithKline; Pfizer; Incyte; Stanford University; Amgen; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Lung cancer; Internal medicine; Cohort; Cancer registry; Pneumonia; Odds ratio; Population; Cancer; Comorbidity; Stage (stratigraphy)","score_opus":0.10391562650031756,"score_gpt":0.43023762820529216,"score_spread":0.3263220017049746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034965161","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9073302,0.000016082733,0.0000397369,0.09044709,0.0000970739,0.0011814431,0.00010451434,0.000045675304,0.00073816726],"genre_scores_gemma":[0.9708415,0.000018455634,0.00024646378,0.028442703,0.00025126824,0.00004435197,0.00010836097,0.00001370379,0.000033157186],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99844855,0.00025701,0.00038847167,0.00030471367,0.00034990234,0.000251348],"domain_scores_gemma":[0.9983909,0.00037473848,0.0002561442,0.00052927656,0.00015921322,0.00028972243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086076465,0.00012908396,0.00055478985,0.000079417514,0.000058615697,0.000009550766,0.00032074066,0.000082149585,0.00005418886],"category_scores_gemma":[0.0020327596,0.00008263246,0.000028150882,0.00025598207,0.00013186278,0.000062667226,0.000056908404,0.00027373366,0.0000072878006],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017938733,0.00078269927,0.9736521,0.00021557907,0.00004963371,0.00013412969,0.003713284,0.00023541908,0.000010956225,0.000024608615,0.0025114454,0.0007314156],"study_design_scores_gemma":[0.01089469,0.006355452,0.9327612,0.00006133563,0.000049525126,0.000004969786,0.00043648764,0.00019337275,0.000027132832,0.000014744568,0.049119633,0.00008144381],"about_ca_topic_score_codex":0.0017906665,"about_ca_topic_score_gemma":0.004250956,"teacher_disagreement_score":0.06351132,"about_ca_system_score_codex":0.00048639323,"about_ca_system_score_gemma":0.001370052,"threshold_uncertainty_score":0.3369654},"labels":[],"label_agreement":null},{"id":"W3035153803","doi":"10.1016/s1470-2045(20)30334-x","title":"Recommendations for head and neck surgical oncology practice in a setting of acute severe resource constraint during the COVID-19 pandemic: an international consensus","year":2020,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Rehabilitation Institute; University of Toronto; University Health Network; Institute for Work & Health; Western University","funders":"National Cancer Institute; Tata Memorial Centre; European Organisation for Research and Treatment of Cancer; National Cancer Centre of Singapore; National Institute for Health and Care Research; National Cancer Research Institute; American College of Radiology Imaging Network","keywords":"Medicine; Pandemic; Context (archaeology); Head and neck cancer; Delphi method; Surgical oncology; Health care; Coronavirus disease 2019 (COVID-19); Intensive care medicine; Radiation therapy; Oncology; Internal medicine; Disease; Infectious disease (medical specialty); Political science","score_opus":0.304603782948215,"score_gpt":0.5523475790488261,"score_spread":0.24774379610061115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035153803","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012518611,0.34286627,0.00003330529,0.64665717,0.0003992453,0.0038055652,0.0010752087,0.0000871183,0.0038242165],"genre_scores_gemma":[0.00088226795,0.97627294,0.0017357442,0.01943873,0.0010596402,0.00022552346,0.00028743173,0.00003289623,0.00006482261],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99610853,0.0019810207,0.0009253227,0.00041190194,0.00016008943,0.0004131293],"domain_scores_gemma":[0.98159456,0.016715491,0.0009040074,0.00037393582,0.00012812075,0.00028386145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030721899,0.00025489702,0.0020388928,0.00013452793,0.00017444635,0.000016295922,0.00032868786,0.00045553452,0.000050867442],"category_scores_gemma":[0.0043403558,0.00015589657,0.00016424543,0.00023516171,0.00034597653,0.000042698728,0.0001951289,0.0013365215,0.0000027520555],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003006997,0.00018594053,0.00078719965,0.006235174,0.0006908706,0.00059449323,0.005841348,0.000004099896,0.0000020039533,0.0008678619,0.0041718115,0.9776122],"study_design_scores_gemma":[0.0043982076,0.00093425,0.0001599816,0.001035606,0.00079123315,0.021024056,0.0011540552,0.00004010661,6.6540785e-8,0.00009767109,0.97023183,0.00013295349],"about_ca_topic_score_codex":0.00028791235,"about_ca_topic_score_gemma":0.0007798888,"teacher_disagreement_score":0.9774792,"about_ca_system_score_codex":0.0013903797,"about_ca_system_score_gemma":0.0047311014,"threshold_uncertainty_score":0.8392771},"labels":[],"label_agreement":null},{"id":"W3037235771","doi":"10.1016/s1470-2045(20)30340-5","title":"New approaches to cancer care in a COVID-19 world","year":2020,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Dalhousie University; St. Michael's Hospital; University of Manitoba; Vancouver General Hospital; CancerCare Manitoba; McMaster University; Canadian Partnership Against Cancer","funders":"Partenariat Canadien Contre Le Cancer; Cancer Research UK; Dalhousie University; McMaster University; Royal Marsden NHS Foundation Trust; Rigshospitalet","keywords":"Scopus; Cancer; Medicine; Health care; Coronavirus disease 2019 (COVID-19); Global health; Pandemic; Population; World population; Lung cancer; Family medicine; Collateral damage; Political science; MEDLINE; Public health; Environmental health; Psychology; Disease; Oncology; Nursing; Pathology; Internal medicine","score_opus":0.45795988683759603,"score_gpt":0.4721732708355843,"score_spread":0.014213383997988271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037235771","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019629336,0.004085982,0.00008682139,0.98687935,0.00070535974,0.0016031425,0.00009467816,0.00013425345,0.0062141465],"genre_scores_gemma":[0.002914417,0.0004801357,0.0006309064,0.965711,0.025656657,0.00028161798,0.00018078349,0.000066104956,0.0040783873],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973915,0.00041450927,0.00040082066,0.00059187267,0.00032780596,0.0008734461],"domain_scores_gemma":[0.997667,0.000798949,0.00016411084,0.00070822786,0.00003125635,0.00063043693],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00030702847,0.00034918264,0.0015514826,0.00032183452,0.00008026679,0.00002374681,0.0005005163,0.000606547,0.000623208],"category_scores_gemma":[0.00054222037,0.00024393895,0.0001300166,0.00070763525,0.0000814742,0.000025321197,0.00018744903,0.003392785,0.00017969472],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010540931,0.000012639014,0.002429046,0.0019916645,0.000061121886,0.0020061736,0.008929772,0.000027151185,0.0000036429715,0.00008166534,0.9571679,0.026235098],"study_design_scores_gemma":[0.0025660188,0.0006091975,0.0018490481,0.00029747983,0.00013339169,0.000051725983,0.0002455126,0.0000075181656,0.0000048476777,0.00040461973,0.9935964,0.00023424701],"about_ca_topic_score_codex":0.013766966,"about_ca_topic_score_gemma":0.064588495,"teacher_disagreement_score":0.05082153,"about_ca_system_score_codex":0.0037270791,"about_ca_system_score_gemma":0.0116394535,"threshold_uncertainty_score":0.99890643},"labels":[],"label_agreement":null},{"id":"W3037987551","doi":"10.1016/s1470-2045(20)30335-1","title":"Moving gastrointestinal stromal tumours towards truly personalised precision therapy","year":2020,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Novartis Pharmaceuticals Canada","keywords":"PDGFRA; Imatinib; Medicine; Stromal cell; Cancer research; GiST; Stromal tumor; Regorafenib; Tyrosine kinase; Tyrosine-kinase inhibitor; Oncology; Targeted therapy; Cancer; Internal medicine; Bioinformatics; Biology; Colorectal cancer; Receptor","score_opus":0.10470251152651992,"score_gpt":0.3630308298079164,"score_spread":0.25832831828139646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037987551","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.038977254,0.00042190208,0.00010253822,0.9506703,0.00019548649,0.0012384484,0.00012708042,0.00020810621,0.008058907],"genre_scores_gemma":[0.08295721,0.0002835988,0.017934581,0.8696587,0.024420466,0.00035003762,0.00093928,0.00021837532,0.003237759],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99592626,0.0007202492,0.00044288643,0.000714048,0.0009446977,0.0012518496],"domain_scores_gemma":[0.9977764,0.0007159959,0.0002961591,0.0006974009,0.00021668154,0.00029738797],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0005198391,0.0005636974,0.001453287,0.00013282648,0.00019100362,0.00006614892,0.0006799465,0.00019384112,0.00071615126],"category_scores_gemma":[0.00066205516,0.00033888593,0.00040238083,0.00021794252,0.00040114266,0.000046117722,0.00020924017,0.004190844,0.00029360384],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00419151,0.00019858488,0.00491157,0.00016407743,0.0001793219,0.031702362,0.00018961579,0.0000016297262,0.0008868675,0.0000158035,0.9458524,0.011706271],"study_design_scores_gemma":[0.0133680245,0.028945785,0.03901725,0.0010892951,0.0004027831,0.03923615,0.00026270468,0.00036078578,0.00033941673,0.00067287177,0.87576157,0.0005433567],"about_ca_topic_score_codex":0.00014803626,"about_ca_topic_score_gemma":0.000009085177,"teacher_disagreement_score":0.08101158,"about_ca_system_score_codex":0.0006210374,"about_ca_system_score_gemma":0.0012432669,"threshold_uncertainty_score":0.9999063},"labels":[],"label_agreement":null},{"id":"W3042132061","doi":"10.1016/s1470-2045(20)30326-0","title":"Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":190,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McMaster University; Juravinski Cancer Centre","funders":"Merck Sharp and Dohme; MacroGenics","keywords":"Pembrolizumab; Gastro-; Medicine; Internal medicine; Adenocarcinoma; Gastroenterology; Oncology; Cancer; Immunotherapy; Reflux; Disease","score_opus":0.07346060626970793,"score_gpt":0.3594422757535952,"score_spread":0.28598166948388726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3042132061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9769991,0.00053653505,0.00006382979,0.012143461,0.00021645924,0.0041780164,0.00012946573,0.00013281836,0.0056003183],"genre_scores_gemma":[0.9930853,0.000051967752,0.00047252176,0.003780975,0.0017152183,0.00039788953,0.00017629845,0.00009237432,0.00022744623],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9956459,0.0010057763,0.000615057,0.0007450034,0.0007401691,0.0012481364],"domain_scores_gemma":[0.9980675,0.0003759349,0.00024081094,0.0006503909,0.00021786329,0.00044751723],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00065237185,0.00040947212,0.0014898216,0.00014746664,0.00012007915,0.000041833144,0.0005511676,0.0002588271,0.00043463844],"category_scores_gemma":[0.00032276163,0.0002764652,0.00013733245,0.0006356877,0.00042437523,0.00010511181,0.0002087242,0.0012231936,0.0001366548],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84753036,0.011064887,0.09510067,0.00034819785,0.00041325204,0.0034193718,0.0062986156,0.000031680785,0.0002798356,0.00009564063,0.015508526,0.019908983],"study_design_scores_gemma":[0.7851749,0.13840075,0.060500804,0.00026999175,0.00038698787,0.00021227692,0.00037908315,0.000628896,0.00070396625,0.000046665285,0.012842107,0.00045357685],"about_ca_topic_score_codex":0.0003152516,"about_ca_topic_score_gemma":0.0001745089,"teacher_disagreement_score":0.12733586,"about_ca_system_score_codex":0.0016427606,"about_ca_system_score_gemma":0.0010900233,"threshold_uncertainty_score":0.99996877},"labels":[],"label_agreement":null},{"id":"W3044038392","doi":"10.1016/s1470-2045(20)30397-1","title":"Disruption of cancer care in Canada during COVID-19","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Coronavirus disease 2019 (COVID-19); Pandemic; Anxiety; Cancer; 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Medicine; Psychology; Psychiatry; Virology; Internal medicine; Disease","score_opus":0.12518384551824777,"score_gpt":0.45260582988743936,"score_spread":0.32742198436919157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3044038392","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.79142743,0.0010574388,0.000004895623,0.20671675,0.00010651938,0.0002182331,0.000031967826,0.000013129763,0.0004236246],"genre_scores_gemma":[0.953428,0.00047809197,0.000017825327,0.045586728,0.00043944406,0.000019398101,0.0000074003947,0.0000067738843,0.000016358932],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99924946,0.00009396519,0.00018204993,0.00012018373,0.00012045881,0.00023390015],"domain_scores_gemma":[0.99936795,0.00015550382,0.000077021636,0.00014813029,0.000036892725,0.00021452426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000112063484,0.00006356534,0.00037164675,0.000024255127,0.0000382808,0.0000011922695,0.00009007311,0.000049031198,0.00014491109],"category_scores_gemma":[0.0003490509,0.000044812827,0.000021313479,0.00016238497,0.00003490188,0.000013653204,0.000035470453,0.00022214785,0.0000023677733],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002281617,0.000018705761,0.96487355,0.0023210314,0.000026876029,0.00025783697,0.013674886,0.00060588965,0.0028390565,0.00012722755,0.0033623395,0.009611],"study_design_scores_gemma":[0.0033896063,0.00031109224,0.877697,0.000054456366,0.00003237064,0.000015617572,0.0029103952,0.000107736334,0.00055979576,0.000024403036,0.114832826,0.0000647169],"about_ca_topic_score_codex":0.9222853,"about_ca_topic_score_gemma":0.98877627,"teacher_disagreement_score":0.16200052,"about_ca_system_score_codex":0.0027179623,"about_ca_system_score_gemma":0.009115813,"threshold_uncertainty_score":0.99650156},"labels":[],"label_agreement":null},{"id":"W3047018002","doi":"10.1016/s1470-2045(20)30171-6","title":"First case of osteosarcoma in a dinosaur: a multimodal diagnosis","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Ontario Museum; Royal Tyrrell Museum; University Health Network; Trent University; McMaster University","funders":"","keywords":"Osteosarcoma; Malignancy; Incidence (geometry); Limiting; Medicine; Multimodal therapy; Biology; Oncology; Pathology; Internal medicine","score_opus":0.07224953716804378,"score_gpt":0.34430150348616584,"score_spread":0.27205196631812206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047018002","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90825677,0.0009570497,0.0000038660232,0.08909518,0.00005262653,0.0004548536,0.000023983803,0.000026773758,0.001128882],"genre_scores_gemma":[0.9939651,0.00039025306,0.00071366143,0.0043649115,0.00026304368,0.0002795635,0.000005976531,0.0000120323475,0.0000054749175],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99912494,0.00011343429,0.00025091233,0.00018656597,0.00008318465,0.00024097315],"domain_scores_gemma":[0.9988235,0.0007175857,0.00008380759,0.00025418703,0.000027513906,0.00009340555],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016458597,0.00011230748,0.00059869984,0.000038476075,0.00003625488,0.0000033512922,0.00010782041,0.00008032371,0.0001518354],"category_scores_gemma":[0.00020550018,0.00007061875,0.00008943204,0.00020137995,0.000101368,0.000019539333,0.00007852048,0.00018037875,0.00004066144],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061787164,0.0012216091,0.9525486,0.00011610607,0.000107251326,0.014536406,0.0032752738,0.000026577221,0.00010258926,0.00060711073,0.003771058,0.0230695],"study_design_scores_gemma":[0.022021765,0.0042806584,0.8733968,0.00018236156,0.00040577335,0.004489216,0.0013701225,0.0025565322,0.0033071465,0.00025776756,0.087492794,0.0002390713],"about_ca_topic_score_codex":0.000848973,"about_ca_topic_score_gemma":0.0018055376,"teacher_disagreement_score":0.085708305,"about_ca_system_score_codex":0.00009192242,"about_ca_system_score_gemma":0.000059842765,"threshold_uncertainty_score":0.2879749},"labels":[],"label_agreement":null},{"id":"W3047025380","doi":"10.1016/s1470-2045(20)30219-9","title":"Hereditary diffuse gastric cancer: updated clinical practice guidelines","year":2020,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":480,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"University of California Davis School of Medicine; Instituto Superior Técnico; Beijing Genomics Institute; Fundação para a Ciência e a Tecnologia; Health Research Council of New Zealand; David Geffen School of Medicine, University of California, Los Angeles; National Institute for Health and Care Research; National Cancer Institute; Medical Research Council; DeGregorio Family Foundation; University of Otago; Roche","keywords":"Medicine; CDH1; Cancer; Genetic testing; Genetic counseling; Cancer syndrome; Germline mutation; Surgical oncology; Breast cancer; Gastrectomy; Oncology; Internal medicine; Mutation; Genetics; Gene; Biology","score_opus":0.305222821832052,"score_gpt":0.5367221859876632,"score_spread":0.23149936415561118,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047025380","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000021338556,0.94115,0.000020524589,0.04598665,0.005213829,0.0016573494,0.00016587465,0.00018760827,0.005596799],"genre_scores_gemma":[0.0000038227467,0.95108646,0.008036854,0.021357432,0.018236574,0.00041335568,0.00020998789,0.0001201069,0.0005354251],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9945169,0.0015908196,0.0019314636,0.0008125289,0.00048278787,0.0006655134],"domain_scores_gemma":[0.9942087,0.002510044,0.0011693151,0.0011331738,0.00065481866,0.0003239745],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0018654438,0.000601344,0.0051172483,0.00009339515,0.0000913841,0.000020627,0.0009162449,0.00094940484,0.00077198603],"category_scores_gemma":[0.0070291506,0.00035153332,0.0006730889,0.0007265536,0.0003542103,0.00004357608,0.0004587456,0.002600831,0.0005306508],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030007414,0.0001246868,0.000016478873,0.0013714321,0.0006116856,0.00047318218,0.000022928189,5.525656e-7,2.769801e-7,0.000010225885,0.40547436,0.5915941],"study_design_scores_gemma":[0.0018942364,0.0013677195,0.000036444184,0.0018938872,0.0059152907,0.0024931333,0.000044413522,0.000022136765,2.9849045e-7,0.000021364702,0.98601264,0.0002984107],"about_ca_topic_score_codex":0.00012679407,"about_ca_topic_score_gemma":0.00006558448,"teacher_disagreement_score":0.5912957,"about_ca_system_score_codex":0.0008106782,"about_ca_system_score_gemma":0.0047659413,"threshold_uncertainty_score":0.99989367},"labels":[],"label_agreement":null},{"id":"W3048697601","doi":"10.1016/s1470-2045(20)30428-9","title":"Final results of the UK Age trial on breast cancer screening age","year":2020,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Public Health Ontario; University of Toronto","funders":"","keywords":"Breast cancer; Medicine; Cancer; Oncology; Gerontology; Demography; Internal medicine; Sociology","score_opus":0.2598885890687011,"score_gpt":0.4076897206584964,"score_spread":0.1478011315897953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3048697601","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007900174,0.00023644022,0.000012070953,0.9645269,0.0015620545,0.0010037445,0.0007294783,0.000052087533,0.02397704],"genre_scores_gemma":[0.066840135,0.00018331359,0.00024115737,0.8953637,0.033778857,0.000104609135,0.00016481009,0.000045057503,0.0032783533],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969988,0.00054415385,0.000615846,0.0004874326,0.0007459041,0.00060784793],"domain_scores_gemma":[0.99768966,0.0005490532,0.0006419459,0.0009446032,0.00010349823,0.00007120536],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00065926486,0.0003399407,0.0013949353,0.00005724243,0.00015414534,0.000020629637,0.000940135,0.00061588164,0.00022235284],"category_scores_gemma":[0.00032778986,0.0001825152,0.00036806863,0.0003111335,0.00044357567,0.000023082455,0.00024395771,0.003443137,0.000029215522],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.067557186,0.000021462425,0.00016273282,0.000085225045,0.00018587311,0.0023988837,0.00029025093,0.000032780645,0.00007618217,0.000035991572,0.9241616,0.004991835],"study_design_scores_gemma":[0.035564233,0.0016030987,0.005514699,0.00083728076,0.00045879895,0.00024907207,0.000055503926,0.000017750835,0.00005309598,0.00016349439,0.95528,0.00020298369],"about_ca_topic_score_codex":0.0017771685,"about_ca_topic_score_gemma":0.000541004,"teacher_disagreement_score":0.0691632,"about_ca_system_score_codex":0.0003051178,"about_ca_system_score_gemma":0.0006026478,"threshold_uncertainty_score":0.99885595},"labels":[],"label_agreement":null},{"id":"W3081315565","doi":"10.1016/s1470-2045(20)30447-2","title":"Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":321,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute; AstraZeneca; Invitae; PharmaMar; Eisai; Pfizer","keywords":"Veliparib; Carboplatin; Oncology; Medicine; Placebo; Breast cancer; Internal medicine; BRCA mutation; Paclitaxel; Cancer; Chemotherapy; Biology; Genetics; Alternative medicine; Poly ADP ribose polymerase; Cisplatin; Pathology","score_opus":0.07829391178294297,"score_gpt":0.3971052690556947,"score_spread":0.3188113572727517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081315565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9326614,0.0015015197,0.00014311692,0.056082655,0.00027443093,0.006016455,0.000102577076,0.00011935085,0.0030984583],"genre_scores_gemma":[0.9857097,0.00078285974,0.0002868385,0.008336835,0.0017096607,0.0029525093,0.00003386688,0.000048618003,0.00013908098],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99764043,0.0004130554,0.0006279975,0.0004898752,0.00028578,0.00054288254],"domain_scores_gemma":[0.9983895,0.00059791637,0.00034252802,0.00031043225,0.00011196867,0.00024767144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073060795,0.00031574076,0.0017032678,0.00009657546,0.00009438824,0.000023503022,0.00017793645,0.00020630559,0.00030606045],"category_scores_gemma":[0.000090552145,0.00019804196,0.00009749698,0.000438664,0.0003055,0.00009982499,0.000041730233,0.00073359016,0.000014889445],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9814091,0.00029073103,0.0002815467,0.000062834115,0.00032940027,0.0001338397,0.0018495368,0.00029942117,0.0067710914,0.0001069876,0.0013017458,0.007163808],"study_design_scores_gemma":[0.9863515,0.002965583,0.00019844565,0.00012573789,0.00028086733,0.00023351092,0.0003802267,0.0011754838,0.00080844865,0.00006856104,0.0071781403,0.000233481],"about_ca_topic_score_codex":0.00019923065,"about_ca_topic_score_gemma":0.00041222188,"teacher_disagreement_score":0.053048294,"about_ca_system_score_codex":0.00030132022,"about_ca_system_score_gemma":0.0006606851,"threshold_uncertainty_score":0.8075917},"labels":[],"label_agreement":null},{"id":"W3081850846","doi":"10.1016/s1470-2045(20)30481-2","title":"Vision 2020: looking back and thinking forward on The Lancet Oncology Commissions","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"Pfizer Canada; Merck KGaA; Roche; Pfizer","keywords":"Psychology; Medical education; Medicine; Medical physics","score_opus":0.061231728302472505,"score_gpt":0.41921254910311156,"score_spread":0.3579808208006391,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081850846","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.057090033,0.0018408818,0.0016537609,0.8309917,0.0009211812,0.00082890346,0.000015499489,0.00015194085,0.10650609],"genre_scores_gemma":[0.51493955,0.009929245,0.013299216,0.44669703,0.013488919,0.000092686954,0.000029067647,0.000080448845,0.0014438467],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978703,0.00073515985,0.0003187552,0.00036830784,0.0001945492,0.00051289797],"domain_scores_gemma":[0.9962175,0.002833885,0.00021387497,0.00052098685,0.000048440284,0.00016530915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013182984,0.00022164432,0.0009900153,0.000029432174,0.00052946876,0.000017847326,0.00050040253,0.00033341313,0.00081886677],"category_scores_gemma":[0.00048680446,0.00011184941,0.000090470865,0.00020482119,0.0006730289,0.000056048546,0.00020437715,0.0013469593,0.00017693068],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008130792,0.0004613256,0.010894365,0.00015999659,0.00047071895,0.00051613967,0.01097096,0.00020160324,0.0047689797,0.0469924,0.78207844,0.13435431],"study_design_scores_gemma":[0.0041892207,0.003779127,0.0037170006,0.00008584849,0.000090845955,0.00033935587,0.0006454533,0.0009837857,0.00013920276,0.0049451464,0.9809483,0.00013667859],"about_ca_topic_score_codex":0.000006138596,"about_ca_topic_score_gemma":0.000026795105,"teacher_disagreement_score":0.4578495,"about_ca_system_score_codex":0.00021548422,"about_ca_system_score_gemma":0.00020659734,"threshold_uncertainty_score":0.8966017},"labels":[],"label_agreement":null},{"id":"W3082650529","doi":"10.1016/s1470-2045(20)30320-x","title":"Development of paediatric non-stage prognosticator guidelines for population-based cancer registries and updates to the 2014 Toronto Paediatric Cancer Stage Guidelines","year":2020,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Pediatric Oncology Group; Princess Margaret Cancer Centre; Hospital for Sick Children","funders":"Hospital for Sick Children; Great Ormond Street Hospital Charity; National Institute for Health and Care Research; World Health Organization","keywords":"Medicine; Stage (stratigraphy); Cancer; Delphi method; Incidence (geometry); Population; Family medicine; Environmental health; Internal medicine; Computer science","score_opus":0.20102718359173113,"score_gpt":0.477977122137466,"score_spread":0.2769499385457349,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3082650529","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021581109,0.9290968,0.0005980128,0.061885692,0.0010498037,0.0051486413,0.001876129,0.00008335287,0.000045746812],"genre_scores_gemma":[0.000032643864,0.95416236,0.023475328,0.009590305,0.007947501,0.003613698,0.0005182666,0.00011455921,0.0005453639],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99513644,0.00038969785,0.002459115,0.00079943915,0.0005876427,0.0006276822],"domain_scores_gemma":[0.99406576,0.0020232864,0.0017193045,0.0009151465,0.0010074603,0.0002690568],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0027584997,0.0006768676,0.0037358475,0.00012381878,0.00025643889,0.000037819347,0.0008036133,0.00038327993,0.00017255527],"category_scores_gemma":[0.0033844286,0.00038395493,0.00037052695,0.0004983017,0.00013486198,0.000059262926,0.00029806848,0.00038948152,0.000012569034],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036464972,0.00007318666,0.0019754325,0.021889448,0.0005981359,0.0000048163083,0.0009568625,0.000046897534,0.0000011607533,0.00011405189,0.28430066,0.6896747],"study_design_scores_gemma":[0.0012623501,0.0002525684,0.00068014173,0.002336691,0.0018359993,0.0000043258365,0.00032007028,0.00009846142,0.000006051354,0.0000070902415,0.992782,0.00041425086],"about_ca_topic_score_codex":0.005516201,"about_ca_topic_score_gemma":0.026537249,"teacher_disagreement_score":0.7084813,"about_ca_system_score_codex":0.0008135839,"about_ca_system_score_gemma":0.006204242,"threshold_uncertainty_score":0.99986124},"labels":[],"label_agreement":null},{"id":"W3082899459","doi":"10.1016/s1470-2045(20)30443-5","title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":327,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"F. Hoffmann-La Roche; AbbVie","keywords":"Obinutuzumab; Chlorambucil; Venetoclax; Medicine; Internal medicine; Oncology; Chronic lymphocytic leukemia; Fludarabine; Open label; Clinical trial; Chemotherapy; Leukemia; Cyclophosphamide","score_opus":0.22414891033952375,"score_gpt":0.4279868705273332,"score_spread":0.20383796018780945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3082899459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9568092,0.0033902547,0.00031797058,0.00386397,0.003487822,0.025471283,0.0010611381,0.00052256195,0.0050757783],"genre_scores_gemma":[0.9764201,0.0016217099,0.0012938414,0.003023563,0.008690153,0.0033118261,0.0022478874,0.00025917077,0.003131734],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9924024,0.001011216,0.001725174,0.0017181303,0.0009386097,0.0022045],"domain_scores_gemma":[0.98966247,0.006108528,0.0008142917,0.0020575866,0.00043461504,0.0009225249],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020157413,0.00084650225,0.0033879923,0.0001268728,0.00047356688,0.00023021092,0.002290241,0.00075968343,0.00040963737],"category_scores_gemma":[0.0066047073,0.0006313731,0.0004215971,0.0008043686,0.0006079522,0.0002566303,0.0009962927,0.0009958685,0.000567469],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.93296367,0.00010351939,1.9817409e-7,0.0003114744,0.0013206255,0.0007789631,0.0037732613,0.0050832317,0.0014695697,0.000097201104,0.04900737,0.005090915],"study_design_scores_gemma":[0.57432973,0.012998026,3.792801e-7,0.00017031812,0.0010810497,0.000067216424,0.00025219965,0.33894697,0.001047077,0.00005175523,0.07068523,0.00037007226],"about_ca_topic_score_codex":0.01265212,"about_ca_topic_score_gemma":0.0020691145,"teacher_disagreement_score":0.35863397,"about_ca_system_score_codex":0.49785936,"about_ca_system_score_gemma":0.27607533,"threshold_uncertainty_score":0.99961376},"labels":[],"label_agreement":null},{"id":"W3083986479","doi":"10.1016/s1470-2045(20)30445-9","title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2492,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Response Evaluation Criteria in Solid Tumors; Oncology; Cohort; Mesothelioma; Biomarker; Clinical endpoint; Prospective cohort study; Cancer; Progressive disease; Disease; Immunotherapy; Pathology; Clinical trial","score_opus":0.03122114611269687,"score_gpt":0.3549706413578277,"score_spread":0.3237494952451308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083986479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936353,0.000024256593,0.000014341999,0.0033696457,0.000020779702,0.0025098473,0.00011045179,0.000015852042,0.00029954268],"genre_scores_gemma":[0.9990866,0.0000059531276,0.00019580373,0.00039005553,0.000022117654,0.00011902197,0.00005353283,0.000020245809,0.00010664745],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982575,0.00032201505,0.0004229108,0.00029665188,0.00046365685,0.0002372351],"domain_scores_gemma":[0.9983468,0.00023017076,0.0007405409,0.00028877557,0.0003498682,0.000043851753],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038588681,0.00019406418,0.0011097577,0.000118374366,0.00006192654,0.000011079438,0.00029736522,0.000059854672,0.00004432455],"category_scores_gemma":[0.00010520706,0.00008896064,0.000056929923,0.0013716598,0.00017759894,0.00008706557,0.0000582186,0.00019220414,6.040575e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09481508,0.0025977786,0.8913,0.000017216027,0.0055998745,0.00001360054,0.0029207706,0.00036367145,0.0015153554,0.0000039608294,0.000039211376,0.0008134344],"study_design_scores_gemma":[0.08969664,0.01016329,0.89551497,0.000043644097,0.0023154549,0.000001899529,0.00092821935,0.0006623731,0.0005366306,0.0000028433878,0.000023754925,0.00011028167],"about_ca_topic_score_codex":0.00049740006,"about_ca_topic_score_gemma":0.0017903713,"teacher_disagreement_score":0.0075655114,"about_ca_system_score_codex":0.00038450488,"about_ca_system_score_gemma":0.0002772972,"threshold_uncertainty_score":0.36277094},"labels":[],"label_agreement":null},{"id":"W3086258129","doi":"10.1016/s1470-2045(20)30446-0","title":"Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":482,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Institut Claudius Regaud; Radboud Universitair Medisch Centrum; Universitair Medisch Centrum Groningen; European Organisation for Research and Treatment of Cancer; Leids Universitair Medisch Centrum; Royal Marsden NHS Foundation Trust; European Commission; Herlev Hospital; Radboud Universiteit; Universiteit Leiden","keywords":"Medicine; Radiation therapy; Clinical endpoint; Surgery; Randomized controlled trial; Sarcoma","score_opus":0.12377641344454836,"score_gpt":0.3730701604643574,"score_spread":0.24929374701980905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3086258129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97689,0.0013679315,0.00006434718,0.011625625,0.0008070208,0.00855565,0.0002099671,0.00008061449,0.00039881203],"genre_scores_gemma":[0.98357457,0.0011386495,0.0030195033,0.006916439,0.0020475448,0.0023413713,0.00081948296,0.000089534755,0.000052892825],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971946,0.0006184781,0.0006416352,0.0005701069,0.00033974613,0.000635442],"domain_scores_gemma":[0.9929155,0.0057832343,0.00035781952,0.00046667567,0.0001937653,0.00028302273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007480198,0.0003752502,0.0023341295,0.000062581035,0.00021667455,0.000068334084,0.00028721621,0.0001591008,0.0002119997],"category_scores_gemma":[0.00057260843,0.0002206047,0.00020103586,0.00023801281,0.00020767511,0.00015329827,0.00008583657,0.00028151195,0.00001357832],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9118149,0.0072207083,0.013824368,0.00008760061,0.0014541988,0.00023625104,0.0007722282,0.0000039130387,0.00009518724,0.000022603743,0.032731265,0.031736758],"study_design_scores_gemma":[0.9435398,0.013673472,0.007846797,0.000079555844,0.0007497202,0.000016221053,0.00010464759,0.00036139242,0.0002627242,0.0000035881435,0.033062167,0.0002998876],"about_ca_topic_score_codex":0.00007609831,"about_ca_topic_score_gemma":0.000049119117,"teacher_disagreement_score":0.031724907,"about_ca_system_score_codex":0.0005882003,"about_ca_system_score_gemma":0.0010181788,"threshold_uncertainty_score":0.8995999},"labels":[],"label_agreement":null},{"id":"W3087466624","doi":"10.1016/s1470-2045(20)30541-6","title":"Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":498,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec; McMaster University; Université Laval; Hamilton Health Sciences; Juravinski Cancer Centre","funders":"Foundation Medicine; EMD Serono; Pharmacyclics; Genentech; AstraZeneca; EUSA Pharma; Astellas Pharma; Eisai; INOVIO Pharmaceuticals; AstraZeneca España; Pfizer; Incyte; Ipsen; Clovis Oncology; Les Laboratories Pierre Fabre; Endocyte; Sanofi; Exelixis; GlaxoSmithKline; Celldex Therapeutics; Amgen; Celgene; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Durvalumab; Medicine; Tremelimumab; Chemotherapy; Metastatic Urothelial Carcinoma; Oncology; Open label; Internal medicine; Urology; Carcinoma; Randomized controlled trial; Urothelial carcinoma; Cancer; Immunotherapy; Bladder cancer","score_opus":0.09417910979039026,"score_gpt":0.3763797989152469,"score_spread":0.28220068912485663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087466624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98035765,0.0007159325,0.00006101171,0.0043714265,0.00027914086,0.0124509325,0.00014536212,0.00008938685,0.0015291334],"genre_scores_gemma":[0.992108,0.000628259,0.0014923994,0.0038360872,0.00039518625,0.001029817,0.00013793394,0.000103739854,0.00026860763],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963966,0.0007890033,0.0007138422,0.00078119163,0.00048272873,0.0008366596],"domain_scores_gemma":[0.99790186,0.00068725017,0.00032407604,0.0005491864,0.00017636282,0.00036124396],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005186896,0.00052522635,0.002032255,0.00009416519,0.00016539716,0.000072191244,0.000503529,0.00014491667,0.00032377156],"category_scores_gemma":[0.000424835,0.00030797702,0.00007014356,0.00055918,0.00027379298,0.00020393867,0.00015630436,0.00045655307,0.000025828853],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9603977,0.0032002477,0.0011559821,0.0001357913,0.00074692105,0.00041999758,0.002624563,0.000033119126,0.00020877592,0.000012723371,0.0004553691,0.030608775],"study_design_scores_gemma":[0.94193184,0.04964035,0.0017553357,0.00011340886,0.0009722415,0.000033586737,0.00029659717,0.0012897833,0.00032192434,0.00001701613,0.003293934,0.00033396235],"about_ca_topic_score_codex":0.0007294038,"about_ca_topic_score_gemma":0.0014673951,"teacher_disagreement_score":0.046440106,"about_ca_system_score_codex":0.00058172195,"about_ca_system_score_gemma":0.001532187,"threshold_uncertainty_score":0.99993724},"labels":[],"label_agreement":null},{"id":"W3087697977","doi":"10.1016/s1470-2045(20)30494-0","title":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":525,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Bristol-Myers Squibb","keywords":"Ipilimumab; Medicine; Nivolumab; Clinical endpoint; Internal medicine; Population; Clinical trial; Adjuvant; Stage (stratigraphy); Randomized controlled trial; Surgery; Phases of clinical research; Adverse effect; Melanoma; Cancer; Oncology; Immunotherapy","score_opus":0.11363129802389245,"score_gpt":0.3789429370514308,"score_spread":0.26531163902753835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087697977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97602093,0.00156092,0.000012454365,0.011868735,0.00081271934,0.005239038,0.0005317677,0.00010922596,0.0038442167],"genre_scores_gemma":[0.9934985,0.0016497524,0.0002240888,0.0016156097,0.0014856019,0.0002969654,0.0002453552,0.000044392364,0.00093972613],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9967379,0.00074272515,0.0009948567,0.0005995172,0.00032340022,0.000601591],"domain_scores_gemma":[0.9969707,0.0016917564,0.00047464916,0.0005649031,0.00008609117,0.00021186307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014545048,0.0003240505,0.0017572996,0.00010356768,0.000117219235,0.000044298667,0.0003035892,0.00028839862,0.00049045193],"category_scores_gemma":[0.00077844324,0.00021920002,0.00020623306,0.0003289657,0.0002870365,0.000090343245,0.00011064682,0.0006441646,0.0000329226],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9774385,0.0005365125,0.00006915225,0.000042798354,0.0007395439,0.0003379725,0.0033320873,0.000008632028,0.010922051,0.000027490234,0.0025853585,0.00395987],"study_design_scores_gemma":[0.94154215,0.00627738,0.00025623976,0.000054666714,0.0003034809,0.0000049405885,0.0016016356,0.0019342655,0.0011296427,0.0000068009763,0.046663366,0.00022545987],"about_ca_topic_score_codex":0.0018486439,"about_ca_topic_score_gemma":0.0022820178,"teacher_disagreement_score":0.044078007,"about_ca_system_score_codex":0.00028733423,"about_ca_system_score_gemma":0.00043121702,"threshold_uncertainty_score":0.8938717},"labels":[],"label_agreement":null},{"id":"W3089740894","doi":"10.1016/s1470-2045(20)30158-3","title":"Oncology training in Latin America: are we ready for 2040?","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Global Public Health Policies and Epidemiology","field":"Business, Management and Accounting","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Latin Americans; Life expectancy; Population; Social determinants of health; Poverty; Health equity; Economic growth; Political science; Medicine; Development economics; Environmental health; Health care; Economics","score_opus":0.32319437441143173,"score_gpt":0.41527400723762065,"score_spread":0.09207963282618892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089740894","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.021515729,0.0001443863,0.00048024996,0.9086245,0.00063734443,0.00053716876,0.000017348937,0.00012534937,0.06791793],"genre_scores_gemma":[0.3284125,0.000272931,0.0011918906,0.65903825,0.010647876,0.00025378194,0.000053103184,0.00003273723,0.000096943244],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980988,0.00015540766,0.000502165,0.00029820084,0.000073280375,0.0008721638],"domain_scores_gemma":[0.99836427,0.0008506347,0.00046847665,0.00020325622,0.00007495615,0.00003842504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013804157,0.00016236158,0.0009031959,0.00007564327,0.00014635266,0.000027412038,0.000472766,0.00020031813,0.00010262015],"category_scores_gemma":[0.0014699871,0.00011732933,0.00006594708,0.0004299695,0.00016140626,0.00015104884,0.00018929986,0.00038562692,0.00021262052],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029871264,0.00004140458,0.002563675,0.00015919699,0.00002019399,0.00001688463,0.00095658266,0.0010691565,0.000026747895,0.07028676,0.88781816,0.03674254],"study_design_scores_gemma":[0.0013113293,0.00014891748,0.0037625972,0.000012177307,0.000016797445,0.0000031629509,0.0035581097,0.015289378,2.552023e-7,0.005944013,0.9698307,0.00012257892],"about_ca_topic_score_codex":0.0018550713,"about_ca_topic_score_gemma":0.0014189646,"teacher_disagreement_score":0.30689678,"about_ca_system_score_codex":0.0001246756,"about_ca_system_score_gemma":0.00015495763,"threshold_uncertainty_score":0.47845513},"labels":[],"label_agreement":null},{"id":"W3092409743","doi":"10.1016/s1470-2045(20)30451-4","title":"Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Chromatin Remodeling and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":406,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Princess Margaret Cancer Centre; Hospital for Sick Children","funders":"University of Colorado Denver","keywords":"Epithelioid sarcoma; SMARCB1; Medicine; Sarcoma; Dermatology; Oncology; Internal medicine; Pathology; Chemistry; Gene","score_opus":0.08187789777292803,"score_gpt":0.41122938910292295,"score_spread":0.3293514913299949,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092409743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99421036,0.00016277943,0.00029432465,0.0026479743,0.000091348506,0.00046374745,0.00005626509,0.000010526013,0.0020626872],"genre_scores_gemma":[0.99558204,0.0002466515,0.0018161001,0.0018875396,0.00025491233,0.000063906184,0.00007203531,0.000019460138,0.000057329253],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99883544,0.00025307847,0.00026394372,0.0003267998,0.000121276054,0.00019943828],"domain_scores_gemma":[0.99926776,0.000031409083,0.00015364925,0.00040393218,0.0000841362,0.000059118767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004226747,0.00012917082,0.00034485257,0.000024344201,0.000035733407,0.00001605744,0.00086632813,0.00006559211,0.000054177028],"category_scores_gemma":[0.00007513901,0.0000900974,0.00001742984,0.00013485861,0.00010732696,0.000011914244,0.0002780734,0.00014800728,0.0000045465567],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034061745,0.009104464,0.058066953,0.000113625174,0.0006137633,0.00018606917,0.0073724277,0.0031135834,0.7336314,0.00029406705,0.0041349134,0.14930704],"study_design_scores_gemma":[0.22334519,0.12247611,0.021211375,0.00020960034,0.00026862288,0.00018347192,0.013381275,0.01415208,0.14429407,0.0008594092,0.4577264,0.0018924176],"about_ca_topic_score_codex":0.00007437521,"about_ca_topic_score_gemma":0.0004524186,"teacher_disagreement_score":0.5893373,"about_ca_system_score_codex":0.000029049603,"about_ca_system_score_gemma":0.00015746996,"threshold_uncertainty_score":0.36740652},"labels":[],"label_agreement":null},{"id":"W3092484545","doi":"10.1016/s1470-2045(20)30441-1","title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":587,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"Cilag; Takeda Pharmaceutical Company; AbbVie; National Cancer Institute; Merck Sharp and Dohme; Pharmacyclics; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer; Roche","keywords":"Open label; Medicine; Follicular lymphoma; Refractory (planetary science); Oncology; Internal medicine; Phases of clinical research; Follicular phase; Clinical trial; Lymphoma","score_opus":0.1386246272526778,"score_gpt":0.38730405804533874,"score_spread":0.24867943079266094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092484545","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840698,0.0001470744,0.000043488923,0.009165845,0.00033698458,0.004950367,0.00014326218,0.00008547128,0.0010577118],"genre_scores_gemma":[0.981441,0.000085079875,0.0055958354,0.010462383,0.0009598135,0.0007688676,0.00046333502,0.000055460405,0.0001681871],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982566,0.0002445173,0.00035296453,0.00045958752,0.00023439324,0.0004518958],"domain_scores_gemma":[0.9982622,0.0005416351,0.00025765784,0.00049777795,0.00015728272,0.00028343612],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025268045,0.00024894864,0.0008928779,0.000029645567,0.00016651428,0.000046346002,0.00035278036,0.00013623504,0.00011788213],"category_scores_gemma":[0.000393605,0.00012776826,0.00005140621,0.00017208132,0.00010274169,0.00015023586,0.000108802444,0.00008927446,0.000035595847],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.76882976,0.0732818,0.0017675017,0.00008116858,0.00074610935,0.00048130803,0.0014660512,0.000002227927,0.0005082683,0.00028071812,0.020814378,0.1317407],"study_design_scores_gemma":[0.58801293,0.12843464,0.0008670066,0.00003154034,0.00062319724,0.000012953134,0.00013805373,0.00016040643,0.0003567439,0.000024282544,0.28118482,0.00015344606],"about_ca_topic_score_codex":0.000052031846,"about_ca_topic_score_gemma":0.000072596835,"teacher_disagreement_score":0.26037043,"about_ca_system_score_codex":0.0004287475,"about_ca_system_score_gemma":0.00041335277,"threshold_uncertainty_score":0.52102387},"labels":[],"label_agreement":null},{"id":"W3093673980","doi":"10.1016/s1470-2045(20)30592-1","title":"How current assay approval policies are leading to unintended imprecision medicine","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Biomedical Ethics and Regulation","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Ontario Institute for Cancer Research","funders":"Breast Cancer Society of Canada; World Health Organization; Merck; AstraZeneca Australia; Bayer; Pfizer","keywords":"Reimbursement; Food and drug administration; Drug; Medicine; Drug approval; Clinical trial; Pharmacology; Clinical research; Health care; Internal medicine; Political science","score_opus":0.204421744804693,"score_gpt":0.42393240281780725,"score_spread":0.21951065801311426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093673980","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013001627,0.0007465973,0.008254792,0.9739155,0.00066689006,0.00034031004,0.00000514583,0.00008200463,0.002987114],"genre_scores_gemma":[0.9738505,0.0002942962,0.00054254965,0.020428462,0.0043409867,0.000015069011,0.000021163554,0.000014892968,0.00049211807],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987715,0.00019096644,0.0001972035,0.0002210715,0.00033408182,0.00028521643],"domain_scores_gemma":[0.9990248,0.00024034228,0.000115926836,0.00023126476,0.0001282545,0.00025940983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091481017,0.000119491546,0.0005530805,0.000059495786,0.00008700694,0.000011889843,0.00019670164,0.00017457492,0.000049810325],"category_scores_gemma":[0.00079453824,0.0000613027,0.000052460626,0.00033275952,0.0006987359,0.00002378967,0.00012287202,0.000616548,0.000038558166],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010948128,0.000116972966,0.0006956228,0.00028487,0.000094865536,0.000040833776,0.008489148,0.0000152286975,0.048093148,0.03651137,0.16746716,0.73709595],"study_design_scores_gemma":[0.0021519493,0.0016644734,0.00539709,0.00020981248,0.00008428603,0.000049955335,0.0013843479,0.0019334336,0.0005533045,0.0032375418,0.9832268,0.00010703183],"about_ca_topic_score_codex":0.000017255328,"about_ca_topic_score_gemma":0.000017427872,"teacher_disagreement_score":0.9608488,"about_ca_system_score_codex":0.00009815581,"about_ca_system_score_gemma":0.00009723039,"threshold_uncertainty_score":0.26786286},"labels":[],"label_agreement":null},{"id":"W3093923068","doi":"10.1016/s1470-2045(20)30436-8","title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":745,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre Hospitalier de l’Université de Montréal","funders":"Merck Sharp and Dohme","keywords":"Axitinib; Medicine; Sunitinib; Renal cell carcinoma; Pembrolizumab; Interim analysis; Internal medicine; Clinical endpoint; Oncology; Population; Kidney cancer; Clinical trial; Cancer; Immunotherapy","score_opus":0.1632971678821501,"score_gpt":0.3918027228166789,"score_spread":0.2285055549345288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093923068","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97017634,0.0022543464,0.00007324859,0.008649216,0.00086133543,0.006145555,0.00031122277,0.00009974232,0.011428998],"genre_scores_gemma":[0.99121886,0.0012724878,0.0014604635,0.0013537926,0.0020770247,0.0010581814,0.0005845616,0.000097496195,0.0008771131],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99629515,0.00069085497,0.0010077322,0.00082340726,0.00045008113,0.00073276676],"domain_scores_gemma":[0.9959354,0.0017036616,0.0006712165,0.001075495,0.00017306233,0.00044117047],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003326864,0.00061336526,0.0026980573,0.00008848085,0.00019180735,0.000036223082,0.00069124135,0.0002795404,0.0010276469],"category_scores_gemma":[0.00023270636,0.0004113963,0.00037066152,0.00030227343,0.00026412852,0.000100129924,0.00016230332,0.000347735,0.000120839075],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9426142,0.0037672508,0.000022634125,0.000049367914,0.00071263337,0.0009889805,0.0037473056,0.000055145207,0.01905299,0.000079131576,0.0011800505,0.027730288],"study_design_scores_gemma":[0.8179444,0.095906876,0.00012936506,0.00003218543,0.0011856892,0.00004222886,0.0004076577,0.0004995486,0.05174773,0.00013900091,0.03167273,0.00029258803],"about_ca_topic_score_codex":0.0010680996,"about_ca_topic_score_gemma":0.00024026542,"teacher_disagreement_score":0.12466982,"about_ca_system_score_codex":0.0008797444,"about_ca_system_score_gemma":0.0011123453,"threshold_uncertainty_score":0.99988556},"labels":[],"label_agreement":null},{"id":"W3095373064","doi":"10.1016/s1470-2045(20)30629-x","title":"Recommendations for breast cancer screening – Author's reply","year":2020,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Public Health Ontario","funders":"","keywords":"Breast cancer; Overdiagnosis; Medicine; Cancer; Family medicine; Breast cancer screening; International agency; Mammography; Gerontology; Gynecology; Internal medicine","score_opus":0.29433173746817676,"score_gpt":0.446158495410637,"score_spread":0.15182675794246026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095373064","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000027254226,0.00056134805,0.002144901,0.9895965,0.0011457095,0.0009005488,0.0012242582,0.00016847791,0.00423103],"genre_scores_gemma":[0.0003992433,0.00031860932,0.010001262,0.95008296,0.034316767,0.00053335255,0.0006356328,0.000065030865,0.0036471416],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99784607,0.00021383695,0.00044377364,0.0005247286,0.00028949065,0.0006820909],"domain_scores_gemma":[0.99815565,0.0005216559,0.00037235222,0.0006006172,0.00024367441,0.000106030355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005472221,0.00029725896,0.0010814674,0.00006973637,0.00027799307,0.000036748435,0.0004882133,0.00048217064,0.00075857056],"category_scores_gemma":[0.00019188935,0.00021116133,0.0002597458,0.00023683195,0.00015495741,0.0000628841,0.00013050939,0.0022356303,0.000052564057],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006111461,0.000008610061,0.00027695403,0.00014810974,0.00024902835,0.00020976867,0.00019372856,0.000004399058,0.00002583991,0.0000691096,0.9506786,0.047524713],"study_design_scores_gemma":[0.0014428903,0.00037352717,0.00075998396,0.00035047854,0.00055312895,0.0005360323,0.0001261017,0.00023508549,0.0000100596935,0.00048389562,0.99490595,0.00022288821],"about_ca_topic_score_codex":0.0005563049,"about_ca_topic_score_gemma":0.00010246699,"teacher_disagreement_score":0.047301825,"about_ca_system_score_codex":0.000390141,"about_ca_system_score_gemma":0.000613695,"threshold_uncertainty_score":0.97128254},"labels":[],"label_agreement":null},{"id":"W3095605271","doi":"10.1016/s1470-2045(20)30587-8","title":"BELLINI: a renaissance for an era of precision therapy in multiple myeloma","year":2020,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada; Genentech; Takeda Pharmaceuticals U.S.A.; Janssen Biotech; Celgene","keywords":"Venetoclax; Bortezomib; Multiple myeloma; Dexamethasone; Context (archaeology); Medicine; Oncology; Internal medicine; Cancer research; Chromosomal translocation; Biology; Leukemia; Chronic lymphocytic leukemia; Genetics; Gene","score_opus":0.1744093802438907,"score_gpt":0.4059269157998305,"score_spread":0.2315175355559398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095605271","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.069300085,0.0016315461,0.00013399778,0.92253345,0.00029396938,0.004283626,0.00033739544,0.00006774768,0.0014181931],"genre_scores_gemma":[0.2911425,0.005023195,0.010942257,0.67633426,0.0115099065,0.001771691,0.0021341504,0.00018494968,0.000957123],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99758524,0.000500427,0.0004707832,0.0004945209,0.000346114,0.00060290634],"domain_scores_gemma":[0.99698097,0.0017407675,0.00026133837,0.00077777106,0.00013947886,0.00009970023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004837922,0.00028050257,0.001364962,0.000098788725,0.00007066469,0.000009258433,0.0004806386,0.00055434735,0.00008528589],"category_scores_gemma":[0.00048957765,0.00017178454,0.00017654263,0.000200833,0.0002355888,0.000041722655,0.00007296994,0.0018120352,0.000029883671],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012754302,0.0004199422,0.006461841,0.0003675696,0.00029009808,0.0007382627,0.00075639423,0.00000426045,0.0015160594,0.000011380024,0.790931,0.1857489],"study_design_scores_gemma":[0.015551554,0.008027347,0.012510634,0.00022674595,0.00005029222,0.00004523229,0.000024815141,0.0010428096,0.0012253141,0.0007335389,0.9603951,0.00016658928],"about_ca_topic_score_codex":0.00019209439,"about_ca_topic_score_gemma":0.00022856538,"teacher_disagreement_score":0.2461992,"about_ca_system_score_codex":0.00016367996,"about_ca_system_score_gemma":0.00038164985,"threshold_uncertainty_score":0.7872492},"labels":[],"label_agreement":null},{"id":"W3096044474","doi":"10.1016/s1470-2045(20)30475-7","title":"Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":124,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; Bristol-Myers Squibb Canada; AbbVie; Genentech; AstraZeneca; National Cancer Institute; National Institutes of Health; Pfizer; Amgen","keywords":"Biomarker; Medicine; Lung cancer; Oncology; Internal medicine; Clinical trial; Cancer","score_opus":0.06882650635968865,"score_gpt":0.39472622814967956,"score_spread":0.32589972178999094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096044474","genre_codex":"protocol","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.29851422,0.0042591076,0.0058123264,0.21006545,0.001268439,0.44673106,0.0011122625,0.0011441871,0.031092951],"genre_scores_gemma":[0.6396458,0.00018520054,0.0044061355,0.011306386,0.0018084357,0.33727315,0.000284639,0.00019142841,0.0048987875],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977799,0.00021187025,0.0004918678,0.00058646273,0.00019376204,0.0007361465],"domain_scores_gemma":[0.998401,0.00029834046,0.00032392464,0.00052596733,0.00020646706,0.00024428556],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002086272,0.00040845253,0.0009479783,0.00008507332,0.00024216618,0.000045764795,0.0003665538,0.00024231491,0.00043527514],"category_scores_gemma":[0.000040288192,0.00025511428,0.0002497643,0.00030820785,0.00017539565,0.00007955953,0.00010495818,0.0002468775,0.000046030575],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027323721,0.003169353,0.32342726,0.009141469,0.008710128,0.00052969536,0.0416483,0.00034493319,0.058459934,0.00031885377,0.4540918,0.07283457],"study_design_scores_gemma":[0.05075167,0.0047527784,0.029956473,0.00041937357,0.0038432677,0.00006065499,0.00074705627,0.03057449,0.0024206368,0.0000721294,0.87566537,0.0007360936],"about_ca_topic_score_codex":0.0002728982,"about_ca_topic_score_gemma":0.00026685421,"teacher_disagreement_score":0.42157358,"about_ca_system_score_codex":0.00052731484,"about_ca_system_score_gemma":0.0007171698,"threshold_uncertainty_score":0.9999901},"labels":[],"label_agreement":null},{"id":"W3096200050","doi":"10.1016/s1470-2045(20)30543-x","title":"Recommendations for breast cancer screening","year":2020,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"British Columbia Centre of Excellence for Women's Health; University of British Columbia; Ontario Institute for Cancer Research; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Mammography; Guideline; Observational study; Family medicine; Breast screening; Randomized controlled trial; Cancer; Gynecology; Internal medicine; Pathology","score_opus":0.29484071213160107,"score_gpt":0.4416033240936061,"score_spread":0.14676261196200502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096200050","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000029689923,0.00055707176,0.0015693228,0.990306,0.00082021556,0.0007453526,0.0011735787,0.00011652972,0.004682229],"genre_scores_gemma":[0.0005416027,0.0004941217,0.006271503,0.95564735,0.034197174,0.00045171505,0.00055483566,0.00005039103,0.0017912892],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983766,0.00014102452,0.00031724863,0.00037720456,0.00022379414,0.0005641357],"domain_scores_gemma":[0.9986631,0.00041926428,0.0002503917,0.00040752802,0.00018194882,0.00007774613],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031015152,0.00023913634,0.0008990711,0.00005146711,0.00021102041,0.000026068428,0.0003994319,0.00045022785,0.00080211705],"category_scores_gemma":[0.000092144895,0.00016531831,0.0002101093,0.00017724013,0.00012699606,0.00004738005,0.00009927235,0.001841658,0.000051116884],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044445708,0.000006848241,0.00027382487,0.0001318273,0.00020667932,0.00014044982,0.00012648877,0.0000035726937,0.000018937484,0.00006237158,0.94601816,0.052566368],"study_design_scores_gemma":[0.0014377342,0.0002851874,0.0006604756,0.0002724499,0.00045766652,0.00038898457,0.00008979713,0.00015722653,0.000008620682,0.00037379994,0.9956929,0.00017515168],"about_ca_topic_score_codex":0.0003236587,"about_ca_topic_score_gemma":0.00009837498,"teacher_disagreement_score":0.052391216,"about_ca_system_score_codex":0.00030308112,"about_ca_system_score_gemma":0.00047274758,"threshold_uncertainty_score":0.8782619},"labels":[],"label_agreement":null},{"id":"W3097553720","doi":"10.1016/s1470-2045(20)30490-3","title":"Mammography screening for breast cancer—the UK Age trial","year":2020,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto; Women's College Hospital","funders":"","keywords":"Medicine; Mammography; Breast cancer; Cancer; Breast cancer screening; Gynecology; Randomized controlled trial; Obstetrics; Demography; Internal medicine","score_opus":0.2247315705978011,"score_gpt":0.41328785790321887,"score_spread":0.18855628730541776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097553720","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006870491,0.0012667321,0.00055146863,0.9886201,0.0017567677,0.0023627111,0.0007357175,0.000121556535,0.0038979205],"genre_scores_gemma":[0.0046037226,0.00039690643,0.0011651132,0.9196744,0.0719328,0.0009355153,0.00027423532,0.000066541834,0.0009507823],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972835,0.00031386988,0.00048097447,0.00053576427,0.0004984489,0.00088745315],"domain_scores_gemma":[0.99782974,0.00077827554,0.00040464452,0.0007359204,0.00014938951,0.00010205992],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00074528134,0.00038962305,0.0014301832,0.00007955073,0.00033458156,0.000057554156,0.00091955456,0.000661478,0.00035557395],"category_scores_gemma":[0.00013703815,0.00021784646,0.0005688243,0.00036268108,0.00042537993,0.000034447552,0.00015975436,0.002745013,0.0000260793],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028472997,0.000010525738,0.0003111104,0.00014029142,0.00041186283,0.00082881795,0.00016974793,0.0000059264735,0.000018775823,0.000069043395,0.95335,0.016210921],"study_design_scores_gemma":[0.022874039,0.0011911094,0.00095063576,0.00021902272,0.00090986333,0.0003964949,0.00009862668,0.00003933742,0.0000056893296,0.000523417,0.97254884,0.00024292218],"about_ca_topic_score_codex":0.0007412676,"about_ca_topic_score_gemma":0.0003721414,"teacher_disagreement_score":0.070176035,"about_ca_system_score_codex":0.00021530797,"about_ca_system_score_gemma":0.0004905729,"threshold_uncertainty_score":0.9995557},"labels":[],"label_agreement":null},{"id":"W3099458684","doi":"10.1016/s1470-2045(20)30605-7","title":"Oncology nursing workforce: challenges, solutions, and future strategies","year":2020,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Healthcare professionals’ stress and burnout","field":"Health Professions","cited_by":155,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Workforce; Nursing; Medicine; Oncology nursing; Nurse education; Occupational health nursing; Workforce planning; Nursing shortage; Health policy; Political science; Public health","score_opus":0.38564723688076513,"score_gpt":0.5618801644795668,"score_spread":0.17623292759880166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3099458684","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000012043421,0.81193334,0.00001926279,0.13437262,0.0038362998,0.001761409,0.00010033562,0.00017013252,0.047805373],"genre_scores_gemma":[0.000010015287,0.97393936,0.00043066996,0.0026776637,0.021343391,0.0009276776,0.00012281151,0.000083568826,0.00046485223],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98748916,0.008726948,0.0013108045,0.0007078932,0.00025886978,0.0015063396],"domain_scores_gemma":[0.99418235,0.0034746968,0.0011568022,0.0006989511,0.00014540032,0.00034179143],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00269151,0.00058785925,0.0041327374,0.00012334206,0.0018219409,0.000018245719,0.0007587814,0.0025318922,0.00030466015],"category_scores_gemma":[0.00015158221,0.00034438274,0.00024179113,0.00029120315,0.00047027195,0.000099761266,0.00045521357,0.0057387967,0.00035990126],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059418617,0.000056400506,0.0000020225723,0.011662312,0.00008897751,0.000052655385,0.003807547,5.5345527e-8,4.971387e-8,0.08330204,0.021726333,0.8792422],"study_design_scores_gemma":[0.00060015806,0.00030495433,0.000039160674,0.02872548,0.00036275334,0.00008862324,0.013687026,0.0000057240054,2.776548e-9,0.0036840562,0.9521961,0.00030594936],"about_ca_topic_score_codex":0.000050987004,"about_ca_topic_score_gemma":0.00025769434,"teacher_disagreement_score":0.93046975,"about_ca_system_score_codex":0.0014651744,"about_ca_system_score_gemma":0.00979559,"threshold_uncertainty_score":0.9999008},"labels":[],"label_agreement":null},{"id":"W3103760605","doi":"10.1016/s1470-2045(20)30612-4","title":"Essential oncology nursing care along the cancer continuum","year":2020,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":116,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Oncology nursing; Nursing; Promotion (chess); Medicine; Oncology; Pillar; Internal medicine; Nurse education; Political science","score_opus":0.32283938954102565,"score_gpt":0.5639838032665098,"score_spread":0.24114441372548412,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3103760605","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005027849,0.96125865,0.000032091117,0.011968144,0.0018510254,0.0010388418,0.000104174425,0.00005741865,0.023639368],"genre_scores_gemma":[0.00014241127,0.9902503,0.00029108473,0.0016126108,0.006964562,0.00023474461,0.00012182341,0.00005585504,0.00032662138],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972135,0.000984464,0.0006708301,0.0004138402,0.00022525618,0.0004921544],"domain_scores_gemma":[0.9969284,0.0014524525,0.0006897767,0.0006309308,0.00019564407,0.000102798855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004514185,0.0003800594,0.0040022796,0.00006315747,0.00012160942,0.000010887958,0.0006743381,0.00054372224,0.00021394023],"category_scores_gemma":[0.00032435154,0.00018977546,0.0005314363,0.00031768475,0.0006796124,0.000020748244,0.00014688933,0.0012321468,0.00007678567],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015675994,0.000048463444,0.00010122231,0.004827797,0.00059125095,0.00018759936,0.0064519444,2.8381191e-7,0.0000044002163,0.00031785155,0.04128701,0.94602543],"study_design_scores_gemma":[0.0010394368,0.00045433154,0.00002465909,0.015871495,0.0037838668,0.00014746297,0.0015253703,0.0000018437524,0.000017029,0.00003077269,0.9769306,0.00017309617],"about_ca_topic_score_codex":0.00037230056,"about_ca_topic_score_gemma":0.00090925145,"teacher_disagreement_score":0.94585234,"about_ca_system_score_codex":0.0011130149,"about_ca_system_score_gemma":0.002658196,"threshold_uncertainty_score":0.7738818},"labels":[],"label_agreement":null},{"id":"W3108852904","doi":"10.1016/s1470-2045(20)30561-1","title":"Drug repurposing in oncology","year":2020,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Computational Drug Discovery Methods","field":"Computer Science","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada; Astellas Pharma; Merck Sharp and Dohme; EMD Serono; Ipsen; Pfizer","keywords":"Drug repositioning; Repurposing; Medicine; Drug; Alternative medicine; Scopus; Pharmacology; Oncology; MEDLINE; Internal medicine; Pathology; Political science","score_opus":0.08677252661125053,"score_gpt":0.37699662881572,"score_spread":0.2902241022044695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3108852904","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001678145,0.00040786277,0.029624429,0.9437489,0.002379493,0.00040624826,0.000009791622,0.00019810359,0.023057355],"genre_scores_gemma":[0.0003748985,0.000105088475,0.06368504,0.92744964,0.007732579,0.00009671034,0.000037974565,0.00003362426,0.000484417],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9933861,0.0040400214,0.0005928126,0.0008478091,0.0003982505,0.00073499157],"domain_scores_gemma":[0.9933554,0.005009719,0.00043299462,0.0010768909,0.000069161506,0.000055861972],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0018890597,0.00032898827,0.0011679439,0.00019939365,0.00011514896,0.00011177746,0.003639022,0.0005030727,0.00003004278],"category_scores_gemma":[0.00036353944,0.0002568212,0.00015013502,0.00069390214,0.00021341922,0.00019329516,0.0013454296,0.0038714244,0.00022519472],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026152427,0.000028899774,0.000018926752,0.000043273194,0.000031415602,0.0025772825,0.0015069762,0.0011242917,0.00001106279,0.006022334,0.94062823,0.047981177],"study_design_scores_gemma":[0.0005773267,0.00013828832,0.00011907531,0.00003165801,0.000014573582,0.00021321932,0.000015734164,0.018945359,0.000016075426,0.048740346,0.9309303,0.00025802513],"about_ca_topic_score_codex":0.00009454891,"about_ca_topic_score_gemma":0.0000958408,"teacher_disagreement_score":0.04772315,"about_ca_system_score_codex":0.0008963211,"about_ca_system_score_gemma":0.0012940163,"threshold_uncertainty_score":0.9999884},"labels":[],"label_agreement":null},{"id":"W3110361823","doi":"10.1016/s1470-2045(20)30586-6","title":"Nadofaragene firadenovec: a new gold standard for BCG-unresponsive bladder cancer?","year":2020,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Cystectomy; Bladder cancer; Medicine; Cancer; Gold standard (test); Disease; Urology; Internal medicine; Oncology; Surgery","score_opus":0.09688751176217797,"score_gpt":0.37808595999089734,"score_spread":0.28119844822871937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3110361823","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015669546,0.005263647,0.00043567788,0.9818407,0.001888055,0.0025579107,0.0021235682,0.00017468934,0.005559038],"genre_scores_gemma":[0.00042775617,0.0015817651,0.0015706617,0.91699934,0.041743603,0.0008422591,0.00047731638,0.0001696973,0.036187626],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971632,0.0002573508,0.00046021762,0.00073640374,0.00045226002,0.0009305646],"domain_scores_gemma":[0.9978018,0.0006640306,0.00032849656,0.0008031738,0.00019003992,0.00021246655],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00019422949,0.00056963525,0.0019561276,0.00009327402,0.00013823953,0.0000373579,0.000546288,0.00087020185,0.0010831766],"category_scores_gemma":[0.00018281526,0.0003812336,0.00039230485,0.00022534303,0.00021156103,0.000036928115,0.00012055994,0.0019248693,0.00014006853],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062332586,0.000033419583,0.00004767245,0.0002837934,0.0015462077,0.0013066554,0.0007121314,0.0000025199693,0.00017076678,0.00005551389,0.9733069,0.016301138],"study_design_scores_gemma":[0.009384457,0.0034881113,0.00011805887,0.00013506475,0.001878069,0.0002356334,0.00004652553,0.000012118965,0.00035336576,0.0015784624,0.9824156,0.00035451015],"about_ca_topic_score_codex":0.0006200072,"about_ca_topic_score_gemma":0.00023052467,"teacher_disagreement_score":0.064841405,"about_ca_system_score_codex":0.0009440039,"about_ca_system_score_gemma":0.0040773614,"threshold_uncertainty_score":0.999864},"labels":[],"label_agreement":null},{"id":"W3117371653","doi":"10.1016/s1470-2045(20)30633-1","title":"Should stereotactic ablative body radiotherapy be the standard of care in oligometastatic cancer?","year":2020,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"SABR volatility model; Medicine; Ablative case; Radiosurgery; Radiation therapy; Observational study; Oncology; Internal medicine","score_opus":0.08530910389744431,"score_gpt":0.3918557738200811,"score_spread":0.3065466699226368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3117371653","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0051015946,0.010109149,0.000033376135,0.9802737,0.00040509878,0.0015552317,0.0009467982,0.00002820405,0.0015468284],"genre_scores_gemma":[0.044439748,0.005027907,0.000864539,0.9454369,0.0030406045,0.00040477712,0.00030034778,0.00008725317,0.00039790687],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99718904,0.0010730891,0.00046643833,0.0003681497,0.00042808702,0.00047516634],"domain_scores_gemma":[0.9974632,0.0012585719,0.00041464303,0.00070725085,0.00010641257,0.000049912032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042202233,0.00035172244,0.0019329474,0.00009881767,0.00006967783,0.000013294225,0.00037763806,0.0002786027,0.00046720137],"category_scores_gemma":[0.00008069286,0.00017446473,0.00021826893,0.00030792042,0.00035442965,0.000023517185,0.000065943175,0.0019948941,0.000005669188],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048672208,0.00010468797,0.0015546269,0.0012952483,0.0032489162,0.0031410623,0.01233136,0.000036501006,0.000054287044,0.00025913864,0.960766,0.012340957],"study_design_scores_gemma":[0.005171913,0.004278525,0.0010340849,0.00019935041,0.0010323314,0.00009074324,0.00086386764,0.00003338266,0.00008890081,0.00021087675,0.98683745,0.00015858686],"about_ca_topic_score_codex":0.0004950148,"about_ca_topic_score_gemma":0.00056953885,"teacher_disagreement_score":0.039338153,"about_ca_system_score_codex":0.00087977375,"about_ca_system_score_gemma":0.00075901474,"threshold_uncertainty_score":0.8666933},"labels":[],"label_agreement":null},{"id":"W3118656197","doi":"10.1016/s1470-2045(20)30606-9","title":"Surgery for malignant pleural mesothelioma after radiotherapy (SMART): final results from a single-centre, phase 2 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Princess Margaret Hospital Foundation","keywords":"Medicine; Extrapleural Pneumonectomy; Mesothelioma; Perioperative; Radiation therapy; Clinical endpoint; Surgery; Pneumonectomy; Cumulative incidence; Randomized controlled trial; Internal medicine; Lung; Pathology","score_opus":0.10286350707183199,"score_gpt":0.35235488199664755,"score_spread":0.24949137492481555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3118656197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97903204,0.0012168763,0.000085664054,0.016882239,0.0005927047,0.0005226867,0.0012715599,0.000033072065,0.00036313964],"genre_scores_gemma":[0.9850441,0.00015836665,0.0017769824,0.0070327986,0.002867997,0.00015661657,0.001074179,0.00002572984,0.0018632105],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.998756,0.00022128192,0.00031037218,0.00026983905,0.00016065233,0.0002818456],"domain_scores_gemma":[0.9982021,0.0012827498,0.00010507302,0.00028897088,0.000028652115,0.0000924732],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002957398,0.00012950822,0.0004830043,0.000028643148,0.000069236594,0.000013230415,0.000069062815,0.00008170667,0.00066056545],"category_scores_gemma":[0.00024428853,0.000085205975,0.00020107423,0.00007335495,0.000110752495,0.000033288616,0.00002709925,0.000097973985,0.00003113794],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8711232,0.0041002384,0.009607054,0.000045101653,0.0003914963,0.0008051164,0.00045441068,0.0000064021283,0.015607582,0.000083829094,0.06914379,0.028631788],"study_design_scores_gemma":[0.309607,0.0033048438,0.080125675,0.00013642413,0.00054152036,0.00012442315,0.00018457309,0.0005809812,0.005769193,0.0011278462,0.59815943,0.00033809408],"about_ca_topic_score_codex":0.000026394317,"about_ca_topic_score_gemma":0.00005374724,"teacher_disagreement_score":0.56151617,"about_ca_system_score_codex":0.0001466034,"about_ca_system_score_gemma":0.00017952225,"threshold_uncertainty_score":0.72327286},"labels":[],"label_agreement":null},{"id":"W3120241209","doi":"10.1016/s1470-2045(20)30642-2","title":"Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":255,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Pfizer","keywords":"Palbociclib; Interim analysis; Medicine; Interim; Adjuvant; Oncology; Breast cancer; Internal medicine; Cancer; Endocrine system; Adjuvant therapy; Gynecology; Clinical trial; Metastatic breast cancer; History; Hormone","score_opus":0.08323415090640111,"score_gpt":0.4366332390939129,"score_spread":0.35339908818751176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120241209","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98999834,0.0020011,0.00009647845,0.005373264,0.00011254498,0.0018247666,0.00012205065,0.000032776206,0.0004387046],"genre_scores_gemma":[0.995307,0.0011420229,0.00073792756,0.0017324683,0.00018952235,0.0005554744,0.000027404392,0.000037581958,0.00027055346],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976203,0.0005930369,0.0005600698,0.0004727787,0.00027039807,0.00048340502],"domain_scores_gemma":[0.9980815,0.00038248286,0.0003427133,0.0007828522,0.00030873172,0.0001017164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051448226,0.0002679033,0.0020042611,0.00018860037,0.00005438863,0.000022574235,0.00045337275,0.00005856576,0.0007633908],"category_scores_gemma":[0.000046250192,0.00016101394,0.00008946756,0.0013406936,0.00021735903,0.00011455419,0.0001839986,0.00036677983,0.0000040390814],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36422944,0.014669919,0.34328464,0.00006347106,0.011490245,0.0014763726,0.013415921,0.0003526935,0.022065891,0.00006431926,0.000081660066,0.22880541],"study_design_scores_gemma":[0.6183466,0.00550858,0.36107126,0.00018017301,0.0024921384,0.00024218507,0.0044778413,0.0007064948,0.0022354682,0.000037001588,0.0043912423,0.00031103558],"about_ca_topic_score_codex":0.001993514,"about_ca_topic_score_gemma":0.009135486,"teacher_disagreement_score":0.25411713,"about_ca_system_score_codex":0.00027803262,"about_ca_system_score_gemma":0.0004498715,"threshold_uncertainty_score":0.83585936},"labels":[],"label_agreement":null},{"id":"W3122379226","doi":"10.1016/s1470-2045(20)30675-6","title":"Global demand for cancer surgery and an estimate of the optimal surgical and anaesthesia workforce between 2018 and 2040: a population-based modelling study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":131,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"University of New South Wales; UK Research and Innovation; World Health Organization","keywords":"Workforce; Cancer surgery; Population; Medicine; Cancer; Operations management; Business; Economics; Environmental health; Economic growth; Internal medicine","score_opus":0.07665875296806546,"score_gpt":0.4412849846689496,"score_spread":0.36462623170088415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3122379226","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866229,0.004690547,0.0035463397,0.00447831,0.00014686695,0.00043927433,0.000029639346,0.0000139930535,0.00003211219],"genre_scores_gemma":[0.99087435,0.0010174747,0.006937658,0.00039454343,0.0006796096,0.000042786858,0.000011401648,0.000010510169,0.000031669657],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99899393,0.0002681104,0.0002240377,0.00022849836,0.00008104883,0.00020437248],"domain_scores_gemma":[0.99877393,0.000774688,0.0001260753,0.00021150426,0.000051259132,0.00006253536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064722716,0.00011338526,0.000624071,0.000017400236,0.00017694787,0.000007520063,0.00006313626,0.0001233053,0.000006550839],"category_scores_gemma":[0.000035959085,0.00006603169,0.000037256545,0.000112368565,0.00028077746,0.000041988438,0.000030051053,0.00011593111,3.9556177e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00093552464,0.00010251789,0.96925646,0.00004256119,0.000079812584,0.00002184633,0.00020837931,0.005847139,0.0000041708563,0.00036177525,0.00007914912,0.02306065],"study_design_scores_gemma":[0.0050201323,0.00087175035,0.9348325,0.00007839669,0.00038783925,0.00018336464,0.0002557451,0.049860768,0.000014526487,0.0012341958,0.0071176114,0.00014316922],"about_ca_topic_score_codex":0.000088165296,"about_ca_topic_score_gemma":0.0002843154,"teacher_disagreement_score":0.044013627,"about_ca_system_score_codex":0.000064424166,"about_ca_system_score_gemma":0.00018865685,"threshold_uncertainty_score":0.2692694},"labels":[],"label_agreement":null},{"id":"W3126453280","doi":"10.1016/s1470-2045(21)00017-6","title":"SARS-CoV-2 vaccination and phase 1 cancer clinical trials","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"SARS-CoV-2 and COVID-19 Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy; National Center for Advancing Translational Sciences; University of Texas MD Anderson Cancer Center; National Institutes of Health; National Cancer Institute; National Institute for Health and Care Research","keywords":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Vaccination; Clinical trial; Cancer; Coronavirus disease 2019 (COVID-19); Virology; 2019-20 coronavirus outbreak; Medicine; Cancer vaccine; Phase (matter); Internal medicine; Immunotherapy; Outbreak; Disease; Infectious disease (medical specialty); Physics","score_opus":0.4146818085413431,"score_gpt":0.59758254373599,"score_spread":0.18290073519464684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3126453280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95438117,0.0027644658,0.00016858318,0.031432558,0.0005626803,0.00041430065,0.00001495552,0.000047254376,0.010214017],"genre_scores_gemma":[0.7558783,0.00090097764,0.00027038495,0.23878805,0.003824552,0.00013876102,0.000008319818,0.000022699374,0.00016791954],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971892,0.0015184209,0.0005055688,0.00028875223,0.0001922677,0.0003057694],"domain_scores_gemma":[0.99721766,0.0020485583,0.00014679789,0.00037096685,0.00018913682,0.000026863041],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0057774857,0.00010427502,0.00092125934,0.000048476246,0.0000763557,0.000022096994,0.00013190825,0.00019695052,0.00008114871],"category_scores_gemma":[0.0034887937,0.000066040135,0.00011540081,0.00020476912,0.0001074946,0.00003961365,0.00010454724,0.00047183395,0.00005654623],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039360896,0.0009194247,0.0370499,0.00013677479,0.0003813546,0.000439003,0.0004888016,1.0374156e-7,0.3625003,0.0022471892,0.060490035,0.531411],"study_design_scores_gemma":[0.015058701,0.00073064264,0.010369969,0.00002582179,0.00017437658,0.00013036226,0.000078855504,0.000313197,0.1341004,0.001440042,0.8374931,0.00008449645],"about_ca_topic_score_codex":0.00009833134,"about_ca_topic_score_gemma":0.00035979276,"teacher_disagreement_score":0.7770031,"about_ca_system_score_codex":0.00011890446,"about_ca_system_score_gemma":0.00081853435,"threshold_uncertainty_score":0.4176664},"labels":[],"label_agreement":null},{"id":"W3127104364","doi":"10.1016/s1470-2045(20)30582-9","title":"Fertility preservation for male patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group","year":2021,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Reproductive Biology and Fertility","field":"Medicine","cited_by":200,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Hospital for Sick Children","funders":"Medical Research Council; European Commission; University of Leeds; UK Research and Innovation; Memorial Sloan-Kettering Cancer Center","keywords":"Fertility; Guideline; Medicine; Fertility preservation; Grading (engineering); Harmonization; Family medicine; Cancer; Psychological intervention; Young adult; Gerontology; Pediatrics; Gynecology; Population; Environmental health; Nursing; Pathology; Internal medicine","score_opus":0.03741093181337938,"score_gpt":0.34715840043879465,"score_spread":0.30974746862541525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3127104364","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0449575,0.9325943,0.00028024564,0.015838914,0.00095835695,0.004428562,0.00088116515,0.000019099381,0.00004186201],"genre_scores_gemma":[0.020840257,0.972582,0.00027348174,0.0020773876,0.00070650835,0.0011251755,0.0023134004,0.000022775765,0.00005902482],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9978455,0.00077477103,0.00058934285,0.00047223354,0.00013876855,0.00017942439],"domain_scores_gemma":[0.99721545,0.0009492273,0.00067236327,0.0005048983,0.0006228001,0.000035236495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008017886,0.00023528229,0.0011994181,0.000023459837,0.000190404,0.000016021695,0.0002458968,0.00020111061,0.000035900415],"category_scores_gemma":[0.0012551062,0.0001042047,0.000108786466,0.00012746897,0.00043415674,0.000063370244,0.00015440132,0.00042301754,3.3704094e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033800642,0.0006100822,0.2623051,0.0020510056,0.0021909145,0.0000010075198,0.0012568042,0.0000020991622,0.000004419746,0.00022695145,0.008800511,0.71917105],"study_design_scores_gemma":[0.0058179446,0.00018025571,0.7251527,0.0027991638,0.0019959528,0.0000069429707,0.000042705273,0.000052304076,0.0000071418262,0.00013289943,0.26369053,0.00012145045],"about_ca_topic_score_codex":0.0008027082,"about_ca_topic_score_gemma":0.0010388073,"teacher_disagreement_score":0.7190496,"about_ca_system_score_codex":0.0001254394,"about_ca_system_score_gemma":0.00029243977,"threshold_uncertainty_score":0.42493445},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"not_applicable","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"split"},{"id":"W3134103265","doi":"10.1016/s1470-2045(20)30756-7","title":"Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group","year":2021,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":268,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Hotel Dieu Hospital","funders":"Janssen Pharmaceuticals; Merck Sharp and Dohme; Genesis Pharma; Genentech; National Natural Science Foundation of China; Takeda Pharmaceutical Company; AbbVie; Sanofi; Roche; Novartis; GlaxoSmithKline; Celgene; Bayer; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer","keywords":"Multiple myeloma; Refractory (planetary science); Medicine; Clinical trial; Internal medicine; Oncology; Clinical Practice; Family medicine","score_opus":0.17899591068222734,"score_gpt":0.42305126285013306,"score_spread":0.24405535216790572,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134103265","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000760783,0.9882635,0.000012327691,0.0060020844,0.00063957914,0.0011937597,0.00035016707,0.00003343875,0.0027443501],"genre_scores_gemma":[0.0021533018,0.9914218,0.0014924805,0.00019053121,0.0013745723,0.0004163248,0.0023097112,0.000040080446,0.0006011995],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99758023,0.00082756125,0.0005605863,0.00042493746,0.00026859422,0.0003380796],"domain_scores_gemma":[0.99403936,0.004572052,0.00043107365,0.000769733,0.00008159036,0.000106219944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038044646,0.00032275298,0.0019084828,0.000085454725,0.00017077544,0.000030475647,0.0003648667,0.0002728726,0.00032547614],"category_scores_gemma":[0.00042180243,0.00015809477,0.00033294308,0.00018890495,0.00022220919,0.000032189335,0.00021049076,0.0004664057,0.000034634137],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022197714,0.00047700628,0.0016189959,0.0002075456,0.0019594657,0.00020049898,0.00029530647,4.7248236e-8,0.000008401273,0.00017677166,0.0027163127,0.99211764],"study_design_scores_gemma":[0.0040140557,0.0005904422,0.0021487512,0.0019947905,0.0010125437,0.00020881958,0.00015059135,0.000022846403,0.0000034139596,0.000033671855,0.98970723,0.00011286181],"about_ca_topic_score_codex":0.00027566933,"about_ca_topic_score_gemma":0.0004389192,"teacher_disagreement_score":0.9920048,"about_ca_system_score_codex":0.0006861472,"about_ca_system_score_gemma":0.00043929016,"threshold_uncertainty_score":0.64469177},"labels":[],"label_agreement":null},{"id":"W3135376158","doi":"10.1016/s1470-2045(21)00006-1","title":"Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":227,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Zhongshan Hospital","keywords":"Medicine; Chemotherapy; Ovarian cancer; Internal medicine; Open label; Oncology; Randomized controlled trial; Surgery; Cancer","score_opus":0.061897894713462485,"score_gpt":0.393795617724443,"score_spread":0.3318977230109805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135376158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9035451,0.0019942352,0.000050001498,0.07919727,0.0029808125,0.004727775,0.00019587624,0.00007187986,0.0072370893],"genre_scores_gemma":[0.9624934,0.009334677,0.003350196,0.015844297,0.0035727182,0.0022844677,0.0005442283,0.00012832254,0.0024476987],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975126,0.000540677,0.00054532377,0.0006236055,0.00023373996,0.0005441029],"domain_scores_gemma":[0.9981855,0.00066942204,0.00030344512,0.00056519825,0.00013312695,0.00014329719],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007102063,0.0003222512,0.0013834548,0.0000614211,0.00014343507,0.000054415123,0.000215503,0.00027315403,0.0014963597],"category_scores_gemma":[0.00013719559,0.0002438614,0.00012435605,0.00037641556,0.00014380246,0.000120344375,0.000062781946,0.0005282808,0.000024756413],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81630564,0.006478872,0.00016135059,0.000029431718,0.0014034214,0.00048103445,0.0026573688,0.000006124053,0.015737465,0.00011492157,0.060125865,0.096498534],"study_design_scores_gemma":[0.8795237,0.0028929391,0.0005519262,0.0000926073,0.00033631778,0.000049403207,0.0004764302,0.00018361202,0.020004975,0.000051914234,0.09560299,0.00023319149],"about_ca_topic_score_codex":0.00078592746,"about_ca_topic_score_gemma":0.0009956204,"teacher_disagreement_score":0.096265346,"about_ca_system_score_codex":0.0011535751,"about_ca_system_score_gemma":0.0011970025,"threshold_uncertainty_score":0.9994164},"labels":[],"label_agreement":null},{"id":"W3135662544","doi":"10.1016/s1470-2045(21)00019-x","title":"Pembrolizumab monotherapy in metastatic triple-negative breast cancer","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Pembrolizumab; Triple-negative breast cancer; Metastatic breast cancer; Oncology; Breast cancer; Internal medicine; Cancer; Immunotherapy","score_opus":0.05430835432453917,"score_gpt":0.3755661800372451,"score_spread":0.32125782571270595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135662544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.876593,0.00607771,0.00006004344,0.10529799,0.000703416,0.00062938867,0.000098909404,0.000059852104,0.010479717],"genre_scores_gemma":[0.97018534,0.0071242047,0.00062322355,0.01823889,0.000627617,0.00021942952,0.000015112155,0.000029782308,0.0029364086],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986964,0.0003326599,0.000271979,0.00022747098,0.00013715352,0.00033435092],"domain_scores_gemma":[0.99920213,0.00023376098,0.00010068502,0.00033784768,0.00008024283,0.00004534686],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00043289305,0.00013591175,0.000588925,0.000058276546,0.000053944797,0.000011248243,0.00013287342,0.00007225252,0.0017815512],"category_scores_gemma":[0.00003860442,0.000088000554,0.000107140564,0.00041746718,0.00016234083,0.00004158451,0.00002654784,0.0002941614,0.000021051297],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12687878,0.0019765492,0.04445989,0.00034026845,0.0029452676,0.0020602855,0.013371906,0.000091595604,0.093615025,0.0024664856,0.052567035,0.6592269],"study_design_scores_gemma":[0.07750298,0.0009395862,0.66996056,0.0002612393,0.00028717436,0.0026499927,0.0021447549,0.00047823827,0.010887011,0.0025555275,0.23191,0.00042294062],"about_ca_topic_score_codex":0.0009871186,"about_ca_topic_score_gemma":0.002582968,"teacher_disagreement_score":0.65880394,"about_ca_system_score_codex":0.00041601044,"about_ca_system_score_gemma":0.00073529856,"threshold_uncertainty_score":0.99913096},"labels":[],"label_agreement":null},{"id":"W3137610925","doi":"10.1016/s1470-2045(21)00005-x","title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":258,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Princess Margaret Cancer Centre","funders":"Merck","keywords":"Brentuximab vedotin; Pembrolizumab; Medicine; Interim analysis; Oncology; Internal medicine; Interim; Refractory (planetary science); Open label; Lymphoma; Hodgkin lymphoma; Clinical trial; Cancer; Immunotherapy; Materials science","score_opus":0.15786344631065277,"score_gpt":0.45622588838626277,"score_spread":0.29836244207561,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3137610925","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938118,0.0004273477,0.0000074486143,0.0018874916,0.00038963024,0.0015103389,0.000054851607,0.00003613673,0.001874949],"genre_scores_gemma":[0.997632,0.00029324065,0.0004980154,0.0006308595,0.00017528169,0.00034090847,0.00015554084,0.000028366103,0.00024577384],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99619216,0.0015574942,0.0008108636,0.00062431116,0.00032275662,0.00049240346],"domain_scores_gemma":[0.9965598,0.0016424159,0.0003601465,0.001088323,0.00016300521,0.0001862901],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008662121,0.0002965576,0.0022129384,0.00024408629,0.000082670354,0.000040325944,0.00047950435,0.00018296964,0.000580889],"category_scores_gemma":[0.0007081621,0.00018655063,0.00017063995,0.0010359944,0.00017067506,0.00008935191,0.00033034387,0.00021868553,0.000023624916],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6686434,0.14145903,0.02049245,0.000059628663,0.007760671,0.006027664,0.0060638157,0.000033490818,0.002480708,0.00017282041,0.0013015642,0.14550476],"study_design_scores_gemma":[0.8747726,0.01935252,0.08423259,0.00007534974,0.0066574104,0.00007013524,0.0035178193,0.004157695,0.00089114986,0.0000108532495,0.0060274894,0.00023437617],"about_ca_topic_score_codex":0.0005968799,"about_ca_topic_score_gemma":0.006125072,"teacher_disagreement_score":0.20612922,"about_ca_system_score_codex":0.0009851027,"about_ca_system_score_gemma":0.00095284206,"threshold_uncertainty_score":0.7607314},"labels":[],"label_agreement":null},{"id":"W3141372695","doi":"10.1016/s1470-2045(21)00034-6","title":"Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":349,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Novartis Pharmaceuticals Corporation","keywords":"Fulvestrant; Medicine; Aromatase inhibitor; Internal medicine; Oncology; Breast cancer; Cancer; Cohort; Regimen; Clinical endpoint; Clinical trial; Estrogen receptor; Aromatase","score_opus":0.05096464552649327,"score_gpt":0.3993410276253444,"score_spread":0.34837638209885113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3141372695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985802,0.0031666746,0.00016606828,0.004376505,0.0003509767,0.004251107,0.0006441794,0.000050389655,0.0011921296],"genre_scores_gemma":[0.991376,0.0007411645,0.0039223973,0.0013173176,0.00051705335,0.0016850181,0.00009132913,0.00006405955,0.00028565203],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99633604,0.00064129604,0.0009027992,0.0008396989,0.00046633842,0.00081383064],"domain_scores_gemma":[0.99749464,0.00036741773,0.00047514244,0.00081784587,0.0006364345,0.00020850061],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00062193,0.00047564472,0.0023317635,0.00013221406,0.0000993648,0.00002923351,0.0004830911,0.00017981787,0.00043147217],"category_scores_gemma":[0.00005702757,0.0003730007,0.00008176919,0.00086486514,0.00045676847,0.00032783885,0.00036162676,0.00081046496,0.00003132568],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30301258,0.044008065,0.029386058,0.00028070403,0.0043626493,0.0027796414,0.06302731,0.0010093768,0.46720022,0.000084025094,0.00094824296,0.0839011],"study_design_scores_gemma":[0.3867896,0.011467324,0.5113239,0.0018806426,0.0013960887,0.0007895908,0.035435762,0.0015030922,0.043459345,0.00014063716,0.0044927737,0.0013212408],"about_ca_topic_score_codex":0.00082829245,"about_ca_topic_score_gemma":0.0026978345,"teacher_disagreement_score":0.48193786,"about_ca_system_score_codex":0.0012225263,"about_ca_system_score_gemma":0.0012237461,"threshold_uncertainty_score":0.9998722},"labels":[],"label_agreement":null},{"id":"W3142845014","doi":"10.1016/s1470-2045(20)30753-1","title":"MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":628,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Elekta; Medizinische Universität Wien; Aarhus Universitetshospital; Varian Medical Systems","keywords":"Brachytherapy; Medicine; Cervical cancer; Prospective cohort study; Cohort; Radiology; Medical physics; Radiation therapy; Oncology; Cancer; Internal medicine","score_opus":0.04642688280566548,"score_gpt":0.3808476131739682,"score_spread":0.3344207303683027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3142845014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9661888,0.0028012726,0.000062788684,0.012889664,0.00055421394,0.003612886,0.000028117449,0.00009452457,0.0137677435],"genre_scores_gemma":[0.9903166,0.0011566428,0.00076664175,0.004540531,0.0007279534,0.0012471759,0.000017498754,0.000034784516,0.0011921542],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99740744,0.00056052714,0.0004481821,0.0006277994,0.00038329337,0.0005727869],"domain_scores_gemma":[0.99839157,0.00049166137,0.00014809465,0.00052907673,0.00028568498,0.00015389375],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00047780268,0.00026588552,0.0011916062,0.000076134216,0.00009368459,0.00001451252,0.0002001489,0.00015477688,0.0009912882],"category_scores_gemma":[0.00021593113,0.0001728388,0.00012239312,0.0008864122,0.00012142885,0.00007001051,0.00012144537,0.00059623976,0.000061312814],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011525353,0.0035768684,0.95231414,0.000039670485,0.0008641439,0.001363763,0.0024542697,0.00023141706,0.000524382,0.00034848286,0.0004364487,0.026321087],"study_design_scores_gemma":[0.03971925,0.0023538943,0.94911474,0.000080590406,0.00030905128,0.00008070415,0.0019397524,0.00027894837,0.0007806227,0.00047929827,0.004663783,0.00019936518],"about_ca_topic_score_codex":0.00096563576,"about_ca_topic_score_gemma":0.0106184995,"teacher_disagreement_score":0.028193898,"about_ca_system_score_codex":0.0011764134,"about_ca_system_score_gemma":0.00068274484,"threshold_uncertainty_score":0.9999219},"labels":[],"label_agreement":null},{"id":"W3145416765","doi":"10.1016/s1470-2045(21)00033-4","title":"Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renin-Angiotensin System Studies","field":"Medicine","cited_by":104,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"NIHR Oxford Biomedical Research Centre; Oxford Martin School, University of Oxford; Medical Research Council; National Institute for Health and Care Research; Department of Health and Social Care; British Heart Foundation; Cancer Research UK","keywords":"Meta-analysis; Medicine; Cancer; Clinical trial; Internal medicine; Oncology","score_opus":0.5616213605570728,"score_gpt":0.4741281292402311,"score_spread":0.08749323131684167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3145416765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9294015,0.056951653,0.000011011732,0.012225362,0.000085204614,0.00026063665,0.0007781546,0.000020527155,0.0002659282],"genre_scores_gemma":[0.989393,0.008166242,0.0011441961,0.00067240803,0.0002596792,0.000040735813,0.00012075644,0.00001053195,0.00019247572],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99815,0.0007218455,0.00033140794,0.0003809867,0.00016201324,0.00025374957],"domain_scores_gemma":[0.9976642,0.0004559912,0.00025721217,0.0013204911,0.00022900995,0.000073094714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007476053,0.00014916304,0.0024551013,0.000054490396,0.000085370884,0.0000091472875,0.0001723944,0.00007113816,0.000091859845],"category_scores_gemma":[0.00021673231,0.000074440715,0.00023924204,0.00030835136,0.00021712684,0.00003634039,0.00024514165,0.00010132648,0.000003448719],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023784592,0.000271894,0.30830842,0.000014716719,0.6788111,0.00022407313,0.0041273762,0.00006119955,0.0009542906,0.00007619759,0.0023780053,0.004534887],"study_design_scores_gemma":[0.0011845387,0.00051591033,0.34002545,0.0000031931177,0.64738536,0.00008019104,0.0007953506,0.00025455613,0.0008258026,0.000022425978,0.00883863,0.00006862793],"about_ca_topic_score_codex":0.0023433634,"about_ca_topic_score_gemma":0.008331083,"teacher_disagreement_score":0.05999145,"about_ca_system_score_codex":0.00002779744,"about_ca_system_score_gemma":0.00019459629,"threshold_uncertainty_score":0.464894},"labels":[],"label_agreement":null},{"id":"W3149244744","doi":"10.1016/s1470-2045(18)30599-0","title":"Exercise as part of routine cancer care","year":2018,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; William Osler Health System; Toronto Rehabilitation Institute; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Context (archaeology); Position statement; Cancer; Alternative medicine; Health care; Family medicine; Clinical Oncology; Regimen; Internal medicine; Pathology","score_opus":0.051085282648173205,"score_gpt":0.3596898286255354,"score_spread":0.3086045459773622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3149244744","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011176169,0.013355154,0.0000018261848,0.89075726,0.0052856323,0.00072494487,0.00035637963,0.000089270005,0.078253336],"genre_scores_gemma":[0.022656383,0.0054070987,0.00003763918,0.89648867,0.054212335,0.0003602835,0.00051996944,0.000095199925,0.02022245],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982754,0.00018147576,0.00034209073,0.00035586144,0.00034405128,0.0005011273],"domain_scores_gemma":[0.9981663,0.00014622005,0.00030441716,0.0009742424,0.00035189264,0.000056902194],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00025072193,0.00027621936,0.0013960337,0.0000706937,0.000057122914,0.00000683568,0.0004228867,0.0008641916,0.002592168],"category_scores_gemma":[0.000041555664,0.00017894153,0.00021531848,0.00016603577,0.00038579016,0.000015735584,0.00012594998,0.0013949455,0.00016712205],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005469674,0.000016858288,0.0006984686,0.0008172195,0.00013867358,0.00020502898,0.0029518793,3.0411636e-7,0.000019154339,0.000019764559,0.9822358,0.0123499185],"study_design_scores_gemma":[0.0012964552,0.0006052953,0.00034779843,0.0007403775,0.00070352317,0.000056918743,0.00048722053,7.936686e-7,0.0004577752,0.000081622384,0.9950441,0.00017808018],"about_ca_topic_score_codex":0.004164636,"about_ca_topic_score_gemma":0.003305403,"teacher_disagreement_score":0.058030885,"about_ca_system_score_codex":0.00034440926,"about_ca_system_score_gemma":0.00078244077,"threshold_uncertainty_score":0.9983196},"labels":[],"label_agreement":null},{"id":"W3149822024","doi":"10.1016/s1470-2045(21)00085-1","title":"Elucidating the association between antihypertensive drugs and cancer: a need for real-world studies","year":2021,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Hormonal Regulation and Hypertension","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Observational study; Thiazide; Calcium channel; Angiotensin Receptor Blockers; Calcium channel blocker; Antihypertensive drug; Meta-analysis; Cancer; Pharmacology; Internal medicine; Angiotensin-converting enzyme; Oncology; Calcium; Diuretic; Blood pressure","score_opus":0.1367906492051603,"score_gpt":0.3990965004591731,"score_spread":0.26230585125401285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3149822024","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015664065,0.0044304715,0.000008114373,0.97668093,0.00046919193,0.00079034857,0.0000676448,0.000044828317,0.0018444016],"genre_scores_gemma":[0.01939535,0.0121215815,0.00032965082,0.9298774,0.023474092,0.00024513627,0.000405055,0.000057067056,0.014094686],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99833286,0.00034954114,0.00033033255,0.0002996506,0.0003016401,0.00038598437],"domain_scores_gemma":[0.9948652,0.0036729672,0.00043181045,0.0003136566,0.00068419427,0.000032208864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009818433,0.00021186804,0.0013482976,0.0000733689,0.00030355045,0.000025567906,0.00012453848,0.000411835,0.00001543446],"category_scores_gemma":[0.0007041926,0.00011071498,0.0001266321,0.0001833768,0.00013506213,0.000025215231,0.00010504521,0.0010379757,0.000004826554],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008336714,0.000007214588,0.0041543464,0.00015888781,0.0011734085,0.000057317247,0.0011351769,7.2577285e-7,0.0002505757,0.00009258026,0.97499406,0.017892353],"study_design_scores_gemma":[0.0016320235,0.00014126426,0.018702144,0.0002003901,0.0014878259,0.000028057026,0.00079063326,0.00008123478,0.00007641036,0.00027705872,0.9764555,0.0001274213],"about_ca_topic_score_codex":0.0002874767,"about_ca_topic_score_gemma":0.00027661532,"teacher_disagreement_score":0.046803553,"about_ca_system_score_codex":0.0005507566,"about_ca_system_score_gemma":0.00031362716,"threshold_uncertainty_score":0.45148256},"labels":[],"label_agreement":null},{"id":"W3152750473","doi":"10.1016/s1470-2045(21)00081-4","title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Pharmacyclics; Novartis Pharma; EMD Serono; Meso Scale Diagnostics; Les Laboratories Pierre Fabre; Johnson and Johnson; Genentech; Eisai; SkylineDx; Array BioPharma; Ipsen; Syndax Pharmaceuticals; Pfizer; Incyte; Sun Pharma; Regeneron Pharmaceuticals; Sanofi; AstraZeneca; EUSA Pharma; Roche; Novartis; GlaxoSmithKline; Amgen; Qbiotics; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Pembrolizumab; Medicine; Clinical endpoint; Hazard ratio; Placebo; Internal medicine; Quality of life (healthcare); Population; Clinical trial; Adverse effect; Oncology; Melanoma; Randomized controlled trial; Surgery; Cancer; Confidence interval; Pathology; Immunotherapy; Alternative medicine","score_opus":0.16983074091665748,"score_gpt":0.43179126405716817,"score_spread":0.26196052314051066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3152750473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95775074,0.0064033624,0.000030690055,0.021184573,0.002084604,0.005310963,0.00045063026,0.0001007153,0.006683711],"genre_scores_gemma":[0.99186605,0.002041897,0.00015598201,0.0019707372,0.0011412433,0.0004714007,0.0008804277,0.00004852422,0.0014237355],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99146503,0.0034937195,0.0029590586,0.0006932384,0.0005620073,0.0008269158],"domain_scores_gemma":[0.9910677,0.0057375086,0.0015240639,0.0011919452,0.00023739514,0.00024137324],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0065113306,0.0003884819,0.0040038796,0.00021125289,0.00016036844,0.000027503515,0.0004135651,0.0004986662,0.0008347452],"category_scores_gemma":[0.002413165,0.00027493088,0.00050327997,0.0007206122,0.00036365268,0.00007582658,0.00011458295,0.0010007828,0.000021225767],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9789946,0.0013631769,0.00003293906,0.00007483942,0.0017002155,0.00028945334,0.002843254,0.0000317415,0.006147485,0.00024078444,0.003523436,0.0047580935],"study_design_scores_gemma":[0.9756864,0.0052947868,0.00049007457,0.00015333042,0.00023689985,0.000024279507,0.0011003684,0.00031924224,0.0008864387,0.00006260873,0.0154812,0.00026439814],"about_ca_topic_score_codex":0.010067097,"about_ca_topic_score_gemma":0.009628176,"teacher_disagreement_score":0.0341153,"about_ca_system_score_codex":0.000713361,"about_ca_system_score_gemma":0.0036595992,"threshold_uncertainty_score":0.9999703},"labels":[],"label_agreement":null},{"id":"W3153228158","doi":"10.1016/s1470-2045(21)00065-6","title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":389,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Merck","keywords":"Medicine; Pembrolizumab; Hazard ratio; Internal medicine; Placebo; Clinical endpoint; Population; Oncology; Clinical trial; Melanoma; Surgery; Cancer; Confidence interval; Pathology; Immunotherapy","score_opus":0.10081132649555286,"score_gpt":0.3732081519797956,"score_spread":0.27239682548424277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3153228158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9241124,0.00079374696,0.00033450822,0.012275834,0.0050898623,0.007005792,0.0005906962,0.00023787832,0.049559303],"genre_scores_gemma":[0.9870614,0.0006278308,0.0003425937,0.0007439847,0.0027211148,0.0009091937,0.00076180545,0.00007114777,0.0067609544],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9939401,0.0019471048,0.001501403,0.00092997105,0.000754947,0.00092643546],"domain_scores_gemma":[0.993312,0.0036652822,0.0006034241,0.0019091872,0.00023144313,0.00027867325],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0032414712,0.00048307728,0.002990994,0.00025552989,0.00020679536,0.000086497865,0.0005976369,0.00032609835,0.0011152287],"category_scores_gemma":[0.00267321,0.00034224903,0.0004478196,0.00058858364,0.00021783292,0.00007855154,0.00040767682,0.0009996493,0.00007658911],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9770991,0.0014358499,0.00000580874,0.00003691756,0.0014668453,0.00586451,0.00081434776,0.00007757153,0.0025828648,0.0010227158,0.0058960277,0.0036974307],"study_design_scores_gemma":[0.8765273,0.0036518655,0.000040027808,0.000046130484,0.0010398427,0.00012259615,0.0013401584,0.00096144644,0.0010297813,0.00015199311,0.11477952,0.00030934755],"about_ca_topic_score_codex":0.0014204283,"about_ca_topic_score_gemma":0.016094575,"teacher_disagreement_score":0.108883485,"about_ca_system_score_codex":0.0007148786,"about_ca_system_score_gemma":0.00079554797,"threshold_uncertainty_score":0.99990296},"labels":[],"label_agreement":null},{"id":"W3155089045","doi":"10.1016/s1470-2045(21)00098-x","title":"Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme; AstraZeneca","keywords":"Medicine; BRCA mutation; Internal medicine; Ovarian cancer; Clinical endpoint; Oncology; Olaparib; Placebo; Quality of life (healthcare); Cancer; Response Evaluation Criteria in Solid Tumors; Progression-free survival; Clinical trial; Progressive disease; Chemotherapy; Pathology","score_opus":0.02288432002918147,"score_gpt":0.3707904252599238,"score_spread":0.34790610523074234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3155089045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890843,0.000989765,0.000028709172,0.005227059,0.0002607075,0.0042272056,0.000112768656,0.00002736359,0.000042103205],"genre_scores_gemma":[0.995641,0.0009740201,0.0005126354,0.0017305639,0.0000683369,0.0009401643,0.000086098,0.000023946404,0.000023223998],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99762255,0.0009075076,0.00043812307,0.0003690903,0.00025677183,0.00040598406],"domain_scores_gemma":[0.9973162,0.0016812404,0.00044295806,0.0002677316,0.000097941636,0.00019393006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037360174,0.00020569359,0.0009839534,0.00007657329,0.00008329705,0.000012025856,0.00004501672,0.00007235478,0.00004374947],"category_scores_gemma":[0.0010106608,0.000113474154,0.00004093829,0.00021171109,0.00015569874,0.000072123614,0.000030392486,0.00024730733,4.3262082e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.77754176,0.00077275845,0.053993244,0.00021935017,0.00008200283,0.000080301186,0.001962863,0.00006167531,0.000061974795,0.000019316652,0.00023855787,0.16496618],"study_design_scores_gemma":[0.89968085,0.015188108,0.08232863,0.0012729132,0.000090730646,0.0000051251022,0.00020039972,0.0001629407,0.00025603714,0.000055131866,0.0006255241,0.00013359883],"about_ca_topic_score_codex":0.00008623534,"about_ca_topic_score_gemma":0.0003466947,"teacher_disagreement_score":0.16483259,"about_ca_system_score_codex":0.0003656444,"about_ca_system_score_gemma":0.00069711055,"threshold_uncertainty_score":0.46273416},"labels":[],"label_agreement":null},{"id":"W3155753566","doi":"10.1016/s1470-2045(21)00076-0","title":"Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":107,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; Institut National Du Cancer; ECOG-ACRIN Cancer Research Group; Ministère des Affaires Sociales, de la Santé et des Droits des Femmes; NRG Oncology; Fondation ARC pour la Recherche sur le Cancer; American College of Radiology Imaging Network","keywords":"Radiation therapy; Head and neck cancer; Head and neck; Meta-analysis; Medicine; Oncology; Medical physics; Radiology; Internal medicine; Surgery","score_opus":0.17483215799017698,"score_gpt":0.4213770556082601,"score_spread":0.24654489761808313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3155753566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8353462,0.12263121,0.000074384014,0.040882662,0.00010900976,0.0003516841,0.000094691306,0.000028191158,0.0004819491],"genre_scores_gemma":[0.8438008,0.09121232,0.013528964,0.049877927,0.00097009446,0.0001994529,0.0001825086,0.000042185206,0.00018578308],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984329,0.0003036835,0.0002812953,0.00046679768,0.00015747946,0.00035784463],"domain_scores_gemma":[0.99885046,0.00019497241,0.00009650628,0.00071290607,0.00005206109,0.00009307487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059425965,0.00016809204,0.0017362995,0.000047285666,0.00009267024,0.000017650846,0.00017546074,0.00008814947,0.00017996175],"category_scores_gemma":[0.00002888053,0.00010642084,0.000078788995,0.00046298568,0.00015925088,0.00007473494,0.00014865749,0.00024654932,4.6395436e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035897659,0.000679847,0.16807696,0.00011478013,0.100024626,0.00031918206,0.010679491,0.001113866,0.00066361536,0.00037216124,0.01200429,0.7023614],"study_design_scores_gemma":[0.015523748,0.003544569,0.43071586,0.00004797167,0.04003185,0.00013895093,0.0010327057,0.0030292943,0.00017283969,0.00040596878,0.50488394,0.00047228453],"about_ca_topic_score_codex":0.00029525146,"about_ca_topic_score_gemma":0.012493558,"teacher_disagreement_score":0.7018891,"about_ca_system_score_codex":0.00006781072,"about_ca_system_score_gemma":0.00022498677,"threshold_uncertainty_score":0.69716984},"labels":[],"label_agreement":null},{"id":"W3156638008","doi":"10.1016/s1470-2045(20)30688-4","title":"Surveillance for subsequent neoplasms of the CNS for childhood, adolescent, and young adult cancer survivors: a systematic review and recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group","year":2021,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster Children's Hospital","funders":"Brain Tumour Charity; CHILDREN with CANCER UK; Academy of Medical Sciences","keywords":"Medicine; Guideline; Psychological intervention; Cancer; Survivorship curve; Harmonization; Quality of life (healthcare); Health care; Family medicine; Intensive care medicine; Pathology; Psychiatry; Nursing; Internal medicine","score_opus":0.035375236342508255,"score_gpt":0.3573884212546502,"score_spread":0.3220131849121419,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3156638008","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006237348,0.97118264,0.00008588908,0.016716233,0.0008020121,0.008326304,0.0022447305,0.000010117491,0.000008324835],"genre_scores_gemma":[0.0012717518,0.9904743,0.00022682632,0.0020195749,0.00036825682,0.0046684197,0.0009143819,0.00003728772,0.000019243233],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9977601,0.0005791222,0.0009674917,0.000331695,0.00016400723,0.00019755556],"domain_scores_gemma":[0.99585617,0.0018989029,0.00128869,0.0004981776,0.00041717428,0.000040902967],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008068906,0.0002894505,0.0026075402,0.00003526923,0.00011039565,0.000017426959,0.00030741145,0.00013612123,0.000019367677],"category_scores_gemma":[0.0009954555,0.00013272282,0.00031886785,0.00019979426,0.00009102723,0.000024924322,0.00012755666,0.00018748394,2.4321523e-7],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006834593,0.0011759842,0.007773014,0.78475106,0.00824131,0.000004187127,0.0010383984,0.000005648746,0.000016743845,0.0011464689,0.02629637,0.1694825],"study_design_scores_gemma":[0.006945333,0.00037135076,0.009306807,0.73208827,0.027944779,0.00010979452,0.000095540985,0.00013318702,0.000046557197,0.00010926754,0.22245266,0.0003964551],"about_ca_topic_score_codex":0.0011163814,"about_ca_topic_score_gemma":0.0072011207,"teacher_disagreement_score":0.19615628,"about_ca_system_score_codex":0.00019895699,"about_ca_system_score_gemma":0.00029286597,"threshold_uncertainty_score":0.54122794},"labels":[],"label_agreement":null},{"id":"W3157621523","doi":"10.1016/s1470-2045(21)00244-8","title":"Cancer and COVID-19 vaccines: a complex global picture","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Guy's and St Thomas' NHS Foundation Trust; Menzies Centre for Australian Studies, King's College London, University of London; Science and Technology Facilities Council; Economic and Social Research Council; Homi Bhabha National Institute; Faculty of Medicine, American University of Beirut; Tata Memorial Centre; Queen's University; Hacettepe Üniversitesi; Universiti Malaya; National Institute for Health and Care Research; American University of Beirut; Cancer Research Institute; Pfizer; University of Warwick; King's College London","keywords":"Medicine; Cancer; Pandemic; Vaccination; Coronavirus disease 2019 (COVID-19); Population; Disadvantaged; Family medicine; Global health; Public health; Disease; Environmental health; Internal medicine; Economic growth; Virology; Pathology; Infectious disease (medical specialty)","score_opus":0.19691557538566312,"score_gpt":0.501693777433073,"score_spread":0.30477820204740985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157621523","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.28972876,0.003777567,0.00023035896,0.70069116,0.00029591392,0.00029893123,0.00009098859,0.00009046004,0.004795815],"genre_scores_gemma":[0.71613735,0.001594579,0.0003004585,0.2799733,0.0014061563,0.000024451434,0.000026163507,0.000008553431,0.00052896386],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99898356,0.00015583048,0.00016417765,0.00022354786,0.00011803535,0.00035482764],"domain_scores_gemma":[0.9988443,0.0003284593,0.000063997184,0.00032983386,0.00009393299,0.00033947724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002821641,0.00011485056,0.0005133944,0.000017883032,0.00013408564,0.000012414034,0.000093497445,0.00013756951,0.00075819396],"category_scores_gemma":[0.00064849434,0.00007317405,0.000041232244,0.00021233156,0.00007419145,0.000019385909,0.00009360918,0.00024874898,0.000016986514],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002804893,0.00026518817,0.35573894,0.0016777528,0.00031826907,0.0017796741,0.004412294,0.00006962614,0.0020597558,0.010863178,0.55886096,0.06114944],"study_design_scores_gemma":[0.0030719351,0.00018278441,0.25227967,0.000022463613,0.00007805924,0.0007400324,0.0003283974,0.00009346606,0.000016684526,0.0015813588,0.741539,0.00006616234],"about_ca_topic_score_codex":0.001101654,"about_ca_topic_score_gemma":0.012098983,"teacher_disagreement_score":0.4264086,"about_ca_system_score_codex":0.0006370717,"about_ca_system_score_gemma":0.002790402,"threshold_uncertainty_score":0.8301692},"labels":[],"label_agreement":null},{"id":"W3158782098","doi":"10.1016/s1470-2045(21)00009-7","title":"Diffuse intrinsic pontine glioma: a clinic in Mexico, social media, and unpublishable data","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Glioma; Brainstem; Medicine; Radiation therapy; Overall survival; Clinical trial; Pons; Oncology; Surgery; Internal medicine; Cancer research","score_opus":0.10263357418394638,"score_gpt":0.3697019884024751,"score_spread":0.2670684142185287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3158782098","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91031235,0.002064047,0.0000012570911,0.08301947,0.00028071614,0.00017763699,0.000056139867,0.000030675015,0.004057682],"genre_scores_gemma":[0.9951954,0.0006570651,0.00025923835,0.0025554516,0.0008967042,0.0000408985,0.00028559935,0.000014596316,0.00009508027],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987079,0.00022243203,0.0002652383,0.00033914697,0.00013712219,0.00032815355],"domain_scores_gemma":[0.9983845,0.0007817654,0.00008534497,0.0006150489,0.000058398513,0.00007493949],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070185045,0.00011795669,0.00064066675,0.00007583404,0.00006835667,0.000029394361,0.0002165869,0.00013093906,0.00031129256],"category_scores_gemma":[0.0007881718,0.000078274876,0.000035153073,0.00035735717,0.00013345396,0.00008152193,0.00044959757,0.00026911945,0.000047928563],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016822977,0.008034243,0.4761235,0.0001782646,0.0007510379,0.011435348,0.0048860493,5.6227486e-7,0.0037562773,0.0056037214,0.37031642,0.11723225],"study_design_scores_gemma":[0.032728687,0.00043116978,0.75701696,0.00007043649,0.00041775216,0.0007315953,0.0009411571,0.000081544786,0.00096847746,0.002872363,0.20353128,0.00020859731],"about_ca_topic_score_codex":0.00006288151,"about_ca_topic_score_gemma":0.0022383814,"teacher_disagreement_score":0.28089342,"about_ca_system_score_codex":0.000084916705,"about_ca_system_score_gemma":0.00021793047,"threshold_uncertainty_score":0.34084353},"labels":[],"label_agreement":null},{"id":"W3161800158","doi":"10.1016/s1470-2045(21)00090-5","title":"Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":327,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Vifor Pharma; European Organisation for Research and Treatment of Cancer; National Cancer Institute; Medac; KWF Kankerbestrijding; Daiichi-Sankyo; Brain Tumour Charity; NRG Oncology; Atara Biotherapeutics; AstraZeneca; American College of Radiology; Novocure; Douglas Pharmaceuticals; Merck Sharp and Dohme; Cancer Australia; National Health and Medical Research Council; Cancer Research UK; Medical Research Council; Celgene","keywords":"Temozolomide; Medicine; Internal medicine; Oncology; Interim analysis; Radiation therapy; Glioma; Dacarbazine; Clinical trial; Chemotherapy; Cancer research","score_opus":0.10069948046989596,"score_gpt":0.4439617932321269,"score_spread":0.34326231276223096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3161800158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916645,0.0007879042,0.0001053887,0.0009333447,0.00025724102,0.005571758,0.00030416943,0.000025099753,0.00035057456],"genre_scores_gemma":[0.9974802,0.00006965391,0.00014221905,0.00037045893,0.00013667278,0.0015070731,0.0001958516,0.000029484598,0.00006834996],"study_design_codex":"nonrandomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972726,0.0005659508,0.0008409418,0.0006461619,0.0002286635,0.0004456732],"domain_scores_gemma":[0.9967959,0.0015452162,0.00042372302,0.00076428545,0.0002910027,0.00017987961],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011937681,0.0003274387,0.0027066667,0.0002961492,0.00015207013,0.00005228664,0.00033891096,0.000096682794,0.00038772027],"category_scores_gemma":[0.0003385326,0.0002144016,0.00017306562,0.00080823863,0.00016924612,0.000063702944,0.00029803062,0.00020543841,0.000006385866],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17101201,0.2477794,0.19916697,0.0007960425,0.106062464,0.009113389,0.031365912,0.00009013338,0.114974804,0.0002710115,0.02050168,0.09886617],"study_design_scores_gemma":[0.7809854,0.056312043,0.10472599,0.00011550744,0.025029095,0.00021032053,0.013825053,0.005414977,0.008942318,0.00004516533,0.0039119613,0.0004821603],"about_ca_topic_score_codex":0.00011511337,"about_ca_topic_score_gemma":0.0025337448,"teacher_disagreement_score":0.6099734,"about_ca_system_score_codex":0.0001716065,"about_ca_system_score_gemma":0.00028054195,"threshold_uncertainty_score":0.87430435},"labels":[],"label_agreement":null},{"id":"W3164197656","doi":"10.1016/s1470-2045(21)00152-2","title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":648,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Sunnybrook Health Science Centre","funders":"Janssen Pharmaceuticals; Merck Sharp and Dohme; British Microcirculation Society; Novartis; Sanofi; Merck; GlaxoSmithKline; Eli Lilly and Company; AstraZeneca; Bayer; Ipsen; Clovis Oncology; Roche; Astellas Pharma US; LEO Pharma Research Foundation; Pfizer","keywords":"Medicine; Pembrolizumab; Carboplatin; Gemcitabine; Chemotherapy; Oncology; Internal medicine; Metastatic Urothelial Carcinoma; Urothelial carcinoma; Population; Cisplatin; Cancer; Immunotherapy; Bladder cancer","score_opus":0.10115703839334929,"score_gpt":0.4104142656501243,"score_spread":0.309257227256775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164197656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9331448,0.0011361414,0.000426427,0.04724117,0.0012210109,0.011846437,0.00017101341,0.00015799745,0.004654972],"genre_scores_gemma":[0.9462907,0.006003082,0.0046645463,0.027668208,0.003895396,0.0042092185,0.00032703337,0.0002662556,0.0066756145],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970204,0.0003269806,0.00062934257,0.0007989886,0.00038916589,0.00083508436],"domain_scores_gemma":[0.9968762,0.0011126096,0.00034874943,0.0010914948,0.00033036774,0.0002406166],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005811644,0.0005705614,0.002098113,0.00006897758,0.000369308,0.00008303918,0.00062121655,0.00027572294,0.0014383445],"category_scores_gemma":[0.00019431283,0.00032992178,0.0002059412,0.00039729185,0.00027546083,0.00013168185,0.00007543431,0.00038633778,0.000033886212],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9276526,0.0058035473,0.00003734816,0.000056854624,0.0012872462,0.00027693054,0.0008339871,0.000005647238,0.0038937987,0.00016075991,0.003990805,0.056000452],"study_design_scores_gemma":[0.75019246,0.08513039,0.00006577921,0.00004934283,0.00034663687,0.00020481658,0.000116664734,0.000095091535,0.021935206,0.0002919314,0.14125642,0.0003152646],"about_ca_topic_score_codex":0.00013728566,"about_ca_topic_score_gemma":0.0003532231,"teacher_disagreement_score":0.17746016,"about_ca_system_score_codex":0.0003806034,"about_ca_system_score_gemma":0.0024027827,"threshold_uncertainty_score":0.9999153},"labels":[],"label_agreement":null},{"id":"W3164781831","doi":"10.1016/s1470-2045(21)00147-9","title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":533,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Janssen Pharmaceuticals; Pfizer Japan; Genentech; Bavarian Nordic; Merck Sharp and Dohme; Ono Pharmaceutical; European Association of Urology; Bayer Fund; Mirati Therapeutics; Clovis Oncology; Sanofi; GlaxoSmithKline; Merck; Genzyme; Genomic Health; Chugai Pharmaceutical; Roche; Astellas Pharma US; Pfizer; Heron Therapeutics; Bristol-Myers Squibb; AstraZeneca; Boehringer Ingelheim","keywords":"Medicine; Pembrolizumab; Cystoscopy; Bladder cancer; Cystectomy; Cancer; Internal medicine; Clinical endpoint; Surgery; Progressive disease; Urology; Oncology; Clinical trial; Immunotherapy; Disease; Urinary system","score_opus":0.11916421107182466,"score_gpt":0.43648497625447374,"score_spread":0.31732076518264907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164781831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97950643,0.0018237918,0.00034230566,0.0093739955,0.0007428222,0.006996357,0.000711795,0.000042053733,0.0004604525],"genre_scores_gemma":[0.9851564,0.0036723278,0.0016670449,0.004390954,0.0011340514,0.002714235,0.000059111437,0.00008251458,0.00112333],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99741304,0.00061233155,0.00046410057,0.0006478565,0.000265525,0.00059717556],"domain_scores_gemma":[0.9963145,0.0015252508,0.00029136008,0.0012083958,0.00045515003,0.00020529648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032110917,0.00038637352,0.0012275347,0.00006992641,0.00032368882,0.000049412247,0.0005185082,0.00013359873,0.00036798915],"category_scores_gemma":[0.00014772781,0.00021669046,0.00010968973,0.0003290406,0.00014805893,0.00008540498,0.000102850194,0.00017605012,0.00001938928],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11472233,0.09657296,0.003440816,0.00007114328,0.0077957134,0.00064004184,0.052642874,0.00046233574,0.032329947,0.00017423248,0.0054197805,0.68572783],"study_design_scores_gemma":[0.4186711,0.30977035,0.03657388,0.00015936611,0.008200466,0.000112354086,0.017124107,0.00053406076,0.07832822,0.0007109439,0.12900852,0.0008066364],"about_ca_topic_score_codex":0.0053556752,"about_ca_topic_score_gemma":0.010832789,"teacher_disagreement_score":0.6849212,"about_ca_system_score_codex":0.0007021311,"about_ca_system_score_gemma":0.0011906433,"threshold_uncertainty_score":0.8836381},"labels":[],"label_agreement":null},{"id":"W3165241302","doi":"10.1016/s1470-2045(21)00151-0","title":"Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":373,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Genentech; F. Hoffmann-La Roche","keywords":"Medicine; Sorafenib; Bevacizumab; Atezolizumab; Internal medicine; Oncology; Hepatocellular carcinoma; Quality of life (healthcare); Response Evaluation Criteria in Solid Tumors; Clinical trial; Progression-free survival; Performance status; Cancer; Clinical endpoint; Phases of clinical research; Surgery; Chemotherapy; Pembrolizumab; Immunotherapy","score_opus":0.1298463038578968,"score_gpt":0.3448993800596667,"score_spread":0.2150530762017699,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165241302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887674,0.00032215504,0.000018577965,0.0014066463,0.0003970134,0.0056771548,0.000049343173,0.000083277504,0.0032784273],"genre_scores_gemma":[0.99615985,0.00003292434,0.00084909704,0.00051373563,0.0002120583,0.0008168048,0.00096324825,0.00008471059,0.00036758572],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99595004,0.00093736494,0.00076360995,0.0008110915,0.0006409114,0.0008969601],"domain_scores_gemma":[0.9972141,0.00042906168,0.00041412507,0.0012706616,0.00036520103,0.0003068509],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006697583,0.0005045771,0.0019245511,0.00014832098,0.00023795407,0.00011074861,0.0004487748,0.00025725257,0.00034544498],"category_scores_gemma":[0.00019640011,0.0002993363,0.000093204486,0.00062790123,0.0002074271,0.00022831566,0.00024524046,0.00053010724,0.000027246297],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5884247,0.004032014,0.3983309,0.000035520166,0.00058321864,0.003652835,0.0006168416,0.0000031261666,0.000082009494,0.000061573024,0.00020358396,0.003973698],"study_design_scores_gemma":[0.94053096,0.034290276,0.017707823,0.00006726325,0.0009985297,0.00009794001,0.00027546112,0.00096712174,0.0015602371,0.000036031775,0.0030511045,0.0004172792],"about_ca_topic_score_codex":0.00052308507,"about_ca_topic_score_gemma":0.00059119007,"teacher_disagreement_score":0.38062307,"about_ca_system_score_codex":0.00067744777,"about_ca_system_score_gemma":0.0017113561,"threshold_uncertainty_score":0.9999459},"labels":[],"label_agreement":null},{"id":"W3165702866","doi":"10.1016/s1470-2045(21)00240-0","title":"Impact of COVID-19 on cancer care in India: a cohort study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":164,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Cancer Society; Cancer Research UK","keywords":"Coronavirus disease 2019 (COVID-19); Cohort; 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Medicine; Cohort study; Cancer; Environmental health; Virology; Geography; Internal medicine; Outbreak; Disease; Infectious disease (medical specialty)","score_opus":0.11952425641143329,"score_gpt":0.5232355036656434,"score_spread":0.40371124725421015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165702866","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9763816,0.0009822664,0.0000016042919,0.018062301,0.0001779836,0.00093608006,0.000051194864,0.000025379119,0.003381566],"genre_scores_gemma":[0.98703206,0.00048996735,0.000012496022,0.0118547855,0.00038195003,0.0001012199,0.000017345827,0.000012989886,0.00009716156],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99848217,0.0004517417,0.00026706554,0.0002364465,0.0002087174,0.00035384757],"domain_scores_gemma":[0.9984907,0.00056397164,0.000112107984,0.0004996644,0.00012935043,0.00020420623],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006644917,0.00012071543,0.00079913496,0.00010815975,0.000048351867,0.0000039155484,0.0001232176,0.00012570385,0.00041138363],"category_scores_gemma":[0.00094642746,0.0000762752,0.000084243955,0.00039152647,0.00006914741,0.000015781337,0.000060628703,0.00044333766,0.000011889712],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016901635,0.0005110051,0.9773528,0.00020867985,0.00013481829,0.0006945176,0.012244587,0.000094543415,0.00015289622,0.0000675125,0.002981442,0.0038670476],"study_design_scores_gemma":[0.005163589,0.003758815,0.97834206,0.00005114303,0.000081306265,0.000043480235,0.0026820356,0.0000057118395,0.000046561985,0.000052935018,0.009707128,0.00006520888],"about_ca_topic_score_codex":0.010660189,"about_ca_topic_score_gemma":0.017615143,"teacher_disagreement_score":0.010650458,"about_ca_system_score_codex":0.0023416327,"about_ca_system_score_gemma":0.0074954326,"threshold_uncertainty_score":0.99813116},"labels":[],"label_agreement":null},{"id":"W3165727183","doi":"10.1016/s1470-2045(21)00290-4","title":"Pembrolizumab for relapsed or refractory Hodgkin lymphoma – Author's reply","year":2021,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck","keywords":"Brentuximab vedotin; Pembrolizumab; Medicine; Oncology; Context (archaeology); Internal medicine; Clinical endpoint; Refractory (planetary science); Population; Lymphoma; Hodgkin lymphoma; Randomized controlled trial; Cancer; Immunotherapy","score_opus":0.10220128046909066,"score_gpt":0.3670396438270521,"score_spread":0.26483836335796146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165727183","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0037388538,0.002365907,0.000023623703,0.9766623,0.002283478,0.0016214054,0.0002295294,0.00018268875,0.012892248],"genre_scores_gemma":[0.0024334532,0.0010415991,0.0022465005,0.922409,0.020565415,0.0016876141,0.0016434678,0.0001454935,0.04782744],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967164,0.0005361055,0.0006144451,0.00083768176,0.0003870126,0.0009083571],"domain_scores_gemma":[0.9954509,0.001994965,0.00049090775,0.0017220771,0.00022813947,0.00011300225],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00062411,0.00052354584,0.0020778242,0.000119142314,0.00020323631,0.000044451725,0.00043174464,0.0013371654,0.0006394321],"category_scores_gemma":[0.00063073554,0.00029675476,0.0004967428,0.00019084319,0.0002096302,0.000036973197,0.00015010935,0.0008257323,0.00016486499],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031538778,0.00046056387,0.0001640093,0.00039217694,0.0008691348,0.007729422,0.00025504123,2.797799e-7,0.000035952242,0.00013221194,0.95171624,0.0350911],"study_design_scores_gemma":[0.01822391,0.003617359,0.002419256,0.000269802,0.0013028536,0.0021265266,0.000062279265,0.000016325965,0.00012784635,0.0002553754,0.9712587,0.00031974696],"about_ca_topic_score_codex":0.00011932216,"about_ca_topic_score_gemma":0.000068096015,"teacher_disagreement_score":0.05425325,"about_ca_system_score_codex":0.0017571531,"about_ca_system_score_gemma":0.0022669327,"threshold_uncertainty_score":0.9999593},"labels":[],"label_agreement":null},{"id":"W3166415013","doi":"10.1016/s1470-2045(21)00189-3","title":"Variation in the risk of colorectal cancer in families with Lynch syndrome: a retrospective cohort study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Health and Medical Research Council; Centre Léon Bérard; Universiti Sultan Zainal Abidin; National Institutes of Health; Ramsay Santé; Assistance publique-Hôpitaux de Paris; University of Colorado School of Medicine, Anschutz Medical Campus; Olav Thon Stiftelsen; Novo Nordisk Fonden; Instrumentariumin Tiedesäätiö; Universidad Pública de Navarra; Centro de Investigación Biomédica en Red de Cáncer; University of Cape Town; Aalborg Universitetshospital; Deutsche Krebshilfe; University of Texas MD Anderson Cancer Center; Leids Universitair Medisch Centrum; Emil Aaltosen Säätiö; City of Hope; Jane ja Aatos Erkon Säätiö; Universiti Sains Malaysia; Peter MacCallum Cancer Centre; Intelligent Manufacturing Research Center; Syöpäsäätiö; Financiadora de Estudos e Projetos; Novo Nordisk; Associazione Italiana per la Ricerca sul Cancro; Aalborg Universitet; Rigshospitalet; Kræftens Bekæmpelse; University of Melbourne; University of New South Wales; National Medical Research Council; Universiteit Leiden; Cancer Council NSW; National Cancer Centre of Singapore; Universiteit van Amsterdam; Universitair Medisch Centrum Groningen; Newcastle University; Health and Care Research Wales; KWF Kankerbestrijding; Cancer Research UK; Canadian Institutes of Health Research; Sigrid Juséliuksen Säätiö; University of Southampton; Amsterdam University Medical Centers; Institut National de la Santé et de la Recherche Médicale; Cancer Council Tasmania; Cedars-Sinai Medical Center; Swedish Cancer Foundation; University Hospitals of Leicester NHS Trust; Parc Geneteg Cymru; Svenska Läkaresällskapet; Gentofte Hospital; Deutsche Forschungsgemeinschaft; Medical Research Council; Nordea-fonden; National Institute for Health and Care Research; Odense Universitetshospital; Nebraska Department of Health and Human Services; Comprehensive Cancer Center, City of Hope; Kreftforeningen; South African Medical Research Council; Deutsches Krebsforschungszentrum; Academy of Finland; Suomen Lääketieteen Säätiö; University of Washington; Helsingin Yliopisto; Royal Adelaide Hospital; NIHR Maudsley Biomedical Research Centre; Rijksuniversiteit Groningen; U.S. Department of Health and Human Services; Creighton University; Instituto de Salud Carlos III; Ohio State University","keywords":"Colorectal cancer; Retrospective cohort study; Variation (astronomy); Lynch syndrome; Medicine; Cohort; Oncology; Cancer; Internal medicine; Demography; DNA mismatch repair; Sociology","score_opus":0.018034424145528947,"score_gpt":0.31292801673736964,"score_spread":0.29489359259184067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166415013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932155,0.00026712648,0.000009098178,0.0015900881,0.0002211921,0.0013533734,0.00002621986,0.000012387308,0.0033050238],"genre_scores_gemma":[0.9984482,0.0004084461,0.00020186977,0.00026699642,0.00008321773,0.0005333702,0.000003666307,0.00001274654,0.00004151169],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980457,0.0008223484,0.00027097305,0.00027755223,0.00033608248,0.00024733396],"domain_scores_gemma":[0.9988368,0.00047075053,0.00016300431,0.00035839935,0.0001515803,0.00001943416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013968222,0.00012534064,0.0006797983,0.000070805705,0.0000406744,0.000006093463,0.00018577349,0.00009676582,0.00014727055],"category_scores_gemma":[0.00033641714,0.00006781409,0.000033516022,0.0007573276,0.00016718349,0.000021811527,0.000059243124,0.0005255366,0.0000026545947],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00084237143,0.00047532277,0.9856584,0.000019345993,0.00017605862,0.00016709618,0.0108638555,0.00033665478,0.0009445069,0.00006133604,0.000093950584,0.00036107597],"study_design_scores_gemma":[0.0033446045,0.0024386079,0.98884237,0.000040029376,0.00019436634,0.00015829758,0.004183336,0.00015940095,0.00023853726,0.00022489228,0.00010218816,0.00007335847],"about_ca_topic_score_codex":0.0028794594,"about_ca_topic_score_gemma":0.045156874,"teacher_disagreement_score":0.042277414,"about_ca_system_score_codex":0.0006697591,"about_ca_system_score_gemma":0.00056648714,"threshold_uncertainty_score":0.9722665},"labels":[],"label_agreement":null},{"id":"W3167396950","doi":"10.1016/s1470-2045(21)00196-0","title":"Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":404,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec; University of Alberta; BC Cancer Agency; Toronto Western Hospital; University of Manitoba; University of Toronto; McMaster University; Queen's University; Princess Margaret Cancer Centre; University of Calgary; Centre Hospitalier de l’Université de Montréal; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Health and Medical Research Council; Canadian Cancer Society","keywords":"Medicine; Radiation therapy; External beam radiotherapy; Stereotactic radiotherapy; Radiosurgery; Randomized controlled trial; Radiology; Surgery; Brachytherapy","score_opus":0.06422644521205337,"score_gpt":0.40031675943005973,"score_spread":0.3360903142180064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167396950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98514616,0.0013084529,0.0015331896,0.0025945671,0.0009014997,0.007780639,0.00007380154,0.00004525424,0.0006164192],"genre_scores_gemma":[0.9616435,0.00070136285,0.019392494,0.012699902,0.001822512,0.0017632862,0.00073056907,0.00014348463,0.0011028727],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99530995,0.0020673592,0.00079413597,0.0005775224,0.0006510142,0.00060001],"domain_scores_gemma":[0.99735546,0.00083630934,0.0005018229,0.00081185874,0.00021978257,0.0002747758],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002355804,0.00035970495,0.0018226516,0.00014082139,0.00012077581,0.0001252225,0.0005165372,0.00008891638,0.0023115666],"category_scores_gemma":[0.00047726373,0.00023760187,0.00012887985,0.00026256274,0.00020735411,0.00029797215,0.000084103245,0.00039505263,0.0000136669505],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9679219,0.017309,0.002084532,0.00006683124,0.0021388642,0.0007160784,0.00018166204,0.000015083995,0.0003604744,0.0004153536,0.0010508271,0.007739356],"study_design_scores_gemma":[0.9587144,0.021824656,0.0041867467,0.00008564612,0.0011703006,0.000023481784,0.00020510296,0.0018446732,0.000028004604,0.00003892915,0.011623005,0.00025504146],"about_ca_topic_score_codex":0.00004244406,"about_ca_topic_score_gemma":0.00005035275,"teacher_disagreement_score":0.02350266,"about_ca_system_score_codex":0.0003806513,"about_ca_system_score_gemma":0.0006517076,"threshold_uncertainty_score":0.9986005},"labels":[],"label_agreement":null},{"id":"W3169849224","doi":"10.1016/s1470-2045(21)00216-3","title":"Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":405,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Eisai; Array BioPharma; Clovis Oncology; Roche; Mersana Therapeutics; Novartis; Merck KGaA; Merck; GlaxoSmithKline; Bristol-Myers Squibb; AstraZeneca; Pfizer","keywords":"Javelin; Ovarian cancer; Avelumab; Medicine; Refractory (planetary science); Chemotherapy; Open label; Oncology; Internal medicine; Cancer; Clinical trial; Immunotherapy; Nivolumab","score_opus":0.09341405805658175,"score_gpt":0.40025337878758066,"score_spread":0.3068393207309989,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169849224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9683591,0.0005811807,0.000097352044,0.0231225,0.00046889696,0.005679166,0.000094798095,0.00007314442,0.0015238741],"genre_scores_gemma":[0.98761374,0.0013103486,0.0033650782,0.0041762977,0.00056222203,0.0020703154,0.00017093148,0.00011851031,0.0006125389],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9961086,0.00077075505,0.00092834386,0.00094222487,0.00049155706,0.00075855624],"domain_scores_gemma":[0.9971265,0.00093628647,0.00046381107,0.0010664089,0.0002047931,0.00020215608],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015881349,0.00052498543,0.0020326036,0.00018651162,0.00018027714,0.00010213998,0.00051512837,0.00027423218,0.00320752],"category_scores_gemma":[0.00014364951,0.00032203313,0.000045201206,0.0009639067,0.0001633264,0.0002523097,0.0001048138,0.00067201495,0.000014231333],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7939706,0.0584125,0.016500423,0.000095199786,0.0017355342,0.004813311,0.007824589,0.00007163743,0.0029418867,0.00038093966,0.0017506492,0.11150275],"study_design_scores_gemma":[0.872629,0.031678014,0.07978816,0.00034016173,0.0003803311,0.00009728161,0.0016961446,0.00088886183,0.0009990536,0.00016034477,0.0108194845,0.0005231928],"about_ca_topic_score_codex":0.0048804544,"about_ca_topic_score_gemma":0.122741364,"teacher_disagreement_score":0.11786091,"about_ca_system_score_codex":0.001559792,"about_ca_system_score_gemma":0.002359773,"threshold_uncertainty_score":0.99992317},"labels":[],"label_agreement":null},{"id":"W3173587834","doi":"10.1016/s1470-2045(21)00271-0","title":"Biomedicine and the soul of medicine: optimising the balance","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Biomedicine; Scopus; Psychological intervention; Health care; Medicine; Palliative care; Alternative medicine; Commission; Family medicine; Soul; Investment (military); Gerontology; Political science; MEDLINE; Nursing; Law; Pathology; Philosophy; Theology","score_opus":0.2011820643592713,"score_gpt":0.4728571802905071,"score_spread":0.27167511593123583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3173587834","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.32628092,0.06263538,0.0006917618,0.55275327,0.00064397143,0.00042991675,0.000012564932,0.000030068386,0.05652216],"genre_scores_gemma":[0.96757406,0.017078957,0.0011773122,0.011965156,0.001468609,0.000014169051,0.000011057697,0.000011439461,0.0006992153],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988913,0.00032702077,0.00027615673,0.0001259289,0.0001845617,0.00019502627],"domain_scores_gemma":[0.9971303,0.0020734388,0.0001744066,0.00042601384,0.0001616107,0.000034257908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013915162,0.00009345251,0.00070482254,0.000023892668,0.00007344033,0.0000021213486,0.0001791421,0.000063476444,0.0001027136],"category_scores_gemma":[0.0011213861,0.00003434246,0.000048402384,0.00024310207,0.0021455514,0.000013518739,0.00009383654,0.00023469291,0.00000270018],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01188193,0.00055609073,0.12572922,0.0021277713,0.0030608852,0.00066912774,0.136745,0.00009008548,0.113939665,0.14658374,0.30688944,0.15172704],"study_design_scores_gemma":[0.026071418,0.0011669305,0.027033698,0.0017245276,0.0009621112,0.0006292185,0.020850077,0.0009940488,0.009732402,0.007201024,0.90347743,0.00015708318],"about_ca_topic_score_codex":0.00011063733,"about_ca_topic_score_gemma":0.000025786627,"teacher_disagreement_score":0.64129317,"about_ca_system_score_codex":0.000023261622,"about_ca_system_score_gemma":0.00011450019,"threshold_uncertainty_score":0.79053736},"labels":[],"label_agreement":null},{"id":"W3176933341","doi":"10.1016/s1470-2045(21)00077-2","title":"The International Collaboration for Research methods Development in Oncology (CReDO) workshops: shaping the future of global oncology research","year":2021,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; Queen's University","funders":"Medical Research Council; National Institutes of Health; Cancer Research UK; World Health Organization","keywords":"Context (archaeology); Oncology; Medicine; Internal medicine; Observational study; Developing country; Capacity building; Clinical trial; Global health; Clinical research; Medical education; Political science; Public health; Nursing; Economic growth","score_opus":0.46434565745183876,"score_gpt":0.6903995163852735,"score_spread":0.22605385893343477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3176933341","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00002908321,0.90772986,0.00092311954,0.07269,0.0050249128,0.0037828456,0.000039496692,0.00002347274,0.009757176],"genre_scores_gemma":[0.0000100475345,0.9414415,0.04596929,0.001241812,0.007137322,0.0030133477,0.00013099702,0.000048669608,0.0010070145],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9801105,0.015415586,0.0016286989,0.0007762641,0.0008016273,0.0012672767],"domain_scores_gemma":[0.95789915,0.038227107,0.0008148954,0.0011006296,0.0018485355,0.000109654495],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0438569,0.00038740993,0.0031499306,0.00026117658,0.001030832,0.000049174963,0.0023194537,0.0017618965,0.00010499976],"category_scores_gemma":[0.0044807857,0.0001893903,0.0003179373,0.0024011408,0.002435436,0.0000632515,0.00071959203,0.004162471,0.000015933469],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0016450208,0.00033494324,0.000022883285,0.000762784,0.00071740086,0.00008627051,0.0017072753,0.00000848288,0.000006879355,0.030720579,0.040540677,0.92344683],"study_design_scores_gemma":[0.0020886883,0.0015309555,0.00003404925,0.0015621431,0.00017007695,0.000489911,0.0059078294,0.00004444471,0.0000059065524,0.0029474248,0.9850565,0.00016204675],"about_ca_topic_score_codex":0.000017047163,"about_ca_topic_score_gemma":0.0033191228,"teacher_disagreement_score":0.9445158,"about_ca_system_score_codex":0.010443351,"about_ca_system_score_gemma":0.021280268,"threshold_uncertainty_score":0.999534},"labels":[],"label_agreement":null},{"id":"W3183035192","doi":"10.1016/s1470-2045(21)00279-5","title":"Global burden of cancer in 2020 attributable to alcohol consumption: a population-based study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Alcohol Consumption and Health Effects","field":"Medicine","cited_by":664,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Addiction and Mental Health; Public Health Ontario; University of Toronto","funders":"Centre International de Recherche sur le Cancer; World Health Organization","keywords":"Alcohol consumption; Environmental health; Alcohol; Attributable risk; Cancer; Consumption (sociology); Medicine; Population; Biology; Internal medicine","score_opus":0.16253989338880298,"score_gpt":0.482128908830147,"score_spread":0.319589015441344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3183035192","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9672605,0.000752299,0.00003576341,0.030167479,0.00026860787,0.0009230271,0.00004751104,0.000028745535,0.00051610975],"genre_scores_gemma":[0.9937379,0.000068420755,0.00025466262,0.005250607,0.00033112982,0.00015821848,0.000024089222,0.0000068363793,0.00016814182],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99866396,0.00036094512,0.00031162953,0.00021286195,0.0001787764,0.00027183632],"domain_scores_gemma":[0.9990981,0.00024450908,0.00009559074,0.00032065276,0.00013777465,0.000103344966],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005863634,0.000093386574,0.00060740055,0.000038446542,0.000051226994,0.0000050093176,0.00009341514,0.00008520083,0.0010590667],"category_scores_gemma":[0.00021376554,0.0000716599,0.00003906179,0.00040815375,0.00002903241,0.000016511156,0.000049287566,0.00016300892,0.00006888023],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074881787,0.0002536888,0.9921657,0.00013884196,0.0000417219,0.00010853944,0.0003043414,0.0012432772,0.00024991579,0.00017007286,0.0016425375,0.002932543],"study_design_scores_gemma":[0.00570385,0.000388597,0.98515916,0.000095845084,0.00007833226,0.000018976156,0.00016774774,0.00043180637,0.000046225683,0.00003424015,0.0078108064,0.00006441328],"about_ca_topic_score_codex":0.0022072853,"about_ca_topic_score_gemma":0.01039337,"teacher_disagreement_score":0.026477437,"about_ca_system_score_codex":0.00048005156,"about_ca_system_score_gemma":0.00064691383,"threshold_uncertainty_score":0.9998541},"labels":[],"label_agreement":null},{"id":"W3188131079","doi":"10.1016/s1470-2045(21)00342-9","title":"Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":284,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck KGaA; Array BioPharma; Russian Academy of Sciences; Pfizer","keywords":"Avelumab; Javelin; Medicine; Chemotherapy; Ovarian cancer; Epithelial ovarian cancer; Oncology; Internal medicine; Open label; Cancer; Immunotherapy; Clinical trial; Pembrolizumab","score_opus":0.05096597704849702,"score_gpt":0.3713370121621499,"score_spread":0.3203710351136529,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3188131079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9704117,0.00033636737,0.00019455921,0.01842793,0.0005784773,0.008290516,0.00031678728,0.000108880675,0.0013347891],"genre_scores_gemma":[0.9780209,0.0016469114,0.005258389,0.007877458,0.0010563824,0.0029869957,0.00072976074,0.00022224676,0.0022009618],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99575037,0.0006984839,0.0007784779,0.001158033,0.0005326753,0.0010819893],"domain_scores_gemma":[0.99716055,0.00032484205,0.0005415187,0.0012766229,0.00036213145,0.0003343266],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008649299,0.00068116386,0.002479112,0.00009814853,0.00022201134,0.00013458387,0.0006133649,0.0003194667,0.0016034958],"category_scores_gemma":[0.000096136275,0.00038181187,0.00008471129,0.0007476641,0.0002919586,0.0002337646,0.000086557564,0.0005572533,0.000018782692],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9306635,0.013233154,0.009345897,0.000043655367,0.0017748481,0.00044993457,0.0016377396,0.000008413721,0.00033726933,0.0000670336,0.005162922,0.037275583],"study_design_scores_gemma":[0.93146855,0.032985028,0.00497527,0.0003311785,0.00074431713,0.00005380706,0.00015338951,0.00017228237,0.0016265531,0.000022976803,0.026921159,0.0005454638],"about_ca_topic_score_codex":0.0021902646,"about_ca_topic_score_gemma":0.0071552037,"teacher_disagreement_score":0.036730118,"about_ca_system_score_codex":0.0012693465,"about_ca_system_score_gemma":0.0025279303,"threshold_uncertainty_score":0.9998634},"labels":[],"label_agreement":null},{"id":"W3190141894","doi":"10.1016/s1470-2045(21)00376-4","title":"Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":277,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Centre for Mathematical Cognition, Loughborough University; Pfizer UK; Pfizer","keywords":"Medicine; Prostate cancer; Enzalutamide; Oncology; Internal medicine; PARP inhibitor; Clinical endpoint; Docetaxel; Cancer; Clinical trial; Poly ADP ribose polymerase; Androgen receptor; Biology","score_opus":0.17274289492622194,"score_gpt":0.47870194846347636,"score_spread":0.3059590535372544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3190141894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97528845,0.0012325951,0.000018045643,0.01857285,0.00016187625,0.0028594967,0.00012381363,0.000058534402,0.0016843101],"genre_scores_gemma":[0.98292035,0.0016011161,0.0037840118,0.002163704,0.00058588607,0.003170527,0.00049895345,0.000051234845,0.0052242437],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99806494,0.0005065115,0.00035107174,0.0004045079,0.00023437361,0.00043860657],"domain_scores_gemma":[0.9989033,0.00014003266,0.00011856565,0.00052459456,0.00018861228,0.00012492931],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006688249,0.00017706456,0.0006237661,0.00006892695,0.00018520509,0.00008682613,0.00019326364,0.00005677312,0.00028981775],"category_scores_gemma":[0.000045928275,0.000103936225,0.000029505603,0.00043244942,0.00018449206,0.00021699899,0.000055552733,0.00031601658,0.000008283193],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.74544084,0.017363215,0.002992389,0.00025153876,0.0015506712,0.0061112135,0.009420419,0.00020863918,0.173393,0.0040030135,0.007933412,0.031331662],"study_design_scores_gemma":[0.86717516,0.035563875,0.0033269466,0.0002479265,0.00049763237,0.00030697713,0.0018807176,0.0024749774,0.021292975,0.0012685123,0.06549625,0.0004680229],"about_ca_topic_score_codex":0.0005419428,"about_ca_topic_score_gemma":0.008999149,"teacher_disagreement_score":0.15210001,"about_ca_system_score_codex":0.0003791163,"about_ca_system_score_gemma":0.0024840713,"threshold_uncertainty_score":0.50217366},"labels":[],"label_agreement":null},{"id":"W3192912903","doi":"10.1016/s1470-2045(21)00405-8","title":"Pathological complete response as a surrogate endpoint after neoadjuvant therapy for lung cancer","year":2021,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Medicine; Neoadjuvant therapy; Lung cancer; Surrogate endpoint; Clinical endpoint; Oncology; Occult; Pathological; Internal medicine; Cancer; Systemic therapy; Clinical trial; Pathology; Breast cancer; Alternative medicine","score_opus":0.08392382717632799,"score_gpt":0.3971788207734106,"score_spread":0.31325499359708264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3192912903","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07277394,0.016054392,0.000023517248,0.9060032,0.0012733032,0.0022210164,0.00091998815,0.000088118206,0.00064257684],"genre_scores_gemma":[0.015992166,0.010353044,0.00062147016,0.95021695,0.010371943,0.0082840165,0.00065659493,0.00010143559,0.0034023863],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965471,0.0010669542,0.0004439653,0.00076366356,0.00031942487,0.0008589022],"domain_scores_gemma":[0.99650776,0.001953542,0.00026746606,0.0009728773,0.00020241717,0.00009594091],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009202332,0.00048409437,0.0017990441,0.00007428046,0.0001277372,0.000039205588,0.00029985482,0.0008278107,0.0017825307],"category_scores_gemma":[0.00012988834,0.00027033797,0.00049638224,0.00011903378,0.0002498093,0.000021532283,0.0001273109,0.001412233,0.00004053673],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020361362,0.00025203533,0.0020936439,0.00027254544,0.0009257357,0.010193953,0.0005717533,0.0000027683716,0.0001668105,0.000034245404,0.96030307,0.0048220563],"study_design_scores_gemma":[0.008034909,0.0024484922,0.016392654,0.00034703172,0.000665985,0.0004210648,0.000027615213,0.000032767683,0.00013943395,0.00016723551,0.9710343,0.00028849533],"about_ca_topic_score_codex":0.00015417376,"about_ca_topic_score_gemma":0.000119525896,"teacher_disagreement_score":0.05678177,"about_ca_system_score_codex":0.001388168,"about_ca_system_score_gemma":0.0010065475,"threshold_uncertainty_score":0.9999749},"labels":[],"label_agreement":null},{"id":"W3196277563","doi":"10.1016/s1470-2045(21)00454-x","title":"Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":134,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Cancer Institute; National Institutes of Health; American Lebanese Syrian Associated Charities","keywords":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Cohort; Medicine; Coronavirus disease 2019 (COVID-19); Cancer; 2019-20 coronavirus outbreak; Cohort study; Sars virus; Pediatrics; Virology; Internal medicine; Disease; Outbreak; Infectious disease (medical specialty)","score_opus":0.05648938914656233,"score_gpt":0.42930313649031693,"score_spread":0.3728137473437546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3196277563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995194,0.00016622196,0.0000054737347,0.0038728178,0.000074879186,0.0005849902,0.000025914584,0.00001242721,0.000063262254],"genre_scores_gemma":[0.99582255,0.00078834133,0.000016468268,0.0032253056,0.00010950155,0.000019287436,0.0000057270026,0.00000555809,0.0000072392922],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99927616,0.0001274336,0.00016865773,0.00015782322,0.0001006436,0.00016926911],"domain_scores_gemma":[0.9996077,0.00003760494,0.0000870388,0.00016423594,0.00006483731,0.00003858686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002728348,0.00008527351,0.00054681033,0.000028324437,0.000028467444,0.0000054673746,0.000028369232,0.00006119371,0.0000033651638],"category_scores_gemma":[0.00010779918,0.00005382293,0.000011668702,0.00014252016,0.00007586488,0.000021485494,0.000049894334,0.00014473674,4.5544252e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048008683,0.00028382245,0.99355525,0.00009687795,0.000092733986,0.000034227476,0.00036188832,2.6408532e-7,0.00011310901,0.000013868553,0.00006871272,0.004899177],"study_design_scores_gemma":[0.0038152703,0.0006603605,0.99484295,0.00010934543,0.0001341767,0.00012418957,0.000037398753,0.0000067612527,0.000039529157,0.00001795765,0.00016213492,0.00004994465],"about_ca_topic_score_codex":0.0072745653,"about_ca_topic_score_gemma":0.023649532,"teacher_disagreement_score":0.016374966,"about_ca_system_score_codex":0.00016930731,"about_ca_system_score_gemma":0.00033975946,"threshold_uncertainty_score":0.99933606},"labels":[],"label_agreement":null},{"id":"W3197518149","doi":"10.1016/s1470-2045(21)00351-x","title":"Radiotherapy resources in Africa: an International Atomic Energy Agency update and analysis of projected needs","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":116,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University of Ottawa","funders":"National Cancer Institute","keywords":"Medicine; Radiation therapy; Brachytherapy; Context (archaeology); External beam radiotherapy; Medical physics; Agency (philosophy); Surgery","score_opus":0.03151376347589045,"score_gpt":0.37579721727884663,"score_spread":0.34428345380295616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197518149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98164886,0.004605859,0.001167536,0.007944045,0.00023911937,0.00008581587,0.00001567371,0.000024669238,0.0042684427],"genre_scores_gemma":[0.96754426,0.019948076,0.0076607266,0.003494541,0.0005804529,0.000028125542,0.00007144983,0.000014846231,0.00065752293],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989211,0.00035089886,0.00025551842,0.00018752922,0.00009620256,0.00018877887],"domain_scores_gemma":[0.9992318,0.00023235157,0.00013010885,0.00030332492,0.0000647449,0.000037673177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039949061,0.000093144015,0.0006362551,0.00031120906,0.000036184825,0.0000045301563,0.00017525621,0.00013634344,0.00030112354],"category_scores_gemma":[0.000053284002,0.00006385533,0.000060715185,0.0008904805,0.0002654566,0.000056966663,0.000031803535,0.00017757638,4.552381e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008135122,0.0017630743,0.5485071,0.00005420113,0.00766232,0.00070642686,0.033005457,0.00056549354,0.04956747,0.060031403,0.0013947015,0.28860724],"study_design_scores_gemma":[0.0063269003,0.0008752158,0.36828226,0.000023081762,0.0006003092,0.00026433152,0.0009580272,0.008423748,0.00063654693,0.0030223248,0.61041504,0.00017219107],"about_ca_topic_score_codex":0.000038004167,"about_ca_topic_score_gemma":0.00025683962,"teacher_disagreement_score":0.60902035,"about_ca_system_score_codex":0.0001355492,"about_ca_system_score_gemma":0.00013884959,"threshold_uncertainty_score":0.32970917},"labels":[],"label_agreement":null},{"id":"W3197866453","doi":"10.1016/s1470-2045(21)00459-9","title":"Stereotactic body radiotherapy for painful spinal metastases – Authors' reply","year":2021,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Princess Margaret Cancer Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"Varian Medical Systems; Elekta; AstraZeneca","keywords":"Medicine; Clinical endpoint; Radiation therapy; Stereotactic radiotherapy; Radiosurgery; Randomized controlled trial; Surgery","score_opus":0.09006943901398826,"score_gpt":0.38638569052977406,"score_spread":0.2963162515157858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197866453","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00045083044,0.0033178455,0.0024884623,0.9860335,0.0015845903,0.002427383,0.00026007788,0.00014833675,0.0032889952],"genre_scores_gemma":[0.00020959007,0.00043679867,0.011368788,0.9519514,0.013519419,0.00070199626,0.0013163213,0.00013174315,0.020363966],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99581933,0.0013416372,0.00066001277,0.00075048,0.0005476127,0.00088090653],"domain_scores_gemma":[0.9961949,0.00115493,0.0005660041,0.0017515739,0.00019698325,0.00013559576],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0024036046,0.00049505034,0.0020291528,0.00018511665,0.00013531998,0.00007099849,0.0005441775,0.00040181717,0.0015685089],"category_scores_gemma":[0.0009529228,0.00034231768,0.00051992503,0.0002057516,0.00023018483,0.000053744123,0.00011952926,0.0016531646,0.000051036437],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019789648,0.00020421826,0.000071979855,0.001701075,0.0023757431,0.003775238,0.000103846214,5.962606e-7,0.00006478299,0.00028453098,0.9834873,0.005951745],"study_design_scores_gemma":[0.005540414,0.002061423,0.00046975672,0.00019010248,0.0032189223,0.00036306772,0.0000903977,0.00014079823,0.000017701032,0.00051038153,0.9870723,0.0003247243],"about_ca_topic_score_codex":0.000032049713,"about_ca_topic_score_gemma":0.000005912612,"teacher_disagreement_score":0.0340821,"about_ca_system_score_codex":0.00034729674,"about_ca_system_score_gemma":0.000643313,"threshold_uncertainty_score":0.9999029},"labels":[],"label_agreement":null},{"id":"W3198462265","doi":"10.1016/s1470-2045(21)00374-0","title":"Transforming Canada's role in global cancer control","year":2021,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Global Health and Surgery","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Hospital for Sick Children; Canadian Partnership Against Cancer; Queen's University; University of Toronto; Centre for Global Health Research; St. Michael's Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Framing (construction); Political science; Corporate governance; Equity (law); Global governance; Global health; Public relations; Work (physics); Economic growth; Politics; Health equity; Public administration; Health care; Engineering; Management; Economics; Law","score_opus":0.053711964667115544,"score_gpt":0.41256117152722743,"score_spread":0.3588492068601119,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3198462265","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000058306396,0.97695374,0.0000031400152,0.0066173566,0.0009451311,0.00083536777,0.0002958822,0.000017068767,0.014273995],"genre_scores_gemma":[0.0003973341,0.9893817,0.000010367918,0.008621842,0.0010711481,0.0002647244,0.0000651771,0.000015303202,0.00017245347],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977599,0.00044268867,0.0005584159,0.0002560034,0.00019125069,0.00079179223],"domain_scores_gemma":[0.99890995,0.00038780298,0.00015376437,0.0003095388,0.000050117902,0.00018881161],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006934365,0.00023874546,0.003462821,0.000029259236,0.000047546386,0.0000046728255,0.0001833136,0.0003354023,0.00019227156],"category_scores_gemma":[0.00010151676,0.00014721564,0.0002109409,0.0003328328,0.000046449488,0.000010646,0.00002013704,0.0006671858,0.000007759388],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000067143075,0.000029983225,0.00047698076,0.00443706,0.00009623669,0.0006601505,0.000016593272,0.0000011534946,3.7113598e-8,0.000362915,0.013405441,0.9804463],"study_design_scores_gemma":[0.0011634366,0.000047645663,0.00015613508,0.004537768,0.00042550667,0.00043959642,0.000039294555,0.000004665967,3.7714205e-8,0.000020246025,0.99304825,0.000117391835],"about_ca_topic_score_codex":0.45453942,"about_ca_topic_score_gemma":0.9072831,"teacher_disagreement_score":0.9803289,"about_ca_system_score_codex":0.0027718015,"about_ca_system_score_gemma":0.017921822,"threshold_uncertainty_score":0.9876456},"labels":[],"label_agreement":null},{"id":"W3200107890","doi":"10.1016/s1470-2045(21)00457-5","title":"Surgery versus SABR for early-stage lung cancer—time to call it a draw?","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; Health Sciences Centre","funders":"Varian Medical Systems; AstraZeneca","keywords":"SABR volatility model; Medicine; Lung cancer; Radiation therapy; Randomized controlled trial; Ablative case; Stage (stratigraphy); Confounding; Surgery; Oncology; Internal medicine","score_opus":0.07140197774656591,"score_gpt":0.4020876706559696,"score_spread":0.3306856929094037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200107890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.69595253,0.0027786319,0.00007106889,0.27432567,0.0019380813,0.0014067155,0.0002558489,0.00011134209,0.023160102],"genre_scores_gemma":[0.88506013,0.0029168504,0.0018413308,0.047602158,0.005983622,0.003620999,0.00019542071,0.00010932865,0.052670132],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988126,0.000093430375,0.00020771154,0.0003027635,0.00013755236,0.00044594085],"domain_scores_gemma":[0.9979805,0.0012428007,0.00007175914,0.00043808893,0.00012561111,0.00014124339],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00033273984,0.0001425317,0.0006816725,0.000035562836,0.00009452801,0.000017403632,0.000103667946,0.00009807356,0.0013949263],"category_scores_gemma":[0.00018766298,0.000098407596,0.00015982968,0.00016712002,0.00004723366,0.000024481158,0.00006786408,0.00012878727,0.00016861343],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041265227,0.00036800912,0.033880323,0.00023453646,0.00089527224,0.00039021496,0.00093361485,0.000048597627,0.00041959205,0.00036786968,0.9448182,0.013517228],"study_design_scores_gemma":[0.0055686035,0.0006298679,0.029731808,0.00014214146,0.00050992024,0.000019942854,0.000058027214,0.00010099442,0.0016335398,0.000018837976,0.96144617,0.00014015834],"about_ca_topic_score_codex":0.00047378655,"about_ca_topic_score_gemma":0.0013119567,"teacher_disagreement_score":0.22672352,"about_ca_system_score_codex":0.00092492567,"about_ca_system_score_gemma":0.0007890375,"threshold_uncertainty_score":0.9995179},"labels":[],"label_agreement":null},{"id":"W3200608261","doi":"10.1016/s1470-2045(21)00463-0","title":"Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":171,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Queen's University; World Health Organization","keywords":"Medicine; Snowball sampling; Essential medicines; Access to medicines; Cross-sectional study; Family medicine; Developing country; Descriptive statistics; Public health; Alternative medicine; Global health; Cancer; Environmental health; Nursing; Economic growth; Pathology","score_opus":0.23093750127483378,"score_gpt":0.4812587039765077,"score_spread":0.2503212027016739,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200608261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95457447,0.00055089424,0.0001476658,0.026889702,0.0028767665,0.00017112188,0.0018973252,0.000020435718,0.012871644],"genre_scores_gemma":[0.96115494,0.002720609,0.00004782794,0.03393634,0.0013841426,0.00010694603,0.00015099123,0.000016187552,0.00048200943],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99846995,0.0001157134,0.0005776199,0.0004174659,0.000041415777,0.000377862],"domain_scores_gemma":[0.9989272,0.00036824823,0.00021041956,0.0002821682,0.00009297308,0.00011903418],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001665211,0.00012509049,0.00048908475,0.000101376194,0.00008520898,0.00017186214,0.00080623734,0.00014760358,0.003280643],"category_scores_gemma":[0.0003741306,0.00011897841,0.000043359698,0.00022788285,0.00016115859,0.0002671804,0.00022279371,0.00025661144,0.00019862193],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022327536,0.00012656284,0.96727604,0.0000076045153,0.0000648899,0.00001070202,0.00015891709,0.0005552324,0.000046874473,0.014603609,0.01655523,0.0003710804],"study_design_scores_gemma":[0.0009216608,0.000035765264,0.61910063,0.0000019763079,0.0000015185635,0.0000051995544,0.0000063193597,0.00067470147,0.0000746928,0.0034764213,0.37560058,0.00010052198],"about_ca_topic_score_codex":0.0018904585,"about_ca_topic_score_gemma":0.011558396,"teacher_disagreement_score":0.35904536,"about_ca_system_score_codex":0.00052846107,"about_ca_system_score_gemma":0.00021945311,"threshold_uncertainty_score":0.9976305},"labels":[],"label_agreement":null},{"id":"W3200717490","doi":"10.1016/s1470-2045(21)00428-9","title":"Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":175,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Janssen Research and Development","keywords":"Daratumumab; Medicine; Autologous stem-cell transplantation; Multiple myeloma; Thalidomide; Bortezomib; Internal medicine; Interim analysis; Clinical endpoint; Oncology; Dexamethasone; Progression-free survival; Surgery; Randomized controlled trial; Chemotherapy","score_opus":0.09038015065881295,"score_gpt":0.36434493194217504,"score_spread":0.2739647812833621,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200717490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906867,0.00027936356,0.00028399224,0.0007157178,0.000061728875,0.007519964,0.0001278016,0.00006202256,0.0002627059],"genre_scores_gemma":[0.98382056,0.00038335545,0.01273556,0.00029385605,0.00008512032,0.0015381661,0.00036465665,0.00008590891,0.0006928387],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962273,0.000889503,0.0005113083,0.0009859313,0.00050401676,0.0008819085],"domain_scores_gemma":[0.997197,0.0011165026,0.00032434054,0.00075986004,0.0001998675,0.0004024636],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00058858254,0.0005926057,0.0020221989,0.00011617722,0.000371983,0.00015227718,0.00025533384,0.00018231475,0.000024851184],"category_scores_gemma":[0.00008036115,0.00024892218,0.00003153806,0.0005005665,0.0003753719,0.00041926434,0.00007502619,0.00041298431,0.0000016752708],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7595892,0.0058511896,0.19359444,0.000088910914,0.00073917623,0.0084710745,0.0015217954,0.000011413997,0.00026236585,0.000006455414,0.000022590166,0.02984139],"study_design_scores_gemma":[0.834258,0.09204221,0.06804283,0.0005210339,0.00077151676,0.0006332262,0.00082763884,0.0013258464,0.00066568435,0.0000026904336,0.0005335549,0.00037575015],"about_ca_topic_score_codex":0.0008505758,"about_ca_topic_score_gemma":0.0252912,"teacher_disagreement_score":0.12555161,"about_ca_system_score_codex":0.00040118015,"about_ca_system_score_gemma":0.0013496823,"threshold_uncertainty_score":0.9999963},"labels":[],"label_agreement":null},{"id":"W3201013983","doi":"10.1016/s1470-2045(21)00375-2","title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":561,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont; McMaster University","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Clinical endpoint; Internal medicine; Refractory (planetary science); Cytokine release syndrome; Oncology; Hematopoietic stem cell transplantation; Chimeric antigen receptor; Cohort; Transplantation; Clinical trial; Immunotherapy; Cancer; Biology","score_opus":0.14921257768924856,"score_gpt":0.4590593045005727,"score_spread":0.30984672681132414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201013983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99253666,0.0002697322,0.000003830933,0.00080118596,0.0003061876,0.0025534676,0.000026896809,0.000028975648,0.0034730316],"genre_scores_gemma":[0.99158174,0.00027298374,0.000530128,0.0013588159,0.00017112056,0.00009773017,0.00006430573,0.0000589181,0.005864256],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957583,0.0016267352,0.00087204034,0.000587235,0.0005590272,0.0005966816],"domain_scores_gemma":[0.9957576,0.0018789989,0.00062302215,0.0011732865,0.00037771024,0.0001894112],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012935429,0.00026962528,0.0016318429,0.00010605504,0.00007406018,0.000030099676,0.00064883503,0.00021939029,0.0019453489],"category_scores_gemma":[0.0010012623,0.0001586251,0.000078771336,0.0004687956,0.00035494828,0.00009412426,0.0005129078,0.00072814734,0.000046637546],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047956515,0.09310974,0.7945369,0.0000778922,0.0005311684,0.003028312,0.0016450561,8.913502e-7,0.0019229373,0.0000026545806,0.00069998216,0.056487966],"study_design_scores_gemma":[0.24618,0.03607895,0.71283954,0.00015527393,0.00029011743,0.00003778403,0.00064855604,0.00002352672,0.0008902606,0.0000069189914,0.002641767,0.00020729087],"about_ca_topic_score_codex":0.00007880131,"about_ca_topic_score_gemma":0.000992425,"teacher_disagreement_score":0.19822349,"about_ca_system_score_codex":0.0004286454,"about_ca_system_score_gemma":0.0010294421,"threshold_uncertainty_score":0.998967},"labels":[],"label_agreement":null},{"id":"W3201981182","doi":"10.1016/s1470-2045(21)00402-2","title":"Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":106,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Janssen Research and Development; National Cancer Institute","keywords":"Abiraterone acetate; Prednisone; Prostate cancer; Medicine; Placebo; Androgen deprivation therapy; Internal medicine; Oncology; Urology; Cancer; Pathology","score_opus":0.10851012393174991,"score_gpt":0.41889350831075456,"score_spread":0.31038338437900465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201981182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97213846,0.008195703,0.000033334305,0.007989517,0.00030601033,0.010484124,0.000178146,0.000065648994,0.0006090459],"genre_scores_gemma":[0.9856231,0.003760232,0.00063590374,0.00022234865,0.00026800382,0.0058377255,0.00017209596,0.000058534806,0.0034220472],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9958997,0.000982314,0.00088199234,0.00082313345,0.0005617132,0.00085119886],"domain_scores_gemma":[0.9974666,0.0010960648,0.0003387323,0.00048699792,0.00034421758,0.0002673596],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019858393,0.0004770556,0.0018906458,0.00021952059,0.00031501384,0.0001481216,0.00018152151,0.00014344367,0.00016357447],"category_scores_gemma":[0.00021646147,0.00032109828,0.0000895949,0.00040886886,0.00047292092,0.00023596975,0.00020146946,0.0005936443,0.000012410365],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96739775,0.0015295601,0.0008961026,0.0002825073,0.0016035844,0.0013836719,0.010586709,0.00067845534,0.01150709,0.00008193561,0.00024648002,0.0038061822],"study_design_scores_gemma":[0.97853845,0.003926834,0.001965536,0.00012818277,0.0010187338,0.00013827521,0.0056620208,0.005183532,0.0022303103,0.00007615587,0.000811963,0.00031997447],"about_ca_topic_score_codex":0.0006236053,"about_ca_topic_score_gemma":0.0056461003,"teacher_disagreement_score":0.013484638,"about_ca_system_score_codex":0.0009200612,"about_ca_system_score_gemma":0.001699949,"threshold_uncertainty_score":0.9999241},"labels":[],"label_agreement":null},{"id":"W3204184651","doi":"10.1016/s1470-2045(21)00344-2","title":"Guidelines for cellular and molecular pathology content in clinical trial protocols: the SPIRIT-Path extension","year":2021,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Women's College Hospital","funders":"Medical Research Council; Health and Care Research Wales; Blood Cancer UK; Prostate Cancer UK; Public Health Agency; Chief Scientist Office; Breast Cancer Now; Department of Health and Social Care; Cancer Research UK; Tenovus; National Institute for Health and Care Research; National Cancer Research Institute","keywords":"Path (computing); Extension (predicate logic); Clinical trial; Pathology; Content (measure theory); Computer science; Medicine; Mathematics; Computer network; Mathematical analysis; Programming language","score_opus":0.9511569958424636,"score_gpt":0.7335990082767821,"score_spread":0.21755798756568145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204184651","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000039948052,0.8975975,0.024104621,0.008137752,0.0023295681,0.06735722,0.0001661122,0.000057191566,0.00021007533],"genre_scores_gemma":[1.9578953e-7,0.6407349,0.32576507,0.0025816113,0.003194983,0.027552713,0.000011217425,0.000070965754,0.00008833606],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.973631,0.019419184,0.0050186,0.000989573,0.00029534855,0.0006462996],"domain_scores_gemma":[0.847387,0.14864425,0.0017931508,0.0015844172,0.00048754213,0.00010364299],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.04518654,0.0005106911,0.00773464,0.0000561438,0.000102890794,0.0000463658,0.0010057382,0.0013307518,0.00005535458],"category_scores_gemma":[0.34640202,0.00024592382,0.0009883696,0.00020124044,0.0007652511,0.000012860386,0.00059666706,0.0015712328,0.00001123781],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025756268,0.0003766016,0.0000010063081,0.0036239678,0.00016812998,0.00031913302,0.000020814787,9.803007e-8,0.000002211944,0.07198895,0.016542101,0.90438133],"study_design_scores_gemma":[0.015290791,0.0013379903,0.0000010833718,0.0032058952,0.00087153044,0.000072118346,0.00002026476,0.000020691476,0.0000013417489,0.23692311,0.74204,0.00021516896],"about_ca_topic_score_codex":0.000005723622,"about_ca_topic_score_gemma":0.000014519596,"teacher_disagreement_score":0.90416616,"about_ca_system_score_codex":0.000099659075,"about_ca_system_score_gemma":0.00062505086,"threshold_uncertainty_score":0.9999993},"labels":[],"label_agreement":null},{"id":"W3205063602","doi":"10.1016/s1470-2045(21)00494-0","title":"Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":191,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institutes of Health; National Cancer Institute; Medical Research Council; National Institute for Health and Care Research; Bristol-Myers Squibb","keywords":"Azacitidine; Medicine; IDH2; Internal medicine; Myeloid leukaemia; Population; Clinical endpoint; Myeloid leukemia; Oncology; Myeloid; Clinical trial; Surgery; IDH1; Mutant; Biology","score_opus":0.04659093949864618,"score_gpt":0.34979027695407056,"score_spread":0.3031993374554244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3205063602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98254365,0.0005975175,0.00013881407,0.009611357,0.00066268584,0.003648409,0.0002592845,0.00013056948,0.002407724],"genre_scores_gemma":[0.9904414,0.0013816729,0.001712124,0.0022046028,0.0020507101,0.0005776241,0.00090144156,0.00012865226,0.00060181087],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99473166,0.0010044804,0.0009818564,0.0009916425,0.0008450841,0.001445256],"domain_scores_gemma":[0.99497616,0.002653814,0.00038347923,0.001077375,0.0003838055,0.0005253468],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014915753,0.0006086588,0.002431788,0.00033765868,0.00023683111,0.0000861112,0.00046490403,0.000439048,0.0004567417],"category_scores_gemma":[0.0017197808,0.00043009684,0.00018296116,0.0010081774,0.00074202736,0.00026545447,0.00035658482,0.0014793496,0.00005629805],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93028367,0.007258024,0.0004327708,0.000108789885,0.000951082,0.010125466,0.0011860823,0.000016842208,0.011414046,0.00010499758,0.0052536433,0.032864567],"study_design_scores_gemma":[0.942632,0.022476442,0.00031657406,0.00015225586,0.0007895258,0.00057820074,0.00040239812,0.00047044354,0.0071697985,0.000069437476,0.024481036,0.00046185468],"about_ca_topic_score_codex":0.00019745922,"about_ca_topic_score_gemma":0.00061420485,"teacher_disagreement_score":0.032402713,"about_ca_system_score_codex":0.0020134083,"about_ca_system_score_gemma":0.0022326703,"threshold_uncertainty_score":0.9998151},"labels":[],"label_agreement":null},{"id":"W3205592551","doi":"10.1016/s1470-2045(21)00519-2","title":"Addressing breast cancer mortality in low-income and middle-income countries: if you can't measure it, it doesn't exist","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Breast cancer; Cancer; Population; Mortality rate; Demography; Public health; Incidence (geometry); Gerontology; Internal medicine; Environmental health; Pathology","score_opus":0.18371567891885437,"score_gpt":0.4131564228314922,"score_spread":0.2294407439126378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3205592551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9175451,0.003275155,0.000013718603,0.0677366,0.00050845183,0.00031085333,0.00021939813,0.000054059765,0.010336656],"genre_scores_gemma":[0.98124564,0.0012992326,0.00017102077,0.015533893,0.0011055018,0.00007267578,0.000018827657,0.000023696164,0.0005294939],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975808,0.00031545287,0.00048431306,0.00047353763,0.00046482368,0.00068106543],"domain_scores_gemma":[0.9985256,0.00021880634,0.00018978381,0.0005868552,0.00029073982,0.0001881661],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012634173,0.00025155672,0.00096634054,0.00006213057,0.00018160406,0.000054630593,0.00025647986,0.00023969445,0.00045732048],"category_scores_gemma":[0.00019605142,0.00018222607,0.000078856814,0.00039603905,0.00037672566,0.000119820565,0.00017433595,0.00065002166,0.000014737192],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009944855,0.00006898025,0.99040544,0.00065948215,0.00017233136,0.0015758551,0.0023407592,0.00007234022,0.00031300896,0.0004684377,0.0015129437,0.0014159591],"study_design_scores_gemma":[0.0040187337,0.00013902962,0.973832,0.0037674082,0.00022262354,0.0013641854,0.0021775458,0.0001511498,0.0002764148,0.00044722515,0.013310703,0.00029296678],"about_ca_topic_score_codex":0.004951109,"about_ca_topic_score_gemma":0.038564518,"teacher_disagreement_score":0.06370055,"about_ca_system_score_codex":0.00079226855,"about_ca_system_score_gemma":0.001218902,"threshold_uncertainty_score":0.9789792},"labels":[],"label_agreement":null},{"id":"W3206192616","doi":"10.1016/s1470-2045(21)00466-6","title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":363,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Alberta; University of Calgary","funders":"Janssen Research and Development; Strong","keywords":"Lenalidomide; Daratumumab; Dexamethasone; Medicine; Multiple myeloma; Open label; Oncology; Internal medicine; Clinical trial","score_opus":0.1690328158794252,"score_gpt":0.4209981267549274,"score_spread":0.2519653108755022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3206192616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9810101,0.00358643,0.00006402154,0.008128872,0.0007079591,0.0034926683,0.00054713985,0.000059617854,0.0024032337],"genre_scores_gemma":[0.9827963,0.0046700197,0.008669512,0.0008095608,0.0011595339,0.0005538255,0.00071942556,0.00006826246,0.0005535481],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9935451,0.0027051952,0.0009985137,0.0011393331,0.0005496701,0.0010621852],"domain_scores_gemma":[0.9813802,0.01647637,0.00035857223,0.001048259,0.00019567471,0.00054090365],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003170471,0.000505158,0.0024419134,0.00016878592,0.0002814279,0.00018459623,0.00045128525,0.00036702515,0.00017062025],"category_scores_gemma":[0.01127028,0.00037238872,0.000109346445,0.0004326808,0.00053354603,0.00025622075,0.0007122263,0.0009255859,0.00003159534],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93391407,0.0028194739,0.0022844174,0.000043215205,0.0009489874,0.0049927155,0.00086213247,0.000005408286,0.009313075,0.000087704764,0.0019265203,0.04280226],"study_design_scores_gemma":[0.96850747,0.0042041773,0.011134474,0.00015632295,0.00037906857,0.00012944045,0.0004142696,0.001354532,0.0031805688,0.0003169373,0.009865488,0.0003572745],"about_ca_topic_score_codex":0.0062952917,"about_ca_topic_score_gemma":0.013044057,"teacher_disagreement_score":0.04244498,"about_ca_system_score_codex":0.00036697576,"about_ca_system_score_gemma":0.00075241824,"threshold_uncertainty_score":0.9998728},"labels":[],"label_agreement":null},{"id":"W3207368269","doi":"10.1016/s1470-2045(21)00522-2","title":"A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Cancer Institute; NIHR Cambridge Biomedical Research Centre; NIHR Oxford Biomedical Research Centre; European Regional Development Fund; Instituto de Salud Carlos III; Fundação para a Ciência e a Tecnologia; Cancer Council South Australia; Manchester Biomedical Research Centre; Cancer Council Tasmania; National Institutes of Health; Royal Marsden NHS Foundation Trust; Cancer Australia; Prostate Cancer Foundation of Australia; Generalitat de Catalunya; Centro de Investigación Biomédica en Red de Cáncer; Fundación Científica Asociación Española Contra el Cáncer; National Institute for Health and Care Research; Institut Català de la Salut; NorthShore University HealthSystem; Ministerio de Economía y Competitividad; Victorian Cancer Agency; Albert Einstein Cancer Center; Prostate Cancer Foundation; Memorial Sloan-Kettering Cancer Center; Cancer Council Victoria; Cancerfonden; Cancer Research UK","keywords":"Prospective cohort study; Prostate cancer; Gene; Cancer; Oncology; Medicine; Internal medicine; Prostate; Genetics; Biology","score_opus":0.06378057788104297,"score_gpt":0.39783938470088165,"score_spread":0.3340588068198387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3207368269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887554,0.0002498635,0.00007205027,0.0032403297,0.0003228534,0.0049303533,0.00063222,0.00012139543,0.001675537],"genre_scores_gemma":[0.9848066,0.0000683763,0.0099809095,0.00035586258,0.0011509785,0.0031866075,0.0001724129,0.000050274026,0.00022795176],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99749035,0.00035528443,0.00044242645,0.00078879547,0.0003592162,0.0005639022],"domain_scores_gemma":[0.99824446,0.00029910446,0.00023732023,0.0005360972,0.00056443363,0.000118550466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008660022,0.00026237787,0.000716118,0.00007287466,0.00010190207,0.000041130304,0.00025158317,0.00013487946,0.000078047735],"category_scores_gemma":[0.0003468141,0.00017196493,0.00009022389,0.0003529538,0.00016923907,0.00011588685,0.00013414072,0.00041456064,0.0000021949757],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051255744,0.0017595543,0.8945101,0.000025706513,0.0012875494,0.00059441576,0.024492623,0.00033466856,0.0034204589,0.00003538338,0.0003259457,0.021957887],"study_design_scores_gemma":[0.026107522,0.0075916923,0.95393616,0.00010596417,0.00025186397,0.00011410605,0.006285762,0.0016741288,0.002033865,0.0006511684,0.0010089957,0.00023875307],"about_ca_topic_score_codex":0.002059204,"about_ca_topic_score_gemma":0.013137445,"teacher_disagreement_score":0.059426114,"about_ca_system_score_codex":0.0010066681,"about_ca_system_score_gemma":0.0013475784,"threshold_uncertainty_score":0.7331003},"labels":[],"label_agreement":null},{"id":"W3208204329","doi":"10.1016/s1470-2045(21)00531-3","title":"Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":371,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme; AstraZeneca","keywords":"Olaparib; Ovarian cancer; Mutation; BRCA mutation; Clinical trial; Cancer","score_opus":0.04020537618833177,"score_gpt":0.3627496910676291,"score_spread":0.32254431487929736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208204329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9805338,0.00058224966,0.0030580754,0.005115569,0.0010247177,0.008479343,0.00020580851,0.000052189873,0.00094828976],"genre_scores_gemma":[0.98567486,0.0005321234,0.003514387,0.0019946895,0.0008555947,0.00648051,0.00019431459,0.000053458683,0.0007000906],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978985,0.00027343104,0.0006334309,0.0004446194,0.0002879424,0.00046207625],"domain_scores_gemma":[0.996686,0.0015360771,0.0006005306,0.00042876048,0.00062286155,0.00012581711],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078436814,0.00025995245,0.0015102553,0.000083555984,0.00013328448,0.000020246302,0.00014079061,0.00018235463,0.00018040418],"category_scores_gemma":[0.000561215,0.00017141049,0.00018451716,0.00026049773,0.00024138675,0.00011264736,0.000031499516,0.0002705628,0.0000029722528],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9824301,0.0007580012,0.00023227367,0.00010311848,0.00062678446,0.000037074064,0.0009652442,0.00010789671,0.0014844767,0.0010946294,0.0022200972,0.009940309],"study_design_scores_gemma":[0.9838487,0.0049564145,0.00018052912,0.00019752458,0.0005985782,0.000025844027,0.00025305967,0.00025150884,0.0013455815,0.0007785377,0.007372088,0.0001916186],"about_ca_topic_score_codex":0.00006928024,"about_ca_topic_score_gemma":0.00042352983,"teacher_disagreement_score":0.009748691,"about_ca_system_score_codex":0.00026097437,"about_ca_system_score_gemma":0.0008816245,"threshold_uncertainty_score":0.69899166},"labels":[],"label_agreement":null},{"id":"W3208718719","doi":"10.1016/s1470-2045(21)00521-0","title":"A growing vulvar mass in a post-menopausal woman","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer and Skin Lesions","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"Myriad Genetics; Purdue Pharma; Roche; Merck; Novartis; Pfizer; Eli Lilly and Company","keywords":"Immunohistochemistry; Vulva; Pathology; Medicine; Cervix; Progesterone receptor; Biopsy; Context (archaeology); Vulvar Carcinoma; Breast cancer; Estrogen receptor; Internal medicine; Cancer; Biology","score_opus":0.04048159202572352,"score_gpt":0.3517853224503171,"score_spread":0.3113037304245936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208718719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88965124,0.0006212377,0.000051797426,0.06612254,0.00031891544,0.00014528834,0.0000072446537,0.00004197837,0.043039747],"genre_scores_gemma":[0.97786814,0.00013785275,0.00094653724,0.019117126,0.00080482813,0.000034657056,0.000016250538,0.000012199576,0.0010624302],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99915504,0.0001490864,0.00014957196,0.00016055626,0.00009741335,0.00028831378],"domain_scores_gemma":[0.9993898,0.00018017142,0.00002755148,0.00029955705,0.00004902331,0.000053849886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032677877,0.00007354132,0.00036006898,0.000040448725,0.000048705984,0.000006507669,0.00009611898,0.00007739119,0.00047600153],"category_scores_gemma":[0.00014485721,0.00005154539,0.00003024327,0.0002083123,0.000059864222,0.000031206513,0.000058744823,0.00032044548,0.000067184665],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024893605,0.0007056457,0.04166812,0.0001924568,0.000281843,0.015815929,0.0074405153,0.000056444944,0.84417444,0.020720161,0.03673253,0.029722575],"study_design_scores_gemma":[0.013898959,0.002275882,0.39885828,0.0002295591,0.00025734727,0.0047382964,0.003960664,0.00022137848,0.007345125,0.005251045,0.56259984,0.00036361066],"about_ca_topic_score_codex":0.0001098381,"about_ca_topic_score_gemma":0.0006619858,"teacher_disagreement_score":0.8368293,"about_ca_system_score_codex":0.00018704642,"about_ca_system_score_gemma":0.00038757603,"threshold_uncertainty_score":0.52118826},"labels":[],"label_agreement":null},{"id":"W3212751896","doi":"10.1016/s1470-2045(21)00536-2","title":"Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Novartis Pharmaceuticals Corporation","keywords":"Ceritinib; Anaplastic large-cell lymphoma; Lymphoma; Phases of clinical research; Phase (matter)","score_opus":0.04317782784484444,"score_gpt":0.3491828933605973,"score_spread":0.3060050655157529,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212751896","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963492,0.00033464603,0.0000046506757,0.0008324833,0.00012640253,0.0017312343,0.000058167978,0.000029764306,0.000533407],"genre_scores_gemma":[0.99770266,0.00018940038,0.0006307701,0.0008232601,0.00014703245,0.00021502383,0.00023783017,0.000022271828,0.000031760694],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981797,0.00047930412,0.00029791464,0.0004648514,0.00022472141,0.0003535442],"domain_scores_gemma":[0.9987513,0.0004330879,0.00014012883,0.0003730715,0.0001663755,0.00013607687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002822873,0.00020879574,0.0006185501,0.00007559545,0.00013964524,0.00005244501,0.00012930634,0.00009246511,0.00003236557],"category_scores_gemma":[0.00011357351,0.000132268,0.000015227773,0.00037015145,0.0000811981,0.00016551813,0.00015695438,0.00009293901,0.000011674323],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009017782,0.043958638,0.825494,0.00004734711,0.00017605971,0.0015794539,0.0035722866,0.000019340017,0.00028349087,0.000117943106,0.00019274751,0.115540914],"study_design_scores_gemma":[0.113133855,0.013805835,0.8700922,0.0000945666,0.00031168936,0.00004255147,0.0015600822,0.00034794142,0.00014676068,0.000022148992,0.00030159607,0.00014078936],"about_ca_topic_score_codex":0.00024854194,"about_ca_topic_score_gemma":0.0012668644,"teacher_disagreement_score":0.11540013,"about_ca_system_score_codex":0.0003918871,"about_ca_system_score_gemma":0.00029961154,"threshold_uncertainty_score":0.5393732},"labels":[],"label_agreement":null},{"id":"W3217142409","doi":"10.1016/s1470-2045(21)00602-1","title":"Global cancer research in the post-pandemic world","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Science and Technology Facilities Council; Economic and Social Research Council; Merck Sharp and Dohme; National Institute for Health and Care Research; Bristol-Myers Squibb; UK Research and Innovation; Janssen Pharmaceuticals; AstraZeneca; Bayer; Astellas Pharma US","keywords":"Pandemic; Cancer; Coronavirus disease 2019 (COVID-19); Political science; Medicine; Disease; Pathology; Internal medicine","score_opus":0.4143096540076404,"score_gpt":0.5965710100512617,"score_spread":0.18226135604362126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217142409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5280366,0.0021765719,0.0000015181241,0.44624448,0.00022587583,0.000246997,0.000014352197,0.000019674633,0.023033934],"genre_scores_gemma":[0.90842766,0.0011134471,0.00003405445,0.08789839,0.0014595082,0.000058385674,0.000008642797,0.0000060306943,0.0009938943],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99781024,0.0009770633,0.00016944887,0.00018311678,0.00029552268,0.0005645881],"domain_scores_gemma":[0.9980074,0.0011967648,0.000032679123,0.000475842,0.00020530896,0.00008197267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002638045,0.000071652285,0.00032436184,0.00005986544,0.00011387233,0.000013586884,0.00025215084,0.00009380345,0.00029911456],"category_scores_gemma":[0.0005609423,0.00003785302,0.00003905851,0.0009740269,0.00015866531,0.000020387404,0.000096845346,0.00075661804,0.00006506927],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001784734,0.0002666005,0.75231934,0.00023852609,0.0000525296,0.0013608531,0.004029278,0.000014116396,0.00094962213,0.010251514,0.13215247,0.09658045],"study_design_scores_gemma":[0.0012513822,0.00020756722,0.5844185,0.00006335104,0.000014644224,0.00020674094,0.0006361671,0.000010326232,0.000019227036,0.0021812988,0.41095626,0.000034570814],"about_ca_topic_score_codex":0.0058584115,"about_ca_topic_score_gemma":0.13897781,"teacher_disagreement_score":0.38039106,"about_ca_system_score_codex":0.0009034807,"about_ca_system_score_gemma":0.0033499205,"threshold_uncertainty_score":0.88562053},"labels":[],"label_agreement":null},{"id":"W3217494531","doi":"10.1016/s1470-2045(21)00578-7","title":"Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":353,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"National Cancer Institute; Loxo Oncology; PharmaMar; Innovent Biologics; Incyte; Sanofi; Andrew Sabin Family Foundation; National Institutes of Health; Helsinn; GlaxoSmithKline; University of Texas MD Anderson Cancer Center; Pfizer; Novartis Pharmaceuticals Corporation; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Dabrafenib; Trametinib; Glioma; Glioblastoma; Temozolomide; Clinical trial","score_opus":0.06301962313348018,"score_gpt":0.34848886777246735,"score_spread":0.28546924463898715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217494531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845632,0.00042913022,0.000005812216,0.011565094,0.00040153635,0.0024355757,0.000108357235,0.00004714894,0.00044417803],"genre_scores_gemma":[0.99575675,0.00010513775,0.0014743445,0.0017751028,0.0003232129,0.00027300557,0.00020707386,0.00004464596,0.00004070175],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973403,0.00054023083,0.0005089027,0.0006209196,0.0003324287,0.0006572072],"domain_scores_gemma":[0.9981026,0.00068739057,0.0002425415,0.0006344827,0.000105709005,0.00022726384],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041391316,0.00033492924,0.001281089,0.0001236395,0.00012162944,0.00008538438,0.00028017335,0.00019227467,0.00017703639],"category_scores_gemma":[0.0002654841,0.00020823542,0.00005078514,0.0005124994,0.00021918847,0.00010773148,0.00022366234,0.00036447647,0.000016630222],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.46324545,0.32459483,0.06432095,0.0004460315,0.0025782774,0.017092213,0.005702504,0.00005642036,0.027909925,0.0026099368,0.009235332,0.08220812],"study_design_scores_gemma":[0.9328076,0.016023766,0.028833846,0.0002760213,0.00065779075,0.00017373792,0.0003403026,0.0003160138,0.011329962,0.00018329988,0.008690294,0.00036732428],"about_ca_topic_score_codex":0.00019481001,"about_ca_topic_score_gemma":0.0006492002,"teacher_disagreement_score":0.4695622,"about_ca_system_score_codex":0.00039524917,"about_ca_system_score_gemma":0.00034489017,"threshold_uncertainty_score":0.84915936},"labels":[],"label_agreement":null},{"id":"W4200028620","doi":"10.1016/s1470-2045(21)00589-1","title":"Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":437,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; Ontario Institute for Cancer Research","funders":"National Institute of General Medical Sciences; Cancer Prevention and Research Institute of Texas; Genentech; National Institutes of Health; Instituto de Investigación Sanitaria Gregorio Marañón; Bristol-Myers Squibb; Max-Planck-Gesellschaft; Eisai; National Institute for Health and Care Research; University of California, San Francisco; Cancer Research UK; Puma Biotechnology; Syndax Pharmaceuticals; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; PharmaMar; Celgene; Intas Pharmaceuticals; Eli Lilly and Company; AstraZeneca; European Regional Development Fund; Breast Cancer Research Foundation; Instituto de Salud Carlos III; Amgen; Pfizer","keywords":"Pooled analysis; Chemotherapy; Breast cancer; Cancer; Survival analysis; Meta-analysis","score_opus":0.012837194240986978,"score_gpt":0.3124301090058624,"score_spread":0.2995929147648754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200028620","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860523,0.003401025,0.000003275675,0.00958838,0.00016349462,0.00015970529,0.00056749553,0.0000059084914,0.00005845555],"genre_scores_gemma":[0.99306685,0.0053875213,0.000045516932,0.00089419354,0.0002433033,0.00012927898,0.0000990982,0.000016096827,0.000118164775],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99875987,0.00019924152,0.00024973595,0.00035817063,0.00012586026,0.00030710132],"domain_scores_gemma":[0.9992783,0.000061171275,0.00014147893,0.0003379654,0.00013949315,0.000041611413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011821174,0.00018672958,0.0007267459,0.00005631631,0.00004049445,0.000008761603,0.00014999541,0.000119233344,0.000116221796],"category_scores_gemma":[0.000019562138,0.00013198509,0.00009977836,0.00022739604,0.00015037875,0.0000040976893,0.00017278889,0.000092820424,7.491733e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012038356,0.00021123711,0.9797904,0.00002355119,0.0029239776,0.000018357332,0.00072819984,0.000077223165,0.0021853007,0.0000031809996,0.00008816181,0.012746588],"study_design_scores_gemma":[0.0045092963,0.00005610217,0.992621,0.00002273349,0.00089543907,0.000003147839,0.00014359172,0.000015071502,0.0012215093,0.0000044339686,0.0003714911,0.00013620229],"about_ca_topic_score_codex":0.0014433207,"about_ca_topic_score_gemma":0.027076548,"teacher_disagreement_score":0.025633227,"about_ca_system_score_codex":0.00009848894,"about_ca_system_score_gemma":0.00013560375,"threshold_uncertainty_score":0.99067676},"labels":[],"label_agreement":null},{"id":"W4200116461","doi":"10.1016/s1470-2045(21)00590-8","title":"USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a prospective cohort study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":161,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Alberta; Centre for Advancing Health Outcomes; Foothills Medical Centre; Brock University; BC Cancer Agency; Simon Fraser University; Vancouver Coastal Health; University of Calgary","funders":"National Health and Medical Research Council; National Cancer Institute; Cancer Research UK; BC Cancer Foundation; Medical Research Council; Terry Fox Research Institute; Alberta Cancer Foundation; Roy Castle Lung Cancer Foundation","keywords":"Lung cancer; Interim analysis; Lung cancer screening; Prospective cohort study; Interim; Cancer; Cohort study; Cohort","score_opus":0.07810916812081006,"score_gpt":0.4749829657438349,"score_spread":0.3968737976230249,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200116461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9861183,0.0010874469,0.0004798425,0.004841844,0.0012577849,0.0017591751,0.00010219912,0.000046811405,0.0043065567],"genre_scores_gemma":[0.9962172,0.00035746626,0.0010990103,0.00038096614,0.000798451,0.0008193702,0.000098996265,0.000018875084,0.00020966196],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99782825,0.00039341382,0.0005224499,0.00053843146,0.0003993389,0.00031814852],"domain_scores_gemma":[0.9979936,0.0005160249,0.00030525192,0.0006723573,0.00042744377,0.00008531261],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010116195,0.00020344024,0.0012801995,0.00014186293,0.00010053568,0.000031286272,0.00023646536,0.000091961614,0.0016202457],"category_scores_gemma":[0.00023688021,0.00014487018,0.00030001276,0.0005859166,0.00011233026,0.00008085215,0.00021693813,0.00026204783,0.0000022878708],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033265933,0.0013842714,0.9377244,0.000037417536,0.021407694,0.00008011796,0.0014214092,0.00015646395,0.000117338066,0.00009872694,0.002672686,0.0016335326],"study_design_scores_gemma":[0.05228838,0.0011506362,0.9280495,0.00009580518,0.011100409,0.0000064484116,0.0008780803,0.0047028917,0.00037981858,0.000010158485,0.0012030465,0.00013480123],"about_ca_topic_score_codex":0.002089392,"about_ca_topic_score_gemma":0.0038357994,"teacher_disagreement_score":0.019022446,"about_ca_system_score_codex":0.0010461701,"about_ca_system_score_gemma":0.00028254814,"threshold_uncertainty_score":0.99929243},"labels":[],"label_agreement":null},{"id":"W4200186760","doi":"10.1016/s1470-2045(21)00719-1","title":"Radiographic progression-free survival in the ACIS trial for prostate cancer","year":2021,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prednisone; Abiraterone acetate; Placebo; Clinical endpoint; Prostate cancer; Internal medicine; Enzalutamide; Oncology; Progression-free survival; Surgery; Randomized controlled trial; Cancer; Androgen deprivation therapy; Pathology; Chemotherapy","score_opus":0.11843179758308021,"score_gpt":0.4310193453638538,"score_spread":0.3125875477807736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200186760","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010042221,0.010394831,0.0000024695332,0.9681808,0.0020234517,0.0066649388,0.00037524576,0.000043255215,0.0022727917],"genre_scores_gemma":[0.0038097869,0.027574956,0.00041136704,0.8573744,0.062896386,0.028742062,0.00302659,0.00020334423,0.015961073],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99637306,0.0010725249,0.00040372866,0.00052298215,0.0006563585,0.0009713744],"domain_scores_gemma":[0.9968022,0.0015782363,0.00021649673,0.0011749323,0.00017776935,0.000050350955],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0020787627,0.0003320501,0.001257897,0.00017956764,0.00018222818,0.000054872507,0.0008916683,0.0006977667,0.00013875817],"category_scores_gemma":[0.0002788241,0.00014949267,0.00032605158,0.0005623079,0.00043642565,0.000031251933,0.00016412322,0.002558573,0.00000620018],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0376269,0.00019459685,0.0013193557,0.00046994517,0.00038850834,0.0013930477,0.0009552182,5.303238e-7,0.000016475859,0.000038214865,0.94501746,0.0125797605],"study_design_scores_gemma":[0.0910712,0.0019442649,0.00064710295,0.00025915928,0.00030763762,0.000061281185,0.00016469702,0.00000910785,0.000029025938,0.0009757341,0.9043673,0.00016343515],"about_ca_topic_score_codex":0.00018351787,"about_ca_topic_score_gemma":0.0005226428,"teacher_disagreement_score":0.11080636,"about_ca_system_score_codex":0.00035019073,"about_ca_system_score_gemma":0.0014380867,"threshold_uncertainty_score":0.99974257},"labels":[],"label_agreement":null},{"id":"W4200333351","doi":"10.1016/s1470-2045(25)00522-4","title":"Correction to Lancet Oncol 2024; 25: 1038–52","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Grail; Program for Creating STart-ups from Advanced Research and Technology; UCLH Biomedical Research Centre; Novartis; Merck Sharp and Dohme; American Association for Cancer Research; Servier; Basilea Pharmaceutica; Medical Research Council; Celgene; Johnson and Johnson; AstraZeneca; Genentech; Ipsen; Vifor Pharma; PharmaMar; Deutsche Krebshilfe; Bayer; Astellas Pharma; MedImmune; Daiichi-Sankyo; National Institutes of Health; CRUK Lung Cancer Centre of Excellence; Rosetrees Trust; Cancer Research UK; Janssen Pharmaceuticals; Breast Cancer Research Foundation; Canadian Cancer Society; Center for Cancer Research; National Institute for Health and Care Research; Clovis Oncology; Astex Pharmaceuticals; Harvard University; Entertainment Industry Foundation; AbbVie; National Cancer Institute; Gilead Sciences; Pfizer; Baxter International; Merck; GlaxoSmithKline; Boehringer Ingelheim; Amgen; American Society of Clinical Oncology; Bristol-Myers Squibb; Deutsche Forschungsgemeinschaft; Roche; Astellas Pharma US","keywords":"Medicine; Family medicine","score_opus":0.04504243712373093,"score_gpt":0.37463845798410506,"score_spread":0.3295960208603741,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200333351","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.097711444,0.00045573962,0.000573508,0.08724792,0.009600664,0.0009058187,0.000020884858,0.00016866619,0.80331534],"genre_scores_gemma":[0.6328479,0.0006698735,0.0016677621,0.16622074,0.00582255,0.00034225368,0.000056921002,0.000034101988,0.19233792],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988215,0.00015304796,0.0002402693,0.00027027552,0.00012465258,0.00039026322],"domain_scores_gemma":[0.9988797,0.0003651802,0.000063996646,0.00052414264,0.000073314586,0.00009369838],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005477937,0.00013730017,0.0006392261,0.00010845869,0.00012174661,0.000014177096,0.00023853107,0.00011462147,0.0012483184],"category_scores_gemma":[0.00025082304,0.00009718769,0.00008214218,0.000356709,0.00008492253,0.0000406414,0.00009819751,0.0005344594,0.0003303398],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013701107,0.00006520853,0.00727114,0.000051993607,0.00009039057,0.000030185656,0.00037537655,0.000039874445,0.0023202805,0.0007172677,0.90379757,0.08387059],"study_design_scores_gemma":[0.0029205063,0.0005702613,0.05314692,0.00006960134,0.00008082839,0.000049796177,0.00021290511,0.00040331882,0.0005980162,0.00017293969,0.94168216,0.0000927509],"about_ca_topic_score_codex":0.0002321809,"about_ca_topic_score_gemma":0.0007646471,"teacher_disagreement_score":0.6109774,"about_ca_system_score_codex":0.0006186663,"about_ca_system_score_gemma":0.0006465872,"threshold_uncertainty_score":0.99966466},"labels":[],"label_agreement":null},{"id":"W4200359149","doi":"10.1016/s1470-2045(21)00581-7","title":"The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":278,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"EIT Health; Fogarty International Center; National Cancer Institute; National Human Genome Research Institute; Guy's and St Thomas' NHS Foundation Trust; Instituto de Salud Carlos III; Sydney Medical School; Fundação para a Ciência e a Tecnologia; National Health and Medical Research Council; Medical Research Council; School of Public Health and Family Medicine, University of Cape Town; College of Science and Engineering, University of Minnesota; University of Florida Health; University of Oklahoma Health Sciences Center; College of Engineering, Michigan State University; University of Veterinary and Animal Sciences; Directorate for Biological Sciences; Debre Markos University; George Institute for Global Health; King Faisal University; Université de Versailles Saint-Quentin-en-Yvelines; Madda Walabu University; King Saud bin Abdulaziz University for Health Science; Alfaisal University; Laboratório Associado para a Química Verde; RUDN University; Universitas Padjadjaran; Jahrom University of Medical Sciences; University at Buffalo; Samara University; Imam Abdulrahman Bin Faisal University; Razi Vaccine and Serum Research Institute; Lorestan University of Medical Sciences; Kwame Nkrumah University of Science and Technology; Peking Union Medical College; University of Toronto; Imperial College London; Syöpäsäätiö; Universidade Federal do Rio Grande do Sul; University of Colombo; Novo Nordisk Fonden; Walailak University; University of Calcutta; The Wellcome Trust DBT India Alliance; Shenzhen University; NSW Ministry of Health; Università degli Studi di Milano; Pomorski Uniwersytet Medyczny W Szczecinie; Universitas Airlangga; Yasuj University of Medical Sciences; Tarbiat Modares University; Department of Biotechnology, Ministry of Science and Technology, India; University of Sulaimani; University of California, Los Angeles; China Medical University; Cairo University; Secretaría Nacional de Ciencia, Tecnología e Innovación; Universidade do Porto; University of Tsukuba; University of Dhaka; Universitatea Sapientia; Universitat de Barcelona; Fasa University of Medical Sciences; University of South Carolina; Qazvin University of Medical Sciences; Chinese Center for Disease Control and Prevention; Oulun Yliopisto; Hokkaido University; Università di Bologna; Universitatea de Medicină şi Farmacie \"Carol Davila\" Bucureşti; Shahid Beheshti University of Medical Sciences; Zanjan University of Medical Sciences; University of Gondar; United Arab Emirates University; Kermanshah University of Medical Sciences; Autoritatea Natională pentru Cercetare Stiintifică; Wolkite University; Universiti Sultan Zainal Abidin; Menofia University; Göteborgs Universitet; Shahrekord University of Medical Sciences; Liverpool University Hospitals NHS Foundation Trust; Centro de Investigación Biomédica en Red de Salud Mental; Monash University; Università degli Studi del Piemonte Orientale; Universidade de São Paulo; Bloomberg Philanthropies; Department of Social Services, Australian Government; Jawaharlal Institute Of Postgraduate Medical Education and Research; Universitetet i Oslo; Tartu Ülikool; Danmarks Tekniske Universitet; Birjand University of Medical Sciences; Universitetet i Bergen; Mazandaran University of Medical Sciences; Shahrekord University; Haramaya University; Tanta University; Hamadan University of Medical Sciences; Semmelweis Egyetem; Universiti Kebangsaan Malaysia; University of Waterloo; Kuwait University; Tabriz University of Medical Sciences; Addis Ababa University; Sultan Qaboos University; Seoul National University Hospital; Qatar University; Babol University of Medical Sciences; Shahroud University of Medical Sciences; National Center for Advancing Translational Sciences; Päivikki ja Sakari Sohlbergin Säätiö; Indian Council of Medical Research; Mahidol University; King Abdulaziz University; Karolinska Institutet; Università degli Studi di Genova; Universidade Federal de Santa Catarina; Eastern Virginia Medical School; Isfahan University of Medical Sciences; Universitas Ahmad Dahlan; Islamic Azad University; Seoul National University; Gachon University; Ajou University; Coordenação de Aperfeiçoamento de Pessoal de Nível Superior; Alborz University of Medical Sciences; Universidad Nacional de Colombia; Nankai University; Flinders University; Debre Tabor University; Universiteit Utrecht; Curtin University of Technology; University of South Australia; Instituto Politécnico do Porto; University of Science and Technology of China; University of Pennsylvania; Tsinghua University; National Taiwan Normal University; National and Kapodistrian University of Athens; Tehran University of Medical Sciences and Health Services; South Eastern Sydney Local Health District; McGovern Medical School; University of Technology Sydney; Charles Sturt University; University of Leicester; Deutsche Forschungsgemeinschaft; Amity University; Ministério da Ciência, Tecnologia e Ensino Superior; Sigrid Juséliuksen Säätiö; Queensland University of Technology; London South Bank University; University of Oxford; King's College London; University of Queensland; National Institute for Health and Care Research; American Lebanese Syrian Associated Charities; Uniwersytet Jagielloński Collegium Medicum; Shaheed Benazir Bhutto University; Sanjay Gandhi Postgraduate Institute of Medical Sciences; Technische Universität München; Arabian Gulf University; Tulane University; Neyshabur University of Medical Sciences; Kashan University of Medical Sciences; Macquarie University; Jordan University of Science and Technology; Hamad Bin Khalifa University; Shanghai Jiao Tong University; Kasturba Medical College, Manipal; Krishna Institute Of Medical Sciences Deemed To Be University; Samsung; Applied Molecular Biosciences Unit; Public Health Foundation of India; Australian Catholic University; University of Cape Town; Khalifa University of Science, Technology and Research; University of Ottawa; National Authority for Scientific Research and Innovation; Aksum University; James Cook University; Trường Đại học Duy Tân; Social Science Research Council; Ohio State University; Johns Hopkins University; Wellcome Trust; Institució Catalana de Recerca i Estudis Avançats; Universidade Federal de Juiz de Fora; Bill and Melinda Gates Foundation; Iran University of Medical Sciences; Student Research Committee, Tabriz University of Medical Sciences; La Trobe University; Deakin University; Uniwersytet Łódzki; Helsingin Yliopisto; Tufts Medical Center; Universidade de Lisboa; Ottawa Hospital Research Institute; Xiamen University; Jazan University; Universiti Brunei Darussalam; University of Rochester; Chinese University of Hong Kong; Florida Department of Health; Georgetown University; National Center of Neurology and Psychiatry; University of Agriculture, Faisalabad; Alexander von Humboldt-Stiftung; University of Southern California; University of Oklahoma; University of Zanjan; Florida International University; Jimma University; Zahedan University of Medical Sciences; Harvard University; Deutsches Krebsforschungszentrum; Conselho Nacional de Desenvolvimento Científico e Tecnológico; Univerzita Karlova v Praze; Michigan State University; Taipei Medical University; U.S. President’s Emergency Plan for AIDS Relief; Cleveland Clinic; Università di Catania; Eesti Teadusagentuur; Wayne State University; National Institutes of Health; Banaras Hindu University; Case Western Reserve University; Hamad Medical Corporation; University of Tabriz; European Commission; Yasouj University; Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute; Jackson State University; United Nations Population Fund; Rush University; Centre Hospitalier Universitaire Vaudois; New Mexico State University; Nazarbayev University; Wuhan University; Alberta Health Services; St. Baldrick's Foundation","keywords":"Burden of disease; Disease; Medicine; Cancer; Disease burden; Gerontology; Internal medicine","score_opus":0.03307815963245642,"score_gpt":0.3786533053267764,"score_spread":0.34557514569431996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200359149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9139815,0.025864542,0.0001904075,0.055398144,0.00058296294,0.003072797,0.00068132684,0.000019733086,0.00020857673],"genre_scores_gemma":[0.9968121,0.0014978522,0.000039782673,0.00071027747,0.0005582961,0.00022019369,0.0000116208885,0.000009748295,0.00014015277],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99710953,0.0009916007,0.00079180696,0.00030907092,0.00045401132,0.00034399316],"domain_scores_gemma":[0.9971167,0.0009928124,0.00047710206,0.00095472677,0.00035491958,0.000103763385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019667225,0.00018132491,0.0013514594,0.000030408733,0.00010456531,0.000018465045,0.0004343831,0.00007267489,0.000017528877],"category_scores_gemma":[0.0009784675,0.00009346143,0.00021996588,0.00068512367,0.00025751372,0.000026212936,0.00020526895,0.0001699697,0.0000017821392],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047608013,0.00076130783,0.9597138,0.007268346,0.0057371296,0.000038924452,0.0119693065,0.0019298993,0.000025197542,0.0021692908,0.0044872607,0.001138748],"study_design_scores_gemma":[0.007315829,0.0005965837,0.9472477,0.0019275633,0.0076707443,0.000027052594,0.030431874,0.0034646008,0.000009505817,0.0006719719,0.00045741387,0.00017919128],"about_ca_topic_score_codex":0.020506604,"about_ca_topic_score_gemma":0.058387134,"teacher_disagreement_score":0.08283056,"about_ca_system_score_codex":0.00043322996,"about_ca_system_score_gemma":0.0006663214,"threshold_uncertainty_score":0.9860159},"labels":[],"label_agreement":null},{"id":"W4200605608","doi":"10.1016/s1470-2045(21)00406-x","title":"Should brachytherapy be added to external beam radiotherapy for prostate cancer?","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Brachytherapy; External beam radiotherapy; Prostate cancer; External beam radiation; Radiation therapy; Medicine; Beam (structure); Radiology; Medical physics; Oncology; Cancer; Internal medicine; Physics; Optics","score_opus":0.09168546390392768,"score_gpt":0.41024865960250145,"score_spread":0.3185631956985738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200605608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7220872,0.016930362,0.00081151334,0.2557539,0.0009452618,0.0022397386,0.0003004331,0.00009617795,0.00083543925],"genre_scores_gemma":[0.5746003,0.056608498,0.024601495,0.31466454,0.008472946,0.0107459435,0.0002219136,0.000193877,0.009890512],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986949,0.00008177036,0.00023312913,0.00035441015,0.0001556711,0.00048013954],"domain_scores_gemma":[0.9989084,0.00024849808,0.00008909941,0.00044337416,0.0001585105,0.0001520998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029628497,0.00018080707,0.00064780837,0.00003390591,0.000112960595,0.00002423006,0.00013791308,0.00009089651,0.000404509],"category_scores_gemma":[0.000039123,0.00011750458,0.00012834284,0.00016672016,0.0000668824,0.000032932003,0.000032352153,0.00017355866,0.000008867277],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010577216,0.0014051587,0.053037606,0.00023133813,0.001426946,0.00052031217,0.0063243876,0.0003204416,0.11652315,0.0020531318,0.21310683,0.5944735],"study_design_scores_gemma":[0.009816671,0.002815879,0.022705648,0.00011004545,0.00014372698,0.00013114896,0.0001321425,0.00008471443,0.05609071,0.0004831331,0.90732086,0.00016530731],"about_ca_topic_score_codex":0.000113778086,"about_ca_topic_score_gemma":0.00031687377,"teacher_disagreement_score":0.69421405,"about_ca_system_score_codex":0.0005262923,"about_ca_system_score_gemma":0.00053582387,"threshold_uncertainty_score":0.4791698},"labels":[],"label_agreement":null},{"id":"W4205245374","doi":"10.1016/s1470-2045(21)00641-0","title":"Prioritising access to cancer drugs","year":2021,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cancer; Family medicine; Resource (disambiguation); Low and middle income countries; Limited resources; Developing country; Internal medicine; Economic growth; Risk analysis (engineering)","score_opus":0.12116397908599112,"score_gpt":0.3447051492846027,"score_spread":0.22354117019861158,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205245374","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00228458,0.008568121,0.00025692413,0.84548235,0.005010432,0.00043655193,0.00074499135,0.00006218982,0.13715385],"genre_scores_gemma":[0.0029234143,0.0040795226,0.00032167003,0.9525927,0.028297264,0.00027605626,0.00008534419,0.00010385211,0.011320207],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972148,0.00007932075,0.0008318885,0.00080525834,0.0000556098,0.0010131085],"domain_scores_gemma":[0.9978604,0.0002484664,0.0007331622,0.0009715882,0.00008416507,0.00010224688],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0008240354,0.00037718538,0.0018296689,0.00019963925,0.00019812532,0.00035872054,0.0016100667,0.0009158959,0.0021607226],"category_scores_gemma":[0.00019510313,0.00036857236,0.0002402944,0.0003019326,0.00014516864,0.00027087796,0.0004921891,0.0018842891,0.0011638739],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024622257,0.000014196792,0.0011539262,0.00007602883,0.000117070915,0.00009440611,0.00048115346,0.000031782776,0.0000014120023,0.0050133537,0.9818355,0.011156575],"study_design_scores_gemma":[0.00054222764,0.0000631112,0.002688812,0.00008496503,0.000024191011,0.00001667375,0.000019793823,0.000014851577,0.00001234352,0.011610549,0.9844387,0.00048379126],"about_ca_topic_score_codex":0.001995749,"about_ca_topic_score_gemma":0.0004886155,"teacher_disagreement_score":0.12583363,"about_ca_system_score_codex":0.0011010783,"about_ca_system_score_gemma":0.0004027773,"threshold_uncertainty_score":0.9998766},"labels":[],"label_agreement":null},{"id":"W4205284185","doi":"10.1016/s1470-2045(21)00705-1","title":"Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":181,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Centre Hospitalier Universitaire de Sherbrooke","funders":"Jonsson Comprehensive Cancer Center; American Society for Radiation Oncology; Prostate Cancer Foundation","keywords":"Prostate cancer; Duration (music); Androgen deprivation therapy; Radiation therapy; Prostate; Androgen; Patient data","score_opus":0.2618211436098287,"score_gpt":0.3853407944443986,"score_spread":0.1235196508345699,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205284185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9718262,0.0075242682,0.0004822477,0.014189821,0.000041895008,0.0024608544,0.0034274147,0.000033345037,0.000013972495],"genre_scores_gemma":[0.97736794,0.0049898694,0.0028994605,0.0073395916,0.000089708315,0.0038989861,0.003377281,0.000023200333,0.000013983863],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99869055,0.00031966707,0.00021239364,0.0003762897,0.00020239784,0.00019871094],"domain_scores_gemma":[0.9988174,0.00027321666,0.00022436614,0.00053512875,0.00009424988,0.00005563872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052383705,0.00013901449,0.00068396854,0.000072145594,0.00024572146,0.000038770326,0.00014039928,0.000030325704,0.00012210145],"category_scores_gemma":[0.000016245785,0.00007764074,0.00007942828,0.00026361318,0.000082851744,0.00016491274,0.000064661064,0.00010764207,1.5805092e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02816119,0.0026150425,0.38203788,0.000058376943,0.3644442,0.000104578656,0.023532894,0.0051132445,0.00058394315,0.001395911,0.0060698474,0.1858829],"study_design_scores_gemma":[0.04278513,0.04041127,0.25148302,0.000010782334,0.28146783,0.00017927871,0.00321796,0.011496702,0.004122223,0.000813128,0.36319274,0.000819938],"about_ca_topic_score_codex":0.00039241367,"about_ca_topic_score_gemma":0.0006901854,"teacher_disagreement_score":0.3571229,"about_ca_system_score_codex":0.00017915429,"about_ca_system_score_gemma":0.00020061628,"threshold_uncertainty_score":0.31660974},"labels":[],"label_agreement":null},{"id":"W4205524306","doi":"10.1016/s1470-2045(21)00723-3","title":"Radiographic progression-free survival in the ACIS trial for prostate cancer – Authors' reply","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Pharmaceuticals; Astellas Pharma Canada; Bayer; AstraZeneca; Bristol-Myers Squibb","keywords":"Prednisone; Prostate cancer; Abiraterone acetate; Enzalutamide; Placebo; Clinical endpoint; Acis","score_opus":0.1013740712609857,"score_gpt":0.44420525823761475,"score_spread":0.34283118697662907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205524306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6233455,0.008714954,0.000016499738,0.35643893,0.001715375,0.0049205315,0.00013353047,0.00006737249,0.004647302],"genre_scores_gemma":[0.938009,0.015044571,0.0017053426,0.012153272,0.00831381,0.012777332,0.00034315983,0.000094890514,0.011558595],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978782,0.00064306747,0.00026689644,0.000317914,0.00034036257,0.00055356853],"domain_scores_gemma":[0.99816287,0.000772751,0.0000939528,0.00075041637,0.0001508585,0.00006913886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024195474,0.0001389581,0.0005311608,0.000074340656,0.00017079756,0.000030155647,0.0003698221,0.00011425976,0.00008383333],"category_scores_gemma":[0.0005094532,0.00006439413,0.00014111874,0.00057231006,0.00024250154,0.00003585829,0.00010285095,0.00045893542,0.000004358198],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39650828,0.0025896206,0.08699053,0.0006624054,0.0009979515,0.0019277639,0.014145947,0.000012926359,0.0025172608,0.0045910203,0.29404205,0.19501425],"study_design_scores_gemma":[0.2122448,0.003996174,0.024713872,0.00018027537,0.00025941746,0.00012309519,0.0014933276,0.00012215663,0.0012790374,0.007269873,0.74812067,0.0001973366],"about_ca_topic_score_codex":0.000113531176,"about_ca_topic_score_gemma":0.0006792443,"teacher_disagreement_score":0.45407858,"about_ca_system_score_codex":0.00015729583,"about_ca_system_score_gemma":0.00086372823,"threshold_uncertainty_score":0.26259166},"labels":[],"label_agreement":null},{"id":"W4210332821","doi":"10.1016/s1470-2045(21)00757-9","title":"Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":186,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of British Columbia","funders":"Janssen Biotech; Daiichi Sankyo Europe; National Cancer Institute; Pharmacyclics; Stand Up To Cancer; Janssen Research and Development; EMD Serono; Genentech; Ipsen; Astellas Pharma; Daiichi-Sankyo; Seagen; Pfizer; Incyte; National Institutes of Health; Menarini Silicon Biosystems; Eli Lilly and Company; U.S. Department of Defense; Sanofi; Exelixis; Flatiron Health; Advanced Accelerator Applications; Endocyte; Prostate Cancer Foundation; Bristol-Myers Squibb; AstraZeneca; American Association for Cancer Research; Amgen","keywords":"Prostate cancer; DNA repair; Gene; DNA; DNA Damage Repair; Phase (matter); Cancer","score_opus":0.08052415143704984,"score_gpt":0.39797207989690686,"score_spread":0.31744792845985703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210332821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916382,0.0005547708,0.000004282063,0.00286471,0.0002885885,0.0039005014,0.000255927,0.00005012623,0.00044290267],"genre_scores_gemma":[0.9922467,0.0001430164,0.0012976038,0.0032473218,0.00017693147,0.0024718756,0.00012492659,0.00003209997,0.00025955352],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9979945,0.00054885756,0.00038885872,0.000369797,0.00031460368,0.00038340865],"domain_scores_gemma":[0.99898326,0.00020914932,0.0002685485,0.00036180308,0.00008542295,0.000091816815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081237906,0.00017628497,0.0006278191,0.00008240715,0.00022255098,0.000024550089,0.00017952968,0.00003482892,0.00024163359],"category_scores_gemma":[0.000055946017,0.00012286931,0.000026252656,0.00033250678,0.00015320214,0.000099751844,0.0001269435,0.00036468776,0.0000029704886],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9305204,0.008661733,0.024905825,0.0001676834,0.0006718786,0.0004481533,0.0058770357,0.00026400885,0.011357681,0.0004992569,0.009280877,0.0073454385],"study_design_scores_gemma":[0.90873975,0.020560721,0.018674962,0.000083192164,0.00038580532,0.000049525475,0.000554871,0.00047096988,0.00096219487,0.00022502965,0.048980445,0.00031256024],"about_ca_topic_score_codex":0.00033912805,"about_ca_topic_score_gemma":0.00091791386,"teacher_disagreement_score":0.03969957,"about_ca_system_score_codex":0.0006083083,"about_ca_system_score_gemma":0.00063168176,"threshold_uncertainty_score":0.5010465},"labels":[],"label_agreement":null},{"id":"W4210538987","doi":"10.1016/s1470-2045(21)00709-9","title":"Global consequences of the US FDA's accelerated approval of cancer drugs","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Mandate; Food and drug administration; Cancer drugs; Compassionate Use; Drug approval; Clinical trial; Scopus; Alternative medicine; Drug","score_opus":0.06840567706329904,"score_gpt":0.3097890429960882,"score_spread":0.2413833659327892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210538987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9131654,0.0033166967,0.000021370675,0.008110706,0.0012832007,0.0002496007,0.0011135797,0.000012513652,0.07272691],"genre_scores_gemma":[0.9968279,0.0004041549,0.000059178543,0.0019237663,0.0002115306,0.000082366765,0.000003432672,0.000008778195,0.0004789082],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99882895,0.00008427191,0.00055069313,0.00020654491,0.0000435234,0.00028603247],"domain_scores_gemma":[0.99859774,0.00007945464,0.00086619315,0.0003880651,0.00004020169,0.000028341858],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008426131,0.000106710766,0.0006386277,0.00003518048,0.00017120775,0.000009656596,0.0008447069,0.00006699998,0.0009990019],"category_scores_gemma":[0.0000714504,0.000080223064,0.00012400231,0.00033337946,0.0005387559,0.00006343305,0.00026223782,0.00020396401,0.000011657727],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045965603,0.0001665879,0.41510653,0.000048931535,0.00022475813,0.0000021763585,0.0015111561,0.0051078033,0.00023750418,0.5517712,0.016255474,0.00910817],"study_design_scores_gemma":[0.0021939855,0.0003626544,0.28469896,0.00001190541,0.000033877463,0.00001656932,0.0004987587,0.00044083843,0.0007906028,0.091822326,0.6188661,0.0002634381],"about_ca_topic_score_codex":0.0055699777,"about_ca_topic_score_gemma":0.000578487,"teacher_disagreement_score":0.6026106,"about_ca_system_score_codex":0.0003865398,"about_ca_system_score_gemma":0.00031731615,"threshold_uncertainty_score":0.9999142},"labels":[],"label_agreement":null},{"id":"W4213247158","doi":"10.1016/s1470-2045(22)00017-1","title":"Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Merck Sharp and Dohme; National Institute for Health and Care Research; Merck; AstraZeneca","keywords":"Prostate cancer; Homologous recombination; Olaparib; Drug; Quality of life (healthcare); Hormonal therapy; Gene","score_opus":0.20043690397895775,"score_gpt":0.42880753078566086,"score_spread":0.22837062680670311,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213247158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99082243,0.000544081,0.000016550688,0.0031910744,0.000082855084,0.0050917054,0.00018779236,0.000018074214,0.00004545159],"genre_scores_gemma":[0.9960564,0.000087675355,0.00084711664,0.00027989838,0.000061160645,0.001526685,0.0010519531,0.000019441191,0.00006966885],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99636906,0.00204212,0.0006085206,0.00031848904,0.00039818435,0.00026362218],"domain_scores_gemma":[0.9983331,0.00037174052,0.0006654956,0.0002716794,0.00026956317,0.0000884314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028627834,0.00015813678,0.0008145297,0.000101213016,0.0002768169,0.00002264295,0.00012647136,0.000028314033,0.00002357975],"category_scores_gemma":[0.00008140466,0.000095408024,0.000018695599,0.00041516326,0.00021752574,0.00022617963,0.00004488287,0.00027498213,1.0732217e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97066516,0.006356804,0.007749213,0.0001658119,0.00072714,0.000016389466,0.00325416,0.00074193825,0.0030895448,0.00025987186,0.00031818144,0.006655777],"study_design_scores_gemma":[0.8950447,0.07650894,0.024253303,0.00005800952,0.00024129328,0.0000030990464,0.00082447205,0.0024878965,0.00025768948,0.00006966136,0.000083848696,0.00016709362],"about_ca_topic_score_codex":0.004082114,"about_ca_topic_score_gemma":0.008301661,"teacher_disagreement_score":0.07562047,"about_ca_system_score_codex":0.0004883006,"about_ca_system_score_gemma":0.0017714634,"threshold_uncertainty_score":0.61709625},"labels":[],"label_agreement":null},{"id":"W4214517876","doi":"10.1016/s1470-2045(22)00058-4","title":"Elective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: an open-label, non-inferiority, multicentre, randomised phase 3 trial","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nasopharyngeal carcinoma; Chemoradiotherapy; Radiation therapy; Clinical endpoint; Surgery; Internal medicine; Head and neck cancer; Stage (stratigraphy); Randomized controlled trial; Oncology","score_opus":0.059944473757817786,"score_gpt":0.36151814264806353,"score_spread":0.3015736688902457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214517876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900318,0.00013941168,7.6361073e-7,0.0023227422,0.0010279376,0.004243561,0.000089775865,0.00002050912,0.002123529],"genre_scores_gemma":[0.99790007,0.000028729548,0.00014367302,0.0008339801,0.00037043524,0.00051158766,0.000096635405,0.000026491536,0.0000883987],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99763215,0.0007589014,0.00042814578,0.0003542463,0.00037918222,0.00044740664],"domain_scores_gemma":[0.99854517,0.00036071037,0.00032487884,0.00052743126,0.00015409736,0.000087707136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006655709,0.0002145069,0.0011340119,0.00007611389,0.00035000738,0.000013941681,0.0005442366,0.000081230995,0.00007007358],"category_scores_gemma":[0.00021402417,0.00013039676,0.000053759337,0.00048453722,0.00017442566,0.00012274388,0.0003708889,0.00058198,0.0000032036985],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8940809,0.0049316543,0.09030527,0.000042873555,0.00021890369,0.00002105359,0.0051159547,0.00003190316,0.0005765866,0.0000636914,0.0020394928,0.002571727],"study_design_scores_gemma":[0.710771,0.023686169,0.2599979,0.000025686611,0.00018242307,0.000002060261,0.000562851,0.0006240988,0.00010010465,0.000017630031,0.0039032295,0.00012679888],"about_ca_topic_score_codex":0.0005691733,"about_ca_topic_score_gemma":0.0010625289,"teacher_disagreement_score":0.18330984,"about_ca_system_score_codex":0.00073754205,"about_ca_system_score_gemma":0.0007978929,"threshold_uncertainty_score":0.5317425},"labels":[],"label_agreement":null},{"id":"W4214704026","doi":"10.1016/s1470-2045(22)00015-8","title":"Progression-free survival: it is time for a new name","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Clinical endpoint; Progression-free survival; Clinical trial; Quality of life (healthcare); Guideline; Internal medicine; Disease; Oncology; Cancer; Overall survival; Pathology; Nursing","score_opus":0.08270184093113529,"score_gpt":0.32196041692389227,"score_spread":0.23925857599275696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214704026","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.025662776,0.007097261,0.003074531,0.5382845,0.004248468,0.0016843202,0.0023645465,0.00017792365,0.4174057],"genre_scores_gemma":[0.43163684,0.002522198,0.019410755,0.28520596,0.018337546,0.0033861634,0.00025998906,0.00043375706,0.2388068],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986655,0.00003798923,0.00044189903,0.00033423264,0.000038711943,0.00048167742],"domain_scores_gemma":[0.99859273,0.00025442257,0.0004092363,0.0006381547,0.000020668635,0.0000848028],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015621893,0.00013756556,0.00066663924,0.000066308334,0.00032114846,0.000035109835,0.00094232423,0.00008655518,0.0052387402],"category_scores_gemma":[0.00025014215,0.00012844813,0.00014335249,0.000120849654,0.00008176757,0.00010340751,0.00034609527,0.00025955218,0.0006887318],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026058484,0.000059562484,0.0017397767,0.000009686166,0.000053363994,0.0000020076006,0.0008675678,0.000045843604,0.000006871728,0.10030787,0.8853895,0.01125735],"study_design_scores_gemma":[0.0017497479,0.00039481113,0.0012306771,0.0000025399966,0.0000069877447,0.0000066449397,0.00005942891,0.00051759934,0.000008468003,0.1591448,0.83672523,0.00015304323],"about_ca_topic_score_codex":0.0001493898,"about_ca_topic_score_gemma":0.00004941033,"teacher_disagreement_score":0.40597406,"about_ca_system_score_codex":0.0003348383,"about_ca_system_score_gemma":0.00018951505,"threshold_uncertainty_score":0.9956706},"labels":[],"label_agreement":null},{"id":"W4220668260","doi":"10.1016/s1470-2045(22)00088-2","title":"Consequences of US FDA approval decisions in high-income countries","year":2022,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Food and drug administration; Drug approval; Cancer drugs; Nomination; Expanded access; Drug; Pharmacology; Political science; Law; Oncology","score_opus":0.06043877707711726,"score_gpt":0.28660405973931713,"score_spread":0.22616528266219987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220668260","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.112727575,0.0064798286,0.0000757072,0.8074091,0.0042072404,0.00068504,0.0031358353,0.000045280296,0.06523439],"genre_scores_gemma":[0.32214156,0.012015965,0.00077218906,0.6532819,0.0065911785,0.00043033645,0.00022842448,0.00011650775,0.0044219294],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973743,0.00013548866,0.0012379697,0.0005167802,0.00007144522,0.00066402333],"domain_scores_gemma":[0.99674016,0.0010888401,0.0013233155,0.0007696435,0.000040400973,0.000037658974],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016549517,0.00029240584,0.0020065631,0.00035219933,0.00013639581,0.000039163806,0.0012583433,0.00064256677,0.0022849308],"category_scores_gemma":[0.00039459296,0.00026885423,0.00018046434,0.00025662943,0.0007980509,0.00013370588,0.0002684136,0.0017922198,0.0002738027],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028021506,0.000048848313,0.0340051,0.000107238986,0.00015416948,0.00021481933,0.00047665247,0.00024197773,0.0000021264746,0.17964658,0.78388864,0.0009336009],"study_design_scores_gemma":[0.000928212,0.0002662076,0.009426588,0.000030757623,0.00001373345,0.000026252688,0.000026779473,0.00001226108,0.000007989878,0.08566842,0.90331745,0.00027534825],"about_ca_topic_score_codex":0.0038883514,"about_ca_topic_score_gemma":0.00060146075,"teacher_disagreement_score":0.20941399,"about_ca_system_score_codex":0.0007306089,"about_ca_system_score_gemma":0.00041127662,"threshold_uncertainty_score":0.99997634},"labels":[],"label_agreement":null},{"id":"W4220672160","doi":"10.1016/s1470-2045(22)00122-x","title":"Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":143,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Clovis Oncology","keywords":"Ovarian cancer; Chemotherapy; Mutation; Cancer; Phases of clinical research; Poly ADP ribose polymerase; Clinical trial","score_opus":0.07535907588749029,"score_gpt":0.4198910124240871,"score_spread":0.3445319365365968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220672160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902804,0.00016068017,0.00005842535,0.0045566885,0.0009530988,0.0028353042,0.00031195596,0.000028053744,0.00081542856],"genre_scores_gemma":[0.9941001,0.00027261704,0.0012356614,0.0024091997,0.00034219358,0.0012680873,0.00026434875,0.000035471196,0.00007230532],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983406,0.0003805698,0.00039405626,0.0003129011,0.00034724077,0.0002246386],"domain_scores_gemma":[0.9988611,0.00024151559,0.00033512615,0.00033278097,0.00016503835,0.000064444874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062914594,0.00015528376,0.0006882032,0.00010470873,0.00014190513,0.000029116236,0.0003333296,0.00007464616,0.00088579353],"category_scores_gemma":[0.000069613845,0.0001082691,0.000024168781,0.00023870257,0.00016409345,0.00015219959,0.00008416198,0.00032317094,6.360544e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95226115,0.0009773719,0.0009207275,0.000022537983,0.00021989965,0.0000373069,0.0049206098,0.000046338624,0.00023471832,0.0001679607,0.0006129754,0.039578408],"study_design_scores_gemma":[0.9209877,0.038322702,0.0010469366,0.000045592653,0.00008400075,0.000018692435,0.0007306434,0.00012986494,0.00029808702,0.00007202832,0.038125806,0.00013792416],"about_ca_topic_score_codex":0.00019266317,"about_ca_topic_score_gemma":0.0005330877,"teacher_disagreement_score":0.039440487,"about_ca_system_score_codex":0.00082993036,"about_ca_system_score_gemma":0.00075080135,"threshold_uncertainty_score":0.9698818},"labels":[],"label_agreement":null},{"id":"W4220833376","doi":"10.1016/s1470-2045(22)00123-1","title":"Prioritising locations for radiotherapy equipment in Brazil: a cross-sectional, population-based study and development of a LINAC shortage index","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; Kingston General Hospital; Queen's University","funders":"","keywords":"Economic shortage; Index (typography); Linear particle accelerator; Radiation therapy","score_opus":0.05928119540905707,"score_gpt":0.4586169276786404,"score_spread":0.3993357322695833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220833376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824499,0.0007664533,0.013498261,0.0013916158,0.00032115876,0.0014659658,0.000012181965,0.000022626107,0.00007184302],"genre_scores_gemma":[0.9807784,0.00003319017,0.016683424,0.0014617675,0.00021887956,0.0006790335,0.00003452552,0.000015138814,0.000095652904],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99887717,0.000177471,0.00039377707,0.00021060716,0.00014797146,0.0001930231],"domain_scores_gemma":[0.9990483,0.000545795,0.00015202377,0.00018405188,0.000041934272,0.000027890466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001147676,0.000092423514,0.00039932827,0.000119238626,0.0003539025,0.0000051924017,0.00011785508,0.000063150146,0.000097259166],"category_scores_gemma":[0.00004685804,0.000075075106,0.000028822451,0.00015318558,0.000099450284,0.000027928058,0.000033739023,0.00019347436,1.8255987e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017748937,0.0008526682,0.9762618,0.00003860379,0.00008398003,0.000008617163,0.0023299241,0.0033214889,0.00028920264,0.00020555624,0.000045238918,0.014788006],"study_design_scores_gemma":[0.007766487,0.0014902417,0.95822734,0.00000943758,0.0000122518595,0.000033348126,0.0005014749,0.0017517421,0.000021784686,0.00022094612,0.029886458,0.00007851368],"about_ca_topic_score_codex":0.00003350167,"about_ca_topic_score_gemma":0.00034061054,"teacher_disagreement_score":0.02984122,"about_ca_system_score_codex":0.0007581957,"about_ca_system_score_gemma":0.0005237757,"threshold_uncertainty_score":0.3061474},"labels":[],"label_agreement":null},{"id":"W4223605782","doi":"10.1016/s1470-2045(22)00127-9","title":"Risk factors and prognostic implications of diagnosis of cancer within 30 days after an emergency hospital admission (emergency presentation): an International Cancer Benchmarking Partnership (ICBP) population-based study","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":131,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Nova Scotia; Alberta Bible College; Government of New Brunswick; Canadian Partnership Against Cancer; Health PEI; Saskatchewan Cancer Agency; St. John’s Health Sciences Centre; CancerCare Manitoba; Alberta Health Services; Cancer Care Ontario","funders":"Cancer Council Victoria; Partenariat Canadien Contre Le Cancer; Public Health England; Public Health Agency; Cancer Society of New Zealand; Cancer Institute NSW; University College London; Cancer Research UK; Public Health Wales; Alberta Health Services","keywords":"Cancer; General partnership; Cancer registry; Norwegian; Benchmarking; Public health; Agency (philosophy); Danish","score_opus":0.10803121393096099,"score_gpt":0.4328404661690418,"score_spread":0.3248092522380808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4223605782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963003,0.0005076796,0.000024512101,0.0013510733,0.00057240145,0.00088499533,0.0002498728,0.000021515827,0.00008767532],"genre_scores_gemma":[0.99744153,0.00032725383,0.00016202762,0.00008903556,0.0003203787,0.0014846172,0.00014675576,0.000014803194,0.000013581313],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982615,0.00037039598,0.00049911084,0.00030455514,0.00036913087,0.00019530197],"domain_scores_gemma":[0.99872434,0.00012472035,0.0005227434,0.00031779736,0.00020415233,0.00010621844],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00049842615,0.0001370674,0.00034523528,0.00008874937,0.00020021199,0.0000053500835,0.0002561433,0.000045958433,0.0032229377],"category_scores_gemma":[0.00018626075,0.000102802675,0.000055507106,0.00026056316,0.000044646084,0.00015445579,0.00009308177,0.00024443492,2.5175925e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004148894,0.000588245,0.98823786,0.000028633418,0.00011777358,0.000002703518,0.0049045356,0.0026773277,0.000072474795,0.00007699177,0.00023943752,0.0026391137],"study_design_scores_gemma":[0.00088763953,0.0018660695,0.99214184,0.000026565125,0.00031190677,0.0000010036184,0.002770838,0.0013792495,0.00007406343,0.00021859234,0.00021513886,0.00010706459],"about_ca_topic_score_codex":0.012032293,"about_ca_topic_score_gemma":0.006258423,"teacher_disagreement_score":0.00577387,"about_ca_system_score_codex":0.00019786133,"about_ca_system_score_gemma":0.00023356693,"threshold_uncertainty_score":0.99768823},"labels":[],"label_agreement":null},{"id":"W4223627834","doi":"10.1016/s1470-2045(22)00223-6","title":"Long-term versus short-term androgen deprivation combined with EBRT for unfavourable prostate cancer","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia, Okanagan Campus","funders":"","keywords":"Prostate cancer; Androgen; Androgen deprivation therapy; Radiation therapy; Androgen suppression; Prostate; Randomized controlled trial","score_opus":0.08354481682497854,"score_gpt":0.3878135536795813,"score_spread":0.30426873685460276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4223627834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98031676,0.0007461487,0.00003067853,0.014657185,0.00034436246,0.0019925705,0.00011693329,0.000064611006,0.0017307572],"genre_scores_gemma":[0.992337,0.00057865353,0.00013106132,0.00049950526,0.00031917437,0.0034927367,0.00026841648,0.000031468022,0.0023420178],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987761,0.00014010991,0.00014876192,0.00025056867,0.00023625778,0.00044823243],"domain_scores_gemma":[0.999181,0.00025938256,0.00006828909,0.00030602005,0.00011039118,0.00007493951],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005090528,0.0001289171,0.0003800515,0.000054389417,0.00035972212,0.000014950177,0.00018551822,0.000044170196,0.00033539842],"category_scores_gemma":[0.000028032522,0.00007757964,0.00004895337,0.00019093437,0.0001299898,0.00004574772,0.000105608546,0.00027056033,0.0000059625445],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16533913,0.0006071681,0.78572124,0.0002614553,0.0009973458,0.0003033033,0.0013879538,0.00018606828,0.003398455,0.0006935371,0.008311551,0.032792784],"study_design_scores_gemma":[0.112599045,0.03735089,0.74198514,0.00016590432,0.0015425575,0.00032905748,0.0009813678,0.0007954586,0.023867602,0.0008534594,0.07877497,0.00075455534],"about_ca_topic_score_codex":0.000054723067,"about_ca_topic_score_gemma":0.00023212194,"teacher_disagreement_score":0.07046342,"about_ca_system_score_codex":0.00066417456,"about_ca_system_score_gemma":0.00062217395,"threshold_uncertainty_score":0.36723778},"labels":[],"label_agreement":null},{"id":"W4224982972","doi":"10.1016/s1470-2045(22)00212-1","title":"Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Cancer Institute; Chugai Pharmaceutical; MSD Australia; EMD Serono; Genentech; Takeda Pharmaceuticals U.S.A.; Merck Sharp and Dohme; Astellas Pharma; Eisai; Pfizer; Incyte; Ipsen; Exelixis; Kissei; Bayer Fund; Sanofi; GlaxoSmithKline; Merck; Memorial Sloan-Kettering Cancer Center; Bristol-Myers Squibb; Eli Lilly and Company; EUSA Pharma; AstraZeneca; Amgen; Alexion Pharmaceuticals; Astellas Pharma US","keywords":"Pembrolizumab; Lenvatinib; Sunitinib; Renal cell carcinoma; Everolimus; Kidney cancer; Phases of clinical research; Carcinoma","score_opus":0.08879883769833696,"score_gpt":0.36365213383543105,"score_spread":0.2748532961370941,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224982972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915819,0.00017795178,0.0000022398879,0.0013380327,0.00011723808,0.0051998147,0.000119235374,0.00007259013,0.001390954],"genre_scores_gemma":[0.99788207,0.000009417301,0.0001494427,0.0004913847,0.000037781716,0.00076597644,0.00024270841,0.000067412235,0.000353802],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9944465,0.0024335482,0.0011396405,0.0005384333,0.00074989477,0.0006919875],"domain_scores_gemma":[0.9965222,0.0013111826,0.0009393402,0.0008342042,0.0001696453,0.00022342947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011556162,0.00041266336,0.0025270842,0.00023896093,0.00024611378,0.000007657271,0.0003233255,0.000078815996,0.00031081046],"category_scores_gemma":[0.00018121411,0.000228379,0.00011693144,0.00068836374,0.0001958024,0.000060814225,0.00014531951,0.00072258007,0.000007262239],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.68973106,0.0059597953,0.29739928,0.00008870813,0.00041331063,0.000377021,0.0037168546,0.00067846896,0.000031613024,0.000010268081,0.00008928929,0.0015043247],"study_design_scores_gemma":[0.5228049,0.08432051,0.38945264,0.000019260824,0.0002366823,0.000024598587,0.0027018131,0.000035829864,0.000052692754,0.000002239101,0.00016548435,0.00018335375],"about_ca_topic_score_codex":0.0019882352,"about_ca_topic_score_gemma":0.0010689984,"teacher_disagreement_score":0.16692618,"about_ca_system_score_codex":0.0013590242,"about_ca_system_score_gemma":0.001441825,"threshold_uncertainty_score":0.93130255},"labels":[],"label_agreement":null},{"id":"W4224983146","doi":"10.1016/s1470-2045(22)00155-3","title":"Sodium thiosulfate for prevention of cisplatin-induced hearing loss: updated survival from ACCL0431","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Cancer Institute","keywords":"Cohort; Chemotherapy; Quality of life (healthcare); Hearing loss; Childhood cancer; Cisplatin; Cancer; Scopus","score_opus":0.16263474852385781,"score_gpt":0.4396365639109289,"score_spread":0.27700181538707114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224983146","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9772165,0.00022956514,0.00011087716,0.016277958,0.0006083562,0.0010115912,0.000111291585,0.00005704243,0.0043768073],"genre_scores_gemma":[0.9969471,0.00006542018,0.00052686874,0.00048481385,0.00063599594,0.00032271392,0.00012370409,0.000019888972,0.00087350834],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99849486,0.00036314482,0.00026659618,0.00022051435,0.0003062848,0.00034860606],"domain_scores_gemma":[0.99880636,0.0005022777,0.00016880542,0.0003698404,0.00011121255,0.00004149532],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012059705,0.000101127946,0.0005877632,0.000053029456,0.00021947383,0.0000054605516,0.00026051342,0.000050895076,0.0003326941],"category_scores_gemma":[0.0002194241,0.000073436684,0.000094264884,0.00017732593,0.0000905358,0.000032506083,0.00038367588,0.00038259933,0.000007775643],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047985803,0.0020063359,0.099978425,0.0009240642,0.0050480627,0.00021449852,0.014111976,0.00033023526,0.6393807,0.008416123,0.1272898,0.05431396],"study_design_scores_gemma":[0.055547867,0.01629354,0.39123416,0.00021793303,0.0013481148,0.00012314897,0.0064459303,0.0025719998,0.07837031,0.022412524,0.4247024,0.0007320476],"about_ca_topic_score_codex":0.0004048721,"about_ca_topic_score_gemma":0.00022022825,"teacher_disagreement_score":0.5610104,"about_ca_system_score_codex":0.0003334223,"about_ca_system_score_gemma":0.00026322991,"threshold_uncertainty_score":0.3642767},"labels":[],"label_agreement":null},{"id":"W4224990434","doi":"10.1016/s1470-2045(22)00063-8","title":"Imaging response assessment for CNS germ cell tumours: consensus recommendations from the European Society for Paediatric Oncology Brain Tumour Group and North American Children's Oncology Group","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Cancer Research UK","keywords":"Germ cell; Germ cell tumors; Disease; Clinical trial; Consensus conference; Homogeneous","score_opus":0.02919742736994963,"score_gpt":0.3310829031241969,"score_spread":0.3018854757542473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224990434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7359742,0.00065216696,0.00030330278,0.25861153,0.0003878338,0.0021953555,0.0012923115,0.000077943994,0.00050539797],"genre_scores_gemma":[0.9585734,0.00034766062,0.013297602,0.023363832,0.0013876882,0.0018775552,0.0010399352,0.0000716523,0.000040652736],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9943925,0.0035949203,0.0005290693,0.0006040528,0.00018303853,0.0006963791],"domain_scores_gemma":[0.984251,0.014341327,0.0006657296,0.00049971824,0.0000846389,0.00015758828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046821344,0.0003015757,0.0009123504,0.00007303024,0.0011235635,0.0000338004,0.00037961232,0.000052744603,0.000050823717],"category_scores_gemma":[0.00030197692,0.00020315018,0.00034679504,0.00033602002,0.00046722687,0.00002868765,0.00040051402,0.0006351568,0.000004422022],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055095064,0.0038465827,0.2747101,0.00003209499,0.00087890256,0.00021403652,0.0047813905,0.00006153772,0.0046044188,0.0007338588,0.52658284,0.17804475],"study_design_scores_gemma":[0.012073403,0.0056923996,0.5810776,0.000005668034,0.00091174874,0.00024281185,0.0038416688,0.00048074,0.000020512816,0.00022465887,0.39522538,0.00020341492],"about_ca_topic_score_codex":0.00035874516,"about_ca_topic_score_gemma":0.00090517435,"teacher_disagreement_score":0.30636752,"about_ca_system_score_codex":0.0011745493,"about_ca_system_score_gemma":0.00053167535,"threshold_uncertainty_score":0.86416554},"labels":[],"label_agreement":null},{"id":"W4229439346","doi":"10.1016/s1470-2045(21)00720-8","title":"Cancer in sub-Saharan Africa: a Lancet Oncology Commission","year":2022,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":361,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Queen's University","funders":"Uganda Cancer Institute; National Cancer Institute; Medical Research Council; Dana-Farber Cancer Institute; World Health Organization","keywords":"Psychological intervention; Medicine; Workforce; Psychosocial; Cancer; Pandemic; Cancer prevention; Family medicine; Business; Environmental health; Economic growth; Nursing; Coronavirus disease 2019 (COVID-19); Disease; Internal medicine","score_opus":0.3942694405909314,"score_gpt":0.49235835738087214,"score_spread":0.09808891678994075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229439346","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000036609752,0.9200509,0.0000036152524,0.005506136,0.0009954293,0.0012759184,0.00016184937,0.000092292175,0.07187723],"genre_scores_gemma":[0.00006209986,0.9923316,0.00014641228,0.00221661,0.002659467,0.0013639813,0.00012907034,0.00006295473,0.0010277961],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99537957,0.0016324455,0.0008982582,0.0006283686,0.00044683254,0.001014546],"domain_scores_gemma":[0.997172,0.0010399767,0.00060964684,0.00094176707,0.000053300108,0.00018332957],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0024951866,0.00048770756,0.0050199525,0.00023892242,0.00019397993,0.000016989032,0.0009968834,0.00065404334,0.0024309617],"category_scores_gemma":[0.0002883376,0.0003149579,0.00041607063,0.0009104653,0.00022654713,0.00005282747,0.00048061422,0.0029031062,0.00015268078],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004695989,0.00011672751,0.00007914796,0.0023726407,0.00014918785,0.0008267847,0.00023525905,0.0000057339703,0.0000033124772,0.00012768566,0.18911365,0.80650026],"study_design_scores_gemma":[0.0020450752,0.00091617776,0.00014801165,0.004216566,0.0008254541,0.0007003128,0.00009150862,0.000014065216,6.768377e-7,0.00010281275,0.9906375,0.00030188373],"about_ca_topic_score_codex":0.0006159938,"about_ca_topic_score_gemma":0.0013433197,"teacher_disagreement_score":0.8061984,"about_ca_system_score_codex":0.0034905039,"about_ca_system_score_gemma":0.002895792,"threshold_uncertainty_score":0.99993026},"labels":[],"label_agreement":null},{"id":"W4233447779","doi":"10.1016/s1470-2045(20)30173-x","title":"Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group","year":2020,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":142,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre; Dalhousie University","funders":"National Cancer Institute; F. Hoffmann-La Roche","keywords":"Medicine; Glioma; Oncology; Medical physics; Internal medicine; Intensive care medicine","score_opus":0.09733537766704278,"score_gpt":0.41390526653161064,"score_spread":0.3165698888645678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233447779","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.023821507,0.7850268,0.000019053847,0.18419732,0.0019856947,0.004256876,0.00023276955,0.00012377274,0.00033623655],"genre_scores_gemma":[0.026347501,0.9614577,0.0021498064,0.00351044,0.0026009136,0.003333717,0.0004575609,0.00012959968,0.000012735561],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.97406024,0.021122666,0.0019485852,0.0012297031,0.0005555865,0.0010832434],"domain_scores_gemma":[0.95979035,0.037275128,0.0012273919,0.00140718,0.000058584304,0.00024139322],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.008284327,0.000865835,0.004499601,0.0009676706,0.0002526715,0.00007694438,0.0011103424,0.0008606119,0.0001929946],"category_scores_gemma":[0.0013640649,0.000518245,0.000591984,0.0033251764,0.0001709494,0.00006942594,0.0006819641,0.0037574272,0.00010009803],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00785861,0.0063745044,0.021418564,0.0010749516,0.0010159701,0.014957674,0.001443646,0.000025087833,0.00007442536,0.0016872912,0.03771961,0.90634966],"study_design_scores_gemma":[0.007532395,0.0018692453,0.08313875,0.00084611063,0.002403759,0.00023830135,0.00024782607,0.000033849494,5.5355866e-7,0.0002081713,0.90309876,0.00038227788],"about_ca_topic_score_codex":0.00034703125,"about_ca_topic_score_gemma":0.0010601365,"teacher_disagreement_score":0.9059674,"about_ca_system_score_codex":0.004460138,"about_ca_system_score_gemma":0.0040090205,"threshold_uncertainty_score":0.9997269},"labels":[],"label_agreement":null},{"id":"W4236289131","doi":"10.1016/s1470-2045(21)00073-5","title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":416,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck; AstraZeneca","keywords":"Olaparib; Medicine; BRCA mutation; Internal medicine; Clinical endpoint; Ovarian cancer; Oncology; Placebo; Progression-free survival; PARP inhibitor; Randomized controlled trial; Cancer; Chemotherapy; Pathology","score_opus":0.05218418572592092,"score_gpt":0.3670435714528127,"score_spread":0.31485938572689176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236289131","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98857445,0.0003609026,0.00027935609,0.0047464264,0.00022317164,0.0039072447,0.0001127913,0.000029383507,0.0017662983],"genre_scores_gemma":[0.99446124,0.00052912114,0.00043994852,0.0024060793,0.00030574386,0.0013453108,0.00018781752,0.00002857634,0.00029613916],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99719626,0.0007050096,0.0007692005,0.00049760216,0.0003881238,0.00044383245],"domain_scores_gemma":[0.9971926,0.0010586248,0.00068603625,0.00044080027,0.000522828,0.00009906299],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012873437,0.0002802238,0.0020615472,0.00031384322,0.00010086359,0.000022526341,0.00011442099,0.00021855009,0.00032911415],"category_scores_gemma":[0.00024108983,0.00018465499,0.00017777091,0.0011538834,0.00028923448,0.00009859209,0.000028818487,0.00047921008,0.0000031484574],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9821005,0.0010810226,0.002179453,0.000022023545,0.0031645778,0.00017727318,0.002687767,0.00052485516,0.0014781944,0.00035918277,0.00027488742,0.0059502707],"study_design_scores_gemma":[0.98369384,0.0041553704,0.006467306,0.00013788437,0.0013426712,0.00004474492,0.0003035956,0.00110283,0.0016857807,0.00013299794,0.0007358519,0.00019713194],"about_ca_topic_score_codex":0.000499985,"about_ca_topic_score_gemma":0.0012403902,"teacher_disagreement_score":0.005886838,"about_ca_system_score_codex":0.00036708268,"about_ca_system_score_gemma":0.00092014193,"threshold_uncertainty_score":0.75300115},"labels":[],"label_agreement":null},{"id":"W4252148737","doi":"10.1016/s1470-2045(15)70040-9","title":"Recalibrating emergency care in the UK","year":2015,"lang":"en","type":"editorial","venue":"The Lancet Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Hotline; Medicine; Accident and emergency; Quarter (Canadian coin); Population; Service (business); Medical emergency; Mental health; Population ageing; Health care; Family medicine; Psychiatry; Environmental health; Business","score_opus":0.2223935450351709,"score_gpt":0.5011679446326861,"score_spread":0.2787743995975152,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4252148737","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0053950674,0.03139444,0.0000072969437,0.0050116414,0.8170095,0.0006228326,0.00017256616,0.000041645635,0.14034502],"genre_scores_gemma":[0.003817129,0.008791728,0.00041235652,0.00049151084,0.98512757,0.00008193998,0.00048552448,0.000029836525,0.0007623806],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980452,0.00058806856,0.00039774328,0.00021104471,0.0004571555,0.00030079728],"domain_scores_gemma":[0.99745226,0.0013743277,0.00026968028,0.0005500457,0.0003136983,0.000039988052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012613516,0.00018624854,0.00092287676,0.00005355289,0.00003985801,0.0000047577164,0.0005125444,0.00059042213,0.00011917351],"category_scores_gemma":[0.0027484938,0.00009547855,0.000099543046,0.00020923278,0.00011050104,0.000018160388,0.00008866032,0.001162695,0.000027351736],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031164527,0.00002561694,0.0026725442,0.00020538436,0.000048441012,0.000055679375,0.014481439,0.0000018301657,0.000011859547,0.000076999015,0.9797573,0.002351239],"study_design_scores_gemma":[0.0013014983,0.00065207033,0.00016812644,0.00036444108,0.00012130134,0.0000035909272,0.0054102847,0.0000035074138,0.00001618075,0.00035997984,0.9915029,0.00009612288],"about_ca_topic_score_codex":0.00036173928,"about_ca_topic_score_gemma":0.0012408845,"teacher_disagreement_score":0.16811812,"about_ca_system_score_codex":0.00020869497,"about_ca_system_score_gemma":0.0007635302,"threshold_uncertainty_score":0.5051396},"labels":[],"label_agreement":null},{"id":"W4281654705","doi":"10.1016/s1470-2045(22)00188-7","title":"The future of precise cancer chronotherapeutics","year":2022,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Circadian rhythm and melatonin","field":"Neuroscience","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Oncology; Internal medicine; Scopus; Clinical trial; Chemotherapy; Systematic review; Intensive care medicine; MEDLINE","score_opus":0.059506148423246655,"score_gpt":0.33308729468559883,"score_spread":0.2735811462623522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281654705","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017543868,0.012454361,0.0000038235107,0.9661268,0.006140604,0.00049699616,0.00027779536,0.000049765535,0.012695475],"genre_scores_gemma":[0.0023317568,0.022660626,0.000012890292,0.93399435,0.025853073,0.00039002037,0.000011736275,0.000068571586,0.014676949],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975914,0.0008798793,0.00028302398,0.00034970694,0.00033177488,0.0005642394],"domain_scores_gemma":[0.9971022,0.0015381055,0.00040163717,0.0009071534,0.000025512216,0.000025394002],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00045021038,0.0002141259,0.00053235894,0.000040401563,0.00040785022,0.000024040046,0.001319532,0.00041345035,0.0010688436],"category_scores_gemma":[0.000045908662,0.00011830158,0.00014221558,0.00021790805,0.0005254288,0.000024060482,0.00020202209,0.0025534816,0.000039932333],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010199514,0.000014317852,0.000024154542,0.00003799002,0.000026842146,0.0000849056,0.0005100412,0.000017065919,0.0008789499,0.0045988564,0.96916234,0.024542563],"study_design_scores_gemma":[0.0004317243,0.00014115915,0.000093111055,0.000009451583,0.000051714058,0.000084594874,0.000040812247,0.000017231028,0.0027511627,0.0006691778,0.9955695,0.00014031545],"about_ca_topic_score_codex":0.000024473318,"about_ca_topic_score_gemma":0.000072962874,"teacher_disagreement_score":0.032132417,"about_ca_system_score_codex":0.00026761828,"about_ca_system_score_gemma":0.00049316266,"threshold_uncertainty_score":0.9998443},"labels":[],"label_agreement":null},{"id":"W4281893891","doi":"10.1016/s1470-2045(22)00271-6","title":"Stereotactic radiosurgery versus whole brain radiotherapy in patients with intracranial metastatic disease and small-cell lung cancer: a systematic review and meta-analysis","year":2022,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Princess Margaret Cancer Centre; Health Sciences Centre; Sunnybrook Health Science Centre; Ontario Institute for Cancer Research; University of Toronto","funders":"Canadian Institutes of Health Research; American Association of Neurological Surgeons; University of Toronto; AstraZeneca; Congress of Neurological Surgeons; Pfizer","keywords":"Medicine; Radiosurgery; Meta-analysis; Oncology; Hazard ratio; Radiation therapy; Internal medicine; Lung cancer; Confidence interval","score_opus":0.1196381221426109,"score_gpt":0.4222014629856351,"score_spread":0.3025633408430242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281893891","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013570694,0.9854595,0.0000041692456,0.0057948916,0.0000720952,0.008133279,0.00034439427,0.000023466966,0.000032493204],"genre_scores_gemma":[0.0000377184,0.9915793,0.00009346602,0.0018718854,0.00008035959,0.005855757,0.00010563034,0.00006303234,0.00031285387],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9937723,0.003618261,0.0009177196,0.00064622815,0.00050428434,0.00054118456],"domain_scores_gemma":[0.99401116,0.0040112077,0.0008058507,0.0008836574,0.00006935367,0.00021875452],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002505461,0.00055246695,0.012814684,0.0003698338,0.00013308728,0.000036632468,0.00031612563,0.00006016846,0.00036109408],"category_scores_gemma":[0.000566731,0.0002780737,0.0006981483,0.0011037026,0.00022473557,0.000057317713,0.00019025768,0.00082715903,0.0000015201116],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008036574,0.00017714695,0.00035583533,0.77674466,0.21682183,0.00030018936,0.00017815511,0.0000015295258,8.121978e-9,0.0000042840534,0.0011171883,0.003495537],"study_design_scores_gemma":[0.003985085,0.00058973226,0.00014849992,0.009185387,0.8799496,0.000030837906,0.00002620519,0.000021201386,2.1631708e-9,0.0000016045572,0.10577401,0.00028781957],"about_ca_topic_score_codex":0.00012849458,"about_ca_topic_score_gemma":0.00026093138,"teacher_disagreement_score":0.76755923,"about_ca_system_score_codex":0.0011180583,"about_ca_system_score_gemma":0.00088259333,"threshold_uncertainty_score":0.99996716},"labels":[],"label_agreement":null},{"id":"W4283205267","doi":"10.1016/s1470-2045(22)00367-9","title":"Ethical considerations for the modification of routine human papillomavirus immunisation schedules","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Health Centre","funders":"","keywords":"Medicine; Population; Immunization; Advisory committee; Vaccination; Human papillomavirus; Regimen; Family medicine; Environmental health; Management; Internal medicine; Immunology","score_opus":0.2937722778644988,"score_gpt":0.4851582535778768,"score_spread":0.191385975713378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283205267","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4463584,0.0015811762,0.0028485327,0.5253663,0.00031980264,0.0025114005,0.00012818063,0.000074908734,0.020811278],"genre_scores_gemma":[0.99463254,0.00007465079,0.00044480604,0.0038384413,0.0003352267,0.00047964975,0.00004377661,0.0000074255013,0.00014349223],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9990193,0.00033893235,0.00019715428,0.00009819994,0.00019880985,0.00014755515],"domain_scores_gemma":[0.9978316,0.0015716401,0.0000775351,0.00034542917,0.00015069144,0.000023136627],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001713691,0.000047222267,0.00021908764,0.000027997778,0.0006048782,0.00000676747,0.00014202768,0.00006509062,0.0018531231],"category_scores_gemma":[0.00043545986,0.000027596905,0.000057658883,0.00009791483,0.00023260075,0.000010429895,0.00009291155,0.0006067579,0.000003737859],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001813397,0.00029517713,0.0012835454,0.000094319155,0.00014650595,0.0000023345553,0.0022443512,0.000552708,0.027452325,0.9338617,0.007916679,0.024336971],"study_design_scores_gemma":[0.014169254,0.0044316384,0.5113408,0.000010514359,0.00046426457,0.00010724508,0.0048237164,0.014107849,0.0070652603,0.19297417,0.25028566,0.00021962762],"about_ca_topic_score_codex":0.00018313123,"about_ca_topic_score_gemma":0.00010834841,"teacher_disagreement_score":0.7408875,"about_ca_system_score_codex":0.00013058056,"about_ca_system_score_gemma":0.00020930864,"threshold_uncertainty_score":0.9990593},"labels":[],"label_agreement":null},{"id":"W4283640661","doi":"10.1016/s1470-2045(22)00126-7","title":"Systemic considerations for the surgical treatment of spinal metastatic disease: a scoping literature review","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University Health Network; Health Sciences Centre; Vancouver General Hospital; University of British Columbia; McGill University; Montreal General Hospital; University of Saskatchewan; Université de Montréal; Université de Sherbrooke; University of Toronto; Dalhousie University","funders":"National Cancer Institute","keywords":"Medicine; Disease; Internal medicine; CINAHL; MEDLINE; Intensive care medicine; Psychological intervention","score_opus":0.1290347138779802,"score_gpt":0.42085890712436425,"score_spread":0.29182419324638403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283640661","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01085887,0.7543241,0.00054442784,0.2204066,0.0005263202,0.011512886,0.00058206095,0.000068563815,0.0011761659],"genre_scores_gemma":[0.8928227,0.07463329,0.0027269511,0.017736148,0.0006199888,0.009265676,0.00025816864,0.000042165742,0.0018949339],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984655,0.000595705,0.00034901823,0.00016854056,0.00022783066,0.00019344618],"domain_scores_gemma":[0.99798584,0.0011750986,0.0001946208,0.0005034543,0.00007276237,0.00006823677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009679197,0.00011349446,0.000645578,0.00003711807,0.00023329582,0.000010347327,0.00011770658,0.000008311217,0.00046508404],"category_scores_gemma":[0.00030657472,0.000057800626,0.00018452888,0.0001645847,0.000092388764,0.00001815407,0.000057324905,0.00010105332,0.000003786574],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031346537,0.009658716,0.0026391011,0.1771155,0.009425339,0.013017105,0.006017825,0.001688111,0.00028417807,0.32884377,0.34304434,0.07691949],"study_design_scores_gemma":[0.035897784,0.012087317,0.0031973622,0.024115903,0.023811055,0.006159243,0.002193633,0.0048863436,0.000022129647,0.0075228037,0.87956345,0.00054299633],"about_ca_topic_score_codex":0.0000038577896,"about_ca_topic_score_gemma":0.0000033679871,"teacher_disagreement_score":0.8819638,"about_ca_system_score_codex":0.00013666892,"about_ca_system_score_gemma":0.0003565904,"threshold_uncertainty_score":0.5092344},"labels":[],"label_agreement":null},{"id":"W4283644627","doi":"10.1016/s1470-2045(22)00160-7","title":"2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19","year":2022,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":448,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McGill University Health Centre","funders":"National Institutes of Health; LEO Pharma; Servier; Astellas Pharma; Nippon Shinyaku; Société Académique de Genève; Incyte; International Society on Thrombosis and Haemostasis; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; CSL Behring; Alnylam Pharmaceuticals; Daiichi-Sankyo; Teva Pharmaceutical Industries; Daiichi Sankyo Europe; Sanofi; Amgen; National Heart, Lung, and Blood Institute; Pfizer; Celgene","keywords":"Medicine; Thrombosis; Rivaroxaban; Cancer; Venous thrombosis; Intensive care medicine; Apixaban; Internal medicine; Surgery; Warfarin; Atrial fibrillation","score_opus":0.27625489733849357,"score_gpt":0.5170136550109575,"score_spread":0.24075875767246396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283644627","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006744309,0.9660545,0.000040591513,0.012287025,0.0016662972,0.0119523825,0.0006089305,0.00003481328,0.0006111648],"genre_scores_gemma":[0.00033612706,0.99046254,0.0009398131,0.004412201,0.00064097205,0.0027866485,0.00032236293,0.00005170817,0.00004764051],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973748,0.0004700166,0.0009322745,0.0004794545,0.0004232934,0.0003201974],"domain_scores_gemma":[0.9949443,0.0028682216,0.001158625,0.0005294125,0.0004102595,0.00008921912],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015527094,0.0003344731,0.0027622548,0.00012629449,0.00020633561,0.000015720325,0.00041345664,0.00014740745,0.00012919148],"category_scores_gemma":[0.0016327003,0.00014891475,0.00015827817,0.00024906982,0.00023597051,0.000053361684,0.00026425102,0.00043475066,0.0000010380479],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014479789,0.0048107337,0.0067554056,0.0022316412,0.002525384,0.000012857582,0.00074119633,0.00003165969,5.2640745e-9,0.00023865291,0.008397942,0.9728065],"study_design_scores_gemma":[0.0072999643,0.0111549925,0.012392121,0.0007119767,0.0032598607,0.000006791078,0.00021893407,0.0000073302144,2.0369333e-8,0.00002088759,0.96476895,0.00015816391],"about_ca_topic_score_codex":0.0007153135,"about_ca_topic_score_gemma":0.00045901636,"teacher_disagreement_score":0.9726484,"about_ca_system_score_codex":0.0011114358,"about_ca_system_score_gemma":0.0011689338,"threshold_uncertainty_score":0.60725677},"labels":[],"label_agreement":null},{"id":"W4283771201","doi":"10.1016/s1470-2045(22)00343-6","title":"Rucaparib for recurrent ovarian cancer with BRCA1 and BRCA2 mutations – Authors' reply","year":2022,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Trabectedin; Topotecan; Oncology; Medicine; Ovarian cancer; Internal medicine; Regimen; Olaparib; BRCA mutation; Chemotherapy; Cancer; Pathology; Sarcoma; Biology","score_opus":0.06730842307923487,"score_gpt":0.3634795755095666,"score_spread":0.29617115243033176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283771201","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00068302493,0.0028725017,0.00006255325,0.9888244,0.001418087,0.0020514354,0.0008598718,0.000074052594,0.0031540692],"genre_scores_gemma":[0.0024564022,0.0021398722,0.0034469208,0.96253073,0.012569951,0.009348849,0.0017194632,0.0001276889,0.0056601344],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980159,0.0002358038,0.0003190272,0.00063678774,0.00026041697,0.00053208304],"domain_scores_gemma":[0.99813765,0.0006557402,0.00032037855,0.0006909961,0.00010818815,0.00008702045],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00044904303,0.0003237994,0.001046948,0.00009826804,0.00031203486,0.000034750214,0.00020403805,0.00031004648,0.0010888627],"category_scores_gemma":[0.000056552737,0.00020130067,0.000118319294,0.00016960251,0.00021265024,0.000027481407,0.000085435975,0.0013941567,0.0000075200514],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011430971,0.00013932891,0.0008738954,0.0002826117,0.00093956233,0.00038374853,0.000802925,0.0000073387246,0.0000021346684,0.000632994,0.9760125,0.018779831],"study_design_scores_gemma":[0.0056705736,0.0036171312,0.0035872306,0.00014721126,0.0017306192,0.00035455415,0.00008406093,0.00003540452,0.000008308764,0.0006732978,0.9838658,0.00022580054],"about_ca_topic_score_codex":0.0005374949,"about_ca_topic_score_gemma":0.00045326175,"teacher_disagreement_score":0.026293686,"about_ca_system_score_codex":0.00088847,"about_ca_system_score_gemma":0.0009263632,"threshold_uncertainty_score":0.9998243},"labels":[],"label_agreement":null},{"id":"W4284987950","doi":"10.1016/s1470-2045(22)00335-7","title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":436,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Princess Margaret Cancer Centre; Jewish General Hospital; University of British Columbia; Spinal Cord Injury BC","funders":"Genentech; F. Hoffmann-La Roche","keywords":"Medicine; Follicular lymphoma; Refractory (planetary science); Internal medicine; Clinical endpoint; Progressive disease; CD20; Follicular phase; Lymphoma; Oncology; Rituximab; Phases of clinical research; Gastroenterology; Chemotherapy; Clinical trial; Biology","score_opus":0.04388713937975811,"score_gpt":0.36045103446850474,"score_spread":0.3165638950887466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4284987950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955609,0.0002536065,0.0000045153934,0.0005407225,0.00010504566,0.0023646676,0.000029819657,0.0000307758,0.001109952],"genre_scores_gemma":[0.9986775,0.00011004024,0.00011489572,0.00020387679,0.00008862918,0.00006504554,0.000059469156,0.000036435013,0.0006440926],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99735403,0.00090686657,0.000416166,0.00036924324,0.00053078996,0.00042289565],"domain_scores_gemma":[0.9982909,0.000692657,0.00019762738,0.0006369515,0.00009158453,0.00009027102],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010379414,0.0001752809,0.0008325018,0.00018197362,0.00013430319,0.000007697706,0.00024696675,0.00006305294,0.0009686145],"category_scores_gemma":[0.0001644679,0.00010841746,0.00004718837,0.00059148396,0.00022615236,0.000036524078,0.00023718899,0.00040164712,0.0000034706538],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.46851313,0.09002679,0.25895998,0.00013617045,0.00081191753,0.0018731208,0.015202362,0.00012498068,0.016376788,0.000048446665,0.0005647847,0.14736152],"study_design_scores_gemma":[0.3183252,0.072765104,0.5026208,0.00006065432,0.00023188413,0.00010352109,0.0040281704,0.0003231793,0.00018454166,0.0000109579605,0.10109096,0.00025502383],"about_ca_topic_score_codex":0.00018268022,"about_ca_topic_score_gemma":0.00016750593,"teacher_disagreement_score":0.24366085,"about_ca_system_score_codex":0.00068564754,"about_ca_system_score_gemma":0.00029388827,"threshold_uncertainty_score":0.9999446},"labels":[],"label_agreement":null},{"id":"W4285045571","doi":"10.1016/s1470-2045(22)00334-5","title":"Comparative effectiveness and risk of preterm birth of local treatments for cervical intraepithelial neoplasia and stage IA1 cervical cancer: a systematic review and network meta-analysis","year":2022,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Research for Patient Benefit Programme; Horizon 2020 Framework Programme; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; European Commission; National Institute for Health and Care Research; Department of Health and Social Care; Institut National Du Cancer; Cancer Research UK; National Science Foundation","keywords":"Medicine; Cryotherapy; Colposcopy; Cervical intraepithelial neoplasia; Meta-analysis; Obstetrics; Randomized controlled trial; Odds ratio; Cervical cancer; Gynecology; Relative risk; Intraepithelial neoplasia; Cancer; Surgery; Internal medicine; Confidence interval","score_opus":0.1973763679235681,"score_gpt":0.4676421479563756,"score_spread":0.2702657800328075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285045571","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024454837,0.9905683,0.00014531937,0.00014776802,0.000037338905,0.006925652,0.001765075,0.0000107778305,0.00015524609],"genre_scores_gemma":[0.0023258291,0.99336153,0.00009134832,0.00013121152,0.00012373472,0.00380298,0.00008055687,0.000028878347,0.000053957745],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99373996,0.0039432743,0.0010344031,0.0005478061,0.00034052375,0.00039404462],"domain_scores_gemma":[0.9920704,0.0061387694,0.00091924117,0.00055397325,0.00014359255,0.00017403607],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.002720666,0.00042962248,0.016594993,0.00013281686,0.00012063986,0.000011172043,0.00025445392,0.00022583027,0.0008522108],"category_scores_gemma":[0.00014465259,0.00022134147,0.0010466598,0.00063923316,0.00055847346,0.000022881415,0.00030190137,0.0006221726,5.631861e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010141785,0.00013351507,0.00028920046,0.79870266,0.15492585,0.000009321147,0.00017389574,0.000009167938,5.0611277e-8,0.00015509302,0.000039979193,0.04454712],"study_design_scores_gemma":[0.0025136375,0.0025678228,0.001995727,0.0076453276,0.94219494,0.000078029116,0.0000693558,0.00020318024,9.873404e-7,0.00008399381,0.04241789,0.00022912763],"about_ca_topic_score_codex":0.00047257703,"about_ca_topic_score_gemma":0.0007304851,"teacher_disagreement_score":0.7910573,"about_ca_system_score_codex":0.00024587737,"about_ca_system_score_gemma":0.00040435023,"threshold_uncertainty_score":0.9980047},"labels":[],"label_agreement":null},{"id":"W4287730147","doi":"10.1016/s1470-2045(22)00139-5","title":"Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup","year":2022,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":142,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University of British Columbia","funders":"Daiichi Sankyo Europe; National Cancer Institute; Chugai Pharmaceutical; Genentech; National Institutes of Health; Mereo BioPharma; Medac; PharmaMar; Eisai; Seagen; Verastem Oncology; Pfizer; NuCana; Incyte; National Medical Research Council; Karyopharm Therapeutics; Kissei; National Institute for Health and Care Research; Clovis Oncology; Nippon Shinyaku; AstraZeneca; Novocure; Mersana Therapeutics; Amgen; Deciphera Pharmaceuticals; Medical Research Council; Teva Pharmaceutical Industries; Fuji Pharma; GlaxoSmithKline; European Commission; PTC Therapeutics; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Consensus conference; Concordance; Ovarian cancer; Medicine; Clinical trial; Deliberation; Gynecologic cancer; Family medicine; Clinical research; MEDLINE; Gynecology; Cancer; Oncology; Internal medicine; Political science","score_opus":0.5870445998710079,"score_gpt":0.5953735657196614,"score_spread":0.008328965848653502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4287730147","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007887182,0.8329444,5.600161e-7,0.15630409,0.003107541,0.0022600766,0.000786947,0.000031692576,0.004485809],"genre_scores_gemma":[0.00018081856,0.9813614,0.00017370813,0.0050683967,0.0037396483,0.008494414,0.0003614031,0.000057337664,0.00056286075],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98995477,0.0069399374,0.0011990351,0.00081188336,0.00034144323,0.0007529315],"domain_scores_gemma":[0.9768097,0.021169715,0.0005195374,0.0012945407,0.000082034436,0.00012449632],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0057005757,0.00036711787,0.0030553974,0.00014928695,0.00038661205,0.000034034994,0.00092409155,0.00047749272,0.010508802],"category_scores_gemma":[0.0005772085,0.0001867897,0.0004683809,0.0008622064,0.00054618565,0.000015440963,0.000623845,0.0038432004,0.00012906721],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014392649,0.00047822032,0.0031024832,0.00036075866,0.00084116985,0.00023482641,0.00019518526,0.0000010683666,2.7114426e-8,0.00068939023,0.15361488,0.84033805],"study_design_scores_gemma":[0.0025380778,0.0006218094,0.0036876067,0.0029108606,0.0013260287,0.000047640868,0.0002540234,0.0000053711337,5.9786146e-8,0.00048069295,0.987957,0.00017082159],"about_ca_topic_score_codex":0.011027712,"about_ca_topic_score_gemma":0.021056864,"teacher_disagreement_score":0.8401672,"about_ca_system_score_codex":0.0035705776,"about_ca_system_score_gemma":0.0041753594,"threshold_uncertainty_score":0.998455},"labels":[],"label_agreement":null},{"id":"W4293708362","doi":"10.1016/s1470-2045(22)00371-0","title":"CNS prophylaxis for diffuse large B-cell lymphoma","year":2022,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Manchester Biomedical Research Centre; National Institute for Health and Care Research","keywords":"Leptomeninges; Medicine; Intensive care medicine; Lymphoma; Parenchyma; Complication; Pathology; Surgery; Central nervous system; Internal medicine","score_opus":0.12355826958781037,"score_gpt":0.3982815940841744,"score_spread":0.27472332449636405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293708362","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015311567,0.98626125,0.0000071822587,0.0008355009,0.00071133394,0.0036733896,0.0005783859,0.00009222808,0.00768762],"genre_scores_gemma":[0.00010134424,0.9869767,0.00025849647,0.0011593079,0.0014575412,0.006456818,0.00072504283,0.00010253382,0.0027622166],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977486,0.00036902167,0.00050564273,0.00050546264,0.00021426282,0.0006570032],"domain_scores_gemma":[0.9970195,0.0014465697,0.0003867881,0.0009947659,0.00003404273,0.00011828724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006399111,0.000431886,0.0031560762,0.00011153358,0.0002568134,0.000017347515,0.00042013373,0.00033570713,0.00054616266],"category_scores_gemma":[0.00012711721,0.0002399655,0.00088704325,0.00024329279,0.00007991292,0.000014611806,0.0002626891,0.00028001686,0.00019608223],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013716334,0.0066889655,0.000014506271,0.007348305,0.00040442066,0.0002026286,0.00010214952,2.0098119e-8,1.343733e-7,0.00062012556,0.028330712,0.9561509],"study_design_scores_gemma":[0.014755628,0.0024471052,0.00003999611,0.000555977,0.0026176076,0.0004102304,0.00003705558,0.0000024482763,0.0000012429222,0.00006140676,0.978853,0.00021830233],"about_ca_topic_score_codex":0.000026898486,"about_ca_topic_score_gemma":0.000027929236,"teacher_disagreement_score":0.95593256,"about_ca_system_score_codex":0.0013941233,"about_ca_system_score_gemma":0.0010758729,"threshold_uncertainty_score":0.9785509},"labels":[],"label_agreement":null},{"id":"W4295838570","doi":"10.1016/s1470-2045(22)00517-4","title":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":303,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Cancer Research UK","keywords":"Medicine; Prostate cancer; Radiation therapy; Toxicity; Dose fractionation; Randomized controlled trial; Androgen deprivation therapy; Urology; Prostate; External beam radiotherapy; Internal medicine; Cancer; Surgery","score_opus":0.08975264517769489,"score_gpt":0.42285274172221715,"score_spread":0.3331000965445223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295838570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95677006,0.0012037603,0.000063775486,0.025658213,0.0029855114,0.010610563,0.0023514456,0.00010146215,0.0002551898],"genre_scores_gemma":[0.9735828,0.0058767768,0.001663628,0.007437899,0.002924972,0.0068829274,0.00112467,0.00011019562,0.0003961179],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9969918,0.0006663492,0.0006313845,0.0007663809,0.00029797188,0.00064609403],"domain_scores_gemma":[0.9971946,0.0009429475,0.00048899447,0.0009737447,0.00017637735,0.00022337236],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001575506,0.0003604474,0.0016369757,0.000074466174,0.0005146932,0.0000895424,0.00056610495,0.00013132965,0.00038359425],"category_scores_gemma":[0.00014664578,0.0002599122,0.0001242124,0.00025391032,0.0001659848,0.00016702047,0.0001637276,0.0005341219,0.0000032692276],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9498542,0.004628061,0.00037316317,0.000020033067,0.0016827805,0.00010661244,0.0026521191,0.00005370034,0.012266373,0.000027347927,0.013322076,0.0150135355],"study_design_scores_gemma":[0.8203274,0.042793654,0.0008154202,0.000028947105,0.00047424078,0.000016627955,0.00020702169,0.002740035,0.0015973332,0.00013111482,0.13059556,0.00027265202],"about_ca_topic_score_codex":0.0023496042,"about_ca_topic_score_gemma":0.0004063566,"teacher_disagreement_score":0.12952681,"about_ca_system_score_codex":0.0021183114,"about_ca_system_score_gemma":0.000844181,"threshold_uncertainty_score":0.99998534},"labels":[],"label_agreement":null},{"id":"W4307906450","doi":"10.1016/s1470-2045(22)00629-5","title":"Clarification needed for pembrolizumab as adjuvant therapy in clear cell renal cell carcinoma","year":2022,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Renal cell carcinoma; Adjuvant therapy; Oncology; Adjuvant; Internal medicine; Immunotherapy; Cancer","score_opus":0.06916348275263576,"score_gpt":0.317035747058509,"score_spread":0.24787226430587325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307906450","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.39998448,0.0028410996,0.000012919877,0.55839556,0.0006763556,0.0035372367,0.00010430405,0.00008250525,0.034365557],"genre_scores_gemma":[0.41128686,0.00093088334,0.00054678455,0.5610615,0.0070243254,0.0021648987,0.0023495853,0.00020493641,0.014430226],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99640864,0.00088616606,0.0006182923,0.00075256475,0.00046590273,0.00086844957],"domain_scores_gemma":[0.99737406,0.0006756962,0.000481861,0.0012786109,0.000107252265,0.00008254887],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008125382,0.0004932459,0.0014766712,0.00027572658,0.00016743275,0.000023340728,0.0006226389,0.00095554325,0.00093954493],"category_scores_gemma":[0.000034106415,0.00034748143,0.00035519758,0.00024935827,0.00014502734,0.000032547217,0.00011838806,0.0030399584,0.00014228611],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011751784,0.000415392,0.00042297086,0.00036220232,0.000084685555,0.0016827998,0.001298668,0.000017906912,0.0060011665,0.00003933268,0.97551215,0.0024109506],"study_design_scores_gemma":[0.014499844,0.010330768,0.0038745673,0.000020726946,0.00027286555,0.00032079668,0.00030522505,0.000078505866,0.0063456944,0.00033279022,0.9632951,0.00032311052],"about_ca_topic_score_codex":0.00080092554,"about_ca_topic_score_gemma":0.000036577436,"teacher_disagreement_score":0.019935332,"about_ca_system_score_codex":0.0015961052,"about_ca_system_score_gemma":0.0008688029,"threshold_uncertainty_score":0.9999737},"labels":[],"label_agreement":null},{"id":"W4308327197","doi":"10.1016/s1470-2045(22)00642-8","title":"Intra-individual comparison of 18F-sodium fluoride PET–CT and 99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trial","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Medical Imaging Techniques and Applications","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; McGill University; Centre Hospitalier de l’Université de Montréal; Western University; St Joseph's Health Care; University Health Network; University of British Columbia; Centre Hospitalier Universitaire de Sherbrooke; Montreal Heart Institute; Université de Montréal; Jewish General Hospital; London Health Sciences Centre; McMaster University","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Prostate cancer; Breast cancer; Bone scintigraphy; Radiology; Bone metastasis; Cancer; Population; Nuclear medicine; Prospective cohort study; Oncology; Internal medicine","score_opus":0.031131532751266087,"score_gpt":0.36561772162705974,"score_spread":0.3344861888757937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308327197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98639953,0.00022045795,0.00003842921,0.006811281,0.00009462724,0.0032629299,0.0031094968,0.000047789432,0.000015484984],"genre_scores_gemma":[0.9914289,0.0002191045,0.0052573727,0.0004598566,0.00020043671,0.002172362,0.00018733671,0.00002597022,0.000048659072],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983389,0.00019567649,0.0003931778,0.00034352974,0.00034670628,0.00038202445],"domain_scores_gemma":[0.99876106,0.0003286519,0.0004114279,0.0002948328,0.00009034458,0.00011370033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005602934,0.00018897478,0.0008677491,0.0001069591,0.00020081001,0.0000092918735,0.00016875981,0.000011921915,0.00022996418],"category_scores_gemma":[0.000052072814,0.00010481246,0.000049970902,0.00034679167,0.00041055641,0.000038794795,0.00012302079,0.000402898,3.4908123e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4482326,0.006968824,0.47534007,0.00033552674,0.00086029555,0.00017203,0.0011883421,0.00008534545,0.00029101077,0.00022985724,0.02249686,0.043799255],"study_design_scores_gemma":[0.6277412,0.029890325,0.23896873,0.0004307445,0.0042015202,0.0005936145,0.0011209211,0.002658451,0.0035161653,0.00023636213,0.08986106,0.00078086794],"about_ca_topic_score_codex":0.0025017557,"about_ca_topic_score_gemma":0.0027973296,"teacher_disagreement_score":0.23637132,"about_ca_system_score_codex":0.000193354,"about_ca_system_score_gemma":0.0002968497,"threshold_uncertainty_score":0.4274128},"labels":[],"label_agreement":null},{"id":"W4309412449","doi":"10.1016/s1470-2045(22)00656-8","title":"5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney)","year":2022,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":133,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; University of Ottawa; Ottawa Hospital; Cancer Care Ontario; McMaster University; Sunnybrook Health Science Centre; McGill University Health Centre; Juravinski Cancer Centre","funders":"Cancer Council Tasmania","keywords":"SABR volatility model; Medicine; Renal cell carcinoma; Radiosurgery; Cyberknife; Radiation therapy; Clinical endpoint; Discontinuation; Urology; Internal medicine; Surgery; Clinical trial","score_opus":0.20941639527428876,"score_gpt":0.3794208878707568,"score_spread":0.17000449259646802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309412449","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0080366125,0.9696837,0.000038894497,0.0036028149,0.0008982445,0.004127415,0.012828744,0.000027241344,0.00075630995],"genre_scores_gemma":[0.040185735,0.91193885,0.0028213798,0.013468468,0.0019095272,0.0055206427,0.021956403,0.00029890746,0.0019000848],"study_design_codex":"meta_analysis","study_design_gemma":"not_applicable","domain_scores_codex":[0.9940628,0.0024493402,0.0012741793,0.00087280234,0.0009085989,0.00043227265],"domain_scores_gemma":[0.9904325,0.0041140495,0.0018164831,0.0033879634,0.000105695275,0.00014333587],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015841776,0.0006069005,0.005557549,0.00024508807,0.00016799927,0.000038897622,0.0022437812,0.00023089448,0.0025240642],"category_scores_gemma":[0.00021022264,0.00025925983,0.0027673,0.00044726182,0.00030935553,0.00009517209,0.000913135,0.00085609726,0.00000599303],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034594112,0.002689896,0.025225118,0.0028079543,0.8681294,0.00036462853,0.0037469198,0.000021597745,0.000028251212,0.000058047517,0.030397952,0.063070826],"study_design_scores_gemma":[0.0012559368,0.00044325652,0.010663333,0.00002984187,0.29862496,0.000041662435,0.00008114325,0.000016477652,0.0000093906565,0.000016215601,0.68862367,0.00019408982],"about_ca_topic_score_codex":0.00019263585,"about_ca_topic_score_gemma":0.000042881315,"teacher_disagreement_score":0.6582257,"about_ca_system_score_codex":0.0007947569,"about_ca_system_score_gemma":0.0014467429,"threshold_uncertainty_score":0.99998593},"labels":[],"label_agreement":null},{"id":"W4309412600","doi":"10.1016/s1470-2045(22)00621-0","title":"Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":182,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada); Ottawa Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Oncology; Internal medicine; Trastuzumab; Adverse effect; Bispecific antibody; Metastatic breast cancer; Response Evaluation Criteria in Solid Tumors; Clinical trial; Phases of clinical research; Cancer; Monoclonal antibody; Antibody; Breast cancer; Immunology","score_opus":0.2538568129815828,"score_gpt":0.5097609920992456,"score_spread":0.25590417911766283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309412600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9795477,0.0015043119,0.005485368,0.005449549,0.00039389642,0.0070872093,0.00032583563,0.00005580044,0.00015036837],"genre_scores_gemma":[0.9913887,0.0014322358,0.0031908245,0.00045509922,0.00034416493,0.0024337866,0.00007865323,0.000051367122,0.0006251877],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976741,0.00044802928,0.00048208237,0.00045000823,0.00047423688,0.00047153144],"domain_scores_gemma":[0.9968846,0.0018722998,0.000261278,0.0007549152,0.00013500494,0.00009190082],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012704653,0.00022184751,0.00084647647,0.00010024682,0.0004484542,0.000027264832,0.00030872817,0.000045558645,0.00042279012],"category_scores_gemma":[0.00019121676,0.00010929429,0.00007494701,0.00043649413,0.0002744471,0.00006208597,0.00014342328,0.00026389695,0.0000018529952],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14326152,0.013373197,0.0021299112,0.0005763394,0.0012029634,0.00029257406,0.025038078,0.0022142287,0.14956397,0.0001701153,0.0032141623,0.6589629],"study_design_scores_gemma":[0.16815011,0.15988615,0.015039213,0.00036175875,0.0017185003,0.0005825471,0.06411113,0.031605393,0.005417978,0.00018113804,0.5523329,0.0006131993],"about_ca_topic_score_codex":0.0007162091,"about_ca_topic_score_gemma":0.0012900116,"teacher_disagreement_score":0.65834975,"about_ca_system_score_codex":0.00089330925,"about_ca_system_score_gemma":0.0011391059,"threshold_uncertainty_score":0.46292552},"labels":[],"label_agreement":null},{"id":"W4310121368","doi":"10.1016/s1470-2045(22)00505-8","title":"International recommendations for plasma Epstein-Barr virus DNA measurement in nasopharyngeal carcinoma in resource-constrained settings: lessons from the COVID-19 pandemic","year":2022,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; University of Hong Kong","keywords":"Nasopharyngeal carcinoma; Medicine; Pandemic; Context (archaeology); Otorhinolaryngology; Intensive care medicine; Personal protective equipment; Health care; Medical emergency; Internal medicine; Radiation therapy; Disease; Surgery; Coronavirus disease 2019 (COVID-19); Infectious disease (medical specialty); Political science","score_opus":0.4414952550388219,"score_gpt":0.4936516964643402,"score_spread":0.052156441425518285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310121368","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007656966,0.52636296,0.000031564658,0.46165505,0.0015107836,0.00489149,0.002771426,0.00010070016,0.0019103393],"genre_scores_gemma":[0.0036457765,0.93632144,0.00016678523,0.05279615,0.0025560586,0.0022781503,0.0020703916,0.00007208201,0.000093169976],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99521965,0.0019187864,0.0011235808,0.00060456956,0.0004699457,0.0006634783],"domain_scores_gemma":[0.9892085,0.009180397,0.00064141746,0.0006789272,0.00006795914,0.00022278356],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00606867,0.00038852863,0.002051821,0.00031507952,0.00028192563,0.000026685679,0.00089406414,0.00038518698,0.0006540261],"category_scores_gemma":[0.0048593073,0.00025348814,0.00032284053,0.00040771643,0.00017236144,0.000029532994,0.00026248343,0.0018200519,0.0000138175365],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00081629184,0.0001868123,0.0012210498,0.002195939,0.00024631023,0.00010705778,0.00285138,0.0000073893084,0.0000048179004,0.00028877333,0.057562888,0.9345113],"study_design_scores_gemma":[0.004808755,0.00031720285,0.0005175247,0.001229929,0.00037322933,0.00022142635,0.00069892727,0.000059361697,3.522639e-7,0.00026366557,0.991301,0.00020862852],"about_ca_topic_score_codex":0.0028522841,"about_ca_topic_score_gemma":0.017798748,"teacher_disagreement_score":0.9343027,"about_ca_system_score_codex":0.0075616254,"about_ca_system_score_gemma":0.0073974943,"threshold_uncertainty_score":0.9999917},"labels":[],"label_agreement":null},{"id":"W4310121745","doi":"10.1016/s1470-2045(22)00689-1","title":"Essential anticancer medicines for children: defining what matters most for Europe","year":2022,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto; SickKids Foundation","funders":"","keywords":"Medicine; Pharmacology; Traditional medicine","score_opus":0.04701082017788962,"score_gpt":0.36283187796006755,"score_spread":0.31582105778217795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310121745","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001572395,0.0034363728,0.00055625965,0.98330766,0.006423954,0.0031127422,0.00073056185,0.00018653569,0.00067353004],"genre_scores_gemma":[0.00021605412,0.0017211159,0.0015288353,0.94919086,0.04059123,0.0012235304,0.00398523,0.0002289538,0.0013141896],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99600554,0.0005579165,0.0008283371,0.00086769613,0.00065786426,0.0010826245],"domain_scores_gemma":[0.9949193,0.0029374573,0.0006977542,0.0011183165,0.00022607802,0.000101086924],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019849734,0.00054077135,0.0021791712,0.00017223008,0.0003939357,0.000080425685,0.00087973,0.00054178404,0.00075301685],"category_scores_gemma":[0.00057975156,0.00040925457,0.00037033102,0.00030108288,0.00046656828,0.0001137137,0.00028134105,0.0021168445,0.000036751768],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014354585,0.00006746355,0.00024996308,0.00094116153,0.000719903,0.000072016024,0.0010474091,0.0000066159996,0.000036024692,0.00018738741,0.99179006,0.003446532],"study_design_scores_gemma":[0.00654515,0.0017312628,0.00054759113,0.0004079304,0.0012274532,0.0003833653,0.0003703734,0.000026122709,0.000041077103,0.00031182685,0.9879827,0.00042513275],"about_ca_topic_score_codex":0.0001919746,"about_ca_topic_score_gemma":0.00011689052,"teacher_disagreement_score":0.034167275,"about_ca_system_score_codex":0.00032531246,"about_ca_system_score_gemma":0.00085750077,"threshold_uncertainty_score":0.9998359},"labels":[],"label_agreement":null},{"id":"W4310554573","doi":"10.1016/s1470-2045(22)00687-8","title":"Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":104,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche; Roche","keywords":"Medicine; Vemurafenib; Atezolizumab; Interim analysis; Placebo; Internal medicine; Tolerability; Oncology; Adverse effect; Surgery; Randomized controlled trial; Metastatic melanoma; Pembrolizumab; Cancer; Immunotherapy; Pathology","score_opus":0.017250538822363423,"score_gpt":0.2996574736859282,"score_spread":0.2824069348635648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310554573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997758,0.00016737058,0.00019004356,0.00019752675,0.000050743147,0.0010291198,0.00010345579,0.0000057341817,0.00049802347],"genre_scores_gemma":[0.9990169,0.000039339553,0.00015142786,0.0001253802,0.000024109973,0.00025325688,0.00031543474,0.000013334728,0.000060831335],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983956,0.00061554485,0.00031939504,0.00032496464,0.00013036348,0.00021408082],"domain_scores_gemma":[0.99918646,0.00022679153,0.00024642245,0.00024415023,0.00006213279,0.000034066827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057454914,0.00015379858,0.0005968349,0.00015992012,0.00007426586,0.000007849265,0.00017165621,0.00004918581,0.000061974206],"category_scores_gemma":[0.0000493604,0.00011188105,0.000040416282,0.00035235088,0.00009217251,0.0000078636585,0.00011860543,0.00016064478,2.92465e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4932207,0.016725782,0.27987722,0.0002258166,0.0058530886,0.0011698763,0.028418144,0.035359927,0.11864242,0.0007811613,0.00015126637,0.019574631],"study_design_scores_gemma":[0.53581834,0.05845401,0.3573609,0.000056330828,0.0013187308,0.00014047469,0.010319115,0.009718267,0.021966653,0.00011421905,0.0038783366,0.00085462356],"about_ca_topic_score_codex":0.00020067526,"about_ca_topic_score_gemma":0.0170622,"teacher_disagreement_score":0.09667577,"about_ca_system_score_codex":0.00006679714,"about_ca_system_score_gemma":0.000096819094,"threshold_uncertainty_score":0.95211077},"labels":[],"label_agreement":null},{"id":"W4313452563","doi":"10.1016/s1470-2045(22)00704-5","title":"Cancer survival in Africa, central and south America, and Asia (SURVCAN-3): a population-based benchmarking study in 32 countries","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Red Cross Society","funders":"Tata Memorial Centre; Centre International de Recherche sur le Cancer; World Health Organization","keywords":"Cancer registry; Population; Medicine; Benchmarking; Cancer; Demography; Environmental health; Internal medicine; Business","score_opus":0.14522996187102502,"score_gpt":0.3965041995073788,"score_spread":0.2512742376363538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313452563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936867,0.0004877562,0.000009277957,0.0044871042,0.00016164662,0.0004205275,0.000018749883,0.00003296179,0.0006953211],"genre_scores_gemma":[0.99875563,0.00017141749,0.000058073896,0.000650929,0.00024351971,0.000070057,0.00001280939,0.0000087135195,0.000028845137],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986795,0.00023160459,0.00022347226,0.00023433265,0.00019144858,0.0004396199],"domain_scores_gemma":[0.99937856,0.00031292127,0.00007863637,0.00014419362,0.000025730993,0.0000599784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070884073,0.0001106459,0.00048301194,0.00011518552,0.00006769062,0.000016834654,0.00007970646,0.000061213395,0.000028667937],"category_scores_gemma":[0.00010612425,0.00008242213,0.000016324551,0.0004727374,0.00009966483,0.00004148933,0.000052937885,0.00023419951,0.0000021309024],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005775855,0.000029911327,0.9896921,0.000023446482,0.000016693728,0.00011854664,0.0044844057,0.00059189973,0.000013507018,0.00006971073,0.0002091836,0.004173007],"study_design_scores_gemma":[0.002613245,0.0003707943,0.987559,0.00006963157,0.00003161097,0.000004559563,0.004455319,0.0030494751,0.0000014783286,0.0000756197,0.0016853393,0.00008390802],"about_ca_topic_score_codex":0.010494081,"about_ca_topic_score_gemma":0.026646174,"teacher_disagreement_score":0.016152093,"about_ca_system_score_codex":0.00022659494,"about_ca_system_score_gemma":0.0001892955,"threshold_uncertainty_score":0.9960951},"labels":[],"label_agreement":null},{"id":"W4318541421","doi":"10.1016/s1470-2045(22)00639-8","title":"Pharmaceutical industry relationships with oncologists in sub-Saharan Africa","year":2023,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Pharmaceutical industry and healthcare","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Queen's University","funders":"","keywords":"Context (archaeology); Pharmaceutical industry; Pharmaceutical policy; Business; Developing country; Health care; Low and middle income countries; TRIPS architecture; Economic growth; Health policy; Medicine; Geography; Economics","score_opus":0.8608037434120723,"score_gpt":0.6449379706512048,"score_spread":0.2158657727608675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318541421","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002811803,0.9631349,0.000004305612,0.009539377,0.0017986796,0.0030632734,0.00045597745,0.0004892492,0.021233056],"genre_scores_gemma":[0.00053959043,0.99007654,0.000052272742,0.0026500376,0.0028359464,0.0016752833,0.00020659382,0.00016258862,0.0018011474],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98183423,0.012801822,0.0016367311,0.0010608936,0.00039341665,0.002272881],"domain_scores_gemma":[0.9874165,0.010000933,0.00074839115,0.00083471264,0.00012419352,0.0008752542],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.009032171,0.0009795076,0.0037379889,0.00045991986,0.0007226474,0.000047952784,0.0017821874,0.0083701005,0.0008462283],"category_scores_gemma":[0.00090047484,0.00063898857,0.00035928053,0.0022192942,0.0014103887,0.00013706426,0.00047581564,0.037781432,0.0028835055],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013449204,0.0009897085,0.00096658577,0.0111991335,0.0011301748,0.003064292,0.00052756356,0.00014362209,0.000005256817,0.003470669,0.1426928,0.83446527],"study_design_scores_gemma":[0.0024743967,0.00032572562,0.00020004429,0.0022460562,0.0016342468,0.00046809769,0.000088318455,0.00013440968,0.0000071090817,0.00049098715,0.991211,0.0007196321],"about_ca_topic_score_codex":0.000027489014,"about_ca_topic_score_gemma":0.00047915787,"teacher_disagreement_score":0.8485182,"about_ca_system_score_codex":0.0014508584,"about_ca_system_score_gemma":0.0024619314,"threshold_uncertainty_score":0.99960613},"labels":[],"label_agreement":null},{"id":"W4318913053","doi":"10.1016/s1470-2045(23)00017-7","title":"18F-NaF PET–CT versus 99mTc SPECT in bone metastasis assessment – Authors' reply","year":2023,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Medical Imaging Techniques and Applications","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Nuclear medicine; Bone metastasis; Positron Emission Tomography-Computed Tomography; Radiology; Metastasis; Positron emission tomography; Internal medicine; Cancer","score_opus":0.14383366091233843,"score_gpt":0.45062370371638627,"score_spread":0.30679004280404787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318913053","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001109968,0.00012869194,0.00023177668,0.97594315,0.0009771698,0.0010067596,0.000080074504,0.0005372467,0.019985178],"genre_scores_gemma":[0.0028464294,0.0013302888,0.03710919,0.93275195,0.011968094,0.0014205587,0.0010330286,0.00016502717,0.011375407],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971466,0.00040762796,0.000601348,0.0006210035,0.00049422163,0.0007292161],"domain_scores_gemma":[0.99684924,0.0012150845,0.0003019963,0.0014646768,0.000059176597,0.00010985105],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0021640272,0.00032566694,0.001415893,0.00022587519,0.00009264863,0.000025014502,0.00056346675,0.000122053134,0.00059123215],"category_scores_gemma":[0.00045477023,0.00022343305,0.00021021948,0.00051550195,0.00031479687,0.000023440276,0.00027090573,0.004287674,0.00031606862],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000964244,0.00008262435,0.000058551446,0.00013889282,0.0001355243,0.010892703,0.000025096839,4.4799887e-7,0.00006929422,0.0008774896,0.98442876,0.0031942131],"study_design_scores_gemma":[0.0019963363,0.00041818316,0.00046283734,0.00014798559,0.00040229576,0.00109301,0.00003655817,0.00020076969,0.000040298553,0.0015292802,0.993464,0.0002084348],"about_ca_topic_score_codex":0.00049667514,"about_ca_topic_score_gemma":0.00008573159,"teacher_disagreement_score":0.043191157,"about_ca_system_score_codex":0.0006609052,"about_ca_system_score_gemma":0.0005160087,"threshold_uncertainty_score":0.9980095},"labels":[],"label_agreement":null},{"id":"W4318919835","doi":"10.1016/s1470-2045(23)00007-4","title":"Accelerating cancer omics and precision oncology in health care and research: a Lancet Oncology Commission","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"Cancer Research UK; World Health Organization","keywords":"Precision oncology; Omics; Clinical Oncology; Medicine; Cancer; Oncology; Precision medicine; Molecular oncology; Bioinformatics; Internal medicine; Computational biology; Biology; Pathology","score_opus":0.16406786068415202,"score_gpt":0.4647747784755713,"score_spread":0.3007069177914193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318919835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9549761,0.01054465,0.000020823516,0.025872994,0.0005030837,0.0005946884,0.000102944105,0.000026690994,0.0073580663],"genre_scores_gemma":[0.90297675,0.08982484,0.0014554542,0.003060385,0.0019241786,0.00024515064,0.00014970872,0.000041620515,0.00032189963],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974574,0.0008818357,0.00038158064,0.0004689009,0.0001276988,0.0006825903],"domain_scores_gemma":[0.9984355,0.0007578931,0.00016540448,0.00038255498,0.000117444644,0.00014122657],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026825622,0.00015998748,0.0005638601,0.0001230448,0.00030265498,0.00003014443,0.00031169926,0.00034983977,0.000013498418],"category_scores_gemma":[0.00053359143,0.00012876301,0.00003104382,0.0002755107,0.00031143747,0.000005277797,0.00076246954,0.00055882573,0.000006285141],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028503384,0.00021469455,0.028459324,0.00042984885,0.0000916941,0.00007904457,0.013117836,0.00091495673,0.06767597,0.0028054635,0.20725553,0.6761053],"study_design_scores_gemma":[0.0026578028,0.0025674165,0.011786692,0.000053277672,0.000007998617,0.00003346393,0.0025614055,0.0005235851,0.0011974659,0.00066451397,0.97778815,0.00015821056],"about_ca_topic_score_codex":0.00095285685,"about_ca_topic_score_gemma":0.0093347225,"teacher_disagreement_score":0.77053267,"about_ca_system_score_codex":0.00042035122,"about_ca_system_score_gemma":0.0010405283,"threshold_uncertainty_score":0.5250803},"labels":[],"label_agreement":null},{"id":"W4318930461","doi":"10.1016/s1470-2045(23)00009-8","title":"Essential medicines for childhood cancer in Europe","year":2023,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre; Dalhousie University","funders":"","keywords":"Childhood cancer; Cancer; Medicine; Traditional medicine; Internal medicine","score_opus":0.06319597506726028,"score_gpt":0.31275034460307777,"score_spread":0.2495543695358175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318930461","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001411454,0.0043059005,0.00013795454,0.95620453,0.0065224613,0.00079712307,0.00179245,0.000085633474,0.028742488],"genre_scores_gemma":[0.0037044142,0.010914651,0.000110867666,0.914257,0.055672057,0.00092532166,0.00027241974,0.00021352159,0.013929788],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99758875,0.000051048446,0.0008653825,0.0005997186,0.00003641946,0.00085867627],"domain_scores_gemma":[0.9981424,0.00046605678,0.0007331906,0.0005508374,0.000065555985,0.000041967283],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001120632,0.0003157398,0.0015995903,0.00027130608,0.00009804031,0.000045128938,0.00087098597,0.00074743264,0.00043298272],"category_scores_gemma":[0.00048750517,0.00027560123,0.00015796507,0.00035632774,0.0002003063,0.00009638386,0.0001256179,0.0013243635,0.0007354202],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004800031,0.00002276801,0.0013219907,0.00009819372,0.00009604091,0.000042683343,0.00035999969,0.000049052083,9.81411e-7,0.007649346,0.98751384,0.0027971133],"study_design_scores_gemma":[0.0015503311,0.0001345743,0.009752838,0.000058514437,0.00002460213,0.000005975514,0.000012148378,0.00009595627,0.0000025852228,0.023358233,0.96468276,0.00032147046],"about_ca_topic_score_codex":0.0009204756,"about_ca_topic_score_gemma":0.0012773424,"teacher_disagreement_score":0.049149595,"about_ca_system_score_codex":0.00034037043,"about_ca_system_score_gemma":0.00028438176,"threshold_uncertainty_score":0.9999696},"labels":[],"label_agreement":null},{"id":"W4320483165","doi":"10.1016/s1470-2045(23)00013-x","title":"Prognostic implications of p16 and HPV discordance in oropharyngeal cancer (HNCIG-EPIC-OPC): a multicentre, multinational, individual patient data analysis","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":281,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"European Regional Development Fund; Universität zu Köln; Cancerföreningen i Stockholm; GlaxoSmithKline; Public Health Agency; University of Birmingham; Stockholms Läns Landsting; Generalitat de Catalunya; National Institute for Health and Care Research; Seagen; ZonMw; Medical Research Council; Swedish Cancer Foundation; Cancer Research UK; AstraZeneca","keywords":"EPIC; Multinational corporation; Medicine; Oncology; Internal medicine; Business; Art","score_opus":0.13685457644282537,"score_gpt":0.42511547419756246,"score_spread":0.28826089775473707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4320483165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97886956,0.0015542501,0.000020698168,0.017595742,0.00008868123,0.0005563609,0.0006985769,0.00003015001,0.00058599334],"genre_scores_gemma":[0.99551535,0.002544055,0.000474159,0.0007280574,0.00013468199,0.00025309063,0.00029170836,0.000008913535,0.00004999979],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988057,0.00011984435,0.00031471773,0.0003073046,0.00017073123,0.00028169245],"domain_scores_gemma":[0.9986303,0.00062398246,0.00013940968,0.00047119026,0.00008203134,0.00005308196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039271664,0.00010484317,0.0006430667,0.00016012149,0.00007905669,0.0000053450035,0.00023690372,0.000047459962,0.000053168438],"category_scores_gemma":[0.00035857497,0.00007053347,0.00003399921,0.0009788923,0.00018586434,0.000056033034,0.0003531968,0.00016634859,0.0000059537774],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020760827,0.00025139947,0.9347997,0.00009720357,0.0005589876,0.00001733218,0.0032205877,0.0000856195,0.0003043358,0.00025162488,0.0045160875,0.055689525],"study_design_scores_gemma":[0.0017565072,0.0002099111,0.989783,0.00003984545,0.0006015242,0.0000046236237,0.00059805356,0.002808394,0.000035584282,0.00009035795,0.004002578,0.000069644535],"about_ca_topic_score_codex":0.0006063292,"about_ca_topic_score_gemma":0.007918824,"teacher_disagreement_score":0.05561988,"about_ca_system_score_codex":0.00008516607,"about_ca_system_score_gemma":0.00018912498,"threshold_uncertainty_score":0.44188902},"labels":[],"label_agreement":null},{"id":"W4320715991","doi":"10.1016/s1470-2045(23)00070-0","title":"Access to new drugs in paediatric oncology: can we learn from the ongoing ONC201 saga?","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Oncology; Internal medicine; Psychology","score_opus":0.08568365502871851,"score_gpt":0.3743098064957676,"score_spread":0.2886261514670491,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4320715991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6596637,0.0006464489,0.00000208129,0.3352999,0.0004495759,0.0005656444,0.000019214152,0.000088496294,0.0032649734],"genre_scores_gemma":[0.97509104,0.0021711998,0.00019639521,0.01858702,0.002836797,0.0002535487,0.000054623146,0.00003498771,0.00077437545],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982055,0.00036613684,0.00029306294,0.00033861905,0.00020971466,0.0005869945],"domain_scores_gemma":[0.9969512,0.0021650838,0.000112590795,0.00056289404,0.00003253613,0.00017567928],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007788216,0.00018169876,0.0006693354,0.00015391382,0.0001208713,0.000035070014,0.0005313294,0.00016818306,0.00023332516],"category_scores_gemma":[0.00028295437,0.00009877747,0.00009136853,0.0010033118,0.000070484806,0.00003872227,0.0003627974,0.00045750977,0.0007180114],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043003733,0.0003276546,0.26180372,0.000015018585,0.00017488936,0.0004717775,0.011687742,0.0002152708,0.00037830303,0.00025352868,0.40258473,0.32165733],"study_design_scores_gemma":[0.0050762156,0.0006048472,0.48038486,0.00006089579,0.0001718398,0.000018088016,0.0012351451,0.00006591425,0.00023791756,0.0017559223,0.51026446,0.00012390535],"about_ca_topic_score_codex":0.006089407,"about_ca_topic_score_gemma":0.017165396,"teacher_disagreement_score":0.3215334,"about_ca_system_score_codex":0.00058208103,"about_ca_system_score_gemma":0.0006035923,"threshold_uncertainty_score":0.95786935},"labels":[],"label_agreement":null},{"id":"W4320716080","doi":"10.1016/s1470-2045(23)00012-8","title":"Systematic review and updated recommendations for cardiomyopathy surveillance for survivors of childhood, adolescent, and young adult cancer from the International Late Effects of Childhood Cancer Guideline Harmonization Group","year":2023,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":136,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Guideline; Asymptomatic; Cardiomyopathy; Pediatrics; Cancer; Intensive care medicine; Internal medicine; Heart failure; Pathology","score_opus":0.04101758170435237,"score_gpt":0.36528840107140564,"score_spread":0.32427081936705326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4320716080","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005051246,0.980355,0.0006172713,0.006199913,0.0008073146,0.008744765,0.0027191667,0.000036231057,0.000015210489],"genre_scores_gemma":[0.00062465906,0.9917147,0.00025666002,0.001868533,0.00072066387,0.002227827,0.002475746,0.00005888794,0.00005230072],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.997751,0.0004913848,0.0010558831,0.00033890078,0.00016598,0.00019687031],"domain_scores_gemma":[0.99666464,0.0012261628,0.0012305775,0.0003907754,0.00044533337,0.000042488315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014561011,0.0002800566,0.0029632812,0.00006698901,0.000089523994,0.000013021088,0.0002606298,0.00021171784,0.0000072770563],"category_scores_gemma":[0.0008463599,0.00016805071,0.00030825334,0.00028425732,0.000091671944,0.00003827804,0.0000710776,0.00024205819,4.6509086e-7],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000115994524,0.0001698523,0.00042579282,0.8106672,0.006664939,0.000001427402,0.0009401986,0.0000035948726,0.00016898398,0.00021863874,0.024442071,0.1561813],"study_design_scores_gemma":[0.009036516,0.0004889885,0.0030624075,0.69531864,0.027996192,0.00009970496,0.00017873583,0.00026006272,0.00028487548,0.0003243153,0.26224136,0.00070819247],"about_ca_topic_score_codex":0.0007440684,"about_ca_topic_score_gemma":0.0012751191,"teacher_disagreement_score":0.2377993,"about_ca_system_score_codex":0.00016904641,"about_ca_system_score_gemma":0.00023251172,"threshold_uncertainty_score":0.6852909},"labels":[],"label_agreement":null},{"id":"W4322422761","doi":"10.1016/s1470-2045(22)00742-2","title":"Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshop","year":2023,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institutes of Health; National Cancer Institute; Canadian Institute of Steel Construction","keywords":"Medical physics; Medicine; Clinical trial; Magnetic resonance imaging; Cancer; Immunotherapy; Steering committee; Radiology; Pathology; Internal medicine; Engineering","score_opus":0.3285918679246932,"score_gpt":0.5010001650143106,"score_spread":0.17240829708961736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322422761","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000034677687,0.94496715,0.0002099854,0.044381082,0.005726459,0.0023065743,0.00072674314,0.00023372188,0.0014136013],"genre_scores_gemma":[0.000009558599,0.95828176,0.00044467463,0.024733575,0.01207981,0.0020793686,0.00027355875,0.00017629443,0.0019214266],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99457663,0.0014052195,0.0017886492,0.0007428314,0.00064389076,0.00084275403],"domain_scores_gemma":[0.99230295,0.00535834,0.0010971593,0.00090206135,0.00023318679,0.00010628415],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0063871117,0.0007105436,0.003974652,0.00022308463,0.00054718467,0.00028063447,0.0013228572,0.0002786725,0.00046464027],"category_scores_gemma":[0.0008727356,0.00039532266,0.00092127663,0.000994205,0.00041318557,0.0002244803,0.00034121829,0.0013482288,0.000067439105],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077737804,0.000028378772,0.000104377796,0.00060619257,0.001622422,0.00004009824,0.00061646814,0.00002185972,0.000118039716,0.000029500558,0.17156135,0.8244739],"study_design_scores_gemma":[0.0026071214,0.000022504351,0.0003617681,0.023809193,0.000918647,0.000049050668,0.0001752734,0.000046191883,0.000004525268,0.000066876724,0.97148854,0.0004503122],"about_ca_topic_score_codex":0.007829903,"about_ca_topic_score_gemma":0.003028478,"teacher_disagreement_score":0.8240236,"about_ca_system_score_codex":0.0029635762,"about_ca_system_score_gemma":0.0034563087,"threshold_uncertainty_score":0.99984986},"labels":[],"label_agreement":null},{"id":"W4322422773","doi":"10.1016/s1470-2045(23)00049-9","title":"Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":163,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; University of Alberta","funders":"","keywords":"Lenvatinib; Medicine; Sunitinib; Renal cell carcinoma; Pembrolizumab; Everolimus; Internal medicine; Oncology; Clinical endpoint; Kidney cancer; Cancer; Clinical trial; Immunotherapy","score_opus":0.11808466686181321,"score_gpt":0.3742417348262079,"score_spread":0.25615706796439464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322422773","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857422,0.0002954958,0.0000046251976,0.0017626196,0.00044671827,0.00650448,0.00026900682,0.000084825086,0.004890015],"genre_scores_gemma":[0.99590427,0.00019076132,0.00019348908,0.00024013988,0.00034307968,0.0010106134,0.0007510589,0.00007379396,0.0012927861],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9969317,0.00067045924,0.00062914594,0.0006016468,0.0005391449,0.00062790903],"domain_scores_gemma":[0.9956392,0.00214718,0.0004747391,0.001334969,0.00023240244,0.00017150844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004562708,0.00045598834,0.0015416613,0.00008732713,0.00031066983,0.000029541136,0.0006420188,0.00011763107,0.00024425055],"category_scores_gemma":[0.00015673245,0.00022785946,0.00013888557,0.0004682135,0.00024658357,0.0000808019,0.00025103948,0.0002653673,0.00012165118],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92958057,0.015070694,0.010268904,0.00004315742,0.0013022083,0.0009142812,0.009230685,0.00010761319,0.00063297834,0.000034271972,0.0018639538,0.03095071],"study_design_scores_gemma":[0.8163802,0.09713788,0.072748296,0.00003885209,0.0015859442,0.000012173727,0.0023084753,0.00015601593,0.003036389,0.000051377363,0.006305909,0.00023849103],"about_ca_topic_score_codex":0.0012981531,"about_ca_topic_score_gemma":0.0011872755,"teacher_disagreement_score":0.113200344,"about_ca_system_score_codex":0.000656269,"about_ca_system_score_gemma":0.000547237,"threshold_uncertainty_score":0.9291839},"labels":[],"label_agreement":null},{"id":"W4323033688","doi":"10.1016/s1470-2045(23)00052-9","title":"Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec; Centre Hospitalier de l’Université de Montréal","funders":"Pfizer Canada; European Society for Medical Oncology; Merck Sharp and Dohme; Eisai; Bayer HealthCare; Seagen; Incyte; Ipsen; Clovis Oncology; PharmaMar; Ipsen Biopharmaceuticals; AstraZeneca Canada; Gilead Sciences; Mersana Therapeutics; Bristol-Myers Squibb; AstraZeneca; Takeda Oncology; Amgen; Pfizer; GlaxoSmithKline","keywords":"Medicine; Bevacizumab; Pembrolizumab; Carboplatin; Chemotherapy; Placebo; Clinical endpoint; Internal medicine; Cervical cancer; Oncology; Cancer; Surgery; Clinical trial; Cisplatin; Immunotherapy; Pathology","score_opus":0.21000950227401172,"score_gpt":0.45566592571097175,"score_spread":0.24565642343696004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323033688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94022304,0.0013338905,0.00041320748,0.028164573,0.000674471,0.027736364,0.00044533255,0.00028307896,0.000726029],"genre_scores_gemma":[0.97320104,0.0016720339,0.0010232911,0.003069511,0.0013047854,0.013149409,0.00028689989,0.00015259757,0.006140444],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.994571,0.0011487544,0.0016732236,0.0007629433,0.000770932,0.001073153],"domain_scores_gemma":[0.99267614,0.004376556,0.0013879063,0.00071038597,0.00033934473,0.000509676],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0028480354,0.00060199556,0.005362674,0.000284529,0.00028195156,0.00003220357,0.00042174794,0.00024433964,0.0013280839],"category_scores_gemma":[0.0007898715,0.00025202363,0.0005257669,0.0014903789,0.00040066426,0.00008885609,0.0000610704,0.00056454696,0.000020366797],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97651494,0.0018226708,0.00011037252,0.001035658,0.0058196606,0.00006567152,0.0019062349,0.00017482134,0.00002173277,0.000061369436,0.0015767523,0.010890104],"study_design_scores_gemma":[0.93874043,0.051935513,0.000050130708,0.00027089863,0.0022717686,0.00013725887,0.0010495278,0.0016280698,0.000046084027,0.000031344836,0.0035062733,0.0003327049],"about_ca_topic_score_codex":0.0016276895,"about_ca_topic_score_gemma":0.0076304455,"teacher_disagreement_score":0.05011284,"about_ca_system_score_codex":0.0009365904,"about_ca_system_score_gemma":0.0054889573,"threshold_uncertainty_score":0.9999932},"labels":[],"label_agreement":null},{"id":"W4361026261","doi":"10.1016/s1470-2045(23)00067-0","title":"Multinational Association of Supportive Care in Cancer (MASCC) clinical practice guidelines for the prevention and management of acute radiation dermatitis: international Delphi consensus-based recommendations","year":2023,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Effects of Radiation Exposure","field":"Medicine","cited_by":117,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; University of Toronto; McMaster University","funders":"National Cancer Institute; University of Rochester","keywords":"Multinational corporation; Medicine; Delphi method; Delphi; Clinical Practice; Family medicine; Intensive care medicine; Medical physics; Political science","score_opus":0.21632425902884972,"score_gpt":0.5777859755552123,"score_spread":0.36146171652636255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361026261","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016144176,0.79575306,0.0012410291,0.19060512,0.0021104869,0.0077443994,0.0019657065,0.000050153645,0.00036861523],"genre_scores_gemma":[0.0001281,0.9840701,0.011297371,0.0011394424,0.00049666397,0.0011815614,0.0014202447,0.000024128185,0.00024237516],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971177,0.0007937467,0.0014206254,0.00021997262,0.00030094394,0.00014704143],"domain_scores_gemma":[0.98814654,0.0076184794,0.0024718873,0.0002097549,0.0015282234,0.00002509923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003271899,0.00015246152,0.0009772308,0.00016442648,0.00005544971,0.000008422378,0.00018211907,0.00025919665,0.000021120039],"category_scores_gemma":[0.0041853706,0.00010294395,0.00022096817,0.00024205066,0.00007352865,0.000055915723,0.000056607892,0.00028856366,0.000002589017],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022732082,0.00017408532,0.00061342586,0.0066083036,0.003032568,0.0000058667542,0.0003038159,0.00014670994,3.5488765e-7,0.00084863,0.050577812,0.9374611],"study_design_scores_gemma":[0.0037347393,0.00035986176,0.004715276,0.0036866344,0.0044766087,0.00001237444,0.0004964026,0.0020760752,0.0000014873855,0.000074583855,0.9802731,0.00009283223],"about_ca_topic_score_codex":0.000043389922,"about_ca_topic_score_gemma":0.0002818792,"teacher_disagreement_score":0.9373683,"about_ca_system_score_codex":0.0006254733,"about_ca_system_score_gemma":0.0007526298,"threshold_uncertainty_score":0.5010582},"labels":[],"label_agreement":null},{"id":"W4361026527","doi":"10.1016/s1470-2045(23)00063-3","title":"Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":188,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; University of Alberta; Ottawa Hospital; Queen's University; Kingston Health Sciences Centre; University of British Columbia","funders":"National Cancer Institute","keywords":"Medicine; Docetaxel; Enzalutamide; Clinical endpoint; Prostate cancer; Internal medicine; Antiandrogen; Population; Flutamide; Oncology; Interim analysis; Bicalutamide; Testosterone (patch); Urology; Randomized controlled trial; Cancer; Androgen receptor","score_opus":0.20026769745623704,"score_gpt":0.4825725563967049,"score_spread":0.28230485894046786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361026527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9704241,0.0019579742,0.000090913265,0.011946645,0.0019991728,0.011205296,0.0016891675,0.00018148989,0.0005052234],"genre_scores_gemma":[0.95942205,0.020572308,0.0019176218,0.0015349148,0.0022476905,0.0069737514,0.0032312458,0.0001930495,0.0039073857],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963876,0.000741692,0.00060714135,0.0007278841,0.0006259655,0.00090973324],"domain_scores_gemma":[0.99676114,0.0015056436,0.0003550971,0.0006990023,0.00040455005,0.00027454435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020235118,0.00040615577,0.0014799468,0.00022813134,0.00041408298,0.00014673857,0.000694857,0.00017198295,0.00014639385],"category_scores_gemma":[0.000411005,0.00024386849,0.0001176357,0.00040805034,0.00035501242,0.00042898676,0.00037310837,0.0004446875,0.00003370228],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87559247,0.0008568862,0.000037866095,0.000059780814,0.0009386254,0.00027476947,0.0031023596,0.00006834698,0.06420645,0.000023470862,0.020184139,0.034654807],"study_design_scores_gemma":[0.8860794,0.02597481,0.00013611026,0.00016366984,0.00043087467,0.00004026199,0.0009549119,0.0030654806,0.0311203,0.00017324212,0.05157603,0.0002849268],"about_ca_topic_score_codex":0.00019955415,"about_ca_topic_score_gemma":0.0000959909,"teacher_disagreement_score":0.034369882,"about_ca_system_score_codex":0.00094011496,"about_ca_system_score_gemma":0.0013997329,"threshold_uncertainty_score":0.99446684},"labels":[],"label_agreement":null},{"id":"W4361026857","doi":"10.1016/s1470-2045(23)00005-0","title":"Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials Conference","year":2023,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institute of Neurological Disorders and Stroke; Foundation Medicine; Genentech; National Institutes of Health; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Servier; Astellas Pharma; Eisai; Ben and Catherine Ivy Foundation; Puma Biotechnology; Boston Pharmaceuticals; Voyager Therapeutics; BeiGene; Deciphera Pharmaceuticals; Agios Pharmaceuticals; Ipsen; Five Prime Therapeutics; Sanofi; GW Pharmaceuticals; Karyopharm Therapeutics; GlaxoSmithKline; AstraZeneca; Novocure; Celldex Therapeutics; Pfizer; Celgene; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Clinical trial; Drug development; Clinical Oncology; Oncology; Internal medicine; Drug; Cancer; Pharmacology","score_opus":0.6506715989117712,"score_gpt":0.5827464133019178,"score_spread":0.06792518560985339,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361026857","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04367926,0.8556312,0.00014062591,0.06904712,0.0085115535,0.021984931,0.00057215773,0.00017559461,0.0002575846],"genre_scores_gemma":[0.00049934536,0.9836542,0.0037333416,0.0041315123,0.004065747,0.0034861169,0.00031833525,0.00009136394,0.000020041469],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98143184,0.00856462,0.0071482887,0.0015825663,0.00037643773,0.0008962675],"domain_scores_gemma":[0.8569597,0.13455029,0.0067233886,0.0011061317,0.00028583297,0.00037462809],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.034517627,0.0007824587,0.014540025,0.00009009459,0.0002749707,0.00003311235,0.0006809981,0.0013636646,0.000021823138],"category_scores_gemma":[0.012054952,0.00042400864,0.0024620066,0.00046411325,0.0025888246,0.00003900262,0.0007570254,0.0026337819,0.000011649119],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059144828,0.002145624,0.0028036304,0.0011742022,0.00232536,0.0002647833,0.0009861793,3.095696e-7,0.0000013551218,0.00010039035,0.095388964,0.88889474],"study_design_scores_gemma":[0.048701864,0.0056009893,0.0036172494,0.0010681708,0.005229047,0.00021727468,0.0004969884,0.00006030406,0.0000015025721,0.00017349618,0.9345201,0.00031299674],"about_ca_topic_score_codex":0.00020311767,"about_ca_topic_score_gemma":0.0014058001,"teacher_disagreement_score":0.88858175,"about_ca_system_score_codex":0.0007303943,"about_ca_system_score_gemma":0.010100827,"threshold_uncertainty_score":0.99993277},"labels":[],"label_agreement":null},{"id":"W4362576010","doi":"10.1016/s1470-2045(23)00072-4","title":"Access to essential cancer medicines for children: a comparative mixed-methods analysis of availability, price, and health-system determinants in east Africa","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Western University; Institute for Clinical Evaluative Sciences; SickKids Foundation; Hospital for Sick Children","funders":"","keywords":"Tanzania; Medicine; Essential medicines; Referral; Health care; Family medicine; Public health; Environmental health; Socioeconomics; Economic growth; Nursing","score_opus":0.2611706477913128,"score_gpt":0.49857130540933786,"score_spread":0.23740065761802503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362576010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9667097,0.0010690516,0.0010889723,0.026802035,0.00044995555,0.0008697284,0.0010292602,0.000024767658,0.0019565583],"genre_scores_gemma":[0.9971028,0.0004186861,0.000491306,0.0014596696,0.00021727088,0.0002562363,0.000009941882,0.000009182659,0.00003493407],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984349,0.00012529606,0.0007072694,0.00032561726,0.000019162315,0.0003877755],"domain_scores_gemma":[0.99879825,0.00043165256,0.0004003023,0.00024283912,0.000026089481,0.000100864665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029033227,0.000114342176,0.0013259128,0.0004650994,0.00006929223,0.000022197362,0.0003711214,0.00006875772,0.000044686094],"category_scores_gemma":[0.00007829098,0.00009777691,0.0000844358,0.0010613599,0.00011212371,0.000058453676,0.00019943426,0.000106083986,0.000015709213],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004908595,0.00020920175,0.8878933,0.00045770864,0.0012477174,0.0000019712897,0.013009879,0.0032420685,0.000047469857,0.036415104,0.028210154,0.028774565],"study_design_scores_gemma":[0.001370498,0.00017173479,0.904808,0.00002174637,0.00007337718,0.0000016636408,0.0002439128,0.05801369,0.00006276865,0.0024879968,0.03258751,0.00015714156],"about_ca_topic_score_codex":0.00088460656,"about_ca_topic_score_gemma":0.0032854355,"teacher_disagreement_score":0.05477162,"about_ca_system_score_codex":0.00017970252,"about_ca_system_score_gemma":0.00006718162,"threshold_uncertainty_score":0.39872265},"labels":[],"label_agreement":null},{"id":"W4366085279","doi":"10.1016/s1470-2045(23)00147-x","title":"Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":190,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; University of Sydney; National Health and Medical Research Council; Hospira","keywords":"Medicine; Chemoradiotherapy; Carboplatin; Cervical cancer; Oncology; Internal medicine; Clinical endpoint; Radiation therapy; Brachytherapy; Surgery; Chemotherapy; Cancer; Randomized controlled trial; Cisplatin","score_opus":0.13857106524791302,"score_gpt":0.47322040351547234,"score_spread":0.3346493382675593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366085279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9415619,0.0022260016,0.00018199658,0.035939917,0.004926234,0.00938452,0.0001959068,0.00036041244,0.0052231215],"genre_scores_gemma":[0.70206463,0.092714004,0.020515833,0.084371686,0.035687413,0.039724078,0.0047897045,0.0009989105,0.019133765],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99701744,0.00023389676,0.00066433504,0.0007975141,0.00048199596,0.0008048446],"domain_scores_gemma":[0.99743605,0.0010196758,0.00030050296,0.0007877903,0.00013604976,0.00031995372],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00094468,0.00049463316,0.0023459417,0.00015580562,0.00024780046,0.00009296114,0.00088337273,0.00026771,0.0009204333],"category_scores_gemma":[0.00014135911,0.00032061842,0.00036703577,0.0006368269,0.00014580213,0.00025532357,0.00007747398,0.00024680514,0.00005598425],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.64640063,0.0030963053,0.00006491951,0.00002996061,0.0017678773,0.00009318153,0.00045200792,0.000019992502,0.008967943,0.00007380135,0.0015407787,0.33749261],"study_design_scores_gemma":[0.7816521,0.024070807,0.00015259297,0.00004971611,0.00037907442,0.000017698398,0.0000920401,0.00051950046,0.0042147874,0.00021645392,0.18834515,0.00029010218],"about_ca_topic_score_codex":0.0003417144,"about_ca_topic_score_gemma":0.00013312418,"teacher_disagreement_score":0.33720252,"about_ca_system_score_codex":0.0019016351,"about_ca_system_score_gemma":0.0008871995,"threshold_uncertainty_score":0.99999285},"labels":[],"label_agreement":null},{"id":"W4367670225","doi":"10.1016/s1470-2045(23)00026-8","title":"The rise of immuno-oncology in China: a challenge to western dominance?","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Institute for Health and Care Research","keywords":"China; Population; Government (linguistics); Political science; Christian ministry; Library science; Scopus; Action plan; Economic growth; Geography; Medicine; Traditional medicine; Demography; Public administration; Management; MEDLINE; Sociology; Environmental health; Law","score_opus":0.04492027790961976,"score_gpt":0.3693331403452687,"score_spread":0.32441286243564893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367670225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8783153,0.003111086,0.000005534812,0.10504105,0.00079601083,0.0006575581,0.0000088070265,0.0000510968,0.012013511],"genre_scores_gemma":[0.9844003,0.0108560575,0.000055985336,0.0012325218,0.000517212,0.00024345056,0.0000038627877,0.000022001745,0.0026686147],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985271,0.00029843042,0.00041037815,0.00018699084,0.00013216732,0.00044494847],"domain_scores_gemma":[0.9987021,0.0005114313,0.00015692336,0.0005517502,0.000038283986,0.00003949592],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020056337,0.00012246969,0.0006014257,0.0000963785,0.000094892144,0.0000045132188,0.00037940432,0.00014124933,0.000054661028],"category_scores_gemma":[0.000113940296,0.000066563,0.00009817643,0.00053764903,0.00030738438,0.00002148324,0.00013362717,0.00026927303,0.000086014894],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.067960724,0.000919161,0.027935375,0.00026551864,0.0006602407,0.0004079997,0.035142697,0.000047846283,0.061787695,0.002075336,0.083763,0.71903443],"study_design_scores_gemma":[0.0051864074,0.001990486,0.22332305,0.00006715254,0.000026378942,0.000051935902,0.0007732472,0.00003412515,0.00047327805,0.00035276098,0.767644,0.00007719688],"about_ca_topic_score_codex":0.000342525,"about_ca_topic_score_gemma":0.0027417473,"teacher_disagreement_score":0.7189572,"about_ca_system_score_codex":0.00025896178,"about_ca_system_score_gemma":0.00024613627,"threshold_uncertainty_score":0.27143604},"labels":[],"label_agreement":null},{"id":"W4367673953","doi":"10.1016/s1470-2045(23)00165-1","title":"Review of the monarchE trial suggests no evidence to support use of adjuvant abemaciclib in women with breast cancer","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University","funders":"","keywords":"Medicine; Breast cancer; Adjuvant; Oncology; Internal medicine; Adjuvant therapy; Clinical trial; Population; Randomized controlled trial; Cancer; Disease; Family medicine","score_opus":0.1417651738107499,"score_gpt":0.42229626471409526,"score_spread":0.2805310909033454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367673953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9483764,0.004214671,0.0000058971286,0.044738073,0.00029925507,0.0020597943,0.00011193667,0.00004199385,0.00015193765],"genre_scores_gemma":[0.9399581,0.036449205,0.00048446015,0.020023955,0.0007423542,0.0013796786,0.000005794815,0.00005497021,0.00090149796],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9982173,0.00033308918,0.00045240272,0.00023884718,0.00031865344,0.00043974235],"domain_scores_gemma":[0.9980632,0.00061212754,0.00028772248,0.00072768907,0.00022967781,0.00007959246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012634086,0.00015288919,0.000998684,0.000070985174,0.000026358051,0.0000024516412,0.000388247,0.00006244437,0.000286785],"category_scores_gemma":[0.000413069,0.00007543413,0.000059427803,0.0009241734,0.00030018625,0.00008622047,0.00016389354,0.0002896641,0.000026497075],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.488188,0.0006352367,0.06775841,0.011872752,0.00050489546,0.00016132803,0.00798961,0.0005933936,0.020470565,0.00018086641,0.028376663,0.3732683],"study_design_scores_gemma":[0.041759577,0.007264873,0.69051933,0.032640632,0.0002503318,0.0003656922,0.00040130274,0.000035187073,0.0011559378,0.0002093011,0.2250547,0.00034315395],"about_ca_topic_score_codex":0.00030280635,"about_ca_topic_score_gemma":0.00033202037,"teacher_disagreement_score":0.6227609,"about_ca_system_score_codex":0.00036766723,"about_ca_system_score_gemma":0.0007534164,"threshold_uncertainty_score":0.31400946},"labels":[],"label_agreement":null},{"id":"W4376126456","doi":"10.1016/s1470-2045(23)00154-7","title":"Cumulative burden of late, major surgical intervention in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study (CCSS) cohort","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute; National Institutes of Health; American Lebanese Syrian Associated Charities; St. Jude Children's Research Hospital","keywords":"Medicine; Psychological intervention; Cancer; Pediatrics; Cohort; Retrospective cohort study; Cohort study; Surgery; Internal medicine; Psychiatry","score_opus":0.05240440087832999,"score_gpt":0.39572720666030364,"score_spread":0.34332280578197366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376126456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97668546,0.0017589456,0.000004838836,0.01600488,0.0011011142,0.0027602282,0.0004016482,0.0001292904,0.0011535799],"genre_scores_gemma":[0.99576277,0.0010956712,0.000029545328,0.00037905402,0.00150595,0.00052621134,0.00017077243,0.00006457855,0.0004654811],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.993745,0.002108335,0.0018363845,0.00073247345,0.0009286495,0.0006491042],"domain_scores_gemma":[0.99483967,0.0022565853,0.0012017599,0.0013017015,0.00027891138,0.00012136542],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0062735053,0.0003848392,0.0021721348,0.0002028426,0.00011559967,0.000013830245,0.00075275474,0.00025801058,0.00046953768],"category_scores_gemma":[0.0007110231,0.0002510654,0.0003606605,0.0013890099,0.00042440987,0.000094155854,0.00042714094,0.00089963246,0.000020798394],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013323661,0.0017102611,0.9487334,0.00011598457,0.0016675002,0.00031773938,0.038876813,0.0006731145,0.0000959207,0.00006156029,0.0020703343,0.0043450403],"study_design_scores_gemma":[0.009074182,0.00080554426,0.9765297,0.00055706536,0.00051721756,0.000050688388,0.0075144353,0.00017424056,0.00019790826,0.00044758164,0.0038924192,0.0002390125],"about_ca_topic_score_codex":0.29063103,"about_ca_topic_score_gemma":0.18722299,"teacher_disagreement_score":0.103408046,"about_ca_system_score_codex":0.00032553158,"about_ca_system_score_gemma":0.00066406024,"threshold_uncertainty_score":0.99999416},"labels":[],"label_agreement":null},{"id":"W4376126708","doi":"10.1016/s1470-2045(23)00166-3","title":"Long-term surgical consequences of childhood cancer","year":2023,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Survivorship curve; Cancer; Psychological intervention; Radiation therapy; Childhood cancer; Disease; Cancer survivorship; Harm; Intervention (counseling); Pediatrics; Gerontology; Surgery; Psychiatry; Psychology; Internal medicine","score_opus":0.09706267654190277,"score_gpt":0.40192848258817643,"score_spread":0.30486580604627367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376126708","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06956239,0.0030775832,0.000002415948,0.9180496,0.002444746,0.00082965364,0.00036728874,0.00023742969,0.005428936],"genre_scores_gemma":[0.022489736,0.006412632,0.00009221764,0.91831684,0.045607146,0.00030260932,0.00056289416,0.00016814134,0.0060478016],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959064,0.00093952625,0.00090523815,0.00062059256,0.00079309865,0.0008351139],"domain_scores_gemma":[0.99580455,0.0020028807,0.00074990146,0.0011628777,0.00017257656,0.00010720311],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014072601,0.0004462758,0.002577685,0.00016692387,0.00009635721,0.000016447104,0.0008330051,0.0011789391,0.0010090783],"category_scores_gemma":[0.00025366983,0.00030213338,0.0004009059,0.0003755921,0.0013889741,0.00003349095,0.00023425798,0.0031389373,0.00022844234],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029827649,0.00011523087,0.013747918,0.0011161349,0.00082616555,0.0027605009,0.0012300651,0.0000018239398,0.000036466474,0.000090796326,0.9772202,0.0025564658],"study_design_scores_gemma":[0.0037156795,0.00074900116,0.06747464,0.0011275309,0.0006842,0.001100868,0.000074911026,9.532018e-7,0.00022360784,0.0005043547,0.9239527,0.00039156122],"about_ca_topic_score_codex":0.0014439565,"about_ca_topic_score_gemma":0.0009413888,"teacher_disagreement_score":0.05372672,"about_ca_system_score_codex":0.0003030616,"about_ca_system_score_gemma":0.0017493882,"threshold_uncertainty_score":0.9999431},"labels":[],"label_agreement":null},{"id":"W4376272229","doi":"10.1016/s1470-2045(23)00170-5","title":"Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":245,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Sinai Health System; University of Toronto; University Health Network; Mount Sinai Hospital","funders":"","keywords":"Cystectomy; Medicine; Propensity score matching; Bladder cancer; Urology; Retrospective cohort study; Stage (stratigraphy); Clinical endpoint; Surgery; Cancer; Internal medicine; Randomized controlled trial","score_opus":0.1688769722248086,"score_gpt":0.3886908834160771,"score_spread":0.2198139111912685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376272229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98449093,0.00064356194,0.00051980925,0.011558703,0.000380658,0.0016448209,0.00024241315,0.00015526058,0.00036384314],"genre_scores_gemma":[0.9944121,0.0017020189,0.0005991618,0.0014437754,0.000677242,0.00072711776,0.00015954352,0.000018879029,0.00026013504],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99861413,0.00017918648,0.00022926442,0.00039096098,0.0001948016,0.000391645],"domain_scores_gemma":[0.99889296,0.00042001164,0.00010183235,0.00033106608,0.00012938159,0.00012471912],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045272164,0.00020128723,0.00087336573,0.00011286932,0.00025790255,0.000015363621,0.00013988942,0.00015966548,0.0001177384],"category_scores_gemma":[0.00008957649,0.00011511937,0.00019459543,0.00062396243,0.00037626614,0.000042963708,0.000055349323,0.00020341494,0.000016335984],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13312998,0.0038972066,0.54545724,0.0009314583,0.051440086,0.001077462,0.010721112,0.0002830504,0.025466539,0.0061273193,0.023712285,0.19775628],"study_design_scores_gemma":[0.06456873,0.0019162431,0.89874864,0.000042049418,0.003785895,0.000035863253,0.00019281793,0.002043011,0.0022983851,0.0004312765,0.025657097,0.00027997422],"about_ca_topic_score_codex":0.0007839921,"about_ca_topic_score_gemma":0.00149303,"teacher_disagreement_score":0.35329142,"about_ca_system_score_codex":0.00025437446,"about_ca_system_score_gemma":0.00089072535,"threshold_uncertainty_score":0.46944317},"labels":[],"label_agreement":null},{"id":"W4378800385","doi":"10.1016/s1470-2045(23)00158-4","title":"Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; BC Cancer Agency","funders":"National Cancer Institute; Medical Research Council; Advanced Accelerator Applications; Astellas Pharma; Clovis Oncology; AstraZeneca; National Institute for Health and Care Research; Novartis; Pfizer","keywords":"Medicine; Prostate cancer; Glutamate carboxypeptidase II; Radioligand; Quality of life (healthcare); Oncology; Internal medicine; Lutetium; Cancer; Nursing; Receptor","score_opus":0.09987168394441787,"score_gpt":0.45554696749601414,"score_spread":0.3556752835515963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378800385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985691,0.0025096785,0.0000035993846,0.0025590982,0.00011200633,0.0066729393,0.0023521355,0.00001865084,0.00008089553],"genre_scores_gemma":[0.99801236,0.0007302831,0.00040111115,0.00006246586,0.000017764387,0.00033044087,0.0003715453,0.00002546982,0.000048562426],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99634826,0.0012847919,0.0009586252,0.00032059822,0.00065677526,0.00043092892],"domain_scores_gemma":[0.99690837,0.0011683638,0.00075470074,0.000367118,0.0006475784,0.00015387623],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020301526,0.00022471718,0.0023248827,0.00015181853,0.000096819764,0.0000138064925,0.00018061949,0.00007089797,0.00002720294],"category_scores_gemma":[0.0004759456,0.00012052561,0.000048283015,0.0005138837,0.00042966317,0.00008193899,0.00008945658,0.0002460838,3.4310762e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94144374,0.0005027154,0.03075646,0.0017154856,0.0007092972,0.000031223368,0.014596183,0.00010717728,0.00004065536,0.00003691485,0.00016761497,0.009892553],"study_design_scores_gemma":[0.8982659,0.06603287,0.021420825,0.0005049818,0.00023870789,3.803966e-7,0.013002641,0.000049277278,0.00016152363,0.000013432202,0.00018046479,0.00012902246],"about_ca_topic_score_codex":0.0023397012,"about_ca_topic_score_gemma":0.018385375,"teacher_disagreement_score":0.06553015,"about_ca_system_score_codex":0.0006714017,"about_ca_system_score_gemma":0.0033803117,"threshold_uncertainty_score":0.99952656},"labels":[],"label_agreement":null},{"id":"W4378803683","doi":"10.1016/s1470-2045(23)00183-3","title":"Global application of National Comprehensive Cancer Network resource-stratified guidelines for systemic treatment of colon cancer: a population-based, customisable model for cost, demand, and procurement","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Institute for Health and Care Research","keywords":"Medicine; Cancer registry; Procurement; Cancer; Population; Intensive care medicine; Business; Environmental health; Internal medicine","score_opus":0.21920006142761905,"score_gpt":0.39798021093759656,"score_spread":0.1787801495099775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378803683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.78278905,0.01977012,0.14248924,0.026088092,0.0007149358,0.012340885,0.014262579,0.000107755186,0.0014373215],"genre_scores_gemma":[0.99076205,0.0012933487,0.002177421,0.0007694271,0.0006158814,0.0040244926,0.00019203722,0.000015974447,0.00014935777],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9988499,0.00001425769,0.0006323788,0.00023287232,0.00003263456,0.00023791399],"domain_scores_gemma":[0.9986153,0.00020737515,0.0007114364,0.00014422528,0.00028940538,0.000032248325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045944535,0.00011639769,0.0006326858,0.00004422093,0.00009814348,0.000008525777,0.000120004624,0.000104307175,0.0000041238936],"category_scores_gemma":[0.0000512718,0.000103191676,0.00007716882,0.00013578853,0.000058950653,0.000040792667,0.0000130746575,0.000023044995,0.0000011339065],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008719267,0.000049994564,0.046761565,0.00023596254,0.00011760102,5.8838804e-8,0.00015334331,0.8552823,0.000028289798,0.070150726,0.020330828,0.00601738],"study_design_scores_gemma":[0.0033317015,0.0002851507,0.008198173,0.00004228046,0.000037182133,0.0000010044014,0.000037068025,0.88045686,0.000029071061,0.027250586,0.08020328,0.00012765669],"about_ca_topic_score_codex":0.0012779008,"about_ca_topic_score_gemma":0.0017940038,"teacher_disagreement_score":0.20797299,"about_ca_system_score_codex":0.00063934416,"about_ca_system_score_gemma":0.00023556166,"threshold_uncertainty_score":0.42080346},"labels":[],"label_agreement":null},{"id":"W4378803794","doi":"10.1016/s1470-2045(23)00175-4","title":"Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Canadian Institutes of Health Research","keywords":"Cross-sectional study; Environmental health; Cancer; Medicine; Geography; Traditional medicine; Pathology; Internal medicine","score_opus":0.4824217619720488,"score_gpt":0.6009260566361347,"score_spread":0.11850429466408596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378803794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.63943964,0.00060244673,0.00031135266,0.355946,0.0017319421,0.0010461301,0.0006002834,0.00008869765,0.00023349821],"genre_scores_gemma":[0.9626994,0.0012830333,0.00029968933,0.031985167,0.0020844308,0.0011201308,0.00005488687,0.000024546773,0.00044869515],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997002,0.0003162919,0.0016867436,0.00043666558,0.000097461205,0.00046082473],"domain_scores_gemma":[0.99660254,0.001619465,0.0011564101,0.00043869103,0.00012083998,0.000062081876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.027017176,0.00012991471,0.00080246176,0.00014094546,0.00079357356,0.00010904423,0.0005774068,0.0001283566,0.00009512853],"category_scores_gemma":[0.000920688,0.00009937431,0.000037302634,0.00021405489,0.0003616344,0.00020487153,0.00014318456,0.0002442366,0.00008533461],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042622796,0.00006863343,0.905978,0.000059603706,0.00011073675,5.850284e-7,0.0036158983,0.00015639316,4.2126743e-7,0.069955125,0.019620994,0.00039094177],"study_design_scores_gemma":[0.0012994058,0.0003633926,0.7035758,0.0000070511487,0.000003211577,0.000009177505,0.00530788,0.0022610056,1.9192746e-7,0.012823928,0.27426726,0.000081706836],"about_ca_topic_score_codex":0.00089805573,"about_ca_topic_score_gemma":0.0061399606,"teacher_disagreement_score":0.32396084,"about_ca_system_score_codex":0.0006881476,"about_ca_system_score_gemma":0.00033529644,"threshold_uncertainty_score":0.9363668},"labels":[],"label_agreement":null},{"id":"W4379114671","doi":"10.1016/s1470-2045(23)00242-5","title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":247,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Medicine; Internal medicine; Cohort; Tolerability; Biliary tract cancer; Clinical endpoint; Oncology; Cancer; Response Evaluation Criteria in Solid Tumors; Biliary tract; Gastroenterology; Immunohistochemistry; Gemcitabine; Phases of clinical research; Clinical trial; Adverse effect","score_opus":0.16486487869779953,"score_gpt":0.43504478601068974,"score_spread":0.2701799073128902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379114671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97055566,0.0030138453,0.00044249388,0.015259892,0.0016608818,0.0063977675,0.0005564067,0.0004882626,0.0016248072],"genre_scores_gemma":[0.9886587,0.001097064,0.0011037281,0.002825332,0.0012776469,0.0024245463,0.00015661516,0.00010120261,0.0023551574],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99702185,0.00029874095,0.0005862979,0.0006947044,0.0003679438,0.0010304317],"domain_scores_gemma":[0.9968816,0.0016623734,0.00024516426,0.0008204391,0.00020328177,0.00018716187],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00087645644,0.0004062538,0.0014213407,0.00015043617,0.00030441213,0.000039101462,0.00043518466,0.00010516759,0.00037976747],"category_scores_gemma":[0.0005885277,0.00025148093,0.00018875948,0.0008118736,0.0002108805,0.00012705514,0.00019804265,0.00043341628,0.000077921206],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12247155,0.04050116,0.031323314,0.002433141,0.0066373413,0.004322937,0.03231204,0.0005697379,0.025163064,0.00020492029,0.2413577,0.4927031],"study_design_scores_gemma":[0.18693127,0.06390268,0.06365952,0.000517963,0.004804386,0.00039910994,0.04543944,0.0041066688,0.0021669497,0.00044828234,0.62619495,0.0014287821],"about_ca_topic_score_codex":0.0004972114,"about_ca_topic_score_gemma":0.0044752248,"teacher_disagreement_score":0.49127433,"about_ca_system_score_codex":0.00039231626,"about_ca_system_score_gemma":0.00058232626,"threshold_uncertainty_score":0.99999374},"labels":[],"label_agreement":null},{"id":"W4379801164","doi":"10.1016/s1470-2045(23)00279-6","title":"Canada to put health warnings on individual cigarettes","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Global Public Health Policies and Epidemiology","field":"Business, Management and Accounting","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Agency (philosophy); Tobacco control; Business; Health protection; Labelling; Advertising; Health claims on food labels; Control (management); Political science; Environmental health; Public health; Medicine; Psychology; Economics; Management; Sociology; Criminology","score_opus":0.09609168010326435,"score_gpt":0.35750838632823806,"score_spread":0.2614167062249737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379801164","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21714073,0.000015704069,0.000003729084,0.75829315,0.0010229353,0.00022227301,0.000019859051,0.00015315853,0.02312848],"genre_scores_gemma":[0.340614,0.000021133494,0.000013134155,0.65547335,0.0034881313,0.000039427963,0.000049525534,0.000012255295,0.00028903745],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981387,0.00010874112,0.00030586735,0.0002272847,0.00019635691,0.0010229986],"domain_scores_gemma":[0.998961,0.00045279873,0.00020065972,0.0002823457,0.00005200834,0.000051212162],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002597559,0.00013157047,0.0004618393,0.000121305384,0.00034857428,0.000042625445,0.00055496773,0.000072865165,0.00009231284],"category_scores_gemma":[0.00090768404,0.00008983013,0.000030159752,0.000685006,0.000047605146,0.00007183985,0.00031925135,0.0002920354,0.00061960897],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002114662,0.000007646646,0.0015014313,0.000027185164,0.000011872369,0.000007284768,0.00009022839,0.0006271253,5.981223e-7,0.031086957,0.9575951,0.009023438],"study_design_scores_gemma":[0.00025146277,0.00006117992,0.078706734,0.000010718944,0.000004081128,0.0000019695017,0.00017825731,0.00058451167,2.0241e-7,0.0011601044,0.9189567,0.00008410974],"about_ca_topic_score_codex":0.80237,"about_ca_topic_score_gemma":0.44527864,"teacher_disagreement_score":0.3570914,"about_ca_system_score_codex":0.00023033647,"about_ca_system_score_gemma":0.0005733731,"threshold_uncertainty_score":0.7964026},"labels":[],"label_agreement":null},{"id":"W4382933931","doi":"10.1016/s1470-2045(23)00212-7","title":"Endoscopic surveillance in hereditary diffuse gastric cancer","year":2023,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Montreal General Hospital","funders":"","keywords":"Medicine; Gastrectomy; Cancer; Signet ring cell carcinoma; Cohort; Surgery; Prospective cohort study; Internal medicine; CDH1; General surgery; Gastroenterology; Adenocarcinoma","score_opus":0.06145302085543939,"score_gpt":0.3409045621487638,"score_spread":0.2794515412933244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382933931","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014245326,0.0016546855,0.0000065982017,0.9727073,0.00399123,0.0008752982,0.000090641035,0.00022605939,0.006202908],"genre_scores_gemma":[0.0075436365,0.0066600596,0.000113048314,0.9171403,0.0338484,0.0006177316,0.0004156682,0.00013344658,0.033527676],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99743056,0.00030645033,0.00044830513,0.0005002012,0.00038481966,0.0009296331],"domain_scores_gemma":[0.9981634,0.0007163247,0.00023312682,0.0007902407,0.000045705005,0.00005117266],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0005594691,0.00035903903,0.0014529281,0.00034143258,0.00005476183,0.0000186751,0.0005452217,0.0005376168,0.00044940898],"category_scores_gemma":[0.00012316958,0.00024643575,0.00015936472,0.00074714725,0.00015712435,0.000031033807,0.00023375405,0.002474812,0.00027597847],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009940831,0.00003648267,0.0836381,0.00038132447,0.00015685648,0.0035301638,0.00008557195,0.000006959002,0.000003943937,0.000008183737,0.90695006,0.005102973],"study_design_scores_gemma":[0.003648687,0.00020756599,0.19824183,0.00012724979,0.00011136904,0.000049957966,0.000031686966,0.000023732613,0.0000010953838,0.000105163745,0.7973156,0.00013605611],"about_ca_topic_score_codex":0.0015739272,"about_ca_topic_score_gemma":0.0027951312,"teacher_disagreement_score":0.11460373,"about_ca_system_score_codex":0.0007372152,"about_ca_system_score_gemma":0.000353137,"threshold_uncertainty_score":0.9999988},"labels":[],"label_agreement":null},{"id":"W4383982112","doi":"10.1016/s1470-2045(23)00276-0","title":"Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":149,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec","funders":"Merck Sharp and Dohme; National Cancer Institute; Eisai","keywords":"Lenvatinib; Pembrolizumab; Medicine; Renal cell carcinoma; Internal medicine; Clinical endpoint; Population; Oncology; Adverse effect; Phases of clinical research; Cancer; Clinical trial; Immunotherapy","score_opus":0.09302847659005466,"score_gpt":0.3660065527882697,"score_spread":0.27297807619821507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383982112","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9735692,0.00073611236,0.0001454968,0.006565378,0.0009173053,0.0054917987,0.000082812876,0.00024798678,0.012243875],"genre_scores_gemma":[0.9858722,0.0006320403,0.00124589,0.001741709,0.0024461204,0.000980743,0.00033795627,0.00012681796,0.006616541],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9966723,0.000271019,0.00072700024,0.00075036654,0.00043473905,0.0011446063],"domain_scores_gemma":[0.9966104,0.0014583685,0.00043011687,0.0010196862,0.00020136204,0.00028004768],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00067750347,0.0005067915,0.0013947216,0.00018601278,0.0003028919,0.00003230676,0.0004510347,0.00031181853,0.0002976515],"category_scores_gemma":[0.00021363983,0.0003485733,0.00041167517,0.00046240116,0.00020137372,0.00007708485,0.00013407745,0.0005132768,0.00047660014],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.82137436,0.007817183,0.00019404027,0.0004042647,0.0002477179,0.0014396355,0.0038194326,0.0006065352,0.111434236,0.000057454152,0.018938448,0.033666708],"study_design_scores_gemma":[0.6882687,0.07865953,0.0007993548,0.000060530405,0.00044897688,0.00013157689,0.0005119597,0.0043792743,0.11563023,0.0002666065,0.110361494,0.0004817265],"about_ca_topic_score_codex":0.000120152195,"about_ca_topic_score_gemma":0.00006793884,"teacher_disagreement_score":0.1331056,"about_ca_system_score_codex":0.0007679005,"about_ca_system_score_gemma":0.00062670803,"threshold_uncertainty_score":0.99989665},"labels":[],"label_agreement":null},{"id":"W4384463924","doi":"10.1016/s1470-2045(23)00319-4","title":"Common Sense Oncology: outcomes that matter","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph; Princess Margaret Cancer Centre; Kingston Health Sciences Centre; Hospital for Sick Children; Queen's University","funders":"National Institute for Health and Care Research","keywords":"Medicine; Quality of life (healthcare); Intensive care medicine; Internal medicine; Oncology; Nursing","score_opus":0.3533455849318626,"score_gpt":0.514592108476374,"score_spread":0.16124652354451147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384463924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82262605,0.0003035979,0.000010212951,0.08480669,0.00051706156,0.00021141802,0.000018934588,0.00012473993,0.091381304],"genre_scores_gemma":[0.96664226,0.0009983464,0.0006765574,0.024582032,0.00058637955,0.000040670417,0.00004791017,0.000025025505,0.0064008343],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99892443,0.00024340175,0.00020657862,0.00015109073,0.00014289937,0.0003316201],"domain_scores_gemma":[0.9982022,0.0011729546,0.00011724129,0.00040327848,0.000045851746,0.000058453057],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000592594,0.000120223594,0.00082528236,0.00007512636,0.000051171377,0.000003436112,0.00014124683,0.00015338269,0.00032393174],"category_scores_gemma":[0.00011817722,0.00007053151,0.000104538005,0.00018542958,0.00021935017,0.000023677438,0.00010926691,0.0002765928,0.0014687808],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031975564,0.000072853436,0.75631225,0.00006577658,0.00015791746,0.00032815294,0.0027315174,0.0000038628277,0.00056981156,0.00040820803,0.23424174,0.004788132],"study_design_scores_gemma":[0.0017029492,0.0003393827,0.33715522,0.00006259048,0.00008971194,0.00005935777,0.0010691225,0.000027280797,0.0009334538,0.0006470919,0.65784496,0.00006888713],"about_ca_topic_score_codex":0.00010871494,"about_ca_topic_score_gemma":0.00011626165,"teacher_disagreement_score":0.4236032,"about_ca_system_score_codex":0.00011681861,"about_ca_system_score_gemma":0.00008594987,"threshold_uncertainty_score":0.9993087},"labels":[],"label_agreement":null},{"id":"W4385297096","doi":"10.1016/s1470-2045(23)00318-2","title":"Treatment-related mortality in children with cancer in low-income and middle-income countries: a systematic review and meta-analysis","year":2023,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stollery Children's Hospital","funders":"National Cancer Institute; American Lebanese Syrian Associated Charities","keywords":"Medicine; Meta-analysis; Cancer; MEDLINE; Mortality rate; Demography; Internal medicine","score_opus":0.1147548615962682,"score_gpt":0.42185105843413184,"score_spread":0.30709619683786366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385297096","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014438959,0.98927015,8.3400363e-7,0.0010533754,0.000016867649,0.007668911,0.0004100356,0.000047230427,0.00008867948],"genre_scores_gemma":[0.00049311103,0.99419063,0.000019038576,0.00027945495,0.000047680653,0.003935055,0.00009689972,0.00006423943,0.0008738987],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9948744,0.0018522415,0.0015128213,0.0007234401,0.00040729312,0.0006297681],"domain_scores_gemma":[0.9962619,0.0016452211,0.00076000136,0.0011021692,0.000078067,0.00015267529],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0023947065,0.0006187663,0.016928282,0.00055423647,0.00005291971,0.000026256906,0.00035399492,0.00041729127,0.00017336401],"category_scores_gemma":[0.00027262513,0.00027628485,0.00055570295,0.0023035712,0.00038092537,0.00004500927,0.00018010441,0.0006744382,0.00004118181],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004521732,0.00006335308,0.00601887,0.7722775,0.22073539,0.0004274615,0.00016556129,0.0000032073465,3.001444e-9,0.00004997374,0.000008090163,0.0002054002],"study_design_scores_gemma":[0.0030176917,0.00035009877,0.0040851124,0.110021465,0.88035643,0.0008460715,0.000016961922,0.00006532542,1.6519428e-8,0.000017137894,0.000928209,0.00029550484],"about_ca_topic_score_codex":0.0028139455,"about_ca_topic_score_gemma":0.005421161,"teacher_disagreement_score":0.662256,"about_ca_system_score_codex":0.0027331188,"about_ca_system_score_gemma":0.0016970984,"threshold_uncertainty_score":0.99996895},"labels":[],"label_agreement":null},{"id":"W4385443610","doi":"10.1016/s1470-2045(23)00346-7","title":"Establishing a Lancet Oncology Commission on the humanitarian crisis of cancer","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Health and Conflict Studies","field":"Health Professions","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Scopus; Political science; Commission; Biomedicine; Cancer; Medicine; Legislation; Humanitarian crisis; MEDLINE; Law; Internal medicine","score_opus":0.3632203274188722,"score_gpt":0.550406581883935,"score_spread":0.18718625446506276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385443610","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19673164,0.00039782518,0.000008966989,0.66340566,0.0019328699,0.0008519374,0.00008266724,0.00018801718,0.1364004],"genre_scores_gemma":[0.86042887,0.0033194472,0.000076699565,0.124671675,0.0054334793,0.001373787,0.000021316282,0.00004574318,0.0046290066],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959323,0.002090756,0.0005631172,0.00023984606,0.00022434941,0.00094962685],"domain_scores_gemma":[0.9922313,0.0064468123,0.0004083887,0.0006489294,0.00016518992,0.00009935137],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.004229117,0.00016196589,0.0008261121,0.000090302965,0.00170737,0.000006350503,0.0007090162,0.00028322247,0.00071734557],"category_scores_gemma":[0.0010137989,0.00008436356,0.00006542012,0.00047266087,0.00018963973,0.000041442312,0.00037756737,0.0014138921,0.0004636749],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005376828,0.00006861462,0.008977597,0.00022035786,0.000082420265,0.000014970625,0.056058645,0.00002085331,0.00016066946,0.033086564,0.8910101,0.0097615095],"study_design_scores_gemma":[0.0011345166,0.00037757438,0.036708277,0.000118996744,0.000033331726,8.015292e-7,0.01660371,0.00007193741,0.000018079376,0.0015286603,0.9433208,0.00008329277],"about_ca_topic_score_codex":0.004861307,"about_ca_topic_score_gemma":0.0056585725,"teacher_disagreement_score":0.6636972,"about_ca_system_score_codex":0.0003634702,"about_ca_system_score_gemma":0.0008200312,"threshold_uncertainty_score":0.99959224},"labels":[],"label_agreement":null},{"id":"W4385448612","doi":"10.1016/s1470-2045(23)00284-x","title":"Radiotherapy resources in Brazil (RT2030): a comprehensive analysis and projections for 2030","year":2023,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital; Queen's University","funders":"","keywords":"Radiation therapy; Medicine; Workload; Action plan; Scarcity; Population; Health care; Economic growth; Environmental health; Surgery; Management","score_opus":0.1447072455974648,"score_gpt":0.5253753254294113,"score_spread":0.3806680798319465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385448612","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000094055926,0.99088216,0.0007726497,0.004331288,0.00047394977,0.0026767482,0.0001006802,0.0001142456,0.00055423204],"genre_scores_gemma":[0.0000017191153,0.9880452,0.0043308605,0.0019275555,0.0020770333,0.0011843302,0.000100846664,0.00006741986,0.0022650352],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976592,0.00062875135,0.0006086037,0.0005222084,0.00010809936,0.00047313652],"domain_scores_gemma":[0.9951422,0.003783352,0.00040083713,0.00054717483,0.000057902507,0.00006850883],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077586435,0.00035192445,0.004201728,0.00067639793,0.00018980815,0.000012754626,0.00028505086,0.00064311246,0.00004625034],"category_scores_gemma":[0.000126801,0.00021056533,0.0005012849,0.0014019229,0.0005761628,0.000028902923,0.000051377552,0.00081070914,0.000009822252],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063898036,0.00016310082,0.00031981838,0.005658914,0.0057495646,0.00009297935,0.0009625002,0.000017138897,0.0000025233346,0.00048713048,0.008422139,0.97748524],"study_design_scores_gemma":[0.0023152714,0.00082121335,0.0004004265,0.00088932196,0.0036965986,0.0003153059,0.00011261901,0.00010059038,1.1735744e-7,0.0003529909,0.99079543,0.00020012433],"about_ca_topic_score_codex":0.000051698178,"about_ca_topic_score_gemma":0.0006286929,"teacher_disagreement_score":0.9823733,"about_ca_system_score_codex":0.0004815469,"about_ca_system_score_gemma":0.00040370523,"threshold_uncertainty_score":0.8586605},"labels":[],"label_agreement":null},{"id":"W4385471203","doi":"10.1016/s1470-2045(23)00322-4","title":"Radical cystectomy vs trimodality therapy for muscle-invasive bladder cancer: further extensive evaluation needed – Authors' reply","year":2023,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; University of Toronto; University Health Network; Mount Sinai Hospital","funders":"","keywords":"Cystectomy; Bladder cancer; Medicine; Urology; Oncology; General surgery; Cancer; Internal medicine","score_opus":0.12795852453085177,"score_gpt":0.4080312789043165,"score_spread":0.28007275437346474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385471203","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012225298,0.0018798131,0.000112908725,0.9721819,0.0037368012,0.007319127,0.00068190484,0.00032426725,0.0015379468],"genre_scores_gemma":[0.012301678,0.002853637,0.0002875951,0.9326754,0.037177023,0.007822983,0.001195705,0.00027428294,0.005411697],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9947624,0.0017331339,0.00066900667,0.0010070212,0.00084609754,0.0009823384],"domain_scores_gemma":[0.99504596,0.0023006557,0.00052994664,0.00126644,0.0007241694,0.00013283978],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0021872972,0.00062578375,0.0019804665,0.00017880545,0.00022383285,0.000036563066,0.0004930987,0.0014204768,0.00077167444],"category_scores_gemma":[0.00074282085,0.00040323095,0.0005324582,0.00034486657,0.0003645859,0.000052460262,0.00008068703,0.0019777955,0.00013550783],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039364574,0.00012780908,0.00012753313,0.00020316649,0.0018201651,0.00026731676,0.0024647443,0.0000075353614,0.0003677343,0.000018466902,0.9652558,0.025403265],"study_design_scores_gemma":[0.021119492,0.0028474224,0.0046190773,0.00021372442,0.0021678405,0.00011674216,0.00040198193,0.00015630503,0.00041928366,0.002167228,0.96533877,0.00043211202],"about_ca_topic_score_codex":0.00176974,"about_ca_topic_score_gemma":0.00026942592,"teacher_disagreement_score":0.039506536,"about_ca_system_score_codex":0.0013540634,"about_ca_system_score_gemma":0.003410342,"threshold_uncertainty_score":0.9998759},"labels":[],"label_agreement":null},{"id":"W4385471264","doi":"10.1016/s1470-2045(23)00287-5","title":"Metastatic seminoma masquerading as sarcoidosis","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; University of British Columbia","funders":"","keywords":"Sarcoidosis; Seminoma; Medicine; Dermatology; Internal medicine; Chemotherapy","score_opus":0.08985608337436563,"score_gpt":0.39786402364675794,"score_spread":0.3080079402723923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385471264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9680719,0.0010220017,0.000014833536,0.017260134,0.00017768372,0.00030535893,0.000012050769,0.0002141942,0.012921851],"genre_scores_gemma":[0.9951952,0.0001758262,0.0005067281,0.001883432,0.00025516868,0.00006587604,0.000035790315,0.000015194729,0.0018667469],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992918,0.00008632645,0.000106930296,0.00013869858,0.00011038585,0.00026585866],"domain_scores_gemma":[0.99932414,0.00024755776,0.00004697182,0.00027512014,0.0000199942,0.000086209024],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00019876259,0.0000846192,0.00030064717,0.000046500398,0.00007590761,0.0000075577,0.000084426116,0.000029613107,0.00018721979],"category_scores_gemma":[0.00016394883,0.000050578547,0.00007286721,0.0002224721,0.000056439152,0.000017391327,0.000046534355,0.00009595014,0.0014124566],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021995334,0.001860623,0.46113038,0.0007737391,0.0040805684,0.018863143,0.0037778392,0.00011822309,0.009910695,0.043709483,0.16034152,0.29323426],"study_design_scores_gemma":[0.008227423,0.0016773789,0.828676,0.00011108848,0.0016768049,0.0013729248,0.0006478686,0.001252069,0.0007540261,0.010219408,0.1451675,0.00021752607],"about_ca_topic_score_codex":0.00005691766,"about_ca_topic_score_gemma":0.0000079671845,"teacher_disagreement_score":0.3675456,"about_ca_system_score_codex":0.00008643892,"about_ca_system_score_gemma":0.00010541754,"threshold_uncertainty_score":0.99936503},"labels":[],"label_agreement":null},{"id":"W4386241120","doi":"10.1016/s1470-2045(23)00386-8","title":"Precision medicine for children with cancer","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Precision medicine; Cancer Medicine; Medicine; Cancer; Medical physics; Internal medicine; Pathology","score_opus":0.030050324620537326,"score_gpt":0.3426169021118465,"score_spread":0.31256657749130917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386241120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97432977,0.001378712,0.0011428796,0.019814335,0.0005046932,0.0005965763,0.00015165533,0.000032657917,0.002048712],"genre_scores_gemma":[0.97803646,0.007603824,0.00065839675,0.005110475,0.0059332796,0.00047670273,0.0004526014,0.00004054599,0.0016877027],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.999421,0.00002813746,0.00009313559,0.00018238023,0.000054501215,0.00022085967],"domain_scores_gemma":[0.9994941,0.000098851604,0.0000552768,0.00026846168,0.000050314316,0.000033028373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029702386,0.00007902319,0.00016985336,0.000019019104,0.00007771291,0.0000050071058,0.00020938244,0.00007411045,0.000023465336],"category_scores_gemma":[0.00010013441,0.00004556132,0.00002532976,0.000090249414,0.00010888647,7.347657e-7,0.000074516036,0.000052942865,0.000009573069],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012862451,0.000037298807,0.016138801,0.000018211034,0.00021485343,0.0000025858212,0.00024332832,0.001368042,0.05197519,0.001456752,0.8596726,0.06758609],"study_design_scores_gemma":[0.0029694196,0.0017313041,0.056115575,0.00001594214,0.000061519495,0.000017772723,0.00005314529,0.00010912266,0.0063426495,0.00092486077,0.93152297,0.00013572996],"about_ca_topic_score_codex":0.00008783071,"about_ca_topic_score_gemma":0.00059538794,"teacher_disagreement_score":0.07185035,"about_ca_system_score_codex":0.00002056504,"about_ca_system_score_gemma":0.00010314704,"threshold_uncertainty_score":0.18579367},"labels":[],"label_agreement":null},{"id":"W4386241167","doi":"10.1016/s1470-2045(23)00384-4","title":"Incorporating absolute effects to enrich interpretation of findings from meta-analyses","year":2023,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Impact; McMaster University","funders":"","keywords":"Nasopharyngeal carcinoma; Meta-analysis; Radiation therapy; Oncology; Medicine; Chemotherapy; Chemoradiotherapy; Internal medicine; Adjuvant chemotherapy; Carcinoma; Cancer","score_opus":0.2207518665985026,"score_gpt":0.4411331526312673,"score_spread":0.2203812860327647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386241167","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.025112709,0.0017482869,0.0003983408,0.96510637,0.001315661,0.00087116245,0.00013712763,0.00013547305,0.0051748557],"genre_scores_gemma":[0.08391937,0.00022653832,0.0029875615,0.9016162,0.0072472566,0.0005097949,0.00032945978,0.0000931591,0.0030706204],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998004,0.0004343152,0.0005143635,0.00037650575,0.00032000043,0.0003508098],"domain_scores_gemma":[0.9959464,0.0030080446,0.00034862186,0.0005210048,0.00013388947,0.000042059917],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007079368,0.0002785398,0.0029096603,0.00018305174,0.00006963302,0.000009920843,0.00029580304,0.00039891186,0.000075595315],"category_scores_gemma":[0.0008508216,0.00016061125,0.00036341243,0.00037531633,0.00011187521,0.000024001849,0.00019887387,0.0010883444,0.00018984388],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021664158,0.000016862963,0.00014088288,0.00039688539,0.0067232233,0.000250106,0.0016847525,0.000013882965,0.0023443638,0.000011479575,0.98592615,0.002274762],"study_design_scores_gemma":[0.00284736,0.0037447421,0.01156373,0.0008574053,0.03614911,0.00003309873,0.00023705825,0.00050678017,0.0029306198,0.0022589,0.93827975,0.0005914427],"about_ca_topic_score_codex":0.0006880695,"about_ca_topic_score_gemma":0.00029713626,"teacher_disagreement_score":0.063490145,"about_ca_system_score_codex":0.00018607556,"about_ca_system_score_gemma":0.00017105896,"threshold_uncertainty_score":0.6549537},"labels":[],"label_agreement":null},{"id":"W4386243714","doi":"10.1016/s1470-2045(23)00344-3","title":"Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Microbial Inactivation Methods","field":"Biochemistry, Genetics and Molecular Biology","cited_by":101,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"National Institutes of Health; Novocure","keywords":"Systemic therapy; Medicine; Lung cancer; Oncology; Cancer therapy; Cancer; Internal medicine; Breast cancer","score_opus":0.07348996886503766,"score_gpt":0.4277260181715512,"score_spread":0.35423604930651353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386243714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865973,0.0032995949,0.0009969627,0.00038412458,0.0004858615,0.007920386,0.00010146261,0.00007405942,0.00014024953],"genre_scores_gemma":[0.99004334,0.0020900986,0.0016424905,0.00092436804,0.00033011482,0.0046062414,0.00007379709,0.00012230757,0.00016726143],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.994902,0.0024084907,0.00073175377,0.0008400297,0.00038776893,0.00072991714],"domain_scores_gemma":[0.9975487,0.0007890541,0.0005594708,0.00083809183,0.00016864637,0.00009602827],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0031816766,0.00057944865,0.0013708594,0.00017172597,0.0002809363,0.00013840018,0.00077082246,0.00021333278,0.00008435462],"category_scores_gemma":[0.00009085572,0.0003322263,0.00013266543,0.0006167866,0.00009591434,0.000025547099,0.00010455755,0.00046518602,0.0000031878615],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.58421063,0.0014161346,0.0037191333,0.00009082531,0.00086935074,0.00032767083,0.0035756207,0.00088300154,0.3713642,0.0000013391929,0.0004908833,0.033051223],"study_design_scores_gemma":[0.6965098,0.055305738,0.00043610035,0.0008773561,0.00012802436,0.000049511687,0.0033882472,0.0010960171,0.23864971,0.0000071393943,0.0025977339,0.0009546677],"about_ca_topic_score_codex":0.00016588537,"about_ca_topic_score_gemma":0.0003712511,"teacher_disagreement_score":0.13271448,"about_ca_system_score_codex":0.0003753663,"about_ca_system_score_gemma":0.0010143607,"threshold_uncertainty_score":0.999913},"labels":[],"label_agreement":null},{"id":"W4386243741","doi":"10.1016/s1470-2045(23)00268-1","title":"Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Genentech; F. Hoffmann-La Roche; Roche; Amgen","keywords":"Anastrozole; Medicine; Palbociclib; Breast cancer; Internal medicine; Oncology; Clinical endpoint; Cancer; Gynecology; Regimen; Phases of clinical research; Tamoxifen; Clinical trial; Metastatic breast cancer","score_opus":0.07426775205635529,"score_gpt":0.41728094600258087,"score_spread":0.3430131939462256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386243741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9683664,0.00046320446,0.00004193318,0.019490508,0.00060671597,0.0085103195,0.001736571,0.00030021626,0.00048416088],"genre_scores_gemma":[0.98655695,0.00099936,0.00046197322,0.0027637496,0.0016200216,0.005803074,0.000080385915,0.00019026933,0.0015242427],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99430805,0.0015478198,0.0010491076,0.0010776123,0.00055465405,0.0014627815],"domain_scores_gemma":[0.9969176,0.0007291394,0.00053082046,0.0010116998,0.00039308143,0.0004176573],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016871955,0.0007268942,0.0030235471,0.00025147173,0.00036554167,0.00012158496,0.0012008125,0.00024950158,0.0018955152],"category_scores_gemma":[0.00008326144,0.00045212975,0.00012304488,0.0013147942,0.00058739417,0.0005351139,0.00032860594,0.00095981744,0.00010631908],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.753777,0.00586485,0.033285487,0.00007570603,0.00213706,0.0012430885,0.010113242,0.0010976709,0.0133078825,0.00007240919,0.0015347411,0.17749085],"study_design_scores_gemma":[0.7934967,0.0070993756,0.1858438,0.00048994715,0.0006193965,0.00068320846,0.0061090803,0.0014693526,0.0004009867,0.00008582977,0.002944551,0.0007577357],"about_ca_topic_score_codex":0.013935042,"about_ca_topic_score_gemma":0.01143871,"teacher_disagreement_score":0.1767331,"about_ca_system_score_codex":0.0012993492,"about_ca_system_score_gemma":0.0017535195,"threshold_uncertainty_score":0.99979305},"labels":[],"label_agreement":null},{"id":"W4386263948","doi":"10.1016/s1470-2045(23)00320-0","title":"Financial hardship in families of children or adolescents with cancer: a systematic literature review","year":2023,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McMaster University","funders":"National Cancer Institute; World Health Organization","keywords":"Psychosocial; Psychological intervention; Childhood cancer; Finance; Public economics; Psychology; Economics; Cancer; Medicine; Psychiatry","score_opus":0.1008015807198064,"score_gpt":0.4195214927809506,"score_spread":0.3187199120611442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386263948","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009582938,0.99070543,0.0000010017225,0.0018109385,0.00038201138,0.006451811,0.00032776562,0.00008625433,0.00013896672],"genre_scores_gemma":[0.000028237102,0.9933282,0.00005166874,0.0034249388,0.0012945783,0.0013239303,0.00013620619,0.00009319182,0.00031902525],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99475485,0.0019136093,0.0017031956,0.00053483347,0.00055180024,0.0005417263],"domain_scores_gemma":[0.9965838,0.0005633519,0.001435616,0.0011873137,0.00014495726,0.000084963816],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002665626,0.00057258253,0.009821558,0.00026134143,0.000045516477,0.000013851081,0.0007664591,0.00048778075,0.000025465793],"category_scores_gemma":[0.0013110297,0.00027867028,0.00043416943,0.0017299381,0.00020257993,0.000039431743,0.00016577115,0.0014252433,0.00004647641],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023096165,0.00012339151,0.00036270526,0.96321577,0.00035094403,0.00013423953,0.0006629685,2.3963113e-7,1.7011407e-8,0.00004366441,0.006281212,0.028593883],"study_design_scores_gemma":[0.0014621606,0.00043429065,0.0011013282,0.8752008,0.0029388885,0.00052634475,0.000029920084,3.1066713e-7,7.370165e-8,0.000009232783,0.11804506,0.0002515685],"about_ca_topic_score_codex":0.0002933754,"about_ca_topic_score_gemma":0.0035504524,"teacher_disagreement_score":0.11176385,"about_ca_system_score_codex":0.00045048547,"about_ca_system_score_gemma":0.0027084798,"threshold_uncertainty_score":0.99996656},"labels":[],"label_agreement":null},{"id":"W4386631299","doi":"10.1016/s1470-2045(23)00382-0","title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":288,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Merck Sharp and Dohme; Genentech; EMD Serono; Bavarian Nordic; Astellas Pharma; Sanofi; Exelixis; Advanced Accelerator Applications; Endocyte; Janssen Pharmaceuticals; Invitae; Gilead Sciences; Merck; Amgen; Pfizer; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Ipsen; BeiGene; Constellation Pharmaceuticals","keywords":"Abiraterone; Prostate cancer; Medicine; Placebo; Olaparib; Urology; Abiraterone acetate; Internal medicine; Oncology; Double blind; Androgen deprivation therapy; Cancer; Androgen receptor; Poly ADP ribose polymerase","score_opus":0.313893449351758,"score_gpt":0.459480059444977,"score_spread":0.145586610093219,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386631299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.980681,0.0006786395,0.0000064121004,0.0071531795,0.0011066269,0.0072148996,0.00042918697,0.00008702447,0.0026430152],"genre_scores_gemma":[0.9869397,0.0016967594,0.00010827395,0.000086427586,0.0008448023,0.0024830948,0.0005420058,0.000053453106,0.0072454773],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99610233,0.00076248473,0.001046533,0.000558023,0.00063142244,0.00089921954],"domain_scores_gemma":[0.9976671,0.0009552161,0.0004112541,0.00058347057,0.00021359889,0.00016940877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026968054,0.00034085134,0.0015055079,0.0002748669,0.00013284177,0.000046749326,0.0003219721,0.00015565664,0.00016605179],"category_scores_gemma":[0.00019966361,0.00021578876,0.00014122161,0.00066765485,0.00037149902,0.00012992231,0.00012532421,0.0005805042,0.000058190548],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9770636,0.0006104671,0.000024514879,0.00023225919,0.00055655406,0.000659377,0.0029939045,0.0010493773,0.010952597,0.00013625328,0.0037960839,0.001925003],"study_design_scores_gemma":[0.98073053,0.0071332688,0.00046341115,0.00013153243,0.00031329016,0.000011007838,0.00051064155,0.0012036037,0.004080847,0.00008565359,0.005126976,0.00020922637],"about_ca_topic_score_codex":0.0019168123,"about_ca_topic_score_gemma":0.0041475995,"teacher_disagreement_score":0.007066752,"about_ca_system_score_codex":0.0009975213,"about_ca_system_score_gemma":0.0023218184,"threshold_uncertainty_score":0.879961},"labels":[],"label_agreement":null},{"id":"W4387246665","doi":"10.1016/s1470-2045(23)00464-3","title":"Common Sense Oncology: including everyone – Authors' reply","year":2023,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Internal medicine; Oncology; Medicine; Geriatric oncology; Cancer","score_opus":0.1723274002211334,"score_gpt":0.4288289530329309,"score_spread":0.2565015528117975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387246665","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0068115196,0.0008492997,0.000030596,0.9554718,0.006621402,0.0012750247,0.0001728375,0.0010332592,0.027734272],"genre_scores_gemma":[0.0015863756,0.0006970498,0.0007536834,0.920317,0.053345885,0.00020164206,0.0007488098,0.00026133299,0.022088202],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99168396,0.0033169088,0.001369703,0.0011065493,0.0010030444,0.0015198122],"domain_scores_gemma":[0.9905268,0.0053888024,0.001107403,0.0025504285,0.00020343908,0.00022312159],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.006047542,0.0007290237,0.0038309887,0.0003443353,0.00038529557,0.00004324331,0.000875985,0.0024911454,0.0003089918],"category_scores_gemma":[0.0014718222,0.0005583641,0.0004928313,0.0006542083,0.0007198976,0.00006715431,0.00091842195,0.008872519,0.0017105023],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071974454,0.00011685495,0.00044874917,0.00067693566,0.00068464427,0.0074346596,0.0032389567,0.0000035884939,0.00008576248,0.00006090973,0.98409384,0.0024353508],"study_design_scores_gemma":[0.0032620884,0.0015317868,0.0024031005,0.00053192215,0.0007337836,0.002029364,0.00038161618,0.000038610247,0.000042569176,0.0013386639,0.98715943,0.0005470904],"about_ca_topic_score_codex":0.0018649104,"about_ca_topic_score_gemma":0.0012484615,"teacher_disagreement_score":0.046724483,"about_ca_system_score_codex":0.0019384515,"about_ca_system_score_gemma":0.0014990014,"threshold_uncertainty_score":0.9996868},"labels":[],"label_agreement":null},{"id":"W4387246862","doi":"10.1016/s1470-2045(23)00387-x","title":"Dysphagia-optimised intensity-modulated radiotherapy versus standard radiotherapy in patients with pharyngeal cancer","year":2023,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Dysphagia; Radiation therapy; Medicine; Swallowing; Head and neck cancer; Radiology; Pharynx; Intensity (physics); Surgery; Optics","score_opus":0.05071362834495731,"score_gpt":0.35270245032102643,"score_spread":0.30198882197606913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387246862","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1440802,0.002906754,0.00001903084,0.8453256,0.003821782,0.0019298806,0.00027196697,0.00030204246,0.0013427628],"genre_scores_gemma":[0.0071355863,0.016590154,0.0010366441,0.95533055,0.015011418,0.0006259909,0.0006519213,0.00039337276,0.0032243833],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969741,0.00031305384,0.0004712157,0.00065887906,0.0005693012,0.0010134318],"domain_scores_gemma":[0.99820036,0.0004465266,0.00027416577,0.00071775215,0.00027354326,0.00008766886],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00044650078,0.000546726,0.0027524221,0.00023184346,0.00012851099,0.000019953764,0.00038017746,0.0007416163,0.00036634176],"category_scores_gemma":[0.000047184894,0.00033695955,0.00013864027,0.0005287363,0.00040067005,0.000045992256,0.000059900154,0.0025822315,0.00002051685],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040042486,0.00009924445,0.016944222,0.00018408008,0.0018767688,0.0007665489,0.001077763,0.000047986905,0.000025640562,0.0000012429356,0.9285056,0.010428391],"study_design_scores_gemma":[0.047788408,0.007846936,0.04981275,0.0003618143,0.0002774054,0.000011294154,0.000030634084,0.00010021336,0.000020212949,0.000007963531,0.8933371,0.00040532008],"about_ca_topic_score_codex":0.0003948587,"about_ca_topic_score_gemma":0.00065598974,"teacher_disagreement_score":0.13694462,"about_ca_system_score_codex":0.0022637073,"about_ca_system_score_gemma":0.0007464367,"threshold_uncertainty_score":0.99990827},"labels":[],"label_agreement":null},{"id":"W4387610595","doi":"10.1016/s1470-2045(23)00473-4","title":"Immunotherapy in renal cell carcinoma","year":2023,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Nivolumab; Ipilimumab; Medicine; Renal cell carcinoma; Oncology; Internal medicine; Immunotherapy; Sunitinib; Kidney cancer; Cancer","score_opus":0.06913184320899503,"score_gpt":0.32171012868270427,"score_spread":0.25257828547370925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387610595","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1336491,0.0018258385,0.0000024474978,0.81552744,0.00080187956,0.00092617515,0.00003185524,0.00012075782,0.04711453],"genre_scores_gemma":[0.06322004,0.000848697,0.00032130058,0.87989515,0.015364982,0.00042486523,0.00055080804,0.00020922188,0.039164912],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99741095,0.0005102114,0.00044895153,0.00048229258,0.0003474954,0.0008001009],"domain_scores_gemma":[0.99797064,0.0005892063,0.00022000622,0.0011231477,0.00004998371,0.000047023776],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00059380895,0.00038341322,0.0013823741,0.00024260746,0.000053367956,0.000014102513,0.00045579328,0.0009326448,0.00030116437],"category_scores_gemma":[0.000024740051,0.00024066995,0.00023838595,0.00030022254,0.00017518747,0.000016791348,0.000106907275,0.0028863756,0.0010363264],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051452307,0.000074981916,0.0026360801,0.00018713251,0.00008560725,0.01351461,0.00038552302,0.000002932033,0.0013910059,0.000008566483,0.97921085,0.001988213],"study_design_scores_gemma":[0.004476118,0.0013095409,0.036527514,0.000065462526,0.00013216095,0.00040071373,0.000030815798,0.000010314997,0.00096464314,0.00023158592,0.9556366,0.0002145204],"about_ca_topic_score_codex":0.0005119968,"about_ca_topic_score_gemma":0.00010380907,"teacher_disagreement_score":0.07042905,"about_ca_system_score_codex":0.000978311,"about_ca_system_score_gemma":0.00047437457,"threshold_uncertainty_score":0.9997415},"labels":[],"label_agreement":null},{"id":"W4388226965","doi":"10.1016/s1470-2045(23)00521-1","title":"Investing in gender equality and equitable access improves outcomes","year":2023,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Commission; Medicine; Cancer; Workforce; Global health; Scopus; Health care; Family medicine; MEDLINE; Political science; Nursing; Public health; Internal medicine; Law","score_opus":0.22837828759137463,"score_gpt":0.5009419345273847,"score_spread":0.27256364693601004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388226965","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01255683,0.0021145276,0.000121394354,0.96357507,0.0021204927,0.00074143003,0.000025849626,0.00018716427,0.01855723],"genre_scores_gemma":[0.0017669837,0.0019636925,0.00139196,0.97650605,0.009191404,0.00016694595,0.000062235355,0.000074090756,0.008876606],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975011,0.0005505168,0.0004534642,0.00046939374,0.00018430133,0.0008412337],"domain_scores_gemma":[0.99627,0.002781681,0.00028378837,0.0005733815,0.000041414372,0.000049745722],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0017746703,0.00029719612,0.0014966523,0.0001513002,0.00013965234,0.0000235223,0.00048793203,0.0011091878,0.00006471446],"category_scores_gemma":[0.0005898789,0.00018092236,0.000079335485,0.00023414446,0.0006246048,0.00010185867,0.00037297426,0.0029131153,0.000028055014],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022891237,0.00005474286,0.07542311,0.00072359934,0.00029956788,0.0011774608,0.0008130997,0.0000074047484,0.00016338969,0.00037210534,0.9053001,0.015436548],"study_design_scores_gemma":[0.0026957258,0.00029709475,0.0585813,0.00008844059,0.000115289375,0.00027779178,0.00008567851,0.00006871938,0.000009092667,0.01056737,0.9269748,0.00023872132],"about_ca_topic_score_codex":0.00019317136,"about_ca_topic_score_gemma":0.00023547711,"teacher_disagreement_score":0.021674711,"about_ca_system_score_codex":0.00035551237,"about_ca_system_score_gemma":0.0003522302,"threshold_uncertainty_score":0.9993872},"labels":[],"label_agreement":null},{"id":"W4388227008","doi":"10.1016/s1470-2045(23)00484-9","title":"Cancer surgery: orchestrating cancer control by strengthening health systems","year":2023,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Commission; Global health; Cancer; Medicine; Scopus; Cancer surgery; Health care; Family medicine; Political science; MEDLINE; Nursing; Law; Public health; Internal medicine","score_opus":0.08129784435503122,"score_gpt":0.441601480565986,"score_spread":0.3603036362109548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388227008","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00064298685,0.039380465,0.00036289217,0.9476681,0.008711632,0.0011844602,0.0007981372,0.00036648312,0.0008848496],"genre_scores_gemma":[0.0015942664,0.03275932,0.00014660698,0.89228654,0.06008325,0.0014778107,0.0004371713,0.00018979517,0.01102525],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.995489,0.0013472526,0.000851846,0.00063057867,0.0003841916,0.0012971349],"domain_scores_gemma":[0.9926396,0.005368942,0.0010871501,0.00067204755,0.000113095,0.0001191439],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0019373416,0.0004908308,0.0029544553,0.00013047582,0.00037161427,0.000025595662,0.0004336422,0.00132104,0.000225523],"category_scores_gemma":[0.00020998188,0.0003194375,0.00022796601,0.00030341515,0.00048998033,0.00004688891,0.000040937175,0.0041505164,0.000044079923],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025685458,0.0000324981,0.0036877214,0.00069492764,0.0008176064,0.0004234611,0.0003489781,0.00021801225,0.000044445256,0.000032465225,0.9719636,0.021479445],"study_design_scores_gemma":[0.0020767138,0.0003407425,0.00020114862,0.00072905567,0.00021796914,0.0002064226,0.00011602159,0.00045039295,0.000003573339,0.00004645117,0.99531394,0.00029756737],"about_ca_topic_score_codex":0.001996681,"about_ca_topic_score_gemma":0.0003678504,"teacher_disagreement_score":0.055381563,"about_ca_system_score_codex":0.0017715872,"about_ca_system_score_gemma":0.0029019094,"threshold_uncertainty_score":0.99997544},"labels":[],"label_agreement":null},{"id":"W4388657015","doi":"10.1016/s1470-2045(23)00510-7","title":"Development and validation of age-specific risk prediction models for primary ovarian insufficiency in long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study and St Jude Lifetime Cohort","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Reproductive Biology and Fertility","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Alberta","funders":"National Cancer Institute; Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Canadian Cancer Society; Canadian Centre for Applied Research in Cancer Control","keywords":"Childhood cancer; Medicine; Cancer; Ovarian cancer; Term (time); Pediatrics; Oncology; Internal medicine","score_opus":0.04398770063291266,"score_gpt":0.3167914911038883,"score_spread":0.2728037904709757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388657015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99459267,0.0013883684,0.0001727374,0.0007370607,0.0003124052,0.0024023857,0.00026954425,0.00003219556,0.00009261701],"genre_scores_gemma":[0.9963586,0.0024368013,0.00018866922,0.000052378608,0.00027511903,0.00044316554,0.00021185442,0.000012628472,0.000020827458],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981336,0.0004082513,0.0005954493,0.00048058474,0.00016708729,0.00021503765],"domain_scores_gemma":[0.9986211,0.00038987384,0.00038505677,0.0004559731,0.00011260233,0.000035400204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031946418,0.00014242194,0.00066505047,0.00006897442,0.00012512288,0.000004728214,0.00013567474,0.00012665072,0.000008297679],"category_scores_gemma":[0.00018696055,0.000087470595,0.000033020453,0.00026568823,0.0002618688,0.00005209732,0.000107686894,0.00024388076,2.5541797e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016653059,0.00088692736,0.9740602,0.0000432554,0.00029905376,0.000010959437,0.010427603,0.00010513668,0.00036255232,0.000009571061,0.00006777834,0.012061658],"study_design_scores_gemma":[0.0022751358,0.00045270816,0.99555707,0.000057324774,0.00016451848,0.000012296054,0.00044058586,0.00008799896,0.00040619212,0.00027797924,0.00019408119,0.000074104566],"about_ca_topic_score_codex":0.0022783123,"about_ca_topic_score_gemma":0.0036142452,"teacher_disagreement_score":0.021496875,"about_ca_system_score_codex":0.00011679403,"about_ca_system_score_gemma":0.00033701886,"threshold_uncertainty_score":0.35669473},"labels":[],"label_agreement":null},{"id":"W4389606368","doi":"10.1016/s1470-2045(23)00540-5","title":"Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"National Health and Medical Research Council; F. Hoffmann-La Roche; Roche","keywords":"Metastatic Urothelial Carcinoma; Atezolizumab; Medicine; Chemotherapy; Placebo; Oncology; Internal medicine; Urothelial carcinoma; Carcinoma; Urology; Cancer; Bladder cancer; Immunotherapy; Pathology; Pembrolizumab","score_opus":0.0867280660593854,"score_gpt":0.389108017368519,"score_spread":0.30237995130913364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389606368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838437,0.00026027366,0.00018330524,0.004830424,0.00061308185,0.0074742516,0.00057536876,0.00024933455,0.0019702914],"genre_scores_gemma":[0.9929017,0.00068047596,0.00027419717,0.0013875839,0.0006840527,0.0013390157,0.00047338157,0.0000958177,0.0021638167],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9949269,0.0012822447,0.0011717905,0.0009813645,0.0006458019,0.0009918943],"domain_scores_gemma":[0.9952033,0.0028830296,0.0004496861,0.0010825126,0.00015457995,0.00022688601],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014928804,0.0006465925,0.003713324,0.00044122984,0.00017379528,0.000048416885,0.0004996244,0.00020223322,0.0007194129],"category_scores_gemma":[0.00042711504,0.00039892056,0.000496647,0.0015978478,0.00020907176,0.000094641335,0.00007554353,0.0005377504,0.000112976304],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96799755,0.0017649994,0.0011977593,0.000020781725,0.007942615,0.0018496494,0.006042912,0.0021943124,0.00039604807,0.000013603222,0.00076903054,0.009810716],"study_design_scores_gemma":[0.95526874,0.009568133,0.012250451,0.00003456294,0.0038245902,0.000018730025,0.0017722398,0.0145480875,0.00023404561,0.00007476622,0.0020191462,0.00038649977],"about_ca_topic_score_codex":0.0050176675,"about_ca_topic_score_gemma":0.0064219893,"teacher_disagreement_score":0.012728826,"about_ca_system_score_codex":0.001199103,"about_ca_system_score_gemma":0.0015821931,"threshold_uncertainty_score":0.9998463},"labels":[],"label_agreement":null},{"id":"W4389608093","doi":"10.1016/s1470-2045(23)00539-9","title":"Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"National Health and Medical Research Council; F. Hoffmann-La Roche; Roche","keywords":"Atezolizumab; Metastatic Urothelial Carcinoma; Medicine; Placebo; Internal medicine; Oncology; Chemotherapy; Cancer; Bladder cancer; Pembrolizumab; Immunotherapy; Urothelial carcinoma; Pathology","score_opus":0.09030359634918199,"score_gpt":0.3988979223683898,"score_spread":0.3085943260192078,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389608093","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896032,0.00036538494,0.00020346134,0.0030720152,0.00046880063,0.0048414255,0.00019830723,0.00018039308,0.0010669978],"genre_scores_gemma":[0.9946878,0.00069908483,0.00022083326,0.0012622835,0.000495458,0.0012974301,0.00018402084,0.00006883615,0.0010842662],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99633527,0.0010568867,0.00076466455,0.0006563675,0.00044867178,0.0007381411],"domain_scores_gemma":[0.99706024,0.0016464238,0.00026364837,0.00076557044,0.00010651271,0.0001575981],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008615688,0.00046623312,0.00285071,0.00037648904,0.00012629692,0.000033848683,0.00035843335,0.00013123835,0.0012151148],"category_scores_gemma":[0.00015611213,0.00027526455,0.00042195758,0.0013823413,0.00014257163,0.000074126896,0.000046492747,0.00037326096,0.00010149904],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9473216,0.002941849,0.013359741,0.000014772418,0.009385383,0.001624234,0.0033288344,0.0005975327,0.0008201215,0.000021414071,0.0003609393,0.020223605],"study_design_scores_gemma":[0.93759865,0.010989079,0.038524766,0.000018426397,0.004002979,0.0000113019205,0.0011864805,0.0051267794,0.00022136646,0.00016148425,0.0018668864,0.00029178054],"about_ca_topic_score_codex":0.00358926,"about_ca_topic_score_gemma":0.0046790717,"teacher_disagreement_score":0.025165023,"about_ca_system_score_codex":0.00046211298,"about_ca_system_score_gemma":0.0006945936,"threshold_uncertainty_score":0.99996996},"labels":[],"label_agreement":null},{"id":"W4390490764","doi":"10.1016/s1470-2045(23)00513-2","title":"Stereotactic body radiotherapy for primary renal cell carcinoma: a systematic review and practice guideline from the International Society of Stereotactic Radiosurgery (ISRS)","year":2024,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Cancer Council Tasmania; Cancer Council Victoria","keywords":"Medicine; Radiosurgery; Guideline; Renal cell carcinoma; Stereotactic biopsy; Radiology; Radiation therapy; Biopsy; Oncology; Pathology","score_opus":0.08282780186880907,"score_gpt":0.38686672395237626,"score_spread":0.3040389220835672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390490764","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003706685,0.9719766,0.000062202496,0.018338379,0.0006479232,0.0074585252,0.0003364941,0.000039929237,0.0011029292],"genre_scores_gemma":[0.000041172992,0.97951764,0.0031853383,0.012615129,0.0016421254,0.0013381899,0.00051316194,0.000111192116,0.0010360348],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99498653,0.0014430662,0.0020177623,0.00065463374,0.00049011153,0.0004079197],"domain_scores_gemma":[0.9855216,0.010684166,0.0020475325,0.0013344906,0.00030515192,0.00010703442],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0043265,0.0006415885,0.005898512,0.000077911165,0.000088676206,0.000057163637,0.00068405265,0.00031970008,0.000053503783],"category_scores_gemma":[0.000745184,0.00029770823,0.0012651489,0.00024729173,0.00021098887,0.00009387101,0.00021944159,0.00086198136,0.000020768912],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036161294,0.00024476697,0.000009477623,0.78284514,0.0058853435,0.00014620354,0.00034854142,6.793385e-8,0.00003071322,0.000031487285,0.20255266,0.007543957],"study_design_scores_gemma":[0.0014751048,0.0005631119,0.000012661549,0.078391075,0.06363953,0.002975835,0.000071930175,0.00002485371,0.0000026929229,0.000019969984,0.8525925,0.00023070091],"about_ca_topic_score_codex":0.00007687556,"about_ca_topic_score_gemma":0.0000034387936,"teacher_disagreement_score":0.7044541,"about_ca_system_score_codex":0.0014119557,"about_ca_system_score_gemma":0.0014671765,"threshold_uncertainty_score":0.9999475},"labels":[],"label_agreement":null},{"id":"W4391329053","doi":"10.1016/s1470-2045(24)00027-5","title":"Primary ovarian insufficiency prediction in adult survivors of childhood cancer: model concerns – Authors' reply","year":2024,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute; Natural Sciences and Engineering Research Council of Canada; National Institutes of Health","keywords":"Childhood cancer; Ovarian cancer; Medicine; Cancer; Primary (astronomy); Oncology; Internal medicine; Physics","score_opus":0.04994628448906693,"score_gpt":0.3439204968099209,"score_spread":0.29397421232085397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391329053","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.032478645,0.0024922735,0.00019077877,0.93658537,0.0040448215,0.0018136979,0.001577346,0.00035439842,0.020462677],"genre_scores_gemma":[0.035044003,0.0024851814,0.0008567318,0.9360347,0.020093337,0.0005091451,0.0009351014,0.00023298644,0.0038088588],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9940718,0.0010045177,0.001698096,0.0011436556,0.0010825356,0.0009994203],"domain_scores_gemma":[0.99641454,0.0006491158,0.00085764576,0.0016536004,0.00029266183,0.00013246047],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0025663,0.00064143114,0.0026928722,0.00046053415,0.0000946344,0.000027661028,0.00091494236,0.0015287923,0.00018067038],"category_scores_gemma":[0.00044287887,0.0004986885,0.00038028153,0.0008098575,0.0005730983,0.000096598276,0.00033491,0.005706385,0.000048103168],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000501126,0.00053315295,0.0032741134,0.0025506488,0.00044330826,0.00029349633,0.010869696,0.00041635765,0.00008458667,0.00044938756,0.97875404,0.0018300586],"study_design_scores_gemma":[0.0060779587,0.0020695229,0.018294882,0.00339193,0.0011773887,0.00029029892,0.0004908592,0.006172057,0.000077909746,0.0024968104,0.9586432,0.00081721356],"about_ca_topic_score_codex":0.0093582785,"about_ca_topic_score_gemma":0.0038164952,"teacher_disagreement_score":0.0201109,"about_ca_system_score_codex":0.0013885793,"about_ca_system_score_gemma":0.0035824603,"threshold_uncertainty_score":0.9997674},"labels":[],"label_agreement":null},{"id":"W4391329144","doi":"10.1016/s1470-2045(24)00010-x","title":"World Oncology Forum amplifies its appeal in global fight against cancer","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Global Public Health Policies and Epidemiology","field":"Business, Management and Accounting","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"World Health Organization","keywords":"Appeal; Political science; Psychological intervention; Medicine; Public relations; Law; Nursing","score_opus":0.08117751442663694,"score_gpt":0.39772835630743103,"score_spread":0.3165508418807941,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391329144","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.036654025,0.0029254179,0.00003570679,0.60896945,0.0039279284,0.0003684087,0.00003655898,0.0002411639,0.34684134],"genre_scores_gemma":[0.5531138,0.0010857352,0.00006361329,0.43410876,0.010010365,0.00027412816,0.000046894827,0.000029184786,0.0012675354],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99749464,0.00016631496,0.0005477178,0.00039383545,0.00012835074,0.0012691295],"domain_scores_gemma":[0.9989961,0.00044052416,0.00017160429,0.00028195267,0.00007421717,0.000035633362],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016736967,0.00023060662,0.0007460197,0.00019433272,0.00017762634,0.0001097324,0.00061454944,0.00023781523,0.0003809562],"category_scores_gemma":[0.00028212345,0.00015630048,0.000095425516,0.0011150046,0.0001679319,0.00034027413,0.0004190271,0.0005399684,0.000954535],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008517152,0.000035437057,0.0035315168,0.00016551492,0.000027632657,0.0000523252,0.00004281969,0.0005004619,0.0000074406803,0.2734029,0.69762844,0.024520304],"study_design_scores_gemma":[0.0005587958,0.00003811071,0.004941435,0.00006283522,0.00002077872,0.0000096218655,0.0002268086,0.008584232,4.9564335e-7,0.0124807255,0.9729131,0.00016309253],"about_ca_topic_score_codex":0.007110125,"about_ca_topic_score_gemma":0.05026331,"teacher_disagreement_score":0.51645976,"about_ca_system_score_codex":0.0007398415,"about_ca_system_score_gemma":0.0003315791,"threshold_uncertainty_score":0.99982333},"labels":[],"label_agreement":null},{"id":"W4391329149","doi":"10.1016/s1470-2045(24)00002-0","title":"Accelerating progress on EU cancer control","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Global Health Research; University of Toronto","funders":"","keywords":"Cancer; Colorectal cancer; Prostate cancer; Lung cancer; Medicine; Breast cancer; Survivorship curve; Obesity; Cancer incidence; Incidence (geometry); Cause of death; Demography; Environmental health; Gerontology; Oncology; Internal medicine","score_opus":0.21879301528132017,"score_gpt":0.4667224805174229,"score_spread":0.2479294652361027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391329149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5684592,0.015852163,0.00016243983,0.28529412,0.002044074,0.0009247291,0.000035296685,0.0004673865,0.12676054],"genre_scores_gemma":[0.9745318,0.00018503373,0.00020322757,0.021370616,0.0029508974,0.0001517222,0.0000031222055,0.000013466696,0.00059007795],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990892,0.00008338463,0.00014567579,0.00019293053,0.00017437586,0.00031448065],"domain_scores_gemma":[0.99947107,0.0001890492,0.000035444657,0.00020327391,0.00004555775,0.000055593096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048245213,0.00009791352,0.00032461746,0.00003058205,0.00008443863,0.00003744747,0.00013926857,0.000078089186,0.0003049092],"category_scores_gemma":[0.000051177576,0.000055660257,0.000057579662,0.00014646947,0.00010259275,0.00004280845,0.000025060499,0.0003853857,0.00012814353],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025493223,0.00010959248,0.035401687,0.000323167,0.0005029107,0.0013903325,0.001864741,0.0002831722,0.0028672325,0.043287512,0.23753779,0.67388254],"study_design_scores_gemma":[0.0024778792,0.0014204727,0.017555913,0.0006337239,0.00020897324,0.00024993974,0.00023237366,0.005348675,0.0005269982,0.00054974534,0.97064364,0.00015167137],"about_ca_topic_score_codex":0.00009175931,"about_ca_topic_score_gemma":0.00009169045,"teacher_disagreement_score":0.73310584,"about_ca_system_score_codex":0.00020957126,"about_ca_system_score_gemma":0.00025081946,"threshold_uncertainty_score":0.3338542},"labels":[],"label_agreement":null},{"id":"W4391329238","doi":"10.1016/s1470-2045(23)00516-8","title":"Treatment of metastatic pancreatic cancer: 25 years of innovation with little progress for patients","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Pancreatic cancer; Medicine; Cancer; Colorectal cancer; Lung cancer; Cause of death; Oncology; Clinical trial; Internal medicine; Overall survival; Disease","score_opus":0.08304822614337355,"score_gpt":0.42812021737297457,"score_spread":0.345071991229601,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391329238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99264294,0.0017158223,0.00016476982,0.002621501,0.00009790065,0.0013665276,0.00008693988,0.000021999045,0.0012815834],"genre_scores_gemma":[0.9930278,0.00070695265,0.0044797626,0.0000670269,0.00015457584,0.00069576834,0.00006357328,0.000016457658,0.0007881057],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99907047,0.000091894086,0.00032151438,0.00014323996,0.00015985397,0.00021303492],"domain_scores_gemma":[0.99869454,0.0006529026,0.00013550179,0.00021472845,0.00027468376,0.000027637123],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000314333,0.00008811792,0.0007263432,0.00011781577,0.000023558538,0.0000036001306,0.00007656595,0.00005277087,0.00006018974],"category_scores_gemma":[0.000110676614,0.000048487713,0.00004127905,0.00043477,0.00030081507,0.000023312075,0.000013527562,0.00006800906,0.000004802977],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060724807,0.0021425716,0.6237665,0.0023631242,0.0026687717,0.000056141256,0.00409751,0.000006460183,0.0007747411,0.014706347,0.0033876542,0.3399577],"study_design_scores_gemma":[0.027521973,0.06356111,0.7015322,0.0010377531,0.0051394026,0.00009956959,0.0006998283,0.0041639837,0.0025468413,0.0027482565,0.19067022,0.00027886766],"about_ca_topic_score_codex":0.00010714926,"about_ca_topic_score_gemma":0.00003057003,"teacher_disagreement_score":0.33967885,"about_ca_system_score_codex":0.00019538902,"about_ca_system_score_gemma":0.0006844886,"threshold_uncertainty_score":0.19772716},"labels":[],"label_agreement":null},{"id":"W4391329318","doi":"10.1016/s1470-2045(23)00568-5","title":"Quality indicators for evaluating cancer care in low-income and middle-income country settings: a multinational modified Delphi study","year":2024,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Delphi Technique in Research","field":"Social Sciences","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Medical Research Council; National Institute for Health and Care Research; World Health Organization","keywords":"Delphi method; Medicine; Quality (philosophy); Delphi; Inclusion (mineral); Health care; Business; Family medicine; Medical physics; Psychology; Computer science; Political science","score_opus":0.37051550147705,"score_gpt":0.6088117163114214,"score_spread":0.2382962148343714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391329318","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00982954,0.9773879,0.00001135644,0.0014163337,0.0006222824,0.0080796145,0.0005815764,0.00018191409,0.0018895026],"genre_scores_gemma":[0.026582044,0.9616739,0.00069173495,0.00014936896,0.001298473,0.009246535,0.00006355074,0.00007532644,0.0002190758],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9921623,0.0043218597,0.0010209823,0.00071830215,0.0009804595,0.0007961108],"domain_scores_gemma":[0.99323535,0.005346481,0.0006081814,0.0004372791,0.00026552987,0.000107172826],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.019235613,0.00034514803,0.0018932483,0.00047606742,0.00050241547,0.00013410208,0.0012969882,0.0006078044,0.000032679214],"category_scores_gemma":[0.0029126543,0.0002459855,0.0001707978,0.0011907272,0.0005779643,0.00008131738,0.00052175426,0.0013054166,0.00001000617],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014074803,0.00021927149,0.0023292135,0.036105234,0.0003241195,0.00004268231,0.05107909,0.000011712596,1.6759132e-7,0.007505189,0.00036841864,0.9018741],"study_design_scores_gemma":[0.0022011618,0.00062440283,0.0016241823,0.017936973,0.00078841933,0.000008597679,0.029733004,0.00026598058,1.4335053e-7,0.0037162402,0.942258,0.00084287085],"about_ca_topic_score_codex":0.003046769,"about_ca_topic_score_gemma":0.021533623,"teacher_disagreement_score":0.9418896,"about_ca_system_score_codex":0.002635662,"about_ca_system_score_gemma":0.003442486,"threshold_uncertainty_score":0.9999992},"labels":[],"label_agreement":null},{"id":"W4392179988","doi":"10.1016/s1470-2045(24)00032-9","title":"Use of radiotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study","year":2024,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Cancer Foundation; Government of New Brunswick; Cancer Care Nova Scotia; Health PEI; Saskatchewan Cancer Agency; St. John’s Health Sciences Centre; CancerCare Manitoba; Alberta Health Services; Cancer Care Ontario","funders":"Medical Research Council; NSW Ministry of Health; Saskatchewan Cancer Agency; Public Health Agency; Cancer Council Victoria; Partenariat Canadien Contre Le Cancer; Cancer Society of New Zealand; Ministry of Health, British Columbia; Cancer Institute NSW; Public Health England; Department of Health, State Government of Victoria; Alberta Health Services; Public Health Wales; Cancer Care Ontario; Cancer Research UK","keywords":"Medicine; Cancer registry; Pancreatic cancer; Colorectal cancer; Population; Cancer; Radiation therapy; Ovarian cancer; Internal medicine; Environmental health","score_opus":0.0853141961814186,"score_gpt":0.453001454189658,"score_spread":0.36768725800823937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392179988","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06750185,0.9276308,0.000027193117,0.00033993908,0.001061728,0.0031519847,0.0001738289,0.000055948698,0.00005676636],"genre_scores_gemma":[0.009825626,0.9850525,0.0016645452,0.00070223195,0.0014562672,0.0007856023,0.00028574705,0.00008697724,0.00014046964],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969678,0.0010222717,0.0007134487,0.00061685435,0.00030819006,0.00037142652],"domain_scores_gemma":[0.9976943,0.0009161814,0.0006560977,0.0005215411,0.00011664011,0.00009520307],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006757181,0.00045003922,0.0025427518,0.00031724718,0.00009706528,0.000026964251,0.00034745474,0.0004032725,0.00023156502],"category_scores_gemma":[0.000060128852,0.0002680045,0.00011535745,0.00041387277,0.00025052717,0.00014735968,0.000044293036,0.0009088961,7.5954e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023794104,0.00088690344,0.587608,0.0023018431,0.001480074,0.00013237594,0.00080400286,0.000119520984,2.0775681e-7,0.000096777156,0.000694812,0.40349612],"study_design_scores_gemma":[0.010017879,0.006192192,0.29730317,0.007422012,0.004077716,0.00004474158,0.000050113897,0.0014845481,2.3690316e-7,0.000022153998,0.6728384,0.00054682774],"about_ca_topic_score_codex":0.0012687983,"about_ca_topic_score_gemma":0.0030110704,"teacher_disagreement_score":0.6721436,"about_ca_system_score_codex":0.0014692376,"about_ca_system_score_gemma":0.000981286,"threshold_uncertainty_score":0.99997723},"labels":[],"label_agreement":null},{"id":"W4392180000","doi":"10.1016/s1470-2045(24)00021-4","title":"Data sharing in cancer research: perceived risks and the consequences of not sharing","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Pancreas Centre (Canada)","funders":"Cancer Research UK","keywords":"Data sharing; Component (thermodynamics); Uniqueness; Data science; Computer science; Research data; Open data; Internet privacy; Psychology; World Wide Web; Medicine; Data curation; Social psychology; Alternative medicine","score_opus":0.9394535900401945,"score_gpt":0.7188992211455324,"score_spread":0.22055436889466207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392180000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.788364,0.0035831693,0.0000038965645,0.19471107,0.00017462597,0.00042506933,0.000047821493,0.000021706112,0.012668648],"genre_scores_gemma":[0.9794807,0.017740745,0.00017743037,0.0011660623,0.0004832292,0.00006313023,0.0000049629093,0.000011976139,0.00087179523],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99760807,0.0006049279,0.00036414855,0.00048623735,0.00054203725,0.00039456948],"domain_scores_gemma":[0.9658664,0.032487437,0.000048217986,0.0013576206,0.00017571001,0.000064651154],"candidate_categories":["metaresearch","sts","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.03499334,0.000069703645,0.00045296107,0.00009796173,0.00009884415,0.000043052532,0.001429468,0.00019562471,0.0001757358],"category_scores_gemma":[0.015639815,0.000034388213,0.000026853779,0.00033547578,0.003791374,0.000054284053,0.002020707,0.003544641,0.000016371934],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009207925,0.00022279225,0.13819027,0.0034892578,0.00058804336,0.00079824537,0.022345215,0.00005748766,0.038552515,0.7450019,0.006131904,0.035414454],"study_design_scores_gemma":[0.010274634,0.0010494365,0.27604735,0.004863389,0.00022459867,0.00019825262,0.0066042338,0.033077434,0.0015817478,0.6273732,0.03844665,0.00025903853],"about_ca_topic_score_codex":0.006230148,"about_ca_topic_score_gemma":0.012196544,"teacher_disagreement_score":0.193545,"about_ca_system_score_codex":0.00013197566,"about_ca_system_score_gemma":0.0008054988,"threshold_uncertainty_score":0.9989197},"labels":[],"label_agreement":null},{"id":"W4392180666","doi":"10.1016/s1470-2045(24)00031-7","title":"Use of chemotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study","year":2024,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Cancer Foundation; Cancer Care Nova Scotia; Health PEI; Saskatchewan Cancer Agency; St. John’s Health Sciences Centre; CancerCare Manitoba; Alberta Health Services; Cancer Care Ontario","funders":"Medical Research Council; NSW Ministry of Health; Saskatchewan Cancer Agency; Public Health Agency; Cancer Council Victoria; Partenariat Canadien Contre Le Cancer; Cancer Society of New Zealand; Cancer Institute NSW; Public Health England; Department of Health, State Government of Victoria; Alberta Health Services; Public Health Wales; Cancer Care Ontario; Cancer Research UK","keywords":"Medicine; Cancer registry; Colorectal cancer; Pancreatic cancer; Internal medicine; Cancer; Population; Oncology","score_opus":0.11423523467180223,"score_gpt":0.4378918221408296,"score_spread":0.32365658746902737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392180666","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13530602,0.8600189,0.0000010714544,0.00034828554,0.00021759175,0.0037408376,0.00027187966,0.000038841656,0.000056541707],"genre_scores_gemma":[0.16200048,0.8350824,0.00018574232,0.00024835308,0.00051126856,0.0013268817,0.0004695345,0.00006821599,0.0001071092],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973433,0.00066016597,0.0005411982,0.0005701343,0.00048208016,0.00040311],"domain_scores_gemma":[0.9984441,0.00039701065,0.0003897135,0.00047680945,0.00014735555,0.00014501046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005220548,0.00039450123,0.0019172906,0.00029010305,0.00006905973,0.000047541427,0.0002668775,0.0001963744,0.00023530742],"category_scores_gemma":[0.000045519046,0.00022986118,0.000106331536,0.00040404822,0.00011375633,0.000108037646,0.00006877038,0.0006583972,0.0000018768668],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022338738,0.0010064589,0.701163,0.0034218128,0.0013267711,0.00022012331,0.00043301686,0.000014159399,4.1506887e-8,0.000037320155,0.00042672918,0.28971672],"study_design_scores_gemma":[0.012304548,0.0078076585,0.8953961,0.008875093,0.004114172,0.000015874513,0.000041145267,0.0005098675,0.0000010018307,0.000016215836,0.07051891,0.00039938843],"about_ca_topic_score_codex":0.0080249645,"about_ca_topic_score_gemma":0.00781275,"teacher_disagreement_score":0.2893173,"about_ca_system_score_codex":0.0015188288,"about_ca_system_score_gemma":0.001215728,"threshold_uncertainty_score":0.9985807},"labels":[],"label_agreement":null},{"id":"W4392180709","doi":"10.1016/s1470-2045(24)00016-0","title":"Surrogate endpoints in clinical trials of p16-positive squamous cell carcinoma of the oropharynx: an individual patient data meta-analysis","year":2024,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute; National Institutes of Health; National Comprehensive Cancer Network; Georgia Research Alliance; NRG Oncology; Regeneron Pharmaceuticals; Castle Biosciences; Varian Medical Systems; Bristol-Myers Squibb; Eli Lilly and Company; American Society of Clinical Oncology; Society for Immunotherapy of Cancer; University of Michigan","keywords":"Medicine; Clinical endpoint; Oncology; Radiation therapy; Internal medicine; Clinical trial; Cancer; Progression-free survival; Chemotherapy; Incidence (geometry); Stage (stratigraphy); Metastasis; Head and neck cancer; Surgery","score_opus":0.6678367344596181,"score_gpt":0.564782398172578,"score_spread":0.10305433628704008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392180709","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0040844884,0.98574585,7.7248836e-7,0.0009557845,0.00056677364,0.0017224405,0.0055424324,0.000011021483,0.0013704591],"genre_scores_gemma":[0.071935914,0.92607886,0.00009248967,0.0004848948,0.0005272414,0.00014343305,0.00057223527,0.000038393024,0.00012652931],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.984147,0.010875212,0.003434609,0.0007123486,0.00046057452,0.0003702705],"domain_scores_gemma":[0.98964196,0.005782095,0.0020814047,0.002282605,0.00012297955,0.00008892661],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0155458,0.00041717122,0.016745089,0.00025650626,0.000044128934,0.000007665233,0.0012849153,0.00040826557,0.00018172403],"category_scores_gemma":[0.0016474304,0.00017159348,0.0029737058,0.0010223719,0.00044938238,0.000035580753,0.0012148608,0.0011946129,0.000014052894],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012261823,0.0025942675,0.001071543,0.019367127,0.23393719,0.00045460268,0.0048119896,0.0000037843756,0.000003912781,0.00016982204,0.017625842,0.7187337],"study_design_scores_gemma":[0.0014798053,0.0018131702,0.0011019004,0.00039334438,0.67780554,0.000023872126,0.0001813684,0.000010788766,0.000016248296,0.00002751489,0.31698057,0.000165851],"about_ca_topic_score_codex":0.0003900455,"about_ca_topic_score_gemma":0.0011244687,"teacher_disagreement_score":0.7185679,"about_ca_system_score_codex":0.000120024306,"about_ca_system_score_gemma":0.0012736551,"threshold_uncertainty_score":0.9978524},"labels":[],"label_agreement":null},{"id":"W4392582468","doi":"10.1016/s1470-2045(24)00070-6","title":"Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Venetoclax; Open label; Medicine; Refractory (planetary science); Oncology; Internal medicine; Chronic lymphocytic leukemia; Clinical trial; Leukemia; Biology","score_opus":0.09800376265592863,"score_gpt":0.4116209237309606,"score_spread":0.31361716107503196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392582468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99528086,0.0005393784,0.000009697501,0.00039198954,0.00036690087,0.0022272333,0.000057895195,0.000025903133,0.0011001447],"genre_scores_gemma":[0.9987895,0.00013180358,0.00008424118,0.00013315606,0.0002278906,0.000101864964,0.000029399856,0.000035444744,0.00046673339],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99708563,0.00073719793,0.00058311544,0.00044416284,0.00060910435,0.00054081436],"domain_scores_gemma":[0.99654526,0.0016825341,0.0003542976,0.0011808084,0.00014755338,0.000089565874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012148719,0.00022159837,0.0013601077,0.00026863074,0.00006089108,0.000022282413,0.0008179583,0.00024411055,0.00020113269],"category_scores_gemma":[0.0006516768,0.000111475674,0.00013114234,0.0020270457,0.00051984,0.0001224104,0.0003974074,0.0006145941,0.000010889381],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.89315003,0.01250033,0.0019095965,0.0017856208,0.0077376124,0.0005075033,0.0033760592,0.0027879628,0.0142290685,0.0003176081,0.0022695675,0.05942903],"study_design_scores_gemma":[0.85569596,0.029250128,0.004683882,0.0008018661,0.0042464947,0.000027262604,0.00010993314,0.09316125,0.0041919937,0.000030269774,0.007542147,0.00025883384],"about_ca_topic_score_codex":0.0018867662,"about_ca_topic_score_gemma":0.0025954414,"teacher_disagreement_score":0.090373285,"about_ca_system_score_codex":0.05986797,"about_ca_system_score_gemma":0.034339014,"threshold_uncertainty_score":0.9711354},"labels":[],"label_agreement":null},{"id":"W4393177013","doi":"10.1016/s1470-2045(24)00099-8","title":"The cost and value of cancer medicines in Ontario, Canada","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Value (mathematics); Granularity; Demography; Family medicine; Environmental health; Statistics; Computer science; Mathematics; Sociology","score_opus":0.04023127997809138,"score_gpt":0.28588100096810326,"score_spread":0.24564972099001187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393177013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82391715,0.046828635,0.000031491727,0.051951647,0.0025317695,0.0002756739,0.00009957662,0.000011115822,0.07435293],"genre_scores_gemma":[0.99175054,0.0044166725,0.00001724017,0.001837168,0.00030103713,0.0000463022,0.0000013695588,0.00000873013,0.0016209293],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99923044,0.000016511387,0.00034159387,0.0001507356,0.000017626267,0.00024311313],"domain_scores_gemma":[0.9993634,0.0003098292,0.00011523235,0.00016866717,0.000011063359,0.000031786352],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073845504,0.00007585357,0.00037473982,0.000035190795,0.00005827483,0.000020105437,0.00020246638,0.000054973676,0.00016611276],"category_scores_gemma":[0.00006862358,0.000049710634,0.000022477916,0.000082958395,0.00016581528,0.000053405434,0.000042879852,0.00023141089,0.0000071859276],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008824995,0.000011796415,0.28349692,0.000043221888,0.00008292845,0.000014295479,0.0014817944,0.00016911289,0.0000067743395,0.6285083,0.056636445,0.029460125],"study_design_scores_gemma":[0.00026460717,0.000030900035,0.26000524,0.000020582243,0.000004367297,0.0000030245826,0.00006220901,0.00039935636,0.000006914387,0.016777303,0.7223734,0.00005206409],"about_ca_topic_score_codex":0.96977115,"about_ca_topic_score_gemma":0.9980472,"teacher_disagreement_score":0.66573703,"about_ca_system_score_codex":0.00065796904,"about_ca_system_score_gemma":0.00074350234,"threshold_uncertainty_score":0.20271409},"labels":[],"label_agreement":null},{"id":"W4393177464","doi":"10.1016/s1470-2045(24)00072-x","title":"Cost and value of cancer medicines in a single-payer public health system in Ontario, Canada: a cross-sectional study","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Cancer Care Ontario; Canadian Centre for Applied Research in Cancer Control; NOSM University; Thunder Bay Regional Health Sciences Centre","funders":"Canada Research Chairs; Government of Canada; Government of Ontario; Ontario Institute for Cancer Research","keywords":"Medicine; Formulary; Cancer; Health economics; Pembrolizumab; Family medicine; Health care; Public health; Internal medicine; Nursing","score_opus":0.14132470748780093,"score_gpt":0.3414761371791186,"score_spread":0.2001514296913177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393177464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9788519,0.007052673,0.000026064203,0.0064611067,0.0012962518,0.00044954868,0.00010578285,0.000012450249,0.0057441797],"genre_scores_gemma":[0.9982315,0.00018141068,0.000018723225,0.0009683342,0.00024641267,0.00010719,0.0000032782536,0.000012121382,0.00023105592],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984916,0.0000527148,0.00075776665,0.00029173424,0.000036207573,0.00036997104],"domain_scores_gemma":[0.99934983,0.00016430843,0.00023256129,0.00016615598,0.000021630824,0.00006549418],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019521192,0.000110471075,0.00071325095,0.00017974035,0.000044697594,0.000041735202,0.0001777207,0.00007785784,0.000110663335],"category_scores_gemma":[0.000069939386,0.00009534533,0.000025639945,0.00020231653,0.0001004072,0.00012303492,0.000052189524,0.00030880378,0.0000045197926],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000047869944,0.00007667025,0.96108687,0.00007993321,0.00003792468,0.000015022312,0.0022815869,0.0001433838,7.2110004e-7,0.033789963,0.0006867168,0.0017533444],"study_design_scores_gemma":[0.0010941185,0.00018531272,0.9170546,0.000044350352,0.0000019695626,0.000009819033,0.00036520147,0.0004962146,5.073978e-7,0.0008444094,0.07982056,0.00008294386],"about_ca_topic_score_codex":0.9760844,"about_ca_topic_score_gemma":0.9981324,"teacher_disagreement_score":0.079133846,"about_ca_system_score_codex":0.0044516646,"about_ca_system_score_gemma":0.0019775934,"threshold_uncertainty_score":0.9993701},"labels":[],"label_agreement":null},{"id":"W4393177495","doi":"10.1016/s1470-2045(24)00136-0","title":"Venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Institute in Oncology and Hematology; University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Venetoclax; Medicine; Chronic lymphocytic leukemia; Lymphoma; Chemotherapy; Refractory (planetary science); Ibrutinib; Oncology; Internal medicine; Immunology; Leukemia; Biology","score_opus":0.03514648133347344,"score_gpt":0.3473009736240493,"score_spread":0.3121544922905759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393177495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98576814,0.0018319297,0.000015785885,0.001361278,0.00040480346,0.0009028516,0.000008225761,0.00015584605,0.009551165],"genre_scores_gemma":[0.9944794,0.00035075215,0.00015099056,0.0008256575,0.00086901605,0.00012431572,0.000034955217,0.00005685373,0.0031080237],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99793154,0.00021934313,0.00030602125,0.000407,0.00042771487,0.00070837233],"domain_scores_gemma":[0.9983497,0.0006968482,0.000054219316,0.0007165674,0.00006505149,0.00011756063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007012165,0.00019526652,0.0005905731,0.00015892772,0.00005540542,0.000026037516,0.0003126802,0.00021801883,0.00047990118],"category_scores_gemma":[0.00018899256,0.00010171437,0.000054139044,0.00057376,0.0003060814,0.00008011301,0.00012345014,0.0006869453,0.0004943858],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.16231939,0.0017260694,0.043299634,0.012151043,0.00325658,0.034818552,0.012906391,0.0067209853,0.0031596373,0.010052227,0.30360746,0.40598202],"study_design_scores_gemma":[0.15620942,0.018186735,0.043971993,0.0020543032,0.00033578658,0.0010798585,0.0001772671,0.05042089,0.00041643783,0.00046331424,0.7260753,0.00060867384],"about_ca_topic_score_codex":0.00049096806,"about_ca_topic_score_gemma":0.0006566366,"teacher_disagreement_score":0.42246786,"about_ca_system_score_codex":0.15884179,"about_ca_system_score_gemma":0.059435677,"threshold_uncertainty_score":0.94589645},"labels":[],"label_agreement":null},{"id":"W4393183638","doi":"10.1016/s1470-2045(24)00026-3","title":"Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; University of Toronto; Université Laval; Jewish General Hospital; Hospital for Sick Children; Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine; Children's Hospital of Eastern Ontario; CancerCare Manitoba; Occupational Cancer Research Centre; University Health Network; Ottawa Hospital; Izaak Walton Killam Health Centre; Princess Margaret Cancer Centre; McGill University Health Centre; Sinai Health System","funders":"Garron Family Cancer Centre; Canadian Institutes of Health Research; Royal Marsden Cancer Charity; Stand Up To Cancer; St. Baldrick's Foundation; Ministerstvo Zdravotnictví Ceské Republiky; V Foundation for Cancer Research","keywords":"Medicine; Cancer; Cohort; Incidence (geometry); Pediatrics; Internal medicine","score_opus":0.08264978873133547,"score_gpt":0.4070467130719613,"score_spread":0.32439692434062584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393183638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98651385,0.0010199032,0.00013094627,0.0014122928,0.0011946763,0.00090191414,0.00003693473,0.00027524756,0.008514254],"genre_scores_gemma":[0.99728507,0.00038247925,0.0014043915,0.0004068547,0.0002807006,0.00011166448,0.000035655106,0.000008713529,0.00008447915],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99784464,0.00036423685,0.0006324425,0.00064035086,0.00029046222,0.0002278486],"domain_scores_gemma":[0.9983593,0.0006271923,0.0001240039,0.000639101,0.00015992638,0.00009045749],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028432768,0.00014248332,0.0005550554,0.00008372321,0.00007724224,0.000013071252,0.00024299667,0.00018690806,0.0002872463],"category_scores_gemma":[0.0007756205,0.00009030877,0.0001224086,0.00020705527,0.0015581861,0.000050825183,0.00013764857,0.00036959277,0.000021956146],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003677193,0.00065432786,0.98726887,0.00004434388,0.00012970153,0.000090756395,0.00021678238,0.000010460191,0.00027849732,0.0079707345,0.0016020541,0.0013657819],"study_design_scores_gemma":[0.0010613251,0.0034774735,0.9840597,0.000032567954,0.00016972829,0.0012693845,0.00031882004,0.0013104185,0.000020704983,0.00046718237,0.007710939,0.000101769285],"about_ca_topic_score_codex":0.000023248553,"about_ca_topic_score_gemma":0.00002001018,"teacher_disagreement_score":0.010771231,"about_ca_system_score_codex":0.00009467383,"about_ca_system_score_gemma":0.00047307956,"threshold_uncertainty_score":0.57412016},"labels":[],"label_agreement":null},{"id":"W4393301802","doi":"10.1016/s1470-2045(24)00100-1","title":"Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":210,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Merck Sharp and Dohme","keywords":"Medicine; Pembrolizumab; Chemoradiotherapy; Placebo; Regimen; Head and neck squamous-cell carcinoma; Clinical endpoint; Internal medicine; Radiation therapy; Oncology; Head and neck cancer; Clinical trial; Surgery; Cancer; Pathology","score_opus":0.0493403772247069,"score_gpt":0.3628449011368754,"score_spread":0.3135045239121685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393301802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97639906,0.011481919,0.00005685571,0.0026852142,0.0022621707,0.0056156935,0.00005113435,0.0000588378,0.0013890875],"genre_scores_gemma":[0.9969535,0.0009048357,0.00005677183,0.0005484708,0.0007433008,0.0005684664,0.000024096296,0.000059028305,0.00014152394],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974481,0.00026761185,0.000656266,0.0005577595,0.00044365527,0.0006266119],"domain_scores_gemma":[0.9982668,0.00067206833,0.00025865642,0.0005271107,0.0001283279,0.00014700813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005083998,0.00043304192,0.0020411839,0.00011109021,0.00012323074,0.000027800466,0.0003166218,0.00018704466,0.000057119898],"category_scores_gemma":[0.000051034185,0.00023896595,0.00018119406,0.0004106752,0.0005802596,0.00007200316,0.00007932018,0.000695913,0.00000393011],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96286714,0.0008503727,0.0010541828,0.00044692188,0.00017354725,0.000045776604,0.004171024,0.00007886157,0.00022238446,0.00010097657,0.001040117,0.028948694],"study_design_scores_gemma":[0.96567583,0.015526395,0.0015031465,0.00026358385,0.00022885848,0.00002178237,0.00018902714,0.0011994606,0.0012299583,0.0000060873335,0.0138823325,0.00027354903],"about_ca_topic_score_codex":0.00013298847,"about_ca_topic_score_gemma":0.00029554966,"teacher_disagreement_score":0.028675146,"about_ca_system_score_codex":0.0009713317,"about_ca_system_score_gemma":0.0013547082,"threshold_uncertainty_score":0.97447485},"labels":[],"label_agreement":null},{"id":"W4396213258","doi":"10.1016/s1470-2045(24)00023-8","title":"Delphi consensus on stereotactic ablative radiotherapy for oligometastatic and oligoprogressive renal cell carcinoma—a European Society for Radiotherapy and Oncology study endorsed by the European Association of Urology","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Health Sciences Centre; Sunnybrook Health Science Centre; London Health Sciences Centre","funders":"Associazione Italiana per la Ricerca sul Cancro; Cancer Council Tasmania; Ministero della Salute; National Institute for Health and Care Research; Institute of Cancer Research; Cancer Research UK; Istituto Europeo di Oncologia; Royal Marsden NHS Foundation Trust","keywords":"Ablative case; Medicine; Radiation therapy; Renal cell carcinoma; Stereotactic radiotherapy; Medical physics; Oncology; Internal medicine; Radiosurgery","score_opus":0.04174781330594428,"score_gpt":0.33545671988045817,"score_spread":0.2937089065745139,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396213258","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9692587,0.009336532,0.00040514924,0.014549019,0.0002474953,0.003959897,0.00013329614,0.00004936914,0.0020605274],"genre_scores_gemma":[0.994333,0.00068780745,0.0016802215,0.001903514,0.00050070445,0.00024157108,0.000030910778,0.00007753745,0.0005447059],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99614817,0.0022998976,0.00046212904,0.0004733613,0.00017728812,0.00043915972],"domain_scores_gemma":[0.9931274,0.0058955722,0.000421115,0.0003367658,0.00013280837,0.000086348715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032727814,0.0002854437,0.0008701996,0.000074246534,0.00018478515,0.000030958443,0.00016187459,0.00010024928,0.000010566206],"category_scores_gemma":[0.00012559592,0.00016332134,0.00019258088,0.00013671805,0.0003558118,0.00002418791,0.00004224327,0.00035854656,0.0000017955643],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03909402,0.00731895,0.042653803,0.0021683692,0.029456599,0.0015710129,0.2252971,0.00022009628,0.18225382,0.0022825655,0.17053917,0.2971445],"study_design_scores_gemma":[0.13821629,0.20843102,0.1528115,0.00017689171,0.0112891765,0.002165876,0.015974466,0.0098207295,0.008578482,0.0013916079,0.44980657,0.0013373956],"about_ca_topic_score_codex":0.00002875827,"about_ca_topic_score_gemma":0.000024623605,"teacher_disagreement_score":0.2958071,"about_ca_system_score_codex":0.0006482008,"about_ca_system_score_gemma":0.00017382104,"threshold_uncertainty_score":0.6660051},"labels":[],"label_agreement":null},{"id":"W4396520760","doi":"10.1016/s1470-2045(24)00142-6","title":"Prognostic impact and causality of age on oncological outcomes in women with endometrial cancer: a multimethod analysis of the randomised PORTEC-1, PORTEC-2, and PORTEC-3 trials","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Leids Universitair Medisch Centrum; KWF Kankerbestrijding; Erasmus Medisch Centrum; Universiteit Leiden","keywords":"Endometrial cancer; Medicine; Oncology; Internal medicine; Cancer; Gynecology; Causal inference; Risk factor; Clinical trial; Pathology","score_opus":0.10855857113639082,"score_gpt":0.4459417076580216,"score_spread":0.33738313652163077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396520760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922812,0.0017478074,0.000017497496,0.0023966918,0.00017659673,0.002503947,0.00020211532,0.000028060384,0.00064608204],"genre_scores_gemma":[0.9977288,0.0008868202,0.00022265506,0.00038539307,0.00015807679,0.00051058125,0.000010522645,0.000014333868,0.000082808176],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996561,0.0013578766,0.0009374225,0.00038953178,0.00037468292,0.00037947812],"domain_scores_gemma":[0.9896629,0.009289575,0.0004755368,0.00037596465,0.00006332133,0.00013271417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005178412,0.00025874062,0.0034951044,0.0004834291,0.000041565978,0.00001460261,0.00015821203,0.00018716011,0.00023415672],"category_scores_gemma":[0.003358866,0.000100594676,0.00030848975,0.0018987106,0.0004101981,0.00003086865,0.00008410627,0.00038702795,4.0368093e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15699282,0.0015206883,0.70941854,0.00034048042,0.015427142,0.0005245322,0.0019551462,0.00010928831,0.0028792287,0.00016259176,0.00009069144,0.11057884],"study_design_scores_gemma":[0.06300256,0.004686291,0.92561525,0.00012639277,0.0051491335,0.000026438775,0.00013169601,0.0001250609,0.00031713338,0.0003269619,0.0003817805,0.00011133324],"about_ca_topic_score_codex":0.001185732,"about_ca_topic_score_gemma":0.0004595288,"teacher_disagreement_score":0.21619667,"about_ca_system_score_codex":0.00038997806,"about_ca_system_score_gemma":0.00039028868,"threshold_uncertainty_score":0.4102132},"labels":[],"label_agreement":null},{"id":"W4396827653","doi":"10.1016/s1470-2045(24)00178-5","title":"Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Foundation Medicine; Sanofi Genzyme; Chugai Pharmaceutical; University of Texas MD Anderson Cancer Center; EMD Serono; Silverback Therapeutics; Bavarian Nordic; Eli Lilly and Company; Ono Pharmaceutical; Astellas Pharma; Seagen; G1 Therapeutics; Genentech; UroGen Pharma; Pfizer; Incyte; Ipsen; Mirati Therapeutics; Amgen; Bladder Cancer Canada; Sanofi; Exelixis; Regeneron Pharmaceuticals; Boston Scientific Corporation; AstraZeneca; Invitae; National Cancer Institute; Gilead Sciences; Bristol-Myers Squibb","keywords":"Pembrolizumab; Medicine; Carcinoma in situ; Cystectomy; Bladder cancer; Cohort; Internal medicine; Oncology; Carcinoma; Cancer; Urology; Immunotherapy","score_opus":0.05105573192091713,"score_gpt":0.3836772905862923,"score_spread":0.3326215586653752,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396827653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98055637,0.0023413983,0.0003200414,0.010279416,0.0011164628,0.004273192,0.00031887845,0.00008207218,0.00071214756],"genre_scores_gemma":[0.99010277,0.0010077338,0.00082736695,0.0038390635,0.0021729502,0.0014462412,0.000028017415,0.00007567831,0.00050017727],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99793595,0.0002695615,0.00038114094,0.0006054268,0.00018862795,0.0006192727],"domain_scores_gemma":[0.99815655,0.0010384045,0.00010787442,0.00039885152,0.000106177635,0.00019214257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036405586,0.00033201027,0.00093890436,0.00019889664,0.000111234775,0.00004572853,0.00016667583,0.00020447117,0.000105716084],"category_scores_gemma":[0.00019002213,0.00022601218,0.00011975832,0.0002830061,0.00013700462,0.000072712966,0.000056154,0.00036072807,0.0000248222],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6197512,0.0029459486,0.003329514,0.00034072806,0.0013783849,0.00086473714,0.023252511,0.000085393986,0.03175519,0.00028425027,0.009063076,0.30694908],"study_design_scores_gemma":[0.79526204,0.061800834,0.027816713,0.0006539145,0.002770047,0.00019453141,0.0019040562,0.0013076223,0.027074907,0.0021002104,0.07815681,0.0009582977],"about_ca_topic_score_codex":0.0021362235,"about_ca_topic_score_gemma":0.0054527437,"teacher_disagreement_score":0.3059908,"about_ca_system_score_codex":0.0006129021,"about_ca_system_score_gemma":0.00087205257,"threshold_uncertainty_score":0.92165095},"labels":[],"label_agreement":null},{"id":"W4399068281","doi":"10.1016/s1470-2045(24)00038-x","title":"Addressing challenges in low-income and middle-income countries through novel radiotherapy research opportunities","year":2024,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Health and Medical Research Council; Medical Research Council; National Institutes of Health; Associazione Italiana per la Ricerca sul Cancro; Astellas Pharma; Cancer Institute NSW; European SocieTy for Radiotherapy and Oncology; National Cancer Institute; Accuray; Australian Government; Fondazione Istituto Europeo di Oncologia e Centro Cardiologico Monzino; Huntsman Cancer Institute","keywords":"Low and middle income countries; Low income; Business; Economic growth; Economics; Demographic economics; Developing country","score_opus":0.6226939617834713,"score_gpt":0.5649439755476936,"score_spread":0.05774998623577765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399068281","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007580406,0.97257227,0.000025494475,0.014506588,0.0014738564,0.0014257304,0.00007240645,0.00012268039,0.009725194],"genre_scores_gemma":[0.000022275595,0.98943114,0.0021200418,0.0009616246,0.004526197,0.0004604911,0.000025845437,0.00013854342,0.0023138183],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955648,0.0013580435,0.0008910036,0.00077459984,0.0004137995,0.0009977159],"domain_scores_gemma":[0.9945238,0.004037933,0.00031092003,0.00090490706,0.000103797174,0.00011861238],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.004178761,0.0005931467,0.0042185425,0.0004719031,0.00027984046,0.000051883595,0.0006344203,0.0011769471,0.00014202828],"category_scores_gemma":[0.00018431009,0.00034456112,0.00023569944,0.0004062793,0.0025850916,0.00011453641,0.00022621267,0.003170088,0.0000424668],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077373325,0.00027205228,0.00006132233,0.103771456,0.001211029,0.002099374,0.0055603827,0.0000013299629,0.0000010240813,0.041061178,0.001496631,0.8436905],"study_design_scores_gemma":[0.0017791064,0.00083858694,0.00004493865,0.05187673,0.00038869504,0.002595191,0.000569957,0.0000127382455,3.3856753e-7,0.0018376778,0.93974286,0.00031316106],"about_ca_topic_score_codex":0.000024784515,"about_ca_topic_score_gemma":0.00014538688,"teacher_disagreement_score":0.93824625,"about_ca_system_score_codex":0.0012959356,"about_ca_system_score_gemma":0.0014557035,"threshold_uncertainty_score":0.99990064},"labels":[],"label_agreement":null},{"id":"W4399068337","doi":"10.1016/s1470-2045(24)00157-8","title":"The burden of cardiovascular disease and risk for subsequent major adverse cardiovascular events in survivors of childhood cancer: a prospective, longitudinal analysis from the St Jude Lifetime Cohort Study","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute; National Institutes of Health; American Lebanese Syrian Associated Charities; St. Jude Children's Research Hospital","keywords":"Medicine; Adverse effect; Prospective cohort study; Cohort; Cancer; Cohort study; Common Terminology Criteria for Adverse Events; Internal medicine; Disease; Pediatrics","score_opus":0.017109048143422075,"score_gpt":0.2914682188470733,"score_spread":0.27435917070365123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399068337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9680357,0.026846219,0.00018408432,0.000950709,0.00017281686,0.0033413738,0.000405421,0.000021043366,0.000042648415],"genre_scores_gemma":[0.99017954,0.008373494,0.000028557957,0.000019907711,0.0006576055,0.00066113274,0.000037440874,0.000021321444,0.000021030624],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977428,0.00074671075,0.00036729572,0.0004227673,0.00047260287,0.00024785855],"domain_scores_gemma":[0.9981464,0.0006293199,0.0001240802,0.00091751106,0.00011862926,0.000064034524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032877254,0.00017642447,0.001195498,0.00007649683,0.00013473732,0.000008799931,0.00023024606,0.00008117195,0.000008882114],"category_scores_gemma":[0.00017241488,0.0000949732,0.0009927435,0.000572188,0.00021746261,0.000037729755,0.00007074052,0.00029651428,6.24023e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00087385793,0.00018181665,0.90786874,0.00007501878,0.076152824,0.000018685476,0.0035884466,0.0056554656,0.00014259656,0.000035557543,0.000039222366,0.0053677713],"study_design_scores_gemma":[0.0030093265,0.00023721886,0.96418625,0.000082103936,0.027316043,0.0000030263288,0.0013609898,0.0007782066,0.00039441232,0.0002986501,0.0022342561,0.00009950015],"about_ca_topic_score_codex":0.020788757,"about_ca_topic_score_gemma":0.0026245338,"teacher_disagreement_score":0.05631753,"about_ca_system_score_codex":0.00022969159,"about_ca_system_score_gemma":0.00025340557,"threshold_uncertainty_score":0.9857319},"labels":[],"label_agreement":null},{"id":"W4399379154","doi":"10.1016/s1470-2045(24)00330-9","title":"New Canadian draft breast screening guidelines issued","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Political science","score_opus":0.22824360181294895,"score_gpt":0.45115737359314967,"score_spread":0.22291377178020072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399379154","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.030153995,0.0145827625,0.0051784837,0.7829686,0.0019572307,0.0005468181,0.00006559414,0.00047390405,0.16407265],"genre_scores_gemma":[0.8979775,0.0003906214,0.023702264,0.049156357,0.012723274,0.000023829834,0.000045844845,0.000048119004,0.015932212],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987944,0.00005683894,0.00023460128,0.00023151416,0.0001867737,0.000495923],"domain_scores_gemma":[0.99914,0.00009105083,0.000029399514,0.000316541,0.00010792157,0.00031505918],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00064999535,0.00012726795,0.00036159426,0.000092874514,0.00011115265,0.000048742015,0.00023603384,0.00012089674,0.0010749392],"category_scores_gemma":[0.00011524621,0.000082580045,0.0000790457,0.00030402886,0.0000606355,0.00007328826,0.000046608522,0.0003529402,0.0003668059],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016120331,0.0000031471925,0.0031512552,0.000026494257,0.000086455475,0.00062513095,0.00038131344,0.0000398621,0.00029697543,0.0031006031,0.7143409,0.27778667],"study_design_scores_gemma":[0.0005625854,0.00016200409,0.009781928,0.00023142502,0.000103204366,0.0020597258,0.00026197094,0.001190664,0.000045231984,0.00057007105,0.9849312,0.00010000628],"about_ca_topic_score_codex":0.18209606,"about_ca_topic_score_gemma":0.14407517,"teacher_disagreement_score":0.8678235,"about_ca_system_score_codex":0.0002688113,"about_ca_system_score_gemma":0.001557087,"threshold_uncertainty_score":0.99983823},"labels":[],"label_agreement":null},{"id":"W4399564385","doi":"10.1016/s1470-2045(24)00220-1","title":"Artificial intelligence and radiologists in prostate cancer detection on MRI (PI-CAI): an international, paired, non-inferiority, confirmatory study","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":273,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Artificial Intelligence in Medicine (Canada)","funders":"National Cancer Institute; HORIZON EUROPE Framework Programme; Genentech; Ipsen; Siemens Healthineers; European Association of Urology; Astellas Pharma; Nvidia; National Institutes of Health; Prostate Cancer UK; AstraZeneca; European Commission; Bayer Vital; Health~Holland; Amgen","keywords":"Prostate cancer; Medicine; Medical physics; Cancer detection; Prostate; Cancer; Psychology; Internal medicine","score_opus":0.09290539477408025,"score_gpt":0.40374125065297256,"score_spread":0.3108358558788923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399564385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869609,0.00079330424,0.000060439852,0.009142546,0.0012253344,0.0011250111,0.000028114753,0.00007381096,0.00059057254],"genre_scores_gemma":[0.9938148,0.0041095903,0.000033187884,0.0007560919,0.0006007116,0.000630228,0.000010798863,0.000014197213,0.000030351164],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9989009,0.00015783391,0.0002557044,0.00034137478,0.00012215144,0.00022207318],"domain_scores_gemma":[0.99945766,0.00016696093,0.000052555413,0.00022286213,0.000039969495,0.000059972288],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059752824,0.00013851609,0.0003490451,0.00010130822,0.000057215082,0.000042709908,0.00010579,0.00006345178,0.000045319517],"category_scores_gemma":[0.00003099756,0.00009040233,0.00002840574,0.00013465801,0.00013909444,0.0000845257,0.000050449555,0.00030436728,0.000021436526],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031621337,0.0016067909,0.31464556,0.00012537492,0.0003512113,0.0014053719,0.009078199,0.00034950292,0.0010838755,0.0013389289,0.0004998854,0.66635317],"study_design_scores_gemma":[0.0030716525,0.015548644,0.90626144,0.00055135234,0.00030067525,0.00032559317,0.0037819478,0.012248768,0.010795484,0.004428139,0.04223966,0.00044662485],"about_ca_topic_score_codex":0.00076400104,"about_ca_topic_score_gemma":0.0032069297,"teacher_disagreement_score":0.66590655,"about_ca_system_score_codex":0.0005233506,"about_ca_system_score_gemma":0.00015794727,"threshold_uncertainty_score":0.36865002},"labels":[],"label_agreement":null},{"id":"W4399703344","doi":"10.1016/s1470-2045(24)00282-1","title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":112,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Adaptive Biotechnologies; Celgene; National Cancer Institute; Yale University; Sanofi; Amgen; Pfizer; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Daratumumab; Medicine; Bortezomib; Multiple myeloma; Thalidomide; Internal medicine; Oncology; Regimen; Dexamethasone; Surgery","score_opus":0.0623832820278561,"score_gpt":0.36822774319097507,"score_spread":0.305844461163119,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399703344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869073,0.0019880654,0.00025378037,0.0026389307,0.00033856888,0.0074006855,0.00016138829,0.000054142834,0.00025713354],"genre_scores_gemma":[0.9943497,0.00158835,0.0004895514,0.00023653576,0.00017460174,0.0012018875,0.000085951506,0.000045970013,0.0018274491],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9969811,0.00079213054,0.00067119236,0.0005378831,0.00040070215,0.0006170209],"domain_scores_gemma":[0.9955883,0.0033891401,0.00023751133,0.00050249224,0.00010108108,0.00018144486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012949853,0.00037054578,0.0018839425,0.00012320672,0.00018631335,0.000066297056,0.00024090035,0.00020626457,0.00005124391],"category_scores_gemma":[0.0010517421,0.00015208226,0.0001420259,0.00045965295,0.0004519856,0.00015201698,0.00006086949,0.0005065661,0.000002251417],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9247387,0.0006937059,0.0543547,0.00028481957,0.00076640403,0.0013551902,0.0012338979,0.000002128327,0.008326411,0.000024472083,0.0012713359,0.0069482154],"study_design_scores_gemma":[0.95915574,0.005008695,0.027023438,0.0007041636,0.00071426167,0.00036354564,0.00017576941,0.0037982573,0.0020341508,0.000017222434,0.00080273935,0.0002020009],"about_ca_topic_score_codex":0.0005026074,"about_ca_topic_score_gemma":0.008249467,"teacher_disagreement_score":0.034417037,"about_ca_system_score_codex":0.00017877718,"about_ca_system_score_gemma":0.00066351506,"threshold_uncertainty_score":0.6201734},"labels":[],"label_agreement":null},{"id":"W4399933562","doi":"10.1016/s1470-2045(24)00261-4","title":"CNS activity of trastuzumab deruxtecan in HER2-expressing non-small-cell lung cancer","year":2024,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Montreal Neurological Institute and Hospital; McGill University","funders":"","keywords":"Trastuzumab; Lung cancer; Medicine; Internal medicine; Oncology; Cancer research; Cancer; Biology; Breast cancer","score_opus":0.04752182909479873,"score_gpt":0.3539609166558717,"score_spread":0.30643908756107296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399933562","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23636928,0.005557772,0.000106962434,0.7460656,0.0009942291,0.0012285742,0.0002490626,0.000053736116,0.009374737],"genre_scores_gemma":[0.5905182,0.002138587,0.0019923537,0.38809016,0.010339399,0.0007715414,0.00020392818,0.00020107118,0.005744771],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980334,0.00038736663,0.0003426971,0.00044961247,0.00022012838,0.0005667878],"domain_scores_gemma":[0.9986913,0.0003627188,0.0002482398,0.00061673985,0.00004121769,0.000039758965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005111665,0.00033891838,0.0014351202,0.00014938352,0.000044584045,0.000014590092,0.0002569942,0.0005918681,0.00024118235],"category_scores_gemma":[0.000019029454,0.00021573051,0.00021259589,0.00020827504,0.00016596155,0.000020205875,0.00012237368,0.0022248572,0.000016693028],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047153173,0.00045903772,0.0020448326,0.0038395487,0.0007875385,0.0035847847,0.001490904,0.00004145822,0.0019445651,0.000013708144,0.96034884,0.024973236],"study_design_scores_gemma":[0.005968506,0.0010343493,0.0064451187,0.0018515029,0.002448957,0.00019815023,0.00011667694,0.00047496005,0.0033515415,0.00030948358,0.97740066,0.0004000821],"about_ca_topic_score_codex":0.0022755587,"about_ca_topic_score_gemma":0.0011953382,"teacher_disagreement_score":0.35797548,"about_ca_system_score_codex":0.00078435626,"about_ca_system_score_gemma":0.0008006848,"threshold_uncertainty_score":0.96660215},"labels":[],"label_agreement":null},{"id":"W4399933819","doi":"10.1016/s1470-2045(24)00067-6","title":"Assessment of endpoint definitions in curative-intent trials for mucosal head and neck squamous cell carcinomas: Head and Neck Cancer International Group consensus recommendations","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Clinical endpoint; Medicine; Head and neck cancer; Clinical trial; Head and neck; Basal cell; Head and neck squamous-cell carcinoma; Oncology; Surrogate endpoint; Cancer; Internal medicine; Surgery","score_opus":0.24070805503133097,"score_gpt":0.4635384935144048,"score_spread":0.22283043848307382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399933819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8723884,0.005408934,0.00021085674,0.1119033,0.0010196067,0.0009735888,0.00073152146,0.000033218417,0.007330563],"genre_scores_gemma":[0.990043,0.004050995,0.0036018677,0.0011781331,0.00037858574,0.0005375052,0.000074579504,0.000013735272,0.00012164166],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986887,0.00023398327,0.00050901336,0.00024758073,0.000097102034,0.00022360006],"domain_scores_gemma":[0.99769974,0.0019026275,0.000120632045,0.00012269222,0.000097790486,0.00005649193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091084855,0.00013330103,0.0008110832,0.000111133704,0.00008164463,0.000015645059,0.00006158591,0.00007087178,0.00008374007],"category_scores_gemma":[0.00024461834,0.000090932255,0.000072385454,0.00010327746,0.0001755932,0.000032067303,0.00006943318,0.00024243002,0.0000010246188],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01099955,0.0040109595,0.34289178,0.0046906197,0.002185083,0.0003658175,0.029127017,0.0000891797,0.025724817,0.23906013,0.20783944,0.1330156],"study_design_scores_gemma":[0.028921345,0.006429172,0.6022865,0.0011535761,0.0006639632,0.0002008287,0.0044970457,0.008333276,0.0006282227,0.0064115,0.34007838,0.00039619036],"about_ca_topic_score_codex":0.0005478163,"about_ca_topic_score_gemma":0.0045727054,"teacher_disagreement_score":0.2593947,"about_ca_system_score_codex":0.00027407496,"about_ca_system_score_gemma":0.00031834916,"threshold_uncertainty_score":0.37081096},"labels":[],"label_agreement":null},{"id":"W4399933845","doi":"10.1016/s1470-2045(24)00255-9","title":"Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, phase 3 trial from the Children's Oncology Group","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre; Princess Margaret Cancer Centre","funders":"National Institutes of Health; Children’s Oncology Group; National Cancer Institute; St. Baldrick's Foundation","keywords":"Medicine; Rhabdomyosarcoma; Temsirolimus; Chemotherapy; Oncology; Internal medicine; Pediatrics; Sarcoma; Discovery and development of mTOR inhibitors; Pathology","score_opus":0.021650026687221706,"score_gpt":0.3291325067953292,"score_spread":0.30748248010810747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399933845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98329735,0.002493327,0.000026204774,0.007265888,0.00033860904,0.0059197517,0.0004328874,0.00004720665,0.00017879566],"genre_scores_gemma":[0.9910155,0.0031285502,0.00042737767,0.0028569757,0.0011706933,0.0010715123,0.00027689795,0.000041996096,0.000010494543],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977142,0.0006501047,0.00051781745,0.00051726494,0.00020817627,0.0003924404],"domain_scores_gemma":[0.99820095,0.0008985051,0.00022422813,0.00051377324,0.00004160299,0.00012091043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008638298,0.00028966586,0.0011379281,0.00011246779,0.000091044676,0.00004855012,0.00040526985,0.00017746948,0.000092814116],"category_scores_gemma":[0.00012485487,0.000147298,0.000075188065,0.00029894602,0.00028077656,0.00007911312,0.00016250771,0.0005128651,0.000016404389],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.51448613,0.0061582467,0.17338875,0.000030569907,0.0009746948,0.00016524206,0.002939947,9.4236447e-7,0.00015888666,0.0001346986,0.006850047,0.29471183],"study_design_scores_gemma":[0.5706971,0.01138534,0.412328,0.0006576752,0.0004893482,0.00025998958,0.0001872974,0.00009210566,0.00011776493,0.00014410386,0.0034868421,0.00015438888],"about_ca_topic_score_codex":0.0021449893,"about_ca_topic_score_gemma":0.0016241563,"teacher_disagreement_score":0.29455742,"about_ca_system_score_codex":0.00023826769,"about_ca_system_score_gemma":0.00019142531,"threshold_uncertainty_score":0.6006638},"labels":[],"label_agreement":null},{"id":"W4399933883","doi":"10.1016/s1470-2045(24)00066-4","title":"Criteria for the diagnosis of extranodal extension detected on radiological imaging in head and neck cancer: Head and Neck Cancer International Group consensus recommendations","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Women's College Hospital","funders":"","keywords":"Medicine; Grading (engineering); Head and neck cancer; Terminology; Radiological weapon; Head and neck; Radiology; Medical physics; Radiation therapy; Delphi method; Cancer; Surgery; Internal medicine; Artificial intelligence","score_opus":0.1111209968390932,"score_gpt":0.43501093644447414,"score_spread":0.3238899396053809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399933883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81206214,0.015130359,0.000025790883,0.17103305,0.00090034195,0.00043869932,0.00013010051,0.00002934086,0.00025018395],"genre_scores_gemma":[0.97221375,0.023169154,0.0005249961,0.00286473,0.00060644525,0.0005592486,0.000011396543,0.000011962847,0.000038344202],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9990929,0.00012004381,0.0002442739,0.00025024178,0.000073483396,0.00021908409],"domain_scores_gemma":[0.9981263,0.0016008655,0.00005084662,0.00012410777,0.000060685063,0.000037194535],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040005083,0.000117783784,0.00042868918,0.00006220152,0.000107930195,0.000013999602,0.00007758293,0.000060971208,0.00008885715],"category_scores_gemma":[0.00018233396,0.00006557305,0.00003971336,0.000100627,0.00025753133,0.000023418115,0.000056177712,0.00022937566,5.919704e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005504342,0.0002603684,0.24621253,0.0003206356,0.00033659616,0.000089261324,0.003902599,0.00002073233,0.01073718,0.0018436738,0.05925655,0.6715155],"study_design_scores_gemma":[0.0052442458,0.0012375221,0.8085671,0.0010654925,0.00014585396,0.00013076607,0.0004207256,0.0066530956,0.00028178378,0.000601877,0.17552054,0.00013097534],"about_ca_topic_score_codex":0.0008474288,"about_ca_topic_score_gemma":0.0034008569,"teacher_disagreement_score":0.6713846,"about_ca_system_score_codex":0.00015040582,"about_ca_system_score_gemma":0.00008276143,"threshold_uncertainty_score":0.26739913},"labels":[],"label_agreement":null},{"id":"W4399933994","doi":"10.1016/s1470-2045(24)00143-8","title":"Standardised definitions and diagnostic criteria for extranodal extension detected on histopathological examination in head and neck cancer: Head and Neck Cancer International Group consensus recommendations","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"National Institute for Health and Care Research","keywords":"Medicine; Head and neck cancer; Histology; Histopathology; Head and neck; Pathology; Cancer; Radiology; Surgery; Internal medicine","score_opus":0.13001224407561246,"score_gpt":0.4175313374934358,"score_spread":0.28751909341782333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399933994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9334907,0.006654955,0.00009765322,0.05725369,0.0007485775,0.0005806215,0.00045939555,0.00005899001,0.000655436],"genre_scores_gemma":[0.97959405,0.016807342,0.0010987158,0.0013934002,0.0003776411,0.0005976912,0.0000620588,0.000014996082,0.000054111395],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9989478,0.00016256825,0.00024273936,0.00033284893,0.000091635186,0.00022241766],"domain_scores_gemma":[0.9981151,0.0015926372,0.00004534005,0.0001003544,0.00008278848,0.0000637633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042429855,0.00013874778,0.00041879213,0.0001084281,0.00016593124,0.00002684543,0.0000396044,0.000101328325,0.00006470273],"category_scores_gemma":[0.00049219443,0.00010025627,0.000026126138,0.000101666694,0.0002295602,0.000038540355,0.000044265827,0.00023270743,8.927494e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0077656345,0.00075676566,0.07904008,0.0010235114,0.00029804106,0.00055788213,0.009217135,0.000016647637,0.019537987,0.012413191,0.033265423,0.83610773],"study_design_scores_gemma":[0.0062759323,0.002032901,0.92617404,0.0010032568,0.00013806105,0.00019064118,0.00026975715,0.0016876545,0.000063358064,0.0016115037,0.06039468,0.00015819949],"about_ca_topic_score_codex":0.00017506906,"about_ca_topic_score_gemma":0.0034817716,"teacher_disagreement_score":0.847134,"about_ca_system_score_codex":0.00030524997,"about_ca_system_score_gemma":0.00010378311,"threshold_uncertainty_score":0.4088332},"labels":[],"label_agreement":null},{"id":"W4399993529","doi":"10.1016/s1470-2045(24)00211-0","title":"Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Saskatchewan","funders":"National Cancer Institute; EMD Serono; Ipsen; Eisai; National Institutes of Health; ECOG-ACRIN Cancer Research Group; Canadian Cancer Society; Sanofi; Exelixis; Dana-Farber/Harvard Cancer Center; Genentech; Coherus Biosciences; Bristol-Myers Squibb; Pfizer; Dana-Farber Cancer Institute; American College of Radiology Imaging Network; Veracyte","keywords":"Medicine; Nivolumab; Renal cell carcinoma; Nephrectomy; Clinical endpoint; Perioperative; Kidney cancer; Internal medicine; Surgery; Clinical trial; Urology; Cancer; Kidney; Immunotherapy","score_opus":0.09033592788829715,"score_gpt":0.3633928836903327,"score_spread":0.27305695580203554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399993529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890164,0.00031769657,0.000017199689,0.0007790131,0.0003563117,0.004416717,0.000015894622,0.00006826124,0.005012468],"genre_scores_gemma":[0.9969372,0.000019102581,0.0010348356,0.0003114301,0.00029881162,0.0005570424,0.00013661267,0.000055054785,0.00064989494],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99761534,0.0006190166,0.0004035295,0.00060007523,0.00030694847,0.0004550847],"domain_scores_gemma":[0.99868727,0.00038379573,0.000105375344,0.00057420006,0.00012569095,0.00012367395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006563278,0.0003082501,0.0008252027,0.000116284755,0.00015391731,0.00012562884,0.00032882486,0.00009917901,0.0001524459],"category_scores_gemma":[0.00004873685,0.00018815475,0.000034934244,0.00038457193,0.00010372574,0.0003265077,0.00015109104,0.00045295383,0.000049184655],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4494388,0.019682415,0.48105887,0.00028951187,0.00075641833,0.002500726,0.021282192,0.00016279389,0.0050652768,0.00028767035,0.0012517504,0.018223584],"study_design_scores_gemma":[0.5979553,0.06754765,0.32659915,0.0001093057,0.00058626675,0.00002653305,0.0018672275,0.0012974512,0.0011154545,0.000019509856,0.0025294027,0.00034678652],"about_ca_topic_score_codex":0.0004585417,"about_ca_topic_score_gemma":0.0020255207,"teacher_disagreement_score":0.15445971,"about_ca_system_score_codex":0.0010574936,"about_ca_system_score_gemma":0.000669726,"threshold_uncertainty_score":0.76727283},"labels":[],"label_agreement":null},{"id":"W4400178708","doi":"10.1016/s1470-2045(24)00327-9","title":"Cancer and premature mortality—pushing the frontiers of cancer care","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton","funders":"","keywords":"Cancer; Medicine; Internal medicine","score_opus":0.10116383091816032,"score_gpt":0.4354763752846711,"score_spread":0.33431254436651076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400178708","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.76443076,0.19579665,0.00003224475,0.03248448,0.0010396021,0.00031059145,0.000054784992,0.000047820773,0.0058030346],"genre_scores_gemma":[0.9891317,0.0058927834,0.00019873994,0.0032925208,0.0010961908,0.00007985467,0.00000414129,0.000011691781,0.0002923756],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991968,0.000067984816,0.00015469987,0.00017482601,0.00017956043,0.00022611981],"domain_scores_gemma":[0.99948746,0.00009179599,0.00005716955,0.00025177543,0.00007000336,0.000041774376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003382504,0.000097998476,0.0003595325,0.000024105044,0.000081059356,0.000019894582,0.00016823591,0.00009886241,0.000050821043],"category_scores_gemma":[0.000036734087,0.000048069764,0.000057465608,0.00016375174,0.00021258631,0.00005105046,0.00006532022,0.00038642815,0.0000017247964],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00095717044,0.000024819305,0.47051662,0.0015367111,0.001378939,0.00021577593,0.03314087,0.00038251135,0.0040764795,0.0055463105,0.32592624,0.15629755],"study_design_scores_gemma":[0.0011215954,0.00032292938,0.24554235,0.0009558892,0.0011508814,0.00010318994,0.010240834,0.0008915909,0.0012855484,0.00094268145,0.73726463,0.0001778867],"about_ca_topic_score_codex":0.0029725651,"about_ca_topic_score_gemma":0.0046096155,"teacher_disagreement_score":0.4113384,"about_ca_system_score_codex":0.00017215755,"about_ca_system_score_gemma":0.00031525892,"threshold_uncertainty_score":0.4493649},"labels":[],"label_agreement":null},{"id":"W4400519828","doi":"10.1016/s1470-2045(24)00286-9","title":"Clinical benefit, reimbursement outcomes, and prices of FDA-approved cancer drugs reviewed through Project Orbis in the USA, Canada, England, and Scotland: a retrospective, comparative analysis","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Arnold Ventures","keywords":"Reimbursement; Medicine; Cancer drugs; Family medicine; Political science; Pharmacology; Drug; Law; Health care","score_opus":0.44982876337795014,"score_gpt":0.5326180964832753,"score_spread":0.08278933310532516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400519828","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92264813,0.018359318,0.00006411712,0.05366218,0.0003815337,0.0011443574,0.00045225632,0.000009385229,0.0032787267],"genre_scores_gemma":[0.9817253,0.008413121,0.0006463256,0.008371213,0.0003112261,0.00028686764,0.000018899402,0.000009167533,0.0002178764],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957289,0.0009149451,0.0024312295,0.00051090424,0.00010928968,0.00030469932],"domain_scores_gemma":[0.99519277,0.003124172,0.0011532122,0.00043582093,0.00005263487,0.00004139381],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018467085,0.0001715039,0.0021648863,0.00014111925,0.00010807724,0.000048413116,0.0003033921,0.000103944054,0.00007441626],"category_scores_gemma":[0.0006644661,0.00011560009,0.00010152924,0.0005231141,0.00019320693,0.00013131503,0.000075243304,0.0003504173,0.000008874032],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000043478667,0.0000503113,0.9387728,0.00029215522,0.0006748922,0.0000019840197,0.012774924,0.00002867312,1.737511e-7,0.0365016,0.010427824,0.0004311722],"study_design_scores_gemma":[0.0009701005,0.0001261352,0.80720013,0.00006974271,0.00013123474,0.0000024363403,0.0013558841,0.001468212,3.3622544e-7,0.0024782785,0.18606375,0.00013374741],"about_ca_topic_score_codex":0.48918518,"about_ca_topic_score_gemma":0.8719011,"teacher_disagreement_score":0.3827159,"about_ca_system_score_codex":0.00052838743,"about_ca_system_score_gemma":0.00047524486,"threshold_uncertainty_score":0.64003605},"labels":[],"label_agreement":null},{"id":"W4400673149","doi":"10.1016/s1470-2045(24)00223-7","title":"Celiac plexus radiosurgery for pain management in advanced cancer: a multicentre, single-arm, phase 2 trial","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Israel Cancer Association USA; Gateway for Cancer Research","keywords":"Medicine; Celiac plexus; Refractory (planetary science); Radiosurgery; Abdominal pain; Ablative case; Plexus; Radiation therapy; Pain management; Pancreatic cancer; Surgery; Cancer; Physical therapy; Internal medicine","score_opus":0.07550196199514499,"score_gpt":0.40167383514007693,"score_spread":0.32617187314493196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400673149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.887314,0.014317218,0.0050320216,0.05406359,0.0076333834,0.012019526,0.0000815852,0.00064926257,0.018889373],"genre_scores_gemma":[0.95505536,0.0066525578,0.0064176177,0.012986214,0.005355694,0.0035622194,0.00015181897,0.00009933284,0.009719185],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982948,0.0002883553,0.00036560296,0.00035287056,0.00015598793,0.0005424293],"domain_scores_gemma":[0.9983854,0.0011032175,0.00007499832,0.000344281,0.000023687793,0.00006839396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022672566,0.00017778583,0.00058702554,0.00018353297,0.000055998935,0.000027682481,0.00018640106,0.00008773161,0.00013745748],"category_scores_gemma":[0.00020731459,0.00012635351,0.00013782497,0.0003135112,0.000067276276,0.000053802305,0.00006198217,0.0002256147,0.00002439941],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08005422,0.0020285232,0.00061904656,0.0011168207,0.0004838408,0.00074150914,0.0010526383,0.00012884973,0.00077537855,0.0032987576,0.12235806,0.78734237],"study_design_scores_gemma":[0.09616206,0.0018403006,0.00040777941,0.00022729239,0.0002739838,0.000001926606,0.0004120026,0.01326744,0.000075437274,0.0008378326,0.88633895,0.00015497179],"about_ca_topic_score_codex":0.000028266397,"about_ca_topic_score_gemma":0.00011385338,"teacher_disagreement_score":0.7871874,"about_ca_system_score_codex":0.00041918023,"about_ca_system_score_gemma":0.00008899737,"threshold_uncertainty_score":0.5152547},"labels":[],"label_agreement":null},{"id":"W4400673370","doi":"10.1016/s1470-2045(24)00285-7","title":"Alleviating retroperitoneal pain with celiac plexus radiosurgery","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Anesthesia and Pain Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Radiosurgery; Celiac plexus; Plexus; Radiology; Surgery; Radiation therapy","score_opus":0.040998421477938245,"score_gpt":0.3095564381240145,"score_spread":0.26855801664607626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400673370","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6391716,0.008143265,0.005098901,0.24148785,0.0006329766,0.0013295938,0.0000025871825,0.0009367966,0.10319643],"genre_scores_gemma":[0.96645164,0.00034953794,0.0022031816,0.024292292,0.0021150503,0.00006305184,0.000014724402,0.00003320511,0.0044773],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99881154,0.00040870844,0.00015092056,0.00018863552,0.00014809225,0.00029209576],"domain_scores_gemma":[0.9990158,0.00059764314,0.000035068137,0.00028087266,0.000019367422,0.000051256586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025007196,0.00010818886,0.00036629476,0.000029942596,0.000073236784,0.00002239725,0.000106091655,0.00006419895,0.00019756882],"category_scores_gemma":[0.00006677688,0.00005633614,0.000053853768,0.00016119986,0.00010247699,0.000024081917,0.000022449516,0.0002775038,0.00011513147],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016251826,0.00017277866,0.12448728,0.0011785687,0.0007220282,0.0069730044,0.0036197563,0.00010391642,0.0009912589,0.01566954,0.5830027,0.261454],"study_design_scores_gemma":[0.00046634342,0.00072462804,0.012803603,0.00014882255,0.00009796726,0.00029205022,0.00036826078,0.0023922555,0.0000228417,0.000112928734,0.98248357,0.00008674005],"about_ca_topic_score_codex":0.000036021975,"about_ca_topic_score_gemma":0.00001695556,"teacher_disagreement_score":0.39948088,"about_ca_system_score_codex":0.000101143254,"about_ca_system_score_gemma":0.00009508646,"threshold_uncertainty_score":0.2297321},"labels":[],"label_agreement":null},{"id":"W4401503118","doi":"10.1016/s1470-2045(24)00338-3","title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"MSD K.K.; Merck","keywords":"Pembrolizumab; Medicine; Quality of life (healthcare); Adjuvant; Internal medicine; Oncology; Placebo; Stage (stratigraphy); Melanoma; Clinical trial; Cancer; Surgery; Immunotherapy; Alternative medicine; Pathology; Nursing","score_opus":0.1603378670695152,"score_gpt":0.4411800088781165,"score_spread":0.2808421418086013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401503118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9568441,0.012426714,0.00005028813,0.015511239,0.0033176225,0.007380259,0.0005129447,0.00020520031,0.0037516486],"genre_scores_gemma":[0.9925885,0.0022409232,0.00005338677,0.0009823198,0.0014844949,0.00059096655,0.0007374968,0.00006147403,0.0012604463],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9924228,0.0024638025,0.0029326703,0.0007541334,0.000567971,0.00085862755],"domain_scores_gemma":[0.9915921,0.0060148374,0.0009973324,0.0010333423,0.00012301921,0.0002393579],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.007118465,0.0004405721,0.0036116273,0.0003643669,0.00013855849,0.00005078653,0.0004910315,0.00051876553,0.0006938407],"category_scores_gemma":[0.0010689445,0.00029392843,0.00054622587,0.0007269134,0.0004278005,0.000105778905,0.000102336955,0.0011629043,0.00004052561],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9777774,0.0008627199,0.000063469495,0.00020581634,0.0022137386,0.0004077575,0.003265407,0.000020220175,0.0032155514,0.0002342171,0.0034999978,0.008233669],"study_design_scores_gemma":[0.98354334,0.00710475,0.0009265474,0.00039237025,0.00032755866,0.000026800622,0.00033459254,0.0005861746,0.00027391274,0.00004727656,0.0061470866,0.00028957194],"about_ca_topic_score_codex":0.008174799,"about_ca_topic_score_gemma":0.006743172,"teacher_disagreement_score":0.03574441,"about_ca_system_score_codex":0.00086565287,"about_ca_system_score_gemma":0.0026615416,"threshold_uncertainty_score":0.9999513},"labels":[],"label_agreement":null},{"id":"W4401899165","doi":"10.1016/s1470-2045(24)00192-x","title":"Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Robarts Clinical Trials; Canadian Cancer Society; Princess Margaret Cancer Centre","funders":"","keywords":"Endometrial cancer; Gynecologic cancer; Medicine; Oncology; Gynecology; Internal medicine; Cancer; Ovarian cancer","score_opus":0.3793100072915736,"score_gpt":0.5548710089520578,"score_spread":0.17556100166048416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401899165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.52571785,0.024427528,0.000007718545,0.43097374,0.0074329106,0.00115003,0.00031162673,0.00010253288,0.009876065],"genre_scores_gemma":[0.96259683,0.02161485,0.00019708351,0.0062714345,0.007524884,0.0008304851,0.00004711888,0.000022292126,0.00089502556],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961667,0.0019649812,0.00058607187,0.00044527382,0.00029358768,0.00054339983],"domain_scores_gemma":[0.9768867,0.022385873,0.00007575782,0.00044305957,0.00010315045,0.000105447805],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0041261152,0.00014951584,0.0007268804,0.00018533836,0.0001581444,0.000042831176,0.00039881136,0.00022121472,0.0030556],"category_scores_gemma":[0.0016066679,0.0000720387,0.00016460985,0.0016088523,0.00049285137,0.000026452979,0.00021466616,0.0015913522,0.00020254555],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043586874,0.00047866648,0.098287985,0.000042806267,0.0007104557,0.00033567415,0.000654104,0.0000072400444,0.00016223952,0.0022914454,0.1499146,0.74275607],"study_design_scores_gemma":[0.009777984,0.0013318968,0.09328203,0.00027870038,0.0002343817,0.000019359148,0.00050742924,0.00017974587,0.00005849669,0.0058334405,0.8883854,0.000111098605],"about_ca_topic_score_codex":0.009681731,"about_ca_topic_score_gemma":0.014052307,"teacher_disagreement_score":0.74264497,"about_ca_system_score_codex":0.0009692401,"about_ca_system_score_gemma":0.0008674558,"threshold_uncertainty_score":0.9978557},"labels":[],"label_agreement":null},{"id":"W4402305047","doi":"10.1016/s1470-2045(24)00438-8","title":"Palliative radiotherapy versus best supportive care in patients with painful hepatic cancer (CCTG HE1): a multicentre, open-label, randomised, controlled, phase 3 study","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Royal Victoria Regional Health Centre; Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre; Kingston General Hospital; Ottawa Hospital; McMaster University; Queen's University; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Dr. H. Bliss Murphy Cancer Centre; University of Ottawa","funders":"Canadian Cancer Society Research Institute; Canadian Cancer Society","keywords":"Medicine; Palliative care; Radiation therapy; Refractory (planetary science); Cancer; Palliative treatment; Internal medicine; Oncology; Nursing","score_opus":0.0600968270802309,"score_gpt":0.4230809140907763,"score_spread":0.3629840870105454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402305047","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97386587,0.0031633005,0.00008439295,0.003397226,0.000601704,0.016405344,0.00013171631,0.00006753248,0.002282933],"genre_scores_gemma":[0.99347305,0.00043698403,0.000510397,0.001613229,0.00021230393,0.003023228,0.00010400781,0.000056136563,0.00057067984],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968774,0.0010430487,0.00056220975,0.00052886276,0.0004523366,0.0005361837],"domain_scores_gemma":[0.9976541,0.0012336826,0.0002341086,0.00052301644,0.0001950074,0.00016011698],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001043128,0.00033635143,0.0015602912,0.00014890007,0.00008604445,0.00007740595,0.00038980844,0.00006398675,0.0006610122],"category_scores_gemma":[0.0003296332,0.00019468064,0.00007274202,0.00037753614,0.00015320475,0.00013191377,0.0001148615,0.00038156737,0.000037341124],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.82988405,0.012795525,0.08170347,0.00047887553,0.0043776734,0.0011858062,0.022448845,0.00005178002,0.000009354791,0.00009649346,0.0027835236,0.04418463],"study_design_scores_gemma":[0.9441346,0.017021982,0.014628397,0.0002941257,0.0024606262,7.7234773e-7,0.010545832,0.0033760283,0.0000033983827,0.000014252659,0.0072604804,0.0002595345],"about_ca_topic_score_codex":0.00047189783,"about_ca_topic_score_gemma":0.0017355179,"teacher_disagreement_score":0.11425055,"about_ca_system_score_codex":0.00077737443,"about_ca_system_score_gemma":0.0005675647,"threshold_uncertainty_score":0.79388463},"labels":[],"label_agreement":null},{"id":"W4402388619","doi":"10.1016/s1470-2045(24)00402-9","title":"[89Zr]Zr-girentuximab for PET–CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":127,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Health and Medical Research Council; Astellas Pharma; Ipsen; National Breast Cancer Foundation; Y-mAbs Therapeutics; Exelixis; Australian and New Zealand Society of Nuclear Medicine; Actinium Pharmaceuticals; Pfizer; Intuitive Surgical; Australian Cancer Research Foundation; Regeneron Pharmaceuticals; Veracyte; Verily Life Sciences; Society of Nuclear Medicine and Molecular Imaging; National Imaging Facility; Medical Research Council; Australian Nuclear Science and Technology Organisation; U.S. Department of Justice; Bristol-Myers Squibb; Progenics Pharmaceuticals","keywords":"Open label; Renal cell carcinoma; Medicine; Nuclear medicine; Oncology; Clinical trial; Internal medicine","score_opus":0.07505544025566038,"score_gpt":0.38647430477783923,"score_spread":0.3114188645221788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402388619","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95461977,0.0035988647,0.000118742035,0.0026908258,0.00087868783,0.0052684355,0.00013002726,0.000097366836,0.03259729],"genre_scores_gemma":[0.9910223,0.00009815827,0.003269926,0.00036873596,0.0010816093,0.0005556777,0.000078262354,0.00007061784,0.0034547246],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99764127,0.00026070245,0.0005690656,0.00061998167,0.0002738246,0.00063513406],"domain_scores_gemma":[0.9981365,0.00066411524,0.00023010455,0.00066373573,0.00015511023,0.00015042724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008595211,0.0003193018,0.0010967756,0.00012447932,0.00012652404,0.00006177796,0.0004732749,0.00004437837,0.0001405608],"category_scores_gemma":[0.000094404044,0.00021026173,0.0001886587,0.00026299723,0.00021815412,0.00011652281,0.00024753416,0.00044110452,0.000074881806],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6042148,0.028505497,0.0050590155,0.0040816865,0.00091591454,0.010937051,0.0043211104,0.000016388864,0.21322675,0.0029476138,0.093599625,0.03217454],"study_design_scores_gemma":[0.74894893,0.026158134,0.0012692426,0.00022849829,0.0024831994,0.0013439477,0.00075903896,0.008662222,0.115012564,0.0009934158,0.09360745,0.0005333724],"about_ca_topic_score_codex":0.00014698497,"about_ca_topic_score_gemma":0.0000286415,"teacher_disagreement_score":0.14473411,"about_ca_system_score_codex":0.0006125254,"about_ca_system_score_gemma":0.0006582807,"threshold_uncertainty_score":0.8574225},"labels":[],"label_agreement":null},{"id":"W4402966374","doi":"10.1016/s1470-2045(24)00494-7","title":"Radiotherapy gaps and new frontiers in the Commonwealth","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Health and Medical Research Council","keywords":"Commonwealth; Radiation therapy; Political science; Medicine; Law","score_opus":0.0443610369808377,"score_gpt":0.42053396302744417,"score_spread":0.37617292604660646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402966374","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.078973405,0.21464615,0.013379362,0.6684179,0.0037721223,0.0010012919,0.0000071562076,0.00016488717,0.019637762],"genre_scores_gemma":[0.37295207,0.25101447,0.07802611,0.26893902,0.019648615,0.00019521572,0.000029691022,0.000121532044,0.009073273],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989728,0.0003245639,0.00016172533,0.0001799845,0.00008617619,0.00027478818],"domain_scores_gemma":[0.9989311,0.00068469247,0.000033274853,0.00029370326,0.0000068458376,0.000050399834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009821171,0.000107483305,0.00042595007,0.000063098516,0.00008402182,0.000014145235,0.00021206778,0.00013697516,0.00007270122],"category_scores_gemma":[0.00003237434,0.000051141644,0.00003976055,0.00021503364,0.00036450737,0.00004123342,0.000014619638,0.0006048702,0.000007780297],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011473225,0.00009590825,0.020003552,0.00009841855,0.0001691441,0.00038641697,0.008556958,0.000016696646,0.00022605724,0.019393625,0.5519805,0.3979254],"study_design_scores_gemma":[0.0020635643,0.00072245667,0.01180813,0.000042550382,0.000033410073,0.0008423345,0.00045295243,0.00056929246,0.0000077474915,0.011755545,0.97163963,0.00006238903],"about_ca_topic_score_codex":0.000039898478,"about_ca_topic_score_gemma":0.00008215968,"teacher_disagreement_score":0.41965914,"about_ca_system_score_codex":0.00018189248,"about_ca_system_score_gemma":0.0002719286,"threshold_uncertainty_score":0.26278937},"labels":[],"label_agreement":null},{"id":"W4402966386","doi":"10.1016/s1470-2045(24)00407-8","title":"Radiotherapy and theranostics: a Lancet Oncology Commission","year":2024,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Advanced Radiotherapy Techniques","field":"Physics and Astronomy","cited_by":120,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brantford Energy (Canada); Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; Sidney Kimmel Comprehensive Cancer Center; National Institutes of Health; Australian and New Zealand Society of Nuclear Medicine; Universität Wien; European Association of Nuclear Medicine; Amgen; Johns Hopkins University; European SocieTy for Radiotherapy and Oncology; Deutsches Krebsforschungszentrum; University of Washington; Society of Nuclear Medicine and Molecular Imaging; American Society for Radiation Oncology","keywords":"Radiation oncology; Commission; Radiation therapy; Medical physics; Medicine; Oncology; Internal medicine; Business; Finance","score_opus":0.07294719185871013,"score_gpt":0.43710483675976836,"score_spread":0.36415764490105823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402966386","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000017155479,0.9692043,0.008109263,0.0025556243,0.0005910055,0.0010223082,0.00015649761,0.000266123,0.018093156],"genre_scores_gemma":[0.0000066808975,0.98018813,0.011352763,0.00058381393,0.0058030346,0.0004203907,0.0000673498,0.00014091555,0.0014369384],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972216,0.00093281525,0.00056657713,0.00055393577,0.00013042035,0.0005946853],"domain_scores_gemma":[0.99763274,0.0009818916,0.00042315613,0.0008280764,0.000033785713,0.00010036994],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008177988,0.0005971544,0.0033823864,0.000121759935,0.00016749615,0.00006448862,0.000814097,0.00044492158,0.00043257792],"category_scores_gemma":[0.000011830286,0.00033678336,0.00032637938,0.00023867266,0.0003822051,0.000053129257,0.00017844058,0.0015545661,0.000038143717],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000040532366,0.00006756928,0.000012009764,0.0013173921,0.00058124575,0.000021419686,0.00030909837,5.4669147e-7,0.000009736923,0.0189743,0.03864866,0.94001746],"study_design_scores_gemma":[0.00062587834,0.00039118767,0.0000011269643,0.0014783966,0.00058042916,0.00008256468,0.000026804719,0.00003735377,0.000002290245,0.007293402,0.9891192,0.00036137088],"about_ca_topic_score_codex":0.000040002342,"about_ca_topic_score_gemma":0.000005362131,"teacher_disagreement_score":0.9504705,"about_ca_system_score_codex":0.00041823182,"about_ca_system_score_gemma":0.00044828292,"threshold_uncertainty_score":0.99990845},"labels":[],"label_agreement":null},{"id":"W4402966446","doi":"10.1016/s1470-2045(24)00493-5","title":"Radiotherapy and conflict: from disruption to expansion and hope","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Political science","score_opus":0.03505174327755152,"score_gpt":0.4141312736031108,"score_spread":0.3790795303255593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402966446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85917115,0.03534029,0.006212984,0.09573268,0.0010153545,0.00043267128,0.000017590755,0.00012803041,0.0019492646],"genre_scores_gemma":[0.8571857,0.063956216,0.021015527,0.04814245,0.0068641487,0.00010743885,0.00003059333,0.00005694278,0.002640985],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993042,0.00010085863,0.000120003475,0.00023921716,0.00006175343,0.00017397072],"domain_scores_gemma":[0.99920005,0.00049534696,0.000021943213,0.00019134478,0.000013375042,0.00007796883],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029142122,0.00010141764,0.00035381294,0.000043930806,0.00008066741,0.000014975253,0.000060321763,0.00013676824,0.0001428346],"category_scores_gemma":[0.000030891773,0.000059641618,0.000021756241,0.000084999636,0.00023851833,0.000046576155,0.000026693744,0.0002359507,0.00001778172],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025026912,0.00008214539,0.0065679788,0.00007733808,0.0002559264,0.00025818008,0.009648339,0.000010889774,0.071476795,0.008312354,0.022245273,0.8785621],"study_design_scores_gemma":[0.0016488031,0.0010955106,0.026487313,0.000066016364,0.000053171218,0.0003435674,0.00014447355,0.00071330677,0.00021621786,0.0018057002,0.96733975,0.00008616195],"about_ca_topic_score_codex":0.000028075025,"about_ca_topic_score_gemma":0.000029561737,"teacher_disagreement_score":0.94509447,"about_ca_system_score_codex":0.00010295103,"about_ca_system_score_gemma":0.000054979533,"threshold_uncertainty_score":0.24321146},"labels":[],"label_agreement":null},{"id":"W4403012542","doi":"10.1016/s1470-2045(24)00386-3","title":"Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial","year":2024,"lang":"nl","type":"article","venue":"The Lancet Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":95,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Agence Nationale de la Recherche","keywords":"Open label; Myeloid leukaemia; Medicine; Refractory (planetary science); Cohort; Internal medicine; Oncology; Clinical trial; Biology","score_opus":0.1475039105224535,"score_gpt":0.46556586142230166,"score_spread":0.3180619508998481,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403012542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9077054,0.012684577,0.00009325274,0.03178261,0.009336829,0.017065795,0.0009568042,0.0005586718,0.019816043],"genre_scores_gemma":[0.5202258,0.057716954,0.009999134,0.014882968,0.020648932,0.0053977673,0.0013820139,0.0009537667,0.36879262],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.9876488,0.0037855892,0.0021902649,0.002068821,0.0011618746,0.003144687],"domain_scores_gemma":[0.98995626,0.0059001152,0.00054137455,0.0025439272,0.0002804844,0.00077782455],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.00906408,0.0010857973,0.003687281,0.0009858261,0.0003925918,0.00042477727,0.0034343486,0.0015264052,0.0065736463],"category_scores_gemma":[0.0030005984,0.00071246224,0.00023171132,0.002297349,0.0011451014,0.0004948476,0.002102406,0.0066461954,0.009587575],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.54024917,0.013265921,0.0002532202,0.0008784503,0.00395636,0.02860711,0.004769021,0.000010748868,0.019675205,0.00058835343,0.32064074,0.067105725],"study_design_scores_gemma":[0.4565805,0.011992675,0.0002604198,0.0006587405,0.0013731818,0.0004711228,0.0007869952,0.017724471,0.00028955893,0.000055816014,0.50916547,0.0006410766],"about_ca_topic_score_codex":0.0023588303,"about_ca_topic_score_gemma":0.0019072242,"teacher_disagreement_score":0.3874796,"about_ca_system_score_codex":0.008525681,"about_ca_system_score_gemma":0.009347195,"threshold_uncertainty_score":0.9997698},"labels":[],"label_agreement":null},{"id":"W4403012546","doi":"10.1016/s1470-2045(24)00500-x","title":"IVLBCL mimicking VEXAS syndrome","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Otitis Media and Relapsing Polychondritis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Fraser Health; University of British Columbia","funders":"","keywords":"Computer science","score_opus":0.044992881539252794,"score_gpt":0.35747957550029386,"score_spread":0.31248669396104106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403012546","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.668434,0.016223159,0.00017764943,0.13408364,0.04809049,0.0004523997,0.000015359083,0.00069498055,0.13182831],"genre_scores_gemma":[0.9568421,0.0010881614,0.0007293494,0.0041262503,0.0021578334,0.000021660453,0.000013575664,0.000033927645,0.03498711],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991424,0.00008244082,0.00014953908,0.00018282513,0.00012497506,0.00031780242],"domain_scores_gemma":[0.9993779,0.00024077472,0.00002286072,0.0002692943,0.000016305377,0.00007284171],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003001317,0.00009461991,0.0003560679,0.00006603939,0.000066487875,0.000023335597,0.0001246025,0.00013835111,0.0003793188],"category_scores_gemma":[0.00006550882,0.000057145204,0.00007881841,0.00017083749,0.00017287342,0.00003006898,0.000041303825,0.00048109892,0.0009397792],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020613539,0.00018841242,0.004913013,0.0006262466,0.00044855592,0.01602315,0.0033712187,0.000004356512,0.010699607,0.01606722,0.85471255,0.09273957],"study_design_scores_gemma":[0.0008013677,0.0004296988,0.004229832,0.00031995383,0.00013146701,0.010970548,0.00007650547,0.00012758862,0.00023476806,0.0009346014,0.9816641,0.00007954983],"about_ca_topic_score_codex":0.000024120569,"about_ca_topic_score_gemma":0.000023470084,"teacher_disagreement_score":0.2884081,"about_ca_system_score_codex":0.000106945474,"about_ca_system_score_gemma":0.00016045652,"threshold_uncertainty_score":0.9998381},"labels":[],"label_agreement":null},{"id":"W4403012554","doi":"10.1016/s1470-2045(24)00492-3","title":"Precision medicine with MET exon 14: a partial success","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Exon; Precision medicine; Computational biology; Genetics; Psychology; Biology; Gene","score_opus":0.04578434813325103,"score_gpt":0.43022742791886226,"score_spread":0.3844430797856112,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403012554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.57628196,0.008526538,0.002670581,0.19782938,0.0022462318,0.0014824091,0.000036186717,0.00046891434,0.2104578],"genre_scores_gemma":[0.99201286,0.00029239515,0.00060241297,0.0018271466,0.0017248724,0.00012538709,0.00003735532,0.000017399609,0.0033601806],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992335,0.000073154966,0.00013655635,0.00019071695,0.00016531536,0.00020079219],"domain_scores_gemma":[0.99936926,0.00023274656,0.0000324511,0.00025604275,0.000047213387,0.00006227588],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003023294,0.00009727022,0.000332121,0.00004935861,0.00006743785,0.000012104273,0.00008639001,0.00005641982,0.0005159141],"category_scores_gemma":[0.00003701321,0.00004168327,0.000029201072,0.00019513065,0.00014763643,0.00004501949,0.000022956183,0.00017525516,0.00008378041],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067332867,0.0006772505,0.017392615,0.00063775043,0.0028223074,0.002836992,0.019721085,0.0001351434,0.0039855894,0.04622365,0.32047534,0.578359],"study_design_scores_gemma":[0.0042750263,0.0036229673,0.0078934245,0.00032382313,0.0010726982,0.0004594386,0.00028995587,0.00032053737,0.00041537403,0.0010031856,0.9802402,0.00008333465],"about_ca_topic_score_codex":0.00013145445,"about_ca_topic_score_gemma":0.00011100767,"teacher_disagreement_score":0.6597649,"about_ca_system_score_codex":0.00015550732,"about_ca_system_score_gemma":0.0002394911,"threshold_uncertainty_score":0.5648898},"labels":[],"label_agreement":null},{"id":"W4403012555","doi":"10.1016/s1470-2045(24)00218-3","title":"The tyranny of non-inferiority trials","year":2024,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Political science; Psychology","score_opus":0.9052723731323669,"score_gpt":0.7364709370930209,"score_spread":0.16880143603934594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403012555","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[3.8169122e-7,0.97357833,0.0028442317,0.0013971634,0.0054385182,0.0022496192,0.00039597464,0.00007375198,0.014021997],"genre_scores_gemma":[3.8136784e-7,0.91241175,0.08180082,0.000103971295,0.0044387556,0.0003752459,0.00000233569,0.00006640923,0.0008003554],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9779552,0.0168473,0.0038430234,0.0004417182,0.0003733167,0.000539394],"domain_scores_gemma":[0.60081035,0.3957396,0.0018634868,0.0014178358,0.00010109396,0.00006764244],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.064054616,0.00042963636,0.010303139,0.00005400709,0.00012926523,0.000049511626,0.0016894889,0.00082481734,0.00017563795],"category_scores_gemma":[0.27095753,0.00016361978,0.0014295712,0.0003754724,0.00080523075,0.000011957253,0.0005058956,0.0017022255,0.00031289316],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000693018,0.00004270886,1.0982756e-7,0.010486083,0.00066037796,0.000011989503,0.000038632836,1.060566e-8,2.0578453e-7,0.15089156,0.04535218,0.79244685],"study_design_scores_gemma":[0.00025441765,0.00012404563,3.1440456e-7,0.001977669,0.0035448063,0.000012535808,0.000005879298,0.0000023479047,5.135898e-7,0.43797055,0.556011,0.000095899304],"about_ca_topic_score_codex":0.000007203046,"about_ca_topic_score_gemma":0.000013748642,"teacher_disagreement_score":0.79235095,"about_ca_system_score_codex":0.00015913397,"about_ca_system_score_gemma":0.00078688347,"threshold_uncertainty_score":0.96375275},"labels":[],"label_agreement":null},{"id":"W4403012565","doi":"10.1016/s1470-2045(24)00190-6","title":"A brave new framework for glioma drug development","year":2024,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Medac; Daiichi Sankyo Europe; National Cancer Institute; Servier; Seagen; University of Oxford; Sanofi; Apollomics; Innovent Biologics; Pfizer; Incyte; AstraZeneca; Novocure; Advanced Accelerator Applications; Voyager Therapeutics; Regeneron Pharmaceuticals; National Institutes of Health; Sage Therapeutics; Australian Government; Varian Medical Systems; ViewRay; Les Laboratories Pierre Fabre; Congress of Neurological Surgeons; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Glioma; Drug development; Drug; Computer science; Medicine; Pharmacology; Cancer research","score_opus":0.15245442751984276,"score_gpt":0.44903900229466864,"score_spread":0.2965845747748259,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403012565","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00002454895,0.98789185,0.00012847292,0.0069635874,0.0011463139,0.0023148216,0.00003240958,0.00011051424,0.0013874908],"genre_scores_gemma":[0.000009523676,0.978896,0.013672064,0.0009355449,0.0033278405,0.0014748471,0.00015911173,0.00008490589,0.0014401395],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99827933,0.00011679505,0.00051457866,0.00044222234,0.00016339736,0.0004836949],"domain_scores_gemma":[0.9979269,0.0010774228,0.00021908256,0.00058611896,0.000031904434,0.00015861008],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00045438428,0.00041613818,0.0027372593,0.0001513564,0.000085618994,0.000036206347,0.00030105773,0.00042168287,0.00010496514],"category_scores_gemma":[0.0001656655,0.00020732217,0.00052611943,0.00031537272,0.000055729543,0.0000108109725,0.00013943827,0.00055931264,0.0008191995],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000036169295,0.00013008992,0.00000190845,0.00649723,0.0011436681,0.0002591475,0.00033089845,2.7073991e-8,1.1338918e-7,0.007662547,0.14969401,0.8342442],"study_design_scores_gemma":[0.00095331384,0.00027899607,0.0000038554617,0.011170269,0.0048920563,0.00041068447,0.000019380992,7.4742206e-7,0.000007324234,0.0036133977,0.978462,0.00018800268],"about_ca_topic_score_codex":0.00001411083,"about_ca_topic_score_gemma":0.000039510964,"teacher_disagreement_score":0.8340562,"about_ca_system_score_codex":0.0005982253,"about_ca_system_score_gemma":0.0019020175,"threshold_uncertainty_score":0.99995875},"labels":[],"label_agreement":null},{"id":"W4403507296","doi":"10.1016/s1470-2045(24)00591-6","title":"Cancer control in the Commonwealth: a roadmap","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Commonwealth; Cancer; Control (management); Medicine; Business; Political science; Computer science; Internal medicine; Artificial intelligence; Law","score_opus":0.052443689666848196,"score_gpt":0.47208242276619383,"score_spread":0.41963873309934563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403507296","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08917399,0.05600321,0.0016840223,0.7937131,0.003685315,0.0013265737,0.0000328288,0.00018379709,0.054197166],"genre_scores_gemma":[0.8966478,0.0049228286,0.00022743233,0.09305776,0.003802076,0.00030324704,0.0000041591848,0.000016056501,0.0010186108],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987788,0.00044592697,0.00018824635,0.0001643774,0.00010398507,0.0003186655],"domain_scores_gemma":[0.99811244,0.0014783902,0.00003935905,0.00032308532,0.0000169408,0.000029775549],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012160067,0.00010110286,0.00042725875,0.000044814846,0.00008735738,0.000009226982,0.0002751267,0.00013994268,0.0002787753],"category_scores_gemma":[0.000050904317,0.000045078013,0.000058601247,0.0002220573,0.00031842376,0.000031901465,0.000014828363,0.0007491731,0.00006243802],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037975616,0.00055730756,0.050476477,0.00030183324,0.0005559858,0.0021851326,0.015218213,0.00030111335,0.0013823225,0.074777596,0.46496403,0.38548243],"study_design_scores_gemma":[0.0026082948,0.00051372085,0.013146346,0.000060091796,0.00006346748,0.00045339312,0.0002454231,0.0012954543,0.0000071151394,0.0031164957,0.97843224,0.00005796956],"about_ca_topic_score_codex":0.00008712648,"about_ca_topic_score_gemma":0.00072185503,"teacher_disagreement_score":0.80747384,"about_ca_system_score_codex":0.00025367146,"about_ca_system_score_gemma":0.00031952345,"threshold_uncertainty_score":0.3254826},"labels":[],"label_agreement":null},{"id":"W4403855182","doi":"10.1016/s1470-2045(24)00316-4","title":"Artificial Intelligence for Response Assessment in Neuro Oncology (AI-RANO), part 1: review of current advancements","year":2024,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Artificial Intelligence in Medicine (Canada)","funders":"DOD Peer Reviewed Cancer Research Program; National Institute of Neurological Disorders and Stroke; National Cancer Institute; Centre For Medical Engineering, King’s College London; Engineering and Physical Sciences Research Council; Servier; Siemens Healthineers; Deutsche Forschungsgemeinschaft; National Institutes of Health; Novocure; National Center for Advancing Translational Sciences; Wellcome Trust; Stryker; University of Wisconsin-Madison; Medical Research Council; Musella Foundation For Brain Tumor Research and Information; U.S. Department of Veterans Affairs; U.S. Department of Defense","keywords":"Current (fluid); Medical physics; Computer science; Medicine; Neuroscience; Engineering; Psychology; Electrical engineering","score_opus":0.21247130692308325,"score_gpt":0.5590866697953906,"score_spread":0.3466153628723073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403855182","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000042571887,0.9651911,0.0023800258,0.026196847,0.0028238336,0.002741515,0.000054146756,0.000035148118,0.0005730827],"genre_scores_gemma":[0.000007547912,0.99144095,0.0014242241,0.0046233595,0.0012900728,0.0009302558,0.00012026663,0.000059473572,0.00010385029],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9948721,0.0019873143,0.001752908,0.0005521172,0.00029890396,0.00053667976],"domain_scores_gemma":[0.9951741,0.003278286,0.00068451045,0.0006405199,0.00010711904,0.000115432005],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00801253,0.00037776228,0.0039632563,0.00024085063,0.000047155412,0.000010978315,0.0005261153,0.00024078846,0.000110237066],"category_scores_gemma":[0.0031491383,0.00022893393,0.00049440126,0.00049146416,0.00028415537,0.000025879535,0.00020959618,0.002521114,0.00004303937],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037997376,0.00024867625,0.0000032283483,0.101127185,0.00010848676,0.00009280215,0.000046372843,0.000002052102,0.0000032644639,0.00198483,0.013760016,0.8822431],"study_design_scores_gemma":[0.00026957496,0.0010342291,0.0000034318548,0.08920908,0.0017268106,0.00015163202,0.000010284599,0.00033024143,7.1165465e-7,0.0009582304,0.9061498,0.00015596952],"about_ca_topic_score_codex":0.0000048266265,"about_ca_topic_score_gemma":0.0000069649113,"teacher_disagreement_score":0.8923898,"about_ca_system_score_codex":0.00074069994,"about_ca_system_score_gemma":0.0027149583,"threshold_uncertainty_score":0.9997801},"labels":[],"label_agreement":null},{"id":"W4403855186","doi":"10.1016/s1470-2045(24)00315-2","title":"Artificial Intelligence for Response Assessment in Neuro Oncology (AI-RANO), part 2: recommendations for standardisation, validation, and good clinical practice","year":2024,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Artificial Intelligence in Medicine (Canada)","funders":"Department of Radiology, Weill Cornell Medical College; DOD Peer Reviewed Cancer Research Program; National Institute of Neurological Disorders and Stroke; Servier; National Cancer Institute; Centre For Medical Engineering, King’s College London; European Research Council; Dana Foundation; Engineering and Physical Sciences Research Council; Perelman School of Medicine, University of Pennsylvania; National Institutes of Health; Siemens Healthineers; Deutsche Forschungsgemeinschaft; Novocure; U.S. Department of Defense; European Commission; University of Pennsylvania; Musella Foundation For Brain Tumor Research and Information; Stryker; Instituto Tecnológico de Costa Rica; University of Wisconsin-Madison; Medical Research Council; National Center for Advancing Translational Sciences; Wellcome Trust; U.S. Department of Veterans Affairs","keywords":"Medical physics; Clinical Practice; Artificial intelligence; Computer science; Psychology; Engineering; Medicine; Family medicine","score_opus":0.2640646117355813,"score_gpt":0.592935452089632,"score_spread":0.32887084035405073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403855186","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00002101223,0.4092954,0.076351576,0.50443614,0.00388563,0.0047957264,0.0002733282,0.00008632908,0.0008548515],"genre_scores_gemma":[0.00002986613,0.95072067,0.037372,0.0072313705,0.0027324762,0.0012894019,0.00038023948,0.00006362307,0.00018037483],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9943203,0.0029134203,0.0016302075,0.00057790754,0.00017518851,0.00038300175],"domain_scores_gemma":[0.9734948,0.025148194,0.0006031354,0.00039782142,0.00023358603,0.00012242803],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.019202184,0.0002682301,0.0020250245,0.00019244275,0.00016453817,0.00006844766,0.00023497382,0.00041809148,0.000033403678],"category_scores_gemma":[0.020008037,0.00018045388,0.00027342484,0.00027629774,0.00027405345,0.00007010118,0.00010940829,0.0018702188,0.000011261574],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011795487,0.00022669857,0.0000111590125,0.0019304617,0.0002199402,0.000023705077,0.00021883922,0.000005058753,7.8704846e-7,0.011347152,0.038174946,0.9466617],"study_design_scores_gemma":[0.00063736946,0.0016762785,0.000012133935,0.0013486166,0.0024143616,0.00028824963,0.00017323792,0.0015509875,4.114527e-7,0.005451485,0.9862894,0.00015748957],"about_ca_topic_score_codex":0.000008400163,"about_ca_topic_score_gemma":0.000017605893,"teacher_disagreement_score":0.94811445,"about_ca_system_score_codex":0.00055016787,"about_ca_system_score_gemma":0.002928742,"threshold_uncertainty_score":0.98824686},"labels":[],"label_agreement":null},{"id":"W4403912554","doi":"10.1016/s1470-2045(24)00503-5","title":"Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"T-cell and Retrovirus Studies","field":"Immunology and Microbiology","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"National Cancer Institute; Daiichi-Sankyo","keywords":"Open label; Refractory (planetary science); Medicine; Peripheral; Phases of clinical research; Lymphoma; Peripheral T-cell lymphoma; Internal medicine; T cell; Clinical trial; Materials science; Immunology","score_opus":0.05829991833264942,"score_gpt":0.3377466569531937,"score_spread":0.2794467386205443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403912554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856078,0.0040798453,0.00006741676,0.00090101035,0.0027438817,0.0028947522,0.0002689556,0.00019835056,0.0032379783],"genre_scores_gemma":[0.9796852,0.00022968695,0.00043500477,0.0005965288,0.00024242494,0.00043049105,0.00015666493,0.00006507697,0.018158952],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99745005,0.00061076705,0.0004447358,0.00062530924,0.00007395822,0.0007951997],"domain_scores_gemma":[0.99819237,0.0009225472,0.0002023558,0.00050091516,0.00014398697,0.0000378327],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055020826,0.0003699841,0.0008438007,0.00008462087,0.0005599988,0.00007756958,0.0007426469,0.00022608768,0.00040257798],"category_scores_gemma":[0.000112542126,0.00019339166,0.000071585564,0.00022499464,0.0003809752,0.00014752496,0.00039428886,0.00034161596,0.000213864],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13564868,0.18038054,0.013886921,0.00087144854,0.006909197,0.00047948136,0.034351468,0.00000775907,0.129448,0.00052692345,0.20957123,0.28791836],"study_design_scores_gemma":[0.108846396,0.041398723,0.00091515086,0.00006831776,0.0006377755,0.000029149714,0.0028881803,0.000022799248,0.0015734251,0.000040451905,0.8431499,0.00042973994],"about_ca_topic_score_codex":0.00009500889,"about_ca_topic_score_gemma":0.00037078452,"teacher_disagreement_score":0.63357866,"about_ca_system_score_codex":0.00024877395,"about_ca_system_score_gemma":0.00022944945,"threshold_uncertainty_score":0.78862834},"labels":[],"label_agreement":null},{"id":"W4404354036","doi":"10.1016/s1470-2045(24)00507-2","title":"Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"National Cancer Institute; NRG Oncology; National Center for Advancing Translational Sciences; AstraZeneca; U.S. Department of Veterans Affairs","keywords":"Cetuximab; Durvalumab; Medicine; Contraindication; Head and neck cancer; Cisplatin; Oncology; Radiation therapy; Internal medicine; Randomized controlled trial; Head and neck; Cancer; Surgery; Chemotherapy; Alternative medicine; Colorectal cancer; Nivolumab","score_opus":0.06597821994464595,"score_gpt":0.42670553737652556,"score_spread":0.3607273174318796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404354036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.975014,0.0013601495,0.00090178405,0.013389039,0.00018630923,0.00876933,0.00012869535,0.000056539786,0.00019415739],"genre_scores_gemma":[0.96837354,0.0013712762,0.016429706,0.005540533,0.000766976,0.0069717416,0.00012400388,0.000081958526,0.00034028484],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983588,0.00014659663,0.0003534995,0.0004911175,0.000203414,0.00044658987],"domain_scores_gemma":[0.9988325,0.0005161338,0.0001238139,0.0002725257,0.00010237045,0.00015263006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049579423,0.00024219432,0.0010985256,0.00008830782,0.00012795985,0.000046200774,0.0001956241,0.00008900278,0.000062010244],"category_scores_gemma":[0.00008190079,0.0001267751,0.000021767026,0.00024384435,0.00014983851,0.00015739852,0.000034493143,0.000207991,0.0000013359755],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8524884,0.0017373492,0.0017682876,0.00013742193,0.00029000672,0.00003270231,0.002544597,0.000039297774,0.00024581727,0.00024132481,0.00060578296,0.13986902],"study_design_scores_gemma":[0.90626425,0.041902762,0.0098631475,0.0005758714,0.00018861597,0.000014099349,0.00016351575,0.002019893,0.000009991452,0.000040126768,0.0387346,0.00022315318],"about_ca_topic_score_codex":0.00009925584,"about_ca_topic_score_gemma":0.0044287913,"teacher_disagreement_score":0.13964587,"about_ca_system_score_codex":0.00033217206,"about_ca_system_score_gemma":0.0005556226,"threshold_uncertainty_score":0.51697385},"labels":[],"label_agreement":null},{"id":"W4404365234","doi":"10.1016/s1470-2045(24)00531-x","title":"Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Intraperitoneal and Appendiceal Malignancies","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Institut National Du Cancer; Unicancer; Ligue Contre le Cancer","keywords":"Hyperthermic intraperitoneal chemotherapy; Medicine; Ovarian cancer; Cytoreductive surgery; Chemotherapy; Intraperitoneal chemotherapy; Oncology; Internal medicine; Surgery; Cancer","score_opus":0.11247817903258171,"score_gpt":0.4409487727974481,"score_spread":0.32847059376486637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404365234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8556026,0.0067656063,0.0002277181,0.11555504,0.005396119,0.0077474825,0.00022968407,0.00026200674,0.008213707],"genre_scores_gemma":[0.93751115,0.0048792693,0.0027250496,0.02353169,0.020109138,0.0067041097,0.00016370747,0.0001575283,0.0042183516],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99820393,0.00017290405,0.00044928622,0.00042754068,0.0001675114,0.00057879975],"domain_scores_gemma":[0.9989068,0.00045325002,0.000101677404,0.00034524818,0.00006844423,0.00012457161],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010130078,0.00025999066,0.0010026891,0.000059639086,0.00020228015,0.000109177185,0.0004553422,0.0001884164,0.0007668536],"category_scores_gemma":[0.00006429496,0.00015368109,0.00014224614,0.00021085089,0.00022795337,0.00008769087,0.000074246345,0.00042360765,0.00004849051],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.57039267,0.0011289774,0.0000031934376,0.00024439182,0.0004273876,0.000111321,0.0010848095,6.134912e-7,0.028614474,0.00575772,0.033957057,0.3582774],"study_design_scores_gemma":[0.3924627,0.006450328,0.000011847526,0.00017103628,0.0002522097,0.00015996258,0.000080608384,0.0010647444,0.0019282001,0.000963205,0.5962835,0.0001716383],"about_ca_topic_score_codex":0.00014415193,"about_ca_topic_score_gemma":0.000109557805,"teacher_disagreement_score":0.56232643,"about_ca_system_score_codex":0.00018684272,"about_ca_system_score_gemma":0.00067832787,"threshold_uncertainty_score":0.8396509},"labels":[],"label_agreement":null},{"id":"W4404404312","doi":"10.1016/s1470-2045(24)00523-0","title":"The current and future global burden of cancer among adolescents and young adults: a population-based study","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Alberta Health Services; Alberta Cancer Foundation; University of Calgary","funders":"","keywords":"Current (fluid); Cancer; Environmental health; Gerontology; Medicine; Demography; Psychology; Sociology; Engineering; Internal medicine","score_opus":0.024185013570832397,"score_gpt":0.37507290568126095,"score_spread":0.35088789211042853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404404312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9574034,0.022385018,0.000005860513,0.017884137,0.0013522647,0.00072426937,0.00005043773,0.00004743888,0.00014715674],"genre_scores_gemma":[0.9958805,0.0011418642,0.000016906559,0.0003593611,0.0025122801,0.000055687455,0.0000072506487,0.000010792976,0.000015376949],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99877775,0.00026520158,0.00027681876,0.00023444543,0.00024117,0.00020464351],"domain_scores_gemma":[0.99934906,0.00014871957,0.00010147322,0.00027950815,0.000055335648,0.000065928645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006336139,0.00012513823,0.00039245473,0.000022180024,0.000109001994,0.00002548591,0.00012531845,0.00005624617,0.000009014709],"category_scores_gemma":[0.00005375099,0.00006954642,0.00003933404,0.00016086975,0.00013742952,0.000029868386,0.00006759364,0.00029314458,0.0000012684402],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006121255,0.0000847645,0.88236463,0.0004176353,0.00010176164,0.000007498778,0.0042870473,0.000004490233,0.0000018789334,0.00015524648,0.00071490265,0.11124799],"study_design_scores_gemma":[0.0022888232,0.0003430439,0.9787416,0.00058245426,0.00019237075,0.0000073388287,0.0019202204,0.00057424884,0.0000011294832,0.00014267371,0.015133214,0.00007292153],"about_ca_topic_score_codex":0.0059043025,"about_ca_topic_score_gemma":0.019824669,"teacher_disagreement_score":0.11117507,"about_ca_system_score_codex":0.00015462958,"about_ca_system_score_gemma":0.00018034107,"threshold_uncertainty_score":0.998061},"labels":[],"label_agreement":null},{"id":"W4404799289","doi":"10.1016/s1470-2045(24)00508-4","title":"Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"CRISPR; Refractory (planetary science); Open label; Medicine; Cancer research; Internal medicine; Adverse effect; Biology; Genetics; Gene","score_opus":0.0810241588147585,"score_gpt":0.3709479855397072,"score_spread":0.2899238267249487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404799289","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99231017,0.0012333905,0.00006528885,0.0007681752,0.00019544469,0.003809394,0.000072768504,0.00008124852,0.0014640994],"genre_scores_gemma":[0.9969431,0.0006690209,0.00026510144,0.00021431407,0.00012953048,0.00014159239,0.00004836416,0.0000776835,0.0015112986],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99691874,0.00091896777,0.0005131797,0.00059680536,0.0004821728,0.0005701299],"domain_scores_gemma":[0.9979955,0.0007520697,0.00019154494,0.0007296905,0.00019548021,0.00013572851],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015445712,0.00033832277,0.0011085441,0.00025188012,0.00009744061,0.000053297437,0.00039304886,0.00022512896,0.00037854465],"category_scores_gemma":[0.000102319675,0.0002071369,0.00004685271,0.0007652996,0.00024444418,0.00018597953,0.0001989734,0.0007142389,0.0000078093135],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12345661,0.02886194,0.019141052,0.0004357244,0.0005268163,0.000355621,0.006238055,0.000045421155,0.7572447,0.000015055274,0.00079717144,0.062881805],"study_design_scores_gemma":[0.34956372,0.23987713,0.27983335,0.00068602106,0.000768736,0.00009456782,0.0022758562,0.0032849922,0.07492622,0.000097694545,0.047277074,0.0013146468],"about_ca_topic_score_codex":0.00034164783,"about_ca_topic_score_gemma":0.00045282903,"teacher_disagreement_score":0.6823185,"about_ca_system_score_codex":0.0005357053,"about_ca_system_score_gemma":0.00058874505,"threshold_uncertainty_score":0.8446798},"labels":[],"label_agreement":null},{"id":"W4404909609","doi":"10.1016/s1470-2045(24)00557-6","title":"Balancing clinical benefit and social value: challenges in HTA assessments","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Gilead Sciences","keywords":"Medicine; Health technology; Reimbursement; Authorization; Judgement; Cancer drugs; Actuarial science; Family medicine; Intensive care medicine; Drug; Psychiatry; Health care; Business","score_opus":0.739947547352971,"score_gpt":0.5849100145302042,"score_spread":0.15503753282276678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404909609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5295682,0.017587597,0.00022203138,0.4133002,0.0022298067,0.00044974362,0.000092710856,0.000087537366,0.036462214],"genre_scores_gemma":[0.97758585,0.0055131465,0.0010015605,0.012632217,0.0028077036,0.000087852364,0.000011230846,0.000027644446,0.00033280373],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99636906,0.00063718704,0.0021007566,0.00046449632,0.000050512816,0.0003779913],"domain_scores_gemma":[0.996676,0.002518297,0.00048168915,0.00025717544,0.0000138510095,0.000052974265],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.031255648,0.00011896579,0.0010700962,0.00013152164,0.00011220119,0.000057973397,0.00024804994,0.00022355794,0.00010607813],"category_scores_gemma":[0.00059623015,0.000116364,0.000068485715,0.00009227001,0.000108285734,0.00016887038,0.00010140414,0.0004201945,0.00057896273],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027167265,0.00007129171,0.05283415,0.0003948821,0.00008818707,0.000006618045,0.0036185267,0.000019573366,8.3618966e-7,0.91529,0.012858513,0.014790242],"study_design_scores_gemma":[0.0011417565,0.00018061863,0.36720222,0.0000745452,0.0000101774185,0.000013825549,0.0014277288,0.008861911,2.2530897e-7,0.1239924,0.496887,0.00020759081],"about_ca_topic_score_codex":0.00020264077,"about_ca_topic_score_gemma":0.0007136551,"teacher_disagreement_score":0.7912976,"about_ca_system_score_codex":0.0004296648,"about_ca_system_score_gemma":0.00013696364,"threshold_uncertainty_score":0.99752617},"labels":[],"label_agreement":null},{"id":"W4404909842","doi":"10.1016/s1470-2045(24)00505-9","title":"Use of the ESMO-Magnitude of Clinical Benefit Scale to guide HTA recommendations on coverage and reimbursement for cancer medicines: a retrospective analysis","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Reimbursement; Health technology; Family medicine; Scale (ratio); Health care; Actuarial science; Economic growth; Business","score_opus":0.5671370179349159,"score_gpt":0.5705790316570364,"score_spread":0.003442013722120496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404909842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.61403865,0.0007327434,0.0026258838,0.3756794,0.0014343206,0.0012570273,0.0020983221,0.000018461275,0.002115183],"genre_scores_gemma":[0.95038503,0.002215321,0.0048559597,0.03874387,0.0011795976,0.0005204837,0.00004030212,0.000028637221,0.002030799],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963849,0.00033015254,0.0026388508,0.00037382406,0.00007005056,0.0002022317],"domain_scores_gemma":[0.9940186,0.0041224365,0.001139756,0.0005395357,0.00011487462,0.00006478438],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013660777,0.00010410039,0.0013212566,0.00019187736,0.00009987817,0.00002027274,0.0002602019,0.000103229824,0.00020441136],"category_scores_gemma":[0.0036717607,0.00007786018,0.00019039525,0.00039637747,0.00013195867,0.00007878425,0.0000813445,0.0001746695,0.000019149375],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020957174,0.00022605006,0.5503052,0.00037040116,0.0019896189,4.1610832e-7,0.0050759735,0.002893914,0.000009923533,0.16433862,0.26809424,0.006486076],"study_design_scores_gemma":[0.0007710614,0.00046989735,0.4769691,0.0001597135,0.00025014768,8.1728206e-7,0.00039454817,0.005503253,0.000014088225,0.012108117,0.5032407,0.00011856021],"about_ca_topic_score_codex":0.002070565,"about_ca_topic_score_gemma":0.007546857,"teacher_disagreement_score":0.33693552,"about_ca_system_score_codex":0.00041365807,"about_ca_system_score_gemma":0.00017666166,"threshold_uncertainty_score":0.47345802},"labels":[],"label_agreement":null},{"id":"W4404910188","doi":"10.1016/s1470-2045(24)00673-9","title":"Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Novartis Pharmaceuticals Corporation; Novartis","keywords":"Fulvestrant; Medicine; Aromatase inhibitor; Internal medicine; Oncology; Breast cancer; Cancer; Cohort; Regimen; Letrozole; Clinical endpoint; Clinical trial; Aromatase; Estrogen receptor","score_opus":0.04917139460894078,"score_gpt":0.40713169796505505,"score_spread":0.3579603033561143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404910188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9811374,0.005904372,0.00021628677,0.0044776783,0.00055282464,0.0056841844,0.00077655975,0.000103012266,0.0011476731],"genre_scores_gemma":[0.9929611,0.0007683119,0.0021479274,0.00077157415,0.00069297047,0.0022320142,0.000061397746,0.00007867787,0.00028600823],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965755,0.0004479014,0.000871974,0.00085337536,0.00045337464,0.0007979279],"domain_scores_gemma":[0.99812126,0.0004243607,0.00029024272,0.00066152686,0.00031087658,0.00019174353],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007599575,0.000497064,0.0020508766,0.00021770918,0.00008267037,0.00004594076,0.0005221373,0.00017746369,0.00033211272],"category_scores_gemma":[0.000030643325,0.000363483,0.0000838632,0.00091126765,0.0004961573,0.00040932934,0.0002843588,0.0009200115,0.000057657246],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34807602,0.030126702,0.011893955,0.0006788081,0.0062841885,0.002768998,0.10425737,0.0011140795,0.3129496,0.00019441107,0.0021512106,0.17950465],"study_design_scores_gemma":[0.44452175,0.03004186,0.41735268,0.0069658863,0.0031789937,0.0011764969,0.041754853,0.010601602,0.02500801,0.00040201703,0.016437111,0.0025587624],"about_ca_topic_score_codex":0.0010528511,"about_ca_topic_score_gemma":0.0015389051,"teacher_disagreement_score":0.40545872,"about_ca_system_score_codex":0.0014176738,"about_ca_system_score_gemma":0.00093308813,"threshold_uncertainty_score":0.9998817},"labels":[],"label_agreement":null},{"id":"W4404910194","doi":"10.1016/s1470-2045(24)00657-0","title":"Palliative radiotherapy for hepatic cancer pain – Authors' reply","year":2024,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Queen's University; University Health Network","funders":"Canadian Cancer Society","keywords":"Radiation therapy; Medicine; Palliative care; Cancer pain; Cancer; Psychology; Internal medicine; Psychotherapist; Nursing","score_opus":0.08584021821421386,"score_gpt":0.4076242109850543,"score_spread":0.32178399277084047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404910194","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000115408984,0.005600383,0.0040413467,0.9818634,0.0019994308,0.0029604905,0.00032833015,0.00019331281,0.0028979373],"genre_scores_gemma":[0.00005894702,0.0013168403,0.005374637,0.9283679,0.0153580075,0.0024081215,0.0004421881,0.00013522888,0.046538122],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968951,0.000939361,0.0004874737,0.0006135664,0.0003935762,0.0006709688],"domain_scores_gemma":[0.9967891,0.0017548073,0.00031983663,0.00094397226,0.00010766254,0.00008463882],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0028655797,0.0003948828,0.0014359595,0.00015032859,0.00007875277,0.000038381466,0.00042495437,0.00041344942,0.0010503237],"category_scores_gemma":[0.00058586797,0.00024979026,0.000338993,0.00019066944,0.00019474553,0.000020445093,0.00006971029,0.0015861113,0.00008347622],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060610526,0.00006208332,0.0001627687,0.0031809208,0.001700497,0.000750226,0.0006998694,0.0000028577683,0.000014249599,0.00025841763,0.9769701,0.015591932],"study_design_scores_gemma":[0.0025032866,0.00082768046,0.00023858256,0.00043066673,0.0019215721,0.000007501657,0.00005819683,0.0025365257,0.0000040012383,0.0035555253,0.987664,0.00025248242],"about_ca_topic_score_codex":0.00011232348,"about_ca_topic_score_gemma":0.00003385284,"teacher_disagreement_score":0.05349545,"about_ca_system_score_codex":0.0006352687,"about_ca_system_score_gemma":0.00053794286,"threshold_uncertainty_score":0.9999954},"labels":[],"label_agreement":null},{"id":"W4405267343","doi":"10.1016/s1470-2045(24)00600-4","title":"Colorectal cancer incidence trends in younger versus older adults: an analysis of population-based cancer registry data","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Colorectal Cancer Screening and Detection","field":"Medicine","cited_by":263,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Institut National Du Cancer; Cancer Research UK; Centre International de Recherche sur le Cancer; World Health Organization; American Cancer Society","keywords":"Incidence (geometry); Medicine; Colorectal cancer; Cancer registry; Cancer incidence; Demography; Cancer; Young adult; Population; Gerontology; Internal medicine; Environmental health","score_opus":0.07133531787502449,"score_gpt":0.4129180765997136,"score_spread":0.3415827587246891,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405267343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925582,0.0023136716,0.000072240946,0.003056095,0.0008451865,0.00015926294,0.0002802527,0.0000931959,0.0006219128],"genre_scores_gemma":[0.9979729,0.0001722216,0.00015309989,0.00032051923,0.00058717636,0.00012368208,0.0005677958,0.000016002406,0.00008659833],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986106,0.00015808684,0.00030177983,0.00044854544,0.00023547656,0.00024549535],"domain_scores_gemma":[0.99879086,0.00030804132,0.00012687396,0.0006490208,0.00006509628,0.000060079117],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000540092,0.00013275062,0.0005868551,0.00041595582,0.00004374194,0.00001575949,0.00030355278,0.00015149878,0.0005115748],"category_scores_gemma":[0.00009973135,0.000096920754,0.00008668486,0.0019254836,0.000092638096,0.00014561183,0.00006811897,0.0003445707,0.0000016486575],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06356946,0.00031215145,0.55238,0.00031906736,0.0018050299,0.00014404545,0.0022690187,0.011851709,0.0009014506,0.00018678649,0.0029380368,0.3633232],"study_design_scores_gemma":[0.002048387,0.0008827113,0.7917163,0.00020264296,0.0012458065,0.0000060347547,0.00018973541,0.20186475,0.00014298434,0.00000737809,0.0015840776,0.00010920229],"about_ca_topic_score_codex":0.04576017,"about_ca_topic_score_gemma":0.1459635,"teacher_disagreement_score":0.36321402,"about_ca_system_score_codex":0.00063709315,"about_ca_system_score_gemma":0.00037315095,"threshold_uncertainty_score":0.9605942},"labels":[],"label_agreement":null},{"id":"W4405436978","doi":"10.1016/s1470-2045(24)00640-5","title":"The landscape of primary mismatch repair deficient gliomas in children, adolescents, and young adults: a multi-cohort study","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Sunnybrook Health Science Centre; Sinai Health System; Princess Margaret Cancer Centre; University of Toronto; University Health Network; SickKids Foundation; Stollery Children's Hospital; Hospital for Sick Children","funders":"Stand Up To Cancer; Canadian Institutes of Health Research; American Lebanese Syrian Associated Charities; Children’s Oncology Group; V Foundation for Cancer Research; Department of Science and Technology, Ministry of Science and Technology, India; National Cancer Institute; National Institutes of Health; U.S. Department of Health and Human Services","keywords":"Cohort; Medicine; Gerontology; Psychology; Internal medicine","score_opus":0.01809468824186251,"score_gpt":0.2981594577119601,"score_spread":0.2800647694700976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405436978","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98832667,0.007565487,0.0000052266337,0.00081627135,0.00052921724,0.0016516965,0.00001034225,0.00007949739,0.0010156102],"genre_scores_gemma":[0.9982591,0.000811458,0.00023435759,0.00023156685,0.00019062974,0.00014481613,0.0000054123752,0.000020308258,0.00010231768],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985617,0.00023294002,0.00033716645,0.000324379,0.00024091228,0.00030294814],"domain_scores_gemma":[0.99919504,0.00018150608,0.00006783163,0.00045912873,0.000051657633,0.00004486596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011855222,0.00014220286,0.00047831918,0.000077342556,0.00006339065,0.000013208442,0.00019053547,0.00009389975,0.00001277822],"category_scores_gemma":[0.000118645265,0.000076576296,0.00006167483,0.0003065211,0.00018643422,0.000015671674,0.00016121859,0.00037517268,0.000006926531],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008979207,0.00038676345,0.99031645,0.00015715403,0.00013538028,0.00004263796,0.0022101232,0.000005658985,0.00027422572,0.000018674791,0.0013949339,0.004160081],"study_design_scores_gemma":[0.0029781323,0.0011509093,0.99250585,0.00020720426,0.00013178815,0.0002279806,0.0010180661,0.0005986932,0.00007375022,0.000016280974,0.0010125895,0.000078742356],"about_ca_topic_score_codex":0.00034482288,"about_ca_topic_score_gemma":0.0013711051,"teacher_disagreement_score":0.009932483,"about_ca_system_score_codex":0.00019671927,"about_ca_system_score_gemma":0.00019180057,"threshold_uncertainty_score":0.31226906},"labels":[],"label_agreement":null},{"id":"W4405535660","doi":"10.1016/s1470-2045(24)00522-9","title":"Integrating cancer into crisis: a global vision for action from WHO and partners","year":2024,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"OpenAI; World Health Organization","keywords":"Action (physics); Cancer; Political science; Medicine","score_opus":0.6945686094663495,"score_gpt":0.6352259290948944,"score_spread":0.05934268037145507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405535660","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009241098,0.9506826,0.0009401724,0.041995816,0.002243615,0.0013164455,0.0015971052,0.00006585001,0.0010660161],"genre_scores_gemma":[0.000050255727,0.9862483,0.0019112509,0.0065010646,0.0034613535,0.001424262,0.00014251725,0.00004695796,0.0002140125],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.995151,0.0006773634,0.0029518108,0.0007612987,0.000052760995,0.00040578764],"domain_scores_gemma":[0.9952641,0.0018075758,0.002302399,0.00048478966,0.000039457333,0.00010164334],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.009941218,0.0003384268,0.0037970028,0.00012722789,0.00020866442,0.00014242626,0.00039648838,0.00051100814,0.00007822279],"category_scores_gemma":[0.0011605053,0.0002718361,0.0002849367,0.00019623674,0.0000907741,0.000167891,0.00013496485,0.0004518506,0.00047868665],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029694093,0.00002783843,0.00008315571,0.016587805,0.0005423006,0.0000012165449,0.0017371986,0.000003272975,3.305793e-8,0.072355166,0.468049,0.44058335],"study_design_scores_gemma":[0.0003262322,0.000097787546,0.0000255339,0.002722936,0.00025751579,0.0000059786557,0.00068613066,0.0007053648,1.4776479e-8,0.04346541,0.9514576,0.00024947993],"about_ca_topic_score_codex":0.004525074,"about_ca_topic_score_gemma":0.0048200237,"teacher_disagreement_score":0.48340863,"about_ca_system_score_codex":0.002292182,"about_ca_system_score_gemma":0.00052470743,"threshold_uncertainty_score":0.99997336},"labels":[],"label_agreement":null},{"id":"W4406069862","doi":"10.1016/s1470-2045(24)00717-4","title":"Non-inferiority trials: tyranny or good governance? – Authors' reply","year":2025,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Certainty; Clinical trial; Outcome (game theory); Imperfect; Corporate governance; Psychology; Actuarial science; Sample size determination; Medicine; Economics; Internal medicine; Epistemology; Statistics; Management; Philosophy; Mathematics","score_opus":0.6947687374654694,"score_gpt":0.6143013693445082,"score_spread":0.08046736812096122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406069862","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000136905965,0.00013521969,0.019571558,0.90087664,0.013098044,0.0023442875,0.0016129735,0.0002966933,0.062050883],"genre_scores_gemma":[0.000008355221,0.00062525424,0.3445925,0.5831289,0.040414095,0.0004654847,0.000021399284,0.000095459174,0.030648524],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.97843826,0.01482074,0.0035057217,0.0011578038,0.0008196999,0.0012577685],"domain_scores_gemma":[0.6560848,0.33780333,0.0028075175,0.0029161633,0.00026751298,0.000120675046],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.039307933,0.0007564858,0.007558109,0.000079049416,0.00022730691,0.00010247068,0.002449064,0.0030905306,0.0027235146],"category_scores_gemma":[0.41751784,0.00042903423,0.0008232122,0.0004640831,0.0006637509,0.00004710322,0.00069958554,0.007171985,0.00031151288],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013477699,0.000111370784,0.000012057352,0.0008321468,0.0005734477,0.0006002207,0.00009124133,1.6917582e-7,0.000005669575,0.028885778,0.95053226,0.017007884],"study_design_scores_gemma":[0.0020956497,0.0003129317,0.000038855214,0.00024587003,0.0007743508,0.00002464438,0.0000075060293,0.000018460962,0.000019538778,0.42218795,0.57398105,0.0002931827],"about_ca_topic_score_codex":0.00008944971,"about_ca_topic_score_gemma":0.00006314462,"teacher_disagreement_score":0.39330217,"about_ca_system_score_codex":0.0005679979,"about_ca_system_score_gemma":0.0014102415,"threshold_uncertainty_score":0.9998161},"labels":[],"label_agreement":null},{"id":"W4406579979","doi":"10.1016/s1470-2045(24)00678-8","title":"Global linear accelerator requirements and personalised country recommendations: a cross-sectional, population-based study","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Queen's University","funders":"National Cancer Institute; Prostate Cancer Fight Foundation","keywords":"Cross-sectional study; Population; Medicine; Environmental health","score_opus":0.07674652482535393,"score_gpt":0.49724009395603236,"score_spread":0.4204935691306784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406579979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.978576,0.00066138693,0.0009520583,0.014060408,0.0013576061,0.00086933776,0.000056834724,0.00008686631,0.0033794867],"genre_scores_gemma":[0.97361994,0.00014780983,0.0040969183,0.020074507,0.0010230419,0.00013902687,0.00010394274,0.00000922609,0.0007855742],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99892443,0.00023221476,0.00027266546,0.0002515114,0.00012046302,0.00019870487],"domain_scores_gemma":[0.99911284,0.00038687125,0.00010917724,0.00025476856,0.0000964896,0.00003985487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063409266,0.00011629916,0.0003553369,0.000045917346,0.00035064362,0.000018257471,0.00013210034,0.00014300983,0.0002419917],"category_scores_gemma":[0.00017953708,0.00008154471,0.00003397803,0.00025799585,0.00015243635,0.00006435705,0.000032530625,0.00020514708,0.0000055054634],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014411571,0.00044399832,0.99035895,0.000024282552,0.00016466534,0.000011220237,0.00009337623,0.00005156152,0.000021425967,0.0011717589,0.00359613,0.0026214977],"study_design_scores_gemma":[0.0066486076,0.000589714,0.87379843,0.000018053759,0.000060611776,0.000019035457,0.00016055105,0.00041733097,0.0000026824725,0.0006909492,0.11752804,0.000065975524],"about_ca_topic_score_codex":0.00006450139,"about_ca_topic_score_gemma":0.00021013472,"teacher_disagreement_score":0.11656048,"about_ca_system_score_codex":0.0005457843,"about_ca_system_score_gemma":0.00032490384,"threshold_uncertainty_score":0.3325297},"labels":[],"label_agreement":null},{"id":"W4406973835","doi":"10.1016/s1470-2045(24)00720-4","title":"The interplay between acute and late toxicity among patients receiving prostate radiotherapy: an individual patient data meta-analysis of six randomised trials","year":2025,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; University of Ottawa; Hamilton Health Sciences; Princess Margaret Cancer Centre; University of Toronto","funders":"Parker Institute for Cancer Immunotherapy; Office of Economic Adjustment; National Institutes of Health; Prostate Cancer Foundation; NRG Oncology; National Institute for Health and Care Research; Swim Across America; National Cancer Institute; Accuray; Institute for Mental Health Research; Cilag; Astellas Pharma; Varian Medical Systems; National Institute on Handicapped Research; Cancer Research Institute; AstraZeneca; Bristol-Myers Squibb; Cancer Research UK; Boston Scientific Corporation; Department of Health and Social Care; Royal Marsden NHS Foundation Trust; Pfizer; National Comprehensive Cancer Network; U.S. Department of Defense","keywords":"Meta-analysis; Medicine; Radiation therapy; Prostate cancer; Acute toxicity; Oncology; Internal medicine; Toxicity; Patient data; Database; Cancer; Computer science","score_opus":0.2174150352659144,"score_gpt":0.4680060619734827,"score_spread":0.2505910267075683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406973835","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0081842095,0.97744197,0.000012137004,0.0008577133,0.00022829227,0.0061458037,0.0069600013,0.000026907719,0.00014295083],"genre_scores_gemma":[0.0020013726,0.9920022,0.00018782752,0.0003475393,0.00016629019,0.0010920963,0.0040683923,0.00003398962,0.00010032048],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9919991,0.004586127,0.0018973113,0.00072218763,0.00036311024,0.00043217762],"domain_scores_gemma":[0.9869136,0.008674921,0.0022724331,0.0018771528,0.00013209955,0.00012975314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006590132,0.0005206684,0.011631445,0.0002530628,0.00018937426,0.000071320224,0.0008755713,0.00027974512,0.000053693217],"category_scores_gemma":[0.0008179694,0.00021839525,0.0013447196,0.0006161098,0.00032542905,0.00009780121,0.000524712,0.00049674994,8.209578e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010198539,0.0001872374,0.0023050397,0.0008353136,0.34941596,0.000008411998,0.0005756934,0.0000015040165,1.4884222e-7,0.000004479436,0.000914226,0.6447321],"study_design_scores_gemma":[0.008549313,0.0012009045,0.0031532361,0.0005897429,0.69118667,0.0000016844234,0.000017718226,0.000014624585,0.0000048883558,0.00001859641,0.29508427,0.0001783285],"about_ca_topic_score_codex":0.00007991551,"about_ca_topic_score_gemma":0.00027282326,"teacher_disagreement_score":0.64455384,"about_ca_system_score_codex":0.00023423728,"about_ca_system_score_gemma":0.0004599629,"threshold_uncertainty_score":0.89058995},"labels":[],"label_agreement":null},{"id":"W4407095407","doi":"10.1016/s1470-2045(24)00682-x","title":"Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"Janssen Alzheimer Immunotherapy Research And Development; Janssen Research and Development","keywords":"Ibrutinib; Venetoclax; Mantle cell lymphoma; Medicine; Placebo; Refractory (planetary science); Internal medicine; Oncology; Double blind; Phases of clinical research; Lymphoma; Clinical trial; Leukemia; Pathology; Chronic lymphocytic leukemia","score_opus":0.06933435470979207,"score_gpt":0.41336113665975854,"score_spread":0.3440267819499665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407095407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9508475,0.0009797071,0.00003482888,0.0017607152,0.00059430435,0.012370744,0.000008761831,0.00011276455,0.033290643],"genre_scores_gemma":[0.98203534,0.00030049888,0.00017647767,0.0013298655,0.0005118739,0.0021534641,0.00002332716,0.00004941631,0.013419738],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9953398,0.0012784454,0.0010818596,0.0006656204,0.00054544024,0.0010888458],"domain_scores_gemma":[0.99387413,0.004149743,0.00031622595,0.0013088679,0.00014894037,0.00020211686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00331887,0.0003904726,0.0021846711,0.00038235888,0.00017158194,0.000041829477,0.00070151786,0.00035563955,0.0004436755],"category_scores_gemma":[0.0009424503,0.00023949916,0.0002033016,0.00073032215,0.00027559052,0.000058302467,0.00031284502,0.0006921642,0.00025035805],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.97684294,0.0045056446,0.00021790009,0.00026840626,0.0004795261,0.0021037452,0.0034704902,0.00029877853,0.0005323575,0.00006991705,0.005349023,0.0058612665],"study_design_scores_gemma":[0.9431031,0.00304977,0.00011664992,0.00014764088,0.0005352228,0.000103457125,0.0026041928,0.031794675,0.0005366368,0.000038612903,0.017757539,0.0002125124],"about_ca_topic_score_codex":0.0013100993,"about_ca_topic_score_gemma":0.0014761286,"teacher_disagreement_score":0.033739854,"about_ca_system_score_codex":0.024373064,"about_ca_system_score_gemma":0.022010641,"threshold_uncertainty_score":0.9835337},"labels":[],"label_agreement":null},{"id":"W4407095785","doi":"10.1016/s1470-2045(24)00451-0","title":"Common Sense Oncology principles for the design, analysis, and reporting of phase 3 randomised clinical trials","year":2025,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Queen's University; McMaster University; Kingston Health Sciences Centre; Cancer Care South East","funders":"","keywords":"Medicine; Clinical trial; Oncology; Internal medicine; Clinical Oncology; Medical physics; Cancer","score_opus":0.953424582561647,"score_gpt":0.7698343604004043,"score_spread":0.18359022216124266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407095785","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000058906944,0.55383503,0.43211195,0.0011948852,0.0013428584,0.010143661,0.00037904503,0.000054257747,0.000932407],"genre_scores_gemma":[0.0000027039791,0.65744865,0.3398357,0.00025990853,0.0012138875,0.00104789,0.000012006892,0.000029369021,0.00014991146],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.871587,0.10252151,0.023924889,0.00094526535,0.00034362724,0.0006777411],"domain_scores_gemma":[0.10240518,0.86902463,0.026533227,0.0016487093,0.00027241273,0.00011582296],"candidate_categories":["metaresearch","metaepi_broad","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.34676886,0.00050935533,0.027372519,0.00018605287,0.0002049711,0.00003105405,0.0008701417,0.0013141133,0.000070303795],"category_scores_gemma":[0.84880215,0.00022858649,0.0032375825,0.00066411553,0.0010819732,0.000014047758,0.00044453377,0.0013538963,0.0000019034866],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061388877,0.00044794954,0.0000049639775,0.007822587,0.008390175,0.000033819462,0.00005147986,0.000002017489,5.44584e-7,0.013000528,0.0035560862,0.96055096],"study_design_scores_gemma":[0.022693459,0.001102437,0.000003125547,0.0016983958,0.07495863,0.00004214493,0.000027511036,0.00041544854,0.000004894736,0.15907425,0.7397462,0.00023349121],"about_ca_topic_score_codex":0.000010247041,"about_ca_topic_score_gemma":0.000037816946,"teacher_disagreement_score":0.9603175,"about_ca_system_score_codex":0.0001359994,"about_ca_system_score_gemma":0.001510466,"threshold_uncertainty_score":0.9999824},"labels":[],"label_agreement":null},{"id":"W4407095946","doi":"10.1016/s1470-2045(24)00674-0","title":"Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Clovis Oncology","keywords":"Oncology; Ovarian cancer; Medicine; Open label; Internal medicine; Chemotherapy; BRCA mutation; Cancer; Randomized controlled trial","score_opus":0.17658309875335135,"score_gpt":0.48424069930187097,"score_spread":0.30765760054851965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407095946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96872044,0.00017353073,0.0015525685,0.018494124,0.0014755384,0.005150709,0.0005025481,0.000037381884,0.0038931933],"genre_scores_gemma":[0.9715672,0.0018157818,0.015003742,0.002942925,0.0015472012,0.0037040547,0.00055494375,0.000050278075,0.0028138377],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9985305,0.00019907572,0.0005941774,0.00030104248,0.00016547753,0.00020974038],"domain_scores_gemma":[0.99791914,0.0007844887,0.00052352017,0.00045857238,0.0002663243,0.000047961963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005718761,0.00017214038,0.000900399,0.00009823893,0.00007387878,0.00001707869,0.000319715,0.00013016397,0.00015530003],"category_scores_gemma":[0.00014355806,0.000104726794,0.00006305886,0.00020451157,0.00021931126,0.00009676197,0.000018377545,0.00007913079,7.279074e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9122495,0.002435719,0.00000920366,0.00003626479,0.0009303228,0.000017825641,0.001285872,0.00004736979,0.008031915,0.00050830905,0.0023450642,0.0721026],"study_design_scores_gemma":[0.8595269,0.034776334,0.00005929843,0.0001076831,0.00030982797,0.000020953998,0.0001236186,0.0006564568,0.028028984,0.00020281768,0.07609541,0.00009173446],"about_ca_topic_score_codex":0.00045856505,"about_ca_topic_score_gemma":0.00061728834,"teacher_disagreement_score":0.07375035,"about_ca_system_score_codex":0.0005241951,"about_ca_system_score_gemma":0.0012704543,"threshold_uncertainty_score":0.42706347},"labels":[],"label_agreement":null},{"id":"W4407096049","doi":"10.1016/s1470-2045(24)00681-8","title":"Transforming oncology care in Latin America: artificial intelligence-driven solutions to bridge workforce gaps","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; Kingston Health Sciences Centre","funders":"National Cancer Institute","keywords":"Workforce; Bridge (graph theory); Latin Americans; Political science; Engineering; Medicine; Internal medicine","score_opus":0.08298119047212708,"score_gpt":0.44054293724503873,"score_spread":0.35756174677291164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407096049","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.25601712,0.007558634,0.23178181,0.30098006,0.005031164,0.004099063,0.00006291462,0.00038110086,0.19408812],"genre_scores_gemma":[0.95317054,0.0024323938,0.016721936,0.024840226,0.0015544405,0.00035241005,0.000032540924,0.00002661926,0.0008689167],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981234,0.00032047174,0.00047610677,0.00033372213,0.0001002405,0.0006460777],"domain_scores_gemma":[0.99853283,0.0008318829,0.00009198508,0.0003819604,0.000075283315,0.000086073705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004206979,0.00018087387,0.0008296655,0.00021480903,0.00023766063,0.0000062336,0.00032727324,0.00031037626,0.00012486173],"category_scores_gemma":[0.00019231594,0.00013509825,0.00009894334,0.0007887945,0.00049455557,0.0000434778,0.00006874014,0.00077005965,0.00007059691],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002547941,0.00029410364,0.0031019386,0.000049022223,0.000082329796,0.00013645929,0.009143107,0.0034088544,0.0017741104,0.031237202,0.0035306474,0.9446943],"study_design_scores_gemma":[0.0013244374,0.002307463,0.0061530983,0.00015554632,0.00010076916,0.00008286249,0.0042662304,0.0007910982,0.0007249299,0.0059061237,0.9779907,0.00019675623],"about_ca_topic_score_codex":0.00006323274,"about_ca_topic_score_gemma":0.0020464929,"teacher_disagreement_score":0.97446007,"about_ca_system_score_codex":0.001164261,"about_ca_system_score_gemma":0.00073580554,"threshold_uncertainty_score":0.5509147},"labels":[],"label_agreement":null},{"id":"W4407164384","doi":"10.1016/s1470-2045(24)00731-9","title":"Comparative efficacy and safety of ablative therapies in the management of primary localised renal cell carcinoma: a systematic review and meta-analysis","year":2025,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Princess Margaret Cancer Centre; University of Toronto; University Health Network; Western University; McMaster University; London Health Sciences Centre","funders":"","keywords":"Ablative case; Renal cell carcinoma; Meta-analysis; Medicine; Systematic review; Oncology; Internal medicine; Intensive care medicine; MEDLINE; Radiation therapy; Chemistry","score_opus":0.14908601705857505,"score_gpt":0.38820661703559206,"score_spread":0.239120599977017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407164384","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000072300674,0.98426247,0.000015749327,0.00074447616,0.000008056983,0.0077289557,0.00008072293,0.0000048042775,0.007082493],"genre_scores_gemma":[0.0071123685,0.9909108,0.00031411918,0.00041096951,0.00001173691,0.0007989087,0.000071937226,0.000010332735,0.00035880884],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99452955,0.0033251883,0.0013066548,0.00036313094,0.00027301107,0.00020247797],"domain_scores_gemma":[0.99515086,0.0026582577,0.0011575948,0.0009115604,0.00008835753,0.00003335037],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022671102,0.00040953222,0.014245722,0.00021362236,0.00003871003,0.000005627639,0.00033789244,0.00012381212,0.000030057334],"category_scores_gemma":[0.000020203295,0.0001641039,0.0008715169,0.0008768202,0.0003316357,0.000015552485,0.00015949558,0.00033761584,0.0000013038075],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015465423,0.00021460801,0.000004570764,0.8996248,0.097291596,0.00006382751,0.0012612968,0.0000015802533,2.7949918e-7,0.00037163307,0.00011202829,0.0008990948],"study_design_scores_gemma":[0.0014544363,0.00047458484,0.0007349164,0.024820082,0.966928,0.00004566737,0.00033099722,0.0000017996823,0.0000019588658,0.000022920443,0.005058883,0.00012572424],"about_ca_topic_score_codex":0.000037641425,"about_ca_topic_score_gemma":0.00001885473,"teacher_disagreement_score":0.87480474,"about_ca_system_score_codex":0.00019321461,"about_ca_system_score_gemma":0.00017617579,"threshold_uncertainty_score":0.9738091},"labels":[],"label_agreement":null},{"id":"W4407989366","doi":"10.1016/s1470-2045(25)00017-8","title":"Cancer incidence and mortality estimates in 2022 in southeast Asia: a comparative analysis","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital; Queen's University","funders":"National Institutes of Health; Institut National Du Cancer; World Health Organization; National Heart, Lung, and Blood Institute; Prostate Cancer Foundation","keywords":"Incidence (geometry); Cancer incidence; Cancer; Southeast asia; Demography; Geography; Medicine; History; Internal medicine; Ancient history; Sociology; Mathematics","score_opus":0.13537473392206062,"score_gpt":0.4686896833084056,"score_spread":0.333314949386345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407989366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9733417,0.0025851382,0.00009686048,0.00707588,0.000058340855,0.00023669656,0.00001183432,0.000015287207,0.01657828],"genre_scores_gemma":[0.9982512,0.00026867073,0.00026753743,0.00097053894,0.000056303452,0.00009436398,0.000005290642,0.0000019432625,0.0000841439],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989987,0.00015351093,0.00024490093,0.000228317,0.000118164484,0.00025638417],"domain_scores_gemma":[0.99940056,0.00022657319,0.0000706492,0.0002221235,0.000044282595,0.000035804154],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077266764,0.00009951832,0.0007445335,0.00017431047,0.000043724947,0.00000972833,0.00013543751,0.0000752184,0.00007384643],"category_scores_gemma":[0.000103090206,0.000069650436,0.000041167455,0.0011349493,0.00018586864,0.000047677935,0.00008976195,0.00032832878,0.000003095986],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037107526,0.00003648745,0.99344885,0.000025172054,0.00019191601,0.000069103495,0.0010434352,0.0006653693,0.00017763203,0.0022989842,0.00038218193,0.0012898075],"study_design_scores_gemma":[0.0010851774,0.000076292185,0.9869173,0.00010970123,0.0003292149,0.000008824616,0.0031340166,0.0063064005,0.000080650854,0.001306607,0.00058694236,0.00005886221],"about_ca_topic_score_codex":0.008124551,"about_ca_topic_score_gemma":0.080618255,"teacher_disagreement_score":0.07249371,"about_ca_system_score_codex":0.0002526252,"about_ca_system_score_gemma":0.000245557,"threshold_uncertainty_score":0.99848044},"labels":[],"label_agreement":null},{"id":"W4408110957","doi":"10.1016/s1470-2045(24)00648-x","title":"Dose optimisation to improve access to effective cancer medicines","year":2025,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"European Commission; Irish Aid; Ministère de l'Europe et des Affaires Étrangères; World Health Organization","keywords":"Access to medicines; Medical physics; Medicine; Computer science; Pathology","score_opus":0.10286992273043866,"score_gpt":0.4117046879583415,"score_spread":0.3088347652279028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408110957","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000035717232,0.9291088,0.0006553283,0.01043001,0.0042382847,0.0032783968,0.0007850035,0.0000526565,0.05141578],"genre_scores_gemma":[0.00006506283,0.97901666,0.00020831809,0.011021246,0.003336753,0.0033794472,0.000027751783,0.000048615304,0.0028961417],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99752706,0.000101658916,0.0009782905,0.00074649695,0.000034346096,0.00061213353],"domain_scores_gemma":[0.99754506,0.000669865,0.0007718844,0.0007629587,0.000067803114,0.00018243359],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012934131,0.00042831368,0.0035559451,0.00042486074,0.00013208731,0.00010864467,0.0013599385,0.00045508382,0.00034651475],"category_scores_gemma":[0.00079954293,0.00033513774,0.00029735183,0.0005903121,0.00008004094,0.00017639589,0.00044869236,0.00051685853,0.0008798068],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000065175846,0.000026505579,0.000056484812,0.002221104,0.00017730646,0.0000027747692,0.00023089533,0.000057986133,1.1442433e-7,0.009632569,0.054370873,0.9331582],"study_design_scores_gemma":[0.00049281894,0.00024007348,0.0005336129,0.0016480885,0.0001444362,0.000002540618,0.0000074132904,0.000007752053,8.704877e-7,0.0027553265,0.99379915,0.0003679359],"about_ca_topic_score_codex":0.0008667818,"about_ca_topic_score_gemma":0.0006962114,"teacher_disagreement_score":0.93942827,"about_ca_system_score_codex":0.0013967621,"about_ca_system_score_gemma":0.0004962288,"threshold_uncertainty_score":0.99991006},"labels":[],"label_agreement":null},{"id":"W4408110958","doi":"10.1016/s1470-2045(24)00730-7","title":"ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"Associazione Italiana per la Ricerca sul Cancro; Ministero della Salute; Istituto Europeo di Oncologia; Fondazione AIRC per la ricerca sul cancro ETS","keywords":"Prostate cancer; Open label; Medicine; Oncology; Randomized controlled trial; Internal medicine; Clinical trial; Urology; Cancer","score_opus":0.17892813163927979,"score_gpt":0.5022070697166905,"score_spread":0.3232789380774107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408110958","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8927735,0.007658145,0.00033787015,0.067237236,0.0044089784,0.021026364,0.0005893841,0.00011423748,0.0058542453],"genre_scores_gemma":[0.9397343,0.024509601,0.0022332983,0.0098102605,0.0034031596,0.0181266,0.0004025681,0.00007593179,0.0017042946],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99762416,0.0003569965,0.00064506487,0.0005886247,0.00017989433,0.0006052372],"domain_scores_gemma":[0.9969757,0.0017321106,0.00031787824,0.00054638885,0.00024847977,0.00017940684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012974405,0.00030584174,0.0017179888,0.000063328065,0.00019466064,0.000044284123,0.0002958257,0.00016212896,0.00003485048],"category_scores_gemma":[0.00029473304,0.00017577894,0.00014071348,0.00024336831,0.0003723921,0.00007223288,0.00014624467,0.00039145586,0.000017359682],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8358114,0.0033966415,0.00022658771,0.00005821644,0.0016946538,0.000118312004,0.00036430842,0.000005776238,0.00007357048,0.0006142967,0.073978856,0.0836574],"study_design_scores_gemma":[0.76826835,0.028962413,0.00039409183,0.00017534354,0.0016033158,0.000014568252,0.00013876175,0.00021060814,0.00065910333,0.00013673815,0.19926736,0.00016937302],"about_ca_topic_score_codex":0.00015535427,"about_ca_topic_score_gemma":0.0003857572,"teacher_disagreement_score":0.1252885,"about_ca_system_score_codex":0.0008033286,"about_ca_system_score_gemma":0.0015987494,"threshold_uncertainty_score":0.71680576},"labels":[],"label_agreement":null},{"id":"W4408511515","doi":"10.1016/s1470-2045(25)00034-8","title":"Hypofractionated radiotherapy for prostate cancer (HYDRA): an individual patient data meta-analysis of randomised trials in the MARCAP consortium","year":2025,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Juravinski Cancer Centre; University of Toronto; Hamilton Health Sciences; Princess Margaret Cancer Centre; McMaster University","funders":"Institute for Mental Health Research; National Institutes of Health; Rising Tide Foundation; NIH Blueprint for Neuroscience Research; Astellas Pharma; U.S. Department of Defense; Sanofi; ViewRay; Accuray; Department of Health and Social Care; Cancer Research Institute; Royal Marsden NHS Foundation Trust; National Institute for Health and Care Research; Swim Across America; Varian Medical Systems; Cancer Research UK; Prostate Cancer Foundation; National Institute on Handicapped Research","keywords":"Prostate cancer; Medicine; Lernaean Hydra; Meta-analysis; Radiation therapy; Oncology; Cancer; Internal medicine; Biology","score_opus":0.46397613657863224,"score_gpt":0.5250809240926702,"score_spread":0.06110478751403792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408511515","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006535694,0.9675233,0.000017154664,0.007177549,0.00026664676,0.012016051,0.012805367,0.000016521299,0.00011209488],"genre_scores_gemma":[0.00010865929,0.9744401,0.00033239057,0.002996419,0.000240078,0.014850535,0.0069002355,0.000028173125,0.00010341474],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9916204,0.0050729592,0.0019480379,0.00064541,0.00033418444,0.00037898222],"domain_scores_gemma":[0.9832097,0.012839738,0.0019932226,0.0017532383,0.00014765235,0.000056440622],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009161665,0.00043110334,0.012230488,0.0004153707,0.00007912965,0.000029140889,0.00086182536,0.00026069797,0.00038019047],"category_scores_gemma":[0.0009244583,0.00018139141,0.0019594426,0.0009911255,0.00018085915,0.00007428985,0.00009997174,0.00040371707,8.150644e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045442726,0.00085110567,0.000030470652,0.0028571635,0.3302565,0.000019886247,0.000617582,0.000044614957,6.276089e-7,0.000099898854,0.012714262,0.64796364],"study_design_scores_gemma":[0.009610159,0.0005271807,0.000040315183,0.00022043398,0.4021734,0.0000052279947,0.00005610027,0.000031567335,0.0000022066863,0.000029097884,0.58720773,0.00009656289],"about_ca_topic_score_codex":0.00046550736,"about_ca_topic_score_gemma":0.0006543524,"teacher_disagreement_score":0.6478671,"about_ca_system_score_codex":0.00034689868,"about_ca_system_score_gemma":0.0018127786,"threshold_uncertainty_score":0.8360517},"labels":[],"label_agreement":null},{"id":"W4408887789","doi":"10.1016/s1470-2045(25)00082-8","title":"Low-dose CT for lung cancer screening in a high-risk population (SUMMIT): a prospective, longitudinal cohort study","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Grail; Medical Research Council; W. Garfield Weston Foundation; CRUK Lung Cancer Centre of Excellence; Longfonds; National Institute for Health and Care Research; Cancer Research UK; Garfield Weston Foundation; HORIZON EUROPE Framework Programme; Rosetrees Trust; American Association for Cancer Research; UK Research and Innovation; Johnson and Johnson","keywords":"Summit; Lung cancer; Medicine; Prospective cohort study; Cohort; Oncology; Population; Demography; Environmental health; Internal medicine; Geography; Cartography; Sociology","score_opus":0.025799135640048675,"score_gpt":0.3853799313955376,"score_spread":0.35958079575548896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408887789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887335,0.0006916587,0.00021311623,0.004809673,0.00037838102,0.0045379344,0.000030491334,0.000047333502,0.0005579381],"genre_scores_gemma":[0.9937292,0.0003064669,0.00049014366,0.00045902698,0.00038635824,0.0042944048,0.00002656436,0.000014956211,0.0002929275],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99877155,0.000143269,0.0002681338,0.00037654827,0.00013154902,0.00030893163],"domain_scores_gemma":[0.99914736,0.0002860795,0.00012762476,0.00033143393,0.0000723207,0.000035179637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065215054,0.00014895659,0.00066449895,0.00009849196,0.00012927088,0.000013551765,0.00010390185,0.00004850532,0.00003401916],"category_scores_gemma":[0.0000911515,0.00009843165,0.00006802084,0.00028453942,0.0000387173,0.000040269275,0.00005286407,0.00022167845,0.000001482997],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016766399,0.00092448643,0.98292804,0.000097007025,0.00069349667,0.000049380473,0.00021785947,0.00026716143,0.0000028295408,0.0007047895,0.0025917264,0.009846579],"study_design_scores_gemma":[0.012776158,0.0007810282,0.9831741,0.00022454842,0.00092343765,0.0000033249478,0.000134662,0.0009489886,0.00004874399,0.0003488707,0.0005516158,0.00008456287],"about_ca_topic_score_codex":0.010122199,"about_ca_topic_score_gemma":0.028333398,"teacher_disagreement_score":0.018211199,"about_ca_system_score_codex":0.0011723209,"about_ca_system_score_gemma":0.0001720354,"threshold_uncertainty_score":0.9964695},"labels":[],"label_agreement":null},{"id":"W4409097319","doi":"10.1016/s1470-2045(25)00021-x","title":"Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"ImmunoGen; AbbVie","keywords":"Open label; Medicine; Oncology; Folate receptor; Chemotherapy; Internal medicine; Ovarian cancer; Randomized controlled trial; Cancer; Cancer cell","score_opus":0.08608806022690466,"score_gpt":0.41194481523072124,"score_spread":0.3258567550038166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409097319","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9601817,0.00047399473,0.0000148601775,0.024134578,0.0019346641,0.01164951,0.00032431868,0.000042318003,0.0012440654],"genre_scores_gemma":[0.98901033,0.00024374164,0.0016242001,0.004788558,0.00064723723,0.00309106,0.0003782202,0.000055684293,0.00016095232],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99648297,0.0009552793,0.0009571952,0.0006233043,0.00045369976,0.0005275515],"domain_scores_gemma":[0.9957123,0.002464092,0.00069669966,0.0008163046,0.00021753884,0.00009305574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011909512,0.00039516366,0.0016471518,0.00007723802,0.0002654848,0.00009039522,0.00039737276,0.00019548943,0.00045367476],"category_scores_gemma":[0.00054976606,0.000204935,0.00010665625,0.000459827,0.000159406,0.00009533576,0.000101942984,0.00046498477,0.000006830719],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8952398,0.0054583247,0.005704466,0.00000933011,0.0024052528,0.000033649074,0.000799714,0.0000039077177,0.00019632085,0.00007569796,0.0027080404,0.08736555],"study_design_scores_gemma":[0.9429347,0.028024765,0.022240741,0.0002808024,0.001170714,6.1273266e-7,0.00009668646,0.00007611971,0.00022554693,0.000083204686,0.004657351,0.00020873976],"about_ca_topic_score_codex":0.0028748868,"about_ca_topic_score_gemma":0.0014713194,"teacher_disagreement_score":0.08715681,"about_ca_system_score_codex":0.00085862103,"about_ca_system_score_gemma":0.0012380612,"threshold_uncertainty_score":0.8357007},"labels":[],"label_agreement":null},{"id":"W4409097322","doi":"10.1016/s1470-2045(25)00031-2","title":"First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Astellas Pharma US; Pfizer","keywords":"Enzalutamide; Prostate cancer; Placebo; Medicine; Homologous recombination; Oncology; Internal medicine; Cancer research; Gene; Cancer; Biology; Genetics; Pathology; Androgen receptor","score_opus":0.07915377553234595,"score_gpt":0.38702915174321567,"score_spread":0.3078753762108697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409097322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95748395,0.003379308,0.00006497019,0.020436889,0.00059234747,0.016557753,0.00016003438,0.00010685627,0.0012179108],"genre_scores_gemma":[0.9818812,0.0019019305,0.00051048235,0.00060322863,0.00026029872,0.012246243,0.00048973004,0.000038826896,0.00206806],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964705,0.00076747744,0.0010700313,0.0006352634,0.00044953162,0.0006072081],"domain_scores_gemma":[0.9951547,0.0032887647,0.00054317963,0.00063202286,0.00026427174,0.0001170578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017854555,0.00041080054,0.0015452208,0.00021473263,0.00045362907,0.000094814124,0.00021137713,0.00015297187,0.00007162358],"category_scores_gemma":[0.00061698165,0.00021399977,0.00016157891,0.00047609603,0.00039244333,0.00016430425,0.000099861245,0.00058912864,0.0000039300753],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.987086,0.00063145783,0.00073373434,0.00006812724,0.0024033273,0.00044405914,0.0026091952,0.0021159742,0.00052332995,0.00018629679,0.00087337394,0.0023251285],"study_design_scores_gemma":[0.98399764,0.0036681746,0.0006377163,0.0001478014,0.0016280066,0.00003363402,0.0010168132,0.006055754,0.0011136829,0.00044557545,0.0010338427,0.00022136769],"about_ca_topic_score_codex":0.0032251433,"about_ca_topic_score_gemma":0.010659794,"teacher_disagreement_score":0.024397269,"about_ca_system_score_codex":0.0013772626,"about_ca_system_score_gemma":0.0021589904,"threshold_uncertainty_score":0.8726657},"labels":[],"label_agreement":null},{"id":"W4409103399","doi":"10.1016/s1470-2045(25)00030-0","title":"First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Astellas Pharma US; Pfizer","keywords":"Enzalutamide; Medicine; Placebo; Prostate cancer; Internal medicine; Clinical trial; Double blind; Oncology; First line; Urology; Cancer; Androgen receptor; Pathology","score_opus":0.12787455261069358,"score_gpt":0.4242313951586915,"score_spread":0.29635684254799793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409103399","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9067606,0.005026379,0.0003224778,0.04502774,0.0031401499,0.036512587,0.0009732755,0.0001769192,0.0020598986],"genre_scores_gemma":[0.9588548,0.0015670517,0.000514718,0.0017727456,0.0012546919,0.029318558,0.0009318841,0.00008398952,0.0057015903],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9953161,0.0006687294,0.001473601,0.0007851839,0.000658853,0.0010975302],"domain_scores_gemma":[0.98949945,0.008039139,0.0008107926,0.0010177926,0.0004186146,0.00021418728],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0021753183,0.00060625107,0.002520963,0.00017726251,0.0007767933,0.00013299358,0.0005211698,0.00022817597,0.00021514365],"category_scores_gemma":[0.001372937,0.00031491756,0.00057173695,0.00046496678,0.0005147652,0.00013680402,0.00016366705,0.0007312452,0.000017525113],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.978634,0.0007128082,0.0001360469,0.00014528721,0.005324168,0.00021133256,0.0017769185,0.0015543057,0.000803622,0.0003597656,0.005742623,0.004599136],"study_design_scores_gemma":[0.9600076,0.0039841705,0.00006852073,0.00014594497,0.0039125816,0.000012460661,0.0010236423,0.0032342868,0.0018305246,0.00062135485,0.024866046,0.00029287313],"about_ca_topic_score_codex":0.0022389167,"about_ca_topic_score_gemma":0.0052678213,"teacher_disagreement_score":0.052094195,"about_ca_system_score_codex":0.0016693353,"about_ca_system_score_gemma":0.0040327865,"threshold_uncertainty_score":0.99993026},"labels":[],"label_agreement":null},{"id":"W4409417639","doi":"10.1016/s1470-2045(25)00150-0","title":"Using patient-reported outcomes and health-related quality of life data in regulatory decisions on cancer treatment: highlights from an EMA-EORTC workshop","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada; Queen's University","funders":"PTC Therapeutics; Pfizer; Merck KGaA; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Quality of life (healthcare); Cancer; Medicine; Quality (philosophy); Gerontology; Internal medicine; Nursing","score_opus":0.7337403083292157,"score_gpt":0.5605171469390939,"score_spread":0.17322316139012173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409417639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90523803,0.0045338124,0.00014547566,0.08738937,0.00072136585,0.0006806698,0.0007413119,0.000028135624,0.00052184775],"genre_scores_gemma":[0.98391104,0.00096477,0.0010577005,0.01360591,0.0001240547,0.00006118853,0.00015055342,0.000017397027,0.00010740022],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9929029,0.0013354269,0.004642277,0.00067685463,0.00008174317,0.0003608018],"domain_scores_gemma":[0.9913264,0.003688161,0.0031274564,0.001685638,0.000038649756,0.00013368184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011799853,0.00019331586,0.0022161424,0.00027844417,0.00018276123,0.000022352875,0.0004394241,0.0002203351,0.00009927418],"category_scores_gemma":[0.0027460367,0.00016861988,0.00005718944,0.00026627042,0.00014385117,0.00021743902,0.00014716286,0.00019577298,0.000017307506],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035066422,0.00066343264,0.8761318,0.00008961921,0.0005605182,0.0000030494782,0.0055054366,0.0011246575,0.0000062190998,0.1047341,0.0048805834,0.0059499466],"study_design_scores_gemma":[0.0031951251,0.0001348381,0.9636229,0.00015727496,0.000019045056,7.844488e-7,0.0008601267,0.0043482147,0.0000020676252,0.018047636,0.009437945,0.00017401435],"about_ca_topic_score_codex":0.0431957,"about_ca_topic_score_gemma":0.03056126,"teacher_disagreement_score":0.087491155,"about_ca_system_score_codex":0.0011296853,"about_ca_system_score_gemma":0.00080046046,"threshold_uncertainty_score":0.9871285},"labels":[],"label_agreement":null},{"id":"W4409417679","doi":"10.1016/s1470-2045(25)00151-2","title":"Use of patient-reported outcomes to inform symptom and functional outcomes in cancer drug regulatory decisions: challenges and future directions","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"","keywords":"Drug; Cancer drugs; Cancer; Regulatory science; Medicine; Psychology; Risk analysis (engineering); Pharmacology; Internal medicine","score_opus":0.37081789683269756,"score_gpt":0.44724596277178247,"score_spread":0.07642806593908491,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409417679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7898346,0.008602615,0.000014934845,0.19905958,0.0009444949,0.00045636963,0.00007608329,0.000020241265,0.0009910774],"genre_scores_gemma":[0.93372583,0.024948455,0.0017614006,0.036583126,0.00041451922,0.00069002167,0.000014621528,0.000027037886,0.0018349751],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99742174,0.0001959209,0.001795145,0.00030109767,0.000060428498,0.00022564232],"domain_scores_gemma":[0.9958639,0.002847555,0.00077096233,0.00038916638,0.000060633967,0.00006774596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037858598,0.00013088387,0.0010504101,0.00037519177,0.0001327886,0.0000188732,0.00010289897,0.00012504958,0.000051516567],"category_scores_gemma":[0.0019709663,0.000113812144,0.000048451202,0.00017817413,0.000095038406,0.00020915165,0.00010645553,0.00015884431,0.00001384061],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000065929395,0.00009085505,0.839789,0.00008377799,0.0001803248,5.661864e-7,0.0054753036,0.00008761951,7.46513e-7,0.12512884,0.008340341,0.020756748],"study_design_scores_gemma":[0.00054792565,0.000026411359,0.7091288,0.0000324808,0.0000076069073,0.0000017737403,0.0011380357,0.00006057935,6.278749e-7,0.0057205535,0.28325987,0.000075362914],"about_ca_topic_score_codex":0.0008765499,"about_ca_topic_score_gemma":0.005262083,"teacher_disagreement_score":0.2749195,"about_ca_system_score_codex":0.00033073736,"about_ca_system_score_gemma":0.00015403099,"threshold_uncertainty_score":0.46411243},"labels":[],"label_agreement":null},{"id":"W4409986468","doi":"10.1016/s1470-2045(25)00212-8","title":"Meta-analysis on SBRT and ablation for localised RCC – Authors' reply","year":2025,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Advanced X-ray and CT Imaging","field":"Engineering","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Ablation; Medicine; Internal medicine","score_opus":0.09482312639389179,"score_gpt":0.33581998624526954,"score_spread":0.24099685985137775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409986468","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000042020485,0.0018735995,0.14031816,0.84387225,0.00074412767,0.00065526355,0.0002276107,0.00034454415,0.011922395],"genre_scores_gemma":[0.0036950049,0.0002793096,0.0071181282,0.9728579,0.0045020347,0.0006128,0.0005716656,0.000081265694,0.010281883],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99872434,0.00016521227,0.0003032003,0.00032400514,0.000117768526,0.000365459],"domain_scores_gemma":[0.9981739,0.0010671862,0.00011168268,0.0005780896,0.000046158435,0.000022989152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005745326,0.00026913374,0.0014337285,0.00019389142,0.00010234005,0.000029159633,0.00026322738,0.00038185084,0.00008334071],"category_scores_gemma":[0.00006496058,0.00018854521,0.00042801496,0.0002780574,0.000065633736,0.00004608178,0.000035606212,0.001009879,0.000010835108],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000048272606,0.000005685617,0.0000045562797,0.000177789,0.03290773,0.000021173639,0.00014068498,0.032076657,0.00001815952,0.00039583739,0.9324027,0.0018008022],"study_design_scores_gemma":[0.00031171303,0.000047416233,0.00001796267,0.000005196579,0.05126618,0.0000031555544,0.000011091204,0.014816982,0.00004423551,0.002817835,0.9304747,0.00018353661],"about_ca_topic_score_codex":0.000009967144,"about_ca_topic_score_gemma":0.000019942185,"teacher_disagreement_score":0.13320003,"about_ca_system_score_codex":0.00013030361,"about_ca_system_score_gemma":0.00002660997,"threshold_uncertainty_score":0.76886505},"labels":[],"label_agreement":null},{"id":"W4410015461","doi":"10.1016/s1470-2045(25)00128-7","title":"Incidence and prevalence of antimicrobial resistance in outpatients with cancer: a multicentre, retrospective, cohort study","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Retrospective cohort study; Medicine; Incidence (geometry); Antimicrobial; Cohort; Cancer; Cancer incidence; Cohort study; Internal medicine; Microbiology; Biology","score_opus":0.015814742378796924,"score_gpt":0.33387405134784404,"score_spread":0.3180593089690471,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410015461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99143714,0.00037576444,0.000011731679,0.0015330032,0.00014623461,0.0012506214,0.000015019865,0.000016205071,0.0052143084],"genre_scores_gemma":[0.99734193,0.00084161875,0.00016043741,0.00045069229,0.000043876465,0.00015800339,6.722249e-7,0.000005534699,0.0009972254],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99914014,0.00013089327,0.00019949286,0.0002402623,0.00011338248,0.00017581094],"domain_scores_gemma":[0.99938303,0.000086669505,0.000109921806,0.000282897,0.00011441654,0.000023086324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029536057,0.0000882807,0.0004581933,0.000064350745,0.00005685467,0.00000453613,0.000112952264,0.000039507264,0.000024870642],"category_scores_gemma":[0.00005944919,0.000058229944,0.000015314858,0.00033593018,0.00020072312,0.000039732044,0.00006250725,0.00022137335,8.892229e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022050526,0.00035529435,0.99448377,0.00024415946,0.00007437491,0.000018147557,0.00083453895,0.000008147846,0.0007392531,0.00019684245,0.000601434,0.00023898503],"study_design_scores_gemma":[0.0046071694,0.00043875724,0.9930765,0.0003605105,0.00018973908,0.000006289762,0.00012511737,0.000006788492,0.00041531253,0.00003576777,0.0006860934,0.000051963503],"about_ca_topic_score_codex":0.0008578638,"about_ca_topic_score_gemma":0.015037326,"teacher_disagreement_score":0.014179463,"about_ca_system_score_codex":0.00027595603,"about_ca_system_score_gemma":0.00023491611,"threshold_uncertainty_score":0.8391181},"labels":[],"label_agreement":null},{"id":"W4410015550","doi":"10.1016/s1470-2045(25)00020-8","title":"International consensus on laryngeal preservation strategies in laryngeal and hypopharyngeal cancer","year":2025,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Rehabilitation Institute","funders":"","keywords":"Hypopharyngeal cancer; Larynx; Medicine; Cancer; General surgery; Surgery; Internal medicine","score_opus":0.13223500994658555,"score_gpt":0.45350917649095857,"score_spread":0.321274166544373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410015550","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005030032,0.912733,6.812012e-7,0.016613804,0.00096322666,0.0008862824,0.00014854595,0.000044544213,0.06810693],"genre_scores_gemma":[0.0002190154,0.9948214,0.00010065716,0.0015411751,0.0013534658,0.00047545347,0.00009212578,0.000020300804,0.001376397],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982587,0.00034144227,0.00047246547,0.0003897183,0.0001929023,0.00034477457],"domain_scores_gemma":[0.99838215,0.0010118915,0.00019247516,0.0002910272,0.000070598544,0.000051879357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004969242,0.00030146894,0.0022872712,0.00019537049,0.00007460902,0.000023310662,0.00024524055,0.0003084272,0.00007585922],"category_scores_gemma":[0.0001535426,0.00019005066,0.000119426884,0.00022530774,0.00019357192,0.0000445526,0.0001723834,0.00083482027,0.000010381994],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005213588,0.00014492797,0.00036872056,0.008978589,0.00041138573,0.0001763583,0.00029628418,0.000002558898,0.0000012172943,0.0029400855,0.03866274,0.94749576],"study_design_scores_gemma":[0.0017592419,0.00046637596,0.0012567835,0.0071343095,0.00038606004,0.000057108376,0.000092835326,0.000017342341,3.6370835e-7,0.00021581369,0.98847,0.00014376991],"about_ca_topic_score_codex":0.00038963795,"about_ca_topic_score_gemma":0.0016588372,"teacher_disagreement_score":0.9498073,"about_ca_system_score_codex":0.00043409306,"about_ca_system_score_gemma":0.0014006543,"threshold_uncertainty_score":0.7750041},"labels":[],"label_agreement":null},{"id":"W4410015558","doi":"10.1016/s1470-2045(25)00079-8","title":"Antimicrobial resistance in patients with haematological malignancies: a scoping review","year":2025,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Kingston Health Sciences Centre; Princess Margaret Cancer Centre; Occupational Cancer Research Centre; Queen's University; Cancer Care Ontario; University of Toronto; Ontario Institute for Cancer Research","funders":"Princess Margaret Cancer Foundation","keywords":"Antimicrobial; Medicine; Antibiotic resistance; Intensive care medicine; Oncology; Internal medicine; Biology; Microbiology; Antibiotics","score_opus":0.06813807971903882,"score_gpt":0.40276218604490405,"score_spread":0.33462410632586526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410015558","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000024124745,0.9830408,0.000006388572,0.0018485527,0.00024025157,0.0038312743,0.000028605109,0.000048502123,0.010931489],"genre_scores_gemma":[0.0000064002425,0.9939011,0.00023262479,0.0042805676,0.00017691392,0.0006769998,0.00006449235,0.000020872452,0.0006400824],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99794847,0.0004941126,0.000624549,0.00039742354,0.00013820312,0.00039722203],"domain_scores_gemma":[0.9985286,0.00037780456,0.00034270974,0.00061819714,0.00008706714,0.00004561551],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043744035,0.00029728707,0.003920051,0.0001012318,0.00008169493,0.000010179697,0.0002980419,0.00024128477,0.00010231063],"category_scores_gemma":[0.00015846873,0.00015366933,0.0002105726,0.00066836807,0.00017343635,0.000026181724,0.00010698738,0.00071122515,0.00004680818],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004011754,0.0003822628,0.0012228567,0.8358813,0.00019059445,0.00027483192,0.00002902304,1.4134035e-7,7.7182825e-8,0.000922658,0.048278403,0.11241666],"study_design_scores_gemma":[0.0008325209,0.00010725966,0.00013432399,0.45730397,0.0006306976,0.000051795192,6.2966865e-7,4.170686e-9,8.750317e-8,0.0000062987215,0.5408347,0.000097672775],"about_ca_topic_score_codex":0.000006743789,"about_ca_topic_score_gemma":0.00035682815,"teacher_disagreement_score":0.49255633,"about_ca_system_score_codex":0.00034245272,"about_ca_system_score_gemma":0.0016927501,"threshold_uncertainty_score":0.6266453},"labels":[],"label_agreement":null},{"id":"W4410080762","doi":"10.1016/s1470-2045(25)00140-8","title":"Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single-arm, phase 2a study","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Ottawa Hospital; Jewish General Hospital","funders":"Jazz Pharmaceuticals; Pfizer","keywords":"Fulvestrant; Palbociclib; Metastatic breast cancer; Medicine; Oncology; Internal medicine; Cancer; Breast cancer; Hormone receptor; Gynecology; Estrogen receptor","score_opus":0.02242860463022142,"score_gpt":0.3244790213498309,"score_spread":0.3020504167196095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410080762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98631465,0.0021299457,0.000072030736,0.0040160036,0.00013915381,0.0037079486,0.0029900505,0.00009975814,0.0005304826],"genre_scores_gemma":[0.9951106,0.0005557733,0.0012276133,0.0014673963,0.00021510501,0.00031103916,0.0009075802,0.000050641913,0.00015425321],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9967597,0.00078032207,0.000671251,0.00080010196,0.00031235363,0.00067626877],"domain_scores_gemma":[0.99776965,0.000839629,0.00038788872,0.0006191241,0.00022956968,0.00015410985],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00040378448,0.00044886043,0.0014171109,0.00014376733,0.00014253215,0.00003363887,0.000252929,0.00009254141,0.000041409185],"category_scores_gemma":[0.000071968214,0.00030081143,0.00005205585,0.0005338352,0.0004062729,0.00019974222,0.00013264838,0.00053576584,0.0000060013444],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43800777,0.024492078,0.119433515,0.00020434085,0.0044614137,0.0008529251,0.03194963,0.00030279718,0.0073544276,0.000047146685,0.00081122195,0.37208274],"study_design_scores_gemma":[0.2681205,0.010817356,0.7109787,0.0011635176,0.0017725353,0.000060832415,0.0030616361,0.00024017204,0.0005997138,0.00008482615,0.0025778422,0.00052237965],"about_ca_topic_score_codex":0.004085582,"about_ca_topic_score_gemma":0.0034332292,"teacher_disagreement_score":0.59154516,"about_ca_system_score_codex":0.0012461169,"about_ca_system_score_gemma":0.00043474342,"threshold_uncertainty_score":0.9999444},"labels":[],"label_agreement":null},{"id":"W4410202982","doi":"10.1016/s1470-2045(25)00152-4","title":"Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"Cancer Council Queensland; National Health and Medical Research Council; National Institutes of Health; Arts South Australia; Associazione Italiana per la Ricerca sul Cancro; Korea Health Industry Development Institute; European Society for Medical Oncology; Ministry of Health and Welfare; Cancer Australia; Peter MacCallum Cancer Centre; National Breast Cancer Foundation; Fondazione AIRC per la ricerca sul cancro ETS; Susan G. Komen; Breast Cancer Research Foundation","keywords":"Medicine; Breast cancer; Oncology; Cohort; Cancer; Cohort study; Gynecology; Internal medicine; Obstetrics","score_opus":0.012886156496256743,"score_gpt":0.32309992416142397,"score_spread":0.31021376766516723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410202982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99434286,0.00009681327,0.000066872904,0.0023628175,0.0005468183,0.0002807369,0.00014504607,0.00001111763,0.0021469241],"genre_scores_gemma":[0.9983446,0.0004007449,0.00009045077,0.000104974904,0.0005195711,0.00013228809,0.000060530085,0.000009799569,0.0003370468],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988824,0.0003667037,0.0001647991,0.00028265346,0.00011509437,0.00018836443],"domain_scores_gemma":[0.9994194,0.00007735085,0.00014049523,0.0002308236,0.0001077975,0.000024154178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010953791,0.00009773299,0.00023622453,0.000049962513,0.00010411603,0.000028717306,0.00020181539,0.00010267302,0.000013151954],"category_scores_gemma":[0.00008514424,0.00007721813,0.000015825486,0.00013154688,0.000083484716,0.000009612833,0.00008725237,0.00016596584,4.3665648e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001901736,0.000039135375,0.9935524,0.0000035522237,0.00044966937,0.0000012302254,0.00049858855,0.00036740035,0.0005162277,0.000021374477,0.0005026558,0.0038576287],"study_design_scores_gemma":[0.0010380965,0.00012269431,0.9937789,0.000007437359,0.00009997503,0.000004186027,0.00084112544,0.000040880583,0.0003528921,0.000035184006,0.0035907167,0.000087947585],"about_ca_topic_score_codex":0.0026810812,"about_ca_topic_score_gemma":0.025710411,"teacher_disagreement_score":0.02302933,"about_ca_system_score_codex":0.00041593867,"about_ca_system_score_gemma":0.00034449363,"threshold_uncertainty_score":0.9920678},"labels":[],"label_agreement":null},{"id":"W4410795851","doi":"10.1016/s1470-2045(25)00157-3","title":"Contributions of cancer treatment and genetic predisposition to risk of subsequent neoplasms in long-term survivors of childhood cancer: a report from the St Jude Lifetime Cohort and the Childhood Cancer Survivor Study","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; National Institutes of Health; Gaming Technologies Association; American Lebanese Syrian Associated Charities","keywords":"Childhood cancer; Cancer; Medicine; Cohort; Term (time); Genetic predisposition; Pediatrics; Oncology; Internal medicine; Disease","score_opus":0.015195685274299956,"score_gpt":0.34656154873407635,"score_spread":0.3313658634597764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410795851","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95693594,0.014860875,0.000043957178,0.020298433,0.00045905457,0.004874034,0.0024229242,0.000022991568,0.00008180906],"genre_scores_gemma":[0.98331624,0.014036902,0.00004269304,0.000794787,0.00036839416,0.0013114025,0.00006037137,0.000023928184,0.000045294502],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958608,0.0015589921,0.0012317812,0.00055422337,0.00039335096,0.0004008112],"domain_scores_gemma":[0.995841,0.0019119182,0.00088064256,0.0009927533,0.00026408696,0.00010956064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020333945,0.00032867887,0.0018252118,0.000113707596,0.00016328997,0.000014059391,0.00034524288,0.00015267804,0.000053051608],"category_scores_gemma":[0.00040941828,0.00018297652,0.00014533832,0.000527912,0.00069568824,0.00003722447,0.00021017595,0.00037713323,3.9358648e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022129684,0.0012899889,0.97423637,0.0000813378,0.0024306206,0.00001812127,0.014561423,0.0003112457,0.0002281876,0.000060125018,0.00018922391,0.004380408],"study_design_scores_gemma":[0.012354742,0.00093293365,0.9810186,0.0005518679,0.0024463008,0.000025587357,0.0010779742,0.000043541844,0.0010605162,0.00016675766,0.0001758151,0.00014538766],"about_ca_topic_score_codex":0.309762,"about_ca_topic_score_gemma":0.48651448,"teacher_disagreement_score":0.1767525,"about_ca_system_score_codex":0.00045865818,"about_ca_system_score_gemma":0.0011691536,"threshold_uncertainty_score":0.74615663},"labels":[],"label_agreement":null},{"id":"W4410799892","doi":"10.1016/s1470-2045(25)00026-9","title":"Impact of suboptimal cancer care in the Commonwealth: a scoping review and call to action","year":2025,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University; University Health Network; University of Toronto; Sault Area Hospital","funders":"","keywords":"Call to action; Commonwealth; Action (physics); Cancer; Medicine; Business; Psychology; Political science; Marketing; Law; Internal medicine","score_opus":0.15009217086490642,"score_gpt":0.6038674467284837,"score_spread":0.45377527586357724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410799892","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000049471037,0.9906374,0.000015701295,0.003995216,0.00027165018,0.0034986543,0.000052485622,0.000012318864,0.0014670996],"genre_scores_gemma":[0.000017040174,0.99281865,0.0002943066,0.005531662,0.00055388175,0.00065301434,0.000026811525,0.000014796462,0.00008980622],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99793255,0.0009417304,0.000502992,0.00024308014,0.000089802845,0.00028986248],"domain_scores_gemma":[0.9975954,0.00147551,0.00033643824,0.0004887363,0.000060004564,0.000043877953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008661955,0.00023530527,0.003140073,0.000103477716,0.00006938659,0.0000029177456,0.00032559707,0.000298082,0.00005249645],"category_scores_gemma":[0.00018596296,0.00010747362,0.00021511455,0.00042254262,0.00018768692,0.0000200501,0.000062488834,0.0008166341,0.0000024231922],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017195655,0.00004416342,0.00027218176,0.14017895,0.000146216,0.000018158276,0.0004894403,0.0000044446724,1.9779512e-7,0.00003245463,0.0043782643,0.8542636],"study_design_scores_gemma":[0.00073371816,0.0011912092,0.0004712037,0.19634397,0.001285016,0.00022700519,0.000042660482,6.0885293e-7,6.928404e-8,0.000008363495,0.79958963,0.000106570624],"about_ca_topic_score_codex":0.00019156521,"about_ca_topic_score_gemma":0.001486783,"teacher_disagreement_score":0.85415703,"about_ca_system_score_codex":0.00076916436,"about_ca_system_score_gemma":0.0021138946,"threshold_uncertainty_score":0.4382647},"labels":[],"label_agreement":null},{"id":"W4410799942","doi":"10.1016/s1470-2045(25)00158-5","title":"Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme; Astellas Pharma; Seagen; Pfizer","keywords":"Pembrolizumab; Urothelial cancer; Medicine; Open label; Oncology; Internal medicine; Chemotherapy; Phases of clinical research; Cancer; Clinical trial; Immunotherapy; Bladder cancer","score_opus":0.054222734857564785,"score_gpt":0.40464735792672296,"score_spread":0.35042462306915817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410799942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9783451,0.00035261142,0.00004951025,0.0014239694,0.0006180142,0.017286593,0.00017737086,0.00010868285,0.0016381278],"genre_scores_gemma":[0.9903501,0.00018242546,0.00039219702,0.0037792344,0.00009950718,0.0042868555,0.00018848879,0.00007543109,0.00064571755],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962102,0.00077325106,0.0010606758,0.0007724031,0.00046315952,0.00072029396],"domain_scores_gemma":[0.9972438,0.00073795684,0.00056114676,0.000991861,0.00028075982,0.00018445445],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044885365,0.0005801446,0.0028947028,0.00016485545,0.00017567637,0.000066497516,0.00058171863,0.00013077247,0.00063349766],"category_scores_gemma":[0.0002570797,0.00030813573,0.00008624191,0.00048438628,0.00017701008,0.0002120503,0.000100629746,0.00040937334,0.0000094826755],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8686654,0.01165278,0.048958134,0.000030676994,0.004466264,0.0003739566,0.0023296976,0.00009375755,0.000057421665,0.000010820792,0.00022679594,0.063134275],"study_design_scores_gemma":[0.9253067,0.03337808,0.036206126,0.00015097069,0.0024773541,0.000005920589,0.00063604285,0.00025754498,0.00012200344,0.00003891686,0.0011133585,0.0003070303],"about_ca_topic_score_codex":0.00503469,"about_ca_topic_score_gemma":0.007007504,"teacher_disagreement_score":0.062827244,"about_ca_system_score_codex":0.0010239085,"about_ca_system_score_gemma":0.0028178145,"threshold_uncertainty_score":0.99993706},"labels":[],"label_agreement":null},{"id":"W4410800041","doi":"10.1016/s1470-2045(25)00039-7","title":"National cancer control plans in Latin America and the Caribbean: challenges and future directions","year":2025,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Cancer Institute","keywords":"Latin Americans; Caribbean region; Political science; Cancer; Regional science; Geography; Medicine","score_opus":0.14339810513901127,"score_gpt":0.43006023449725245,"score_spread":0.2866621293582412,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410800041","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000007711729,0.93069094,0.0000019563388,0.049775194,0.00029183435,0.000669794,0.0001346972,0.000017607823,0.018410275],"genre_scores_gemma":[0.00013145873,0.99395466,0.000034289682,0.0030074895,0.0021215158,0.0005072477,0.000016907987,0.000008094278,0.00021833644],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987156,0.0004458359,0.0002548569,0.00022968996,0.0001460637,0.00020797193],"domain_scores_gemma":[0.99826646,0.0013182206,0.00015496777,0.00016824546,0.00005750016,0.000034618613],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054346485,0.00017468464,0.0015168139,0.00007435943,0.00009794311,0.000009860406,0.00013310405,0.0002040444,0.000022108436],"category_scores_gemma":[0.00014838825,0.00008540808,0.00008342626,0.00017106852,0.0002897338,0.000018644281,0.000055998018,0.00062964007,0.000001895452],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016959278,0.000009711436,0.000050039962,0.0013913128,0.00016621895,0.000011806071,0.0005685865,0.0000010436809,2.25447e-8,0.0044993116,0.002645628,0.99048674],"study_design_scores_gemma":[0.0019153458,0.00006918071,0.001367578,0.0019777478,0.0005612702,0.00010294095,0.00032908635,0.000021012303,5.6814384e-9,0.00026760777,0.9933112,0.00007698503],"about_ca_topic_score_codex":0.00041127662,"about_ca_topic_score_gemma":0.003504657,"teacher_disagreement_score":0.9906656,"about_ca_system_score_codex":0.00019840153,"about_ca_system_score_gemma":0.00063970196,"threshold_uncertainty_score":0.34828404},"labels":[],"label_agreement":null},{"id":"W4410952304","doi":"10.1016/s1470-2045(25)00287-6","title":"Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Jazz Pharmaceuticals","keywords":"Oxaliplatin; Medicine; Capecitabine; Regimen; Internal medicine; Tolerability; Chemotherapy; Gastroenterology; Dosing; Oncology; Adenocarcinoma; Adverse effect; Cancer; Colorectal cancer","score_opus":0.04556820725942549,"score_gpt":0.3980022265406252,"score_spread":0.3524340192811997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410952304","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9827899,0.00046817286,0.00019682485,0.005807636,0.00017809178,0.0073698075,0.0006391565,0.00005853551,0.0024919226],"genre_scores_gemma":[0.993867,0.00015554842,0.0024044944,0.0011064234,0.00027449962,0.0006658932,0.00037332525,0.00004459183,0.0011082586],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976073,0.00027234078,0.00053667615,0.0005666037,0.00038614232,0.0006309622],"domain_scores_gemma":[0.997391,0.00097468373,0.0002714689,0.00083378406,0.00040369792,0.00012535656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004656738,0.00030428602,0.0011285045,0.00012662435,0.0001393372,0.000013043853,0.00033291374,0.0001116801,0.00004320843],"category_scores_gemma":[0.00022799423,0.00019087702,0.00009629117,0.00032181357,0.00025506722,0.000056323614,0.000100022466,0.00027076082,0.000008056421],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.57886034,0.084385425,0.097573094,0.00072022603,0.0024686267,0.00041640183,0.013488793,0.00023439403,0.0014580463,0.000075365366,0.00400632,0.21631299],"study_design_scores_gemma":[0.52574223,0.25448158,0.1816354,0.00049617677,0.00092756574,0.000025999943,0.0020303156,0.0005064929,0.008165769,0.000071006456,0.02558662,0.00033080392],"about_ca_topic_score_codex":0.00028380528,"about_ca_topic_score_gemma":0.00035538248,"teacher_disagreement_score":0.21598218,"about_ca_system_score_codex":0.001843206,"about_ca_system_score_gemma":0.00088103476,"threshold_uncertainty_score":0.7783739},"labels":[],"label_agreement":null},{"id":"W4411197793","doi":"10.1016/s1470-2045(25)00194-9","title":"Partial-breast radiotherapy after breast conservation surgery for women with early breast cancer (UK IMPORT LOW): 10-year outcomes from a multicentre, open-label, randomised, controlled, phase 3, non-inferiority trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Health Service Corps; Department of Health and Social Care; National Institute for Health and Care Research; Royal Marsden NHS Foundation Trust; Health and Care Research Wales; Institute of Cancer Research; Cancer Research UK; NIHR Cambridge Biomedical Research Centre; National Institute on Handicapped Research","keywords":"Medicine; Breast cancer; Open label; Breast-conserving surgery; Randomized controlled trial; Radiation therapy; Oncology; Surgery; Cancer; Internal medicine; Mastectomy","score_opus":0.023654093187701838,"score_gpt":0.33913521222369725,"score_spread":0.3154811190359954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411197793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9768922,0.0005159701,0.00049670757,0.0141156595,0.0006869284,0.004350851,0.0027166572,0.000030227136,0.00019480899],"genre_scores_gemma":[0.98327327,0.00046661074,0.00031731246,0.0035265156,0.0013255932,0.0101661775,0.00022348763,0.000045390054,0.00065566227],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975919,0.00034759365,0.00058095914,0.0006405567,0.00015728232,0.00068171025],"domain_scores_gemma":[0.997924,0.0006467182,0.00041008537,0.00063675316,0.00026887754,0.00011358128],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007914247,0.00043100538,0.0016616218,0.000054866938,0.00022663425,0.00009624598,0.00042173415,0.00023542624,0.00031164743],"category_scores_gemma":[0.00006998519,0.0002749912,0.00016527927,0.00014751323,0.00029349842,0.000023114148,0.00016051582,0.00014088924,0.0000050163994],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8762986,0.0012170178,0.10353131,0.000030489357,0.0032552788,0.000013832417,0.00025609724,0.0000040969967,0.00164277,0.000012956203,0.0071349856,0.006602541],"study_design_scores_gemma":[0.83065623,0.0007037298,0.1589301,0.000064128624,0.00047312057,0.00002910112,0.00014304856,0.00008645774,0.0002438826,0.000047759855,0.008248023,0.0003744428],"about_ca_topic_score_codex":0.0016702914,"about_ca_topic_score_gemma":0.0015235851,"teacher_disagreement_score":0.055398785,"about_ca_system_score_codex":0.00030193344,"about_ca_system_score_gemma":0.0009002391,"threshold_uncertainty_score":0.9999702},"labels":[],"label_agreement":null},{"id":"W4411225252","doi":"10.1016/s1470-2045(25)00205-0","title":"Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Health Service Corps; Auckland Medical Research Foundation; National Institute for Health and Care Research; Institute of Cancer Research; Cancer Research UK; Royal Marsden Cancer Charity; Accuray; Royal Marsden NHS Foundation Trust","keywords":"Prostate cancer; Medicine; Radiation therapy; Toxicity; Oncology; Prostate; Internal medicine; Cancer","score_opus":0.09065600622373889,"score_gpt":0.42525760184701067,"score_spread":0.3346015956232718,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411225252","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9459915,0.0018409055,0.00049339124,0.035444207,0.0030957016,0.01133199,0.0010142948,0.00012212228,0.00066587137],"genre_scores_gemma":[0.97443837,0.009373069,0.0017306147,0.006978161,0.0014416511,0.0043786094,0.0004599595,0.000068331596,0.0011312402],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972305,0.0003796919,0.0007628082,0.0007783911,0.0002135075,0.00063508126],"domain_scores_gemma":[0.9964598,0.0017075137,0.000459194,0.0007912248,0.00041774934,0.00016454468],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009687997,0.00042284388,0.0018227849,0.0001166166,0.00035066163,0.0001566233,0.0003914766,0.0002807562,0.000090985704],"category_scores_gemma":[0.00031313664,0.0002939813,0.00015917011,0.00036447207,0.00018587885,0.0002629521,0.00008307497,0.0005031688,0.000005935653],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93828565,0.0030018662,0.00028645975,0.000036352605,0.0034997065,0.000065683045,0.000906954,0.000044513705,0.013985169,0.000044031396,0.013362544,0.026481058],"study_design_scores_gemma":[0.9073468,0.012114966,0.0035411408,0.00016283503,0.00079230114,0.000007740598,0.000049467537,0.008664032,0.006236753,0.00038921626,0.06040599,0.00028877403],"about_ca_topic_score_codex":0.004069467,"about_ca_topic_score_gemma":0.00043254907,"teacher_disagreement_score":0.047043446,"about_ca_system_score_codex":0.0017903564,"about_ca_system_score_gemma":0.0011994398,"threshold_uncertainty_score":0.99995124},"labels":[],"label_agreement":null},{"id":"W4411260753","doi":"10.1016/s1470-2045(25)00209-8","title":"Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Exelixis","keywords":"Atezolizumab; Cabozantinib; Medicine; Oncology; Prostate cancer; Prostate; Internal medicine; Cancer; Immunotherapy; Pembrolizumab","score_opus":0.3279042008534256,"score_gpt":0.5471206174015985,"score_spread":0.21921641654817287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411260753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96120507,0.0062031997,0.00004097176,0.018446265,0.000536032,0.0054151267,0.00027173388,0.00004410277,0.007837519],"genre_scores_gemma":[0.9779148,0.0048620855,0.0006644693,0.0025612533,0.00042826906,0.0030826118,0.0002943411,0.0000290364,0.010163148],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974264,0.00071709335,0.0005533071,0.00044334686,0.00022901112,0.0006308745],"domain_scores_gemma":[0.998264,0.0008514334,0.00018343278,0.00048782837,0.00010879863,0.000104512845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00096314,0.00024521878,0.0015435094,0.00019561996,0.00014100433,0.00006706235,0.00047973156,0.00010182802,0.0005411818],"category_scores_gemma":[0.00024305074,0.0001424246,0.00008667423,0.0005952769,0.00018944562,0.00010558576,0.00021635427,0.00051333907,0.000027962904],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9502315,0.0018708805,0.0006753194,0.000092233066,0.0012038874,0.0007381397,0.0011969476,0.000025895144,0.006405275,0.00022427474,0.012075089,0.025260573],"study_design_scores_gemma":[0.9494996,0.002646715,0.0011200857,0.00022464035,0.00076652225,0.000008757085,0.00029208002,0.0011977267,0.0028358183,0.00082877517,0.04042696,0.00015230346],"about_ca_topic_score_codex":0.0069145756,"about_ca_topic_score_gemma":0.0029591296,"teacher_disagreement_score":0.02835187,"about_ca_system_score_codex":0.00065036624,"about_ca_system_score_gemma":0.0028478322,"threshold_uncertainty_score":0.99969846},"labels":[],"label_agreement":null},{"id":"W4411847959","doi":"10.1016/s1470-2045(25)00237-2","title":"SANO trial: innovations, risks, and unanswered questions","year":2025,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Psychology","score_opus":0.14373754334454894,"score_gpt":0.4464597041298731,"score_spread":0.3027221607853242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411847959","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006382495,0.0068236594,0.000023016686,0.9708894,0.00048396824,0.0014984362,0.00014889028,0.00008601793,0.019408388],"genre_scores_gemma":[0.0074421745,0.005363668,0.00065765285,0.9512297,0.010058464,0.000951576,0.0008684612,0.00003435557,0.023393977],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998395,0.0003868932,0.0002783669,0.00030332818,0.00022655696,0.00040981593],"domain_scores_gemma":[0.99847275,0.00062607846,0.00012347502,0.00058800663,0.00013944341,0.00005023806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048946304,0.0001963185,0.00077280344,0.00017386953,0.00014937276,0.000023764278,0.000181984,0.0004939801,0.00018239257],"category_scores_gemma":[0.00031005187,0.00012178334,0.000069804926,0.0003057217,0.00024615237,0.000020549196,0.00009911522,0.0018237986,0.00004543949],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003987669,0.00007615043,0.00031672398,0.00018372093,0.00030717687,0.000632986,0.00004208643,1.6411893e-7,0.0000022589606,0.0013401113,0.9839615,0.009149409],"study_design_scores_gemma":[0.025190594,0.001461862,0.0022886929,0.00011182185,0.00029656017,0.000079517275,0.00000968183,0.0000029162284,0.00001153719,0.0025780553,0.96788514,0.00008363026],"about_ca_topic_score_codex":0.0004973194,"about_ca_topic_score_gemma":0.00010605124,"teacher_disagreement_score":0.021202924,"about_ca_system_score_codex":0.00039249044,"about_ca_system_score_gemma":0.0011318716,"threshold_uncertainty_score":0.7923599},"labels":[],"label_agreement":null},{"id":"W4411848010","doi":"10.1016/s1470-2045(25)00211-6","title":"Hormone therapy use and young-onset breast cancer: a pooled analysis of prospective cohorts included in the Premenopausal Breast Cancer Collaborative Group","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; Ontario Institute for Cancer Research","funders":"National Center for Chronic Disease Prevention and Health Promotion; National Health Service Corps; National Institute of Environmental Health Sciences; National Cancer Institute; Centers for Disease Control and Prevention; Breast Cancer Now; California Department of Public Health; Instituto Nacional del Cáncer; Breast Cancer Research Foundation; Avon Foundation for Women; Foundation for the National Institutes of Health; American Cancer Society; U.S. Department of Health and Human Services; National Institutes of Health; Institute of Cancer Research","keywords":"Breast cancer; Medicine; Cancer; Oncology; Prospective cohort study; Internal medicine; Gynecology; Hormone therapy; Obstetrics","score_opus":0.014502982720521989,"score_gpt":0.31586021876895537,"score_spread":0.3013572360484334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411848010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9811633,0.0065658554,0.000017279248,0.009041512,0.00010880656,0.0008052245,0.001977106,0.00001073505,0.00031016686],"genre_scores_gemma":[0.9859812,0.011457823,0.000039658797,0.0013039225,0.00014426575,0.0009312627,0.00008137333,0.000011594063,0.000048864043],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983512,0.00051295536,0.00027486865,0.0004088963,0.00014086443,0.0003111791],"domain_scores_gemma":[0.9989621,0.00013222542,0.00020754315,0.00042507978,0.0002470031,0.000026063253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044137167,0.00023395059,0.00070731144,0.00010998222,0.00015590839,0.000026546655,0.00029774307,0.00013257681,0.000015699918],"category_scores_gemma":[0.000025301793,0.00013817287,0.00006376186,0.0010458993,0.00044726566,0.0000110560195,0.00018122095,0.00015551422,2.521261e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005970718,0.00040858862,0.9590974,0.000013507168,0.0071372064,0.0000077725335,0.0027465564,0.00007579696,0.017659456,0.0003029094,0.0034326364,0.003147451],"study_design_scores_gemma":[0.0032612346,0.000258505,0.9922328,0.000019296436,0.0011382535,0.00002496397,0.00073241367,0.000028910701,0.0008068057,0.0001152867,0.0012467123,0.0001347999],"about_ca_topic_score_codex":0.004984873,"about_ca_topic_score_gemma":0.03360317,"teacher_disagreement_score":0.033135418,"about_ca_system_score_codex":0.00018918843,"about_ca_system_score_gemma":0.00028201853,"threshold_uncertainty_score":0.9840311},"labels":[],"label_agreement":null},{"id":"W4412006675","doi":"10.1016/s1470-2045(25)00222-0","title":"Oral contraceptive use and risk of liver cancer: a population-based study, systematic review, and meta-analysis","year":2025,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Reproductive Health and Contraception","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Canadian Institutes of Health Research; National Institutes of Health; Cancer Research UK; NHS Health Scotland","keywords":"Meta-analysis; Medicine; Cancer; Gynecology; Obstetrics; Internal medicine","score_opus":0.18014328231167145,"score_gpt":0.4543361045288443,"score_spread":0.2741928222171729,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412006675","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025749198,0.9894536,0.000032480395,0.0008718801,0.000032788772,0.009074093,0.00024414336,0.000016296566,0.000017184784],"genre_scores_gemma":[0.00095801527,0.9957315,0.000105079875,0.00076996034,0.00008652741,0.0018992603,0.00005144609,0.000012658317,0.0003855569],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99424607,0.0038951996,0.0010081049,0.00046908646,0.00017785911,0.00020370811],"domain_scores_gemma":[0.9954607,0.0019662126,0.0014497286,0.00076608284,0.0002876129,0.00006968471],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027568098,0.00030123323,0.01218607,0.00020329669,0.00008290598,0.000011150966,0.00011120208,0.00017159621,0.00008180007],"category_scores_gemma":[0.0015095002,0.00014880169,0.0007144285,0.0005552709,0.00008478103,0.00003816526,0.000040549196,0.00042038623,0.000001909056],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010249516,0.00015898625,0.003895419,0.8515106,0.13170084,0.000009125003,0.00011565776,0.0000020529117,1.9894838e-8,0.000033886434,0.00017408139,0.012296838],"study_design_scores_gemma":[0.00058792473,0.00033092187,0.0074104196,0.011129437,0.9725727,0.000009432903,0.000028897579,0.000016229118,1.4332527e-8,0.0000063693424,0.0077993763,0.000108295084],"about_ca_topic_score_codex":0.0030149124,"about_ca_topic_score_gemma":0.0023654653,"teacher_disagreement_score":0.8408718,"about_ca_system_score_codex":0.00015842794,"about_ca_system_score_gemma":0.0003854619,"threshold_uncertainty_score":0.8330154},"labels":[],"label_agreement":null},{"id":"W4412391704","doi":"10.1016/s1470-2045(25)00281-5","title":"Derivation and validation of the AJCC9V pathological stage classification for HPV-positive oropharyngeal carcinoma: a multicentre registry analysis","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cohort; Oncology; Internal medicine; Lymph node; Pathological; Proportional hazards model; Hazard ratio; Stage (stratigraphy); Cancer; Cancer registry; Cancer staging; Confidence interval","score_opus":0.06605659301961105,"score_gpt":0.3736456508279245,"score_spread":0.30758905780831347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412391704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97460115,0.00028855063,0.0017226707,0.020254798,0.000092195325,0.00054824405,0.000043981865,0.000013377705,0.002435046],"genre_scores_gemma":[0.99787223,0.000109321416,0.00047202996,0.0008940327,0.00009688635,0.00007620933,0.00003369804,0.000002905147,0.00044266623],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99930537,0.00016455399,0.00018341847,0.00015641385,0.000069997055,0.00012022545],"domain_scores_gemma":[0.9991413,0.00034949605,0.00014104848,0.00022467283,0.000127733,0.00001576931],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032983793,0.00006695794,0.00040344728,0.000041265288,0.00012368454,0.000004503464,0.00007627833,0.000080423626,0.0000092217115],"category_scores_gemma":[0.00026512978,0.000036117468,0.00006864674,0.00028161655,0.00017054004,0.0000195924,0.000047104713,0.000105835126,3.1648156e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039658565,0.0004472744,0.8616511,0.0005585209,0.0011470808,0.000009738631,0.005502784,0.00006141561,0.07112923,0.012446703,0.0042192005,0.038861047],"study_design_scores_gemma":[0.0020539276,0.00023357202,0.98467076,0.000018780938,0.00089850667,0.000002471849,0.0008148397,0.0014916046,0.007301798,0.00014819228,0.002329652,0.000035896097],"about_ca_topic_score_codex":0.000040169416,"about_ca_topic_score_gemma":0.0000661231,"teacher_disagreement_score":0.12301961,"about_ca_system_score_codex":0.00010273551,"about_ca_system_score_gemma":0.000098944816,"threshold_uncertainty_score":0.14728276},"labels":[],"label_agreement":null},{"id":"W4412461073","doi":"10.1016/s1470-2045(25)00330-4","title":"Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"GlaxoSmithKline","keywords":"Bortezomib; Dexamethasone; Multiple myeloma; Medicine; Refractory (planetary science); Open label; Oncology; Internal medicine; Lenalidomide; Clinical trial; Materials science","score_opus":0.06159927844167269,"score_gpt":0.3929654672770072,"score_spread":0.33136618883533453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412461073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99178505,0.00023878436,0.000117552896,0.0013586206,0.00018043171,0.0041641598,0.00057086075,0.00005434376,0.0015302026],"genre_scores_gemma":[0.9944672,0.00021527501,0.0020424337,0.000695979,0.0001323575,0.0003157905,0.001541142,0.000022841516,0.00056700886],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963621,0.0012442744,0.00062108843,0.0006858523,0.00040847488,0.0006782258],"domain_scores_gemma":[0.99684864,0.0016929308,0.0002729357,0.00079962215,0.00015113101,0.00023472728],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010723833,0.0003467461,0.0020203425,0.00023962738,0.00016180471,0.00007260547,0.00046157732,0.00025234735,0.00030392758],"category_scores_gemma":[0.0009394904,0.00019930319,0.00008029799,0.0010774626,0.0002407948,0.00013670343,0.0003351606,0.0004978556,0.000014873494],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7358918,0.0035875104,0.24205993,0.000018147986,0.0034290026,0.00035610693,0.00012000491,0.0000053950366,0.000078920566,0.000025151729,0.001219666,0.013208312],"study_design_scores_gemma":[0.6651188,0.0041963933,0.32561967,0.00005115441,0.001261053,0.0000032393425,0.00006594802,0.0013052643,0.000026989142,0.000044372755,0.0021613927,0.0001457097],"about_ca_topic_score_codex":0.0054829596,"about_ca_topic_score_gemma":0.011305032,"teacher_disagreement_score":0.08355974,"about_ca_system_score_codex":0.000785464,"about_ca_system_score_gemma":0.0008241126,"threshold_uncertainty_score":0.82886314},"labels":[],"label_agreement":null},{"id":"W4412855756","doi":"10.1016/s1470-2045(25)00364-x","title":"Cancer clinical trials should capture tobacco smoking status","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Cancer Care Ontario","funders":"World Health Organization","keywords":"Cancer; Medicine; Clinical trial; Tobacco use; Environmental health; Oncology; Internal medicine","score_opus":0.247731422496764,"score_gpt":0.5755754296091893,"score_spread":0.3278440071124253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412855756","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.40956455,0.015710395,0.00049837946,0.27546877,0.0070090084,0.0021393935,0.00019271908,0.0002398698,0.28917694],"genre_scores_gemma":[0.9456189,0.0034350466,0.0005134689,0.038137946,0.0022051677,0.0002953522,0.000044338976,0.000016180093,0.009733545],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983385,0.0005479689,0.0004761635,0.0002116652,0.000105667976,0.00032000034],"domain_scores_gemma":[0.9981939,0.0011377268,0.0001604614,0.00035123946,0.000081033875,0.00007559296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018359283,0.000110512316,0.0008725747,0.00004487516,0.00010569481,0.000013627958,0.000113805996,0.0001890749,0.0003898824],"category_scores_gemma":[0.00074679824,0.000059746977,0.00015388301,0.00017510261,0.00011443721,0.00002432148,0.000047507976,0.0004045594,0.000015484413],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012295465,0.00029072468,0.41312245,0.00004583235,0.0017507066,0.000057609526,0.000899806,0.000035668396,0.00011587933,0.0076968935,0.23660634,0.33814856],"study_design_scores_gemma":[0.005946516,0.0001812376,0.14196189,0.00007111413,0.0013071375,0.000007209901,0.00035585725,0.000024986877,0.000050877134,0.0007080567,0.8493254,0.000059705115],"about_ca_topic_score_codex":0.0007515554,"about_ca_topic_score_gemma":0.00066528236,"teacher_disagreement_score":0.61271906,"about_ca_system_score_codex":0.0003878259,"about_ca_system_score_gemma":0.0011346958,"threshold_uncertainty_score":0.42689386},"labels":[],"label_agreement":null},{"id":"W4413439141","doi":"10.1016/s1470-2045(25)00519-4","title":"Australia invests in cancer research grants led by First Nations communities","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Global Health and Surgery","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Political science; Cancer; Geography; Economic growth; Regional science; Medicine; Economics; Internal medicine","score_opus":0.2703629004057976,"score_gpt":0.5305050538835938,"score_spread":0.26014215347779623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413439141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85367906,0.00083687436,0.0000012700208,0.111162536,0.0003734856,0.00032317583,0.000023732615,0.000022568705,0.033577308],"genre_scores_gemma":[0.9854776,0.0018359378,0.000024775394,0.0058620665,0.000120554534,0.00017528138,0.000024761544,0.0000040373443,0.006474981],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99858963,0.00051552925,0.0001945648,0.000081977705,0.0001338403,0.00048446332],"domain_scores_gemma":[0.99812526,0.0014054615,0.000026725122,0.00026952318,0.00010636204,0.00006664868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016347215,0.000061624414,0.0003235732,0.00018100473,0.00028248294,0.000006817812,0.00017940947,0.0001135693,0.00014709814],"category_scores_gemma":[0.00032261305,0.000043529097,0.00002213561,0.00060107716,0.00028913555,0.000021669624,0.00006378593,0.0006077912,0.000035256035],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005245076,0.00021342211,0.31516418,0.00029875783,0.00002844134,0.000024485227,0.0014374086,0.000007755477,0.00012905977,0.014797126,0.66616344,0.0012113997],"study_design_scores_gemma":[0.0018700913,0.0001274679,0.23005491,0.0002670596,0.000011160448,0.000007423099,0.00095631776,0.000046280915,0.00007165854,0.0018839261,0.7646581,0.00004561391],"about_ca_topic_score_codex":0.017964315,"about_ca_topic_score_gemma":0.17415053,"teacher_disagreement_score":0.15618621,"about_ca_system_score_codex":0.00037105987,"about_ca_system_score_gemma":0.0005141606,"threshold_uncertainty_score":0.98857516},"labels":[],"label_agreement":null},{"id":"W4413935657","doi":"10.1016/s1470-2045(25)00422-x","title":"The effect of TERT promoter mutation on predicting meningioma outcomes: a multi-institutional cohort analysis","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Meningioma and schwannoma management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Department of Pathology, University of Utah; National Institute of Neurological Disorders and Stroke; National Institutes of Health; National Cancer Institute; Friedberg Charitable Foundation; Deutsche Forschungsgemeinschaft; Gray Family Foundation; Division of Cancer Epidemiology and Genetics, National Cancer Institute; Cancer Prevention and Research Institute of Texas","keywords":"Cohort; Meningioma; Internal medicine; Mutation; Medicine; Oncology; Cancer research; Genetics; Biology; Surgery; Gene","score_opus":0.02548517251654213,"score_gpt":0.35857804164688917,"score_spread":0.333092869130347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413935657","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9768431,0.000056974426,0.002240498,0.005611345,0.00026292223,0.0008801253,0.0000041511194,0.00004652041,0.014054364],"genre_scores_gemma":[0.9975951,0.0000024479266,0.00058363343,0.00023870348,0.0000831071,0.00017020977,0.000023460118,0.0000042940087,0.0012990598],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99875283,0.00031043382,0.00031372305,0.00019204423,0.0002182952,0.00021264177],"domain_scores_gemma":[0.99861753,0.000776403,0.00013716352,0.00039176445,0.000050282404,0.00002682719],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001806726,0.00012601247,0.00057173776,0.00016172013,0.00023381575,0.000013559556,0.00017989444,0.000065512664,0.000017436707],"category_scores_gemma":[0.00032334376,0.000055413057,0.00017777995,0.00044168186,0.0001470302,0.00002162012,0.000067817644,0.00017068227,0.000009663321],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013618951,0.000112113994,0.9790014,0.00012931548,0.005714432,0.0002674861,0.00042866703,0.00052635476,0.00061048166,0.0030390394,0.0007241652,0.008084658],"study_design_scores_gemma":[0.003841304,0.0012389363,0.9717913,0.00007183881,0.0031258988,0.000054446664,0.00007029013,0.014663545,0.001283849,0.00006923046,0.0037223257,0.000067018824],"about_ca_topic_score_codex":0.000039153736,"about_ca_topic_score_gemma":0.000021516313,"teacher_disagreement_score":0.020751985,"about_ca_system_score_codex":0.00014122695,"about_ca_system_score_gemma":0.00006021699,"threshold_uncertainty_score":0.22596788},"labels":[],"label_agreement":null},{"id":"W4413939355","doi":"10.1016/s1470-2045(25)00326-2","title":"Primary target volume delineation for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas","year":2025,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Guangzhou Municipal Health and Family Planning Commission; Chinese Society of Clinical Oncology; Sun Yat-sen University Cancer Center; Overseas Expertise Introduction Project for Discipline Innovation; National Medical Research Council; National Natural Science Foundation of China; Higher Education Discipline Innovation Project; American Society for Radiation Oncology; Canadian Cancer Society; GOH Foundation; National Cancer Centre of Singapore","keywords":"Contouring; Nasopharyngeal carcinoma; Atlas (anatomy); Medicine; Radiation therapy; Medical physics; Radiology; Computer science; Anatomy; Computer graphics (images)","score_opus":0.10156185675425393,"score_gpt":0.41643085071343705,"score_spread":0.3148689939591831,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413939355","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012813495,0.9908818,0.00042631905,0.004069295,0.00039488278,0.0019681037,0.00012404598,0.000038320173,0.00081586966],"genre_scores_gemma":[0.00008447131,0.9850088,0.008285631,0.001458206,0.002759351,0.0006073254,0.00018324863,0.000038998773,0.0015740105],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99787444,0.00023250295,0.0007951939,0.00048541377,0.00012544374,0.00048700982],"domain_scores_gemma":[0.9984958,0.0006896821,0.00027328474,0.00030625713,0.00014906765,0.0000858637],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00093239767,0.0003987283,0.003628166,0.00016521454,0.00012291373,0.000016826647,0.0001596202,0.00033266336,0.00001246795],"category_scores_gemma":[0.00028196617,0.0002669257,0.0001646434,0.00015660105,0.00017056128,0.00004521402,0.00010929726,0.00048188464,0.0000011022323],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055455335,0.00005626645,0.0040941485,0.020259118,0.00028966618,0.000047214056,0.00020734112,0.0000025549305,0.000010770903,0.0000796454,0.03650248,0.93789625],"study_design_scores_gemma":[0.0044702645,0.00079510995,0.0022079963,0.0043939627,0.0005783978,0.00013550307,0.00003518716,0.00022299225,0.000001126154,0.000021871543,0.9869405,0.0001970897],"about_ca_topic_score_codex":0.0001770004,"about_ca_topic_score_gemma":0.00023999538,"teacher_disagreement_score":0.950438,"about_ca_system_score_codex":0.00048701873,"about_ca_system_score_gemma":0.0009809238,"threshold_uncertainty_score":0.9999783},"labels":[],"label_agreement":null},{"id":"W4413942740","doi":"10.1016/s1470-2045(25)00267-0","title":"Analysis of TERT association with clinical outcome in meningiomas: a multi-institutional cohort study","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Meningioma and schwannoma management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Toronto; SickKids Foundation; Hospital for Sick Children; Princess Margaret Cancer Centre","funders":"Canadian Institutes of Health Research; University Health Network Foundation; National Cancer Institute; National Institutes of Health; Foundation for the National Institutes of Health; Brain Tumour Charity; V Foundation for Cancer Research","keywords":"Cohort; Outcome (game theory); Association (psychology); Medicine; Internal medicine; Cohort study; Psychology; Economics; Psychotherapist","score_opus":0.09450548751622428,"score_gpt":0.4393346326823405,"score_spread":0.34482914516611624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413942740","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98669475,0.000023886218,0.00081808126,0.0023835301,0.00014126874,0.000702045,0.0000034106558,0.000021453161,0.009211577],"genre_scores_gemma":[0.99649954,0.0000032889059,0.0011557696,0.0003721695,0.00005365292,0.00007988439,0.0000163795,0.0000031425113,0.0018161527],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99847955,0.00034293058,0.000564153,0.00021083499,0.0002271365,0.00017538355],"domain_scores_gemma":[0.9990176,0.00035353855,0.00021414402,0.00030896574,0.00008054662,0.000025231542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034950494,0.00008817047,0.0009625588,0.00026274117,0.000051591738,0.0000066089265,0.00013557922,0.000080478996,0.00003802759],"category_scores_gemma":[0.00026715794,0.000050307357,0.00010741883,0.00088689727,0.000066639186,0.000021806603,0.0000671951,0.00020996781,0.0000040022755],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005558059,0.000883633,0.99225104,0.000017380846,0.004484272,0.0001950972,0.00025802245,0.00016534326,0.000014266257,0.00041817958,0.0003214626,0.00043548422],"study_design_scores_gemma":[0.0048061954,0.000452533,0.98727906,0.000016542579,0.0032996512,0.00000419052,0.00025982445,0.0026272202,0.0000037297787,0.000011376354,0.0011951658,0.000044490993],"about_ca_topic_score_codex":0.00020863065,"about_ca_topic_score_gemma":0.0005927865,"teacher_disagreement_score":0.009804812,"about_ca_system_score_codex":0.00031764325,"about_ca_system_score_gemma":0.0001253143,"threshold_uncertainty_score":0.20514745},"labels":[],"label_agreement":null},{"id":"W4414005916","doi":"10.1016/s1470-2045(25)00379-1","title":"Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre; Université de Sherbrooke","funders":"National Health and Medical Research Council; Cancer Australia; Cancer Research UK; Canadian Cancer Society Research Institute; KWF Kankerbestrijding; Agenzia Italiana del Farmaco, Ministero della Salute; National Cancer Research Institute; Australia New Zealand Gynaecological Oncology Group","keywords":"Medicine; Post-hoc analysis; Chemoradiotherapy; Oncology; Post hoc; Endometrial cancer; Internal medicine; Adjuvant; Radiation therapy; Clinical trial; Adjuvant radiotherapy; Randomized controlled trial; Cancer","score_opus":0.04016505597897605,"score_gpt":0.3997591718153088,"score_spread":0.3595941158363327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414005916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847168,0.004177529,0.00029549998,0.007879828,0.0005759336,0.0018394241,0.0002694327,0.000048393485,0.00019716723],"genre_scores_gemma":[0.98253393,0.011646728,0.00090293505,0.002824333,0.00072253397,0.00091093924,0.00017719669,0.000029010163,0.0002524211],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970962,0.00082047156,0.00077296165,0.0005807787,0.00030684163,0.00042276352],"domain_scores_gemma":[0.99620265,0.0025843757,0.00040780846,0.0005481215,0.00009253854,0.00016453436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013435818,0.00028654793,0.0026143012,0.00037081784,0.000071607414,0.000027691198,0.00021890411,0.0002593401,0.0008095788],"category_scores_gemma":[0.0005012859,0.00016832298,0.00023183855,0.0015417016,0.00025350714,0.00004510346,0.000027028003,0.00040802703,0.0000033261545],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8710437,0.0012331372,0.016789818,0.000008992296,0.008017319,0.00003650181,0.00018784982,0.000006632801,0.0014898271,0.000023774714,0.00046730234,0.10069514],"study_design_scores_gemma":[0.9201039,0.012064164,0.057206254,0.000016277696,0.002745498,7.700664e-7,0.00013543837,0.00010546403,0.00022346173,0.000077892015,0.007148627,0.00017221432],"about_ca_topic_score_codex":0.0023402814,"about_ca_topic_score_gemma":0.0004839047,"teacher_disagreement_score":0.10052293,"about_ca_system_score_codex":0.00071089366,"about_ca_system_score_gemma":0.00037711998,"threshold_uncertainty_score":0.886432},"labels":[],"label_agreement":null},{"id":"W4414035458","doi":"10.1016/s1470-2045(25)00333-x","title":"Broadening our view of power in clinician–patient relationships in oncology","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Ethics in medical practice","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Cancer Care Ontario; University of British Columbia","funders":"","keywords":"Power (physics); Medicine; Oncology; Medical physics; Internal medicine; Physics","score_opus":0.3067056193040064,"score_gpt":0.599955963446697,"score_spread":0.2932503441426906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414035458","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.287592,0.0010046293,0.000183439,0.2722541,0.0030101412,0.00095705304,0.0000041538647,0.00003729943,0.43495718],"genre_scores_gemma":[0.973992,0.00056049787,0.0016610142,0.02280363,0.00017702601,0.00015330201,0.0000029134587,0.0000100838215,0.00063954404],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.97807235,0.019755367,0.0012609711,0.00023380337,0.00018369852,0.0004938191],"domain_scores_gemma":[0.965092,0.03374998,0.0005379426,0.00045194742,0.00012456921,0.0000435729],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.02055717,0.00009976893,0.0007207935,0.00019051321,0.00028211751,0.0000014668484,0.00043115966,0.0008389402,0.000149758],"category_scores_gemma":[0.031328417,0.000075117714,0.000038339866,0.00061312784,0.00018383947,0.000060725695,0.0003086424,0.009258331,0.00016584386],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014719552,0.0008095929,0.48342687,0.00050355715,0.00006291074,0.00010581394,0.048518326,0.0001457207,0.00013338891,0.36641175,0.057714287,0.04069584],"study_design_scores_gemma":[0.0034782314,0.00044377745,0.18473089,0.00090138766,0.000031911015,0.0000042781153,0.038685136,0.00013684898,0.0000069301077,0.09616903,0.6753018,0.00010979258],"about_ca_topic_score_codex":0.0003988795,"about_ca_topic_score_gemma":0.007481537,"teacher_disagreement_score":0.6864,"about_ca_system_score_codex":0.00067859015,"about_ca_system_score_gemma":0.0015767497,"threshold_uncertainty_score":0.9930273},"labels":[],"label_agreement":null},{"id":"W4414035513","doi":"10.1016/s1470-2045(25)00467-x","title":"Clarifying the consensus on laryngeal preservation strategies – Authors' reply","year":2025,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Tracheal and airway disorders","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Rehabilitation Institute","funders":"","keywords":"Medicine; Intensive care medicine","score_opus":0.09091201991477084,"score_gpt":0.36808724687035965,"score_spread":0.2771752269555888,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414035513","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025232534,0.000456646,0.000026836688,0.89713925,0.00090598123,0.00070958247,0.00003901476,0.00014273795,0.098056726],"genre_scores_gemma":[0.0082603535,0.00020885548,0.00016965525,0.96624666,0.0075381156,0.0001196797,0.00027585856,0.000029206141,0.017151607],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99787277,0.00065248355,0.000339872,0.00036283658,0.00028408584,0.00048793058],"domain_scores_gemma":[0.99742144,0.0013893283,0.00022230635,0.00084685604,0.000090983136,0.000029090068],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0008105282,0.00026353833,0.00072329794,0.0000728315,0.00024135478,0.00004518373,0.00042975714,0.00085919397,0.00009258156],"category_scores_gemma":[0.00026294988,0.00013438267,0.00014155702,0.00017861916,0.00032350328,0.00002803233,0.00008411769,0.004551863,0.000053033662],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043446236,0.000042702595,0.00018799526,0.00030933588,0.00015151611,0.0001918234,0.0003615762,0.000027222672,0.00002397648,0.0027774763,0.99107003,0.0044219103],"study_design_scores_gemma":[0.0011419066,0.0005981776,0.003287702,0.00015546236,0.000240281,0.0000550184,0.00040375738,0.000092109476,0.000009333289,0.0050440654,0.988845,0.00012721121],"about_ca_topic_score_codex":0.00039382378,"about_ca_topic_score_gemma":0.00018665897,"teacher_disagreement_score":0.08090512,"about_ca_system_score_codex":0.00012169496,"about_ca_system_score_gemma":0.0007123291,"threshold_uncertainty_score":0.9977447},"labels":[],"label_agreement":null},{"id":"W4414035571","doi":"10.1016/s1470-2045(25)00327-4","title":"Target volume delineation of the neck for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas","year":2025,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Guangzhou Municipal Health and Family Planning Commission; Chinese Society of Clinical Oncology; Sun Yat-sen University Cancer Center; Overseas Expertise Introduction Project for Discipline Innovation; National Medical Research Council; National Natural Science Foundation of China; Higher Education Discipline Innovation Project; American Society for Radiation Oncology; Canadian Cancer Society; GOH Foundation; National Cancer Centre of Singapore","keywords":"Contouring; Nasopharyngeal carcinoma; Medicine; Atlas (anatomy); Radiation therapy; Nuclear medicine; Medical physics; Radiology; Anatomy; Computer science; Computer graphics (images)","score_opus":0.09640573677932696,"score_gpt":0.41333095173065165,"score_spread":0.3169252149513247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414035571","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005168091,0.98766077,0.00013592186,0.0043556225,0.00039126407,0.0017782975,0.00011640147,0.000015374188,0.00037825722],"genre_scores_gemma":[0.0006996976,0.99245465,0.003247933,0.0006856696,0.0015261449,0.0003300971,0.000038109996,0.000026965201,0.0009907277],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982085,0.00023688981,0.0007508604,0.0003330527,0.00012051567,0.00035014178],"domain_scores_gemma":[0.9985496,0.00055097934,0.00034931736,0.00034339464,0.0001578091,0.00004889619],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007348793,0.00030149645,0.002867457,0.00009643733,0.000103120394,0.0000083541745,0.00020130855,0.00025032338,0.000009260926],"category_scores_gemma":[0.000380217,0.00016617146,0.0001864743,0.00017478979,0.00021199061,0.000027439188,0.000117613126,0.00038832132,3.2569972e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065507554,0.00008342824,0.016479328,0.02439955,0.00045133004,0.00001634039,0.0005043419,0.000009830015,0.000025265628,0.00025156894,0.033096924,0.924027],"study_design_scores_gemma":[0.0037159205,0.0006128524,0.0039990456,0.005303496,0.0005687016,0.000070024,0.000056441353,0.0003320949,0.0000050171393,0.000029710036,0.98517555,0.00013116981],"about_ca_topic_score_codex":0.00026087824,"about_ca_topic_score_gemma":0.00039589158,"teacher_disagreement_score":0.9520786,"about_ca_system_score_codex":0.00022772833,"about_ca_system_score_gemma":0.00074911996,"threshold_uncertainty_score":0.6776275},"labels":[],"label_agreement":null},{"id":"W4414035684","doi":"10.1016/s1470-2045(25)00288-8","title":"Importance of responder criteria for reporting health-related quality-of-life data in clinical trials for advanced cancer: recommendations of Common Sense Oncology and the European Organisation for Research and Treatment of Cancer","year":2025,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Queen's University; Princess Margaret Cancer Centre","funders":"European Organisation for Research and Treatment of Cancer","keywords":"Medicine; Clinical trial; Quality of life (healthcare); Cancer; Oncology; Clinical Oncology; Cancer treatment; Internal medicine; Medical physics; Nursing","score_opus":0.8211171485551215,"score_gpt":0.7051988091568826,"score_spread":0.11591833939823892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414035684","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012662825,0.9497048,0.00011277197,0.021356126,0.0007457077,0.010320037,0.0049025775,0.00000890968,0.00018622358],"genre_scores_gemma":[0.004590111,0.9917019,0.0008263179,0.00022839353,0.0003446577,0.0013251255,0.0008237861,0.00003194735,0.00012773884],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.980114,0.01167571,0.0072023366,0.0005287463,0.000156793,0.00032244224],"domain_scores_gemma":[0.94925207,0.040922545,0.008382642,0.0009323239,0.00045095934,0.000059436024],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.06544325,0.00019512934,0.0064652613,0.00016528464,0.00009134345,0.00000381056,0.00024091228,0.00024253865,0.00000950273],"category_scores_gemma":[0.01613744,0.00011412977,0.00026714295,0.00028486905,0.0005675653,0.000027562548,0.00015217067,0.00028982369,2.8410401e-8],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013821911,0.0002897923,0.00091463455,0.020818306,0.00065407273,0.000001115506,0.0021361297,6.6695117e-7,0.000018836672,0.0012164909,0.0017751594,0.95835286],"study_design_scores_gemma":[0.026593497,0.0052366382,0.001561645,0.0078367265,0.0018460111,0.000012491194,0.0021799884,0.00006560154,0.000020180974,0.0012694487,0.95321256,0.00016520162],"about_ca_topic_score_codex":0.003775582,"about_ca_topic_score_gemma":0.035931792,"teacher_disagreement_score":0.9581877,"about_ca_system_score_codex":0.00039758914,"about_ca_system_score_gemma":0.0037894226,"threshold_uncertainty_score":0.99215007},"labels":[],"label_agreement":null},{"id":"W4414035710","doi":"10.1016/s1470-2045(25)00351-1","title":"Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration-resistant prostate cancer in Canada (GROUQ-PCS 9): a multicentre, open-label, randomised, phase 2 trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Nova Scotia Cancer Centre; Dalhousie University; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; McMaster University; Juravinski Cancer Centre; Trillium Health Centre; London Health Sciences Centre; CancerCare Manitoba; University Health Network; Princess Margaret Cancer Centre; Credit Valley Hospital; Centre hospitalier universitaire de Québec; Université du Québec en Outaouais; Université de Montréal; McGill University Health Centre; McGill University; Hôpital Charles-Le Moyne; Centre Hospitalier de l’Université de Montréal; Jewish General Hospital","funders":"Jewish General Hospital; Astellas Pharma Canada","keywords":"Medicine; Prostate cancer; Systemic therapy; Open label; Oncology; Randomized controlled trial; Internal medicine; Castration; Clinical trial; Cancer; Hormone","score_opus":0.0798744365701188,"score_gpt":0.42850142216545367,"score_spread":0.3486269855953349,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414035710","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9739133,0.004967959,0.0000055803816,0.007466954,0.00039229702,0.011912014,0.0008949031,0.000025797095,0.00042117768],"genre_scores_gemma":[0.98333174,0.008852317,0.00018878536,0.0014941163,0.00010690526,0.005437494,0.00020463763,0.000024567033,0.00035942055],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963955,0.0013322763,0.00078736903,0.0004407974,0.00035320924,0.00069082965],"domain_scores_gemma":[0.99835664,0.0008139465,0.0001743396,0.0003745314,0.00016233297,0.00011819269],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001656426,0.00026743158,0.001297,0.0003741866,0.000080981685,0.000050300612,0.00032637414,0.00007698501,0.00024042574],"category_scores_gemma":[0.00022755524,0.00017163012,0.000038108457,0.0013423437,0.000072301045,0.00010494046,0.00005783869,0.0004252404,0.0000029253529],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.8931202,0.0013587604,0.0019888747,0.00013010898,0.0003160437,0.00077258213,0.0016886119,0.00024448277,0.009133848,0.00004515679,0.0040726867,0.08712863],"study_design_scores_gemma":[0.9766292,0.004225576,0.004017558,0.0007480131,0.00006798487,0.000011864575,0.001421002,0.0006292636,0.002701261,0.00010486652,0.009224046,0.00021936135],"about_ca_topic_score_codex":0.4394241,"about_ca_topic_score_gemma":0.89252037,"teacher_disagreement_score":0.45309627,"about_ca_system_score_codex":0.0044384697,"about_ca_system_score_gemma":0.008700025,"threshold_uncertainty_score":0.99938333},"labels":[],"label_agreement":null},{"id":"W4414711510","doi":"10.1016/s1470-2045(25)00360-2","title":"Digital health and artificial intelligence innovations for oncology in sub-Saharan Africa","year":2025,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Artificial Intelligence in Healthcare and Education","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Neurological Institute and Hospital; McGill University; Queen's University","funders":"","keywords":"Digital health; mHealth; Workforce; eHealth; Health care; Global health; Health policy","score_opus":0.47746124249957994,"score_gpt":0.5504750179637085,"score_spread":0.07301377546412852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414711510","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000023693681,0.9658133,0.0010406483,0.024666764,0.0011426117,0.0029443258,0.00009956101,0.000041718202,0.004227406],"genre_scores_gemma":[0.00009400863,0.9949715,0.0003908759,0.0014147044,0.0013453593,0.00094783533,0.0003526066,0.000022015967,0.00046108037],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997294,0.0003002372,0.0013553045,0.00040683695,0.00009678085,0.0005468041],"domain_scores_gemma":[0.9955606,0.0032867063,0.00046377216,0.0003879239,0.00017905403,0.00012197537],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014508853,0.0002447059,0.0020591037,0.00038322646,0.00017427323,0.000026175352,0.00023012522,0.00046985358,0.00001908984],"category_scores_gemma":[0.0017554748,0.00017420427,0.00013514476,0.0009148655,0.00024462905,0.00005391813,0.00007625409,0.0007865228,0.000042113963],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012817883,0.00019043451,0.000008866345,0.0077301655,0.00003440992,0.0000033097763,0.0007401389,4.323991e-7,1.8116887e-7,0.004611862,0.014048327,0.9725037],"study_design_scores_gemma":[0.00003729738,0.001039079,0.0000027373283,0.003202887,0.00009917569,0.00004740246,0.00050211605,0.000028978235,0.0000019868278,0.008241955,0.9866747,0.00012164344],"about_ca_topic_score_codex":0.00006885536,"about_ca_topic_score_gemma":0.0004309922,"teacher_disagreement_score":0.9726264,"about_ca_system_score_codex":0.00087031035,"about_ca_system_score_gemma":0.0065509826,"threshold_uncertainty_score":0.99908096},"labels":[],"label_agreement":null},{"id":"W4414711646","doi":"10.1016/s1470-2045(25)00554-6","title":"AJCC9V classification for HPV-positive oropharyngeal carcinoma – Authors' reply","year":2025,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Carcinoma; Epidermoid carcinoma; MEDLINE; Cancer","score_opus":0.09648121623464327,"score_gpt":0.3844868367144086,"score_spread":0.2880056204797653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414711646","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00057023915,0.0013190424,0.0002322815,0.9259619,0.0019961663,0.0014538886,0.0002939748,0.00010562639,0.06806685],"genre_scores_gemma":[0.006961099,0.0004088792,0.00081346295,0.9378637,0.021032853,0.0009316626,0.0007461043,0.000047241007,0.031195002],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99789184,0.00031917027,0.00040897552,0.00056199904,0.00020726373,0.00061076524],"domain_scores_gemma":[0.9975762,0.0010963808,0.0002491229,0.00075392425,0.00027274078,0.000051650855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006072787,0.00030991857,0.0015951236,0.000114265145,0.00024347723,0.000014590859,0.00032091571,0.00074640836,0.00008172165],"category_scores_gemma":[0.00026760594,0.0002066602,0.00022299576,0.0001714112,0.0002548891,0.000024822091,0.000105566265,0.0017048119,0.000040982904],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00083502545,0.00004049197,0.00026828286,0.00053668994,0.0002704288,0.00018239966,0.0005226211,8.8770456e-8,0.00016258763,0.00037382927,0.97934,0.017467551],"study_design_scores_gemma":[0.0024302956,0.0014027423,0.014006808,0.0001424847,0.0006583924,0.00007006781,0.00007773634,0.000071526025,0.00013100273,0.0003747058,0.9804492,0.00018505304],"about_ca_topic_score_codex":0.00011506591,"about_ca_topic_score_gemma":0.0000334885,"teacher_disagreement_score":0.036871847,"about_ca_system_score_codex":0.0006310532,"about_ca_system_score_gemma":0.0009123705,"threshold_uncertainty_score":0.8427358},"labels":[],"label_agreement":null},{"id":"W4415023189","doi":"10.1016/s1470-2045(25)00400-0","title":"Clinical potential of whole-genome data linked to mortality statistics in patients with breast cancer in the UK: a retrospective analysis","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Cancer Research UK Cambridge Institute, University of Cambridge; Medical Research Council; Fru Berta Kamprads Stiftelse; Lunds Universitet; Cancerfonden; Vetenskapsrådet; Sunway University; Cancer Research UK; National Institute for Health and Care Research; Heart of England NHS Foundation Trust; Dr. Josef Steiner Krebsstiftung; Department of Health and Social Care; Mats Paulssons Stiftelse; Wellcome Trust; NIHR Cambridge Biomedical Research Centre; Breast Cancer Research Foundation","keywords":"Breast cancer; Linked data; Cancer; Population; Retrospective cohort study; Epidemiology","score_opus":0.025687368576819285,"score_gpt":0.3671962507591854,"score_spread":0.3415088821823661,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415023189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890122,0.00009645416,0.0019036185,0.0014928528,0.00013013097,0.0003363258,0.006837418,0.0000015293083,0.00018950798],"genre_scores_gemma":[0.9968607,0.00023345964,0.00043695257,0.0015054104,0.00019022034,0.000028692659,0.00071859756,0.000005430499,0.000020573625],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987823,0.0002309869,0.00034448173,0.00033027036,0.000107768596,0.00020421512],"domain_scores_gemma":[0.9987259,0.00009259052,0.00013396029,0.0009004351,0.00012101869,0.000026099464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086783234,0.00009691454,0.00041016395,0.000060806073,0.000029164547,0.0000108978065,0.0006795218,0.00010386665,0.000017380617],"category_scores_gemma":[0.00014454646,0.000060999886,0.0000385184,0.0004415804,0.0001436306,0.000001976933,0.00033069507,0.00018226738,7.6137997e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007327416,0.00022777563,0.99314034,0.0000073688757,0.0003653144,0.000004248447,0.00007661937,0.001797029,0.00033947022,0.00018350167,0.001639597,0.001486021],"study_design_scores_gemma":[0.0015657799,0.00029571733,0.9947891,0.000006796796,0.0002690714,3.8116735e-7,0.000056462195,0.00017893115,0.0000044867143,0.0001510511,0.0026092909,0.00007290677],"about_ca_topic_score_codex":0.0009617177,"about_ca_topic_score_gemma":0.03545281,"teacher_disagreement_score":0.034491092,"about_ca_system_score_codex":0.000068439884,"about_ca_system_score_gemma":0.00028793863,"threshold_uncertainty_score":0.98214763},"labels":[],"label_agreement":null},{"id":"W4415255286","doi":"10.1016/s1470-2045(25)00606-0","title":"Overall survival assessment in cancer drug trials: a luxury or a necessity?","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Overall survival; Drug; Cancer drugs; Cancer; Survival analysis; Cancer survival","score_opus":0.06787061010744802,"score_gpt":0.42730788821816773,"score_spread":0.3594372781107197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415255286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9394918,0.0034503965,0.0006920893,0.028740587,0.0021823535,0.0005769496,0.000116807874,0.000017038383,0.024731956],"genre_scores_gemma":[0.9745629,0.009675169,0.0006114623,0.008879476,0.0015671853,0.000293522,0.00005231973,0.000016980524,0.0043409965],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985073,0.0005071296,0.00033292032,0.0002754251,0.00007388397,0.0003032906],"domain_scores_gemma":[0.9989816,0.00042902378,0.00013252153,0.00037726536,0.00004508969,0.000034522574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017530578,0.00013227141,0.0005337143,0.000043052853,0.00006376212,0.000026248925,0.00035678686,0.00013447352,0.000087060456],"category_scores_gemma":[0.00039455562,0.00008771471,0.00008088697,0.00012313394,0.00007901873,0.0000021245648,0.00023868328,0.00021624031,0.0000032594608],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010467937,0.0012730559,0.09941455,0.00027020887,0.0009586314,0.0001221827,0.00086327275,0.0035662055,0.09308754,0.03219149,0.60181534,0.15596958],"study_design_scores_gemma":[0.004943367,0.00024718078,0.03400273,0.000039739007,0.000071217626,0.0000037168577,0.00019087462,0.0002293813,0.0026862698,0.0019426201,0.95545137,0.00019154453],"about_ca_topic_score_codex":0.0008878505,"about_ca_topic_score_gemma":0.014584552,"teacher_disagreement_score":0.35363603,"about_ca_system_score_codex":0.00016222081,"about_ca_system_score_gemma":0.0011368471,"threshold_uncertainty_score":0.8138522},"labels":[],"label_agreement":null},{"id":"W4415255311","doi":"10.1016/s1470-2045(25)00619-9","title":"British Columbia's proposed law to combat deceptive practices promoting vaping products","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Sexuality, Behavior, and Technology","field":"Psychology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Legislation; Deception; Government (linguistics); Liability; Punitive damages","score_opus":0.08475969968865377,"score_gpt":0.4157463258595791,"score_spread":0.33098662617092534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415255311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83729625,0.0003808457,0.000036642276,0.029485015,0.0023422076,0.0017300455,0.000013829043,0.00050044764,0.12821472],"genre_scores_gemma":[0.96402985,0.000019876461,0.0016058951,0.009868727,0.00072126964,0.00051449286,0.00001774821,0.000038478833,0.023183638],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968616,0.0009998631,0.0004373489,0.0007513702,0.00015086755,0.0007989967],"domain_scores_gemma":[0.9977009,0.00059823727,0.0004535558,0.0009491971,0.00023302095,0.000065051565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017587477,0.00017137588,0.00066078396,0.00007078209,0.00038538047,0.00017166624,0.0009157182,0.0003684802,0.0008019609],"category_scores_gemma":[0.0010230843,0.00019569488,0.00004808939,0.00069144904,0.00052242685,0.00009648265,0.00037330028,0.0007472703,0.0001918849],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070007564,0.003039998,0.08011528,0.00022178507,0.00071842235,0.00066349166,0.02134318,0.0000018424262,0.021874158,0.245485,0.30869547,0.31714132],"study_design_scores_gemma":[0.0026008908,0.0011862,0.03996996,0.00011641998,0.00018642798,0.0003235724,0.005908715,0.0000050854965,0.0015395287,0.006164037,0.9416253,0.00037389045],"about_ca_topic_score_codex":0.028613048,"about_ca_topic_score_gemma":0.12233637,"teacher_disagreement_score":0.6329298,"about_ca_system_score_codex":0.00019406965,"about_ca_system_score_gemma":0.00019550187,"threshold_uncertainty_score":0.9778555},"labels":[],"label_agreement":null},{"id":"W4415601999","doi":"10.1016/s1470-2045(25)00561-3","title":"Systemic therapy for brain metastases: a changing landscape","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Systemic therapy; Disease; Action (physics); MEDLINE; Systemic risk","score_opus":0.04806460891737202,"score_gpt":0.37635903967958295,"score_spread":0.32829443076221093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415601999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5803606,0.02753957,0.022330666,0.33297485,0.0017427495,0.0067717675,0.00029412136,0.000384587,0.027601078],"genre_scores_gemma":[0.964996,0.00049694563,0.0029694457,0.026419023,0.0007103172,0.000720572,0.000090902984,0.000019260991,0.0035775665],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990226,0.00021465142,0.00017038516,0.0001830534,0.000068537265,0.0003407429],"domain_scores_gemma":[0.99873036,0.0007632932,0.0000660631,0.00035694774,0.000047492835,0.00003583854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013300617,0.00011815288,0.0005358186,0.00010360836,0.00012096699,0.000011029682,0.00011973393,0.00006232784,0.000073351795],"category_scores_gemma":[0.000106565996,0.00006468263,0.0001271395,0.00022023496,0.000045729394,0.0000148512645,0.00003452673,0.00010662453,0.000016524133],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008313705,0.0011486695,0.007083735,0.000936869,0.0040572807,0.00022248604,0.002830647,0.000062883395,0.0049236636,0.13432272,0.40904343,0.4270539],"study_design_scores_gemma":[0.01666726,0.0016289338,0.0014641337,0.0001607393,0.00042811333,0.0002782573,0.0013754579,0.0005180679,0.0008669895,0.0018273267,0.974669,0.00011571621],"about_ca_topic_score_codex":0.00001189578,"about_ca_topic_score_gemma":0.000011991875,"teacher_disagreement_score":0.56562555,"about_ca_system_score_codex":0.00007905993,"about_ca_system_score_gemma":0.00015456395,"threshold_uncertainty_score":0.2637681},"labels":[],"label_agreement":null},{"id":"W4415678781","doi":"10.1016/s1470-2045(25)00472-3","title":"Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; Health Sciences Centre; University Health Network","funders":"Servier","keywords":"Phase (matter); Glioma; Clinical trial; Phases of clinical research; Glioblastoma","score_opus":0.05830452800028042,"score_gpt":0.3686986930068263,"score_spread":0.3103941650065459,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415678781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97819185,0.0028038041,0.000016627582,0.009354681,0.00097624434,0.0067318627,0.00010475341,0.00008418243,0.0017360065],"genre_scores_gemma":[0.9932364,0.0006943496,0.0001074826,0.0018367316,0.00087876193,0.0030776467,0.000066817156,0.00003586264,0.00006592182],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.996718,0.0007113192,0.0009825804,0.0006406984,0.00028441122,0.0006630033],"domain_scores_gemma":[0.9963273,0.0023865597,0.00033137747,0.00068696396,0.00006791807,0.00019987146],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015063498,0.00043293327,0.0024100954,0.00041437324,0.0001650826,0.00006303492,0.00028293824,0.0003367101,0.00046076407],"category_scores_gemma":[0.00036023982,0.0002529234,0.00024156942,0.00047983657,0.00025203064,0.00011816488,0.0001486993,0.0006102725,0.00004962565],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9440402,0.00271127,0.0003431665,0.00006412152,0.0010125558,0.0038642706,0.001283514,0.0000028192794,0.037681077,0.00024840378,0.0015470171,0.0072016343],"study_design_scores_gemma":[0.9539198,0.0019714476,0.00021007787,0.00024121773,0.00089604186,0.00014289029,0.00074992003,0.000119595476,0.035443936,0.0009451058,0.0051361397,0.00022380952],"about_ca_topic_score_codex":0.00018620487,"about_ca_topic_score_gemma":0.0015951267,"teacher_disagreement_score":0.015044588,"about_ca_system_score_codex":0.000406877,"about_ca_system_score_gemma":0.0010527533,"threshold_uncertainty_score":0.9999923},"labels":[],"label_agreement":null},{"id":"W4415829162","doi":"10.1016/s1470-2045(25)00530-3","title":"The human crisis in cancer: a Lancet Oncology Commission","year":2025,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"Canadian Institutes of Health Research; Princess Margaret Cancer Foundation; World Health Organization","keywords":"Commission; Existentialism; Compassion; Incentive; Blame; Ideology","score_opus":0.17682488692619072,"score_gpt":0.4226891298372398,"score_spread":0.24586424291104905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415829162","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000019967756,0.809547,0.000017396334,0.01214065,0.0018681168,0.0007745357,0.00039167318,0.000043731645,0.17519692],"genre_scores_gemma":[0.00017591057,0.9886519,0.000056842146,0.0022797033,0.0023069603,0.000863105,0.000040077768,0.000053396667,0.005572104],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959849,0.00041125814,0.0018050239,0.0007111985,0.000042675416,0.0010449106],"domain_scores_gemma":[0.9956329,0.0013055042,0.0016429867,0.0012726708,0.000042059037,0.00010390358],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003431,0.0005074866,0.005031973,0.00030068992,0.0005108631,0.00010738917,0.0021300563,0.00090388133,0.0003092685],"category_scores_gemma":[0.00034974032,0.00034567298,0.00048756044,0.0005240376,0.0003238727,0.00011055421,0.0004469908,0.0016558517,0.00038607678],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004333772,0.00008782949,0.000279351,0.0015878569,0.00015967687,0.000014903086,0.00022365442,0.000006000812,3.551876e-8,0.15780585,0.20847288,0.6313186],"study_design_scores_gemma":[0.0009799243,0.00016400072,0.00024263337,0.0011370342,0.00009364726,0.0000107093,0.000059527465,0.000008919847,1.2278569e-7,0.021152327,0.97577965,0.0003715296],"about_ca_topic_score_codex":0.0023319933,"about_ca_topic_score_gemma":0.0050359345,"teacher_disagreement_score":0.76730675,"about_ca_system_score_codex":0.0023695058,"about_ca_system_score_gemma":0.0009889951,"threshold_uncertainty_score":0.9998995},"labels":[],"label_agreement":null},{"id":"W4416589081","doi":"10.1016/s1470-2045(25)00543-1","title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Jiangsu Hengrui Medicine","keywords":"Hepatocellular carcinoma; Sorafenib; Overall survival; Phases of clinical research; Phase (matter); Clinical trial; Carcinoma","score_opus":0.25364071666358595,"score_gpt":0.43083491518274847,"score_spread":0.17719419851916252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416589081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98057044,0.0023912466,0.00037897882,0.005800161,0.0006576157,0.0060880133,0.00013494154,0.000048619957,0.0039300146],"genre_scores_gemma":[0.99411726,0.0006895136,0.00036634132,0.0006317272,0.00028471206,0.0017808317,0.00047301693,0.000030461133,0.0016261182],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975709,0.00040718776,0.0006903839,0.0005487347,0.0003179789,0.00046485884],"domain_scores_gemma":[0.9970478,0.0013020999,0.00030352653,0.00082241045,0.0004208669,0.00010333677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012708228,0.00033043165,0.001798709,0.00043538798,0.00026809104,0.000060963353,0.00085941463,0.00017789657,0.00048441943],"category_scores_gemma":[0.00030768447,0.00022940499,0.00034476034,0.0010553015,0.00014562714,0.00008818718,0.00022183839,0.00026052023,0.0000120397435],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.61569494,0.01150981,0.32101673,0.00014935152,0.022978272,0.0006284116,0.0029961236,0.00008684663,0.0018566649,0.0010267362,0.0077509973,0.014305113],"study_design_scores_gemma":[0.8079694,0.022322556,0.0039748065,0.00005950116,0.011839775,0.000017536604,0.0008885677,0.083975464,0.0044172835,0.00029151698,0.063888684,0.0003549107],"about_ca_topic_score_codex":0.0016749684,"about_ca_topic_score_gemma":0.0007882347,"teacher_disagreement_score":0.3170419,"about_ca_system_score_codex":0.000452073,"about_ca_system_score_gemma":0.00079215574,"threshold_uncertainty_score":0.9354864},"labels":[],"label_agreement":null},{"id":"W4416589103","doi":"10.1016/s1470-2045(25)00492-9","title":"Microbubble-enhanced transcranial focused ultrasound with temozolomide for patients with high-grade glioma (BT008NA): a multicentre, open-label, phase 1/2 trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Ultrasound and Hyperthermia Applications","field":"Engineering","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Institute of Neurological Disorders and Stroke; National Institutes of Health; University of Maryland; School of Medicine, University of Maryland; National Center for Advancing Translational Sciences; Institute for Clinical and Translational Research, University of Maryland, Baltimore; Johns Hopkins University","keywords":"Temozolomide; Glioma; Focused ultrasound; Glioblastoma; Ultrasound; Phase (matter); Clinical trial","score_opus":0.025370552062386205,"score_gpt":0.3028433950160666,"score_spread":0.2774728429536804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416589103","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9766299,0.0000733865,0.015780607,0.0011480291,0.00035031265,0.0039728787,0.00026780556,0.00022912706,0.0015479358],"genre_scores_gemma":[0.9872223,0.000041711828,0.010182659,0.00041124347,0.0003169407,0.0014575099,0.00014449365,0.000056197317,0.0001669372],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99864304,0.000085723565,0.0003152979,0.00032669053,0.00011048867,0.00051876897],"domain_scores_gemma":[0.9984082,0.0008741771,0.00008861052,0.00046635262,0.000092813665,0.000069877366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019065222,0.00027547404,0.0006328959,0.000070727,0.0002653976,0.00009086376,0.0007018184,0.00015049799,0.000035968314],"category_scores_gemma":[0.000036805555,0.00017684087,0.00003972456,0.00038038768,0.00015850179,0.00012414472,0.000022622755,0.00024793568,0.000011357292],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39725056,0.013343318,0.00037638235,0.00042439165,0.0028915685,0.000017600125,0.0036477149,0.0022881858,0.5135387,0.008748544,0.020895097,0.036577903],"study_design_scores_gemma":[0.8449151,0.0070494614,0.00072022184,0.00010783111,0.0008002369,0.0000148459285,0.00019053396,0.0007066927,0.022887178,0.0010626621,0.12080267,0.00074258435],"about_ca_topic_score_codex":0.000048148624,"about_ca_topic_score_gemma":0.0006051694,"teacher_disagreement_score":0.49065155,"about_ca_system_score_codex":0.00014261495,"about_ca_system_score_gemma":0.0001355441,"threshold_uncertainty_score":0.72113615},"labels":[],"label_agreement":null},{"id":"W4416589127","doi":"10.1016/s1470-2045(25)00520-0","title":"SISAQOL-IMI consensus-based guidelines to design, analyse, interpret, and present patient-reported outcomes in cancer clinical trials","year":2025,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada; University Health Network; Queen's University","funders":"Health Canada; Horizon 2020 Framework Programme; U.S. Food and Drug Administration; National Cancer Institute; National Institutes of Health; European Medicines Agency; European Society for Medical Oncology; European Commission; Innovative Health Initiative; European Federation of Pharmaceutical Industries and Associations; American Society of Clinical Oncology","keywords":"Clinical trial; Quality (philosophy); Selection (genetic algorithm); Quality of life (healthcare); Cancer; Alternative medicine; MEDLINE","score_opus":0.5470586733715724,"score_gpt":0.6086951238402815,"score_spread":0.061636450468709025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416589127","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005221832,0.9729924,0.00025680126,0.019034002,0.002353289,0.004000186,0.00015992379,0.0000638169,0.000617356],"genre_scores_gemma":[0.00032904564,0.9850805,0.00058711023,0.010953434,0.0010028294,0.0013378653,0.000056846384,0.000040135328,0.0006122799],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9889537,0.0060558002,0.0035113175,0.0007244333,0.0002844015,0.00047035827],"domain_scores_gemma":[0.983907,0.013627619,0.00091262354,0.0009895526,0.00035183583,0.0002113999],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.008405023,0.0004954943,0.008513587,0.00037874587,0.000045407563,0.000023772305,0.0003371837,0.0006254645,0.00012920155],"category_scores_gemma":[0.012338733,0.00027644512,0.0008178603,0.00061262026,0.0001962761,0.000011074854,0.00022731724,0.00085002417,0.000007998996],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013217813,0.00015969029,0.0062512225,0.0039514466,0.0011603818,0.00018159306,0.00017535695,0.000019004186,5.658752e-7,0.000008465838,0.05702558,0.9297449],"study_design_scores_gemma":[0.0024284036,0.00070046005,0.00036331927,0.009445332,0.004305685,0.000029036099,0.000101507205,0.000069848626,0.000002424392,0.000029541738,0.98225564,0.00026878057],"about_ca_topic_score_codex":0.0019477834,"about_ca_topic_score_gemma":0.0074375807,"teacher_disagreement_score":0.92947614,"about_ca_system_score_codex":0.00044094815,"about_ca_system_score_gemma":0.0034606897,"threshold_uncertainty_score":0.99996877},"labels":[],"label_agreement":null},{"id":"W7116858522","doi":"10.1016/s1470-2045(25)00566-2","title":"Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Bristol-Myers Squibb","keywords":"Docetaxel; Prostate cancer; Placebo; Nivolumab; Androgen receptor; Enzalutamide; Clinical trial; Phases of clinical research","score_opus":0.10426939970091895,"score_gpt":0.42134323272015745,"score_spread":0.3170738330192385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116858522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9586022,0.0061582844,0.0000830699,0.014738918,0.0012037841,0.016185291,0.0007353067,0.00014033513,0.0021528178],"genre_scores_gemma":[0.9562754,0.008068232,0.0012983395,0.001199231,0.0018080845,0.014493546,0.0008959882,0.00013398333,0.015827186],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99704933,0.00035882552,0.00069774175,0.00067448715,0.00035415535,0.0008654581],"domain_scores_gemma":[0.9977196,0.0008561181,0.00034161264,0.0005059825,0.00035454237,0.00022216894],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012571906,0.00045531793,0.0015206691,0.0002138995,0.00041216263,0.00010501069,0.0002485759,0.00022608033,0.00018167967],"category_scores_gemma":[0.00017070868,0.00029461127,0.00022424718,0.00048247795,0.0004797854,0.00013898413,0.00008511395,0.00045532326,0.000012727672],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9683922,0.0004646204,0.000035116118,0.00044884096,0.0020471606,0.00007258833,0.0020178517,0.000031817133,0.0096221045,0.00023100816,0.006983397,0.009653301],"study_design_scores_gemma":[0.932622,0.005193081,0.000016128848,0.0001941538,0.0009849804,0.00001960412,0.0007358502,0.0008944758,0.023786131,0.0002043387,0.03507334,0.0002759012],"about_ca_topic_score_codex":0.00043198504,"about_ca_topic_score_gemma":0.00051101216,"teacher_disagreement_score":0.035770178,"about_ca_system_score_codex":0.0012869914,"about_ca_system_score_gemma":0.0030267162,"threshold_uncertainty_score":0.9999506},"labels":[],"label_agreement":null},{"id":"W7116870583","doi":"10.1016/s1470-2045(25)00614-x","title":"Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Health and Medical Research Council; Brain Tumour Charity; Cancer Research UK; Cancer Australia; American College of Radiology; KWF Kankerbestrijding; NRG Oncology; European Organisation for Research and Treatment of Cancer; MSD","keywords":"Temozolomide; Adjuvant; Glioblastoma; Clinical trial; Phases of clinical research; Anaplastic astrocytoma","score_opus":0.21907793404736797,"score_gpt":0.49292166654188846,"score_spread":0.2738437324945205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116870583","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891167,0.0020466836,0.00016227532,0.0015607562,0.00032892195,0.0064308625,0.00009599111,0.000022850518,0.00023490765],"genre_scores_gemma":[0.99703825,0.00028761642,0.0001486843,0.00035204887,0.0002086338,0.0018658233,0.000051141866,0.00001658231,0.000031231386],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980728,0.0003602353,0.0006344671,0.00043606714,0.00015224017,0.00034420498],"domain_scores_gemma":[0.9972461,0.0017858144,0.00030361026,0.00040089185,0.00014147308,0.00012212638],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001010608,0.00026413653,0.0017208786,0.00021015856,0.00016413642,0.000034930625,0.00022504984,0.000105524756,0.000026380438],"category_scores_gemma":[0.00043081146,0.00016476998,0.00007798287,0.00028742227,0.0002796726,0.00006587324,0.00017052573,0.0001622089,0.0000021182323],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.811234,0.02758475,0.006620736,0.00047934023,0.0051221517,0.0006340134,0.002454615,0.000011589034,0.044700995,0.00040607524,0.023535213,0.0772165],"study_design_scores_gemma":[0.9553582,0.026468406,0.003773867,0.00014785203,0.0025335718,0.00004103726,0.0012016691,0.0010697506,0.006265471,0.00012898355,0.0028367583,0.00017444113],"about_ca_topic_score_codex":0.000079088066,"about_ca_topic_score_gemma":0.000203306,"teacher_disagreement_score":0.14412417,"about_ca_system_score_codex":0.000100655874,"about_ca_system_score_gemma":0.0003624953,"threshold_uncertainty_score":0.6719125},"labels":[],"label_agreement":null},{"id":"W7116980363","doi":"10.1016/s1470-2045(25)00598-4","title":"Oncological outcomes with and without axillary lymph node dissection in patients with residual micrometastases after neoadjuvant chemotherapy (OPBC-07/microNAC): an international, retrospective cohort study","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"National Cancer Institute; National Institutes of Health","keywords":"Retrospective cohort study; Chemotherapy; Dissection (medical); Breast cancer; Cancer; Lymph node; Axillary Dissection; Cohort study","score_opus":0.008727459523990287,"score_gpt":0.2993103599565483,"score_spread":0.290582900432558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116980363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969735,0.00014553194,0.000027921606,0.0015792124,0.00011747909,0.000710647,0.000063716136,0.000018439268,0.00036351863],"genre_scores_gemma":[0.9976125,0.0001649357,0.00042107105,0.0012066985,0.00010193806,0.00029407843,0.00009441552,0.000016965872,0.000087402484],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987394,0.00020203536,0.0001801528,0.00049709826,0.00013901146,0.00024226356],"domain_scores_gemma":[0.9993938,0.000031448024,0.0000994864,0.00033984936,0.0001060158,0.00002936423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023828329,0.00022510685,0.00048065864,0.000059118283,0.00009495478,0.000023860819,0.00018820788,0.00009534781,0.000015094076],"category_scores_gemma":[0.000026102944,0.00012711242,0.000021758873,0.00010254449,0.00024998342,0.000013256102,0.0001367292,0.00012122106,0.0000012477349],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007790673,0.0010912452,0.9889021,0.000004782685,0.00067681854,0.000012163438,0.0002552442,0.000006993421,0.0002466118,0.000012756143,0.000082413404,0.0009182182],"study_design_scores_gemma":[0.009188297,0.001762835,0.98753417,0.000017658645,0.00010397159,0.000013243751,0.00035682376,0.0000011926081,0.00021338249,0.00002348306,0.0006314417,0.00015352244],"about_ca_topic_score_codex":0.00018919077,"about_ca_topic_score_gemma":0.0016145189,"teacher_disagreement_score":0.0014253281,"about_ca_system_score_codex":0.00024874427,"about_ca_system_score_gemma":0.000084349456,"threshold_uncertainty_score":0.5183494},"labels":[],"label_agreement":null},{"id":"W7117077043","doi":"10.1016/s1470-2045(25)00535-2","title":"International consensus recommendations and alignment of terminology for the histopathological diagnosis of extranodal extension in head and neck squamous cell carcinoma: an HN-CLEAR initiative","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre; Dalhousie University","funders":"National Health and Medical Research Council","keywords":"Terminology; Head and neck; Concordance; Head and neck cancer; Squamous cell cancer; MEDLINE","score_opus":0.10401294649971668,"score_gpt":0.3851906460608598,"score_spread":0.28117769956114314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117077043","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93256956,0.0013923952,0.000026619742,0.06326497,0.000186776,0.00037695258,0.00004038437,0.0000052073897,0.0021371536],"genre_scores_gemma":[0.99607885,0.0012948363,0.00090582744,0.0015010535,0.000053482312,0.00011470196,0.000006450529,0.000003366055,0.00004143117],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993055,0.00015417447,0.00023142797,0.00014631529,0.00004223616,0.00012037071],"domain_scores_gemma":[0.9983412,0.00135954,0.00008718429,0.00012645518,0.000068005436,0.000017590715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035104726,0.00006780206,0.00039795402,0.000053538304,0.00005848867,0.0000014791406,0.000068157635,0.00006624963,0.000015276684],"category_scores_gemma":[0.00017780424,0.000040024515,0.000023281105,0.00004919112,0.00037805256,0.00001085637,0.000071762195,0.000114382965,1.4052537e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009675004,0.0020224517,0.80315375,0.0004089047,0.00011471384,0.00009562406,0.016333215,0.000011701062,0.011744693,0.008994176,0.016802933,0.13064285],"study_design_scores_gemma":[0.0075619253,0.0036981562,0.95590997,0.00006796399,0.00012050846,0.000057914116,0.0024071878,0.00039123764,0.0017579651,0.001101829,0.026864294,0.00006106417],"about_ca_topic_score_codex":0.00009152708,"about_ca_topic_score_gemma":0.00024419106,"teacher_disagreement_score":0.15275621,"about_ca_system_score_codex":0.00006309977,"about_ca_system_score_gemma":0.000064122076,"threshold_uncertainty_score":0.16321523},"labels":[],"label_agreement":null}]}